<rows>
  <row para_id="302377" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<h3 id="post">Postdoctoral Fellowships</h3>
<p>Fellowship training is up to five years under the supervision of DCEG scientists. In order to be eligible, an applicant:</p>
<ul>
<li>Must have an M.D. or doctoral degree in epidemiology, biostatistics, genetics, or other related research fields, or be pursuing a degree in these areas.</li>
<li>Must also be a U.S. citizen, resident alien, or foreign national eligible for a training visa.</li>
</ul>
<p><b>Special Fellowships:</b></p>
<ul>
<li><a href="http://www.cancer.gov/researchandfunding/training/srk">Sallie Rosen Kaplan Postdoctoral Fellowship - For Women Scientists in Cancer Research</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302475" inlinetype="rxhyperlink" sys_relationshipid="7252956" sys_dependentvariantid="1418" sys_dependentid="302475" rxinlineslot="103" sys_variantid="1418" sys_contentid="302475">The Robert A. Welch Postdoctoral Fellowship</a></li>
</ul>
<h3 id="pre">Pre-doctoral Fellowships</h3>
<p>Fellowships up to three years are offered to doctoral students for dissertation research and to master's level graduates. Applicants may be U.S. citizens, resident aliens, or those eligible for a training visa.</p>
<h3>Graduate Partnership Programs</h3>
<p>Students from relevant accredited doctoral programs are encouraged to consider working with our scientific mentors for their doctoral dissertation research. The student conducts research within DCEG as a full-time doctoral fellow. Competitive stipends and partial tuition benefits are available.</p>
<p>Through the&nbsp;<a href="https://www.training.nih.gov/programs/gpp">NIH Graduate Partnership Program (NIH GPP)</a>, an agreement will be set up between the graduate school, NIH/NCI, and the student to ensure that all dissertation requirements are fulfilled within two to three years.</p>
<h3 id="inquiry">Inquiries</h3>
<p>E-mail: <a href="mailto:ncidceged-r@mail.nih.gov">ncidceged-r@mail.nih.gov</a></p>
<p>Telephone: 240-276-7270</p>
</div>
</div>]]></content>
  </row>
  <row para_id="302381" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><a href="http://riskfactor.cancer.gov/DHQ/database/#gl"><b>Glycemic Index Values Database</b></a>&nbsp;<br /> Database that provides glycemic index values for common foods. Glycemic load can be calculated for each portion size of food consumed using these numbers.</p>
<p><b><a href="http://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/i-131">Get the Facts About Exposure to I-131 Radiation</a></b><br /> Information and resources for Americans exposed to I-131 (a form of radioactive iodine) through fallout from above-ground nuclear testing in the 1950s and early 60s.</p>
</div>]]></content>
  </row>
  <row para_id="302382" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>No opportunities with specific investigators are available at this time. Please check the&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302518" inlinetype="rxhyperlink" sys_relationshipid="7299176" sys_siteid="475" rxinlineslot="103" sys_dependentid="302518" sys_dependentvariantid="1418" sys_folderid="" sys_variantid="1418" sys_contentid="302518">Research Training Opportunities in Biostatistics</a> page for future postings.</p>
</div>]]></content>
  </row>
  <row para_id="302385" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This software is a SAS macro that projects absolute invasive breast cancer risk for white women in the batch mode based on measurements of mammographic density following the methods of Chen et al. (JNCI 2006;98:1215-1226).</p>
<p>Users can enter risk factor data (mammographic density, age at first live birth, number of affected sisters or mother, weight and number of previous benign breast biopsies) and projection interval ages for a group of women, and the macro will return the corresponding absolute risk projections. This program may be useful for research purposes when one needs risk projections for an entire study population.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=326985" sys_contentid="326985" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317700" sys_dependentvariantid="1418" sys_dependentid="326985" rxinlineslot="103">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302406" sys_contentid="302406" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317699" sys_dependentvariantid="1418" sys_dependentid="302406" rxinlineslot="103">License Agreement</a></li>
</ul>
<h3>Software Download:</h3>
<ul class="grey-bullets">
<li><a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=302991" sys_contentid="302991" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317698" sys_dependentvariantid="1500" sys_dependentid="302991" rxinlineslot="103">BrCa_MD_RAM.zip</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>Support:</h3>
<p>Statistical issues: &nbsp;<a href="mailto:gailm@exchange.nih.gov">Dr. Mitchell Gail</a><br />Technical&nbsp;details: &nbsp;<a href="mailto:peed@imsweb.com">Mr. David Pee</a></p>
</div>]]></content>
  </row>
  <row para_id="302387" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Benzene is a widely distributed environmental contaminant known to cause acute myeloid leukemia, aplastic anemia, and perhaps other hematopoietic neoplasms, related hematopoietic disorders, and possibly other cancers. In a binational, multidisciplinary effort, investigators from NCI and the Chinese Centers for Disease Control have conducted a follow-up investigation during 1972-87 of approximately 75,000 Chinese benzene-exposed workers and 35,000 unexposed workers from more than 700 factories in 12 cities.&nbsp;</p>
<p>Investigators from the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7270544" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103">Occupational and Environmental Epidemiology Branch</a>, the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7270545" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103">Radiation Epidemiology Branch</a>, the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7270546" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103">Biostatistics Branch</a> and the Chinese collaborators found that workers exposed to benzene were at significantly higher risk of developing acute myeloid leukemia, myelodysplastic syndromes, and non-Hodgkin lymphoma. Risk varied by temporal patterns of exposure with recent exposure mostly strongly linked with acute myeloid leukemia and myelodysplastic syndrome, whereas distant exposure was more strongly associated with non-Hodgkin lymphoma.&nbsp;</p>
<p>In parallel cross-sectional investigations carried out in Shanghai during 1992 and Tianjin during 2001, NCI and CDC collaborators have made steady progress in elucidating the mechanisms of benzene-induced carcinogenesis, biomarkers of benzene&rsquo;s early effects, and identifying genetic markers of susceptibility. Currently, a case-cohort study is in progress that extends the follow-up through 1999 and will quantify benzene-related dose-response in relation to hematopoietic malignancies and related disorders, benzene hematotoxicity, and lung cancer. Molecular and genetic studies are underway to assess potential genetic susceptibility in relation to development of benzene hematotoxicity.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270547" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103">Dr. Nathaniel Rothman</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270548" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103">Dr. Qing Lan</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270549" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302390" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG fellows are encouraged to participate in a range of <a href="#DCEG">DCEG fellow-initiated activities</a> and <a href="#NIH">trans-NIH fellow-initiated activities</a>.</p>
<h3 id="DCEG">DCEG Fellow-Initiated Activities</h3>
<p><b>Annual DCEG Fellows Training Symposium<br /></b>The Annual DCEG Fellows Training Symposium is held each spring, usually in March. DCEG fellows plan the symposium, which is a full-day, off-site event that includes invited keynote speakers, a fellows' poster event, and scientific presentations by fellows.</p>
<p><b>Career Development Seminar Series (CDSS)<br /></b>The CDSS is a venue for fellows in three NCI groups, including DCEG, to organize monthly seminars focused on career development topics for junior investigators in populations sciences. These topics include strengthening skills in grantsmanship, manuscript writing, and strategic career planning.</p>
<p><b>DCEG Fellows Committee (DFEL)<br /></b>DFel was formed in January of 2011. Our vision is to create a vibrant, supportive and long-lasting fellows community within DCEG. DFel, together with the DCEG Office of Education, represents, preserves, and promotes the interests of all DCEG fellows.</p>
<p><b>DCEG Fellows Editorial Board (DFEB)<br /></b>DFEB reviews and edits the manuscripts of DCEG fellows. The group provides feedback on the grammar, organization and flow of scientific manuscripts. Authors receive comments from DFEB within 10 days of their assigned review date.<br /><em>User quote: &ldquo;THANK YOU!!! DFEB&rsquo;s insight was so pertinent, prompt and professional that, after following their advice and recommendations, now I feel the manuscript is ready for submission to the journal. I will definitively continue recommending DFEB services to other DCEG fellows."</em></p>
<p><b>DCEG Fellows Monthly Colloquia<br /></b>The fellows&rsquo; colloquia series was created in the spring of 2004 to offer DCEG fellows the opportunity to gather on a regular basis for scientific and social exchanges. The colloquia were conceived as a forum for fellows to present their research in a relaxed, collegial atmosphere, to learn about the other fellows&rsquo; research, and to have featured presentations.</p>
<p>For onsite fellows, please see <a href="http://intranet.dceg.cancer.gov/fellows">intranet</a> for additional information.</p>
<h3 id="NIH">Trans-NIH Fellow-Initiated Activities</h3>
<p><b>Fellows Committe (FELCOM)<br /></b>Felcom serves the NIH fellows community through the actions of eight subcommittees and fourteen committee liaisons. The eight subcommittees that comprise FelCom were created to focus on particular aspects of the advanced training experience at NIH and include Career Development, Distinguished Clinical Teacher Award (DCTA), Fellows Award for Research Excellence (FARE), Job Fair, Mentoring, Publicity, Social, and Web page. <a href="https://www.training.nih.gov/felcom">Learn more about FELCOM</a></p>
<p><b>Annual NIH Career Symposium</b><br />The Annual NIH Career Symposium aims to highlight the diversity of career choices available to your generation of biomedical researchers. Whether you are a new graduate student, postdoc, or clinical fellow just beginning to consider career options or a senior student/fellow ready to look for a job, the NIH Career Symposium is for you. <a href="https://www.training.nih.gov/nih_career_symposium">Learn more about the NIH Career Symposium</a></p>
</div>]]></content>
  </row>
  <row para_id="302392" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<h3>Leukemia Risk in Chernobyl Clean-up Workers</h3>

<p>Following the accident at the Chernobyl nuclear power plant, hundreds of thousands of clean-up workers were exposed primarily to external radiation with those sent earliest receiving the highest doses. (140 mGy in 1986, 90 mGy in 1987 and 40 mGy in 1988-89). Studies of cancer among clean-up workers have focused on leukemia. Investigators in DCEG have conducted a case-control study of leukemia and other hematological diseases based on a large cohort of male clean-up workers from Ukraine (~110,000). Individual doses to the bone marrow were estimated using a new method developed for this study. In part because of the intriguing findings, the study has been extended to accrue cases for an additional five years.</p>

<h3>Leukemia Risk in Baltic Clean-up Workers</h3>

<p>In a separate study of cancer incidence among Chernobyl clean-up workers from Estonia and Latvia, DCEG investigators did not observe a significantly elevated risk of leukemia. Thyroid cancer was increased, but this appeared to be due largely to screening.</p>

<p>For more information on both studies, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349690" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349690" sys_dependentvariantid="1965" sys_relationshipid="7087200" sys_siteid="475" sys_variantid="1965" sys_contentid="349690">Kiyohiko Mabuchi</a>.</p>

<h4>Related Information</h4>

<ul>
<li><a href="http://chernobyl.cancer.gov/studies.html">Read about other Chernobyl accident studies</a></li>

<li><a href="http://chernobyl.cancer.gov/studies.html">Chernobyl studies fact sheets</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302397" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators are leading a multi-center international study of second primary gastrointestinal (GI) cancers among survivors of Hodgkin lymphoma and cancers of the testis, breast, and cervix. This is the first study to comprehensively investigate the radiation dose-response for upper GI cancers following fractionated, higher dose radiation exposures. It is also one of the few studies to investigate the risk of secondary, non-hematologic malignancies following treatment with&nbsp;chemotherapy.&nbsp;The primary aim of the study is to provide new information on the relation between radiation dose and cancer risk for three GI organs (stomach, esophagus, and pancreas), for which few quantitative data exist.&nbsp;</p>
<p>Four international population-based cohorts including over 900,000 1-year survivors of Hodgkin lymphoma and cancers of the testis, breast, and cervix were assembled. Analyses of these cohorts have newly quantified the age and temporal patterns of risk for subsequent cancer and non-cancer outcomes, and highlighted that many of the excess risks often persist for over 25 years following the first cancer diagnosis.</p>
<ul>
<li>Survivors of testicular cancer were demonstrated to have increased risk of mortality from infections, digestive diseases, and circulatory diseases when compared with the general population;</li>
<li>Survivors of both breast and cervical cancer experienced excess risks of subsequent cancer at least 25 years after diagnosis, particularly for women diagnosed at young ages;</li>
<li>In addition, breast cancer survivors had a higher risk of suicide than women in the general population;</li>
<li>Risk of solid cancers following Hodgkin lymphoma was&nbsp;strongly related to both young age at diagnosis and attained age, but did not appear to have changed over calendar time. In contrast, risk of acute myeloid leukemia following Hodgkin lymphoma decreased over time, likely due to changes in chemotherapy.</li>
</ul>
<p>Given the extensive nature of data collection required for a detailed evaluation of dose response relations for radiotherapy and chemotherapy, a nested-case control design was chosen to address this aim, resulting in a total of seven case-control studies. Analyses have demonstrated linear increase in risk associated with increasing radiation dose for stomach, pancreas, and esophagus cancers after Hodgkin lymphoma; stomach and pancreas cancers after testis cancer; esophagus cancer after breast cancer; and stomach cancer after cervical cancer.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349616" sys_dependentvariantid="1965" sys_relationshipid="7183454" sys_siteid="475" sys_variantid="1965">Lindsay Morton</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=51&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7183455" sys_siteid="475" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302400" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<p>The CARE Model is a SAS macro that allows researchers to estimate an African American woman's risk of developing invasive breast cancer. The CARE Model may be updated periodically as new data or research becomes available.&nbsp;</p>
<p>Users can enter data on risk factors and projection interval ages for a group of women, and the macro will return the corresponding absolute risk projections. This program may be useful for researchers who need risk projections for an entire study population.</p>
<p>The <a href="https://bcrisktool.cancer.gov/">NCI Breast Cancer Risk Assessment Tool</a> has been updated to include the CARE Model information. Both the tool and SAS macro are designed for use by health professionals and researchers.&nbsp;</p>
<p>If you are not a health professional, you are encouraged to discuss the results and your personal risk of breast cancer with your healthcare provider.</p>
<div>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=306402" sys_contentid="306402" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7391788" sys_dependentvariantid="1500" sys_dependentid="306402" rxinlineslot="103">ReadMe</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302572" sys_contentid="302572" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391787" sys_dependentvariantid="1418" sys_dependentid="302572" rxinlineslot="103">License Agreement</a></li>
</ul>
</div>
<h3>Download Software:&nbsp;</h3>
Download the zip file and unpack it an appropriate directory. The zip file contains ReadMe.pdf with further instructions.
<ul>
<li>Download the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=306401" sys_contentid="306401" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7391789" sys_dependentvariantid="1500" sys_dependentid="306401" rxinlineslot="103">AABrCa_RAM.zip</a> file and unpack it an appropriate directory.</li>
<li>Follow the instructions in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=306402" sys_contentid="306402" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7391790" sys_dependentvariantid="1500" sys_dependentid="306402" rxinlineslot="103">ReadMe</a> file.</li>
</ul>
<h3>Reference:</h3>
<p>Gail MH, Costantino JP, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18042936">Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women</a>.&nbsp;<em>J Natl Cancer Inst</em>&nbsp;2007 Nov 27; [Epub ahead of print].</p>
<h3>Support:</h3>
<p>Questions on statistical/medical issues? Contact: <a href="mailto:gailm@mail.nih.gov">Dr. Mitchell Gail</a></p>
<p>Questions on software issues? Contact: <a href="mailto:zhangf@imsweb.com">Fanni Zhang</a></p>
</div>
</div>]]></content>
  </row>
  <row para_id="302404" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Between 1945 and 1980, the U.S., the U.S.S.R., the U.K., France and China carried out more than 500 atmospheric tests of nuclear weapons totaling the explosive equivalent of 440 megatons of TNT. These tests injected radioactive material into the atmosphere, much of which became widely dispersed before being deposited as fallout. Cancer investigators have been studying the health effects of radiation for decades, including radioactive fallout, making radiation one of the best-understood agents of environmental injury. The legacy of open-air nuclear weapons testing includes a small but significant increase in thyroid cancer, leukemia, and certain solid tumors.</p>
<p>The NCI developed an <a href="https://radiationcalculators.cancer.gov/fallout">online calculator to estimate the radiation dose received by the thyroid gland from radionuclides in fallout from nuclear tests</a>. The early version of this tool estimated exposure and risk from fallout from the Nevada Test Site (NTS). In 2017, investigators released a new version of the tool that includes exposures from sites outside of the United States (global fallout). <a href="https://radiationcalculators.cancer.gov/fallout/update/">Read more about this and additional enhancements.</a></p>
<p>The calculator estimates an individual&rsquo;s risk of developing thyroid cancer from their exposure and provides an estimate of probability of causation, sometimes called assigned share (PC/AS) for individuals who have been diagnosed with thyroid cancer.</p>
<p>For more general information, read&nbsp;<a href="http://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/i-131#keyfacts">Get the Facts About Exposure to I-131 Radiation</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302405" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Getting Started</h3>
<p>Before applying for a fellowship in DCEG, take a look at what <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303774" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303774" sys_dependentvariantid="1418" sys_relationshipid="7310935" sys_siteid="475" sys_variantid="1418" sys_contentid="303774">our current fellows</a> are doing, and explore the training opportunities in our research areas.&nbsp;</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302518" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302518" sys_dependentvariantid="1418" sys_relationshipid="7310936" sys_siteid="475" sys_variantid="1418" sys_contentid="302518">Biostatistics</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302644" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302644" sys_dependentvariantid="1418" sys_relationshipid="7310937" sys_siteid="475" sys_variantid="1418" sys_contentid="302644">Clinical Genetics</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=981039" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="981039" sys_dependentvariantid="1418" sys_relationshipid="7310945" sys_siteid="475" sys_variantid="1418" sys_contentid="981039">Genetic Susceptibility</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302544" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302544" sys_dependentvariantid="1418" sys_relationshipid="7310938" sys_siteid="475" sys_variantid="1418" sys_contentid="302544">Infections and Immunoepidemology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=46&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302414" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302414" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7310946" sys_variantid="1418" sys_contentid="302414">Integrative Tumor Epidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033658" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1033658" sys_dependentvariantid="1418" sys_relationshipid="7310944" sys_siteid="475" sys_variantid="1418" sys_contentid="1033658">Metabolic Epidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302511" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302511" sys_dependentvariantid="1418" sys_relationshipid="7310939" sys_siteid="475" sys_variantid="1418" sys_contentid="302511">Occupational and Environmental Epidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302664" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302664" sys_dependentvariantid="1418" sys_relationshipid="7310940" sys_siteid="475" sys_variantid="1418" sys_contentid="302664">Radiation Epidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302498" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302498" sys_dependentvariantid="1418" sys_relationshipid="7310941" sys_siteid="475" sys_variantid="1418" sys_contentid="302498">Translational Genomics</a></li>
</ul>
<h3>How to Apply</h3>
<p>Fellowship applications are accepted on an ongoing basis for flexible start dates. To apply:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 1. &nbsp;Complete the online <a href="http://dceg2.cancer.gov/SumAppForm.html">Summary Application Form</a>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 2. &nbsp;Submit the following documents to <a href="mailto:ncidceged-r@mail.nih.gov">ncidceged-r@mail.nih.gov</a>:</p>
<ul class="bullet-blu">
<li style="list-style: none;">
<ul class="bullet-blu">
<li>Curriculum vitae (CV) and bibliography.</li>
<li>Cover letter describing areas of research interest.</li>
<li>Three letters of recommendation (Note: applicants may send referees' names initially, after which letters will be requested if interviewed. Letters may be sent via e-mail attachment.)</li>
</ul>
</li>
</ul>
<p>Once you submit your summary application form, cover letter, and CV, your summary application will be made available to Division investigators. You can obtain information about the program and access the summary application form on the Become a Fellow page.</p>
<h3>Approximate Timeline</h3>
<ul>
<li>Summary applications are circulated division-wide every 2-4 weeks</li>
<li>Investigators review summary applications for up to 2-3 weeks</li>
<li>If interested, the investigators will request that your letters of recommendation be sent and that an interview be scheduled.</li>
<li>Interviews are typically scheduled approximately 4-6 weeks after the application is circulated. An investigator may arrange to speak to an applicant and/or the referees by phone before determining whether to schedule a full interview.</li>
</ul>
<h3 id="Interview">Interview Process</h3>
<ul>
<li>Fellowship candidates may be asked to come to the division offices or laboratory to meet with investigators. Travel, one-night hotel accommodation, taxis, and meal expenses are covered for out-of-town applicants.</li>
<li>Postdoctoral applicants will be asked to give a talk (approximately 45 minutes with 15 minutes for discussion) on their current research and describe areas of interest for their future research.</li>
<li>Candidates may also meet with individual investigators and current fellows.</li>
<li>Decisions to make a fellowship offer are usually made within 2-3 weeks of the interview.
<ul>
<li>Offer letter, with the stipend level are sent to the candidate, via email.</li>
<li>Stipend levels are set under the Cancer Research Training Award policy, based on degrees and experience.</li>
</ul>
</li>
</ul>
<h3>Mentor and Research Topic Selection</h3>
<ul>
<li><b><i>Selecting a mentor</i></b> &ndash; To become a fellow, a mentoring match must be formed with a scientist who has mutual research interests, appropriate research data and projects, and has the time to mentor.</li>
<li><b><i>Explore research interests</i></b> &ndash; A list of current research for all division senior and tenure-track investigators, with a link to contact information, may be found on: <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?by=piinterest">Current Research &ndash; Principal Investigators</a>. Prospective fellows are encouraged to explore the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302557" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302557" sys_dependentvariantid="1422" sys_relationshipid="7310942" sys_siteid="475" sys_variantid="1422" sys_contentid="302557">DCEG web site</a> to learn about research being conducted.</li>
<li><b><i>Research mentoring</i></b> &ndash; Fellows have a primary mentor in their home branch. Once established, fellows may also work with secondary mentors in the branch or throughout the division on other projects of interest, at the discretion of the primary mentor. Some branches have mentoring committees for their fellows, comprised of 3-4 branch and division scientists to help guide the fellow&rsquo;s scientific and career progress.</li>
</ul>
<h3 id="Relocate">Relocating</h3>
<p>DCEG is close to all of the cultural and educational resources of the Washington, D.C. area. &nbsp;Our branch offices are located a few miles north of the main NIH campus in Rockville, Maryland and our laboratory is located in Gaithersburg, Maryland.&nbsp;</p>
<p>Important resources for relocating to the Washington, DC area:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302566" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302566" sys_dependentvariantid="1418" sys_relationshipid="7310934" sys_siteid="475" sys_variantid="1418" sys_contentid="302566">Local map</a> and directions to DCEG, NCI</li>
<li><a href="https://www.training.nih.gov/assets/Moving_Guide.pdf">Moving to the National Institutes of Health</a> (PDF)</li>
<li>NIH Fellowship Handbooks (see below)</li>
</ul>
<p>These publications offer valuable information about housing, banking, child care resources, and other information that is needed when settling into a new area and learning about NIH policies and procedures. The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302473" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302473" sys_dependentvariantid="1418" sys_relationshipid="7310933" sys_variantid="1418" sys_contentid="302473">Office of Training and Education</a> is happy to assist with any questions you may have about moving to the Washington D.C. metropolitan area.</p>
<!--
<div class="rxbodyfield">
<h3 id="housing">Housing Information</h3>

<p>Below are web sites which have information about available housing in the area.</p>

<p class="tight"><a href="http://www.training.nih.gov/handbook/housing.html">NIH Fellows Handbook - Housing Information</a></p>

<p class="tight"><a href="http://gazettenet.ca.kaango.com/">Montgomery County Gazette Classifieds</a><br />
Local county newspaper classified ads page with search capabilities for housing, employment, goods, and services.</p>

<p class="tight"><a href="http://www.dcregistry.com/classifieds/welcome.html">Washington, DC Registry</a><br />
The Washington, DC Registry is an Internet guide to the Washington, DC metropolitan area. It has a comprehensive directory listing of Washington, DC area web sites, including housing rental ads.</p>

<p class="tight"><a href="http://www.ishdc.org">International Student House</a> (For men and women. Students only.)<br />
1825 R St., N.W.<br />
Washington D.C., 20009<br />
(202)387-6445 or (202) 232-4007<br />
Fax: (202) 387-4115<br />
Metro: Dupont Circle - Red line</p>

<p class="tight"><a href="http://www.american.edu/ocl/housing/intern-housing.cfm">American University</a><br />
Phone: (202) 885- 2599 or (202) 885- 3370<br />
Email: <a href="mailto:summerhousing@american.edu">summerhousing@american.edu</a><br />
Metro: Tenleytown/ AU - Red line<br />
Open: Mid-May through mid-August</p>

<p class="tight"><a href="http://conferences.cua.edu/summer/housing.cfm">Catholic University</a><br />
Phone: (202) 319- 5277<br />
Email: <a href="mailto:cua-summer@cua.edu">cua-summer@cua.edu</a><br />
Metro: Brookland/CUA Red line<br />
Open: Mid May through mid-August</p>

<p class="tight"><a href="http://www.georgetown.edu/home/housing.html">Georgetown University</a><br />
Information about on- and off-campus housing.</p>

<p class="tight"><a href="http://gwired.gwu.edu/gwhousing/?url=gwhousing">George Washington University</a><br />
Phone: (202) 994- 9193<br />
Metro: Foggy Bottom Orange/Blue line<br />
Open: Early May through mid-August</p>

<p><a href="http://www.howard.edu/residencelife/">Howard University</a><br />
Phone: (202) 806- 5661<br />
Metro: Shaw/Howard - Green line<br />
Open: June 1 through July 31</p>

<p><a href="https://www.training.nih.gov/resources/justarrived">Summer Research Fellowship Program Catalog Living Arrangements</a><br />
This list is provided by the NIH Office of Education to summer students.</p>

<p><a href="http://www.tmhdc.org/Accommodations.html">Thompson-Markward Hall</a> (For women aged 18 - 35 yrs. Mostly students and interns.)<br />
235 2nd Street, N.E.<br />
Washington D.C., 20002<br />
(202) 546-3255 Metro: Union Station - Red line</p>
</div>

<p>&#160;</p>
-->
<h3>NIH Fellows Handbook</h3>
<p>The three handbooks below provide an introduction to NIH, an orientation to some area services, and information specific to your fellowship program.</p>
<ul>
<li><a href="https://www.training.nih.gov/assets/Postdoc_Handbook.pdf">The NIH Postdoc Handbook</a> (PDF) is for postdoctoral, clinical, and research fellows.</li>
<li><a href="https://www.training.nih.gov/assets/GPP_Handbook.pdf">The Graduate Partnerships Program Student Handbook</a> (PDF) has information specific for doctoral level fellows.</li>
<li><a href="https://www.training.nih.gov/assets/Postbac_Handbook.pdf">The NIH PostBac Handbook</a> (PDF) provides information for recent college graduates and masters level fellows.</li>
</ul>
<h3>Inquiries</h3>
<p>E-mail: <a href="mailto:ncidceged-r@mail.nih.gov">ncidceged-r@mail.nih.gov</a><br />Telephone: 240-276-7270</p>
</div>]]></content>
  </row>
  <row para_id="302406" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Breast Cancer with Mammographic Density Risk Assessment Macro</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The BrCa MD RAM may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302407" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p></p>
<p>Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302506" sys_dependentvariantid="1422" sys_relationshipid="7370911" sys_siteid="475" sys_variantid="1422">Integrative Tumor Epidemiology Branch</a> and learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=46&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302414" sys_contentid="302414" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302414" sys_dependentvariantid="1418" sys_relationshipid="7370912" sys_siteid="475" sys_variantid="1418">ITEB research training opportunities</a>.</p>
<h3><a id="Abubakar"></a>Mustapha Abubakar, M.D., Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101394" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370946">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101394&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Mustapha Abubakar, M.D., Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) as a postdoctoral fellow in June 2017. Dr. Abubakar earned his medical degree from Bayero University, Kano, Nigeria in 2006. He trained in general pathology from 2009-2011 in the Department of Pathology, Aminu Kano Teaching Hospital, Nigeria. In 2012, he received his M.Sc. in epidemiology from the Imperial College London, United Kingdom, and obtained his Ph.D. in molecular epidemiology from the University of London&rsquo;s Institute of Cancer Research (ICR), London in 2017. During his doctoral studies, Dr. Abubakar worked under the direction of Professors Montserrat Garc&iacute;a-Closas, Anthony Swerdlow, and Mitch Dowsett to develop a digital pathology protocol for the high-throughput scoring of KI67 in breast cancer tissue microarrays and investigate etiological and prognostic heterogeneity among breast cancer subtypes defined by KI67 and other immunohistochemical markers. In DCEG, he is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/gierach-gretchen">Gretchen Gierach, Ph.D., M.P.H.</a>, senior investigator, Metabolic Epidemiology Branch, to conduct molecular epidemiological studies that evaluate the relationship between histopathological characteristics of breast tissues with radiologically determined mammographic density and breast cancer risk. He is also working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/garcia-closas-montserrat">Montserrat Garc&iacute;a-Closas, M.D., Dr.P.H.</a>, Deputy Director, DCEG, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/yang-rose">Xiaohong Rose Yang, Ph.D., M.P.H.</a>, senior investigator ITEB, to conduct molecular epidemiological studies of breast cancer subtypes in different populations.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Abubakar%2C%20Mustapha%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications&nbsp;- Mustapha Abubakar</a></p>
<h3><a id="Jia"></a>Mengmeng Jia, M.D. &ndash; Predoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1135864" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370947">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1135864&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Mengmeng Jia, M.D., joined the Integrative Tumor Epidemiology Branch (ITEB) as a predoctoral fellow in October 2018. Dr. Jia earned her M.D. in preventive medicine from Shanghai Jiao Tong University, China, in 2015. She is currently pursuing her Ph.D. in cancer epidemiology at the Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Jia&rsquo;s research focuses on the screening and early detection of breast cancer and evaluation of different screening modalities, especially in resource-limited areas.</p>
<p>Dr. Jia works with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/gierach-gretchen">Gretchen Gierach, Ph.D., M.P.H.</a>, Deputy Director, ITEB, to conduct molecular epidemiologic studies of breast density and breast cancer.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/mengmeng.jia.1/bibliography/57000824/public/?sort=date&amp;direction=descending">Scientific Publications - Mengmeng Jia</a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Kebede"></a>Michael Kebede B.S. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1133133" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370948">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133133&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Michael Kebede, B.S, joined the Integrative Tumor Epidemiology Branch (ITEB) in September 2018 as a postbaccalaureate fellow, while pursuing an M.P.H. in epidemiology from George Washington University (GWU), Washington, DC. Prior joining ITEB, Mr. Kebede graduated from GWU in 2017 with a bachelor&rsquo;s degree in exercise science with a pre-med concentration. While earning his M.P.H., he previously worked as a departmental graduate teaching assistant for the GWU Exercise and Nutrition Science department, where he taught anatomy and physiology in a laboratory and nutrition science. More recently, he worked as a summer intern in the Clinical Genetics Branch (CGB) with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/gadalla-shahinaz">Shahinaz Gadalla, M.D., Ph.D.,</a> investigator, and <a href="https://dceg.cancer.gov/fellowship-training/what-our-fellows-do/meet-current-fellows/cgb-fellows">Rotana Alsaggaf, Ph.D., M.S.,</a> postdoctoral fellow, on a study of myotonic dystrophy and cancer&mdash;work that he is continuing for his master&rsquo;s thesis. Following this, he spent one month at the World Health Organization completing an influenza surveillance internship for which he was selected.<span>&nbsp;</span>&nbsp;In ITEB, he is working under the mentorship of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/landi-maria">Maria Tere Landi, M.D., Ph.D.</a><u>,</u> senior investigator, studying the etiology and epidemiology of lung cancer in never smokers. Mr. Kebede&rsquo;s primary research interests include the epidemiology and quantitative analysis of chronic diseases including cancer.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Kebede%2C%20Michael%20A%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications &ndash; Michael Kebede</a></p>
<h3><strong><a id="Lin"></a>Shu-Hong Lin, Ph.D., M.S. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1144400" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370949">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1144400&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Shu-Hong Lin, Ph.D., M.S., joined the Integrative Tumor Epidemiology Branch (ITEB) as a postdoctoral fellow in January 2018. He earned his bachelor&rsquo;s degree in veterinary medicine from National Taiwan University in 2005 and received an M.S. degree in veterinary biosciences from the Ohio State University in 2012. In 2018, he graduated with a Ph.D. in cancer biology with an area of concentration in biostatistics, bioinformatics and systems biology from the University of Texas Graduate School of Biomedical Sciences. Dr. Lin's doctoral research focused on identifying genomic and transcriptomic markers related to tumor progression in colorectal adenomas using next-generation sequencing. He also studied circulating biomarkers predictive of outcomes in non-invasive bladder cancer. In DCEG, he works with&nbsp;<a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/machiela-mitchell">Mitchell&nbsp;Machiela, Sc.D., M.P.H.</a>, Earl Stadtman Tenure-Track Investigator, ITEB, to explore associations among genetic mosaicism, environmental factors, and cancer risk.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/57973971/">Scientific Publications &ndash; Shu-Hong Lin</a></p>
<h3><a id="Davis-Lynn"></a>Brittny Davis Lynn, Ph.D., M.P.H. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1067281" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370950">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="Brittny Davis Lynn, postdoctoral fellow" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1067281&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Brittny Davis Lynn, Ph.D., MPH joined the Division of Cancer Epidemiology and Genetics (DCEG) as an NCI Cancer Prevention Fellow in September 2016.&nbsp; Dr. Davis Lynn earned her B.S. in chemistry from Jackson State University in 2009, and completed her Ph.D. in computational chemistry at the University of Maryland, Baltimore County, in 2015. Dr. Davis Lynn received a Ruth L. Kirschstein National Research Service Award (NRSA, F-31) for her dissertation work, which investigated the molecular origins of allostery for the RNA Polymerase from the hepatitis C virus via computational methods. As part of the Cancer Prevention Fellowship, Dr. Davis Lynn completed her M.P.H. at Johns Hopkins Bloomberg School of Public Health in May 2016. Since her arrival at NCI, Dr. Davis Lynn has searched for creative ways to merge her background in computational chemistry with her interests in descriptive and molecular epidemiology, with a focus on breast cancer prevention, racial and geographic disparities, and risk prediction. In the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=103&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302407" sys_contentid="302407" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302407" sys_dependentvariantid="1418" sys_relationshipid="7370915" sys_siteid="475" sys_variantid="1418">Integrative Tumor Epidemiology Branch</a>, Dr. Davis Lynn works with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349652" sys_dependentvariantid="1965" sys_relationshipid="7370916" sys_siteid="475" sys_variantid="1965">Gretchen Gierach, Ph.D.</a>, senior investigator, performing molecular epidemiologic studies of breast cancer.</p>
<p><a href="&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pubmed?term=Davis%2C%20Brittny%5bFull%20Author%20Name%5d&amp;amp;cmd=DetailsSearch&quot;&gt;">Scientific Publications &ndash; Brittny Davis Lynn</a></p>
<h3><strong><a id="Pal_Choudhury"></a>Parichoy Pal Choudhury, Ph.D. &ndash; Research Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1147798" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370951">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1147798&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Parichoy Pal Choudhury, Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) and the Biostatistics Branch (BB) of DCEG as a research fellow in 2019. He earned his bachelor and master degrees in statistics from the Indian Statistical Institute (2008 and 2010, respectively) and a Ph.D. in biostatistics from the Johns Hopkins Bloomberg School of Public Health in 2016. Dr. Pal Choudhury&rsquo;s doctoral research focused on scientific and etiological questions using multiple data sources in scenarios where a single data source does not suffice. He continued his postdoctoral research with Dr. Nilanjan Chatterjee at Johns Hopkins, with a major focus on developing methods and software for independent validation of risk prediction models in prospective cohort studies that employ complex two-phase sampling. In DCEG, Dr. Pal Choudhury continues his research on risk prediction methods&mdash;specifically, studying the heterogeneity of risk factor associations across breast cancer subtypes and developing and validating subtype specific risk prediction models among women of both European and non-European ancestries. He is working under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" sys_contentid="1004366" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1004366" sys_dependentvariantid="1965" sys_relationshipid="7370919" sys_siteid="475" sys_variantid="1965">Montserrat Garc&iacute;a-Closas, M.D., Dr.P.H., DCEG Deputy Director and ITEB Acting Chief</a>. He is also working on developing and validating models for predicting risk of mortality using data from the NIH-AARP Diet and Health Study and the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial.</p>
<h3><a id="Yepes-Torres"></a>Sally Lilian Yepes Torres, Ph.D., M.Sc. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1133134" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370952">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133134&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Sally Yepes, M.Sc., Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) and the Clinical Genetics Branch (CGB) as a postdoctoral fellow in May 2018. Dr. Yepes has a B.S. in biology, an M.Sc. in human genetics; she received her Ph.D. in biology in 2016 from the Universidad de los Andes in Bogot&aacute;, Colombia. Her research interests focus on cancer genomics, in particular on the generation of knowledge from a data-driven perspective, and application of methodological frameworks from the statistical genomics, bioinformatics and elements of systems biology. In DCEG, she is working under the mentorship of&nbsp;&nbsp;<a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/yang-rose">Xiaohong Rose Yang, Ph.D., M.P.H.</a>, senior investigator, ITEB, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/goldstein-alisa">Alisa Goldstein, Ph.D.</a>, senior investigator, CGB, to identify and further investigate cancer susceptibility genes in familial melanoma and chordoma using integrative analyses of next-generation sequencing and other &lsquo;omics data.</p>
<h3><a id="Zhang"></a>Haoyu Zhang, B.S. &ndash; Predoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1111026" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370953">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1111026&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Haoyu Zhang, B.S., joined the Integrative Tumor Epidemiology Branch (ITEB) as a predoctoral fellow in July 2017. Mr. Zhang earned his B.S. in mathematics from Zhejiang University, China, in 2014 and is currently pursuing his Ph.D. in biostatistics at the Johns Hopkins Bloomberg School of Public Health. He is doing his doctoral dissertation research jointly with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" sys_contentid="1004366" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1004366" sys_dependentvariantid="1965" sys_relationshipid="7370913" sys_siteid="475" sys_variantid="1965">Montserrat Garc&iacute;a-Closas, M.D., Dr.P.H</a>., Deputy Director, DCEG, and Acting Chief, ITEB, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349625" sys_contentid="349625" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349625" sys_dependentvariantid="1965" sys_relationshipid="7370914" sys_siteid="475" sys_variantid="1965">Nilanjan Chatterjee, Ph.D.</a>, Bloomberg Distinguished Professor at the Bloomberg School. Mr. Zhang&rsquo;s research is focused on methods for genetic association testing and polygenetic models utilizing multivariate tumor characteristics for breast cancer. His ultimate goals are to improve breast cancer risk assessment, improve decision making for targeted screening, and develop strategies for personalized breast cancer prevention.</p>
<h3><strong><a id="Zhao"></a>Wei Zhao, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1146741" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370954">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1146741&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Wei Zhao, Ph.D., joined the&nbsp;Integrative Tumor Epidemiology Branch (ITEB) as a postdoctoral fellow in November 2018. Dr. Zhao earned her Ph.D. in bioinformatics from the University of North Carolina at Chapel Hill under the supervision of Dr. Chuck Perou in 2014. Her doctoral research focused on characterization of the genomic and clinical heterogeneity of breast cancer subtypes using deep- sequencing and microarray. Prior to joining NCI, Dr. Zhao conducted postdoctoral training in the Department of Systems Biology in MD Anderson Cancer Center for four years. Working with Dr. Gordon Mills and Dr. Han Liang, she identified predictive molecular markers and drug targets for rational combinatorial therapy in gynecologic cancers, and developed computational tools for analysis of proteomic data. In ITEB, Dr. Zhao is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/landi-maria">Maria Teresa Landi, Ph.D., M.D.</a>, senior investigator, to investigate the etiology and progression of lung cancer in never smokers through a comprehensive genomic analysis and clinical and epidemiologic assessment.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/1p5vZIS5nx5Aq/bibliography/public/ ">Scientific publication -Wei Zhao</a></p>
<p></p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/psx_cegenGeneral/genGeneral.html?sys_revision=64&amp;sys_contentid=302407&amp;sys_command=edit&amp;sys_pageid=0&amp;sys_view=sys_All#top">Back to Top</a></p>
<p>Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=46&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302414" sys_contentid="302414" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302414" sys_dependentvariantid="1418" sys_relationshipid="7370917" sys_siteid="475" sys_variantid="1418">research training opportunities</a> in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302506" sys_dependentvariantid="1422" sys_relationshipid="7370918" sys_siteid="475" sys_variantid="1422"> Integrative Tumor Epidemiology Branch</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302408" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p><b>This is a trial version of the software</b>. The blm - R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302410" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Esophageal and gastric cancers together cause over 1,000,000 deaths each year. Because these upper gastrointestinal (UGI) cancers have very poor prognoses, discovering etiologic agents and improving methods of early detection for these cancers are of prime importance.</p>
<p>The overriding goal of the DCEG UGI Cancer Research Group is to foster the exchange of ideas and expertise on UGI cancers among investigators from DCEG, NCI, and the extramural community. Additionally, this exchange of ideas and expertise will enhance use of our existing research resources and more thoughtful conceptualization and execution of future research. This working group also serves as a magnet for the recruitment and training of junior investigators interested in UGI cancer research.</p>
<h2>Objectives</h2>
<ol>
<li>Promote the exchange of ideas and expertise on UGI cancers within DCEG and among other NCI and extramural researchers in the field</li>
<li>Discuss research priorities in UGI cancer research</li>
<li>Organize, coordinate, and optimize the use of UGI cancer research resources in DCEG</li>
<li>Identify and explore unique opportunities afforded by DCEG resources (e.g., large sample sizes for UGI cancers to study rare exposures and gene-environment interactions)</li>
<li>Recruit outstanding junior investigators and fellows to conduct research in UGI cancer</li>
</ol>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1033924" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033924" sys_dependentvariantid="1965" sys_relationshipid="7270552" sys_variantid="1965" sys_contentid="1033924">Gwen A. Murphy, Ph.D., M.P.H.</a>, or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349612" sys_dependentvariantid="1965" sys_relationshipid="7270553" sys_variantid="1965" sys_contentid="349612">Christian C. Abnet, Ph.D., M.P.H.</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033621" sys_dependentvariantid="1418" sys_relationshipid="7270554" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302412" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Colon Cancer Risk Assessment Tool Gauss Program License Agreement</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The CCRAT Gauss Program may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302414" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-hgp/iteb">ITEB Home</a></h3>
<p><a title="" href="/about/organization/programs-hgp/iteb/research">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=ITEB">ITEB Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/ITEB-fellows">Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/iteb-training">Research Training Opportunities</a></p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ITEB">Publications</a></p>
</div>
<h3 id="Overview">Overview</h3>
<p>The goals of the&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7391598" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103">Integrative&nbsp;Tumor Epidemiology Branch&nbsp;(ITEB)</a> are to advance understanding of cancer etiology and progression through integrative analyses of environmental and germline risk factors with comprehensive data on histological and molecular profiling of tumors and their precursors, including somatic genomic analyses. The branch also develops methods to support this cutting-edge research.</p>
<p>ITEB&nbsp;provides an exciting and collaborative environment which offers extraordinary opportunities for young scientists embarking on research careers. New fellows are matched with mentors who work with them to develop a research training program and guide them through the training experience. Fellows also work with other researchers in the Branch and Division on a variety of projects. Fellows work on interdisciplinary and/or multicenter collaborations, conduct studies on their own, participate in all Branch activities, and attend scientific meetings.</p>
<p>Our fellows gain experience in all aspects of research including protocol development, feasibility studies, data collection, and data analysis. Taking course work and participating in workshops to broaden knowledge in areas related to fellows' research endeavors is encouraged and supported. Clinically-trained fellows may rotate through the Branch's Cancer Genetics Clinic to gain practical knowledge in the conduct of clinical studies. Laboratory-trained fellows may conduct part of their research in the Branch's Molecular Epidemiology Laboratory Unit.</p>
<p>For application details, see below. To discuss potential research opportunities, you may contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=GEB">branch investigators</a> directly. Meet current fellows in the&nbsp;Integrative Tumor&nbsp;Epidemiology Branch<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=104&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302407" sys_contentid="302407" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391591" sys_dependentvariantid="1418" sys_dependentid="302407" rxinlineslot="103">.</a></p>
<h3 id="Qualifications">Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Individuals must hold an M.D. or Ph.D. in epidemiology, genetic epidemiology, statistical genetics, genetics, biostatistics, human or molecular genetics, clinical cancer genetics, or public health.</p>
<p><i>Predoctoral fellowships:</i> Individuals must be enrolled in a doctoral program with a desire to complete their dissertation in the Branch or have completed a master's degree in a field of relevance to the Branch.</p>
<h3 id="Application-Process">Application Process</h3>
<p>Predoctoral and postdoctoral fellowship applications in the branch are accepted on an ongoing basis. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391592" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103">Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3><a id="Specific-Investigators"></a>Selected Research Opportunities with Specific Investigators</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=906271#Machiela" sys_contentid="906271#machiela" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391595" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="906271" rxinlineslot="103">Genetic Epidemiology of Cancer - Postdoctoral Fellowship</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=906271#Landi" sys_contentid="906271#landi" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391596" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="906271" rxinlineslot="103">Studies of Lung Cancer, Melanoma, and Kidney Cancer using Genomic Data - Postdoctoral Fellowship</a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=906271" sys_contentid="906271" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391594" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="906271" rxinlineslot="103"> </a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=906271#Yang" sys_contentid="906271#yang" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391597" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="906271" rxinlineslot="103">Integrating Genomic and Epidemiological Data to Understand Breast Cancer Etiology - Postdoctoral Fellowship</a></li>
<li>Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=906271" sys_contentid="906271" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7391593" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="906271" rxinlineslot="103">Selected Research Opportunities with Specific Investigators</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302415" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=114&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312436" sys_variantid="1422" sys_contentid="302459">About REB</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312437" sys_variantid="1418" sys_contentid="401127">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">REB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=261&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302501" sys_dependentvariantid="1418" sys_dependentid="302501" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312438" sys_variantid="1418" sys_contentid="302501">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-training" title="">Research Training Opportunities</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302415" sys_dependentvariantid="1418" sys_dependentid="302415" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312439" sys_variantid="1418" sys_contentid="302415">Tenure-Track Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302426" sys_dependentvariantid="1418" sys_dependentid="302426" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312440" sys_variantid="1418" sys_contentid="302426">Staff Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302443" sys_dependentvariantid="1418" sys_dependentid="302443" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312441" sys_variantid="1418" sys_contentid="302443">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=REB">Publications</a></p>
</div>
<h3>Elizabeth Cahoon</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_relationshipid="7312432" sys_variantid="1965" sys_dependentid="1087122" rxinlineslot="103" sys_dependentvariantid="1965" sys_siteid="475">Elizabeth Cahoon, Ph.D.</a>, studies <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=826431" sys_contentid="826431" inlinetype="rxhyperlink" sys_relationshipid="7312434" sys_variantid="1418" sys_dependentid="826431" rxinlineslot="103" sys_dependentvariantid="1418" sys_siteid="475">cancer and precancer risks conferred by environmental sources of ultraviolet (UV) radiation</a> and ionizing radiation exposure. Her research currently focuses on the influence of external factors, such as photosensitizing medications, to skin sensitivity to sunlight. In a nationwide occupational cohort of U.S. radiological technologists, Dr. Cahoon found significantly increased risks of basal cell carcinoma for several photosensitizing agents, including prescription diuretics and menopausal hormone therapy. She has initiated several studies of photosensitizing medications in relation to melanoma in the NIH-AARP cohort and keratinocyte carcinomas in Medicare. She is also evaluating the UV radiation dose-response relationship for skin cancer risks by wavelength, age at exposure, and anatomic site.</p>
<div sys_dependentvariantid="2088" sys_dependentid="1089396" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7312443">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302161&amp;sys_siteid=475&amp;sys_contentid=1089396&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Dr. Cahoon also investigates whether ionizing radiation in environmentally exposed populations is related to several outcomes that have been little studied (e.g., precancers, histological subtypes) and whether radiation-related risks are modified by factors for which there are limited data (e.g., age at exposure). Part of this effort involves the assessment of radiation-related risk for various cancers in the Lifespan Study of Japanese atomic bomb survivors. Through a collaboration with the National Research Centre for Radiation Medicine in Ukraine, she is also leading a thyroid cancer case-control study nested in a cohort of emergency clean-up workers who were exposed to a wide range of external radiation doses at the Chernobyl nuclear plant.</p>
<p>Dr. Cahoon received her B.S.E. in bioengineering from the University of Pennsylvania, S.M. from the Engineering Systems Division at MIT, and M.H.S. in biostatistics and Ph.D. in environmental epidemiology from the Johns Hopkins Bloomberg School of Public Health. She conducted her postdoctoral work in REB and was promoted to research fellow in 2014. In early 2017, Dr. Cahoon was selected through a highly competitive process at NIH as an <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=52&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302437" sys_contentid="302437" inlinetype="rxhyperlink" sys_relationshipid="7312433" sys_variantid="1418" sys_dependentid="302437" rxinlineslot="103" sys_dependentvariantid="1418" sys_siteid="475">Earl Stadtman Tenure-track Investigator</a>, an extremely prestigious distinction for her innovative approach to epidemiologic research in environmental radiation.</p>
</div>]]></content>
  </row>
  <row para_id="302417" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p id="top">Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7390475" sys_siteid="475">Clinical Genetics Branch</a> and learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302644" sys_contentid="302644" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302644" sys_dependentvariantid="1418" sys_relationshipid="7390476" sys_siteid="475">current research training opportunities</a>.</p>
<h3><strong><a id="Alsaggaf"></a>Rotana Alsaggaf, Ph.D., M.S. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1074351" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390521">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1074351&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Rotana Alsaggaf, Ph.D., M.S., became a&nbsp;postdoctoral fellow at the Clinical Genetics Branch (CGB) in June 2018. Dr. Alsaggaf&nbsp;earned a B.S. in biological science with an interdisciplinary certificate in biomedical engineering from Colorado State University in 2009, an M.S. in epidemiology and preventive medicine with a concentration in human genetics in 2015 and a Ph.D. in epidemiology in 2018&mdash;both from the University of Maryland, Baltimore. As a predoctoral fellow&nbsp;under the mentorship of&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349606" sys_contentid="349606" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349606" sys_dependentvariantid="1965" sys_relationshipid="7390486" sys_siteid="475">Shahinaz Gadalla, M.D, Ph.D.</a>, she conducted her doctoral research utilizing the United Kingdom Clinical Practice Research Datalink to evaluate the risk of benign and malignant tumors in patients with myotonic dystrophy type I and explore factors associated with their development. As a postdoctoral fellow, Dr. Alsaggaf continues to work with Dr. Gadalla on epidemiological and molecular analyses to inform cancer predisposition in myotonic dystrophy, and to study the role of telomere biology in cancer susceptibility.</p>
<p>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Alsaggaf%2C%20Rotana[Full%20Author%20Name]&amp;cmd=DetailsSearch ">Scientific Publications &ndash; Rotana Alsaggaf</a></p>
<h3><a id="de Andrade"></a>Kelvin C. de Andrade, Ph.D., M.Sc. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1074270" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390522">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1074270&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Kelvin C&eacute;sar de Andrade became a postdoctoral fellow in the Clinical Genetics Branch (CGB) after successfully defending his doctoral dissertation in May 2018. He first joined the branch in March 2015, while a student at&nbsp;the A.C. Camargo Cancer Center, S&atilde;o Paulo, Brazil, to complete the research component of his master's degree. As a postdoctoral fellow under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_contentid="349621" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349621" sys_dependentvariantid="1965" sys_relationshipid="7390487" sys_siteid="475">Sharon Savage, M.D.</a>, Chief of CGB, Dr. de Andrade continues to study genetic and behavioral factors that could be associated with cancer risk, progression, and phenotypic variability in Li-Fraumeni Syndrome patients.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=De%20Andrade%2C%20Kelvin%20Cesar%5bFull%20Author%20Name%5d&amp;cmd=DetailsSearch">Scientific Publications &ndash; Kelvin C&eacute;sar de Andrade<br /></a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Clarke"></a></strong><strong>Megan Clarke, Ph.D., M.H.S &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1067259" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390523">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1067259&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Megan Clarke, Ph.D., M.H.S., joined the Clinical Genetics Branch (CGB) as an NCI Cancer Prevention Fellow in September 2016. Dr. Clarke earned an M.H.S. in biochemistry and molecular biology in 2010 and a Ph.D. in epidemiology in 2016, both from the Johns Hopkins Bloomberg School of Public Health. Prior to completing her Ph.D., Dr. Clarke was a postbaccalaureate fellow in CGB working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349609" sys_dependentvariantid="1965" sys_relationshipid="7390480" sys_siteid="475">Mark Schiffman, M.D., M.P.H.</a>, senior investigator, on human papillomavirus (HPV) molecular epidemiology and natural history studies. For her doctoral dissertation, Dr. Clarke analyzed electronic medical records to explore patient and provider factors related to HPV vaccine initiation and completion. She also pursued her interests in obesity and molecular epidemiology by investigating the influence of maternal body mass index and weight gain on cord blood DNA methylation patterns in genes related to cancer and obesity. Under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349668" sys_dependentvariantid="1965" sys_relationshipid="7390481" sys_siteid="475">Nicolas Wentzensen, M.D., Ph.D.</a>, Deputy Chief and senior investigator, CGB, Dr. Clarke works on molecular epidemiologic studies of gynecological cancers, with a particular focus on etiologic biomarkers that have a high potential for improving early detection and risk stratification.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=%22Clarke%2C%20Megan%20A%22[Full%20Author%20Name]%20OR%2024275260[uid]%20OR%2023093560[uid]%20NOT%2024275260[uid]&amp;cmd=DetailsSearch">Scientific Publications &ndash; Megan Clarke</a></p>
<h3><a id="Demarco"></a>Maria Demarco, Ph.D., M.P.H. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1067280" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390524">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1067280&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Maria Demarco, Ph.D., M.P.H., started her postdoctoral fellowship at the Clinical Genetics Branch (CGB) in May 2017. She joined the branch as a predoctoral fellow in September 2015, while working on her Ph.D. in epidemiology at the University of Maryland. Her main research interest is translational epidemiology, particularly focused on cancer screening and prevention. As a predoctoral fellow, Maria Demarco worked under the mentorship of &nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349609" sys_dependentvariantid="1965" sys_relationshipid="7390482" sys_siteid="475">Mark Schiffman, M.D., M.P.H</a>, senior investigator, CGB, and Sam Mbulaiteye, M.D., senior investigator, Infections and Immunoepidemiology Branch, to study: (1) the high prevalence of HPV in sub-Saharan (Nigerian) older women, and (2) viral and behavioral co-factors of HPV progression to precancer with clinical implications in risk stratification. As a postdoctoral fellow Dr. Demarco continues to work with Dr. Schiffman on risk estimates and analyses to inform US cervical cancer screening guidelines.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=demarco%20m&amp;authorOption=exact&amp;pi=0013465521">Scientific Publications &ndash; Maria Demarco</a></p>
<h3><a id="Gianferante"></a>Matthew Gianferante, M.D. - Clinical Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1027734" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390525">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1027734&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Matthew Gianferante, M.D., joined the DCEG, as a postdoctoral clinical fellow.&nbsp; Dr. Gianferante obtained his M.D. at the Uniformed Service University in 2011 and completed his pediatric residency at Tufts Floating Hospital for Children in 2014. Dr. Gianferante is a Pediatric Hematology Oncology Clinical Fellow at Walter Reed National Military Medical Center, and an officer in the United States Public Health Service. He joins the division for the final two years of his clinical fellowship to study pediatric cancer genetic etiology. In the Clinical Genetics Branch (CGB), Dr. Gianferante will be working with <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592">Dr. Lisa Mirabello</a> and <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621">Dr. Sharon Savage</a> to investigate the disease-associated mutations in nevoid basal cell carcinoma syndrome families and pediatric medulloblastoma trios using whole-exome sequencing data.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gianferante%2C%20Matthew%22%5bFull%20Author%20Name%5d%20OR%20%22Gianferante%20M%22%5bAuthor%5d&amp;cmd=DetailsSearch">Scientific Publications - Matthew Gianferante</a></p>
<h3><strong>&nbsp;</strong></h3>
<h3><a id="Irvin"></a>Sarah Irvin, M.S. - Predoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1111771" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390526">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="portrait of Sarah Irvin" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1111771&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Sarah Irvin, M.S., joined the Clinical Genetics Branch (CGB) in November 2017 as a predoctoral fellow. Ms. Irvin earned her M.S. in epidemiology from the Harvard T.H. Chan School of Public Health, with a concentration in cancer epidemiology. Prior to joining NCI, Sarah worked as a consultant in the field of pharmacoepidemiology, and interned at Bayer AG in Berlin, Germany. Ms. Irvin is working under the direction of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349668" sys_dependentvariantid="1965" sys_relationshipid="7390485" sys_siteid="475">Dr. Nicolas Wentzensen </a>on projects investigating immune markers in cervical cancer development and the risk of ovarian cancer by subtype after exposure to multiple inflammatory exposures.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><a id="Kim"></a>Jung Kim, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1074269" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390527">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1074269&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Jung Kim, Ph.D., joined the Clinical Genetics Branch (CGB) as a postdoctoral fellow in October 2016. Dr. Kim earned her Ph.D. in cancer biology from the Driskill Graduate Program in Life Sciences at Northwestern University in 2015, after which she completed a one-year postdoctoral fellowship working with Dr. Jindan Yu. Her doctoral and postdoctoral research focused on the transcriptional regulation of key signaling pathways in prostate cancer, including miRNA and epigenetic regulators. In DCEG, she is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349631" sys_contentid="349631" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349631" sys_dependentvariantid="1965" sys_relationshipid="7390483" sys_siteid="475">Douglas Stewart, M.D.</a>, investigator, CGB, to study the population genetics and phenotype of <em>DICER1</em> and associated miRNA processing genes, and to analyze somatic genomic data of <em>DICER1</em>-associated malignancies.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1lSPABzm-sm5S/bibliography/43517396/public/?sort=date&amp;direction=descending">Scientific Publications - Jung Kim</a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><a id="Litwin"></a>Tamara Litwin, Ph.D., M.P.H. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1065615" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390528">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1065615&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Tamara Litwin, Ph.D., M.P.H., joined the Clinical Genetics Branch (CGB) as a Cancer Prevention Fellow in September 2016. &nbsp;Dr. Litwin earned her Ph.D. in biological sciences in 2014 from the University of Cambridge through the NIH-Oxford-Cambridge Scholars Program.&nbsp; She then went on to earn her M.P.H. with a concentration in epidemiology and biostatistics from the Johns Hopkins Bloomberg School of Public Health in 2016. For her doctoral research, performed at the National Heart, Lung, and Blood Institute and with the United Kingdom Medical Research Council&rsquo;s Mitochondrial Biology Unit, Dr. Litwin used biophysical methods to investigate how DNA topology affects DNA interactions with topoisomerases and other DNA binding proteins. &nbsp;Dr. Litwin&rsquo;s research interests include the discovery and translation of biomarkers for risk prediction, prevention, and early detection of gynecologic cancers. &nbsp;She is working with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/wentzensen-nicolas">Nicolas Wentzensen, M.D., Ph.D.,</a> Deputy Chief and senior investigator, CGB, on projects related to the molecular epidemiology of gynecologic cancers.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Litwin%20TR%5bAuthor%5d&amp;cmd=DetailsSearch">Scientific Publications &ndash; Tamara Litwin</a></p>
<h3><a id="McReynolds"></a>Lisa J. McReynolds, M.D., Ph.D. &ndash; Clinical Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1064688" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390529">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1064688&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Lisa J. McReynolds, M.D., Ph.D., joined the Clinical Genetics Branch (CGB) in August 2016. She earned her M.D. and her Ph.D. at Albert Einstein College of Medicine as a Rudin Scholar in the Medical Scientist Training Program (2009). &nbsp;She completed her dissertation work in the laboratory of Todd Evans, Ph.D., focusing on Smad signaling in a zebrafish model of hematopoiesis. &nbsp;She completed a residency in pediatrics at Morgan Stanley Children&rsquo;s Hospital of New York-Presbyterian Columbia University Medical Center in 2012, and a fellowship in Pediatric Hematology-Oncology in the combined NCI-Johns Hopkins University program in 2016. During her clinical fellowship, Dr. McReynolds developed expertise in GATA2-deficiency, an inherited primary immunodeficiency disorder associated with very high rates of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), under the mentorship of Steven Holland, M.D., National Institute of Allergy and Infectious Diseases. She is working under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_contentid="349621" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349621" sys_dependentvariantid="1965" sys_relationshipid="7390479" sys_siteid="475">Sharon A. Savage</a>, M.D., Chief and senior investigator, CGB, on the inherited bone marrow failure study. She is focused on gene discovery and genome characterization in marrow failure patients.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=McReynolds%20LJ%5bAuthor%5d&amp;cmd=DetailsSearch">Scientific Publications &ndash; Lisa McReynolds</a></p>
<h3><strong><a id="Oba"></a>Leatrisse Oba, M.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1111027" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390530">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1111027&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Leatrisse Oba, M.D., joined the Clinical Genetics Branch (CGB) as a postdoctoral fellow in March 2018. Dr. Oba earned her M.D. from the University of Brasilia, Brazil in 2001, and worked in clinical research for four years. She completed her residency in pediatrics in 2009 at Asa Sul&rsquo;s Regional Hospital, FEPECS, Bras&iacute;lia, Brazil. After her residency, she worked as a pediatrician and a clinical assistant in the Emergency department, collaborating with the Pediatrics Residency Program at the University Hospital of Brasilia and Asa Sul&rsquo;s Regional Hospital, Brazil. Dr. Oba first joined CGB as a special volunteer in December 2016, working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/achatz-maria-isabel">Maria Isabel Achatz, M.D., Ph.D.</a>, adjunct investigator, and <a href="http://dceg.cancer.gov/fellowship-training/fellowship-program/meet-current-fellows/cgb-fellows#Khincha">Payal Khincha, M.D., M.B.B.S.</a>, staff clinician, on a collaborative project evaluating the effect of cancer treatment on the development of subsequent cancers in Li-Fraumeni syndrome (LFS) patients. As a postdoctoral fellow, Dr. Oba is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/savage-sharon">Sharon A. Savage, M.D.</a>, Chief and senior investigator, CGB, and Dr. Khincha, continuing the study of radiotherapy and chemotherapy effects on LFS patients, as well as researching screening exam findings on LFS patients, and novel clinical findings in other cancer predisposition syndromes.</p>
<p><a href="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1TSNW3JJ2DCoNFlTD5n4e9LZibFq6jDK9mdki6pFyWTLxdog3_">Scientific Publications &ndash; Leatrisse Oba</a></p>
<h3><strong><a id="Pinheiro"></a>Maisa Pinheiro, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1075783" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390531">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1075783&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Dr. Maisa Pinheiro joined the Clinical Genetics Branch as a postdoctoral fellow in January 2017. She completed a Bachelor`s degree in biology at the State University of North Paran&aacute;, Brazil, and received her Ph.D. in genetics from the S&atilde;o Paulo State University, Brazil, in 2016. Her Ph.D. research was focused on evaluating whole exome sequencing data to identify novel candidate genes that predispose to familial breast and thyroid cancers. Dr. Pinheiro performed part of her thesis work at the Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Canada. Under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="639592" sys_dependentvariantid="1965" sys_relationshipid="7390484" sys_siteid="475">Lisa Mirabello, Ph.D.</a>, Earl Stadtman Investigator, CGB, her work in DCEG is focused on HPV genomic studies including the evaluation of HPV genome variation and its associations with carcinogenicity.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Pinheiro%2C%20Maisa%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch ">Scientific Publications - Maisa Pinheiro</a></p>
<h3><strong><a id="Sargen"></a>Michael Sargen, M.D. &ndash; Postdoctoral Fellow </strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1126512" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390532">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1126512&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Michael Sargen, M.D., joined the Clinical Genetics Branch (CGB) in July 2018 as a postdoctoral clinical fellow. Dr. Sargen obtained his M.D. from the University of Pennsylvania Perelman School of Medicine in 2013 and completed his dermatology residency at Emory University, Atlanta, Georgia. He subsequently completed a dermatopathology fellowship at Stanford University, Palo Alto, California. Dr. Sargen is board-certified in dermatology and dermatopathology. He joins DCEG to study the clinical, histopathologic, and genetic characteristics of melanoma families. Dr. Sargen is also interested in genetic and environmental factors that modify melanoma risk within this patient population. In the Clinical Genetics Branch, Dr. Sargen works with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349658" sys_contentid="349658" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349658" sys_dependentvariantid="1965" sys_relationshipid="7390488" sys_siteid="475">Alisa Goldstein, Ph.D.</a>, senior investigator, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349685" sys_contentid="349685" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349685" sys_dependentvariantid="1965" sys_relationshipid="7390489" sys_siteid="475">Margaret Tucker, M.D.</a>, scientist emerita, to investigate these questions as well as provide dermatology care to an American cohort of melanoma families.</p>
<p>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Sargen%2C%20Michael%20R%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications</a></p>
<h3><strong><a id="Thompson"></a>Ashley Thompson, B.S. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1126507" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390533">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1126507&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Ashley Thompson, B.S., joined the Clinical Genetics Branch (CGB) as a postbaccalaureate fellow through the NIH Undergraduate Scholarship Program in June 2018. Ms. Thompson earned her B.S. in biochemistry from Converse College, Spartanburg, South Carolina. Her undergraduate research focused on analyzing the molecular weight distribution of&nbsp;a commercially-available synthetic biocide, in order to ascertain its biological efficacy. Ms. Thompson is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/savage-sharon">Sharon A. Savage, M.D.</a>, Chief and senior investigator, CGB, to determine if novel genetic variants in the regulator of telomere elongation helicase 1 gene (<em>RTEL1</em>) will result in alternative isoforms of the protein. The novel genetic variants will be studied for functional changes or changes in gene expression using RNA sequencing from patient-derived samples. Ms. Thompson is also involved with other genomic efforts in the Inherited Bone Marrow Failure Syndromes Study. She hopes to attend medical school to obtain her M.D./Ph.D. after her time at the NCI.</p>
<h3><a id="Monet-Thompson"></a>Mone't Thompson, B.S. - Postbaccalaureate Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1139438" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390534">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="Mone't Thompson, post-baccalaureate fellow in the Clinical Genetics Branch" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1139438&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Mone't Thompson, B.S., joined the Clinical Genetics Branch (CGB) in November 2018 as a postbaccalaureate fellow in the inaugural Intramural Continuing Umbrella of Research Experiences (iCURE) program, a new NCI program that supports mentored research experiences in the multidisciplinary research environment of the NCI for qualified scientists. Ms. Thompson received her B.S. in biology from Bowie State University, during which time she worked on research involving the key signaling pathway modulations that precede the development of sarcopenia. Ms. Thompson is an aspiring M.D./Ph.D. student and is interested in cancer biology, treatment, and prevention. As a postbaccalaureate fellow under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_contentid="349621" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349621" sys_dependentvariantid="1965" sys_relationshipid="7390490">Sharon Savage, M.D.</a>, Chief and senior investigator, CGB, Ms. Thompson is working on different aspects of myotonic dystrophy and Li-Fraumeni Syndrome.</p>
<h3><a id="Wang"></a>Youjin Wang, Ph.D. -&nbsp;Research Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1064689" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390535">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1064689&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Youjin Wang, Ph.D., joined the Clinical Genetics Branch (CGB) as a postdoctoral fellow in June 2016. Dr. Wang earned her Ph.D. in epidemiology from the University at Buffalo, SUNY School of Public Health and Health Professions in 2016. Working with Dr. Jean Wactawski-Wende, her doctoral research focused on the interactions of genetic susceptibility, menopausal estrogen use, and calcium/vitamin D supplementation on fracture risk among postmenopausal women. Dr. Wang&rsquo;s research interests are to study the interplay of genetic and environmental factors in cancer risk and cancer treatment outcome. In July&nbsp;2018 Dr. Wang was promoted to Research fellow. She is working with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/kreimer-aimee">Shahinaz Gadalla, M.D., Ph.D.</a>, Earl Stadtman Tenure Track Investigator, CGB, to evaluate the effect of pre-transplant molecular markers and genetic alterations on outcomes after hematopoietic cell transplantation and to examine the association between pharmaceutical agents and the risk of cancer.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Wang%2C%20Youjin%5bFull%20Author%20Name%5d&amp;cmd=DetailsSearch">Scientific Publications &ndash; Youjin Wang</a></p>
<p><a href="#top">Back to Top</a></p>
<p>Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302644" sys_contentid="302644" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302644" sys_dependentvariantid="1418" sys_relationshipid="7390477" sys_siteid="475">research training opportunities</a> in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7390478" sys_siteid="475">Clinical Genetics Branch</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302418" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>POWER V3.0 NON-PROPRIETARY SOFTWARE TRANSFER AGREEMENT</h3><p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p><p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient&#39;s confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:</p><p>Ms. Holly Brown (<a href="mailto:Brownh@exchange.nih.gov">Brownh@exchange.nih.gov</a>)</p><p>This Software has been developed using the True DBGrid component which is developed and published by ComponentOne LLC. Recipient of this Software is not licensed to use True DBGrid for development, and may not redistribute any of the included control files.</p></div>]]></content>
  </row>
  <row para_id="302421" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">This is a list of topics covered by the Help system. To view a topic, select its heading below.
<div class="pagetoc" id="top">
<ul>
<li>[..<a class="bodylink" href="#intro">Introduction</a>]</li>
<li>Concepts
<div>
<ul>
<li>[..<a class="bodylink" href="#datafiles">Data files</a>]</li>
<li>[..<a class="bodylink" href="#variables">Variables</a>]
<ul>
<li>[..<a class="bodylink" href="#filevars">File variables</a>]</li>
<li>[..<a class="bodylink" href="#definedvars">Defined Variables</a>]</li>
</ul>
</li>
<li>[..<a class="bodylink" href="#models">Models</a>]
<ul>
<li>[..<a class="bodylink" href="#parameters">Parameterization</a>]</li>
<li>[..<a class="bodylink" href="#effects">Effects</a>]</li>
<li>[..<a class="bodylink" href="#convcriteria">Convergence Criteria</a>]</li>
</ul>
</li>
</ul>
</div>
</li>
<li>Commands
<ul>
<li>The File Menu
<ul>
<li>[..<a class="bodylink" href="#new">New library</a>]</li>
<li>[..<a class="bodylink" href="#open">Open library</a>]</li>
<li>[..<a class="bodylink" href="#save">Save library</a>]</li>
<li>[..<a class="bodylink" href="#dos">DOS</a>]</li>
<li>[..<a class="bodylink" href="#exit">Exit</a>]</li>
</ul>
</li>
<li>The Variables Menu
<ul>
<li>[..<a class="bodylink" href="#add">Add</a>]</li>
<li>[..<a class="bodylink" href="#modify">Modify</a>]</li>
<li>[..<a class="bodylink" href="#delete">Delete</a>]</li>
</ul>
</li>
<li>The Model Menu
<ul>
<li>[..<a class="bodylink" href="#modnew">New</a>]</li>
<li>[..<a class="bodylink" href="#modmodify">Define model</a>]</li>
<li>[..<a class="bodylink" href="#modsamp">Sampling scheme</a>]</li>
<li>[..<a class="bodylink" href="#modconv">Convergence criteria</a>]</li>
<li>[..<a class="bodylink" href="#modrun">Run</a>]</li>
</ul>
</li>
<li>The Options Menu
<ul>
<li>[..<a class="bodylink" href="#variable">Variable columns</a>]</li>
<li>[..<a class="bodylink" href="#automatic">Automatic tiling</a>]</li>
<li>[..<a class="bodylink" href="#display">Display</a>]</li>
<li>[..<a class="bodylink" href="#saveconf">Save configuration</a>]</li>
<li>[..<a class="bodylink" href="#about">About</a>]</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<p>; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;] <a name="intro" id="intro"></a>&nbsp;</p>
<p>Introduction<br />IRAP is an interactive computer program which calculates both point estimates and confidence intervals for attributable risk, based on regression models. Modeling consists of three conceptual phases: creating a library of variables, defining the model, and running the model.</p>
<p>IRAP keeps a "library" of variables which the user has defined. A variable can take its value directly from the data file, or it can be defined in terms of other variables in the library. Typically, the user will create a separate library for each data file that he or she uses. A library can be saved to disk, then loaded whenever the corresponding data file is used.</p>
<p>Once a library of variables has been created (or loaded from disk), the user may define a model. IRAP supports six data sampling methods:</p>
<div>
<ul>
<li>Simple Random Sampling</li>
<li>Stratified Random Sampling</li>
<li>Frequency Matching</li>
<li>Individual Matching</li>
<li>Cohort Analysis</li>
<li>Cross-Sectional Analysis</li>
</ul>
</div>
<p>After choosing the appropriate sampling method, the user defines a model by specifying the appropriate variable names. A model can contain both discrete and continuous variables. IRAP correctly parameterizes the discrete variables, so the user need not explicitly create "dummy variables."</p>
<p>Once the model has been specified, the user tells IRAP to fit the model. The program asks for the names of the input and output files. It then reads the data, and fits the model.</p>
<p>While these three phases are conceptually distinct, they can be interleaved. For example, after fitting a model, the user may decide to combine two levels of exposure into one. It is easy to define a new variable, then rerun the model, substituting the new exposure variable for the old.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="datafiles" id="datafiles"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; DataFiles<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Data Files<br />The data files used by IRAP are very simple: they are standard text files (i.e., "ASCII" or "flat" files, not word processor files), with one line per record. The lines are "column-delimited." That is, a variable is defined by the value occupying a given range of columns in the file. Each line is considered a separate record. Leading and trailing blanks are allowed. Thus, a small data file such as</p>
<p>00<br />100<br />101<br />&nbsp;</p>
<p>contains three records. Assuming that each variable in this particular file occupies exactly one column, it contains separate variables. The variable in column 1 would be missing for the first record.</p>
<p>Records do not need to be sorted, and they may contain missing data. If a record contains a missing value for a variable which is actually used in the model, then it will not be used for fitting the model. In the above example, a model which uses the variable in column 1 would only use two records; models which do not use that variable will use all three. A "missing value" is anything that cannot be interpreted as a number, for example, a blank field or a letter. A field may contain leading and trailing blanks, so long as it has a real value in it somewhere. There is no upper limit on the length of a record. Most types of model require individual data. The exception is the cohort model, which takes data in the form of a person-year table.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="variables" id="variables"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; Variables<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Variables<br />Although the data file is laid out in columns, IRAP's models are defined in terms of named variables. IRAP maintains a list of variables that may be used in the model, called the "library." Variables can be added to or deleted from the library, and the entire library may be saved to disk for future reference. Typically, an entire file specification will be saved as a library. Then, that library will be loaded at the beginning of a session, and used to define models.</p>
<p>There are two types of variable: the "file variable" and the "defined variable." A file variable takes its values directly from the data file; a defined variable is a function of any number of file variables. Each variable has three attributes: its name, its number (that is, its position in the library), and optionally, a "missing code." In addition, file variables must include a starting column and field length, and may also specify an implicit decimal point's position. Defined variables replace these attributes with a definition.</p>
<p>IRAP's variable names are much like those in many programming and statistical languages. They may consist of letters, numbers, and underscores ('_'), but may not begin with a number. Variable names are "case insensitive." That is, uppercase and lowercase letters are interchangeable. Although IRAP variable names can use mixed case for readability (for example, "Age" or "GroupedWeight"), case alone does not distinguish two different variables (for example, "AGE" and "age" both refer to the same variable). In certain contexts, a variable can be specified either by name or by number. However, the number is merely the variable's current position in the library: if a variable is added or removed, then the numbers of all the variables after it will be shifted.</p>
<p>Both file variables and defined variables can have a "missing code." This is a value which, when encountered, is converted to an internal "missing" value, as if the field in the data file were blank. Consider a variable called "AGE," with values 0, 1, 2, and 3. Many files may contain a "9" for subjects whose age is unknown. Declaring 9 to be the "missing code" for AGE will cause those subjects to be excluded from any analysis involving the AGE variable. The function of a missing code in defined variables is a bit more subtle. As would be expected, a defined variable is automatically considered missing if it depends on any missing variables. Using the "AGE" variable as above, the defined variable</p>
<p>AGEp1 = AGE + 1</p>
<p>will assume the values 1, 2, 3, and 4. No missing code is needed for AGEp1, because AGE's missing status (whether due to a blank or a "9" in the data file) is propagated through the definition.</p>
<p>Although IRAP only allows one missing code per variable, a defined variable with a missing code can be used to account for several different missing codes in the file. Consider the file variable RACE:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">Race</th>
<th scope="col">Meaning</th>
</tr>
<tr class="odd">
<td>1</td>
<td>white</td>
</tr>
<tr>
<td>2</td>
<td>black</td>
</tr>
<tr class="odd">
<td>3</td>
<td>other</td>
</tr>
<tr>
<td>4</td>
<td>refused to answer</td>
</tr>
<tr class="odd">
<td>5</td>
<td>misc. unknown</td>
</tr>
</tbody>
</table>
<p>For most analyses, both 4 and 5 should be considered "missing," but IRAP only allows one missing code. A workaround is to define RACE_1, with missing code 4, as follows:</p>
<p>RACE_1 = RACE * (RACE &lt;_3d_&gt;&lt;/_3d_&gt;<br />+ 4 * (RACE &gt; 3)</p>
<p>When RACE is 1, 2, or 3, the expression will be evaluated as</p>
<p>RACE_1 = RACE * (1) + 4 * (0)<br />= RACE</p>
<p>but when RACE is 4 or 5,</p>
<p>RACE_1 = RACE * (0) + 4 * (1)<br />= 4</p>
<p>which is its missing code. There is nothing magic about which number is used as the missing code--it must only be outside of the variable's normal range. In the above example, 5, 6, -1 or 99 could just as easily have been used as a missing code (with the corresponding change in the definition).</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="filevars" id="filevars"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; FileVars<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>File Variables<br />IRAP's data files are column-delimited: file variables are specified in terms of starting column and field length. Often, the decimal point is omitted from column-delimited data; because it occurs in the same place in all records, its position can be inferred. This situation is handled by the "precision" attribute of file variables. A variable with two implied decimal places (e.g., 1.23 represented as "123") has a precision of 2. An explicit decimal in the data will override the implied decimal, so "12." will always be interpreted as 12, not as 0.12 or 1.2.</p>
<p>Please note that leading and trailing spaces can present some odd results if values are not lined up consistently in their fields. Consider the file:</p>
<p>81009<br />81019<br />8 209<br />820 9</p>
<p>The variable "a" starts at column 2, has length 3, and precision 2. Leading and trailing blanks are ignored, so the records are interpreted as follows:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">data</th>
<th scope="col">a</th>
</tr>
<tr class="odd">
<td>100</td>
<td>1.00</td>
</tr>
<tr>
<td>101</td>
<td>1.01</td>
</tr>
<tr class="odd">
<td>20</td>
<td>0.20</td>
</tr>
<tr>
<td>20</td>
<td>0.20</td>
</tr>
</tbody>
</table>
This situation occurs rarely, if ever, because data represented with implicit decimal places are usually right-justified in the field.
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="definedvars" id="definedvars"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; DefinedVars<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Defined Variables<br />Like its naming rules, IRAP's variable definition language borrows from more general languages. It combines arithmetic and boolean operators, assigning precedence levels which naturally group expressions as would normally be expected. Parentheses may be used to override the default operator precedence, or simply for clarity. The operators are as follows, in order of descending precedence:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<td>( )</td>
<td>grouping</td>
</tr>
<tr class="odd">
<td colspan="2">&nbsp;</td>
</tr>
<tr>
<td>- (unary minus)<br />* /<br />+ -</td>
<td>arithmetic</td>
</tr>
<tr class="odd">
<td colspan="2">&nbsp;</td>
</tr>
<tr>
<td>&lt;_3d_&gt; &gt;= == !=<br />&amp;&amp;<br />||&lt;/_3d_&gt;</td>
<td>boolean</td>
</tr>
<tr class="odd">
<td colspan="2">&nbsp;</td>
</tr>
<tr>
<td>@saturate(...)</td>
<td>combination</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>The first line of boolean operators contains the relational operators, "less than" (&lt;_29_2c_ _22_less="" or="" _equal22_=""&gt;&lt;/_29_2c_&gt;&lt;_3d_29_2c_ _22_greater="" _than22_="" _28_=""&gt;), "greater or equal" (&gt;=), "equals" (==), and "not equal" (!=). Below them are the "and" (&amp;&amp;) and "or" (||) operators.</p>
<p>&nbsp;</p>
<p>As IRAP only handles real numbers, the boolean operators bear some explanation Any boolean expression will evaluate to 1 if true, or 0 if false. The operands of a boolean operator may have any value; zero is interpreted as false, nonzero as true. Thus,</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">expression</th>
<th scope="col">result</th>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>2 &lt;_3d_&gt;&lt;/_3d_&gt;</td>
<td>1</td>
</tr>
<tr class="odd">
<td>4.98 &amp;&amp; -3</td>
<td>1</td>
</tr>
<tr>
<td>0 &amp;&amp; 3.14</td>
<td>0</td>
</tr>
<tr class="odd">
<td>2 || 3.14 &amp;&amp; 0</td>
<td>1 (&amp;&amp; is evaluated first)</td>
</tr>
<tr>
<td>(2 || 3.14) &amp;&amp; 0</td>
<td>0 (explicit grouping)</td>
</tr>
</tbody>
</table>
<p>The operators may be mixed freely, with the exception of the "@saturate()" operator, which may not be part of a larger expression. This operator creates a "saturation variable," which is a variable with a unique value for each observed combination of its operands' values. The syntax is:</p>
<p>@saturate(var1, var2, ...)</p>
<p>One or more variables may be listed, separated by commas. Given variables var1 (1..2) and var2 (0..1), a saturation variable will have the following values:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">@saturate(var1, var2)</th>
<th scope="col">var1</th>
<th scope="col">var2</th>
</tr>
<tr class="odd">
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr class="odd">
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>
Note that the baseline level of the saturation variable represents the lowest observed value of all the component variables. The saturation operator is offered primarily as a convenient way to create saturated models. The above example could be modeled with three effects: var1, var2, and an interaction term. However, in models with more variables, it becomes more convenient to define a saturation variable than to explicitly model many interaction terms. Another use for the saturation operator involves the trivial case, "@saturate(var1)". No matter what values var1 assumes, the operator will map them to integers (0, 1, ...). This matter will be discussed more in the next section.
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="models" id="models"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; Models<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Models<br />IRAP supports six data sampling methods, based on three types of regression model. Simple and stratified random sampling, frequency matched, and cross-sectional data fit a logistic model; individual-matched data fits a conditional logistic model; and cohort data fits a Poisson model. All models except for the conditional logistic model may be fit either with or without an intercept parameter, and stratified models may include or exclude parameters representing the stratification variables.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="parameters" id="parameters"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; Parameters<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Parameterization<br />The model makes a syntactic distinction between discrete and continuous variables. A discrete variable with n levels is automatically modeled as n-1 0/1 parameters, using the variable's minimum value as the baseline. A continuous variable, marked by a "#" in the model definition, is modeled as a single parameter, whose values reflect the data literally. Continuous variables are assumed to have a baseline value of 0.</p>
<p>Discrete variables are assumed to take on consecutive integer values; fractions are rounded down. While this rule causes no problems in most cases, variables that have non-integer values, or whose values are not consecutive integers, cause problems. Consider the variable "fat," which has the following values:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">fat</th>
</tr>
<tr>
<td>1</td>
</tr>
<tr class="odd">
<td>2</td>
</tr>
<tr>
<td>4.1</td>
</tr>
<tr class="odd">
<td>4.2</td>
</tr>
<tr>
<td>4.3</td>
</tr>
</tbody>
</table>
If fat really is a discrete variable, then it should be modeled with four parameters: "fat=2," "fat=4.1," "fat=4.2," and "fat=4.3." However, IRAP rounds the highest three values to 4, so it is interpreted as follows:
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">fat</th>
<th scope="col">IRAP interpretation</th>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr class="odd">
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4.1</td>
<td>4</td>
</tr>
<tr class="odd">
<td>4.2</td>
<td>4</td>
</tr>
<tr>
<td>4.3</td>
<td>4</td>
</tr>
</tbody>
</table>
<p>Now, seeing that "fat" has a minimum value of 1, and a maximum value of 4, IRAP creates three model parameters: "fat=2," "fat=3," and "fat=4." Thus, the model would look something like this:</p>
<p>Parameters</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">fat</th>
<th scope="col">fat=2</th>
<th scope="col">fat=3</th>
<th scope="col">fat=4</th>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4.1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr class="odd">
<td>4.2</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>4.3</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
<p>Three levels of the variable have been collapsed into the "fat=4" parameter, while the "fat=3" parameter has no use at all.</p>
<p>The solution to this problem is to define a new variable as "satfat = @saturate(fat)." The new variable will be defined as follows:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">satfat</th>
<th scope="col">fat</th>
</tr>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr class="odd">
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>4.1</td>
</tr>
<tr class="odd">
<td>3</td>
<td>4.2</td>
</tr>
<tr>
<td>4</td>
<td>4.3</td>
</tr>
</tbody>
</table>
This variable will be modeled correctly, contributing four meaningful parameters to the model:
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th colspan="2" scope="col">Variables</th>
<th colspan="4" scope="col">Parameters</th>
</tr>
<tr>
<th scope="col">fat</th>
<th scope="col">satfat</th>
<th>satfat=1</th>
<th scope="col">satfat=2</th>
<th scope="col">satfat=3</th>
<th scope="col">satfat=4</th>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4.1</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>4.2</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>4.3</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
<p>IRAP automates the modeling of interactions in much the same way as with main effects. An interaction is expressed as the product of two or more variables, such as:</p>
<p>sex * age</p>
<p>or</p>
<p>sex * age * race.</p>
<p>An interaction can contain any combination of discrete and continuous terms. Continuous variables are marked with a number sign:</p>
<p>sex * #ContAge.</p>
<p>Discrete terms are parameterized automatically. An interaction of discrete variables results in one model parameter representing each combination of non-baseline levels of the component variables. Thus, an interaction of any number of binary variables will result in a single model parameter, which is 1 when all of the interaction terms are "exposed." Consider the following examples:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">Variable</th>
<th scope="col">Values</th>
</tr>
<tr>
<td>age</td>
<td>1, 2, 3</td>
</tr>
<tr class="odd">
<td>sex</td>
<td>1, 2</td>
</tr>
<tr>
<td>exposed</td>
<td>1, 2</td>
</tr>
</tbody>
</table>
a) sex * exposed
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th colspan="2" scope="col">Values</th>
<th scope="col">Model Parameters</th>
</tr>
<tr>
<th scope="col">sex</th>
<th scope="col">exposed</th>
<th scope="col">(sex=2)*(exposed=2)</th>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr class="odd">
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr class="odd">
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>
b) age * sex
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th colspan="2" scope="col">Values</th>
<th colspan="2" scope="col">Model Parameters</th>
</tr>
<tr>
<th scope="col">age</th>
<th scope="col">sex</th>
<th scope="col">(age=2)*(sex=2)</th>
<th scope="col">(age=3)*(sex=2)</th>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
Continuous terms are treated literally, as demonstrated below:
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th scope="col">Variable</th>
<th scope="col">Values</th>
</tr>
<tr>
<td>ContAge</td>
<td>10, 25, 50</td>
</tr>
<tr class="odd">
<td>ContWgt</td>
<td>120, 155</td>
</tr>
<tr>
<td>age</td>
<td>1, 2, 3</td>
</tr>
</tbody>
</table>
a) #ContAge * #ContWgt
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th colspan="2" scope="col">Values</th>
<th scope="col">Model Parameters</th>
</tr>
<tr>
<th scope="col">ContAge</th>
<th scope="col">ContWgt</th>
<th scope="col">ContAge*ContWgt</th>
</tr>
<tr>
<td>10</td>
<td>120</td>
<td>1200</td>
</tr>
<tr class="odd">
<td>10</td>
<td>155</td>
<td>1550</td>
</tr>
<tr>
<td>25</td>
<td>120</td>
<td>3000</td>
</tr>
<tr class="odd">
<td>25</td>
<td>155</td>
<td>3875</td>
</tr>
<tr>
<td>50</td>
<td>120</td>
<td>6000</td>
</tr>
<tr class="odd">
<td>50</td>
<td>155</td>
<td>7750</td>
</tr>
</tbody>
</table>
b) #ContWgt * age
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th colspan="2" scope="col">Values</th>
<th colspan="2" scope="col">Model Parameters</th>
</tr>
<tr>
<th scope="col">ContWgt</th>
<th scope="col">age</th>
<th scope="col">ContWgt*(age=2)</th>
<th scope="col">ContWgt*(age=3)</th>
</tr>
<tr>
<td>120</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr class="odd">
<td>120</td>
<td>2</td>
<td>120</td>
<td>0</td>
</tr>
<tr>
<td>120</td>
<td>3</td>
<td>0</td>
<td>120</td>
</tr>
<tr class="odd">
<td>155</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>155</td>
<td>2</td>
<td>155</td>
<td>0</td>
</tr>
<tr class="odd">
<td>155</td>
<td>3</td>
<td>0</td>
<td>155</td>
</tr>
</tbody>
</table>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="effects" id="effects"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; Effects<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Effects<br />The variables that contribute to a model are grouped by function into lists of "effects." Some lists are common to all models, while others, such as "case indicator," are specific to certain types of model. Similarly, some lists may contain many variables, while others are limited to one. The following types of model effect occur in all models:</p>
<div>
<ul>
<li>Exposures - Each model must have one or more exposure variables. These are the variables used to determine exposure level in calculating attributable risk.</li>
<li>Confounders - Optional. These variables do not contribute to the attributable risk, but are modeled in the regression.</li>
<li>By-variables - Optional. Separate analyses are performed for each combination of values for these variables.</li>
<li>Interactions - Optional. This is a special type of effect that allows interactions to be modeled without resorting to huge lists of defined variables. An interaction can contain any combination of discrete and continuous variables, and as with main effects, discrete variables are automatically parameterized. To correctly calculate attributable risk, IRAP automatically treats any interactions involving an exposure variable as exposures as well.</li>
</ul>
</div>
<p>In addition to these effects, each type of model also has other, required, effects, as listed below.</p>
<p>Simple Random Sampling, Cross-sectional:</p>
<div>
<ul>
<li>Case indicator - A model must have exactly one case indicator. This variable must be a file variable. 0 represents a control; other (non-missing) values indicate a case.</li>
</ul>
</div>
Stratified Random Sampling, Frequency Matching:
<div>
<ul>
<li>Case indicator - A model must have exactly one case indicator. This variable must be a file variable. 0 represents a control; other (non-missing) values indicate a case.</li>
<li>Stratifiers - The model may be stratified by one or more discrete variables. The "Stratifiers Modeled" checkbox indicates whether these will also be included as covariates in the regression, or merely used for stratifying the attributable risk.</li>
</ul>
</div>
1:Ki Individual Matching:
<div>
<ul>
<li>Case indicator - A model must have exactly one case indicator. This variable must be a file variable. 0 represents a control; other (non-missing) values indicate a case.</li>
<li>Set number - This variable tells which matched set each individual belongs to. The specific values are arbitrary, but must be the same for each member of a given matched set.</li>
</ul>
</div>
Cohort Analysis:
<div>
<ul>
<li>Event count - The number of events that occured in the specific cell.</li>
<li>Person-years - The number of person-years in the specific cell.</li>
</ul>
</div>
<p>All types of model except for "1:Ki individual matching" allow an "Include Intercept" option. By default, an intercept parameter will be included in the regression model. However, you may choose instead to use one of the model's discrete variables to span the intercept. In this case, the baseline level of one variable will also be represented by a parameter in the model. This variable is chosen automatically. The first discrete confounder, if it exists, is used. Otherwise, the first discrete exposure variable is used. However, the baseline parameter never contributes to the attributable risk estimate.</p>
<p>A similar option exists for modeling stratifiers. By default, stratifier variables are modeled as discrete covariates. If you disable this option, they will not be modeled, but will still define the strata in the attributable risk analysis.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="convcriteria" id="convcriteria"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ConvCriteria<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Convergence Criteria<br />The final set of modeling options offered by IRAP adjusts how the model is fit, not the model's contents per se. IRAP allows you to tune three parameters: maximum iterations, convergence tolerance, and singularity threshold. The maximum iterations parameter (default, 30) adjusts how long the regression is allowed to run before the model is deemed divergent. The convergence tolerance (default, 1x10**-8) is used to test for convergence in the regression. The singularity threshold (default, 1x10**-12) tests for information matrix singularity. While these defaults are usually adequate, you may change them to suit individual needs and tastes. They are saved as part of the program configuration, so your settings will be restored every time you start the program.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="new" id="new"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_VARNEW<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>New library<br />This command clears the entire library of variables. Because the model cannot contain variables which are not defined in the library, the "New library" command has the side-effect of destroying the model definition.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="open" id="open"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_VAROPEN<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Open library<br />Oening a library replaces the current library with one that was previously saved.</p>
<p>The Files window shows the names of files in the current directory. The Directories window lists subdirectories, and all of your disk drives. You will notice that only filenames ending in ".var" are shown.</p>
<p>&gt; To change the criterion for displaying filenames</p>
<ol>
<li>Move to the Filename field.</li>
<li>Type the pattern for files you wish to see.
<div>
<ul>
<li>"*" matches zero or more characters</li>
<li>"?" matches exactly one character</li>
<li>"*.*" shows all files.</li>
<li>"a*.v" shows all files beginning</li>
<li>with "a", with a ".v" extension.</li>
</ul>
</div>
</li>
<li>Click the "OK" button, or press RETURN.</li>
</ol>
<p>&gt; To change disk drive or directory</p>
<ol>
<li>Click on the Directories window, or press Alt+D.</li>
<li>Double-click on the drive letter or directory name of your choice. Or, use the arrow keys to select your choice, then press RETURN. Choose ".." to move to the parent directory.</li>
</ol>
<p>OR</p>
<ol>
<li>Type the name of the directory in the Filename field, followed by a backslash ("\").</li>
<li>Press RETURN.</li>
</ol>
<p>&gt; To load a file</p>
<ol>
<li>Move to the Filename field.</li>
<li>Type the name of the file.</li>
<li>Press RETURN.</li>
</ol>
<p>OR</p>
<ol>
<li>Select the file in the Files window.</li>
<li>Click the "OK" button.</li>
</ol>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="save" id="save"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_VARSAVE<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Save library<br />Having created a library of variables, you can save it to disk for future reference. By building a library that contains all of the variables used in a study, you ensure that the same variables are used throughout the study, and that they are named consistently.</p>
<p>The "Directories" window contains a list of all the subdirectories of the current directory, and all of your disk drives.</p>
<p>&gt; To change disk drive or directory</p>
<ol>
<li>Click on the Directories window, or press Alt+D.</li>
<li>Double-click on the drive letter or directory name of your choice. Or, use the arrow keys to select your choice, then press RETURN. Choose ".." to move to the parent directory.</li>
</ol>
<p>OR</p>
<ol>
<li>Type the name of the directory in the Filename field, followed by a backslash ("\").</li>
<li>Press RETURN.</li>
</ol>
<p>Once the "Directory:" field shows the proper directory, you can save your library by typing its name.</p>
<p>&gt; To save the library</p>
<ol>
<li>Move to the Filename field.</li>
<li>Type the name under which you want to save the library. If you did not change to the desired directory, you may explicitly specify the drive letter, directory, or both:
<blockquote>d:\directory\subdir\file.var</blockquote>
</li>
<li>Click the "OK" button, or press RETURN.</li>
</ol>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="dos" id="dos"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_DOS<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>DOS<br />When fitting several models at once, it is often convenient to check a report, or copy a data file without exiting IRAP. For this reason, IRAP offers a DOS "shell" facility. By choosing this command, you will start a command prompt while IRAP is still running. From this prompt, you can do routine chores without having to leave IRAP. Because IRAP is still running behind the shell, less memory than normal will be available, but most programs will not be hindered by this condition.</p>
<p>To return to IRAP, type "exit" at the DOS prompt. Do not restart IRAP with the "irap" command; doing so will start another copy of the program, not return you to your previous session.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="exit" id="exit"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_EXIT<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Exit<br />This command terminates the program. The current model definition and library will be lost. Of course, you can save the library (see "Save library," above) for use in future sessions. At present, there is no way to save a model definition.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="add" id="add"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_VARADD<br /><br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Add<br />Choose this command to add a new variable to the library. There are two types of variable: the "file variable" and the "defined variable." In short, a file variable takes its value directly from the data. Because it is often desirable to recode data without creating a special data file, IRAP also provides "defined variables," which are specified as functions of any number of file variables.</p>
<p>Initially, IRAP presents you with a dialog for adding file variables.</p>
<p>&gt; To add a file variable</p>
<ol>
<li>Fill in the Name, Column, and Length fields with the information for this variable. Use TAB or the mouse to move between fields.</li>
<li>If the field in your data contains an implicit decimal point (e.g., 1.5 represented as "15"), enter the number of decimal places in the "Precision" field (in the above example, you would enter "1").</li>
<li>If the data file contains a numeric value which should be interpreted as "missing," then enter that value in the "Missing Code" field. Some files have several codes that mean "missing." To handle this problem, see the "Concepts" section.</li>
<li>By default, the variable will be added after the last variable in the library. If you want to insert it elsewhere, enter the position in the "Number" field.</li>
<li>Click the "Add" button, or press RETURN.</li>
</ol>
<p>At this point, the dialog box will clear itself, so that you may add another variable.</p>
<p>&gt; To quit adding variables</p>
<ul>
<li>Click the "End" button, or press ESCAPE.</li>
</ul>
<p>&gt; To add a defined variable</p>
<ol>
<li>From the dialog box described above, click the "Defined Variable" button, or press Alt+D.</li>
<li>Fill in the "Name" and "Definition fields. The variable definition language is described in the "Concepts" section.</li>
<li>If you wish to define a missing code for the variable, type it in the "Missing Code" field.</li>
<li>By default, the variable will be added after the last variable in the library. If you want to insert it elsewhere, enter the position in the "Number" field.</li>
<li>Click the "Add" button, or press RETURN.</li>
</ol>
<p>Again, the dialog box will ready itself for another variable. To stop adding variables, click the "End" button, or press ESCAPE. IRAP will remember that you were adding defined variables, and return you to that dialog box the next time you add variables.</p>
<p>&gt; To return to adding file variables</p>
<div>
<ul>
<li>Click the "File Variable" button, or press Alt+F.</li>
</ul>
</div>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="modify" id="modify"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_VARMODIFY<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Modify<br />Modifying a variable is essentially like adding one. You will be presented with a dialog box that is completed with the variable's current specifications. Simply make any necessary changes.</p>
<p>&gt; To modify a variable</p>
<ol>
<li>You will be asked which variable you want to modify. Enter the variable's name, or its number. Click the "OK" button, or press RETURN.</li>
<li>A dialog box similar to the "Add Variables" dialog will appear. Make all necessary changes to the information that is displayed.</li>
<li>Click the "Add" button, or press RETURN.</li>
<li>To cancel the operation, clidk the "End" button, or press ESCAPE.</li>
</ol>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="delete" id="delete"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_VARDEL<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Delete<br />Deleting a variable removes it from both the library and the model. To delete a variable, you need only give its name or number. If it was a part of the model, a message will appear indicating that the model was changed.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="modnew" id="modnew"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_MODNEW<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>New<br />The "New" command clears the entire model definition. The sampling scheme does not change, but the "Stratifiers Modeled" and "Intercept Modeled" options (if applicable to the sampling scheme) are returned to their default values.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="modmodify" id="modmodify"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_MODMODIFY<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Define Model<br />This command allows you to specify the contents of the model. It presents a dialog box with a field for entering each part of the model. The exact form of the dialog depends on the current sampling scheme (see the "Sampling scheme" command, below), but all versions are similar. When the program starts, the sampling scheme is "Simple Random."</p>
<p>&gt; To enter a model definition</p>
<ol>
<li>When the dialog box apears, the cursor will be in the "Case indicator" field. Type the name of the case indicator variable.</li>
<li>Using the mouse, or by pressing Alt+E or TAB, move to the "Exposures" field. Type the names of one or more exposure variables, separated by spaces.</li>
<li>If the model includes any covariates which do not contribute to attributable risk, move to the "Confounders" field. Type the names of the confounder variables, separated by spaces.</li>
<li>If the model should be fit separately for each value of one or more variables, move to the "By-variables" field. Type the variable names, separated by spaces.</li>
<li>IRAP can automatically create interactions involving any number of variables. To specify an interaction, move to the "Interactions" field. An interaction has the form
<blockquote>var1*var2</blockquote>
Type as many interactions as you wish, separating the terms of each with an asterisk ("*"), and separating different interaction with spaces.</li>
<li>IRAP can include a separate parameter to model the intercept, or use a covariate in the model to span the intercept. To span the intercept, clear the "Intercept Modeled" checkbox by clicking it with the mouse, or by pressing Alt+N.</li>
<li>When done, click the "OK" button, or press RETURN to accept the model. Click the "Cancel" button, or press ESCAPE to cancel the model definition.</li>
</ol>
<p>Although the other sampling schemes require slightly different information, the form is the same.</p>
<p>The stratified models (Stratified Random Sampling and Frequency Matching) offer a checkbox labeled "Stratifiers Modeled." When this option is checked, the stratification variables will appear in the regression model as discrete covariates. Clearing the checkbox will remove the stratification variables from the regression model, while retaining the stratification of the attributable risk estimate.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="modsamp" id="modsamp"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_MOD_SAM<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Sampling Scheme<br />The "Sampling scheme" command offers a submenu listing the six modeling options:</p>
<div>
<ul>
<li>Simple Random Sampling</li>
<li>Stratified Random Sampling</li>
<li>Frequency Matching</li>
<li>1:k Individual Matching</li>
<li>Cohort Analysis</li>
<li>Cross-sectional Analysis</li>
</ul>
</div>
&gt; To select a sampling scheme
<div>
<ul>
<li>Click your choice with the mouse, or use the arrow keys to highlight your choice, then press RETURN.</li>
</ul>
</div>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="modconv" id="modconv"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_MODCONV<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Convergence Criteria<br />This command is used to tune several parameters used in fitting the model. These parameters are saved by the "Save configuration" command in the "Options" menu, and restored automatically when the program starts.</p>
<p>The first line adjusts the number of iterations allowed before the regression model is deemed divergent. The second line adjusts the convergence threshold for the regression models. A larger convergence tolerance will cause the model to converge in fewer iterations. The third line adjusts the constant used to detect singular information matrices.</p>
<p>&gt; To change a convergence criterion</p>
<ol>
<li>Move to the field you want to change.</li>
<li>Enter the new value.</li>
<li>Cleck the "OK" button, or press RETURN.</li>
</ol>
<p>&gt; To restore the original values</p>
<ol>
<li>Click the "Defaults" button, or press Alt+D.</li>
<li>Click the "OK" button, or press Alt+O.</li>
</ol>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="modrun" id="modrun"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_MODRUN<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Run<br />Use this command to fit the completed model. When you "run" a model, IRAP first reads the data into memory. Little is gained by creating a file that only contains the variables for a certain model; only the values which are used by the current model are actually read from the file. With the data in core, the program builds its parameter tables, then fits the model.</p>
<p>&gt; To run the model</p>
<ol>
<li>In the "Data file" field, type the name of the input file.</li>
<li>In the "Report file" field, type the name under which the model's output should be stored.</li>
<li>The report file can have up to two title lines at the top of each page. To specify a title, type its text in the "Title 1" and "Title 2" fields.</li>
<li>IRAP always computes an estimate of attributable risk for all levels of exposure combined. To produce an estimate for each individual exposure pattern as well, check the "Partial attributable risk estimates" box by clicking it with the mouse, or by pressing Alt+P.</li>
<li>By default, IRAP prints the entire file description at the beginning of its report. To suppress this list, clear the "List variable definitions" checkbox by clicking it with the mouse, or by pressing Alt+L.</li>
<li>When all settings are correct, click the "OK" button, or press RETURN.</li>
</ol>
<p>If you specify a report file which already exists, IRAP offers three options:</p>
<p>Overwrite (Alt+O) - Replace the old file with the new one.<br />Append (Alt+A) - Add the report to the end of the old file.<br />New name (Alt+N) - Go back, and enter a new name for the report.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="variable" id="variable"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_PREF_COLS<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Variable Columns<br />When the library becomes large, not all of the variables will fit into the "Variables" window at once. While you can always scroll through its contents to find a particular variable, life is easier if you do not need to do so. For this reason, the library can be displayed in one, two, three, or five columns, trading the number of variables displayed against the amount of information shown for each.</p>
<p>&gt; To select the number of variable columns</p>
<ol>
<li>The "Variable columns" command will offer a submenu listing the display options.</li>
<li>Click the option of your choice with the mouse, or type the number of columns you wish to see (1, 2, 3, or 5).</li>
</ol>
<p>In one column, all information is displayed about each variable, but only about 13 or 14 can be seen at once. A horizontal scroll bar will appear for viewing definitions that do not fit in one line. This mode is good for checking long variable names or definitions, but can be annoying for general use.</p>
<p>The default setting is two columns. This mode also shows all of the attributes for file variables, but it truncates variable names longer than nine characters. For defined variables, only the beginning of the definition appears, and the missing code is not shown at all.</p>
<p>In three column mode, the missing codes disappear for file variables, as well. In five columns, only the variable names themselves are displayed, but about 65 of them will fit into the window at once.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="automatic" id="automatic"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_PREF_TILE<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Automatic Tiling<br />Regardless of the variable format chosen, you may want to manually move or resize the windows, for example to hide part of the model definition in order to see more variables at once. Unfortunately, IRAP has its own idea of how the screen should look. In an effort to be helpful, the program automatically positions the variable window above the model window, so that the model window is just large enough to show the whole model, and the variable window gets the rest of the screen. This feature is called "automatic tiling," because it places the windows next to each other like tiles on a floor.</p>
<p>&gt; To turn Automatic tiling on or off</p>
<blockquote>* choose the "Automatic tiling" command from the Options menu.</blockquote>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="display" id="display"></a>&nbsp;</p>
<p>; --------------------------------------------------------------------------<br />; ID_DISPLAY<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Display<br />The display command is used to change the color scheme and the display mode used by your computer. Because it depends on the video hardware in your computer, its action changes depending on your computer. Most computers that support IRAP have some form of VGA display.</p>
<p>The default choices of "color" and "25 lines" are appropriate for most cases. Two alternative color schemes, "mono" and "reverse mono," are offered; these may look better on monochrome screens. The "Lines" option offers a choice of video modes. More lines means more information, but it also means smaller type.</p>
<p>&gt; To change the color scheme</p>
<ol>
<li>click the button of your choice, or press:
<div>
<ul>
<li>Alt+L for color</li>
<li>Alt+M for monochrome</li>
<li>Alt+R for reverse monochrome.</li>
</ul>
</div>
</li>
<li>Click the "OK" button, or press RETURN.</li>
</ol>
<p>&gt; To change the number of screen lines</p>
<ol>
<li>click the button of your choice, or press:
<div>
<ul>
<li>Alt+2 for 25 lines</li>
<li>Alt+4 for 43 lines</li>
<li>Alt+5 for 50 lines.</li>
</ul>
</div>
</li>
<li>Click the "OK" button, or press RETURN.</li>
</ol>
<p>On a system with a CGA or Herculese display, you will find a checkbox marked "Snowy." On some systems, mostly those with CGA monitors, the screen will become snowy when the computer is updating its contents. While this is not dangerous to you or your computer, it can be extremely annoyint. If this is a problem on your screen, marking the "Snowy" box should help to alleviate it. Because the EGA and VGA displays handle the problem themselves, the option is not offered for them.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="saveconf" id="saveconf"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_SAVEOPTIONS<br />; ---------------------------------------------------------------------------<br />[<br />[&gt;&gt;]</p>
<p>Save Configuration<br />IRAP can save its configuration settings for future use. To save the current configuration, simply choose the "Save configuration" command in the "Options" menu. No dialog boxes or submenus will appear, but a file called "irap.cfg" will be created in the directory that contains irap.exe. The next time IRAP is started, it will read this file, setting the configuration options automatically.</p>
<p>To have IRAP look for (and save) the configuration file in a different place</p>
<blockquote>start the program with the command:<br />irap @filepath</blockquote>
<p>The "filepath" can be any valid DOS file specifier. For example,</p>
<p>irap c:\home\williams\williams.cfg<br />irap mine.cfg<br />irap \i.c</p>
<p>The following settings are saved in the configuration file:</p>
<div>
<ul>
<li>"Color scheme" display setting</li>
<li>"Lines" display setting</li>
<li>"Snowy" display setting</li>
<li>Variable columns</li>
<li>Automatic tiling</li>
<li>Maximum iterations for regression</li>
<li>Tolerance for convergence of regression</li>
<li>Singularity threshold for generalized inverse</li>
</ul>
</div>
<div class="dceg-top"><a href="#top">Back to List</a></div>
<p><a name="about" id="about"></a>&nbsp;</p>
<p>; ---------------------------------------------------------------------------<br />; ID_ABOUT<br />; ---------------------------------------------------------------------------<br /><br />[<br />[&gt;&gt;]</p>
<p>About<br />This command displays a brief message about the IRAP program, including the version number.</p>
<div class="dceg-top"><a href="#top">Back to List</a></div>
&lt;/_3d_29_2c_&gt;</div>]]></content>
  </row>
  <row para_id="302422" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This software is a SAS Macro that projects absolute breast cancer risk over defined age intervals for Asian and Pacific Islander American women with specific risk factors.</p>
<p>Users can enter data on risk factors and projection interval ages for a group of women, and the macro will return the corresponding absolute risk projections. This program may be useful for researchers who need risk projections for an entire study population.</p>
<p>The projections are calibrated separately for the following groups: Chinese, Japanese, Filipino, Hawaiian, Other Pacific Islander, and Other Asian. Confidence intervals are also provided for the projections.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=326988" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="326988" sys_dependentvariantid="1418" sys_relationshipid="7316225" sys_siteid="475" sys_variantid="1418" sys_contentid="326988">ReadMe</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302499" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302499" sys_dependentvariantid="1418" sys_relationshipid="7316223" sys_variantid="1418" sys_contentid="302499">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<p>Save this file in an appropriate folder on your disk.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303072" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303072" sys_dependentvariantid="1500" sys_relationshipid="7316224" sys_variantid="1500" sys_contentid="303072">APA_BrCa_RAM.zip</a></li>
</ul>
<h3>Reference:</h3>
<ul class="grey-bullets">
<li>Matsuno, Costantino, Ziegler et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21562243">Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women</a>. <em>J Natl Cancer Inst</em> 2011</li>
</ul>
<h3>Support:</h3>
<ul>
<li>Questions on statistical/medical issues? Contact: <a href="mailto:gailm@mail.nih.gov">Dr. Mitchell Gail</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302426" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302459&amp;sys_revision=114&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312445">About REB</a></h3>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=401127&amp;sys_revision=59&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312446">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">REB Staff Directory</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302501&amp;sys_revision=260&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302501" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312447">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-training" title="">Research Training Opportunities</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302415&amp;sys_revision=26&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302415" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312448">Tenure-Track Spotlight</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302426&amp;sys_revision=32&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302426" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312449">Staff Spotlight</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302443&amp;sys_revision=23&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302443" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312450">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=REB">Publications</a></p>
</div>
<h3>Sara Schonfeld</h3>
<p><a href="http://dceg.cancer.gov/about/staff-directory/biographies/O-Z/schonfeld-sara">Sara Schonfeld, Ph.D.</a>, is a staff scientist in the Radiation Epidemiology Branch (REB). No stranger to REB, Sara first joined the Branch as a summer student in 2004 seeking to apply the cancer epidemiology skills acquired during her M.P.H. program at the George Washington University. The summer turned into a year, during which she was introduced to the fields of second cancers, and occupational and environmental radiation epidemiology.</p>
<p>&ldquo;It quickly became clear that my next step was a Ph.D. in epidemiology, which I pursued at the Johns Hopkins Bloomberg School of Public Health.&rdquo; Dr. Schonfeld said. &ldquo;I was very fortunate to remain a part of REB, completing pre- and postdoctoral training in the Branch.&rdquo;</p>
<div sys_dependentvariantid="2088" sys_dependentid="1047363" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7312451">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302161&amp;sys_siteid=475&amp;sys_contentid=1047363&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>For her doctoral dissertation, Dr. Schonfeld pooled data from four DCEG prospective studies to investigate the associations between hormone-related risk factors and risk of breast and endometrial cancers among nulliparous women (i.e., women having no previous births).&nbsp;As a fellow, she also collaborated on studies concerned with medical, environmental, and occupational radiation exposures, and developed a strong research interest in the association between ionizing radiation exposure and cancer risk. Much of the research was conducted in the Russian Federation and Kazakhstan, which allowed her to combine training in epidemiology with her undergraduate degree in Russian studies.</p>
<p>During the second year of her postdoc, Dr. Schonfeld sought advice from REB mentors and colleagues on next steps. A conversation with Dr. Elaine Ron, then branch chief,&nbsp;set the wheels in motion for a very big change.</p>
<p>&ldquo;I vividly remember her saying to me &lsquo;You have to go away. You may choose to come back but you have to go away for some time. You can&rsquo;t do all of your growing up as an epidemiologist in one place.&rsquo;&rdquo; Dr. Schonfeld said.</p>
<p>Dr. Schonfeld took her advice seriously and by early 2012, accepted a position at the International Agency for Research on Cancer (IARC) in Lyon, France. While at IARC, she worked primarily on developing a retrospective cohort study of occupational asbestos exposure and cancer mortality. Although the exposure of interest was different, her previous experiences from REB studies of radiation in the Russian Federation provided a strong foundation for the work at IARC. In return, Dr. Schonfeld gained tremendous training at IARC, particularly in terms of fieldwork and project leadership.</p>
<p>In early 2016, Dr. Schonfeld returned to REB to take on the role of staff scientist. Currently, she supports Branch research to explore the relationship between cancer treatment and the development of <a href="http://dceg.cancer.gov/research/what-we-study/second-cancers">second malignancies</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302427" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<ul>
<li>Download the zip file to an appropriate directory.</li>
<li>Open up R and go to the menu Packages, drop down to Install Package(s) from local zip file.</li>
<li>Choose the zip file you downloaded. R will automatically download any necessary packages from the Internet that are needed to install NestedCohort.</li>
<li>To use the functions in NestedCohort in each R session, type library (NestedCohort) to attach the library so your R session can find the functions.</li>
</ul>
</div>
</div>]]></content>
  </row>
  <row para_id="302433" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Ionizing radiation is the only established risk factor for thyroid cancer. An international pooled analysis of 14 case-control studies of thyroid cancer (2,725 cases and 4,776 controls) was conducted to further describe the etiology of this cancer. By combining many small studies, investigators were able to explore many suspected risk factors for thyroid cancer with adequate statistical power. The pooled analysis identified goiter and benign nodules as the strongest risk factors apart from radiation. The large excess risk of thyroid cancer in females was not strongly associated with menstrual or reproductive factors. Cigarette smoking was associated with a reduced risk of thyroid cancer in both men and women. The analysis did not find any evidence for an increased risk of thyroid cancer with increased iodine intake from seafood or fish.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_dependentvariantid="1965" sys_dependentid="939428" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270563" sys_variantid="1965" sys_contentid="939428">Cari Kitahara</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270564" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302434" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators have been closely associated with studies of atomic bomb survivors in Hiroshima and Nagasaki for several decades. Data from studies of the survivors are widely regarded as the gold standard in radiation risk assessment for acute, external exposure, and are the major source of information for setting international and national radiological protection standards and guidelines. A new updated cancer incidence report recently has been completed, which adds approximately 50% more cancers from the additional nine years of follow-up and uses the recently introduced DS02 dose estimates. In addition, a series of site-specific cancer incidence studies have been conducted to gain insights into radiation-related risks. These include studies of ovarian, thyroid, lung and breast cancers and lymphoid tumors. A number of molecular genetics studies are also now underway and as well as a number of new site-specific studies including studies of bladder and colon cancer, second cancers and sarcomas.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349690" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270565" sys_dependentvariantid="1965" sys_dependentid="349690" rxinlineslot="103" sys_variantid="1965" sys_contentid="349690">Kiyohiko Mabuchi</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270566" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302436" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>ARTP2 is an R package of biological pathway analysis or pathway meta-analysis for genome-wide association studies (GWAS). It also provides tools for gene-level test as a special case. ARTP2 is an enhanced version of two previously released packages ARTP and AdaJoint. The current version is 0.9.20.</p>
<p>ARTP2 has an&nbsp;<a href="http://analysistools.nci.nih.gov/pathway/">online version</a> accepting inputs from summary statistics of GWAS.</p>
<h3>Features</h3>
<ul>
<li>Association test on user-defined genes or pathways</li>
<li>No need to assume independence between genes in a pathway (genes can be closeby or overlapped)</li>
<li>Accepting individual-level genetic data or SNP-level summary statistics from one or multiple GWAS</li>
<li>Supporting continuous or binary outcome (case-control studies)</li>
<li>Comprehensive data pre-processing options</li>
<li>Automatic allele validation and matching in processing inputs from summary data</li>
<li>Inflation factor adjustment</li>
<li>Toolkit for SNP-level meta-analysis</li>
<li>Parallelization under Linux-like OS using OpenMP</li>
</ul>
<h3>Download Software:</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302558" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302558" sys_dependentvariantid="1418" sys_relationshipid="6986758" sys_variantid="1418" sys_contentid="302558">License Agreement</a></li>
<li>Package source: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1048331" sys_dependentvariantid="1500" sys_dependentid="1048331" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6986759" sys_variantid="1500" sys_contentid="1048331">ARTP2_0.9.28.tar.gz</a></li>
<li>Windows binary: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1048330" sys_dependentvariantid="1500" sys_dependentid="1048330" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6986760" sys_variantid="1500" sys_contentid="1048330">ARTP2_0.9.28.zip</a></li>
<li>OS X binary: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1048332" sys_dependentvariantid="1500" sys_dependentid="1048332" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6986761" sys_variantid="1500" sys_contentid="1048332">ARTP2_0.9.28.tgz</a></li>
<li><a href="https://cran.r-project.org/web/packages/ARTP2/ ">Download from CRAN</a></li>
</ul>
<p>Note: While this page is updated frequently, the github page, accessible through CRAN, is updated most frequently.</p>
<h3>References:</h3>
<ul>
<li>Zhang H, Wheeler W, Shi J, Hyland P, Yang Y, Chatterjee N, Yu K. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27362418"><span class="show-for-sr">Pubmed Abstract: </span> A powerful procedure for pathway meta-analysis using summary statistics identifies multiple pathways associated with type 2 diabetes</a>. <em>PLOS Genet</em> 2016, June 30.</li>
<li>Zhang H, Shi J, Liang F, Wheeler W, Stolzenberg-Solomon R, Yu K. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24022295"><span class="show-for-sr">Pubmed Abstract: </span> A fast multilocus test with adaptive SNP selection for large-scale genetic association studies</a>. <em>Eur J Human Genet</em> 2014 May; Epub 2013 Sep 11.</li>
<li>Yu K, Li Q, Bergen AW, Pfeiffer RM, Rosenberg PS, Caporaso N, Kraft P, Chatterjee N. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19333968"><span class="show-for-sr">Pubmed Abstract: </span> Pathway analysis by adaptive combination of p-values</a>. <em>Genet Epidemiol</em> 2009, Dec.</li>
</ul>
<h3>Notes</h3>
<p>ARTP version 1 and AdaJoint are no longer being maintained. For access to those files, please email&nbsp;<a href="mailto:zhangh12@mail.nih.gov">Han Zhang</a> or <a href="mailto:yuk@mail.nih.gov">Kai Yu</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302437" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The NIH Intramural Research Program annually considers candidates to be named Earl Stadtman Investigators. These tenure-track level positions are for creative, independent thinkers eager to take on high-risk, high-impact research. Applicants are asked to share their ideas for a novel research program, their career aspirations, and how they would contribute to the NIH mission. The areas of active recruitment include basic, clinical, epidemiological, and population sciences research.</p>
<p>The Scientific Directors of the NIH&rsquo;s 23 intramural programs, and the search committee chairs work together to identify the finalists to be recruited as Earl Stadtman Investigators. The NCI Division of Cancer Epidemiology and Genetics (DCEG) selects successful candidates as tenure-track investigators for its research programs. DCEG conducts a national and international program of multidisciplinary, population- and family-based studies to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention.</p>
<div class="callout-box" style="width: 80%; margin: 1em auto;">
<h3>Earl Stadtman Investigators in DCEG</h3>
<p>Find out about DCEG's Earl Stadtman investigators and their research:</p>
<div style="width: 100%; overflow: auto;">
<div style="float: left; width: 45%; padding-right: 5%;">
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391618" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965">Elizabeth K. Cahoon, Ph.D.</a> <br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052539" sys_contentid="1052539" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391616" sys_siteid="475" rxinlineslot="103" sys_dependentid="1052539" sys_dependentvariantid="1965">Maria Constanza Camargo, Ph.D.<br /></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349606" sys_contentid="349606" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391612" sys_siteid="475" rxinlineslot="103" sys_dependentid="349606" sys_dependentvariantid="1965"></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349606" sys_contentid="349606" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391617" sys_siteid="475" rxinlineslot="103" sys_dependentid="349606" sys_dependentvariantid="1965">Shahinaz Gadalla, M.D., Ph.D.</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349671" sys_contentid="349671" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391613" sys_siteid="475" rxinlineslot="103" sys_dependentid="349671" sys_dependentvariantid="1965">Jill Koshiol, Ph.D.</a></p>
</div>
<div style="float: left; width: 45%; padding-right: 5%;">
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=638988" sys_contentid="638988" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391614" sys_siteid="475" rxinlineslot="103" sys_dependentid="638988" sys_dependentvariantid="1965">Steven Moore, Ph.D.</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1088176" sys_contentid="1088176" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391619" sys_siteid="475" rxinlineslot="103" sys_dependentid="1088176" sys_dependentvariantid="1965">Mitchell Machiela, Sc.D., M.P.H.</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=802306" sys_contentid="802306" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391615" sys_siteid="475" rxinlineslot="103" sys_dependentid="802306" sys_dependentvariantid="1965">Britton Trabert, Ph.D., M.S.</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1134872" sys_contentid="1134872" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391620" sys_siteid="475" rxinlineslot="103" sys_dependentid="1134872" sys_dependentvariantid="1965">Emily Vogtmann, Ph.D., M.P.H.</a></p>
</div>
</div>
</div>
<p><b>Qualifications/eligibility:</b> Candidates must have a Ph.D., M.D., or equivalent doctoral degree and have an outstanding record of research accomplishments as evidenced by publications in major peer-reviewed journals. Preference is given to applicants who are in the early stages of their research careers; only non-tenured applicants are considered. Appointees may be U.S. citizens, resident aliens or non-resident aliens with, or eligible to obtain, a valid employment-authorization visa.</p>
<p><b>Salary:</b> Successful candidates are offered competitive salaries commensurate with experience and qualifications, and they are assigned ample research space and resources, supported positions and an operating budget. Scientists focus entirely on their research with ample opportunities to mentor and train outstanding fellows at all levels.<br /><!-- The online application process has begun and applications will be accepted through September 30, 2018. Applications must include a curriculum vitae, a three-page research plan, a one-page description of their vision for their future research and its potential impact, as well as contact information for three professional references. Letters of recommendation will be requested automatically when you submit your application. No paper applications will be accepted. <a href="https://irp.nih.gov/careers/trans-nih-scientific-recruitments/stadtman-tenure-track-investigators">Learn more about the Earl Stadtman process</a> and <a href="https://irp.nih.gov/careers/trans-nih-scientific-recruitments/stadtman-tenure-track-investigators/application-details-for-stadtman-investigators">access the NIH online application</a>.</p>--></p>
<p><b>Selection Process:</b> Search committees composed of subject-matter experts review and evaluate applicants based on the following criteria: publication record, potential scientific impact of current and proposed research, scientific vision, demonstrated independence, and public health awards. Representatives from the NIH research programs then invite candidates of interest to them to discuss their research at a lecture open to the NIH scientific staff, and to interview with search committee members. Top candidates will be nominated as finalists for Earl Stadtman tenure-track positions.</p>
<p>Candidates not selected as Stadtman finalists can be considered for other open NIH research positions. The entire process from application review to job offer may take several months, depending on the volume of applications.</p>
<p><strong>How to apply</strong>: The NIH online application&nbsp;system will be accepting&nbsp;applications&nbsp;from August 1st through September 30th for the 2019 cycle. Please visit the <a href="https://irp.nih.gov/careers/trans-nih-scientific-recruitments/stadtman-tenure-track-investigators/application-details-for-stadtman-investigators">application page</a> for more information.</p>
<p>***</p>
<p>Read the inspiring story of <a href="http://history.nih.gov/exhibits/stadtman/">Earl and Thressa Stadtman's research</a>. You can find more information on the <a href="http://irp.nih.gov/">NIH Intramural Research Program website</a> and in the <a href="http://sourcebook.od.nih.gov/sourcebook">NIH Sourcebook</a>. Specific questions regarding this recruitment effort may be directed to <a href="https://oir.nih.gov/about/leadership-staff/roland-owens">Dr. Roland Owens</a>, Assistant Director, NIH Office of Intramural Research.</p>
<p>For questions specific to DCEG, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349643" sys_contentid="349643" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7391611" sys_siteid="475" rxinlineslot="103" sys_dependentid="349643" sys_dependentvariantid="1965">Dr. Jackie Lavigne</a>, Chief, DCEG Office of Education.</p>
<p>The NIH Intramural Research Program, with its extensive infrastructure and critical mass of expertise well established, has a crucial role in both maintaining America&rsquo;s research excellence and advancing treatments and cures. Come join the team whose hallmarks are scientific excellence, intellectual freedom, shared resources and broad expertise.</p>
<p>DHHS and NIH are Equal Opportunity Employers.</p>
</div>]]></content>
  </row>
  <row para_id="302440" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>CNVfam <strong>Non-Proprietary Software Transfer Agreement</strong></h3><h4>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</h4><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><b>This is a trial version of the software</b>. The CNVfam may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="302442" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The DCEG Administrative Resource Center (ARC), located in space within the Division, is responsible for facilitating administrative processes involved in conducting the research activities of the Division's intramural program.</p>
<p>The DCEG ARC strives to provide high quality service that is responsive, creative, and flexible. Our team of professional and technical employees has knowledge and expertise in finance and budget, personnel, procurement, contracts management, travel, property management, space utilization, and facilities management. We will continually strive to improve services in support of the mission of this Division.</p>
<p>Roberto Minutillo, ARC Manager/Director, Admin Services, DCEG, NCI</p>
<p><a title="List all Administrative Resource Center staff." href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?1=ARC">Administrative Resource Center staff</a></p>
</div>]]></content>
  </row>
  <row para_id="302443" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=115&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312488" sys_variantid="1422" sys_contentid="302459">About REB</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=61&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312489" sys_variantid="1418" sys_contentid="401127">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">REB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=261&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302501" sys_dependentvariantid="1418" sys_dependentid="302501" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312490" sys_variantid="1418" sys_contentid="302501">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-training" title="">Research Training Opportunities</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302415&amp;sys_revision=27&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302415" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312494">Tenure-Track Spotlight</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302426&amp;sys_revision=33&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302426" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312495">Staff Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302443" sys_dependentvariantid="1418" sys_dependentid="302443" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312493" sys_variantid="1418" sys_contentid="302443">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=REB">Publications</a></p>
</div>
<p>Investigators in the Radiation Epidemiology Branch (REB) provide a variety of tools and resources to be used by the scientific community.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302547" sys_contentid="302547" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312482" rxinlineslot="103" sys_dependentid="302547" sys_dependentvariantid="1418" sys_siteid="475">Interactive Radioepidemiological Computer Program</a><br /> IRCP was created to fulfill a Congressional mandate (Public Law 97-414, Section 7(b)) to create a set of summary tables which might be used to help evaluate the merits of compensation claims for cancer cases thought to have been caused by radiation exposure.</p>
<p><a href="https://ncidose.cancer.gov/#home">NCIDose</a><br /> A collection of tools and data for use in medical radiation dosimetry</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1108341" sys_contentid="1108341" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312485" rxinlineslot="103" sys_dependentid="1108341" sys_dependentvariantid="1418" sys_siteid="475">Radiation Dosimetry Methods and Tools </a><br /> Methods and tools for determining radiation doses to organs using innovative modeling and computational and physical human phantoms</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=395633" sys_contentid="395633" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312483" rxinlineslot="103" sys_dependentid="395633" sys_dependentvariantid="1418" sys_siteid="475">Radiation Risk Assessment Tool (RadRAT)</a> <br />An online calculator for estimating the lifetime risk of cancer incidence for members of the U.S. population (or countries with similar cancer incidence rates) from exposure to ionizing radiation for doses below 1 Gy&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302404" sys_contentid="302404" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312486" rxinlineslot="103" sys_dependentid="302404" sys_dependentvariantid="1418" sys_siteid="475">Thyroid Dose and Risk Calculator for Nuclear Weapons Fallout for the U.S. Population</a><br />An online calculator to estimate the I-131 radiation dose&nbsp;received by the thyroid gland from radionuclides in fallout from nuclear tests</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=48&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302671" sys_contentid="302671" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312484" rxinlineslot="103" sys_dependentid="302671" sys_dependentvariantid="1418" sys_siteid="475">Training Resources</a><br />REB&nbsp;offers a&nbsp;number of seminars and workshops to trainees and staff as well as to&nbsp;the greater scientific community. This includes a week-long <strong>Radiation Epidemiology and Dosimetry Course</strong>, given periodically by experts in the radiation field. The next course will be offered September 9-12, 2019. <a href="https://events.cancer.gov/2019RADEPI">Register for the Radiation Epidemiology &amp; Dosimetry Course</a>.</p>
<p>Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=937894" sys_contentid="937894" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312487" rxinlineslot="103" sys_dependentid="937894" sys_dependentvariantid="1418" sys_siteid="475">2019 Radiation Epidemiology &amp; Dosimetry Course</a> and view videos and course content from the 2015 course.</p>
<h3>Useful Links</h3>
<p><a href="http://www.icrp.org/">ICRP: International Commission on Radiological Protection</a></p>
<p><a href="http://www.niaid.nih.gov/topics/radnuc/pages/default.aspx">NIAID: Medical Countermeasures Against Radiological and Nuclear Threats</a></p>
<p><a href="http://www.hpa.org.uk/radiation/">HPA: Health Protection Agency (UK)</a></p>
<p><a href="http://www.iaea.org/">IAEA: International Atomic Energy Agency</a></p>
<p><a href="http://www.icru.org/">ICRU: International Commission on Radiation Units and Measurements</a></p>
<p><a href="http://www.iarc.fr/">International Agency for Research on Cancer</a></p>
<p><a href="http://www.icnirp.de/">International Commission on Non-Ionizing Radiation Protection</a></p>
<p><a href="http://dels.nas.edu/nrsb">NRSB: Nuclear and Radiation Studies Board</a></p>
<p><a href="http://www.ncrponline.org/">NCRP: National Council on Radiation Protection and Measurements</a></p>
<p><a href="http://www.rerf.or.jp/index_e.html">RERF Publications: Radiation Effects Research Foundation</a></p>
<p><a href="http://www.unscear.org/unscear/index.html">UNSCEAR: United Nations Scientific Committee on the Effects of Atomic Radiation</a></p>
<p><a href="http://www.who.int/ionizing_radiation/en/">WHO, Ionizing Radiation Section: World Health Organization</a></p>
<p><a href="http://www.radres.org/">Radiation Research Society</a></p>
<p><a href="http://www.hps.org/links.html">Health Physics Society</a></p>
<p><a href="http://www.physics.isu.edu/radinf/#orgs">The Radiation Information Network</a></p>
</div>]]></content>
  </row>
  <row para_id="302449" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3 id="Koshiol">Jill Koshiol, Ph.D.</h3>
<div sys_dependentvariantid="2090" sys_dependentid="915973" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7282373">
<figure class="image-right-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302161&amp;sys_siteid=475&amp;sys_contentid=915973&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Jill Koshiol</p>
</div>
</figcaption>
</figure>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349671" sys_contentid="349671" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349671" sys_relationshipid="7282369" sys_variantid="1965">Jill Koshiol, Ph.D.</a>, investigates the natural history of biliary tract cancers and role of inflammation in their development. Gallbladder cancer is a particularly good model for understanding inflammation-related carcinogenesis since gallstones are present in the vast majority of gallbladder cancer cases and cause substantial inflammation in the gallbladder. Measuring infection and immune responses in biological specimens can provide novel insights into carcinogenesis and disease outcomes, and identify molecular subtypes associated with each. As principal investigator for the Chile Biliary Longitudinal Study (BiLS), Biliary Tract Cancer Pooling Project (BiTCaPP), and Shanghai Biliary Tract Cancer Study, Dr. Koshiol evaluates the epidemiology of biliary tract cancers and associations with inflammation and other immune responses to elucidate etiologic mechanisms and identify cancer-related molecular pathways and targets that one day may be used in cancer prevention.</p>
<div style="clear: both;"></div>
<h3>Meredith Shiels, Ph.D.</h3>
<div sys_dependentvariantid="2090" sys_dependentid="1066553" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7282374">
<figure class="image-right-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=568389&amp;sys_siteid=475&amp;sys_contentid=1066553&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Meredith Shiels</p>
</div>
</figcaption>
</figure>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052540" sys_contentid="1052540" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1052540" sys_relationshipid="7282370" sys_variantid="1965">Meredith Shiels, Ph.D.</a>, uses innovative approaches to confront high-impact public health questions with population-based data resources and descriptive analyses. She combines multiple population-based data resources, quantifies the contribution of risk factors to time trends, and disaggregates cancer incidence and mortality rates to reveal underlying patterns and explanatory mechanisms. Currently, her research program focuses on 1) quantifying cancer risk and burden in people living with HIV; 2) estimating the impact of risk factors on changing cancer rates over time; and 3) understanding rising rates of premature mortality in the United States. Dr. Shiels is the co-principal investigator of the HIV/AIDS Cancer Match Study and collaborates widely with colleagues throughout DCEG, across NIH, at the CDC, and at state cancer registries.</p>
</div>]]></content>
  </row>
  <row para_id="302450" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">

<div class="bullet-blu">
<ul>
<li>Download the zip file and unpack it in an appropriate directory.</li>
<li>In MATLAB, use the (file--&gt; set path) menu to add the directory to the search path in which the files have been placed.</li>
<li>The main function the user needs to call is 'multilocus_test'.</li>
<li>Please read input_output.txt file for instruction about the input and output arguments.</li>
</ul>
</div>

</div>]]></content>
  </row>
  <row para_id="302451" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Over the last three decades, advances in treatment and supportive care have translated into steady improvements in survival after bone marrow transplantation (BMT) given for patients with leukemia and other malignant and nonmalignant diseases. With larger numbers of transplant recipients surviving long-term, concern has turned to quantifying the late effects of this treatment, particularly total-body irradiation (doses from 8 to 15 Gy), and severe immune dysfunction. Radiation Epidemiology Branch investigators have expanded and updated their previously assembled multi-institutional cohort to evaluate risk factors for new solid malignancies and posttransplant lymphoproliferative disorders among nearly 30,000 allogeneic transplant recipients, thereby doubling the numbers of 5 and 10-year survivors at risk for new malignancies. Preliminary results from the expanded study show that overall, patients developed new invasive solid cancers at twice the rate expected based on general population rates with risk rising steeply over time. Results show a markedly high risk associated with radiation conditioning regimens delivered at ages under 10 years with a rapidly declining trend in both relative and absolute risks with increasing age at radiation.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349648" sys_contentid="349648" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349648" sys_dependentvariantid="1965" sys_relationshipid="7270575" sys_siteid="475" sys_variantid="1965">Rochelle Curtis</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7270576" sys_siteid="475" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302453" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Polymorphisms in genes might modify the effects of exogenous and endogenous carcinogens in brain tumor development. DCEG investigators have evaluated the glutathione-S-transferase and cytochrome P-450 families of genes, both of which encode enzymes involved in the metabolism of solvents and other substrates. Occupational exposure to lead might cause meningioma, and a polymorphism in a gene for an enzyme that influences blood levels of lead [delta-aminolevulinic acid dehydratase, (ALAD)] was positively associated with the risk of meningioma. The association between glioma risk and history of allergies is being explored by examining the relation between glioma risk and polymorphisms in cytokine genes, and polymorphisms in a large panel of genes related to innate immunity also are under study. A recent paper from this study concerning apoptosis and cell cycle control genes identified caspase 8 as a possible susceptibility gene. Analyses concerning polymorphisms in oxidative stress genes, DNA repair genes, and insulin-like growth factor genes are in progress.</p>
<p>No single epidemiological study of brain tumors has adequate statistical power to evaluate most gene-environment or gene-gene interactions. An international consortium of brain tumor epidemiological studies (BTEC) was organized so that brain tumor risks associated with genetic susceptibility and specific exposures can be evaluated in the combined studies.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349666" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270577" sys_dependentvariantid="1965" sys_dependentid="349666" rxinlineslot="103" sys_variantid="1965" sys_contentid="349666">Martha Linet</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270578" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
<p><b>Related information:</b> <a href="http://dceg.cancer.gov/research/cancer-types/brain-nervous-system/multi-center-us-study-adult-brain-tumors">Multi-Center U.S. Study of Adult Brain Tumors</a></p>
</div>]]></content>
  </row>
  <row para_id="302455" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>KinCohort</strong> is a MATLAB software package for likelihood-based analysis of kin-cohort data.</p>
<p>Readme text:</p>
<ol>
<li>Download the zip file and unpack it in an appropriate directory.</li>
<li>In MATLAB, use the (file--&gt; set path) menu to add the directory to the search path in which the files have been placed.</li>
<li>The main user interface programs are:
<div class="bullet-blu">
<ul>
<li>'pexpsurv_kk' which produces the kin-cohort estimate of survival curves, and</li>
<li>'bspexpsurv_kk' which produces bootstrap estimates of the survival curves.</li>
</ul>
<div></div>
</div>
</li>
<li>Both of these functions have been annotated to explain the input and output arguments.</li>
</ol>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302608" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302608" sys_dependentvariantid="1418" sys_relationshipid="7279365" sys_siteid="475" sys_variantid="1418" sys_contentid="302608">License Agreement&nbsp;</a></p>
<h3>Download Software:</h3>
<div class="bullet-blu">
<ul>
<li>Download the zip file <a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303130" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303130" sys_dependentvariantid="1500" sys_relationshipid="7279364" sys_variantid="1500" sys_contentid="303130">KinCohort.ZIP</a> and unpack it in an appropriate directory.</li>
<li>In MATLAB, use the (file--&gt; set path) menu to add the directory to the search path in which the files have been placed.</li>
<li>The main user interface programs are:
<ul>
<li>&lsquo;pexpsurv_kk&rsquo; which produces the kin-cohort estimate of survival curves, and</li>
<li>&lsquo;bspexpsurv_kk&rsquo; which produces bootstrap estimates of the survival curves.</li>
</ul>
</li>
<li>Both of these functions have been annotated to explain the input and output arguments.</li>
</ul>
</div>
<h3>Reference:</h3>
<ul class="stacked-nobullets">
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/11252606">A marginal likelihood approach for estimating penetrance from kin-cohort designs</a>. Chatterjee N and Wacholder S. <cite>Biometrics</cite>&nbsp;2001 Mar;57(1):245-52.</li>
</ul>
<p>See also:</p>
<ul class="stacked-nobullets">
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/9778168">The kin-cohort study for estimating penetrance</a>. Wacholder et al. <em>Am J Epidemiol</em> 1998 Oct 1;148(7):623-630.</li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/11180447">Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study</a>. Moore et al. <cite>Genet Epidemiol</cite>&nbsp;2001 Feb;20(2):210-27.</li>
</ul>
<h3>Support:</h3>
<p><strong>Questions?</strong> <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302457" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1126836" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390811">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=301993&amp;sys_siteid=475&amp;sys_contentid=1126836&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Exposure to medical diagnostic tools involving radiation has increased dramatically among the U.S. population. DCEG researchers are assessing cancer risks associated with CT scan exposure in childhood. In addition, they are examining cancer risk associated with newer diagnostic radiologic examinations, such as high-dose nuclear medicine tests and fluoroscopically-guided interventional procedures. Researchers are studying radiation exposure from cancer treatment with the aim to quantify second cancers occurring among cancer survivors.</p>
<div class="callout-box right">
<h3>Radiation Epidemiology Course Registration</h3>
<p>The next <strong>Radiation Epidemiology &amp; Dosimetry Course</strong> will be held September 9-12, 2019, at NCI Shady Grove, Rockville, Maryland. <a href="https://events.cancer.gov/2019RADEPI">Register for the Radiation Epidemiology &amp; Dosimetry Course</a>.</p>
<p>Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=937894" sys_contentid="937894" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="937894" sys_variantid="1418" sys_relationshipid="7390809">2019 Radiation Epidemiology &amp; Dosimetry Course</a> and view videos and course content from the 2015 course.</p>
</div>
<h3 id="Diagnostic">Diagnostic Radiation Exposures</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302614" sys_contentid="302614" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302614" sys_variantid="1418" sys_relationshipid="7390802">Pediatric CT Scans and Cancer</a><br />A retrospective cohort study to evaluate the relationship between radiation exposure from CT scans conducted during childhood and adolescence and the subsequent development of cancer</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=810220" sys_contentid="810220" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="810220" sys_variantid="1418" sys_relationshipid="7390806">Risk Assessment: Computer Tomography (CT) Scans and Screening Examinations</a><br />DCEG and colleagues have developed a state-of-the-art risk projection model for radiation-related lung cancer that takes into account the interaction with smoking</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302563" sys_contentid="302563" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302563" sys_variantid="1418" sys_relationshipid="7390801">Tuberculosis Fluoroscopy</a><br />A study of site-specific cancer mortality among tuberculosis (TB) patients exposed to chest fluoroscopy</p>
<h3 id="Treatment-Benign">Radiation Treatment for Benign Diseases</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302530" sys_contentid="302530" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302530" sys_variantid="1418" sys_relationshipid="7390803">Tonsil Irradiation and Risk of Thyroid and Other Cancers</a><br />A study of individuals irradiated during childhood for benign head and neck conditions and monitored for the risk of thyroid and other cancers</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302536" sys_contentid="302536" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302536" sys_variantid="1418" sys_relationshipid="7390804">Hyperthyroidism I-131 Treatment</a><br />A study that compares cancer risks in patients treated for hyperthyroidism with Iodine-131 vs. antithyroid drugs or surgery</p>
<h3 id="Late-Effects">Late Effects of Radiotherapy, Chemotherapy and Other Cancer Treatment</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=804883" sys_contentid="804883" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="804883" sys_variantid="1418" sys_relationshipid="7390807">Second Primary Cancers</a><br />DCEG investigators are actively engaged in research to address risks associated with treatment-related second cancers, lifestyle, environmental, and medical history factors, and genetic susceptibility</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302605&amp;sys_revision=16&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302605" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7390812">Childhood Cancer Survivor Study (CCSS)</a><br /> A study of genetic susceptibility to radiotherapy among survivors of childhood cancer</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302509" sys_contentid="302509" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302509" sys_variantid="1418" sys_relationshipid="7390805">Multiple Primary Cancers Monograph</a><br />To identify groups of cancer survivors that are at increased risk for multiple primary cancers, investigators led an effort to provide the first comprehensive population-based analysis of the risk of subsequent cancer in the U.S., resulting in a monograph</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302397" sys_contentid="302397" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302397" sys_variantid="1418" sys_relationshipid="7390808">Second primary gastrointestinal (GI) cancers</a> <br />A multi-center study of second primary gastrointestinal (GI) cancers among survivors of Hodgkin lymphoma and cancers of the testis, breast, and cervix. This study comprehensively investigates the dose-response following fractionated, higher dose radiation treatment&nbsp;and risk of secondary, non-hematologic malignancies associated with chemotherapy.</p>
</div>]]></content>
  </row>
  <row para_id="302461" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>IRAP is an interactive computer program which calculates both point estimates and confidence intervals for attributable risk, based on regression models. Modeling consists of three conceptual phases: creating a library of variables, defining the model, and running the model.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302421" sys_contentid="302421" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317647" sys_dependentvariantid="1418" sys_dependentid="302421" rxinlineslot="103">Readme File</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303434" target="_blank" rel="noopener noreferrer" sys_contentid="303434" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317644" sys_dependentvariantid="1500" sys_dependentid="303434" rxinlineslot="103">User's Manual</a> (pdf, 209kb)</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303435" sys_contentid="303435" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317645" sys_dependentvariantid="1500" sys_dependentid="303435" rxinlineslot="103">Notes for Windows 7 64-bit Users</a> (pdf, 77kb)</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302551" sys_contentid="302551" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317648" sys_dependentvariantid="1418" sys_dependentid="302551" rxinlineslot="103">License Agreement</a></li>
</ul>
<h3>Software Download:</h3>
<ul>
<li>Download the self extracting zip file for <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=302987" sys_contentid="302987" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317646" sys_dependentvariantid="1500" sys_dependentid="302987" rxinlineslot="103">IRAP</a></li>
<li>Save this file in an appropriate folder on your disk.</li>
<li>Click on it, and the IRAP files will be extracted to a designated location on your harddrive.</li>
</ul>
<h4><span style="color: #000000;">Contact:</span></h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349622" sys_contentid="349622" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7317649" sys_dependentvariantid="1965" sys_dependentid="349622" rxinlineslot="103">Dr. Mitchell Gail</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302463" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>A comparison of alternative exposure assessment methods</h2>
<p>Sun exposure has been associated with skin cancer as well as potential protection against various other cancers. Few studies have examined alternative methods to retrospectively assess exposure to ultraviolet radiation (UV), particularly for women whose outdoor behavior patterns likely differ from those of men. DCEG investigators initiated a small pilot study to explore questionnaire-based UV exposure patterns and assessment methods. For one week, participants were asked to keep a diary of outdoor activities during 9am-5pm, while simultaneously wearing a personal UV dosimeter. The subjects subsequently completed surveys on their recollection of time outdoors during the study week and during their lifetime. This feasibility study was designed to evaluate patterns of outdoor behavior and the validity and reproducibility of alternative assessment methods for a one-week period, as well as the reproducibility of alternative methods of assessing lifetime sun exposure. In their evaluation of the reproducibility of hour-based and activity-based measures of lifetime UV exposure, investigators found that the activity-based approach was more reproducible during adult ages and over the lifetime, primarily due to the reports of women. (Yu CL et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19190171">Assessment of lifetime cumulative sun exposure using a self-administered questionnaire: reliability of two approaches.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2009; 18: 464-7).</p>
<p>Investigators are also assessing the choice of non-questionnaire surrogates for individual exposure to UVR.&nbsp;To guide the choice of surrogates for long-term UVR exposure, they are examining how well stable sun-related individual characteristics, such as skin sun-sensitivity, and environmental/climatic factors predict daily personal UVR exposure measurements as measured by these personal UVR dosimeters.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="1087122" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270591" sys_variantid="1965">Elizabeth Cahoon</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270592" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302468" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Hand-held cellular telephones are used close to the head and there is concern that the radiofrequency (RF) energy produced by these devices may affect the brain and nervous system tissue in the head. Researchers have focused on whether RF energy can cause malignant (cancerous) brain tumors such as gliomas (cancers of the brain that begin in the glial cells, which are cells that surround and support nerve cells), as well as benign (non-cancerous) tumors, such as acoustic neuromas (tumors that arise in the cells of the nerve that supplies the ear) and meningiomas (tumors that occur in the meninges, which are the membranes that cover and protect the brain and spinal cord).&nbsp;</p>
<p>As a result of public and Congressional concern, DCEG investigators launched an early study and found no relationship between cell phone use and risk of glioma or meningioma (Inskip et al., <i>NEJM</i> 2001). &nbsp;A more recent Danish study linked a roster of 358,403 cellular phone subscribers with records in the Danish Cancer Register and did not observe evidence of increased risk of glioma or meningioma, either overall or for persons with subscriptions exceeding 10 years (Frei et al,, <i>BMJ</i> 2011). &nbsp;A recent multicenter, international study also reported no relationship between cell phone use and meningioma (Interphone, <i>Int J Epidemiol</i> 2010). &nbsp;However, the same investigators reported increased risk of glioma in a small group of the heaviest users, but no indication of increasing risk with increasing level or duration of use. &nbsp;In contrast, a Swedish study (Hardell et al., <i>Int J Oncol</i> 2011) reported substantially higher estimates of the risk of glioma in relation to cell phone use as compared to these other studies.</p>
<p>In a 2012 study (Little et al., <i>BMJ</i> 2012), DCEG researchers compared observed glioma incidence rates from cancer registries in NCI&rsquo;s Surveillance, Epidemiology, and End Results program from 1992 to 2008, with projected rates based on risks observed in the Interphone study (2010)&nbsp;and the Swedish study (2011). Over the entire study period, glioma incidence patterns held roughly constant in all age groups. Projections based on the Interphone study, which found slight increases in risk among a small number of heavy users, were not statistically distinguishable from the observed U.S. rates. On the other hand, projections based on the Swedish study were at least 40 percent higher than, and incompatible with, the observed U.S. rates.&nbsp;</p>
<p>DCEG researchers have conducted a series of studies of time trends on U.S. incidence rates (Inskip et al., <i>Neuro Oncol</i> 2010, Little et al., <i>BMJ</i> 2012, Withrow et al. <em>CEBP</em>, 2018). This coincides with a period when there has been a substantial increase in usage of mobile phones in the U.S. population. They found little evidence for any change in rates of brain cancer overall or for glioma, the most common type of brain cancer. DCEG researchers plan to continue surveillance of glioma rates and changing usage patterns and technology of cell phones.</p>
<p style="text-align: left;">For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349666" sys_contentid="349666" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349666" sys_dependentvariantid="1965" sys_relationshipid="7338241" sys_siteid="475" sys_variantid="1965">Martha Linet</a>.</p>
<p style="text-align: left;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349666" sys_contentid="349666" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349666" sys_dependentvariantid="1965" sys_relationshipid="7338242" sys_siteid="475" sys_variantid="1965">Radiation Epidemiology Branch - Research Areas</a></p>
<h3 style="text-align: left;">References</h3>
<p>Inskip PD et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/11150357">Cellular-telephone use and brain tumors</a> <em>N Engl J Med</em> 2001.</p>
<p>Frei P et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22016439">Use of mobile phones and risk of brain tumours: Update of Danish cohort study</a>. <em>BMJ</em> 2011.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/20483835">Interphone Study Group. Brain tumour risk in relation to mobile telephone use: Results of the INTERPHONE international case-control study</a>. <em>Int J Epidemiol</em> 2010 Jun; Epub 2010 May 7.</p>
<p>Hardell L et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21331446">Pooled analysis of case-control studies on malignant brain tumours and the use of mobile and cordless phones including living and deceased subjects</a>. <em>Int J Oncol</em> 2011 May; Epub 2011 Feb 17.</p>
<p>Little MP et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22403263">Mobile phone use and glioma risk: Comparison of epidemiological study results with incidence trends in the United States</a>. <em>BMJ</em> 2012.</p>
<p>Inskip PD et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20639214">Brain cancer incidence trends in relation to cellular telephone use in the United States</a>. <em>Neuro Oncol</em> 2010 Nov; Epub 2010 Jul 16.</p>
<p>Withrow DR et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30464022">Trends in pediatric central nervous system tumor incidence in the United States, 1998-2013</a>. <em>Cancer Epidemiol Biomarkers Prev</em> 2019 Mar; Epub 2018 Nov 21.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="302469" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Breast Cancer Risk Assessment Macro License Agreement</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The BrCaRAM may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302471" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><!--
<h2>2004 Request and Related Correspondence</h2>
<ul class="bullet-blu">
  <li><a href="/files/6-7Request.pdf">Senate Request to NCI</a> (PDF, 213kb)</li>
  <li><a href="/files/9-28Response_letter.pdf">NCI Response to the Senate: Letter</a> (PDF, 142kb)</li>
  <li><a href="/files/9-28Response_appendix.pdf">Appendix</a> (PDF, 366kb)</li>
</ul>

<h2>2005 House Hearing  and Related Correspondence (5/25/2005)</h2>
<ul class="bullet-blu">
  <li><a href="/files/5-16Invitation.pdf">Invitation Letter from Congress</a> (PDF, 452kb)</li>
  <li><a href="/files/testimony052505.pdf">Testimony of Dr. Andre Bouville, NCI</a> (PDF, 197kb)</li>
</ul>

<h2>2005 Senate Hearing and Related Corresponence (7/19/2005)</h2>
<ul class="bullet-blu">
  <li><a href="/files/7-5Invitation.pdf">Invitation Letter from Senate</a> (PDF, 183kb)</li>
  <li><a href="/files/testimony071905.pdf">Testimony of Dr. Kiyohiko Mabuchi, NCI</a> (PDF, 67kb)</li>
</ul>

<h2>Related Publications</h2> -->
<h4>2010 Health Physics Publications</h4>
<p>Papers published in a special issue of <a href="http://journals.lww.com/health-physics/toc/2010/08000 "><i>Health Physics</i></a>, 99(2), August 2010.</p>
<ul class="bullet-blu">
<li>Simon SL, Bouville A, Land CE, Beck HL. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/RADIATION_DOSES_AND_CANCER_RISKS_IN_THE_MARSHALL.1.aspx">Radiation Doses and Cancer Risks in the Marshall Islands Associated with Exposure to Radioactive Fallout from Bikini and Enewetak Nuclear Weapons Tests: Summary</a>. <em>Health Physics</em> 99(2): 105-124; 2010.</li>
<li>Beck HL, Bouville A, Moroz BE and Simon SL. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/FALLOUT_DEPOSITION_IN_THE_MARSHALL_ISLANDS_FROM.2.aspx">Fallout Deposition in the Marshall Islands from Bikini and Enewetak Nuclear Weapons Tests</a>. <em>Health Physics</em> 99(2): 124-142; 2010.</li>
<li>Bouville A, Beck HL, Simon SL. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/DOSES_FROM_EXTERNAL_IRRADIATION_TO_MARSHALL.3.aspx">Doses from External Irradiation to Marshall Islanders from Bikini and Enewetak Nuclear Weapons Tests</a>. <em>Health Physics</em> 99(2): 143-156; 2010.</li>
<li>Simon SL, Bouville A, Melo D, Beck HL, Weinstock RM. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/ACUTE_AND_CHRONIC_INTAKES_OF_FALLOUT_RADIONUCLIDES.4.aspx">Acute and Chronic Intakes of Fallout Radionuclides by Marshallese from Nuclear Weapons Testing at Bikini and Enewetak and Related Internal Radiation Doses</a>. <em>Health Physics</em> 99(2): 157-200; 2010.</li>
<li>Land CE, Bouville A, Apostoaei I, Simon SL. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/PROJECTED_LIFETIME_CANCER_RISKS_FROM_EXPOSURE_TO.5.aspx">Projected lifetime cancer risks from exposure to regional radioactive fallout in the Marshall Islands</a>. <em>Health Physics</em> 99(2):201&ndash;215; 2010.</li>
<li>Simon SL. Dedication: <a href="https://journals.lww.com/health-physics/Citation/2010/08000/DEDICATION__PAYNE_S__HARRIS__1922_2010_.6.aspx">Payne S. Harris (1922&ndash;2010)</a>. <em>Health Physics</em> 99(2):216; 2010.</li>
<li>Harris PS, Simon SL, Ibrahim, SA. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/URINARY_EXCRETION_OF_RADIONUCLIDES_FROM.7.aspx">Urinary Excretion of Radionuclides from Marshallese Exposed to Fallout from the 1954 Bravo Nuclear Test</a>. <em>Health Physics</em> 99(2): 217-232; 2010.</li>
<li>Ibrahim SA, Simon SL, Bouville A, Melo D, Beck HL. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/ALIMENTARY_TRACT_ABSORPTION__f1_VALUES__FOR.8.aspx">Alimentary Tract Absorption (f1 Values) for Radionuclides in Local and Regional Fallout from Nuclear Tests</a>. <em>Health Physics</em> 99(2): 233-251; 2010.</li>
<li>Moroz BE, Beck HL, Bouville A, Simon SL. <a href="https://journals.lww.com/health-physics/Abstract/2010/08000/PREDICTIONS_OF_DISPERSION_AND_DEPOSITION_OF.9.aspx">Predictions of Dispersion and Deposition of Fallout from Nuclear Testing Using the NOAA-HYSPLIT Meteorological Model</a>. <em>Health Physics</em> 99(2): 252-269; 2010.</li>
</ul>
<h4>Earlier Publications</h4>
<ul class="bullet-blu">
<li>Bouville A, Simon SL, Miller CW, Beck HL, Anspaugh LR, Bennett BG. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12003019">Estimates of doses from global fallout.</a> <em><cite>Health Phys</cite></em> 2002 May;82(5):690-705. Review.</li>
<li>Gilbert ES, Land CE, Simon SL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12003021">Health effects from fallout.</a><em><cite>Health Phys</cite></em> 2002 May;82(5):726-35. Review.</li>
<li>Simon SL, Bouville A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12003020">Radiation doses to local populations near nuclear weapons test sites worldwide.</a> <em><cite>Health Phys</cite></em> 2002 May;82(5):706-25. Review.</li>
<li>Takahashi T, Trott KR, Fujimori K, Nakashima N, Ohtomo H, Minouk J, Schoemaker MJ, Simon SL. Thyroid Disease In The Marshall Islands, Findings from 10 Years of Study. Tohoku University Press, Sendai, Japan. 2001.</li>
<li>Simon SL, Graham JC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9199219">Findings of the first comprehensive radiological monitoring program of the Republic of the Marshall Islands.</a><a href="http://hss.doe.gov/healthsafety/IHS/marshall/marsh/journal/"><em><cite>Health Phys</cite></em> 1997 Jul;73(1):66-85.</a></li>
<li>Simon SL, Vetter RJ. Consequences of Nuclear Testing in the Marshall Islands. <em><cite>Health Phys</cite></em> 1997;73(1).</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302472" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="1839" sys_dependentid="1064855" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7359335">
<figure class="video right size50">
<div class="flex-video widescreen" id="ytplayer-IQuOZIZIsG4" data-video-id="IQuOZIZIsG4" data-video-title="DCEG Summer Interns"><noscript>			&lt;p&gt;				&lt;a href="https://www.youtube.com/watch?v=IQuOZIZIsG4" target="_blank" title="DCEG Summer Interns"&gt;					View this video on YouTube.				&lt;/a&gt;			&lt;/p&gt;		</noscript></div>
<figcaption class="caption-container">
<p>DCEG summer interns describe what they learned and valued most about their time in the Division. Video produced by Diane Wigfield, Program Analyst in the DCEG Office of Education. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1410&amp;sys_context=0&amp;sys_folderid=871050&amp;sys_siteid=475&amp;sys_contentid=1064855&amp;sys_command=editrc" title="" sys_variantid="1410" sys_contentid="1064855">Play the video in a new window</a>.</p>
<p></p>
</figcaption>
</figure>
</div>
<p>The Division of Cancer Epidemiology and Genetics (DCEG) offers a summer research internship for students interested in exploring careers in cancer epidemiology, biostatistics, and genetics. The program is open to high school, college, postbaccalaureate masters-level students, and graduate students, including medical and dental students. Successful applicants join the Division for at least 8 weeks between May and September. Under the supervision of a Division researcher, summer interns conduct research in selected areas of epidemiologic or genetic investigation.</p>
<p>Interns are encouraged to attend lectures offered under the NIH Summer Seminar Series, participate in DCEG meetings and seminars, attend formal NIH lectures and symposia, and participate in the NIH Summer Research Program Poster Day and the DCEG Poster Day.</p>
<p><strong>Important change for high school students for summer 2019</strong>: High school students must be at least 17 years of age by June 15, 2019, must be either juniors or seniors, and if they are under 18 at the time of application, must reside within 40 miles of the NIH campus on which they hope to intern. See more information on the <a href="https://www.training.nih.gov/programs/hs-sip">Summer High School Internship Program (HS-SIP)</a>.</p>
<p>Watch <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1410&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=1099499&amp;sys_command=editrc" sys_contentid="1099499" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7359333" rxinlineslot="103" sys_dependentid="1099499" sys_dependentvariantid="1410" sys_siteid="475">DCEG: Uncovering the causes of cancer, training future researchers</a></p>
<p><em>On this page</em>:</p>
<ul>
<li><a href="#Why">Why Study Epidemiology?</a></li>
<li><a href="#Research">DCEG Research Portfolio</a></li>
<li><a href="#Areas">Specific Research Areas</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?by=piinterest">DCEG Principal Investigators and their Research Interests</a></li>
<li><a href="#FAQ">Frequently Asked Questions</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=48&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=303775&amp;sys_command=editrc" sys_contentid="303775" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7359322" rxinlineslot="103" sys_dependentid="303775" sys_dependentvariantid="1418" sys_siteid="475">How to Apply</a></li>
</ul>
<h3 id="Why">Why Study Epidemiology?</h3>
<p>Epidemiology is often called the science of public health. It is described as the study of the distribution and determinants of disease risk in human populations. Epidemiologists study a diverse range of health conditions as well as the impact that various exposures have on the manifestation of disease. DCEG research has had tremendous <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=303763&amp;sys_command=editrc" sys_contentid="303763" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359323" rxinlineslot="103" sys_dependentid="303763" sys_dependentvariantid="1422" sys_siteid="475">impact on public health</a>.</p>
<h3 id="Research">DCEG Research Portfolio</h3>
<h4>Epidemiology and Biostatistics Research</h4>
<p>DCEG researchers work on a variety of population studies and develop novel analytic techniques. Our investigators serve as invaluable mentors to interns on a wide range of research topics. Read more on our <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?by=piinterest">Principal Investigators page</a>.</p>
<h4 id="Lab">Laboratory Research</h4>
<p>DCEG offers a limited number of summer laboratory research positions, mostly in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_contentid=302432&amp;sys_command=editrc" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359320" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422">Laboratory of Translational Genomics</a>. Students who are interested in laboratory research should also visit the <a href="https://www.training.nih.gov/other_summer_programs_at_the_nih">NIH Research and Training website</a> for information about research at other NIH institutes.</p>
<h3 id="Areas">Specific Research Areas</h3>
<div style="width: 48%; float: left; margin-right: 2%;">
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302568&amp;sys_command=editrc" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359325" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_siteid="475"><b>Biostatistics</b></a></h4>
<ul>
<li>Descriptive studies to characterize cancer trends</li>
<li>Analysis of large-scale data sets</li>
<li>Statistical models for predicting cancer risk</li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302430&amp;sys_command=editrc" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359326" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_siteid="475"><b>Clinical Genetics</b></a></h4>
<ul>
<li>Cancer predisposition syndromes</li>
<li>Genetic modifiers of cancer risk</li>
<li>Telomere biology disorders</li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302506&amp;sys_command=editrc" sys_contentid="302506" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359327" rxinlineslot="103" sys_dependentid="302506" sys_dependentvariantid="1422" sys_siteid="475"><b>Integrative Tumor&nbsp;Epidemiology</b></a></h4>
<ul>
<li>Advance understanding of cancer etiology and progression</li>
<li>Perform integrative analyses of environmental and germline risk factors with comprehensive data on histological and molecular profiling of tumors and their precursors</li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=66&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302590&amp;sys_command=editrc" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359331" rxinlineslot="103" sys_dependentid="302590" sys_dependentvariantid="1422" sys_siteid="475"><b>Infections and Immunoepidemiology</b></a></h4>
<ul>
<li>Prospective cohorts at high risk of AIDS</li>
<li>Oncogenic viruses</li>
<li>Immunosuppression and cancer</li>
</ul>
</div>
<div style="width: 48%; float: right;">
<h4><b><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=1033171&amp;sys_command=editrc" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359332" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_siteid="475">Metabolic Epidemiology</a></b></h4>
<ul>
<li>Hormones</li>
<li>Tobacco and other exposures</li>
<li>Energy balance /obesity</li>
<li>Dietary intake and micronutrients</li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302610&amp;sys_command=editrc" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359328" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_siteid="475"><b>Occupational and Environmental Epidemiology</b></a></h4>
<ul>
<li>Pesticides and agricultural exposures</li>
<li>Industrial chemicals</li>
<li>Environmental exposures</li>
<li>Exposure assessment</li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=115&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302459&amp;sys_command=editrc" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359329" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_siteid="475"><b>Radiation Epidemiology</b></a></h4>
<ul>
<li>Medical radiation exposures</li>
<li>Occupational radiation exposures</li>
<li>Environmental radiation exposures</li>
<li>Radiation dosimetry</li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302432&amp;sys_command=editrc" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7359330" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_siteid="475"><b>Translational Genomics</b></a></h4>
<ul>
<li>Relationship of germline genetic variation to cancer</li>
<li>Detection and mapping of cancer susceptibility alleles</li>
<li>Bioinformatic analyses of genetic variants</li>
</ul>
</div>
<p style="text-align: left; clear: both;"></p>
<h3><a id="FAQ"></a>Frequently Asked Questions</h3>
<p><strong>Who is eligible to apply? </strong></p>
<ul>
<li>High school students who are at least 17 years of age by June 15, 2019, must be either juniors or seniors, and who, if they are under 18 at the time of application, must&nbsp;reside within 40 miles of the NIH campus on which they hope to intern. (See <a href="https://www.training.nih.gov/programs/hs-sip">more information on the summer high school program</a>)</li>
<li>College students and individuals who will be starting college in the fall</li>
<li>Graduate students (that is, individuals working towards a Ph.D. or master's degree)</li>
<li>Professional school (medical, dental, pharmacy, etc) students</li>
</ul>
<p>Candidates must be U.S. citizens or permanent residents, who are enrolled in (or accepted to) high school, college or university as undergraduate, graduate, or professional students.</p>
<p><strong>When does the application process start?</strong><br /> The application process for summer 2019 will begin in mid-December&nbsp;and end on March 1st.</p>
<p><strong>How long is a summer internship?</strong><br /> A typical summer internship lasts 8 to 10 weeks with a minimum requirement of 8 weeks. There is some flexibility depending on the student's schedule.</p>
<p><strong>When does the summer internship start and end?</strong><br /> The internship begins in late May or early June and ends in August or September, but exact dates depend on the student's and the mentor's schedules.</p>
<p><strong>Is the summer internship a paid position?</strong><br /> Yes. Summer interns receive a stipend based on academic level.</p>
<p><strong>Where is the Division of Cancer Epidemiology and Genetics (DCEG) located?</strong><br /> DCEG is located on the NCI Shady Grove campus at 9609 Medical Center Drive, Rockville, Maryland, 20850. Parking is available at the building. &nbsp;Public transportation, using a combination of Metro and NCI shuttle bus, is also available. The closest Metro stop is &ldquo;Shady Grove&rdquo; on the Red Line, from which NCI shuttle buses run regularly to the NCI campus. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302566&amp;sys_command=editrc" sys_contentid="302566" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7359321" rxinlineslot="103" sys_dependentid="302566" sys_dependentvariantid="1418" sys_siteid="475">Find more transportation information</a>.</p>
<p><strong>Where do summer interns live?</strong><br /> There are a variety of housing options in the surrounding area, including Rockville and Bethesda, Maryland, and Washington, DC. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=804879&amp;sys_command=editrc" sys_contentid="804879" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7359324" rxinlineslot="103" sys_dependentid="804879" sys_dependentvariantid="1418" sys_siteid="475">Find housing information</a>.</p>
<p>NIH training programs welcome applications from all qualified individuals. The NIH does not discriminate based on race, color, religion, sex, national origin, disability, age, genetic make-up, gender identity, or sexual orientation.</p>
</div>]]></content>
  </row>
  <row para_id="302473" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="1833" sys_dependentid="1065273" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7273232">
<figure class="video right size50">
<h4>Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology &amp; Genetics for the SACNAS Conference</h4>
<div class="flex-video widescreen" id="ytplayer-_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" data-video-id="_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" data-video-title="Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology &amp; Genetics for the SACNAS Conference"><noscript>			<p>				<a href="https://www.youtube.com/watch?v=_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" target="_blank" title="Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology & Genetics for the SACNAS Conference">					View this video on YouTube.				</a>			</p>		</noscript></div>
</figure>
</div>
<p></p>
<p>The Office of Education oversees training and career development for all DCEG scientific staff, including directing the development of new fellowship training opportunities, and evaluating policies and practices for training and education within the Division. The Division trains postdoctoral fellows, doctoral candidates, graduate and baccalaureate students, summer students, and interns. The Office of Education designs and implements ongoing educational programs for all scientific staff, including seminars and lectures.</p>
<p></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349643" sys_contentid="349643" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7273230" sys_dependentvariantid="1965" sys_dependentid="349643" rxinlineslot="103"><b>Jackie Lavigne, Ph.D., M.P.H.</b></a><b>, Chief</b><br />Shady Grove Building, 7E450<br />240-276-7237</p>
<p><b>Diane Wigfield</b><br />Fellowship Coordinator<br />Shady Grove Building, 7E<span>406</span><br />240-276-7004</p>
<p><span><b>Cara Murray</b><br />Program Analyst<br />Shady Grove Building, 7E416<br />240-276-5841&nbsp;</span></p>
<p><a href="http://dceg.cancer.gov/news-events/linkage-newsletter/2016-03/fellowship-news/training-value">DCEG <em>Linkage</em> newsletter article on the Office of Education</a></p>
</div>]]></content>
  </row>
  <row para_id="302475" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><img class="left" alt="Robert A. Welch" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_contentid=303421" inlinetype="rximage" sys_relationshipid="7252957" sys_dependentvariantid="1482" sys_dependentid="303421" rxinlineslot="104" height="196" width="148" /> The Robert A. Welch Fellowship is a competitive program for postdoctoral fellows applying to train in the National Cancer Institute's Division of Cancer Epidemiology and Genetics (DCEG). The fellowship supports mentored research in molecular epidemiology with special emphasis on the application of emerging genetic and genomic technology. The fellowship also includes support for annual travel to a scientific conference with a focus on genetic or genomic technology.</p>
<p>The fellowship is named in honor of Robert A. Welch, the founding Director of Operations of the NCI-Frederick <a href="http://cgf.nci.nih.gov/">Cancer Genomics Research Laboratory</a> (CGR), formerly known as the Core Genotyping Facility. Mr. Welch played a key role in developing and managing the CGR, which carries out large-scale studies of common genetic variations and cancer. His skill, dedication, and hard work were major contributions to the CGR's success. His commitment and leadership inspired his colleagues at the CGR and elsewhere, and the CGR continues to work toward his vision.</p>
<h3>Former and Current Fellows</h3>
<ul class="bullet-blu">
<li>2009 - Jesus Gonzalez-Bosquet, M.D., Ph.D.</li>
<li>2010 - Hemang Parikh, Ph.D.</li>
<li>2012 - Wei Tang, Ph.D.</li>
<li>2015 - Jiyeon Choi, Ph.D.</li>
<li>2018 - Rouf Banday, Ph.D.</li>
</ul>
<h3>Eligibility</h3>
<p>An applicant must have an M.D. or doctoral degree in epidemiology, biostatistics, genetics, or other related research fields, or be pursuing a degree in these areas. The applicant must also be a U.S. citizen, resident alien, or foreign national eligible for a training visa.</p>
<h3>Application Process</h3>
<p>This year's fellow has been named; thus, applications are not being accepted at this time. Please check back in the future for updates on new application processing.</p>
<h3>Selection Process</h3>
<p>Candidates for the Robert A. Welch Fellow are reviewed by the Senior Leadership in Genomics Committee on a monthly basis. The committee is comprised of the Director and Deputy Director of DCEG, Director of the Human Genetics Program, Director of the Epidemiology and Biostatistics Program, and Chiefs of the Office of Education and the Laboratory of Translational Genomics. The committee ranks candidates and the final selection is made by the Director, DCEG.</p>
<p>Generally, there is one Robert A. Welch fellow at a time, with training typically lasting two to three years. However, multiple fellows training simultaneously are possible. The fellows have no future service obligation to NIH or its contractors.</p>
<h3>Funding</h3>
<p>The Fellowship is funded by donations from colleagues, family, friends, and companies through the <a href="http://www.fnih.org">Foundation for the NIH</a>, and by the DCEG. Donations may be made online or by check to FNIH, designating that the gift is being made in honor of Robert A. Welch.</p>
<h3 id="inquiry">Inquiries</h3>
<p class="indent">Email: <a href="mailto:ncidceged-r@mail.nih.gov">ncidceged-r@mail.nih.gov</a><br />Telephone: 240-276-7270</p>
<p>NIH is an Equal Opportunity Employer.</p>
</div>]]></content>
  </row>
  <row para_id="302479" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-hgp/cgb" title="">CGB Home</a></h3>
<p><a href="/about/organization/programs-hgp/cgb/clinical-epi-unit" title="">Clinical Epidemiology Unit</a></p>
<p><a href="/about/organization/programs-hgp/cgb/research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=CGB">CGB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/cgb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/cgb-training" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-hgp/cgb/tools-useful-links" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=CGB">Publications</a></p>
</div>
<h4><a href="http://jncimono.oxfordjournals.org/content/2008/38/3.full.pdf+html">Familial Cancer Syndromes Summary</a></h4>
<p>Clinical Genetics Branch senior investigator, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349677" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="349677" rxinlineslot="103" sys_relationshipid="7239808" sys_variantid="1965" sys_contentid="349677">Dr. Mark H. Greene</a>, and staff clinician, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349660" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="349660" rxinlineslot="103" sys_relationshipid="7239809" sys_variantid="1965" sys_contentid="349660">Dr. Mary L. McMaster</a>, collaborated with Mayo Clinic colleague Dr. Noralane Lindor, to produce the <a href="http://jncimono.oxfordjournals.org/content/2008/38/3.full.pdf+html">second edition of The Concise Handbook of Familial Cancer Susceptibility Syndromes</a>, published as a <i>Journal of the National Cancer Institute</i> Monograph.</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302620" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239805" sys_dependentvariantid="1418" sys_dependentid="302620" rxinlineslot="103" sys_variantid="1418" sys_contentid="302620">Family and Individual Registry Event Management System (FAIR-EM)</a></h4>
<p>Study management system used for monitoring clinical research protocols.&nbsp;</p>
<div id="genSlotBody">
<div class="contentid-434002 slot-item only-SI">
<h3>CGB Study Brochures and Newsletters</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1056276" sys_dependentvariantid="1500" sys_dependentid="1056276" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7239810" sys_variantid="1500" sys_contentid="1056276">Family Research Matters 2016 Study newsletter (pdf, 893 KB)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=434058" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239807" sys_dependentvariantid="1500" sys_dependentid="434058" rxinlineslot="103" sys_variantid="1500" sys_contentid="434058">Inherited Bone Marrow Failure Syndromes brochure (pdf, 909kb)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=303433" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239806" sys_dependentvariantid="1500" sys_dependentid="303433" rxinlineslot="103" sys_variantid="1500" sys_contentid="303433">Hereditary Bone Marrow Failure Syndromes Study newsletter, Summer 2008 edition (pdf, 6,142kb)</a></li>
</ul>
</div>
</div>
<h3>Useful Links</h3>
<p><a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq">Cancer Genetics Overview (PDQ)</a></p>
<p><a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet">Understanding Gene Testing</a></p>
<p><a href="http://www.cancer.gov/publications/dictionaries/genetics-dictionary">Glossary of Genetic Terms</a></p>
<p><a href="http://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq">Genetics of Breast and Ovarian Cancer (PDQ)</a></p>
<p><a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Elements of Cancer Genetics Risk Assessment and Counseling (PDQ)</a></p>
<p><a href="https://www.cancer.gov/types/testicular/hp/testicular-treatment-pdq">Testicular Cancer (PDQ)</a></p>
<p><a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/directory">Cancer Genetic Services Directory</a></p>
</div>]]></content>
  </row>
  <row para_id="302485" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This is a R package implementing the Bayeisan model for detecting gene environment interaction described in the following manucript. An important follow-up step after genetic markers are found to be associated with a disease outcome is a more detailed analysis investigating how the associated gene or a chromosomal region and an established environment risk factor interact to influence the disease risk. The standard approach to this study of gene-environment interaction considers one genetic marker at a time, and therefore could misrepresent and underestimate the genetic contribution to the joint effect when one or more functional loci, some of which might not be genotyped, exist in the region and interact with the environment risk factor in a complex way. We develop a more global approach based on a Bayesian model that uses a latent genetic profile variable to capture all of the genetic variation in the entire targeted region and allows the environment effect to vary across different genetic profile categories.</p>
<h3>Download Software:</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303066" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303066" sys_dependentvariantid="1500" sys_relationshipid="6986747" sys_variantid="1500" sys_contentid="303066">BaDGE_1.1.7.zip (Windows 7)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303067" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303067" sys_dependentvariantid="1500" sys_relationshipid="6986748" sys_variantid="1500" sys_contentid="303067">BaDGE_1.1.7.tar.gz (Unix)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303068" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303068" sys_dependentvariantid="1500" sys_relationshipid="6986749" sys_variantid="1500" sys_contentid="303068">BaDGE Manual</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303069" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303069" sys_dependentvariantid="1500" sys_relationshipid="6986750" sys_variantid="1500" sys_contentid="303069">Vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302684" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302684" sys_dependentvariantid="1418" sys_relationshipid="6986751" sys_variantid="1418" sys_contentid="302684">License Agreement</a></li>
</ul>
<h3>Reference:</h3>
<ul class="grey-bullets">
<li>Yu K , Wacholder S , Wheeler W , Wang Z , Caporaso N , et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22291610">A Flexible Bayesian Model for Studying Gene&ndash;Environment Interaction</a>. <em>PLoS Genet</em> 8(1): e1002482, 2012.</li>
</ul>
<p>Questions? <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302487" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>IN.power is an R package for estimating the number of susceptibility SNPs and power of future studies.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302681" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302681" sys_dependentvariantid="1418" sys_relationshipid="7276092" sys_variantid="1418" sys_contentid="302681">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302672" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302672" sys_dependentvariantid="1418" sys_relationshipid="7276093" sys_variantid="1418" sys_contentid="302672">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Windows - <a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303123" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303123" sys_dependentvariantid="1500" sys_relationshipid="7276090" sys_variantid="1500" sys_contentid="303123">IN.power_0.0.1.zip</a></li>
<li>Unix - <a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303124" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303124" sys_dependentvariantid="1500" sys_relationshipid="7276091" sys_variantid="1500" sys_contentid="303124">IN.power_0.0.1.tar.gz</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>References:</h3>
<p>Park J-H, Wacholder S, Gail M, Peters U, Jacobs K, Chanock S, Chatterjee N. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20562874">Estimation of effect size distribution from genome-wide association studies and implications for future discoveries</a>. <cite>Nature Genetics,</cite> 2010, 42, pp.570-575.</p>
<h3>Support:</h3>
<b>Questions?</b> <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</div>]]></content>
  </row>
  <row para_id="302492" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Health Professionals Follow-up Study (HPFS) questionnaire had the following questions involving chicken skin.</p>
<p><em>When you eat chicken, is it usually cooked with skin on?<br />Answer: <strong>yes/no</strong></em></p>
<p><em>Do you usually eat the skin?<br />Answer: <strong>yes/no</strong></em></p>
<p>Three chicken/skin combinations were possible:</p>
<ul class="bullet-blu">
<li>chicken cooked and eaten with skin,</li>
<li>chicken cooked with skin but not eaten with skin,</li>
<li>and chicken cooked without skin.</li>
</ul>
<p>The Charred database was developed with questionnaires that asked if the respondent ate skin but did not include the question on whether the chicken was cooked with skin. Therefore, the Charred values are based on a mean of cooked with skin and without skin.</p>
<p>For the HPFS study, heterocyclic amines (HCA) intake and meat derived mutagenicity from chicken was calculated using specific values from the database developed at NCI. This database contained measurements on HCA and meat derived mutagenicity for different types of chicken (white boneless chicken, white chicken meat and bone, dark boneless chicken and dark chicken meat and bone) prepared using different cooking methods (pan-fried, grilled/barbequed and broiled) and doneness levels (just, well and very). In addition, the database contained HCA and meat derived mutagenicity measurements for white chicken skin and dark chicken skin separately.</p>
<p>The three types of chicken/skin combinations, specific examples, and the final values used follow.</p>
<ol>
<li><strong>Chicken cooked and eaten with skin:</strong><br />The values can be obtained directly from the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302546" sys_contentid="302546" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7143184" sys_dependentvariantid="1418" sys_dependentid="302546" rxinlineslot="103">Charred Database</a><i><strong>.<br /><br /></strong></i></li>
<li><strong>Chicken cooked without skin<br /></strong>To calculate HCA for chicken cooked without skin we computed a weighted average of the HCA measurements from white boneless chicken and dark boneless chicken. For pan fried chicken the weights used were 1/3 for white meat and 2/3 for dark meat. For broiled and grilled chicken the split was evenly at 1/2 for both white meat and dark meat.<br /><br /></li>
<li><strong>Chicken cooked with skin but not eaten with skin<br /></strong>HCA values for chicken cooked with skin but not eaten with skin were computed by calculating a weighted average for white chicken with bone and dark chicken with bone using the same weights for white and dark meat as mentioned above for pan fried, broiled and grilled chicken.</li>
</ol>
<p><strong>The following examples illustrate the three different combinations for pan fried, just done chicken for PhIP.</strong></p>
<p>&nbsp;</p>
<p>Chicken Cooked and Eaten with Skin (from Charred database)&nbsp;</p>
<table class="blue-table">
<tbody>
<tr>
<td width="20%">&nbsp;</td>
<td width="36%">&nbsp;</td>
<th align="right" scope="col"><strong>Just</strong></th>
</tr>
<tr>
<th valign="top" rowspan="4" scope="rowgroup"><strong>PhIP</strong></th>
<th width="36%" scope="row">white skin</th>
<td align="right">20.92</td>
</tr>
<tr>
<th width="36%" scope="row">white meat &amp; bone</th>
<td align="right">4.16</td>
</tr>
<tr>
<th width="36%" scope="row">dark skin</th>
<td align="right">2.87</td>
</tr>
<tr>
<th width="36%" scope="row">dark meat &amp; bone</th>
<td align="right">0</td>
</tr>
<tr>
<td colspan="3"><strong>Calculation:<br /></strong><span style="font-family: Courier New, Courier, mono;" face="Courier New, Courier, mono">(((4.16 * 86%) + (20.92 * 14%)) * 1/3) +<br />(((2.87 * 86.6%) + (0 * 13.4%)) * 2/3) = 2.43<br /></span>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>Chicken Cooked without Skin&nbsp;</p>
<table class="blue-table">
<tbody>
<tr>
<td width="28%" height="19">&nbsp;</td>
<td width="45%" height="19">&nbsp;</td>
<th width="27%" height="19" align="right" scope="col"><strong>Just</strong></th>
</tr>
<tr>
<th valign="top" rowspan="2" scope="rowgroup"><strong>PhIP</strong></th>
<th width="45%" scope="row">white boneless</th>
<td width="27%" align="right">0</td>
</tr>
<tr>
<th width="45%" scope="row">dark boneless</th>
<td width="27%" align="right">0.81</td>
</tr>
<tr>
<td colspan="3"><strong>Calculation:</strong><span style="font-family: Courier New, Courier, mono;" face="Courier New, Courier, mono"><br />(0 * 1/3) + (0.81 * 2/3) = 0.54</span></td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>Chicken Cooked with skin but not Eaten with Skin&nbsp;</p>
<table class="blue-table">
<tbody>
<tr>
<td width="25%">&nbsp;</td>
<td width="40%">&nbsp;</td>
<th width="35%" align="right" scope="col"><strong>Just</strong></th>
</tr>
<tr>
<th valign="top" rowspan="2" scope="rowgroup"><strong>PhIP</strong></th>
<th width="40%" scope="row">white meat &amp; bone</th>
<td width="35%" align="right">4.16</td>
</tr>
<tr>
<th width="40%" scope="row">dark meat &amp; bone</th>
<td width="35%" align="right">0</td>
</tr>
<tr>
<td colspan="3"><strong>Calculation:<br /></strong><span style="font-family: Courier New, Courier, mono;" face="Courier New, Courier, mono">(4.16 * 1/3) + (0 * 2/3) = 1.39</span></td>
</tr>
</tbody>
</table>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302502" sys_contentid="302502" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7143185" sys_dependentvariantid="1418" sys_dependentid="302502" rxinlineslot="103">All Final Values used for the HPFS</a> are also available.</p>
<hr />
<p>For more information:</p>
<p><strong><em>Kana Wu, MD, PhD</em></strong><br />Harvard School of Public Health<br />Department of Nutrition<br />665 Huntington Avenue<br />Boston, MA 02115<br />Tel. 617-432-1842<br />Fax. 617-432-2435<br />e-mail:<a href="mailto:kana.wu@channing.harvard.edu">kana.wu@channing.harvard.edu</a></p>
</div>]]></content>
  </row>
  <row para_id="302494" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div id="pagetoc">
<h2>About the Study</h2>
<p>Chordoma is a rare bone cancer that is diagnosed in only about 300 patients in the U.S. each year. It develops at the base of the skull, in a vertebra, or at end of the spine (in the sacrum or the coccyx [the tail bone]) with about equal frequency. The cells that give rise to chordoma come from the notochord. The notochord is an important structure in the early embryo that disappears before birth. However, even after birth, some cells from the notochord remain in bones at the base of the skull, in vertebrae, and in the tail bone. Rarely, one of these cells, which are called notochord remnants, undergoes changes that give rise to a chordoma.</p>
<p>Chordoma is diagnosed most often in people who are in their late 50s, but it can occur much earlier or later. It develops in males more often than females and, for unknown reasons, is rare in African Americans. There are few effective treatments and no cure for chordoma. Most people with chordoma die within 10 years of diagnosis.</p>
<p>No specific environmental factors that increase the risk of developing chordoma have been identified. And, the vast majority of people with chordoma have no other family members with this cancer. However, a small number of families with multiple relatives with chordoma have been reported worldwide. In most of them, chordoma has occurred in a parent and one or more of his/her children. This pattern suggests that in these families, chordoma results from the presence of an altered or mutated gene that has been passed from the affected parent to some of his/her children.</p>
<h3 id="background">Background</h3>
<p>NCI&nbsp;investigators have been studying chordoma families (families with multiple relatives with chordoma) since 1996. Recently, they identified the altered gene that caused chordoma to develop in members of four of these families. The altered gene is the <i>T</i> gene on the long arm of chromosome 6. The way in which the <i>T</i> gene is altered in these families is unusual. The sequence of the DNA within this gene has not been changed or mutated; instead the entire <i>T</i> gene has been duplicated.</p>
<p>The <i>T</i> gene makes a protein called brachyury that plays an important role in the development of the notochord. Brachyury is present in notochord cells and also in chordomas, but it is not found in most other types of cancer or in the normal cells around a chordoma. At the present time, no one knows why an extra copy of the <i>T</i> gene in members of these four families increases their risk of developing chordoma.</p>
<p>Some of the chordoma families studied by investigators did not have an extra copy of the <i>T</i> gene. This suggests that mutations of other gene(s) or an as yet unidentified process involving the <i>T</i> gene caused the increased risk for chordoma in these families.</p>
<h3 id="purpose">DCEG Chordoma Research</h3>
<p>The goals of the research are to:</p>
<ul>
<li>Find the genes that cause chordoma to occur in multiple relatives in a chordoma family;</li>
<li>Describe the clinical findings in people with familial chordoma;</li>
<li>Determine whether families prone to chordoma are at increased risk of other types of cancer;</li>
<li>Develop better health care choices for families who have an increased risk for developing chordoma; and,</li>
<li>Determine whether the genes that are altered in members of chordoma families play a role in the development of chordoma in people without a family history of this cancer in the general population.</li>
</ul>
<p>DCEG&nbsp;investigators are seeking chordoma families to participate in research to identify additional genes that increase the risk of family members developing chordoma. To learn more, please see our research on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303761" sys_contentid="303761" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="303761" sys_dependentvariantid="1418" sys_relationshipid="7270597" sys_siteid="475">Familial Chordoma</a>.</p>
<p>DCEG&nbsp;investigators are also seeking individuals with chordoma who are the <span style="text-decoration: underline;">only</span> member of their family with this cancer. These types of individuals may participate in research to determine whether &ldquo;familial chordoma&rdquo; genes play a role in causing people without a family history of chordoma to develop this cancer. To learn more, please see our research on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303762" sys_contentid="303762" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="303762" sys_dependentvariantid="1418" sys_relationshipid="7270598" sys_siteid="475">Non-Familial Chordoma</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349593" sys_contentid="349593" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349593" sys_dependentvariantid="1965" sys_relationshipid="7270599" sys_siteid="475">Xiaohong Rose Yang</a>.</p>
</div>
</div>]]></content>
  </row>
  <row para_id="302498" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3 id="top">Overview</h3>
<p>The goal of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7126409" sys_siteid="475" sys_variantid="1422" sys_contentid="302432">Laboratory of Translational Genomics</a> (LTG) is to develop new approaches to the study of the genetic basis of cancer and its outcomes. LTG has developed expertise in bio-informatics and advanced genetic analyses with new platforms designed to test dense sets of single nucleotide polymorphisms (SNPs), which are the most common genetic variants in the human genome. Specifically, the laboratory has integrated approaches to identify and validate common SNPs and ancestral haplotypes, which could be used to dissect the genetic basis of disease susceptibility. LTG utilizes programs and approaches in population genetics, epidemiology and molecular evolution, which assist in the choice and analysis of genetic variants under study. Recently, the focus of LTG has shifted to dissect the genetic basis of SNP markers validated in large scale, genome-wide association studies (GWAS). This new approach can identify new regions to be studied in great detail and eventually applied to large molecular epidemiology studies to estimate the magnitude of the effect. It will also be possible to investigate the interaction between genes and environmental factors.</p>
<p>For application details, see below. To discuss potential research opportunities, you may contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=LTG">branch investigators</a> directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=275&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302640" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302640" sys_dependentvariantid="1418" sys_relationshipid="7126407" sys_variantid="1418" sys_contentid="302640">Meet fellows in the Laboratory of Translational Genomics (LTG).</a></p>
<h3>Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Fellowship training is for up to 5 years under the supervision of NCI senior scientists. Individuals must hold either an M.D. or Ph.D. in genetics, epidemiology, bio-informatics, molecular biology or a related field. Individuals with laboratory experience and/or expertise in manipulating and analyzing dense genomic data sets are encouraged to apply. Individuals with clinical or epidemiologic training are encouraged to apply.</p>
<p><i>Predoctoral fellowships:</i> Individuals must be enrolled in a doctoral program with a desire to complete their dissertation in LTG or have completed a master&rsquo;s degree in a field relevant to the mission of LTG.</p>
<p><i>Postbaccalaureate fellowships:</i> Fellowships are also available for individuals who have recently completed an undergraduate degree in biology, genetics or laboratory science.</p>
<h3>Application Process</h3>
<p>Postdoctoral and predoctoral fellowship applications in LTG are accepted on an ongoing basis. Fellowships in LTG are provided through the DCEG fellowship program. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=58&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7126408" sys_variantid="1418" sys_contentid="302629">Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3>Current Training Opportunities</h3>
<p>Postdoctoral and predoctoral positions are available.&nbsp;</p>
<h3 id="Specific">Training Opportunity with Specific Investigators</h3>
<p>Check back for new opportunities.</p>
</div>]]></content>
  </row>
  <row para_id="302499" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p><b>This is a trial version of the software</b>. The APA BrCa RAM may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302501" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=116&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7376240" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422">About REB</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=61&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7376241" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">REB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=264&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302501" sys_contentid="302501" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7376242" sys_siteid="475" rxinlineslot="103" sys_dependentid="302501" sys_dependentvariantid="1418">Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/reb-training">Research Training Opportunities</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302415" sys_contentid="302415" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7376243" sys_siteid="475" rxinlineslot="103" sys_dependentid="302415" sys_dependentvariantid="1418">Tenure-Track Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302426" sys_contentid="302426" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7376244" sys_siteid="475" rxinlineslot="103" sys_dependentid="302426" sys_dependentvariantid="1418">Staff Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302443" sys_contentid="302443" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7376245" sys_siteid="475" rxinlineslot="103" sys_dependentid="302443" sys_dependentvariantid="1418">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=REB">Publications</a></p>
</div>
<p id="top">Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=116&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7376230" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422">Radiation Epidemiology Branch</a> and learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302664" sys_contentid="302664" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7376231" sys_siteid="475" rxinlineslot="103" sys_dependentid="302664" sys_dependentvariantid="1418">research training opportunities</a>.</p>
<h3><strong><a id="Advani"></a>Pragati Gole Advani, M.D., Dr.P.H., M.P.H. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1105308" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376258">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1105308&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Pragati Gole Advani, M.D., Dr.P.H., M.P.H. joined the Radiation Epidemiology Branch (REB) as a Cancer Research Training Award post-doctoral fellow in November 2017. Dr. Advani earned her doctoral degree from the University of Texas, School of Public Health in May 2016 with a major in health promotion and behavioral sciences and minor in cancer epidemiology. During doctoral program, she served as a Susan G. Komen pre-doctoral fellow and her dissertation examined disparities in patient adherence to surgical management of breast cancer and survivorship practices at the MD Anderson Cancer Center (MDACC). During the last year, Dr. Advani served as a first-year post-doctoral fellow in the Division of Radiation Oncology at the MDACC, where she worked on a population-based study examining the burden of local therapy (surgery and radiation) decisions and associated outcomes among older breast cancer patients. In May 2011, Dr. Advani earned her M.P.H from the Western Kentucky University with a concentration in Health education and Leadership studies. In October 2008, she earned her degree in Medicine from University of Seychelles. At the REB, Dr. Advani is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/morton-lindsay">Lindsay Morton</a>, Ph.D., senior investigator, to broaden her experience in cancer survivorship research by investigating etiology for treatment-related second cancers.</p>
<p>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Pragati+Advani">Scientific Publications &ndash; Pragati Advani</a></p>
<h3 id="Borrego"><strong><a id="Borrego"></a>David Borrego, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1060103" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376259">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1060103&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>David Borrego, Ph.D., joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in June 2016. Dr. Borrego earned a B.S. in nuclear and radiological engineering (2010) and both an M.S. (2012) and Ph.D. (2016) in biomedical engineering with a concentration in medical physics from the University of Florida. His doctoral dissertation work focused on assessment of organ doses for fluoroscopically guided interventional procedures. Dr. Borrego&rsquo;s main research interests are in Monte Carlo estimation of organ doses for patients undergoing radiography and fluoroscopy examinations and organ dose reconstruction based on occupational radiation exposure. In REB, Dr. Borrego is working closely with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376232" sys_siteid="475" rxinlineslot="103" sys_dependentid="349634" sys_dependentvariantid="1965">Choonsik Lee, Ph.D.</a><a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/lee-choonsik">,</a> investigator, REB,<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349666" sys_contentid="349666" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376233" sys_siteid="475" rxinlineslot="103" sys_dependentid="349666" sys_dependentvariantid="1965"> </a><a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/linet-martha">Martha Linet, M.D., M.P.H.</a><a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/linet-martha">,</a> senior investigator, REB, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_contentid="939428" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376234" sys_siteid="475" rxinlineslot="103" sys_dependentid="939428" sys_dependentvariantid="1965">Cari Kitahara, Ph.D., M.H.S.</a><a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/kitahara-cari">,</a> investigator, REB, on estimating organ and tissue-specific absorbed doses in members of the U.S. Radiologic Technologist Cohort and for use in epidemiological studies.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Borrego%2C%20David%5bFull%20Author%20Name%5d&amp;cmd=DetailsSearch">Scientific Publications &ndash; David Borrego</a></p>
<h3><strong><a id="Chen"></a>Yingxi (Cimo) Chen, M.D., Ph.D - Postdoctoral fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1105343" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376260">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1105343&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Yingxi (Cimo) Chen, M.D., Ph.D, joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in September 2017. Dr. Chen received a Bachelor&rsquo;s degree in Medicine (2011) from the Sichuan University and a M.P.H. (Res) (2013) and Ph.D in Epidemiology (2017) from the Australian National University. For her dissertation research, Dr. Chen estimated the burden of gastrointestinal infections in middle-aged and older adults, and investigated factors that were associated with adverse clinical outcomes using linked data from a large-scale cohort study to multiple administrative and clinical databases. In the Radiation Epidemiology Branch, Dr. Chen is working with Dr. <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/berrington-amy">Amy Berrington de Gonz&aacute;lez, D.Phil.</a>, Branch Chief and senior investigator, REB, on several projects with the goal of evaluating trends in disease incidence and mortality data.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/1VGEUl2xY1mAu/bibliography/public/">Scientific Publications - Yingxi (Cimo) Chen</a></p>
<h3><strong><a id="dalal"></a>Nicole Dalal, B.A. &ndash; &shy;&shy;&shy;</strong><strong>Predoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1133136" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376261">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133136&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Nicole Dalal, B.A., joined the Radiation Epidemiology Branch (REB) as a Medical Research Scholars Program (MRSP) Fellow in August 2018. She received her B.A. in human biology with a concentration in public health systems and interventions in 2016 from Stanford University. Since then, she has been working towards her M.D. at the Duke University School of Medicine. Prior to joining REB, Ms. Dalal was involved in a wide variety of research work, including research on communication about physical activity between pediatric oncology survivors and providers, field work studying informal provision of healthcare via the Stanford India Health Policy Initiative, and studies on clinical quality improvement at Duke University. Ms. Dalal has a clinical interest in oncology and survivorship and will be working with&nbsp;<a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/morton-lindsay">Lindsay Morton, Ph.D.</a>, senior investigator, REB, to investigate cause-specific mortality among lymphoma survivors and treatment-related leukemia occurring after chemotherapy and radiotherapy.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Donahoe"></a>Tim Ryan Donahoe, B.S. </strong><strong>&ndash;</strong><strong> Medical Research Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1135913" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376262">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1135913&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Tim Donahoe, B.S., joined the Radiation and Epidemiology Branch (REB) through the Medical Research Scholars Program in August 2018. Tim earned B.S. degrees in biomedical engineering and neurobiology from the University of Connecticut in 2015. He is currently enrolled as a medical student at Weill Cornell Medicine, and plans to graduate in 2020. His interests in medical school include emergency medicine, disaster medicine, medical simulation, and aerospace medicine, and he led development of the aerospace medicine area of concentration at Weill Cornell. Tim is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/berrington-amy">Amy Berrington de Gonz&aacute;lez</a>, D.Phil., branch chief and senior investigator, REB, to investigate the cardiovascular health effects of cosmic radiation exposure in a joint project with NASA researchers at Langley Air Force Base, and to examine radiation exposure and subsequent cancer risk from emergency department computed tomography scanning.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Griffin"></a>Keith T. Griffin, M.S. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1093296" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376263">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1093296&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Keith T. Griffin, M.S., joined the Radiation Epidemiology Branch (REB) as a postbaccalaureate fellow in June 2017. He earned both his B.S. (2015) and M.S. (2016) in nuclear and radiological engineering from the Georgia Institute of Technology in Atlanta. Previously, Mr. Griffin worked two summers with the Center for Radiation Protection Knowledge team at Oak Ridge National Laboratory as an intern. As part of his core research interests, he has employed Monte Carlo computational simulations to calculate organ absorbed doses associated with dozens of environmental and medical external exposures. Recently Mr. Griffin returned to school to earn a doctorate degree from Georgia Tech in nuclear engineering with a minor concentration in medical physics. At NCI, he is working under the mentorship of&nbsp;<a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/lee-choonsik">Choonsik Lee, Ph.D</a>, senior investigator, REB, to help establish the computational dosimetry methods needed for future epidemiological studies of proton therapy on a patient-specific basis.&rdquo;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/keith.griffin.1/bibliography/public/">Scientific Publications - Keith Griffin</a></p>
<p></p>
<p></p>
<h3><a id="Ramin"></a>Cody Ramin, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1141805" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376264">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1141805&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Cody Ramin, Ph.D., joined the Radiation Epidemiology Branch (REB) as a Cancer Prevention Fellow in September 2018. Dr. Ramin earned her Ph.D. in epidemiology from the Johns Hopkins Bloomberg School of Public Health in 2018 and her M.S. in epidemiology from the Harvard T.H. Chan School of Public Health in 2013. Dr. Ramin&rsquo;s research interests focus on breast cancer etiology and the role of cancer therapy on second cancer risk and cardiovascular disease among breast cancer survivors. Dr. Ramin is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376238" sys_siteid="475" rxinlineslot="103" sys_dependentid="349642" sys_dependentvariantid="1965">Amy Berrington de Gonz&aacute;lez, D.Phil.</a>, Branch Chief and senior investigator, REB, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376239" sys_siteid="475" rxinlineslot="103" sys_dependentid="349652" sys_dependentvariantid="1965">Gretchen Gierach, Ph.D., M.P.H.</a>, Deputy Chief and senior investigator, Integrative Tumor Epidemiology Branch, on studies to advance our understanding of contralateral breast cancer.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Ramin%2C%20Cody%20A%5BFull%20Author%20Name%5D%20OR%20%22Ramin%20CA%22%5BAuthor%5D&amp;cmd=DetailsSearch">Scientific Publications &ndash; Cody Ramin</a></p>
<div style="clear: both; margin-top: 28px;">
<h3><strong><a id="Rose"></a>Andr&eacute; Rose, M.D., Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
</div>
<div style="clear: both; margin-top: 28px;">
<div sys_dependentvariantid="2088" sys_dependentid="1146434" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376265">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1146434&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Andr&eacute; Rose, M.D., Ph.D., joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in March 2019. Dr. Rose earned his medical degree from the University of the Witwatersrand (Johannesburg, South Africa) in 1999 and his Ph.D. in epidemiology and medical physics from the University of the Free State (Bloemfontein, South Africa) in 2018. While at the University of the Free State, he worked with Prof. William Rae and focused on radiation induced cataracts and radiation safety practices in a catheterization laboratory. Dr. Rose&rsquo;s research interests include occupational radiation safety and occupational radiation epidemiology. In REB, Dr. Rose is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_contentid="939428" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376246" sys_siteid="475" rxinlineslot="103" sys_dependentid="939428" sys_dependentvariantid="1965">Cari Kitahara, Ph.D., investigator</a>, to explore risks associated with work history practices, including radiation safety, among nuclear medicine technologists, and long-term health risks in medical radiation workers more broadly&nbsp;.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/andre.rose.1/bibliography/58087993/public/?sort=date&amp;direction=ascending">Scientific publications</a></p>
<p></p>
</div>
<h3><a id="Villoing"></a>Daphn&eacute;e Villoing, Ph.D.&nbsp;&ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1047406" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376266">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="Daphnee Villoing, Ph.D. " src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1047406&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Daphn&eacute;e Villoing, Ph.D., joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in April 2016. Dr. Villoing received an M.Sc. in biomedical engineering (2010), an M.Sc. in medical physics (2011), and a Ph.D. in medical physics (October 2015) from Paul Sabatier University, Toulouse, France.&nbsp; Her doctoral dissertation work was focused on the impact of the Monte Carlo code GATE on imaging and dosimetric calculations for targeted radionuclide therapy. Dr. Villoing&rsquo;s main research interests are Monte Carlo modelling, dosimetry of ionizing radiation in medical imaging and radiation therapy, radiation protection, and computational anthropomorphic models for medical imaging and radiation therapy. In REB, Dr. Villoing is working on the calculation of organ doses to patients who underwent diagnostic nuclear medicine procedures between the early 1960s and the present, under the supervision of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376235" sys_siteid="475" rxinlineslot="103" sys_dependentid="349634" sys_dependentvariantid="1965">Choonsik Lee, Ph.D. </a>,and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_contentid="939611" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376236" sys_siteid="475" rxinlineslot="103" sys_dependentid="939611" sys_dependentvariantid="1965">Vladimir Drozdovitch, Ph.D.</a> She is also involved in the evaluation of historical trends for occupational doses received by participants in the U.S. Radiologic Technologists Study and the U.S. Nuclear Medicine Technologists Pilot Study from 1960-2010, under the supervision of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_contentid="939428" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7376237" sys_siteid="475" rxinlineslot="103" sys_dependentid="939428" sys_dependentvariantid="1965">Cari Kitahara, Ph.D.</a> Another component of her postdoctoral work is to estimate uncertainty and to increase dosimetric accuracy for organ doses for patients who underwent nuclear medicine procedures, using Monte Carlo radiation transport coupled with computational human phantoms, under Dr. Lee&rsquo;s supervision.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/18YK8FksLp7AKr/bibliography/public/">Scientific Publications - Daphn&eacute;e Villoing</a></p>
<h3><strong></strong></h3>
<h3 id="Withrow"><strong>Diana Withrow, Ph.D. &ndash; Research Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1052627" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376267">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1052627&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Diana Withrow, Ph.D., joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in May 2016 and promoted to Research Fellow in June 2018. Dr. Withrow earned her Ph.D. in epidemiology from the University of Toronto Dalla Lana School of Public Health in 2016. Working with Dr. Loraine Marrett, her doctoral research comprised the first national-level analysis of cancer survival among First Nations and M&eacute;tis adults in Canada. In 2010, Dr. Withrow earned an M.Sc. in epidemiology from the London School of Hygiene and Tropical Medicine. Dr. Withrow&rsquo;s research interests include socio-demographic and economic disparities in survival and survivorship, the role of therapy on second cancer risk, and the optimal application of survival analysis techniques to these research areas. At NCI, Dr. Withrow is working with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/berrington-amy">Amy Berrington de Gonz&aacute;lez, D.Phil.</a>, Branch Chief and senior investigator, REB, and <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/morton-lindsay">Lindsay Morton, Ph.D.</a>, senior investigator, REB. Dr. Withrow is currently working on several projects with the goal of characterizing patterns in second cancer incidence, particularly among breast cancer survivors.&nbsp;</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Withrow%20D[Author]%20AND%20%28%222011%22[PDAT]%20%3A%20%223000%22[PDAT]%29&amp;cmd=DetailsSearch">Scientific Publications - Diana Withrow</a></p>
<h3><strong><a id="Yeom"></a>Yeon Soo Yeom, Ph.D. - Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1119851" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7376268">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1119851&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Yeon Soo Yeom, Ph.D., joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in March 2018. Dr. Yeom earned his B.S. (2011) and Ph.D. (2017) in nuclear engineering from Hanyang University, Seoul, South Korea, where he subsequently served as a postdoctoral researcher prior to joining REB. During his doctoral and postdoctoral training at Hanyang University, working with Prof. Chan Hyeong Kim, Dr. Yeom developed new adult male and female mesh-type reference computational phantoms for the International Commission on Radiological Protection (ICRP). Currently, Dr. Yeom is a full member on the International Commission of Radiological Protection (ICRP) Task Group 103 and a corresponding member on the ICRP Task Group 90. In REB, Dr. Yeom is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/lee-choonsik">Choonsik Lee, Ph.D.</a>, head of the Dosimetry Unit and senior investigator, REB, to expand his research experience to dosimetry studies for radiation epidemiology focusing on dose reconstruction for proton therapy patients.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Yeom+Yeon+Soo%5BAuthor%5D">Scientific Publications &ndash; Yeon Soo Yeom</a></p>
<h3><a href="#top">Back to Top</a></h3>
</div>]]></content>
  </row>
  <row para_id="302502" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel">Abbreviations:<br /><br />Not cooked and not eaten=NOT cooked with skin and NOT eaten with skin<br />Yes cooked and not eaten=YES cooked with skin and NOT eaten with skin<br />Yes cooked and yes eaten=YES cooked with skin and YES eaten with skin<br /><br />Pred mutagen=Predicted mutagenicity<br />Meat mutagen=Actual mutagenicity (Ames)<br /><br />Note for grilled chicken, the values for medium and well are the same<br />since they were unreasonably high for the well done chicken with regard<br />to actual and predicted mutagenicity.<br /><br />***********************Pan Fried chicken******************************;<br /><br />/* Meiqx*/<br /><br />Meiqx Fried Chicken Not Cooked And Not Eaten Just Done =0.09;<br />Meiqx Fried Chicken Not Cooked And Not Eaten Medium Done =0.34;<br />Meiqx Fried Chicken Not Cooked And Not Eaten Very Done =1.04;<br /><br />Meiqx Fried Chicken Yes Cooked And Not Eaten Just Done =0.14;<br />Meiqx Fried Chicken Yes Cooked And Not Eaten Medium Done =0.49;<br />Meiqx Fried Chicken Yes Cooked And Not Eaten Very Done =0.25;<br /><br />Meiqx Fried Chicken Yes Cooked And Yes Eaten Just Done =0.25;<br />Meiqx Fried Chicken Yes Cooked And Yes Eaten Medium Done =0.65;<br />Meiqx Fried Chicken Yes Cooked And Yes Eaten Well Done =0.72;<br /><br />/* Phip*/<br /><br />Phip Fried Chicken Not Cooked And Not Eaten Just Done =0.54;<br />Phip Fried Chicken Not Cooked And Not Eaten Medium Done =1.53;<br />Phip Fried Chicken Not Cooked And Not Eaten Very Done =7.64;<br /><br />Phip Fried Chicken Yes Cooked And Not Eaten Just Done =1.39;<br />Phip Fried Chicken Yes Cooked And Not Eaten Medium Done =3.18;<br />Phip Fried Chicken Yes Cooked And Not Eaten Very Done =5.80;<br /><br />Phip Fried Chicken Yes Cooked And Yes Eaten Just Done =2.43;<br />Phip Fried Chicken Yes Cooked And Yes Eaten Medium Done =7.86;<br />Phip Fried Chicken Yes Cooked And Yes Eaten Well Done =21.13;<br /><br />/*Dimeiqx*/<br /><br />Dimeiqx Fried Chicken Not Cooked And Not Eaten Just Done =0;<br />Dimeiqx Fried Chicken Not Cooked And Not Eaten Medium Done =0;<br />Dimeiqx Fried Chicken Not Cooked And Not Eaten Very Done =0.51;<br /><br />Dimeiqx Fried Chicken Yes Cooked And Not Eaten Just Done =0;<br />Dimeiqx Fried Chicken Yes Cooked And Not Eaten Medium Done =0;<br />Dimeiqx Fried Chicken Yes Cooked And Not Eaten Very Done =0;<br /><br />Dimeiqx Fried Chicken Yes Cooked And Yes Eaten Just Done =0.06;<br />Dimeiqx Fried Chicken Yes Cooked And Yes Eaten Medium Done =0.06;<br />Dimeiqx Fried Chicken Yes Cooked And Yes Eaten Well Done =0;<br /><br />/* Pred Mutagenicity*/<br /><br />Pred Mutagen Fried Chicken Not Cooked And Not Eaten Just Done =9.33;<br />Pred Mutagen Fried Chicken Not Cooked And Not Eaten Medium Done =36.67;<br />Pred Mutagen Fried Chicken Not Cooked And Not Eaten Very Done =281;<br /><br />Pred Mutagen Fried Chicken Yes Cooked And Not Eaten Just Done =50;<br />Pred Mutagen Fried Chicken Yes Cooked And Not Eaten Medium Done =55;<br />Pred Mutagen Fried Chicken Yes Cooked And Not Eaten Very Done =36.77;<br /><br />Pred Mutagen Fried Chicken Yes Cooked And Yes Eaten Just Done =77.17;<br />Pred Mutagen Fried Chicken Yes Cooked And Yes Eaten Medium Done =100.5;<br />Pred Mutagen Fried Chicken Yes Cooked And Yes Eaten Well Done =113.80;<br /><br />/* Actual Mutagenicity*/<br /><br />Meat Mutagen Fried Chicken Not Cooked And Not Eaten Just Done =43.33;<br />Meat Mutagen Fried Chicken Not Cooked And Not Eaten Medium Done =359.33;<br />Meat Mutagen Fried Chicken Not Cooked And Not Eaten Very Done =122.67;<br /><br />Meat Mutagen Fried Chicken Yes Cooked And Not Eaten Just Done =35.33;<br />Meat Mutagen Fried Chicken Yes Cooked And Not Eaten Medium Done =116;<br />Meat Mutagen Fried Chicken Yes Cooked And Not Eaten Very Done =89.67;<br /><br />Meat Mutagen Fried Chicken Yes Cooked And Yes Eaten Just Done =41.61;<br />Meat Mutagen Fried Chicken Yes Cooked And Yes Eaten Medium Done =142.81;<br />Meat Mutagen Fried Chicken Yes Cooked And Yes Eaten Well Done =153.78;<br /><br />**********************************Broiled Chicken********************;<br /><br />/* Meiqx*/<br /><br />Meiqx Broiled Chicken Not Cooked And Not Eaten Just Done =0;<br />Meiqx Broiled Chicken Not Cooked And Not Eaten Medium Done =0.09;<br />Meiqx Broiled Chicken Not Cooked And Not Eaten Very Done =0.5;<br /><br />Meiqx Broiled Chicken Yes Cooked And Not Eaten Just Done =0;<br />Meiqx Broiled Chicken Yes Cooked And Not Eaten Medium Done =0;<br />Meiqx Broiled Chicken Yes Cooked And Not Eaten Very Done =0.18;<br /><br />Meiqx Broiled Chicken Yes Cooked And Yes Eaten Just Done =0.04;<br />Meiqx Broiled Chicken Yes Cooked And Yes Eaten Medium Done =0.02;<br />Meiqx Broiled Chicken Yes Cooked And Yes Eaten Well Done =0.32;<br /><br />/* Phip*/<br /><br />Phip Broiled Chicken Not Cooked And Not Eaten Just Done =0.49;<br />Phip Broiled Chicken Not Cooked And Not Eaten Medium Done =2.18;<br />Phip Broiled Chicken Not Cooked And Not Eaten Very Done =18.91;<br /><br />Phip Broiled Chicken Yes Cooked And Not Eaten Just Done =0;<br />Phip Broiled Chicken Yes Cooked And Not Eaten Medium Done =1.75;<br />Phip Broiled Chicken Yes Cooked And Not Eaten Very Done =10.65;<br /><br />Phip Broiled Chicken Yes Cooked And Yes Eaten Just Done =2.61;<br />Phip Broiled Chicken Yes Cooked And Yes Eaten Medium Done =8.06;<br />Phip Broiled Chicken Yes Cooked And Yes Eaten Well Done =22.87;<br /><br />/*Dimeiqx*/<br /><br />Dimeiqx Broiled Chicken Not Cooked And Not Eaten Just Done =0;<br />Dimeiqx Broiled Chicken Not Cooked And Not Eaten Medium Done =0;<br />Dimeiqx Broiled Chicken Not Cooked And Not Eaten Very Done =0.19;<br /><br />Dimeiqx Broiled Chicken Yes Cooked And Not Eaten Just Done =0;<br />Dimeiqx Broiled Chicken Yes Cooked And Not Eaten Medium Done =0;<br />Dimeiqx Broiled Chicken Yes Cooked And Not Eaten Very Done =0;<br /><br />Dimeiqx Broiled Chicken Yes Cooked And Yes Eaten Just Done =0;<br />Dimeiqx Broiled Chicken Yes Cooked And Yes Eaten Medium Done =0;<br />Dimeiqx Broiled Chicken Yes Cooked And Yes Eaten Well Done =0.09;<br /><br />/* Pred Mutagenicity*/<br /><br />Pred Mutagen Broiled Chicken Not Cooked And Not Eaten Just Done =1;<br />Pred Mutagen Broiled Chicken Not Cooked And Not Eaten Medium Done =13;<br />Pred Mutagen Broiled Chicken Not Cooked And Not Eaten Very Done =146;<br /><br />Pred Mutagen Broiled Chicken Yes Cooked And Not Eaten Just Done =0;<br />Pred Mutagen Broiled Chicken Yes Cooked And Not Eaten Medium Done =3.5;<br />Pred Mutagen Broiled Chicken Yes Cooked And Not Eaten Very Done =38.5;<br /><br />Pred Mutagen Broiled Chicken Yes Cooked And Yes Eaten Just Done =9.45;<br />Pred Mutagen Broiled Chicken Yes Cooked And Yes Eaten Medium Done =17.76;<br />Pred Mutagen Broiled Chicken Yes Cooked And Yes Eaten Well Done =105.18;<br /><br />/* Actual Mutagenicity*/<br /><br />Meat Mutagen Broiled Chicken Not Cooked And Not Eaten Just Done =237;<br />Meat Mutagen Broiled Chicken Not Cooked And Not Eaten Medium Done =98;<br />Meat Mutagen Broiled Chicken Not Cooked And Not Eaten Very Done =135.5;<br /><br />Meat Mutagen Broiled Chicken Yes Cooked And Not Eaten Just Done =36;<br />Meat Mutagen Broiled Chicken Yes Cooked And Not Eaten Medium Done =13;<br />Meat Mutagen Broiled Chicken Yes Cooked And Not Eaten Very Done =94.5;<br /><br />Meat Mutagen Broiled Chicken Yes Cooked And Yes Eaten Just Done =69.51;<br />Meat Mutagen Broiled Chicken Yes Cooked And Yes Eaten Medium Done=72.00;<br />Meat Mutagen Broiled Chicken Yes Cooked And Yes Eaten Well Done =310.51;<br /><br />***********************Grilled Chicken********************************;<br /><br />/* Meiqx*/<br /><br />Meiqx Grilled Chicken Not Cooked And Not Eaten Just Done =0;<br />Meiqx Grilled Chicken Not Cooked And Not Eaten Medium Done =0.36;<br />Meiqx Grilled Chicken Not Cooked And Not Eaten Very Done =1.15;<br /><br />Meiqx Grilled Chicken Yes Cooked And Not Eaten Just Done =0;<br />Meiqx Grilled Chicken Yes Cooked And Not Eaten Medium Done =0.12;<br />Meiqx Grilled Chicken Yes Cooked And Not Eaten Very Done =0.38;<br /><br />Meiqx Grilled Chicken Yes Cooked And Yes Eaten Just Done =0.07;<br />Meiqx Grilled Chicken Yes Cooked And Yes Eaten Medium Done =0.11;<br />Meiqx Grilled Chicken Yes Cooked And Yes Eaten Well Done =0.55;<br /><br />/* Phip*/<br /><br />Phip Grilled Chicken Not Cooked And Not Eaten Just Done =1.53;<br />Phip Grilled Chicken Not Cooked And Not Eaten Medium Done =11.33;<br />Phip Grilled Chicken Not Cooked And Not Eaten Very Done =11.33;<br /><br />Phip Grilled Chicken Yes Cooked And Not Eaten Just Done =1.52;<br />Phip Grilled Chicken Yes Cooked And Not Eaten Medium Done =5.75;<br />Phip Grilled Chicken Yes Cooked And Not Eaten Very Done =5.75;<br /><br />Phip Grilled Chicken Yes Cooked And Yes Eaten Just Done =5.12;<br />Phip Grilled Chicken Yes Cooked And Yes Eaten Medium Done =10.24;<br />Phip Grilled Chicken Yes Cooked And Yes Eaten Well Done =10.24;<br /><br />/*Dimeiqx*/<br /><br />Dimeiqx Grilled Chicken Not Cooked And Not Eaten Just Done =0;<br />Dimeiqx Grilled Chicken Not Cooked And Not Eaten Medium Done =0.37;<br />Dimeiqx Grilled Chicken Not Cooked And Not Eaten Very Done =0.45;<br /><br />Dimeiqx Grilled Chicken Yes Cooked And Not Eaten Just Done =0;<br />Dimeiqx Grilled Chicken Yes Cooked And Not Eaten Medium Done =0;<br />Dimeiqx Grilled Chicken Yes Cooked And Not Eaten Very Done =0;<br /><br />Dimeiqx Grilled Chicken Yes Cooked And Yes Eaten Just Done =0;<br />Dimeiqx Grilled Chicken Yes Cooked And Yes Eaten Medium Done =0;<br />Dimeiqx Grilled Chicken Yes Cooked And Yes Eaten Well Done =0;<br /><br />/* Pred Mutagenicity*/<br /><br />Pred Mutagen Grilled Chicken Not Cooked And Not Eaten Just Done =3;<br />Pred Mutagen Grilled Chicken Not Cooked And Not Eaten Medium Done=174.5;<br />Pred Mutagen Grilled Chicken Not Cooked And Not Eaten Very Done =174.5;<br /><br />Pred Mutagen Grilled Chicken Yes Cooked And Not Eaten Just Done =3;<br />Pred Mutagen Grilled Chicken Yes Cooked And Not Eaten Medium Done =23.5;<br />Pred Mutagen Grilled Chicken Yes Cooked And Not Eaten Very Done =23.5;<br /><br />Pred Mutagen Grilled Chicken Yes Cooked And Yes Eaten Just Done =17.03;<br />Pred Mutagen Grilled Chicken Yes Cooked And Yes Eaten Medium Done =32.15;<br />Pred Mutagen Grilled Chicken Yes Cooked And Yes Eaten Well Done =32.15;<br /><br />/* Actual Mutagenicity*/<br /><br />Meat Mutagen Grilled Chicken Not Cooked And Not Eaten Just Done =39.5;<br />Meat Mutagen Grilled Chicken Not Cooked And Not Eaten Medium Done =161;<br />Meat Mutagen Grilled Chicken Not Cooked And Not Eaten Very Done =161;<br /><br />Meat Mutagen Grilled Chicken Yes Cooked And Not Eaten Just Done =93.5;<br />Meat Mutagen Grilled Chicken Yes Cooked And Not Eaten Medium Done =166.5;<br />Meat Mutagen Grilled Chicken Yes Cooked And Not Eaten Very Done =166.5;<br /><br />Meat Mutagen Grilled Chicken Yes Cooked And Yes Eaten Just Done =129.48;<br />Meat Mutagen Grilled Chicken Yes Cooked And Yes Eaten Medium Done=271.12;<br />Meat Mutagen Grilled Chicken Yes Cooked And Yes Eaten Well Done =271.12;</div>]]></content>
  </row>
  <row para_id="302507" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="top"></a>
<p style="float: right; text-align: center; margin-left: 1em;"><img alt="Thumbnail image of the cover of Health Physics, Volume 99, Issue 2, August 2010, featuring a map of the Marshall Islands." inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_contentid=303450" style="width: 150px; height: 199px; border: 0px;" sys_dependentid="303450" sys_dependentvariantid="1482" sys_relationshipid="7390399" title="Thumbnail image of the cover of Health Physics, Volume 99, Issue 2, August 2010, featuring a map of the Marshall Islands." /><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302471" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302471" sys_dependentvariantid="1418" sys_relationshipid="7390400" sys_siteid="475" sys_variantid="1418" sys_contentid="302471">View bibliography of published articles</a></p>
<p>Between 1946 and 1958 the United States tested 66 nuclear weapons on or near Bikini and Enewetak atolls, which had previously been evacuated. NCI investigators concluded, based on extensive analyses described in their publications, that populations living on any of the other atolls in the Marshall Islands archipelago were exposed to measurable radioactive fallout from 20 of those tests.</p>
<p>In this carefully considered analysis, National Cancer Institute (NCI) experts estimate that as much as 1.6% of all cancers among those residents of the Marshall Islands alive between 1948 and 1970 might be attributable to radiation exposures resulting from nuclear testing fallout. Due to uncertainly inherent to these analyses, the authors calculated a 90% confidence interval of 0.4% to 3.6%.</p>
<ul class="grey-bullets" style="margin-left: 2em;">
<li><a href="#purpose">Purpose of the NCI Investigation</a></li>
<li><a href="#summary_analyses">Summary of Analyses and Results</a></li>
<li><a href="#summary_methods">Summary of Research Methods</a></li>
<li><a href="#summary_exposure">Summary of Radioactive Fallout Exposure from Testing for Residents of the Marshall Islands</a></li>
<li><a href="#summary_doses">Summary of Radiation Doses</a></li>
<li><a href="#background">Background and History of this Investigation</a></li>
</ul>
<h2 id="purpose">Purpose of the NCI Investigation</h2>
<p>In June 2004, the U.S. Senate Committee on Energy and Natural Resources asked the NCI to provide its expert opinion on the baseline cancer risk and number of cancers expected among residents of the Marshall Islands as a result of exposures to radioactive fallout from U.S. nuclear weapons tests that were conducted there from 1946 through 1958. In September 2004, the NCI provided the Committee with preliminary cancer risk estimates and a discussion of their basis in a report titled <!--<a href="/files/9-28Response_appendix.pdf"> -->Estimation of the Baseline Number of Cancers Among Marshallese and the Number of Cancers Attributable to Exposure to Fallout from Nuclear Weapons Testing Conducted in the Marshall Islands (PDF)<!--</a> -->. That analysis was based on a number of conservative assumptions designed to avoid underestimating the actual cancer risks and used information that could be collected quickly to provide a timely response.</p>
<p>In a considerably more thorough analysis published in the August 2010 issue of the journal <i>Health Physics</i>, NCI presents revised estimates of the number of excess (radiation-related) cancers for those residents who were exposed to radioactive fallout. These findings, reported in eight papers covering the subjects of external dose, internal dose, cancer risk projections, as well as the methodologies of dose reconstruction, are the result of several years of work to provide more precise estimates of cancer risk.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h2 id="summary_analyses">Summary of Analyses and Results</h2>
<p>NCI's findings are based on the most detailed dose reconstruction to date. The analyses include populations living on all inhabited atolls (except the nuclear test site atolls which were unoccupied) and include dose contributions from each of the 20 nuclear tests that resulted in measurable fallout according to the NCI analysis.</p>
<p>The investigators estimated tissue-specific absorbed doses at all historically inhabited atolls from internal (ingested) and external radiation. The information is presented by atoll, nuclear test, and year of age of the population at time of exposure. The assessment of cancer risks is for all Marshallese alive at any time during the years 1948 through 1970.</p>
<p>The authors estimate that as much as 1.6% of all cancers (about 170 cancers) among those alive between 1948 and 1970 might be attributable to radiation exposures resulting from nuclear testing fallout. Due to uncertainly inherent to these analyses, the authors calculated a 90% confidence interval of 0.4% to 3.6%. For specific populations the doses and the risk varied widely depending on location. People living in northern atoll locations received higher doses and were subject to greater cancer risks. For the 82 people who lived on Rongelap atoll, the authors projected 55% of all cancers might be attributed to fallout exposure. For Utrik, where 157 people were exposed, 10% of all cancers might be attributed to fallout. For the much larger populations exposed in mid-latitude and southern atolls (e.g., Kwajalein and Majuro), about 2% or 1% (respectively) could be due to fallout. Confidence bounds were also calculated for these estimates.</p>
<p>The completed analysis projects about 170 excess cancers (radiation-related cases) to occur among more than 25,000 Marshallese, half of whom were born before 1948. This estimate is considerably lower than the 500 cases (9% of all cancers) projected by NCI in the preliminary response to the Senate request in 2004. That analysis, produced quickly, was purposely intended to avoid underestimation of the true cancer risk.</p>
<p>The estimated 170 excess cancers occurred in the context of about 10,600 cancers that would have spontaneously arisen among the same cohort of Marshallese for reasons unrelated to fallout. In the absence of reliable cancer incidence data from the Marshall Islands, the NCI investigators used the <a href="http://seer.cancer.gov/">NCI Surveillance, Epidemiology, and End Results (SEER)</a> database that tracks cancer incidence in a representative sample of the United States population. At the time of this analysis, the authors expect that all but about 65 of the 170 projected radiation-related cancers have already developed in the population.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h3>Comparison of Published Estimates to Preliminary Figures Provided to Congress</h3>
<p>The preliminary analysis conducted in 2004 was based on a number of conservative assumptions designed to avoid underestimating the actual cancer risks. The researchers used available information that could be collected quickly to provide a timely response. The present report was a scientifically rigorous study based on a more thorough and painstaking gathering of exposure data.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h3>Expected Cancer Types</h3>
<p>While most cancer types can be related to radiation exposure, certain organs appear more susceptible to the cancer-causing effects of the exposure. For this reason, the NCI estimated risks for the four cancers most likely to occur given the nature of the fallout exposures. They are cancers of the thyroid, stomach, and colon, as well as leukemia.</p>
<p>The percentage of cancers expected from the exposure to fallout varied by location of the population during the years of exposure. The lowest values are for residents of the southern atolls during the testing years, while highest values are for members of the Rongelap community in the northern atolls. The corresponding percentages of cancers due to radiation in the two locations are as follows: thyroid cancer (12% and 95%), leukemia (2% and 78%), stomach (1% and 48%), colon (1% and 64%), and all cancers combined (1% and 55%).</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h2 id="summary_methods">Summary of Research Methods</h2>
<p>These improved estimates resulted from an extensive effort by NCI scientists over three years to collect and analyze all available relevant data, including many historical documents from the Atomic Energy Commission laboratory that conducted the fallout monitoring for the U.S. nuclear testing program. These historical measurements were collected, re-reviewed, and systematically integrated with more contemporary environmental radiation measurement data. In addition, scientists at the National Oceanic and Atmospheric Administration assisted NCI investigators with interpreting historical meteorological data and provided meteorological models to assist in reconstructing fallout deposition patterns. These new resources allowed investigators to construct exposure estimates for every atoll and from all nuclear tests conducted in the Marshall Islands.</p>
<p>Using the refined estimates of radiation doses, the investigators at NCI calculated cancer risks by applying statistical models for dose-specific risks from a recent report by an expert committee of the U.S. National Academies. As with any historical risk assessment of this kind, fallout-related radiation doses and associated cancer risks cannot be determined exactly and so are presented in the form of a "best" estimate and a range, consistent with the available data. This range is based on dose estimates from the study and the larger body of information from studies of cancer risk in other radiation-exposed populations. NCI investigators believe these efforts have resulted in substantially more accurate and judicious conclusions.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h2 id="summary_exposure">Summary of Radioactive Fallout Exposure from Testing for Residents of the Marshall Islands</h2>
<p>Nuclear testing took place on the islands and lagoons of Bikini Atoll and Enewetak Atoll or in nearby ocean waters. Radioactive debris from the detonations was dispersed into the atmosphere and was generally blown by the predominantly easterly winds towards the open ocean west of the Marshall Islands. In many cases, however, the winds at different altitudes blew in different directions, and upon occasion carried radioactive fallout to inhabited atolls. The radioactive debris that fell to the ground is termed fallout. The radiation doses resulting from fallout deposited on the atolls include three components: (1) doses from external radiation emitted by fallout deposited on the ground; (2) doses from ingested radioactive particles immediately or soon after fallout deposition, including accidental ingestion of particles, contamination of food, plates and eating utensils, as well as hands and faces; and (3) doses from contaminated seafood and locally grown fruits and vegetables, which occurred over long periods of time (months to years) after the fallout was deposited.</p>
<p>Radiation doses received by the residents of the Marshall Islands differed greatly by geographic location and year of birth. Of special concern is exposure at an early age because, in general, young children are more sensitive to radiation damage and received higher doses of radiation than adults.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h2 id="summary_doses">Summary of Radiation Doses</h2>
<p>The larger population residing on the southern atolls received the lowest doses. Permanent residents of the southern atolls who were of adult age at the beginning of the testing period received external doses ranging from 5 to 12 mGy on average. In contrast, the external doses to adults at the mid-latitude atolls ranged from 22 to 60 mGy on average, while the residents of the northern atolls received external doses in the hundreds to over 2000 mGy. The doses received by residents of the northern atolls were essentially due to a single test, Castle-Bravo, which was detonated in 1954 and led to evacuation of the northern atolls to avert continued exposure.</p>
<p>Internal doses were calculated for the thyroid, red bone marrow, stomach wall, and colon wall. The internal doses were found to vary as a function of location, age at exposure, and type of organ or tissue. The thyroid doses were higher than the doses to the other organs and tissues. Average thyroid doses to adults ranged from 12 to 34 mGy in the southern atolls, from 67 to 160 mGy in the mid-latitude atolls, and from 760 to 7,600 mGy in the northern atolls.</p>
<p>By comparison, the annual dose from external radiation arising from exposure to natural radiation from the environment is 1 mGy in the U.S. and the dose from a single CT scan of the abdomen is typically 10 mGy.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
<h2 id="background">Background and History of this Investigation</h2>
<p>In June 2004, the U.S. Senate Committee on Energy and Natural Resources asked the NCI to provide its expert opinion on the baseline cancer risk and number of cancers expected among residents of the Marshall Islands as a result of exposures to radioactive fallout. In September 2004, the NCI provided the Committee with preliminary estimates and a discussion of their basis. In the summer of 2005, the U.S. House Committees on Natural Resources and on International Relations, Subcommittee on Asia and the Pacific, convened a joint oversight hearing on the "United States Nuclear Legacy in the Marshall Islands: Consideration of Issues Relating to the Changed Circumstances Petition". The Senate Committee on Energy and Natural Resources conducted a hearing on the same topic. At those hearings, NCI investigators summarized their 2004 analysis and specified plans to develop and submit for publication in the peer-reviewed literature refined estimates of doses and cancer risks and the methods employed to derive them. From 2005 to 2008, with assistance from experts at other federal agencies, NCI radiation dosimetrists and statisticians have worked to improve the 2004 estimates and their documentation. In December 2008, the manuscripts were submitted to <i>Health Physics</i> for extensive anonymous scientific peer review, followed by publication in August 2010.</p>
<p style="text-align: right;"><a href="#top">[Return to top]</a></p>
</div>]]></content>
  </row>
  <row para_id="302509" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The last three decades have seen dramatic improvements in cancer survival, mainly due to advances in treatment and the increased detection of cancer at an early stage. With more than 15 million cancer survivors in the U.S. alone, concern has turned to potential late effects, particularly the development of a new malignancy. To identify groups of cancer survivors&nbsp;who are at increased risk for multiple primary cancers, investigators in the Radiation Epidemiology Branch (REB) led a collaborative effort to provide the first comprehensive population-based analysis of the risk of subsequent cancer in the U.S., published in 2006 as a monograph entitled&nbsp;<a href="https://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf">New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000 (PDF, 3.1MB)</a>,&nbsp;Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker D, Edwards B, Tucker P, Fraumeni JF, Jr., editors.&nbsp;</p>
<p>The 500-page monograph utilized data from nine cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program from 1973 to 2000. The monograph describes the patterns of subsequent cancer risk for over 50 adult first primary cancers and 19 types of childhood cancers, by gender, age at initial diagnosis, time since diagnosis, initial treatment by radiation, and histologic type. Each chapter focuses on a specific initial cancer, presents the risk of subsequent cancers, and discusses potential causal mechanisms. The monograph provides a resource that will be useful to clinicians, researchers, policy makers, and cancer survivors, especially in tailoring appropriate guidelines and strategies for prevention and early detection of new malignancies. Other studies have evaluated risk of subsequent cancers for individual cancer types or groups of cancers, usually related to the late effects of treatment, but this report provides the first complete evaluation of subsequent cancer risk in the U.S.</p>
<p>The survey of 2 million cancer survivors (including 76,000 20-year survivors) revealed that 9.1% (n = 186,000) developed a new malignancy. Development of a second cancer was likely dependent on multiple factors, including tobacco use, alcohol use, hormonal influences, viral infections, genetic predisposition, and the adverse effects of treatment. Risks of developing a new malignancy were substantially higher among children (relative risks of 6-fold) than among adults. Expanded use of aggressive cancer treatments, particularly combined modality radiotherapy and chemotherapy, likely contributed to the increased incidence of second malignancies. The highest treatment-related risks were apparent for children and young adults. Overall, radiotherapy for most adult-onset cancers (at age 50 or older) was not associated with a large increase in subsequent cancer risk, except in specific patient subgroups (e.g., 10-year survivors of breast cancer treated with high dose radiotherapy to the chest wall and lymph nodes had excess subsequent cancers of the esophagus, bone, soft tissue, and lung).</p>
<p>The monograph&rsquo;s results reveal variation in the burden of second cancers among cancer survivors. Combined tobacco and alcohol use likely accounted for a substantial excess of subsequent cancers following initial upper aerodigestive and respiratory tract cancers. Because of shared reproductive risk factors, cancers of the breast, uterine corpus, and ovary tended to cluster as multiple tumors within individual survivors. Increased risks of certain subsequent malignancies among younger patients (e.g., colon, ovarian, or breast cancer following initial breast cancer) suggested possible genetic predisposition. Evidence of virally-related second tumors was noted for initial cancers of the cervix and anus and for Kaposi sarcoma. The monograph&rsquo;s identification of patient groups at increased risk for secondary malignancy should lead to the implementation of early diagnosis programs and reduction of morbidity and mortality associated with late cancer occurrence.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=804883" sys_dependentvariantid="1418" sys_dependentid="804883" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280449" sys_variantid="1418" sys_contentid="804883">Learn more about second primary research in DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302511" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3 id="top">Overview</h3>
<p>The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7389907" sys_siteid="475" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a> (OEEB) conducts studies in the U.S. and abroad to identify and clarify causes of cancer, with a focus on occupational and environmental exposures. Our overall research philosophy is to (1) merge epidemiology, quantitative exposure assessment, and molecular&nbsp;epidemiology and genetic components into multi-disciplinary investigations to identify carcinogens, clarify exposure-response relationships, and enhance mechanistic understanding of carcinogenesis, (2) conduct methodologic investigations to develop and improve exposure assessment and other procedures, and (3) develop and maintain resources for occupational and environmental epidemiology and exposure assessment. Fellows work on studies that typically involve intensive collaboration among epidemiologists, experts in occupational and environmental exposure assessment, and molecular&nbsp;epidemiologists in OEEB and other DCEG branches. Senior staff assist fellows in preparing and publishing manuscripts in the peer-reviewed scientific literature and provide advice on career development. Fellows participate in all OEEB activities and are encouraged to present the results of their research at scientific meetings.</p>
<p>To discuss potential opportunities in your research area of interest, you may contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=OEEB">Branch investigators</a> directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=158&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302622" sys_contentid="302622" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302622" sys_dependentvariantid="1418" sys_relationshipid="7389904" sys_variantid="1418">Meet current fellows in the Occupational and Environmental Epidemiology Branch.</a></p>
<h3>Qualifications</h3>
<p>Fellowships in OEEB are provided through the DCEG fellowship program. Qualifications for postdoctoral and predoctoral fellowships in DCEG are listed below. The Division <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389905" sys_variantid="1418">Fellowship Information</a> page also provides information on graduate partnerships with schools of public health and other special fellowship opportunities.</p>
<p><i>Postdoctoral fellowships:</i> Individuals must hold an M.D. or Ph.D. in epidemiology or related field. Individuals with strong quantitative skills and training or experience in the fields of occupational or environmental epidemiology, occupational or environmental exposure assessment, industrial hygiene, genetics, molecular epidemiology, or bioinformatics&nbsp;are encouraged to apply.</p>
<p><i>Predoctoral fellowships:</i> Individuals must be enrolled in a doctoral program with a desire to complete their dissertation in OEEB or have completed a master's degree in a field of relevance to OEEB.</p>
<h3>Application Process</h3>
<p>Postdoctoral and predoctoral fellowship applications in OEEB are accepted on an ongoing basis. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389906" sys_variantid="1418">Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3 id="specific">Training Opportunities with Specific Investigators</h3>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Friesen" sys_contentid="302576#friesen" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389915" sys_siteid="475" sys_variantid="1418">Occupational Exposure Assessment Methods in Cancer Studies with Dr. Melissa Friesen</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Ward-Jones" sys_contentid="302576#ward-jones" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389914" sys_siteid="475" sys_variantid="1418">Environmental Epidemiology with Dr. Mary Ward and Dr. Rena Jones</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Berndt" sys_contentid="302576#berndt" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389908" sys_siteid="475" sys_variantid="1418">Genetic Epidemiology with Dr. Sonja Berndt</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Rothman-Lan" sys_contentid="302576#rothman-lan" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389909" sys_siteid="475" sys_variantid="1418">Molecular Epidemiology of Lung Cancer in Non-Smokers Associated with Indoor Air Pollution, Chemicals, and Particulates / Molecular Epidemiology of Lymphoma and Leukemia Associated with Occupational and Environmental Chemicals with Dr. Qing Lan and Dr. Nathaniel Rothman</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Hofmann" sys_contentid="302576#hofmann" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389910" sys_siteid="475" sys_variantid="1418">Molecular Epidemiology of Pesticides and Other Agricultural Exposures and Cancer Risk with Dr. Jonathan Hoffman</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Koutros" sys_contentid="302576#koutros" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389913" sys_siteid="475" sys_variantid="1418">Molecular Pathology Studies in Exposed Populations with Dr. Stella Koutros</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576#Beane-Freeman" sys_contentid="302576#beane-freeman" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302576" sys_dependentvariantid="1418" sys_relationshipid="7389911" sys_siteid="475" sys_variantid="1418">Occupational and Agricultural Exposures with Dr. Laura Beane Freeman</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302517" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3><strong>Division of Cancer Epidemiology and Genetics (DCEG), NCI</strong></h3>
<h4>Mailing address:</h4>
<p>9609 Medical Center Drive<br />MSC 9776<br />Bethesda, Maryland 20892<br />Telephone: 240-276-7150</p>
<h4>Private carriers/couriers:</h4>
<p>9609 Medical Center Drive<br />Rockville, MD 20850</p>
<p><a href="mailto:ncicontactdceg@mail.nih.gov">Email questions/ information requests to us</a>.</p>
<p>To send us feedback about our website, please email <a href="mailto:ncicontactdceg@mail.nih.gov">ncicontactdceg@mail.nih.gov</a>.</p>
<h4><strong>Useful Information</strong></h4>
<div class="bullet-blu">
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302566" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302566" sys_dependentvariantid="1418" sys_relationshipid="7251633" sys_variantid="1418" sys_contentid="302566">Directions and Local Map</a></li>
<li><a href="http://www.nih.gov/about/visitor/index.htm">NIH Visitor Information</a></li>
<li><a href="http://www.ors.od.nih.gov/pes/dats/parking/Pages/parking_info.aspx">NIH Campus Parking</a></li>
<li><a href="https://www.wmata.com/schedules/maps/index.cfm?t=maps-rail-wrapper">Washington D.C. Metro (Subway) System</a></li>
</ul>
</div>
</div>]]></content>
  </row>
  <row para_id="302518" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3 id="top">Overview</h3>
<p>Investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_relationshipid="7300274" sys_siteid="475" sys_variantid="1422">Biostatistics Branch</a> (BB) work with fellows to develop statistical methods and data resources to strengthen observational studies, intervention trials, and laboratory investigations of cancer. Researchers provide information on cancer rates for generating etiologic leads and developing appropriate study designs.</p>
<p>Research opportunities exist in projects related to statistical methods for epidemiologic research, molecular and genetic epidemiology, risk assessment, environmental epidemiology, screening and to analytic and descriptive epidemiology. Additionally, fellows have opportunities to collaborate across branches in these areas.</p>
<p>For application details, see below. To discuss potential research opportunities, you may contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=BB">branch investigators</a> directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=175&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302619" sys_contentid="302619" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302619" sys_dependentvariantid="1418" sys_relationshipid="7300272" sys_variantid="1418">Meet fellows in the Biostatistics Branch</a>.</p>
<h3>Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Individuals must either hold a doctorate degree in or be enrolled in a doctoral program in statistics, biostatistics, or similar quantitative fields. Individuals with strong computational skills are encouraged to apply.</p>
<p><i>Predoctoral fellowships:</i> Individuals must be enrolled in a doctoral program with the desire to complete their dissertation in the Biostatistics Branch.</p>
<h3>Training Opportunities</h3>
<ul>
<li><a href="/Rhythmyx/assembler/render?sys_contentid=1116544&amp;sys_revision=4&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1116544" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7300277">Postdoctoral Fellowship in Biostatistics</a></li>
<li><a href="/Rhythmyx/assembler/render?sys_contentid=1142712&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1142712" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7300278">Postdoctoral Fellowships for Interdisciplinary Research in Radiation Epidemiology and Biostatistics</a></li>
</ul>
<h3>Application Process</h3>
<p>Besides the training opportunities specifically listed above, predoctoral and postdoctoral fellowship applications in the Biostatistics branch are accepted on an ongoing basis. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7300273" sys_variantid="1418">Division Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
</div>]]></content>
  </row>
  <row para_id="302520" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel">
    <h3>ASSET <strong>Non-Proprietary Software Transfer Agreement</strong></h3><h4>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</h4><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><b>This is a beta version of the software</b>. The ASSET package may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="302522" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Date Updated: 10/28/2014</p>
<p>Date Created: 05/26/2010</p>
<p><b>Short instruction file on the use of the men's colorectal cancer (CRC) absolute risk<br /> projection SAS macro (Men_CRC_RAM),</b></p>
<p>The men's colorectal cancer absolute risk projection SAS macro, &nbsp;Men_CRC_RAM &nbsp;needs<br /> the following information as input to estimate absolute risk of colorectal cancer:</p>
<p>&nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, white<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, african-american<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, hispanic<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=4, asian-american</p>
<p>&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T1, &nbsp;&nbsp;&nbsp;current age ranges from: &nbsp;50 to 85</p>
<p>&nbsp;&nbsp;T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T2, projection age ranges from: &nbsp;T2&gt;T1 &nbsp;and &nbsp;T2&lt;=90</p>
<p>&nbsp;&nbsp;Sigmoid_Polyps &nbsp;&nbsp;=0, yes sigmoidoscopy and/or colonscopy last 10 years, &nbsp;no history of polyps<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1. &nbsp;no sigmoidoscopy and/or colonscopy last 10 years<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, yes sigmoidoscopy and/or colonscopy last 10 years, yes history of polyps</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, unk sigmoidoscopy and/or colonscopy last 10 years, unk history of polyps &nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;yes sigmoidoscopy and/or colonscopy last 10 years, unk history of polyps</p>
<p>&nbsp;&nbsp;NoIBuprofin &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, regular user of non aspirin containin NSaids, e.g. IBuprofin only &nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dont know &nbsp;&nbsp;denoted on the input data as -9</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;&nbsp;&nbsp;non user of non aspirin containin NSaids, e.g. IBuprofin only</p>
<p>&nbsp;&nbsp;Vigorus_Xrcis &nbsp;&nbsp;&nbsp;=0, 0 hrs/wk<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, greater than 0 and less than equal 2 hrs/wk<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, greater than 2 and less than equal 4 hrs/wk<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, greater than 4 hrs/wk</p>
<p>&nbsp;&nbsp;Cig_Yrs &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, # yrs cigarette smoking &nbsp;= &nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dont know &nbsp;&nbsp;denoted on the input data as -9</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, # yrs cigarette smoking &nbsp;&gt; &nbsp;0 &nbsp;and &nbsp;&lt; 15<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, # yrs cigarette smoking &gt;= 15 &nbsp;and &nbsp;&lt; 35<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, # yrs cigarette smoking &gt;= 35</p>
<p>&nbsp;&nbsp;Vegetable &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, greater &nbsp;&nbsp;equal to five servings of vegetables per day<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, less &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than &nbsp;&nbsp;&nbsp;&nbsp;five servings of vegetables per day</p>
<p>&nbsp;&nbsp;Num_Cigs &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, # cigarettes smokes &nbsp;&nbsp;= &nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dont know &nbsp;&nbsp;denoted on the input data as -9</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, # cigarettes smokes &nbsp;&gt;= &nbsp;1 &nbsp;and &nbsp;&lt; &nbsp;11<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, # cigarettes smokes &nbsp;&gt;= 11 &nbsp;and &nbsp;&lt;= 20<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, # cigarettes smokes &nbsp;&gt;= 21</p>
<p>&nbsp;&nbsp;BMI_Trnd &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, BMI &lt;= 24.9<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, BMI &nbsp;&gt; 24.9 &nbsp;and &nbsp;BMI &lt;= 29.9<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, BMI &nbsp;&gt; 29.9</p>
<p>&nbsp;&nbsp;No_NSaids &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, regular user of asprin containing NSaids &nbsp;&nbsp;&nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dont know &nbsp;&nbsp;denoted on the input data as -9</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;&nbsp;&nbsp;non user of asprin containing NSaids</p>
<p>&nbsp;&nbsp;Fam_Hist_CRC &nbsp;&nbsp;&nbsp;&nbsp;=0, 0 relative &nbsp;with CRC &nbsp;(CRC=Colorectal Cancer) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dont know if any relatives with CRC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;denoted by -9</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, 1 relative &nbsp;with CRC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have relative with CRC, dont know how many &nbsp;&nbsp;denoted by -8</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, 2 or more relatives with CRC</p>
<p>&nbsp;&nbsp;!!!!!!!!!!!! &nbsp;Warning Warning Warning Warning Warning Warning &nbsp;!!!!!!!!!!!!<br /> &nbsp;&nbsp;!!!!!!!!!!!! &nbsp;&nbsp;Warning about an inadmissible error condition &nbsp;&nbsp;!!!!!!!!!!!!</p>
<p>&nbsp;&nbsp;Inadmissable condition of &nbsp;NoIBuprofin=0 &nbsp;&nbsp;and &nbsp;No_NSAIDS=1<br /> &nbsp;&nbsp;i.e. &nbsp;individual uses IBuprofin &nbsp;but does not use NSaids.<br /> &nbsp;&nbsp;This is contradictory since IBuprofin is a NSaid drug<br /> &nbsp;&nbsp;projected absolute risk for records with this contradition will be missing</p>
<p>&nbsp;&nbsp;!!!!!!!!!!!! &nbsp;&nbsp;Warning about an inadmissible error condition &nbsp;&nbsp;!!!!!!!!!!!!<br /> &nbsp;&nbsp;!!!!!!!!!!!! &nbsp;Warning Warning Warning Warning Warning Warning &nbsp;!!!!!!!!!!!!</p>
<p>A short SAS sample program, &nbsp;Men_CRC_Template.sas, &nbsp;which reads a covariate input dataset, &nbsp;Men_CRC_raw.in,<br /> are included to more clearly demonstrate the use of the SAS macro &nbsp;Men_CRC_RAM. &nbsp;User's can run<br /> the program &nbsp;Men_CRC_Template.sas &nbsp;for instructional and clarification purposes</p>
<p>Ref: "Colorectal Cancer Risk Prediction Tool for White Men and Women Without Known<br /> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Susceptibility". &nbsp;&nbsp;A Freedman et al. &nbsp;JCO &nbsp;27:686-693 2008.</p>
<h3>References:</h3>
<ul>
<li>Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann B, Pee D, Gail MH, Pfeiffer RM. A colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 2009 Feb 10;27(5):686-93.</li>
<li>Park Y, Freedman AN, Gail MH, Pee D, Hollenbeck A, Schatzkin A, Pfeiffer RM. Validation of a colorectal cancer risk prediction model among whites 50 years old and over. J Clin Oncol 2009 Feb 10;27(5):694-8.</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302523" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>MultiAssoc is a MATLAB software package for test of association of a disease with a group of SNPs after accounting for their interaction with another group of SNPs or environmental exposures. In addition to implementing two standard logistic regression based tests, the package implements a novel method, called TukAssoc , that uses the Tukey&rsquo;s 1 d.f. model for interaction between two groups of covariates.</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302450" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302450" sys_dependentvariantid="1418" sys_relationshipid="6819716">Readme text</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302618" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302618" sys_dependentvariantid="1418" sys_relationshipid="6819717">License Agreement</a>&nbsp;</li>
</ul>
<h3>Download Software:&nbsp;</h3>
<ul>
<li>Download the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303023" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303023" sys_dependentvariantid="1500" sys_relationshipid="6819715">MultAssoc.zip</a> file and unpack it in an appropriate directoty.&nbsp;</li>
<li>In MATLAB, use the (file--&gt; set path) menu to add the directory to the search path in which the files have been placed. The main function the user needs to call is 'multilocus_test'.&nbsp;</li>
<li>Please read input_output.txt file for instruction about the input and output arguments.</li>
</ul>
<h3>Reference:</h3>
<p>Chatterjee N., Kalaylioglu Z., Moslehi R., Peters U., Wacholder S. (2006). <a href="http://dceg2.cancer.gov/pdfs/chatterjee7910022006.pdf">Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions</a>. <cite>American Journal of Human Genetics</cite>, Vol. 79, 1002-16.</p>
<h3>Support:</h3>
<p><b>Questions?</b> <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302525" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>1. Download and install R packages BB, alabama, and MASS if not already installed</p>
<p>2. Download zip or tar.gz file for your operating system from the download page</p>
<p>3. Install from R (GUI) package installer or using the install.packages() function, e.g., install.packages(&ldquo;C:/temp/blm_1.2.zip&rdquo;, repos=NULL)</p>
<p>4. Load the blm package from the GUI or with the command library(blm)</p>
<p>5. Type library(help="blm") in R console to list the functions and data sets for the package. For more information on any of these, use help(function_name). Use the example(function_name) for illustrations of usage.</p>
</div>]]></content>
  </row>
  <row para_id="302527" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Colon Cancer Risk Assessment Tool SAS Macro License Agreement</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The CCRAT SAS macro may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302529" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel">Download the program files in a local directory. Then uncompress the file by tar command (tar -vxfz CNVfam.tar.gz), which will automatically generate the CNVfam directory containing executable files, library files and example files. Re-compile the source codes to ensure the program runs correctly in your system. Please refer to &quot;CNVfam/README_CNVfam.txt&quot; in the package for more details.</div>]]></content>
  </row>
  <row para_id="302530" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A cohort of about 3,000 individuals who were irradiated during childhood for benign head and neck conditions at Michael Reese Hospital was assembled and monitored for the risk of thyroid and other cancers. The thyroid cancer recurrence rate was significantly lower in patients diagnosed at screening than routine medical care, however, the difference was limited to small tumors (smaller than 10 mm). Investigators also noted that the main factors for the excess of multiple tumors occurring in conjunction with thyroid cancers were radiation-related, rather than a more general increased host susceptibility or the clinical characteristics of the thyroid cancer.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_contentid="939428" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7308073" sys_siteid="475" rxinlineslot="103" sys_dependentid="939428" sys_dependentvariantid="1965">Cari Kitahara</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7308074" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302532" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Breast Cancer Risk Assessment Macro (commonly referred to as the Gail Model) is a SAS macro that &nbsp;projects absolute risk of invasive breast cancer in the batch mode, according to <a href="https://bcrisktool.cancer.gov/">NCI&rsquo;s Breast Cancer Risk Assessment Tool</a> (BCRAT) algorithm for specific race/ethnic groups.</p>
<p>Users enter data on risk factors and projection interval ages for a group of women, and the macro will return the corresponding absolute risk projections. This program may be useful for researchers who need risk projections for an entire study population. <b>Latest Update (March 2018)</b>: Includes the new Hispanic model</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=411185" sys_contentid="411185" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="411185" sys_dependentvariantid="1418" sys_relationshipid="7317690" sys_siteid="475" sys_variantid="1418">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302469" sys_contentid="302469" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302469" sys_dependentvariantid="1418" sys_relationshipid="7317689" sys_variantid="1418">License Agreement</a></li>
</ul>
<h3>Software Download:</h3>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1109372" sys_contentid="1109372" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1109372" sys_dependentvariantid="1500" sys_relationshipid="7317692" sys_siteid="475" sys_variantid="1500">BrCa_RAM Ver4_1.zip</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>References:</h3>
<ul class="grey-bullets">
<li>Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, LaCroix AZ, Pee D, Chlebowski RT, Hines LM, Thompson CA, Gail MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28003316">Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women</a>. <cite>JNCI</cite> 2016; 109&nbsp;</li>
<li>Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21562243">Projecting individualized absolute invasive breast cancer risk in asian and pacific islander american women</a>. <cite>JNCI</cite> 2011; 103:951-61.</li>
<li>Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Berstein L. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18042936">Projecting individualized absolute invasive breast cancer risk in African American women</a>. <cite>JNCI</cite> 2007; 99:1782-92.&nbsp;</li>
<li>Costantino J, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS. <a href="https://www.ncbi.nlm.nih.gov/pubmed/10491430">Validation studies for models to project the risk of invasive and total breast cancer</a>. <cite>JNCI</cite> 1999; 91:1541-8.</li>
</ul>
<h3>Support:</h3>
<p><b>Questions?</b></p>
<p>Statistical issues&nbsp;should be directed to: &nbsp;&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349622" sys_contentid="349622" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349622" sys_dependentvariantid="1965" sys_relationshipid="7317691" sys_siteid="475" sys_variantid="1965">Dr. Mitchell Gail</a> &nbsp;&nbsp;&nbsp;</p>
<p>Technical details should be directed to: &nbsp; Fanni Zhang (<a href="mailto:zhangf10@mail.nih.gov?subject=Breast%20Cancer%20Risk%20Assessment%20Macro">zhangf@imsweb.com</a>)</p>
</div>]]></content>
  </row>
  <row para_id="302534" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:w="urn:www.microsoft.com/word" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:x="urn:www.microsoft.com/excel" xmlns:st2="urn:www.microsoft.com/smarttags2"><p><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p>The Genetic Analysis of Case-Control Data - R package may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="302535" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>CGEN (Case-control.Genetics) is an R package for analyzing genetic data on case-control samples, with particular emphasis on novel methods for detecting Gene-Gene and Gene-Environment interactions.</p>
<ul>
<li><a href="http://bioconductor.org/packages/release/bioc/html/CGEN.html">Download from Bioconductor</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302534" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302534" sys_dependentvariantid="1418" sys_relationshipid="7122173" sys_variantid="1418" sys_contentid="302534">License Agreement</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302656" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302656" sys_dependentvariantid="1418" sys_relationshipid="7122174" sys_siteid="475" sys_variantid="1418" sys_contentid="302656">ReadMe</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1016599" sys_dependentvariantid="1500" sys_dependentid="1016599" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7122175" sys_variantid="1500" sys_contentid="1016599">Manual</a></li>
</ul>
<h3>Updates</h3>
<ul>
<li>The new version includes snp.score function that implements a variety of score-tests for genetic association incorporating gene-environment interactions. The function, with certain options, also allows analysis of imputed SNPs.</li>
</ul>
<h3>Authors</h3>
<p>Samsiddhi Bhattacharjee, Nilanjan Chatterjee and William Wheeler.</p>
<h3>References</h3>
<ul>
<li>Han SS, Rosenberg PS, Garcia-Closas M, Figueroa JD, Silverman D, Chanock SJ, Rothman N, Chatterjee N. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23118105">Likelihood ratio test for detecting gene (G) environment (E) interactions under the additive risk model exploiting G-E independence for case-control data</a>. <cite>Am J Epidemiol</cite> 2012; 176:1060-7.</li>
<li>Chatterjee N, Carroll R. <a href="http://www.stat.tamu.edu/~carroll/ftp/2005.papers.directory/chatterjee_biometrika_2005.pdf">Semiparametric maximum likelihood estimation exploiting gene-environment independence in case-control studies (pdf)</a>. <cite>Biometrika</cite> 2005; 92:399-418.</li>
</ul>
<p><strong>Questions?</strong> <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302536" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators conduct a study of 35,573 patients treated for hyperthyroidism to determine whether post-therapeutic leukemia or other malignancies occurred more often in patients receiving Iodine-131 treatment compared to patients receiving antithyroid drugs or surgery.</p>
<p>To reconstruct the organ doses due to oral administration of Iodine-131, DCEG dosimetrists developed a new biokinetic model for iodine for hyperthyroid patients. Parameters of the model were obtained from results of measurements of iodine in blood, urine, and the thyroid following treatments for thyrotoxicosis for 3,138 patients. For these patients with available measured data, the individual organ doses were calculated based on the administered activity of Iodine-131 and the predictions of the amounts of iodide and protein-bound-iodine present in each organ and tissue, as well as the biological behavior of iodine in the body. Estimation of organ doses to all cohort members is in progress.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="939428" rxinlineslot="103" sys_relationshipid="7270609" sys_variantid="1965" sys_contentid="939428">Cari Kitahara</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270608" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103">Radation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302537" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>NestedCohort is an R software package for fitting Kaplan-Meier and Cox Models to estimate standardized survival and attributable risks for studies where covariates of interest are observed on only a sample of the cohort. Standard designs that can be handled by this software include the case-cohort and case-control studies conducted within defined cohorts. At this time, the software does not yet support nested case-control designs.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302427" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302427" sys_dependentvariantid="1418" sys_relationshipid="7279378" sys_variantid="1418" sys_contentid="302427">Readme text</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302555" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302555" sys_dependentvariantid="1418" sys_relationshipid="7279379" sys_variantid="1418" sys_contentid="302555">License Agreement</a></li>
<li><a href="http://www.r-project.org/doc/Rnews/Rnews_2008-1.pdf">Survival Analysis for Cohorts with Missing Covariate Information (See pg 14-19)</a></li>
</ul>
<p>This software requires you to have <span style="text-decoration: underline;">R 2.15.2 or higher</span> installed on your computer. R is freely-available statistical software that is very similar to S-PLUS. To install R on your computer, visit the <a href="http://www.r-project.org/">R homepage</a>. In the manual included with NestedCohort, I show how to import SAS data into R for NestedCohort to analyze.</p>
<h3>Download Software</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=303028" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303028" sys_dependentvariantid="1500" sys_relationshipid="7279380" sys_siteid="475" sys_variantid="1500" sys_contentid="303028">NestedCohort R Package</a></li>
</ul>
<h3>References</h3>
<p><b>Suggested reference for the NestedCohort program:</b></p>
<div class="bullet-blu">
<ul>
<li>Mark SD and Katki HA. <a href="https://doi.org/10.1198/016214505000000952">Specifying and implementing nonparametric and semiparametric survival estimators in two-stage (sampled) cohort studies with missing case data</a>. Journal of the American Statistical Association 2006;101(474):460-471.</li>
</ul>
<p><b>Studies that have utilized this software:</b></p>
<ul>
<li>Abnet, C. C., Lai, B., Qiao, Y.-L., Vogt, S., Luo, X.-M., Taylor, P. R., Dong, Z.-W., Mark, S. D., and Dawsey, S. M. (2005). <a href="https://www.ncbi.nlm.nih.gov/pubmed/15713965">Zinc concentration in esophageal biopsies measured by x-ray fluorescence and cancer risk</a>.<br /><em>J Natl Cancer Inst </em>2005; 97(4):301-306.</li>
<li>Kamangar F, Qiao YL, Blaser MJ, Katki H, Perez-Perez GI, Abnet CC, Dong ZW, Mark SD, Taylor PR, Dawsey SM. <a href="https://www.ncbi.nlm.nih.gov/pubmed/17179990">Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China</a>.<br /><em>Br J Cancer</em> 2007; 96(1):172-176</li>
</ul>
</div>
<h3>Support</h3>
<p><b>Questions?</b> Contact: <a href="mailto:katkih@mail.nih.gov">katkih@mail.nih.gov</a></p>
</div>]]></content>
  </row>
  <row para_id="302538" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>segCNV</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p><b>This is a trial version of the software</b>. The segCNV may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
</div>]]></content>
  </row>
  <row para_id="302539" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Colon Cancer Risk Assessment Macro (in SAS software) projects absolute colon cancer risk according to <a href="https://ccrisktool.cancer.gov/">NCI&rsquo;s Colorectal Cancer Risk Assessment Tool</a> (CCRAT) algorithm in the batch mode.</p>
<p>Users can enter risk factor data and projection interval ages for a group of men or women, and the macro will return the corresponding absolute risk projections. This program may be useful for research purposes when one needs risk projections for an entire study population. Mistake in error listing for men&rsquo;s model was corrected. To find a GAUSS version of this program that also computes 95% confidence intervals, please see the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302628" sys_contentid="302628" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302628" sys_dependentvariantid="1418" sys_relationshipid="7317657" sys_siteid="475" sys_variantid="1418">Colon Cancer Risk Assessment - Gauss Program</a> page.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302522" sys_contentid="302522" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302522" sys_dependentvariantid="1418" sys_relationshipid="7317655" sys_variantid="1418">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302527" sys_contentid="302527" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302527" sys_dependentvariantid="1418" sys_relationshipid="7317656" sys_variantid="1418">License Agreement</a></li>
</ul>
<h3><b>Software Download:</b></h3>
<ul>
<li><a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=302993" sys_contentid="302993" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302993" sys_dependentvariantid="1500" sys_relationshipid="7317653" sys_variantid="1500">Men_CRC_RAM.zip</a></li>
<li><a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=302994" sys_contentid="302994" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302994" sys_dependentvariantid="1500" sys_relationshipid="7317654" sys_variantid="1500">Women_CRC_RAM.zip</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>References:</h3>
<ul>
<li>Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann B, Pee D, Gail MH, Pfeiffer RM. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19114701">A colorectal cancer risk prediction tool for white men and women without known susceptibility [PubMed abstract]</a>. <em>J Clin Oncol</em> 2009 Feb 10;27(5):686-93.</li>
<li>Park Y, Freedman AN, Gail MH, Pee D, Hollenbeck A, Schatzkin A, Pfeiffer RM. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/19114700">Validation of a colorectal cancer risk prediction model among whites 50 years old and over [PubMed abstract]. <em>J Clin Oncol</em> 2009 Feb 10;27(5):694-8.</a></li>
</ul>
<h3>Support:</h3>
<p><b>Questions?</b> Contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349627" sys_contentid="349627" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349627" sys_dependentvariantid="1965" sys_relationshipid="7317658" sys_siteid="475" sys_variantid="1965">Ruth Pfeiffer</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302541" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<p><a title="" href="/about/organization/dceg-orgchart.pdf">DCEG Organization Chart (pdf)</a></p>
</div>
<p>DCEG is organized into research program areas and associated branches and laboratories, and works closely with the Leidos Cancer Genomics Research (CGR) Laboratory. To learn more about specific areas, click on the links below:</p>
<h3>Office of the Division Director</h3>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349630" sys_contentid="349630" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7313308" sys_dependentvariantid="1965" sys_dependentid="349630" rxinlineslot="103">Stephen J. Chanock, M.D.,</a> Director</h4>
<ul>
<li><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?1=OD">Office of the Director Staff</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302473" sys_contentid="302473" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7313310" sys_dependentvariantid="1418" sys_dependentid="302473" rxinlineslot="103">Office of Education</a></li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302673" sys_contentid="302673" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313300" sys_dependentvariantid="1422" sys_dependentid="302673" rxinlineslot="103">Epidemiology and Biostatistics Program</a></h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313301" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103">Biostatistics</a></li>
<li><a href="/Rhythmyx/assembler/render?sys_contentid=1142925&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1142925" rxinlineslot="103" sys_folderid="" sys_relationshipid="7313315">Data Science Research</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=63&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313302" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103">Infections and Immunoepidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7313313" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103">Metabolic Epidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313303" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103">Occupational and Environmental Epidemiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=115&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313304" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103">Radiation Epidemiology</a></li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302429" sys_contentid="302429" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313305" sys_dependentvariantid="1422" sys_dependentid="302429" rxinlineslot="103">Human Genetics Program</a></h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313306" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103">Clinical Genetics</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=460151" sys_contentid="460151" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7313309" sys_dependentvariantid="1422" sys_dependentid="460151" rxinlineslot="103">Cancer Genomics Research (CGR) Laboratory</a> (Leidos), formerly the Core Genotyping Facility</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7313314" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103">Integrative Tumor Epidemiology Branch</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7313307" sys_dependentvariantid="1422" sys_dependentid="302432" rxinlineslot="103">Laboratory of Translational Genomics</a></li>
</ul>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=966088" sys_contentid="966088" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7313312" sys_dependentvariantid="1422" sys_dependentid="966088" rxinlineslot="103">Laboratory of Genetic Susceptibility</a></h4>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302442" sys_contentid="302442" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7313311" sys_dependentvariantid="1418" sys_dependentid="302442" rxinlineslot="103">Administrative Resource Center</a></h4>
</div>]]></content>
  </row>
  <row para_id="302544" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3 id="top">Overview</h3>
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-ebp/iib">IIB Home</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389813" sys_siteid="475" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=IIB">IIB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=160&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302548" sys_contentid="302548" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389814" sys_siteid="475" rxinlineslot="103" sys_dependentid="302548" sys_dependentvariantid="1418">Current Fellows</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302544" sys_contentid="302544" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389815" sys_siteid="475" rxinlineslot="103" sys_dependentid="302544" sys_dependentvariantid="1418">Research Training Opportunities</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=34&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302449" sys_contentid="302449" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389816" sys_siteid="475" rxinlineslot="103" sys_dependentid="302449" sys_dependentvariantid="1418">Spotlight on Investigators</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=IIB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=0&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>The mission of the Infections and Immunoepidemiology Branch (IIB) is to discover infectious causes of cancer, to elucidate the determinants of malignancy for established oncogenic infections, and to clarify how alterations in immunity and inflammation relate to cancer risk. At least 15% of cancers are directly related to known infectious agents, and many more result from chronic inflammation or dysfunctional immunity.</p>
<p>Current areas of emphasis include malignancies among people with AIDS or organ transplant, Burkitt lymphoma, other lymphomas, Kaposi sarcoma, and cancers of the stomach, gallbladder, liver, cervix, other HPV-related sites, oral cavity, nasopharynx, and lung. In addition to evaluating the role of infectious agents in these tumors, we are interested in evaluating the role of immunity in cancer development. IIB houses the community-based Costa Rica HPV 16/18 Vaccine Trial and other large field studies designed to evaluate the safety and efficacy of the HPV 16/18 virus-like particle vaccine and examine other factors of etiological and immunologic relevance.</p>
<p>In collaboration with laboratory scientists, clinicians, and statisticians, IIB uses appropriate designs (cohort, case-control, registry matching, and others) to conduct multidisciplinary research studies in domestic and international sites. In addition to epidemiologic and clinical data, many IIB field studies include an extensive biological specimen collection component that allows for careful molecular testing to better define both exposures and outcomes of interest. Descriptive epidemiology studies aimed at quantifying and explaining national and international trends in cancer incidence and mortality are also a focus.</p>
<p>Working closely with tenured and tenure-track investigators, fellows take lead responsibility for analyzing and summarizing previously collected data. Senior staff assist them in writing manuscripts and bringing these to publication in the peer-reviewed scientific literature. Fellows become familiar with the entire IIB portfolio and are encouraged to participate in on-going and newly proposed studies within the Branch and throughout the Division. Advice on scientific and career development is provided to all fellows. To discuss potential opportunities in your area of research interest, you may contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=IIB">branch investigators</a> directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=160&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302548" sys_contentid="302548" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389809" rxinlineslot="103" sys_dependentid="302548" sys_dependentvariantid="1418">Meet fellows in the Infections and Immunoepidemiology Branch</a>.</p>
<h3>Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Individuals must hold an MD or Ph.D. in epidemiology or related field. Individuals with strong quantitative skills are encouraged to apply. Familiarity with infectious diseases, immunology, and/or cancers associated with infectious agents is also desirable.</p>
<p><i>Predoctoral fellowships:</i> Individuals should be enrolled in a doctoral program in epidemiology or related field with a desire to complete their dissertation in the Infections and Immunoepidemiology Branch.</p>
<h3>Application Process</h3>
<p>Predoctoral and postdoctoral fellowship applications in the branch are accepted on an ongoing basis. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389810" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3 id="specific">Current Training Program(s)</h3>
<p>Postdoctoral and predoctoral positions in infectious and immunoepidemiology are available. To apply, visit the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389811" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Fellowship Program page</a>.</p>
<h3>Selected Research Opportunities with Specific Investigators</h3>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1066576&amp;sys_revision=3&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=#Engels-Shiels" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1066576" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7389819">Epidemiology of Cancer in Immunosuppressed Populations &ndash; Postdoctoral Fellowship</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1066576&amp;sys_revision=3&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=#OBrien" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1066576" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7389820">Hepatitis Virus Infections and their Relationship to Liver Cancer &ndash; Postdoctoral Fellowship</a></p>
</div>]]></content>
  </row>
  <row para_id="302546" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>The Charred database contains each type of meat by method and doneness.</p><p>The method definitions are:</p><table class="blue-table"><tbody><tr><th scope="col" width="26%">Method Name</th><th scope="col" width="74%">Definition</th></tr><tr><td width="26%">Baked</td><td width="74%">Cooked in an oven with very little or no added liquid.</td></tr><tr class="odd"><td width="26%">Boiled</td><td width="74%">Cooked in large amount of boiling liquid.</td></tr><tr><td width="26%">Deep-fat fried</td><td width="74%">Cooked by immersing completely in hot fat.</td></tr><tr class="odd"><td width="26%">Grilled/Barbecued</td><td width="74%">Cooked over a charcoal or gas grill.</td></tr><tr><td width="26%">Microwaved</td><td width="74%">Cooked completely in a microwave oven.</td></tr><tr class="odd"><td width="26%">Oven-broiled</td><td width="74%">Cooked by direct exposure to the heat source in the oven.</td></tr><tr><td width="26%">Pan-fried</td><td width="74%">Cooked in a small amount of hot fat in an open shallow pan.</td></tr><tr class="odd"><td width="26%">Stewed</td><td width="74%">Cooked by simmering in liquid in the oven, on the stovetop, or in a slow cooker.</td></tr></tbody></table><p>Chicken is also broken down into chicken with skin and chicken without skin as well as lines for &#39;both&#39;. Questionnaires may ask whether the person ate skin on chicken. The answers are usually:</p><ul class="bullet-blu"><li>all the time</li><li>some of the time</li><li>never</li></ul><p>If they responded never, then the skinless type is used.<br />If they responded all the time, then the skin type is used.<br />If they responded some of the time, or if the question was not asked on the questionnaire, then &#39;both&#39; is used. Both is an average of skin and skinless.</p><p>For the gravy items, there are several different types. &#39;Gravy average of all doneness&#39; (link 140) is the average of all doneness methods. This is appropriate to use when the doneness levels of gravy are not asked on the questionnaire. These values should be used only for gravy made with meat drippings. Questionnaires may ask how the subject prepared their gravy. If the subject ate gravy made from meat drippings and also from packages or jars, then the &#39;Gravy 1/2 values of average&#39; should be used. These values represents values that are 1/2 that of the gravy line (140). If the subject did not eat gravy made from meat drippings, then their gravy data should not be used in the Charred analysis. If doneness levels are asked, then the gravy doneness levels are appropriate to use.</p><p>Fish values were measured for HCA compounds. However, the results were incomplete due to the fish sticking to the grill when cooked at higher doneness levels. Therefore, the values are not included in Charred.</p></div>]]></content>
  </row>
  <row para_id="302547" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Far more than for any other common environmental cause of human cancer, the relationship between radiation dose to a population, individual, or organ site and subsequent cancer risk is well understood, and quantified. This fact led to a Congressional mandate (Public Law 97-414, Section 7(b)) to create a set of summary tables which might be used to help evaluate the merits of compensation claims for cancer cases thought to have been caused by radiation exposure.</p>
<p>In 1985, the NIH published the so-called NIH radioepidemiological tables (NIH Publication 85-2748). In 2003, a revised report was published - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=303007" inlinetype="rxhyperlink" sys_relationshipid="7276100" sys_dependentvariantid="1500" sys_dependentid="303007" rxinlineslot="103" sys_siteid="475" sys_variantid="1500" sys_contentid="303007">NIH No. 03-5387 pdf, 1.05mb</a>. A hard copy of this report is available from the <a href="mailto:cisocc@mail.nih.gov">NCI Publications Ordering Service</a>.</p>
<p>In 2003 the tables were replaced with a web-based program called, <a href="https://www.irep.nci.nih.gov/irep">Interactive Radio-Epidemiological computer Program (IREP)</a>. A variant of this program, called NIOSH-IREP, was adapted by the <a href="http://www.cdc.gov/niosh/homepage.html">National Institute of Occupational Safety and Health (NIOSH)</a> for adjudication of radiation-related claims by employees of the Department of Energy and its contractors, in accordance with Public Law 106-398 (the Energy Employees Occupational Illness Compensation Program Act of 2000). That program and related material can be accessed from the website of the <a href="http://www.cdc.gov/niosh/ocas/ocasirep.html">NIOSH Office of Compensation Analysis and Support, "Probability of Causation (NIOSH-IREP)</a>".</p>
</div>]]></content>
  </row>
  <row para_id="302548" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=66&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372342" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103" sys_variantid="1422">Infections and Immunoepidemiology Branch</a> and learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302544" sys_contentid="302544" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372340" sys_dependentvariantid="1418" sys_dependentid="302544" rxinlineslot="103" sys_variantid="1418">research training opportunities</a>.</p>
<h3><strong><a id="D'Arcy"></a>Monica D&rsquo;Arcy, Ph.D. - Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1084809" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372355">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1084809&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Monica D&rsquo;Arcy, Ph.D., joined the Infections and Immunology Branch (IIB) as a postdoctoral fellow in March 2017.&nbsp; Dr. D&rsquo;Arcy received a B.A. in mathematics and a B.A.S. in computer science engineering from the University of Pennsylvania. &nbsp;She then earned an M.S. in epidemiology from Temple University. Prior to beginning her doctoral program, she worked as a bioinformatics specialist at the Children&rsquo;s Hospital of Philadelphia.&nbsp; She earned her Ph.D. in cancer and pharmacoepidemiology from the Gillings School of Global Public Health at the University of North Carolina (UNC) at Chapel Hill in 2016. For her dissertation research she examined the association between antidepressants and colorectal cancer (CRC) in a Medicare population (2007-2013) under the mentorship of Jennifer Lund and Til St&uuml;rmer.&nbsp; In DCEG, she is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372344" sys_dependentvariantid="1965" sys_dependentid="349601" rxinlineslot="103" sys_variantid="1965">Eric Engels, M.D., M.P.H.</a>, senior investigator and Acting Chief, IIB, to use large databases, including the Transplant-Cancer Match Study and the SEER-Medicare linked database, to study risk factors for several cancers.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=D%27Arcy%2C%20Monica[Full%20Author%20Name]&amp;cmd=DetailsSearch">Scientific Publications &ndash; Monica D'Arcy</a></p>
<h3><strong><a id="Jackson"></a>Sarah S. Jackson, </strong>&nbsp;<strong>Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1127256" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372356">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1127256&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Sarah S. Jackson, Ph.D., joined the Infectious and Immunoepidemiology Branch (IIB) in May 2018 as a postdoctoral fellow. She earned her Ph.D. in epidemiology at the University of Maryland, Baltimore. Dr. Jackson&rsquo;s doctoral research focused on risk prediction models for healthcare-associated infections. Prior to joining IIB, she worked in vaccine clinical trials at The EMMES Corporation and with the AIDS Clinical Trials Group at Social &amp; Scientific Systems. Dr. Jackson&rsquo;s research interests include epidemiologic methods, predictive modeling, infections associated with biliary tract cancer, and the role of genetics in disease development. She is currently working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/koshiol-jill">Jill Koshiol, Ph.D.</a>, investigator, IIB, utilizing the Biliary Tract Cancers Pooling Project (BiTCaPP) to study risk factors for biliary tract cancer. She is also working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/obrien-thomas">Thomas O&rsquo;Brien, M.D., M.P.H.</a>, senior investigator, IIB, to study the role of <em>IFNL4</em> genotype in several infections.</p>
<h3><br /><a id="Liu"></a>Zhiwei Liu, Ph.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1093298" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372357">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1093298&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Zhiwei Liu, Ph.D., joined the Infections and Immunoepidemiology Branch (IIB) as a postdoctoral fellow in October 2016.&nbsp; He received a B.S. in preventive medicine from Sun Yat-sen University, China (2009) and a Ph.D. in epidemiology from the Karolinska Institutet, Sweden in 2016, where he examined the etiology and early detection of nasopharyngeal carcinoma (NPC) under the mentorship of Profs. Weimin Ye and Hans-Olov Adami.&nbsp; During his postdoctoral training, Dr. Liu has continued to explore the etiology of NPC, with a focus on genetic susceptibility and anti-Epstein-Barr virus (EBV) antibodies, under the mentorship of&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349694" sys_contentid="349694" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372345" sys_dependentvariantid="1965" sys_dependentid="349694" rxinlineslot="103" sys_variantid="1965">Allan Hildesheim, Ph.D.</a>, senior investigator, IIB and Anna Coghill, Ph.D. Research Fellow. He is also working on projects to understand the immune response to EBV in relation to other EBV-related cancers, including Burkitt lymphoma and Hodgkin lymphoma. He is also working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349671" sys_contentid="349671" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372346" sys_dependentvariantid="1965" sys_dependentid="349671" rxinlineslot="103" sys_variantid="1965">Jill Koshiol, Ph.D.</a>, investigator, IIB, on the Shanghai Biliary Cancer Study, the Taiwan Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer (REVEAL)-HBV and REVEAL-HCV cohorts and other research projects evaluating the role of inflammation and infection in hepatobiliary cancers.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/1HqJfCPDRDCA0/bibliography/public/">Scientific Publications - Zhiwei Liu</a></p>
<h3 id="Mahale"><a id="Mahale"></a>Parag Mahale, M.B.B.S., Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1061490" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372358">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1061490&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Parag Mahale, M.B.B.S., Ph.D., joined the Infections and Immunoepidemiology Branch (IIB) as a postdoctoral fellow in July 2016. Dr. Mahale earned his M.B.B.S. degree from Seth G.S. Medical College and K.E.M. Hospital in Mumbai, India (2006) and an M.P.H. in epidemiology and biostatistics from the University of Texas Health Science Center, Houston, Texas (2011). Dr. Mahale earned his Ph.D. in epidemiology (2016) from the University of Texas Health Science Center, where he utilized data from the SEER-Medicare database and the Veterans Affairs Clinical Case Registries to determine the associations of hepatitis C virus (HCV) with non-liver cancers and the effect of anti-HCV therapy on the incidence of extrahepatic manifestations of chronic HCV infection. During his graduate studies, Dr. Mahale also worked as a graduate research assistant with&nbsp;Dr. Harrys A. Torres at the MD Anderson Cancer Center, focusing on the epidemiology of HCV infections in cancer patients.&nbsp;In DCEG, he is working with&nbsp;<a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/engels-eric">Eric A. Engels, M.D., M.P.H.</a>, senior investigator, IIB. Dr. Mahale is examining the risk factors for cancers associated with infections, immunosuppression, and inflammation by utilizing data from the Transplant-Cancer Match study, the HIV-Cancer Match study, and the SEER-Medicare linked database. He is also working with&nbsp;<a href="http://dceg.cancer.gov/about/staff-directory/biographies/O-Z/obrien-thomas">Thomas O&rsquo;Brien, M.D., M.P.H.</a>, senior investigator, IIB, to determine the risk of hepatocellular carcinoma in HDV-infected individuals in the Gambia Liver Cancer study. &nbsp;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/parag.mahale.1/bibliography/public/">Scientific Publications &ndash; Parag Mahale</a></p>
<h3><a id="Peprah"></a>Sally Peprah, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101463" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372359">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101463&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Sally Peprah, Ph.D., joined the Infections and Immunoepidemiology Branch (IIB) as a postdoctoral fellow in October 2017. Dr. Peprah earned a B. Pharm degree in 2009 from Kwame Nkrumah University of Science and Technology in Kumasi, Ghana. She then obtained an M.S.P.H in international health in 2013 and a Ph.D. in epidemiology in 2017, both from the Johns Hopkins Bloomberg School of Public Health. For her doctoral research, Dr. Peprah examined prevention and control of cervical cancer among high-risk women; she was mentored by Dr. Amber D&rsquo;Souza. During her postdoctoral fellowship, Dr. Peprah will continue her research work on oncogenic viruses and virus associated cancers. Working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/mbulaiteye-sam">Sam Mbulaiteye, M.D.</a>, investigator, IIB, Dr. Peprah will investigate environmental, sociodemographic and genetic risk factors in addition to the role of malaria immunology in the etiology of Burkitt Lymphoma&mdash;work that will utilize data from the&nbsp;<a href="http://emblem.cancer.gov/">Epidemiology of Burkitt Lymphoma in East-African Children and Minors</a> (EMBLEM) study. Dr. Peprah will also work with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/kreimer-aimee">Aim&eacute;e R. Kreimer, Ph.D.</a>, investigator, IIB, to assess the ecology of non-16/18 HPV infections among HPV 16/18 vaccinated women in the Costa Rica Vaccine Trial. Working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/Shiels-Meredith">Meredith Shiels, Ph.D.</a>, investigator, IIB, Dr. Peprah will conduct descriptive studies of Kaposi Sarcoma among HIV-infected people in the United States.</p>
<p><a href="https://dceg.cancer.gov/fellowship-training/what-our-fellows-do/meet-current-fellows/iib-fellows#Peprah%20">Scientific Publications &ndash; Sally Peprah</a></p>
<h3 id="Song"><a id="Song"></a>Minkyo Song, M.D., Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1061491" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372360">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1061491&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Minkyo Song, M.D., Ph.D, joined the Infectious and Immunoepidemiology Branch (IIB) in June 2016 as a postdoctoral fellow. Dr. Song earned her M.D. in 2005 at Seoul National University College of Medicine and completed her residency in preventive medicine in 2012 at the same institution. Prior to joining IIB, Dr. Song received her Ph.D. in epidemiology in 2015 from the Department of Biomedical Sciences at Seoul National University College of Medicine, working with Dr. Daehee Kang. Her doctoral research focused on developing gastric cancer risk prediction models for the Korean population. She has been a collaborating investigator of the Asian Cohort Consortium since 2009. Dr. Song&rsquo;s research interests include chronic infection and inflammation associated with gastric and other cancers, and the complex roles of genetics and epigenetics in carcinogenesis. Dr. Song is currently working with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/rabkin-charles">Charles Rabkin, M.D.</a>, senior investigator, IIB, <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/Camargo-Maria">Maria Constanza Camargo, Ph.D.</a>, investigator, Metabolic Epidemiology Branch (MEB), to investigate the epidemiology of <em>Helicobacter pylori</em> (<em>H. pylori</em>) infection and Epstein-Barr virus (EBV) associated with the risk of gastric cancer.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=%22Minkyo+Song%22">Scient</a><a href="https://www.ncbi.nlm.nih.gov/myncbi/12Sqb6mTzS-Aw/bibliography/public/">ific Publications &ndash; Minkyo Song</a></p>
<h3><strong><a id="Tsang"></a>Sabrina H. Tsang, Ph.D., M.P.H. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101328" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7372361">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101328&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Sabrina H. Tsang, Ph.D., M.P.H., joined the Infections and Immunoepidemiology Branch (IIB) as an NCI Cancer Prevention Fellow in September 2017. She received a B.S. in biology from the Massachusetts Institute of Technology, Cambridge, in 2010 and earned her Ph.D. in cell and molecular biology from the University of Pennsylvania Perelman School of Medicine, Philadelphia, in 2015. Working with Dr. Jianxin You, her doctoral research focused on the tumor antigens of Merkel cell polyomavirus, particularly their role in viral replication. Upon acceptance to the Cancer Prevention Fellowship Program in 2016, Dr. Tsang pursued her M.P.H. at the Harvard T.H. Chan School of Public Health, where she focused on quantitative methods in epidemiology and biostatistics. Under the mentorship of Dr. Lorelei Mucci, she performed a survival analysis, comparing prostate cancer patients with or without trichomoniasis. Guided by her interest in infection-related cancers, Dr. Tsang is now working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349605" sys_contentid="349605" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372347" sys_dependentvariantid="1965" sys_dependentid="349605" rxinlineslot="103" sys_variantid="1965">Aimee R. Kreimer, Ph.D.</a>, senior investigator, IIB, to better understand human papillomavirus vaccine efficacy in the Costa Rica Vaccine Trial.</p>
<p><a href="https://dceg.cancer.gov/fellowship-training/what-our-fellows-do/meet-current-fellows/iib-fellows#Tsang%20">Scientific Publications &ndash; Sabrina H. Tsang<br /></a></p>
<p><a href="#top">Back to Top</a></p>
<p>Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302544" sys_contentid="302544" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372341" sys_dependentvariantid="1418" sys_dependentid="302544" rxinlineslot="103" sys_variantid="1418">research training opportunities</a> in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=66&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7372343" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103" sys_variantid="1422">Infections and Immunoepidemiology Branch</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302551" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>NON-PROPRIETARY SOFTWARE TRANSFER AGREEMENT</h3>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")<br /><br />By accepting Software, Recipient agrees to the terms of this Agreement.<br /><br />The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.<br /><br />Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.<br /><br />All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.<br /><br />Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:<br /><br /><a href="mailto:checkd@mail.nih.gov">Mr. David Check</a><br /><br />This Software has been developed using the True DBGrid component which is developed and published by ComponentOne LLC. Recipient of this Software is not licensed to use True DBGrid for development, and may not redistribute any of the included control files.</p>
</div>]]></content>
  </row>
  <row para_id="302552" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<p>In order to study cancer and other serious disease risks associated with protracted low-to-moderate dose radiation exposures, scientists identified a nationwide population of 146,022 radiologic technologists, certified for two or more years during 1926-1982, from the American Registry of Radiologic Technologists (ARRT). The technologists have been followed from 1983 to the present to obtain data on employment history and cancer risk factor information for investigations of mortality, cancer incidence, cataract, and cardiovascular disease risks as well as health risks among those conducting certain types of radiologic procedures.&nbsp;</p>
<p>Efforts are underway to estimate annual and cumulative doses of individual technologists to enable assessment of occupational radiation-related dose-response patterns. The potential modification of breast and thyroid cancer risks by genetic susceptibility factors has also been investigated. Genetic studies of breast, thyroid and skin cancer are ongoing.&nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349666" sys_contentid="349666" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349666" sys_dependentvariantid="1965" sys_relationshipid="7390401" sys_siteid="475">Martha Linet</a> or visit <a href="http://radtechstudy.nci.nih.gov/">http://radtechstudy.nci.nih.gov/</a>.</p>
<ul>
<li><a href="#Summary of Cancer Risks">Summary of cancer risks</a></li>
<li><a href="#Lifestyle Risk Factors">Lifestyle risk factors</a></li>
<li><a href="#Technologists Performing or Assisting with Interventional Radiographic Procedures">Technologists performing or assisting with interventional radiographic procedures</a></li>
</ul>
<h3><a id="Summary of Cancer Risks"></a>Summary of Cancer Risks</h3>
<h4>Leukemia, multiple myeloma, and lymphoma</h4>
<p>Relative risks of the combined category of acute myelocytic, acute lymphocytic, and chronic myeloid leukemias were increased among technologists working five or more years before 1950 or holding patients 50 or more times for x-ray examinations, but risks were not significantly related to working in more recent time periods, the year or age technologists first worked, the total years worked, specific procedures or equipment used or personal radiotherapy. Working as a radiologic technologist was not significantly associated with risk of multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, or chronic lymphocytic leukemia.</p>
<h4>Breast cancer</h4>
<p>Based on 1,050 incident breast cancers, risks were 2.9-fold increased among technologists who began working before 1935. Risks rose with number of years worked before 1940, and were significantly elevated among those who began working before age 17, but were not related to the total years worked in the 1940s or later. The risk was 1.5-fold and significantly greater for those technologists with the highest proxy index of cumulative occupational radiation exposure compared to those with a minimal exposure index.</p>
<h4>Thyroid cancer</h4>
<p>A statistically significant 1.5-fold elevated risk of thyroid cancer was observed among technologists who held patients for x-ray procedures at least 50 times. Total years worked as a radiologic technologist, years performing diagnostic, therapeutic, and nuclear medicine procedures, first employment at ages younger than 20 years, and calendar period of first employment were not associated with thyroid cancer risk. Risk of thyroid cancers diagnosed before completion of the baseline questionnaire (1983-89) were higher among those who began working in earlier decades and significantly elevated among those working more than five years prior to 1950.</p>
<h4>Non-melanoma skin cancer</h4>
<p>Among 1,355 incident cases of basal cell carcinoma (BCC) and 270 with squamous cell carcinoma (SCC) in 65,304 white radiologic technologists, relative risk of BCC was 2.2-fold increased among those who first worked before 1940, but declined with more recent first year of employment. Ultraviolet radiation exposure did not modify the effect of year first worked on BCC risk, although risks were significantly stronger among technologists with lighter compared with darker eye and hair color. This study provides some evidence that chronic occupational radiation exposure at low-to-moderate levels can increase the risk of BCC, and that this risk may be modified by pigment characteristics.</p>
<h4>Melanoma</h4>
<p>Melanoma risk was increased among those who first worked before 1950, particularly among those who worked five or more years, but this finding was based on small numbers of technologists. Risk was also modestly elevated among technologists who did not customarily use a lead apron or shield when they first began working</p>
<p><a href="#Top">Back to Top</a></p>
<h3><a id="Lifestyle Risk Factors"></a>Lifestyle Risk Factors</h3>
<p>The U.S. Radiologic Technologists Study (USRT) Cohort has been particularly useful in examining issues related to the growing prevalence of obesity, including the nature of the relationship between body mass index and all-cause mortality. In addition, investigators are studying the risk of cancer associated with physical activity, alcohol consumption, and smoking.</p>
<p><a href="#Top">Back to Top</a></p>
<h3><a id="Technologists Performing or Assisting with Interventional Radiographic Procedures"></a>Technologists Performing or Assisting with Interventional Radiographic Procedures</h3>
<p>Among technologists who completed a questionnaire during 1994-1998 and were followed up through 2003, there were 3,581 deaths. Compared to radiologic technologists who never or rarely performed or assisted with fluoroscopically-guided interventional procedures, mortality was not increased overall, nor from total circulatory disease, total cancer or breast cancer among those working with such procedures daily. Based on small numbers of deaths, there were non-significant excesses (40-70%) in mortality from cerebrovascular disease among technologists ever working with these procedures, but no significant increases in technologists performing the highest frequency of such procedures. The findings should be interpreted cautiously in light of the small numbers of deaths, inability to assess risks for less common cancers, and relatively short follow-up. In addition, several genetic studies are under way in this cohort.</p>
<p><a href="#Top">Back to Top</a></p>
<p><b>Related information:</b> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302586" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302586" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7390402" sys_variantid="1418" sys_contentid="302586">Radiation Dose Estimation for Medical Radiation Workers</a></p>
</div>]]></content>
  </row>
  <row para_id="302555" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">

<p><strong>Provider:</strong> National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
<p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:</p>
<p>Questions? Contact: <a href="mailto:katkih@mail.nih.gov">katkih@mail.nih.gov</a></p>

</div>]]></content>
  </row>
  <row para_id="302558" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>ARTP2 - R Package</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The ARTP2 - R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="302561" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>There are no opportunities open at this time.</p>
</div>]]></content>
  </row>
  <row para_id="302563" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Follow-up though Dec 31, 2002 has been completed for a study of site-specific cancer mortality among tuberculosis (TB) patients treated with artificial lung collapse therapy in Massachusetts TB sanatoria (1930-1950). Treatment involved frequent chest fluoroscopy examinations, which delivered highly fractionated radiation doses to breast, lung, and other thoracic organs. The estimated mean doses to breast and lung for these patients are 0.74 and 0.84 Gy, respectively. In earlier analyses, breast cancer but not lung cancer was linked to cumulative radiation dose. Those results are consistent with the other cohort of tuberculosis patients exposed to chest fluoroscopy in Canada. Acquiring new cancer cases, particularly lung cancer, should allow DCEG investigators to conduct a more detailed dose-response analysis and refine risk estimates for fractionated radiation.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349604" sys_dependentvariantid="1965" sys_dependentid="349604" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7262284" sys_variantid="1965" sys_contentid="349604">Mark Little</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7262285" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302566" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG&rsquo;s offices at the NCI are located at 9609 Medical Center Drive, Rockville, Maryland.</p>
<h3>Directions</h3>
<h4>By Metro</h4>
<div sys_dependentvariantid="2066" sys_dependentid="857678" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7251638">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=301965&amp;sys_siteid=475&amp;sys_contentid=857678&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Metrorail service is available from Washington's Reagan National Airport and from Union Station (railway). To get to NCI Shady Grove, take the <a href="http://www.wmata.com/">Washington, DC Metro</a> Red line to the Shady Grove stop (terminal station). Shuttle buses depart from the Shady Grove Metro station beginning at 6:00 a.m. and 6:15 a.m. respectively. During peak commuting times from 6:00 &ndash; 9:30 a.m. and 3:00 &ndash; 7:00 p.m., service runs more frequently. During non-peak times, from 9:30 a.m. &ndash; 3:00 p.m., shuttles run every 30 minutes. The last shuttle leaves for the Metro at 6:45 p.m.</p>
<p>The NCI Shady Grove Metro shuttle picks up passengers on the west side of the Metro. To reach it:&nbsp;</p>
<p>1. Take the exit on your left when exiting the metro station &ndash; at the top of the escalator.<br /> 2. The shuttle stops on your right side as you walk up the stairs.<br /> 3. Look for the signs saying &ldquo;NCI shuttle stops here&rdquo; written in red letters on a white background.</p>
<p>For your convenience, you can download the <a href="http://newcampus.cancer.gov/wp-content/uploads/2014/04/NCI-Shady-Grove-Shuttle-Schedule.pdf">NCI Shady Grove Shuttle Schedule (pdf)</a>, or check on the status of the next shuttle in real-time using the <a href="http://ncishadygroveshuttle.com/map">NCI live shuttle schedule</a>.</p>
<p><strong><cite>Alternatively:</cite></strong> you may choose to take Metro Red line to the Medical Center stop at the NIH main campus, then take the NIH Express Shuttle from the main lobby of Building 31 to NCI Shady Grove. &nbsp;Shuttle service runs every thirty minutes nonstop from 7:15 a.m. &ndash; 6:45 p.m.</p>
<h4>By Taxi</h4>
<p>From the Shady Grove Metro, exit the station to the left, and the taxi stand will be visible.</p>
<h4>By Bus</h4>
<p>Various Montgomery County Ride-On bus routes service NCI Shady Grove. These buses all have bike racks. Additionally, the Maryland Transit Administration (MTA) offers commuter bus routes to the Shady Grove Metro.<br /> Select a route number below for a complete timetable and a map of each Ride-On bus route:</p>
<ul type="disc">
<li><a href="http://www.montgomerycountymd.gov/DOT-Transit/routesandschedules/allroutes/route043.html">Route 43</a> &ndash; From Traville Transit Center and Shady Grove Metro. Drops off/Picks up in front of NCI Shady Grove on Medical Center Dr.</li>
<li><a href="http://www.montgomerycountymd.gov/DOT-Transit/routesandschedules/allroutes/route056.html">Route 56</a> &ndash; From Rockville Metro and Lakeville Center. Drops off/Picks up at the intersection of Medical Way and Shady Grove Rd., approximately 200 yards away from NCI Shady Grove.</li>
<li><a href="http://www.montgomerycountymd.gov/DOT-Transit/routesandschedules/allroutes/route066.html">Route 66</a> &ndash; From Traville Transit Center and Shady Grove Metro. Drops off/Picks up in front of NCI Shady Grove on Medical Center Dr.</li>
<li><a href="http://www.montgomerycountymd.gov/DOT-Transit/routesandschedules/allroutes/route074.html">Route 74</a> &ndash; From Germantown Transit Center and Shady Grove Metro. Drops off/Picks up on Key West Ave., approximately 100 yards from NCI Shady Grove entrance.</li>
</ul>
<p>&nbsp;<strong>By Car</strong></p>
<p>Arriving from the <b>south</b> of Rockville using Route 270, take exit 8 toward Shady Grove Road. &nbsp;Keep left on the exit ramp, and at the end of the ramp, turn left at the light onto Shady Grove Road heading west. Get into the right lane, and turn right onto Key West Avenue (MD 28 W). &nbsp;Turn left at the next light onto Medical Center Drive. &nbsp;From there, turn right onto Blackwell Road and turn right again into the NCI employee parking garage. Visitors can have their parking ticket validated at the guard station inside the main lobby.</p>
<p>Arriving from the <b>north</b> of Rockville using Route 270, take exit 8 and keep right to take the Omega Drive ramp. The ramp will bring you to a stop sign. Turn left, and continue on Omega Drive, which turns into Medical Center Drive. From Medical Center Drive, turn right onto Blackwell Road and turn right again into the NCI employee parking garage. Visitors can have their parking ticket validated at the guard station inside the main lobby.</p>
<h4>Upon Arrival at NCI Shady Grove</h4>
<p>Upon arrival at the NCI Shady Grove building you will need to call your NCI host to be signed in and escorted upstairs. You will also need a government-issued photo ID, such as a driver&rsquo;s license. You also have to put your bags through a scanner and walk through a scanner yourself, just as in an airport.</p>
<p>To return to the Shady Grove Metro stop, take the shuttle labeled "Shady Grove Metro" from the same place in front of the building where you were dropped off.&nbsp;</p>
<p><a href="https://www.google.com/maps/place/9609+Medical+Center+Dr,+Johns+Hopkins+University+-+Montgomery+County+Campus,+Rockville,+MD+20850/@39.1034113,-77.1965533,711m/data=!3m2!1e3!4b1!4m2!3m1!1s0x89b632ac9b828531:0x155ac728a5a28e15?hl=en">View our location on a Google Map</a>.</p>
<p><a href="http://www.rockvillemd.gov/">City of Rockville Web site</a></p>
</div>]]></content>
  </row>
  <row para_id="302567" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>PGA is a package of algorithms and graphical user interfaces developed in Matlab for power and sample size calculation under various genetic models and statistical constraints. The software is designed to facilitate decision making for case-control association studies of candidate genes, fine-mapping studies, and whole-genome scans.</p>
<div class="bullet-blu">
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302580" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302580" sys_dependentvariantid="1418" sys_relationshipid="7313954" sys_siteid="475" sys_variantid="1418" sys_contentid="302580">Readme file</a></li>
</ul>
</div>
<h3>Download Software:</h3>
<p>PGA is a package of algorithms and graphical user interfaces developed in MATLAB&reg; for power and sample size calculation under various genetic models and statistical constraints. The software is designed to facilitate decision making for case-control association studies of candidate genes, fine-mapping studies, and whole-genome scans.</p>
<ol>
<li>Users without&nbsp;MATLAB software should install first the MATLAB Component Runtime (MCR): <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=608384" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="608384" sys_dependentvariantid="1500" sys_relationshipid="7313955" sys_siteid="475" sys_variantid="1500" sys_contentid="608384">MCRInstaller</a></li>
<li>Download the self extracting zip file for <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303091" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303091" sys_dependentvariantid="1500" sys_relationshipid="7313953" sys_variantid="1500" sys_contentid="303091">PGA</a></li>
<li>Save this file in an appropriate folder on your disk.</li>
<li>Click on it, and the PGA files will be extracted to a designated location on your hard drive.</li>
</ol>
<h3>Reference:</h3>
<p>Please cite the following reference when reporting results obtained from PGA:<br />Menashe I., Rosenberg P.S., and Chen B.E. (2008) <a href="http://www.ncbi.nlm.nih.gov/pubmed/18477402">PGA: Power calculator for case-control genetic association analyses</a><i>. BMC Genetics</i>, 9:36.</p>
<h3>Support:</h3>
<p>For questions regarding the PGA tool, please email <a href="mailto:rosenbep@exchange.nih.gov">Dr. Philip Rosenberg</a>.</p>
<p>Updates and Bug Fixes:</p>
<div class="bullet-blu">
<ul>
<li>September 9th 2008 - <b>PGA1</b> was updated to fix a bug that caused a bias in the power calculation for a co-dominant (1df) model.</li>
<li>July 29th 2008 - <b>EDF</b> was updated to fix a bug that generated an error message when genotype input files were uploaded.</li>
</ul>
</div>
</div>]]></content>
  </row>
  <row para_id="302569" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The DCEG Fellowship Program offers training for fellows with varied backgrounds and prepares them for a wide range of careers in epidemiology, genomics, biostatistics, and bioinformatics. The majority of postbaccalaureate fellows continue on to graduate or medical school programs after completing a fellowship in DCEG. Our postdoctoral fellows find careers in a variety of sectors, such as academia, government, private industry, and non-profit organizations.</p>
<div sys_dependentvariantid="2082" sys_dependentid="805095" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390060">
<figure class="image-center centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=805095&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>&nbsp;</p>
<p>Here is a list of some of the positions our fellow alumni have obtained:</p>
<p><b>U.S. Academia</b></p>
<p>&bull; Research Associate, John Hopkins Bloomberg School of Public Health Department of Epidemiology<br />&bull; Assistant Professor of Medicine, Baylor College of Medicine<br />&bull; Professor of Epidemiology, Boston University<br />&bull; Statistical Analyst, Dartmouth College<br />&bull; Graduate Research Assistant, Institute of Human Virology, University of Maryland School of Medicine<br />&bull; Assistant Professor, University of Maryland School of Public Health<br />&bull; Assistant Professor, Virginia Commonwealth University<br />&bull; Research Associate, Stanford University, School of Medicine<br />&bull; Professor, Rutgers University<br />&bull; Research Associate, Stanford University, School of Medicine<br />&bull; Department Director, Children's Hospital and Clinics of Minnesota<br />&bull; Investigator, Emma's Children's Hospital/Academic Medical Center</p>
<p><b>Federal Government</b></p>
<p>&bull; Biologist, National Cancer Institute<br />&bull; Investigator, National Cancer Institute<br />&bull; Staff Scientist, National Cancer Institute<br />&bull; Epidemiologist, Office of Science, Center for Tobacco Products, FDA<br />&bull; Associate Adjunct Professor, UC Berkeley School of Public Health<br />&bull; Assistant Professor, University of Arkansas for Medical Sciences<br />&bull; Associate Professor of Epidemiology, University of Louisville<br />&bull; Scientist II, SAIC-Frederick</p>
<p><b>International Academia/Agency</b></p>
<p>&bull; Research Assistant, Imperial College, London<br />&bull; Scientist, International Agency for Research on Cancer<br />&bull; Scientist II, International Agency for Research on Cancer<br />&bull; Senior Scientist, Statens Serum Institute</p>
<p><b>Private/Non-Profit Organization</b></p>
<p>&bull; Senior Epidemiologist, American Cancer Society<br />&bull; Director, American Cancer Society<br />&bull; Senior Staff Scientist, Cancer Prevention Institute of California (CPIC)<br />&bull; Epidemiologist, Merck<br />&bull; Biostatistician, Sanofi<br />&bull; Scientific Analyst, Sarah Canon Research Institute</p>
</div>]]></content>
  </row>
  <row para_id="302571" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>The mission of DCEG is to conduct broad-based, high quality, high impact research to uncover the causes of cancer and the means of its prevention. DCEG maintains a national and international perspective, giving priority to emergent issues identified through epidemiologic, clinical, and laboratory observations, as well as to public health concerns identified by the NCI, Congress, regulatory agencies, and other appropriate bodies. The Division develops research resources and strategic partnerships in molecular epidemiology across NCI, NIH, and the global research community. The Division holds as its top priority the training and development of the next generation of scientists in cancer epidemiology and related fields.</p><p>DCEG is uniquely able to conduct epidemiology research projects that:</p><ul><li>Are high risk,</li><li>Need long-term commitments of funding and scientific staff,</li><li>Require a national programmatic approach,</li><li>Need a quick response to emerging public health or scientific issues,</li><li>Might go unattended by groups without a national and international reach, or</li><li>Require an interdisciplinary approach that is fostered by the breadth and interactive potential of the intramural research program of NCI and NIH.</li></ul></div>]]></content>
  </row>
  <row para_id="302572" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>NON-PROPRIETARY SOFTWARE TRANSFER AGREEMENT</h3>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The CARE model risk calculator may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third partie</p>
</div>]]></content>
  </row>
  <row para_id="302576" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Occupational and Environmental Epidemiology Branch (OEEB) offers postdoctoral fellowships in molecular epidemiology, environmental and occupational epidemiology, and exposure assessment.</p>
<p><em>On this page:</em><a id="top"></a></p>
<ul>
<li><a href="#Friesen">Occupational Exposure Assessment Methods in Cancer Studies</a></li>
<li><a href="#Ward-Jones">Environmental Epidemiology</a></li>
<li><a href="#Berndt">Genetic Epidemiology</a></li>
<li><a href="#Rothman-Lan">Molecular Epidemiology of Lung Cancer in Non-Smokers Associated with Indoor Air Pollution, Chemicals, and Particulates / Molecular Epidemiology of Lymphoma and Leukemia Associated with Occupational and Environmental Chemicals</a></li>
<li><a href="#Hofmann">Molecular Epidemiology of Pesticides and Other Agricultural Exposures and Cancer Risk</a></li>
<li><a href="#Koutros">Molecular Pathology Studies in Exposed Populations</a></li>
<li><a href="#Beane-Freeman">Occupational and Agricultural Exposures</a></li>
</ul>
<p><a href="#top">Back to top</a></p>
<h3><a id="Friesen"></a>Occupational Exposure Assessment Methods in Cancer Studies &ndash; Postdoctoral Fellowship</h3>
<p>The Occupational and Environmental Epidemiology Branch (OEEB) is seeking a postdoctoral fellow with an interest in occupational exposure assessment approaches in cancer epidemiology studies. This fellowship is under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389901" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475">Melissa C. Friesen, Ph.D.</a></p>
<p>The studies of occupation-related risk carried out by OEEB include retrospective assessment of historical exposures, through industry and questionnaire-based evaluations in case-control and cohort studies, and on-site evaluation of exposures through air, dermal and biological monitoring. OEEB studies are international in scope and cover a wide range of occupational exposures, such as pesticides, bioaerosols (e.g., endotoxin, glucan), solvents, diesel exhaust, metals, and benzene.</p>
<p><strong>Qualifications</strong>: A doctoral degree in an exposure science field (such as occupational and environmental hygiene) is required. Experience in characterizing historical and recent workplace exposures for participants in epidemiologic studies is preferred. For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389902" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475">Dr. Melissa Friesen</a>.</p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389900" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103" sys_siteid="475">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Ward-Jones"></a>Environmental Epidemiology - Postdoctoral Fellowship</h3>
<p>The Occupational and Environmental Epidemiology Branch is seeking a postdoctoral fellow interested in studying environmental risk factors for cancer, including industrial, agricultural, and other chemical contaminants. This fellowship is under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349624" sys_contentid="349624" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389896" sys_dependentvariantid="1965" sys_dependentid="349624" rxinlineslot="103" sys_siteid="475">Mary H. Ward, Ph.D.</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389897" sys_dependentvariantid="1965" sys_dependentid="1080328" rxinlineslot="103" sys_siteid="475">Rena R. Jones, Ph.D., M.S.</a></p>
<p>Drs. Ward and Jones are leading multiple cancer investigations of outdoor air pollution, drinking water contaminants, pesticides, and other agricultural and industrial exposures in relation to cancer risk. Many of these studies include Geographic Information Systems (GIS)-based exposure assessments and linkages of regulatory and other environmental monitoring data or modelled environmental contaminants to geocoded residential history data. Potential fellows will work on existing collaborative studies of cancer etiology with experts in cancer epidemiology, GIS, and environmental exposure assessment. They will also have opportunities to develop new projects addressing these and other environmental research topics with data from multiple cohorts, case-control, and other studies.</p>
<p>Candidates should possess a doctoral degree in epidemiology, environmental health, or environmental exposure assessment. In addition to strong quantitative and writing skills, this position requires familiarity with the applications of GIS technology to environmental and health data. A background in environmental sciences is also desirable, but not required. For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349624" sys_contentid="349624" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389898" sys_dependentvariantid="1965" sys_dependentid="349624" rxinlineslot="103" sys_siteid="475">Dr. Ward</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389899" sys_dependentvariantid="1965" sys_dependentid="1080328" rxinlineslot="103" sys_siteid="475">Dr. Jones</a>.</p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389903" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103" sys_siteid="475">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Berndt"></a>Genetic Epidemiology - Postdoctoral Fellowship</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349684" sys_contentid="349684" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389885" sys_dependentvariantid="1965" sys_dependentid="349684" rxinlineslot="103" sys_siteid="475">Sonja Berndt, Pharm.D., Ph.D.</a>,&nbsp;in the Occupational and Environmental Epidemiology Branch (OEEB) is recruiting a postdoctoral fellow with a strong background in genetic epidemiology, biostatistics, or bioinformatics. Candidates with an interest in exploring the genetic architecture of complex diseases through genome-wide association studies (GWAS) and next-generation sequencing, analyzing large datasets, conducting bioinformatic analyses, or with an interest in developing new methods for genetic data are encouraged to apply.</p>
<p>The primary focus of our research group is to investigate the genetic etiology of prostate cancer and lymphoid malignancies as well as anthropometric traits. We have ongoing GWAS and sequencing projects in prostate cancer and lymphoid malignancies, including non-Hodgkin lymphoma (NHL), and we collaborate with the GIANT consortium to investigate the genetics of anthropometric traits, including obesity, which is an important risk factor for many cancers. There are opportunities to work on existing GWAS and sequencing projects as well as to develop new projects in areas such as sequencing, transcriptomics, and statistical methods for genetic association studies. A wealth of data is available for analysis. Opportunities also exist to conduct research on the genetic underpinning of molecular markers or to explore gene-environment interactions with environmental and occupational risk factors.</p>
<p><strong>Qualifications</strong>: Candidates should possess a strong background in genetic epidemiology and/or biostatistics or bioinformatics, be able to perform parallel computing, and have a working knowledge of statistical methods for genetic association studies.</p>
<p>For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349684" sys_contentid="349684" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389891" sys_dependentvariantid="1965" sys_dependentid="349684" rxinlineslot="103" sys_siteid="475">Dr. Sonja Berndt</a>.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389886" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103" sys_siteid="475">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Rothman-Lan"></a>Molecular Epidemiology of Lung Cancer in Non-Smokers Associated with Indoor Air Pollution, Chemicals, and Particulates / Molecular Epidemiology of Lymphoma and Leukemia Associated with Occupational and Environmental Chemicals &ndash; Postdoctoral Fellowships</h3>
<p>The Occupational and Environmental Epidemiology Branch (OEEB) is seeking postdoctoral fellows interested in working on environmental molecular epidemiological studies of indoor air pollution and lung cancer, chemical exposures and lymphoma and leukemia, and occupational and environmental cross-sectional molecular epidemiology studies of chemicals and particulates. This fellowship is under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389874" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103" sys_siteid="475">Qing Lan, M.D., Ph.D., </a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389875" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103" sys_siteid="475">Nathaniel Rothman, M.D., M.P.H., M.H.S</a>.</p>
<p>We have ongoing studies of indoor air pollution, genetic susceptibility, and lung cancer, as well as studies evaluating the etiology of lung cancer in non-smoking women across Asia, where lung cancer rates are particularly elevated. We also have studies evaluating early biologic effects of known or suspected occupational hematopoietic carcinogens, with a particular focus on hematotoxicity, genotoxicity, genetic susceptibility, and emerging "omic" technologies. There are opportunities to work on existing projects as well as to develop new projects on environmental and occupational risk factors for lung cancer, lymphoma, and leukemia, using cross-sectional, case-control, and prospective cohort study designs. For further information about&nbsp;these positions, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389881" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103" sys_siteid="475">Dr. Lan</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389882" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103" sys_siteid="475">Dr. Rothman.</a></p>
<p><strong>Qualifications</strong>: <em>Epidemiology candidates</em> should possess a strong background in epidemiology and statistical analysis, a background in environmental science, environmental health, or occupational health, and excellent writing skills. <em>Bioinformatician candidates</em> should have a background in bioinformatics and/or statistics and experience analyzing data from metabolomic, transcriptomic, epigenetic, microbiome, GWAS, and/or other relevant platforms. An interest in the etiology of cancer arising from environmental and/or occupational exposures is required as well.</p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389873" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Hofmann"></a>Molecular Epidemiology of Pesticides and Other Agricultural Exposures and Cancer Risk - Postdoctoral Fellowship</h3>
<p>The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7389878" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475">Occupational and Environmental Epidemiology Branch</a> (OEEB) is seeking a postdoctoral fellow with an interest in conducting epidemiologic research into occupational, environmental, and molecular/genetic risk factors for multiple myeloma, kidney cancer, and other malignancies, with a particular focus on agricultural exposures and cancer risk. This fellowship is&nbsp;under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=917441" sys_contentid="917441" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389879" sys_dependentvariantid="1965" sys_dependentid="917441" rxinlineslot="103" sys_siteid="475">Jonathan Hofmann, Ph.D.</a></p>
<p>Dr. Hofmann is leading the study of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1134698" sys_contentid="1134698" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389890" sys_dependentvariantid="1418" sys_dependentid="1134698" rxinlineslot="103" sys_siteid="475">Biomarkers of Exposure and Effect in Agriculture (BEEA)</a>, a molecular epidemiologic effort within the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_contentid="303742" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389880" sys_dependentvariantid="1418" sys_dependentid="303742" rxinlineslot="103" sys_siteid="475">Agricultural Health Study cohort</a>. Specifically, he is investigating the potential biological mechanisms through which pesticides and other agricultural exposures influence risk of various malignancies. In addition, Dr. Hofmann is also leading other molecular and genetic studies of the etiology of multiple myeloma and kidney cancer.</p>
<p>Potential fellows will have the opportunity to work on existing projects and to develop new projects addressing these and other research topics. In addition to research opportunities within the BEEA study, fellows would be able to conduct investigations using data and biospecimens from a rich collection of prospective cohorts and other studies.</p>
<p><strong>Qualifications</strong>: Candidates should possess a doctoral degree in epidemiology or occupational/environmental health, and have a strong background in molecular epidemiology and statistical analysis, as well as excellent writing skills. For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302576" sys_contentid="302576" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389877" sys_dependentvariantid="1418" sys_dependentid="302576" rxinlineslot="103" sys_siteid="475">Dr. Hofmann.</a></p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389876" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Koutros"></a>Molecular Pathology Studies in Exposed Populations - Postdoctoral Fellowship</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=919003" sys_contentid="919003" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389893" sys_dependentvariantid="1965" sys_dependentid="919003" rxinlineslot="103" sys_siteid="475">Stella Koutros, Ph.D., M.P.H.</a>, in the Occupational and Environmental Epidemiology Branch (OEEB) is seeking to recruit a postdoctoral fellow with an interest in conducting integrative molecular pathology studies in populations with detailed history of environmental and occupational.&nbsp;Dr. Koutros is conducting several investigations characterizing the genomic landscape of urologic cancers in large epidemiologic studies. Many opportunities exist to incorporate these data with detailed risk factors, special exposures and germline genetic susceptibility to conducted integrative studies on etiology, disease heterogeneity and mechanisms for cancer.&nbsp; Access is available to core genomics facilities and high-performance computing clusters to develop new projects in large existing data sets. In addition, candidate will have access to large variety of career development training, including grant writing.</p>
<p><strong>Qualifications</strong>: Applicants must have a doctoral degree or be enrolled in a graduate degree program in epidemiology or related field (cancer biology, genomics, related biomedical sciences).&nbsp; Experience with research on tumors in observational studies or population genetics is desirable, but not required.&nbsp; Individuals with training in epidemiologic methods and statistics, strong quantitative skills, and excellent writing skills are encouraged to apply.</p>
<p>For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=919003" sys_contentid="919003" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389894" sys_dependentvariantid="1965" sys_dependentid="919003" rxinlineslot="103" sys_siteid="475">Dr. Stella Koutros</a>.</p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389895" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Beane-Freeman"></a>Occupational and Agricultural Exposures - Postdoctoral Fellowship</h3>
<p>The Occupational and Environmental Epidemiology Branch (OEEB) is seeking a postdoctoral fellow with an interest in conducting epidemiologic research into agricultural exposures, including pesticides and cancer risk. This fellowship is under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389887" sys_dependentvariantid="1965" sys_dependentid="349661" rxinlineslot="103">Laura Beane Freeman, Ph.D.</a></p>
<p>Dr. Beane Freeman is the principal investigator of the Agricultural Health Study (AHS) cohort, and is leading investigations of occupational and environmental pesticide exposure, as well as other exposures found in the agricultural environment.&nbsp;Potential fellows will have the opportunity to work on existing projects and to develop new projects addressing these and other research topics. In addition to research opportunities within the AHS, fellows would have the opportunity to conduct investigations using data and biospecimens from a number of other studies.</p>
<p><strong>Qualifications</strong>:&nbsp;Candidates should possess a doctoral degree in epidemiology, and have a strong background in occupational or environmental epidemiology and quantitative methods, as well as excellent writing skills.&nbsp; Experience with research on pesticides is desirable, but not required. For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389883" sys_dependentvariantid="1965" sys_dependentid="349661" rxinlineslot="103" sys_siteid="475">Dr. Beane Freeman.</a></p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389884" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3>DHHS and NIH are Equal Opportunity Employers.</h3>
</div>]]></content>
  </row>
  <row para_id="302577" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Questionnaires may ask the participants to list other types of cooking methods. If the type of cooking method is not listed in the Charred database, then the method must be converted to the most appropriate type of method already in Charred. Below is a suggested list that we have used that will aid you in this decision. However, you may wish to categorize them differently.</p>
<div class="bullet-blu">
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302617" sys_dependentvariantid="1418" sys_dependentid="302617" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="6932327">Cooking Method Conversions (Web</a><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302617" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302617" sys_dependentvariantid="1418" sys_relationshipid="6932326"></a>)</li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=303057" sys_dependentvariantid="1500" sys_dependentid="303057" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="6932328">Cooking Method Conversions (pdf, 206KB)</a></li>
</ul>
</div>
</div>]]></content>
  </row>
  <row para_id="302580" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong><u>Introduction:</u></strong></p>
<p>PGA is a package of algorithms and graphical user interfaces developed in Matlab for power and sample size calculation in case-control genetic association studies. The software comprises a wide verity of genetic models and statistical constraints and hence may facilitate decision making for case-control association studies of candidate genes, fine-mapping studies, and whole-genome scans.</p>
<p><strong><u>Download and installation:</u></strong></p>
<ul>
<li>To install the PGA, save the pga.exe file in an appropriate folder on your disk. Click on it, to extract the folder to a designated location on your hard drive.</li>
<li><b>Users without Matlab software should install first the MATLAB Component Runtime (MCR) on their computers. To install the MCR component, double-click on the &lsquo;MCRInstaller.exe&rsquo; file and follow the installation instructions.</b></li>
<li>Ensure that the MCR is installed on your computer in C:\Program Files\MATLAB\MATLAB_Component_Runtime\v76 or in the folder you selected in the installation process. Once the MCR is installed, you can download and run the different PGA stand-alone GUIs (pga1.exe, pga2.exe and edf.exe.</li>
</ul>
<p>** The MCR is needed to be installed only once.</p>
<p><strong><u>Software description:</u></strong></p>
<p><strong><u>PGA1:</u></strong></p>
<p>PGA1 calculates and plot the relation between statistical power and sample size for a variety of genetic and statistical parameters. The user can determine the following parameters:</p>
<ul class="bullet-blu">
<li>Type of genetic variation &ndash; SNP or Haplotype</li>
<li>Genetic mode of inheritance &ndash; Recessive, Dominant, Co-dominant(1df) or Co-dominant(2df).</li>
<li>Relative risk (RR) &ndash; The relative risk of the disease predisposing alleles. A second relative risk (RR2) is applicable only in Co-dominant model with 2 degrees of freedom (2df).</li>
<li>Linkage disequilibrium (LD) &ndash; The linkage disequilibrium value (in the form of r2 or D&rsquo;) between the causative SNP and the genotyped marker.</li>
<li>Disease prevalence.</li>
<li>Disease allele frequency - the frequency of the disease predisposing allele.</li>
<li>Marker allele frequency &ndash; the allele frequency of the genotyped marker.</li>
<li>Effective degrees of freedom (EDF) - accounts for multiple testing in the study.</li>
<li>Alpha (Type I error).</li>
<li>Control to Case ratio.</li>
<li>Maximum sample size &ndash; the maximum number of cases to be considered in the calculations</li>
<li style="list-style: none;">** The parameter values in the legend of the graph are ordered according to their order in the GUI.</li>
</ul>
<p><strong><u>PGA2:</u></strong></p>
<p>PGA2 calculates and plots the minimum detectable relative risk (MDRR) for genotyped markers with different allele frequencies. The user can determine the following parameters:</p>
<ul class="bullet-blu">
<li>Type of genetic variation &ndash; SNP or Haplotype.</li>
<li>Genetic mode of inheritance &ndash; Recessive, Dominant, Co-dominant(1df) or Co-dominant(2df).</li>
<li>Relative risk ratio (RR1/RR2) &ndash; The ratio between the two relative risks of the disease predisposing genetic alleles. This parameter is applicable only in the Co-dominant(2df) model.</li>
<li>Linkage disequilibrium (LD) &ndash; The linkage disequilibrium value (in the form of r2 or D&rsquo;) between the causative SNP and the genotyped marker.</li>
<li>Effective degrees of freedom (EDF) - accounts for multiple testing in the study.</li>
<li>Disease allele frequency - the frequency of the disease predisposing allele.</li>
<li>Case number &ndash; the number of cases in the study.</li>
<li>Control to Case ratio.</li>
<li>Disease prevalence.</li>
<li>Power (1- Type II error).</li>
<li>Alpha (Type I error).</li>
<li>Maximum sample size &ndash; the maximum number of cases to be considered in the calculations.</li>
</ul>
<p>** The parameter values in the legend of the graph are ordered according to their order in the GUI.</p>
<p><strong><u>EDF:</u></strong></p>
<p>EDF calculates the effective degrees of freedom for a particular set of SNP in linkage disequilibrium. It accepts SNP genotype data files from Hapmap (<a href="http://www.hapmap.org/">http://www.hapmap.org</a>)or tab-delimited text files with SNP genotypes (in columns) coded as 0/1/2 for major homozygous, heterozygous and minor homozygous respectively and missing data encoded as NaN. Please see example input files (<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=410768" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="410768" sys_dependentvariantid="1500" sys_relationshipid="7316217" sys_siteid="475" sys_variantid="1500" sys_contentid="410768">hapmap_example.pdf</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=410767" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="410767" sys_dependentvariantid="1500" sys_relationshipid="7316218" sys_siteid="475" sys_variantid="1500" sys_contentid="410767">genotype_example.pdf</a>). From these data, it computes a summary measure of the EDF (Nyholt et al., 2004) and produces a map of linkage disequilibrium patterns (r2) for the SNPs in the dataset. It allows filtering SNP according to their allele frequencies by determining a threshold of minor allele frequency (MAF).</p>
<p>The resulted EDF value can be incorporated into PGA1 and PGA2 computations.</p>
</div>]]></content>
  </row>
  <row para_id="302581" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7368864" sys_dependentid="1072158" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="1833" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<figure class="video right size50">	<h4>Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"</h4>
	<div id="ytplayer-Q_yycIT2ZjM" class="flex-video widescreen" data-video-id="Q_yycIT2ZjM" data-video-title="Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"">		<noscript>			<p>				<a href="https://www.youtube.com/watch?v=Q_yycIT2ZjM" target="_blank" title="Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"">					View this video on YouTube.				</a>			</p>		</noscript>							</div>			<figcaption class="caption-container">
<div class="contentid-1071885 slot-item only-SI">
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_folderid=401214&amp;sys_siteid=475&amp;sys_contentid=349621&amp;sys_command=editrc" title="" sys_variantid="1965" sys_contentid="349621">Sharon Savage, M.D.</a>, and investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_folderid=301997&amp;sys_siteid=475&amp;sys_contentid=302430&amp;sys_command=editrc" title="" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a> study families with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=335952&amp;sys_command=editrc" title="" sys_variantid="1418" sys_contentid="335952">dyskeratosis congenita (DC)</a>, a rare and complex inherited cancer predisposition syndrome. Patients with DC have extremely short telomeres and elevated risk for multiple cancers. As they study the effect of shortened telomeres on this unique population, the research team searches for genetic variations associated with abnormal telomeres and telomere biology.&nbsp;</p>
<p><a href="https://irp.nih.gov/our-research/research-in-action/decoding-telomere-biology-and-cancer-risk">Read the full article on telomere biology and cancer risk</a>.</p>
</div>
</figcaption>	</figure></div>
<p>Telomeres, specialized structures consisting of long DNA nucleotide repeats and a protein complex, are designed to protect the ends of chromosomes and are critical to chromosome stability. Each time a cell divides, the telomeres lose a small amount of DNA and become shorter. Eventually, telomeres become critically short, causing cellular senescence or cellular crisis, which result in apoptosis, genomic instability or a reduction in cellular lifespan. If cells bypass natural processes and continue to divide despite the presence of genomic instability, cancer can develop. DCEG investigators have been studying telomeres and their associations with cancer risk. Types of studies include</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=335952&amp;sys_command=editrc" sys_contentid="335952" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="335952" sys_relationshipid="7368860" sys_variantid="1418">Dyskeratosis Congenita Study</a></h4>
<p>DCEG studies of dyskeratosis congenita, an inherited bone marrow failure syndrome and cancer predisposition disorder characterized by abnormalities in telomere biology</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=511115&amp;sys_command=editrc" sys_contentid="511115" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="511115" sys_relationshipid="7368861" sys_variantid="1418">Genetic Contribution to Telomere Biology</a></h4>
<p>Studies of possible germline genetic variations in genes that code for proteins integral in telomere biology, which may be important in cancer etiology</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=349621&amp;sys_command=editrc" sys_contentid="349621" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349621" sys_relationshipid="7368862" sys_variantid="1965">Sharon Savage</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302430&amp;sys_command=editrc" sys_contentid="302430" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302430" sys_relationshipid="7368863" sys_variantid="1422">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302582" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators have been studying the causes of familial blood and lymph node cancers for over 30 years. Ongoing advances in genetics, anticipated applications of advanced technologies, and our data from the families we have studied have led us to expand and intensify our research efforts in this area. We are actively recruiting new families to participate in our research. The primary focus of our protocol is on five major areas that together make up a group of diseases called "lymphoproliferative disorders":</p>
<ul>
<li>Chronic lymphocytic leukemia (CLL)</li>
<li>Hodgkin lymphoma (HL)</li>
<li>Non-Hodgkin lymphoma (NHL)</li>
<li>Waldenstr&ouml;m's macroglobulinemia (WM)</li>
<li>Multiple myeloma (MM)</li>
</ul>
<p>With certain exceptions, we are studying families who have at least two living members who both have the same lymphoproliferative disorder (for example, a family with two members who both have CLL). The specific goals and methods vary somewhat according to the specific disease under study. The studies may include: completion of detailed medical history questionnaires, review of pertinent medical records and pathology materials, clinical evaluation, and donation of blood and/or cheek cell samples for research. The clinical evaluation includes a medical history and physical examination and may also entail disease-related laboratory or imaging studies. In certain cases, patients may be invited to visit the NIH Warren G. Magnuson Clinical Center in Bethesda, Maryland, for evaluation. Otherwise, study components can often be completed in or near the patient's home community.</p>
<p><b>Contact Information&nbsp;</b></p>
<p>To refer new families to us, or to discuss one of our studies in greater detail, family members or health professionals can contact Stephanie Steinbart, our Cancer Genetics Referral Nurse, at 1-800-518-8474,&nbsp;or email her at <a href="mailto:stephaniesteinbart@westat.com">stephaniesteinbart@westat.com</a>.</p>
<p><b>Resources</b></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302601" sys_contentid="302601" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302601" sys_dependentvariantid="1418" sys_relationshipid="7357580" sys_siteid="475">Familial Chronic Lymphocytic Leukemia Study Information</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302639" sys_contentid="302639" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302639" sys_dependentvariantid="1418" sys_relationshipid="7357581" sys_siteid="475">Waldenstr&ouml;m's Macroglobulinemia Study Information</a></p>
<p><b>Links</b></p>
<p><a href="http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_02-C-0210.html@familial@leukemia">NIH Clinical Studies for Blood and Lymph Node Cancers Protocol #02-C-0210</a><br /><a href="http://www.cancer.gov/cancertopics/types/leukemia/">Cancer.gov - Leukemia</a><br /><a href="http://www.cancer.gov/cancertopics/types/hodgkin/">Cancer.gov - Hodgkin Lymphoma</a><br /><a href="http://www.cancer.gov/cancertopics/types/non-hodgkin">Cancer.gov - Non-Hodgkin Lymphoma</a><br /><a href="http://www.cancer.org/">The American Cancer Society</a><br /><a href="http://www.lls.org/">Leukemia and Lymphoma Society</a><br /><a href="http://www.acor.org/">Association of Cancer Online Resources</a><br /><a href="http://www.iwmf.com/">International Waldenstr&ocirc;m's Macroglobulinemia Foundation</a><br /><a href="http://www.waldenstromsresearch.org/">Research Fund for Waldenstr&ocirc;m's</a><br /><a href="http://www.cancer.net/Cancer/cancer.html">People Living with Cancer</a></p>
</div>]]></content>
  </row>
  <row para_id="302584" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Recent experimental and epidemiologic studies of cancers of the breast, colon, rectum, and prostate, as well as non-Hodgkin lymphoma (NHL), suggest that vitamin D metabolites may help prevent cancer or cancer mortality. DCEG investigators undertook the first study to examine the prospective relationship between the vitamin D status metabolite, 25-hydroxyvitamin D in serum and cancer mortality. The study was conducted in more than 15,000 persons aged 17 and older who participated in the third National Health and Nutrition Examination Survey (NHANES III). It found total cancer mortality was unrelated to baseline vitamin D status in the entire population, including men, women, non-Hispanic whites, non-Hispanic blacks, Mexican Americans in persons younger than 70 or 70 years or older. Investigators found no interaction between vitamin D and season or vitamin D and serum retinol. Colorectal cancer mortality was inversely related to serum 25(OH)D level.&nbsp;</p>
<p>Another study is examining the relationship between two vitamin D metabolites (25(OH)D and 1,25(OH)D and breast cancer in the Prostate, Lung, Colon, and Ovarian (PLCO) screening study cohort.</p>
<p>Investigators are also examining the relationship between pre-diagnostic 25(OH)D and lymphoid cancer risk in a case-control study nested in the Alpha-Tocopherol Beta Carotene Prevention Study cohort of Finnish smokers.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7159347" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965">Elizabeth Cahoon</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=401127&amp;sys_revision=46&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7159363">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302586" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators in the Radiation Epidemiology Branch (REB) have reconstructed radiation dose for radiation technologists included in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_dependentvariantid="1418" sys_dependentid="302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270624" sys_variantid="1418" sys_contentid="302552">United States Radiologic Technologists (USRT) study</a>. Different sources of data as well as relevant dosimetric models were used in the process, including extensive historical information collected from the literature; more than 1,000,000 film-badge measurements from private laboratories, employers, the military and commercial dosimetric service providers; and detailed work history data. Annual and cumulative occupational badge doses for radiation technologists were reconstructed and used to estimate organ-specific radiation absorbed doses: the thyroid, female breast, ovary, lens of eye, lung, colon, testes, heart, skin, and red bone marrow. The uncertainty of both badge and organ doses for each year of each technologist&rsquo;s working career was characterized using Monte Carlo simulation methods.</p>
<p>Major improvements in the revision included:</p>
<ul>
<li>Increased numbers of annual badge dose measurements</li>
<li>Additional information on individual apron usage</li>
<li>Refined modeling of annual badge dose probability density functions</li>
<li>Refinements in organ dose conversion coefficients to account for uncertainties in machine settings and radiographic techniques</li>
</ul>
<p>In addition, investigators found a statistically significant dose response using chromosome aberrations with estimated dose to bone marrow.</p>
<h3>New Initiatives for Improved Occupational Exposure Assessment</h3>
<p>Two new initiatives have been undertaken to improve estimation of occupational radiation doses in radiologic technologists administering radionuclides and those conducting fluoroscopically-guided interventional procedures. Investigators collected historical information on nuclear medicine practices in the 1950s &ndash; 1970s through a focus group meeting with experts to estimate occupational doses for each procedure and radiopharmaceuticals available at that time.</p>
<p>In addition, the fourth survey in the USRT cohort includes two specialized work history modules for the radiologic technologists administering radionuclides and those carrying out fluoroscopically-guided interventional procedures. The survey has been completed and results are being used to refine dose estimates for those technologists.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_dependentvariantid="1965" sys_dependentid="939611" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270622" sys_variantid="1965" sys_contentid="939611">Dr. Vladimir Drozdovitch</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_dependentvariantid="1965" sys_dependentid="349634" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270623" sys_variantid="1965" sys_contentid="349634">Dr. Choonsik Lee</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270625" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302589" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<p><b>DCEG Molecular Epidemiology Course</b><a href="http://intranet.dceg.cancer.gov/training/courses/molecular-epidemiology-course-winter-2008"><b><br /></b></a>This course is offered to DCEG fellows every 2-3 years. Led by DCEG investigators, this comprehensive course includes didactic sessions and laboratory visits, culminating in fellows developing research proposals that integrate methodological and analytical principles of molecular epidemiology. In the past, DCEG investigators have evaluated and funded four proposals for up to $10,000.</p>
<p><b>Genetics Analysis Course by the NCI Core Genotyping Facility</b><a href="http://intranet.dceg.cancer.gov/training/courses/Genetic%20Analysis%20Course%202008/GenAnalysisCourse/"><b><br /></b></a>Complementing the DCEG Molecular Epidemiology Course, this one-day course on genetics reviews basic issues in germline variation, population genetics, and analysis strategies for common genetic variations.</p>
<p><b>DCEG Fellows&rsquo; Annual Media Training<br /></b>This annual training is designed to help fellows learn how to manage media inquiries and how to describe their research in interviews with science and health reporters. The session reviews what motivates reporters and their questions, common principles for giving a good interview and staying in control, as well as suggestions for how to most effectively communicate the main messages of a particular study. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=936140" sys_dependentvariantid="1965" sys_dependentid="936140" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276786" sys_variantid="1965" sys_contentid="936140">For more information, contact Ms.&nbsp;Jennifer Loukissas</a>.</p>
<p><b>Workshop on Delivering Effective Presentations<br /> </b> An interactive workshop to provide fellows and other staff with skills to improve the development and delivery of scientific talks&nbsp;and&nbsp;preparing for and responding to questions. To reinforce the concepts of data visualization and design, participants work together to critique and revise their slides. To raise awareness of the qualities of effective presentation delivery, participants give 2-3 minute &lsquo;mini&rsquo; presentations that are videotaped and played back to the group for feedback.&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=936140" sys_dependentvariantid="1965" sys_dependentid="936140" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276787" sys_variantid="1965" sys_contentid="936140">For more information, contact Ms.&nbsp;Jennifer Loukissas</a><span>.</span></p>
<b>Grants and Grantsmanship Workshop<br /></b>The annual grant writing workshop enables fellows from DCEG and the CPFP to learn grant writing skills, develope a written research proposal and participate in a mock study section. It is designed to prepare participants to be better equipped to compete for funding opportunities in the future. For more information contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349643" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349643" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7276785" sys_variantid="1965" sys_contentid="349643">Dr. Jackie Lavigne</a>.</div>
<div>
<p><b>Radiation Epidemiology and Dosimetry Course</b><a href="http://web.ncifcrf.gov/events/radiationepidemiology/default.asp"><b><br /></b></a>The DCEG Radiation Epidemiology Branch periodically offers a course on radiation epidemiology, with a focus on radiation-related cancers. Lecturers discuss radiation dosimetry in epidemiologic studies, methodologic issues, and challenges in studying low-dose effects. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=937894" inlinetype="rxhyperlink" sys_relationshipid="7276784" rxinlineslot="103" sys_dependentid="937894" sys_dependentvariantid="1418" sys_siteid="475" sys_variantid="1418" sys_contentid="937894">View course information from the latest Radiation Epidemiology and Dosimetry Course</a>.</p>
<p><a href="https://cpfp.cancer.gov/summer/summer.php"><b>NCI Summer Curriculum in Cancer Prevention<br /></b></a>The Cancer Prevention Fellowship Program (CPFP) provides two summer courses annually in cancer prevention and control. Both courses are open to physicians, scientists, and other health care professionals. It is comprised of a four week "Principles and Practice of Cancer Prevention and Control" course, and a one week "Molecular Prevention" course.</p>
</div>
</div>]]></content>
  </row>
  <row para_id="302591" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<p><em>On this page:</em></p>
<p><a href="#Pediatric-Cancers">Genomic Studies of Pediatric Cancers</a><br /><a href="#Lymphoproliferative-Gastrointestinal">Cancer Genomics of Lymphoproliferative or Gastrointestinal Cancers</a><br /> <a href="#IBMFS">Inherited Bone Marrow Failure Syndromes of Childhood</a></p>
<!--<a href="#Human-Cancer-Genomics">Postdoctoral Position in Human Cancer Genomics / Carcinogenic HPV Genomics</a></p>-->
<h3><a id="Pediatric-Cancers"></a>Genomic Studies of Pediatric Cancers - Postdoctoral Fellowship</h3>
<p>The Clinical Genetics Branch is seeking a postdoctoral fellow with an interest in conducting genomic studies to identify susceptibility genes and modifier factors for pediatric cancers. The goal of our research is to identify and characterize genetic variants that underlie the development of pediatric cancers and patient outcomes. The potential fellow will use bioinformatic, genetic, epidemiologic, and/or biostatistic methods to analyze complex data derived from genome-wide association and next-generation sequencing (e.g., whole-exome sequencing) pediatric cancer studies.</p>
<p>The candidate will have the opportunity of working closely with researchers with expertise in pediatric cancer, epidemiology, biostatistics, bioinformatics, genetics, and genomics. DCEG fellows have access to data from state-of-the-art studies in cancer genomics and work with highly committed and talented researchers. DCEG offers extensive career development training through its Office of Education.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree and background in genetics/genomics, genetic epidemiology, or statistical genetics are encouraged to apply. Candidates with a doctoral degree in related fields with strong quantitative skills are also encouraged to apply. Experience in analyses of large genomic datasets, next-generation sequencing, and/or bioinformatics methods is required. A successful candidate will have excellent communication skills, be highly motivated and able to work in a large multidisciplinary team. Salary and benefits are competitive and commensurate with experience.</p>
<p>For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7343094" sys_siteid="475" rxinlineslot="103" sys_dependentid="639592" sys_dependentvariantid="1965">Lisa Mirabello, Ph.D.</a>, or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_contentid="349621" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7343095" sys_siteid="475" rxinlineslot="103" sys_dependentid="349621" sys_dependentvariantid="1965">Sharon Savage, M.D</a>.</p>
<p><strong>To apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7343096" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information</a> page for an overview, qualifications, and application details.</p>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Lymphoproliferative-Gastrointestinal"></a>Cancer Genomics of Lymphoproliferative or Gastrointestinal Cancers - Postdoctoral Fellowship</h3>
<p>Investigators in the Clinical Genetics Branch are seeking a postdoctoral fellow with an interest in conducting multi-omics analyses to identify major susceptibility genes and modifier factors for lymphoproliferative and gastrointestinal cancers. The potential fellow will be analyzing high-dimensional germline genomic data (e.g., whole-exome sequencing, SNP array, RNASeq, methylation array) derived primarily from multi-generational families with lymphoproliferative or gastrointestinal diseases, such as lymphoma, leukemia, Waldenstr&ouml;m macroglobulinemia, and esophageal, gastric, or pancreatic cancer. The candidate will have the opportunity of working closely with researchers with expertise in epidemiology, biostatistics, bioinformatics, genetics, and genomics and will have extensive career development training opportunities through the DCEG Office of Education.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree in genetic epidemiology, statistical genetics, bioinformatics, or biostatistics are preferred. Candidates with a doctoral degree in related fields with strong quantitative skills are also encouraged to apply. Experience in analyses of lymphoproliferative diseases, gastrointestinal cancer or omics data is a plus.</p>
<p>For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349658" sys_contentid="349658" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7343092" sys_siteid="475" rxinlineslot="103" sys_dependentid="349658" sys_dependentvariantid="1965">Alisa Goldstein, Ph.D.</a>, or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349660" sys_contentid="349660" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7343093" sys_siteid="475" rxinlineslot="103" sys_dependentid="349660" sys_dependentvariantid="1965">Mary L. McMaster, M.D</a>.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7343097" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information</a> page for an overview, qualifications, and application details.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="IBMFS"><a id="IBMFS"></a>Training in the Inherited Bone Marrow Failure Syndromes of Childhood</h3>
<p>CGB is seeking a clinically-trained pediatric or medical hematology/oncology physician with research interests in the Inherited Bone Marrow Failure disorders, e.g., Fanconi anemia, dyskeratosis congenita, Diamond Blackfan anemia, Shwachman Diamond syndrome, Thrombocytopenia Absent Radii syndrome, etc., who desires a postdoctoral research opportunity which is focused on these rare conditions.</p>
<div class="callout-box" style="float: right; width: 50%; margin: 0 0 5px 10px;">
<h4>IBMFS Study Information</h4>
<ul>
<li><a href="http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_02-C-0052.html@etiologic">Protocol: Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes</a></li>
<li><a href="http://marrowfailure.cancer.gov/">Patient/Family Literature on the Inherited Bone Marrow Failure Syndromes cohort</a></li>
</ul>
</div>
<p>The Branch is now more than 15 years into assembling and analyzing the world's largest cohort of affected families, systematically collecting demographic, medical, epidemiologic, genetic, and psychosocial/behavioral data plus carefully-annotated biospecimens, to support etiologically-oriented translational research. This includes the opportunity to learn the clinical phenotype of these diseases first-hand, participate in the evaluation of clinical research protocol participants, become involved in the analysis and publication of data derived from this cohort, and acquire new skills related to clinical genetics and epidemiology.</p>
<p><b>Qualifications:</b> Individuals with clinical training in pediatric or medical hematology/oncology or genetics who also have a strong interest in inherited bone marrow failure and cancer predisposition syndromes are sought for this position. Previous training or experience in genetics, epidemiology, and/or biostatistics would be highly beneficial, although not required.</p>
<p>For further information, please contact either <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349651" sys_contentid="349651" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7343090" sys_siteid="475" rxinlineslot="103" sys_dependentid="349651" sys_dependentvariantid="1965">Dr. Blanche Alter</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_contentid="349621" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7343091" sys_siteid="475" rxinlineslot="103" sys_dependentid="349621" sys_dependentvariantid="1965">Dr. Sharon Savage</a>.</p>
<p>See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7343089" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information page</a> for general overview, qualifications, and application details.</p>
<!--<h3><a id="#Human-Cancer-Genomics"></a>Postdoctoral Position in Human Cancer Genomics / Carcinogenic HPV Genomics</h3>
<p>We are using high-throughput genomic approaches to examine carcinogenic HPV genome-wide variation to investigate the molecular basis of human papillomavirus&nbsp;(HPV) carcinogenicity. Another goal of our research is to identify and characterize human genome variants that underlie the development of human pediatric cancers. To these ends, we use next-generation sequencing data to evaluate the HPV genome and human genome in large case-control or cohort studies. We are applying bioinformatics methods, phylogenetics, and genetic epidemiologic analyses to analyze these data.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree or background in genetics/genomics, genetic epidemiology, or related field, are encouraged to apply. Experience in analyses of large complex genomic datasets, next-generation sequencing, and/or bioinformatics methods is a plus. A successful candidate will have excellent communication skills, be highly motivated and able to work in a large multidisciplinary team. Salary and benefits are highly competitive and commensurate with experience and accomplishments.</p>
<p>Contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="639592" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6441624">Lisa Mirabello, Ph.D., M.S.</a>, for more information.</p>
<p>See the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=45&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103" sys_relationshipid="6441625">Division Fellowship Information page</a> for general overview, qualifications, and application details.</p>-->
<p><a href="#Top">Back to top</a></p>
<p style="text-align: center;">DHHS and NIH are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="302592" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>SegCNV is a software package, implemented in C++, to detect germline copy number variations in SNP array data. Currently, SegCNV supports Illumina 550K and 610K genotyping platforms.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302538" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302538" sys_dependentvariantid="1418" sys_relationshipid="7279628" sys_siteid="475" sys_variantid="1418" sys_contentid="302538">License Agreement</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=326171" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="326171" sys_dependentvariantid="1418" sys_relationshipid="7279629" sys_siteid="475" sys_variantid="1418" sys_contentid="326171">ReadMe</a></li>
</ul>
<h3>Download Software:</h3>
<p>Download the following file to install <b><u>segCNV</u></b></p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=410786" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="410786" sys_dependentvariantid="1500" sys_relationshipid="7279630" sys_siteid="475" sys_variantid="1500" sys_contentid="410786">segcnv.tar.gz.zip</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>Support:</h3>
<ul>
<li>Questions on software issues? Contact: <a href="mailto:jianxin.shi@nih.gov">Dr. Jianxin Shi</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302594" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=856668" inlinetype="rxhyperlink" sys_relationshipid="7280016" sys_siteid="475" rxinlineslot="103" sys_dependentid="856668" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="856668">Age Period Cohort Analysis Web Tool</a></strong><br /> A panel of easy-to-interpret estimable Age-Period-Cohort functions and corresponding Wald tests in R code that can be accessed through a user-friendly web tool.</p>
<p><strong><a href="https://gis.cancer.gov/geoviewer/">NCI GeoViewer</a></strong><br />NCI GeoViewer is a mapping tool designed to provide visualization of national cancer data. The tool enables users to create maps of cancer statistics, demographics, and risk factors for use in research. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1047458" inlinetype="rxhyperlink" sys_relationshipid="7280015" sys_siteid="475" rxinlineslot="103" sys_dependentid="1047458" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="1047458">GeoViewer has been&nbsp;expanded with cancer mortality data</a> previously available through the legacy Cancer Mortality Maps application.</p>
<p><a href="http://seer.cancer.gov/seerstat/"><b>MP-SIR SEER*Stat<br /></b></a>Interactive PC-based software module developed to perform multiple primary analyses with the goal of facilitating research into the etiology of second cancers. It calculates standardized incidence ratios by:</p>
<ul>
<li>Second cancer site</li>
<li>Histology</li>
<li>Treatment</li>
<li>Sex</li>
<li>Race</li>
<li>Calendar year</li>
<li>Age and time since diagnosis</li>
<li>Registry</li>
</ul>
<p>Utilizing the&nbsp;<a href="http://seer.cancer.gov/">NCI Surveillance, Epidemiology, and End Results (SEER) database</a>, the program allows scientists within and outside of NIH to test hypotheses about the relationships between two cancers on their PCs.</p>
</div>]]></content>
  </row>
  <row para_id="302598" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This is a R package for rapid evaluation of extremely small p-value for resampling-based test (EXPERT). The stochastic approximation Markov chain Monte Carlo algorithm is adopted. The new procedure can be used easily for estimating the p-value for any resampling-based test. Numerical simulations demonstrate that the proposed procedure can be 100 to 500,000 times as efficient (in term of computing time) as the standard resampling-based procedure when evaluating a test statistic with a small p-value (e.g., less than 1e-6 ).</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=303227" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303227" sys_dependentvariantid="1500" sys_relationshipid="6888134" sys_siteid="475">Readme</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302607" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302607" sys_dependentvariantid="1418" sys_relationshipid="6888135" sys_siteid="475">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<p>Save this file in an appropriate folder on your disk.</p>
<ul>
<li>Windows O/S Pre-Vista - <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303252" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303252" sys_dependentvariantid="1500" sys_relationshipid="6888131">EXPERT0_0.0.1.zip</a></li>
<li>Windows O/S Vista - <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303252" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303252" sys_dependentvariantid="1500" sys_relationshipid="6888132">EXPERT_0.0.1.zip</a></li>
<li>Windows O/S 7 - <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1008629" sys_dependentvariantid="1500" sys_dependentid="1008629" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6888136">EXPERT_0.0.8.zip</a></li>
<li>Unix O/S - <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303254" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303254" sys_dependentvariantid="1500" sys_relationshipid="6888133">EXPERT_0.0.7.tar.gz</a></li>
</ul>
<h3>Reference:</h3>
<p>Yu K, Liang F, Ciampa J, Chatterjee N. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21209154">Efficient p-value evaluation for resampling-based tests</a>.&nbsp; <em>Biostatistics</em> 2011 Jul; Epub Jan 5.</p>
<h3>Support:</h3>
<p><b>Questions?</b> Contact: <a href="mailto:yuka@mail.nih.gov">Dr. Kai Yu</a></p>
</div>]]></content>
  </row>
  <row para_id="302600" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This readme file contains important information about the Power Program V.3.0.0.</p>
<h3 id="list">Table of Contents</h3>
<p style="margin-left: 20.0px;">0. <a href="#0">Enhancements for V.3.0.0<br /></a>I. <a href="#I">Introduction<br /></a>II. <a href="#II">Installation<br /></a>III. <a href="#III">Running the Program<br /></a>IV. <a href="#IV">Power and Sample Size Calculations<br /></a>V. <a href="#V">Results<br /></a>VI. <a href="#VI">Contacting the Developers<br /></a>VII. <a href="#VII">References</a></p>
<h3 id="0">0. Enhancements for V.3.0.0</h3>
<p>POWER V.3.0.0 has been upgraded to include:</p>
<div class="bullet-blu">
<ul>
<li>Power/sample size for one exposure (binary or categorical with multiple levels)</li>
<li>For two exposures, the specification of a dependent joint probability distribution<br />for exposures</li>
<li>Entry of values for either marginal odds ratios or main effects odds ratios for the specification of the alternative hypothesis</li>
<li>Improved handling of log and output files; and minor bug fixes</li>
</ul>
</div>
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="I">I. Introduction</h3>
<p>The Power program permits you to determine the power or the sample size for epidemiological studies testing interactions between two factors or testing a null odds ratio or a trend in the odds ratio for a single exposure.</p>
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="II">II. Installation</h3>
<p>To install the Power program run the "install.exe" file. This must be done from Windows, and it is recommended that all Windows programs are closed before doing so. Follow the instructions given to complete the installation.<br />Note: If your computer is running under the Windows 2000 operating system, the install program must be run from an account with installation privileges (i.e., Power User or Administrator). If you are not sure what privileges you have, please contact your System Administrator.</p>
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="III">III. Running the Program</h3>
<p>To launch the Power program, select and run the file Power.exe. This may be done through Explorer or an icon on the desktop or in a program group.</p>
<p>Please note that the calculation engine (PowerCalc.exe) is not intended to be run independently of the interface (Power.exe). The interface facilitates selection of analysis options and it ensures that all parameters are properly specified. It then launches the calculation engine appropriately.</p>
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="IV">IV. Power and Sample Size Calculations</h3>
<p>POWER bases calculations on the prospective binary response model:</p>
<blockquote>P(D|x,y) = [exp(a) X OR(x,y)]^D / [1 + exp(a) X OR(x,y)],</blockquote>
<p>where P(D=1|0,0) = exp(a)/[1 + exp(a)] is the probability of disease at baseline, and where the odds ratio (OR) for joint exposures under the alternative hypothesis may be derived from a multiplicative (i.e., logistic model),</p>
<blockquote>OR (x-x_0,y-y_0) = OR(1,0)^(x-x_0) * OR(0,1)^(y-y_0) * theta^[(x-x_0)(y-y_0)],</blockquote>
<p>or an additive,</p>
<blockquote>OR (x-x_0,y-y_0) = 1 + [OR(1,0)^(x-x_0) - 1 + OR(0,1)^(y-y_0) - 1] *<br />gamma^[(x-x_0)(y-y_0)] relationship.</blockquote>
<p>Power/sample size is based on the OR for interaction (theta) or the excess OR for interaction (gamma), and a test of the null hypothesis theta = 1 (or gamma = 1), when the true theta (or gamma) is a specified value (alternative hypothesis).</p>
<p>For one exposure, the current version of POWER bases calculations on a prospective binary response model, where the odds ratio (or trend in odds ratio with exposure) is linear in the log-odds,</p>
<blockquote>P(D|x) = [exp(a) X OR(x)]^D / [1 + exp(a) X OR(x)] where<br />OR (x-x_0) = OR(1,0)^(x-x_0).</blockquote>
<p>Power/sample size is based on the null hypothesis that OR(x)=1 for all x.</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th colspan="2">Definitions</th>
</tr>
<tr>
<td class="first">theta</td>
<td class="second">OR for interaction; the proportional interaction parameter at unit increases in each exposure. For a multiplicative model and for scores, x_0,...,x_K-1, theta = OR(1,1) / OR(1,0) * OR(0,1)</td>
</tr>
<tr class="odd">
<td class="first">OR^tb</td>
<td class="second">"top-to-bottom" OR; the OR for the highest category relative to the lowest category. For scores, x_0,...,x_K-1, OR^tb = OR(x_K-1,0) / OR(x_0,0) = OR(1,0)^(x_K-1 - x_0)</td>
</tr>
<tr>
<td class="first">theta^tb</td>
<td class="second">"top-to-bottom" interaction OR; the proportionality factor at the highest categories for each exposure relative to the lowest categories. For Exposure1 with K categories and Exposure2 with L categories, theta^tb = theta^[(x_K-1 - x_0) * (y_L-1 - y_0)]</td>
</tr>
<tr class="odd">
<td class="first">gamma</td>
<td class="second">Excess OR for interaction; the proportional interaction parameter at unit increase of the excess OR in each exposure. For an additive model, gamma = [OR(1,1)-1]/[OR(1,0)-1 + OR(0,1)-1]</td>
</tr>
<tr>
<td class="first">EOR^tb</td>
<td class="second">Excess "top-to-bottom" OR; the excess OR for the highest category relative to the lowest category. For scores, x_0,...,x_K-1, EOR^tb = OR(x_K-1,0) / OR(x_0,0) - 1 = OR(1,0)^(x_K-1 - x_0) - 1</td>
</tr>
<tr class="odd">
<td class="first">gamma^tb</td>
<td class="second">Excess "top-to-bottom" interaction OR; the proportionality factor at the highest categories for the excess ORs for each exposure. For Exposure1 with K categories and Exposure2 with L categories, gamma^tb = [OR(x_K-1- x_0,y_L-1 - y_0) - 1]/[OR(x_K-1 - x_0,y_0)-1 + OR(x_0,y_L-1 - y_0) - 1 ]</td>
</tr>
</tbody>
</table>
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="V">V. Results</h3>
<p>V.A. Log File - A log file is created to which the description of the results and the parameters are added. This file is appended with each subsequent run. It is displayed at the completion of a run. It is a simple text file that may be saved for later use.</p>
<p>V.B. Data File - In addition to the log file, a file listing the relevant values for each run is created. This data file contains a header row with column titles at the beginning of each run. The fields are separated by commas. The columns included are as follows:</p>
<table class="blue-table" cellspacing="0">
<tbody>
<tr>
<th>Column Title</th>
<th>Description</th>
</tr>
<tr>
<td class="first">Run</td>
<td class="second">Number of a given run. This count is reset each time the application is started</td>
</tr>
<tr class="odd">
<td class="first">Power</td>
<td class="second">Power</td>
</tr>
<tr>
<td class="first">Cases</td>
<td class="second">For case control studies this is the number of cases or the sample size. For cohort studies this is the number of events.</td>
</tr>
<tr>
<td class="first">Total Subjects</td>
<td class="second">Total subjects</td>
</tr>
<tr class="odd">
<td class="first">OR1</td>
<td class="second">Odds ratio for exposure 1</td>
</tr>
<tr>
<td class="first">OR2</td>
<td class="second">Odds ratio for exposure 2</td>
</tr>
<tr class="odd">
<td class="first">Theta/Gamma</td>
<td class="second">Odds ratio interaction term</td>
</tr>
<tr>
<td class="first">Study</td>
<td class="second">Study type (CC=case/control, CO=cohort)</td>
</tr>
<tr class="odd">
<td class="first">Model</td>
<td class="second">Model type (A=additive, M=multiplicative)</td>
</tr>
<tr>
<td class="first">E1_1</td>
<td class="second">1st score value for exposure 1</td>
</tr>
<tr class="odd">
<td class="first">E1_2</td>
<td class="second">2nd score value for exposure 1</td>
</tr>
<tr>
<td colspan="2">...&nbsp;</td>
</tr>
<tr class="odd">
<td class="first">E1_K</td>
<td class="second">Kth score value for exposure 1</td>
</tr>
<tr>
<td class="first">P1_1</td>
<td class="second">1st probability for exposure 1</td>
</tr>
<tr class="odd">
<td class="first">P1_2</td>
<td class="second">2nd probability for exposure 1</td>
</tr>
<tr>
<td class="first">P1_K</td>
<td class="second">Kth probability for exposure 1</td>
</tr>
<tr class="odd">
<td class="first">E2_1</td>
<td class="second">1st score value for exposure 2</td>
</tr>
<tr class="odd">
<td class="first">E2_2</td>
<td class="second">2nd score value for exposure 2</td>
</tr>
<tr>
<td colspan="2">...&nbsp;</td>
</tr>
<tr class="odd">
<td class="first">E2_L</td>
<td class="second">Lth score value for exposure 2</td>
</tr>
<tr class="odd">
<td class="first">P2_1</td>
<td class="second">1st probability for exposure 2</td>
</tr>
<tr>
<td class="first">P2_2</td>
<td class="second">2nd probability for exposure 2</td>
</tr>
<tr class="odd">
<td colspan="2">...&nbsp;</td>
</tr>
<tr>
<td class="first">P2_L</td>
<td class="second">Lth probability for exposure 2</td>
</tr>
</tbody>
</table>
This file is also appended with each subsequent run and may be saved for later use. It is a text file but may also be read into any spreadsheet program that will handle comma-delimited files.
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="VI">VI. Contacting the Developers</h3>
<p>Send requests to Ms. Holly Brown (<a href="mailto:Brownh@exchange.nih.gov">Brownh@exchange.nih.gov</a>).</p>
<div class="dceg-top"><a href="#list">Back to Table of Contents</a></div>
<h3 id="VII">VII. References</h3>
<ul class="stack-nobullets">
<li>Lubin JH, Gail MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/2301364">On power and sample size for studying features of the relative odds of disease</a>. <cite>Am J Epidemiol</cite> 1990.</li>
<li>Garc&iacute;a-Closas M, Lubin JH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/10206617">Power and sample size calculations in case-control studies of gene-environmental interactions: Comments on different approaches</a>. <cite>Am J Epidemiol</cite> 1999.</li>
</ul>
<div class="dceg-top"><a href="#top">Back to Top</a></div>
</div>]]></content>
  </row>
  <row para_id="302601" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The National Cancer Institute (NCI) is studying families with multiple cases of chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the Western Hemisphere. CLL is described as one of the "lymphoproliferative disorders". &nbsp;If CLL runs in your family, NCI invites you and your family to discuss joining our study, in order to help us learn more about this disease.</p>
<h4>Purpose</h4>
<p>The purpose of the study is to:</p>
<div class="bullet-blu">
<ul>
<li>Find the gene or genes that cause this type of leukemia to occur in families.</li>
<li>Describe the clinical features of familial CLL.</li>
<li>Explore whether families prone to familial CLL are also at greater risk of other types of leukemia or cancer.</li>
<li>Identify biomarkers or markers that predict risk in family members.</li>
</ul>
</div>
<h4>Who is Eligible?</h4>
<p>To participate, a family must have one of the following:</p>
<div class="bullet-blu">
<ul>
<li>Two or more living individuals in the family with a history of CLL.</li>
<li>Parents, siblings and adult children of affected family members, along with other blood relatives who are genetically linked, may also join.</li>
<li>Spouses of affected family members are welcome to participate if their children (generally aged 35 and over) are participating.</li>
<li>We may consider families in which one family member has CLL, and one or more close relatives have a related blood or lymph cancer such as Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Waldenstr&ouml;m's Macroglobulinemia.</li>
</ul>
</div>
<h4>Participating in Research</h4>
<p>Those who join the study will be asked to:</p>
<div class="bullet-blu">
<ul>
<li>Provide a blood sample or cells rinsed from the inside of the cheek for genetic studies.</li>
<li>Provide personal and medical history and family history information.</li>
<li>Give consent to obtain medical records for cancer and related conditions.</li>
</ul>
</div>
<p>Since the genes that increase the risk of this type of familial cancer have not yet been discovered, clinical genetic testing is not part of this study. If our research finds one of these important genes, then interested individuals may be able to have formal genetic testing, either as part of this study or through an additional study.</p>
<p>Some participants will be offered the opportunity to visit the Clinical Center in Bethesda Maryland at no cost to them for more detailed clinical, genetic and laboratory studies aimed at finding other factors that contribute to risk among family members.</p>
<p>Although treatment is not a part of this study, treatment options will be discussed with participants. NCI will provide assistance in establishing care with appropriate physicians as needed. Study participants remain under the care of their primary doctors while participating in this study.</p>
<h4>Continuing Contact</h4>
<p>Participants and families will be asked periodically to complete a follow-up form in order to update medical and family information.</p>
<p>Participants are encouraged to contact the Familial CLL Team with questions or family news.</p>
<p>Information that would change a patient's clinical status, such as the results of routine clinical studies, will be shared with participants.</p>
<h4>Other Details:</h4>
<p><b>Confidentiality&nbsp;</b></p>
<p>NCI is required by Federal Law not to reveal information that is collected from study participants to anyone other than persons directly involved in the study. No personal identifying information will be released or published.</p>
<p>Participants are asked if they would like us to send their health care providers a copy of the clinical findings (physical exam, routine blood work) from their visit to NIH.</p>
<p><b>Costs</b></p>
<p>All study related medical expenses and travel costs to the NIH Clinical Center for participants are paid by NCI.</p>
<h4>For More Information</h4>
<p>If you are interested in more information about our Familial CLL study, please contact Stephanie Steinbart, our Cancer Genetics Referral Nurse, at 1-800-518-8474, or email her at <a href="mailto:stephaniesteinbart@westat.com">stephaniesteinbart@westat.com</a>. For information about familial CLL research, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349591" sys_contentid="349591" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7357579" sys_dependentvariantid="1965" sys_dependentid="349591" rxinlineslot="103" sys_variantid="1965">Neil Caporaso</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302603" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>During the past few decades, there has been dramatic growth in the numbers of higher-dose diagnostic x-ray examinations and fluoroscopically&ndash;guided (FG) procedures. These complex procedures use long and on-time radiological imaging, resulting in high radiation exposure not only to patients but also to physicians. The mortality experience and cumulative radiation exposure level to radiologists, cardiologists and other physicians performing FG procedures are not well known. Although cancer mortality has been studied previously in the U.S. radiologists, this study will update the previous findings and will provide longer term follow-up of radiologists who started practicing more recently who should have been exposed to much lower levels of exposure compared to those radiologists practicing in earlier years. Cancer mortality has not been investigated in the other physicians exposed to radiation from FG procedures. A large cohort of radiologists and other physicians exposed to radiation has been assembled to determine the cause of death compared to physicians who are not exposed to radiation.&nbsp;</p>
<p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=939428&amp;sys_revision=9&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="939428" sys_dependentvariantid="1965" sys_folderid="" sys_relationshipid="7197068">Cari Kitahara</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7197067" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302604" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>CNVfam is a software package for jointly detecting copy number variations (CNV) in nuclear families genotyped using the Illumina platform. CNVfam has the ability to detect both inherited CNVs and de novo CNVs. Compared to algorithms designed for unrelated subjects, CNVfam substantially improves the power of detecting short CNVs carried by multiple family members. CNVfam is computationally very fast, taking less than one minute to analyze a trio and five minutes to analyze a nuclear family with five offsprings.<br /><br />CNVfam detects CNVs in two steps. In the first step, CNVfam infers haplotype sharing pattern at each probe using high quality genotype data. In the second step, CNVfam jointly detects CNVs conditioning on the inferred haplotype sharing pattern by maximizing a penalized likelihood function. Once the haplotype sharing is inferred using SNP genotype data, CNVfam allows the detection of CNVs for subjects with poor intensity data (but with acceptable SNP data).<br /><br />CNVfam is implemented using C++ and currently running in Linux platform. The package has been tested in Illumina 550K, 610K and 660K genotyping platforms. The package includes a readme file and a data example. Please contact Peng.Li2@nih.gov or Jianxin.Shi@nih.gov if you have questions.</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302529" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302529" sys_dependentvariantid="1418" sys_relationshipid="6816168">ReadMe</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302440" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302440" sys_dependentvariantid="1418" sys_relationshipid="6816169">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Click to download: <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=410525" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="410525" sys_dependentvariantid="1500" sys_relationshipid="6816170" sys_siteid="475">CNVfam.tar.gz.zip</a></li>
<li>Save this file in an appropriate folder on your disk.</li>
</ul>
<h3>Support:</h3>
<p><b>Questions?</b> Contact: <a href="mailto:Jianxin.Shi@nih.gov">Dr. Jianxin Shi</a></p>
</div>]]></content>
  </row>
  <row para_id="302605" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Childhood Cancer Survivor Study (CCSS) was established in the early 1990s as a cohort of more than 14,000 childhood cancer survivors from 26 centers in North America who were originally diagnosed between 1970 and 1986. Investigators from the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=84&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7124502" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a> played major roles in CCSS collaborative efforts during the 2000s in case-control studies to quantify the dose-response relationship between radiotherapy exposures and second primary cancers of the thyroid, central nervous system, breast, and sarcomas after childhood cancer. A strong dose-response relationship for glioma and meningioma was noted over a wide range of doses, up to 50 Gy. In addition, risk of thyroid cancer increased through doses of 15 to 20 Gy, but decreased at higher doses. A study of breast cancer among members of the cohort indicated an association with chest irradiation and a personal or family history of bone or soft tissue sarcoma. In the last 10 years, CCSS has broadened to include a similar number of survivors diagnosed between 1987 and 1999, and expanded to include patients from additional centers.</p>
<p>In 2011, DCEG initiated a collaboration with CCSS to conduct a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1057944" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7124503" sys_dependentvariantid="1418" sys_dependentid="1057944" rxinlineslot="103" sys_variantid="1418" sys_contentid="1057944">genome-wide association study</a> (GWAS) aimed at identifying genetic variants associated with 1) development of second cancers (either independent of treatment exposures or jointly with specific treatments), 2) development of childhood cancer, and 3) development of non-malignant late adverse effects of treatment (e.g., cardiomyopathy, obesity, ototoxicity). The GWAS includes over 5700 survivors. Analyses for aims 1-2 are ongoing, and the data are being posted to the <a href="https://www.ncbi.nlm.nih.gov/gap">database of Genotypes and Phenotypes</a> (dbGaP) to facilitate analyses related to aim 3. <a href="https://ccss.stjude.org/develop-a-study/gwas-data-resource.html">Find out more about the CCSS GWAS data resource</a>.</p>
<p>DCEG and CCSS investigators are now conducting whole exome sequencing of the cohort to identify other types of genetic variants (e.g., rare variants, multi-allelic substitutions, insertions, and deletions) that may be related to the development of childhood cancer and late effects following childhood cancer diagnosis.</p>
<p>REB and CCSS investigators are also collaborating on a case-control study of breast cancer occurring after childhood cancer. Previous studies have shown that chest radiotherapy for childhood cancer confers strikingly elevated risk for developing subsequent breast cancer. The current study aims to understand whether the radiation-related risks are modified by other key risk factors and if the risks are consistent for all types of breast cancer, which has important implications both for understanding breast cancer etiology as well as for decision-making for long-term follow-up of childhood cancer survivors.</p>
<p><a href="https://ccss.stjude.org/">Learn more about the Childhood Cancer Survivor Study</a>.&nbsp;</p>
<h4>Selected publications:</h4>
<p>Sigurdson et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/15950715">Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study</a>. <em>Lancet</em>. June 11-17, 2005. DOI: 10.1016/S0140-6736(05)66695-0</p>
<p>Neglia et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/17077355">New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study</a>. <em>JNCI</em>. November 1, 2006. DOI: 10.1093/jnci/djj411</p>
<p>Inskip et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19620485">Radiation dose and breast cancer risk in the childhood cancer survivor study</a>. <em>J Clin Oncol</em>. August 20, 2009. DOI: 10.1200/JCO.2008.20.7738</p>
<p>Henderson et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22795729">Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study</a>. <em>Int J Radiat Oncol Biol Phys</em>. September 1, 2012. DOI: 10.1016/j.ijrobp.2011.11.022</p>
<p><a href="https://ccss.stjude.org/published-research/publications.html">See a full list of publications from the Childhood Cancer Survivor Study</a>.&nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7124501" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_variantid="1965" sys_contentid="349616">Lindsay Morton</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=401127&amp;sys_revision=35&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7124504">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302606" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel">
    <h3>CompareTests - R Package</h3><p><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><b>This is a trial version of the software</b>. The CompareTests - R package may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="302607" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>EXPERT - R Package</h3><p><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><b>This is a trial version of the software</b>. The EXPERT - R package may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="302608" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Non-Proprietary Software Transfer Agreement</h3>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
<p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:</p>
<p>Nilanjan Chatterjee (<a href="mailto:chattern@mail.nih.gov">chattern@mail.nih.gov</a>)</p>
</div>]]></content>
  </row>
  <row para_id="302612" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A multi-center U.S. case-control study of benign and malignant brain tumors is addressing a variety of possible risk factors for these poorly understood tumors. Analyses did not indicate associations with use of cellular telephones, which emit radiofrequency radiation, nor with exposure to low-frequency electromagnetic fields (EMF) from electrical appliances used in the home. Employment in several occupations was associated with these tumors. These observations are being followed in detailed studies of the possible role of specific exposures, including solvents, lead, pesticides and EMF. One of these suggested a gene-environment interaction involving occupational exposure to lead and risk of meningioma that depended on a polymorphism in the gene (<i>ALAD</i>) that&nbsp;influences the toxicokinetics of lead.</p>
<p>Investigators did not observe associations between glioma or meningioma and occupational exposure to insecticides or herbicides. Additional occupational exposures can be evaluated in this study. No association was seen for use of hair dyes, which contain aromatic amines. A significant inverse association between the risk of glioma and history of allergies or autoimmune diseases was observed, as well as a positive association of glioma with age at menarche and an inverse association with age at first live birth. Studies of self-reported family history and brain tumor risk indicated increased risk of glioma in persons with a first degree relative with stomach cancer, prostate cancer or Hodgkin lymphoma. DNA, serum and plasma samples are available for future studies.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_contentid="939428" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="939428" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7308101" sys_variantid="1965">Cari Kitahara</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7308102" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
<p><b>Related study:</b> <a href="http://dceg.cancer.gov/research/what-we-study/genes-host/genetic-susceptibility-brain-tumors">Genetic Susceptibility and Brain Tumors</a></p>
</div>]]></content>
  </row>
  <row para_id="302614" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Cancer incidence among children undergoing computed tomography (CT) scans</h2>
<p>Due to the lack of empirical data on CT use and cancer, DCEG has initiated a retrospective cohort study with the University of Newcastle to evaluate the relationship between radiation exposure from CT scans conducted during childhood and adolescence and the subsequent development of cancer. We currently are identifying a cohort of 200,000 people who received CT scans as children or adolescents in the UK during 1985-2002. The cohort will be followed for cancer incidence and mortality using national records. We also are assessing trends in use of CT examinations in various parts of the UK.</p>
<p>In addition, two studies of CT examinations were conducted in Israel. In a descriptive study of pediatric and adolescent CT scan use during 1999-2003 in a large health maintenance organization in Israel we found that the cranium was the most frequently scanned region of the body, ranging from 78% in young children to 39% in adolescents. The highest annual CT examination rate (per 1,000) was recorded in 2001 (10.1) compared to 7.0 and 6.3 in 1999 and 2003, respectively. The lowest rate (three scans per 1,000) was found for 3-year-old children, with increasing rates with age. In the second study, we estimated that 17,686 pediatric scans were conducted annually in Israel during 1999-2003. We projected that 9.5 lifetime deaths would be associated with 1 year of pediatric CT scanning. This number represents an excess of 0.29% over the total number of patients who are eventually estimated to die from cancer in their lifetime.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7233105" sys_dependentvariantid="1965" sys_dependentid="349642" rxinlineslot="103">Amy Berrington de Gonz&aacute;lez</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7233107" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302615" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>NCI Resources</h2>
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-hgp/ltg">LTG Home</a></h3>
<p><a title="" href="/about/organization/programs-hgp/ltg/research">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=LTG">LTG Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/ltg-fellows">Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/ltg-training">Research Training Opportunities</a></p>
<p><a title="" href="/about/organization/programs-hgp/ltg/tools">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=LTG">Publications</a></p>
</div>
<p>Learn about the&nbsp;<a href="http://cgf.nci.nih.gov/">NCI Cancer Genomics Research Laboratory</a> (formerly the Core Genotyping Facility)</p>
<p>Read an overview of<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1057944" sys_contentid="1057944" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1057944" sys_variantid="1418" sys_relationshipid="7266852"> Genome-wide Association Studies</a></p>
<p>Learn about the&nbsp;<a href="http://cgap.nci.nih.gov">Cancer Genome Anatomy Project</a></p>
<h2>Apply for controlled access data</h2>
<p>The <a href="https://www.ncbi.nlm.nih.gov/gap">database of Genotypes and Phenotypes (dbGaP)</a> was developed to archive and distribute the results of studies that have investigated the interaction of genotype and phenotype.</p>
<h2>Additional bioinformatics tools</h2>
<p><a href="https://analysistools.nci.nih.gov/LDlink/">LDlink</a><br />LDlink is a suite of web-based applications designed to easily and efficiently interrogate linkage disequilibrium in population groups. All population genotype data originates from Phase 3 (Version 5) of the 1000 Genomes Project and variant RS numbers are indexed based on dbSNP build 142. Where coordinates are specified, GRCh37/hg19 is used. Only bi-allelic variants are permitted as input.</p>
<p>Access the <a href="https://www.ebi.ac.uk/gwas/">Catalog of published Genome-Wide Association Studies</a></p>
</div>]]></content>
  </row>
  <row para_id="302617" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel">Hamburger <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>air cooker</td><td>microwave</td></tr><tr><td>baked</td><td>microwave</td></tr><tr><td>boil</td><td>microwave</td></tr><tr><td>braised</td><td>microwave</td></tr><tr><td>browned (loose meat)</td><td>microwave</td></tr><tr><td>browned (patty form)</td><td>pan fried</td></tr><tr><td>casseroles</td><td>microwave</td></tr><tr><td>ceramic grill</td><td>grilled/bbq</td></tr><tr><td>char broiled</td><td>grilled/bbq</td></tr><tr><td>cooked in sauce/water</td><td>microwave</td></tr><tr><td>electric broiler</td><td>broiled</td></tr><tr><td>electric grill</td><td>grilled/bbq</td></tr><tr><td>electric over briquets</td><td>grilled/bbq</td></tr><tr><td>George Forman grill</td><td>grilled/bbq</td></tr><tr><td>griddled</td><td>pan fried</td></tr><tr><td>grill pan</td><td>pan fried</td></tr><tr><td>meat balls</td><td>microwave</td></tr><tr><td>meat loaf</td><td>microwave</td></tr><tr><td>par broil</td><td>microwave</td></tr><tr><td>pressure cooked</td><td>microwave</td></tr><tr><td>saut&#233;ed</td><td>microwave</td></tr><tr><td>simmer</td><td>microwave</td></tr><tr><td>skillet</td><td>pan fried</td></tr><tr><td>spaghetti meat sauce</td><td>microwave</td></tr><tr><td>steamed</td><td>microwave</td></tr></table><p class="breakhere">&#160;</p>Steak <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>air cooker</td><td>microwave</td></tr><tr><td>baked</td><td>microwave</td></tr><tr><td>boiled</td><td>microwave</td></tr><tr><td>braise</td><td>microwave</td></tr><tr><td>breaded-fried</td><td>pan fried just done</td></tr><tr><td>browned</td><td>pan fried</td></tr><tr><td>char-broiled</td><td>grilled/bbq</td></tr><tr><td>charbroiled</td><td>grilled/bbq</td></tr><tr><td>cooked in water/sauce</td><td>microwave</td></tr><tr><td>crock pot/slow cooker</td><td>microwave</td></tr><tr><td>electric skillet</td><td>pan fried</td></tr><tr><td>farberware</td><td>grilled/bbq</td></tr><tr><td>frozen entree</td><td>microwave</td></tr><tr><td>George Forman grill</td><td>grilled/bbq</td></tr><tr><td>grill pan</td><td>pan fried</td></tr><tr><td>jenn-aire</td><td>grilled/bbq</td></tr><tr><td>mixed dishes</td><td>microwave</td></tr><tr><td>pot roast</td><td>microwave</td></tr><tr><td>pressure cooked</td><td>microwave</td></tr><tr><td>restaurant</td><td>pan fried</td></tr><tr><td>rotisserie</td><td>broil</td></tr><tr><td>saut&#233;ed</td><td>microwave</td></tr><tr><td>skillet</td><td>pan fried</td></tr><tr><td>steamed</td><td>microwave</td></tr><tr><td>stew</td><td>microwave</td></tr><tr><td>stir fry</td><td>microwave</td></tr><tr><td>table top grill</td><td>grilled/bbq</td></tr></table><p class="breakhere">&#160;</p>Pork <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>boiled</td><td>baked</td></tr><tr><td>braised<br />&#160;</td><td>baked</td></tr><tr><td>breaded then fried</td><td>baked</td></tr><tr><td>convection oven</td><td>baked</td></tr><tr><td>crock pot</td><td>baked</td></tr><tr><td>deep fried</td><td>baked</td></tr><tr><td>electric grill</td><td>grilled/bbq</td></tr><tr><td>frozen entree</td><td>microwave</td></tr><tr><td>George Forman grill</td><td>grilled/bbq</td></tr><tr><td>in casseroles</td><td>baked</td></tr><tr><td>pre-cooked</td><td>baked</td></tr><tr><td>pressure cooker</td><td>baked</td></tr><tr><td>rotisserie</td><td>broiled</td></tr><tr><td>saut&#233;ed</td><td>microwave</td></tr><tr><td>shake and bake</td><td>baked</td></tr><tr><td>simmered</td><td>microwave</td></tr><tr><td>slow cooked</td><td>baked</td></tr><tr><td>smoked</td><td>baked</td></tr><tr><td>steamed</td><td>baked</td></tr><tr><td>stews, soup</td><td>baked</td></tr><tr><td>stir fry</td><td>microwave</td></tr><tr><td>stove top grill</td><td>grilled/bbq</td></tr><tr><td>stuffed/breaded</td><td>microwave</td></tr><tr><td>toaster oven</td><td>baked</td></tr></table><p class="breakhere">&#160;</p>Sausage <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>baked</td><td>microwave</td></tr><tr><td>boiled</td><td>microwave</td></tr><tr><td>casserole</td><td>microwave</td></tr><tr><td>cooked in sauce</td><td>microwave</td></tr><tr><td>electric grill</td><td>pan fried</td></tr><tr><td>faberware</td><td>pan fried</td></tr><tr><td>fried and drained</td><td>pan fried</td></tr><tr><td>frozen sausage biscuit</td><td>microwave</td></tr><tr><td>George Forman</td><td>pan fried</td></tr><tr><td>griddle</td><td>pan fried</td></tr><tr><td>grill pan</td><td>pan fried</td></tr><tr><td>grilled/barbecued</td><td>pan fried</td></tr><tr><td>heat rollers</td><td>microwave</td></tr><tr><td>on pizza</td><td>microwave</td></tr><tr><td>par boiled</td><td>microwave</td></tr><tr><td>poached</td><td>microwave</td></tr><tr><td>precooked</td><td>microwave</td></tr><tr><td>restaurants</td><td>pan fried</td></tr><tr><td>simmered</td><td>microwave</td></tr><tr><td>smoked</td><td>microwave</td></tr><tr><td>steamed</td><td>microwave</td></tr><tr><td>stewed</td><td>microwave</td></tr><tr><td>stir fry</td><td>microwave</td></tr></table><p class="breakhere">&#160;</p>Bacon <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>baked</td><td>microwave</td></tr><tr><td>electric baconer</td><td>pan fried</td></tr><tr><td>electric grill</td><td>pan fried</td></tr><tr><td>fast food</td><td>pan fried well done</td></tr><tr><td>griddle</td><td>pan fried</td></tr><tr><td>grilled/barbecued</td><td>pan fried</td></tr><tr><td>precooked</td><td>microwave just done</td></tr><tr><td>restaurant</td><td>pan-fried</td></tr><tr><td>roasted</td><td>microwave</td></tr><tr><td>steamed</td><td>microwave</td></tr><tr><td>turkey bacon</td><td>chicken microwave</td></tr></table><p class="breakhere">&#160;</p>Chicken <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>air cooked</td><td>baked</td></tr><tr><td>boiled</td><td>stew</td></tr><tr><td>canned</td><td>baked</td></tr><tr><td>casserole</td><td>stew</td></tr><tr><td>chinese</td><td>baked</td></tr><tr><td>creamed</td><td>stew</td></tr><tr><td>crock pot</td><td>stew</td></tr><tr><td>curried</td><td>stew</td></tr><tr><td>electric grill</td><td>grilled/bbq</td></tr><tr><td>frozen entree</td><td>microwave</td></tr><tr><td>George Forman grill</td><td>grilled/bbq</td></tr><tr><td>in casseroles/soup</td><td>stew</td></tr><tr><td>in salads</td><td>baked</td></tr><tr><td>indoor grill</td><td>grilled/bbq</td></tr><tr><td>lunch meat/deli</td><td>baked</td></tr><tr><td>mexican dishes</td><td>baked</td></tr><tr><td>mixed dishes</td><td>baked</td></tr><tr><td>oven fried</td><td>broiled well done</td></tr><tr><td>parboil</td><td>stew</td></tr><tr><td>poached</td><td>stew</td></tr><tr><td>pressure cooker</td><td>stew</td></tr><tr><td>roasted</td><td>baked</td></tr><tr><td>rotisserie</td><td>rotisserie</td></tr><tr><td>saut&#233;ed</td><td>baked</td></tr><tr><td>simmer</td><td>stew</td></tr><tr><td>skillet</td><td>pan fried</td></tr><tr><td>smoked</td><td>baked</td></tr><tr><td>spit</td><td>baked</td></tr><tr><td>steamed</td><td>stew</td></tr><tr><td>stir fry</td><td>microwave</td></tr><tr><td>turkey burger/bacon/sausage</td><td>microwave</td></tr></table><p class="breakhere">&#160;</p>Fried Chicken <table class="blue-table"><tr><th scope="col" width="350">Response</th><th scope="col" width="250">Method Applied</th></tr><tr><td>baked</td><td>baked</td></tr><tr><td>boiled</td><td>stew</td></tr><tr><td>cajun fr. turkey</td><td>deep fried</td></tr><tr><td>fast food</td><td>deep fried</td></tr><tr><td>frozen entree</td><td>deep fried</td></tr><tr><td>George Foreman grill</td><td>grilled/bbq</td></tr><tr><td>oven broiled</td><td>deep fried</td></tr><tr><td>oven fried</td><td>baked</td></tr><tr><td>oven roasted</td><td>broiled well done</td></tr><tr><td>Pam</td><td>pan fried</td></tr><tr><td>pan fried/stewed in sauce</td><td>stew</td></tr><tr><td>poached</td><td>stew</td></tr><tr><td>pressure cooked</td><td>stew</td></tr><tr><td>pressure fried</td><td>deep fried</td></tr><tr><td>roasted</td><td>baked</td></tr><tr><td>saut&#233;ed</td><td>baked</td></tr><tr><td>shake and bake</td><td>deep fried</td></tr><tr><td>smothered</td><td>deep fried</td></tr><tr><td>steamed</td><td>stew</td></tr><tr><td>stir fry</td><td>microwave</td></tr></table></div>]]></content>
  </row>
  <row para_id="302618" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">

<p><strong>Provider:</strong> National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
<p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:</p>
<p>Nilanjan Chatterjee (<a href="mailto:chattern@mail.nih.gov">chattern@mail.nih.gov</a>)</p>

</div>]]></content>
  </row>
  <row para_id="302619" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7370792" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103">Biostatistics Branch</a> and learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302518" sys_contentid="302518" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7370793" sys_dependentvariantid="1418" sys_dependentid="302518" rxinlineslot="103">current research training opportunities</a>.</p>
<h3><strong><a id="Aron"></a>Jordan Aron, B.A. &ndash; Postbaccalaureate Fellow </strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1133135" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370818">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133135&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Jordan Aron, B.A., joined the Biostatistics Branch (BB) as a postbaccalaureate fellow in August 2018 after receiving his B.A. in mathematics from Carleton College, Northfield, Minnesota. During the summer of 2017, Mr. Aron was an intern at Cincinnati Children&rsquo;s Hospital Medical Center in Dr. Emily Miraldi&rsquo;s lab, where he worked on creating transcriptional regulatory networks from single-cell RNAseq data. As a BB postbaccalaureate fellow, Mr. Aron works under the mentorship of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/albert-paul">Paul Albert, Ph.D.</a>, senior investigator and Chief, BB, <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/cheung-li">Li Cheung, Ph.D.</a>, staff scientist, BB, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/katki-hormuzd">Hormuzd Katki, Ph.D.</a>, senior investigator, BB, on applying hidden Markov models to study the natural history of HPV.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3 id="Choo-Wosoba"><strong><a id="Choo-Wosoba"></a>Hyoyoung Choo-Wosoba, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1064686" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370819">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="Hyoyoung Choo-Wosoba, postdoctoral fellow" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1064686&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Hyoyoung Choo-Wosoba, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in August 2016. She earned her Ph.D. from the Department of Bioinformatics and Biostatistics at the University of Louisville, Kentucky, under the supervision of Dr. Somnath Datta. Dr. Choo-Wosoba&lsquo;s doctoral research focused on developing statistical methodology to analyze zero-inflated clustered count data. She is currently working under the mentorship of <a href="https://irp.nih.gov/pi/paul-albert">Paul Albert, Ph.D.</a>, senior investigator and Chief, BB, on a collaborative project with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/bin-zhu">Bin Zhu, Ph.D.</a>, investigator, BB, concerning statistical approaches for copy number variation detection using next-generation sequencing data.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Choo%20Wosoba%20H%5bAuthor%5d&amp;cmd=DetailsSearch">Scientific Publications - Hyoyoung Choo-Wosoba<br /></a></p>
<div style="clear: both; margin-top: 28px;">
<h3><strong><a id="Deng"></a>Lu Deng, Ph.D. &ndash; </strong><strong>Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101331" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370820">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101331&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Lu Deng, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in September 2017. Dr. Deng received his Ph.D. (2017) in mathematical statistics from Nankai University of China, under the supervision of Drs. Zhaojun Wang and Changliang Zou. His Ph.D. dissertation research focused on statistical inference for high-dimensional data, including multiple hypothesis testing, variable selection, and sufficient dimension reduction. Currently, he is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/yu-kai">Kai Yu, Ph.D.</a>, senior investigator, BB, on developing statistical methodologies to address emerging challenges from current genetic and molecular epidemiology studies.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3 id="Derkach"><a id="Derkach"></a>Andriy Derkach, Ph.D. -&nbsp;Research Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="854594" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370821">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=854594&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Andriy Derkach, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow after receiving his Ph.D. from the Department of Statistical Sciences at the University of Toronto. For his doctoral dissertation, Dr. Derkach developed new methods for testing associations with groups of rare genetic variants, and extended the underlying theory to make general claims about the properties of score tests for association under response-dependent sampling. Dr. Derkach works with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349649" sys_contentid="349649" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7370796" sys_dependentvariantid="1965" sys_dependentid="349649" rxinlineslot="103">Joshua Sampson, Ph.D.</a>, investigator in BB, to identify biological mediators that link exposures with the risk of cancer.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=derkach+a&amp;authorOption=exact&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=0&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications - Andriy Derkach<br /></a></p>
<div style="clear: both; margin-top: 28px;">
<h3 id="Haber"><a id="Haber"></a>Gregory Haber, Ph.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1126526" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370822">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1126526&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Gregory Haber, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in June 2018. He earned his Ph.D. from the Department of Mathematics and Statistics at the University of Maryland, Baltimore County, under the supervision of Yaakov Malinovsky, Ph.D. Prior to joining BB, Gregory spent two years as a predoctoral fellow in the Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Currently, Dr. Haber is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/graubard-barry">Barry Graubard, Ph.D.</a>, senior investigator, BB, <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/albert-paul">Paul Albert, Ph.D.</a>, Chief and senior investigator, BB, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/liu-danping">Danping Liu, Ph.D.</a>, investigator, BB. His research is focused on the analysis of record-linked data with measurement error due to incorrect linkage as well as the transportability of prediction models across finite populations in epidemiological studies.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/56186979/?sort=date&amp;direction=descending">Scientific Publications &ndash; Gregory Haber<br /></a></p>
<h3><a id="Han"></a>Justin Yongli Han, Ph.D. - Postdoctoral Fellow&nbsp;</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1110980" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370823">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1110980&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Justin Yongli Han, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in January 2018. Prior to joining BB, Dr. Han was a postdoctoral fellow in the Biostatistics and Bioinformatics Branch, Division of intramural Population and Health Research of the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development. In 2016, Dr. Han earned his Ph.D. in statistics from the University of Hong Kong. Currently, Dr. Han works with <u></u><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1100757" sys_contentid="1100757" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7370798" sys_dependentvariantid="1965" sys_dependentid="1100757" rxinlineslot="103"><u>Danping Liu, Ph.D</u></a>., investigator, BB, on diagnostic testing, biomarker evaluation and combination, risk prediction, joint analysis of complex longitudinal and survival data, and missing data methodologies in cancer studies and health behavior research.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Han%2C+Yongli">Scientific Publications - Yongli Han<br /></a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3 id="Hua"><a id="Hua"></a>Xing Hua, Ph.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="800477" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370824">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="Xing Hua, postdoctoral fellow" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=800477&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Xing Hua, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in April 2013. Dr. Hua worked in the Department of Physiology and Cancer Center of the Medical College of Wisconsin (MCW) as a visiting scholar from 2011 and received his Ph.D. in statistics from the University of Science and Technology of China in 2012. His Ph.D. thesis focused on developing statistical methods and algorithms for analyzing cancer genome sequencing data, including calling somatic mutations and detecting driver genes. Dr. Hua is now working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349594" sys_contentid="349594" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7370797" sys_dependentvariantid="1965" sys_dependentid="349594" rxinlineslot="103">Jianxin Shi, Ph.D.</a>, Investigator, BB, to develop methods for driver gene detection across cancer sites, detect mutations affecting survival, and perform statistical analysis of lung cancer tumor sequencing data.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=hua%20x&amp;authorOption=exact">Scientific Publications - Xing Hua<br /></a></p>
<h3><strong><a id="Kim"></a>Do Hyun Kim, B.S. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1133141" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370825">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133141&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Do Hyun Kim, B.S., joined the Biostatistics Branch (BB) as a postbaccalaureate fellow in July 2018. Mr. Kim graduated from Johns Hopkins University in 2013 with a bachelor&rsquo;s degree in molecular and cellular biology and second major in neuroscience. Mr. Kim is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/shi-jianxin">Jianxin Shi, Ph.D.</a>, senior investigator, BB, on the genome-wide association studies of lung cancer and copy number variation analysis of chordomas.</p>
</div>
<div style="clear: both; margin-top: 28px;"></div>
<h3><a id="Landy"></a>Rebecca Landy, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1108116" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370826">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1108116&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Rebecca Landy, Ph.D., joined the Biostatistics Branch (BB) and Clinical Genetics Branch (CGB) as a postdoctoral fellow in February 2018. Dr. Landy earned her Ph.D. in epidemiology and statistics in 2012 from University College London, U.K., under the supervision of Prof. Rebecca Hardy. Her doctoral research focused on missing data in longitudinal studies. Prior to joining NCI, she worked as a statistician at the Centre for Cancer Prevention, Queen Mary University of London with Prof. Peter Sasieni, evaluating cervical cancer screening in England. Dr. Landy is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/chaturvedi-anil">Anil Chaturvedi, Ph.D.</a>, senior investigator, CGB, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/katki-hormuzd">Hormuzd Katki, Ph.D.</a>, senior investigator, BB, to understand the natural history of human papillomavirus-related oropharyngeal cancers, and the appropriate use of risk estimation methods when evaluating cancer screening.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/rebecca.landy.1/bibliography/public/">Scientific Publications - Rebecca Landy<br /></a></p>
<h3><strong><a id="Lee"></a>DongHyuk Lee, Ph.D. </strong><strong>&ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1142187" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370827">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1142187&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1142187&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>DongHyuk Lee, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in October 2018. Dr. Lee completed his Ph.D. in statistics from the Department of Statistics at Texas A&amp;M University in August 2018 under the supervision of Dr. Samiran Sinha. His dissertation research focused on developing statistical testing in the latent variable context and algorithms for computational aspects. Dr. Lee is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/bin-zhu">Bin Zhu, Ph.D.</a>, investigator, BB, on statistical methods for analyzing mutational signatures in cancer research.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Mandal"></a>Soutrik Mandal, Ph.D.</strong><strong> &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1135865" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370828">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1135865&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Soutrik Mandal, Ph.D., joined the Biostatistics Branch (BB) as a postdoctoral fellow in September 2018. Dr. Mandal earned his Ph.D. in statistics from Texas A&amp;M University. His doctoral dissertation focused on estimation and testing problems in the analysis of linear transformation models in the context of interval-censored time-to-event data with covariate measurement error. Dr. Mandal is currently working with mentors <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/pfeiffer-ruth"></a>&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349627" sys_contentid="349627" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7370799" sys_dependentvariantid="1965" sys_dependentid="349627" rxinlineslot="103">Ruth Pfeiffer, Ph.D.</a>, senior investigator, BB, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349594" sys_contentid="349594" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7370800" sys_dependentvariantid="1965" sys_dependentid="349594" rxinlineslot="103">Jianxin Shi,&nbsp;Ph.D.</a> , senior investigator, BB, to develop semiparametric methods for inferential problems in case-control studies with incident and prevalent cases.</p>
<p>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/myncbi/1fMir8ZnVGbQWD/bibliography/public/">Scientific Publications - Soutrik Mandal<br /></a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Patel"></a>Ankur Patel, M.S. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1144421" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370829">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1144421&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Mr. Ankur Patel joined DCEG in&nbsp;November 2018. He is working jointly in the Biostatistics Branch (BB) and the Radiation Epidemiology Branch (REB). Mr. Patel received a B.S. in mathematics with a concentration in statistics from the University of Maryland, College Park in 2016, and an M.S. in statistics from the University of North Carolina, Chapel Hill in May 2018. Prior to finishing his master&rsquo;s studies, Mr. Patel completed a summer internship at NIST, where he worked with Dr. John Liu in forensic footwear analysis. He is currently working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/little-mark">Mark Little, D.Phil.</a>, senior investigator, REB, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/albert-paul">Paul S. Albert, Ph.D.</a>, Chief and senior investigator, BB, on several projects related to dosimetry and survival analysis. In particular, he is working on the U.S. Radiologic Technologists cohort study, using dose realizations from a Monte Carlo Dosimetry System to estimate exposure and how the estimated exposure along with other covariates affects the time until development of a cataract.</p>
<div style="clear: both; margin-top: 28px;">
<h3><strong><a id="Shin"></a>Yei Eun Shin, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101447" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370830">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="bank" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101447&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Yei Eun Shin, Ph.D., joined the Biostatistic Branch (BB) as a postdoctoral fellow in October 2017. Dr. Shin completed her Ph.D. in statistics from Texas A&amp;M University, College Station, in August 2017. For her doctoral dissertation, she developed statistical research on covariate matching methods, monotone functional data analysis, and binary spatio-temporal data modeling. Dr. Shin is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/gail-mitchell">Mitchell H. Gail, M.D., Ph.D.</a>, senior investigator, BB, to enhance the survival model from the two-phase sampling design of a cohort.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Skarzynski"></a>Martin Skarzynski, Ph.D., M.P.H. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1143801" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370831">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1143801&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Martin Skarzynski, Ph.D., M.P.H., joined the Biostatistics Branch (BB) as a Cancer Prevention Fellow in November 2018.&nbsp; He holds an M.P.H. in epidemiologic and biostatistical methods for public health and clinical research, and a certificate in data science from the Johns Hopkins Bloomberg School of Public Health.&nbsp; He earned his Ph.D. in tumor biology from Georgetown University, an M.S. in biotechnology from Jagiellonian University in Poland, and a B.A. in biology from St. Mary&rsquo;s College of Maryland. Dr. Skarzynski is passionate about bioinformatics, data science, epidemiology, and statistical computing. He uses the Python and R programming languages and command line tools to explore, analyze, visualize and present data, and he has a strong interest in reproducibility, scientific publishing workflows, and open data/science best practices. Dr. Skarzynski applies his computational skills in combination with his genomics and immunology background to the study and prevention of cancer. In DCEG, Dr. Skarzynski is working under the mentorship of<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" sys_contentid="349618" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7370801" sys_dependentvariantid="1965" sys_dependentid="349618" rxinlineslot="103"> Hormuzd Katki, Ph.D., senior investigator, BB</a>. Outside of DCEG, Dr. Skarzynski is co-chair of the Bioinformatics and Data Science Department at the Foundation for the Advancement of Education in the Sciences (FAES), where he has been an instructor since 2015, and he currently teaches Introduction to Python. Dr. Skarzynski is also an instructor for Software and Data Carpentry, a non-profit organization that teaches computational skills.<strong>&shy;</strong></p>
<h3 id="Lingxiao-Wang"><a id="Lingxiao-Wang"></a>Lingxiao Wang, M.S. &ndash; Predoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1084806" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370832">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1084806&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Lingxiao Wang, M.S., joined the Biostatistics Branch (BB) as a predoctoral fellow in March 2017. She received her M.S. in survey methodology (statistics track) from the University of Maryland, College Park (UMCP), and an M.A in applied statistics from the University of California, Santa Barbara. She is now pursuing a Ph.D. degree in survey methodology at UMCP. Her Ph.D. dissertation research is being done under the NIH Graduate Partnership Program with BB mentors <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/katki-hormuzd">Hormuzd Katki</a>, Ph.D., senior investigator, <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/graubard-barry">Barry Graubard</a>, Ph.D., senior investigator, and her UMCP mentor Yan Li, Ph.D. Her research focuses on improving representativeness of non-probability epidemiological cohorts in the analysis, and developing statistical methods for analyzing health and genetic survey data.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/52593828/?sort=date&amp;direction=ascending">Scientific Publications - Lingxiao Wang<br /></a></p>
</div>
<h3><a id="Zhang"></a>Han Zhang, Ph.D. -&nbsp;Research Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="303351" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7370833">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="Han Zhang" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=303351&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Han Zhang, Ph.D., joined the Biostatistics Branch (BB) as a visiting fellow in August 2011. Dr. Zhang received Ph.D. in statistics from the University of Science and Technology of China (USTC). His Ph.D. thesis focused on developing algorithms for haplotype analysis under pooling and individual design. He is now working with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/yu-kai">Kai Yu, Ph.D.</a>, Senior Investigator, BB, on the statistical approaches for rare variants association analysis and gene-gene interaction analysis in case-control studies.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Zhang%20h&amp;authorOption=exact">Scientific Publications - Han Zhang</a></p>
<div style="clear: both; margin-top: 28px;"></div>
<p>Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302518" sys_contentid="302518" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7370794" sys_dependentvariantid="1418" sys_dependentid="302518" rxinlineslot="103">current research training opportunities</a> in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7370795" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103">Biostatistics Branch</a>.</p>
</div>
</div>]]></content>
  </row>
  <row para_id="302620" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-hgp/cgb" title="">CGB Home</a></h3>
<p><a href="/about/organization/programs-hgp/cgb/clinical-epi-unit" title="">Clinical Epidemiology Unit</a></p>
<p><a href="/about/organization/programs-hgp/cgb/research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=CGB">CGB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/cgb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/cgb-training" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-hgp/cgb/tools-useful-links" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=CGB">Publications</a></p>
</div>
<p>FAIR-EM is a study management system used for monitoring clinical research protocols. The system provides a secure Web interface allowing the user to track the status of day-to-day study-related events and information as the study subjects move through the pre-clinic, clinic, post-clinic, and follow-up phases.</p>
<h3>Features</h3>
<ul class="stacked-nobullets">
<li>Efficient and accurate means to monitor all aspects of data collection</li>
<li>Rapid, up-to-date report generation</li>
<li>Timely evaluation of study's recruitment status and overall progress</li>
<li>Interactive status updating</li>
</ul>
<h3>Benefits</h3>
<ul class="stacked-nobullets">
<li>Simplify project management</li>
<li>Dramatically reduce human error</li>
<li>Flexible system template permits rapid, relatively inexpensive tailoring to meet the needs of new projects</li>
</ul>
<p>For more information contact <a href="mailto:greenem@mail.nih.gov">Mark H. Greene</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302621" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>CompareTests is an R package to estimate agreement and diagnostic accuracy statistics for two diagnostic tests when one is conducted on only a subsample of specimens. A standard test is observed on all specimens. We treat the second test (or sampled test) as being conducted on only a stratified sample of specimens. We treat the total sample as stratified two-phase sampling and use inverse probability weighting. We estimate diagnostic accuracy (category-specific classification probabilities; for binary tests reduces to specificity and sensitivity, and also predictive values) and agreement statistics (percent agreement, percent agreement by category, Kappa (unweighted), and symmetry tests (reduces to McNemar's test for binary tests)).</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302643" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302643" sys_dependentvariantid="1418" sys_relationshipid="6798329">ReadMe</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302606" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302606" sys_dependentvariantid="1418" sys_relationshipid="6798330">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>UNIX O/S- <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303037" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303037" sys_dependentvariantid="1500" sys_relationshipid="6798331">CompareTests_1.0.tar.gz</a></li>
<li>Windows O/S - <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303038" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303038" sys_dependentvariantid="1500" sys_relationshipid="6798332">CompareTests_1.0.zip</a></li>
<li>Mac O/S - <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303039" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303039" sys_dependentvariantid="1500" sys_relationshipid="6798333">CompareTests_1.0.tgz</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>Reference:</h3>
<ul>
<li>Katki HA, Li Y, Edelstein DW, Castle PE. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22139832">Estimating the agreement and diagnostic accuracy of two diagnostic tests when one test is conducted on only a subsample of specimens</a>. <em>Stat Med</em> 2012</li>
</ul>
<h3>Support:</h3>
<p><b>Questions?</b> Contact: <a href="mailto:katkih@mail.nih.gov">Dr. Hormuzd Katki</a></p>
</div>]]></content>
  </row>
  <row para_id="302622" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257636" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a> and learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302511" sys_contentid="302511" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257637" sys_dependentvariantid="1418" sys_dependentid="302511" rxinlineslot="103" sys_variantid="1418">research training opportunities</a>.</p>
<h3><a id="Bassig"></a>Bryan Bassig, Ph.D., M.P.H - Research Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="610567" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257657">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=303016&amp;sys_siteid=475&amp;sys_contentid=610567&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Bryan Bassig, Ph.D., M.P.H., joined the Occupational and Environmental Epidemiology Branch (OEEB) as a predoctoral fellow in August 2012 as part of the Yale/NCI Training Program in Cancer Epidemiology. He became a postdoctoral fellow in June 2015 and was promoted to research fellow in June 2016. Dr. Bassig received his M.P.H. degree in chronic disease epidemiology from Yale University in 2010, and his Ph.D. in environmental epidemiology from Yale University in 2015. Working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257647" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103" sys_variantid="1965">Qing Lan, M.D., Ph.D., M.P.H.</a>&nbsp;and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257648" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103" sys_variantid="1965">Nathaniel Rothman, M.D., M.P.H., M.H.S.</a>, both senior investigators, OEEB, Dr. Bassig&rsquo;s research primarily focuses on the environmental, occupational, and molecular epidemiology of non-Hodgkin lymphoma and myeloid leukemia. In addition, his research utilizes cutting-edge molecular epidemiologic methods to investigate the biologic effects associated with a wide range of environmental and occupational exposures, including benzene, chlorinated solvents, diesel engine exhaust, and other air particulates.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=bassig%20b&amp;authorOption=exact&amp;pi=0014324363">Scientific Publications - Bryan Bassig</a></p>
<h3><strong><a id="Fisher"></a>Jared Fisher, Ph.D., M.P.H. - Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1097486" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257658">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1097486&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Jared Fisher, Ph.D., M.P.H., joined the Occupational and Environmental Epidemiology Branch (OEEB) as a postdoctoral fellow in July 2017. Dr. Fisher received his Ph.D. in epidemiology from the University of Maryland in 2017. His dissertation research focused on the relationship between short-term ambient particulate matter exposures and cerebrovascular and cardiovascular endpoints. Dr. Fisher has an M.P.H. from Emory University in Atlanta, Georgia, as well as prior work experience as a health analyst at the Walter Reed Army Institute of Research in Silver Spring, Maryland. In OEEB, Dr. Fisher works with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/jones-rena">Rena Jones, Ph.D.</a>, investigator, OEEB, to investigate potential carcinogens in the general environment&mdash;especially ambient air pollutants&mdash;and to explore novel environmental exposure estimation and validation approaches for studies of cancer etiology.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Fisher%2C%20Jared%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications - Jared Fisher</a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><a id="Lerro"></a>Catherine Lerro, Ph.D., M.P.H. -&nbsp;Research Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="656546" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257659">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=656546&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Catherine Lerro, Ph.D., joined the Occupational and Environmental Epidemiology Branch (OEEB) in August, 2013 as a predoctoral fellow within the Yale-NCI Cooperative Graduate Training Program in cancer epidemiology. She became a postdoctoral fellow in December 2015, after successfully defending her dissertation, and was promoted to research fellow in December 2018. Dr. Lerro received her B.A. in public health studies from Johns Hopkins University in Baltimore, Maryland, her M.P.H. in chronic disease epidemiology from Yale University in New Haven, Connecticut, and her Ph.D. in environmental epidemiology from Yale. She was previously a summer fellow at NCI and wrote her master&rsquo;s thesis under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349597" sys_contentid="349597" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257640" sys_dependentvariantid="1965" sys_dependentid="349597" rxinlineslot="103" sys_variantid="1965">Michael B. Cook, Ph.D.</a>, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" sys_contentid="349637" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257641" sys_dependentvariantid="1965" sys_dependentid="349637" rxinlineslot="103" sys_variantid="1965">Katherine A. McGlynn, Ph.D., M.P.H.</a> Dr. Lerro also spent two years working as an epidemiologist at the American Cancer Society in Atlanta, Georgia. She is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257642" sys_dependentvariantid="1965" sys_dependentid="349661" rxinlineslot="103" sys_variantid="1965">Laura Beane Freeman, Ph.D.</a>, senior&nbsp;investigator, OEEB, examining agricultural exposures and cancer risk in men and women.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=lerro%20c&amp;authorOption=exact&amp;pi=0014323617">Scientific Publications - Catherine Lerro</a></p>
<h3><a id="Louis"></a>Lydia Louis, M.P.H. - Predoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="854617" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257660">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=854617&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Lydia Louis, M.P.H., joined the Occupational and Environmental Epidemiology Branch (OEEB) as a predoctoral fellow. Ms. Louis completed an M.P.H. in environmental and occupational health from the University of Medicine and Dentistry of New Jersey. Her master&rsquo;s thesis focused on the effect of the herbicide 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) on human lung epithelial cells. &nbsp;She is currently a Ph.D. candidate in the Department of Environmental and Occupational Health at Rutgers University. While in OEEB, Ms. Louis is working with senior investigators&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257643" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_variantid="1965">Melissa Friesen, Ph.D.</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257644" sys_dependentvariantid="1965" sys_dependentid="349661" rxinlineslot="103" sys_variantid="1965">Laura Beane Freeman, Ph.D.</a>, on studies of pesticide exposure determinants and cancer epidemiology related to pesticide exposure.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=louis%20l&amp;authorOption=exact&amp;pi=2001570981">Scientific Publications - Lydia Louis<br /></a></p>
<h3><strong><a id="Patel"></a>Deven Patel, Ph.D., M.P.H. - Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1093297" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257661">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1093297&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Deven M. Patel, Ph.D., M.P.H., joined the Occupational and Environmental Epidemiology Branch (OEEB) as a postdoctoral fellow in June 2017. Dr. Patel earned his B.S. in environmental sciences from the University of Florida, his M.P.H. from Nova Southeastern University, Florida, and his Ph.D. in epidemiology from the University of Rochester School of Medicine and Dentistry in New York in 2017. His doctoral research focused on the association between green spaces near the home and mental illness in a cardiac rehabilitation population. During his doctoral program, he also acted as a health project coordinator for the Center for Disease Control&rsquo;s HPV-Impact project. Dr. Patel&rsquo;s research interests include the health impacts of natural and built environments near the home or workplace. He is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/ward-mary">Mary Ward, Ph.D.</a>, senior investigator, OEEB, to investigate the health effects of drinking water contaminants, environmental exposures to pesticides, and other risks associated with agricultural life.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=patel%20d&amp;authorOption=exact&amp;pi=2002314449">Scientific Publications - Deven Patel</a></p>
<h3><a id="Sauve"></a><strong>Jean-Fran&ccedil;ois Sauv&eacute;, Ph.D., M.Sc. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1107514" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257662">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1107514&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Jean-Fran&ccedil;ois Sauv&eacute;, Ph.D., M.Sc., joined the Occupational and Environmental Epidemiology Branch (OEEB) as a postdoctoral fellow in December 2017. Dr. Sauv&eacute; obtained his doctoral degree in public health, specializing in toxicology and risk analysis, from the University of Montr&eacute;al School of Public Health in 2017. His doctoral research focused on using a database of expert evaluations of occupational exposures as a source of information applicable for assessing exposures in new population-based studies of disease etiology and surveillance. Dr. Sauv&eacute; also holds an M.Sc. in environmental and occupational health from the University of Montr&eacute;al. In OEEB, he is working with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/friesen-melissa">Melissa Friesen, Ph.D.</a>, senior investigator, on methods to characterize current and past endotoxin and glucan exposure for participants in the Biological Exposures and Effects in Agriculture Study and the Agricultural Health Study.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=sauv%C3%A9%20jf%5BAuthor%5D">Scientific publications<u> &ndash; Jean-Fran&ccedil;ois Sauv&eacute;</u></a></p>
<h3><strong><a id="Shearer"></a>Joe Shearer, Ph.D., M.P.H. &shy;&ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101326" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257663">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101326&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Joe Shearer, Ph.D., M.P.H., joined the Occupational and Environmental Epidemiology Branch (OEEB) as an NCI Cancer Prevention Fellow in August 2017. Dr. Shearer earned his B.A. in chemistry from Macalester College in 2011, his M.P.H. from the University of Texas Medical Branch, Galveston in 2016, and a Ph.D. in basic medical sciences from Purdue University in 2017. His dissertation focused on the molecular mechanisms of arsenic exposure and the prostate tumor microenvironment. Dr. Shearer&rsquo;s research interests include understanding how occupational and environmental exposures contribute to immune dysregulation and signaling. In OEEB, Dr. Shearer is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/hofmann-jonathan">Jonathan Hofmann Ph.D., M.P.H.</a>, investigator, on studies characterizing the molecular mechanisms through which pesticides and other agricultural exposures may influence cancer risk in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study. BEEA is a molecular epidemiologic effort within the Agricultural Health Study.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Shearer%2C+Joseph+%5BFull+Author+Name%5D">Scientific Publications - Joe Shearer</a></p>
<h3><a id="Wong"></a>Jason Wong, Sc.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1032043" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257664">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1032043&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Jason Wong, Sc.D, joined the Occupational and Environmental Epidemiology Branch (OEEB) in October 2015 as a postdoctoral fellow. Dr. Wong obtained his bachelor&rsquo;s degree in cell and molecular biology from Simon Fraser University and his dual-doctorate in epidemiology and environmental health from the Harvard T.H. Chan School of Public Health. For his doctoral dissertation research, he examined the detrimental effects of fine particulate matter on telomere length, DNA methylation, and inflammation. Prior to joining OEEB, Dr. Wong completed a postdoctoral fellowship at Stanford University School of Medicine where he examined the chronic health effects of secondhand smoke. Dr. Wong also has extensive experience in molecular biology honed from nearly a decade as a laboratory manager at the Brigham and Women&rsquo;s Hospital. Dr. Wong previously characterized genetic variants related to risk of Endometrial Cancer in the Nurses&rsquo; Health Study, and he is best known for developing a high-throughput assay to measure telomere length. In DCEG, Dr. Wong&nbsp;is investigating environmental, occupational, and molecular factors related to risk of cancers in various Asian cohorts. He is working under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257645" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103" sys_variantid="1965">Qing Lan, M.D., Ph.D.</a>, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257646" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103" sys_variantid="1965">Nathaniel Rothman, M.D., M.P.H., M.H.S.</a>, senior investigators in OEEB, to uncover the etiologic underpinnings of cancer risk.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Wong%2C%20Jason%20Y[Full%20Author%20Name]&amp;cmd=DetailsSearch">Scientific Publications - Jason Wong</a></p>
<p>Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302511" sys_contentid="302511" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257638" sys_dependentvariantid="1418" sys_dependentid="302511" rxinlineslot="103" sys_variantid="1418">research training opportunities</a> in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7257639" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302628" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Colon Cancer Risk Assessment-Gauss Program is an executable file that projects absolute colon cancer risk according to <a href="https://ccrisktool.cancer.gov/">NCI&rsquo;s Colorectal Cancer Risk Assessment Tool</a> (CCRAT) algorithm in the batch mode. It also computes 95% confidence intervals for the risk projections.</p>
<p>Users can enter risk factor data and projection interval ages for a group of men or women, and the program will return the corresponding absolute risk projections. This program may be useful for research purposes when one needs risk projections for an entire study population. The program can be run on either a 32-bit or a 64-bit system. To find a program in SAS to compute absolute risk projections (without confidence intervals), please see the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302539" sys_contentid="302539" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302539" sys_dependentvariantid="1418" sys_relationshipid="7317663" sys_siteid="475" sys_variantid="1418">Colon Cancer Risk Assessment - SAS Macro</a> page.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=327156" sys_contentid="327156" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327156" sys_dependentvariantid="1418" sys_relationshipid="7317664" sys_siteid="475" sys_variantid="1418">Male Model Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=327148" sys_contentid="327148" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327148" sys_dependentvariantid="1418" sys_relationshipid="7317665" sys_siteid="475" sys_variantid="1418">Female Model Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302412" sys_contentid="302412" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302412" sys_dependentvariantid="1418" sys_relationshipid="7317666" sys_variantid="1418">License Agreement</a></li>
</ul>
<h3>Software Download</h3>
<ul class="grey-bullets">
<li>Males: <a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303042" sys_contentid="303042" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303042" sys_dependentvariantid="1500" sys_relationshipid="7317667" sys_variantid="1500">M_CRCAbsRsk_32bit.zip (44.9 MB)</a></li>
<li>Females: <a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303043" sys_contentid="303043" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303043" sys_dependentvariantid="1500" sys_relationshipid="7317668" sys_variantid="1500">W_CRCAbsRsk_32bit.zip (44.2 MB)</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>References</h3>
<ul>
<li>Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann B, Pee D, Gail MH, Pfeiffer RM. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19114701">A colorectal cancer risk prediction tool for white men and women without known susceptibility [PubMed abstract]</a>. <em>J Clin Oncol</em> 2009 Feb 10;27(5):686-93.</li>
<li>Park Y, Freedman AN, Gail MH, Pee D, Hollenbeck A, Schatzkin A, Pfeiffer RM. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19114700">Validation of a colorectal cancer risk prediction model among whites 50 years old and over [PubMed abstract]</a>. <em>J Clin Oncol</em> 2009 Feb 10;27(5):694-8.</li>
</ul>
<h3>Support:</h3>
<p><b>Questions?</b> Contact: <a href="mailto:pfeiffer@mail.nih.gov">Ruth Pfeiffer</a></p>
</div>]]></content>
  </row>
  <row para_id="302629" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>In DCEG, one of our top priorities is the training and development of the next generation of scientists in cancer epidemiology and related fields. The Division currently has over 100 trainees, including postdoctoral, graduate, master and postbaccalaureate level fellows.</p>
<h3>Why Become a DCEG Fellow?</h3>
<p>DCEG champions innovative opportunities for fellows to obtain integrated scientific and career training. DCEG fellows:</p>
<div sys_relationshipid="7252257" sys_dependentid="1065273" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="1833" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<figure class="video right size50">	<h4>Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology & Genetics for the SACNAS Conference</h4>
	<div id="ytplayer-_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" class="flex-video widescreen" data-video-id="_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" data-video-title="Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology & Genetics for the SACNAS Conference">		<noscript>			<p>				<a href="https://www.youtube.com/watch?v=_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" target="_blank" title="Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology & Genetics for the SACNAS Conference">					View this video on YouTube.				</a>			</p>		</noscript>							</div>	</figure></div>
<ul>
<li><b>Are involved in every stage of research</b> &ndash; DCEG fellows design, carry out, analyze and publish population, family, health disparities and genetic/genomic studies.</li>
<li><b>Expand their scientific skills</b> &ndash; Trainees receive mentoring and gain experience in study design, novel analytic techniques, genomics and informatics.</li>
<li><b>Have robust opportunities for professional development</b> &ndash; The Division offers workshops to build skills in molecular epidemiology, science management, grant writing, scientific presentation, mentoring, and other professional communication and networking opportunities. DCEG fellows are also encouraged to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302390" sys_contentid="302390" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302390" sys_variantid="1418" sys_relationshipid="7252253">participate in a range of fellow-initiated activities</a>.</li>
<li><b>Receive competitive stipends</b> &ndash; Fellows also receive an array of benefits, such as health insurance, loan deferments (postdoctoral trainees) and tuition reimbursement (graduate trainees).</li>
</ul>
<h3>Interested? &nbsp;Explore Further</h3>
<div sys_relationshipid="7252258" sys_dependentid="1099499" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="1833" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<figure class="video right size50">	<h4>DCEG: Uncovering the causes of cancer, training future researchers</h4>
	<div id="ytplayer-aoqwfrMDeOc" class="flex-video widescreen" data-video-id="aoqwfrMDeOc" data-video-title="DCEG: Uncovering the causes of cancer, training future researchers">		<noscript>			<p>				<a href="https://www.youtube.com/watch?v=aoqwfrMDeOc" target="_blank" title="DCEG: Uncovering the causes of cancer, training future researchers">					View this video on YouTube.				</a>			</p>		</noscript>							</div>			<figcaption class="caption-container">
<p>Researchers in the NCI Division of Cancer Epidemiology and Genetics (DCEG) investigate the causes of cancer at the population level. Together with their trainees, our experts pair genetic and genomic studies of common and rare malignancies with classical epidemiological approaches. We utilize cutting-edge technology for large-scale processing of biological samples that yield data rich with clues to etiologic patterns. Families with rare inherited cancer syndromes, such as Li-Fraumeni syndrome, participate in DCEG clinical studies. Their contributions to research allow us to advance our understanding of genetic and modifiable factors in disease risk, and to generate cancer screening or prevention techniques for these unique populations.</p>
<p>Watch our scientists discussing aspects of DCEG research in interviews done in conjunction with the American Society of Human Genetics (ASHG).</p>
<p style="text-align: right;"><a href="https://youtu.be/NtgsodVLEX8">Access the audio-described version</a>.</p>
</figcaption>	</figure></div>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302377" sys_contentid="302377" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302377" sys_variantid="1418" sys_relationshipid="7252249">Program Requirements</a>: View lists of qualifications for fellows (pre- and postdoctoral) and details about special programs.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=107&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302477" sys_contentid="302477" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302477" sys_variantid="1418" sys_relationshipid="7252250">Research Training Areas</a>: Explore research opportunities for fellows, and view a list of <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?by=piinterest">DCEG Principal Investigators and their research interests</a>.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302405" sys_contentid="302405" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302405" sys_variantid="1418" sys_relationshipid="7252251">Application Process</a>: &nbsp;See how to get started and what to expect throughout the application process.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302569" sys_contentid="302569" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302569" sys_variantid="1418" sys_relationshipid="7252252">Where Former Fellows Have Gone</a>: DCEG fellows have secured competitive positions across the country within academic, non-profit, and industry institutions.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1097514" sys_contentid="1097514" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1097514" sys_variantid="1418" sys_relationshipid="7252256">Conversations with Former Fellows</a>: DCEG alumni discuss their career paths and offer advice.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1066000" sys_contentid="1066000" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1066000" sys_variantid="1418" sys_relationshipid="7252254">NCI Communications Fellowship (NCF)</a>:&nbsp;Learn about this opportunity to hone science writing and communications skills in the world&rsquo;s largest cancer epidemiology research group.</li>
</ul>
<h3>Awards, Spotlights, and Milestones</h3>
<ul>
<li>NCI has been selected more than once as one of "<a href="http://www.the-scientist.com/images/April2013/top10.pdf">The 25 Best Places to Work for PostDocs</a>" by <i>The Scientist</i> -- the latest in 2013.<img class="right" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=688227" inlinetype="rximage" sys_siteid="475" sys_dependentvariantid="1482" rxinlineslot="104" sys_dependentid="688227" sys_relationshipid="7252247" /></li>
<li>DCEG won the Inaugural Alexander D. Langmuir Award for Training Program Excellence and Innovation. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1955&amp;sys_contentid=401809" sys_contentid="401809" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1955" rxinlineslot="103" sys_dependentid="401809" sys_variantid="1955" sys_relationshipid="7252245">Read more about the Langmuir Award in the DCEG <i>Linkage</i> newsletter</a>.</li>
<li>The results of DCEG's research have served to inform public policy and have played an important role in improving public health. Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=34&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303763" sys_contentid="303763" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="303763" sys_variantid="1422" sys_relationshipid="7252246">public health impacts of DCEG research</a>. DCEG Public Health Impacts</li>
<li>DCEG has a long-standing commitment to the recruitment, retention, and development of a diverse group of investigators and trainees. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1081661" sys_contentid="1081661" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1081661" sys_variantid="1418" sys_relationshipid="7252255">Learn more about our efforts to build a diverse workforce</a>.</li>
</ul>
<h3>Questions?</h3>
<p>The DCEG <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302473" sys_contentid="302473" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302473" sys_variantid="1418" sys_relationshipid="7252248">Office of Training and Education</a> oversees the Division&rsquo;s fellowship programs. E-mail <a href="mailto:ncidceged-r@mail.nih.gov">ncidceged-r@mail.nih.gov</a> or call (240) 276-7270 if you have additional questions.</p>
<p>&nbsp;</p>
<p>NIH training programs welcome applications from all qualified individuals. The NIH does not discriminate based on race, color, religion, sex, national origin, disability, age, genetic make-up, gender identity, or sexual orientation.</p>
</div>]]></content>
  </row>
  <row para_id="302631" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2 class="firstli">Closed to Patient Enrollment, Data Analysis Ongoing</h2>
<p class="firstli">DCEG has been studying the Hereditary Breast/Ovarian Cancer (HBOC) syndrome since the 1960s; it now comprises a genetic disease paradigm for addressing vital translational clinical cancer genetics research questions. Resources include a prospective cohort of 32 <i>BRCA</i> mutation-positive families with extensive clinical and epidemiologic information, as well as biological samples. One hundred fifty new mutation-positive families have enrolled during the past several years. <b>This study is now closed to new patient enrollment. Patient- related clinical activities have ended.</b> Our focus will be on analyzing previously-collected data.</p>
<p>The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7270629" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103">Clinical Genetics Branch</a> (CGB) HBOC family cohort was part of the original international collaborative research effort coordinated by the Breast Cancer Linkage Consortium that contributed to the mapping and cloning of <i>BRCA1</i> and <i>BRCA2</i>. More recent research highlights include documenting a 62% reduction in breast cancer risk among women undergoing risk-reducing salpingo-oophorectomy in a prospective cohort of <i>BRCA</i> mutation-positive families, a series of counseling/psychosocial reports of our early experience with HBOC families undergoing genetic risk assessment, and definitive-negative candidate gene studies analyzing genetic modifiers of <i>BRCA1/2</i>-related breast cancer risk as part of the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> ("CIMBA") project, and. The most noteworthy CIMBA-related findings include confirmation that <i>RAD51</i> significantly modifies the risk of <i>BRCA2</i>-related breast cancer, and that <i>FGFR2</i> and <i>TNRC9</i> (modifiers of sporadic breast cancer risk that were identified through the analysis of unselected breast cancer cases) also play important roles in the risk of <i>BRCA</i>-related breast cancer.</p>
<p>We plan additional clinical, genetic, behavioral and translational research studies of the cohort of DCEG hereditary breast/ovarian cancer (HBOC) families. In those families in which we have documented disease-related mutations in <i>BRCA1</i> and <i>BRCA2</i>, the initial effort will be focused on providing genetic risk assessment, pre-test counseling and clinical germline mutation testing for those members of the CGB cohort of HBOC families who have been long-term participants in DCEG studies over the past 30 years. The members of these families have been invited to participate in other CGB protocols, including the Breast Imaging/Breast Duct Lavage study, the National Ovarian Cancer Prevention and Early Detection study, and a Phase I PARP-inhibitor trial targeting women at increased genetic risk of ovarian cancer being run by investigators in NCI's Center for Cancer Research (CCR). We have also collaborated with CCR's breast cancer Phase II chemoprevention trials of raloxifene and exemestane, and its pilot study of increasing physical activity as a breast cancer risk-reduction strategy.</p>
<p>DNA collected from these families is being contributed to an international collaboration seeking genetic modifiers of <i>BRCA1</i> and <i>BRCA2</i> penetrance, using both the candidate gene and genome-wide association study (GWAS) research strategies. Our <i>BRCA</i> mutation-negative families are being used to evaluate new candidate breast/ovarian cancer susceptibility genes. These families are also eligible to participate in various ancillary studies evaluating behavioral and psychosocial aspects of being at increased genetic risk of breast and ovarian cancer. We are currently analyzing the prospective risk of breast cancer among <i>BRCA</i> mutation-negative members of mutation-positive families, after an average of 18 years of follow-up. This is one of the very few long-term prospective studies of cancer risk in families with known <i>BRCA</i> mutations.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302662" sys_contentid="302662" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270632" sys_dependentvariantid="1418" sys_dependentid="302662" rxinlineslot="103">Browse study-related publications</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349677" sys_contentid="349677" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270630" sys_dependentvariantid="1965" sys_dependentid="349677" rxinlineslot="103">Mark H. Greene</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270631" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302635" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Description</h3>
<p>This package is for subset-based association analysis of heterogeneous but possibly related traits.</p>
<h3>Details</h3>
<p>ASSET is a suite of statistical tools specifically designed to be powerful for pooling association signals across multiple studies when true effects may exist only in a subset of the studies and could be in opposite directions across studies. The method explores all possible subsets (or a restricted set if user specifies so) of studies and evaluates fixed-effect meta-analysis-type test-statistics for each subset. The final test-statistic is obtained by maximizing the subset-specific test-statistics over all possible subsets and then evaluating its significance after efficient adjustment for multiple-testing, taking into account the correlation between test-statistics across different subsets due to overlapping subjects. The method not only returns a p-value for significance for the overall evidence of association of a SNP across studies, but also outputs the "best subset" containing the studies that contributed to the overall association signal. For detection of association signals with effects in opposite directions, ASSET allows subset search separately for positively- and negatively- associated studies and then combines association signals from two directions using a chi-square test-statistic. The method can take into account correlation due to overlapping subjects across studies (e.g. shared controls). Although the method is originally developed for conducting genetic association scans, it can also be applied for analysis of non-genetic risk factors as well.</p>
<ul class="bullet-blu">
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302520" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302520" sys_dependentvariantid="1418" sys_relationshipid="6816072">License Agreement</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=315077" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="315077" sys_dependentvariantid="1418" sys_relationshipid="6816073" sys_siteid="475">ReadMe File</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1016597" sys_dependentvariantid="1500" sys_dependentid="1016597" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6816074">Manual</a></li>
</ul>
<h4>Updates:</h4>
<ul>
<li>The new version includes option to pre-screen phenotypes based on significance of marginal association tests. It increases computational speed for ASSET when analyzing larger number of phenotypes</li>
</ul>
<h2>Download Software from Bioconductor:</h2>
<ul>
<li><a href="http://www.bioconductor.org/packages/devel/bioc/html/ASSET.html">Asset</a></li>
</ul>
<h3>Reference:</h3>
<ul class="grey-bullets">
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22560090">A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits.</a><br /> Bhattacharjee S, Rajaraman P, Jacobs KB, Wheeler WA, Melin BS, Hartge P; GliomaScan Consortium, Yeager M, Chung CC, Chanock SJ, Chatterjee N.<br /> Am J Hum Genet. 2012 May 4;90(5):821-35. doi: 10.1016/j.ajhg.2012.03.015..</li>
</ul>
<h3>Support:</h3>
<ul>
<li>Questions? <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302637" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG research has identified that red and processed meats are associated with an increased risk of several cancers, while poultry and fish intake may be protective. Investigators are currently studying carcinogenic compounds formed in meat during processing or cooking, such as:</p>
<ul class="bullet-blu">
<li>Heterocyclic amines</li>
<li><i>N</i>-nitroso compounds</li>
<li>Polycyclic aromatic hydrocarbons</li>
</ul>
<p>DCEG investigators have developed a variety of specialized questionnaires and databases to help study nutritional aspects of cancer causation such as diet and physical activity. Measuring exposures to carcinogenic compounds requires different kinds of measurements. To accommodate this need, investigators are performing studies on the metabolism and excretion of these compounds, analyzing their metabolites to help identify biomarkers that we can use to measure internal exposures.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349692" sys_contentid="349692" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270633" sys_dependentvariantid="1965" sys_dependentid="349692" rxinlineslot="103" sys_variantid="1965">Rashmi Sinha</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270634" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103" sys_variantid="1418">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302639" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Waldenstr&ouml;m's macroglobulinemia (WM) is a rare type of tumor that belongs to a group of disorders called lymphoproliferative diseases. It occurs in approximately 1100 people/year in the U.S. Although WM can occur in people of both sexes and any race, the majority of patients are white males. The cause of WM is unknown. The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is conducting a study to obtain clinical information about WM and to determine what causes WM to sometimes develop in two or more family members.</p>
<h4>Definition of Familial WM</h4>
<p>Most people who have WM are the only member of their family with this condition. Sometimes, however, WM occurs in two or more blood relatives; the affected family members are said to have familial WM. The reasons why WM may run in families are unknown. It might be that the affected family members shared a susceptibility to WM, or they may have been exposed to similar environmental factors. At the present time, little is known about either host factors or environmental exposures that might be associated with WM. We want to study families in which two or more blood relatives have developed WM because they might provide important clues about what causes WM in the general population.</p>
<h4>Our Study</h4>
<p>We are especially interested in persons from families with 2 or more members affected with WM. Persons who were diagnosed with WM at an early age (less than 35 years old) are of interest to us even if no one else in their family has WM.</p>
<p>If you participate in our study, we would ask you to:</p>
<ul>
<li>Complete a questionnaire that asks about your family's structure and medical history and about certain factors that may be important in causing WM.</li>
<li>Give us permission to obtain medical records documenting cancer&nbsp;diagnosis in the affected family members.</li>
<li>Allow us to obtain blood and/or saliva samples from both affected and unaffected family members for a variety of laboratory studies.</li>
</ul>
<p>Some study participants may be invited to the NIH for clinical and other studies. All information obtained from our study would remain confidential to the extent permitted by law, and participation in any part of it is voluntary.</p>
<p>If you are interested in more information about the study, please contact Stephanie Steinbart, our Cancer Genetics Referral Nurse, at 1-800-518-8474, or e-mail her at <a href="mailto:stephaniesteinbart@westat.com">stephaniesteinbart@westat.com</a>.</p>
<p>For more general information about WM, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349660" sys_contentid="349660" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349660" sys_dependentvariantid="1965" sys_relationshipid="7272342" sys_siteid="475">Mary L. McMaster</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7272343" sys_siteid="475">Clinical&nbsp;Genetics&nbsp;Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302640" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p></p>
<p>Meet current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7355480" sys_siteid="475">Laboratory of Translational Genomics</a> and learn more about our <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302498" sys_contentid="302498" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302498" sys_dependentvariantid="1418" sys_relationshipid="7355477" sys_siteid="475">research training opportunities.</a></p>
<p>Fellows are organized by their PI mentors, with postdoctoral followed by postbaccalaureate.</p>
<a id="top"></a>
<div style="width: 100%; overflow: auto;">
<div style="float: left; width: 45%; padding-right: 5%;">
<h4><a href="#Amundadottir-Lab">Laufey Amundadottir</a></h4>
<p style="padding-bottom: 12px;"><a href="#Connelly">Katelyn Connelly</a><br /><a href="#Eiser ">Daina Eiser </a><br /><a href="#Gordon">Naomi Gordon</a><br /><a href="#Jermusyk">Ashley Jermusyk</a><br /><a href="#Zhong">Jun Zhong</a></p>
<h4><a href="#Brown-Lab">Kevin Brown</a><a h4=""></a></h4>
<p><a href="#Choi">Jiyeon Choi</a><br /> <a href="#Hennessey">Rebecca Hennessey<br /></a><a href="#Kong">Hyunkyung Kong</a><a href="#Kong"><br /></a><a href="#Mehl">Lindsey Mehl</a><a href="#Hennessey"><br /></a><a href="#Vu">Andrew Vu</a></p>
</div>
<div style="float: left; width: 45%; padding-right: 5%;">
<h4><a href="#Dean-Lab">Michael Dean</a></h4>
<p></p>
<h4><a href="#Prokunina-Olsson-Lab">Ludmila Prokunina-Olsson</a></h4>
<p style="padding-bottom: 12px;"><a href="#Banday">Abdul Rouf Banday</a><a href="#Bayanjargal ">&nbsp;</a><br /><a href="#Florez-Vargas">Oscar Florez-Vargas</a><br /><a href="#Lin">Seraph Han-Yin Lin</a><br /><a href="#Rao">Nina Rao</a><br /><a href="#Vargas">Joselin Vargas</a><br /><a href="#Wang">Fang Wang</a></p>
<p style="padding-bottom: 12px;"></p>
</div>
</div>
<div style="clear: both; margin-top: 28px;"></div>
<h3 id="Amundadottir-Lab"><a id="Amundadottir-Lab"></a>AMUNDADOTTIR LAB</h3>
<h3><strong><a id="Connelly"></a>Katelyn E. Connelly, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1143671" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355505">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1143671&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Katelyn E. Connelly, Ph.D., joined the Laboratory of Translational Genomics (LTG) in February 2019 as a postdoctoral fellow in the laboratory of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349595" sys_contentid="349595" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349595" sys_dependentvariantid="1965" sys_relationshipid="7355490" sys_siteid="475">Laufey Amundadottir, Ph.D., senior investigator</a>. Dr. Connelly earned her Ph.D. in medicinal chemistry and molecular pharmacology from Purdue University in 2018. Working with Dr. Emily C. Dykhuizen, her doctoral research focused on understanding the binding and oncogenic mechanisms of the epigenetic regulator CBX8. In DCEG, Dr. Connelly is investigating the functional roles of germline variants, identified by genome-wide association studies, in pancreatic cancer risk.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1fIe8OQBlvR5S/bibliography/44585910/public/?sort=date&amp;direction=descending">Scientific Publications - Katelyn Connelly</a></p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Eiser"></a>Daina Eiser &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1126532" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355506">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1126532&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Daina Eiser joined the Laboratory of Translational Genomics (LTG) in July 2018 as a postbaccalaureate fellow in the laboratory of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349595" sys_contentid="349595" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349595" sys_dependentvariantid="1965" sys_relationshipid="7355487" sys_siteid="475">Laufey Amundadottir, Ph.D.</a> , senior investigator. She graduated in May 2018 from the University of Maryland, College Park, where she completed her B.S. in cell biology with a minor in computer science.&nbsp;Ms. Eiser previously worked as a summer intern at NCI for two years. First, she investigated protein-protein interactions in cancer cells in the laboratory of Thorkell Andresson, Ph.D. She subsequently worked under the mentorship of Jason Hoskins, Ph.D., staff scientist, in Dr. Amundadottir&rsquo;s laboratory, where she studied transcription factor networks in pancreatic cancer cells.&nbsp; As a postbaccalaureate fellow in LTG, she continues her research on transcription factor networks in pancreatic cancer using bioinformatic tools and on finding functional variants of pancreatic cancer risk loci.</p>
<h3><strong><a id="Gordon"></a>Naomi Gordon, B.A. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1143670" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" sys_folderid="" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355507">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1143670" /><!--Comment--></div>
</figure>
</div>
<p>Naomi Gordon joined the Laboratory of Translational Genomics (LTG) in July 2018 as a postbaccalaureate fellow in the laboratory of <a href="/Rhythmyx/assembler/render?sys_contentid=349595&amp;sys_revision=44&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349595" sys_dependentvariantid="1965" sys_siteid="475" sys_folderid="" sys_relationshipid="7355508">Laufey Amundadottir, Ph.D., senior investigator</a>. She graduated in May 2018 from the University of Pennsylvania, where she completed her B.A. in biological basis of behavior (neuroscience) and Hispanic studies. As an undergraduate, she worked in the laboratory of Dr. Leonard Zon at Boston Children&rsquo;s Hospital to interrogate mechanisms of drug resistance in BRAFV600E-driven melanoma. She subsequently worked in the laboratory of Dr. Ben Stanger at the Perelman School of Medicine, University of Pennsylvania, to identify the mechanisms behind tumor cell-intrinsic immune suppression and the subsequent impact on response to immunotherapy. As a postbaccalaureate fellow in LTG, Ms. Gordon is currently working on finding functional variants at pancreatic risk loci and determining their role in mediating pancreatic cancer risk.</p>
<h3><a id="Jermusyk"></a>Ashley Jermusyk, Ph.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1047567" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355509">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1047567&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Ashley Jermusyk, Ph.D., joined the Laboratory of Translational Genomics (LTG) in March 2016 as a postdoctoral fellow in the laboratory of <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/amundadottir-laufey"></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349595" sys_contentid="349595" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349595" sys_dependentvariantid="1965" sys_relationshipid="7355484" sys_siteid="475"></a><a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/amundadottir-laufey">Laufey Amundadottir, Ph.D.</a>, investigator, LTG.&nbsp; Dr. Jermusyk received her Ph.D. in chemical engineering from North Carolina State University in 2016.&nbsp; Her doctoral research, done in the laboratory of Dr. Greg Reeves, focused on developing new approaches for understanding gene regulation using the <em>Drosophila melanogaster</em> embryo.&nbsp; Currently, her work focuses on studying the molecular mechanisms through which susceptibility variants identified by genome-wide studies (GWAS) influence the risk of pancreatic cancer.</p>
<div style="clear: both; margin-top: 28px;"><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=jermusyk%20a&amp;authorOption=exact&amp;pi=2001950842">Scientific Publications - Ashley Jermusyk</a></div>
<h3><strong><a id="Zhong"></a>Jun Zhong</strong><strong>, Ph.D. - Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1097487" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355510">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1097487&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Jun Zhong, Ph.D., joined the Laboratory of Translational Genomics (LTG) in July 2017 as a postdoctoral fellow under the mentorship of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/amundadottir-laufey">Laufey Amundadottir, Ph.D</a>., senior investigator. Dr. Zhong completed his Ph.D. in bioinformatics from the Beijing Institute of Genomics, Chinese Academy of Sciences (BIG, CAS) in 2014, and then stayed in BIG as assistant investigator until July 2017. While at BIG, he became skilled at the use of next-generation sequencing, single-molecule real-time sequencing technology (SMRT), and whole genome methylome sequencing. His research focused on pathogenic mechanisms of human infectious disease with pan-genome and epigenetic regulation analysis. His doctoral research focused primarily on whole genome sequencing (WGS) and resequencing analysis of industrial fungus and biomedical minipigs. In DCEG, he is studying inherited predisposition to pancreatic cancer and digging out common and rare risk variants identified by genome-wide association studies (GWAS), sequence-based (WGS and transcriptome/TWAS) and other &ldquo;Omic&rdquo; technologies.</p>
<p><a href="https://scholar.google.com/citations?hl=en&amp;user=u8RNN5sAAAAJ&amp;view_op=list_works&amp;sortby=pubdate">Scientific Publications - Jun Zhong</a></p>
<h4><a href="#top">Back to Top</a></h4>
<h3 id="Brown-Lab"><a id="Brown-Lab"></a>BROWN LAB</h3>
<h3><a id="Choi"></a>Jiyeon Choi, Ph.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="749146" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355511">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="&quot;&quot;" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=749146&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Jiyeon Choi, Ph.D., joined the Laboratory of Translational Genomics (LTG) in October 2011 as a postdoctoral Cancer Research Training Award fellow in the lab of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349626" sys_contentid="349626" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349626" sys_dependentvariantid="1965" sys_relationshipid="7355479" sys_siteid="475">Kevin M. Brown, Ph.D</a>., investigator, LTG. In the lab, Dr. Choi is currently working on the functional characterization of common and rare genetic variants contributing to melanoma susceptibility by following up recent genome-wide association studies and family re-sequencing work. Dr. Choi has a Ph.D. in cell and developmental biology from the University of Medicine and Dentistry of New Jersey, where she pursued functional studies of autism-associated common genetic variants with Dr. James Millonig. She also has an M.S. in molecular biology from Korea University and a B.S. in biological sciences from Ewha Womans University, South Korea.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=choi%20j&amp;authorOption=exact&amp;pi=2000815187">Scientific Publications - Jiyeon Choi</a></p>
<h3><a id="Hennessey"></a>Rebecca Hennessey, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1141806" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355512">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1141806&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Rebecca (Becky) Hennessey, Ph.D., joined the Laboratory of Translational Genomics (LTG) in November 2018 as a postdoctoral fellow in the research group of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349626" sys_contentid="349626" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349626" sys_dependentvariantid="1965" sys_relationshipid="7355488" sys_siteid="475">Kevin Brown, Ph.D.</a>, senior investigator, LTG. Dr. Hennessey earned her Ph.D. in biomedical sciences from the Ohio State University College of Medicine in 2018. Her doctoral research, performed under the guidance of Dr. Christin Burd, focused on the use of melanoma mouse models to study the role of ultraviolet radiation in melanomagenesis as well as to test the efficacy of sunscreens in preventing melanoma. In LTG, Dr. Hennessy&rsquo;s work focuses on utilizing screening methods to functionally characterize multiple and complex melanoma susceptibility loci that were identified via genome-wide association studies.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Hennessey%2C%20Rebecca%5BFull%20Author%20Name%5D%20OR%20%22Hennessey%20RC%22%5BAuthor%5D&amp;cmd=DetailsSearch">Scientific Publications &ndash; Rebecca Hennessey</a></p>
<h3><strong><a id="Kong"></a>Hyunkyung Kong, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1143668" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355513">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1143668&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Hyunkyung Kong, Ph.D., joined the Laboratory of Translational Genomics (LTG) in November 2017 as a postdoctoral fellow in the lab of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349626" sys_contentid="349626" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349626" sys_dependentvariantid="1965" sys_relationshipid="7355489" sys_siteid="475">Kevin M. Brown, Ph.D., senior investigator</a>. Dr. Kong completed her M.S. &minus; Ph.D. unified course in biological sciences from Sookmyung Women&rsquo;s University, South Korea. There, working with Dr. Jong Hoon Park, she focused on the genetic analysis and epigenetic mechanisms regulating drug susceptibility of breast cancer using a diverse panel of breast cancer cell lines and patient samples. In LTG, her work focuses on the functional characterization of susceptibility variants identified by genome-wide association studies, and how they influence the risk of melanoma.</p>
<a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/58019237/?sort=date&amp;direction=ascending">Scientific Publications - Hyunkyung Kong</a>
<div style="clear: both; margin-top: 28px;">
<h3><strong><a id="Mehl"></a>Lindsey Mehl, B.A. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101327" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355514">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="bank" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101327&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Lindsey Mehl joined the Laboratory of Translational Genomics (LTG) in August 2017 as a postbaccalaureate fellow in the laboratory of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/brown-kevin">Kevin M. Brown, Ph.D</a>., investigator. Ms. Mehl graduated from Northwestern University, Evanston, Illinois, in June 2017 with a B.A. in biological sciences with a focus in biochemistry and biophysics. She previously worked in Northwestern University&rsquo;s Pathology Department studying the interface between chronic inflammation and tumor development and metastasis in the lab of Dr. Ronen Sumagin. There, she specifically explored the role of myeloperoxidase (MPO) in inhibiting wound healing during chronic inflammation as well as the role of miRNAs secreted by polymorphonuclear neutrophils in chromatin instability and tumor heterogeneity. Currently, she focuses on characterizing the function of melanoma susceptibility gene variants that were identified via genome-wide association studies.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=mehl+lc">Scientific Publications-Lindsey Mehl </a></p>
<h3><a id="Vu"></a>Andrew Vu, B.S. - Postbaccalaureate Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1068086" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355515">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1068086&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Andrew Vu joined the Laboratory of Translational Genomics (LTG) in October 2016 as a postbaccalaureate fellow in the laboratory of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/brown-kevin">Kevin M. Brown, Ph.D.</a>, investigator, LTG. Mr. Vu graduated from the University of Michigan with a B.S. in biomolecular science in May 2016. He previously worked as a research assistant in the laboratory of Dr. Yossi Holoshitz at the University of Michigan to identify and characterize intracellular signaling pathways of the rheumatoid arthritis shared epitope. He also worked with the laboratory of Dr. Joseph M. Corey at the University of Michigan in conjunction with the Veterans Affairs Ann Arbor Healthcare System. There, he harvested and identified neuronal cells and glia with advanced growth and differentiation through the use of novel biomaterials with prospective utilization in rehabilitation after neurological injury. In LTG, Mr. Vu is working on characterizing the function of melanoma susceptibility genetic variants identified through genome-wide association studies.</p>
<h4></h4>
<p><a href="#top">Back to Top</a></p>
<h3 id="Michael Dean"><a id="Dean-Lab"></a>DEAN LAB</h3>
<p>Learn more about our <a href="https://dcegpreview.cancer.gov/fellowship-training/become-a-fellow/research-training-areas/ltg-training">research training opportunities</a> in the Laboratory of Genetic Susceptibility.</p>
<p></p>
<p><a href="#top">Back to Top</a></p>
<h3 id="Prokunina-Olsson-Lab"><a id="Prokunina-Olsson-Lab"></a>PROKUNINA-OLSSON LAB</h3>
<h3><a id="Banday"></a>Abdul Rouf Banday, Ph.D. &ndash; Research Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1069904" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355516">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1069904&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Abdul Rouf Banday, Ph.D., joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in February 2014 and was promoted to research fellow in May 2016. Dr. Banday received his bachelor&rsquo;s degree in biochemistry from University of Kashmir, India, in 2006. He received his M.Sc. (2008) and Ph.D. (2012) degrees in biochemistry, with specialization in bioinformatics, from A.M. University, Aligarh, India. For his Ph.D., he used computational and molecular biology tools to study mechanisms of alternative splicing (AS) of mouse genome kinases. In 2009, he was awarded the Council of Scientific Industrial Research Junior Research Fellowship in India and a European Science Foundation summer school fellowship for training in bioinformatics at the University of Nottingham, United Kingdom. Prior to joining NCI, Dr. Banday worked as a postdoctoral fellow in the lab of Dr. Rahul Kanadia at the University of Connecticut. He studied role of alternative splicing in mouse retinal development using both next-generation sequencing and cell biology approaches.</p>
<p>In LTG, Dr. Banday is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349662" sys_contentid="349662" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349662" sys_dependentvariantid="1965" sys_relationshipid="7355482" sys_siteid="475">Ludmila Prokunina-Olsson, Ph.D.</a>,senior investigator. He is using computational and laboratory methods to explore underlying molecular mechanisms of genetic signals identified by GWAS for bladder cancer. During his time at NCI, Dr. Banday has received several awards including the NCI Director&rsquo;s Innovation Award (career development), Fellows Award for Research Excellence (FARE), DCEG-FARE, AACR Scholar-in-Training Award, DCEG Intramural Research Award, and John Quale Travel Award from the Bladder Cancer Advocacy Network.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=banday+ar">Scientific Publications - Abdul Rouf Banday<br /></a></p>
<h3><a id="Florez-Vargas"></a>Oscar Florez-Vargas, Ph.D., M.Sc. &ndash; Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1068164" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355517">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1068164&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Oscar Florez-Vargas, Ph.D., M.Sc., joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in October 2016. Dr. Florez-Vargas earned his Ph.D. in computer science from the University of Manchester, United Kingdom, in 2016, and his M.Sc. in biochemistry from the National University of Colombia in 2008. For his doctoral research, he developed computer-based strategies for reviewing biomedical scientific manuscript methods and predicting their reproducibility under the mentorship of Professors Andy Brass and Robert Stevens.&nbsp; His master research focused on identifying microRNAs associated with pharmacologically-induced senescence in an <em>in vitro</em> model of melanoma. In LTG, Dr. Florez-Vargas is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/prokunina-olsson-ludmila">Ludmila Prokunina-Olsson, Ph.D</a><span>., senior investigator, </span>on multiple genomic regions that have been associated via GWAS with increased risk of several cancers. He is involved in computational analysis of genotype-phenotype relationships to further evaluate the contribution of specific genomic regions, genes, and genetic variants to cancer phenotypes. Prior to joining LTG, Dr. Florez-Vargas was involved as a researcher in a number of studies examining genetic associations with infectious diseases and toxicological exposures in Colombia.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Florez%2C+Oscar+%5BFull+Author+Name%5D+OR+Florez-Vargas%2C+Oscar+%5BFull+Author+Name%5D">Scientific Publications-Oscar Florez-Vargas</a></p>
<h3><strong><a id="Lin"></a>Seraph Han-Yin Lin, B.M. &ndash; Postbaccalaureate Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101324" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355518">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101324&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Seraph Lin joined the Laboratory of Translational Genomics (LTG) in July 2017 as a postbaccalaureate fellow in the laboratory of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349662" sys_contentid="349662" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349662" sys_dependentvariantid="1965" sys_relationshipid="7355485" sys_siteid="475">Ludmila Prokunina-Olsson, Ph.D</a>., senior investigator. She earned her B.M. in piano performance with a minor in education from the University of California, Irvine in 2013, attended Pasadena City College from 2014&ndash;2017, and currently attends the University of Maryland, College Park, as a Science in the Evening (SIE) postbaccalaureate student. Ms. Lin first joined the Prokunina-Olsson lab in 2016 as a Community College Summer Enrichment Program (CCSEP) intern, where she worked on isoform specificity in <em>APOBEC</em> mutagenesis. She is currently investigating genome-wide association study (GWAS)-identified genomic regions associated with bladder cancer risk, and regulation of <em>APOBEC</em> mutagenesis in cancer.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Rao"></a>Nina Rao, B.S. &ndash; Predoctoral Fellow</strong></h3>
<div sys_dependentvariantid="2088" sys_dependentid="1147816" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" sys_folderid="" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355519">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1147816" /><!--Comment--></div>
</figure>
</div>
<p>Nina Rao, B.S., joined the Laboratory of Translational Genomics (LTG) in August 2017 as a predoctoral fellow through the NIH-Johns Hopkins Graduate Partnership Program. After graduating with a B.S. in biochemistry and molecular biology from the Pennsylvania State University, Ms. Rao spent a year as a postbaccalaureate fellow in the laboratory of Dan Fowler, M.D., Center for Cancer Research, NCI. There she studied the effects of rapamycin on T cell-based therapies for blood malignancies. Ms. Rao then joined the laboratory of <a href="/Rhythmyx/assembler/render?sys_contentid=349662&amp;sys_revision=38&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349662" sys_dependentvariantid="1965" sys_siteid="475" sys_folderid="" sys_relationshipid="7355520">Ludmila Prokunina-Olsson, Ph.D., Chief and senior investigator, LTG</a>, as a postbaccalaureate fellow, where she worked for two years on the functional characterization of the novel interferon, IFN-&lambda;4. As a current graduate student in LTG, Nina is mentored by Dr. Prokunina-Olsson and <a href="/Rhythmyx/assembler/render?sys_contentid=966087&amp;sys_revision=17&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="966087" sys_dependentvariantid="1965" sys_siteid="475" sys_folderid="" sys_relationshipid="7355521">Michael Dean, Ph.D., senior investigator</a>.&nbsp;She studies genetics and molecular epidemiology of bladder cancer, currently focusing on factors affecting APOBEC mutagenesis.</p>
<h3><a id="Vargas"></a>Joselin Vargas, B.S. &ndash; Postbaccalaureate Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101329" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355522">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101329&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Joselin Vargas joined the Laboratory of Translational Genomics (LTG) in June 2017 first as a summer intern through the NCI Introduction to Cancer Research Careers (ICRC) program, and then as a postbaccalaureate fellow in the laboratory of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349662" sys_contentid="349662" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349662" sys_dependentvariantid="1965" sys_relationshipid="7355486" sys_siteid="475">Ludmila Prokunina-Olsson, Ph.D</a>, senior investigator. Ms. Vargas earned her B.S. in biology with a minor in leadership development from Stony Brook University, New York, in 2017. Working with Dr. Gerardo G. Mackenzie, she focused her undergraduate research on pancreatic cancer and performed <em>in vitro</em> testing of a novel drug alone and in combination with FDA-approved drugs. In 2014, she worked in the laboratory of Dr. Ruel Desamero, where she identified the molar extinction coefficient and emission of phenylalanine amino acid derivatives to access the role of aromatic residues in driving amyloid formation. In the Prokunina-Olsson lab, Ms. Vargas is exploring a novel interferon (<em>IFNL4</em>) and its association with infection and cancer.</p>
<h3><a id="Wang"></a>Fang Wang, Ph.D. - Postdoctoral Fellow</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1031967" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7355523">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1031967&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Fang Wang, Ph.D., joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in June 2015. Dr. Wang received her Ph.D. in pathobiology and molecular biology from Tianjin Medical University, China in 2011. Her doctoral research focused on the role and mechanisms of tumor-associated genes, including miRNAs, in tumorigenesis and tumor progression. In LTG, Dr. Wang is working under the mentorship of<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349662" sys_contentid="349662" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349662" sys_dependentvariantid="1965" sys_relationshipid="7355483" sys_siteid="475">&nbsp;Ludmila Prokunina-Olsson, Ph.D.</a>, senior investigator. She is involved in exploring genetic and functional connections of a novel interferon (IFNL4) with infection-associated cancers. She is also working on the molecular phenotypes of several regions that have recently been associated with increased risk of bladder cancer through genome-wide association studies (GWAS).</p>
<p><a href="http://www.researcherid.com/ProfileView.action?SID=2FJ3dOPIzeKPy3PbPIF&amp;returnCode=ROUTER.Success&amp;queryString=KG0UuZjN5WkFC6Cq2BvNR3av6JYa7z92bd1Q3gqojT8%253D&amp;SrcApp=CR&amp;Init=Yes">Scientific Publications &ndash; Fang Wang</a></p>
<p><a href="#top">Back to Top</a></p>
<p style="text-align: left;">Learn about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302498" sys_contentid="302498" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302498" sys_dependentvariantid="1418" sys_relationshipid="7355478" sys_siteid="475">research training opportunities</a> in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7355481" sys_siteid="475">Laboratory of Translational Genomics</a>.</p>
</div>
</div>]]></content>
  </row>
  <row para_id="302643" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel">
     <ul class="grey-bullets"><li>Depending on your system, download the zip (Windows), tar.gz (UNIX), or.tgz (Mac) file for your operating system from the download page.</li><li>Install from R (GUI) package installer or using the install.packages() function, e.g., install.packages(&#8220;C:/temp/CompareTests_1.0.zip&#8221;, repos=NULL)</li><li>Load the CompareTests package from the GUI or with the command library(CompareTests)</li><li>Type CompareTests in R console to access help files and package manual</li></ul></div>]]></content>
  </row>
  <row para_id="302644" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="Top"></a>&nbsp;
<p><em>On this page:</em></p>
<p><a href="#Overview">Overview</a><br /> <a href="#Qualifications">Qualifications</a><br /> <a href="#Application">Application Process</a><br /> <a href="#Specific">Training Opportunities with Specific Investigators</a><br /> <a href="#Clinical-Research-Mentoring">Clinical Research Mentoring for Participants in Other Programs</a><br /> <a href="#Genetic-Counseling">Training Program in Genetic Counseling</a></p>
<h3 id="Overview">Overview</h3>
<p>Clinical cancer genetics research aims to understand cancer etiology and to translate this knowledge into evidence-based management strategies for persons at increased risk of cancer. Investigators work to identify new cancer susceptibility genes and factors contributing to elevated cancer risk in individuals and populations. They also characterize phenotypic manifestations of inherited cancer syndromes and study the psychological and social challenges related to being at high risk of cancer.&nbsp;</p>
<p>Fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7294810">Clinical Genetics Branch</a> work with researchers engaged in conducting clinical research studies targeting high-risk individuals and families, in pursuing astute clinical observations of unusual cancer occurrences, and in applying genomic and epidemiologic methods to the study of high-risk individuals. They gain practical knowledge about conducting clinical studies and learn about basic molecular laboratory techniques and approaches. Fellows work on interdisciplinary epidemiologic, genomic, and translational studies. These are not primary laboratory-based positions. Instead, they involve extensive collaboration with core facilities and laboratory collaborators. Postdoctoral and predoctoral positions in CGB are available and applications are accepted on a continuous basis.</p>
<p>To discuss potential opportunities in your area of research interest, you may contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=CGB">CGB branch investigators</a> directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=193&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302417" sys_contentid="302417" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302417" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7294811">Meet fellows in the Clinical Genetics Branch</a>.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="Qualifications">Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Individuals must either hold a doctorate degree in or be enrolled in a doctoral program related to medicine, genetics, oncology, biology, or the psychosocial/behavioral sciences. Familiarity with genomic studies is a plus, although not required.</p>
<p><i>Predoctoral fellowships:</i> Individuals must either be enrolled in a doctoral program with the desire to complete their dissertation in CGB or have a Master's degree in a field relevant to CGB research.</p>
<p><i>Postbaccalaureate fellowships:</i> These may be offered on a selective basis to individuals on a career path towards medicine, genetics or epidemiology. These are typically one- or two-year appointments, with most fellows moving on to doctoral degree programs of one kind or another after their work at CGB is complete.</p>
<h3 id="Application">Application Process</h3>
<p>Predoctoral and postdoctoral fellowship applications in the branch are accepted on an ongoing basis. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103" sys_relationshipid="7294809">Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3 id="Specific">Training Opportunities with Specific Investigators</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302591" sys_contentid="302591" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302591" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7294814">Genomic Studies of Pediatric Cancers</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302591" sys_contentid="302591" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302591" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7294815">Cancer Genomics of Lymphoproliferative or Gastrointestinal Cancers</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302591#IBMFS" sys_contentid="302591#ibmfs" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302591" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7294816">Training in the Inherited Bone Marrow Failure Syndromes of Childhood - Postdoctoral Fellowship</a></li>
</ul>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302591" sys_contentid="302591" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302591" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7294812">Find out more about training opportunities with specific investigators</a>.</p>
<h3 id="Clinical-Research-Mentoring">Clinical Research Mentoring for Participants in Other Programs</h3>
<p>In addition to guiding our own CGB fellows, CGB investigators often mentor clinical fellows from other training programs for the research component of their programs. Such programs include:</p>
<ul>
<li><a href="http://home.ccr.cancer.gov/med/fellowship/mofp.html">NCI Medical Oncology Fellowship Program</a></li>
<li><a href="http://pediatrics.cancer.gov/training/fellowship.asp">NCI Pediatric Oncology Branch Fellowship Program</a></li>
<li><a href="http://www.childrensnational.org/ForDoctors/gme/fellowship/hematology/hematology.aspx">The Pediatric Hematology Oncology Training Program</a> at Children's National Medical Center - These candidates are frequently pursuing concurrent M.P.H. degrees at the <a href="http://publichealth.gwu.edu/">George Washington University School of Public Health</a>.</li>
<li><a href="http://www.genome.gov/10000555">NIH Medical Genetics Fellowship Program</a> - Medical genetics fellows also rotate through CGB's Familial Cancer Clinic.</li>
<li><a href="http://cpfp.nci.nih.gov/index.shtml">The NCI Cancer Prevention Fellowship Program</a></li>
</ul>
<p>If you are a fellow in one of these programs and you wish more information, contact your program director.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="Genetic-Counseling">Training Program in Genetic Counseling</h3>
<p>CGB is a training site for <a href="http://www.genome.gov/10001156">The Johns Hopkins University/National Human Genome Research Institute Genetic Counseling Training Program</a>.This program leads to a master's degree in genetic counseling from the Johns Hopkins Bloomberg School of Public Health. CGB is also mentoring student interns from the <a href="http://medschool.umaryland.edu/mgc/">University of Maryland Baltimore Master&rsquo;s in Genetic Counseling program</a>. Genetic counseling students rotate through the CGB Familial Cancer Clinics, and have the option of doing a more extended research fellowship (e.g., during the summer) or performing their master's thesis project with a CGB mentor.</p>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="302646" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Diets containing substantial amounts of red meat may increase the risk of various types of cancer. The association with red meat intake may be due to a combination of factors, such as content of fat, protein, and iron, and/or meat preparation (e.g. cooking or preserving methods). Experimental studies have shown that meats cooked at high temperatures contain heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs), which are mutagenic and carcinogenic in animals. To estimate intake of these meat-cooking mutagens, a detailed meat cooking module within a Food Frequency Questionnaire in conjunction with a mutagen database was developed. Charred is a software application to estimate intake of the mutagenic compounds in cooked meats.</p>
<ul class="bullet-blu">
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=5&amp;sys_contentid=302657&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6268372" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="302657" rxinlineslot="103">Example Questionnaire (web format)&nbsp;</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1500&amp;sys_revision=2&amp;sys_contentid=303120&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6268373" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="303120" rxinlineslot="103">Download Example Questionnaire (PDF, 39KB)</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=10&amp;sys_contentid=302546&amp;sys_context=0" inlinetype="rxhyperlink" sys_relationshipid="6268365" sys_dependentvariantid="1418" sys_dependentid="302546" rxinlineslot="103">Description of the Database</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=302577&amp;sys_context=0" inlinetype="rxhyperlink" sys_relationshipid="6268366" sys_dependentvariantid="1418" sys_dependentid="302577" rxinlineslot="103">Cooking Method Conversions</a></li>
<li>Examples of Modifications for Specific Studies</li>
<li style="list-style: none;"><ol>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=302492&amp;sys_context=0" inlinetype="rxhyperlink" sys_relationshipid="6268367" sys_dependentvariantid="1418" sys_dependentid="302492" rxinlineslot="103">Health Professionals Follow-up Study</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=302655&amp;sys_context=0" inlinetype="rxhyperlink" sys_relationshipid="6268368" sys_dependentvariantid="1418" sys_dependentid="302655" rxinlineslot="103">Nurses Health Study I</a></li>
</ol></li>
</ul>
<p><a href="mailto:charredhelp@imsweb.com?subject=Charred Software Request"><strong>Request Software</strong></a><br />CHARRED Version 1.7 was released October 27, 2006. A revision history describing changes made for this release is provided in the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=326282&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6268369" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="326282" rxinlineslot="103">CHARRED software Read-me</a> page.</p>
<h4><strong><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1500&amp;sys_revision=2&amp;sys_contentid=1045421&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="1045421" rxinlineslot="103" sys_relationshipid="6268374">Access the heme iron database</a></strong></h4>
<p><strong><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1500&amp;sys_revision=1&amp;sys_contentid=1045422&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6268370" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="1045422" rxinlineslot="103">Macro SAS code for use with the heme iron database</a></strong>- Note that this macro code can be pasted into a SAS program or included with an "include" statement and then called from the SAS program in order to generate the three variables below from food frequency data that corresponds to meats in the database file:</p>
<p>heme_iron = 'heme iron from meat (bhnrc) (mcg/day)'</p>
<p>rheme_iron = 'heme iron from red meat (bhnrc) (mcg/day)'</p>
<p>wheme_iron = 'heme iron from white meat (bhnrc) (mcg/day)'</p>
<p><strong><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1500&amp;sys_revision=1&amp;sys_contentid=1045423&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6268371" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="1045423" rxinlineslot="103">SAS code for calculating nitrate and nitrite values for processed meats</a></strong> - Note that this file contains SAS code for calculating nitrate and nitrite values based on grams of certain processed meats. There are two sets of calculations that were done for the AARP study, one based on previously published values and the other based on a database of measured levels in processed meats purchased in 2004.</p>
<p><a href="mailto:charredhelp@imsweb.com"><strong>Contact Us</strong></a><br />If you have problems accessing CHARRED, please send an e-mail to <a href="mailto:charredhelp@imsweb.com">charredhelp@imsweb.com</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302649" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>In Remembrance of Arthur Schatzkin, M.D., Dr.P.H., 1948 - 2011</h3>
<p><img width="150" height="194" style="float: left; margin: 5px 10px 5px 0;" alt=" Arthur Schatzkin, M.D., Dr.P.H." src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_contentid=303093" inlinetype="rximage" sys_relationshipid="7251743" sys_dependentvariantid="1482" sys_dependentid="303093" rxinlineslot="104" />Dr. Arthur Schatzkin, an outstanding scientist, mentor, and leader in the field of nutritional epidemiology, passed away on January 20, 2011 from cancer. An internationally renowned pioneer in the field of nutrition and cancer and a gifted public speaker, he was a man of great personal and professional integrity who cared deeply about the impact of his work on public health.</p>
<p>Dr. Schatzkin received a B.A. from Yale University, an M.D. from the State University of New York, and an M.P.H. and Dr.P.H. from Columbia University. He came to NCI in 1984, and in 1999 was appointed as the Chief of the Nutritional Epidemiology Branch (NEB) in the Division of Cancer Epidemiology and Genetics (DCEG).</p>
<p>Dr. Schatzkin was committed to understanding the role of nutrition in cancer etiology and prevention. Early in his career, he was the first to describe an association between moderate alcohol intake and breast cancer risk. He then turned his attention to the role of diet in the prevention of colorectal cancer. He led the landmark NCI Polyp Prevention Trial, which determined that eating fiber did not prevent the recurrence of polyps in the colon.</p>
<p>Dr. Schatzkin was instrumental in addressing the major methodological issues that have limited progress in nutritional epidemiology. As an example, to overcome the limited range of reported dietary intake in cohort studies, he conceived and launched the NIH-AARP Diet and Health Study, which at the time was the largest prospective cohort investigation of diet and nutrition in relation to cancer causation. This long-term study of approximately 500,000 men and women already has generated more than 100 original scientific papers and continues to be an invaluable resource utilized by investigators worldwide.</p>
<p>Dr. Schatzkin was dedicated to the pursuit of strategies in nutritional epidemiology and to the training, mentoring, and support of young scientists. During his tenure as Branch Chief, NEB grew from two investigators to a highly productive team of more than 20 scientists.</p>
<p>Dr. Schatzkin was at the forefront of efforts to meet the challenges of research in nutritional epidemiology. By developing new methods to assess the components of nutritional status, he provided strong leadership that inspired creativity and passion in trainees and senior scientists alike. His great personal warmth, intellectual curiosity, and genuine commitment to improve public health through exemplary science will be greatly missed.</p>
</div>]]></content>
  </row>
  <row para_id="302650" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/oeeb" title="">OEEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/oeeb/oeeb-research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=OEEB">OEEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/oeeb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/training-oeeb" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/oeeb/tools" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=OEEB">Publications</a></p>
</div>
<p>Our research emphasis is also on developing innovative tools and approaches for assessing carcinogenic risks from occupational and environmental exposures.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=326867" sys_contentid="326867" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7252128" sys_dependentvariantid="1418" sys_dependentid="326867" rxinlineslot="103">Job Modules for Occupational Questionnaires</a></p>
<p><a href="http://soccer.nci.nih.gov">SOCcer: Standardized Occupation Coding for Computer-assisted Epidemiologic Research</a></p>
<h3>Useful Links</h3>
<p><a href="http://monographs.iarc.fr/">IARC Monographs</a></p>
<p><a href="https://www.epa.gov/pesticides">EPA Pesticide Programs</a></p>
<p><a href="http://www.cancer.gov/cancertopics/factsheet">NCI Fact Sheets</a></p>
<p><a href="http://www.cdc.gov/niosh/">National Institute for Occupational Safety and Health</a></p>
</div>]]></content>
  </row>
  <row para_id="302655" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>The Nurses Health Study (NHS) questionnaire had the following questions involving chicken skin.</p><p><em>When you eat chicken, how often is it cooked with the skin on?</em></p><ul class="bullet-blu"><li><em>always</em></li><li><em>most of the time</em></li><li><em>sometimes</em></li><li><em>never</em></li></ul><p><em>How often do you eat the skin?</em></p><ul class="bullet-blu"><li><em>always</em></li><li><em>most of the time</em></li><li><em>sometimes</em></li><li><em>never</em></li></ul><p>The same calculations were applied to NHS as the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=302492&amp;sys_context=0" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302492" sys_dependentvariantid="1418" sys_relationshipid="3746015">Health Professionals Follow-up Study (HPFS)</a>. In order to account for the four answers, the following percentages were applied:</p><ul class="bullet-blu"><li>Always (100%)</li><li>Most of the time (75%)</li><li>Sometimes (50%)</li><li>Never (0%)</li></ul><p>The following table illustrates the number of different combinations possible.</p><table border="0" cellpadding="3" cellspacing="1" class="blue-table"><tr bgcolor="#CCCCCC"><th scope="col"><strong>Percentage used in calculation</strong></th><th scope="col"><strong>Cook with skin</strong></th><th scope="col"><strong>Eat skin</strong></th></tr><tr><td>100% cook w/skin and eat w/skin</td><td>Always</td><td>Always</td></tr><tr><td bgcolor="#EEEEEE">75% cook w/skin and eat w/skin<br />25% cook w/skin and eat w/o skin</td><td bgcolor="#EEEEEE">Always</td><td bgcolor="#EEEEEE">Most</td></tr><tr><td>50% cook w/skin and eat w/skin<br />50% cook w/skin and eat w/o skin</td><td>Always</td><td>Sometimes</td></tr><tr><td bgcolor="#EEEEEE">100% cook w/skin and eat w/o skin</td><td bgcolor="#EEEEEE">Always</td><td bgcolor="#EEEEEE">Never</td></tr><tr><td>25% cooked w/o skin<br />75% cooked w/skin and eat w/skin</td><td>Most</td><td>Always</td></tr><tr><td bgcolor="#EEEEEE">25% cooked w/o skin,<br />56% cooked w/ skin and eat w/skin<br />19% cooked with skin and eat w/o skin</td><td bgcolor="#EEEEEE">Most</td><td bgcolor="#EEEEEE">Most</td></tr><tr><td>25% cooked w/o skin<br />37.5% cooked w/skin and eat w/skin<br />37.5% cooked with skin and eat w/o skin</td><td>Most</td><td>Sometimes</td></tr><tr bgcolor="#EEEEEE"><td>25% cooked w/o skin<br />75% cooked w/skin and eat w/o skin</td><td>Most</td><td>Never</td></tr><tr><td>50% cooked w/o skin<br />50% cooked w/skin and eat w/skin</td><td>Sometimes</td><td>Always</td></tr><tr bgcolor="#EEEEEE"><td>50% cooked w/o skin<br />37.5% cooked w/skin and eat w/skin<br />12.5% cooked with skin and eat w/o skin</td><td>Sometimes</td><td>Most</td></tr><tr><td>50% cooked w/o skin<br />25% cooked w/skin and eat w/skin<br />25% cooked with skin and eat w/o skin</td><td>Sometimes</td><td>Sometimes</td></tr><tr bgcolor="#EEEEEE"><td>50% cooked w/o skin<br />50% cooked with skin and eat w/o skin</td><td>Sometimes</td><td>Never</td></tr><tr><td>100% cooked w/o skin</td><td>Never</td><td>Never</td></tr></table><p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=302502&amp;sys_context=0" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302502" sys_dependentvariantid="1418" sys_relationshipid="3746016" target="_blank">A complete listing of the values</a> is available.</p><hr /><p>For more information:</p><p><strong><em>Kana Wu, MD, PhD</em></strong><br />Harvard School of Public Health<br />Department of Nutrition<br />665 Huntington Avenue<br />Boston, MA 02115<br />Tel. 617-432-1842<br />Fax. 617-432-2435<br />e-mail:<a href="mailto:kana.wu@channing.harvard.edu">kana.wu@channing.harvard.edu</a></p></div>]]></content>
  </row>
  <row para_id="302656" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:w="urn:www.microsoft.com/word" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:x="urn:www.microsoft.com/excel"><ul><li>1. Download and install R packages <a href="http://cran.r-project.org/web/packages/survival/index.html" target="_blank">survival</a> and <a href="http://cran.r-project.org/web/packages/optmatch/index.html" target="_blank">optmatch</a> if not already installed.</li><li>2. Download zip or tar.gz file for your operating system from the <a href="http://bioconductor.org/packages/release/bioc/html/CGEN.html">download</a> page.</li><li>3. Install from R (GUI) package installer or using the install.packages() function, e.g., install.packages(&#8220;C:/temp/CGEN_1.0.0_beta.zip&#8221;, repos=NULL)</li><li>4. Load the CGEN package from the GUI or with the command library(CGEN)</li><li>5. Type ?CGEN in R console to access help files and package manual</li></ul><h3>Description</h3><p>This package is for logistic regression analyses of SNP data in case-control studies. It is designed to give the users flexibility of using a number of different methods for analysis of SNP-environment or SNP-SNP interactions. It is known that power of interaction analysis in case-control studies can be greatly enhanced if it can be assumed that the factors (e.g. two SNPs) under study are independently distributed in the underlying population. The package implements a number of different methods that can incorporate such independence constraints into analysis of interactions in the setting of both unmatched and matched case-control studies. These methods are more general and flexible than the popular case-only method of analysis of interaction that also assumes gene-gene or/and gene-environment independence for the underlying factors in the underlying population. The package also implements various methods, based on shrinkage estimation and conditional-likelihoods, that can automatically adjust for possible violation of the independence assumption that could arise due to direct causal relationship (e.g. between a gene and a behavior exposure) or indirect correlation (e.g due to population stratification). A number of convenient summary and printing functions are included. The package will continue to be updated with new methods as they are developed. The methods are currently not suitable for analysis of SNPs on sex chromosomes.</p><h3>Details</h3><p>The main functions for unmatched data are snp.logistic and snp.scan.logistic. Whereas snp.logistic analyzes one SNP with each function call, snp.scan.logistic analyzes a collection of SNPs and writes the summary results to an external file. With snp.logistic, a data frame is input in which the SNP variable must be coded as 0-1-2 (or 0-1). If not, recode.geno can be used for recoding the SNP variable before calling snp.logistic. The functions getSummary, getWaldTest and snp.effects can be called for creating summary tables, computing Wald tests and joint/stratified effects using the returned object from snp.logistic (see Examples in snp.logistic). With snp.scan.logistic, the data is read in from external files defined in snp.list and pheno.list. The collection of p-values computed in snp.scan.logistic, can be plotted using the functions QQ.plot and chromosome.plot.<br /><br />The function for analysis of matched case-control data is snp.matched. Optimal matching can be obtained from the function getMatchedSets.<br /><br />This package contains sample genotype data SNPdata, sample covariate data Xdata, and sample SNP meta data LocusMapData. The current version of the packag is only suitable for analysis of SNPs on non-sex chromosomes.<br />&#160;</p><h3>Author(s):</h3>Samsiddhi Bhattacharjee, Nilanjan Chatterjee and William Wheeler<br /><h3>References:</h3><h3>Maximum-likelihood estimation under independence:</h3>Chatterjee, N. and Carroll, R. Semiparametric maximum likelihood estimation exploting gene-environment independence in case-control studies. <cite>Biometrika,</cite> 2005, 92, 2, pp.399-418.<br /><h3>Shrinkage estimation:</h3>Mukherjee B, Chatterjee N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18162111">Exploiting gene-environment independence in analysis of case-control studies: An empirical Bayes approach to trade-off between bias and efficiency.</a> <cite>Biometrics</cite> 2008, 64(3):685-94.<br /><br />Mukherjee B et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18473390">Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs.</a><cite>Genetic Epidemiology</cite>, 2008, 32:615-26.<br /><br />Chen YH, Chatterjee N, Carroll R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19430598">Shrinkage estimators for robust and efficient inference in haplotype-based case-control studies.</a><cite>Journal of the American Statistical Association</cite>, 2009, 104: 220-233.<br /><h3>Conditional Logistic Regression and Adjustment for Population stratification:</h3>Chatterjee N, Zeynep K and Carroll R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15593088">Exploiting gene-environmentindependence in family-based case-control studies: Increased power for detecting associations, interactions and joint-effects.</a><cite>Genetic Epidemiology</cite> 2005; 28:138-156.<br /><br />Bhattacharjee S, Wang Z, Ciampa J, Kraft P, Chanock S, Yu K, Chatterjee N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20206333">Using Principal Components of Genetic Variation for Robust and Powerful Detection of Gene-Gene Interactions in Case-Control and Case-Only studies.</a><cite>American Journal of Human Genetics</cite> 2010, 86(3):331-342.</div>]]></content>
  </row>
  <row para_id="302657" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for hamburgers or cheeseburgers (including fast food)">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">a. Hamburgers or<br />cheeseburgers<br />(including fast food)</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>1 medium<br />or 4 oz.</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Pan fried</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Grilled or Barbecued</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Oven-broiled</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for beef steaks">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">b. Beef Steaks</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>4 oz.</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Pan fried</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Grilled or Barbecued</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Oven-broiled</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for pork chops or ham steaks">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">c. Pork chops or ham steaks</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>2 chops or<br />or 4 oz.</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Pan fried</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Oven-broiled</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Baked or Roasted</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for bacon">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">d. Bacon</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>2 strips</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Pan fried</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Oven-broiled</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for breakfast sausage">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">e. Breakfast sausage</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>2 links or 2 patties</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Pan fried</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Grilled or Barbecued</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Oven-broiled</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for fried chicken">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">f. Fried chicken</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>2 small or 1 large piece</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Deep-fat fried or fast food</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Pan fried</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for chicken or turkey, including sandwiches">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">g. Chicken or turkey, including sandwiches</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>2 small or 1 large piece</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Baked or Roasted</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="5" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Stewed</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Oven-broiled</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Grilled or Barbecued</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Cooked another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table width="90%" class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is for gravy">
<tbody>
<tr>
<td rowspan="2">&nbsp;</td>
<th bgcolor="#cccccc" rowspan="2" scope="col">Never</th>
<th rowspan="2" scope="col">Less<br />Than<br />Once<br />Per<br />Month</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Mo.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Mo.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">2-3<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">3-4<br />Per<br />Wk.</th>
<th rowspan="2" scope="col">5-6<br />Per<br />Wk.</th>
<th bgcolor="#cccccc" rowspan="2" scope="col">1<br />Per<br />Day</th>
<th rowspan="2" scope="col">2+<br />Per<br />Day</th>
<th rowspan="2" scope="col">Medium Serving</th>
<th colspan="3" scope="col">Size</th>
</tr>
<tr>
<th scope="col">S</th>
<th scope="col">M</th>
<th scope="col">L</th>
</tr>
<tr>
<th align="left" scope="row">h. Gravy</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td>2 tbsp</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Made from meat drippings</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc" rowspan="4" colspan="4">&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Store-bought cans</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Store-bought packets</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="right" scope="row">Made another way<br />(SPECIFY)<br />_______________</th>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
<td bgcolor="#cccccc">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table class="blue-table" bordercolor="#000000" border="1" cellspacing="0" cellpadding="3" summary="This section is to record the doneness of each meat">
<tbody>
<tr>
<th align="left" valign="top" rowspan="8" scope="row">A hamburger or cheeseburger</th>
<td>Rare</td>
<td width="20">&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Medium-rare</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Medium</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Medium-well</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Very well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Don't know</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Did not eat</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<th align="left" valign="top" rowspan="8" scope="row">Steak</th>
<td>Rare</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Medium-rare</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Medium</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Medium-well</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Very well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Don't know</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Did not eat</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<th align="left" valign="top" rowspan="5" scope="row">Pork chop or ham steak</th>
<td>Just until done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Very well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Don't know</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Did not eat</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="left" valign="top" rowspan="5" scope="row">Bacon</th>
<td bgcolor="#cccccc">Just until done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Very well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Don't know</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Did not eat</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<th align="left" valign="top" rowspan="5" scope="row">Breakfast sausage</th>
<td>Just until done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Very well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Don't know</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Did not eat</td>
<td>&nbsp;</td>
</tr>
<tr>
<th align="left" valign="top" rowspan="5" scope="row">Fried chicken</th>
<td bgcolor="#cccccc">Just until done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Very well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Don't know</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Did not eat</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<th align="left" valign="top" rowspan="5" scope="row">Chicken</th>
<td>Just until done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Well-done</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Very well-done</td>
<td>&nbsp;</td>
</tr>
<tr>
<td bgcolor="#cccccc">Don't know</td>
<td bgcolor="#cccccc">&nbsp;</td>
</tr>
<tr>
<td>Did not eat</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</div>]]></content>
  </row>
  <row para_id="302660" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>POWER</strong> is a windows-based program for computation of sample size and power for binary outcome studies (case-control and cohort studies) based on a logistic-like regression model with one covariate or two covariates (e.g., gene X exposure interactions).</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302600" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302600" sys_dependentvariantid="1418" sys_relationshipid="6835415" sys_siteid="475">Readme&nbsp;instructions</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302418" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302418" sys_dependentvariantid="1418" sys_relationshipid="6835416" sys_siteid="475">License Agreement</a></li>
</ul>
<div class="bullet-blu">
<h3>Download Software:</h3>
<ul>
<li>Download: <a class="bodylink" href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303219" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303219" sys_dependentvariantid="1500" sys_relationshipid="6835414">Install_PowerV3.exe</a></li>
<li>Save this file in an appropriate folder on your disk.</li>
<li><span style="color: #000000;">Click on it, and the POWER program will be installed on your machine.</span></li>
</ul>
<p><span style="color: #000000;">Note: If your computer is running under the Windows 2000 operating system,</span><br />the install program must be run from an account with installation privileges (ie. Power User or Administrator).</p>
<p>If you are not sure what privileges you have, please contact your System Administrator.&nbsp;</p>
<h3>References:</h3>
</div>
<p>Suggested reference for the POWER program:</p>
<p style="margin-left: 20.0px;">Garcia-Closas M, Lubin JH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/10206617">Power and sample size calculations in case-control studies of gene-environmental interactions: Comments on different approaches</a>. <cite>Am J Epidemiol</cite> 1999;149:689-93.</p>
<h3>Support:</h3>
<p><strong>Questions?</strong> <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="302661" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>It is estimated that more than 16 million cancer survivors are currently alive in the United States, which has led to an increasing focus on the long-term outcome of cancer treatment. DCEG has a long-standing interest in cancer survivorship research, particularly the role of radiation, chemotherapy, and hormonal treatments in second cancer risk. DCEG investigators monitor NCI&rsquo;s Surveillance, Epidemiology, and End Results (SEER) cancer registry database to assess patterns and trends in the occurrence of second primary cancers. The overall objective is to identify cancer survivors who appear to be at increased risk for developing second primary cancers. These survivors can then be targeted for increased surveillance and primary and secondary prevention strategies, as well as identifying areas that require additional analytic study.</p>
<p>To facilitate research into the etiology of second cancers, investigators from DCEG's Radiation Epidemiology Branch led the development of an interactive PC-based software module (&ldquo;SIR&rdquo;) to perform analyses of multiple primary cancers using NCI&rsquo;s SEER database. The analysis module was added to the SEER*Stat program, a publicly available software package created by NCI that calculates SEER incidence, mortality, and survival rates (<a href="http://seer.cancer.gov/seerstat/">http://seer.cancer.gov/seerstat/</a>). The multiple primary cancer module calculates standardized incidence ratios by second cancer site, histology, treatment, sex, race, calendar year, age, time since diagnosis, and registry. DCEG researchers have used this software tool to evaluate the risk of second cancers in SEER among survivors of a number of malignancies, including breast cancer, childhood cancer, and non-Hodgkin lymphoma.&nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270691" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103">Lindsay Morton</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270692" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302662" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><ul><li>Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H, Aittom&#228;ki K, Simard J, Spurdle AB; KConFab, Couch FJ, Pereira LH, Greene MH, Andrulis IL; Ontario Cancer Genetics Network, Pasche B, Kaklamani V; Breast Cancer Family Registry, Hamann U, Szabo C, Peock S, Cook M, Harrington PA, Donaldson A, Male AM, Gardiner CA, Gregory H, Side LE, Robinson AC, Emmerson L, Ellis I; EMBRACE, Peyrat JP, Fournier J, Vennin P, Adenis C, Muller D, Fricker JP, Longy M, Sinilnikova OM, Stoppa-Lyonnet D; GEMO, Schmutzler RK, Versmold B, Engel C, Meindl A, Kast K, Schaefer D, Froster UG, Chenevix-Trench G, Easton DF. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18523885">No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.</a><em><cite>Breast Cancer Res Treat</cite></em> 2009 May;115(1):185-92.</li><li>Greene MH, Mai PL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19141782">What have we learned from risk-reducing salpingo-oophorectomy?</a><em><cite>J Natl Cancer Inst</cite></em> 2009 Jan 21;101(2):70-1.</li><li>Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, K&#228;mpj&#228;rvi K, Nevanlinna H, Simard J, Beesley J, Chen X; Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LH, Greene MH, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H; OCGN, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E; Swedish BRCA1 and BRCA2 study collaborators, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Ben&#237;tez J, Hamann U, Hogervorst FB, Manders P, Ligtenberg MJ, van den Ouweland AM; DNA-HEBON collaborators, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F; EMBRACE, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D; GEMO, Chenevix-Trench G, Easton DF; CIMBA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18355772">Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.</a><em><cite>Am J Hum Genet</cite></em> 2008 Apr;82(4):937-48.</li><li>Osorio A, Poll&#225;n M, Pita G, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Preisler-Adams S, Niederacher D, Hofmann W, Gadzicki D, Jakubowska A, Hamann U, Lubinski J, Toloczko-Grabarek A, Cybulski C, Debniak T, Llort G, Yannoukakos D, D&#237;ez O, Peissel B, Peterlongo P, Radice P, Heikkinen T, Nevanlinna H, Mai PL, Loud JT, McGuffog L, Antoniou AC, Benitez J; CIMBA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18781154">An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.</a><em><cite>Br J Cancer</cite></em> 2008 Sep 16;99(6):974-7.</li><li>Katki HA, Gail MH, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18054868">Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.</a><em><cite>Lancet Oncol</cite></em> 2007 Dec;8(12):1042-3.</li><li>Antoniou AC, Sinilnikova OM, Simard J, L&#233;on&#233; M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, G&#243;rski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <a href="http://www.ncbi.nlm.nih.gov/pubmed/17999359">RAD51 135G--&gt;C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.</a><em><cite>Am J Hum Genet</cite></em> 2007 Dec;81(6):1186-200.</li><li>Pereira LH, Pineda MA, Rowe WH, Fonseca LR, Greene MH, Offit K, Ellis NA, Zhang J, Collins A, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17916242">The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies.</a><em><cite>BMC Genet</cite></em> 2007 Oct 4;8:68.</li><li>Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; CIMBA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17466083">An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).</a><em><cite>Breast Cancer Res</cite></em> 2007;9(2):104.</li><li>Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakubowska A, Lubinski J, Gronwald J, Spurdle AB; kConFab, Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, Andrulis IL, Ilyushik E, Glendon G, Devilee P, Vreeswijk MP, Vasen HF, Borg A, Backenhorn K, Struewing JP, Greene MH, Neuhausen SL, Rebbeck TR, Nathanson K, Domchek S, Wagner T, Garber JE, Szabo C, Zikan M, Foretova L, Olson JE, Sellers TA, Lindor N, Nevanlinna H, Tommiska J, Aittomaki K, Hamann U, Rashid MU, Torres D, Simard J, Durocher F, Guenard F, Lynch HT, Isaacs C, Weitzel J, Olopade OI, Narod S, Daly MB, Godwin AK, Tomlinson G, Easton DF, Chenevix-Trench G, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17627006">AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.</a><em><cite>Cancer Epidemiol Biomarkers Prev</cite></em> 2007 Jul;16(7):1416-21.</li><li>Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G; Australian Breast Cancer Family Study; Australian Jewish Breast Cancer Study; Breast Cancer Family Registry; Interdisciplinary Health Research International Team on Breast Cancer Susceptibility; The Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Epidemiological Study of Familial Breast Cancer Study Collaborators. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16434590">The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.</a><em><cite>Cancer Epidemiol Biomarkers Prev</cite></em> 2006 Jan;15(1):76-9.</li><li>Kazerouni N, Greene MH, Lacey JV Jr, Mink PJ, Schairer C. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16881078">Family history of breast cancer as a risk factor for ovarian cancer in a prospective study.</a><em><cite>Cancer</cite></em> 2006 Sep 1;107(5):1075-83.</li><li>McInerney-Leo A, Hadley D, Kase RG, Giambarresi TR, Struewing JP, Biesecker BB. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16969872">BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening.</a><em><cite>Am J Med Genet A</cite></em> 2006 Oct 15;140(20):2198-206.</li><li>Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15784723">Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians.</a><em><cite>J Med Genet</cite></em> 2005 Oct;42(10):749-55.</li><li>McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15633195">BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.</a><em><cite>Am J Med Genet A</cite></em> 2005 Mar 1;133A(2):165-9.</li><li>Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16314625">Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.</a><em><cite>J Clin Oncol</cite></em> 2005 Dec 1;23(34):8629-35.</li><li>Struewing JP, Hartge P, Wacholder S, Tucker MA, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15114373">BRCA1 and sex ratio.</a><em><cite>Eur J Hum Genet</cite></em> 2004 Aug;12(8):663-7.</li><li>Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH, Greene MH, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15382084">CHEK2:1100delC and female breast cancer in the United States.</a><em><cite>Int J Cancer</cite></em> 2004 Nov 10;112(3):541-3.</li><li>McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15378542">BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.</a><em><cite>Am J Med Genet A</cite></em> 2004 Oct 15;130A(3):221-7.</li><li>Rutter JL, Smith AM, D&#225;vila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12872252">Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.</a><em><cite>Hum Mutat</cite></em> 2003 Aug;22(2):121-8.</li><li>Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14569130">A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology.</a><em><cite>J Med Genet</cite></em> 2003 Oct;40(10):787-92. Erratum in: J Med Genet. 2004 Jan;41(1):51.</li><li>Kazerouni N, Schairer C, Friedman HB, Lacey JV Jr, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12414823">Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study.</a><em><cite>J Med Genet</cite></em> 2002 Nov;39(11):826-32.</li><li>Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman C, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10946349">Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families.</a><em><cite>Am J Med Genet</cite></em> 2000 Aug 14;93(4):257-63.</li></ul></div>]]></content>
  </row>
  <row para_id="302664" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=116&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391585" sys_variantid="1422" sys_contentid="302459">About REB</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=61&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391586" sys_variantid="1418" sys_contentid="401127">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">REB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=265&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302501" sys_dependentvariantid="1418" sys_dependentid="302501" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391587" sys_variantid="1418" sys_contentid="302501">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-training" title="">Research Training Opportunities</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302415" sys_dependentvariantid="1418" sys_dependentid="302415" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391588" sys_variantid="1418" sys_contentid="302415">Tenure-Track Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302426" sys_dependentvariantid="1418" sys_dependentid="302426" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391589" sys_variantid="1418" sys_contentid="302426">Staff Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302443" sys_dependentvariantid="1418" sys_dependentid="302443" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391590" sys_variantid="1418" sys_contentid="302443">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=REB">Publications</a></p>
</div>
<h3>Overview</h3>
<p>In the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=116&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7391579" sys_siteid="475" sys_variantid="1422">Radiation Epidemiology Branch</a> (REB), fellows receive training in radiation epidemiology, biostatistics, molecular epidemiology, radiation biology, and risk assessment of cancer from radiation exposure. Fellowships in the branch provide a unique opportunity to conduct research on populations exposed to a variety of ionizing and non-ionizing radiation sources. Fellows work with internationally known scientists, can work on multiple studies (see below), and can conduct research in collaboration with other investigators in the Division of Cancer Epidemiology and Genetics. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=265&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302501" sys_contentid="302501" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302501" sys_dependentvariantid="1418" sys_relationshipid="7391573" sys_variantid="1418">Meet the current fellows in the Radiation Epidemiology Branch</a>, and find out what they do.</p>
<p>For application details, see below. To discuss potential research opportunities, you may also contact <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">Branch investigators</a> directly.&nbsp;</p>
<h3>Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Individuals must hold an M.D. or Ph.D. in epidemiology or related field. Individuals with strong quantitative skills are encouraged to apply. Familiarity with statistical software such as SAS, Stata, SPSS, or Epicure, and genetic analysis software such as HaploStats/Haploview or SAS Genetics is also desirable, but not required. The software and approaches to analyzing genetic data are rapidly advancing so that certain tools may be more advantageous or appropriate, depending on the application.</p>
<p><i>Predoctoral fellowships:</i> Individuals must be enrolled in a doctoral program with a desire to complete their dissertation in the Radiation Epidemiology Branch (REB) or have completed a master's degree in a field of relevance to REB.</p>
<div class="callout-box right">
<h3>Radiation Epidemiology Course</h3>
<p>The next <strong>Radiation Epidemiology &amp; Dosimetry Course</strong> will be held September 9-12, 2019, at NCI Shady Grove, Rockville, Maryland. <a href="https://events.cancer.gov/2019RADEPI">Register for the Radiation Epidemiology &amp; Dosimetry Course</a>.</p>
<p>Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=937894" sys_contentid="937894" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="937894" sys_dependentvariantid="1418" sys_relationshipid="7391582" sys_siteid="475" sys_variantid="1418">2019 Radiation Epidemiology &amp; Dosimetry Course</a> and view videos and course content from the 2015 course.</p>
</div>
<h3>Application Process</h3>
<p>Predoctoral and postdoctoral fellowship applications in the Radiation Epidemiology branch are accepted on an ongoing basis. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7391574" sys_variantid="1418">Fellowship Information</a> page for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3 id="specific">Training Opportunities</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1142712" sys_contentid="1142712" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1142712" sys_dependentvariantid="1418" sys_relationshipid="7391583" sys_siteid="475" sys_variantid="1418">Postdoctoral Fellowships for Interdisciplinary Research in Radiation Epidemiology and Biostatistics</a></li>
</ul>
<p>Opportunities are available to work on multiple studies:</p>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302661" sys_contentid="302661" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302661" sys_dependentvariantid="1418" sys_relationshipid="7391575" sys_variantid="1418">Treatment-related second cancers</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302457" sys_contentid="302457" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302457" sys_dependentvariantid="1418" sys_relationshipid="7391576" sys_variantid="1418">Cancer risks associated with medical sources of ionizing radiation</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302552" sys_dependentvariantid="1418" sys_relationshipid="7391577" sys_variantid="1418">Cohort and case-control studies of selected cancers in the U.S. Radiologic Technologists cohort</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302434" sys_contentid="302434" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302434" sys_dependentvariantid="1418" sys_relationshipid="7391578" sys_variantid="1418">Studies in Japanese atomic bomb survivors</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303665" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303665" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7391584" sys_variantid="1418" sys_contentid="303665">Thyroid cancer risk factors and genetics</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303648" sys_contentid="303648" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303648" sys_dependentvariantid="1418" sys_relationshipid="7391580" sys_siteid="475" sys_variantid="1418">Cohort study of retinoblastoma survivors</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068" sys_contentid="1091068" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1091068" sys_dependentvariantid="1418" sys_relationshipid="7391581" sys_siteid="475" sys_variantid="1418">Radiation Dosimetry to Support Epidemiologic Studies</a></li>
</ul>
<h3>Training Opportunities in Radiation Epidemiology with Specific Investigators</h3>
<ul>
<li><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-specific#Chernobyl">Environmental Epidemiology Research on the Health Consequences of the Chernobyl Nuclear Accident - Postbaccalaureate (Masters level) or Postdoctoral Fellowship with Dr. Elizabeth Khaykin Cahoon</a></li>
<li><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-specific#Skin-Cancer">Skin Cancer Prevention and Etiology - Postdoctoral Fellowship with Dr. Elizabeth Khaykin Cahoon</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="302665" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>BLM is an R package for estimating absolute risk and risk differences from cohort data with a binomial linear or LEXPIT regression model.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302525" sys_contentid="302525" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317686" sys_dependentvariantid="1418" sys_dependentid="302525" rxinlineslot="103">ReadMe</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302408" sys_contentid="302408" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317687" sys_dependentvariantid="1418" sys_dependentid="302408" rxinlineslot="103">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul class="bullet-blu">
<li><a class="bodylink" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=303033" sys_contentid="303033" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317688" sys_dependentvariantid="1500" sys_dependentid="303033" rxinlineslot="103">blm_2011.1.3.tar.gz (535k)</a></li>
</ul>
<p>Save this file in an appropriate folder on your disk.</p>
<h3>Support:</h3>
<p><b>Questions?</b> Contact: <a href="mailto:katkih@mail.nih.gov?subject=blm">Dr. Hormuzd Katki</a></p>
</div>]]></content>
  </row>
  <row para_id="302670" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Occupational exposure to electromagnetic fields (EMF) has been linked with brain tumors based on job titles and industry. A multi-center U.S. case-control study of benign and malignant brain tumors investigated occupational exposure to EMF using a detailed, rigorous assessment strategy to improve exposure assessment for EMF, in conjunction with industrial hygienists in DCEG. Four exposure metrics were evaluated: (1) maximum exposed job; (2) total years of exposure &gt; 1.5 mG; (3) cumulative lifetime exposure; and (4) average lifetime exposure. No statistically significant elevation in odds ratios or trends in odds ratios across exposure categories were seen for glioma or meningioma.</p>
<p>For more information, contact&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7270694" sys_dependentvariantid="1965" sys_dependentid="1087122" rxinlineslot="103" sys_siteid="475">Elizabeth Cahoon</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7270695" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="302672" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">

<h3>IN.power R-Package</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The IN.power R-Package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>

</div>]]></content>
  </row>
  <row para_id="302680" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-ebp/bb">BB Home</a></h3>
<p><a title="" href="/about/organization/programs-ebp/bb/research-areas">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=BB">BB Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/bb-fellows">Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/bb-training">Research Training Opportunities</a></p>
<p><a title="" href="/about/organization/programs-ebp/bb/resources">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=BB">Publications</a></p>
<p><a title="" href="/news-events/events/bb-events">Seminars</a></p>
</div>
<p>Biostatistics Branch investigators develop statistical and computational tools for epidemiologic and laboratory studies, and distribute those tools to collaborators and the greater scientific community.</p>
<h2>BB Descriptive Epidemiology Resources</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=856668" sys_dependentvariantid="1418" sys_dependentid="856668" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297288" sys_variantid="1418" sys_contentid="856668">Age Period Cohort Analysis Web Tool</a></h3>
<p>A panel of easy-to-interpret estimable APC functions and corresponding Wald tests in R code that can be accessed through a user-friendly web tool.</p>
<h2>BB Risk Assessment Tools</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=939444" sys_dependentvariantid="1418" sys_dependentid="939444" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297289" sys_variantid="1418" sys_contentid="939444">BCRA R Package</a></h3>
<p>BCRA is an R package that projects absolute risk of invasive breast cancer according to NCI&rsquo;s Breast Cancer Risk Assessment Tool (BCRAT) algorithm for specified race/ethnic groups and age intervals.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302532" sys_dependentvariantid="1418" sys_dependentid="302532" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297290" sys_variantid="1418" sys_contentid="302532">Breast Cancer Risk Assessment SAS Macro (Version 4, Gail Model)</a></h3>
<p>A SAS macro (commonly referred to as the Gail Model) that projects absolute risk of invasive breast cancer according to NCI&rsquo;s Breast Cancer Risk Assessment Tool (BCRAT) algorithm for specified race/ethnic groups and age intervals.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302385" sys_dependentvariantid="1418" sys_dependentid="302385" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297291" sys_variantid="1418" sys_contentid="302385">Breast Cancer with Mammographic Density Risk Assessment SAS Macro</a></h3>
<p>A SAS macro that projects absolute invasive breast cancer risk for white women based on measurements of mammographic density and other risk factors.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=595704" sys_dependentvariantid="1418" sys_dependentid="595704" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297292" sys_variantid="1418" sys_contentid="595704">Breast, Endometrial, and Ovarian Risk Assessment SAS Macros</a></h3>
<p>Software that projects absolute risk for breast, endometrial, and ovarian cancer in Caucasian and African American women.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302665" sys_dependentvariantid="1418" sys_dependentid="302665" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297293" sys_variantid="1418" sys_contentid="302665">BLM (Binomial Linear Model) - R Package</a></h3>
<p>BLM is an R package for estimating absolute risk and risk differences from cohort data with a binomial linear or LEXPIT regression model.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302422" sys_dependentvariantid="1418" sys_dependentid="302422" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297294" sys_variantid="1418" sys_contentid="302422">Asian Pacific Islander American Women - Breast Cancer Risk Assessment SAS Macro</a></h3>
<p>Software that projects absolute breast cancer risk over defined age intervals for Asian and Pacific Islander American women with specific risk factors.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302400" sys_dependentvariantid="1418" sys_dependentid="302400" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297295" sys_variantid="1418" sys_contentid="302400">CARE Model SAS Macro: Breast Cancer Risk Assessment for African American Women</a></h3>
<p>The CARE Model is a SAS macro that allows researchers to estimate an African American woman's risk of developing invasive breast cancer over specified age intervals.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302628" sys_dependentvariantid="1418" sys_dependentid="302628" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297296" sys_variantid="1418" sys_contentid="302628">Colon Cancer Risk Assessment - Gauss Program</a></h3>
<p>An executable file (in GAUSS) that projects absolute colon cancer risk (with confidence intervals) according to NCI&rsquo;s Colorectal Cancer Risk Assessment Tool (CCRAT) algorithm. GAUSS is not needed to run the program.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302539" sys_dependentvariantid="1418" sys_dependentid="302539" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297297" sys_variantid="1418" sys_contentid="302539">Colon Cancer Risk Assessment - SAS Macro</a></h3>
<p>A SAS macro that projects absolute risk of colon cancer according to NCI&rsquo;s Colorectal Cancer Risk Assessment Tool (CCRAT) algorithm.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1067861" sys_dependentvariantid="1418" sys_dependentid="1067861" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297298" sys_variantid="1418" sys_contentid="1067861">Lung Cancer Risk Models for Screening (R package: lcrisks)</a></h3>
<p>In both the absence and presence of screening, the R package lcrisks, calculates individual risks of lung cancer and lung cancer death based on covariates: age, education, sex, race, smoking intensity/duration/quit-years, Body Mass Index, family history of lung-cancer, and self-reported emphysema. In the presence of CT screening akin to the NLST (3 yearly screens, 5 years of follow-up), it uses the covariates to estimate risk of false-positive CT screen as well as the reduction in risk of lung cancer death and increase in risk of lung cancer screening.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=501305" sys_dependentvariantid="1418" sys_dependentid="501305" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297299" sys_variantid="1418" sys_contentid="501305">Thyroid Cancer Risk Assessment Tool (tcrat)</a></h3>
<p>The R package thyroid implements a risk prediction model developed by NCI researchers to calculate the absolute risk of developing a second primary thyroid cancer (SPTC) in individuals who were diagnosed with a cancer during their childhood.</p>
<h2>BB Analysis Tools</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=856668" sys_dependentvariantid="1418" sys_dependentid="856668" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297300" sys_variantid="1418" sys_contentid="856668">Age Period Cohort Analysis Web Tool</a></h3>
<p>A panel of easy-to-interpret estimable APC functions and corresponding Wald tests in R code that can be accessed through a user-friendly web tool.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302436" sys_dependentvariantid="1418" sys_dependentid="302436" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297301" sys_variantid="1418" sys_contentid="302436">Adaptive Rank Truncated Product - Version 2 (ARTP2)</a></h3>
<p>ARTP2 is an R package of biological pathway analysis or pathway meta-analysis for genome-wide association studies (GWAS). It also provides tools for gene-level test as a special case. ARTP2 is an enhanced version of two previously released packages ARTP and AdaJoint.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302635" sys_dependentvariantid="1418" sys_dependentid="302635" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297302" sys_variantid="1418" sys_contentid="302635">Association analysis based on SubSETs (ASSET)</a></h3>
<p>A subset-based approach improves power and interpretation for combined analysis of genetic assocation studies of heterogeneous traits.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302485" sys_dependentvariantid="1418" sys_dependentid="302485" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297303" sys_variantid="1418" sys_contentid="302485">BaDGE (Bayesian model for Detecting Gene Environment interaction)</a></h3>
<p>Bayesian model for Detecting Gene Environment interaction</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=725733" sys_dependentvariantid="1418" sys_dependentid="725733" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297304" sys_variantid="1418" sys_contentid="725733">Bayesian Subset Regression (BSR)</a></h3>
<p>BSR (Bayesian Subset Regression) is an R package that implements the Bayesian subset modeling procedure for high-dimensional generalized linear models.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=753548" sys_dependentvariantid="1418" sys_dependentid="753548" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297305" sys_variantid="1418" sys_contentid="753548">CBRM</a></h3>
<p>An R package for testing Calibration of Binary Risk Model (CBRM) using different goodness-of-fit statistics</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302535" sys_dependentvariantid="1418" sys_dependentid="302535" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297306" sys_variantid="1418" sys_contentid="302535">CGEN R Package</a></h3>
<p>CGEN (Case-control.Genetics) is an R package for analyzing genetic data on case-control samples, with particular emphasis on novel methods for detecting Gene-Gene and Gene-Environment interactions.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302604" sys_dependentvariantid="1418" sys_dependentid="302604" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297307" sys_variantid="1418" sys_contentid="302604">CNVfam</a></h3>
<p>CNVfam is a software package for jointly detecting copy number variations (CNV) in nuclear families genotyped using the Illumina platform.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302621" sys_dependentvariantid="1418" sys_dependentid="302621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297308" sys_variantid="1418" sys_contentid="302621">CompareTests</a></h3>
<p>CompareTests is an R package to estimate agreement and diagnostic accuracy statistics for two diagnostic tests when one is conducted on only a subsample of specimens. A standard test is observed on all specimens.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420656" sys_dependentvariantid="1418" sys_dependentid="420656" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297309" sys_variantid="1418" sys_contentid="420656">CRaVe</a></h3>
<p>Software package designed to perform a range of association tests between sets of SNPs and a phenotype.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302598" sys_dependentvariantid="1418" sys_dependentid="302598" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297310" sys_variantid="1418" sys_contentid="302598">Extremely small Pvalue Evaluation for Resampling-based Test</a></h3>
<p>This is a R package for rapid evaluation of extremely small p-value for resampling-based test (EXPERT).</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=746739" sys_dependentvariantid="1418" sys_dependentid="746739" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297311" sys_variantid="1418" sys_contentid="746739">Het-Tree</a></h3>
<p>This is the R package implementing the testing procedure described in the referred manuscript</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=1028461&amp;sys_revision=11&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1028461" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297320">iCARE: An R package to compute Individualized Coherent Absolute Risk Estimators</a></h3>
<p>The iCARE R Package allows researchers to quickly build models for absolute risk, and apply them to estimate an individual's risk of developing disease during a specifed time interval, based on a set of user defined input parameters.</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302487&amp;sys_revision=8&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302487" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297321">INPower</a></h3>
<p>IN.power is an R package for estimating the number of susceptibility SNPs and power of future studies.</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302455&amp;sys_revision=7&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302455" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297322">KinCohort</a></h3>
<p>Different approaches for handling varied error structures in studies of irradiated populations</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302523&amp;sys_revision=4&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302523" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297323">MultAssoc</a></h3>
<p>MultiAssoc is a MATLAB software package for test of association of a disease with a group of SNPs after accounting for their interaction with another group of SNPs or environmental exposures.</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302537&amp;sys_revision=8&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302537" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297324">Nested Cohort</a></h3>
<p>NestedCohort is an R software package for fitting Kaplan-Meier and Cox Models to estimate standardized survival and attributable risks for studies where covariates of interest are observed on only a sample of the cohort.</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302592&amp;sys_revision=6&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302592" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297325">segCNV</a></h3>
<p>SegCNV is a software package, implemented in C++, to detect germline copy number variations in SNP array data.</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=751494&amp;sys_revision=3&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="751494" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297326">TREAT (TREe-based Association Test)</a></h3>
<p>TREAT is an R package for detecting complex joint effects in case-control studies. The test statistic is derived from a tree-structure model by recursive partitioning the data. Ultra-fast algorithm is designed to evaluate the significance of association between candidate gene and disease outcome</p>
<h2>BB Study Design &amp; Planning Tools</h2>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302660&amp;sys_revision=6&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302660" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297327">POWER V3.0 Software</a></h3>
<p>POWER V3.0 Software is used for computing sample size and power for binary outcome studies.</p>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=302567&amp;sys_revision=10&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302567" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297328">Power for Genetic Association Analyses (PGA)</a></h3>
<p>PGA is a software package containing algorithms and graphical user interfaces developed in Matlab for power and sample size calculation under various genetic models and statistical constraints.</p>
</div>]]></content>
  </row>
  <row para_id="302681" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<ul>
<li>1. Download and install R packages <a href="http://cran.r-project.org/web/packages/mvtnorm/index.html" target="_blank" rel="noopener noreferrer">mvtnorm</a> if not already installed.</li>
<li>2. Download zip or tar.gz file for your operating system from the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302487" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302487" sys_dependentvariantid="1418" sys_relationshipid="7276094" sys_siteid="475" sys_variantid="1418" sys_contentid="302487">download</a> page.</li>
<li>3. Install from R (GUI) package installer or using the install.packages() function, e.g., install.packages(&ldquo;C:/temp/in.power_1.0.0.zip&rdquo;, repos=NULL)</li>
<li>4. Load the IN.power package from the GUI or with the command library(IN.Power)</li>
<li>5. Type INPower in R console to access help files and package manual</li>
</ul>
<h3>Description</h3>
<p>This function uses the effect sizes for a set of known susceptibility SNPs and the power of detection of these SNPs from the original discovery samples to obtain an estimate of the total number of underlying susceptibility SNP for that trait and the distribution of their effect sizes. The function can further use the estimated number of loci and distribution of effect sizes to evaluate the power for discovery of a future GWAS study (up to three-stage).</p>
<h3>Author(s):</h3>
<p>Ju-Hyun Park, Nilanjan Chatterjee and William Wheeler</p>
<h3>References:</h3>
Park J-H, Wacholder S, Gail M, Peters U, Jacobs K, Chanock S, Chatterjee N. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. <cite>Nature Genetics,</cite> 2010, 42, pp.570-575.</div>]]></content>
  </row>
  <row para_id="302684" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>BaDGE</h3><p><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><b>This is a trial version of the software</b>. The BaDGE software may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p></div>]]></content>
  </row>
  <row para_id="303538" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators are studying risk of anal cancer in HIV-positive men who have sex with men. They have established a cohort of 370 HIV-positive men through the Kaiser Permanente Northern California (KPNC) health maintenance program. Under written, informed consent, participating KPNC members responded to a self-administered risk factor questionnaire and underwent two anal specimen collections, using liquid-based cytology (LBC) medium, as well as a digital exam and high resolution anoscopy. Participants were followed annually for two years to collect follow-up clinical data related to outcomes.&nbsp;</p>
<p>Baseline clinician-collected specimens were tested in a masked fashion for the following clinical biomarkers: 1) carcinogenic HPV DNA in aggregate and individual carcinogenic HPV genotypes; 2) carcinogenic HPV RNA and HPV16/18 RNA; 3) p16INK4a and Ki-67 immunocytochemical staining. For reference, clinician-collected specimens are being used to make LBC slides and for evaluation by an expert cytopathology laboratory. Investigators are estimating the HPV genotype-specific risk and the clinical performance (sensitivity, specificity, positive and negative predictive values, and referral rates) of individual tests and combinations of tests for detection of prevalently-detected, one-year cumulative, and two-year cumulative histologically-confirmed anal precancer (anal intraepithelial neoplasia grade 3) or worse (=AIN3).</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22%28Wentzensen%2C%20Nicolas%22[Author%20-%20Full]%20AND%20%28%22anal%20cytology%22[Title/Abstract]%20OR%20%22anal%20cancer%22[Title/Abstract]%20OR%20%22anal%20precancer%22[Title/Abstract]%29&amp;cmd=DetailsSearch">View publications related to Anal Precancer and Cancer in HIV-Positive Men (Anal Cancer Screening Study)</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270699" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_relationshipid="7270700" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303539" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>To better understand the etiology of rare cancers that form in the biliary tract (bile duct, gallbladder, ampulla of Vater), DCEG researchers are conducting studies to examine the molecular and epidemiologic characteristics of cancer at different sites in the biliary tract and identify potential molecular subtypes. Tumor and other biologic samples are compiled from various efforts in China and Chile, where incidence of these cancers is higher than in the United States.</p>
<p>As more samples and accompanying exposure information are collected, investigators are able to study increasingly rare subtypes with cutting-edge techniques to determine the epidemiologic and molecular contributors to the development of biliary tract cancers. A better understanding of the molecular differences across these malignancies can lead to more precise diagnosis and effective treatment, as well as provide clues as to etiology.</p>
<p>Studies include:</p>
<h2>Chile Biliary Longitudinal Study (Chile BiLS)</h2>
<p>The Chile Biliary Longitudinal Study (Chile BiLS) is a cohort of women diagnosed with gallstones in an area of Chile with high risk for gallbladder cancer. The purpose of this study is to explore the etiology and natural history of gallbladder dysplasia and biliary cancer, identify potential non-invasive risk stratification methods, such as inflammatory markers, and develop strategies for prevention.</p>
<h2>Biliary Tract Cancer Pooling Project (BiTCaPP)</h2>
<p>The Biliary Tract Cancer Pooling Project (BiTCaPP) is an international study involving 28 cohorts with over 4,500 biliary tract cancer cases from over 2.8 million participants. This resource allows for the prospective evaluation of risk factors. BiTCaPP is the first effort of its kind for the joint evaluation of cancers throughout the biliary tract and offers great promise for a more definitive understanding of the etiology of cancer across the entire biliary tract.</p>
<h2>Cholecystectomy Risk Stratification (CRS) Study</h2>
<p>The Cholecystectomy Risk Stratification (CRS) Study is a cross-sectional study of 1645 cholecystectomy patients with pre-surgery blood recruited from hospital wards in Chile. This study allows the evaluation of circulating blood markers to assess their potential for risk stratification. Current work is focused on circulating inflammatory markers.</p>
<h2>Shanghai Biliary Tract Cancer Study</h2>
<p>The Shanghai Biliary Tract Cancer Study is a case-control study conducted in China, including 627 BTC cases, 1,037 patients with biliary stones, and 959 population-based controls. This study allows cross-sectional evaluation of biologic markers and epidemiologic risk factors for gallbladder, extrahepatic bile duct, and ampulla of Vater cancer.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349671" sys_contentid="349671" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349671" sys_dependentvariantid="1965" sys_relationshipid="7276863" sys_variantid="1965">Jill Koshiol</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7276864" sys_variantid="1418">Infections and Immunoepidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303543" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG conducted a large interdisciplinary case-control study of bladder cancer (1,200 cases and 1,200 controls) in 18 hospitals from five different regions in Spain. This effort was a collaboration between investigators in DCEG's Occupational and Environmental Epidemiology Branch (OEEB) and investigators from the Centre for Research in Environmental Epidemiology (CREAL) in Barcelona and Centro Nacional de Investigaciones Oncologicas (CNIO) in Madrid, Spain. A computer-aided personal interview (CAPI) system was developed to collect detailed information on tobacco use (black or blond), occupational and environmental exposures, medical history and drug use, family history and diet. Blood collection and processing allowed for testing for genetic susceptibility markers such as <i>CYP1A1</i>, <i>NAT1</i>, <i>NAT2</i>, <i>GSTM1</i>, DNA repair capacity, and mutagen sensitivity.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270704" sys_dependentvariantid="1965" sys_dependentid="349599" rxinlineslot="103">Dr. Debra Silverman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270705" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303546" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Osteosarcoma, the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged 60 and older. Most osteosarcoma epidemiology studies have been embedded in large analyses of bone tumors in general, all histologic subtypes combined, or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival in particular, with direct comparisons among patients of all ages and ethnicities, are not available. Investigators in DCEG have completed and published several analyses of cancer registry data from the National Cancer Institute's population-based Surveillance, Epidemiology, and End Results (SEER) Program from U.S. (SEER) and international cancer registries, to more fully characterize the descriptive epidemiology of osteosarcoma.</p>
<p>From NCI/SEER, investigators identified frequency, incidence, and survival rates for 3,482 patients with osteosarcoma diagnosed between 1973 and 2004. They described these cases by age, race, sex, pathology subtype, stage, and anatomic site. There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage, and did not improve significantly from 1984 to 2004. In this comprehensive, population-based description of osteosarcoma, investigators identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology.</p>
<p>The international patterns of osteosarcoma incidence in children have been described, whereas those for young, middle age or elderly adults have not. Using the Cancer Incidence in Five Continents, International Agency for Cancer Research database,&nbsp;DCEG investigators compared incidence rates for children and adolescents (age 0-24 years), the middle age group (25-59 years) and elderly (&gt; or = 60 years) persons by world regions and individual countries. Overall, worldwide osteosarcoma incidence rates were quite similar in the younger age groups. The greatest variation in incidence rates was observed in the elderly.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=osteosarcoma&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Osteosarcoma Study-Related Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270706" sys_dependentvariantid="1965" sys_dependentid="639592" rxinlineslot="103">Lisa Mirabello</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270707" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303550" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>A Case-Control Study of Osteosarcoma</h2>
<p>As part of a case-control study of osteosarcoma&nbsp;initiated in 1995 between the NCI and the Harvard Dental School (the Bone Disease and Injury Study of Osteosarcoma [BDISO]), DCEG investigators have studied genetic variation in many genes potentially important in growth pathways. They identified a small haplotype block that was associated with two-fold increase in risk of&nbsp;osteosarcoma in the <i>IGF2R</i> gene. This region (around exon 16) consisted of CpG islands, and functional analysis of the SNPs in this block suggested that a SNP associated with&nbsp;osteosarcoma risk results in differential methylation at that SNP site.&nbsp;</p>
<p>Although most cases of&nbsp;osteosarcoma are sporadic, it is also a prototypic syndrome-related malignancy in the Li-Fraumeni syndrome; germline <i>TP53</i> mutations are the primary genetic basis for this rare disorder. Therefore, we investigated the role of germline genetic variation in <i>TP53</i> as risk factors for sporadic osteosarcoma. Although our data did not indicate a strong link between variation in <i>TP53</i> and&nbsp;osteosarcoma risk, they did provide preliminary evidence suggesting an increased risk of&nbsp;osteosarcoma associated with <i>TP53</i> variants IVS2+38 and Pro72Arg. While this was a small study, genetic variation across the <i>TP53</i> gene was thoroughly investigated. Genetic variants in telomere maintenance genes are the focus of ongoing analysis. Preliminary data suggest a possible protective effect associated with specific variants in several different telomere pathway genes.&nbsp;</p>
<p>A formal meta-analysis of this plus other published osteosarcoma case-control studies is now underway, under the leadership of&nbsp;DCEG investigators. It will focus on a pooled analysis of birth weight, birth length and height as&nbsp;osteosarcoma risk factors.&nbsp;</p>
<p>As a follow-up to these pilot observations, subjects from the BDISO case-control study were genotyped as part of DCEG's Rare Cancer iSelect project. Comprehensive analysis of more than 25,000 variants in several hundred carcinogenesis-related candidate genes and pathways is being conducted. Increased statistical power will be achieved through pooling of control subjects obtained from other DCEG studies, after careful correction for population stratification. Analysis of these data is currently underway.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=osteosarcoma&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Osteosarcoma Study-Related&nbsp;Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="639592" sys_dependentvariantid="1965" sys_relationshipid="7270714" sys_siteid="475">Lisa Mirabello</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7270715" sys_siteid="475">Clinical Genetics Branch&nbsp;- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303551" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators are currently collaborating with U.S. Children's Oncology Group (COG) investigators from the University of Minnesota, in the implementation and conduct of specimen collection from newly-diagnosed osteosarcoma patients now enrolling on various COG protocols. Epidemiologic data are also being collected. This project is employing a parent/affected offspring ("trio") design, and data collection is underway.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=osteosarcoma&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Osteosarcoma Study-Related Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270716" sys_dependentvariantid="1965" sys_dependentid="639592" rxinlineslot="103">Lisa Mirabello</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270717" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics&nbsp;Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303559" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Closed to Patient Enrollment, Data Analysis Ongoing</h2>
<p>Women who are at high genetic risk of cancer because they have a mutation in one of the BReast CAncer susceptibility genes, <i>BRCA1</i> or <i>BRCA2</i>, are at increased risk of developing breast cancer. Many high-risk women develop breast cancer before the age of 50. For these women, cancer risk is managed through vigilant surveillance, in hopes of identifying the disease at an early stage. The Breast Imaging Study evaluated the use of several new, promising breast cancer screening techniques in women at high genetic risk of breast cancer. These techniques include magnetic resonance imaging (MRI) and breast duct lavage (BDL) and/or nipple aspiration. This study has completed accrual and follow-up. Investigators found no differences in mammographic density between <i>BRCA</i> mutation carriers and non-carriers, and demonstrated that breast duct lavage is an unsatisfactory clinical procedure. Data from this cohort led to the development of a novel breast MRI imaging phantom and has been used to identify novel breast imaging features (e.g., &ldquo;texture&rdquo;) which may permit discrimination between mutation-negative and mutation-positive women.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=533930" sys_contentid="533930" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="533930" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7270721" sys_variantid="1418">View breast imaging study publications</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349675" sys_contentid="349675" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349675" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7270719" sys_variantid="1965">Jennifer Loud</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7270720" sys_variantid="1418">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303561" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Columbia, Missouri serum bank was established as part of the National Cancer Institute&rsquo;s Biological Markers Project to identify serum markers for breast cancer. A total of 7,224 women living in and around Columbia, MO who were free of cancer other than non-melanoma skin cancer, donated blood to the serum bank on one or more occasions between 1977 and 1987. Approximately 25% of the women were premenopausal. At the time of each blood collection, interview information was obtained from participants on the major known breast cancer risk factors including age, height, weight, reproductive and menstrual histories, family history of breast cancer, medical conditions, and drug use, including oral contraceptives and menopausal hormone therapy. Date of last menstrual period was obtained for women who were premenopausal at the time of each blood collection. Approximately 30% of the women donated multiple samples over the first 10 years of the study, including 20% who had 3 or more samples, with collections occurring on average one year apart. In 1989, the first follow-up ascertained 107 breast cancers among women who were cancer-free at blood collection. A subset of these breast cancers was included in a number of biomarker studies, including the measurement of sex steroid hormones, carotenoids, alpha-tocopherol, selenium, organochlorine pesticides and PCBs. A more recent follow-up was completed in 2002, at which time an additional 279 breast cancers were identified.</p>
<p>Using the expanded group of breast cancer cases in the Columbia, MO Serum Bank Follow-up Study, additional biomarker studies have been conducted, including how adipokines relate to breast cancer risk factors. These analyses showed lower levels of adiponectin and higher levels of absolute plasminogen activator inhibitor (aPAI-1) were associated with increasing body mass index, but not with breast cancer risk. In more recently completed analyses, a newly developed tandem mass spectrometry assay was used to measure a panel of 15 estrogens and estrogen metabolites in relation to postmenopausal breast cancer risk. This showed that both a higher ratio of the 2/16 hydroxylation pathway and of the ratios of 2- or 4- hydroxylation were associated with reduced breast cancer risk. These findings support that analyses of metabolic pathways may help elucidate the role of estrogen metabolism in breast carcinogenesis.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=848053" sys_contentid="848053" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="848053" sys_dependentvariantid="1418" sys_relationshipid="7270726" sys_siteid="475">View publications related to the Columbia, Missouri Serum Bank Follow-up Study</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349652" sys_dependentvariantid="1965" sys_relationshipid="7270727" sys_siteid="475">Gretchen Gierach</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="420600" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7270728" sys_variantid="1418" sys_contentid="420600">Integrative Tumor Epidemiology Branch- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303562" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Breast Cancer Detection Demonstration Project Follow-up Study involves approximately 64,000 women who were participants in the Breast Cancer Detection Demonstration Project, a 5-year screening program conducted between 1973 and 1980 at 29 centers throughout the United States. The follow-up study began in 1980 and follow-up continued through 2005. Information on cancer diagnoses, benign breast procedures, and exposure to established and hypothesized cancer risk factors has been ascertained through questionnaires administered over the course of the follow-up study. Researchers are analyzing exogenous hormones, lifestyle factors, and other risk factors for breast, ovarian, endometrial, and colorectal cancers.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349652" sys_relationshipid="7270729" sys_variantid="1965">Gretchen Gierach</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1074440" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1074440" sys_relationshipid="7270731" sys_variantid="1965" sys_contentid="1074440">Catherine Schairer</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="420600" sys_relationshipid="7270730" sys_variantid="1418">Integrative Tumor Epidemiology Branch- Research Areas</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1033621" sys_relationshipid="7270732" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303564" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Terminal duct lobular units (TDLUs)&mdash;also referred to as lobules&mdash;are epithelial structures within the breast that produce milk during lactation; they are also the primary anatomical source of most breast cancer precursors and cancers. With completion of childbearing and physiological aging, TDLUs involute (shrink), resulting in a reduction in the number of acini (epithelial substructures) per TDLU and total TDLU counts. Delayed age-appropriate TDLU involution could be associated with increased breast cancer risk because of a higher amount of &ldquo;at-risk&rdquo; epithelium.&nbsp;</p>
<div sys_dependentvariantid="2066" sys_dependentid="840888" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7130381">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Side view of normal breast anatomy includes chest wall and muscle, lobes with lobules, ducts, nipple and areola. Inset close-up of acini, which are found in lobules." src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302177&amp;sys_siteid=475&amp;sys_contentid=840888&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302177&amp;sys_siteid=475&amp;sys_contentid=840888&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="840888">Enlarge</a></div>
</figure>
</div>
<p>We are conducting molecular epidemiologic studies of TDLU involution, which could provide insights into early carcinogenic events. We are performing these studies&nbsp;in collaboration with the Susan G. Komen&reg; Tissue Bank at the Indiana University Simon Cancer Center (KTB)&mdash;a unique resource of normal breast tissues, questionnaire data, saliva, and blood donated by volunteers for use in research. Quantitative measures of TDLU involution have been annotated on 1938 women ages 18-74 from this repository without any evidence of breast cancer. The aims of this study are to assess how breast cancer risk factors relate to TDLU involution, which could clarify the natural history of the disease and could lead to novel strategies for risk assessment, early detection and prevention.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349652" sys_variantid="1965" sys_relationshipid="7130378">Gretchen Gierach</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=420600&amp;sys_revision=37&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="420600" sys_folderid="" sys_relationshipid="7130382">Integrative Tumor Epidemiology Branch- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303565" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>Several studies are designed to evaluate the possible role of occupational and environmental factors in the origin of breast cancer. In collaboration with the Michigan Department of Health and the Centers for Disease Control, a case-control study of breast cancer and benign breast disease is being conducted in a cohort of women accidentally exposed to polybrominated biphenyls (PBB) in the mid-1970s. The risk of breast cancer and benign breast disease will be related to PBB in serum from bloods collected at the time of the exposure. Occupational and Environmental Epidemiology Branch investigators are collaborating in case-control studies of breast cancer in Mexico and Alaska to evaluate the hypothesized relationship between serum levels of DDT and the risk of breast cancer. Evaluation of breast cancer and occupational exposures is occurring in a hospital-based case-control study at an oncologic hospital in Turkey and a study in Warsaw and Lodz, Poland.</p><p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1965&amp;sys_revision=4&amp;sys_contentid=349624&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349624" sys_dependentvariantid="1965" sys_folderid="" sys_relationshipid="2740314" sys_siteid="475">Mary Ward</a>.</p><p><a href="/Rhythmyx/assembler/render?sys_contentid=418935&amp;sys_revision=8&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="2740323" sys_siteid="475">Occupational and Environmental Epidemiology Branch - Research Areas</a></p></div>]]></content>
  </row>
  <row para_id="303566" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This population-based case-control study was conducted from 2000-2003 in two major cities in Poland, Warsaw and Lodz, and enrolled 2,386 breast cancer cases and 2,798 age and site matched controls. The study utilized state-of-the art exposure assessment techniques, including detailed personal interviews, anthropometric measurements, physical activity monitors, and collection of dust samples from the participants&rsquo; homes. In order to facilitate study of a wide range of biomarkers, biological specimen collection included blood samples processed as cryopreserved whole blood, serum+ blood clot, plasma+buffy coat+red blood cells; 12-hour overnight urine; paraffin-embedded tumor and normal tissue; and fresh tissue from tumors, non-neoplastic breast tissue, and mammary fat tissue.</p>
<p>Investigators in DCEG obtained ten-year follow-up information from medical records for approximately 1,300 breast cancer cases recruited in Warsaw and 300 cases recruited in Lodz, as well as mortality data on most cases in the study using the Cancer Registry and Death Certificate Office database in Poland. The main research projects being conducted include:</p>
<ul>
<li>Analyses of questionnaire-based factors and anthropometric/physical activity measurements in relation to cancer risk and clinical outcomes;</li>
<li>Identifying genetic susceptibility markers of cancer risk and clinical outcomes using candidate gene and genome-wide association (GWAS) approaches;</li>
<li>Analyses of breast tissue/tumor markers to evaluate relationships with cancer risk factors (known or suspected), and their impact on predicting recurrence and survival after diagnosis;</li>
<li>Analyses of biomarkers in DNA (somatic changes), cryopreserved blood cells, serum/plasma, and urine in relationship to cancer risk and clinical outcomes</li>
</ul>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" sys_contentid="1004366" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7270747" rxinlineslot="103" sys_dependentid="1004366" sys_dependentvariantid="1965" sys_siteid="475">Montserrat Garc&iacute;a-Closas</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7270748" rxinlineslot="103" sys_dependentid="420600" sys_dependentvariantid="1418" sys_siteid="475">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303567" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Investigators in DCEG are currently collaborating with colleagues in NCI&rsquo;s Breast Cancer Surveillance Consortium at the University of Vermont, the University of California at San Francisco, and in NCI&rsquo;s Division of Cancer Control and Population Sciences, on the Breast Radiology Evaluation and Study of Tissues (or &ldquo;BREAST&rdquo;) Stamp Project. A total of 466 women ages 40-65 years who were clinically referred to radiologically-guided breast biopsy were enrolled from fall 2007 through summer 2010. The BREAST Stamp Project aims to characterize the radiologic, histologic, molecular, and biochemical features of dense breast tissue and to understand how the microenvironment of dense breasts promotes neoplastic transformation of the breast epithelium. Risk factor data and biological specimens (blood, buccal cells, tissue fluids, and tissue) required to discover mechanisms and biomarkers that link high mammographic density (as measured quantitatively using computerized methods) to breast cancer risk were collected from study participants.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349652" sys_dependentvariantid="1965" sys_relationshipid="7270749" sys_siteid="475" sys_variantid="1965">Gretchen Gierach</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="420600" sys_dependentvariantid="1418" sys_relationshipid="7270750" sys_siteid="475" sys_variantid="1418">Integrative Tumor Epidemiology Branch- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303569" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Mammographic breast density, the radiological representation of the fibroglandular composition of the breast, is one of the strongest risk factors for breast cancer. Epidemiologic evidence suggests that changes in breast density are related to changes in breast cancer risk. Ultrasound tomography (UST) is a novel radiological method that provides a three-dimensional image of the breast. Collaborators at Karmanos Cancer Institute have developed a UST device that allows the calculation of sound speed, an objective physical measurement that is positively correlated with breast density. Thus, UST offers the possibility of determining breast density serially over time as a volume, without compression of the breast or exposure to potentially harmful ionizing radiation.&nbsp;</p>
<p>In collaboration with researchers at Karmanos Cancer Institute and the University of Toronto, DCEG investigators are using UST to define the time course of volumetric breast density changes among women receiving tamoxifen treatment. Tamoxifen is known to reduce breast density and breast cancer risk. Investigators enrolled women receiving tamoxifen for atypical lobular or ductal hyperplasia, lobular or ductal carcinoma <i>in situ</i>, or invasive breast cancer at Karmanos Cancer Institute to undergo repeated volumetric breast density assessment with UST. Investigators are assessing whether UST examinations performed as early as 1-3 months following initiation of tamoxifen can identify women whose breast density is demonstrated to have declined at one year using mammography. For comparison, they enrolled age-, race-, and menopausal status-matched women without breast cancer to assess changes in UST density over time without tamoxifen exposure. Risk factor data and blood have also been collected from study participants. The broader study objective is to assess the concept of breast density as a biosensor of tamoxifen response and UST as a useful tool for making this determination.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270759" sys_dependentvariantid="1965" sys_dependentid="349652" rxinlineslot="103">Gretchen Gierach</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="420600" rxinlineslot="103" sys_relationshipid="7270760" sys_variantid="1418" sys_contentid="420600">Integrative Tumor Epidemiology Branch- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303570" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Investigators in DCEG conducted a population-based case-control study of breast cancer to address a number of etiologic hypotheses best addressed among younger women, including effects on risk of oral contraceptive usage, dietary and physical activity patterns early in life, and prenatal factors. The study was conducted in three different geographic areas: Atlanta, New Jersey, and Seattle. Controls were identified through random digit dialing, although one site also employed a series of women identified through a complex area survey sampling technique. The majority of the subjects were younger than 45 years of age, although the age range was extended at one site to 55 years to allow a broader perspective on several issues. Detailed interviews and anthropometric measurements were undertaken. Pre-operative blood samples were obtained at one site from early stage cases and controls.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349664" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="349664" rxinlineslot="103" sys_relationshipid="7270762" sys_variantid="1965" sys_contentid="349664">Robert Hoover</a>.</p>
</div>]]></content>
  </row>
  <row para_id="303573" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Investigators in DCEG and the Division of Cancer Prevention conducted a study of the clinical management of minor cervical cytologic abnormalities. The major hypothesis tested was whether HPV testing could be used reliably and accurately to triage the common cytologic diagnoses of ASC-US (atypical squamous cells of undetermined significance) and LSIL (low-grade squamous intraepithelial lesions), which represent the bulk of cervical abnormalities seen on Pap smears. &#160;&#160;This clinical trial of management alternatives consisted of three arms: immediate colposcopic referral of all patients; triage using HPV testing as an adjunct to cytology; and conservative management with repeat Pap smears. All participants were followed every six months for two years. Over 5,000 women were randomized during enrollment that ended in December, 1998. The data showed that HPV DNA testing is a viable strategy for clarifying ASC-US cytology. However, HPV DNA prevalence in cases of LSIL proved too uniformly high to permit use of HPV DNA testing for triage. &#160;Residual specimens from ALTS are being used to validate new HPV tests, and to explore natural history questions.</p>

<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349609" sys_dependentvariantid="1965" sys_relationshipid="7270779" sys_siteid="475" sys_variantid="1965" sys_contentid="349609">Mark Schiffman</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349668" sys_dependentvariantid="1965" sys_relationshipid="7270781" sys_siteid="475" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7270780" sys_siteid="475" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303575" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Researchers now know that human papillomavirus (HPV) infection is the necessary but not sufficient cause of cervical cancer. Cervical pathogenesis evolves as follows: normal cervical tissue, to oncogenic HPV infection, to precancer and then to invasive cancer. The majority of women with oncogenic HPV infections will not develop cancer, and most HPV infections, even those with associated cellular changes, regress in 1-2 years, probably eradicated or controlled by cellular immune response. Moreover, while invasive cancer and precancer are histologically well-defined, the histological classification of low-grade lesions, now better defined as HPV infection, is very heterogeneous and poorly reproducible. Identifying women at highest risk for cancer prior to neoplastic progression is therefore a challenge. At present, researchers are unable to predict with any accuracy which HPV infections will progress and which are among the majority that regress. It is therefore of etiologic interest and of public health benefit to develop a method for identifying the HPV-infected women at risk for progressing to precancer and invasion.</p>
<p>In order to develop an accurate and reproducible division of precursor lesions (HPV infection and precancer), researchers must gain knowledge about the molecular distinctions at each progressive disease state. The goal of SUCCEED (Study to Understand Cervical Cancer Early Endpoints and Determinants) is to comprehensively assess biomarkers of risk for progressive cervical neoplasia, and thus develop biomarkers that can distinguish those at highest risk of cervical cancer from those with benign infection.</p>
<p>Investigators in DCEG have implemented a cross-sectional study to develop a comprehensive list of potential biomarkers by examining biospecimens and cervical tissues from over 2,500 women with HPV infection, precancer, and cancer. Several HPV-based markers, including HPV genotyping and detection of HPV integration have been evaluated in SUCCEED. A major focus is the evaluation of gene expression profiles to gain an accurate and comprehensive <i>in vivo</i> picture of cervical carcinogenesis. Investigators will validate the most promising identified candidate biomarkers in a prospective design by assessing their predictive values for key outcomes related to progression (HPV persistence, diagnosis of precancer) or non-progression (HPV clearance).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=842493" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270783" sys_dependentvariantid="1418" sys_dependentid="842493" rxinlineslot="103" sys_variantid="1418" sys_contentid="842493">View publications related to SUCCEED</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270782" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_relationshipid="7270784" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303576" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A collaborative study on colposcopic biopsy is being conducted at the University of Oklahoma, as part of an established project on cervical cancer risk-marker discovery. The aims of the study are to study cervical disease on the lesion level, to optimize criteria for biopsy placement, and to analyze the incremental benefit of taking multiple biopsies. The study is being conducted in close collaboration with the American Society for Colposcopy and Cervical Pathology.&nbsp;</p>
<p>Following a standardized protocol for biopsy placement based on decreasing order of lesion severity as judged by colposcopic impression, up to four biopsies, including one randomly taken, were performed on 700 women referred to colposcopy. Endocervical curettage was performed in women age 30 and older. Colposcopic impression, acetowhitening, and biopsy placement was documented using the Boundary Marking Tool (BMT), a digital imaging system developed in collaboration with the National Library of Medicine. All biopsies taken from each woman were analyzed separately using conventional histology, HPV typing, and biomarkers.&nbsp;</p>
<p>Investigators quantified the incremental benefit of taking additional targeted and random biopsies, and found that a single targeted biopsy missed over a third of prevalent precancers. Very few precancers were found with random biopsies. The results of the study will impact colposcopy and cervical cancer screening procedures in general. Making colposcopy more effective is important in a time of extensive screening (smaller lesions are detected) and vaccination against HPV (leading to an overall reduction of high grade lesions).</p>
<p>Several secondary aims are addressed in the study, including evaluation of biomarkers for cervical precancers like p16/Ki-67 cytology and urinary HPV testing. Investigators are also studying the topographic distribution and functional relation of multiple lesions on the cervix using HPV genotyping and biomarkers for viral transformation.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=842207" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270786" sys_dependentvariantid="1418" sys_dependentid="842207" rxinlineslot="103" sys_variantid="1418" sys_contentid="842207">View publications related to the Biopsy Study</a>.&nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270785" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_relationshipid="7270787" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303577" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Human papillomavirus (HPV) infections and HPV-related cancers are a growing problem among HIV-infected populations, particularly in low-resource countries. Traditional cytology-based screening programs for cervical cancer prevention have failed everywhere other than resource-abundant settings. In resource-constrained settings, tests such as visual inspection with acetic acid (VIA) can provide a suitable platform for clinical evaluation and are very cheap, however they are highly rater-dependent and suffer from substantial false positivity. Carcinogenic HPV DNA detection (e.g., HPV DNA testing by Hybrid Capture-2 assay) is less specific than cytology and cannot differentiate between the great majority of benign infections and the few persistent infections linked to cervical pre-cancer. A reliable and robust test that improves both the sensitivity and specificity of screening may provide better alternatives for HIV-infected women than conventional cytology screening or VIA.</p>
<p>This study, funded through the NIH Office of AIDS Research &lsquo;Intramural-to-India&rsquo; initiative, is being conducted in collaboration with the National AIDS Research Institute, a permanent institute of the Indian Council of Medical Research in Pune, India. A cohort of 1,000 HIV-infected women are undergoing evaluation using two novel and potentially sustainable, lower-cost tests for accurate screening for cervical cancer. These tests include HPV mRNA testing and immunocytochemical staining using p16INK4a/Ki-67 (a biomarker correlated with the oncogenic transformation of cervical cells following persistent carcinogenic HPV infection). The study involves simultaneous and independent evaluation of these novel biomarkers along with confirmation by colposcopy/histopathology for all participants. This observational study is enabling investigators to describe the sensitivity and specificity of any of the tests or combinations with reasonable precision in HIV-infected women. It is allowing evaluation of the field adoption and efficacy of these newer assays and is permitting validation of collection, transport, storage, and evaluation protocols.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270788" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a> or <a href="mailto:sahasrabuddhevv@mail.nih.gov">Vikrant Sahasrabuddhe</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_relationshipid="7270789" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303579" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Colorectal Neoplasia Screening with Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Centers (CONCeRN) study is a multi-center study of asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening. The primary purpose of the study is to determine the extent to which advanced neoplastic lesions will be missed if clinicians only perform sigmoidoscopies rather than full colonoscopies as a screening procedure and to resolve current debate about the significance of sigmoidoscopic detection of single, small, tubular adenomas. Women enrolled in the study receive colonoscopy during which all identified polyps are removed and also during which two pinch biopsies of apparently-normal tissue are taken. A NCI-led sub-study added a more extensive questionnaire to assess dietary and other lifestyle factors potentially related to colorectal cancer, and obtained additional blood for assessment of nutritional status and for analysis of genetic polymorphisms related to colorectal cancer. With the additional information, it will be possible to explore the extent to which various dietary and genetic risk factors are related to colorectal polyps in asymptomatic women of average risk for disease.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349692" sys_contentid="349692" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270791" sys_dependentvariantid="1965" sys_dependentid="349692" rxinlineslot="103">Rashmi Sinha</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270792" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303581" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Currently, there are no convincing early detection approaches for endometrial and ovarian cancers. Although it is well established that some endometrial and ovarian tumors shed cytologically recognizable cells in routinely prepared Pap tests, it is clear that this approach rarely detects occult tumors. Accordingly, we need to develop strategies for collecting biological samples that have high patient acceptability, good sensitivity for detecting early disease, and excellent specificity.</p>
<p>DCEG investigators have been assessing the feasibility of using alternative sampling techniques in combination with molecular assays to detect endometrial and ovarian cancers. They are comparing two sampling techniques &ndash; one using a tampon, and the other using a sheathed endometrial brush (called a Tao brush), and are assessing the quality of DNA extracted from the different samplers. The investigators aim to study the association between methylation of somatic DNA for a selected marker panel and cancer status.</p>
<p>Testing began with a pilot study of 117 women aged 45 years and older with suspected endometrial cancer or ovarian cancer, and 53 age-matched controls without malignancy, conducted in collaboration with researchers at the Mayo Clinic. Several candidate methylation markers for endometrial cancer were successfully evaluated in tampon and Tao brush specimens collected from women with endometrial cancer. &nbsp;</p>
<p>Investigators seek to replicate their findings in a larger study to evaluate biomarkers for endometrial cancer at the Mayo Clinic. Samples are being collected, using Tao brush and tampon, from over 800 women who present with increased risk of endometrial cancer. Women will be prospectively followed for endometrial hyperplasia and cancer endpoints.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Wentzensen%20N[Author]%20AND%20%28%22endometrial%20cancer%22[Title/Abstract]%20AND%20%22methylation%20markers%22[Title/Abstract]%29&amp;cmd=DetailsSearch">View publications related to Assessment of Screening Modalities for Gynecologic Cancers</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270794" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_relationshipid="7270795" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303582" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This is a case-control study nested within a retrospective cohort of approximately 8,000 women diagnosed with endometrial hyperplasia from 1970-2002 in a pre-paid health plan. The goal of the study is to define risks of progression for histological categories of endometrial hyperplasia, the precursor of typical forms on endometrial carcinoma, and to validate candidate molecular pathological prognostic markers to assess risk of subsequent carcinoma. Cases included 138 women with pathology panel confirmed endometrial hyperplasia who progressed to carcinoma; controls consisted of 241 women with pathology confirmed endometrial hyperplasia matched on age, date of diagnosis and duration of follow-up and counter-matched on severity of hyperplasia. The study has shown that the risk of progression among women with atypical hyperplasia, the most severe form, is 8% through four years rising to 28% through 19 years of follow-up. The study has shown that non-atypical forms of endometrial hyperplasia are far less likely to progress than atypical hyperplasia. The study includes basic data related to patient characteristics and treatment and multiple tissues from initial and repeat biopsies. A tissue microarray has been prepared from the endometrial cancer tissues. Current activities are focusing on validating biomarkers in endometrial hyperplasia that predict risk of progression to cancer, including immunohistochemical stains and molecular assays.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349668" sys_dependentvariantid="1965" sys_relationshipid="7270796" sys_siteid="475">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7270797" sys_siteid="475">Clinical Genetics&nbsp;Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303585" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The <a href="http://beacon.tlvnet.net/">International Barrett&rsquo;s and Esophageal Adenocarcinoma Consortium</a> (BEACON) was established in 2005 with support from the National Cancer Institute. BEACON is composed of over three dozen investigators with completed or ongoing epidemiologic studies of Barrett&rsquo;s esophagus and/or esophageal adenocarcinoma. This open scientific forum now has more than 50 members who have research interests in the etiology and prevention of these diseases. The current chair is Dr. Thomas L. Vaughan, a Professor of Epidemiology at the Fred Hutchinson Cancer Research Center.&nbsp;</p>
<p>Analyses from the BEACON group so far have included alcohol consumption, anthropometry, cigarette smoking, excess risk models, gastroesophageal reflux disease, non-steroidal anti-inflammatory drugs, reproductive factors, and genome-wide studies to identify susceptibility loci associated with Barrett&rsquo;s esophagus and/or adenocarcinomas of the esophagus.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%22Cook+MB%22%5BAuthor%5D+AND+(%22BEACON%22%5BTitle%2FAbstract%5D+AND+(%22esophageal%22%5BTitle%2FAbstract%5D+OR+%22oesophageal%22%5BTitle%2FAbstract%5D)+)">Search for publications by BEACON members</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349597" sys_contentid="349597" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270859" sys_dependentvariantid="1965" sys_dependentid="349597" rxinlineslot="103">Michael Cook</a>.</p>
</div>]]></content>
  </row>
  <row para_id="303586" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Barrett Esophagus Early Detection Study was initiated in 2006, with the primary goal of identifying a practical blood-based biomarker to distinguish persons with Barrett esophagus (BE) from those without it. This BE case-control study is being conducted at the Walter Reed National Military Medical Center in Bethesda, Maryland, among Barrett Esophagus Registry patients and non-BE patients who have endoscopies in the Gastroenterology Clinic.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349597" sys_dependentvariantid="1965" sys_dependentid="349597" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7270861" sys_variantid="1965" sys_contentid="349597">Michael Cook</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103" sys_relationshipid="7270860" sys_variantid="1418" sys_contentid="1033621">Metabolic&nbsp;Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303588" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This cohort study is evaluating the environmental and genetic risk factors for esophageal squamous cell carcinoma (ESCC) in Golestan Province, Iran. The study is led by the Digestive Disease Research Center of Tehran University of Medical Sciences in collaboration with DCEG and the International Agency for Research on Cancer (IARC) in Lyon. From 2004 &ndash; 2008, the study recruited approximately 50,000 adults. Baseline assessments included a lifestyle questionnaire, a semi-quantitative food frequency questionnaire, and collection of blood, hair, nails and urine. Measurements included height, weight, waist and hip circumference, body size at different ages, and physical activity. Annual follow-up is ongoing.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_contentid="349612" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270862" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103">Christian Abnet</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270863" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303592" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This population-based case-control study was conducted in the metropolitan areas of Detroit and Chicago in collaboration with Wayne State University and the University of Illinois at Chicago. The aims of this study are to evaluate risk factors for renal cell cancer and examine why rates of this disease are higher among U.S. blacks than whites. Between 2002 and 2007, DCEG investigators interviewed and collected saliva and blood samples from 1,217 cases (856 white, 361 black) and 1,235 controls (712 white, 523 black). Tumor tissue blocks, diagnostic slides, and medical records were also collected from cases. Factors being evaluated include hypertension and other medical conditions, medication use, obesity and weight fluctuation, cigarette smoking, occupational exposures, markers of genetic susceptibility, and several molecular markers in tumor tissue and peripheral blood. Findings to date suggest that black-white differences in hypertension and chronic kidney disease might explain a substantial portion of the racial disparity in kidney cancer incidence.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=983937" sys_contentid="983937" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7270882" sys_siteid="475" rxinlineslot="103" sys_dependentid="983937" sys_dependentvariantid="1965">Dr. Mark Purdue</a> or&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=917441" sys_contentid="917441" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7270880" sys_siteid="475" rxinlineslot="103" sys_dependentid="917441" sys_dependentvariantid="1965">Dr. Jonathan Hofmann</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7270881" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303593" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This hospital-based case-control study was conducted from 1999 to 2003 in collaboration with the International Agency for Research on Cancer to evaluate kidney cancer risks in relation to occupational and other environmental and lifestyle exposures in six centers across Eastern Europe (Moscow, Russia; Brno, Prague, and Central Moravia, Czech Republic; Lodz, Poland; Bucharest, Romania). Strengths of this study include its large sample size (1,100 cases and 1,500 controls), detailed occupational exposure assessment, collection of pre-treatment blood and frozen tumor tissue specimens, and case survival follow-up. Factors being evaluated include occupational exposures, lifestyle factors, medical conditions, markers of genetic susceptibility and tumor molecular characteristics.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=983937" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="983937" rxinlineslot="103" sys_relationshipid="7270884" sys_variantid="1965" sys_contentid="983937">Dr. Mark Purdue</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270883" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303596" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Childhood leukemia is the most common type of childhood cancer and its etiology is largely unknown. Investigators in DCEG are collaborating with investigators at University of California at Berkeley on a population-based case-control study of childhood leukemia in the San Francisco Bay area and the agricultural Central Valley (35 counties). A substantial proportion of the population in this area is employed in agriculture or lives in close proximity to agricultural fields, making this an ideal study population to evaluate agricultural pesticide exposures and risk of childhood leukemia. Furthermore, a large proportion of the study population is Hispanic. No previous large-scale childhood leukemia studies have targeted Hispanics or agricultural populations. A major aim of the collaboration is to improve the exposure assessment of agricultural and home and garden pesticides by measuring pesticides in house dust samples. Investigators are also measuring other chemical exposures including cotinine, PCBs, polycyclic aromatic hydrocarbons, and polybrominated diphenyl ethers. In addition to evaluating specific chemical levels in dust and risk of childhood leukemia, investigators are conducting several methodological studies to evaluate factors associated with residential exposure to these chemicals.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349624" sys_contentid="349624" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270891" sys_dependentvariantid="1965" sys_dependentid="349624" rxinlineslot="103">Dr. Mary Ward</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270892" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103">Occupational and Environmental Epidemiology - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303602" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Liver cancer incidence and mortality have been increasing in the United States since 1980. Reasons for the increases are not clear. Known risk factors include chronic infections with hepatitis B virus and hepatitis C virus, excessive consumption of alcohol, certain rare metabolic disorders (e.g., hemochromatosis), diabetes and obesity. Whether these factors explain liver cancer in the U.S. has not been adequately examined. As a result, investigators in DCEG are conducting a liver cancer pooling project among existing U.S. cohorts in order to explore liver cancer etiology in a prospective manner. Cohorts are contributing questionnaire data and serum samples to this effort. As liver cancer remains a rare disease, despite the increasing incidence, additional U.S. cohorts are being sought to participate in this investigation.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" sys_contentid="349637" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7270897" sys_dependentvariantid="1965" sys_dependentid="349637" rxinlineslot="103">Katherine McGlynn</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7270898" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303605" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>EAGLE (<span style="text-decoration: underline;">E</span>nvironment <span style="text-decoration: underline;">A</span>nd <span style="text-decoration: underline;">G</span>enetics in <span style="text-decoration: underline;">L</span>ung cancer <span style="text-decoration: underline;">E</span>tiology) is a large population-based case-control study designed and conducted to investigate the genetic and environmental determinants of lung cancer and smoking persistence using an integrative approach that allows combined analysis of genetic, environmental, clinical, and behavioral data. The study includes over 2,000 incident lung cancer cases, both males and females of Italian nationality, ages 35 to 79 years old, with verified lung cancer of any histological type, and over 2,000 healthy population-based controls matched to cases by age, gender, and residence.&nbsp;</p>
<p>View the <a href="https://eagle.cancer.gov/">Environment And Genetics in Lung cancer Etiology study website</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" sys_contentid="349623" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349623" sys_dependentvariantid="1965" sys_relationshipid="7270900" sys_siteid="475">Maria Teresa Landi</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="420600" sys_dependentvariantid="1418" sys_relationshipid="7270901" sys_siteid="475">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303608" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7270906" sys_dependentid="1138000" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2388" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<div class="topic-feature large-4 columns card right">
	<div class="feature-card genExternalLink">
		<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=2428&amp;sys_context=0&amp;sys_folderid=385162&amp;sys_siteid=475&amp;sys_contentid=1138000&amp;sys_command=preview" sys_variantid="2428" sys_contentid="1138000">
							    				<div class="image-hover">
    					<img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=2074&amp;sys_context=0&amp;sys_folderid=385162&amp;sys_siteid=475&amp;sys_contentid=1138002&amp;sys_command=preview" alt="">
    				</div>
				    		    		    			<h3>Burkitt lymphoma studies may also advance research on other cancers, HIV, malaria</h3>
    					        		        			<p>Read about Dr. Mbulaiteye's research on Burkitt lymphoma in the NIH Fogarty Global Health Matters newsletter. </p>
        							</a>
    </div>
	</div>
</div>
<p></p>
<p>The <a href="http://emblem.cancer.gov/">Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM)</a> study is a large, multidisciplinary epidemiological effort designed to evaluate environmental and host factors associated with childhood Burkitt lymphoma (BL) in sub-Saharan Africa. The study is expected to enroll 1,500 BL cases and 3,000 population controls from six rural sites in the East African regions northern Uganda, northeastern Tanzania, and western Kenya. The primary objectives of EMBLEM are to characterize and quantify the association between BL and: a) malaria, based on carriage of malaria-resistance genes; b) carcinogenic Epstein-Barr virus variants; and c) non-malaria-resistance related germline and somatic genetic polymorphisms. In addition to collecting a unique data and sample resource for study of the interplay between infectious agents, genetics, and behavioral/lifestyle factors in the pathogenesis of childhood BL, EMBLEM provides a new model for direct and immediate improvements in BL communication, diagnosis, and treatment of BL in Africa.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349676" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349676" sys_dependentvariantid="1965" sys_relationshipid="7270904" sys_siteid="475" sys_variantid="1965" sys_contentid="349676">Sam Mbulaiteye</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7270905" sys_siteid="475" sys_variantid="1418" sys_contentid="419183">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
<p><a href="http://emblem.cancer.gov/">EMBLEM study website</a></p>
</div>]]></content>
  </row>
  <row para_id="303611" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The goal of the <a href="http://epi.grants.cancer.gov/InterLymph/">International Lymphoma Epidemiology Consortium</a> (InterLymph) is to enhance collaboration among epidemiologists studying lymphoma, provide a forum for the exchange of research ideas, and create a framework for collaborating on analyses that pool data from multiple studies. Within the consortium, DCEG investigators are currently leading pooled analyses to 1) investigate whether the risk of non-Hodgkin lymphoma associated with cigarette smoking and personal hair dye use is modified by genetic variation in N-acetyltransferase 1 (<i>NAT1</i>) and 2 (<i>NAT2</i>), which encode enzymes that metabolize aromatic and heterocyclic amines, and 2) provide the first comprehensive assessments of risk factors for several rare lymphoma subtypes.</p>
<p>For more information, refer to the InterLymph website (<a href="http://epi.grants.cancer.gov/InterLymph/">http://epi.grants.cancer.gov/InterLymph/</a>).</p>
</div>]]></content>
  </row>
  <row para_id="303612" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>For the last decade, DCEG investigators have collaborated on the NCI-SEER Non-Hodgkin Lymphoma (NHL) Case-Control Study, a multi-center, population-based study of 1,321 NHL cases and 1,057 controls that includes detailed interview data, biospecimens, and environmental samples. Currently, DCEG investigators are collaborating on studies using the candidate gene approach to identify common genetic variants in relation to both NHL susceptibility and survival within the NCI-SEER NHL Study, focusing on key genes in cell cycle control, DNA repair, and immune function pathways that likely contribute to lymphomagenesis. They are also conducting molecular studies utilizing the paraffin-embedded tumor tissue collected for approximately 70% of the cases.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7270907" sys_siteid="475" rxinlineslot="103" sys_dependentid="349644" sys_dependentvariantid="1965">Dr. Nathaniel Rothman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7270908" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303614" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Data from case-control studies of non-Hodgkin lymphoma among men from Iowa, Minnesota, Kansas, and Nebraska have been pooled to create a large resource to evaluate potential risks from pesticide and other exposures. The pooled data set contains detailed information on pesticide use and other factors for 1,000 cases and 3,000 controls. These NCI studies have been additionally pooled with studies from Canada to evaluate associations between pesticides and NHL sub-types.</p>

<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349661" sys_dependentvariantid="1965" sys_relationshipid="7270927" sys_siteid="475" sys_variantid="1965" sys_contentid="349661">Dr. Laura Beane Freeman</a>.</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7270928" sys_siteid="475" sys_variantid="1418" sys_contentid="418935">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303616" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators conducted a case-control study of 718 non-Hispanic white patients with cutaneous melanoma from melanoma clinics in Philadelphia and San Francisco, and are completing analyses of the risk factors for melanoma and nevi. Investigators have also analyzed data on sunbed use and found that sunbed use is a significant risk factor for melanoma, after adjustment for all other UV exposure. Sunscreen use provided some protection, particularly in those most susceptible.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349685" sys_contentid="349685" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7270948" sys_siteid="475" rxinlineslot="103" sys_dependentid="349685" sys_dependentvariantid="1965">Margaret Tucker</a>.</p>
</div>]]></content>
  </row>
  <row para_id="303618" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A case-control study is being conducted in Italy to study the role of pigmentation and other host factors in the etiology of melanoma in a population with a wide range of pigmentary phenotypes and intense sun exposure. This is a collaborative study between the NCI, Bufalini Hospital, Cesena, and the University of L&rsquo;Aquila, L&rsquo;Aquila, Italy. The study includes over 350 melanoma cases and 350 healthy controls, matched by age, sex and residence. To address the genetic determinants of melanoma in the Mediterranean population through a different approach, a family study of melanoma is also currently ongoing in the same areas of Italy. To date, the study includes 76 families with two&nbsp;to five&nbsp;melanoma-affected individuals per family. Unaffected relatives from these families are also enrolled.</p>
<p>An additional project includes melanoma patients participating in either the Italian case/control or the Italian family study of melanoma who have agreed to donate multiple tissue biopsies from normal skin, common melanocytic nevi, dysplastic nevi and melanoma to allow the investigation of the pathways potentially involved in the transition from common nevi to melanoma.</p>
<p>The data from this study contribute to the <a href="https://melanostrum.nci.nih.gov/">MelaNostrum Consortium</a>, a project to study&nbsp;genetic, environmental and clinical features of melanoma risk and progression in Mediterranean populations.</p>
<p></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7359705" sys_dependentvariantid="1965" sys_dependentid="349623" rxinlineslot="103" sys_variantid="1965" sys_contentid="349623">Maria Teresa Landi</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="420600" rxinlineslot="103" sys_relationshipid="7359706" sys_variantid="1418" sys_contentid="420600">Integrative Tumor&nbsp;Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303622" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Two case-control studies were conducted in Taiwan between 1991-1994 and 2010-2014. Together, these two studies included more than 2,000 NPC cases and more than 2,400 controls and were designed to examine the role of viral, environmental, and genetic factors associated with the development of nasopharyngeal carcinoma (NPC). Factors investigated include Epstein-Barr virus, diet, smoking, occupation, HLA, and other genetic polymorphisms. Histologically confirmed incident cases of nasopharyngeal cancer and two controls groups (hospital and community) were recruited. Participants completed an in-depth, in-person risk factor questionnaire that obtained information on adult and early life exposures. Blood and other specimens were collected from participants to allow for molecular assessment of various environmental and genetic factors of interest.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349694" sys_contentid="349694" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349694" sys_dependentvariantid="1965" sys_relationshipid="7275765" sys_siteid="475" sys_variantid="1965">Allan Hildesheim</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7275766" sys_siteid="475" sys_variantid="1418">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303623" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A family study is currently ongoing in Taiwan to elucidate genetic factors linked to the development of nasopharyngeal cancer (NPC). Approximately 350 multiplex families with two or more individuals affected with NPC have been identified and recruited into the study. Active clinic follow-up and passive follow-up via linkage to the national tumor registry is ongoing. Whole-exome sequencing was recently completed and evaluation of viral markers of risk that might be of clinical utility are under evaluation. A risk factor questionnaire is administered to all participants and blood, saliva and nasopharyngeal swabs is collected at study visits to allow us to examine the joint effects of genetic and environmental factors in the pathogenesis of NPC.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349694" sys_contentid="349694" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349694" sys_dependentvariantid="1965" sys_relationshipid="7275767" sys_siteid="475" sys_variantid="1965">Allan Hildesheim</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7275768" sys_siteid="475" sys_variantid="1418">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303630" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Benign Reproductive Tissue Evaluation (BRTE) Study was initiated by DCEG investigators in collaboration with Magee-Womens Hospital of the University of Pittsburgh, to study the association of risk factors with molecular changes in the ovaries and endometrium. This ongoing study enrolls women undergoing hysterectomy and oophorectomy for benign reasons. An extensive risk factor questionnaire is administered and blood and urine samples are collected before surgery. Normal endometrial and ovarian tissues are collected during surgery.</p>
<p>In the current phase of the study, investigators are also collecting normal ovarian surface epithelial cells intraoperatively using a Tao brush. More than 160 women have been enrolled in the study so far. Several analyses are currently ongoing, including methylation profiling and telomere length measurement of endometrial tissues as well as RNA sequencing and methylation profiling of ovarian surface epithelial cells. Molecular profiles are related to important risk factors for endometrial and ovarian cancers. Following recent evidence that a subset of ovarian cancers may originate in the fallopian tubes, in a planned extension of the study, brush-based sampling of fallopian tubes will be added to the protocol.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22Wentzensen%2C%20Nicolas%22[Author%20-%20Full]%20AND%20%22serous%20carcinoma%22[Title/Abstract]%29%20OR%20%28%22Wentzensen%2C%20Nicolas%22[Author%20-%20Full]%20AND%20%22endometrial%20cancer%22[Title/Abstract]%20AND%20%22methylation%20markers%22[Title/Abstract]%29&amp;cmd=DetailsSearch">View publications related to the Benign Reproductive Tissue Evaluation Study</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270990" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_relationshipid="7270991" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303632" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Closed to Patient Enrollment, Data Analysis Ongoing</h2>
<p><a href="http://ovariancancer.gog199.cancer.gov/">The National Ovarian Cancer and Early Detection Study (GOG-0199)</a> is a prospective study of women who are at increased risk of ovarian cancer, either because they or a close relative have a mutation in the <i>BRCA1</i> or <i>BRCA2</i> genes, or because they have a strong family history of breast and/or ovarian cancer. This study is being led by the Clinical Genetics Branch, in close collaboration with the <a href="http://www.gog.org/">Gynecologic Oncology Group</a> and the <a href="http://epi.grants.cancer.gov/CGN/">Cancer Genetics Network</a>. After discussion with their own health care providers, high-risk women chose either risk-reducing surgery or ovarian cancer screening to manage their ovarian cancer risk. Both groups of women have now been followed for five years to assess the impact of their choice on cancer occurrence and quality of life. <b>The clinical phase of this study is complete</b>, having enrolled 2,605 study participants, and efforts are now focused on addressing the specific endpoints that the study was designed to evaluate.&nbsp;</p>
<p>Ongoing analyses include: (1) the histopathology of risk-reducing salpingo-oophorectomy (RRSO) surgical pathology samples obtained from subjects enrolling in the RRSO arm of this study; (2) performance characteristics of the ROCA screening algorithm in the combined GOG-0199/Cancer Genetics Network screening cohort; (3) baseline quality of life in surgical versus screening arm enrollees; (4) medical decision-making among study participants, assessed at the time of study entry; (5) correlation between ovarian volume and levels of clinically important sex-steroid hormones and the effect of RRSO on serum hormone levels; (6) reproducibility of fallopian tube mucosal atypia histologic diagnosis (a blinded review); (7) prospective risk of breast and serous pelvic cancers in study participants; and (8) natural history of <i>BRCA</i> mutation-negative/strong family history positive breast/ovarian cancer families.</p>
<p>There have been two major publications to date from this project, plus a large number of publications related to our collaboration with the Consortium of Modifiers of <i>BRCA1/2</i> ("CIMBA"), which aims to discover other genes which influence the likelihood that mutation carriers will develop breast or ovarian cancer.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=530177" sys_contentid="530177" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270994" sys_dependentvariantid="1418" sys_dependentid="530177" rxinlineslot="103" sys_variantid="1418">View study publications from the National Ovarian Prevention and Early Detection Study</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349677" sys_contentid="349677" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270992" sys_dependentvariantid="1965" sys_dependentid="349677" rxinlineslot="103" sys_variantid="1965">Mark H. Greene</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7270993" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_variantid="1418">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303633" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This population-based case-control study of ovarian and endometrial cancer was conducted among female residents of Warsaw and Lodz (Poland) between 2001 and 2003. Investigators in DCEG identified all women with histologically-confirmed ovarian and endometrial carcinoma through a rapid ascertainment system in participating hospitals and cancer registries. The collection of biological specimens included blood, urine, and paraffin-embedded tumor tissue. Control women were randomly selected from complete population lists and were frequency matched to cases on age and study site. A personal interview and blood/mouthwash sample was collected. A total of 347 women with invasive ovarian cancer and 555 women with endometrial cancer were enrolled. Researchers share 2,798 controls between breast, ovarian, and endometrial cancer cases. Researchers constructed tissue microarrays including tumor samples from approximately 200 ovarian cancer cases and 300 endometrial cancer cases for immunohistochemical analyses. Nucleic acids were extracted from tissue cores to create a resource for DNA-based studies.</p>
<p>Investigators are conducting the following:</p>
<ul>
<li>Analyses of questionnaire-based factors and anthropometric/physical activity measurements in relation to cancer risk and clinical outcomes;</li>
<li>Identifying genetic susceptibility markers of cancer risk and clinical outcomes using candidate gene and genome-wide association (GWAS) approaches;</li>
<li>Analyses of tissue/tumor markers to evaluate relationships with cancer risk factors (known or suspected), and their impact on predicting recurrence and survival after diagnosis;</li>
<li>Analyses of biomarkers in DNA (somatic changes), cryopreserved blood cells, serum/plasma, and urine in relationship to cancer risk and clinical outcomes.</li>
</ul>
<p>Current projects include methylation profiling, tumor gene sequencing, microsatellite instability analysis, and immunohistochemistry to study the etiologic heterogeneity of endometrial and ovarian cancers.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=844039" sys_contentid="844039" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="844039" sys_dependentvariantid="1418" sys_relationshipid="7270996" sys_siteid="475">View publications related to the Ovarian and Endometrial Cancer Case-Control Study in Poland</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349668" sys_dependentvariantid="1965" sys_relationshipid="7270995" sys_siteid="475">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7270997" sys_siteid="475">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303634" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Women&rsquo;s Health Initiative Observational Study Cohort</h2>
<p>In collaboration with investigators from the Women&rsquo;s Health Initiative, investigators in DCEG are conducting a nested case-control study of endometrial and ovarian cancers to assess the roles of estrogens, estrogen metabolites, and androgens in the etiologies of these cancers. Cases and shared controls have been drawn from the Women&rsquo;s Health Initiative Observational Study (WHIOS) cohort. This effort benefits from unique WHIOS resources, including large numbers of cancer cases, prospectively collected serum and baseline data on important cancer risk factors.</p>
<p>A comprehensive profile of endogenous estrogens, including 15 estrogens and estrogen metabolites, were measured in pre-diagnostic serum using the LC-MS/MS assay developed at the Protein Characterization Laboratory at the Frederick National Cancer Center. These measures were examined in relation to ovarian (n~169) and endometrial (n~313) cancers. For ovarian cancer, we found striking heterogeneity in risks by histologic subtype with results supporting a role for estrogen metabolites in the etiology of non-serous, but not serous ovarian cancers. Elevated circulating levels of both parent estrogens and estrogen metabolites were associated with increased endometrial cancer risk, suggesting that estrogen receptor-mediated mechanisms explain a portion of the effects of obesity on endometrial cancer risk. Within this study, investigators have also evaluated the full panel of circulating estrogens and estrogen metabolites to investigate relationships with cancer risk factors (e.g., body mass index, sedentary behavior, alcohol use). Currently underway are efforts to evaluate associations of 11 androgens and androgen metabolites as measured by LC-MS/MS to ovarian and endometrial cancer risks as well as cancer risk factors.</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Women%27s+Health+Initiative+Observational+Study&amp;titleOption=exact&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">View publications from the WHI-OS nested case-control study</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=802306" sys_contentid="802306" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="802306" sys_dependentvariantid="1965" sys_relationshipid="7271001" sys_siteid="475">Britton Trabert</a>.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="1033621" sys_dependentvariantid="1418" sys_relationshipid="7271002" sys_siteid="475">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303643" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Ghana Prostate Study is designed to assess the burden, risk factor profiles and biomarkers of prostate cancer in Ghanaian men. In the United States, incidence rates of prostate cancer in African-Americans are 1.6-fold higher than those observed in European Americans, yet the causes of this difference remain unknown. Since West Africa is the principal ancestral origin of a substantial proportion of African-American men, one may hypothesize that genetic susceptibility loci that vary in allele frequency by ancestral population could account for part of the observed differences in prostate cancer rates within the U.S. In addition, little is known about the prostate cancer risk factors in African men.</p>
<div sys_relationshipid="7271020" sys_dependentid="1113261" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=303013&amp;sys_siteid=475&amp;sys_contentid=1113261&amp;sys_command=preview" alt="Map depicting Ghana next to its neighbors in West Africa"><!--Comment--></img>
                                                </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>Map of Ghana, West Africa</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<p>The Ghana Prostate Study has two components: a clinical component to recruit prostate cancer cases in Accra, the capital of Ghana, and a population screening survey component to estimate the prevalence of prostate cancer in the male Accra population. The clinical component of the study includes the collection of clinical and pathological data for&nbsp;677 prostate cancer cases. The population component of the study includes 1,000 healthy men who underwent screening using serum prostate specific antigen (PSA) testing and digital rectal examination, followed by biopsy confirmation as required. Interviews elicited information on demographics, diet, smoking, alcohol consumption, body size, medical history, health care utilization, and urinary symptoms. Blood samples are being used for PSA testing and for measurements of genetic, hormonal, and nutritional markers.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=844106" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="844106" sys_dependentvariantid="1418" sys_relationshipid="7271018" sys_siteid="475" sys_variantid="1418" sys_contentid="844106">View publications from the Ghana Prostate Study</a>.</p>
<p>For more information, contact <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/cook-michael-b">Michael Cook</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271019" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303652" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Gastric cancer and nasopharyngeal carcinoma are the only two epithelial tumors known to be associated with Epstein-Barr virus (EBV) infection. However, in contrast to near universal involvement in nasopharyngeal carcinoma, only 8-10 percent&nbsp;of gastric cancers are positive for EBV. Despite differences in primary etiology of cancers of the upper (cardia) and lower (noncardia)&nbsp;stomach, EBV-positive tumors occur at both of these anatomic subsites.&nbsp;To date, most studies that have evaluated EBV-associated gastric cancer have been modest in size, and it is unclear whether co-factors associated with these cancers differ from those associated with the more common EBV-negative tumors. To&nbsp;study this scientifically important subgroup efficiently, DCEG leads the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=827356" sys_contentid="827356" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271068" rxinlineslot="103" sys_dependentid="827356" sys_dependentvariantid="1418" sys_siteid="475">NCI-International EBV-Gastric Cancer Consortium</a>, a research collaboration pooling data and biospecimens from 18 completed and ongoing observational studies of gastric cancer.&nbsp;Consortium projects have included comparisons of tumor characteristics, antiviral antibodies and markers of inflammation in patients with EBV-positive vs. -negative gastric cancer.&nbsp;Ongoing efforts are examining additional biomarkers such as circulating cell-free DNA methylation and viral as well as human-encoded microRNA.&nbsp;Collaborative work with The Cancer Genome Atlas has helped to establish EBV-positive gastric cancer as a distinct molecular subtype of gastrointestinal tract adenocarcinoma.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7271066" rxinlineslot="103" sys_dependentid="349628" sys_dependentvariantid="1965" sys_siteid="475">Charles Rabkin</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271067" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_siteid="475">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303653" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This case-control study is evaluating environmental and genetic risk factors for esophageal squamous cell carcinoma (ESCC) in Golestan Province, Iran. Age standardized ESCC incidence rates of 109/100,000 in men and 175/100,000 in women were reported from this area in the 1970s, and no studies have been performed since that time. Atrak Clinic, a referral clinic for upper gastrointestinal diseases, was recently established in Golestan Province by physicians from the Digestive Diseases Research Center of Tehran University of Medical Sciences, and this Clinic serves as the field center for this study. All patients referred to the Clinic routinely undergo upper endoscopy and biopsy for evaluation and diagnosis. Patients who have histologically confirmed ESCC and consent to join the study have been enrolled as cases. Two control groups have also been enrolled in this study, one selected from the neighborhoods of case subjects (primary controls) and one from the patients referred to Atrak Clinic who do not have cancer (secondary controls). Both the cases and the controls were interviewed and underwent collection of biological specimens including blood, hair and nails. After a 3 1/2 year accrual period (2003-2007) 300 cases, 571 neighborhood controls and 300 Atrak Clinic controls were successfuly enrolled and are currently being analyzed. Environmental risk factors (including life-style, habits, and nutritional status) are being assessed through questionnaires and objective measurements in biological specimens. The role of genetic polymorphisms is also being studied using genomic DNA from cases and controls. Biopsy samples collected from cases and clinic controls are also being used to evaluate the association of esophageal PAH exposure and case status.</p>
<p>For more information, contract <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_contentid="349612" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7271039" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103">Christian Abnet</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7271040" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303656" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Nutrition Intervention Trials (NIT) were launched in 1985 as randomized controlled trials which tested the effects of multiple vitamin and mineral interventions on total mortality and total and cause-specific cancer mortality in a rural Chinese population. The original goal of the NIT was to evaluate the role of nutrition in the etiology and prevention of upper gastrointestinal cancers in over 32,000 residents in Linxian, China. With the conclusion of the intervention phase in 1991, and the determination that the micronutrient combination of selenium/vitamin E/&szlig;-carotene reduced total mortality, total cancer mortality, and gastric cancer mortality, objectives now include:&nbsp;</p>
<ul>
<li>Determination of post-trial effects of the interventions;&nbsp;</li>
<li>Evaluation of etiologic hypotheses, including nutrition, carcinogens, infections, genetics, and other exposures;&nbsp;</li>
<li>Studies of natural history; and&nbsp;</li>
<li>Examination of interactions (gene-environment, gene-gene, and gene-intervention).</li>
</ul>
<p>In collaboration with the Cancer Institute of the Chinese Academy of Medical Sciences in Beijing, DCEG investigators continue to follow trial participants to ascertain endpoints, conduct nested case-control and case-cohort studies using baseline serum, and perform expanded DNA and biochemical analyses on additional blood samples collected during follow-up. To date, investigators have accrued almost 3,500 esophageal squamous cell carcinoma cases and over 2,500 gastric adenocarcinoma cases among the original 32,000 subjects.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_dependentvariantid="1965" sys_dependentid="349612" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271042" sys_variantid="1965" sys_contentid="349612">Christian Abnet</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1033621" sys_dependentvariantid="1418" sys_relationshipid="7271041" sys_siteid="475" sys_variantid="1418" sys_contentid="1033621">Metabolic&nbsp;Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303657" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Upper Gastrointestinal Cancer Genetic Studies in Shanxi Province, China, were started to look for major susceptibility genes for upper gastrointestinal (UGI) cancers and to identify the genetic changes associated with their development. This project was initiated to study esophageal squamous cell carcinomas, but also includes other UGI cancers (gastric cardia cancer and gastric non-cardia cancer).&nbsp; The project goals include:&nbsp;</p>
<ul>
<li>Identification of somatic genetic alterations, including changes that might serve as early detection biomarkers</li>
<li>Examination of cancer-associated germline genetic variants to identify major risk and moderate risk susceptibility genes to enable development of risk stratification strategies and to gain a better understanding of the biology of these UGI cancers</li>
</ul>
<p>Following a pilot study in 1995, we initiated a collaboration with the Shanxi Cancer Hospital and Institute, Taiyuan, Shanxi Province, China in 1996 to perform clinical and field studies. These studies have been the core of our UGI cancer genome-wide association studies (GWAS) in Asians.</p>
<h4>Tumor/non-tumor study</h4>
<p>To enable study of somatic alterations in tumors, we developed a tumor/non-tumor study by recruiting cancer cases surgically resected at the Shanxi Cancer Hospital, who answer a standardized risk factor questionnaire and provide a blood sample and tumor/non-tumor surgical specimens.</p>
<h4>Endoscopy study</h4>
<p>To permit evaluation of somatic molecular markers in pre-malignant tissues in our search for early detection markers, we added an endoscopy study in 2006, which targets collection of esophageal biopsies, blood, and risk factor questionnaire data on patients presenting to the Endoscopy Clinic at the Shanxi Cancer Hospital.</p>
<h4>Family study</h4>
<p>To examine germline genetic variants in relation to cancer in our search for major risk susceptibility genes, we developed a family study, which recruits highly informative multiplex families (pedigrees with 2+ UGI cancer cases and available DNA) and obtains blood samples and questionnaire-based risk factor information on all living first-degree relatives over 20 years of age for linkage (and association study) analysis.</p>
<h4>Case-control study</h4>
<p>To evaluate germline genetic variants in relation to cancer in our search for moderate risk susceptibility genes, as well as to study environment, gene-environment, and gene-gene interactions, we developed a case-control study that enrolls histologically-confirmed UGI cancer cases and neighborhood-matched controls, obtains information from a structured risk factor questionnaire, and collects biologic samples (a venous blood sample, a finger stick blood sample, a buccal smear, and a tumor specimen from surgical resections of cases).</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349658" sys_dependentvariantid="1965" sys_dependentid="349658" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271043" sys_variantid="1965" sys_contentid="349658">Alisa Goldstein</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_dependentvariantid="1418" sys_dependentid="433261" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271044" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303659" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Testicular cancer is the most common form of cancer in young men ages 15 to 35. It accounts for about one percent of all cancer in men, with approximately 7,400 cases diagnosed in the United States every year. It is much more common in white males than in black males. DCEG investigators are conducting the <a href="http://familial-testicular-cancer.cancer.gov/">Familiar Testicular Cancer Study</a> to pursue research into the genetic causes of testicular cancer, &nbsp;using carefully-collected biological samples from members of multiple-case families, in which we are also studying the relationship between testicular microlithiasis (calcium deposits within testicular tissue) and the risk of familial testicular cancer.&nbsp;</p>
<p>Previous work has focused on defining the clinical characteristics of the familial testicular cancer syndrome. This is proving to be a remarkably interesting project because the genetic mechanisms that are just now being identified seem quite different from those that had been previously found to cause other hereditary cancer disorders such as hereditary breast and hereditary colon cancer. The current hypothesis is that familial testicular cancer results from the combined effects of many genes, each of which by itself causes only a small increase in cancer risk. Those genes appear to be deeply involved in the normal growth and development of the testes in the fetus, and in regulating male fertility and the production of sperm.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22familial%20testicular%20cancer%22[Title]%20OR%20%22familial%20testicular%20germ%20cell%22[Title]%20OR%20%22testicular%20neoplasms%22[MeSH%20Major%20Topic]%20OR%20%22testicular%20diseases/genetics%22[MeSH%20Terms]%20AND%20%28%22Greene%2C%20Mark%20H%22[Author%20-%20Full]%20OR%20%22Loud%2C%20Jennifer%20T%22[Author%20-%20Full]%20OR%20%22Savage%2C%20Sharon%20A%22[Full]%20OR%20%22Greene%20MH%22[Author]%29&amp;cmd=DetailsSearch">Familiar Testicular Cancer - Research Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349675" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7297549" sys_dependentvariantid="1965" sys_dependentid="349675" rxinlineslot="103" sys_variantid="1965" sys_contentid="349675">Jennifer Loud</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7297550" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303661" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Testicular germ cell cancer has been increasing among men during most of the 20th century. Despite this increase, the etiology of testicular cancer is poorly understood. To better understand the molecular epidemiology of testicular cancer, the National Cancer Institute and the Department of Defense are conducting a case-control study of testicular cancer among military servicemen. The project includes obtaining biosamples and questionnaire data from all participants. Pre-diagnostic serum samples are available from the approximately 1,100 cases and 1,100 controls enrolled in the study. Mothers of all participants are also invited to participate by donating a biosample and responding to a questionnaire.</p>
<h4>Hormone Levels Related to Testicular Germ Cell Tumors in STEED</h4>
<p>Testicular germ cell tumors (TGCTs) are cancers that occur, primarily, among young men. TGCTs, as well as several other male reproductive disorders, may have a perinatal etiology that also results in aberrant hormonal levels. To examine this hypothesis, investigators in DCEG have been studying hormone levels in men who went on to develop TGCT and men who did not, as part of the STEED study. Thus far, investigators have examined the gonadotropins, LH and FSH, the steroid hormones, estradiol, testosterone, and sex- androstane-3a,17&szlig;-diol glucuronide (3adiol-G) levels, and sex-hormone binding globulin. To more completely characterize the hormonal milieu that may precede TGCT, DCEG investigators also plan to examine hCG, inhibin, dihydrotestosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and androsterone glucuronide.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" sys_contentid="349637" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7271048" sys_dependentvariantid="1965" sys_dependentid="349637" rxinlineslot="103">Katherine McGlynn</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7271049" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303662" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The heritability of testicular germ cell tumors (TGCT) is high, with studies suggesting TGCT risks of eight-fold in brothers and four-fold in fathers of affected men, compared to men in the general population. However, genome-wide association studies of single-nucleotide polymorphisms have found limited heritable risk. In addition to TGCT being a complex genetic disease, with many alleles contributing small changes in risk, heritable risk could also manifest itself in DNA methylation which can affect gene expression. Recent studies examining genes involved in tumor suppression or cell-cycling have suggested there may be differences in methylation patterns between normal and TGCT tissue. At the National Cancer Institute, investigators have the opportunity to use a high-throughput assay to assess methylation across 450,000 genes. This study will compare the methylation profiles of specific TGCT histologies, such as seminoma, embryonal carcinoma and teratoma, with one another and with adjacent &lsquo;normal&rsquo; tissue. This agnostic and powerful approach may provide clues into the etiology of TGCTs.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" sys_contentid="349637" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7271064" sys_dependentvariantid="1965" sys_dependentid="349637" rxinlineslot="103">Katherine McGlynn</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7271065" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303668" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers investigate the cancer risk from air pollutants. In particular, they are exploring the lung cancer risk from exposure to smoke from open fires in homes, a major health risk in developing countries. These efforts include the study of variation in genes that activate and detoxify chemicals in the smoke, DNA repair and cell cycle control, and potential gene-environment interactions.</p>
</div>]]></content>
  </row>
  <row para_id="303671" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div id="ctl00_ctl01_MainTargetZone">
<div class="htmlContent onlyzoneitem">
<p>Researchers in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271104" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a> (OEEB) have been conducting studies of occupational formaldehyde exposure and cancer risk since the 1980s. Early studies focused on surveys of professionals who are potentially exposed to formaldehyde in their work, such as anatomists and embalmers (Walrath and Fraumeni, 1983; Walrath and Fraumeni, 1984; Stroup et al., 1986; Hayes et al., 1990). Although these early studies reported that these professionals were at increased risk for leukemia compared to the general population, they did not evaluate specific exposures or work practices.</p>
<div class="callout-box" style="float: right; width: 25%; margin: 0 0 5px 10px;">
<h3>Related Content</h3>
<p><a href="https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/formaldehyde/formaldehyde-fact-sheet">NCI&rsquo;s Fact Sheet on Formaldehyde and Cancer Risk</a></p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=formaldehyde&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Search DCEG Formaldehyde Study Publications</a></p>
</div>
<p>More recently, OEEB scientists conducted a study investigating the relationship between work practices and formaldehyde exposure with risk for selected malignancies among workers in the funeral industry. Occupational histories were obtained from next of kin and co-workers for cases of lymphohematopoietic malignancies (n=167) and for a control group of deaths due to other causes. Risk of death from myeloid (n=34) but not other types of leukemia, was increased among those whose peak exposure to formaldehyde was highest. There was also evidence that greater than average levels of exposure to formaldehyde in these jobs was related to risk of death from myeloid leukemia (Hauptmann et al., 2009).</p>
<p>In the NCI Formaldehyde Industrial Cohort study, which began in the 1980s and includes 25,619 workers in industries with potential formaldehyde exposure, OEEB scientists estimated exposure based on work histories and plant-specific measurement data. In the most recent publication from this cohort that focused on deaths from lympohematopoietic malignancies, a possible link between formaldehyde exposure and lymphohematopoietic malignancies, particularly myeloid leukemia (n=48), was observed with peak exposure. When cumulative risk was evaluated, risks declined steadily over time, such that the cumulative excess risk of myeloid leukemia was no longer statistically significant at the end of the follow-up period. Similar to patterns of risk over time seen for known leukemogens, the risk for myeloid leukemia appeared to be highest earlier in the follow-up period. By the end of the follow-up period, the risk was no longer statistically significant (Beane Freeman et al., 2009). Formaldehyde exposure was also associated with increased risk of death from nasopharyngeal cancer, a rare malignancy.&nbsp;No association with lung cancer was observed in this update of the cohort (Beane Freeman et al., 2013).</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271105" sys_dependentvariantid="1965" sys_dependentid="349661" rxinlineslot="103" sys_variantid="1965">Dr. Laura Beane-Freeman</a>.</p>
<h2>Molecular Epidemiology Study of Formaldehyde</h2>
<p>In the first chromosome-wide association study (CWAS) using cultured myeloid progenitor cells from workers exposed to formaldehyde, there was an increase in monosomy and trisomy of multiple chromosomes and an increase in structural chromosomal aberrations of chromosome 5 (Lan et al., 2015), which are often present in acute myeloid leukemia. Formaldehyde exposure was also associated with a decrease in levels of CD8<sup>+</sup> effector memory T cells and regulatory T cells (Hosgood et al., 2013).</p>
<p>Results from these studies have been cited in several reviews on the carcinogenicity of formaldehyde, including those conducted by the International Agency for Research on Cancer and the National Toxicology Program Report on Carcinogens Outside Expert Panel.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271106" sys_dependentvariantid="1965" sys_dependentid="349661" rxinlineslot="103" sys_variantid="1965"></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271107" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103" sys_variantid="1965">Dr. Qing Lan</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271108" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>
</div>
</div>]]></content>
  </row>
  <row para_id="303672" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Information for Journalists</h3>
<p>To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:</p>
<p><b>E-mail:</b><br /><a href="mailto:ncipressofficers@mail.nih.gov">ncipressofficers@<br />mail.nih.gov</a></p>
<p><b>Phone:</b> 240-760-6600</p>
</div>
<p>In March 2012, the National Cancer Institute (NCI) and the National Institute for Occupational Safety and Health (NIOSH) completed a retrospective cohort mortality and nested case-control study of 12,315 workers at eight non-metal mining facilities to investigate risk of lung cancer in relation to quantitative measures of historical exposure to diesel exhaust, after taking into account smoking and other lung cancer risk factors. Elevated mortality from other causes among diesel exhaust-exposed miners was examined as well. An extensive effort to characterize current and historical exposures to diesel exhaust and to develop estimates of personal exposures was an intrinsic part of the study. The methods for this effort were published in five papers in the <i>Annals of Occupational Hygiene</i>. In 2012, results from the NCI-led case-control study and the NIOSH-led cohort study were published in the <i>Journal of the National Cancer Institute</i>. For more information about the study email <a href="mailto:silvermd@mail.nih.gov">Dr. Debra Silverman</a>.&nbsp;</p>
<ul>
<li><a href="#Study-Publications"><b>Study Publications</b></a></li>
<li><a href="#Study-Data"><b>Requests for Study Data</b></a></li>
</ul>
<h3><a id="Study-Publications"></a>Study Publications</h3>
<h4 id="Case-Control">Nested Case-Control Study</h4>
<ul>
<li>Silverman DT, Samanic CM, Lubin JH, Blair A, Stewart PA, Vermeulen R, Coble JB, Rothman N, Schleiff PL, Travis WD, Ziegler RG, Wacholder S, Attfield MD. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22393209" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: A Nested Case-Control Study of Lung Cancer and Diesel Exhaust</a>. <i>J Natl Cancer Inst,</i> 2012; Epub Mar 5, 2012.</li>
</ul>
<h4 id="Cohort-Mortality">Cohort Mortality Study</h4>
<ul>
<li>Attfield MD, Schleiff PL, Lubin JH, Blair A, Stewart PA, Vermeulen R, Coble JB, Silverman DT. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22393207" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: A Cohort Mortality Study with Emphasis on Lung Cancer</a>. <i>J Natl Cancer Inst</i> 2012; Epub Mar 5, 2012.</li>
<li>
<p>Costello S, Attfield MD, Lubin JH, Neophytou AM, Blair A, Brown DM, Stewart PA, Vermeulen R, Eisen EA, Silverman DT. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30137203">Ischemic heart disease mortality and diesel exhaust and respirable dust exposure in the Diesel Exhaust in Miners Study</a>.&nbsp;<em>Am J Epidemiol</em> 2018; Epub August 2018.</p>
</li>
<li>
<p>Neophytou AM, Costello S, Picciotto S, Brown DM, Attfield MD, Blair A, Lubin JH, Stewart PA, Vermeulen R, Silverman DT, Eisen EA. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30489348">Diesel exhaust, respirable dust, and ischemic heart disease: An application of the parametric g-formula</a>. <em>Epidemiology</em> 2018; Epub Nov 27 2018.</p>
</li>
</ul>
<h4 id="Exposure-Assessment"><a id="Exposure-Assessment"></a>Exposure Assessment</h4>
<ul>
<li>Stewart PA, Coble JB, Vermeulen R, Schleiff P, Blair A, Lubin J, Attfield M, Silverman DT. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20876233" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: I. Overview of the exposure assessment process</a>. <i>Ann Occup Hyg</i> 2010 Oct.</li>
<li>Coble JB, Stewart PA, Vermeulen R, Yereb D, Stanevich R, Blair A, Silverman DT, Attfield M. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20876232" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: II. Exposure monitoring surveys and development of exposure groups</a>. <i>Ann Occup Hyg </i>2010 Oct.</li>
<li>Vermeulen R, Coble JB, Yereb D, Lubin JH, Blair A, Portengen L, Stewart PA, Attfield M, Silverman DT. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20876234" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: III. Interrelations between respirable elemental carbon and gaseous and particulate components of diesel exhaust derived from area sampling in underground non-metal mining facilities</a>. <i>Ann Occup Hyg&nbsp;</i>2010 Oct.</li>
<li>Vermeulen R, Coble JB, Lubin JH, Portengen L, Blair A, Attfield MD, Silverman DT, Stewart PA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20876235" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: IV. Estimating historical exposures to diesel exhaust in underground non-metal mining facilities.</a> <i>Ann Occup Hyg</i> 2010 Oct.</li>
<li>Stewart PA, Vermeulen R, Coble JB, Blair A., Schleiff P, Lubin JH, Attfield M, Silverman DT. <a href="http://annhyg.oxfordjournals.org/content/56/4/389.full.pdf+html" target="_blank" rel="noopener noreferrer">The Diesel Exhaust in Miners Study: V. Evaluation of the Exposure Assessment Method</a>. <i>Ann Occup Hyg</i>&nbsp;2012 Mar.</li>
</ul>
<h4 id="Editorials">Editorials, Letters-to-the-Editor and Response</h4>
<ul>
<li>Ogden TL. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20940422" target="_blank" rel="noopener noreferrer">Diesel exhaust and underground miners - Letter from the Editor</a>. <i>Ann Occup Hyg</i>&nbsp;2010 Oct.</li>
<ul>
<li>Borak J, Bunn WB, Chase GR, Hall TA, Head HJ, Hesterberg TW, Sirianni G, Slavin TJ. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21402871" target="_blank" rel="noopener noreferrer">Comments on the Diesel Exhaust in Miners Study - Letter to the Editor</a>. <i>Ann Occup Hyg </i>2011<i>&nbsp;</i>Apr.</li>
<li>Stewart PA, Coble JB, Vermeulen R, Blair A, Lubin J, Attfield M, Silverman DT. <a href="http://annhyg.oxfordjournals.org/content/55/3/343.full" target="_blank" rel="noopener noreferrer">Comments on the Diesel Exhaust in Miners Study - Author's Reply</a>. <i>Ann Occup Hyg </i>2011 Apr.</li>
</ul>
<li>Rushton L. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22393208" target="_blank" rel="noopener noreferrer">The problem with diesel</a>. <i>J Natl Cancer Inst, </i>Epub Mar 5,<i> </i>2012. (Editorial appearing in issue with published cohort and nested case-control papers)</li>
<li>Silverman DT, Attfield MD.&nbsp;<a href="http://jnci.oxfordjournals.org/content/104/23/1848.full">Response to &ldquo;The Diesel Exhaust in Miners Study: A nested case-control study of lung cancer and diesel exhaust&rdquo; and &ldquo;The Diesel Exhaust in Miners Study: A cohort mortality study with emphasis on lung cancer.&rdquo;</a>&nbsp; <i>J Natl Cancer Inst</i>&nbsp;2012; Epub Dec 5, 2012. (Response to 5 letters)</li>
<li>Morfeld P. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22676299">Diesel exhaust in miners study: How to understand the findings</a>? <em>J Occup Med Toxicol</em> 2012 June 7. (Commentary)</li>
<ul>
<li>Silverman DT, Attfield M. <a href="https://occup-med.biomedcentral.com/articles/10.1186/1745-6673-7-10/comments">Letter to the Editor; RE: &lsquo;Diesel exhaust in miners study: How to understand the findings?&rsquo;</a> by Peter Morfeld.&nbsp;<em>J Occup Med Tox</em> 2013.</li>
</ul>
<li>Silverman DT, Lubin JH, Blair BE, Vermeulen R, Stewart PA, Schleiff PL, Attfield MD. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25063325">RE: &ldquo;The Diesel Exhaust in Miners Study (DEMS): A nested case-control study of lung cancer and diesel exhaust.&rdquo;</a>&nbsp;<i>J Natl Cancer Inst</i>&nbsp;2014. (presents additional smoking data from nested case-control study)</li>
<li>M&ouml;hner M. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27226080">The hidden impact of a healthy-worker effect on the results of the Diesel Exhaust in Miners Study</a>. <em>Eur J Epidemiol</em> 2016. (Correspondence)</li>
<ul>
<li>Silverman, DT, Attfield, MD, Blair, AE et al.&nbsp; <a href="https://www.ncbi.nlm.nih.gov/pubmed/27518301">Re: &ldquo;The hidden impact of a healthy-worker effect on the results of the Diesel Exhaust in Miners Study&rdquo;</a>. <em>Eur J Epidemiol</em> 2016.</li>
</ul>
<li>Silverman DT.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352477/">Diesel exhaust causes lung cancer &ndash; now what</a>? (Invited Commentary) <em>Occup Environ Med</em> 2017.</li>
<li>Silverman DT.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/29522191">Commentary: Diesel exhaust and lung cancer &ndash; Aftermath of becoming an IARC Group 1 Carcinogen</a>.&nbsp;<em>Am J Epidemiol</em> 2018.</li>
<ul>
<li>Chang ET, Lau EC, Van Landingham C, Crump KS, McCleelan RO, Moolgavkar SH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30192919">Response to "Invited commentary: diesel exhaust and lung cancer -- aftermath of becoming an IARC Group 1 carcinogen" by Debra T. Silverman. <em>Am J Epidemiol</em> 2018 Mar 7. doi: 10.1093/aje/kwy036</a>.&nbsp;<em>Am J Epidemiol</em> 2018; Epub Sept 6, 2018.</li>
<li>Silverman DT. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+30192912">Response to Letter-to-the-Editor: &ldquo;Invited commentary: Diesel exhaust and lung cancer &ndash; aftermath of becoming an IARC Group 1 carcinogen&rdquo; by Ellen T. Chang, Edmund C. Lau, Cynthia Van Landingham, Kenny S. Crump, Roger O. McClellan, Suresh H. Moolgavkar</a>. <em>Am J Epidemiol</em> 2018; Epub Sept 6, 2018.</li>
<li>M&ouml;hner M. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30124752">On the ongoing discussion about the risk of lung cancer due to diesel engine exhaust</a>. <em>Am J Epidemiol</em> 2018; Epub Aug 14, 2018.</li>
<li>Silverman DT. <a href="https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwy168/5074373">Response to Letter-to-the-Editor: &ldquo;On the ongoing discussion about the risk of lung cancer due to diesel engine exhaust&rdquo; by Matthias M&ouml;hner</a>.&nbsp;<em>Am J Epidemiol</em> 2018; Epub Aug 14 2018.</li>
</ul>
</ul>
<h3><a id="Study-Data"></a>Requests for Study Data</h3>
<p>NCI and NIOSH believe that transparency and public health and scientific advancements are best served when, for an appropriate and legitimate public health purpose, data are shared with researchers and other public health agencies in an open, timely, and appropriate way. The Diesel Exhaust in Miners Study (DEMS) has ended and has fulfilled the objectives reported in the research protocol. Requestors interested in the data supporting the Diesel Exhaust in Miners Study (DEMS) can access these data through the Research Data Center (RDC) at the National Center for Health Statistics by following the <a href="https://www.cdc.gov/rdc/b1datatype/dt130.htm">standard RDC procedures for accessing non-NCHS Restricted Data </a>(<a href="https://www.cdc.gov/rdc/b1datatype/dt130.htm">https://www.cdc.gov/rdc/b1datatype/dt130.htm</a>). Data requestors must have a legitimate public health or scientific need for the data and must agree to comply with certain restrictions on the use of the data.</p>
<p>Interested parties are required to submit an application and sign a data use agreement prior to receiving any dataset. To receive an application for the DEMS&ndash; Case-Control Study data, send an email to <a href="mailto:silvermd@mail.nih.gov">Dr. Debra Silverman</a>. In the subject line, type "Request for DEMS &ndash; Case-Control Study Data," and in the body of the email include all contact information.</p>
<p>In addition, NCI is providing the opportunity to download the exposure data and documentation underlying the exposure assessment methods described in the five published exposure assessment papers shown above in the <a href="#Study_Publications">Study Publications</a>. To access exposure data underlying the exposure assessment papers, you may download (1) <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=386807" sys_contentid="386807" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="386807" sys_dependentvariantid="1500" sys_siteid="475" sys_relationshipid="7312608" sys_variantid="1500">a zip archive of the data</a> and (2) <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=386809" sys_contentid="386809" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="386809" sys_dependentvariantid="1500" sys_siteid="475" sys_relationshipid="7312609" sys_variantid="1500">the documentation</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349599" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7312610" sys_variantid="1965">Dr. Debra Silverman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7312611" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303673" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers in the Occupational and Environmental Epidemiology Branch (OEEB) investigate a number of water contaminants that are thought to be associated with cancer risk. These include naturally-occurring substances, like arsenic, fertilizer by-products like nitrate, as well as compounds formed when chlorine to disinfect water comes into contact with organic material in water.</p>
<a id="top"></a>
<p><em>On this page</em>:</p>
<p><a href="#Arsenic">Arsenic</a><br /><a href="#Disinfection-Byproducts">Disinfection Byproducts</a><br /><a href="#Nitrate">Nitrate</a></p>
<h3><a id="Arsenic"></a>Arsenic</h3>
<p>Ingestion of high levels of arsenic is an accepted cause of bladder cancer, but risk at lower levels is uncertain. Large populations are needed to adequately characterize bladder cancer risk from lower levels of arsenic exposure in drinking water.&nbsp;DCEG investigators&nbsp;conducted the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="438648" sys_dependentvariantid="1418" sys_relationshipid="7271121" sys_siteid="475" sys_variantid="1418">New England Bladder Cancer Study</a>, a population-based case-control study in Maine, New Hampshire, and Vermont, to identify risk factors that might explain the persistent high rates in these states, to evaluate exposure to arsenic at low to moderate levels, and to evaluate possible gene-exposure interactions. Exposure to arsenic and other drinking water contaminants (i.e., DBP and nitrates) was assessed based on drinking water samples taken at current and former homes, monitoring data obtained from public water utilities, and a geographic information system (GIS)-based predictive model based on geologic characteristics at the wells when measurements were missing. &nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349599" sys_dependentvariantid="1965" sys_relationshipid="7271117" sys_siteid="475" sys_variantid="1965">Dr. Debra Silverman</a>.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Disinfection-Byproducts"></a>Disinfection Byproducts</h3>
<p>Chlorine interacts with organic materials in water to form a mixture of disinfection byproducts (DBP). Although concentrations in the United States are quite low, there is concern that some chemicals in the mixture may increase cancer risk. A DCEG study of six cancer sites conducted in Iowa found associations of rectal and bladder cancers with long-term (&gt;40 years) exposure to drinking water high in these unintentional byproducts. The data from these and additional cancer sites included in the study are under evaluation following an improved historical exposure assessment effort in which DBP exposures were estimated for each individual water utility, taking into account changes in water source and treatments over time.</p>
<p>Studies indicate that dermal and inhalation exposures to trihalomethanes (THM), a major component of DBPs in treated water, can be significant. With collaborators in Spain,&nbsp;DCEG investigators&nbsp;evaluated DBP in relation to bladder cancer risk in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303543" sys_contentid="303543" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303543" sys_dependentvariantid="1418" sys_relationshipid="7271122" sys_siteid="475" sys_variantid="1418">Interdisciplinary Case-Control Study of Bladder Cancer in Spain</a>, considering exposure via ingestion, showering/bathing, and swimming in pools. THM exposure estimates revealed an excess of bladder cancer among individuals with estimated household levels above 49 mg/L and the association was modified by polymorphisms in DBP metabolizing enzymes. A similar elevation of risk was seen in the New England Bladder Cancer Study at the same levels of THM exposure, and confirmed the risk observed associated with showering/bathing. In this study, there was also indication that brominated species were potentially more important than the chlorinated species, which is supported by the toxicologic data.</p>
<p>DCEG investigators are now evaluating interactions with genes involved in pathways that activate or detoxify DBP. With collaborators at the University of Minnesota and the University of Iowa, they evaluated intake of DBP from public drinking water in relation to cancer risk in the Iowa Women&rsquo;s Health Study. They found that women with higher average THM in public water supplies had increased risks of rectal cancer, but evidence of associations with colon, kidney, bladder, and ovarian cancers was inconsistent. These analyses considered concomitant exposure to nitrate, another common drinking water contaminant.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349661" sys_dependentvariantid="1965" sys_relationshipid="7271119" sys_siteid="475" sys_variantid="1965">Dr. Laura Beane Freeman</a>&nbsp;or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1080328" sys_dependentvariantid="1965" sys_relationshipid="7271123" sys_siteid="475" sys_variantid="1965">Dr. Rena Jones</a>.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Nitrate"></a>Nitrate</h3>
<p>Contamination of drinking water by nitrate is a growing problem in many agricultural areas of the country. Ingested nitrate can lead to the endogenous formation of N-nitroso compounds (NOC), which are potent animal carcinogens. Population-based case-control studies in Iowa and Nebraska evaluated community-supplied drinking water nitrate levels and cancers of the stomach, esophagus, bladder, brain, colon, rectum, pancreas, and kidney. Increased risks of colon, kidney, and stomach cancer were observed among those with higher ingestion of water nitrate and higher meat intake compared with low intakes of both, a dietary pattern that results in increased NOC formation.</p>
<p>With collaborators at the University of Minnesota and the University of Iowa, DCEG investigators are evaluating nitrate intake from drinking water in relation to cancer risk in the Iowa Women&rsquo;s Health Study. So far, they found that women with higher average nitrate levels in public water supplies had increased risks of thyroid, ovarian, bladder, and kidney cancers. There was no association with drinking water nitrate ingestion and colorectal and pancreas cancers.&nbsp;The population using private wells can have considerably higher exposure to nitrate because private wells are not regulated, and because&nbsp;they are often located in agricultural areas. Using a Geographic Information System (GIS)-based model that incorporates land use, soil characteristics, nitrogen inputs, and other factors, DCEG investigators estimated private well nitrate levels for the Agricultural Health Study cohort and are evaluating cancer risk among the applicators and their spouses.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349624" sys_contentid="349624" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349624" sys_dependentvariantid="1965" sys_relationshipid="7271120" sys_siteid="475" sys_variantid="1965">Dr. Mary Ward</a>&nbsp;or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1080328" sys_dependentvariantid="1965" sys_relationshipid="7271124" sys_siteid="475" sys_variantid="1965">Dr. Rena Jones</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7271118" sys_siteid="475" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
<p><a href="#top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="303674" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators seek to clarify the roles of Epstein-Barr virus (EBV) and common variants in genes controlling immunity and inflammation on the risk of AIDS-related non-Hodgkin lymphoma. In collaboration with the Multicenter AIDS Cohort Study, the interactions of EBV load, EBV cellular and humoral immunity, and variants in candidate genes are being studied in 181 incident lymphomas and matched controls. To identify novel genetic associations, investigators plan to genotype 800 additional cases assembled from several sources with a haplotype-tagging panel of more than 150 genes on pathways implicated in lymphomagenesis.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7271125" sys_dependentvariantid="1965" sys_dependentid="349601" rxinlineslot="103">Eric Engels</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7271126" sys_dependentvariantid="1418" sys_dependentid="419183" rxinlineslot="103">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303675" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Estrogens play important roles in the pathophysiology of breast tumors and are recognized causal factors in the etiology of breast cancer; this central insight has led to many of the available preventive and therapeutic interventions for breast cancer. Endogenous estrogens may also play causal roles in endometrial and ovarian cancers and could also be important in male reproductive cancers, such as male breast cancer, testicular cancer, and prostate cancer. Substantial inter-individual variability has been observed in levels of circulating and excreted estrogens and estrogen metabolites (jointly referred to as EM) among men, postmenopausal women, and premenopausal women. Because EM vary with respect to bioavailability, affinity to estrogen receptors, and mutagenic potential, investigators have hypothesized that variations in estrogen profiles may account for inter-individual differences in cancer risks. Until recently, it has been difficult to study this hypothesis in epidemiologic settings. Development of a liquid chromatography-tandem mass spectrometry (LC/MS-MS) method for measurement of estrogens and estrogen metabolites in urine (Xu et al., <i>Anal Chem</i> 2006;78:1553) and serum (Xu et al., <i>Anal Chem</i> 2007;79:7813) represents an important methodologic development because it provides an assay with characteristics that make it feasible for use in epidemiologic studies: high sensitivity, specificity, reliability, and scalability for high-throughput work.</p>
<p>Expanding on our research evaluating endogenous estrogens and estrogen metabolites and cancer risk, recent methodologic advances in the measurement of androgens and androgen metabolites as well as progesterone, pregnenolone, and progesterone metabolites in serum will facilitate epidemiologic studies to evaluate the role of principal estrogens, androgens and progesterone, together with their major metabolites, in cancer etiology.</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303756&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296801">Bone Density and Cancer Risk: A Follow-Up Study of Women in the Fracture Intervention Trial (BFIT)</a></h2>
<p>A retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303566&amp;sys_revision=20&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303566" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296802">Breast Cancer Case-Control Study in Poland</a></h2>
<p>A population-based case-control study of breast cancer in Poland that combines state-of-the art techniques of exposure assessment and collection of biological specimens</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303567&amp;sys_revision=14&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303567" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296803">Breast Radiology Evaluation and Study of Tissues (BREAST) Stamp Project</a></h2>
<p>A study that aims to characterize the radiologic, histologic, and molecular features of dense breast tissue</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303561&amp;sys_revision=15&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303561" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296804">Columbia, Missouri Serum Bank Follow-up Study</a></h2>
<p>A study established as part of NCI's Biological Markers Project to identify serum markers for breast cancer</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=330697&amp;sys_revision=12&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="330697" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296805">Reproducibility and Validity of Hormone Assays</a></h2>
<p>Studies to assess methods for measurement of estrogens/estrogen metabolites, androgens/androgen metabolites, pregnenolone, and progesterone/progesterone metabolites</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303634&amp;sys_revision=22&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303634" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296806">Serum Sex Steroids and Their Metabolites in Relation to Ovarian and Endometrial Cancer</a></h2>
<p>A nested case-control study of endometrial and ovarian cancers assessing the roles of estrogens, estrogen metabolites, androgens, and androgen metabolites in the etiologies of these cancers</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303661&amp;sys_revision=9&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303661" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296807">Testicular Cancer among Military Servicemen: the STEED Study</a></h2>
<p>A case-control study of testicular cancer among military servicemen</p>
</div>]]></content>
  </row>
  <row para_id="303678" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The <a href="http://hivmatch.cancer.gov/">HIV/AIDS Cancer Match Study</a> is designed to examine cancer risk in people living with HIV infection in the United States. The study utilizes data collected by state and regional HIV and cancer registries throughout the United States. The NCI uses these study data to determine the spectrum of cancers that occur in HIV-infected people. The risk of cancer in HIV-infected people is compared with that in the general population to determine which cancers arise more frequently than expected. Investigators compare different groups of HIV-infected people to determine whether certain individuals are at especially high risk of cancer. Through frequent updates of the data, investigators also monitor changing trends in cancer risk over time.</p>
<p>People who are infected with HIV have an elevated risk for some cancers. This high risk occurs because HIV weakens the immune system, and because many other cancer risk factors are common in HIV-infected people. By studying the patterns of cancer among HIV-infected people, DCEG investigators seek to better understand how the immune system protects people from developing cancer. Another goal of the study is to look for trends in cancer risk in the HIV populations and identify important opportunities for cancer prevention.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349601" sys_dependentvariantid="1965" sys_relationshipid="7277595" sys_siteid="475" sys_variantid="1965">Eric Engels</a>&nbsp;or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052540" sys_contentid="1052540" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1052540" sys_dependentvariantid="1965" sys_relationshipid="7277598" sys_siteid="475" sys_variantid="1965">Meredith Shiels</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7277596" sys_siteid="475" sys_variantid="1418">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
<p><a href="https://hivmatch.cancer.gov/">HIV/AIDS Cancer Match Study Website</a></p>
</div>]]></content>
  </row>
  <row para_id="303684" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p style="text-align: justify;">DCEG researchers conduct studies in the United States and abroad to identify and evaluate environmental and workplace exposures that may be associated with cancer risk. Workers often have heavier and more prolonged exposures to hazardous chemicals that also occur in the general environment, but at lower levels. When excess risks are detected from workplace studies, they may provide important leads as to the etiology of cancer in other settings. Occupational studies have identified many chemicals that cause cancer in humans, and they have provided direction for initiatives aimed at reducing or eliminating these carcinogens in the workplace and elsewhere. Selected studies include:</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_dependentvariantid="1418" sys_dependentid="303742" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296519" sys_variantid="1418" sys_contentid="303742">Agricultural Health Study (AHS)</a></h2>
<p>The Agricultural Health Study (AHS) is prospective cohort of commercial pesticide applicators and their spouses in Iowa and North Carolina. AHS is conducted in collaboration among the National Cancer Institute, the National Institute of Environmental Health Sciences, the U.S. Environmental Protection Agency and the National Institute for Occupational Safety and Health.&nbsp;</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302387" sys_dependentvariantid="1418" sys_dependentid="302387" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296520" sys_variantid="1418" sys_contentid="302387">Benzene-Exposed Workers in China</a></h2>
<p>A binational, multidisciplinary study of Chinese benzene-exposed workers and unexposed workers from more than 700 factories in 12 cities</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303671&amp;sys_revision=21&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303671" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296523">DCEG Research on Formaldehyde Exposure</a></h2>
<p>Studies to investigate occupational formaldehyde exposure and cancer risk, including an industrial cohort study of over 25,000 workers, a case-control study of workers in the funeral industry, and a cross-sectional study to quantify leukemia-specific chromosome changes associated with formaldehyde exposure</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303672" sys_dependentvariantid="1418" sys_dependentid="303672" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296521" sys_variantid="1418" sys_contentid="303672">Diesel Exhaust in Miners Study (DEMS)</a></h2>
<p>In March 2012, the National Cancer Institute (NCI) and the National Institute for Occupational Safety and Health (NIOSH) completed a retrospective cohort mortality and nested case-control study of 12,315 workers at eight non-metal mining facilities to investigate risk of lung cancer in relation to quantitative measures of historical exposure to diesel exhaust, after taking into account smoking and other lung cancer risk factors</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_dependentvariantid="1418" sys_dependentid="302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296522" sys_variantid="1418" sys_contentid="302552">U.S. Radiologic Technologists Cohort (USRT)</a></h2>
<p>The U.S. Radiologic Technologists (USRT) cohort is a study of cancer and other serious disease risks associated with protracted low-to-moderate dose radiation exposures in an occupational exposed cohort.</p>
</div>]]></content>
  </row>
  <row para_id="303685" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>There is substantial variation in the annual mean concentration of radon in the same North American homes measured several years apart. These findings call into question the assumption that year-long indoor air radon measurements offer a valid estimate of cumulative radon exposures in homes over a period of 15-20 years, the most biologically meaningful exposure period. All previous studies used detectors that measure current radon in air. In a new case-control study, DCEG investigators carried out both standard year-long air measurements and CR-39 alpha detector measurements (call surface monitors) which directly measure long-term (20- year and more) cumulative exposure using glass objects in the home. The surface monitors take advantage of the fact that the first long-lived radon progeny, 210-lead (half-life 22 yrs), becomes embedded in glass surfaces in homes. The alpha activity of 210-polonium, a decay product of 210-lead, is measured in glass objects in the home and serves as a long-term retrospective exposure-meter for residential radon. This population-based case-control study of lung cancer was specifically designed to complement an earlier DCEG study by evaluating the effect of cumulative residential radon exposure among Missouri women who were predominantly smokers and former smokers using a control selection technique that minimized the inherent imbalance in smoking frequency between cases and controls.</p>
<p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=349599&amp;sys_revision=22&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="349599" rxinlineslot="103" sys_folderid="" sys_relationshipid="6186746">Dr. Debra Silverman</a>.&nbsp;</p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=10&amp;sys_contentid=418935&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6186745" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303686" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Human papillomavirus (HPV), the cause of cervical cancer, is recognized as an important cause of some oropharyngeal, vulvar, and anal cancers. Given the many similarities between HPV-related cancers at the cervix and other anatomic sites, researchers are optimistic that the HPV vaccine will&nbsp;provide long-term protection&nbsp;against extra-cervical infections with high vaccine efficacy. In fact, the vaccine has already been shown to confer near-complete protection over four years against oral, vulvar/vaginal, and anal HPV infections&nbsp;for targeted HPV types.&nbsp;To determine whether the HPV 16/18 prophylactic vaccine protects against HPV 16/18 infections in the oral, vulvar, and anal regions over 10 years, DCEG investigators recently completed collection of oral, vulvar, and anal specimens from women in the long-term follow-up phase of the&nbsp;NCI-sponsored Costa Rican community-based randomized phase III clinical trial and plan to test these specimens for presence of HPV DNA. The main aim of this proof-of-principle study is to determine the long-term&nbsp;impact of HPV vaccination in preventing infections at all mucosal epithelial surfaces.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349605" sys_contentid="349605" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349605" sys_dependentvariantid="1965" sys_relationshipid="7275395" sys_siteid="475">Aim&eacute;e Kreimer</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7275396" sys_siteid="475">Infections and Immunoepidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303687" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers investigate a number of water contaminants that are thought to be associated with cancer risk. These include naturally-occurring substances, like arsenic, fertilizer by-products like nitrate, as well as compounds formed when chlorine to disinfect water comes into contact with organic material in water.</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303673" sys_dependentvariantid="1418" sys_dependentid="303673" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296346" sys_variantid="1418" sys_contentid="303673">Drinking Water Contaminants</a></h2>
<p>Studies of water contaminants thought to be associated with cancer risk, including arsenic, disinfection byproducts, and nitrate</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303543" sys_dependentvariantid="1418" sys_dependentid="303543" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296347" sys_variantid="1418" sys_contentid="303543">Interdisciplinary Case-Control Study of Bladder Cancer in Spain</a></h2>
<p>A large interdisciplinary case-control study of bladder cancer in 18 hospitals from five different regions in Spain</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_dependentvariantid="1418" sys_dependentid="438648" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296348" sys_variantid="1418" sys_contentid="438648">New England Bladder Cancer Study</a></h2>
<p>A population-based case-control study that investigates the reason for the persistent excess of bladder cancer mortality and incidence in the northern New England area.</p>
</div>]]></content>
  </row>
  <row para_id="303688" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Acrylonitrile is a commercially important chemical used in the production of synthetic fibers and resins, plastics, nitrile rubbers, and many other products. Results from animal bioassays and epidemiologic studies suggest it might cause cancers of the lung, brain, prostate, stomach, hematopoietic and lymphatic systems. However, findings from early epidemiologic studies were inconsistent and inconclusive due to being underpowered and lack of exposure characterization.</p>
<p>The NCI Acrylonitrile Cohort is a study of 25,460 workers employed at eight facilities that produce or use acrylonitrile in the United States.&nbsp;Follow-up of this cohort through 1989 found no elevated risk for any cancer, but there was an excess for lung cancer in the highest quintile of cumulative exposure more than 20 years after first exposure. The NCI cohort is the largest study to date, with the most detailed exposure assessment.&nbsp;Currently, the mortality experience of the cohort is being extended an additional 20 years to re-evaluate the association between acrylonitrile exposure and cancer mortality, as well as other health outcomes.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=919003" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="919003" sys_dependentvariantid="1965" sys_relationshipid="7271186" sys_variantid="1965" sys_contentid="919003">Dr. Stella Koutros</a> or&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7271185" sys_siteid="475" rxinlineslot="103" sys_dependentid="349599" sys_dependentvariantid="1965">Dr. Debra Silverman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7271187" sys_variantid="1418" sys_contentid="418935">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303691" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="1833" sys_dependentid="1072158" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7271200">
<figure class="video right size50">
<h4>Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"</h4>
<div class="flex-video widescreen" id="ytplayer-Q_yycIT2ZjM" data-video-title="Highlights from " data-video-id="Q_yycIT2ZjM"><noscript>			&lt;p&gt;				&lt;a href="https://www.youtube.com/watch?v=Q_yycIT2ZjM" target="_blank" title="Highlights from "Telomere Biology and Cancer Risk with Sharon Savage""&gt;					View this video on YouTube.				&lt;/a&gt;			&lt;/p&gt;		</noscript></div>
<figcaption class="caption-container">
<div class="contentid-1071885 slot-item only-SI">
<p><a title="" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_folderid=401214&amp;sys_siteid=475&amp;sys_contentid=349621&amp;sys_command=editrc" sys_variantid="1965" sys_contentid="349621">Sharon Savage, M.D.</a>, and investigators in the <a title="" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_folderid=301997&amp;sys_siteid=475&amp;sys_contentid=302430&amp;sys_command=editrc" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a> study families with <a title="" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=335952&amp;sys_command=editrc" sys_variantid="1418" sys_contentid="335952">dyskeratosis congenita (DC)</a>, a rare and complex inherited cancer predisposition syndrome. Patients with DC have extremely short telomeres and elevated risk for multiple cancers. As they study the effect of shortened telomeres on this unique population, the research team searches for genetic variations associated with abnormal telomeres and telomere biology.&nbsp;</p>
<p><a href="https://irp.nih.gov/our-research/research-in-action/decoding-telomere-biology-and-cancer-risk">Read the full article on telomere biology and cancer risk</a>.</p>
</div>
</figcaption>
</figure>
</div>
<p>The inherited bone marrow failure syndromes (IBMFS) are a group of <b>rare genetic blood disorders</b> in which there is usually some form of aplastic anemia (failure of the bone marrow to produce blood), associated with a family history of the same disorder. Some of these conditions have typical changes in physical appearance or in laboratory findings which suggest a specific diagnosis. There are several well-described syndromes, which can be recognized by health care experts. There are also patients who are harder to classify, but who appear to belong in this category. Patients with these syndromes have a very high risk of development of cancer (either leukemia or certain solid tumors).</p>
<p>The major disorders are:</p>
<ul>
<li>Amegakaryocytic thrombocytopenia (Amega)</li>
<li>Diamond Blackfan anemia (DBA)</li>
<li>Dyskeratosis congenita (DC)</li>
<li>Fanconi anemia (FA)</li>
<li>Pearson syndrome</li>
<li>Severe congenital neutropenia (SCN)</li>
<li>Shwachman Diamond syndrome (SDS)</li>
<li>Thrombocytopenia absent radii (TAR)</li>
<li>Other bone marrow failure syndromes</li>
</ul>
<h3>Clinical Study of IBMFS</h3>
<p>DCEG investigators have been leading an ongoing clinical study in order to better understand how cancers develop in persons with IBMFS, with the aim of improving the healthcare that can be offered to persons with these disorders. <a href="http://marrowfailure.cancer.gov/index.html">Learn more about the IBMFS study</a>.&nbsp;(<a href="http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_02-C-0052.html@etiologic">IBMFS study protocol: 02-C-0052</a>).&nbsp;</p>
<p>This study is open for enrollment.</p>
<p>For more information, contact the referral nurse by phone (1-800-518-8474), or by <a href="mailto:NCI.IBMFS@westat.com">email</a>.</p>
<h2>Inherited Bone Marrow Failure Syndromes Study Literature</h2>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1500&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=1056276&amp;sys_command=editrc" sys_contentid="1056276" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" rxinlineslot="103" sys_dependentid="1056276" sys_relationshipid="7271196" sys_variantid="1500">Family Research Matters 2016 Study Newsletter</a> (pdf, 893 KB)</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1500&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=303433&amp;sys_command=editrc" sys_contentid="303433" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" rxinlineslot="103" sys_dependentid="303433" sys_relationshipid="7271197" sys_variantid="1500">Family Research Matters 2008 Study Newsletter</a> (pdf, 142 KB)</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1500&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=491879&amp;sys_command=editrc" sys_contentid="491879" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" rxinlineslot="103" sys_dependentid="491879" sys_relationshipid="7271198" sys_variantid="1500">IBMFS Study Brochure</a> (pdf, 149 kb)</li>
</ul>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=433261&amp;sys_command=editrc" sys_contentid="433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_relationshipid="7271195" sys_variantid="1418">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303692" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers actively investigate the role of common and uncommon inherited variations in the genetic code&nbsp;associated with&nbsp;risk of cancer. This work is carried out using biological samples from study participant and techniques like genome-wide association studies, whole genome scans, and new and emerging technologies and methods. Examples of studies include:</p>
<h2>Brain</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302453" sys_contentid="302453" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302453" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326149" sys_variantid="1418">Genetic Susceptibility and Brain Tumors</a></h3>
<p>Study of common genetic variation associated with risk for brain tumors</p>
<h2>Breast</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=837951" sys_contentid="837951" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="837951" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326150" sys_variantid="1418">Breast Cancer Among Asian Women</a></h3>
<p>A study of breast cancer among Asian populations, including mainland China, Hong Kong, and Malaysia, with the aim of identifying distinct molecular alterations in tumors and adjacent normal tissues, and examining the associations of these molecular changes with risk factors (genetic and environmental), breast tissue composition and density, and breast cancer subtypes.</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303566" sys_contentid="303566" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303566" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326151" sys_variantid="1418">Breast Cancer Case-Control Study in Poland</a></h3>
<p>A population-based case-control study of breast cancer in Poland that combines state-of-the art techniques of exposure assessment and collection of biological specimens</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303562" sys_contentid="303562" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303562" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326152" sys_variantid="1418">Breast Cancer Detection Demonstration Project Follow-up Study</a></h3>
<p>A follow-up study of women who were participants in the Breast Cancer Detection Demonstration Project</p>
<h2>Melanoma</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303752" sys_contentid="303752" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303752" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326153" sys_variantid="1418">Familial Melanoma Studies</a></h3>
<p>A search for new genes associated with melanoma susceptibility in melanoma-prone families</p>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303618" sys_contentid="303618" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303618" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326154" sys_variantid="1418">Genetic and Molecular Epidemiology Studies of Melanoma in Italy</a></h3>
<p>A case-control study in Italy to study the role of pigmentation and other host factors in the etiology of melanoma</p>
<h2>Pancreas</h2>
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=459581&amp;sys_revision=12&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="459581" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7326157">PanScan Study</a></h3>
<p>A multi-stage genome-wide association study (GWAS) of pancreatic cancer launched to identify the genetic variants that predict pancreatic cancer risk</p>
<h2>Ovary and Endometrium</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303633" sys_contentid="303633" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303633" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326155" sys_variantid="1418">Ovarian and Endometrial Cancer Case-Control Study in Poland</a></h3>
<p>A study of common inherited variation associated with risk of ovarian cancer, carried out using data and biospeciments from a population-based case-control study of ovarian and endometrial cancer conducted among female residents of Warsaw and Lodz (Poland).</p>
<h2>Upper Gastrointestinal Tract</h2>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303657" sys_contentid="303657" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303657" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7326156" sys_variantid="1418">Upper Gastrointestinal Cancer Genetic Studies in Shanxi Province, China</a></h3>
<p>Studies initiated to look for major susceptibility genes for upper gastrointestinal cancers and to identify the genetic changes associated with their development</p>
</div>]]></content>
  </row>
  <row para_id="303693" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers study a range of inherited syndromes that may predispose affected individuals and their family members to cancer. These include inherited bone marrow failure syndromes, Li-Fraumeni Syndrome, dyskeratosis congenita, and other inherited cancer predisposition syndromes. We use an interdisciplinary clinical research approach to systematically investigate cancers related to these syndromes.</p>
<p><a href="http://ppb.cancer.gov/">Pleuropulmonary Blastoma Cancer Predisposition Syndrome</a><br /> Pleuropulmonary blastoma (PPB) is a rare tumor of the lung. Research has shown that PPB may be part of an inherited cancer predisposition syndrome caused by changes in a gene known as <i>DICER1</i>. The PPB Cancer Study is an observational study of children with PPB and their families.</p>
<p><a href="http://dceg.cancer.gov/research/who-we-study/families/familial-melanoma-study">Familial Melanoma Studies</a>&nbsp;<br /> DCEG researchers are searching for melanoma susceptibility genes in melanoma-prone families.</p>
<p><a href="http://dceg.cancer.gov/research/what-we-study/genes-host/li-fraumeni-syndrome-study">Li-Fraumeni Syndrome Study</a><br /> Li-Fraumeni Syndrome (LFS) is a rare, inherited disorder which leads to a higher risk of certain cancers. NCI has evaluated families with LFS since the syndrome was first recognized in 1969. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/blood-lymph-cancers">Familial Blood and Lymph Node Cancers Study</a>&nbsp;<br /> DCEG investigators have been studying the causes of familial blood and lymph node cancers for over 30 years. Ongoing advances in genetics, anticipated applications of advanced technologies, and data from families have allowed research efforts to expand.</p>
<p><a href="http://dceg.cancer.gov/research/what-we-study/genes-host/bone-marrow-failure-syndromes">Inherited Bone Marrow Failure Syndromes</a>&nbsp;<br /> The inherited bone marrow failure syndromes (IBMFS) are a group of rare genetic blood disorders. DCEG investigators are leading a clinical study to better understand how cancers develop in persons with IBMFS.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/blood-wm">Waldenstr&ouml;m's Macroglobulinemia Study</a><br /> Waldenstr&ouml;m's macroglobulinemia (WM) is a rare type of tumor that belongs to a group of disorders called lymphoproliferative diseases. DCEG researchers are leading a study to determine what causes WM to sometimes develop in two or more family members.</p>
<p><a href="http://dceg.cancer.gov/research/cancer-types/testes/familial-testicular-cancer-study">Familial Testicular Cancer Study</a>&nbsp;<br /> DCEG investigators are conducting the Familiar Testicular Cancer Study to research the genetic causes of testicular cancer.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/blood-cll-info">Familial Chronic Lymphocytic Leukemia Study</a><br /> DCEG investigators are studying families with multiple cases of chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the Western Hemisphere.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/hboc-overview">Multidisciplinary Etiologic Studies of Hereditary Breast/Ovarian Cancer</a><br /> DCEG researchers have been studying the Hereditary Breast/Ovarian Cancer (HBOC) syndrome since the 1960s. This study is now closed to patient enrollment, and researchers are analyzing previously collected data.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/chordoma">Chordoma Study</a><br /> Chordoma is a rare bone cancer that develops at the base of the skull, in a vertebra, or at end of the spine. DCEG investigators are studying families with multiple relatives with chordoma.</p>
<p><a href="http://dceg.cancer.gov/research/cancer-types/ovary/ovarian-cancer-prevention-early-detection-study">National Ovarian Cancer Prevention and Early Detection Study</a><br /> The National Ovarian Cancer and Early Detection Study (GOG-0199) is a prospective study of women who are at increased risk of ovarian cancer, either because they or a close relative have a mutation in the <i>BRCA1</i> or <i>BRCA2</i> genes, or because they have a strong family history of breast and/or ovarian cancer. The clinical phase of this study is complete, and efforts are focused on data analysis.</p>
</div>]]></content>
  </row>
  <row para_id="303694" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7271209" sys_dependentid="512269" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2392" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<div class="topic-feature large-4 columns card right no-image">
	<div class="feature-card genNewsletterArticle">
		<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_authtype=0&amp;sys_variantid=1955&amp;sys_context=0&amp;sys_folderid=502988&amp;sys_siteid=475&amp;sys_contentid=512269&amp;sys_command=preview" sys_variantid="1955" sys_contentid="512269">
			    		    			<h3>How a Hereditary Multicancer Syndrome Was Discovered</h3>
    					        							</a>
    </div>
	</div>
</div>
<p></p>
<p>Li-Fraumeni Syndrome (LFS) is an inherited disorder that leads to a higher risk of certain cancers, including sarcomas, brain tumors, breast cancer, and many others. It is inherited in an autosomal dominant manner and is often the result of heritable changes in the <i>TP53</i> gene. The NCI has evaluated families with LFS since the syndrome was first recognized in 1969. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration. This <a href="http://lfs.cancer.gov/">LFS study</a> is now open to patient enrollment. (<a href="http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_11-C-0255.html@Li-Fraumeni">LFS study protocol: 11-C-0255</a>)</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Li-Fraumeni+Syndrome+&amp;titleOption=exact&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Li-Fraumeni Syndrome Study &ndash; Research Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1113558" sys_dependentvariantid="1965" sys_dependentid="1113558" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271208" sys_variantid="1965" sys_contentid="1113558">Payal Khincha</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271207" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303696" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Alcohol consumption is a well-established risk factor for certain cancers. DCEG researchers investigate the relationship between alcohol use and risk of various cancers, specifically as it relates to liver disease and liver cancer, breast cancer, and other malignancies.&nbsp;</p>
<p>Search for <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=or&amp;searchTxtTitle=alcohol+&amp;titleOption=exact&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">DCEG publications on alcohol and cancer</a>.</p>
<p>Examples of studies that have included alcohol among other risk factors:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_contentid="303750" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7355893" sys_dependentvariantid="1418" sys_dependentid="303750" rxinlineslot="103">Prostate, Lung, Colon, and Ovary Prospective Study</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_contentid="303748" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7355894" sys_dependentvariantid="1418" sys_dependentid="303748" rxinlineslot="103">NIH-AARP Diet and Health Study</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7355896" sys_dependentvariantid="1418" sys_dependentid="302552" rxinlineslot="103">U.S. Radiologic Technologists Cohort</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303539" sys_contentid="303539" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7355897" sys_dependentvariantid="1418" sys_dependentid="303539" rxinlineslot="103">Case-Control Study of Biliary Tract Cancer in Shanghai</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303620#Case-Control-MM" sys_contentid="303620#case-control-mm" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7355898" sys_dependentvariantid="1418" sys_dependentid="303620" rxinlineslot="103">Case-Control Studies of Multiple Myeloma and Cancers of the Pancreas and Prostate Among Blacks and Whites in the United States</a></p>
</div>]]></content>
  </row>
  <row para_id="303697" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>ASA24 is a freely available web-based tool for epidemiologic, interventional, behavioral, or clinical research from NCI that enables multiple automatically coded self-administered 24-hour recalls and food records. There are U.S., Canadian, and Australian versions.</p>
<p>ASA24 consists of a <a href="https://epi.grants.cancer.gov/asa24/respondent/">Respondent Web site</a> used to collect recall and food record data in English or Spanish for the U.S. version, and in English and French for the Canadian version. There is also a <a href="https://epi.grants.cancer.gov/asa24/researcher/">Researcher Web site</a> used to manage study logistics and obtain data analyses. The ASA24 system can also be used by clinicians for diet assessment and nutritional counseling, and by educators for teaching about nutrition or dietary assessment.</p>
<h4>Related links:</h4>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_dependentvariantid="1422" sys_dependentid="1033171" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390397" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303701" sys_dependentvariantid="1418" sys_dependentid="303701" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390398" sys_variantid="1418" sys_contentid="303701">Physical Activities Completed over Time in 24 Hours (ACT-24)</a></p>
</div>]]></content>
  </row>
  <row para_id="303698" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers investigate the relationship between dietary intake, nutritional status, and cancer risk using data from a number of large, population-based studies in the United States and abroad. Analyses from these studies consider diet and nutrition in terms of whole foods consumed, micronutrients, and chemicals formed through cooking methods. Selected studies include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303743" sys_dependentvariantid="1418" sys_relationshipid="7271252" sys_siteid="475" sys_variantid="1418" sys_contentid="303743">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302637" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302637" sys_dependentvariantid="1418" sys_relationshipid="7271253" sys_siteid="475" sys_variantid="1418" sys_contentid="302637">Meat Intake</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303748" sys_dependentvariantid="1418" sys_relationshipid="7271254" sys_siteid="475" sys_variantid="1418" sys_contentid="303748">NIH-AARP Diet and Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303656" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303656" sys_dependentvariantid="1418" sys_relationshipid="7271255" sys_siteid="475" sys_variantid="1418" sys_contentid="303656">Nutrition Intervention Trials in Linxian, China</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303703" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303703" sys_dependentvariantid="1418" sys_relationshipid="7271256" sys_siteid="475" sys_variantid="1418" sys_contentid="303703">Polyp Prevention Trial</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303750" sys_dependentvariantid="1418" sys_relationshipid="7271257" sys_siteid="475" sys_variantid="1418" sys_contentid="303750">Prostate, Lung, Colon, and Ovary Prospective Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303749" sys_dependentvariantid="1418" sys_dependentid="303749" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271260" sys_variantid="1418" sys_contentid="303749">Shanghai Women's Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=454178" sys_dependentvariantid="1418" sys_dependentid="454178" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271259" sys_variantid="1418" sys_contentid="454178">Vitamin D and Cancer Risk</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302552" sys_dependentvariantid="1418" sys_relationshipid="7271258" sys_siteid="475" sys_variantid="1418" sys_contentid="302552">U.S. Radiologic Technologists Cohort</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="303699" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Energy balance &mdash; the difference between dietary energy intake and energy expended through physical activity and resting metabolism &mdash; has been implicated in a host of diseases, including cancer. This is an area of research of great significance, since two-thirds of the adult U.S. population and at least one-half of the population of many other developed countries are now overweight or obese.</p>
<p>DCEG&rsquo;s research portfolio includes studies that focus on different aspects of energy balance, including the effects of body mass index (BMI), dietary intake, and physical activity on various malignancies. Longitudinal cohorts, case-control studies, and dietary assessment methodological studies provide valuable data to DCEG researchers. &nbsp;Data include dietary intake, physical activity, and anthropometric characteristics, such as waist circumference.&nbsp;</p>
<p>Search for <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=or&amp;searchTxtTitle=obesity+OR+BMI+OR+anthropometric+OR+%22dietary+AND+intake%22+OR+%22physical+AND+activity%22&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">DCEG publications on energy balance, obesity, and BMI.</a></p>
<p><span>A variety of studies are being conducted among the following cohorts:</span></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_contentid="303743" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="303743" sys_dependentvariantid="1418" sys_relationshipid="7271262" sys_siteid="475">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_contentid="303748" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="303748" sys_dependentvariantid="1418" sys_relationshipid="7271261" sys_siteid="475">NIH-AARP Diet and Health Study</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_contentid="303750" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="303750" sys_dependentvariantid="1418" sys_relationshipid="7271264" sys_siteid="475">Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial<br /></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303749" sys_contentid="303749" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="303749" sys_dependentvariantid="1418" sys_relationshipid="7271263" sys_siteid="475">Shanghai Women&rsquo;s Health Study</a><br /><a href="http://epi.grants.cancer.gov/Consortia/cohort.html">NCI Cohort Consortium</a></p>
</div>]]></content>
  </row>
  <row para_id="303700" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Pharmaceutical agents may increase or decrease cancer risk. DCEG researchers actively investigate the use of over-the-counter medications like nonsteroidal anti-inflammatory drugs (commonly known as NSAIDs), or prescription drugs like those that reduce cholesterol levels. &nbsp;</p>
<p>Exogenous hormones, like those commonly found in oral contraceptives or menopausal hormone therapy, or more rarely in medications like diethylstilbestrol (DES), are also associated with cancer risk.&nbsp;DCEG researchers evaluate the use of these medications, as well as how they relate to other factors to influence risk of breast, ovarian, or other cancers. Examples of studies include:</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303585" sys_dependentvariantid="1418" sys_dependentid="303585" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296508" sys_variantid="1418" sys_contentid="303585">Barrett&rsquo;s and Esophageal Adenocarcinoma Consortium</a></h2>
<p>An international consortium with epidemiologic studies of Barrett's Esophagus and esophageal adenocarcinoma. Analyses so far have included alcohol consumption, anthropometry, cigarette smoking, excess risk models, gastroesophageal reflux disease, non-steroidal anti-inflammatory drugs, reproductive factors, and genome-wide studies to identify susceptibility loci associated with Barrett&rsquo;s esophagus and/or adenocarcinomas of the esophagus.</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303756" sys_dependentvariantid="1418" sys_dependentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296509" sys_variantid="1418" sys_contentid="303756">Bone Density and Cancer Risk: A Follow-Up Study of Women in the Fracture Intervention Trial (BFIT)</a></h2>
<p>A retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303561" sys_dependentvariantid="1418" sys_dependentid="303561" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296510" sys_variantid="1418" sys_contentid="303561">Columbia, Missouri Serum Bank Follow-up Study</a></h2>
<p>A study established as part of NCI's Biological Markers Project to identify serum markers for breast cancer</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=350301" sys_dependentvariantid="1418" sys_dependentid="350301" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296511" sys_variantid="1418" sys_contentid="350301">DES Follow-up Study</a></h2>
<p>A study investigating the long-term health consequences associated with exposure to diethylstilbestrol (DES)</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303757" sys_dependentvariantid="1418" sys_dependentid="303757" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296512" sys_variantid="1418" sys_contentid="303757">Follow-up Studies of Women Evaluated and Treated for Infertility</a></h2>
<p>Retrospective cohort studies of women treated for infertility with ovulation-stimulating drugs to evaluate risk of breast and gynecologic cancers</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303569" sys_dependentvariantid="1418" sys_dependentid="303569" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296513" sys_variantid="1418" sys_contentid="303569">Ultrasound Study of the Effects of Tamoxifen on Breast Tissue</a></h2>
<p>A study using ultrasound tomography to define the time course of volumetric breast density changes among women receiving tamoxifen treatment</p>
</div>]]></content>
  </row>
  <row para_id="303701" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This is a web-based physical activity evaluation tool developed by the NCI where participants can enter the activities they engaged in during the previous day. The tool will be employed in future NIH-AARP Diet and Health Studies as well as in other cohorts to improve our understanding of physical activity and disease.</p>
<h4>Related links:</h4>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7271266" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422">Metabolic Epidemiology Branch</a></p>
<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303697" sys_contentid="303697" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271265" sys_siteid="475" rxinlineslot="103" sys_dependentid="303697" sys_dependentvariantid="1418">Automated Self-Administered 24 Hour Dietary Recall (ASA24)</a></div>]]></content>
  </row>
  <row para_id="303702" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers investigate the role of physical activity in cancer risk. This broad category includes exercise, leisure-time activities, sedentary behaviors like sitting or television-watching, and other lifestyle factors related to activity in relation to cancer risk.&nbsp;</p>
<p>Search for <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=or&amp;searchTxtTitle=physical+activity&amp;titleOption=exact&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">DCEG publications on physical activity and cancer</a>.</p>
<p>Examples of studies that include measures of physical activity on some level:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303566" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7390536" sys_dependentvariantid="1418" sys_dependentid="303566" rxinlineslot="103" sys_variantid="1418" sys_contentid="303566">Breast Cancer Case-Control Study in Poland</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303633" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7390537" sys_dependentvariantid="1418" sys_dependentid="303633" rxinlineslot="103" sys_variantid="1418" sys_contentid="303633">Ovarian and Endometrial Cancer Case-Control Study in Poland</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303570" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7390538" sys_dependentvariantid="1418" sys_dependentid="303570" rxinlineslot="103" sys_variantid="1418" sys_contentid="303570">Women's Interview Study of Health (WISH): A Case-Control Study of Breast Cancer Among Younger Women</a><br /> <a href="http://dceg.cancer.gov/research/who-we-study/cohorts/us-radiologic-technologists#Lifestyle Risk Factors">U.S. Radiologic Technologists Cohort</a></p>
</div>]]></content>
  </row>
  <row para_id="303703" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The primary objective of the Polyp Prevention Trial (PPT) is to determine whether a low fat, high fiber, high vegetable and fruit eating plan will decrease the recurrence of adenomatous polyps of the large bowel. Secondary objectives of the PPT include 1) evaluating the effectiveness of the intervention program with respect to participant achievement of dietary goals; 2) examining the relation of dietary change and biochemical markers in blood; and 3) assessing the impact of the intervention on quality of life indicators.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1965&amp;sys_revision=8&amp;sys_contentid=349692&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349692" sys_dependentvariantid="1965" sys_relationshipid="6182591" sys_siteid="475">Rashmi Sinha</a>&nbsp;or <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1965&amp;sys_revision=2&amp;sys_contentid=1033924&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1033924" sys_dependentvariantid="1965" sys_relationshipid="6187548" sys_siteid="475" sys_folderid="">Gwen Murphy</a>.</p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=8&amp;sys_contentid=1033621&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1033621" sys_dependentvariantid="1418" sys_relationshipid="6182592" sys_siteid="475">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303704" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>Reproductive factors are known to influence hormone-related cancers like those of the breast and ovary. Some can be classified as lifestyle factors (such as parity), while others are classified as host factors (age at menarche). &#160;DCEG researchers investigate the role of parity (the number of live-born children a woman has delivered), infertility, age at menarche and menopause and other factors in relation to cancer risk.&#160;</p><p>Search for <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=or&amp;searchTxtTitle=reproductive+parity+menarche+menopause+infertility+&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">DCEG publications on reproductive factors and cancer risk</a>.</p><p>Examples of studies used in these investigations include:</p><p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=6&amp;sys_contentid=303739&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303739" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832157" sys_siteid="475">Breast, Ovary and Endometrial Cancer Studies in Poland</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=9&amp;sys_contentid=303561&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303561" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832158" sys_siteid="475">Columbia, Missouri Serum Bank Follow-up Study</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=6&amp;sys_contentid=303757&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303757" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832159" sys_siteid="475">Follow-up Study of Women Evaluated and Treated for Infertility</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=7&amp;sys_contentid=303756&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303756" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832160" sys_siteid="475">Follow-Up Study of Women in the Fracture Intervention Trial (FIT)</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=303724&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303724" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832161" sys_siteid="475">Methodologic Study of Tissue Hormones</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=303748&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303748" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832162" sys_siteid="475">NIH-AARP Diet and Health Study</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=6&amp;sys_contentid=303750&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303750" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832163" sys_siteid="475">Prostate, Lung, Colon, and Ovary Prospective Study</a><br /><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=7&amp;sys_contentid=303661&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303661" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="3832164" sys_siteid="475">Testicular Cancer among Military Servicemen: the STEED Study</a></p></div>]]></content>
  </row>
  <row para_id="303705" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Tobacco use is well understood to be a risk factor for cancer. Although smoking rates in the United States have declined, tobacco continues to exert a tremendous burden on the health of populations in the U.S. and world-wide. Investigators throughout DCEG have used case-control, prospective studies, and consortia to characterize changing associations between cigarette smoking and cancer, and are engaged in determining the health risks of other tobacco and tobacco-related products, including smokeless tobacco, flavored cigarillos, electronic cigarettes, and hookah (water pipe).&nbsp;</p>
<p>Search for <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=or&amp;searchTxtTitle=%22tobacco%22+OR+%22smoking%22+&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">DCEG publications on tobacco use and cancer</a>.</p>
<p>Examples of studies used in these investigations include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_contentid="303743" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355874" sys_siteid="475" rxinlineslot="103" sys_dependentid="303743" sys_dependentvariantid="1418">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_contentid="303750" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355875" sys_siteid="475" rxinlineslot="103" sys_dependentid="303750" sys_dependentvariantid="1418">Prostate, Lung, Colon, and Ovary Prospective Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_contentid="303748" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355876" sys_siteid="475" rxinlineslot="103" sys_dependentid="303748" sys_dependentvariantid="1418">NIH-AARP Diet and Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303605" sys_contentid="303605" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355877" sys_siteid="475" rxinlineslot="103" sys_dependentid="303605" sys_dependentvariantid="1418">Environment And Genetics in Lung cancer Etiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303585" sys_contentid="303585" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355878" sys_siteid="475" rxinlineslot="103" sys_dependentid="303585" sys_dependentvariantid="1418">Barrett&rsquo;s and Esophageal Adenocarcinoma Consortium</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303653" sys_contentid="303653" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355880" sys_siteid="475" rxinlineslot="103" sys_dependentid="303653" sys_dependentvariantid="1418">Gastric and Esophageal Malignancies in Northern Iran (GEMINI)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303588" sys_contentid="303588" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355881" sys_siteid="475" rxinlineslot="103" sys_dependentid="303588" sys_dependentvariantid="1418">Golestan Cohort Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355882" sys_siteid="475" rxinlineslot="103" sys_dependentid="302552" sys_dependentvariantid="1418">U.S. Radiologic Technologists Cohort (USRT)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355883" sys_siteid="475" rxinlineslot="103" sys_dependentid="438648" sys_dependentvariantid="1418">New England Bladder Cancer Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303543" sys_contentid="303543" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355884" sys_siteid="475" rxinlineslot="103" sys_dependentid="303543" sys_dependentvariantid="1418">Interdisciplinary Case-Control Study of Bladder Cancer in Spain</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="303707" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h4>Research in Action</h4>
<br />
<p><img width="75" height="75" title="" class="left" alt="Mark Schiffman drawing a graph" src="/PublishedContent/Images/about/staff-directory/biographies/K-N/Mark Schiffman IRP video_85x85.__v60013949.jpg" /><a title="" href="/about/staff-directory/biographies/K-N/schiffman-mark">Mark Schiffman</a> uses molecular epidemiology to predict and prevent cervical cancer.&nbsp;</p>
<p><b>Article &amp; Video:</b> <a href="http://irp.nih.gov/our-research/research-in-action/taking-the-long-view" target="_blank" rel="noopener noreferrer">Taking the Long View</a></p>
</div>
<p>Viral and bacterial infections are known to cause a number of different malignancies in populations world-wide. DCEG carries out multidisciplinary studies of carefully selected populations in the United States and abroad, with the goal of clarifying the relationship of infectious agents, especially viruses, to human cancer and other conditions. Recent research has concentrated on human retroviruses (HIV-1), with additional studies on human papillomaviruses (HPV), hepatitis viruses, and papovaviruses.</p>
<ul>
<li><a href="/research/what-we-study/environment/infectious-agents#Human+Papillomavirus+(HPV)">Human Papillomavirus</a></li>
<li><a href="/research/what-we-study/environment/infectious-agents#Human+Immunodeficiency+Virus+(HIV)">Human Immunodeficiency Virus (HIV)</a></li>
<li><a href="/research/what-we-study/environment/infectious-agents#Epstein-Barr+Virus+(EBV)">Epstein-Barr Virus (EBV)</a></li>
</ul>
<h2><a id="HPV"></a>Human Papillomavirus (HPV)</h2>
<ul style="list-style-type: square;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303745" sys_contentid="303745" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317187" sys_siteid="475" rxinlineslot="103" sys_dependentid="303745" sys_dependentvariantid="1418">HPV Vaccine Trial in Costa Rica</a><br /> A randomized, controlled phase III trial of a vaccine to prevent human papillomavirus (HPV) 16 and 18 infections and their associated cervical lesions in Costa Rica</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303686" sys_contentid="303686" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317188" sys_siteid="475" rxinlineslot="103" sys_dependentid="303686" sys_dependentvariantid="1418">Study of HPV Vaccine Efficacy at Extracervical sites</a><br /> A study to determine the impact of HPV vaccination in preventing infections in the oral, vulvar, and anal regions</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1102867" sys_contentid="1102867" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317189" sys_siteid="475" rxinlineslot="103" sys_dependentid="1102867" sys_dependentvariantid="1418">Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines&mdash;The ESCUDDO* Study</a><br /> Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines--the ESCUDDO study (Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)).</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303538" sys_contentid="303538" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317190" sys_siteid="475" rxinlineslot="103" sys_dependentid="303538" sys_dependentvariantid="1418">Anal Precancer and Cancer in HIV-Positive Men (Anal Cancer Screening Study)</a><br /> A study of anal cancer risk in HIV-positive men who have sex with men</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303573" sys_contentid="303573" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317191" sys_siteid="475" rxinlineslot="103" sys_dependentid="303573" sys_dependentvariantid="1418">ASC-US/LSIL Triage Study (ALTS)</a><br /> A study of the clinical management of low-grade cervical cytologic abnormalities</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303575" sys_contentid="303575" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317192" sys_siteid="475" rxinlineslot="103" sys_dependentid="303575" sys_dependentvariantid="1418">Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED)</a><br /> A study to comprehensively assess biomarkers of risk for progressive cervical neoplasia, and thus develop a new set of biomarkers that can distinguish those at highest risk of cervical cancer from those with benign infection</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303576" sys_contentid="303576" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317193" sys_siteid="475" rxinlineslot="103" sys_dependentid="303576" sys_dependentvariantid="1418">Biopsy Study to Improve Detection of Cervical Precancer</a><br /> A collaborative study on colposcopic biopsy with aims to study cervical disease on the lesion level, optimize criteria for biopsy placement, and analyze the incremental benefit of taking multiple biopsies</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303577" sys_contentid="303577" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317194" sys_siteid="475" rxinlineslot="103" sys_dependentid="303577" sys_dependentvariantid="1418">Cervical Cancer Screening Among HIV-Infected Women in India</a><br /> A study to evaluate a cohort of HIV-infected women using two novel and potentially sustainable, lower-cost tests for accurate screening for cervical cancer</li>
<li><a href="https://dceg.cancer.gov/research/cancer-types/cervix/cervix-mississippi" title="">STRIDES: Studying Risk and Improving Disparities of Cervical Cancer in Mississippi</a> <br />The NCI is partnering with the University of Mississippi Medical Center to evaluate risk of cervical precancer and to study novel biomarkers in women undergoing cervical cancer screening.</li>
</ul>
<h2><a id="HIV"></a>Human Immunodeficiency Virus (HIV)</h2>
<ul style="list-style-type: square;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_contentid="303678" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317195" sys_siteid="475" rxinlineslot="103" sys_dependentid="303678" sys_dependentvariantid="1418">HIV/AIDS Cancer Match Study</a><br /> HIV/AIDS cancer match study examines cancer risk among people living with HIV infection in the United States.</li>
</ul>
<h2><a id="EBV"></a>Epstein-Barr Virus (EBV)</h2>
<ul style="list-style-type: square;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303652" sys_contentid="303652" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317198" sys_siteid="475" rxinlineslot="103" sys_dependentid="303652" sys_dependentvariantid="1418">EBV-Associated Gastric Cancer</a><br /> DCEG studies of Epstein-Barr virus (EBV) and gastric cancer</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303674" sys_contentid="303674" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317196" sys_siteid="475" rxinlineslot="103" sys_dependentid="303674" sys_dependentvariantid="1418">EBV and Genetics in AIDS NHL</a><br /> Epstein-Barr virus and genetics in AIDS-related non-Hodgkin lymphoma</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140727" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140727" sys_dependentvariantid="1418" sys_relationshipid="7317199" sys_variantid="1418" sys_contentid="1140727">EBV Screening for the Early Detection of Nasopharyngeal Carcinoma</a><br />The Epstein-Barr virus (EBV) Screening for the Early Detection of Nasopharyngeal Carcinoma (NPC) in China demonstration project includes a group of approximately 30,000 men and women ages 35-69 recruited into the active screening arm of a community-randomized trial to evaluate the impact of EBV-based antibody screening on NPC mortality rates.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303608" sys_contentid="303608" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317197" sys_siteid="475" rxinlineslot="103" sys_dependentid="303608" sys_dependentvariantid="1418">Epidemiology of Burkitt Lymphoma in East African Children and Minors (EMBLEM)</a><br /> A large, multidisciplinary epidemiological effort designed to evaluate environmental and host factors associated with childhood Burkitt lymphoma in sub-Saharan Africa</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="303708" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>NCI launched the Vitamin D Pooling Project (VDPP) in 2007 with the goal of providing reliable estimates of the relative risk of cancer that would fill the gaps in knowledge of the associations between vitamin D levels and cancer. Through the use of the resources available in the NCI Cohort Consortium, funding was allocated for measuring circulating 25-hydroxyvitamin D (25[OH]D) in prospectively collected and stored samples of plasma and serum from eight extramural cohorts supported by the NCI Division of Cancer Control and Populations Sciences and from two DCEG cohorts. The VDPP examined associations between vitamin D and cancer at several less common sites, including cancers of the endometrium, kidney, ovary, pancreas, stomach, and esophagus, as well as non-Hodgkin lymphoma. The results from the VDPP were published in nine articles in the July 1, 2010, issue of the <i>American Journal of Epidemiology</i>, including an overview, a description of the project design and methods, findings on the correlates of circulating vitamin D, and six cancer site&ndash;specific reports. Investigators found that women and men with higher concentrations of circulating vitamin D did not experience reduced risk for any of the cancers examined during the follow-up periods for the cohorts. The analysis of pancreatic cancer, however, found a significantly elevated risk in a relatively small number of subjects with circulating 25(OH)D greater than 100 nmol/L, which represents approximately the 95th percentile of the U.S. population.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1965&amp;sys_revision=8&amp;sys_contentid=349619&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349619" sys_dependentvariantid="1965" sys_relationshipid="6178964" sys_siteid="475">Demetrius Albanes</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033621&amp;sys_revision=3&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="6178967">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303710" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG scientists form collaborative working groups to enhance the exchange of information and support interdisciplinary approaches to epidemiological and genetic research. Working groups draw their members from across the Division and other organizations in NCI, enabling them to apply a wide range of expertise to the study of complex questions. Examples include: </p>
<ul>
<li><strong><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302410" sys_dependentvariantid="1418" sys_dependentid="302410" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7271290" sys_variantid="1418" sys_contentid="302410">Upper Gastrointestinal Cancer Working Group</a></strong> &ndash; conducts studies of esophageal and gastric cancer in the U.S. and elsewhere. Contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271286" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103" sys_variantid="1965" sys_contentid="349612">Christian C. Abnet, Ph.D., M.P.H.</a></li>
<li><strong>Immune Marker</strong> <b>Working Group</b> &ndash; includes members evaluating the association between immune/inflammatory markers and cancer risk. &nbsp;Contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349667" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271288" sys_dependentvariantid="1965" sys_dependentid="349667" rxinlineslot="103" sys_variantid="1965" sys_contentid="349667">Anil K. Chaturvedi, Ph.D.</a></li>
<li><b>Metabolomics Working Group</b> &ndash; studies small-molecule metabolites as indicators of exposure and future cancer risk. &nbsp;Contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=638988" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271289" sys_dependentvariantid="1965" sys_dependentid="638988" rxinlineslot="103" sys_variantid="1965" sys_contentid="638988">Steven C. Moore, Ph.D.</a></li>
<li><strong>Tobacco Control Science Working Group</strong> &ndash; encourages etiologic research especially relevant to tobacco control, in partnership with DCCPS and the Intramural Center for Tobacco Regulatory Sciences (a joint effort of NIH and FDA). &nbsp;Contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349608" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7271287" sys_dependentvariantid="1965" sys_dependentid="349608" rxinlineslot="103" sys_variantid="1965" sys_contentid="349608">Neal D. Freedman, Ph.D.</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="303711" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7271297" sys_dependentid="1067436" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="1833" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<figure class="video right size50">	<h4>Descriptive Epidemiology: Historical Perspectives and Future Opportunities</h4>
	<div id="ytplayer-1p7oU37BZ-I" class="flex-video widescreen" data-video-id="1p7oU37BZ-I" data-video-title="Descriptive Epidemiology: Historical Perspectives and Future Opportunities">		<noscript>			<p>				<a href="https://www.youtube.com/watch?v=1p7oU37BZ-I" target="_blank" title="Descriptive Epidemiology: Historical Perspectives and Future Opportunities">					View this video on YouTube.				</a>			</p>		</noscript>							</div>			<figcaption class="caption-container">
<p>Dr. Joseph F Fraumeni, Jr. and Dr. Robert N. Hoover present&nbsp;a retrospective&nbsp;on decades of groundbreaking research in descriptive epidemiology.</p>
</figcaption>	</figure></div>
<p>The Division maintains a broad-ranging, multi-faceted program of descriptive epidemiological studies utilizing a variety of methodological approaches to identify novel risk factors, evaluate tumor heterogeneity, describe current and future trends of common and rare malignancies, and project risk for <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=804883" sys_contentid="804883" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="804883" rxinlineslot="103" sys_relationshipid="7271295">second primary cancers</a>.</p>
<h3>Mapping Cancer Rates by Geography, Race, and Ethnicity</h3>
<p>To identify novel carcinogenic exposures our investigators utilize the <a href="https://gis.cancer.gov/geoviewer/">NCI Geoviewer tool</a>, a visualization mapping tool, to characterize the geographic distribution of cancer as well as differences by race and ethnicity.</p>
<h3>Molecular Epidemiology in Cancer Trends</h3>
<p>In order to take advantage of emerging molecular, genetic, hormonal, and viral markers that influence cancer treatment and prognosis, DCEG investigators are integrating pathology report information into descriptive studies and cancer registries. This effort dovetails with the broader Division program on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1065271" sys_contentid="1065271" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1065271" rxinlineslot="103" sys_relationshipid="7271291">tumor profiling in relation to cancer etiology</a>.</p>
<h3>Data Linkage Studies</h3>
<p>Large databases linked to cancer registries allow DCEG investigators to assess influence of cancer risk factors on population-level incidence rates. Linked studies include the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_contentid="303678" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303678" rxinlineslot="103" sys_relationshipid="7271292">HIV/AIDS Cancer Match Study</a>, the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_contentid="303740" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303740" rxinlineslot="103" sys_relationshipid="7271293">Transplant Cancer Match Study</a>, and <a href="http://healthcaredelivery.cancer.gov/seermedicare/">SEER-Medicare</a>.</p>
<h3>Novel Methods and Tools</h3>
<p>DCEG investigators have developed sophisticated biostatistical models and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302594" sys_contentid="302594" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="302594" rxinlineslot="103" sys_relationshipid="7271296">analytic tools</a> to help explain changes in cancer incidence and mortality trends over time. An example is the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=856668" sys_contentid="856668" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="856668" rxinlineslot="103" sys_relationshipid="7271294">Age-Period-Cohort (APC) tool</a>, designed to enable researchers to disentangle the interactive effects of age-related biology, calendar-period effects (e.g., screening), and birth-cohort exposures from one generation to the next.</p>
</div>]]></content>
  </row>
  <row para_id="303716" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators devote considerable effort to improving exposure assessment techniques and evaluating the reliability and validity of procedures used in cohort and case-control studies of occupational, lifestyle, and environmental exposures.</p>
<h3>Radiation-related Exposure Assessment Studies</h3>
<p>Investigators work to identify, understand, and quantify the risk of cancer in populations exposed to medical, occupational, or environmental radiation, and to advance understanding of radiation carcinogenesis. To support these epidemiological studies, DCEG radiation dosimetrists focus on developing new dosimetry methods and refining existing methods to achieve more accurate dose estimates, as well as quantifying and incorporating related uncertainties.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068" sys_contentid="1091068" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271305" sys_siteid="475" rxinlineslot="103" sys_dependentid="1091068" sys_dependentvariantid="1418">Radiation Dosimetry Research to Support Epidemiologic Studies</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302463" sys_contentid="302463" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271298" sys_siteid="475" rxinlineslot="103" sys_dependentid="302463" sys_dependentvariantid="1418">Ultraviolet Sunlight Exposure Assessment</a></li>
</ul>
<h3>Occupational and Environmental Exposure Assessment Studies</h3>
<p>DCEG investigators continually develop and refine quantitative exposure assessment methods that maximize the available measurements and exposure determinant information to predict historical exposure levels in industry-based studies such as diesel exhaust in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303672" sys_contentid="303672" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271299" sys_siteid="475" rxinlineslot="103" sys_dependentid="303672" sys_dependentvariantid="1418">Diesel Exhaust in Miners study</a>, benzene in the cohort study <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302387" sys_contentid="302387" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271300" sys_siteid="475" rxinlineslot="103" sys_dependentid="302387" sys_dependentvariantid="1418">Benzene-Exposed Workers in China</a>, and specific pesticides within the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_contentid="303742" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271301" sys_siteid="475" rxinlineslot="103" sys_dependentid="303742" sys_dependentvariantid="1418">Agricultural Health Study</a>.</p>
<p>In addition, investigators use a variety of tools and methods to perform exposure estimates in population-based studies. Examples include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087390" sys_contentid="1087390" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271302" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087390" sys_dependentvariantid="1418">Geographic Information Systems and Environmental Exposure Assessment</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438694" sys_contentid="438694" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271303" sys_siteid="475" rxinlineslot="103" sys_dependentid="438694" sys_dependentvariantid="1418">Exposure Assessment Using Job Exposure Matrices</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438710" sys_contentid="438710" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7271304" sys_siteid="475" rxinlineslot="103" sys_dependentid="438710" sys_dependentvariantid="1418">Exposure Assessment Using Occupation- and Industry-Specific Modules</a></li>
</ul>
<p></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303719" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigates the biological basis of inherited and acquired genetic variants associated with cancer susceptibility, utilizing genome-wide association studies, exome sequencing, and candidate gene studies. DCEG scientists and their collaborators employ and array of advanced statistical methods to support these studies.</p>
<h4>Genome-wide Association Studies</h4>
<p>A genome-wide association study (GWAS) is an approach that involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. The goal is to understand how genes contribute to the disease and to use that understanding to help develop better prevention and treatment strategies. DCEG has developed a robust research program with GWAS for a number of cancers, and more recently, exposures and survival. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1057944" inlinetype="rxhyperlink" sys_relationshipid="7271314" rxinlineslot="103" sys_dependentid="1057944" sys_dependentvariantid="1418" sys_siteid="475" sys_variantid="1418" sys_contentid="1057944">Read more about genome-wide association studies</a>.</p>
<h4>Exome Studies</h4>
<p>Whole exome sequencing enables researchers to sequence all of the exons (protein coding parts of a gene) in the genome, with the goal of identifying the genetic cause of a specific disease. &nbsp;</p>
<h4>Candidate Gene Studies</h4>
<p>A candidate gene is a gene suspected to be involved with a particular disease, condition, or abnormality, based on previous findings. Candidate gene studies test an identified gene and mutation in a group of subjects both with the disease (cases) and without the disease (controls).</p>
<h4>Statistical Methods</h4>
<p>DCEG investigators collaborate with scientists at the <a href="http://cgf.nci.nih.gov/">Cancer Genomics Research (CGR) Laboratory</a> (formerly the Core Genotyping Facility) to formulate design and analysis strategies in support of genetic association. Such strategies include determining the number of SNPs to be followed in various stages of multistage GWAS; choosing association test statistics; analyzing and adjusting for population stratification using principal component methods; conducting haplotype-based association scans; and exploring genetic pathways and interactions.</p>
<p>In addition, investigators have developed a number of tools and resources that are made available to the general scientific public for download and use. For example, Biostatistics Branch investigators have developed a number of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302528" inlinetype="rxhyperlink" sys_relationshipid="7271313" rxinlineslot="103" sys_dependentid="302528" sys_dependentvariantid="1418" sys_siteid="475" sys_variantid="1418" sys_contentid="302528">genetic analysis software tools</a>.</p>
</div>]]></content>
  </row>
  <row para_id="303721" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Metabolomics is the study of small-molecule metabolites in cells, tissues, and organisms that are present in biofluids such as plasma and urine.&nbsp;An emerging field of study, metabolomics has the potential to improve exposure measures and delineate mechanistic links between exposures and cancer.&nbsp;</p>
<p>DCEG investigators launched the DCEG Metabolomics Initiative in 2011 to pilot the available technologies and evaluate their potential use in etiologic studies. &nbsp;In studying the metabolomics of energy balance, nutritional status, and cancer, they uncovered biomarkers for body mass index, diet, and smoking, along with associations between smoking-related metabolites and colorectal cancer. DCEG is now collaborating with investigators from Vanderbilt-Ingram Cancer Center and Shanghai Cancer Institute to conduct a large study of the metabolomic risk factors for breast cancer in Shanghai women and a replication study in PLCO, with other studies in planning.</p>
<p>For more information on this early research, contact <a href="mailto:moorest@mail.nih.gov">Steven Moore</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7259850" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303724" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>A Study of Intraprostatic and Circulating Sex Steroid Hormones</h2>
<p>DCEG investigators are conducting a study to investigate to what extent blood (circulating) concentrations of sex hormones represent concentrations within the prostate. A total of 260 subjects, including African Americans and European Americans, diagnosed with prostate cancer, benign prostatic hyperplasia, or bladder cancer and undergoing prostatectomy were recruited for tissue and blood collection. Hormone levels in prostatic tissue are being measured and compared with serum levels and polymorphisms of hormone-related genes. Levels of androgen receptor and its associated proteins in prostate tissue are being measured directly. In addition, factors such as age, smoking, and body size that might alter serum-tissue correlations are being examined.</p>
<p>For more information, contact <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/cook-michael-b">Michael Cook</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7193883">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303730" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The microbiome refers to the collection of all of the gene sequences from a community of microbes in the human body. High-throughput DNA amplification and sequencing technologies to characterize the microbial communities provide data for investigations of microbial associations with human disease. Our goal is to establish cohorts with fecal and oral specimens to prospectively evaluate the association between the human microbiome and cancer risk.</p>
<p>While microbiome research has grown exponentially over the past several years, findings have been difficult to reproduce across studies. The variability induced by sample collection and handling has not been systematically assessed. DCEG investigators are pursuing a multi-pronged approach to address microbiome methodologic issues.</p>
<h3><a id="Methods-Development"></a>Methods Development</h3>
<p><strong>Sample collection</strong>: DCEG investigators are evaluating and standardizing fecal and oral sample collection protocols to reliably measure the human microbiome in the context of large-scale population studies. Several issues are being considered, such as, preservation of a microbial signature, stability of samples under field conditions, and preservation of samples to maximize multi &lsquo;omics assays.</p>
<p><strong>Standard reference materials</strong>: It is crucial to develop appropriate standard reference materials for quality control of samples in large epidemiologic studies. DCEG investigators have developed two types of standards, chemostat produced in an artificial gut system, also called a &ldquo;Robogut,&rdquo; and artificial communities with known bacterial mixtures. Negative controls are equally critical; the need to include them in studies is also being evaluated.</p>
<p><a href="http://www.mbqc.org/">Microbiome Quality Control (MBQC) project</a>: The degree of standardization in microbiome measurement necessary for translation to large-scale studies is early in its development. Sources of variation in microbial profiling must be evaluated and optimized so that independent epidemiologic studies can be pooled. DCEG investigators helped coordinate and conduct the MBQC study, a collaborative effort designed to comprehensively evaluate methods for measuring the human microbiome. The MBQC study evaluated the impact of various DNA extraction, sequencing, and bioinformatics methods for fecal samples.</p>
<p><strong>Feasibility of setting up cohort studies</strong>: Large, prospective, population-based cohorts are well suited to address numerous important epidemiologic questions about the pathophysiology of human diseases. Given the growing understanding of the role of human microbiome in diverse health conditions, it is imperative to implement an appropriate sample collection strategy. DCEG investigators are conducting numerous feasibility studies to evaluate whether fecal and oral samples can be collected in existing cohorts, prepaid health plans, or screening populations.</p>
<h3><a id="Etiologic-Studies"></a>Etiologic Studies</h3>
<p><strong>Prospective study of the oral microbiome and cancer</strong>: Poor oral health and periodontal pathogens have been associated with a number of cancers, mortality, and other chronic diseases, which suggests a role for the oral microbiome in the development of these conditions. DCEG investigators are assessing the association between the oral microbiome and incident cancers of the bronchus/lung, colorectum, esophagus, head/neck, hepatobiliary tract, pancreas, small intestine and stomach, using a case-cohort design within a number of existing cohorts. This multi-cancer, multi-cohort project will allow us to test several hypotheses simultaneously, provide greater insight into the role of the oral microbiome in cancer at several sites, and allow us to evaluate common mechanisms across cancer sites.</p>
<p><strong>Lower gastrointestinal cancer studies</strong>: The association between the human gut microbiome and colorectal cancer (CRC) is an important focus of our research. In a case-control study with data and fecal specimens previously collected in DCEG, we found that CRC cases had reduced fecal microbiome alpha diversity, increased carriage of <em>Fusobacterium</em> and <em>Porphyromonas</em> taxa, and reduced abundance of <em>Clostridia</em> taxa. Metabolomic analysis of the same specimens uncovered 41 small molecules that differed between cases and controls, providing potentially improved diagnostic methods or insights on carcinogenesis. Metagenome analyses of associations with CRC and with fecal metabolites corroborated the 16S analyses.</p>
<p><strong>Upper gastrointestinal cancer studies</strong>: Gastric cancer is currently the model of bacterially associated cancer; <em>Helicobacter pylori</em> has been classified as carcinogenetic in humans by the International Agency for Research on Cancer. Research within DCEG has evaluated how risk factors for cancer, such as tobacco, body mass index, and pepsinogen levels, are associated with microbial diversity using samples collected in China. We found that among participants with esophageal squamous dysplasia, participants at greater risk for gastric cancer (low pepsinogen I/II ratio) had lower microbial richness than those at lower risk for gastric cancer. Associations were also detected with smoking history and body mass index in these samples. Ongoing studies are being conducted to further evaluate the impact of the oral microbiome on upper gastrointestinal cancer risk.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349692" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349692" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7274568" sys_variantid="1965" sys_contentid="349692">Rashmi Sinha</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1033621" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7274569" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch &ndash; Research Areas </a></p>
</div>]]></content>
  </row>
  <row para_id="303735" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A case-control study compares two groups of people: those with the cancer under study (cases) and those who do not have the cancer (controls). Researchers compare the genetic, environmental, lifestyle, and medical histories of the people in the two groups to identify factors associated with cancer.</p>
<p>Selected examples of DCEG case-control studies:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=459575" sys_dependentvariantid="1418" sys_dependentid="459575" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296278" sys_variantid="1418" sys_contentid="459575">AsiaLymph Study </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303739" sys_dependentvariantid="1418" sys_dependentid="303739" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296279" sys_variantid="1418" sys_contentid="303739">Breast, Ovary and Endometrial Cancer Studies in Poland </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=447527" sys_dependentvariantid="1418" sys_dependentid="447527" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296280" sys_variantid="1418" sys_contentid="447527">Case-control Studies of Renal Cell Cancer </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303605" sys_dependentvariantid="1418" sys_dependentid="303605" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296281" sys_variantid="1418" sys_contentid="303605">Environment And Genetics in Lung cancer Etiology </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303608" sys_dependentvariantid="1418" sys_dependentid="303608" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296282" sys_variantid="1418" sys_contentid="303608">Epidemiology of Burkitt Lymphoma in East African Children and Minors (EMBLEM) </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303622" sys_dependentvariantid="1418" sys_dependentid="303622" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296283" sys_variantid="1418" sys_contentid="303622">Nasopharyngeal Case-Control Study </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303612" sys_dependentvariantid="1418" sys_dependentid="303612" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296284" sys_variantid="1418" sys_contentid="303612">NCI-SEER Non-Hodgkin Lymphoma (NHL) Case-Control Study </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_dependentvariantid="1418" sys_dependentid="438648" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296285" sys_variantid="1418" sys_contentid="438648">New England Bladder Cancer Study </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303661" sys_dependentvariantid="1418" sys_dependentid="303661" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296286" sys_variantid="1418" sys_contentid="303661">Testicular Cancer among Military Servicemen: the STEED Study </a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_dependentvariantid="1418" sys_dependentid="303740" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7296287" sys_variantid="1418" sys_contentid="303740">Transplant Cancer Match Study </a></p>
</div>]]></content>
  </row>
  <row para_id="303739" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>DCEG researchers conduct population-based case-control studies of breast and gynecologic cancers in Poland.</p><ul><li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=9&amp;sys_contentid=303566&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303566" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="2691200" sys_siteid="475">Breast Cancer Case-Control Study in Poland</a></li><li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=303633&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303633" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="2691201" sys_siteid="475">Ovarian and Endometrial Cancer Case-Control Study in Poland</a></li></ul></div>]]></content>
  </row>
  <row para_id="303740" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Cancer risk is substantially elevated among solid organ transplant recipients, who receive long-term immunosuppressant medications to prevent organ rejection. To better understand the etiology of cancer in this population, investigators are conducting the <a href="http://transplantmatch.cancer.gov/">Transplant Cancer Match Study</a>. This study is a collaborative effort with the Health Resources and Services Administration, which oversees the U.S. solid organ transplant network. Data from multiple state and regional cancer registries are linked with the U.S. registry of transplant recipients, to cover&nbsp;more than&nbsp;50% of the U.S. transplant population.&nbsp;</p>
<p>Goals of the project include: 1) description of the spectrum of cancer risk in solid organ transplant recipients; 2) elucidation of the role of oncogenic viruses in causing cancer in this setting; and 3) understanding the role of other factors in causing cancer, such as demographic factors, medical conditions, and specific immunosuppressive medication.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7268324" sys_dependentvariantid="1965" sys_dependentid="349601" rxinlineslot="103">Eric Engels</a>.</p>
<p><a href="http://dceg.cancer.gov/about/organization/programs-ebp/iib/research">Infections and Immunoepidemiology Branch &ndash; Research Areas</a></p>
<p><a href="https://transplantmatch.cancer.gov/">Transplant Cancer Match Study Website</a></p>
</div>]]></content>
  </row>
  <row para_id="303741" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A cohort is a defined population observed over time, either prospectively or retrospectively.&nbsp;In some cohorts, members share a characteristic such as an occupational exposure or medical condition, while some other cohorts are samples of the general population. In addition, some DCEG cohorts were first enrolled in clinical or prevention trials, but continue to be followed as a general population cohort.</p>
<p>Cohort members are often surveyed to gather information on lifestyle factors such as diet and nutrition, exercise, use of alcohol or tobacco, because these factors can be related to cancer risk. They are followed over time to gather updates on their general health.&nbsp;In addition, in some studies, members agree to donate biospecimens such as blood, buccal cell, and urine.</p>
<p>For cancer studies that require large numbers of subjects and biospecimens, DCEG investigators often participate in large consortia (collaborative partnerships) that pool data and biospecimens across numerous cohorts. For example, the <a href="http://epi.grants.cancer.gov/Consortia/cohort.html">NCI Cohort Consortium</a> includes investigators responsible for more than 40 high-quality cohorts, involving more than 4 million people.</p>
<p>Following are examples of DCEG cohort studies:</p>
<h3>General population cohorts</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_contentid="303743" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303743" sys_dependentvariantid="1418" sys_relationshipid="7278030" sys_siteid="475" sys_variantid="1418">Alpha-Tocopheral Beta-Carotene Cancer Prevention (ATBC) Study</a><br /><a href="/Rhythmyx/assembler/render?sys_contentid=1140986&amp;sys_revision=2&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1140986" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7278058">Connect Study</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_contentid="303748" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303748" sys_dependentvariantid="1418" sys_relationshipid="7278031" sys_siteid="475" sys_variantid="1418">NIH-AARP Diet and Health Study</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_contentid="303750" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303750" sys_dependentvariantid="1418" sys_relationshipid="7278032" sys_siteid="475" sys_variantid="1418">Prostate, Lung, Colon, and Ovarian (PLCO) Cancer Study</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303749" sys_contentid="303749" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303749" sys_dependentvariantid="1418" sys_relationshipid="7278033" sys_siteid="475" sys_variantid="1418">Shanghai Women&rsquo;s Health Study</a></p>
<h3>Occupational cohorts</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_contentid="303742" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303742" sys_dependentvariantid="1418" sys_relationshipid="7278034" sys_siteid="475" sys_variantid="1418">Agricultural Health Study</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302387" sys_contentid="302387" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302387" sys_dependentvariantid="1418" sys_relationshipid="7278035" sys_siteid="475" sys_variantid="1418">Benzene-Exposed Workers in China</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1134691" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1134691" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7278051" sys_variantid="1418" sys_contentid="1134691">Cohort Mortality Study of Dry Cleaning Industry Workers</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1083375" sys_contentid="1083375" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1083375" sys_dependentvariantid="1418" sys_relationshipid="7278048" sys_siteid="475" sys_variantid="1418">Cohort Mortality Study of Philadelphia Firefighters</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303672" sys_contentid="303672" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303672" sys_dependentvariantid="1418" sys_relationshipid="7278036" sys_siteid="475" sys_variantid="1418">Diesel Exhaust in Miners Study</a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302603" sys_contentid="302603" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302603" sys_dependentvariantid="1418" sys_relationshipid="7278045" sys_siteid="475" sys_variantid="1418"><br />Interventional Fluoroscopists</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303688" sys_contentid="303688" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303688" sys_dependentvariantid="1418" sys_relationshipid="7278050" sys_siteid="475" sys_variantid="1418">NCI Acrylonite Cohort</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302552" sys_dependentvariantid="1418" sys_relationshipid="7278037" sys_siteid="475" sys_variantid="1418">U.S. Radiologic Technologists</a></p>
<h3>Environmental Exposure Cohorts</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1030358" sys_dependentvariantid="1418" sys_relationshipid="7278047" sys_siteid="475" sys_variantid="1418">Thyroid Disease in Young Persons Exposed Near Chernobyl</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1105314" sys_contentid="1105314" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1105314" sys_dependentvariantid="1418" sys_relationshipid="7278049" sys_siteid="475" sys_variantid="1418">Methodologic Studies of Radioactive Fallout</a></p>
<h3>Medical Conditions or Treatment Cohorts</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302605" sys_contentid="302605" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302605" sys_dependentvariantid="1418" sys_relationshipid="7278040" sys_siteid="475" sys_variantid="1418">Childhood Cancer Survivors</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=350301" sys_contentid="350301" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="350301" sys_dependentvariantid="1418" sys_relationshipid="7278039" sys_siteid="475" sys_variantid="1418">DES Follow-up Study</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303756" sys_contentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303756" sys_dependentvariantid="1418" sys_relationshipid="7278042" sys_siteid="475" sys_variantid="1418">Follow-up Study of Women in the Fracture Intervention Trial</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303745" sys_contentid="303745" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303745" sys_dependentvariantid="1418" sys_relationshipid="7278038" sys_siteid="475" sys_variantid="1418">HPV Vaccine Study in Costa Rica</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=827356" sys_contentid="827356" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="827356" sys_dependentvariantid="1418" sys_relationshipid="7278046" sys_siteid="475" sys_variantid="1418">NCI International EBV-Gastric Cancer Consortium</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303656" sys_contentid="303656" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303656" sys_dependentvariantid="1418" sys_relationshipid="7278044" sys_siteid="475" sys_variantid="1418">Nutritional Intervention Trials in Linxian, China</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302397" sys_contentid="302397" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302397" sys_dependentvariantid="1418" sys_relationshipid="7278043" sys_siteid="475" sys_variantid="1418">Second Primary Gastrointestinal Cancers</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303757" sys_contentid="303757" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303757" sys_dependentvariantid="1418" sys_relationshipid="7278041" sys_siteid="475" sys_variantid="1418">Study of Women Evaluated and Treated for Infertility</a></p>
</div>]]></content>
  </row>
  <row para_id="303742" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Agricultural Health Study works to understand how agricultural, lifestyle, and genetic factors affect the health of farming populations.&nbsp; This prospective cohort study of approximately 90,000 participants includes licensed private pesticide applicators and their spouses in Iowa and North Carolina, and commercial applicators in Iowa.</p>
<div class="callout-box" style="float: right; width: 25%; margin: 0 0 5px 10px;">
<p>Learn about <a href="https://www.aghealth.nih.gov/">participants and collaborators with the Agricultural Health Study</a>.</p>
</div>
<p>The study&nbsp;is a collaborative project of the National Cancer Institute, the National Institute of Environmental Health Sciences, the U.S. Environmental Protection Agency and the National Institute for Occupational Safety and Health.</p>
<p>Since it began in 1993, the study has included three cohort-wide interviews to obtain information on agricultural practices and pesticide use, other occupational exposures, lifestyle factors, diseases and medication use, and one cohort-wide interview focused primarily on updating information on non-cancer health outcomes. Cancer incidence has been ascertained via linkage to population-based cancer registries in the study states, and mortality through linkage to state mortality registries and the National Death Index. Mouth rinse samples including buccal cell DNA, were collected from 39 percent of the cohort.</p>
<p>In addition, there have been a number of targeted sub-studies, focused on specific scientific questions. These studies include information on pesticide exposure monitoring from a sample of farms and the collection of a variety of biologic tissues from selected samples of participants. Collaborative ventures with extramural investigators are encouraged.</p>
<p>View <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=461884" sys_contentid="461884" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="461884" sys_dependentvariantid="1418" sys_relationshipid="7238266" sys_siteid="475" sys_variantid="1418">Agricultural Health Study Publications</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349661" sys_contentid="349661" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349661" sys_dependentvariantid="1965" sys_relationshipid="7238264" sys_siteid="475" sys_variantid="1965">Dr. Laura Beane Freeman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7238265" sys_siteid="475" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303743" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study conducted in southwestern Finland has been an integral cohort research resource for NCI for nearly three decades. The study was designed to test hypotheses based on epidemiological and experimental evidence supporting nutritional prevention of cancer, including lower risk among persons with higher vitamin status and vegetable consumption, and the biological and anti-neoplastic properties of several antioxidants and micronutrients. It tested supplementation with &beta;-carotene (20 mg/day) and vitamin E (50 mg/day, as dl-&alpha;-tocopheryl acetate) for five-eight years (1985-1993) in 29,133 male smokers (&gt;5 cigarettes daily), and found 8% higher overall mortality and 18% increased lung cancer incidence in the &beta;-carotene arm, and 32% lower prostate cancer incidence in the men supplemented with vitamin E.</p>
<p>Baseline questionnaire data and biospecimens (serum, whole blood, and toenail clippings) were collected, and fasting serum &alpha;-tocopherol, &beta;-carotene, retinol, and HDL/total cholesterol were measured for the entire cohort. Ongoing linkage with the Finnish Cancer and Mortality Registries has provided complete case ascertainment and causes of death.</p>
<p>The high-quality study data, biological specimens, and ongoing endpoint ascertainment have tested biochemical/molecular and genetic hypotheses with respect to cancers of the lung (4,171 cases currently), prostate (n=2,874), colorectum (979), bladder (871), upper gastrointestinal tract (640), pancreas (488), and kidney (391), and lymphomas/ leukemias (639). The ATBC study collaborates with extramural researchers and participates in a large number of international consortium projects such as BPC3, the Dietary Pooling Project, COMETS, EHPCCG, PRACTICAL, GAME-ON, PanScan, LC3, TRICL, GECCO, CORECT, Interlymph, and other NCI Cohort Consortium analyses.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349619" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349619" sys_dependentvariantid="1965" sys_relationshipid="6918424" sys_siteid="475">Demetrius Albanes</a>.</p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6918425">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303745" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The HPV Vaccine Trial in Costa Rica (CVT) is a collaboration between investigators in Costa Rica and the National Cancer Institute. The trial was designed as a blinded, randomized, phase III clinical trial to evaluate the efficacy of a bivalent HPV-16/18 virus-like particle (VLP) vaccine. The vaccine used in the trial was developed by investigators at NCI and other research institutions and is manufactured by GlaxoSmithKline Biologicals. The trial was initiated in June 2004 and enrollment was completed in December 2005; there were 7,466 women enrolled.&nbsp;</p>
<p>Trial staff followed all enrolled women for a period of four years. Women who were eligible, consented, and were randomized into the trial received three doses of the HPV 16/18 VLP or Havrix (Hepatitis A) vaccine over a period of six months. At entry and throughout follow-up, women were carefully monitored and received state-of-the-art screening for cervical neoplasia.&nbsp;</p>
<p>This study was designed to evaluate vaccine efficacy, immunological correlates of long-term vaccine success and failure, and other factors of immunological and etiological interest. Data from the trial demonstrated that three doses of the HPV vaccine may not be necessary, as similar vaccine efficacy against cervical HPV 16/18 infection was observed among women who received two, and even a single dose, of the HPV vaccine after four years of follow-up.</p>
<p>For more information, contact&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349605" sys_contentid="349605" sys_variantid="1965">Aim&eacute;e Kreimer</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" sys_variantid="1418">Infections and Immunoepidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303748" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>The NIH-AARP Diet and Health Study was developed at NCI to improve our understanding of the relationship between diet and health. The study was conducted among members of the AARP aged 50-71 years in areas of the U.S. A total of 500,000 people filled out and returned the initial study questionnaire containing questions on diet and lifestyle, making it the largest study of diet and health ever conducted. Follow-up questionnaires on topics such as risk factors are mailed out periodically.</p><p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=832328&amp;sys_revision=1&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="832328" sys_dependentvariantid="1965" sys_folderid="" sys_relationshipid="4733009" sys_siteid="475">Linda Liao</a>.</p><p><a href="http://dietandhealth.cancer.gov/">NIH-AARP Diet and Health Study website</a></p></div>]]></content>
  </row>
  <row para_id="303749" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Shanghai Women's Health Study (SWHS), a collaborative study by NCI, Vanderbilt University, and the Shanghai Cancer Institute, is a prospective cohort study of approximately 75,000 Chinese women who were recruited between 1997 and 2000. Members of the cohort have been followed through multiple in-person interviews to obtain information on diet, occupational and environmental exposures, and various lifestyle factors. Information from the follow-ups is linked to vital records and the tumor registry to obtain information on disease.</p>
<p>Special characteristics of the cohort include the following:&nbsp;It is a population-based sample with very high response rates; it is composed of almost entirely never-smokers; and it uses a detailed exposure database that includes tens of thousands of workplace measurements collected over many decades in Shanghai.</p>
<p>Over the years, data and biological samples (blood/buccal cell and urine) collected in the SWHS have been used to evaluate many important etiologic hypotheses and support multiple studies. Most recently, nested case-control molecular epidemiology studies and occupational exposure analyses of lung cancer, brain cancer, and non-Hodgkin lymphoma have been conducted.</p>
<p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=349613&amp;sys_revision=16&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349613" sys_dependentvariantid="1965" sys_folderid="" sys_relationshipid="7204926">Dr. Qing Lan</a>.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7204925" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303750" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>PLCO is a large NCI trial (<em>n</em>=155,000) that evaluated screening for early detection of prostate, lung, colon, and ovarian cancer. In addition to these aims, it is widely used as an observational cohort for early detection and etiologic studies.</p>
<p>Starting in 1993, participants were randomized in equal proportions to an intervention arm (<em>n</em>=77,500), which received trial screening, or to a control arm (<em>n</em>=77,500), which received usual care. Intervention arm participants provided annual blood samples for six years, whereas control arm participants provided a single oral wash sample. All participants have been followed for cancer incidence and mortality since enrollment in 1993.</p>
<p>The large size of this cohort and availability of serial samples make PLCO a unique and widely used resource for etiologic and early detection studies. More than 250 projects have been approved to use the biological resources in the cohort so far, as have more than 250 data-only projects. PLCO participates in more than 30 consortia and has resulted in more than 1000 publications to date. Highlights include playing a key role in the discovery of nearly three-quarters of the known genomic susceptibility loci for cancer identified in genome-wide association studies; studies of acquired mutations; and studies of obesity and physical activity.</p>
<p>Learn more about the <a href="https://biometry.nci.nih.gov/cdas/plco/">Prostate, Lung, Colon, and Ovary Prospective Study</a>.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349608" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349608" sys_dependentvariantid="1965" sys_relationshipid="6937318" sys_siteid="475">Neal Freedman</a>.</p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1033621" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="6937319">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303751" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2392" sys_dependentid="789805" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7267072">
<div class="topic-feature large-4 columns card right no-image">
<div class="feature-card genGeneral">
<h3>Telomere Biology Disorders and Cancer</h3>
<p>Telomere biology and cancer mechanisms</p>
</div>
</div>
</div>
<p>Cancer is a complex disease driven by numerous factors: environment, lifestyle, and genetic make-up. In some cases, genetic variation shared within families is related to risk for disease. For over three decades, NCI scientists have studied families in which multiple individuals have developed specific cancers. This research, now aided by new genomic technologies, has led to the discovery of genes and environmental exposures that affect cancer risk in families and the general population.</p>
<p>To see a list of family studies that are actively recruiting participants, visit the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=49&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303758" sys_contentid="303758" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="303758" sys_relationshipid="7267069" sys_variantid="1422">Active Clinical Studies</a> page. To enroll or inquire about our active clinical studies, please&nbsp;email the referral nurse,&nbsp;<a href="mailto:StephanieSteinbart@westat.com">Stephanie Steinbart,</a> or contact by phone:&nbsp;1-800-518-8474.</p>
<p><a href="http://ppb.cancer.gov/">Pleuropulmonary Blastoma Cancer Predisposition Syndrome</a> (actively recruiting)<br />Pleuropulmonary blastoma (PPB) is a rare tumor of the lung. Research has shown that PPB may be part of an inherited cancer predisposition syndrome caused by changes in a gene known as <i>DICER1</i>. The PPB Cancer Study is an observational study of children with PPB and their families.</p>
<p><a href="http://dceg.cancer.gov/research/who-we-study/families/familial-melanoma-study">Familial Melanoma Studies</a> (actively recruiting)<br />DCEG researchers are searching for melanoma susceptibility genes in melanoma-prone families.</p>
<p><a href="http://dceg.cancer.gov/research/what-we-study/genes-host/li-fraumeni-syndrome-study">Li-Fraumeni Syndrome Study</a> (actively recruiting)<br />Li-Fraumeni Syndrome (LFS) is a rare, inherited disorder which leads to a higher risk of certain cancers. NCI has evaluated families with LFS since the syndrome was first recognized in 1969. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/blood-lymph-cancers">Familial Blood and Lymph Node Cancers Study</a> (actively recruiting)<br />DCEG investigators have been studying the causes of familial blood and lymph node cancers for over 30 years. Ongoing advances in genetics, anticipated applications of advanced technologies, and data from families have allowed research efforts to expand.</p>
<p><a href="http://dceg.cancer.gov/research/what-we-study/genes-host/bone-marrow-failure-syndromes">Inherited Bone Marrow Failure Syndromes</a> (actively recruiting)<br />The inherited bone marrow failure syndromes (IBMFS) are a group of rare genetic blood disorders. DCEG investigators are leading a clinical study to better understand how cancers develop in persons with IBMFS.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/blood-wm">Waldenstr&ouml;m's Macroglobulinemia Study</a> (actively recruiting)<br />Waldenstr&ouml;m's macroglobulinemia (WM) is a rare type of tumor that belongs to a group of disorders called lymphoproliferative diseases. DCEG researchers are leading a study to determine what causes WM to sometimes develop in two or more family members.</p>
<p><a href="http://dceg.cancer.gov/research/cancer-types/testes/familial-testicular-cancer-study">Familial Testicular Cancer Study</a> (actively recruiting)<br />DCEG investigators are conducting the Familiar Testicular Cancer Study to research the genetic causes of testicular cancer.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/blood-cll-info">Familial Chronic Lymphocytic Leukemia Study</a> (actively recruiting)<br />DCEG investigators are studying families with multiple cases of chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the Western Hemisphere.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/hboc-overview">Multidisciplinary Etiologic Studies of Hereditary Breast/Ovarian Cancer</a><br />DCEG researchers have been studying the Hereditary Breast/Ovarian Cancer (HBOC) syndrome since the 1960s. This study is now closed to patient enrollment, and researchers are analyzing previously collected data.</p>
<p><a href="http://dceg.cancer.gov/research/clinical-studies/chordoma">Chordoma Study</a> (actively recruiting)<br />Chordoma is a rare bone cancer that develops at the base of the skull, in a vertebra, or at end of the spine. DCEG investigators are studying families with multiple relatives with chordoma.</p>
<p><a href="http://dceg.cancer.gov/research/cancer-types/ovary/ovarian-cancer-prevention-early-detection-study">National Ovarian Cancer Prevention and Early Detection Study</a><br />The National Ovarian Cancer and Early Detection Study (GOG-0199) is a prospective study of women who are at increased risk of ovarian cancer, either because they or a close relative have a mutation in the <i>BRCA1</i> or <i>BRCA2</i> genes, or because they have a strong family history of breast and/or ovarian cancer. The clinical phase of this study is complete, and efforts are focused on data analysis.</p>
<p>Read more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=462207" sys_contentid="462207" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="462207" sys_relationshipid="7267070" sys_variantid="1418">public health impact of family studies</a>.</p>
</div>]]></content>
  </row>
  <row para_id="303752" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2392" sys_dependentid="380875" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7258963">
<div class="topic-feature large-4 columns card right no-image">
<div class="feature-card genNewsletterArticle">
<h3>Unraveling Genetic Susceptibility to Melanoma</h3>
</div>
</div>
</div>
<p></p>
<p>Most genetic epidemiology investigations evaluate the contributions of host susceptibility and environmental exposure in the development of cancer. In family studies, the host susceptibility measure is frequently an alteration in specific gene(s). These studies tend to be very long term with varying activity.&nbsp;</p>
<p>Although two genes associated with melanoma susceptibility have been identified (<i>CDKN2A</i> and <i>CDK4</i>), alterations in these genes are found in only a small percentage of melanoma-prone families. The search for other genes continues. In collaboration with GenoMEL (Melanoma Genetics Consortium), an international consortium, DCEG investigators are searching for new melanoma susceptibility genes both within families and a genome-wide association study. In a methodologic study, investigators compared <i>CDKN2A</i> mutation detection using denaturing high performance liquid chromatography to usual screening across nine different centers in GenoMEL. They found that mutation detection across the groups was consistent and of high quality.&nbsp;</p>
<p>Investigators have also conducted an association study of familial melanoma using a candidate gene approach, and analysis is continuing. &nbsp;They continue to accrue and evaluate new families while continuing to evaluate families of individuals with heritable retinoblastoma and melanoma.</p>
<div class="callout-box center">
<h3>Moles to Melanoma: Recognizing the ABCDE Features</h3>
<p>This online tool contains serial photographs of pigmented lesions: common moles, dysplastic nevi, and melanomas, taken over time. Includes associated clinical descriptors. <a href="https://analysistools.nci.nih.gov/nevustool/?page=home">Explore the Moles to Melanoma website</a>.</p>
</div>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349658" sys_contentid="349658" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349658" sys_variantid="1965" sys_relationshipid="7258960">Alisa Goldstein</a>.</p>
<p><a href="http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_02-C-0211.html@melanoma">Familial Melanoma Study Protocol</a></p>
</div>]]></content>
  </row>
  <row para_id="303756" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Bone density has emerged as a potentially important predictor of risk for certain cancers that are influenced by hormones, such as breast and endometrial cancers. In 1992, over 25,000 postmenopausal women volunteered for FIT, a clinical trial to determine whether the drug alendronate could reduce the incidence of osteoporosis fractures. The BFIT study is a retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk.</p>
<p>NCI and FIT investigators contacted FIT volunteers to identify incident cancers, and to evaluate whether risk factor information collected in 1992, such as measured bone mineral density, lifestyle factors, and certain growth factors, predicts subsequent cancer risk. Collection of additional risk factor information during this follow-up, including updated lifestyle factors and a buccal cell sample for genetic analyses, is allowing investigators to further explore the complex relationships between bone mass and other risk factors for breast, endometrial, and other cancers. Currently underway are efforts to understand associations between androgens and androgen metabolites as well as progesterone-related metabolites and breast cancer risk and the interrelationships between bone mass and endogenous hormones and risk of breast, endometrial, and other cancers.</p>
<h3>Serum Estrogen Metabolites and Cancer Risk in the BFIT Study</h3>
<p>Although circulating estrogens have been evaluated in prior epidemiological studies of cancer, numerous questions remain with regard to the role of estrogen metabolites in the development of hormone-related cancers. Investigators conducted a case-cohort study within BFIT to examine circulating estrogens and estrogen metabolites in relation to four specific cancer endpoints. Women who were screened for participation in the trial completed a risk factor questionnaire, provided a baseline blood sample and underwent a bone mineral density scan. As part of the BFIT study, these women were followed (median 10.3 years) to ascertain incident cancer outcomes and incident fractures through the period of 2001-2004.</p>
<p>A comprehensive profile of endogenous estrogens, including 15 estrogens and estrogen metabolites, were measured in pre-diagnostic serum using the LC-MS/MS assay developed at the Protein Characterization Laboratory at the Frederick National Cancer Center. These measures were examined in relation to breast (n~420), endometrial (n~62), ovarian (n~65), and colorectal (n~178) cancers. Elevated circulating estradiol levels were found associated with increased breast cancer risk. &nbsp;Further, elevated levels of metabolites in the 2- and 4-hydroxylation pathways to parent estrogens were inversely related to risk. A higher ratio of the 2/16-hydroxylation pathway was also associated with reduced risk. Elevated estradiol levels were also related to increases in endometrial cancer risk, without meaningful associations with individual metabolites. In contrast, neither parent estrogens nor metabolites were found to be related to either ovarian or colorectal cancer risks.</p>
<h3>Adipocytokines and Endometrial Cancer Risk in the BFIT Study</h3>
<p>Obesity is a well-established risk factor for endometrial cancer and may independently affect endometrial cancer risk, even after adjustment for sex steroids. Adipose tissue produces several adipocytokines, including leptin and adiponectin, and although few studies have assessed these markers in relation to endometrial cancer risk, the majority of studies have utilized post-diagnostic blood samples. Investigators are currently conducting a nested case-control study to examine circulating pre-diagnostic levels of adiponectin, high molecular weight adiponectin, leptin, and C-peptide in relation to endometrial cancer risk among a subset of postmenopausal women (~60 cases/120 controls) in the BFIT follow-up study. Within this study, investigators will also be able to evaluate a full panel of circulating estrogens and estrogen metabolites as well as investigate relationships with obesity metrics such as body mass index and waist-to-hip ratio.&nbsp;</p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=B-FIT&amp;titleOption=or&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">View publications from the BFIT Study</a>.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=802306" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6929746" sys_dependentvariantid="1965" sys_dependentid="802306" rxinlineslot="103">Britton Trabert</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033621&amp;sys_revision=15&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="6929747">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303757" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Infertility has long been recognized as a risk factor for various cancers, including breast and gynecologic cancers. More recently, concern has been raised regarding effects of drugs used to treat infertility, particularly since these drugs stimulate ovulation and raise endogenous estrogen levels. Investigators in DCEG have been involved with a number of investigations to clarify effects of fertility drug exposures on risk of various cancers.</p>
<p>One of these investigations involved a retrospective cohort study that identified 12,193 women who had been evaluated and/or treated for infertility at five large reproductive endocrinology practices between the early 1960&rsquo;s and 1989.&nbsp;Detailed information was abstracted from medical records, and located patients were administered questionnaires to obtain updated information regarding disease risk factors and health status. Linkages were also performed with thirteen cancer registries and the National Death Index. The latest follow-up, which assessed cancer incidence through 2010, revealed 749 breast, 118 endometrial and 85 ovarian cancer cases, and allowed a detailed assessment of risk in relation to both clomiphene and gonadotropins.</p>
<p>Results regarding effects of ovulation-stimulating drugs on endometrial and ovarian&nbsp;cancers were largely reassuring.&nbsp;The only significant excess risk was that of ovarian cancer associated with clomiphene exposures among women who remained nulligravid during follow-up. This most likely reflected that these women had more resistant infertility rather than an effect of the drug exposures. For medically validated invasive breast cancers, however, there was a significantly elevated risk observed for women who received 12 or more clomiphene cycles&mdash;a dosage much higher than would be prescribed in current practice.&nbsp;The excess risk was highest among women who remained nulligravid during follow-up. This also leads to questions regarding the biologic plausibility of the association. Nonetheless, the results do support the need for continued monitoring of risks, particularly given the relatively young age of women in this cohort (average age at follow-up was only 50 years of age). &nbsp;</p>
<p>In addition to evaluating effects of older fertility drugs, more recently prescribed fertility treatments have been of interest, including those associated with <i>in vitro</i> fertilization (IVF). For such analyses, collaborations have been established in both Israel and Norway, given that these countries both have very high rates of such procedures. Two record linkage efforts have been undertaken, one at Maccabi Healthcare Services, the second largest health maintenance organization in Israel, and the other among a cohort of parous women in Norway. The Israeli study showed generally reassuring results regarding IVF exposures for most cancers, with the only evidence of any risk elevation being a non-significant risk for ovarian cancer among women receiving 4 or more IVF cycles.&nbsp;In contrast, the risk among women receiving IVF of <i>in situ</i> cervical cancer was significantly reduced and that of invasive cervical cancer non-significantly reduced&mdash;most likely reflecting more intensive Pap smear screening among women seeking IVF. In contrast to the Israeli study, results from Norway suggested increasing risks of breast cancer among the women followed for the longest periods of time. These results support the need for continued follow-up to fully clarify long-term cancer risks associated with IVF exposures.</p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=841537" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6929748" sys_dependentvariantid="1418" sys_dependentid="841537" rxinlineslot="103">View publications related to the Follow-up Study of Women Evaluated and Treated for Infertility</a>.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=802306" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="802306" rxinlineslot="103" sys_relationshipid="6929749">Britton Trabert</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033621&amp;sys_revision=15&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="6929750">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303759" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>One of the special features of the research conducted by DCEG investigators is that it is carried out by a dedicated study team. Each member of the team brings special expertise to the study.</p>
<p>The Study Team for DCEG's chordoma research consists of the following individuals:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349658" sys_contentid="349658" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349658" sys_dependentvariantid="1965" sys_relationshipid="7274536" sys_siteid="475">Alisa M. Goldstein, Ph.D.,</a> is a board certified Ph.D. medical geneticist. She has been involved in research to identify genes and environmental factors that increase a person's risk for develping cancer for over 20 years. She is the principal investigator of the Non-Familial Chordoma Study and serves as the senior consultant on laboratory and analytic aspects of both the Familial Chordoma Study and the Non-Familial Chordoma Study.</p>
<p>Dilys M. Parry, Ph.D., is a board certified Ph.D. medical geneticist. She has been involved in research on familial and hereditary cancers for 30 years. She began studying chordoma families in 1996 and then initiated the Familial Chordoma study. She is responsible for obtaining and analyzing the clinical information from both the Familial Chordoma Study and the Non-Familial Chordoma Study.</p>
<p>Deborah Zametkin, R.N., M.S.N., is a senior research nurse who has been working with patients with familial and hereditary cancers for 18 years. She has been involved in the Familial Chordoma Study since 1996 and now serves as the study manager for the Non-Familial Chordoma Study.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349593" sys_contentid="349593" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349593" sys_dependentvariantid="1965" sys_relationshipid="7274537" sys_siteid="475">Xiaohong Rose Yang, Ph.D.</a>, is a senior investigator who is interested in identifying genes and environmental factors that increase a person&rsquo;s risk for developing cancer. She is responsible for deciding which laboratory studies should be done on DNA from members of chordoma families and from individuals who are the only person in their family with chordoma. She serves as the liaison between any laboratories involved in the chordoma research and the study team. She is also responsible for analyzing the laboratory data from the chordoma studies.</p>
<p>The study team collaborates with investigators from other institutions who are also studying chordoma or who have expertise in the diagnosis and treatment of chordoma or in state-of-the-art laboratory methods that can be used to examine biological specimens from members of chordoma families or from individuals who are the only person in their family with chordoma.</p>
</div>]]></content>
  </row>
  <row para_id="303760" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following list of websites is provided as a service to you. The NCI is not responsible for the information at these sites and does not endorse any products or services found there. The NCI cannot ensure the privacy or security of information that you may provide to the listed sites. However, you may find that the following sites are helpful.</p>
<p><a href="http://www.cancer.gov/">National Cancer Institute (NCI)</a><br />The NCI provides information on cancer to the public at no charge. Call 1-800-4-CANCER (1-800-422-6237) to speak with an information specialist about cancer-related questions. The website provides information on current research, including clinical trials located both within and outside NCI, for a variety of cancer sites. It is an excellent resource for patients who wish to find out whether there are clinical trials available that are testing new drugs for a particular type of cancer.</p>
<p><a href="http://www.cancer.org/">American Cancer Society (ACS)</a><br />The ACS is a nationwide community-based voluntary health organization. Its website and the ACS free phone line (1-800-227-2345) provide information on cancer treatment, early detection, and prevention, as well as cancer statistics and information on a variety of services available to cancer patients and their families.</p>
<p><a href="http://www.cancer.net/">Cancer Net</a><br />This website is from the American Society of Clinical Oncology (ASCO), an organization of physicians and other professionals involved in the care of people with cancer. This site provides information on more than 50 different types of cancer. It includes information about symptoms, treatments and side effects, clinical trials, coping, risk factors and prevention. Additional resources include live chats, message boards, a drug database, medical dictionary, and links to patient support organizations.</p>
<p><a href="http://www.chordomafoundation.org/">The Chordoma Foundation</a><br />This is a nonprofit organization started by a mother and her son after he was diagnosed with chordoma in 2006. The foundation&rsquo;s mission is to improve the lives of chordoma patients by stimulating research to develop effective treatments and eventually a cure for chordoma. The foundation fosters a coordinated international research effort to find a cure while improving the diagnosis, treatment and quality of life for people affected by chordoma. In addition to initiating and supporting research and research collaborations, the foundation provides support and guidance for a growing community of patients/care givers who are seeking treatment options and medical care.</p>
<p><a href="https://www.facebook.com/groups/ChordomasurvivorsPrivate/">Chordoma Survivors&rsquo; Group on Facebook (Private)</a></p>
<p>This group was formed in 2012 by chordoma survivors with a major goal being to offer support to chordoma patients and family members from the time of the initial diagnosis through long term treatment and survival. Group members endeavor to mutually support each other in every way possible.&nbsp;Since the group was founded more than 350 people have joined it from the US and elsewhere and more individuals continue to join it each week. Because the group is private, no one can read a post unless he/she is a&nbsp;member.</p>
</div>]]></content>
  </row>
  <row para_id="303761" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>What is Chordoma?</h3>
<p>Chordoma is a rare bone cancer that is diagnosed in only about 300 patients in the U.S. each year. NCI investigators have been studying chordoma families (families with multiple relatives with chordoma) since 1996. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302494" sys_contentid="302494" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302494" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7329615" sys_variantid="1418">Read more about the Chordoma study</a>.</p>
</div>
<ul>
<li style="list-style: none;"><a id="Top"></a></li>
<li><a href="#What Does Participation in the Familial Chordoma Study Involve?">What Does Participation in the Familial Chordoma Study Involve?</a></li>
<li><a href="#Cost">Cost</a></li>
<li><a href="#Treatment">Treatment</a></li>
<li><a href="#Who is Eligible to Participate in the Familial Chordoma Study?">Who is Eligible to Participate?</a></li>
<li><a href="#How to Contact Us about the Familial Chordoma Study">Contact Information</a></li>
</ul>
<a id="What Does Participation in the Familial Chordoma Study Involve?"></a>
<h3>What Does Participation in the Familial Chordoma Study Involve?</h3>
<p>Those who choose to participate in the Familial Chordoma Study will be asked to:&nbsp;</p>
<ul>
<li>Provide a blood sample or saliva as a source of DNA for genetic studies on chordoma or related cancers&nbsp;</li>
<li>Provide personal medical and family history information; and,&nbsp;</li>
<li>Give us permission to obtain past medical records about chordoma, other cancers and related illnesses, and a small piece of chordoma or any other cancer that was stored after surgery.&nbsp;</li>
</ul>
<p>Blood for the research can be drawn by a participant&rsquo;s own physician or at a local laboratory and mailed to us. The other activities can be carried out in a participant&rsquo;s home.&nbsp;</p>
<p>In addition, individuals from some chordoma families may be invited to the Clinical Center of the National Institutes of Health (NIH), in Bethesda, MD, to participate in clinical studies. These studies include having a physical examination and donating blood for research; they may also include undergoing magnetic resonance (MR) imaging studies of the base of the skull and entire spine. Results of the clinical studies will be discussed with the participants before they return home and given to them to share with their primary doctors.&nbsp;</p>
<p>Participants and family members will be able to ask questions and stay in touch with the research team. Participants will be asked to complete a yearly follow-up form to update medical information. We will provide participants with the overall findings of the study when analysis of information from the study is completed.&nbsp;</p>
<p>This study has been reviewed and approved by the Institutional Review Board (IRB) of the NCI. NCI is required by Federal law not to reveal any personal information that is collected from study participants to anyone other than persons directly involved with the study. A system is in place to ensure your privacy; in addition, all information obtained as part of this research is protected from disclosure by a Certificate of Confidentiality issued by the NCI.&nbsp;</p>
<p><a href="#Top">Back to top</a></p>
<a id="Cost"></a>
<h3>Cost</h3>
<p>NCI will pay for all clinical studies done at the NIH Clinical Center and for travel to and from Bethesda, MD, for participants.&nbsp;</p>
<p><a href="#Top">Back to top</a></p>
<a id="Treatment"></a>
<h3>Treatment</h3>
<p>Treatment is not offered as part of this study. However, if the need arises, we will discuss treatment options with participants. We will also provide assistance in establishing care with appropriate physicians as needed. Study participants will remain under the care of their primary doctors while participating in the study.&nbsp;</p>
<p><a href="#Top">Back to top</a></p>
<a id="Who is Eligible to Participate in the Familial Chordoma Study?"></a>
<h3>Who is Eligible to Participate in the Familial Chordoma Study?</h3>
<p>To participate in the Familial Chordoma study, a family must have the following:&nbsp;</p>
<ul>
<li>Two or more blood relatives with a history of chordoma&nbsp;</li>
</ul>
<p>Family members who are eligible to participate include those with chordoma, and their parents, siblings and children. We may also invite other blood relatives to join the study if they are genetically linked to family members with chordoma.&nbsp;</p>
<p>In addition, if children who have a parent with chordoma participate, we may invite their unaffected parent to join the study.&nbsp;</p>
<p><a href="#Top">Back to top</a></p>
<a id="How to Contact Us about the Familial Chordoma Study"></a>
<h3>How to Contact Us about the Familial Chordoma Study</h3>
<p>If your family has two or more blood relatives who have been diagnosed with chordoma and you and other family members are interested in contributing to research on <strong>familial chordoma</strong>, please <a href="mailto:stephaniesteinbart@westat.com">email Ms. Stephanie Steinbart</a>, our research&nbsp;nurse, or call her toll-free&nbsp;1-800-518-8474.</p>
<p>For more information about the Familial Chordoma study, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349593" sys_contentid="349593" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349593" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7329613" sys_variantid="1965">Xiaohong Rose Yang, Ph.D.</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="420600" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7329614" sys_variantid="1418">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303762" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>What is Chordoma?</h3>
<p>Chordoma is a rare bone cancer that is diagnosed in only about 300 patients in the U.S. each year. NCI investigators have been studying chordoma families (families with multiple relatives with chordoma) since 1996. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302494" sys_contentid="302494" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302494" sys_dependentvariantid="1418" sys_relationshipid="7329584" sys_siteid="475">Read more about the Chordoma study</a>.</p>
</div>
<ul>
<li style="list-style: none;"><a id="top"></a></li>
<li><a href="#What Does Participation in the Non-Familial Chordoma Study Involve?">What Does Participation in the Non-Familial Chordoma Study Involve?</a></li>
<li><a href="#Who is Eligible to Participate in the Non-Familial Chordoma Study?">Who is Eligible to Participate?</a></li>
<li><a href="#How to Contact Us about the Non-Familial Chordoma Study">Contact Information</a></li>
</ul>
<a id="What Does Participation in the Non-Familial Chordoma Study Involve?"></a>
<h3>What Does Participation in the Non-Familial Chordoma Study Involve?</h3>
<p>Those who choose to participate in the Non-Familial Chordoma Study will be asked to:</p>
<ul>
<li>Provide a saliva sample as a source of DNA for genetic studies on chordoma or related cancers;</li>
<li>Provide personal medical and family history information by completing a self-administered questionnaire; and</li>
<li>Give us permission to obtain past medical records about chordoma, and a small piece of chordoma that was stored after surgery.</li>
</ul>
<p>People will be able to participate in this study from their homes. After they have contacted us to ask about this study, if they are interested in learning more about it, we will send them a letter that describes the study in more detail. We will then telephone them to determine whether they wish to participate in the research. If they decide to participate, we will mail a package to their home that contains all of the materials needed for the study. The package includes the study consent form, the personal and family medical history questionnaire, and the kit that contains a special plastic cup and a lid for using to collect a saliva sample. After they have signed the consent form, completed the questionnaire and collected the saliva sample, they can mail these back to us in a pre-addressed postage-paid envelope included in the package.</p>
<p>We will provide participants with the overall findings of the study when analysis of information from the study is completed.</p>
<p>Based on information we learn about a participant&rsquo;s personal or family medical history or from the laboratory tests done on DNA from the saliva or chordoma samples, we may re-contact a participant and invite him/her, and possibly some close relatives, to participate in a separate clinical study related to the development of chordoma. If we re-contact people about the clinical study, they can decide at that time whether they want to participate in it.</p>
<p>This study has been reviewed and approved by the Special Studies Institutional Review Board (SSIRB) of the NCI. NCI is required by Federal law not to reveal any personal information that is collected from study participants to anyone other than persons directly involved with the study. A system is in place to ensure the privacy of all participants; in addition, all information obtained as part of this research is protected from disclosure by a Certificate of Confidentiality issued by the NCI.</p>
<p><a href="#top">Back to top</a></p>
<a id="Who is Eligible to Participate in the Non-Familial Chordoma Study?"></a>
<h3>Who is Eligible to Participate in the Non-Familial Chordoma Study?</h3>
<p>To participate in the Non-Familial Chordoma study, a person must be:</p>
<ul>
<li>the only individual in his/her extended family diagnosed with chordoma, and</li>
<li>at least 6 years old.</li>
</ul>
<p>If the individuals with chordoma are between the ages of 6 and 17 years of age, a parent can serve as a proxy for them and complete the personal and family medical history questionnaire. A parent may also help them collect the saliva sample.</p>
<p><a href="#top">Back to top</a></p>
<a id="How to Contact Us about the Non-Familial Chordoma Study"></a>
<h3>How to Contact Us about the Non-Familial Chordoma Study</h3>
<p>If only one person in your family has ever been diagnosed with chordoma and you are interested in contributing to research on <strong>non-familial chordoma</strong>, please&nbsp;<a href="mailto:stephaniesteinbart@westat.com">email Ms. Stephanie Steinbart</a>, our&nbsp;research nurse, or call her toll-free 1-800-518-8474.</p>
<p>For more information about the Non-Familial Chordoma study, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349658" sys_contentid="349658" inlinetype="rxhyperlink" sys_variantid="1965" rxinlineslot="103" sys_dependentid="349658" sys_dependentvariantid="1965" sys_relationshipid="7329582" sys_siteid="475">Alisa Goldstein, Ph.D.</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7329583" sys_siteid="475">Clinical Genetics Branch - Research Areas</a></p>
<p><a href="#top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="303764" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A series of DCEG occupational and molecular epidemiology studies on benzene exposure in Chinese workers, part of a twenty-year collaboration with the China CDC, led to a seminal report which provided the first direct evidence in humans that benzene harms the progenitor cells that give rise to blood cells, and that benzene causes hematologic effects at or below 1 ppm, particularly among susceptible subpopulations. These findings informed a pivotal 2007 EPA ruling limiting the benzene content in gasoline and adopting controls on passenger vehicles and portable fuel containers in order to significantly reduce emissions of hazardous air pollutants. More recently, the National Research Council of the National Academies recommended, based primarily on the NCI-CDC findings, that the 90 day exposure standard for benzene air levels in U.S. Navy submarines be reduced from 1.0 to 0.2 ppm.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349644" sys_dependentvariantid="1965" sys_relationshipid="7274587" sys_variantid="1965" sys_contentid="349644">Dr. Nat Rothman</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349613" sys_dependentvariantid="1965" sys_relationshipid="7274588" sys_variantid="1965" sys_contentid="349613">Dr. Qing Lan</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7274589" sys_variantid="1418" sys_contentid="418935">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="303765" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>The carcinogenicity of diesel exhaust in humans has remained unclear despite 35 previous studies that investigated lung cancer risk in relation to diesel engine exhaust.</p>
<h3>Advance</h3>
<p>In 1992, researchers led by <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7274591" sys_dependentvariantid="1965" sys_dependentid="349599" rxinlineslot="103">Debra T. Silverman, Sc.D.,</a> and colleagues at the National Institute for Occupational Safety and Health launched a study designed to clarify the relationship between exposure to diesel engine exhaust and the risk of death from lung cancer. &nbsp;The study is the first to show a statistically significant exposure-response of increasing lung cancer risk associated with increasing exposure to diesel exhaust based on quantitative estimates of workers&rsquo; exposure, after adjusting for other lung cancer risk factors including cigarette smoking</p>
<h3>Impact</h3>
<p>The broad range of diesel exposure in this study allowed researchers to estimate lung cancer risk for heavily exposed workers, as well as those exposed to low levels of diesel exhaust. The new findings are important not just for miners, but also for the 12 million American workers and tens of millions more worldwide who are exposed to diesel exhaust in the workplace and for people who live in cities with high levels of diesel exhaust, the study authors noted.</p>
<p>In June 2012, the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified diesel engine exhaust as carcinogenic to humans (a group 1 carcinogen). The decision was based on an IARC working group&rsquo;s opinion that the body of evidence supports an association between diesel exhaust exposure and an increased risk of lung cancer. The classification was based on results from several large human studies. The Diesel Exhaust in Miners Study played a pivotal role in the IARC evaluation.</p>
</div>]]></content>
  </row>
  <row para_id="303768" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>More than 20 years of epidemiologic research by DCEG investigators has helped to establish the central causal role of carcinogenic genotypes of human papillomavirus (HPV) in the development of virtually all cases of cervical cancer. NCI&rsquo;s natural history studies have shown that it is persistent HPV infection, and not the infection itself, that increases the risk of developing cervical cancer. This finding led to the creation and adoption of new screening guidelines by the American Cancer Society and the Association of Clinical Obstetricians and Gynecologists. &nbsp;</p>
<p>NCI scientists also developed and validated HPV DNA testing that directly assays the causal virus. Now in widespread use in the U.S., the test provides greater accuracy than ambiguous Pap smears, and has led to improved clinical management strategies, with lengthened screening intervals. In addition, NCI scientists invented the virus-like particle technology that enabled the development of HPV vaccines to prevent infection and resultant cancer. &nbsp;An NCI-sponsored Phase III clinical trial to evaluate the efficacy of a vaccine against HPV types 16 and 18 has shown near complete protection against new infections and precancerous lesions. As a result of NCI research, the U.S. strategy for the prevention of cervical cancer has been transformed from reliance on untargeted, frequent, and lifelong repetition of Pap smears to a combination of vaccination and targeted HPV-based screening. &nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="303775" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3 id="how"><br /> How to Apply</h3>
<!--<p>Thank you for your interest in the DCEG Summer Program. The DCEG and NIH application sites for summer 2019 are now open. To apply, please submit <em>both</em> of the following:</p>
<h4>1. Statement of Interest in the Division of Cancer Epidemiology and Genetics</h4>
<p>Regardless of education level, please submit a brief (300-word) statement about your research interests/experience using our <a href="http://dceg2.cancer.gov/BrfAppForm.html">brief summary application form.</a> The information you provide will be made available to DCEG investigators for review.</p>
<h4>2. NIH Online Application</h4>
<p>All summer applicants must also apply online through the NIH Research and Training Opportunities website. Please note that the NIH now has two different applications, and you must select the correct one for your current education level.</p>
<ul>
<li>For those in high school, please apply through the <a href="https://www.training.nih.gov/programs/hs-sip">High School Summer Internship Program (HS-SIP)</a>.</li>
<li>For those in college or beyond, please apply through the regular <a href="https://www.training.nih.gov/programs/sip">Summer Internship Program (SIP)</a>.</li>
</ul>
<p><strong>Note for all</strong>: The NIH application form allows you to submit keywords describing your research interests (question 7). To have your application considered by investigators in the Division of Cancer Epidemiology and Genetics, be sure to include <b>"Epidemiology"</b> and/or <b>"Biostatistics"</b> in your list of keywords.</p>
<p>Find more details on the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302472" sys_contentid="302472" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="302472" sys_dependentvariantid="1418" sys_relationshipid="7269768" sys_siteid="475">Summer Program Overview</a> page.</p>-->
<p>Thank you for your interest in our summer program. The application process for summer 2019 is now closed. Applications for summer 2020 will be accepted online starting in mid-November 2019.</p>
<p>Please check this page periodically for an updated link to the online application.</p>
</div>]]></content>
  </row>
  <row para_id="303777" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303778" sys_dependentvariantid="1418" sys_dependentid="303778" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296174" sys_variantid="1418" sys_contentid="303778">Data Sources</a></h4>
<p>Summary of data sources used for the Pesticide-Exposure Matrix.</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303780" sys_dependentvariantid="1418" sys_dependentid="303780" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296175" sys_variantid="1418" sys_contentid="303780">Methods and Confidence Levels</a></h4>
<p>Pesticide-Exposure Matrix methods used to develop active ingredient lists and estimate probabilities.</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781" sys_dependentvariantid="1418" sys_dependentid="303781" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296176" sys_variantid="1418" sys_contentid="303781">References</a></h4>
<p>List of publications</p>
</div>
<p>The "Pesticide-exposure Matrix" was developed to help epidemiologists and other researchers identify the active ingredients to which people were likely exposed when their homes and gardens were treated for pests in past years. Its derivation is described in full in Colt J, Cyr MJ, Zahm SH, Tobias GS, Hartge P. 2006. <a href="http://ehp03.niehs.nih.gov/article/info:doi/10.1289/ehp.9538">Inferring past pesticide-exposures: a matrix of individual active ingredients in home and garden pesticides used in past decades</a>. <i>Environmental Health Perspective</i> (epub).</p>
<p>The matrix is designed to be used in conjunction with self-reported information about the types of pests that were treated in a person's home or garden. (<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327412" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327412" sys_dependentvariantid="1500" sys_relationshipid="7296171" sys_siteid="475" sys_variantid="1500" sys_contentid="327412">Example questionnaire</a>)</p>
<p>The matrix covers four distinct time periods (1976, 1980, 1990, and 2000), two categories of pesticide appliers (consumers, using products purchased in retail stores, and professional applicators such as pest control operators and lawn services), and 12 types of pests:</p>
<ul>
<li>lawn insects</li>
<li>lawn weeds</li>
<li>outdoor plant/tree insects</li>
<li>outdoor plant/tree weeds</li>
<li>outdoor plant/tree diseases</li>
<li>insects on indoor plants</li>
<li>crawling insects in/around the home</li>
<li>flying insects in/around the home</li>
<li>termites in/around the home</li>
<li>fleas/ticks on pets</li>
<li>fleas/ticks in/around the home</li>
<li>rodents</li>
</ul>
<p>Thus, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=316842" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="316842" sys_dependentvariantid="1500" sys_relationshipid="7296170" sys_siteid="475" sys_variantid="1500" sys_contentid="316842">96 distinct "scenarios"</a> (4 years x 2 appliers x 12 pest types) are covered. For each scenario, the matrix lists the active ingredients that were on the market and provides a rough estimate of the probability that a product containing each ingredient was used. The probabilities are unrelated to the concentrations of the active ingredients in the product. The matrix does not cover synergists, repellents, solvents, emulsifiers, spreaders, stickers, buffering agents, or other ingredients that are not considered active ingredients but must be listed on the label.</p>
<p>Questions? <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
<div class="callout-box center">
<h3>Pesticide-Exposure Matrix</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=316842" sys_dependentvariantid="1500" sys_dependentid="316842" inlinetype="rxhyperlink" rxinlineslot="103" sys_relationshipid="7296173" sys_variantid="1500" sys_contentid="316842">PDF of Pesticide Exposure Matrix</a> including type of pesticide, description of who applied it, what year, method used and confidence level.</p>
</div>
</div>]]></content>
  </row>
  <row para_id="303778" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303777" sys_dependentvariantid="1418" sys_dependentid="303777" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296192" sys_variantid="1418" sys_contentid="303777">Pesticide-Exposure Matrix</a></h4>
<p>Pesticide-exposure Matrix was developed to help epidemiologists and other researchers identify the active ingredients to which people were likely exposed when their homes and gardens were treated for pests in past years</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303780" sys_dependentvariantid="1418" sys_dependentid="303780" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296194" sys_variantid="1418" sys_contentid="303780">Methods and Confidence Levels</a></h4>
<p>Pesticide-Exposure Matrix methods used to develop active ingredient lists and estimate probabilities.</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781" sys_dependentvariantid="1418" sys_dependentid="303781" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296195" sys_variantid="1418" sys_contentid="303781">References</a></h4>
<p>List of publications</p>
</div>
<p>The data sources used for the matrix are summarized here. Additional detail is provided in Colt J, Cyr MJ, Zahm SH, Tobias GS, Hartge P. 2006. <a href="http://ehp03.niehs.nih.gov/article/info:doi/10.1289/ehp.9538">Inferring past pesticide-exposures: a matrix of individual active ingredients in home and garden pesticides used in past decades</a>. Environmental Health Perspectives (epub).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781#kline" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303781" sys_dependentvariantid="1418" sys_relationshipid="7296187" sys_siteid="475" sys_variantid="1418" sys_contentid="303781#kline">Reports prepared by Kline &amp; Company, Inc</a>. were the major information source. Since 1976, Kline has conducted proprietary analyses of product sales, market share, and active ingredient sales of home and garden pesticides and fertilizers for both the consumer and professional markets. All major pesticide manufacturers in the U.S. are regular or periodic purchasers of these reports. The data are typically used for market planning purposes in developing business strategies focused on the consumer and professional markets. The types of information presented in the reports vary, depending on the type of market (consumer versus professional), the pest type, and the year (data have become more detailed with time). Data may be provided on the number of acres treated nationwide with individual products, pounds of specific active ingredients purchased or used, dollar sales of products or active ingredients, prices per pound of product, dollar sales by company, and/or main products by company.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781#epa" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303781" sys_dependentvariantid="1418" sys_relationshipid="7296188" sys_siteid="475" sys_variantid="1418" sys_contentid="303781#epa">Two U.S. Environmental Protection Agency (U.S. EPA) databases</a> were used. The Pesticide Product Information System (PPIS) contains information on pesticide products that have been registered in the U.S. Included are registrant names and addresses, ingredients, toxicity category, product names, distributor brand names, site uses, pest uses, pesticidal type, formulation code, and registration status. A related resource is the Pesticide Product Label System (PPLS), a collection of pesticide label images. Another information source was the U.S. EPA National Home and Garden Pesticide Use Survey (the &ldquo;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781#whitmore" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303781" sys_dependentvariantid="1418" sys_relationshipid="7296189" sys_siteid="475" sys_variantid="1418" sys_contentid="303781#whitmore">U.S. EPA Survey</a>&rdquo;). This survey involved home interviews with over 2,000 households nationwide in 1990. Interviewers inventoried stored pesticide products, recorded the active ingredients on the label, and asked respondents to identify the pests on which the product had been used during the past year.</p>
<p>Several other sources were used to help identify active ingredients in specific products and to estimate application rates: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781#meister" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303781" sys_dependentvariantid="1418" sys_relationshipid="7296190" sys_siteid="475" sys_variantid="1418" sys_contentid="303781#meister">Meister Publishing Company</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303781#cp" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303781" sys_dependentvariantid="1418" sys_relationshipid="7296191" sys_siteid="475" sys_variantid="1418" sys_contentid="303781#cp">C&amp;P Press publications</a>, <a href="http://www.cdms.net/LabelsMsds/LMDefault.aspx?t=">Crop Data Management Systems, Inc</a>. (2004), and <a href="http://www.aces.edu/pubs/docs/A/ANR-0816/">Hagan et al</a>. (1993).</p>
</div>]]></content>
  </row>
  <row para_id="303780" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h4><a href="/Rhythmyx/assembler/render?sys_contentid=303777&amp;sys_revision=12&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303777" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296183">Pesticide-Exposure Matrix</a></h4>
<p>Pesticide-exposure Matrix was developed to help epidemiologists and other researchers identify the active ingredients to which people were likely exposed when their homes and gardens were treated for pests in past years</p>
<h4><a href="/Rhythmyx/assembler/render?sys_contentid=303778&amp;sys_revision=11&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303778" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296184">Data Sources</a></h4>
<p>Summary of data sources used for the Pesticide-Exposure Matrix.</p>
<h4><a href="/Rhythmyx/assembler/render?sys_contentid=303781&amp;sys_revision=6&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303781" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7296185">References</a></h4>
<p>List of publications</p>
</div>
<p>We used several different methods to develop the active ingredient lists and estimate the probabilities. Our choice of a method for each scenario was based on the types and quality of information available. Professional judgment played a large role in many scenarios. Our level of confidence varies by scenario, depending on the type of method used, the extent to which judgment played a role, the quality of the data in the source materials, and other factors.</p>
<p>The methods used for deriving the active ingredient lists and probabilities are summarized here. Additional detail is provided in Colt J, Cyr MJ, Zahm SH, Tobias GS, Hartge P. 2006. <a href="http://ehp03.niehs.nih.gov/article/info:doi/10.1289/ehp.9538">Inferring past pesticide-exposures: a matrix of individual active ingredients in home and garden pesticides used in past decades</a>. <i>Environmental Health Perspectives</i> (epub).</p>
<p>The scenarios to which each method applies, and the confidence level in the probability estimates for each scenario, can be found in the &ldquo;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=316842" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="316842" sys_dependentvariantid="1500" sys_relationshipid="7296182" sys_siteid="475" sys_variantid="1500" sys_contentid="316842">Pesticide-Exposure Matrix</a>&rdquo; PDF file.</p>
<h3>Method 1: Number of Acres Treated</h3>
<p style="margin-left: 20.0px;">This method was used when the Kline reports provided the number of acres nationwide treated with specific pesticide products. We assumed that the probability that a product (and each active ingredient in it) was used is equal to the percent of acres treated with that product.</p>
<p style="margin-left: 20.0px;">We have a medium confidence level in the estimates for outdoor plant/tree insects (1990, 2000) and a high confidence level for the others. This is because the Kline data for outdoor plants do not include mature trees, which are often sprayed with insecticides by professional applicators. This use might be significant but is likely smaller than the market for insecticides applied to gardens and landscaping areas, upon which the Kline estimates are based. We do not believe this to be an important limitation for outdoor plant/tree pests other than insects.</p>
<h3>Method 2: Number of Acres Treated&nbsp;<br />(Derived from Pounds of Active Ingredients and Application Rates)</h3>
<p style="margin-left: 20.0px;">This method was used for lawns and outdoor plants/trees when Kline reported the pounds of individual active ingredients sold. We divided the pounds of each active ingredient by an estimated application rate (pounds/acre) to derive the number of acres treated with each active ingredient, and then proceeded as in Method 1.</p>
<p style="margin-left: 20.0px;">Judgment was used for all of these scenarios and we have a medium level of confidence in the probability estimates. For lawn weeds (1980, 1990, 2000), we modified the Kline-reported pounds of some active ingredients to reflect our judgment about actual product formulations. For lawn and outdoor plant/tree insects (1980, 1990, 2000), Kline provided the active ingredient pounds aggregated across three pest types (lawn insects, outdoor plant insects, and non-plant insects), requiring us to allocate the pounds to each individual pest type. A similar situation was encountered for outdoor plant/tree diseases (1980, 1990, 2000).</p>
<h3>Method 3: Number of Acres Treated&nbsp;<br />(Derived from Dollar Sales, Unit Prices, and Application Rates)</h3>
<p style="margin-left: 20.0px;">This approach was used when Kline reported both dollar sales and unit prices (dollars per pound or gallon) for individual products. We divided the dollar sales by the unit price to estimate the pounds or gallons of each product sold. We then divided the pounds or gallons sold by an estimated application rate (pounds or gallons per acre) to derive the number of outdoor plant/tree acres treated with each product, and proceeded as in Method 1. We have a medium level of confidence in the probability estimates.</p>
<h3>Method 4: Product Sales</h3>
<p style="margin-left: 20.0px;">We used this method when Kline reported dollar sales for individual products or active ingredients, but not unit prices. We assumed that the probability that a product (and each active ingredient in it) was used is equal to the product&rsquo;s proportion of total dollar sales.</p>
<p style="margin-left: 20.0px;">Because of the uncertainty associated with using product sales as the basis for probability of use, we have a medium confidence level in the probabilities for most of these scenarios. We gave high confidence ratings to the 1990 and 2000 professional termite scenarios, the former because the market was well understood by Kline and the latter because of the large sample size used by Kline. The consumer rodent market was rated high because it has been dominated by d-Con during the entire period of interest, and the professional segment was high because it has used a small number of active ingredients in a well-documented market. Our confidence level is low for professional treatment of outdoor plant/tree insects in 1976 and 1980 because the Kline data excluded insecticide applications to mature trees, and because the 1976 data were aggregated across more than one pest type. We have low confidence in the probabilities for flying insects in 2000 because they were based only on bees.</p>
<h3>Method 5: Product Sales<br />(Calculated from Company Sales)</h3>
<p style="margin-left: 20.0px;">This method was used when Kline reported dollar sales by manufacturer (but not by product or active ingredient) and identified each manufacturer&rsquo;s main products and (typically) each product&rsquo;s main active ingredients, but did not provide unit prices. We identified the active ingredients in each product when necessary. We apportioned each manufacturer&rsquo;s dollar sales to its individual products or active ingredients using judgment. We assumed that the probability that a product (and each active ingredient in it) was used is equal to the product&rsquo;s percent of total dollar sales.</p>
<p style="margin-left: 20.0px;">For indoor plants in 1990, Kline reported sales by manufacturer and we used the U.S. EPA PPIS to identify the active ingredients that each manufacturer might have used. Probabilities for indoor plants pertain to insects only.</p>
<p style="margin-left: 20.0px;">Our confidence level is medium for all scenarios except lawn weeds (1976) and outdoor plant/tree weeds (1976), which are rated low because our allocation of sales to active ingredients required more judgment than the other scenarios.</p>
<h3>Method 6: Active Ingredient Frequencies from Pesticide Product Information System (PPIS)</h3>
<p style="margin-left: 20.0px;">For consumer treatment of household insects, the Kline reports were not sufficiently detailed for our purposes. Therefore, for scenarios 25-40, we used data from the U.S. EPA PPIS and the U.S. EPA Survey to estimate the active ingredient probabilities. This approach is described in detail in Colt J, Cyr MJ, Zahm SH, Tobias GS, Hartge P. 2006. <a href="http://ehp03.niehs.nih.gov/article/info:doi/10.1289/ehp.9538">Inferring past pesticide-exposures: a matrix of individual active ingredients in home and garden pesticides used in past decades</a>. <i>Environmental Health Perspectives</i> (epub). We have a medium level of confidence in the probability estimates.</p>
<h3>Method 7: Professional Judgment Based on Descriptive Data</h3>
<p style="margin-left: 20.0px;">Here, probabilities were based mostly on judgment, sometimes with a small amount of quantitative and/or descriptive data in the Kline reports, the literature, and the U.S. EPA PPLS . For indoor plants, the estimates pertain to treatment of insects only. Our confidence level is low.</p>
<h3>Method 8: Active Ingredients Listed, Probabilities Not Estimated</h3>
<p style="margin-left: 20.0px;">For some scenarios, Kline does not maintain data and there was not enough information from other sources to support a probability estimate. Therefore, we developed lists of likely active ingredients but did not estimate probabilities. The lists were based on information from the Kline reports, the U.S. EPA PPLS, selected information from the literature, and judgment.</p>
<h3>Method 9: No Active Ingredients Listed or Probabilities Estimated</h3>
<p style="margin-left: 20.0px;">We were unable to list active ingredients or estimate probabilities for consumer treatment of termites and professional treatment of indoor plants. There is no evidence that a significant number of consumers purchased products to self-apply termiticides until the late 1990s, and the market remains extremely small. Indoor plants are rarely treated by professional applicators.</p>
</div>]]></content>
  </row>
  <row para_id="303781" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303777" sys_dependentvariantid="1418" sys_dependentid="303777" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391766" sys_variantid="1418" sys_contentid="303777">Pesticide-Exposure Matrix</a></h4>
<p>Pesticide-exposure Matrix was developed to help epidemiologists and other researchers identify the active ingredients to which people were likely exposed when their homes and gardens were treated for pests in past years</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303778" sys_dependentvariantid="1418" sys_dependentid="303778" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391767" sys_variantid="1418" sys_contentid="303778">Data Sources</a></h4>
<p>Summary of data sources used for the Pesticide-Exposure Matrix.</p>
<h4><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303780" sys_dependentvariantid="1418" sys_dependentid="303780" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391768" sys_variantid="1418" sys_contentid="303780">Methods and Confidence Levels</a></h4>
<p>Pesticide-Exposure Matrix methods used to develop active ingredient lists and estimate probabilities.</p>
</div>
<h3><a id="kline" name="kline"></a>Kline &amp; Company, Inc.</h3>
<div>
<ul>
<li>Anonymous. 1982. Consumer Markets for Pesticides and Fertilizers, 1981. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Anonymous. 1991b. Professional Markets for Pesticides and Fertilizers Volume I, 1990. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Cyr M, Dansbury L. 2000. The U.S. Market for Flea and Tick Control Products in Companion Animal Protection, 1999-2000. Little Falls, NJ: Kline &amp; Company, Inc.</li>
<li>Fugate D, Cyr M. 1997. The U.S. Market for Flea and Tick Control Products in Companion Animal Protection, 1996-1997. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Fugate D, Frister S, Cyr M, Dansbury L. 2000. Super Sample PCO Report, 1999. Little Falls, NJ: Kline &amp; Company, Inc.</li>
<li>Fugate D, Cyr M, Frister S, Hall K. 2001. Professional Turf &amp; Ornamental Markets for Pesticides and Fertilizers, 2000. Little Falls, NJ: Kline &amp; Company, Inc.</li>
<li>Fugate D, Hall K. 2002. Consumer Markets for Pesticides and Fertilizers, 2001. Little Falls, NJ: Kline &amp; Company, Inc.</li>
<li>Fugate D, Frister S, Cyr M. 2002. The U.S. Professional Pest Management Market, 2001. Little Falls, NJ: Kline &amp; Company, Inc.</li>
<li>Garushenko P, Schreiber P, Kollonitsch V. 1977. Professional Markets for Pesticides and Fertilizers, 1976. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Goodbread AR, Cuono LC, Tarantola JV, Kollonitsch V. 1983. Professional Markets for Pesticides and Fertilizers, 1982. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Hall K, Dansbury L. 2000. Consumer Markets for Pesticides and Fertilizers, 1999. Little Falls, NJ: Kline &amp; Company, Inc.</li>
<li>Hodge J, Rafter BL. 1991. Consumer Markets for Pesticides and Fertilizers, 1990. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Hodge J, Rafter BL. 1992a. .Consumer Markets for Pesticides and Fertilizers, 1991. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Hodge J, Rafter BL. 1992b. Professional Markets for Pesticides and Fertilizers Volume II, 1991. Fairfield, NJ: Kline &amp; Company, Inc.</li>
<li>Ramsey G, Kollonitsch V. 1977. Lawn, Garden, and Houseplant Chemicals. Fairfield, NJ: Kline &amp; Company, Inc.</li>
</ul>
</div>
<h3><a id="epa" name="epa"></a>U.S. Environmental Protection Agency</h3>
<div>
<ul>
<li>U.S. EPA (U.S. Environmental Protection Agency). 2003a. <a href="http://www.epa.gov/opppmsd1/PPISdata/">Pesticide Product Information System</a>. [accessed July 29, 2003].</li>
<li>U.S. EPA (U.S. Environmental Protection Agency). 2003b. <a href="http://www.epa.gov/pesticides/pestlabels/">Pesticide Product Label System</a>. [accessed July 21, 2003].</li>
<li><a id="whitmore" name="whitmore"></a>Whitmore RW, Kelly JE, Reading PL. 1992. National Home and Garden Pesticide Use Survey. Research Triangle Institute, Research Triangle Park, NC (Prepared for U.S. Environmental Protection Agency, Office of Pesticides and Toxic Substances).</li>
</ul>
</div>
<h3><a id="meister" name="meister"></a>Meister Publishing Company Manuals</h3>
<div>
<ul>
<li>Anonymous. 1999a. Farm Chemicals Handbook 1999. Meister Publishing Company. Willoughby, OH.</li>
<li>Anonymous. 1999b. Insect and Disease Control Guide. Meister Publishing Company. Willoughby, OH.</li>
<li>Anonymous. 2000. Weed Control Manual, Volume 32, 2000. Meister Publishing Company. Willoughby, OH.</li>
<li>Anomymous. 2003. Crop Protection Handbook, Volume 89, 2003. Meister Publishing Company. Willoughby, OH.</li>
<li>Anonymous. 2005. Crop Protection Handbook 2005. Meister Publishing Company. Willoughby, OH.</li>
</ul>
</div>
<h3><a id="cp" name="cp"></a>C&amp;P Press Publications</h3>
<div>
<ul>
<li>Anonymous. 1994. Crop Protection Chemicals Reference, 10th Edition, 1994. C&amp;P Press. New York, NY.</li>
<li>Anonymous. 1995. Turf &amp; Ornamental Reference for Plant Protection Products, 4th Edition, 1995. C&amp;P Press. New York, NY.</li>
<li>C&amp;P Press. 2004. <a href="http://www.greenbook.net/">C&amp;P Press Label Website</a> 2003-2004. [accessed March 15, 2004].</li>
</ul>
</div>
<h3><a id="other" name="other"></a>Other</h3>
<div>
<ul>
<li>Hagan AK, Gazaway WS, Ogborn C. 1993. <a href="http://www.aces.edu/pubs/docs/A/ANR-0816">Home Application of Fungicides</a>. Auburn University Cooperative Extension Publication ANR-816. July 1993.</li>
<li>Crop Data Management Systems, Inc. 2004. <a href="http://www.cdms.net/manuf/manuf.asp">CDMS Website</a> 2003-2004. [accessed June 1, 2004].</li>
</ul>
</div>
</div>]]></content>
  </row>
  <row para_id="303784" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335373">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Alcohol Use&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Black and White Americans&nbsp;</p>
<h4>Study Keywords:&nbsp;</h4>
<p>Alcohol use&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brown&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1989&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brown LM, Hoover R, Gridley G, et al. Drinking practices and risk of squamous-cell esophageal cancer among Black and White men in the United States. Cancer Causes Control 1997;8(4):605-9.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=325947" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335370" sys_dependentvariantid="1500" sys_dependentid="325947" rxinlineslot="103">Black_White_Americans_Study_Alcohol_Use_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="/Rhythmyx/assembler/render?sys_contentid=303783&amp;sys_revision=2&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303783" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335374">Alcohol, Tobacco, and Recreational Drug Use</a></p>
<p>Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335375">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303785" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335389" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Tobacco Use Study&nbsp;</p>
<h4>Title:&nbsp;</h4>
<p>Black and White Americans Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>tobacco use&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brown&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1989&nbsp;</p>
<h4>Short/Long Form:</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brown LM, Pottern LM, Silverman DT, et al. Multiple myeloma among Blacks and Whites in the United States: Role of cigarettes and alcoholic beverages. Cancer Causes Control.1997;8(4):610-4.&nbsp;&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326030" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335388" sys_dependentvariantid="1500" sys_dependentid="326030" rxinlineslot="103">Tobacco_Use_Black-White-Americans_Study_questionnaire (Word, 24 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303783" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335390" sys_dependentvariantid="1418" sys_dependentid="303783" rxinlineslot="103" sys_folderid="">Alcohol, Tobacco, and Recreational Drug Use</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335391" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303786" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335385" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Recreational Drug Use&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>D.C.Gays Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>AIDS, HIV, homosexuals&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>J. Goedert&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1999&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Goedert JJ, Sarngadharan MG, Biggar RJ, et al. Determinants of retrovirus (HTV-III) antibody and immunodeficiency conditions in homosexual men. Lancet 1984; 2:711-716&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326011" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335383" sys_dependentvariantid="1500" sys_dependentid="326011" rxinlineslot="103">Recreational_Drug_Use_History_DC_Gays_Study_questionnaire (Word, 16 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303783" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335386" sys_dependentvariantid="1418" sys_dependentid="303783" rxinlineslot="103" sys_folderid="">Alcohol, Tobacco, and Recreational Drug Use</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335387" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303787" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335380">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Alcohol Use&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Oral Cancer -- Second Primary&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>pharyngeal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>G. Day&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1990&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancer: role of tobacco and alcohol. J Natl Cancer Inst. 1994; 86(2):131-7</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326010" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335377" sys_dependentvariantid="1500" sys_dependentid="326010" rxinlineslot="103">Oral_Second_Primary_Cancer_Alcohol_Use_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="/Rhythmyx/assembler/render?sys_contentid=303783&amp;sys_revision=2&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303783" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335381">Alcohol, Tobacco, and Recreational Drug Use</a></p>
<p>Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335382">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303789" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about DCEG Questionnaire Development Resources.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Anthropometric Measurements/Women&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Asian-American Breast Cancer Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Chinese, Filipino, Japanese, women, breast cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>R. Ziegler&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1991&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Ursin G, Wu AH, Hoover RN, et al. Breast cancer and oral contraceptive use in Asian-American women. Am J Epidemiol 1999;150(6):561-7.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326031" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335351" sys_dependentvariantid="1500" sys_dependentid="326031" rxinlineslot="103">Anthropometric_Measurements_Women_Asian-American_questionnaire (Word, 18 KB)</a></p>
<p>Back to <a href="/Rhythmyx/assembler/render?sys_contentid=303788&amp;sys_revision=2&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303788" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335353">Anthropometric Measurements</a></p>
<p>Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335354">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303790" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335348" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Anthropometric Measurements/Men&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Men's Health Study in Shanghai&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Chinese, China&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>A. Hsing&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2000&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, Xie T, Gao YT. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1335-41.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326032" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335340" sys_dependentvariantid="1500" sys_dependentid="326032" rxinlineslot="103">Anthropometric_Measurements_Men_Shanghai_questionnaire (Word, 19 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303788" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335349" sys_dependentvariantid="1418" sys_dependentid="303788" rxinlineslot="103" sys_folderid="">Anthropometric Measurements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335350" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303792" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335208" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Breast Cancer Risk Factors&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Women's Health Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brinton&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1996&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brinton LA, Brown SL, Colton T, et al. Characteristics of a population of women with breasts implants compared with women seeking other types of plastic surgery. Plastic &amp; Reconstructive Surgery. 2000;105(3):919-27.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326569" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335207" sys_dependentvariantid="1500" sys_dependentid="326569" rxinlineslot="103">Breast_Cancer_Risk_Womens_Health_questionnaire_ShortForm (Word, 25 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303791" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335209" sys_dependentvariantid="1418" sys_dependentid="303791" rxinlineslot="103" sys_folderid="">Breast Cancer Risk Factors</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335210" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303793" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about DCEG Questionnaire Development Resources.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Breast Cancer Risk Factors&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Women's Interview Study of Health&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brinton&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87(11):827-35.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326570" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6335204" sys_dependentvariantid="1500" sys_dependentid="326570" rxinlineslot="103">Breast_Cancer_Risk_Womens_Health_questionnaire_LongForm (Word, 157 KB)</a></p>
<p>Back to <a href="/Rhythmyx/assembler/render?sys_contentid=303791&amp;sys_revision=4&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303791" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335205">Breast Cancer Risk Factors</a></p>
<p>Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6335206">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303795" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6332917">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Family History of Cancer&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Case-referent Study of Adults with Brain Tumors&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>D.Parry, P.Inskip, M.Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Hill DA, Inskip PD, Shapiro WR, Selker RG, Fine HA, Black PM, Linet MS. Cancer in first-degree relatives and risk of glioma in adults. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1443-8.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327332" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327332" sys_dependentvariantid="1500" sys_relationshipid="6332914" sys_siteid="475">Adult_Brain_Tumors_Family_Cancer_History_Questionnaire (Word, 50 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303794" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303794" sys_dependentvariantid="1418" sys_relationshipid="6332915" sys_siteid="475">Family History of Cancer</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6332916" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303796" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="6798530">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Family History of Cancer&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Childhood Medulloblastoma study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>A. Goldstein&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1999&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>NA</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327322" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327322" sys_dependentvariantid="1500" sys_relationshipid="6798525" sys_siteid="475">Childhood_Medulloblastoma_Main_Family_Cancer_History (Word, 54 KB)</a></p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327323" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327323" sys_dependentvariantid="1500" sys_relationshipid="6798526" sys_siteid="475">Childhood_Medulloblastoma_Mother_Family_Cancer_History (Word, 64 KB)</a></p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327325" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327325" sys_dependentvariantid="1500" sys_relationshipid="6798527" sys_siteid="475">Childhood_Medulloblastoma_Father_Family_Cancer_History (Word, 58 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303794" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303794" sys_dependentvariantid="1418" sys_relationshipid="6798528" sys_siteid="475">Family History of Cancer</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6798529" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303797" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_relationshipid="6332913" sys_folderid="" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Family History of Cancer&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Family Studies Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Tucker&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>Ongoing&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Novakovic B et al. Increased risk of neuroectodermal tumors and stomach cancer in relatives of patients with ewing's sarcoma family of tumors. J Natl Cancer Inst 1994;86:1702-6.&nbsp;</p>
<p>Novakovic B, Goldstein AM, Tucker MA. Validation of family history of cancer in deceased family members. J Natl Cancer Inst 1996;88:1492-3.&nbsp;</p>
<p>Love RR et al. The accuracy of patient reports of a family history of cancer. J Chronic Dis 1985;38:289-93.&nbsp;</p>
<p>Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am j Epidemiol 1997;146:244-8.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327320" inlinetype="rxhyperlink" sys_relationshipid="6332909" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="327320" rxinlineslot="103">Relatives_Part1_Family_Studies_Family_Cancer_History (Word, 71 KB)</a></p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327321" inlinetype="rxhyperlink" sys_relationshipid="6332910" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="327321" rxinlineslot="103">Relatives_Part2_Family_Studies_Family_Cancer_History (Word, 255 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303794" inlinetype="rxhyperlink" sys_relationshipid="6332911" sys_folderid="" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303794" rxinlineslot="103">Family History of Cancer</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_relationshipid="6332912" sys_folderid="" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303798" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332960" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Family History of Cancer&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Melanoma -- Case-Control Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Tucker&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>In-person Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1992&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327273" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332925" sys_dependentvariantid="1500" sys_dependentid="327273" rxinlineslot="103">Melanoma_Family_Cancer_History (Word, 24 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303794" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332961" sys_dependentvariantid="1418" sys_dependentid="303794" rxinlineslot="103" sys_folderid="">Family History of Cancer</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332962" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303799" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about DCEG Questionnaire Development Resources.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Family History of Cancer&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>X-ray Technicians--Second Survey&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>radiologic technologists, radiation, breast cancer, thyroid cancer, radiology, radiologic technicians&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M.Doody, M.Tucker&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=326571" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332963" sys_dependentvariantid="1500" sys_dependentid="326571" rxinlineslot="103">X-ray Technicians Family Cancer History questionnaire (Word, 156 KB)</a></p>
<p>Back to <a href="/Rhythmyx/assembler/render?sys_contentid=303794&amp;sys_revision=4&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303794" rxinlineslot="103" sys_folderid="" sys_relationshipid="6332971">Family History of Cancer</a></p>
<p>Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6332972">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303801" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333033">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Background information</p>
<h4>Study Title:&nbsp;</h4>
<p>Asian-American Breast Cancer Study</p>
<h4>Keywords:&nbsp;</h4>
<p>Chinese, Filipino, Japanese, women, breast cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>R. Ziegler&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1991&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327429" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333022" sys_dependentvariantid="1500" sys_dependentid="327429" rxinlineslot="103">Cultural_assimilation_Asian-Americans_questionnaire (Word, 21 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303800" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333023" sys_dependentvariantid="1418" sys_dependentid="303800" rxinlineslot="103">Background Information</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333024" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303802" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333041">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Ethnicity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Asian-American Breast Cancer Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Chinese, Filipino, Japanese, women, breast cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>R. Ziegler&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1991&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327336" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327336" sys_dependentvariantid="1500" sys_relationshipid="6333038" sys_siteid="475">Ethnicity_Asian-American_questionnaire (Word, 18 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303800" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303800" sys_dependentvariantid="1418" sys_relationshipid="6333039" sys_siteid="475">Background Information</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333040" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303803" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333046">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Ethnicity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Used in multiple studies&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>ethnicity&nbsp;</p>
<h4>DCEG Principal Investigator(s):&nbsp;</h4>
<p>S. Zahm&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Standard&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>Standard&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327334" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327334" sys_dependentvariantid="1500" sys_relationshipid="6333042" sys_siteid="475">Ethnicity_ long form_questionnaire (Word, 22 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303800" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303800" sys_dependentvariantid="1418" sys_relationshipid="6333043" sys_siteid="475">Background Information</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333044" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303804" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333051">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Ethnicity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Office of Management and Budget&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>OMB&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>S. Zahm&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Standard&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>Standard&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327333" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327333" sys_dependentvariantid="1500" sys_relationshipid="6333047" sys_siteid="475">Ethnicity_ OMB_approved_questions (Word, 16 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303800" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303800" sys_dependentvariantid="1418" sys_relationshipid="6333048" sys_siteid="475">Background Information</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333049" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303805" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333037">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Demographic Information (Date/Place of Birth, Income, Education, Religion)&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Women's Interview Study of Health&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>breast cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brinton&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87(11):827-35.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327430" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327430" sys_dependentvariantid="1500" sys_relationshipid="6333034" sys_siteid="475">Demographics_Womens_Interview_Study_of_Health_questionnaire (Word, 22 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303800" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303800" sys_dependentvariantid="1418" sys_relationshipid="6333035" sys_siteid="475">Background Information</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333036" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303807" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h4>Questionnaire Topic:&nbsp;</h4>
<p>EMF and Radon Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Hatch EE, Kleinerman RA, Linet MS, et al. Do confounding or selection factors of residential wiring codes and magnetic fields distort findings of Electromagnetic field studies? Epidemiology 2000;11:189-198.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327431" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332690" sys_dependentvariantid="1500" sys_dependentid="327431" rxinlineslot="103">EMF_Radon_Childhood_Leukemia_Study_questionnaire (Word, 22 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303806" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332698" sys_dependentvariantid="1418" sys_dependentid="303806" rxinlineslot="103" sys_folderid="">EMF, Radon, and UVR Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6332699" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303808" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333210">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>EMF and Radon Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Childhood Leukemia Study&nbsp;</p>
<h4>Principal Investigator(s):</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Kaune WT, Miller MC, Linet MS, et al. Children's exposure to magnetic fields produced by U.S. television sets used for viewing programs and playing video games. Bioelectromagnetics 2000;21(3):214-27.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327432" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327432" sys_dependentvariantid="1500" sys_relationshipid="6333207" sys_siteid="475">Personal_EMF_Exposures_Childhood_Leukemia_Study_Questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303806" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303806" sys_dependentvariantid="1418" sys_relationshipid="6333208" sys_siteid="475">EMF, Radon, and UVR Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333209" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303809" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333202">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Sun Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Melanoma -- Case-Control Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Tucker&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>In-person Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p>Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327487" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327487" sys_dependentvariantid="1500" sys_relationshipid="6333199" sys_siteid="475">Sun_Exposure_History_Melanoma_Study_questionnaire (Word, 26 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303806" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303806" sys_dependentvariantid="1418" sys_relationshipid="6333200" sys_siteid="475">EMF, Radon, and UVR Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333201" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303810" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333206">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Sun Exposures</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma Study (NHL)&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>P. Hartge&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327486" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327486" sys_dependentvariantid="1500" sys_relationshipid="6333203" sys_siteid="475">Sun_Exposure_History_NHL_Study_questionnaire (Word, 29 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303806" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303806" sys_dependentvariantid="1418" sys_relationshipid="6333204" sys_siteid="475">EMF, Radon, and UVR Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333205" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303812" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333216">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exposures from Carpeting and Vacuuming&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Childhood Leukemia Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327540" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327540" sys_dependentvariantid="1500" sys_relationshipid="6333213" sys_siteid="475">Carpeting_Vacuuming_Exposures_Childhood_Leukemia_Study_questionnaire (Word, 17 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333214" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333215" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303813" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333220">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exposures to Electrical Appliances&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Keywords:</h4>
<p>Childhood Leukemia Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Hatch EE, Linet MS, Kleinerman RA, et al. Association between childhood acute lymphoblastic leukemia and use of electrical appliances during pregnancy and childhood. Epidemiology 1998;9:234-45.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327536" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327536" sys_dependentvariantid="1500" sys_relationshipid="6333217" sys_siteid="475">Electrical_Appliance_Exposure_Childhood_Leukemia_Study_questionnaire (Word, 52 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333218" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333219" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303814" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333228">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exposures from Hobbies and/or Household Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Childhood Leukemia Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Wen W, Shu XO, Linet MS, et al. Allergic disorders and the risk of childhood acute lymphoblastic leukemia. Cancer causes control. 2000;11(4):303-7.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327533" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327533" sys_dependentvariantid="1500" sys_relationshipid="6333225" sys_siteid="475">Hobbies-Household_Exposures_Childhood_Leukemia_Study_questionnaire (Word, 25 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333226" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333227" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303815" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333310">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Household Pesticide Exposures (inside and outside)&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Nebraska Health Study II&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>stomach cancer, esophageal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Ward&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Ward MH, Sinha R, Heineman EF, et al. Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference. Int J Cancer. 1997;71(1)14-9.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327512" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327512" sys_dependentvariantid="1500" sys_relationshipid="6333307" sys_siteid="475">Household_pesticide_exposure_Nebraska_Health_II_questionnaire (Word, 15 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333308" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333309" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303816" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333224">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Use of Hair Dyes&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma (NHL) Study</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>S. Zahm&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327534" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327534" sys_dependentvariantid="1500" sys_relationshipid="6333221" sys_siteid="475">Hair_dye_NHL_study_questionnaire (Word, 27 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333222" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333223" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303817" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333314">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Household Pesticide Exposures (inside and outside)&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma Study (NHL)&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>pesticides, herbicides, residential, garden, crowding, drinking water&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>P. Hartge&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Colt JS, Davis S, Severson RK, Lynch CF, Cozen W, Camann D, Engels EA, Blair A, Hartge P. Residential insecticide use and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):251-7.&nbsp;</p>
<p>Hartge P, Colt JS, Severson RK, Cerhan JR, Cozen W, Camann D, Zahm SH, Davis S. Residential herbicide use and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):934-7. Review.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327511" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327511" sys_dependentvariantid="1500" sys_relationshipid="6333311" sys_siteid="475">Household_pesticide_exposure_NHL_Study_questionnaire (Word, 49 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333312" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333313" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303818" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333327">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exposures to Pets&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Childhood Leukemia Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327509" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327509" sys_dependentvariantid="1500" sys_relationshipid="6333322" sys_siteid="475">Pet_Exposure_Childhood_ Leukemia_questionnaire (Word, 18 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333323" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333324" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303819" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333331">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Water Source History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Nebraska Health Study II&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>stomach cancer, esophageal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Ward&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Ward MH, Sinha R, Heineman EF, et al. Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference. Int J Cancer. 1997;71(1)14-9.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327507" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327507" sys_dependentvariantid="1500" sys_relationshipid="6333328" sys_siteid="475">Water_Source_History_Nebraska_health_questionnaire (Word, 24 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303811" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303811" sys_dependentvariantid="1418" sys_relationshipid="6333329" sys_siteid="475">Household Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333330" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303821" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333347" sys_siteid="475" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>X-ray and Other Radiation Exposures (Work History)&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>X-ray Technicians--Second Survey&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>radiologic technologists, radiation, breast cancer, thyroid cancer, radiology, radiologic technicians&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Doody&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Boice JD, Mandel JS, Doody M, et al. A health survey of radiologic technologists. Cancer 1992;69(2):586-98.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327542" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327542" sys_dependentvariantid="1500" sys_relationshipid="6333344" sys_siteid="475">Occupational_Exposure_X-ray_Technicians_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303820" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303820" sys_dependentvariantid="1418" sys_relationshipid="6333345" sys_siteid="475">Ionizing Radiation Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333346" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303822" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333358">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>X-ray and Other Radiation Exposures (Personal History)&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>X-ray Technicians--Second Survey&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>radiologic technologists, radiation, breast cancer, thyroid cancer, radiology, radiologic technicians&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Doody&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Doody M, Mandel JS, Lubin JH, et al. Mortality among United States radiologic technologists, 1926-90. Cancer Causes and Control 1998;9:67-75.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327541" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327541" sys_dependentvariantid="1500" sys_relationshipid="6333355" sys_siteid="475">Personal_exposure_X-ray_Technicians_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303820" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303820" sys_dependentvariantid="1418" sys_relationshipid="6333356" sys_siteid="475">Ionizing Radiation Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333357" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303824" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333441">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Medical History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma (NHL) Study</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327545" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327545" sys_dependentvariantid="1500" sys_relationshipid="6333438" sys_siteid="475">Medical_History_NHL_study_long-form_questionnaire (Word, 52 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303823" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303823" sys_dependentvariantid="1418" sys_relationshipid="6333439" sys_siteid="475">Medical History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333440" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303825" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333432">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Medical History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma&nbsp;(NHL) Study</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327546" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327546" sys_dependentvariantid="1500" sys_relationshipid="6333427" sys_siteid="475">Medical_History_NHL_study_short-form_questionnaire (Word, 31 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303823" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303823" sys_dependentvariantid="1418" sys_relationshipid="6333428" sys_siteid="475">Medical History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333429" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303826" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333454">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Personal Medical History of Cancer&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>X-ray Technicians--Second Survey&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>radiologic technologists, radiation, breast cancer, thyroid cancer, radiology, radiologic technicians&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Doody&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Boice JD, Mandel JS, Doody M, et al. Breast cancer among radiologic technologists. JAMA 1995;274(5):394-401.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327543" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327543" sys_dependentvariantid="1500" sys_relationshipid="6333450" sys_siteid="475">Personal_Medical_History_Cancer_X-ray_Technicians_questionnaire (Word, 17 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303823" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303823" sys_dependentvariantid="1418" sys_relationshipid="6333451" sys_siteid="475">Medical History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333452" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303827" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333445">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Non-Cancer Personal Medical History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>X-ray Technicians--Second Survey&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>radiologic technologists, radiation, breast cancer, thyroid cancer, radiology, radiologic technicians&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Doody&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Boice JD, Mandel JS, Doody M, et al. Breast cancer among radiologic technologists. JAMA 1995;274(5):394-401.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327544" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327544" sys_dependentvariantid="1500" sys_relationshipid="6333442" sys_siteid="475">Non-Cancer_Personal_Medical_History_X-ray_Technicians_questionnaire (Word, 17 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303823" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303823" sys_dependentvariantid="1418" sys_relationshipid="6333443" sys_siteid="475">Medical History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333444" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303829" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333510">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Consumption of Coffee, Tea, Other Beverages&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Population Health Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Black and White Americans Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>D. Silverman&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1989&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Silverman DT, Swanson CA, Gridley G, et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interview. Journal of the National Cancer Institute. 1998;90(22):1710-19.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327726" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333507" sys_dependentvariantid="1500" sys_dependentid="327726" rxinlineslot="103">Black-White-Americans_Beverage_Consumption_questionnaire (Word, 22 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333508" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333509" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303830" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333514">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Use of Dietary Supplements&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Diet History Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>A. Subar&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2000&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form</p>
<h4>Citation(s):</h4>
<p>Subar AF, Ziegler RG, Thompson FE, Johnson CC, Weissfeld JL, Reding D, Kavounis KH, Hayes RB. Is shorter always better? Relative importance of dietary questionnaire length and cognitive ease on response rates and data quality. Am J Epidemiol 2001;153:404-409.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327634" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333511" sys_dependentvariantid="1500" sys_dependentid="327634" rxinlineslot="103">Dietary_Supplements_short-form_self-admin_questionnaire (Word 672 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333512" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333513" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303831" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333522">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Food Frequency Questionnaire -- American Diet&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Diet History Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>A. Subar&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2000&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Subar AF, Ziegler RG, Thompson FE, Johnson CC, Weissfeld JL, Reding D, Kavounis KH, Hayes RB. Is shorter always better? Relative importance of dietary questionnaire length and cognitive ease on response rates and data quality. Am J Epidemiol 2001;153:404-409.&nbsp;</p>
<p>Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt S, McIntosh A, Rosenfeld S. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: The Eating at America's Table Study (EATS). Am J Epidemiol 2001; In Press.&nbsp;</p>
<p><strong>Download</strong><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327632" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333519" sys_dependentvariantid="1500" sys_dependentid="327632" rxinlineslot="103"> Long-Form_Food_Frequency_American_Diet_questionnaire (Word, 339 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333520" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333521" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303832" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333518" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Consumption of Coffee, Tea, Other Beverages&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Digestive tract diseases -- Shanghai Study&nbsp;</p>
<h4>Keywords:</h4>
<p>pancreatic cancer, esophageal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>W.H. Chow&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Gao YT, McLaughlin JK, Blot WJ, et al. Reduced Risk of Esophageal Cancer Associated With Green Tea Consumption. J of the Natl Cancer Inst. 1994;86(11):855-58.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327633" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333515" sys_dependentvariantid="1500" sys_dependentid="327633" rxinlineslot="103"> Digestive_Tract_Beverage_Consumption_Shanghai_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333516" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333517" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303833" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333533">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Food Frequency Questionnaire -- Shanghai Diet&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Digestive tract diseases -- Shanghai Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>pancreatic cancer, esophageal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>W.H. Chow&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Ji BT, Chow WH, Gridley G, et al. Dietary Factors and the Risk of Pancreatic Cancer: A Case-Control Study in Shanghai, China. Cancer Epidemiol, Biomarkers &amp; Prevention. 1995;4:885-893.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327580" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333527" sys_dependentvariantid="1500" sys_dependentid="327580" rxinlineslot="103">Shanghai_Diet_Digestive_Tract_Food_ Frequency_questionnaire (Word, 32 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333528" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333529" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303834" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333526">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Consumption of Coffee, Tea, Other Beverages&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Oral Cancer -- Second Primary&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>pharyngeal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>G. Day&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1990&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancer: role of tobacco and alcohol. J Natl Cancer Inst. 1994; 86(2):131-7.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327581" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333523" sys_dependentvariantid="1500" sys_dependentid="327581" rxinlineslot="103">Beverage_second_primary_cancer_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333524" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333525" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303835" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333506">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Food Frequency Questionnaire -- American Diet&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Oral Cancer -- Second Primary&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>pharyngeal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>G. Day&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Telephone Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1990&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Day GL, Shore RE, Blot WJ, et al. Dietary factors and second primary cancers: a follow-up of oral and pharyngeal cancer patients. Nutr Cancer. 1994; 21(3):223-32.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327727" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333482" sys_dependentvariantid="1500" sys_dependentid="327727" rxinlineslot="103">American_Diet_ Food_Freq_Second_Primary_Cancer_questionnaire (Word, 34 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333483" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103">Non-alcoholic Beverage, Food, and Dietary Supplements</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333484" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303837" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333542">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Occupational History/ Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Study of Brain Tumors in Adults&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>P. Inskip&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Stewart PA, Stewart WF, Heineman EF, Dosemeci M, Linet M, Inskip P. A novel approach to data collection in a case-control study of cancer and occupational exposures. Int J Epidemiol 1996;25:744-52.</p>
<p>Stewart PA, Stewart WF, Siemiatycki J, Heineman EF, Dosemeci M. Questionnaires for collecting detailed occupational information for community-based case-control studies. Am Ind Hyg Assoc J 1998;59:39-44</p>
<h4>Main questionnaire:&nbsp;</h4>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327738" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333537" sys_dependentvariantid="1500" sys_dependentid="327738" rxinlineslot="103">Occupational_Hist_Exp_Adult_Brain_Tumor_questionnaire (Word, 25 KB)</a></p>
<h5>Sample Job Modules:&nbsp;</h5>
<p>Butcher &ndash; Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327739" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333538" sys_dependentvariantid="1500" sys_dependentid="327739" rxinlineslot="103">Butcher_Occupational_Hist_Exp_Adult_Brain_Tumor_questionnaire (Word, 18 KB)</a></p>
<p>Electrician &ndash; Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327740" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333539" sys_dependentvariantid="1500" sys_dependentid="327740" rxinlineslot="103">Electrician_Occupational_Hist_Exp_Adult_Brain_Tumor_questionnaire (Word, 37 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303836" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333540" sys_dependentvariantid="1418" sys_dependentid="303836" rxinlineslot="103">Occupational History and Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333541" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303838" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333546" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Occupational History/ Exposures&nbsp;</p>
<h4>Study&nbsp;Title:&nbsp;</h4>
<p>Agricultural Health Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>farms, pesticides&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Alavanja&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Alavanja MC, Sandler DP, McMaster SB, et al. The agricultural health study. Environ Health Perspect.1996;104(4): 362-9.</p>
<p>Alavanja M. Occupational cancer risk associated with the storage and bulk handling of agricultural foodstuff. J Toxicol Environ Health.1987;22(3):247-54.</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327737" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333543" sys_dependentvariantid="1500" sys_dependentid="327737" rxinlineslot="103">Occupational_History_Exposure_Agricultural_Health_questionnaire (Word, 38 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303836" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333544" sys_dependentvariantid="1418" sys_dependentid="303836" rxinlineslot="103">Occupational History and Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333545" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303839" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333557">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Occupational History/ Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>AIDS Cancer Cohort Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>C. Rabkin&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1999&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327736" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333554" sys_dependentvariantid="1500" sys_dependentid="327736" rxinlineslot="103">Occupational_Hist_Exp_AIDS_Cancer_Cohort_questionnaire2 (Word, 18 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303836" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333555" sys_dependentvariantid="1418" sys_dependentid="303836" rxinlineslot="103">Occupational History and Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333556" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303840" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333570">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Occupational History/Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma&nbsp;(NHL) Study</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>P. Hartge&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327728" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333564" sys_dependentvariantid="1500" sys_dependentid="327728" rxinlineslot="103">Occupational_Hist_Exp_NHL_study_questionnaire (Word, 26 KB)</a></p>
<h5>Sample Job Modules:</h5>
<p>Chemical Industry &ndash; Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327730" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333565" sys_dependentvariantid="1500" sys_dependentid="327730" rxinlineslot="103">Chemical_Ind_Occupational_Hist_Exp_NHL_questionnaire (Word, 36 KB)&nbsp;</a></p>
<p>Engineer &ndash; Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327731" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333566" sys_dependentvariantid="1500" sys_dependentid="327731" rxinlineslot="103">Engineer_Occupational_Hist_Exp_NHL_questionnaire (Word, 25 KB)</a></p>
<p>Painter &ndash; Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327732" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333567" sys_dependentvariantid="1500" sys_dependentid="327732" rxinlineslot="103">Painter_ Occupational_Hist_Exp_NHL_questionnaire (Word, 26 KB)</a></p>
<p></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303836" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333568" sys_dependentvariantid="1418" sys_dependentid="303836" rxinlineslot="103">Occupational History and Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333569" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303841" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333563" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Occupational History/ Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Spanish Bladder Cancer Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Spain&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Dosemeci&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>CAPI&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>Ongoing&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<h4>Main questionnaire:&nbsp;</h4>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327733" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333558" sys_dependentvariantid="1500" sys_dependentid="327733" rxinlineslot="103">Occupational_History_Exposure_Spanish_Bladder_Cancer_questionnaire (Word, 31 KB)</a></p>
<h5>Sample Job Modules:&nbsp;</h5>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327734" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333559" sys_dependentvariantid="1500" sys_dependentid="327734" rxinlineslot="103">Chemical_Ind_Occupational_Hist_Exp_Spanish_Bladder_Cancer_questionnaire (Word, 69 KB)</a></p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327735" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333560" sys_dependentvariantid="1500" sys_dependentid="327735" rxinlineslot="103">Gardener_Occupational_Hist_Exp_Spanish_Bladder_Cancer_questionnaire (Word, 49 KB)</a></p>
<p></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303836" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333561" sys_dependentvariantid="1418" sys_dependentid="303836" rxinlineslot="103">Occupational History and Exposures</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333562" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303843" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333590">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exercise and Physical Activity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>BCDDP-Female Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Breast Cancer Detection Demonstration Project&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>C. Schairer&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Kant AK, Schatzkin A, Graubard BI, Schairer C. A prospective study of diet quality and mortality in women. JAMA. 2000 Apr 26;283(16):2109-15.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327745" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333574" sys_dependentvariantid="1500" sys_dependentid="327745" rxinlineslot="103">Exercise_Physical_Activity_BCDDP-female_questionnaire (Word, 16 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333575" sys_dependentvariantid="1418" sys_dependentid="303842" rxinlineslot="103">Physical Activity</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333576" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303844" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333594">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exercise and Physical Activity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Familial Breast and Ovarian Cancer Study&nbsp;</p>
<h4>Keywords:</h4>
<p>N/A&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>H. Anton-Culver&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>Ongoing&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Ziogas A, Gildea M, Cohen P, et al. Cancer risk estimates for family members of a population- based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9 (1):103-11.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327744" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333591" sys_dependentvariantid="1500" sys_dependentid="327744" rxinlineslot="103">Exercise_Physical_Activity_Familial_Breast_Ovarian_Cancer_questionnaire (Word, 20 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333592" sys_dependentvariantid="1418" sys_dependentid="303842" rxinlineslot="103">Physical Activity</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333593" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303845" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333598">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exercise and Physical Activity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Physical Activity Questions from the Framingham Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>W. Kannel&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>In-person interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>Ongoing&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Kannel WB, Sorlie P. Some health benefits of physical activity: The Framingham Heart Study. Arch Intern Med 1979;139:857-861.&nbsp;</p>
<p>Albanes D, Conway JM, Taylor PR, et al. Validation and comparison of eight physical activity questionnaires. Epidemiology 1990;1:65-71.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327743" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333595" sys_dependentvariantid="1500" sys_dependentid="327743" rxinlineslot="103">Exercise_Physical_Activity_Framingham_Study_questionnaire (Word, 16 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333596" sys_dependentvariantid="1418" sys_dependentid="303842" rxinlineslot="103">Physical Activity</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333597" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303846" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333602">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exercise and Physical Activity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Godin Exercise Leisure-time Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>G. Godin&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1985&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985;10:141-146.&nbsp;</p>
<p>Gionet NJ, Godin G. Self-reported exercise behavior of employees: a validity study. J Occup Med 1989;31:969-973.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327742" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333599" sys_dependentvariantid="1500" sys_dependentid="327742" rxinlineslot="103">Exercise_Godin-Leisure-time_questionnaire (Word, 17 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333600" sys_dependentvariantid="1418" sys_dependentid="303842" rxinlineslot="103">Physical Activity</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333601" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303847" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="" sys_relationshipid="6333606">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Exercise and Physical Activity&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Lifetime Physical Activity Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Chasan-Taber&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Mail Questionnaire&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Chasan-Taber L, Erickson JB, McBride JW, Nasca PC, Chasan-Taber S, Freedson PS. Reproducibility of a self-administered lifetime physical activity questionnaire among female college alumnae. Am J Epidemiol 2002;155:282-289.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327741" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333603" sys_dependentvariantid="1500" sys_dependentid="327741" rxinlineslot="103">Lifetime_Physical_Activity_questionnaire (Word, 23 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333604" sys_dependentvariantid="1418" sys_dependentid="303842" rxinlineslot="103">Physical Activity</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6333605" sys_dependentvariantid="1418" sys_dependentid="303842" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303849" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333613">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Use of Prescription, non-Prescription Medicines&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Study of the Health of Adults (Kidney Cancer)&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>W.H. Chow&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1991&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form</p>
<h4>Citation(s):&nbsp;</h4>
<p>Chow WH, McLaughlin JK, Mandel JS, et al. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers 1995;4:327-331.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=328795" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="328795" sys_dependentvariantid="1500" sys_relationshipid="6333610" sys_siteid="475">Adult_Kidney_Cancer_ Prescript_non-Prescript_Medicine_Use_questionnaire (Word, 20 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303848" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303848" sys_dependentvariantid="1418" sys_relationshipid="6333611" sys_siteid="475">Prescriptions, Hormones, Immunizations</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333612" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303850" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333633">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Use of Hormone Supplements&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>BCDDP-Female Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Breast Cancer Detection Demonstration Project&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>C. Schairer&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered optical scan&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Schairer C, Lubin JH, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283(4):485-491.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327769" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327769" sys_dependentvariantid="1500" sys_relationshipid="6333630" sys_siteid="475">Hormone_Supplements_Breast_Cancer Project-Female_questionnaire (Word, 20 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303848" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303848" sys_dependentvariantid="1418" sys_relationshipid="6333631" sys_siteid="475">Prescriptions, Hormones, Immunizations</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333632" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303851" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333617">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Use of Prescription, non-Prescription Medicines&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>BCDDP-Female Questionnaire&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Breast Cancer Detection Demonstration Project&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>C. Schairer&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1998&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=328756" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="328756" sys_dependentvariantid="1500" sys_relationshipid="6333614" sys_siteid="475">Breast_Cancer_Project-Female_Medicine_Use_questionnaire (Word, 18 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303848" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303848" sys_dependentvariantid="1418" sys_relationshipid="6333615" sys_siteid="475">Prescriptions, Hormones, Immunizations</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333616" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303852" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333629">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Use of Prescription, non-Prescription Medicines&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Study of Digestive Health (Esophagus)&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>esophageal cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>W.H. Chow&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1996&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers 1998;7:749-756.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=327770" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="327770" sys_dependentvariantid="1500" sys_relationshipid="6333626" sys_siteid="475">Digestive-Health_Prescript_non-Prescript_Medicine_Use_questionnaire (Word, 46 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303848" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303848" sys_dependentvariantid="1418" sys_relationshipid="6333627" sys_siteid="475">Prescriptions, Hormones, Immunizations</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333628" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303853" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333621">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Childhood Immunizations&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>EMF and Radon Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Childhood Leukemia Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Linet&nbsp;</p>
<h4>Type of Questionnaire:</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1994&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Groves FD, Gridley G, Wacholder S, et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Br J Cancer. 1999;81(1):175-8.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=328650" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="328650" sys_dependentvariantid="1500" sys_relationshipid="6333618" sys_siteid="475">Childhood_Immunization_Childhood_Leukemia_questionnaire (Word, 22 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303848" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303848" sys_dependentvariantid="1418" sys_relationshipid="6333619" sys_siteid="475">Prescriptions, Hormones, Immunizations</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333620" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303854" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="/Rhythmyx/assembler/render?sys_contentid=303782&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_folderid="" sys_relationshipid="6333625">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:</h4>
<p>Use of Contraceptives &amp; Other Exogenous Hormones&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Women's Interview Study of Health&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):</h4>
<p>L. Brinton&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87(11):827-35.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=328576" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="328576" sys_dependentvariantid="1500" sys_relationshipid="6333622" sys_siteid="475">Contraceptive_Use_Womens_Health_questionaire (Word, 154 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303848" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303848" sys_dependentvariantid="1418" sys_relationshipid="6333623" sys_siteid="475">Prescriptions, Hormones, Immunizations</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333624" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303856" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate. Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333644" sys_siteid="475" sys_folderid="">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Menstruation/Menopause History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Women's Interview Study of Health&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brinton&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87(11):827-35.&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=328929" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="328929" sys_dependentvariantid="1500" sys_relationshipid="6333637" sys_siteid="475">Menstruation_Menopause_History_Womens_Health_questionnaire (Word, 479 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303855" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303855" sys_dependentvariantid="1418" sys_relationshipid="6333638" sys_siteid="475">Reproductive History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6333639" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303857" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Reproductive History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Women's Interview Study of Health&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>L. Brinton&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1993&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87(11):827-35.&nbsp;</p>
<p>Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1500&amp;sys_revision=1&amp;sys_contentid=328970&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6311131" sys_dependentvariantid="1500" sys_dependentid="328970" rxinlineslot="103">Reproductive_History_Womens_Health_questionnaire (Word, 479 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=1&amp;sys_contentid=303855&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6311132" sys_dependentvariantid="1418" sys_dependentid="303855" rxinlineslot="103" sys_folderid="">Reproductive History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=17&amp;sys_contentid=303782&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6311133" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_folderid="">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303859" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_relationshipid="6335120">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Residential History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Melanoma -- Case-Control Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Tucker&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>In-person Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1992&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>N/A&nbsp;</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=329944" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="329944" rxinlineslot="103" sys_relationshipid="6335119">Residential_History_Melanoma_questionnaire (Word, 16 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303858" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303858" rxinlineslot="103" sys_relationshipid="6335121">Residential History</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_relationshipid="6335122">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303860" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;<a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_relationshipid="6335124">Learn more about DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Residential History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Non-Hodgkin Lymphoma (NHL) Study</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>P. Hartge&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>2001&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4><span>Citation(s):</span>&nbsp;</h4>
<p>N/A</p>
<p><strong>Download</strong> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=329098" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="329098" rxinlineslot="103" sys_relationshipid="6335123">Residential_History_NHL_questionnaire (Word, 21 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303858" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303858" rxinlineslot="103" sys_relationshipid="6335125">Residential History</a></p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103" sys_relationshipid="6335126">Learn more about DCEG Questionnaire Development Resources</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="303862" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Download</strong> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=333039" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="333039" sys_dependentvariantid="1500" sys_relationshipid="7317619" sys_siteid="475" sys_variantid="1500" sys_contentid="333039">Active Smoking Questionnaire (Word, 27 KB)</a></p>
<h4>About the reviewed questionnaires:&nbsp;</h4>
<p>The questionnaires share the following characteristics. They are:&nbsp;</p>
<p>&bull; Designed to address covariates (confounding) exposures, not main variables or the principal subject of a study, which might require more detailed questions</p>
<p>&bull; Developed primarily for use in cohort studies, rather than case-control studies, which often require more questions about lifetime and historic, rather than current, exposures&nbsp;</p>
<p>&bull; Predicated on English-speaking literate adult respondents, not special populations&nbsp;</p>
<p>&bull; Designed to be self-explanatory, assuming that the questionnaire will be self-administered, not by interview.&nbsp;</p>
<p>In questionnaire development, there is often a choice between open-ended and categorical questions. We included open-ended questions only when responses were likely to be both easily remembered by the participant and straightforward to analyze.&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="303863" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Download</strong> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=333099" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7317621" sys_dependentvariantid="1500" sys_dependentid="333099" rxinlineslot="103" sys_variantid="1500" sys_contentid="333099">Alcohol Use Questionnaire (Word, 27.8 KB)</a></p>
<h4>About the reviewed questionnaires:&nbsp;</h4>
<p>The questionnaires share the following characteristics. They are:&nbsp;</p>
<p>&bull; Designed to address covariates (confounding) exposures, not main variables or the principal subject of a study, which might require more detailed questions</p>
<p>&bull; Developed primarily for use in cohort studies, rather than case-control studies, which often require more questions about lifetime and historic, rather than current, exposures&nbsp;</p>
<p>&bull; Predicated on English-speaking literate adult respondents, not special populations&nbsp;</p>
<p>&bull; Designed to be self-explanatory, assuming that the questionnaire will be self-administered, not by interview.&nbsp;</p>
<p>In questionnaire development, there is often a choice between open-ended and categorical questions. We included open-ended questions only when responses were likely to be both easily remembered by the participant and straightforward to analyze.&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="303864" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Download</strong> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=325922" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7317622" sys_dependentvariantid="1500" sys_dependentid="325922" rxinlineslot="103" sys_variantid="1500" sys_contentid="325922">Hormonal and Reproductive Factors Questionnaire (Word, 24.4 KB)</a></p>
<h4>About the reviewed questionnaires:&nbsp;</h4>
<p>The questionnaires share the following characteristics. They are:&nbsp;</p>
<p>&bull; Designed to address covariates (confounding) exposures, not main variables or the principal subject of a study, which might require more detailed questions</p>
<p>&bull; Developed primarily for use in cohort studies, rather than case-control studies, which often require more questions about lifetime and historic, rather than current, exposures&nbsp;</p>
<p>&bull; Predicated on English-speaking literate adult respondents, not special populations&nbsp;</p>
<p>&bull; Designed to be self-explanatory, assuming that the questionnaire will be self-administered, not by interview.&nbsp;</p>
<p>In questionnaire development, there is often a choice between open-ended and categorical questions. We included open-ended questions only when responses were likely to be both easily remembered by the participant and straightforward to analyze.&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="303865" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Download</strong> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=333040" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="333040" sys_dependentvariantid="1500" sys_relationshipid="7317627" sys_siteid="475" sys_variantid="1500" sys_contentid="333040">Passive Smoking Questionnaire (Word, 15.4 KB)</a></p>
<h4>About the reviewed questionnaires:&nbsp;</h4>
<p>The questionnaires share the following characteristics. They are:&nbsp;</p>
<p>&bull; Designed to address covariates (confounding) exposures, not main variables or the principal subject of a study, which might require more detailed questions</p>
<p>&bull; Developed primarily for use in cohort studies, rather than case-control studies, which often require more questions about lifetime and historic, rather than current, exposures&nbsp;</p>
<p>&bull; Predicated on English-speaking literate adult respondents, not special populations&nbsp;</p>
<p>&bull; Designed to be self-explanatory, assuming that the questionnaire will be self-administered, not by interview.&nbsp;</p>
<p>In questionnaire development, there is often a choice between open-ended and categorical questions. We included open-ended questions only when responses were likely to be both easily remembered by the participant and straightforward to analyze.&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="303866" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Download</strong> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=333037" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7317625" sys_dependentvariantid="1500" sys_dependentid="333037" rxinlineslot="103" sys_variantid="1500" sys_contentid="333037">Socioeconomic Status Questionnaire (Word, 27 KB)</a></p>
<h4>About the reviewed questionnaires:&nbsp;</h4>
<p>The questionnaires share the following characteristics. They are:&nbsp;</p>
<p>&bull; Designed to address covariates (confounding) exposures, not main variables or the principal subject of a study, which might require more detailed questions</p>
<p>&bull; Developed primarily for use in cohort studies, rather than case-control studies, which often require more questions about lifetime and historic, rather than current, exposures&nbsp;</p>
<p>&bull; Predicated on English-speaking literate adult respondents, not special populations&nbsp;</p>
<p>&bull; Designed to be self-explanatory, assuming that the questionnaire will be self-administered, not by interview.&nbsp;</p>
<p>In questionnaire development, there is often a choice between open-ended and categorical questions. We included open-ended questions only when responses were likely to be both easily remembered by the participant and straightforward to analyze.&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="303868" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;Learn more about DCEG <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6335199" sys_siteid="475">Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Sexual History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Black and White Americans Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Black and White Americans Study&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>R. Hayes&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1989&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Hayes RB, Pottern LM, Strickler H, et al. Sexual behavior, STDs and risks for prostate cancer. Br J Cancer 2000;82(3):718-25.&nbsp;</p>
<p><b>Download</b> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=329973" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="329973" sys_dependentvariantid="1500" sys_relationshipid="6335198" sys_siteid="475">Sexual_History_Black-and-White-Americans_Study_questionnaire (Word, 21 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303867" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303867" sys_dependentvariantid="1418" sys_relationshipid="6335200" sys_siteid="475">Sexual History and Practices</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_relationshipid="6335201" sys_siteid="475">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303869" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_relationshipid="6335197" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Sexual History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Guanacaste Project&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>Costa Rica, HPV, human papillomavirus infection, cervical cancer&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>M. Schiffman&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Interview&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1995&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6):464-74.&nbsp;</p>
<p>Schiffman M. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283(1):87-93.&nbsp;</p>
<p><b>Download</b> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=330002" inlinetype="rxhyperlink" sys_relationshipid="6335194" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="330002" rxinlineslot="103">Costa-Rica_Sexual_History_HPV_Testing_questionnaire (Word, 18 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303867" inlinetype="rxhyperlink" sys_relationshipid="6335195" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303867" rxinlineslot="103">Sexual History and Practices</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_relationshipid="6335196" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303870" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="6335193">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Sexual History&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>Danish Postal Survey&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>N/A</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>R. Biggar&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1995&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Biggar RJ, Melbye M. Responses to anonymous questionnaires concerning sexual behavior: a method to examine potential biases. Am J Public Health. 1992;82(11):1506-12.&nbsp;</p>
<p><b>Download</b> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=330061" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="330061" sys_dependentvariantid="1500" sys_siteid="475" sys_relationshipid="6335190">Danish_Postal_Study_Sexual_History_questionnaire (Word, 20 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303867" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303867" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="6335192">Sexual History and Practices</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="6335191">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303871" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_relationshipid="6335186" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>Gay Sexual Practices and HIV Exposures&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>D.C. Gays Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>AIDS, HIV, homosexuals&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>J. Goedert&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1999&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Long Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Goedert JJ, Biggar RJ, Winn DM, et al. Decreased helper T-lymphocytes in homosexual men: II. Sexual practices. Am J Epidemiol 1985;121:637-44.&nbsp;</p>
<p><b>Download</b> <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=330138" inlinetype="rxhyperlink" sys_relationshipid="6335184" rxinlineslot="103" sys_dependentid="330138" sys_dependentvariantid="1500" sys_siteid="475">Sexual_Practices_HIV_DC_Gays_Study_questionnaire (Word, 83 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303867" inlinetype="rxhyperlink" sys_relationshipid="6335187" rxinlineslot="103" sys_dependentid="303867" sys_dependentvariantid="1418" sys_siteid="475">Sexual History and Practices</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303782" inlinetype="rxhyperlink" sys_relationshipid="6335185" rxinlineslot="103" sys_dependentid="303782" sys_dependentvariantid="1418" sys_siteid="475">Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="303872" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The following questionnaire segment contains questions that have been used as part of DCEG or other epidemiologic studies. This segment has not necessarily been reviewed or analyzed by the Technical Evaluation Committee. Please view it as a starting point that can be adapted or improved upon as appropriate.&nbsp;Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=17&amp;sys_contentid=303782&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6311128" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a>.</p>
<h4>Questionnaire Topic:&nbsp;</h4>
<p>History of Sexually Transmitted Diseases&nbsp;</p>
<h4>Study Title:&nbsp;</h4>
<p>D.C. Gays Study&nbsp;</p>
<h4>Keywords:&nbsp;</h4>
<p>AIDS, HIV, homosexuals&nbsp;</p>
<h4>Principal Investigator(s):&nbsp;</h4>
<p>J. Goedert&nbsp;</p>
<h4>Type of Questionnaire:&nbsp;</h4>
<p>Self-administered&nbsp;</p>
<h4>Last Year of Data Collection:&nbsp;</h4>
<p>1999&nbsp;</p>
<h4>Short/Long Form:&nbsp;</h4>
<p>Short Form&nbsp;</p>
<h4>Citation(s):&nbsp;</h4>
<p>Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. J Am Med Assoc 1987;257(3):331-34.&nbsp;</p>
<p>Download <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1500&amp;sys_revision=1&amp;sys_contentid=330137&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6311125" sys_siteid="475" sys_dependentvariantid="1500" sys_dependentid="330137" rxinlineslot="103">STD_History_DC_Gays_Study_questionnaire (Word, 16 KB)</a></p>
<p>Back to <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=303867&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6311126" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303867" rxinlineslot="103">Sexual History and Practices</a></p>
<p>Learn more about <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=17&amp;sys_contentid=303782&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_relationshipid="6311127" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303782" rxinlineslot="103">DCEG Questionnaire Development Resources</a></p>
</div>]]></content>
  </row>
  <row para_id="315077" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p><b>For installing on Windows 7 (64 bit):</b></p><ol><li>From the RGUI, select Packages-&gt;Install package(s) from local zip files &#8230;</li><li>Select ASSET_1.1.1.zip</li><li>Select Packages-&gt;Load package-&gt;ASSET to load the ASSET package.</li></ol><p><b>For installing on Unix:</b></p><ol><li>From the Unix command prompt type<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;R CMD INSTALL ASSET_1.1.1.tar.gz -l &lt;folder&gt;<br />&#160;where &lt;folder&gt; is the path to the folder you wish to install the ASSET package.</li><li>Start R and type library(ASSET, lib.loc=&lt;folder&gt;) to load the ASSET package.</li></ol><p>Once the ASSET package is loaded, type ?ASSET in the R command line to get started.</p></div>]]></content>
  </row>
  <row para_id="320892" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div style="width: 50%; float: left; margin-right: 2%;">
<h3 class="tight"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302378" sys_contentid="302378" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302378" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252310">About DCEG</a></h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302571" sys_contentid="302571" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302571" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252311">Mission</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302541" sys_contentid="302541" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302541" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252312"> </a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302541" sys_contentid="302541" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302541" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252296">Organization</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=966088" sys_contentid="966088" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="966088" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252304">Laboratory of Genetic Susceptibility</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302473" sys_contentid="302473" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302473" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252314">Office of Education</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302442" sys_contentid="302442" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302442" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252313">Administrative Resource Center</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302673" sys_contentid="302673" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302673" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252315"><strong>Epidemiology and Biostatistics Program</strong></a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252316">Biostatistics Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=47&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252317">Infections and Immunoepidemiology Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252344">Metabolic Epidemiology Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252318">Occupational and Environmental Epidemiology Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252297">Radiation Epidemiology Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302429" sys_contentid="302429" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302429" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252319"><strong>Human Genetics Program</strong></a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252320">Clinical Genetics Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252345">Integrative&nbsp;Tumor&nbsp;Epidemiology Branch</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302432" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252321">Laboratory of Translational Genomics</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302626" sys_contentid="302626" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302626" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252322">Staff Directory</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302517" sys_contentid="302517" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302517" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252323">Contact DCEG</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=76&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302394" sys_contentid="302394" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302394" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252324">Scientific Position Openings</a></li>
</ul>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302557" sys_contentid="302557" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302557" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252298">Our Research</a></h3>
<ul>
<li>Cancer Types</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303666" sys_contentid="303666" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="303666" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252325">What We Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303734" sys_contentid="303734" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="303734" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252299">Who We Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=636667" sys_contentid="636667" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="636667" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252326">How We Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303758" sys_contentid="303758" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="303758" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252327">Active Clinical Studies</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=34&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303763" sys_contentid="303763" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="303763" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252328">Public Health Impacts of DCEG Research</a></li>
</ul>
</div>
<div style="width: 46%; float: right;">
<h3 class="tight"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303770" sys_contentid="303770" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="303770" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252329">Fellowships &amp; Training</a></h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302629" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252330">Become a Fellow</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302377" sys_contentid="302377" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302377" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252331">Program Requirements</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=107&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302477" sys_contentid="302477" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302477" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252332">Research Training Areas</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302405" sys_contentid="302405" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302405" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252333">Application Process</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302472" sys_contentid="302472" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302472" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252334">Become a Summer Intern</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=46&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303775" sys_contentid="303775" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303775" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252335">Summer Program Application Process</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=799682" sys_contentid="799682" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="799682" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252336">What Our Fellows Do</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303774" sys_contentid="303774" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303774" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252337">Meet Current Fellows</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=93&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=801791" sys_contentid="801791" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="801791" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252305">Fellows in the News</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302671" sys_contentid="302671" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302671" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252300">Training Resources for Fellows and Staff</a></li>
</ul>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302671" sys_contentid="302671" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302671" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252338">Tools &amp; Resources</a></h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302556" sys_contentid="302556" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302556" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252339">Study Design / Planning Tools</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302528" sys_contentid="302528" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302528" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252340">Analysis Tools</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302594" sys_contentid="302594" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302594" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252341">Descriptive Epidemiology Resources</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302611" sys_contentid="302611" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302611" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252342">Risk Assessment Macros and Software Programs</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302381" sys_contentid="302381" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302381" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252343">Publicly Available Data</a></li>
</ul>
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=427&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302403" sys_contentid="302403" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302403" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252301">News &amp; Events</a></h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1524&amp;sys_contentid=392762" sys_contentid="392762" inlinetype="rxhyperlink" sys_variantid="1524" sys_dependentvariantid="1524" sys_dependentid="392762" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252306">Research News and Highlights</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=193&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303874" sys_contentid="303874" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="303874" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252302">Linkage Newsletter</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=336461" sys_contentid="336461" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="336461" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252307">Archived Issues</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=699&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302395" sys_contentid="302395" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302395" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252308">People in the News</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302641" sys_contentid="302641" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302641" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252303">Events</a></li>
<li style="margin-left: 20.0px;"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1524&amp;sys_contentid=307959" sys_contentid="307959" inlinetype="rxhyperlink" sys_variantid="1524" sys_dependentvariantid="1524" sys_dependentid="307959" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252309">Past Events</a></li>
</ul>
<h3><a href="http://dceg2.cancer.gov/publications.html">Publications</a></h3>
</div>
</div>]]></content>
  </row>
  <row para_id="326171" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>*******************************************************************************************<br />** SegCNV<br />**<br />**<br />** 2011-1-18<br />*******************************************************************************************</p>
<p>### Introduction<br />SegCNV is a software package, implemented in C++, to detect germline copy number variations in SNP array data.<br />Currently, SegCNV supports Illumina 550K and 610K &nbsp;genotyping platforms. We are working to include more platforms.</p>
<p>## Installation</p>
<p>&nbsp;&nbsp;&nbsp;If the precompiled binary program segcnv works in in your platform, then<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Create a work folder WORK, copy the binary file segcnv to WORK;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Copy folder configuration (and all files in the folder) to WORK.<br />&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;If the precompiled binary program segcnv does not work in your platform, please run &nbsp;<br />&nbsp;&nbsp;&nbsp;"g++ Single.Seg.CNV.cpp -o segcnv" to generate executable segcnv file and then copy<br />&nbsp;&nbsp;&nbsp;it to the folder WORK.</p>
<p>## &nbsp;Usage</p>
<p>&nbsp;&nbsp;&nbsp;Preprocessing of the intensity file:<br />&nbsp;&nbsp;&nbsp;We strongly encourage you to remove the wave effect correlated with the GC content first.</p>
<p>&nbsp;&nbsp;&nbsp;Data format:<br />&nbsp;&nbsp;&nbsp;Each intensity file (for one subject) has three columns: probe name, BAF and LRR.</p>
<p>&nbsp;&nbsp;&nbsp;We use one example to illustrate the usage of segcnv. We call CNVs of ten Hapmap samples genotyped using 550K platform.<br />&nbsp;&nbsp;&nbsp;To run the program, type &nbsp;&nbsp;"./segcnv --callcnv --filelist filelist --outfile outfile".<br />&nbsp;&nbsp;&nbsp;Here, filelist specifies the intensity file names and its subject ID. In this example, filelist file is:<br />&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA06991.GCA &nbsp;&nbsp;NA06991<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA06993.GCA &nbsp;&nbsp;NA06993<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA06994.GCA &nbsp;&nbsp;NA06994<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA07029.GCA &nbsp;&nbsp;NA07029<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA07345.GCA &nbsp;&nbsp;NA07345<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA07348.GCA &nbsp;&nbsp;NA07348<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA07357.GCA &nbsp;&nbsp;NA07357<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA10830.GCA &nbsp;&nbsp;NA10830<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA10835.GCA &nbsp;&nbsp;NA10835<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;./Hapmap/NA10847.GCA &nbsp;&nbsp;NA10847</p>
<p>&nbsp;&nbsp;&nbsp;"outfile" specifies the ourput file. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;The program will search for all CNVs covered by at least 3 probes. You can run analysis in other specifications. For example:<br />&nbsp;&nbsp;&nbsp;"./segcnv --callcnv --filelist filelist --platform 1 -chrid 2 -min 5 --outfile outfile" will call CNVs covered by at least 5<br />&nbsp;&nbsp;&nbsp;probes, only on chromosome 2 for the data produced from the Illumina 610K platform. Here is the full explanation of the usage:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;usage: ./seg_cnv &nbsp;&lt;flags (optional)&gt;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;flags:<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Platform<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt; --platform &gt; &nbsp;Currently support two platforms:<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina.550K (Default)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina.610K<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. CNV Calling<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;--callcnv &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Call CNV for each sample.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;--filelist &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filelist with File_Name, sample_ID.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt; -chrid &gt; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Call CNV on the chromosome chrid specifies. Default analyzes all 22 chromosomes.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt; -min &gt; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Min number of probes covered by the CNV. Default is 3.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Out File<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;--outfile &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Out file.</p>
<p># Output file</p>
<p>&nbsp;&nbsp;&nbsp;The output file has 14 columns:</p>
<p>* Sample ID<br />* Chromosome ID<br />* Segment starting probe order<br />* Segment ending probe order<br />* Total probes in the segment<br />* Segment starting probe bp location<br />* Segment ending probe bp location<br />* Start probe name<br />* End probe name<br />* Copy number (0: hyterozygous deletion, 1: hemizygous deletion, 2: normal copy, 3: duplication with copy number)<br />* Score(Z score of the called segments based only on LRR.)<br />* Score(Z score of the called segments integrating both LRR and BAF for duplication segments.)<br />* Expected false positive calls per genome scan at this threshold. Smaller is more stringent and results in less calls.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Suggested value: 0.01 or 0.05. IMPORTANTLY, segcnv calls segments even with very modest evidence of CNV (|z| score &gt; 3.5).<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At this threshold, most are false positives, but many are true CNVs. You choose a threshold to filter out weak candidate CNVs.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# Example of two rows from an out file.<br />NA06991 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;622 &nbsp;&nbsp;&nbsp;&nbsp;624 &nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4441250 4444038 2789 &nbsp;&nbsp;&nbsp;rs11799990 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rs350170 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.88739 3.88739 18.2598<br />NA06991 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1635 &nbsp;&nbsp;&nbsp;1638 &nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8503602 8539425 35824 &nbsp;&nbsp;rs6656249 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rs1473420 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.91556 2.91556 18.2598</p>
</div>]]></content>
  </row>
  <row para_id="326282" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>CHARRED (Computerized Heterocyclic Amines Resource for Research in Epidemiology of Disease)<br />is a program that:<br />- Examines the amount of various compounds contained in different meats.<br />- Examines the frequency with which individuals consume these meats.<br />- Calculates the amount of each compound consumed daily by each individual.</p><p>-------------------<br />SYSTEM REQUIREMENTS<br />-------------------</p><p>&#160;- &#160;Pentium-based PC<br />&#160;- &#160;32-bit Microsoft Windows (95, 98, NT, 2000, etc.)<br />&#160;- &#160;800 x 600 or greater monitor resolution<br />&#160;- &#160;Microsoft Internet Explorer 4.0+ for viewing help<br />&#160;- &#160;Support for long filenames by PC and LAN (if utilized)<br />&#160;- &#160;32 MBs application RAM<br />&#160;<br />-------------------------------<br />REMOVING PREVIOUS INSTALLATIONS<br />-------------------------------</p><p>Existing versions of CHARRED do not need to be removed from your<br />system prior to installing this newer version. &#160;</p><p>If you wish to completely remove an earlier version prior to<br />installing this current version, use the<br />Add/Remove Programs icon in the Windows Control Panel.</p><p>NOTE: &#160;If you have modified the database by adding your own meats or<br />compounds, save a copy of this database to another area of your hard drive<br />or to another disk. &#160;Otherwise, your changes will be lost when the database<br />is overwritten on the new install. &#160;After completing the install, copy your<br />version of the database back to the CHARRED directory. &#160;If you need help<br />with this, please contact Technical Support.</p><p>----------------<br />REVISION HISTORY<br />----------------<br />version 1.7 (10/25/2006):<br />- Modified the database for ham slice (160-165). &#160;It was incorrectly categorized as a white meat. &#160;The lines were changed to red meat.<br />- Updated to use ZD543 and Basis 2.0 as well.</p><p>version 1.6 (2/10/05):<br />- Added a charred.ini startup file that contains the name of the meats database file. &#160;This allows the user to change<br />&#160;the name of the database file to a file of their choosing just prior to runtime by modifying the .ini file.<br />- Added the generation of source compound files for any user-defined compounds that may exist in the database.<br />- Added better error checking for the input and output file names prior to running an analysis.<br />- Changed the temporary database name that is used when compounds are added, edited, and deleted from the database.<br />&#160;Previously the temp database was named meats2. &#160;This was changed to be the name of the meats database with &#39;000&#39; appended to the name. &#160;This change does not affect the end-user and is not seen.<br />- Fixed bug that the help system was not accessible after clicking on the file browse buttons.</p><p>version 1.5.1 (1/7/05):<br />- Fixed .zds file needed by the meats database to make the Linker field length 5. &#160;This fixed the problem of the &#39;Add<br />&#160;Compound&#39; functionality no longer working.<br />- Fixed bug that an exception was thrown when the &#39;Add Compound&#39; window was moved.<br />- Removed red error indicators in the compound name and compound units edit boxes on startup of the &#39;Add Compound&#39; window.<br />- Fixed bug that the decimal digits of a user-defined compound value were getting truncated when it was editted by<br />&#160;means of the &#39;edit meat&#39; dialog box<br />- Modified meats database: &#160;the portion sizes for fast food hamburgers are now the same as for all other types of hamburger</p><p>version 1.5 &#160;&#160;&#160;(9/9/04):<br />- Removed zero values from the output of the 6 source files for each standard compound (files added in version 1.3).<br />- Added the creation of a grams source output file. &#160;This new output file contains the user ID, the meat ID, and the<br />&#160;daily serving size in grams. &#160;It contains the same number of records as the input file.</p><p>version 1.4.1 &#160;(8/9/04):<br />- updated help file</p><p>version 1.4:</p><p>version 1.3 &#160;&#160;&#160;(3/8/2004):<br />- Added the creation of 6 source files, one for each standard compound. &#160;The source files contain<br />&#160;the user ID, the meat ID, and the calculated amount of the compound.<br />- Resolved an error in the which printing the database was skipping lines and not<br />&#160;spacing properly on the page for a landscape printout<br />- Resolved an error in which a user-defined meat could not be edited when a sort on a column<br />&#160;other than the first column was in effect.</p><p>version 1.2.1 &#160;(2/2/2004):<br />- Serving size of 0 is now allowed<br />- Resolved an error in which the database description for newly added meats was not lining up<br />&#160;with previous values.</p><p>version 1.2.0.3 (12/30/2003):<br />- Resolved an error which was printing illegible characters into the comma seperated values<br />&#160;output file.</p><p>version 1.2.0.2 (12/24/2003):<br />- Resolved an error which disallowed a user from selecting the meat type when adding a meat.</p><p>version 1.2.0.1 (12/18/2003) :<br />- Added the program&#39;s version number to the program&#39;s title bar.<br />- Resolved an error in the Add Meat dialog which did not re-enable the OK button.<br />- Resolved an index error when trying to Add a new Meat</p><p>version 1.2 (11/7/2003) :<br />- Added specific doneness levels of gravy to the database (links 142 through 145)<br />- Added ham slice values to the database (links 160 through 165)<br />- Changed the phip value for steak/pan fried/medium (link 31) from 0.00 to 1.89<br />- Changed the bap value for gravy average all doneness (link 140) from 0.05 to 0.01<br />- Changed the bap value for gravy 1/2 values of average (link 141) from 0.02 to 0.00</p><p>version 1.1.2 (7/15/2003) :<br />- Resolved an error in adding and editing user defined meats. The method for handling<br />&#160;assigning compound and portion values was not properly rounding values in the database.<br />&#160;<br />version 1.1.1 (1/27/2003) (continued) :<br />- Made changes to the help file which included:<br />&#160;&#160;- The input file frequency description has been changed to better reflect allowable<br />&#160;&#160;&#160;&#160;precision of input values.<br />&#160;&#160;- The database description section has been changed to include the definitions of the<br />&#160;&#160;&#160;&#160;age ranges of the three groups. &#160;&#160;</p><p>version 1.1.1 (12/10/2002):<br />- Resolved an error in the portions section of the database for Chicken Rotisserie<br />- Implemented version numbers for the executable for each website release build of Charred<br />- Improved the error recognition of values read in for age in Age/Sex Analyses from the<br />&#160;input file</p><p>versions prior to 1.1.1 (11/19/2002):<br />- &#160;Replaced part of the calculation engine to significantly increase the speed<br />&#160;&#160;of calculation in the program. This should resolve locking problems with large data<br />&#160;&#160;sets.</p><p>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br />-----------------<br />TECHNICAL SUPPORT<br />-----------------</p><p>Email: charredhelp@imsweb.com</p></div>]]></content>
  </row>
  <row para_id="326867" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<p>Assessment of occupational exposures in case-control studies has traditionally been limited because of the lack of information on the variability of exposures across and within jobs. NCI has developed special questionnaires with modules designed to obtain detailed exposure-oriented information for over 40 specific jobs and over 10 specific industries. These modules include questions on tasks, work practices, chemicals, equipment, engineering controls, personal protective equipment and indirect exposures specific to those jobs and industries.</p>
<p>Examples of jobs and industries for which questionnaires have been developed include:</p>
<h2>Job-based modules</h2>
<ul>
<li>Cabinet makers</li>
<li>Carpenters</li>
<li>Janitors</li>
<li>Laborer</li>
<li>Managers</li>
<li>Machinists</li>
<li>Mechanics</li>
<li>Office professionals</li>
<li>Packagers</li>
<li>Painters</li>
<li>Plumbers</li>
<li>Production inspectors</li>
<li>Roofers</li>
<li>Steel workers</li>
<li>Welders/Cutters/Burners</li>
</ul>
<h2>Industry-based modules</h2>
<ul>
<li>Dry cleaning/Laundry industry</li>
<li>Heavy construction industry</li>
<li>Oil refining industry</li>
<li>Printing industry</li>
<li>Rubber industry</li>
<li>Shoe industry</li>
<li>Textile industry</li>
</ul>
</div>
A wide variety of exposures are addressed including:
<div>
<ul>
<li>Diesel and gasoline engine exhaust</li>
<li>Solvents, e.g., degreasing solvents, trichloroethylene</li>
<li>Metals, e.g., lead</li>
<li>Metalworking fluids</li>
<li>Wood dust</li>
</ul>
</div>
<p>For more information or to obtain these modules, please contact <a href="mailto:friesenmc@mail.nih.gov">Dr. Melissa Friesen</a>.</p>
</div>]]></content>
  </row>
  <row para_id="326985" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>ReadMe.fil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7/17/09</p>
<p>Documentation and user guide for a SAS macro to project for white women BrCa absolute<br />risk based on a RR model which includes % mammographic density, body weight and a<br />subset of the standard breast cancer relative risk covariates.</p>
<p>Relative risk covariates, 1-AR, composite breast cancer incidences, competing hazards<br />are described in "Projecting absolute invasive breast cancer risk in white women with<br />a model that includes mammographic density". &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JNCI 2006 98(17) 1215-26.</p>
<p>Handling of missing covariate values and covariate editing procedures follow NCI BrCa<br />Risk Assessment Tool (NCI BCRAT).</p>
<p>A simple 3 step example on the use of the SAS macro: &nbsp;"BrCa_MD_RAM"<br />(Br)east (Ca)ncer with (M)ammographic (D)ensity (R)isk (A)ssessment (M)acro</p>
<p>Step 1: &nbsp;the included sas program &nbsp;"BC_MD_example.sas" &nbsp;reads the supplied data file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Sample.in", which contains the BrCa risk covarites and projection<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age interval for 50 hypothetical women. &nbsp;It then saves a SAS system file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with name of "ExampleIn" to be used as input to the SAS macro "BrCa_MD_RAM":</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;data &nbsp;&nbsp;&nbsp;ExampleIn; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** name of the saved sas system file;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;infile 'Sample.in'; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** sample RR covariate input file;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** SAS variable names selected by user;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;input &nbsp;&nbsp;InitalAge<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ProjtnAge</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PerCent_Den<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeFstLive<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Body_Weight;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rec_Num = _n_;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;run;</p>
<p>Step 2: &nbsp;the included sas program BCRAM_example.sas then runs the SAS macro<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"BrCa_MD_RAM":</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%include &nbsp;"BrCa_MD_RAM"; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** include the sas MACRO &nbsp;"BrCa_MD_RAM";</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Involking the sas macro &nbsp;"BrCa_MD_RAM" &nbsp;to perform the BrCa projections.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The temporary sas input &nbsp;file is set to &nbsp;&nbsp;"ExampleIn".<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The temporary sas output file is set to &nbsp;&nbsp;"ExampleOut".</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The macro parameters &nbsp;T1, T2, PDensty, N_Rels, N_Biop, Age1st and<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BdyWght point to their corresponding sas variables on the sas file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"ExampleIn", &nbsp;namely &nbsp;InitalAge, ProjtnAge, PerCent_Den, Num_Rels,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop, AgeFstLive and Body_Weight.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The macro parameter AbsRsk points to the sas variable Absolute_Risk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;which will be added to the output sas file &nbsp;"ExampleOut". &nbsp;The output<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sas file will also contain all the variables on the input sas file.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macro &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pointing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAS file name or<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;parameter &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAS variable name;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%BrCa_MD_RAM (In_File &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ExampleIn &nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Out_File &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ExampleOut &nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;InitalAge &nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ProjtnAge &nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PDensty &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PerCent_Den &nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels &nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Biop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1st &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeFstLive &nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BdyWght &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Body_Weight &nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absolute_Risk);</p>
<p>Step 3 &nbsp;It thens list the contents of the temporary output sas system file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"ExampleOut" which contains the projected absolute risk as well as the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative risk covariate values. &nbsp;Note that any further processing<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requiring the projected absolute risk, must be performed on the output<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sas system file;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;data &nbsp;&nbsp;&nbsp;ExampleOut;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;set &nbsp;&nbsp;&nbsp;&nbsp;ExampleOut;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file print;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if (_N_ eq 1) then do;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " Record &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% &nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;Age &nbsp;&nbsp;&nbsp;Body"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;" &nbsp;(1-ar)RR &nbsp;(1-ar)RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pattrn";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;Dens &nbsp;Rel &nbsp;Biop &nbsp;1st &nbsp;&nbsp;&nbsp;Wght"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;" &nbsp;&nbsp;&nbsp;Age&lt;50 &nbsp;&nbsp;&nbsp;Age&gt;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " ";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;end;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** all variables below take on their SAS variable names, not<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;their macro names<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;see SAS variable names defined in Step 1;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if (Rec_Num le 100) then &nbsp;put<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rec_Num &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;InitalAge &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ProjtnAge &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PerCent_Den &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeFstLive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Body_Weight &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One_AR_RR1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One_AR_RR2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absolute_Risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.6<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PattrnNumber &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.0;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;run;</p>
<p>Detailed description of the operation and output items from the SAS macro "BrCa_MD_RAM":</p>
<p>Input data:<br />----------<br />In_File= should "point" to a SAS data set containing all the required input data<br />items needed &nbsp;to perform risk projections, such as initial age, projection age, BrCa<br />relative risk covariates. &nbsp;See the paragraph "Input data items ... " below,<br />for a detailed description of all required data items.</p>
<p>Output data:<br />-----------<br />Out_File= should "point" to a SAS output data set which will contain the projected<br />absolute risk of BrCa as well as the original input data items.</p>
<p>Macro structure:<br />---------------<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macro &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macro<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;name &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;parameters &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"points" to SAS names</p>
<p>%macro &nbsp;BrCa_MD_RAM &nbsp;&nbsp;(In_File &nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;name of input &nbsp;sas data set</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Out_File &nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;name of output sas data set</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;initial age, &nbsp;&nbsp;&nbsp;age at beginning of<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection interval</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection age, age at end of<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection interval</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PDensty &nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% mammographic density<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# 1st degree relatives with brca<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Biop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# biopsies performed<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1st &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age at 1st live birth<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BdyWght &nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;body weight in lbs</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=); &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projected absolute risk of brca</p>
<p>appropriate sas file/sas variable names must be associated with each macro parameters<br />on the invocation of the sas macro &nbsp;"BrCa_MD_RAM".</p>
<p>For example coding &nbsp;"In_File = AARPin" &nbsp;tells the macro that the user created<br />sas file &nbsp;"AARPin" &nbsp;is to be used for input of variables. &nbsp;Similarly, coding<br />"N_Biop = Num_Biops", &nbsp;lets the macro know that the sas variable "Num_Biops" in the<br />sas input file &nbsp;"AARPin" &nbsp;contiains the count of the # of biopsies performed.</p>
<p>To involke the sas macro in your sas program, an #include statement must be coded in<br />your sas program.</p>
<p>For example:</p>
<p>the statement: %include "BrCa_MD_RAM"; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;points to the sas macro &nbsp;BrCa_MD_RAM<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stored in your current directory</p>
<p>the statement: %include "c:\sas.macro\BrCa_MD_RAM"; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;points to the sas macro<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BrCa_MD_RAM stored in the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;directory c:\sas.macro</p>
<p>Input data items needed to project for BrCa absolute risk and consistency<br />requirements:</p>
<p>Macro<br />parameter &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definition &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Valid values</p>
<p>T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any real number T1 in [20,85]<br />T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BrCa projection age &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any real number T2 such that T2 &gt; T1</p>
<p>PDensty &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% mammographic density &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any real number in [0,100]</p>
<p>N_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# 1st degree relatives &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0,1,2 ... &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99=unk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with BrCa</p>
<p>N_Biop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# of biopsies &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0,1,2 ... &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99=unk</p>
<p>Age1st &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age at first live birth &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;less than or equal to initial age.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;98=nulliparous,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99=unk</p>
<p>BdyWght &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Body weight in lbs &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any positive real number</p>
<p>Recoding and checking of relative risk covariate values performed by the SAS macro:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;raw value &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recoded to</p>
<p>PDensty: % mammographic density &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;( 0, 25) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[25, 50) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[50, 75) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[75,100] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4</p>
<p>N_Rels : # 1st degree rel with BrCa &nbsp;0 or 99=unk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,3,4 ... and not 99=unk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p>
<p>N_Biop : # biopsies &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 or 99=unk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,3,4 ... and not 99=unk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p>
<p>Age1st : age at 1st live birth &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 and younger &nbsp;or &nbsp;99=unk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20,21,22,23,24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25,26,27,28,29 &nbsp;or &nbsp;98(nulliparous) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30,31,32 ... &nbsp;&nbsp;&nbsp;and not 98 and not 99 &nbsp;&nbsp;&nbsp;3</p>
<p>BdyWght: body weight in lbs &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;( &nbsp;0,100] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(100,125] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(125,150] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(150,175] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(175,200] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(200, &nbsp;+] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5</p>
<p>In the above, note the liberal use of "open", "closed" interval limits notation.</p>
<p>Edit checking for relative risk covariates, PDensty,N_Rels,N_Biop,Age1st &amp; BdyWght:</p>
<p>PDensty: &nbsp;% mammographic density must be between 0 and 100 inclusive.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no accomodating for unknown % density. &nbsp;unkown %density results in an<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unknown absolute risk projection.</p>
<p>N_Rels : &nbsp;# of 1st degree relatives with BrCa must be 0,1,2... unk=99</p>
<p>N_Biop : &nbsp;# biopsies must be 0,1,2... unk=99</p>
<p>Age1st : &nbsp;age first live birth must be less than or equal to Initial age T1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nulliparous=98, &nbsp;unk=99</p>
<p>BdyWght: &nbsp;body weight must be a positive real number. &nbsp;no accomodation for<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unknown body weight. &nbsp;unknown weight results in an unknown absolute risk.</p>
<p>Following is a listing of the sample raw input data set "Sample.in"<br />(column heading included for clarity):</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inital &nbsp;&nbsp;&nbsp;Projtn &nbsp;&nbsp;&nbsp;PerCent_ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fst &nbsp;&nbsp;&nbsp;&nbsp;Body_<br />Rec_Num &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Den &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels &nbsp;&nbsp;&nbsp;NBiop &nbsp;&nbsp;&nbsp;Live &nbsp;&nbsp;&nbsp;Weight</p>
<p>&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175<br />&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;&nbsp;5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;&nbsp;6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150<br />&nbsp;&nbsp;&nbsp;7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;&nbsp;8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150<br />&nbsp;&nbsp;&nbsp;9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150<br />&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;12 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;15 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;16 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;17 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;18 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150<br />&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;21 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175<br />&nbsp;&nbsp;23 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175<br />&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;26 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;27 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150<br />&nbsp;&nbsp;28 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;29 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;31 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;32 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175<br />&nbsp;&nbsp;33 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250<br />&nbsp;&nbsp;34 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250<br />&nbsp;&nbsp;35 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;36 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175<br />&nbsp;&nbsp;37 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;38 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;39 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100<br />&nbsp;&nbsp;40 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;41 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250<br />&nbsp;&nbsp;42 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;43 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;45 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250<br />&nbsp;&nbsp;46 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150<br />&nbsp;&nbsp;47 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125<br />&nbsp;&nbsp;48 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175<br />&nbsp;&nbsp;49 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200<br />&nbsp;&nbsp;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250</p>
<p>Following is a listing of the consequence of applying the macro to the input file<br />Note the raw values for the RR covaraties are listed and not the recoded values of<br />0,1,2,3,4 or 5</p>
<p>Record &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% &nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;Age &nbsp;&nbsp;&nbsp;Body &nbsp;(1-ar)RR &nbsp;(1-ar)RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pattrn<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;Dens &nbsp;Rel &nbsp;Biop &nbsp;1st &nbsp;&nbsp;&nbsp;Wght &nbsp;&nbsp;&nbsp;Age&lt;50 &nbsp;&nbsp;&nbsp;Age&gt;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;25 &nbsp;&nbsp;175.0 &nbsp;&nbsp;&nbsp;3.6546 &nbsp;&nbsp;&nbsp;4.1787 &nbsp;&nbsp;&nbsp;0.092145 &nbsp;&nbsp;&nbsp;&nbsp;928<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;30 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;0.7936 &nbsp;&nbsp;&nbsp;0.9074 &nbsp;&nbsp;&nbsp;0.007421 &nbsp;&nbsp;&nbsp;&nbsp;260<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;38.0 &nbsp;43.0 &nbsp;&nbsp;&nbsp;0.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;1.1110 &nbsp;&nbsp;&nbsp;1.2703 &nbsp;&nbsp;&nbsp;0.005499 &nbsp;&nbsp;&nbsp;&nbsp;194<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;1.4190 &nbsp;&nbsp;&nbsp;1.6225 &nbsp;&nbsp;&nbsp;0.026740 &nbsp;&nbsp;&nbsp;&nbsp;653<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;1.9960 &nbsp;&nbsp;&nbsp;2.2822 &nbsp;&nbsp;&nbsp;0.037406 &nbsp;&nbsp;&nbsp;&nbsp;805<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;150.0 &nbsp;&nbsp;&nbsp;1.2335 &nbsp;&nbsp;&nbsp;1.4104 &nbsp;&nbsp;&nbsp;0.011511 &nbsp;&nbsp;&nbsp;&nbsp;339<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;25 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;2.1257 &nbsp;&nbsp;&nbsp;2.4305 &nbsp;&nbsp;&nbsp;0.019753 &nbsp;&nbsp;&nbsp;&nbsp;422<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;25 &nbsp;&nbsp;150.0 &nbsp;&nbsp;&nbsp;1.0861 &nbsp;&nbsp;&nbsp;1.2418 &nbsp;&nbsp;&nbsp;0.010142 &nbsp;&nbsp;&nbsp;&nbsp;279<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;2.2110 &nbsp;&nbsp;&nbsp;2.5281 &nbsp;&nbsp;&nbsp;0.041351 &nbsp;&nbsp;&nbsp;&nbsp;725<br />&nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;30 &nbsp;&nbsp;150.0 &nbsp;&nbsp;&nbsp;1.8498 &nbsp;&nbsp;&nbsp;2.1150 &nbsp;&nbsp;&nbsp;0.017211 &nbsp;&nbsp;&nbsp;&nbsp;381<br />&nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;2.1743 &nbsp;&nbsp;&nbsp;2.4861 &nbsp;&nbsp;&nbsp;0.055917 &nbsp;&nbsp;&nbsp;&nbsp;985<br />&nbsp;&nbsp;&nbsp;&nbsp;12 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;30 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;1.4302 &nbsp;&nbsp;&nbsp;1.6353 &nbsp;&nbsp;&nbsp;0.030560 &nbsp;&nbsp;&nbsp;&nbsp;500<br />&nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;25 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;1.4815 &nbsp;&nbsp;&nbsp;1.6940 &nbsp;&nbsp;&nbsp;0.038458 &nbsp;&nbsp;&nbsp;&nbsp;901<br />&nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;19 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;1.6153 &nbsp;&nbsp;&nbsp;1.8469 &nbsp;&nbsp;&nbsp;0.041855 &nbsp;&nbsp;&nbsp;&nbsp;938<br />&nbsp;&nbsp;&nbsp;&nbsp;15 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;30 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;3.8077 &nbsp;&nbsp;&nbsp;4.3537 &nbsp;&nbsp;&nbsp;0.070136 &nbsp;&nbsp;&nbsp;&nbsp;719<br />&nbsp;&nbsp;&nbsp;&nbsp;16 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;1.9789 &nbsp;&nbsp;&nbsp;2.2627 &nbsp;&nbsp;&nbsp;0.051028 &nbsp;&nbsp;&nbsp;&nbsp;869<br />&nbsp;&nbsp;&nbsp;&nbsp;17 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;3.3044 &nbsp;&nbsp;&nbsp;3.7783 &nbsp;&nbsp;&nbsp;0.083705 &nbsp;&nbsp;&nbsp;&nbsp;917<br />&nbsp;&nbsp;&nbsp;&nbsp;18 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;19 &nbsp;&nbsp;150.0 &nbsp;&nbsp;&nbsp;1.1511 &nbsp;&nbsp;&nbsp;1.3161 &nbsp;&nbsp;&nbsp;0.010745 &nbsp;&nbsp;&nbsp;&nbsp;363<br />&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;0.6381 &nbsp;&nbsp;&nbsp;0.7297 &nbsp;&nbsp;&nbsp;0.005972 &nbsp;&nbsp;&nbsp;&nbsp;266<br />&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;2.0486 &nbsp;&nbsp;&nbsp;2.3424 &nbsp;&nbsp;&nbsp;0.043481 &nbsp;&nbsp;&nbsp;&nbsp;533<br />&nbsp;&nbsp;&nbsp;&nbsp;21 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;20 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;0.9013 &nbsp;&nbsp;&nbsp;1.0306 &nbsp;&nbsp;&nbsp;0.008424 &nbsp;&nbsp;&nbsp;&nbsp;320<br />&nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;25 &nbsp;&nbsp;175.0 &nbsp;&nbsp;&nbsp;2.0994 &nbsp;&nbsp;&nbsp;2.4004 &nbsp;&nbsp;&nbsp;0.019511 &nbsp;&nbsp;&nbsp;&nbsp;352<br />&nbsp;&nbsp;&nbsp;&nbsp;23 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;20 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;0.5623 &nbsp;&nbsp;&nbsp;0.6429 &nbsp;&nbsp;&nbsp;0.005264 &nbsp;&nbsp;&nbsp;&nbsp;295<br />&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;20 &nbsp;&nbsp;175.0 &nbsp;&nbsp;&nbsp;1.2414 &nbsp;&nbsp;&nbsp;1.4194 &nbsp;&nbsp;&nbsp;0.026581 &nbsp;&nbsp;&nbsp;&nbsp;466<br />&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;38.0 &nbsp;43.0 &nbsp;&nbsp;&nbsp;0.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;25 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;0.3916 &nbsp;&nbsp;&nbsp;0.4478 &nbsp;&nbsp;&nbsp;0.001942 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37<br />&nbsp;&nbsp;&nbsp;&nbsp;26 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;30 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;1.2443 &nbsp;&nbsp;&nbsp;1.4227 &nbsp;&nbsp;&nbsp;0.023487 &nbsp;&nbsp;&nbsp;&nbsp;691<br />&nbsp;&nbsp;&nbsp;&nbsp;27 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;30 &nbsp;&nbsp;150.0 &nbsp;&nbsp;&nbsp;2.0666 &nbsp;&nbsp;&nbsp;2.3630 &nbsp;&nbsp;&nbsp;0.053225 &nbsp;&nbsp;&nbsp;&nbsp;885<br />&nbsp;&nbsp;&nbsp;&nbsp;28 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;1.5891 &nbsp;&nbsp;&nbsp;1.8169 &nbsp;&nbsp;&nbsp;0.029896 &nbsp;&nbsp;&nbsp;&nbsp;734<br />&nbsp;&nbsp;&nbsp;&nbsp;29 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;4.7268 &nbsp;&nbsp;&nbsp;5.4046 &nbsp;&nbsp;&nbsp;0.086309 &nbsp;&nbsp;&nbsp;&nbsp;809<br />&nbsp;&nbsp;&nbsp;&nbsp;30 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;25 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;4.4622 &nbsp;&nbsp;&nbsp;5.1021 &nbsp;&nbsp;&nbsp;0.111303 &nbsp;&nbsp;&nbsp;1046<br />&nbsp;&nbsp;&nbsp;&nbsp;31 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;30 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;2.7992 &nbsp;&nbsp;&nbsp;3.2006 &nbsp;&nbsp;&nbsp;0.058928 &nbsp;&nbsp;&nbsp;&nbsp;643<br />&nbsp;&nbsp;&nbsp;&nbsp;32 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;20 &nbsp;&nbsp;175.0 &nbsp;&nbsp;&nbsp;1.9344 &nbsp;&nbsp;&nbsp;2.2118 &nbsp;&nbsp;&nbsp;0.041106 &nbsp;&nbsp;&nbsp;&nbsp;538<br />&nbsp;&nbsp;&nbsp;&nbsp;33 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;19 &nbsp;&nbsp;250.0 &nbsp;&nbsp;&nbsp;3.9599 &nbsp;&nbsp;&nbsp;4.5278 &nbsp;&nbsp;&nbsp;0.082322 &nbsp;&nbsp;&nbsp;&nbsp;606<br />&nbsp;&nbsp;&nbsp;&nbsp;34 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;19 &nbsp;&nbsp;250.0 &nbsp;&nbsp;&nbsp;2.5414 &nbsp;&nbsp;&nbsp;2.9058 &nbsp;&nbsp;&nbsp;0.053650 &nbsp;&nbsp;&nbsp;&nbsp;534<br />&nbsp;&nbsp;&nbsp;&nbsp;35 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;1.7754 &nbsp;&nbsp;&nbsp;2.0300 &nbsp;&nbsp;&nbsp;0.037794 &nbsp;&nbsp;&nbsp;&nbsp;590<br />&nbsp;&nbsp;&nbsp;&nbsp;36 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;175.0 &nbsp;&nbsp;&nbsp;1.9590 &nbsp;&nbsp;&nbsp;2.2400 &nbsp;&nbsp;&nbsp;0.018219 &nbsp;&nbsp;&nbsp;&nbsp;376<br />&nbsp;&nbsp;&nbsp;&nbsp;37 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;30 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;5.3103 &nbsp;&nbsp;&nbsp;6.0718 &nbsp;&nbsp;&nbsp;0.130975 &nbsp;&nbsp;&nbsp;&nbsp;935<br />&nbsp;&nbsp;&nbsp;&nbsp;38 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;1.9468 &nbsp;&nbsp;&nbsp;2.2260 &nbsp;&nbsp;&nbsp;0.036501 &nbsp;&nbsp;&nbsp;&nbsp;665<br />&nbsp;&nbsp;&nbsp;&nbsp;39 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;25 &nbsp;&nbsp;100.0 &nbsp;&nbsp;&nbsp;0.7617 &nbsp;&nbsp;&nbsp;0.8709 &nbsp;&nbsp;&nbsp;0.016395 &nbsp;&nbsp;&nbsp;&nbsp;469<br />&nbsp;&nbsp;&nbsp;&nbsp;40 &nbsp;38.0 &nbsp;43.0 &nbsp;&nbsp;&nbsp;0.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;25 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;1.1984 &nbsp;&nbsp;&nbsp;1.3703 &nbsp;&nbsp;&nbsp;0.005930 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65<br />&nbsp;&nbsp;&nbsp;&nbsp;41 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;250.0 &nbsp;&nbsp;&nbsp;4.5799 &nbsp;&nbsp;&nbsp;5.2367 &nbsp;&nbsp;&nbsp;0.083744 &nbsp;&nbsp;&nbsp;&nbsp;774<br />&nbsp;&nbsp;&nbsp;&nbsp;42 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;2.6972 &nbsp;&nbsp;&nbsp;3.0840 &nbsp;&nbsp;&nbsp;0.068881 &nbsp;&nbsp;&nbsp;&nbsp;986<br />&nbsp;&nbsp;&nbsp;&nbsp;43 &nbsp;58.0 &nbsp;63.0 &nbsp;&nbsp;48.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;25 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;2.1751 &nbsp;&nbsp;&nbsp;2.4870 &nbsp;&nbsp;&nbsp;0.046102 &nbsp;&nbsp;&nbsp;&nbsp;521<br />&nbsp;&nbsp;&nbsp;&nbsp;44 &nbsp;38.0 &nbsp;43.0 &nbsp;&nbsp;&nbsp;0.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;0.8735 &nbsp;&nbsp;&nbsp;0.9988 &nbsp;&nbsp;&nbsp;0.004326 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;53<br />&nbsp;&nbsp;&nbsp;&nbsp;45 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;19 &nbsp;&nbsp;250.0 &nbsp;&nbsp;&nbsp;9.9526 &nbsp;&nbsp;11.3798 &nbsp;&nbsp;&nbsp;0.231001 &nbsp;&nbsp;&nbsp;1062<br />&nbsp;&nbsp;&nbsp;&nbsp;46 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;20 &nbsp;&nbsp;150.0 &nbsp;&nbsp;&nbsp;1.5063 &nbsp;&nbsp;&nbsp;1.7223 &nbsp;&nbsp;&nbsp;0.039088 &nbsp;&nbsp;&nbsp;&nbsp;873<br />&nbsp;&nbsp;&nbsp;&nbsp;47 &nbsp;44.0 &nbsp;49.0 &nbsp;&nbsp;24.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;25 &nbsp;&nbsp;125.0 &nbsp;&nbsp;&nbsp;0.8755 &nbsp;&nbsp;&nbsp;1.0011 &nbsp;&nbsp;&nbsp;0.008184 &nbsp;&nbsp;&nbsp;&nbsp;278<br />&nbsp;&nbsp;&nbsp;&nbsp;48 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;19 &nbsp;&nbsp;175.0 &nbsp;&nbsp;&nbsp;1.5953 &nbsp;&nbsp;&nbsp;1.8240 &nbsp;&nbsp;&nbsp;0.041347 &nbsp;&nbsp;&nbsp;&nbsp;868<br />&nbsp;&nbsp;&nbsp;&nbsp;49 &nbsp;54.0 &nbsp;59.0 &nbsp;&nbsp;72.0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;19 &nbsp;&nbsp;200.0 &nbsp;&nbsp;&nbsp;2.8571 &nbsp;&nbsp;&nbsp;3.2668 &nbsp;&nbsp;&nbsp;0.053105 &nbsp;&nbsp;&nbsp;&nbsp;749<br />&nbsp;&nbsp;&nbsp;&nbsp;50 &nbsp;67.0 &nbsp;72.0 &nbsp;&nbsp;96.0 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;20 &nbsp;&nbsp;250.0 &nbsp;&nbsp;&nbsp;9.0215 &nbsp;&nbsp;10.3152 &nbsp;&nbsp;&nbsp;0.211935 &nbsp;&nbsp;&nbsp;1044</p>
<p>After the absolute risks have been generated, descriptive statistics by applying PROC<br />MEANS to the quantities Error_Ind, AbsRsk, One_AR_RR1 and One_AR_RR2 is performed. &nbsp;When<br />the mean and standard deviation for the variable &nbsp;"Error_Ind" &nbsp;is 0, implies that no<br />errors have not been found. &nbsp;Otherwise when the mean and std for &nbsp;"Error_Ind" is not 0,<br />implies that errors have been found. &nbsp;When errors are found, the # of records with errors<br />is the count asscociated with "AbsRsk" listed under NMiss (# of missing). &nbsp;Furthermore, a<br />listing file for erroronious records follows the PROC Means output. &nbsp;For example:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10:52 Wednesday, July 15, 2009<br />BrCa_MD_RAM, &nbsp;sas macro to project for BrCa absolute risk<br />Quick check for errornous records on input file</p>
<p>IF MEAN OF &nbsp;'Error_Ind' &nbsp;&nbsp;EQUALS &nbsp;0, &nbsp;&nbsp;ERROR &nbsp;FREE. &nbsp;&nbsp;&nbsp;ERROR LISTING BELOW WILL BE EMPTY.<br />IF MEAN OF &nbsp;'Error_Ind' &nbsp;&nbsp;IS NOT &nbsp;0, &nbsp;&nbsp;ERRORS EXISTS. &nbsp;CHECK ERROR LISTING BELOW.</p>
<p>(# of records with errors is the # listed under the NMiss column in the 'AbsRsk' line)</p>
<p>The MEANS Procedure</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N<br />Variable &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Label &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mean &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Std Dev &nbsp;&nbsp;&nbsp;N &nbsp;&nbsp;Miss<br />--------------------------------------------------------------------------------------------------<br />Error_Ind &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If mean not 0, implies ERROR in file &nbsp;-----&gt; &nbsp;&nbsp;&nbsp;0.00000 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.00000 &nbsp;&nbsp;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />Absolute_Risk &nbsp;&nbsp;Abs risk of BrCa in age interval [T1,T2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.04673 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.04672 &nbsp;&nbsp;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />One_AR_RR1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1-AR)*RelRsk age lt 50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.33432 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.87141 &nbsp;&nbsp;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />One_AR_RR2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1-AR)*RelRsk age ge 50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.66907 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13977 &nbsp;&nbsp;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />--------------------------------------------------------------------------------------------------</p>
<p>BC_MD_example.sas, example sas program using sas macro &nbsp;BrCa_MD_RAM &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10:52 Wednesday, July 15, 2009<br />BrCa_MD_RAM, &nbsp;sas macro to project for BrCa absolute risk<br />Error listing for the input file</p>
<p>Record &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% &nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;Age &nbsp;&nbsp;&nbsp;Body &nbsp;(1-ar)RR &nbsp;(1-ar)RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patrn<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;T2 &nbsp;Dens &nbsp;Rel &nbsp;Biop &nbsp;1st &nbsp;&nbsp;&nbsp;Wght &nbsp;&nbsp;&nbsp;Age&lt;50 &nbsp;&nbsp;&nbsp;Age&gt;50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No errors detected for initial age, projection age and relative risk covaraites<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-------------------------------------------------------------------------------</p>
<p>Statistical issues &nbsp;should be addressed to: &nbsp;Dr. Mitchell Gail &nbsp;&nbsp;&nbsp;gailm@exchange.nih.gov<br />Technical &nbsp;&nbsp;details should be addressed to: &nbsp;Mr. David Pee &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;peed@imsweb.com</p>
</div>]]></content>
  </row>
  <row para_id="326988" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>APA_BrCa_RAM: &nbsp;&nbsp;&nbsp;(A)sian-(P)acific-(A)merican (BrCa) (R)isk (A)ssessment (M)acro</p>
<p>Installing the Asian-Pacific-American BrCa Risk Assessment Macro &nbsp;&nbsp;&nbsp;Ver 1.0 &nbsp;&nbsp;05/12/11</p>
<p>&nbsp;&nbsp;"Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and<br />&nbsp;&nbsp;&nbsp;Pacific Islander American Women" &nbsp;&nbsp;Matsuno, Costantino, Ziegler et al. &nbsp;&nbsp;JNCI 2011</p>
<p>This module pertains to Windows 2000, Windows XP, Windows Vista and Windows 7<br />operating systems for desktop/laptop PCs with installed SAS 9 software.</p>
<p>Contents of the Zip file "APA_BrCa_RAM.zip":</p>
<p>(a) APA_BrCa_RAM &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sas macro which performs abs risk and 95% CI calculations<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for Asian-Pacific-American women based on the Asian-American<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Breast Cancer Study (AABCS) Relative Risk (RR) model.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the first 350 lines of the sas macro &nbsp;"APA_BrCa_RAM" &nbsp;contains<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;extensive documentaion/clarification on the use and operation<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of this macro.</p>
<p>(b) APA_BrCa_example.sas &nbsp;a simple demonstration sas program which reads in raw data,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;involkes the sas macro &nbsp;"APA_ABrCa_RAM" &nbsp;and obtains abs risk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and 95% CI.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the first 30 lines of this sas program contains a brief<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;description of what this program accomplishes. &nbsp;additional<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;clarification is scattered throughout the program.</p>
<p>(c) APA_RR.fil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;raw data file for input to &nbsp;"APA_BrCa_example.sas"</p>
<p>(d) APA_BrCa_example.out &nbsp;sample output from &nbsp;"APA_BrCa_example.sas"</p>
<p>(e) ReadMe.fil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this file you are reading</p>
<p>After unzipping &nbsp;"APA_BrCa_AbsRsk.zip", &nbsp;check to see that all files listed above are<br />included. &nbsp;At this point, a cursory examination of &nbsp;"APA_BrCa_RAM", &nbsp;"APA_BrCa_example.sas"<br />and "APA_RR.fil" &nbsp;will prove helpful. &nbsp;These files can be veiwed using your favorite text<br />editor or &nbsp;Notepad &nbsp;which is included with Windows.</p>
<p>Installation and operation of the sas macro &nbsp;"APA_BrCa_RAM":</p>
<p>(a) unzip the entire contentes of the zip file "APA_BrCa_RAM.zip" into a folder on<br />&nbsp;&nbsp;&nbsp;your hard drive.</p>
<p>(b) execute the provided demonstration sas program &nbsp;"APA_BrCa_example.sas".</p>
<p>(c) compare the output &nbsp;"APA_BrCa_example.lst" &nbsp;with the provided file<br />&nbsp;&nbsp;"APA_BrCa_example.out". &nbsp;The two files should be identical. &nbsp;If so, congratulations,<br />&nbsp;&nbsp;&nbsp;you have successfully installed the software.</p>
<p>Characteristics of the input sas file for the Asian-Pacific-American Risk Assessment SAS Macro:</p>
<p>(a) the input sas file name and output sas file name are provided by the user upon the<br />&nbsp;&nbsp;&nbsp;invocation of the sas macro &nbsp;"APA_BrCa_RAM".</p>
<p>(b) the input sas file must contain the following 9 quantities. &nbsp;any additional variables<br />&nbsp;&nbsp;&nbsp;on the input sas file are ignored. &nbsp;No particular ordering is required.</p>
<p>&nbsp;&nbsp;&nbsp;(1) ID unique ID &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(non-negative integer 1,2,3....9999999)</p>
<p>&nbsp;&nbsp;&nbsp;(2) current age in years in the age interval [20, 90) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.g. 35.8</p>
<p>&nbsp;&nbsp;&nbsp;(3) projctn age in years in the age interval (current age, 90] &nbsp;e.g. 58.9<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;constraint of: &nbsp;20 =&lt; current age &lt; projctn age &lt;= 90</p>
<p>&nbsp;&nbsp;&nbsp;(4) # of breast biopsies &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(non-negative integer counts 1,2,3...)</p>
<p>&nbsp;&nbsp;&nbsp;(5) age at menarche in years &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(non-negative integer years)</p>
<p>&nbsp;&nbsp;&nbsp;(6) age of first live birth in years &nbsp;(non-negative integer years)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;constraint of: &nbsp;age menarche &lt;= age at first live birth</p>
<p>&nbsp;&nbsp;&nbsp;(7) # of first degree relatives with breast cancer<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(non-negative integer counts 1,2,3...)</p>
<p>&nbsp;&nbsp;&nbsp;(8) biopsy displays atypical hyperplasia?<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;= no<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;= yes<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 = unk or not applicable response</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IF # breast biopsies = 0, &nbsp;hyperplasia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MUST BE 99 (not applicable)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IF # breast biopsies &gt; 0, &nbsp;hyperplasia &nbsp;can be &nbsp;0,1 or 99 (unknown)</p>
<p>&nbsp;&nbsp;&nbsp;(9) race of women<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1=Chinese &nbsp;2=Japanese &nbsp;3=Filipino 4=Hawaiian 5=Other Pacific Islander 6=Other Asian<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for records where race is not 1 or 2 or 3 or 4 or 5 or 6<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projected &nbsp;abs risk &nbsp;defaults to the sas missing value "." .</p>
<p>&nbsp;&nbsp;&nbsp;more detailed documentation is provided in the first 350 lines of the SAS macro<br />&nbsp;&nbsp;"APA_BrCa_RAM"</p>
<p>&nbsp;&nbsp;&nbsp;in the above [) represents an interval closed on the left and &nbsp;&nbsp;open on the right<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(] represents an interval &nbsp;&nbsp;open on the left and closed on the right</p>
<p>&nbsp;&nbsp;&nbsp;this program will categorize the raw values of # breast biopsies, age menarche,<br />&nbsp;&nbsp;&nbsp;age first live birth and # 1st degree relatives with brca into risk categories<br />&nbsp;&nbsp;&nbsp;according to the rules outlined in the JNCI 2011 manuscript listed at the beginning<br />&nbsp;&nbsp;&nbsp;of this document.</p>
<p>&nbsp;&nbsp;&nbsp;note that the program, being an analytical tool, will make the most rudimentary<br />&nbsp;&nbsp;&nbsp;checks for logical consistency between the input variables. &nbsp;It is the user's<br />&nbsp;&nbsp;&nbsp;responsibility to make sure that all input covariate values are logically<br />&nbsp;&nbsp;&nbsp;consistent and correct within each person. &nbsp;As a final step, the program<br />&nbsp;&nbsp;&nbsp;will generate a missing projected Absolute Risk for records which it deems to<br />&nbsp;&nbsp;&nbsp;be in error. &nbsp;The user should examine the output file for any records with a<br />&nbsp;&nbsp;&nbsp;missing Absolute Risk and rectify the error(s) for these records.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.g. if NBiops equals zero than atypical hyperplasia must be 99 (not applicable)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or &nbsp;Projection Age in years must be greater than Current Age</p>
<p>Contacts:<br />Dr. Mitchell Gail &nbsp;&nbsp;&nbsp;&nbsp;gailm@exchange.nih.gov &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scientific/Statistical issues<br />Mr. David &nbsp;&nbsp;&nbsp;Pee &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;peed@imsweb.com &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technical/software problems</p>
<p>Terms &amp; Conditions</p>
<p>Source Code for APA model: Asian-Pacific American Women Breast Cancer Risk Calculation Module</p>
<p>Non-Proprietary Software Transfer Agreement</p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in<br />the course of official duties. Transfer of Software to Recipient does not constitute<br />endorsement by the NCI of the Recipient or any product, service or company and no endorsement<br />should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.<br />The APA model risk calculator may be updated periodically as new data or research becomes<br />available. Software is supplied AS IS, without any accompanying services or improvements from<br />NIH. &nbsp;SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY<br />WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations<br />that the use of Software will not infringe any patent or proprietary rights of third parties.<br />All risk as to quality and performance of Software is with Recipient. In no event will the<br />United States Government or NCI be liable to Recipient for damages arising out of the use or<br />inability to use Software, including but not limited to loss of data or data being rendered<br />inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="327148" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;04/04/2012</p>
<p>Installing and operating the Women Colorectal Cancer Absolute Risk Assessment Tool<br />version 1.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;creation date 04/02/12</p>
<p>This installation and operation pertains to Windows 2000, Windows XP,<br />Windows Vista and Windows 7 for either 32 or 64 bit operating systems.</p>
<p>(1) Contents of the Zip file "W_CRCAbsRsk.zip":</p>
<p>(a) Women_CRC_Risk_Tool.gcg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gauss program which performs the CRC Risk Projection<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and 95% confidence interval calculations<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(32-bit version &nbsp;operable on both 32 or 64 bit OS)</p>
<p>(b) Women_CRC_Risk_Input.dat &nbsp;&nbsp;&nbsp;&nbsp;sample relative risk profile input file read by the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;risk program &nbsp;"Women_CRC_Risk_Tool.gcg"</p>
<p>(c) Women_CRC_Risk_Tool.list &nbsp;&nbsp;&nbsp;&nbsp;projected risks by reading the above sample input file</p>
<p>(d) WomenColnCaCovPat &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ancillary file used by the risk program<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Women_CRC_Risk_Tool.gcg for data editing of the input<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file &nbsp;Women_CRC_Risk_Input.dat. &nbsp;If it is not found,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;data editing on the input file will not be performed</p>
<p>(e) Women_CRC_Risk_Tool.err &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;input data editing error file listing</p>
<p>(f) WomenCov_1_AR_RPD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ancillary file used by the risk program<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Women_CRC_Risk_Tool.gcg for 95% for confidence interval<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calculations. &nbsp;If not found, confidence intervals will<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not be produced.</p>
<p>(g) GRTM_11_Win_32.msi &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;setup file for Gauss Run Time Module for Windows with<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a 32 or 64 bit operating system</p>
<p>(h) WReadMe.fil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this file you are reading</p>
<p>After unzipping the contents of &nbsp;"W_CRCAbsRsk.zip", &nbsp;check to see that all files<br />listed above are included.</p>
<p>Ref: "Colorectal Cancer Risk Prediction Tool for White Men and Women Without Known<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Susceptibility". &nbsp;&nbsp;A Freedman et al. &nbsp;JCO &nbsp;27:686-693 2008.</p>
<p>(2) Installing the Gauss Run Time Moduel:</p>
<p>Note: &nbsp;If you have previously installed the gauss run-time module using<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GRTM_11_Win_32.msi, &nbsp;you can ignore this section.</p>
<p>The gauss run-time module will execute any pre-compiled gauss program. &nbsp;It is<br />needed for the user to perform CRC Absolute Risk Projections for women by executing<br />the provided pre-compiled Gauss program &nbsp;&nbsp;"Women_CRC_Risk_Tool.gcg".</p>
<p>click on &nbsp;"GRTM_11_Win_32.msi" &nbsp;to start the installation process and you are<br />using 32-bit Windows operating system.</p>
<p>(a) the installer will ask you to accept the standard license agreement. After<br />&nbsp;&nbsp;&nbsp;you accept the agreement, it will ask you where you want to install the<br />&nbsp;&nbsp;&nbsp;gauss run-time module. &nbsp;The default folder is &nbsp;"C:\gsrun11". &nbsp;If the default<br />&nbsp;&nbsp;&nbsp;is acceptable click "next", otherwise click "browse". &nbsp;If you clicked "browse",<br />&nbsp;&nbsp;&nbsp;a box will appear where you can type in the destination of your installation<br />&nbsp;&nbsp;&nbsp;process. &nbsp;In the following discussion, the installation will be into the folder<br />&nbsp;&nbsp;&nbsp;"c:\CRC_AbsRisk"</p>
<p>(b) at the completion of the installation process, the installer will place a<br />&nbsp;&nbsp;&nbsp;gauss run time module icon on your desktop. &nbsp;It is recommended leaving the<br />&nbsp;&nbsp;&nbsp;icon on the desktop for ease of use.</p>
<p>(c) copy the six files:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Women_CRC_Risk_Tool.gcg"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Women_CRC_Risk_Input.dat"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Women_CRC_Risk_Tool.list"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"WomenColnCaCovPat"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Women_CRC_Risk_Tool.err"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"WomenCov_1_AR_RPD"</p>
<p>&nbsp;&nbsp;&nbsp;to where you installed the gauss run time module, i.e. in this example,<br />&nbsp;&nbsp;&nbsp;c:\CRC_AbsRisk.</p>
<p>(d) you may want to copy this "WReadMe.fil" to the folder c:\CRC_AbsRisk.</p>
<p>(e) the installation process is now complete.</p>
<p>(3) &nbsp;Input file desciription:</p>
<p>The women's colorectal cancer absolute risk projection Gauss program, &nbsp;Women_CRC_Risk_Tool.gcg,<br />needs the following information as input to project for absolute risk of colorectal cancer.<br />The ordering of each field &nbsp;MUST &nbsp;be in the indicated order given below. So Col 11 must<br />contain &nbsp;BMI &gt;= 30. &nbsp;Similarly for all of the columns.<br />Compare following with the header area of the sample input file &nbsp;&nbsp;Women_CRC_Risk_Input.dat:</p>
<p>Col &nbsp;1 &nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, white<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, african-american<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, hispanic<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=4, asian-american</p>
<p>Col &nbsp;2 &nbsp;&nbsp;Posi 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, yes sigmoidoscopy and/or colonscopy last 10 years, &nbsp;no history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;3 &nbsp;&nbsp;Posi 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1. no sigmoidoscopy and/or colonscopy last 10 years<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;4 &nbsp;&nbsp;Posi 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, yes sigmoidoscopy and/or colonscopy last 10 years, yes history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;5 &nbsp;&nbsp;No Strogn &nbsp;&nbsp;&nbsp;&nbsp;=0, regular user of Estrogen<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;&nbsp;&nbsp;non user of Estrogen</p>
<p>Col &nbsp;6 &nbsp;&nbsp;Rel CRC &gt;=1 &nbsp;&nbsp;=0, 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative &nbsp;with CRC &nbsp;(CRC=Colorectal Cancer)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, 1 or more relatives with CRC</p>
<p>Col &nbsp;7 &nbsp;&nbsp;No NSaids &nbsp;&nbsp;&nbsp;&nbsp;=0, regular user of asprin/NSaids<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;&nbsp;&nbsp;non user of asprin/NSaids</p>
<p>Col &nbsp;8 &nbsp;&nbsp;VigrXrcis 0 &nbsp;&nbsp;=1, 0 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;9 &nbsp;&nbsp;VigrXrcis 1 &nbsp;&nbsp;=1, greater than 2 and less than equal 4 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 10 &nbsp;&nbsp;VigrXrcis 2 &nbsp;&nbsp;=1, greater than 0 and less than equal 2 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 11 &nbsp;&nbsp;BMI &gt;= 30 &nbsp;&nbsp;&nbsp;&nbsp;=0, BMI &lt; &nbsp;30<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, BMI &gt;= 30</p>
<p>Col 12 &nbsp;&nbsp;Hours Xrcise &nbsp;=0, greater than 4 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, greater than 2 and less than equal 4 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, greater than 0 and less than equal 2 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, 0 hrs/wk</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note: Hours Xrcise coding is "backward" i.e. &nbsp;0 is most exercise, &nbsp;3 is no exercise</p>
<p>Col 13 &nbsp;&nbsp;Veg &lt;5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, less &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than &nbsp;&nbsp;&nbsp;&nbsp;five servings of vegetables per day<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, greater &nbsp;&nbsp;equal to five servings of vegetables per day</p>
<p>Col 14 &nbsp;&nbsp;Posi 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1. no &nbsp;sigmoidoscopy and/or colonscopy last 10 years<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 15 &nbsp;&nbsp;Posi 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, yes sigmoidoscopy and/or colonscopy last 10 years, yes history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 16 &nbsp;&nbsp;Posi 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, unk sigmoidoscopy and/or colonscopy last 10 years, unk history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 17 &nbsp;&nbsp;#Rel Trend &nbsp;&nbsp;&nbsp;=0, 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative &nbsp;with CRC &nbsp;(CRC=Colorectal Cancer)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative &nbsp;with CRC<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, 2 or more relatives with CRC</p>
<p>Col 18 &nbsp;&nbsp;BMI30YesStrgn =0, &nbsp;&nbsp;BMI ge 30 * (1 - No Strogn) = 0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;BMI ge 30 * (1 - No Strogn) = 1</p>
<p>Col 19 &nbsp;&nbsp;Age1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;current age,<br />Col 20 &nbsp;&nbsp;Age2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection age, &nbsp;ranges from: &nbsp;50 &lt;= Age1 &lt; Age2 &lt;=90</p>
<p>Alogrithm used for calculating Risk Covariate Pattern ID for each input covariate pattern:</p>
<p>Pattrn_ID &nbsp;= &nbsp;2*2*2*4*2*3*1* Hours Exercis (0,1,2,3) &nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2*2*4*2*3*1* NoStrogen &nbsp;&nbsp;&nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2*4*2*3*1* VEGlt5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4*2*3*1* BMIge30 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2*3*1* sigmod &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2,3) &nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3*1* NoNSaids &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1* #RelTrnd &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2) &nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1* 1</p>
<p>Pattrn_ID ranges in values from 1:768</p>
<p>Pattrn_ID used for input Risk Covariate Pattern edit checking as well as<br />for 95% CI calculations. &nbsp;The numbers separated by commas in the parenthesis<br />is the number of levels and valid values for the levels for the associated<br />risk covariate. &nbsp;Note that &nbsp;"sigmod" &nbsp;is the trend variable created from<br />Posi 0, Posi 1, Posi 2 and Posi 3:</p>
<p>&nbsp;sigmod = 0 &nbsp;&nbsp;&nbsp;if Posi 0=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;if Posi 1=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;if Posi 2=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;if Posi 3=1</p>
<p>Before exeucting the risk projection program, it should prove beneficial to<br />take a brief examination of the input file &nbsp;"Women_CRC_Risk_Input.dat"<br />included with this package.</p>
<p>(4) Executing Women's colorectal cancer (CRC) risk program &nbsp;"Women_CRC_Risk_Tool.gcg":</p>
<p>Method 1: &nbsp;Associate any file which ends with &nbsp;".gcg" &nbsp;with the gauss run time module.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once this has been performed, you can just click on &nbsp;"Women_CRC_Risk_Tool.gcg"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or any file ending with &nbsp;".gcg" for that matter, and the gauss run time<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;moduele will execute the file and the absolute risk program will start to<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;execute.</p>
<p>Method 2: &nbsp;Click on the gauss run time module icon which has been placed on your desktop<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the installer. &nbsp;The gauss run time module window will open. &nbsp;On top of the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;window, will be a white rectangular box, with the name of the folder which the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gauss run time module is pointing. &nbsp;If it is pointing at the folder which<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contains &nbsp;"Women_CRC_Risk_Tool.gcg" then you don't have to navigate anywhere. &nbsp;If<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it is not pointing at the folder which contains &nbsp;"Women_CRC_Risk_Tools.gcg", then<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;either use the browse buttom &nbsp;(the little gray rectangle with three dots on it)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to navigate to the correct folder, or just type in the name of the folder in the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;white rectangle. &nbsp;In this discussion, you would type &nbsp;"c:\CRC_AbsRisk". &nbsp;Once<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this is done, at the "&gt;&gt;" symbol, type &nbsp;"run &nbsp;Women_CRC_Risk_Tool.gcg" and the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;absolute risk program will start to execute.</p>
<p>Once the absolute risk program &nbsp;"Women_CRC_Risk_Tool.gcg" &nbsp;completes execution, it will output<br />two files. &nbsp;&nbsp;One is the output file:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Women_CRC_Risk_Tool.out" &nbsp;which contains absolute risk associated quantities.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the other is the edit error file :</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Women_CRC_Risk_Tool.err" &nbsp;which indicates input records with editing errors.</p>
<p>It would be beneficial to look at both files. &nbsp;If the error file only contains a table heading,<br />this means that no editing errors was discovered by the program. &nbsp;Please note that this does<br />not guarantee that unanticipated errors have not occured in the input file. &nbsp;Integrity of the<br />input data is still the user's responsibility.</p>
<p>The included error file lists errors for seven records.</p>
<p>&nbsp;&nbsp;1st error: Incorrect value &nbsp;5 for race. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Race takes on the values 1,2,3 and 4<br />&nbsp;&nbsp;2nd error: Incorrect value 49 for Age1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1 must be ge 50.<br />&nbsp;&nbsp;3rd error: Incorrect value 60 for Age1 and Age2. Age2 must be gt Age1.<br />&nbsp;&nbsp;4th error: Incorrect value 91 for Age2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age2 must be le 90.<br />&nbsp;&nbsp;5th error: Incorrect value &nbsp;9 for #Rel012. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#Rel012 takes only values of 0,1,2.<br />&nbsp;&nbsp;6th error: Incorrect value &nbsp;9 for Hours Xrcise. &nbsp;Hours Xrcise takes only values of 0,1,2,3.<br />&nbsp;&nbsp;7th error: NoStrgn=1, BMIge30=1 but BMI*YesStrgn=1. &nbsp;BMI*YesStrogn should be ZERO.</p>
<p>The above seven errors are but a sub-set of all possible errors and are not meant to be exhaustive<br />of all possible errors.</p>
<p>Note that if the Pattrn_ID obtained for an input covariateis pattern from the above formula, is<br />not within the range of 1:768, the inputted covariate pattern is inadmissable and flagged.</p>
<p>Even when the Pattrn_ID is within this range, different covariate patterns may give rise to the<br />same Pattrn_ID. &nbsp;So if an input covariate pattern is flagged, the "correct" covariate pattern<br />associated with the Pattrn_ID is given below the "incorrect" input covariate pattern and a<br />covariate by covariate comparison might help in pinpointing the error.</p>
<p>Looking at the output file &nbsp;"Women_CRC_Risk_Tool.out", &nbsp;first note all the constants utilized by<br />this tool are listed. &nbsp;Next you will see all the inputed risk covariate information for each<br />person, as well the the projected absolute risk and 95% confidence interval. &nbsp;Note that for<br />covariate patterns which have editing errors (the first 7 records in this case), all the<br />absolute risk related output quantities are set to a missing value of &nbsp;".". &nbsp;Compare the output<br />which you obtained with the file &nbsp;"Women_CRC_Risk_Tool.list". &nbsp;There should be complete agreement,<br />with the exception of the date when the program was executed.</p>
</div>]]></content>
  </row>
  <row para_id="327156" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;04/02/2012</p>
<p>Installing and operating the Men Colorectal Cancer Absolute Risk Assessment Tool<br />version 1.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;creation date 04/02/12</p>
<p>This installation and operation pertains to Windows 2000, Windows XP,<br />Windows Vista and Windows 7 32-bit operating systems for desktop/laptop PCs.</p>
<p>(1) Contents of the Zip file "M_CRCAbsRsk.zip":</p>
<p>(a) Men_CRC_Risk_Tool.gcg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gauss program which performs the CRC Risk Projection<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and 95% confidence interval calculations<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(32-bit version)</p>
<p>(b) Men_CRC_Risk_Input.dat &nbsp;&nbsp;&nbsp;&nbsp;sample relative risk profile input file read by the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;risk program &nbsp;"Men_CRC_Risk_Tool.gcg"</p>
<p>(c) Men_CRC_Risk_Tool.list &nbsp;&nbsp;&nbsp;&nbsp;projected risks by reading the above sample input file</p>
<p>(d) MenColnCaCovPat &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ancillary file used by the risk program<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Men_CRC_Risk_Tool.gcg for data editing of the input<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file &nbsp;Men_CRC_Risk_Input.dat. &nbsp;If it is not found,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;data editing on the input file will not be performed</p>
<p>(e) Men_CRC_Risk_Tool.err &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;input data editing error file listing</p>
<p>(f) MenCov_1_AR_RPD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ancillary file used by the risk program<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Men_CRC_Risk_Tool.gcg for 95% for confidence interval<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calculations. &nbsp;If not found, confidence intervals will<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not be produced.</p>
<p>(g) GRTM_11_Win_32.msi &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;setup file for Gauss Run Time Module for Windows with<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a 32 or 64 bit operating system</p>
<p>(h) MReadMe.fil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this file you are reading</p>
<p>After unzipping the contents of &nbsp;"M_CRCAbsRsk.zip", &nbsp;check to see that all files<br />listed above are included.</p>
<p>Ref: "Colorectal Cancer Risk Prediction Tool for White Men and Women Without Known<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Susceptibility". &nbsp;&nbsp;A Freedman et al. &nbsp;JCO &nbsp;27:686-693 2008.</p>
<p>(2) Installing the Gauss Run Time Moduel:</p>
<p>Note: &nbsp;If you have previously installed the gauss run-time module using<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GRTM_11_Win_32.msi, &nbsp;you can ignore this section.</p>
<p>The gauss run-time module will execute any pre-compiled gauss program. &nbsp;It is<br />needed for the user to perform CRC Absolute Risk Projections for men by executing<br />the provided pre-compiled Gauss program &nbsp;&nbsp;"Men_CRC_Risk_Tool.gcg".</p>
<p>click on &nbsp;"GRTM_11_Win_32.msi" &nbsp;to start the installation process and you are<br />using 32-bit Windows operating system.</p>
<p>(a) the installer will ask you to accept the standard license agreement. After<br />&nbsp;&nbsp;&nbsp;you accept the agreement, it will ask you where you want to install the<br />&nbsp;&nbsp;&nbsp;gauss run-time module. &nbsp;The default folder is &nbsp;"C:\gsrun11". &nbsp;If the default<br />&nbsp;&nbsp;&nbsp;is acceptable click "next", otherwise click "browse". &nbsp;If you clicked "browse",<br />&nbsp;&nbsp;&nbsp;a box will appear where you can type in the destination of your installation<br />&nbsp;&nbsp;&nbsp;process. &nbsp;In the following discussion, the installation will be into the folder<br />&nbsp;&nbsp;&nbsp;"c:\CRC_AbsRisk"</p>
<p>(b) at the completion of the installation process, the installer will place a<br />&nbsp;&nbsp;&nbsp;gauss run time module icon on your desktop. &nbsp;It is recommended leaving the<br />&nbsp;&nbsp;&nbsp;icon on the desktop for ease of use.</p>
<p>(c) copy the six files:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Men_CRC_Risk_Tool.gcg"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Men_CRC_Risk_Input.dat"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Men_CRC_Risk_Tool.list"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"MenColnCaCovPat"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Men_CRC_Risk_Tool.err"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"MenCov_1_AR_RPD"</p>
<p>&nbsp;&nbsp;&nbsp;to where you installed the gauss run time module, i.e. in this example,<br />&nbsp;&nbsp;&nbsp;c:\CRC_AbsRisk.</p>
<p>(d) you may want to copy this "MReadMe.fil" to the folder c:\CRC_AbsRisk.</p>
<p>(e) the installation process is now complete.</p>
<p>(3) &nbsp;Input file desciription:</p>
<p>The men's colorectal cancer absolute risk projection Gauss program, &nbsp;Men_CRC_Risk_Tool.gcg,<br />needs the following information as input to project for absolute risk of colorectal cancer.<br />The ordering of each field &nbsp;MUST &nbsp;be in the indicated order given below. So Col 13 must<br />contain &nbsp;BMI Trend. &nbsp;Similarly for all of the columns.<br />Compare following with the header area of the sample input file &nbsp;&nbsp;Men_CRC_Risk_Input.dat:</p>
<p>Col &nbsp;1 &nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, white<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, african-american<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, hispanic<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=4, asian-american</p>
<p>Col &nbsp;2 &nbsp;&nbsp;Posi 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, yes sigmoidoscopy and/or colonscopy last 10 years, &nbsp;no history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;3 &nbsp;&nbsp;Posi 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1. no sigmoidoscopy and/or colonscopy last 10 years<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;4 &nbsp;&nbsp;Posi 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, yes sigmoidoscopy and/or colonscopy last 10 years, yes history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;5 &nbsp;&nbsp;No IBupro &nbsp;&nbsp;&nbsp;&nbsp;=0, regular user of IBuprofin only<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;&nbsp;&nbsp;non user of IBuprofin only</p>
<p>Col &nbsp;6 &nbsp;&nbsp;Rel CRC &gt;=1 &nbsp;&nbsp;=0, 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative &nbsp;with CRC &nbsp;(CRC=Colorectal Cancer)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, 1 or more relatives with CRC</p>
<p>Col &nbsp;7 &nbsp;&nbsp;Hours Xrcise &nbsp;=0, greater than 4 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, greater than 2 and less than equal 4 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, greater than 0 and less than equal 2 hrs/wk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, 0 hrs/wk</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note: Hours Xrcise coding is "backward" i.e. &nbsp;0 is most exercise, &nbsp;3 is no exercise</p>
<p>Col &nbsp;8 &nbsp;&nbsp;CigYrs 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, # yrs cigarette smoking &nbsp;= &nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col &nbsp;9 &nbsp;&nbsp;CigYrs 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, # yrs cigarette smoking &gt;= 15 &nbsp;and &nbsp;&lt; 35<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 10 &nbsp;&nbsp;CigYrs 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, # yrs cigarette smoking &gt;= 35<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 11 &nbsp;&nbsp;Veg &lt;5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, less &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than &nbsp;&nbsp;&nbsp;&nbsp;five servings of vegetables per day<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, greater &nbsp;&nbsp;equal to five servings of vegetables per day</p>
<p>Col 12 &nbsp;&nbsp;#Cigs Trend &nbsp;&nbsp;=0, # cigarettes smokes &nbsp;&nbsp;= &nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, # cigarettes smokes &nbsp;&gt;= &nbsp;1 &nbsp;and &nbsp;&lt; &nbsp;11<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, # cigarettes smokes &nbsp;&gt;= 11 &nbsp;and &nbsp;&lt;= 20<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=3, # cigarettes smokes &nbsp;&gt;= 21</p>
<p>Col 13 &nbsp;&nbsp;BMI Trend &nbsp;&nbsp;&nbsp;&nbsp;=0, BMI &lt;= 24.9<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, BMI &nbsp;&gt; 24.9 &nbsp;and &nbsp;BMI &lt;= 29.9<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, BMI &nbsp;&gt; 29.9</p>
<p>Col 14 &nbsp;&nbsp;Posi 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1. no sigmoidoscopy and/or colonscopy last 10 years<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 15 &nbsp;&nbsp;Posi 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, yes sigmoidoscopy and/or colonscopy last 10 years, yes history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 16 &nbsp;&nbsp;Posi 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, unk sigmoidoscopy and/or colonscopy last 10 years, unk history of polyps<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=0, otherwise</p>
<p>Col 17 &nbsp;&nbsp;No NSaids &nbsp;&nbsp;&nbsp;&nbsp;=0, regular user of asprin/NSaids<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, &nbsp;&nbsp;&nbsp;&nbsp;non user of asprin/NSaids</p>
<p>Col 18 &nbsp;&nbsp;#Rel Trend &nbsp;&nbsp;&nbsp;=0, 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative &nbsp;with CRC &nbsp;(CRC=Colorectal Cancer)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=1, 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative &nbsp;with CRC<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=2, 2 or more relatives with CRC</p>
<p>Col 19 &nbsp;&nbsp;Age1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;current age,<br />Col 20 &nbsp;&nbsp;Age2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection age, &nbsp;ranges from: &nbsp;50 &lt;= Age1 &lt; Age2 &lt;=90</p>
<p>&nbsp;&nbsp;!!!!!!!!!!!! &nbsp;Warning Warning Warning Warning Warning Warning &nbsp;!!!!!!!!!!!!<br />&nbsp;&nbsp;!!!!!!!!!!!! &nbsp;&nbsp;Warning about an inadmissible error condition &nbsp;&nbsp;!!!!!!!!!!!!</p>
<p>&nbsp;&nbsp;Inadmissable condition of &nbsp;NoIBupro=0 &nbsp;&nbsp;and &nbsp;NoNSAIDS=1<br />&nbsp;&nbsp;i.e. &nbsp;individual uses IBuprofin &nbsp;but does not use NSaids.<br />&nbsp;&nbsp;This is contradictory since IBuprofin is a NSaid drug<br />&nbsp;&nbsp;projected absolute risk for records with this contradition will be missing</p>
<p>&nbsp;&nbsp;!!!!!!!!!!!! &nbsp;&nbsp;Warning about an inadmissible error condition &nbsp;&nbsp;!!!!!!!!!!!!<br />&nbsp;&nbsp;!!!!!!!!!!!! &nbsp;Warning Warning Warning Warning Warning Warning &nbsp;!!!!!!!!!!!!</p>
<p>Alogrithm used for calculating Risk Covariate Pattern ID for each input covariate pattern:</p>
<p>Pattrn_ID &nbsp;= &nbsp;4*2*3*4*2*2*4*3*1* Hours Exercis (0,1,2,3) &nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2*3*4*2*2*4*3*1* CigYr &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2,3) &nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3*4*2*2*4*3*1* VEGlt5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4*2*2*4*3*1* BMItrnd &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2) &nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2*2*4*3*1* sigmod &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2,3) &nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2*4*3*1* NoNSaids &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4*3*1* NoIBuprofen &nbsp;&nbsp;(0,1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3*1* #CigTrnd &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2,3) &nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1* NRel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0,1,2) &nbsp;&nbsp;&nbsp;&nbsp;+<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1* 1</p>
<p>Pattrn_ID ranges in values from 1:18432</p>
<p>Pattrn_ID used for input Risk Covariate Pattern edit checking as well as<br />for 95% CI calculations. &nbsp;The numbers separated by commas in the parenthesis<br />is the number of levels and valid values for the levels for the associated<br />risk covariate. &nbsp;Note that &nbsp;"sigmod" &nbsp;is the trend variable created from<br />Posi 0, Posi 1, Posi 2 and Posi 3:</p>
<p>&nbsp;&nbsp;sigmod = 0 &nbsp;&nbsp;&nbsp;if Posi 0=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;if Posi 1=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;if Posi 2=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;if Posi 3=1</p>
<p>Similarly for CigYr:</p>
<p>&nbsp;&nbsp;CigYr = 0 &nbsp;&nbsp;&nbsp;&nbsp;if CigYrs 0=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;if CigYrs 0=0 &nbsp;and &nbsp;CigYrs 2=0 &nbsp;and &nbsp;CigYrs 3=0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;if CigYrs 2=1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;&nbsp;if CigYrs 3=1</p>
<p>Before exeucting the risk projection program, it should prove beneficial to<br />take a brief examination of the input file &nbsp;"Men_CRC_Risk_Input.dat"<br />included with this package.</p>
<p>(4) Executing Men's colorectal cancer (CRC) risk program &nbsp;"Men_CRC_Risk_Tool.gcg":</p>
<p>Method 1: &nbsp;Associate any file which ends with &nbsp;".gcg" &nbsp;with the gauss run time module.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once this has been performed, you can just click on &nbsp;"Men_CRC_Risk_Tool.gcg"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or any file ending with &nbsp;".gcg" for that matter, and the gauss run time<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;moduele will execute the file and the absolute risk program will start to<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;execute.</p>
<p>Method 2: &nbsp;Click on the gauss run time module icon which has been placed on your desktop<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the installer. &nbsp;The gauss run time module window will open. &nbsp;On top of the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;window, will be a white rectangular box, with the name of the folder which the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gauss run time module is pointing. &nbsp;If it is pointing at the folder which<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contains &nbsp;"Men_CRC_Risk_Tool.gcg" then you don't have to navigate anywhere. &nbsp;If<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it is not pointing at the folder which contains &nbsp;"Men_CRC_Risk_Tools.gcg", then<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;either use the browse buttom &nbsp;(the little gray rectangle with three dots on it)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to navigate to the correct folder, or just type in the name of the folder in the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;white rectangle. &nbsp;In this discussion, you would type &nbsp;"c:\CRC_AbsRisk". &nbsp;Once<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this is done, at the "&gt;&gt;" symbol, type &nbsp;"run &nbsp;Men_CRC_Risk_Tool.gcg" and the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;absolute risk program will start to execute.</p>
<p>Once the absolute risk program &nbsp;"Men_CRC_Risk_Tool.gcg" &nbsp;completes execution, it will output<br />two files. &nbsp;&nbsp;One is the output file:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Men_CRC_Risk_Tool.out" &nbsp;which contains absolute risk associated quantities.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the other is the edit error file :</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Men_CRC_Risk_Tool.err" &nbsp;which indicates input records with editing errors.</p>
<p>It would be beneficial to look at both files. &nbsp;If the error file only contains a table heading,<br />this means that no editing errors was discovered by the program. &nbsp;Please note that this does<br />not guarantee that unanticipated errors have not occured in the input file. &nbsp;Integrity of the<br />input data is still &nbsp;the user's responsibility.</p>
<p>The included error file lists errors for seven records.</p>
<p>&nbsp;&nbsp;1st error: Incorrect value &nbsp;5 for race. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Race takes on the values 1,2,3 and 4<br />&nbsp;&nbsp;2nd error: Incorrect value 49 for Age1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1 must be ge 50.<br />&nbsp;&nbsp;3rd error: Incorrect value 60 for Age1 and Age2. Age2 must be gt Age1.<br />&nbsp;&nbsp;4th error: Incorrect value 91 for Age2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age2 must be le 90.<br />&nbsp;&nbsp;5th error: Incorrect value &nbsp;9 for #Rel012. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#Rel012 takes only values of 0,1,2.<br />&nbsp;&nbsp;6th error: Incorrect value &nbsp;9 for Hours Xrcise &nbsp;&nbsp;Hours Xrcise takes only values of 0,1,2,3.<br />&nbsp;&nbsp;7th error: Incorrect value &nbsp;0 for noIBup &nbsp;and &nbsp;1 for noNSAD. &nbsp;This scenairo is inadmissable.</p>
<p>The above seven errors are but a sub-set of all possible errors and are not meant to be exhaustive<br />of all possible errors.</p>
<p>Note that if the Pattrn_ID obtained for an input covariateis pattern from the above formula, is<br />not within the range of 1:18432, the inputted covariate pattern is inadmissable and flagged.</p>
<p>Even when the Pattrn_ID is within this range, different covariate patterns may give rise to the<br />same Pattrn_ID. &nbsp;So if an input covariate pattern is flagged, the "correct" covariate pattern<br />associated with the Pattrn_ID is given below the "incorrect" input covariate pattern and a<br />covariate by covariate comparison might help in pinpointing the error.</p>
<p>Looking at the output file &nbsp;"Men_CRC_Risk_Tool.out", &nbsp;first note all the constants utilized by<br />this tool are listed. &nbsp;Next you will see all the inputed risk covariate information for each<br />person, as well the the projected absolute risk and 95% confidence interval. &nbsp;Note that for<br />covariate patterns which have editing errors (the first 7 records in this case), all the<br />absolute risk related output quantities are set to a missing value of &nbsp;".". &nbsp;Compare the output<br />which you obtained with the file &nbsp;"Men_CRC_Risk_Tool.list". &nbsp;There should be complete agreement,<br />with the exception of the date when the program was executed.</p>
</div>]]></content>
  </row>
  <row para_id="330697" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>In preparation for large-scale epidemiologic studies, investigators have conducted a number of studies to assess methods for measurement of estrogens and estrogen metabolites. They have conducted formal proofs-of-performance to describe <a href="http://www.ncbi.nlm.nih.gov/pubmed/19064556">reliability of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for measurement of 15 estrogens and estrogen metabolites in urine</a>, and another to characterize the assay for use in measuring serum EM in unconjugated and total (conjugated + unconjugated) forms. Additional studies have documented the <a href="http://www.ncbi.nlm.nih.gov/pubmed/%2021161939">stability of urinary EM under varying conditions of processing and storage</a>, and the <a href="http://www.ncbi.nlm.nih.gov/pubmed/20056650">comparability of LC-MS/MS measures of urinary EM to previously employed immunoassays</a>.</p>
<p>Following the success of the estrogen metabolite assays, investigators&nbsp;conducted formal proofs-of-performance to describe the reproducibility of LC-MS/MS methods for measurement of <a href="http://www.ncbi.nlm.nih.gov/pubmed/26416142">11 androgens and androgen metabolites in serum</a>, as well as <a href="http://www.ncbi.nlm.nih.gov/pubmed/26353176">progesterone, pregnenolone, and progesterone metabolites in serum</a>. Efforts are currently underway to validate assays in heparin and ethylenediaminetetraacetic acid (EDTA) plasma, and to estimate measures of temporal stability.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=802306" sys_dependentvariantid="1965" sys_dependentid="802306" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274609" sys_variantid="1965" sys_contentid="802306">Britton Trabert</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274610" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="334796" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Dr. Joseph F. Fraumeni, Jr., director of NCI's Division of Cancer Epidemiology and Genetics, delivered the Third Annual Alan S. Rabson Award Lecture for Intramural Research, "Genes and the Environment in Cancer Causation," during the 2007 Intramural Scientific Retreat in Bethesda, MD. The Rabson Award was created in recognition of Dr. Rabson's dedication and enthusiasm for NCI and its intramural program during his 50-year tenure at NCI.</p>
<p><a href="http://videocast.nih.gov/launch.asp?17671">Access the recorded videocast</a>.</p>
</div>]]></content>
  </row>
  <row para_id="335952" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7274615" sys_dependentid="1072158" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="1833" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<figure class="video right size50">	<h4>Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"</h4>
	<div id="ytplayer-Q_yycIT2ZjM" class="flex-video widescreen" data-video-id="Q_yycIT2ZjM" data-video-title="Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"">		<noscript>			<p>				<a href="https://www.youtube.com/watch?v=Q_yycIT2ZjM" target="_blank" title="Highlights from "Telomere Biology and Cancer Risk with Sharon Savage"">					View this video on YouTube.				</a>			</p>		</noscript>							</div>			<figcaption class="caption-container">
<div class="contentid-1071885 slot-item only-SI">
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_folderid=401214&amp;sys_siteid=475&amp;sys_contentid=349621&amp;sys_command=editrc" title="" sys_variantid="1965" sys_contentid="349621">Sharon Savage, M.D.</a>, and investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_folderid=301997&amp;sys_siteid=475&amp;sys_contentid=302430&amp;sys_command=editrc" title="" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a> study families with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=335952&amp;sys_command=editrc" title="" sys_variantid="1418" sys_contentid="335952">dyskeratosis congenita (DC)</a>, a rare and complex inherited cancer predisposition syndrome. Patients with DC have extremely short telomeres and elevated risk for multiple cancers. As they study the effect of shortened telomeres on this unique population, the research team searches for genetic variations associated with abnormal telomeres and telomere biology.&nbsp;</p>
<p><a href="https://irp.nih.gov/our-research/research-in-action/decoding-telomere-biology-and-cancer-risk">Read the full article on telomere biology and cancer risk</a>.</p>
</div>
</figcaption>	</figure></div>
<p>Dyskeratosis Congenita (DC) is a cancer-prone <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=303691&amp;sys_command=editrc" sys_contentid="303691" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="303691" sys_variantid="1418" sys_relationshipid="7274611">inherited bone marrow failure syndrome</a> (IBMFS) caused by aberrant telomere biology. DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=302430&amp;sys_command=editrc" sys_contentid="302430" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302430" sys_variantid="1422" sys_relationshipid="7274612">Clinical Genetics Branch</a> (CGB) showed that telomere length, as measured by flow cytometry-FISH was both sensitive and specific for distinguishing DC from healthy individuals and from those with other IBMFS.</p>
<p>Work at CGB has led to the discovery of three of the known causes of DC, <i>TINF2</i>, <i>WRAP53</i>, and <i>RTEL1</i>. &nbsp;DC can be inherited in X-linked (<i>DKC1</i>), autosomal dominant (<i>TERT</i>, <i>TERC</i>, <i>TINF2</i>, <i>RTEL1</i>), and autosomal recessive (<i>TERT</i>, <i>NHP2</i>, <i>NOP10</i>, <i>CTC1</i>, <i>WRAP53</i>, and <i>RTEL1</i>) patterns, or can arise due to a <i>de novo</i> germline mutation. However, approximately 40% of patients with DC do not yet have an identified causative mutation. Consequently, discovery of new high-penetrance susceptibility genes as well as low-penetrance genetic modifiers of the major genes, is a major focus of this project.</p>
<p>This study also focuses on comprehensive, systematic clinical phenotyping of DC patients, aimed at refining our understanding of the features of this rare disorder. Investigators have identified novel ophthalmologic and dental abnormalities as part of the DC spectrum of abnormalities. These studies will provide more specific data on genotype-phenotype interactions and aid in diagnosis of DC.</p>

<p>In addition, DCEG investigators recently performed a quantitative analysis of the reported literature on DC-related malignancy, and published the first quantitative estimates of the risks of acute leukemia, squamous cell cancers of the skin, head/neck and anogenital region in this disorder. The cumulative cancer risk in DC patients is nearly as high as those seen in patients with Fanconi anemia.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Savage%2C%20Sharon%20A[Full%20Author%20Name]%20AND%20%22dyskeratosis%20congenita%22[Text%20Word]&amp;amp;cmd=DetailsSearch">Dyskeratosis Congenita Study - Research Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=349621&amp;sys_command=editrc" sys_contentid="349621" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349621" sys_variantid="1965" sys_relationshipid="7274613">Sharon Savage</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_authtype=0&amp;sys_activeitemid=&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_siteid=475&amp;sys_contentid=433261&amp;sys_command=editrc" sys_contentid="433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_variantid="1418" sys_relationshipid="7274614">Clinical Genetics Branch - Research Areas</a></p></div>]]></content>
  </row>
  <row para_id="349590" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/bb" title="">BB Home</a></h3>
<p><a href="/about/organization/programs-ebp/bb/research-areas" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=BB">BB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/bb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/bb-training" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/bb/resources" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=BB">Publications</a></p>
<p><a href="/news-events/events/bb-events" title="">Seminars</a></p>
</div>
<p>Investigators in the Biostatistics Branch (BB) apply advanced statistical methods and data resources for many types of studies, described below.</p>
<p><em><a id="Top"></a>On this page:</em><br /><a href="#Descriptive">Descriptive Epidemiology Studies</a><br /><a href="#Analytic">Analytic Studies</a><br /><a href="#Collaboration">Collaboration Across Major DCEG Studies</a><br /><a href="#Translational">Translational Research</a><br /><a href="#Methodological">Methodological Research</a></p>
<h3><a id="Descriptive"></a>Descriptive Epidemiology Studies</h3>
<p>Descriptive epidemiology studies characterize cancer incidence and mortality temporal trends, age-specific rates, geographic distribution of cancer, race and ethnic differences in cancer rates, and birth cohort effects. BB investigators utilize novel analytic tools to obtain etiologic clues from descriptive studies, for example:</p>
<ul>
<li>Identification of novel data sources through national and international collaboration
<ul style="padding-bottom: 0;">
<li>ACS, IARC, Danish breast cancer group</li>
</ul>
</li>
<li>Integration of novel analytic tools to obtain etiologic clues from descriptive studies
<ul style="padding-bottom: 0;">
<li>Modeling age-period-cohort effects and etiologic heterogeneity</li>
</ul>
</li>
<li>Performing record linkage studies, using SEER and other population-based databases
<ul style="padding-bottom: 0;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_dependentvariantid="1418" sys_dependentid="303678" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251686" sys_variantid="1418" sys_contentid="303678">SEER-AIDS</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_dependentvariantid="1418" sys_dependentid="303740" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251687" sys_variantid="1418" sys_contentid="303740">SEER-Transplant</a> studies, NHANES-NDI</li>
</ul>
</li>
</ul>
<h3><a id="Analytic"></a>Analytical Studies</h3>
<p>Increased participation in domestic and international consortia has yielded large-scale datasets and biospecimens, supporting various types of analytic studies:</p>
<ul>
<li>Cohort, case-control, and cross-sectional designs</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_dependentvariantid="1418" sys_dependentid="303742" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251702" sys_variantid="1418" sys_contentid="303742">Incorporating chemical mixtures for characterizing chemical exposure in cancer risk prediction</a></li>
<li>Genome-wide association studies and next-generation sequencing
<ul style="padding-bottom: 0;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303719" sys_dependentvariantid="1418" sys_dependentid="303719" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251688" sys_variantid="1418" sys_contentid="303719">Development and use of novel statistical and bioinformatic tools to perform value-added analysis of existing GWAS datasets</a></li>
</ul>
</li>
<li>Assessment of emerging technologies and defining methods for integrating them into etiologic studies
<ul>
<li>NGS, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303730" sys_dependentvariantid="1418" sys_dependentid="303730" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251689" sys_variantid="1418" sys_contentid="303730">microbiome</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303721" sys_dependentvariantid="1418" sys_dependentid="303721" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251690" sys_variantid="1418" sys_contentid="303721">metabolomics</a> etc.</li>
</ul>
</li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Collaboration"></a>Collaboration Across Major DCEG Studies</h3>
<p>BB investigators collaborate in major studies across DCEG, providing statistical and analytical leadership. &nbsp;Selected studies include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_dependentvariantid="1418" sys_dependentid="303742" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251691" sys_variantid="1418" sys_contentid="303742">Agricultural Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_dependentvariantid="1418" sys_dependentid="303750" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251692" sys_variantid="1418" sys_contentid="303750">Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_dependentvariantid="1418" sys_dependentid="303748" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251693" sys_variantid="1418" sys_contentid="303748">AARP Cohort</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_dependentvariantid="1418" sys_dependentid="302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251694" sys_variantid="1418" sys_contentid="302552">U.S. Radiologic Technologists Cohort</a></li>
<li>Human Papillomavirus (HPV) Natural History Study</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1102867" sys_dependentvariantid="1418" sys_dependentid="1102867" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251695" sys_variantid="1418" sys_contentid="1102867">HPV and Vaccine Dose Studies</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303612" sys_dependentvariantid="1418" sys_dependentid="303612" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251696" sys_variantid="1418" sys_contentid="303612">Non-Hodgkin lymphoma Case-Control Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_dependentvariantid="1418" sys_dependentid="438648" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251697" sys_variantid="1418" sys_contentid="438648">New England Bladder Cancer Case-Control Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303661" sys_dependentvariantid="1418" sys_dependentid="303661" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251698" sys_variantid="1418" sys_contentid="303661">Testicular Cancer Case-control Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303691" sys_dependentvariantid="1418" sys_dependentid="303691" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251699" sys_variantid="1418" sys_contentid="303691">Fanconi Anemia (an inherited bone marrow failure syndrome)</a></li>
</ul>
<h3><a id="Translational"></a>Translational Research</h3>
<p>BB investigators strive to apply what is learned from research discoveries and findings to practical applications in support of public health. &nbsp;Examples of these efforts include:</p>
<ul>
<li>Development and validation of models for minority populations</li>
<li>Refinement of screening guidelines based on HPV testing</li>
<li>Evaluation of potential utility of genetic and other biomarkers</li>
<li>Development and validation of cancer risk models
<ul style="padding-bottom: 0;">
<li><a href="https://bcrisktool.cancer.gov/">Breast cancer<span class="show-for-sr"> risk tool</span></a>, <a href="https://www.cancer.gov/melanomarisktool/">Melanoma<span class="show-for-sr"> risk tool</span></a>, <a href="https://www.cancer.gov/colorectalcancerrisk/">Colorectal cancer <span class="show-for-sr">risk tool</span></a><br /> Thyroid cancer, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491089" sys_dependentvariantid="1418" sys_dependentid="491089" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251700" sys_variantid="1418" sys_contentid="491089">Cervical cancer <span class="show-for-sr">risk prediction</span></a></li>
</ul>
</li>
<li>Evaluation of specific public health applications
<ul>
<li>Risk-benefit calculations for the use of Tamoxifen</li>
</ul>
</li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Methodological"></a>Methodological Research</h3>
<p>BB maintains active methodological research programs in a wide range of topics that directly relate to analytic problems encountered in DCEG and at NCI, more generally. Investigators publish their methodological research in leading statistical, biostatistics, and bioinformatics as well as epidemiology, genetics, and clinical journals. Examples of research topics include:</p>
<ul>
<li>New approaches for cancer risk prediction that are used for counseling and screening recommendations</li>
<li>Sampling-based designs and analysis approaches for generalizing the results of a cohort study to a representative population</li>
<li>Development of new methods for assessing complex environmental exposure (possibly, longitudinally) on cancer incidence</li>
<li>Novel approaches for the analysis of microbiome, metabolomic, and genomic biomarkers</li>
<li>New methods for characterizing identifying both germline and somatic mutational patterns in the genome</li>
<li>Modeling natural history of cancer progression through precursors and stages of cancer using stochastic modeling</li>
<li>Novel approaches for <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=856668" sys_dependentvariantid="1418" sys_dependentid="856668" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251701" sys_variantid="1418" sys_contentid="856668">cancer surveillance using age-period-cohort</a> and other methodology</li>
<li>Statistical methods that account for errors in linkage when analyzing cohort data in which the outcomes are obtained through linkage to a large registry</li>
<li>Novel design strategies for pooling or combining samples for disease screening or prevalence estimations</li>
</ul>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="350301" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Since 1992, DCEG and other NCI investigators, along with collaborators from five field study centers, have been actively following diethylstilbestrol (DES) exposed and unexposed mothers, daughters and sons, and granddaughters for adverse health effects resulting from this exposure. As DES-exposed offspring are currently reaching the age when cancer rates begin to rise, it is important to continue to monitor long-term risk of cancer and other adverse health outcomes in this unique population.</p>
<div sys_relationshipid="7274621" sys_dependentid="592581" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="1841" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<figure class="video center size75">	<h4>The DES Story: Lessons Learned</h4>
	<div id="ytplayer-pEn9PkwUKM0" class="flex-video widescreen" data-video-id="pEn9PkwUKM0" data-video-title="The DES Story: Lessons Learned">		<noscript>			<p>				<a href="https://www.youtube.com/watch?v=pEn9PkwUKM0" target="_blank" title="The DES Story: Lessons Learned">					View this video on YouTube.				</a>			</p>		</noscript>							</div>			<figcaption class="caption-container">Dr. Robert Hoover discusses a followup study of diethylstilbestrol (DES), a drug once prescribed to pregnant women. (Video produced and edited by Natalie Giannosa)</figcaption>	</figure></div>
<p>The study also provides a model for assessing a number of hypotheses that address concerns about prenatal hormonal influences on disease risk, both an intriguing area of science and an increasingly controversial environmental issue that affects a substantial proportion of the population.</p>
<p>To date the study has identified excess female breast cancer after age 40 that shows a dose-response effect, as well as increased risk for high-grade lesions of the cervix and vagina. Concern over other hormone-related cancers remains; though to date analyses have been limited due to small numbers of cases. In the sons, investigators observed an excess risk for urogenital anomalies and infertility, and a likely excess of testicular cancer. To examine the effects in the third generation (the daughters of the prenatally exposed daughters), investigators assembled a small cohort in 2000. Given their average age, there have been few relevant disease outcomes. However, investigators noted an elevated risk for infertility&mdash;though not statistically significant, this outcome was also seen in DES-daughters. In addition, there were three cases of ovarian cancer in the granddaughters, even though substantially less than one had been expected. While both of these observations remain difficult to interpret, they have added some urgency to expand the cohort and continue to follow-up.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349664" sys_contentid="349664" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349664" sys_relationshipid="7274617" sys_variantid="1965">Dr. Robert N. Hoover</a>.</p>
</div>]]></content>
  </row>
  <row para_id="352825" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<p>In cancer research, absolute risk is defined as the likelihood that a person who is free of a specific type of cancer at a given age will develop that cancer over a certain period of time. DCEG investigators have developed models (such as the Gail model) for projecting the individualized absolute risk of certain types of cancer. These models have been used to counsel individual patients on their disease risk; to make more formal management recommendations, such as whether or not to take tamoxifen to prevent breast cancer; to design cancer prevention trials; and to assess the potential reductions in population absolute risk from preventive activities.&nbsp;</p>
<h3>NCI Risk Assessment Tools</h3>
<p>DCEG investigators and their colleagues have employed absolute risk modeling to develop tools that clinicians and their patients can use to calculate risk of developing the following cancers:</p>
<ul>
<li><a href="https://bcrisktool.cancer.gov/">Breast cancer</a></li>
<li><a href="https://ccrisktool.cancer.gov/">Colorectal cancer</a></li>
<li><a href="https://mrisktool.cancer.gov/">Melanoma</a> &nbsp;&nbsp;&nbsp;</li>
</ul>
<p>The breast cancer risk assessment tool has been monitored to check its calibration over time and has been enhanced to improve projections for African-American and Asian-American women.&nbsp;Studies to improve projections for Hispanic women are ongoing.&nbsp;Computer programs for projections for these models are available in the Tools and Resources section of this web site under <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302611" sys_contentid="302611" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7274624" sys_dependentvariantid="1418" sys_dependentid="302611" rxinlineslot="103">Risk Assessment Macros and Software Programs</a>. &nbsp;&nbsp;&nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349622" sys_contentid="349622" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7274622" sys_dependentvariantid="1965" sys_dependentid="349622" rxinlineslot="103">Mitchell Gail</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349627" sys_contentid="349627" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7274623" sys_dependentvariantid="1965" sys_dependentid="349627" rxinlineslot="103">Ruth Pfeiffer</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=349590" sys_contentid="349590" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7274625" sys_dependentvariantid="1418" sys_dependentid="349590" rxinlineslot="103">Biostatistics Branch &nbsp;- Research Areas</a></p>
</div>
</div>]]></content>
  </row>
  <row para_id="395633" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Radiation Risk Assessment Tool is an online calculator for estimating the lifetime risk of cancer incidence for members of the U.S. population (or countries with similar cancer incidence rates) from exposure to ionizing radiation for doses below 1 Gy.</p>
<p>The calculator works using organ-specific dose estimates according to age at exposure and sex. Lifetime total cancer risk and organ-specific risk estimates are reported along with a 90% uncertainty range.</p>
<p>The reported lifetime risks are based on the risk models for the eleven cancers included in the 2006 report of the National Academies of Sciences' BEIR VII Committee and on the risk models for an additional eight cancers, developed by the NCI after the publication of the BEIR VII report.</p>
<p>Access the <a href="https://radiationcalculators.cancer.gov/radrat/">Radiation Risk Assessment Tool (RadRAT) Online Calculator.</a></p>
<h3>Reference</h3>
<p>Berrington de Gonz&aacute;lez A, Apostoaei J, Veiga L, Rajaraman P, Thomas BA, Hoffman FO, Gilbert E, Land C. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22810503">RadRAT: A radiation risk assessment tool for lifetime cancer risk projection</a>. <i>J Radiol Prot</i> 32 (2012) 1&ndash;18.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7194028" sys_dependentvariantid="1965" sys_dependentid="349642" rxinlineslot="103" sys_siteid="475">Amy Berrington de Gonz&aacute;lez</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=54&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7194027" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="401127" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=115&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312476" sys_variantid="1422" sys_contentid="302459">About REB</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=60&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312477" sys_variantid="1418" sys_contentid="401127">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=REB">REB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=261&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302501" sys_dependentvariantid="1418" sys_dependentid="302501" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312478" sys_variantid="1418" sys_contentid="302501">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/reb-training" title="">Research Training Opportunities</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302415" sys_dependentvariantid="1418" sys_dependentid="302415" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312479" sys_variantid="1418" sys_contentid="302415">Tenure-Track Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302426" sys_dependentvariantid="1418" sys_dependentid="302426" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312480" sys_variantid="1418" sys_contentid="302426">Staff Spotlight</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302443" sys_dependentvariantid="1418" sys_dependentid="302443" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312481" sys_variantid="1418" sys_contentid="302443">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=REB">Publications</a></p>
</div>
<p>DCEG investigators in the Radiation Epidemiology Branch (REB) conduct research that informs radiation protection, addresses public health and clinical needs, and develops innovative dosimetry methods and tools to help further these research goals.</p>
<a id="top"></a>
<p><em>On this page</em>:</p>
<p><a href="#Medical">Medical Radiation Exposures</a><br /><a href="#Environmental">Environmental Radiation Exposures</a><br /><a href="#Occupational-Radiation">Occupational Radiation Exposures</a><br /> <a href="#Dosimetry-Research">Dosimetry for Radiation Studies</a></p>
<h3><a id="Medical"></a>Medical Radiation Exposures</h3>
<p>Exposure to medical radiation has increased dramatically among the U.S. population. DCEG researchers are assessing cancer risks associated with these exposures, especially newer, higher dose diagnostic tests and treatments, radiation treatment for benign diseases, and late effects of radiotherapy, chemotherapy and other cancer treatment. Selected studies include:</p>
<p><a href="https://dceg.cancer.gov/research/what-we-study/pediatric-ct-scans">Pediatric CT Scans and Cancer</a><br />A retrospective cohort study to evaluate the relationship between radiation exposure from CT scans conducted during childhood and adolescence and the subsequent development of cancer</p>
<p><a href="https://dceg.cancer.gov/research/what-we-study/second-cancers">Second Primary Cancers</a><br />DCEG investigators are actively engaged in research to address risks associated with treatment-related second cancers, lifestyle, environmental, and medical history factors, and genetic susceptibility</p>
<p>Learn more about our studies on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302457" sys_contentid="302457" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302457" sys_variantid="1418" sys_relationshipid="7312464">medical radiation exposures</a>.</p>
<h3><a id="Environmental"></a>Environmental Radiation Exposures</h3>
<p>REB scientists are studying cancer risks among populations exposed to radiation from environmental sources, such as nuclear reactor accidents and fallout from weapons testing. In addition, they are studying cancer risks from background radiation and ultraviolet radiation. Select studies include:</p>
<h4>Background Radiation and Ultraviolet Radiation</h4>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=810219" sys_contentid="810219" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="810219" sys_variantid="1418" sys_relationshipid="7312468">Childhood Leukemia and Background Radiation</a><br />A record linkage study designed to investigate the association of childhood leukemia with natural background radiation exposure.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=826431" sys_contentid="826431" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="826431" sys_variantid="1418" sys_relationshipid="7312469">Ultraviolet Radiation Exposure and Cancer Risks</a><br />Ultraviolet radiation (UVR) is the primary risk factor for skin cancer. Investigators are using the U.S. Radiologic Technologists Cohort to further understand the risks of UVR exposure.</p>
<h4>Nuclear Reactor Accidents and Fallout from Weapons and Weapons Testing</h4>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302434" sys_contentid="302434" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302434" sys_variantid="1418" sys_relationshipid="7312467">Atomic Bomb Survivors</a><br />Studies of atomic bomb survivors in Hiroshima and Nagasaki, including updates to cancer incidence, radiation dose risk assessment, and molecular genetics studies.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1030353" sys_variantid="1418" sys_relationshipid="7312473">Chernobyl Nuclear Accident</a><br />DCEG researchers have been conducting epidemiologic, molecular genomic, and dosimetric research on health effects to populations exposed to radiation by the 1986 Chernobyl accident in Ukraine.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Occupational-Radiation"></a>Occupational Radiation Exposures</h3>
<p>DCEG researchers are studying cancer risks among populations (called cohorts) who have been occupationally exposed to radiation for varying periods of time. These populations include:</p>
<p><a href="https://dceg.cancer.gov/research/what-we-study/chernobyl-research#Leukemia-Chernobyl">Chernobyl Clean-up Workers</a><br />Studies of leukemia and other hematological diseases in a large cohort of clean-up workers exposed to radiation after the Chernobyl accident. Learn more about our research on the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1030353" sys_variantid="1418" sys_relationshipid="7312472">Chernobyl nuclear accident</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302603" sys_contentid="302603" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302603" sys_variantid="1418" sys_relationshipid="7312465">Interventional Fluoroscopists</a><br />A large cohort of radiologists and other physicians assembled to determine the contribution of occupational exposure to ionizing radiation to cancer mortality.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302552" sys_variantid="1418" sys_relationshipid="7312466">U.S. Radiologic Technologists</a><br />A prospective cohort study of 146,022 radiologic technologists designed to evaluate risks of cancer and other health effects associated with protracted exposure to low-to-moderate radiation doses.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Dosimetry-Research"></a>Dosimetry for Radiation Studies</h3>
<p>DCEG scientists combine <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068" sys_contentid="1091068" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1091068" sys_variantid="1418" sys_relationshipid="7312470">advanced radiation dosimetry research</a> with high-quality exposure assessments to support epidemiological studies. REB dosimetrists develop cutting-edge methods to estimate individualized organ-specific doses. They also evaluate and quantify the sources of uncertainty in their dose estimates, which can then be taken into account in risk analyses. Recent examples of dosimetry with uncertainty estimates include:</p>
<ul>
<li><span><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090901" sys_dependentvariantid="1418" sys_dependentid="1090901" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312474" sys_variantid="1418" sys_contentid="1090901">Estimating Radiation Dose to Patients Undergoing Radiography/Fluoroscopy Exams</a></span></li>
<li><span><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1089023" sys_dependentvariantid="1418" sys_dependentid="1089023" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312475" sys_variantid="1418" sys_contentid="1089023">Normal Tissue Dose for External Radiation Therapy Patients</a></span></li>
</ul>
<p>Learn more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068" sys_contentid="1091068" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1091068" sys_variantid="1418" sys_relationshipid="7312471">Radiation Dosimetry Research</a>.</p>
<h4><a href="#top">Back to top</a></h4>
</div>]]></content>
  </row>
  <row para_id="410191" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3><a id="Background"></a>I. Background</h3>
<p>As part of the Division of Cancer Epidemiology and Genetics&rsquo; mission to discover the causes of cancer and the means of its prevention, DCEG is committed to sharing research data to further advance science, improve public health, and leverage the investment made by the U.S. taxpayers in the Division&rsquo;s research program.</p>
<p>Data sharing must be conducted in a manner consistent with federal, state, and local laws and policies concerning privacy, confidentiality, protection from discrimination, the honoring of informed consent, as well as other restrictions related to institutional review board (IRB) approvals. For some studies, there may be data that cannot be shared because of conditions placed upon DCEG by the individuals or organizations who supplied the data to DCEG for the original research.</p>
<h3><a id="General-Considerations"></a>II. General Considerations</h3>
<h4><a id="Privacy-Confidentiality"></a>A. Protecting Privacy and Confidentiality</h4>
<p>DCEG has the highest commitment to protecting the identity of study participants against undesired intrusions (privacy) and to limiting access to study information that might individually identify them (confidentiality). All direct identifiers are omitted from data sets; however, because study data often include extremely detailed personal information (<em>e.g.</em>, age, gender, race, residence, employment histories, medical histories), it may be possible in rare cases through complex analysis and with outside information, to identify specific subjects.&nbsp;Therefore, DCEG will redact data as necessary to protect study subject privacy, particularly for data requested under the Freedom of Information Act (FOIA) mechanism (<a href="#Freedom-of-Information-Act">see Section III.D</a>). Less data redaction may be necessary under Data Transfer Agreements (DTA) that contain provisions assuring that the researchers will not try to learn the identity of subjects or link the shared data with individually identifiable records from other sources (<a href="#Data-Transfer-Agreement">see Section III.C</a>).</p>
<h4><a id="Timing-Data-Sharing"></a>B. Timing of Data Sharing</h4>
<p>While DCEG is committed to data sharing, we believe the optimal time to provide data is after the cleaning and quality control processes have been completed and there is a final analytic data set.&nbsp;The reasons for this are related to NIH policy and data quality.&nbsp;Prior to this time-point, study data sets cannot be considered &ldquo;final.&rdquo; Throughout data collection and analysis, various actions are undertaken to detect out-of-range, illogical, and inconsistent data, to check original sources, and to correct data as needed.&nbsp;Because this process can continue up to the time a paper is accepted for publication, sharing data prior to that time is not advisable.</p>
<h4><a id="Assistance-Investigators"></a>C.&nbsp;Assistance from DCEG Investigators</h4>
<p>In response to outside requests, DCEG will provide the necessary documentation (<em>e.g.</em>, questionnaires, coding manual, data dictionaries) to understand and analyze study data. Further assistance from DCEG investigators, however, may not be possible due to time constraints and the competing demands of their positions.&nbsp;Researchers requesting data through mechanisms other than a mutually&ndash;agreed upon scientific collaboration with a DCEG investigator should not expect assistance beyond the provision of standard study documentation.</p>
<h4><a id="Cost"></a>D.&nbsp;Cost</h4>
<p>Due to fiscal constraints, DCEG reserves the right to require payments to cover the cost of producing data sets and accompanying documentation.</p>
<h3><a id="Methods-Access-Data"></a>III. Methods to Access Data</h3>
<p>There are various methods to access data, depending on whether there are established study-specific application and review procedures, whether the requestor prefers to collaborate with DCEG investigators or to work independently, and whether special precautions are needed to protect the privacy of study subjects or the confidentiality of study data. Depending on the data elements of interest, there may be special considerations affecting requests from investigators outside the U.S.</p>
<h4><a id="Study-Specific"></a>A. Study-specific Application and Review Procedures</h4>
<p><em>Epidemiologic data</em>: Several of DCEG&rsquo;s large prospective cohort studies have established procedures whereby researchers can request data, and some have publicly available data posted on their study websites. Some have regularly scheduled calls for proposals, while others accept proposals or more general requests for data on an ongoing basis.&nbsp;Typically, researchers must submit proposals detailing their research plans.&nbsp;Information on the following studies can be found at these websites:</p>
<p style="padding-left: 30px;"><a href="http://aghealth.nci.nih.gov">Agricultural Health Study</a><br /><a href="http://atbcstudy.cancer.gov">Alpha-Tocopherol, Beta-Carotene Study</a>&nbsp; <br /><a href="http://dietandhealth.cancer.gov">NIH-AARP Diet and Health Study</a>&nbsp; <br /><a href="https://biometry.nci.nih.gov/cdas/plco/">PLCO Study</a><br /><a href="http://radtechstudy.nci.nih.gov">Radiologic Technologists Study</a></p>
<p>Other DCEG studies have published findings in journals that require access to data that underlie the results described in their manuscripts. Most DCEG studies involve human subjects, and the protection of study participants and their private information is required by law. The DCEG Data Repository Committee accepts requests for these published data sets, and reviews the data sets prior to release to ensure that confidentiality of individuals participating in DCEG studies is maintained.</p>
<p><em>Genomic Data</em>:&nbsp;In accordance with the <a href="http://www.cancer.gov/grants-training/grants-management/nci-policies/genomic-data">NIH Genomic Data Sharing (GDS) Policy</a>, qualified genomic data generated by DCEG will generally be made available through an NIH-designated repository such as the National Center for Biotechnology Information&rsquo;s <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap">Database of Genotypes and Phenotypes (dbGaP)</a> and/or the <a href="http://www.ncbi.nlm.nih.gov/sra">Sequence Read Archive (SRA)</a>, and the NCI&rsquo;s <a href="https://gdc.nci.nih.gov/">Genomic Data Commons (GDC)</a>.&nbsp;Researchers may obtain controlled-access data only with the permission of the NCI Data Access Committee (DAC), which operates according to the policies established by the NIH.&nbsp;For controlled-access data, the requestor must stipulate in a Data Use Certification that they will comply with federal, state, and local policy; will only use the data for the specified research use; will not identify study participants; will not transfer the data; and other provisions.&nbsp;An institute official must vouch that the requestor is a bona fide researcher, and must also stipulate to the provisions related to privacy and use of the data.&nbsp;Additionally, an IT Director at the requesting institution must be identified to vouch that the data are being stored and maintained in a secure fashion.&nbsp;The federal Genetic Information Nondiscrimination Act, which makes it illegal for health insurance companies, group health plans, and most employers to discriminate based on genetic information, is also relevant to these requests.&nbsp;&nbsp;</p>
<p><a href="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?login=&amp;page=login">Obtain information on submitting a Data Access Request for data stored in dbGap</a>.</p>
<h4><a id="Collaboration-Investigators"></a>B. Collaboration with DCEG Investigators</h4>
<p>Many researchers interested in accessing data from DCEG studies prefer to do so by establishing a scientific collaboration with DCEG investigators.&nbsp;Through these formal collaborations, the DCEG team members can share their expertise and knowledge of the intricacies of the study data, which greatly enhances the research endeavor.&nbsp;A collaborative agreement is developed which details the data to be shared, the roles and responsibilities of the parties involved, and consistency of the proposed research with the study informed consent and IRB approvals.</p>
<p>Researchers should <a href="http://dceg.cancer.gov/about/directory">contact the appropriate DCEG investigator directly</a> to determine if a mutually agreeable scientific collaboration can be established.</p>
<h4><a id="Data-Transfer-Agreement"></a>C. Data Transfer Agreement</h4>
<p>DCEG data for collaborative and non-collaborative research will be released under the terms of a Data Transfer Agreement, which must be signed by the DCEG Director, the recipient scientist, and an official representing the recipient scientist&rsquo;s institution. The agreement will specify the proposed research plan, identify who will have access to the data, and contain provisions related to protecting privacy. These provisions will require that: 1) the requesting researcher will neither attempt to link nor permit others to link the data set with individually-identifiable records from any other data set, and 2) the researcher will not attempt to use the data set or permit others to use it to learn the identify of any person.&nbsp;In addition, the relevant NIH IRB must provide an assurance that the proposed research and data transfer are consistent with informed consent.&nbsp;If the agreement is for non-collaborative research, DCEG investigators will not be able to assist the requestor beyond provision of standard study documentation.</p>
<p>Researchers should <a href="http://dceg.cancer.gov/about/directory">contact the appropriate DCEG investigator directly</a> to request data and develop a Data Transfer Agreement.</p>
<h4><a id="Freedom-of-Information-Act"></a>D.&nbsp;Freedom of Information Act Request (FOIA)</h4>
<p>FOIA requires federal agencies to provide access to agency records except to the extent that such records are protected from public disclosure by one of nine exemptions or three law enforcement exclusions. The exemptions that most often apply to DCEG records are those that prohibit disclosure of records that are: 1) specifically exempted by another federal law (e.g., the Privacy Act of 1974) (Exemption 3); 2) privileged inter-agency or intra-agency communications that are pre-decisional and part of an agency&rsquo;s deliberative process (Exemption 5); and 3) personnel, medical, or similar files, release of which would constitute a clearly unwarranted invasion of personal privacy (Exemption 6). Requestors should note that because there are no restrictions placed on use or further dissemination of records obtained through a FOIA request, DCEG takes special care to protect subjects from invasion of privacy that might result from linking the data set to individually identifiable records from any other data set.&nbsp;FOIA allows the agency to recover part of the cost of responding to a request.&nbsp;DCEG investigators will not be able to assist the requestor to use or interpret the data beyond provision of standard study documentation. Details on FOIA are available at the <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act Office</a>.&nbsp;</p>
<p>FOIA requests for DCEG records should be submitted to the National Cancer Institute FOIA Coordinator, Building 31, Room 10A48, 9000 Rockville Pike, Bethesda, MD 20892.</p>
</div>]]></content>
  </row>
  <row para_id="411185" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>ReadMe.fil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12/14/12</p>
<p>Documentation and user guide for SAS macro to project for absolute risk based on<br />the relative risk models for (whites, hispanic, other), asian-american, or<br />african-american. 1-AR, composite breast cancer incidences, competing hazards<br />handling of missing covariate values and covariate editing procedures follow<br />NCI BrCa Risk Assessment Tool (NCI BCRAT).</p>
<p>In this release of the SAS macro, in addition to the abs risk projection for the<br />women with under investigation, for each women, an associated race specific<br />abs risk projection for an "average" women is also provided. &nbsp;This quantity is<br />included to follow the NCI Breast Cancer Risk Assessment Tool which provides an<br />"avg" women risk projection as well.</p>
<p>Life time risk for a women can be obtained by setting her "projection age" to 90.</p>
<p>A simple 3 step example program &nbsp;(BCRAM_example.sas) &nbsp;on the use of the SAS macro<br />(Br)east (Ca)ncer (R)isk (A)ssessment (M)acro &nbsp;-- &nbsp;BrCa_RAM.</p>
<p>Step 1: &nbsp;the included sas program &nbsp;BCRAM_example.sas &nbsp;reads the supplied data file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Sample.in", which contains the Gail BrCa risk covarites and projection<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age interval for 26 hypothetical women. &nbsp;It then saves a temporary SAS<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;system file with name of "ExampleIn" to be used as input to the SAS macro<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BrCa_RAM:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;data &nbsp;&nbsp;&nbsp;ExampleIn; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** name of the sas system file which the macro parameter<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp;In_File &nbsp;should point to upon macro invocation;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;infile 'Sample.in' &nbsp;&nbsp;&nbsp;firstobs=9; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** "Sample.in" &nbsp;is the RR covariate input file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;firstobs=9 &nbsp;skips first 8 header<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;records on input file &nbsp;"Sample.in";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** SAS variable names;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;input &nbsp;&nbsp;IDD</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;InitalAge<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ProjtnAge</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HP</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeMenarchy<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeFstLive<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ethnicity;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;run;</p>
<p>Step 2: &nbsp;sas program &nbsp;BCRAM_example.sas &nbsp;runs the SAS macro &nbsp;BrCa_RAM:</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%include &nbsp;"BrCa_RAM"; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** include the sas MACRO BrCa_RAM;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Involking the sas macro BrCa_RAM to perform the BrCa projections.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The temporary sas input &nbsp;file is set to &nbsp;&nbsp;"ExampleIn".<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The temporary sas output file is set to &nbsp;&nbsp;"ExampleOut".</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The macro parameters &nbsp;WID, T1, T2, N_Biop, HyperPlasia, AgeMen,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1st, N_Rels, and Race point to their corresponding sas variables<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;on the sas file &nbsp;"ExampleIn", &nbsp;namely<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IDD, InitalAge, ProjtnAge, NBiop, HP, AgeMenarchy, AgeFstLive,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels and Ethnicity respectively.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The macro parameter AbsRsk points to the sas variable Abs_Risk which<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will be added to the output sas file &nbsp;"ExampleOut". &nbsp;The output sas<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file will also contain all the variables on the input sas file.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macro &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pointing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAS file name or<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;parameter &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAS variable name;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%BrCa_RAM &nbsp;&nbsp;&nbsp;(In_File &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ExampleIn &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Out_File &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ExampleOut &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WID &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IDD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;InitalAge &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ProjtnAge &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Biop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HyperPlasia &nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeMen &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeMenarchy &nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1st &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeFstLive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ethnicity &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CharRace &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CharRace &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absolute_Risk);</p>
<p>Step 3 &nbsp;&nbsp;&nbsp;It thens list the contents of the temporary output sas system file<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"ExampleOut" which contains the projected absolute risk as well as the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relative risk covariate values. &nbsp;Note that any further processing<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requiring the projected absolute risk, must be performed on the output<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sas system file &nbsp;"ExampleOut" &nbsp;named in this sample program;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;data &nbsp;ExampleOut; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** output file from macro, defined by pointing the;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;set &nbsp;&nbsp;ExampleOut; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** macro parameter &nbsp;&amp;Out_File &nbsp;to &nbsp;"ExampleOut";</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file print;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if (_N_ eq 1) then do;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;Hypr &nbsp;&nbsp;&nbsp;HP &nbsp;Age &nbsp;Age &nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;" &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR &nbsp;&nbsp;&nbsp;&nbsp;Abs";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " &nbsp;&nbsp;&nbsp;&nbsp;ID &nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;T2 &nbsp;Biop &nbsp;plas &nbsp;&nbsp;&nbsp;RR &nbsp;Men &nbsp;1st &nbsp;Rel &nbsp;&nbsp;Race"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;" &nbsp;Age&lt;50 &nbsp;Age&gt;50 &nbsp;&nbsp;&nbsp;Risk(%)";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put " ";<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;end;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** all variables below take on their SAS variable names, not their macro names;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** see SAS variable names defined in Step 1;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if (_n_ le 100) then</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;put IDD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;InitalAge &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ProjtnAge &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NBiop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R_Hyp &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeMenarchy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeFstLive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.0</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;" &nbsp;"<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ethnicity &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"="<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CharRace &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$char2.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absolute_Risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;run;</p>
<p>Detailed description of the operation and output items from the SAS macro BrCa_RAM:</p>
<p>Input data:<br />----------<br />In_File= should "point" to a SAS data set containing all the required input data<br />items needed &nbsp;to perform risk projections, such as initial age, projection age, BrCa<br />relative risk covariates and race. &nbsp;See the paragraph "Input data items ... " below,<br />for a detailed description of all required data items.</p>
<p>Output data:<br />-----------<br />Out_File= should "point" to a SAS output data set which will contain the projected<br />absolute risk of BrCa as well as the original input data items.</p>
<p>Macro structure:<br />---------------<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macro &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macro<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;name &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;parameters &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"points" to SAS names</p>
<p>%macro &nbsp;BrCa_RAM &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(In_File &nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;name of input &nbsp;sas data set</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Out_File &nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;name of output sas data set</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WID &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ID # &nbsp;&nbsp;1,2,3 ... &nbsp;postive integers</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;initial age, &nbsp;&nbsp;&nbsp;age at beginning of<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection interval</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection age, age at end of<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projection interval</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Biop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# biopsies performed<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HyperPlasia =, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;did biopsy exhibit atypical hyperplasia?</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AgeMen &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age at menarchy<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age1st &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age at 1st live birth<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# 1st degree relatives with brca</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;race<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CharRace &nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 character abbreviation for race</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star1 &nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rr for ages lt 50<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR_Star2 &nbsp;&nbsp;&nbsp;=, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rr for ages ge 50</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbsRsk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=); &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;projected absolute risk of brca (%)</p>
<p>appropriate sas file/sas variable names must be associated with all macro parameters<br />on the invocation of the sas macro &nbsp;"BrCa_RAM".</p>
<p>For example by coding &nbsp;"In_File = AARPin" &nbsp;tells the macro that the user created<br />sas file &nbsp;"AARPin" &nbsp;is to be used for input of variables. &nbsp;Similarly coding<br />"N_Biop = Num_Biops", &nbsp;lets the macro know that the sas variable "Num_Biops" in the<br />sas input file &nbsp;"AARPin" &nbsp;contiains the count of the # of biopsies performed.</p>
<p>To involke the sas macro in your sas program, an %include statement must be coded in<br />your sas program, which points to the sas macro &nbsp;"BrCa_RAM".</p>
<p>For example:</p>
<p>the statement: %include "BrCa_RAM"; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;points to the sas macro &nbsp;BrCa_RAM<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stored in your current directory</p>
<p>the statement: %include "c:\sas.macro\BrCa_RAM"; &nbsp;&nbsp;points to the sas macro &nbsp;BrCa_RAM<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stored in the directory<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c:\sas.macro</p>
<p>Input data items needed to project for BrCa absolute risk and consistency requirements:</p>
<p>Macro<br />parameter &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definition &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Valid values</p>
<p>WID &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ID # for each woman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;postive integers 1,2,3....</p>
<p>T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;age &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all real numbers T1 in [20,90)<br />T2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BrCa projection age &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all real numbers T2 such that T2 &gt; T1</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONSTRAINT on T1 and T2: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 &lt;= T1 &lt; T2 &lt;= 90</p>
<p>N_Biop &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# of biopsies &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0,1,2 ... &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99=unk (99 recoded to 0)</p>
<p>HyperPlasia &nbsp;&nbsp;&nbsp;Did biopsy display &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0=no, &nbsp;1=yes, &nbsp;&nbsp;99=unk or no biopsy<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;atypical hyperplasia?</p>
<p>AgeMen &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age at menarchy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;positive integer age less than or equal to T1, 99=unk</p>
<p>Age1st &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age at first live birth &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;integer age greater or equal to age at menarchy<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and less than or equal to initial age.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;98=nulliparous (no live birth),<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99=unk</p>
<p>N_Rels &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# 1st degree relatives &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0,1,2 ... &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99=unk<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with BrCa</p>
<p>Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1=Wh &nbsp;&nbsp;white 1983-87 SEER rates (rates used by NCI BrCa Risk Assessment Tool)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2=AA &nbsp;&nbsp;african-american,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3=Hi &nbsp;&nbsp;hispanic,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4=NA &nbsp;&nbsp;other &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(native americans and unknown race)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5=Wo &nbsp;&nbsp;white 1995-03 SEER rates (rates used for further research)</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6=Ch &nbsp;&nbsp;chinese<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7=Ja &nbsp;&nbsp;japanese<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8=Fi &nbsp;&nbsp;filipino<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9=Hw &nbsp;&nbsp;hawaiian<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10=oP &nbsp;&nbsp;other pacific islander<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11=oA &nbsp;&nbsp;other asian</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;note that hispanic and other ethnic women<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;risks are based on white women log relative<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;risks. &nbsp;hispanic women risk are also based on<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;hispanic seer rates while other women<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;risk are based on white women seer rates.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTE: even though it is allowed, from good data processing practice<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it is recommended NOT to mix the two different rates for<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;white women during the same analysis. &nbsp;if a comparison<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the change in absolute risk is desired from using the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;two different rates, two analysis runs should be performed,<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;once when one rate is used (i.e. Race=1, 1983-87 seer rates) and<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;once when the other rate is used (i.e. Race=5, 1995-2003 seer rates).<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The rates used by tne NCI Breast Cancer Risk Assessment Tool is the<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11983-1987 seer rates.</p>
<p>Recoding and checking of relative risk covariate values performed by &nbsp;"BrCa_RAM":</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;raw value &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recoded to</p>
<p>N_Biop: # biopsies &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 or 99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,3,4 ... and not 99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p>
<p>AgeMen: age at menarchy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14,15,16 ... 99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12,13 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 and younger &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p>
<p>Age1st: age at 1st live birth &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 and younger &nbsp;or &nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20,21,22,23,24 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25,26,27,28,29 &nbsp;or &nbsp;98=(nulliparous) &nbsp;&nbsp;&nbsp;&nbsp;2<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30,31,32 ... &nbsp;&nbsp;&nbsp;and not 98 and not 99 &nbsp;&nbsp;&nbsp;3</p>
<p>N_Rels: # 1st degree rel with BrCa &nbsp;&nbsp;0 or 99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,3,4 ... and not 99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p>
<p>Consistency patterns for &nbsp;# of Biopsies and Hyperplasia:</p>
<p>Requirment: (A) N_Biops = 0 &nbsp;or &nbsp;&nbsp;99 &nbsp;then &nbsp;Hyperplasia &nbsp;MUST = 99 (not applicable)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) N_Biops &gt; 0 and &lt; 99 &nbsp;then &nbsp;Hyperplasia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;0, 1 or 99 (unk)</p>
<p>if ANY of the above 2 REQUIREMENTS are violated, the absolute risk will be set to the<br />sas missing value ".". &nbsp;The consequences to the relative risk (RR) for the above two<br />requirements is:</p>
<p>(A) # biopsies = 0 or &nbsp;&nbsp;99 &nbsp;&amp; &nbsp;Hyperplasia &nbsp;=99 (not applicable) inflates &nbsp;RR &nbsp;by &nbsp;1.00</p>
<p>(B) # biopsies &gt; 0 and &lt;99 &nbsp;&amp; &nbsp;Hyperplasia &nbsp;= 0 ( no hyprplasia) inflates &nbsp;RR &nbsp;by &nbsp;0.93<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;= 1 (yes hyprplasia) inflates &nbsp;RR &nbsp;by &nbsp;1.82<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=99 (unk hyprplasia) inflates &nbsp;RR &nbsp;by &nbsp;1.00</p>
<p>Edit checking for remaining relative risk covariates, AgeMen, Age1st and N_Rels:</p>
<p>AgeMen: &nbsp;age at menarchy must be postive integer less than equal to initial age T1</p>
<p>&nbsp;&nbsp;NOTE &nbsp;For African-American women &nbsp;AgeMen &lt;= 11 are grouped with AgeMen = 12 or 13</p>
<p>Age1st: &nbsp;age at 1st live birth must be postive integer greater than equal to AgeMen and<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;less than or equal to Initial age T1</p>
<p>&nbsp;&nbsp;NOTE &nbsp;For African-American women Age1st is not included in the RR model and all values<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for this variable are recoded to 0</p>
<p>N_Rels: &nbsp;# of 1st degree relatives with BrCa must be 0,1,2...</p>
<p>Following is a listing of the sample raw input data set "Sample.in"<br />(column heading included for clarity):</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Num &nbsp;&nbsp;&nbsp;Hyp &nbsp;&nbsp;&nbsp;Age &nbsp;&nbsp;&nbsp;Age &nbsp;&nbsp;&nbsp;Num<br />&nbsp;IDD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T2 &nbsp;&nbsp;&nbsp;Biop &nbsp;&nbsp;Plas &nbsp;&nbsp;&nbsp;Men &nbsp;&nbsp;&nbsp;1st &nbsp;&nbsp;&nbsp;Rel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Race</p>
<p>&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2<br />&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3<br />&nbsp;&nbsp;&nbsp;5 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4<br />&nbsp;&nbsp;&nbsp;6 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5<br />&nbsp;&nbsp;&nbsp;7 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6<br />&nbsp;&nbsp;&nbsp;8 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7<br />&nbsp;&nbsp;&nbsp;9 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8<br />&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9<br />&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10<br />&nbsp;&nbsp;12 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11<br />&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12<br />&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;15 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;16 &nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;&nbsp;&nbsp;&nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2<br />&nbsp;&nbsp;17 &nbsp;&nbsp;&nbsp;&nbsp;35.0 &nbsp;&nbsp;&nbsp;&nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3<br />&nbsp;&nbsp;18 &nbsp;&nbsp;&nbsp;&nbsp;35.0 &nbsp;&nbsp;&nbsp;&nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;&nbsp;98 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4<br />&nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;&nbsp;35.0 &nbsp;&nbsp;&nbsp;&nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5<br />&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;35.0 &nbsp;&nbsp;&nbsp;&nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;36 &nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6<br />&nbsp;&nbsp;21 &nbsp;&nbsp;&nbsp;&nbsp;27.0 &nbsp;&nbsp;&nbsp;&nbsp;90.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7<br />&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;27.0 &nbsp;&nbsp;&nbsp;&nbsp;90.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8<br />&nbsp;&nbsp;23 &nbsp;&nbsp;&nbsp;&nbsp;18.0 &nbsp;&nbsp;&nbsp;&nbsp;26.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9<br />&nbsp;&nbsp;24 &nbsp;&nbsp;&nbsp;&nbsp;27.0 &nbsp;&nbsp;&nbsp;&nbsp;26.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10<br />&nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;&nbsp;85.0 &nbsp;&nbsp;&nbsp;&nbsp;91.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11<br />&nbsp;&nbsp;26 &nbsp;&nbsp;&nbsp;&nbsp;86.0 &nbsp;&nbsp;&nbsp;&nbsp;90.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12</p>
<p>After the absolute risks have been generated, descriptive statistics by applying PROC<br />MEANS to the quantities Error_Ind, AbsRsk, RR_Star1 and RR_Star2 is performed. &nbsp;When the<br />mean and standard deviation for the variable &nbsp;"Error_Ind" &nbsp;is 0, implies that no errors<br />have not been found. &nbsp;Otherwise when the mean and std for &nbsp;"Error_Ind" is not 0, implies<br />that errors have been found. &nbsp;When errors are found, the # of records with errors is<br />the count asscociated with "AbsRsk" listed under NMiss (# of missing). &nbsp;Furthermore, a<br />listing file for erroronious records follows the PROC Means output. &nbsp;For example:</p>
<p>BrCa_RAM, &nbsp;sas macro to project for BrCa absolute risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;September 15, 2010<br />Quick check for errornous records on input file</p>
<p>IF MEAN OF &nbsp;'Error_Ind' &nbsp;&nbsp;EQUALS &nbsp;0, &nbsp;&nbsp;ERROR &nbsp;FREE. &nbsp;&nbsp;&nbsp;ERROR LISTING BELOW WILL BE EMPTY.<br />IF MEAN OF &nbsp;'Error_Ind' &nbsp;&nbsp;IS NOT &nbsp;0, &nbsp;&nbsp;ERRORS EXISTS. &nbsp;CHECK ERROR LISTING BELOW.</p>
<p>(# of records with errors is the # listed under the NMiss column in the 'AbsRsk' line)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N<br />Variable &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Label &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mean &nbsp;&nbsp;Std Dev &nbsp;&nbsp;N &nbsp;Miss<br />-----------------------------------------------------------------------------------------<br />Error_Ind &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If mean not 0, implies ERROR in file &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.57692 &nbsp;&nbsp;0.50383 &nbsp;26 &nbsp;&nbsp;&nbsp;&nbsp;0<br />Absolute_Risk &nbsp;&nbsp;&nbsp;Abs risk(%) of BrCa in age interval [T1,T2) &nbsp;3.76766 &nbsp;&nbsp;2.57844 &nbsp;11 &nbsp;&nbsp;&nbsp;15<br />RR_Star1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relative risk age lt 50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.43948 &nbsp;&nbsp;1.92321 &nbsp;13 &nbsp;&nbsp;&nbsp;13<br />RR_Star2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relative risk age ge 50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.86656 &nbsp;&nbsp;1.54840 &nbsp;13 &nbsp;&nbsp;&nbsp;13<br />-----------------------------------------------------------------------------------------</p>
<p>Since NMiss=15 for Absolute Risk, we note that the error listing lists 15 records below:</p>
<p>Error listing for the input file</p>
<p>&nbsp;ID &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;Hypr &nbsp;Hypr &nbsp;Age &nbsp;Age &nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pat<br />&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;T2 &nbsp;Biop &nbsp;plas &nbsp;&nbsp;&nbsp;RR &nbsp;Men &nbsp;1st &nbsp;Rel &nbsp;&nbsp;Race &nbsp;Age&lt;50 &nbsp;Age&gt;50 &nbsp;&nbsp;AbsRsk(%) &nbsp;&nbsp;&nbsp;#</p>
<p>&nbsp;&nbsp;1 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;??</p>
<p>&nbsp;&nbsp;2 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;Wh</p>
<p>&nbsp;&nbsp;3 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;AA</p>
<p>&nbsp;&nbsp;9 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;Fi</p>
<p>&nbsp;11 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;oP</p>
<p>&nbsp;12 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;oA</p>
<p>&nbsp;13 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;12 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;??</p>
<p>&nbsp;14 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;??</p>
<p>&nbsp;15 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;A &nbsp;&nbsp;A &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;Wh</p>
<p>&nbsp;19 &nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;11 &nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;Wo</p>
<p>&nbsp;20 &nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;36 &nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;Ch</p>
<p>&nbsp;23 &nbsp;18.0 &nbsp;26.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;26.0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;Hw</p>
<p>&nbsp;24 &nbsp;27.0 &nbsp;26.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;1.42 &nbsp;&nbsp;&nbsp;1.42 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;oP</p>
<p>&nbsp;25 &nbsp;85.0 &nbsp;91.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;&nbsp;&nbsp;1.42 &nbsp;&nbsp;&nbsp;1.42 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;85.0 &nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;oA</p>
<p>&nbsp;26 &nbsp;86.0 &nbsp;90.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;12 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86.0 &nbsp;90.0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;??</p>
<p>For each of the records with error, the record is listed followed by a line which gives<br />some indication as to where the error occured. &nbsp;For example, the record with ID=2 has<br />an "A" listed under the 3 variables associated with Biopy i.e. N_Biop, Hyperplasia<br />and Hypr_RR. &nbsp;This means that ID=2 has violated consistency defined by Requirement<br />(A). Similarly for IDs 3,9,11,12,14 and 15 which display violations of<br />Requirements (A). &nbsp;For IDs 19 and 20, violation of AgeMen and/or Age1st consistency<br />are seen. &nbsp;Note the SAS missing value "." listed under AgeMen and/or Age1st.<br />For IDs 23, 24 and 25 violation of T1 and/or T2 consistency requirements are seen.<br />Again, note the "." listed under T1 and/or T2. &nbsp;This small sample data set "Sample.in"<br />in no way exhausts all the possible ways in which the data can be in error, but it should<br />give a guide and indication on how to check and correct errors when they do occur.</p>
<p>Finally, &nbsp;the listing from Step3:</p>
<p>Listing of the first 100 records in temporary output sas system file &nbsp;ExampleOut<br />Further analysis depending on the projected abs risk must be performed using the<br />output sas system file which is invoked by the sas macro parameter &nbsp;'Out_File'</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# &nbsp;Hypr &nbsp;&nbsp;&nbsp;HP &nbsp;Age &nbsp;Age &nbsp;&nbsp;&nbsp;# &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RR &nbsp;&nbsp;AbsRisk &nbsp;&nbsp;AbsRisk<br />&nbsp;&nbsp;&nbsp;&nbsp;ID &nbsp;&nbsp;&nbsp;T1 &nbsp;&nbsp;&nbsp;T2 &nbsp;Biop &nbsp;plas &nbsp;&nbsp;&nbsp;RR &nbsp;Men &nbsp;1st &nbsp;Rel &nbsp;&nbsp;Race &nbsp;&nbsp;&nbsp;Age&lt;50 &nbsp;&nbsp;Age&gt;=50 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(%) &nbsp;AvgWm(%)</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;0=?? &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;1=Wh &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;2=AA &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;3=Hi &nbsp;&nbsp;&nbsp;3.2354 &nbsp;&nbsp;&nbsp;3.2354 &nbsp;&nbsp;&nbsp;2.1081 &nbsp;&nbsp;&nbsp;1.1313<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;4=NA &nbsp;&nbsp;&nbsp;5.4926 &nbsp;&nbsp;&nbsp;4.1180 &nbsp;&nbsp;&nbsp;4.4413 &nbsp;&nbsp;&nbsp;1.7673<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;14 &nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;5=Wo &nbsp;&nbsp;&nbsp;4.4263 &nbsp;&nbsp;&nbsp;3.3185 &nbsp;&nbsp;&nbsp;3.9762 &nbsp;&nbsp;&nbsp;1.7673<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;99 &nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;6=Ch &nbsp;&nbsp;&nbsp;2.2075 &nbsp;&nbsp;&nbsp;2.2075 &nbsp;&nbsp;&nbsp;1.2496 &nbsp;&nbsp;&nbsp;1.1644<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;1.82 &nbsp;&nbsp;14 &nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;7=Ja &nbsp;&nbsp;&nbsp;6.9820 &nbsp;&nbsp;&nbsp;6.9820 &nbsp;&nbsp;&nbsp;5.7757 &nbsp;&nbsp;&nbsp;1.7279<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;8=Fi &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;0.93 &nbsp;&nbsp;14 &nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;9=Hw &nbsp;&nbsp;&nbsp;3.5677 &nbsp;&nbsp;&nbsp;3.5677 &nbsp;&nbsp;&nbsp;3.9061 &nbsp;&nbsp;&nbsp;2.2614<br />&nbsp;&nbsp;&nbsp;&nbsp;11 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;1 &nbsp;10=oP &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;12 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;19 &nbsp;&nbsp;&nbsp;1 &nbsp;11=oA &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;12=?? &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;0=?? &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;15 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;1=Wh &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;16 &nbsp;45.2 &nbsp;53.3 &nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;0.93 &nbsp;&nbsp;10 &nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;2=AA &nbsp;&nbsp;&nbsp;2.3458 &nbsp;&nbsp;&nbsp;2.0974 &nbsp;&nbsp;&nbsp;2.6899 &nbsp;&nbsp;&nbsp;1.6479<br />&nbsp;&nbsp;&nbsp;&nbsp;17 &nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;11 &nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;3=Hi &nbsp;&nbsp;&nbsp;5.3860 &nbsp;&nbsp;&nbsp;3.0274 &nbsp;&nbsp;&nbsp;0.6789 &nbsp;&nbsp;&nbsp;0.2183<br />&nbsp;&nbsp;&nbsp;&nbsp;18 &nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;11 &nbsp;&nbsp;98 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;4=NA &nbsp;&nbsp;&nbsp;5.3860 &nbsp;&nbsp;&nbsp;3.0274 &nbsp;&nbsp;&nbsp;1.0230 &nbsp;&nbsp;&nbsp;0.2814<br />&nbsp;&nbsp;&nbsp;&nbsp;19 &nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;11 &nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;5=Wo &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;35.0 &nbsp;40.0 &nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;36 &nbsp;&nbsp;25 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;6=Ch &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;21 &nbsp;27.0 &nbsp;90.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;7=Ja &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;8.8277 &nbsp;&nbsp;12.2076<br />&nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;27.0 &nbsp;90.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;&nbsp;8=Fi &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;6.7678 &nbsp;&nbsp;&nbsp;9.4245<br />&nbsp;&nbsp;&nbsp;&nbsp;23 &nbsp;18.0 &nbsp;26.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;&nbsp;9=Hw &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;24 &nbsp;27.0 &nbsp;26.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;10=oP &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;25 &nbsp;85.0 &nbsp;91.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;11=oA &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;1.4210 &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.<br />&nbsp;&nbsp;&nbsp;&nbsp;26 &nbsp;86.0 &nbsp;90.0 &nbsp;&nbsp;&nbsp;99 &nbsp;&nbsp;&nbsp;99 &nbsp;1.00 &nbsp;&nbsp;13 &nbsp;&nbsp;22 &nbsp;&nbsp;99 &nbsp;12=?? &nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p>Statistical issues &nbsp;should be directed to: &nbsp;&nbsp;Dr. Mitchell Gail &nbsp;&nbsp;&nbsp;gailm@exchange.nih.gov<br />Technical &nbsp;&nbsp;details should be directed to: &nbsp;&nbsp;Mr. David Pee &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;peed@imsweb.com</p>
</div>]]></content>
  </row>
  <row para_id="417416" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>DCEG researchers conduct studies on breast cancer, a cancer that usually forms in the breast ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). Breast cancer occurs in both men and women, although male breast cancer is rare. Selected studies include:</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303756" sys_dependentvariantid="1418" sys_dependentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297218" sys_variantid="1418" sys_contentid="303756">Bone Density and Cancer Risk: A Follow-Up Study of Women in the Fracture Intervention Trial (BFIT)</a></h2>
<p>A retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303562" sys_dependentvariantid="1418" sys_dependentid="303562" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297219" sys_variantid="1418" sys_contentid="303562">Breast Cancer Detection Demonstration Project Follow-up Study</a></h2>
<p>A follow-up study of women who were participants in the Breast Cancer Detection Demonstration Project</p>
</div>]]></content>
  </row>
  <row para_id="417518" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Testicular cancer is the most commonly occurring cancer among young men (ages 15&ndash;40 years) in many countries, including the United States. The great majority of testicular cancers are testicular germ cell tumors (TGCTs), which can be further subdivided into seminomas, nonseminomas and spermatocytic tumors. Seminomas and nonseminomas are associated with other male reproductive disorders and are thought to be initiated <em>in utero</em>. MEB investigators conduct research on a variety of factors in relationship to testicular cancer including:</p>
<ul>
<li>Hormonal hypotheses</li>
<li>Endocrine disrupting chemicals</li>
<li>Racial/ethnic disparity in risk</li>
<li>Genetic susceptibility</li>
</ul>
<p>Resources focused specifically on testicular cancer include:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303661" sys_dependentvariantid="1418" sys_dependentid="303661" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248619" sys_variantid="1418" sys_contentid="303661">Testicular Cancer Among Military Servicemen: The STEED Study</a><br /> A case-control study of testicular cancer among military servicemen</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=843812" sys_dependentvariantid="1418" sys_dependentid="843812" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248620" sys_variantid="1418" sys_contentid="843812">Testicular Cancer Consortium (TECAC)</a><br /> A consortium of international studies to examine genetic susceptibility to testicular cancer</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" sys_dependentvariantid="1965" sys_dependentid="349637" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248621" sys_variantid="1965" sys_contentid="349637">Katherine McGlynn</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248622" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="417525" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Overview</h3>
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-ebp/meb">MEB Home</a></h3>
<p><a title="" href="/about/organization/programs-ebp/meb/research">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows">Meet Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific">Research Training Opportunities</a></p>
<p><a title="" href="/about/organization/programs-ebp/meb/tools">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Estrogens play important roles in the pathophysiology of breast tumors and are recognized causal factors in the etiology of breast cancer; this central insight has led to many of the available preventive and therapeutic interventions for breast cancer. Endogenous estrogens may also play causal roles in endometrial and ovarian cancers and could also be important in male reproductive cancers, such as male breast cancer, testicular cancer, and prostate cancer. Substantial inter-individual variability has been observed in levels of circulating and excreted estrogens and estrogen metabolites (jointly referred to as EM) among men, postmenopausal women, and premenopausal women. Because EM vary with respect to bioavailability, affinity to estrogen receptors, and mutagenic potential, investigators have hypothesized that variations in estrogen profiles may account for inter-individual differences in cancer risks. Until recently, it has been difficult to study this hypothesis in epidemiologic settings. Development of a liquid chromatography-tandem mass spectrometry (LC/MS-MS) method for measurement of estrogens and estrogen metabolites in urine (Xu et al., <i>Anal Chem</i> 2006;78:1553) and serum (Xu et al., <i>Anal Chem</i> 2007;79:7813) represents an important methodologic development because it provides an assay with characteristics that make it feasible for use in epidemiologic studies: high sensitivity, specificity, reliability, and scalability for high-throughput work.</p>
<p>Expanding on our research evaluating endogenous estrogens and estrogen metabolites and cancer risk, recent methodologic advances in the measurement of androgens and androgen metabolites as well as progesterone, pregnenolone, and progesterone metabolites in serum will facilitate epidemiologic studies to evaluate the role of principal estrogens, androgens and progesterone, together with their major metabolites, in cancer etiology.</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303756" sys_dependentvariantid="1418" sys_dependentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297201" sys_variantid="1418" sys_contentid="303756">Bone Density and Cancer Risk: A Follow-Up Study of Women in the Fracture Intervention Trial (BFIT)</a></h2>
<p>A retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=330697" sys_dependentvariantid="1418" sys_dependentid="330697" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297202" sys_variantid="1418" sys_contentid="330697">Reproducibility and Validity of Hormone Assays</a></h2>
<p>Studies to assess methods for measurement of estrogens/estrogen metabolites, androgens/androgen metabolites, pregnenolone, and progesterone/progesterone metabolites</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303634" sys_dependentvariantid="1418" sys_dependentid="303634" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297203" sys_variantid="1418" sys_contentid="303634">Serum Sex Steroids and Their Metabolites in Relation to Ovarian and Endometrial Cancer</a></h2>
<p>A nested case-control study of endometrial and ovarian cancers assessing the roles of estrogens, estrogen metabolites, androgens, and androgen metabolites in the etiologies of these cancers</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303661" sys_dependentvariantid="1418" sys_dependentid="303661" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297204" sys_variantid="1418" sys_contentid="303661">Testicular Cancer among Military Servicemen: the STEED Study</a></h2>
<p>A case-control study of testicular cancer among military servicemen</p>
</div>]]></content>
  </row>
  <row para_id="417527" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Evaluating lifestyle factors (called exposures) and cancer risk sometimes requires identifying population subgroups (called cohorts) that have the exposure to be studied. MEB researchers investigate the relationship between less common, or unique, exposures and cancer risk in the following cohort studies:</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303757&amp;sys_revision=15&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303757" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297215">Follow-up Studies of Women Evaluated and Treated for Infertility</a></h2>
<p>Retrospective cohort studies of women treated for infertility with ovulation-stimulating drugs to evaluate risk of breast and gynecologic cancers</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303756" sys_dependentvariantid="1418" sys_dependentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297216" sys_variantid="1418" sys_contentid="303756">Bone Density and Cancer Risk: A Follow-Up Study of Women in the Fracture Intervention Trial (BFIT)</a></h2>
<p>A retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk</p>
</div>]]></content>
  </row>
  <row para_id="418935" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/oeeb" title="">OEEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/oeeb/oeeb-research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=OEEB">OEEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/oeeb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/training-oeeb" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/oeeb/tools" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=OEEB">Publications</a></p>
</div>
<p>Investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7251794" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a> (OEEB) conduct studies in the United States and abroad to identify and evaluate environmental and workplace exposures that may be associated with cancer risk. Areas include:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419037" sys_contentid="419037" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7251795" sys_dependentvariantid="1418" sys_dependentid="419037" rxinlineslot="103" sys_variantid="1418">Industrial and Occupational Exposures</a><br />Investigators have identified many chemicals that cause cancer in humans, and they have provided direction for initiatives aimed at reducing or eliminating these carcinogens in the workplace and elsewhere.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419038" sys_contentid="419038" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7251796" sys_dependentvariantid="1418" sys_dependentid="419038" rxinlineslot="103" sys_variantid="1418">Environmental Exposures</a><br /> Investigators conduct studies of environmental exposures to known or suspected carcinogens including&mdash;but not limited to&mdash;indoor air pollution, outdoor air pollution, arsenic, water disinfection byproducts, and nitrate.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419041" sys_contentid="419041" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7251793" sys_dependentvariantid="1418" sys_dependentid="419041" rxinlineslot="103" sys_variantid="1418">Exposure Assessment Methods</a><br /> Evaluation of exposure-response relationships is a crucial component in assessment of causes of cancer. Investigators devote considerable effort to improving exposure assessment techniques and evaluating the reliability and validity of procedures used in cohort and case-control studies of occupational and environmental exposures.</p>
</div>]]></content>
  </row>
  <row para_id="419037" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="top"></a>
<div class="callout-box right">
<h3>OEEB Research Areas</h3>
<p><a title="" href="/about/organization/programs-ebp/oeeb/industrial-exposures">Industrial and Occupational Exposures</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/environmental-exposures">Environmental Exposures</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/exposure-assessment-methods">Exposure Assessment Methods</a></p>
</div>
<p>Workers often have heavier and more prolonged exposures to hazardous chemicals that also occur in the general environment, but at lower levels. When excess risks are detected from workplace studies, they may provide important leads as to the etiology of cancer in other settings. Occupational studies conducted by OEEB investigators have identified many chemicals that cause cancer in humans, and they have provided direction for initiatives aimed at reducing or eliminating these carcinogens in the workplace and elsewhere.</p>
<p><em>On this page</em>:</p>
<p><a href="#Cohort-Studies">Cohort Studies</a><br /><a href="#Case-Control">Case-Control Studies with Occupational Components</a></p>
<h2><a id="Cohort-Studies"></a>Cohort Studies</h2>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303672" sys_contentid="303672" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303672" sys_dependentvariantid="1418" sys_relationshipid="7267074" sys_variantid="1418">Diesel Exhaust in Miners Study (DEMS)</a><br /> In March 2012, the National Cancer Institute (NCI) and the National Institute for Occupational Safety and Health (NIOSH) completed a retrospective cohort mortality and nested case-control study of 12,315 workers at eight non-metal mining facilities to investigate risk of lung cancer in relation to quantitative measures of historical exposure to diesel exhaust, after taking into account smoking and other lung cancer risk factors.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_contentid="303742" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303742" sys_dependentvariantid="1418" sys_relationshipid="7267075" sys_variantid="1418">Agricultural Health Study</a><br /> A prospective cohort study of commercial pesticide applicators, farmers and farmers' spouses in Iowa and North Carolina conducted in collaboration among the National Cancer Institute, the National Institute of Environmental Health Sciences, the U.S. Environmental Protection Agency and the National Institute for Occupational Safety and Health.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1134698" sys_contentid="1134698" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1134698" sys_dependentvariantid="1418" sys_relationshipid="7267086" sys_variantid="1418">Biomarkers of Exposure and Effect in Agriculture (BEEA)</a><br /> The BEEA study, a subcohort for molecular epidemiologic investigations within the Agricultural Health Study, was conducted to better understand the biological mechanisms through which pesticides and other agricultural exposures may influence risk of various cancers.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302387" sys_contentid="302387" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302387" sys_dependentvariantid="1418" sys_relationshipid="7267076" sys_variantid="1418">Benzene-Exposed Workers in China</a><br /> A binational, multidisciplinary study of Chinese benzene-exposed workers and unexposed workers from more than 700 factories in 12 cities</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303688" sys_contentid="303688" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303688" sys_dependentvariantid="1418" sys_relationshipid="7267077" sys_variantid="1418">NCI Acrylonitrile Cohort</a><br /> A study of 25,460 workers employed at eight facilities in the U.S. that produce or use acrylonitrile</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1134691" sys_contentid="1134691" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1134691" sys_dependentvariantid="1418" sys_relationshipid="7267087" sys_variantid="1418">Cohort Mortality Study of Dry Cleaning Industry Workers</a><br /> A retrospective cohort study of 5,369 workers who were members of a dry cleaning union in St Louis, Missouri, between 1948 and 1978 for at least one year</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303749" sys_contentid="303749" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303749" sys_dependentvariantid="1418" sys_relationshipid="7267078" sys_variantid="1418">Shanghai Women's Health Study</a><br /> The Shanghai Women's Health Study, a collaborative study by NCI, Vanderbilt University, and the Shanghai Cancer Institute, is a prospective cohort study of approximately 75,000 women, which aims to evaluate the causes of cancer among Chinese women.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303671" sys_contentid="303671" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303671" sys_dependentvariantid="1418" sys_relationshipid="7267079" sys_variantid="1418">Research on Formaldehyde Exposure</a><br /> Studies to investigate occupational formaldehyde exposure and cancer risk, including an industrial cohort study of over 25,000 workers, a case-control study of workers in the funeral industry, and a cross-sectional study to quantify leukemia-specific chromosome changes associated with formaldehyde exposure.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1083375" sys_contentid="1083375" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1083375" sys_dependentvariantid="1418" sys_relationshipid="7267080" sys_variantid="1418">Cohort Mortality Study of Philadelphia Firefighters</a><br /> A cohort study examining the mortality rate among 7,789 firefighters employed by the city of Philadelphia between 1910 and 1987. Later, these data were pooled with other studies to form a cohort totaling 29,993 U.S. firefighters.</p>
<p><a href="#top">Back to top</a></p>
<h2><a id="Case-Control"></a>Case-Control Studies with Occupational Components</h2>
<h3>Kidney Cancer</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303592" sys_contentid="303592" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303592" sys_dependentvariantid="1418" sys_relationshipid="7267081" sys_variantid="1418">Case-Control Study of Renal Cell Cancer among Caucasians and African Americans in the United States</a><br /> This population-based case-control study is evaluating risk factors for renal cell cancer to examine why rates of this disease are higher among U.S. blacks than whites.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303593" sys_contentid="303593" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303593" sys_dependentvariantid="1418" sys_relationshipid="7267082" sys_variantid="1418">Case-Control Study of Renal Cell Cancer in Eastern Europe</a><br /> A hospital-based case-control study evaluating kidney cancer risks in relation to occupational and other environmental and lifestyle exposures in six centers across Eastern Europe</p>
<h3>Bladder Cancer</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="438648" sys_dependentvariantid="1418" sys_relationshipid="7267083" sys_variantid="1418">New England Bladder Cancer Study</a><br /> This population-based, case-control study of bladder cancer sought to explain the reasons for the persistent excess of rates of bladder cancer in the northern New England area.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303543" sys_contentid="303543" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303543" sys_dependentvariantid="1418" sys_relationshipid="7267084" sys_variantid="1418">Interdisciplinary Case-Control Study of Bladder Cancer in Spain</a><br /> A large interdisciplinary case-control study of bladder cancer in 18 hospitals from five different regions in Spain</p>
<h3>Lymphoma</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303612" sys_contentid="303612" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303612" sys_dependentvariantid="1418" sys_relationshipid="7267085" sys_variantid="1418">NCI-SEER Non-Hodgkin Lymphoma (NHL) Case-Control Study</a><br /> A multi-center, population-based study of 1,321 NHL cases and 1,057 controls that includes detailed interview data, biospecimens, and environmental samples</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=459575" sys_contentid="459575" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="459575" sys_dependentvariantid="1418" sys_relationshipid="7267088" sys_variantid="1418">AsiaLymph Study</a><br />A multi-center, international case-control study of lymphoma in Eastern Asia studying the occupational, environmental, and genetic contributions to lymphoid neoplasia</p>
<p><a href="#top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="419038" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>OEEB Research Areas</h3>
<p><a title="" href="/about/organization/programs-ebp/oeeb/industrial-exposures">Industrial and Occupational Exposures</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/environmental-exposures">Environmental Exposures</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/exposure-assessment-methods">Exposure Assessment Methods</a></p>
</div>
<p>Investigators in the Occupational and Environmental Epidemiology Branch (OEEB) conduct studies of environmental exposures to known or suspected carcinogens including&mdash;but not limited to&mdash;indoor air pollution, outdoor air pollution, arsenic, water disinfection byproducts, and nitrate. Results of such research can have important public health implications. Selected studies include:&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303673" sys_contentid="303673" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303673" sys_dependentvariantid="1418" sys_relationshipid="7267089" sys_variantid="1418">Drinking Water Contaminants</a><br />Studies of water contaminants thought to be associated with cancer risk, including arsenic, disinfection byproducts, and nitrate</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=473466" sys_contentid="473466" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="473466" sys_dependentvariantid="1418" sys_relationshipid="7267090" sys_variantid="1418">Indoor Air Pollution and Lung Cancer in Asia</a><br />Investigation of the role of indoor air pollution from solid fuel use in lung cancer in Asia</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303543" sys_contentid="303543" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303543" sys_dependentvariantid="1418" sys_relationshipid="7267091" sys_variantid="1418">Interdisciplinary Case-Control Study of Bladder Cancer in Spain</a><br />A large interdisciplinary case-control study of bladder cancer in 18 hospitals from five different regions in Spain</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="438648" sys_dependentvariantid="1418" sys_relationshipid="7267092" sys_variantid="1418">New England Bladder Cancer Study</a><br />A population-based case-control study that investigates the reason for the persistent excess of bladder cancer mortality and incidence in the northern New England area</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087367" sys_contentid="1087367" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087367" sys_dependentvariantid="1418" sys_relationshipid="7267094" sys_variantid="1418">Outdoor Air Pollution</a><br /> Studies of cancer risk associated with exposure to outdoor air pollutants arising from traffic, industrial, and agricultural sources, including ultrafine particulate matter and dioxins</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303596" sys_contentid="303596" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303596" sys_dependentvariantid="1418" sys_relationshipid="7267093" sys_variantid="1418">Study of Childhood Leukemia and Environmental Pesticide and Other Chemical Exposures in California</a><br />A population-based case-control study of childhood leukemia in the San Francisco Bay area and the agricultural Central Valley</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="419041" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>OEEB Research Areas</h3>
<p><a title="" href="/about/organization/programs-ebp/oeeb/industrial-exposures">Industrial and Occupational Exposures</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/environmental-exposures">Environmental Exposures</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/exposure-assessment-methods">Exposure Assessment Methods</a></p>
</div>
<p>Evaluation of exposure-response relationships is a crucial component in assessment of causes of cancer. Quantitative exposure assessment is therefore an essential element in high-quality epidemiologic investigations. Occupational and Environmental Epidemiology Branch (OEEB) investigators devote considerable effort to improving exposure assessment techniques and evaluating the reliability and validity of procedures used in cohort and case-control studies of occupational and environmental exposures.&nbsp;Below are a few examples.</p>
<h2>Geographic Information Systems (GIS) Methods in Environmental Epidemiology</h2>
<p>Epidemiologic investigations of environment-cancer relationships rely on accurate, quantifiable exposure measurements. Such studies may use <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087390" sys_contentid="1087390" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1087390" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267104">Geographic Information Systems (GIS)</a> and regulatory and other environmental monitoring data to complement retrospective surveys, which are sometimes limited by participants&rsquo; knowledge of exposures in their surrounding environments. Cancer studies have benefited from the increasing availability of historical air and water monitoring data, satellite imagery, census, commercial databases, and other geographic datasets that allow for reconstruction of residence- and other location-based exposures over a substantial portion of a person&rsquo;s lifetime.</p>
<p>OEEB investigators implement GIS-based exposure assessments using georeferenced data resources and residential histories collected in our studies of environmental hazards and cancer risk. Our approaches include using GIS and spatial-analytic methods to characterize exposure to environmental risk factors, incorporating space-time-activity information in exposure assessments, and employing biological and environmental measurements for exposure validation. This work addresses important epidemiologic considerations in geography-based environmental exposure assessments, including residential mobility and time spent in various microenvironments, positional error, and the challenges of extrapolation over space and time. These approaches have been implemented in a number of DCEG and OEEB studies, including to assess drinking water nitrate exposure among private well users in the Agricultural Health Study, to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=976905" sys_contentid="976905" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="976905" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267105">estimate ambient air pollution in the Southern California Ultrafines Study</a>, and to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087366" sys_contentid="1087366" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1087366" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267106">validate estimated dioxin exposure metrics</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1135726" sys_contentid="1135726" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1135726" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267110">Publications on the use of GIS Methods in Environmental Epidemiology</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349624" sys_contentid="349624" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349624" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267102">Dr. Mary Ward</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="1080328" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267103">Dr. Rena Jones</a>.</p>
<h2>Industry-based Studies</h2>
<p>OEEB investigators have developed state-of-the-art quantitative exposure assessment methods that maximized the available measurements and exposure determinant information to predict historical exposure levels in several studies including diesel exhaust in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303672" sys_contentid="303672" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303672" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267099">Diesel Exhaust in Miners Study</a>, benzene in a cohort study of&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302387" sys_contentid="302387" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302387" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267095">Benzene-Exposed Workers in China</a>, and specific pesticides within the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_contentid="303742" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303742" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267096">Agricultural Health Study</a>.&nbsp;</p>
<h2>Population-based Studies</h2>
<h3>Exposure Assessment Using Job Exposure Matrices</h3>
<p>Job Exposure Matrices (JEMs) are an efficient way to assign exposure estimates in population-based studies and may be the only exposure assessment option when only job and industry are available for study participants. DCEG investigators develop methods to improve JEMs by incorporating databases of exposure measurements to calibrate JEMs across time and across jobs and industries. For example, in the Shanghai Women's Health Study, investigators developed a novel framework to systematically combine a JEM with historical measurements to calibrate JEM exposure ratings used to estimate historical benzene and lead exposure.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=473518" sys_contentid="473518" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="473518" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267100">Publications on the use of Job Exposure Matrices</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267107">Dr. Melissa Friesen</a>.</p>
<h3>Exposure Assessment Using Occupation- and Industry-specific Modules</h3>
<p>Occupation- and industry-specific modules ask detailed questions about work activities and exposures within its population-based case-control studies to better capture within-occupation differences in exposure. Usually these module responses are reviewed job-by-job by an exposure assessor to assign exposure estimates. OEEB investigators develop methods to more efficiently and transparently assign exposure in studies that use modules and examine the validity and reliability of these methods. Decision rules that link questionnaire responses to exposure estimates have been developed to assess occupational exposures in US case-control studies, including metalworking fluids, diesel exhaust, lead and benzene. In an evaluation of the reliability of decision rule approaches we found that decision rule estimates of occupational diesel exhaust exposure for the New England Bladder Cancer Study had moderately-high agreement with estimates obtained from expert reviews of each job. Exposure estimates in the decision rules are data-driven wherever possible, including use of subjects&rsquo; answers to occupation and industry-specific modules and use of job group medians derived from module responses to assign exposure to those in similar jobs without a completed module. Intensity estimates are based on synthesis of publicly available data sources whenever possible (see next section). We have also developed a method to extract patterns in the questionnaire responses that predict an expert&rsquo;s exposure assignments using classification and regression tree (CART) models. The extracted decision rules have been used to improve the transparency and efficiency of applying the exposure decisions to other study subjects.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=473518" sys_contentid="473518" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="473518" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267101">Publications on the use of occupation- and industry-specific modules</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267108">Dr. Melissa Friesen</a>.</p>
<h3>Synthesis of Publicly Available Exposure Data Sources</h3>
<p>To assist exposure assessment efforts, OEEB conducts comprehensive literature reviews for specific agents to identify when, where, and how much exposure to that agent was likely to occur. Exposure concentrations identified in these reviews are extracted into exposure databases that can be used to characterize exposure determinants, such as time trends. We extended the use meta-regression models to identify exposure determinants of published occupational and environmental measurements, which are generally reported as summary statistics, for several exposures, including lead, benzene, and pesticides.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=473518" sys_contentid="473518" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="473518" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267098">Publications on the synthesis of publicly available exposure data sources</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267097">Dr. Melissa Friesen</a>.</p>
<h3>Use of Sensors and Smartphone Technologies</h3>
<p>OEEB investigators use state-of-the-art technologies in field studies to characterize exposure, including use of direct reading sensors (e.g., black carbon, ultrafine particulate, PM<sub>2.5</sub>) and smartphone apps to collect work activity diaries.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7267109">Dr. Melissa Friesen</a>.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="419183" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-ebp/iib">IIB Home</a></h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_dependentvariantid="1418" sys_dependentid="419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312277" sys_variantid="1418" sys_contentid="419183">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=IIB">IIB Staff Directory</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=157&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302548" sys_dependentvariantid="1418" sys_dependentid="302548" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312278" sys_variantid="1418" sys_contentid="302548">Current Fellows</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302544" sys_dependentvariantid="1418" sys_dependentid="302544" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7312279" sys_variantid="1418" sys_contentid="302544">Research Training Opportunities</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=302449&amp;sys_revision=34&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="302449" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7312280">Spotlight on Investigators</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=IIB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=0&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Immunoepidemiology Branch (IIB) conduct research on 1) infectious agents with established or postulated associations with cancer and 2) immune perturbations relevant for cancer risk, including severe immunosuppression, autoimmune diseases, and chronic inflammation. Based on findings from etiologic research, IIB investigators look for opportunities to translate findings to cancer prevention, risk stratification, and screening.</p>
<p>Approximately 15 percent&nbsp;of all cancers are attributable to infectious agents. Infection-related cancers thus represent a major public health burden. For cancers where the role of an infection is established, IIB research aims to further elucidate the etiologic association by investigating topics ranging from acquisition of infection to the occurrence of cancer, including the natural history of infections, genetic and environmental cofactors that modulate cancer risk, biomarkers of cancer risk, and accurate estimation of absolute cancer risk among infected individuals. We also examine primary and secondary prevention strategies for these cancers.<br />&nbsp;<br />Another important focus of IIB research is the etiologic role of immunity and inflammation in cancer. IIB researchers address key questions regarding the spectrum of cancer among immunosuppressed individuals and the mechanisms underlying increased cancer risk in those populations. IIB investigators study both systemic and local immunity and inflammation to unravel their contributions to cancer etiology. We also look for opportunities to identify novel infections that contribute to cancer, which are often signaled when a rare cancer is found to occur at markedly increased incidence in immunosuppressed populations.</p>
<h3>Research Areas</h3>
<ul>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303539" sys_contentid="303539" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312268" sys_siteid="475" rxinlineslot="103" sys_dependentid="303539" sys_dependentvariantid="1418">Biliary Cancer</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419299" sys_contentid="419299" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312269" sys_siteid="475" rxinlineslot="103" sys_dependentid="419299" sys_dependentvariantid="1418">Gastric Cancer</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419257" sys_contentid="419257" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312270" sys_siteid="475" rxinlineslot="103" sys_dependentid="419257" sys_dependentvariantid="1418">HIV-Associated Malignancies</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419301" sys_contentid="419301" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312266" sys_siteid="475" rxinlineslot="103" sys_dependentid="419301" sys_dependentvariantid="1418">Human Papillomavirus (HPV) Vaccine</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140677" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140677" sys_dependentvariantid="1418" sys_relationshipid="7312274" sys_variantid="1418" sys_contentid="1140677">Interferon Lambda 4 (IFNL4)</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140233" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140233" sys_dependentvariantid="1418" sys_relationshipid="7312275" sys_variantid="1418" sys_contentid="1140233">Liver Cancer</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419307" sys_contentid="419307" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312267" sys_siteid="475" rxinlineslot="103" sys_dependentid="419307" sys_dependentvariantid="1418">Nasopharyngeal Cancer</a></li>
<!--
<li class="lastli"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&#38;sys_variantid=1418&#38;sys_revision=2&#38;sys_contentid=419309&#38;sys_context=0&#38;sys_siteid=475" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="419309" sys_dependentvariantid="1418" sys_relationshipid="5257174" sys_siteid="475">Prostate Cancer</a></li>-->
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_contentid="303740" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312271" sys_siteid="475" rxinlineslot="103" sys_dependentid="303740" sys_dependentvariantid="1418">Transplant-Associated&nbsp;Malignancies</a></li>
</ul>
<h3>Study Links</h3>
<ul>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_contentid="303678" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312272" sys_siteid="475" rxinlineslot="103" sys_dependentid="303678" sys_dependentvariantid="1418">HIV/AIDS Cancer Match Study</a></li>
<li class="lastli"><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_contentid="303740" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7312273" sys_siteid="475" rxinlineslot="103" sys_dependentid="303740" sys_dependentvariantid="1418">Transplant Cancer Match Study</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="419257" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>IIB Research Areas</h3>
<p><a title="" href="/research/cancer-types/biliary-tract-bile-duct">Biliary Tract Cancers</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/gastric">Gastric Cancer</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=419257&amp;sys_revision=16&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="419257" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7290776">HIV-Associated Malignancies</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/hpv">Human Papillomavirus (HPV) Vaccine</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140677" sys_contentid="1140677" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140677" sys_dependentvariantid="1418" sys_relationshipid="7290774" sys_variantid="1418">Interferon Lambda 4 (IFNL4)</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140233" sys_contentid="1140233" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140233" sys_dependentvariantid="1418" sys_relationshipid="7290775" sys_variantid="1418">Liver Cancer<br /></a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/nasopharyngeal">Nasopharyngeal Cancer</a></p>
<p><a title="" href="/research/who-we-study/cancer-cases-controls/transplant-cancer-match-study">Transplant-Associated Malignancies</a></p>
</div>
<p>Individuals with human immunodeficiency virus (HIV) infection are at increased risk for a range of cancers due to loss of cell-mediated immune function. Researchers in the Infections and Immunoepidemiology Branch (IIB) evaluate the spectrum of cancer risk in this population and study risk factors for specific cancers related to immunosuppression, viral infections, and other conditions. Non-Hodgkin lymphoma is one cancer of interest due to its close association with immunosuppression and viral infections.</p>
<h2>HIV/AIDS Cancer Match Study</h2>
<p>IIB researchers examine cancer risk in people living with HIV infection in the United States, utilizing data collected by state and regional HIV and cancer registries throughout the United States. Learn more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_contentid="303678" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303678" sys_dependentvariantid="1418" sys_relationshipid="7290773" sys_variantid="1418">HIV/ AIDS Cancer Match Study</a>.</p>
<h2>EBV and Genetics in AIDS NHL</h2>
<p>DCEG investigators seek to clarify the roles of Epstein-Barr virus (EBV) and common variants in genes controlling immunity and inflammation on the risk of AIDS-related non-Hodgkin lymphoma (NHL). Learn more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303674" sys_contentid="303674" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303674" sys_dependentvariantid="1418" sys_relationshipid="7290772" sys_variantid="1418">EBV and Genetics in AIDS NHL</a>.</p>
</div>]]></content>
  </row>
  <row para_id="419299" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>IIB Research Areas</h3>
<p><a title="" href="/research/cancer-types/biliary-tract-bile-duct">Biliary Tract Cancers</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/gastric">Gastric Cancer</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419257" sys_contentid="419257" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280217" sys_dependentvariantid="1418" sys_dependentid="419257" rxinlineslot="103" sys_siteid="475">HIV-Associated Malignancies</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/hpv">Human Papillomavirus (HPV) Vaccine</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140677" sys_contentid="1140677" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280223" sys_dependentvariantid="1418" sys_dependentid="1140677" rxinlineslot="103" sys_siteid="475">Interferon Lambda 4 (IFNL4)</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140233" sys_contentid="1140233" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280224" sys_dependentvariantid="1418" sys_dependentid="1140233" rxinlineslot="103" sys_siteid="475">Liver Cancer<br /></a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/nasopharyngeal">Nasopharyngeal Cancer</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_contentid="303740" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280220" sys_dependentvariantid="1418" sys_dependentid="303740" rxinlineslot="103" sys_siteid="475">Transplant-Associated Malignancies</a></p>
</div>
<p>Gastric (stomach) cancer occurs when cancer cells form in the lining of the stomach. Increased incidence of noncardia gastric cancer among specific populations in the U.S. have led investigators in the Infections and Immunoepidemiology Branch (IIB) to study serologic screening markers, pathogenic microbes and molecular pathology in order to increase knowledge of disease etiology and decrease the burden of disease. Selected studies include:</p>
<h2>Autoimmune Gastritis</h2>
<p>DCEG investigators in the Infections and Immunoepidemiology Branch (IIB) have documented unprecedented increases of noncardia gastric cancer among younger generations in the U.S. Analyses of incidence trends reveal a coherent set of features that suggest autoimmune gastritis may be the underlying cause. Further efforts are underway. Read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1141199" sys_contentid="1141199" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280221" sys_dependentvariantid="1418" sys_dependentid="1141199" rxinlineslot="103" sys_siteid="475">Autoimmune Gastritis and Gastric Cancer</a>.</p>
<h2><em>H. pylori</em> Genome Project (<em>Hp</em>GP)</h2>
<p>DCEG investigators in IIB and the Metabolic Epidemiology Branch are undertaking a joint effort to&nbsp;catalog comprehensively bacterial genetic and epigenetic variation potentially related to long-term outcomes of infection. Read more about the <em></em><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1141200" sys_contentid="1141200" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280222" sys_dependentvariantid="1418" sys_dependentid="1141200" rxinlineslot="103" sys_siteid="475"><em>H. pylori</em> Genome Project</a>.</p>
<h2>EBV-Associated Gastric Cancer</h2>
<p>Studies evaluating gastric cancers associated with the Epstein-Barr virus (EBV) infection. Read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303652" sys_contentid="303652" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280218" sys_dependentvariantid="1418" sys_dependentid="303652" rxinlineslot="103" sys_siteid="475">EBV-associated Gastric Cancer</a>.</p>
<h2>NCI International EBV-Gastric Cancer Consortium</h2>
<p>A collaboration among NCI and extramural investigators, established by DCEG in 2006, that utilizes data and biospecimens from 18 completed and ongoing case series and observational studies of gastric cancer to replicate and extend findings from previous studies hindered by small numbers of EBV-positive cases, and to stimulate multidisciplinary research in this area. Read more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=827356" sys_contentid="827356" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7280219" sys_dependentvariantid="1418" sys_dependentid="827356" rxinlineslot="103" sys_siteid="475">NCI International EBV-Gastric Cancer Consortium</a>.</p>
</div>]]></content>
  </row>
  <row para_id="419301" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>IIB Research Areas</h3>
<p><a title="" href="/research/cancer-types/biliary-tract-bile-duct">Biliary Tract Cancers</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/gastric">Gastric Cancer</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419257" sys_contentid="419257" inlinetype="rxhyperlink" sys_relationshipid="7280225" sys_dependentvariantid="1418" sys_dependentid="419257" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">HIV-Associated Malignancies</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/hpv">Human Papillomavirus (HPV) Vaccine</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140677" sys_contentid="1140677" inlinetype="rxhyperlink" sys_relationshipid="7280230" sys_dependentvariantid="1418" sys_dependentid="1140677" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">Interferon Lambda 4 (IFNL4)</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140233" sys_contentid="1140233" inlinetype="rxhyperlink" sys_relationshipid="7280231" sys_dependentvariantid="1418" sys_dependentid="1140233" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">Liver Cancer<br /></a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/nasopharyngeal">Nasopharyngeal Cancer</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_contentid="303740" inlinetype="rxhyperlink" sys_relationshipid="7280229" sys_dependentvariantid="1418" sys_dependentid="303740" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">Transplant-Associated Malignancies</a></p>
</div>
<p>Human papillomavirus (HPV) causes a number of cancers, including cervical cancer, which is one of the leading causes of cancer incidence and death globally, and oropharyngeal cancer (OPC), which is one of the fastest increasing cancers in the Unites States. Researchers in the Infections and Immunoepidemiology Branch (IIB) are investigating primary prevention via prophylactic HPV vaccination. Selected studies include:</p>
<h2>HPV Vaccine Trial in Costa Rica</h2>
<p>A randomized, controlled phase III trial of a vaccine to prevent human papillomavirus (HPV) 16 and 18 infections and their associated cervical lesions in Costa Rica. Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303745" sys_contentid="303745" inlinetype="rxhyperlink" sys_relationshipid="7280226" sys_dependentvariantid="1418" sys_dependentid="303745" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">HPV Vaccine Trial in Costa Rica</a>.</p>
<h2>Study of HPV Vaccine Efficacy at Extracervical Sites</h2>
<p>A study to determine the impact of HPV vaccination in preventing infections in the oral, vulvar, and anal regions. Learn more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303686" sys_contentid="303686" inlinetype="rxhyperlink" sys_relationshipid="7280227" sys_dependentvariantid="1418" sys_dependentid="303686" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">HPV vaccine effiicacy at extracervical sites</a>.</p>
<h2>Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines&mdash;The ESCUDDO* Study</h2>
<p>Study to evaluate the efficacy of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines. Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1102867" sys_contentid="1102867" inlinetype="rxhyperlink" sys_relationshipid="7280228" sys_dependentvariantid="1418" sys_dependentid="1102867" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">ESCUDDO Study</a>.</p>
</div>]]></content>
  </row>
  <row para_id="419307" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>IIB Research Areas</h3>
<p><a title="" href="/research/cancer-types/biliary-tract-bile-duct">Biliary Tract Cancers</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/gastric">Gastric Cancer</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419257" sys_contentid="419257" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="419257" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280236" sys_variantid="1418">HIV-Associated Malignancies</a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/hpv">Human Papillomavirus (HPV) Vaccine</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140677" sys_contentid="1140677" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1140677" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280237" sys_variantid="1418">Interferon Lambda 4 (IFNL4)</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140233" sys_contentid="1140233" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1140233" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280238" sys_variantid="1418">Liver Cancer<br /></a></p>
<p><a title="" href="/about/organization/programs-ebp/iib/nasopharyngeal">Nasopharyngeal Cancer</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" sys_contentid="303740" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303740" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280232" sys_variantid="1418">Transplant-Associated Malignancies</a></p>
</div>
<p>Nasopharyngeal carcinoma (NPC) is one of the cancers caused by Epstein-Barr virus (EBV), and a family history of the disease is the strongest nonviral risk factor. Investigators in the Infections and Immunoepidemiology Branch (IIB) have been evaluating EBV-based markers for use in early detection of NPC, and are also studying the genetic risk factors associated with the disease. Selected studies include:</p>
<h2>Nasopharyngeal Case-Control Study</h2>
<p>Two case-control studies were conducted in Taiwan between 1991-1994 and 2010-2014.&nbsp; Together, these two studies included more than 2,000 NPC cases and more than 2,400 controls and were designed to examine the role of viral, environmental, and genetic factors associated with the development of nasopharyngeal carcinoma. Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303622" sys_contentid="303622" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303622" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280233" sys_variantid="1418">Nasopharyngeal Case-Control Study</a>.</p>
<h2>Nasopharyngeal Family Study</h2>
<p>A family study in Taiwan to elucidate genetic factors linked to the development of nasopharyngeal cancer and to evaluate clinically useful viral markers of disease risk was started in the mid 1990s. Using the national cancer registry, investigators identified and recruited more than 3,200 individuals from 358 nasopharyngeal carcinoma multiplex families. Active and passive follow-up of these families and their members is ongoing. Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303623" sys_contentid="303623" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303623" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280234" sys_variantid="1418">Nasopharyngeal Family Study</a>.</p>
<h2>EBV Screening for the Early Detection of Nasopharyngeal Carcinoma</h2>
<p>The Epstein-Barr virus (EBV)&nbsp;screening for the early detection of NPC in China demonstration project includes a group of approximately 30,000 men and women ages 35-69 recruited into the active screening arm of a community-randomized trial to evaluate the impact of EBV-based antibody screening on NPC mortality rates. As part of this effort, NCI is collaborating on a substudy to evaluate the sensitivity and specificity of endoscopy versus MRI for the detection of NPC and the utility of nasopharynx viral load testing to triage EBV antibody positive individuals. Learn more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140727" sys_contentid="1140727" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1140727" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7280235" sys_variantid="1418">EBV Screening for the Early Detection of Nasopharyngeal Carcinoma</a>.</p>
</div>]]></content>
  </row>
  <row para_id="420419" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Energy balance &mdash; the difference between dietary energy intake and energy expended through physical activity and resting metabolism - is thought to increase the risk of several important cancers, including colon, post-menopausal breast, endometrium, kidney, and esophagus.&nbsp;</p>
<p>The high prevalence of obesity and physical inactivity is a worldwide public health issue, yet the mechanisms by which energy imbalance and obesity cause cancer remain unclear. MEB investigators are pursuing several approaches to address these issues, including:</p>
<ul>
<li>Improvement of assessment tools for diet, physical activity, and body size, in order to disentangle these interrelated exposures;</li>
<li>Performance of etiologic studies in high-risk populations (e.g., South Asians);</li>
<li>Studies of biochemical mechanisms, including the use of high-throughput multiplex assays of possible obesity-related biomarkers (such as inflammatory markers/cytokines, metabolic hormones, and sex hormones).</li>
</ul>
<p>A wide variety of studies are conducted using the following cohorts:&nbsp;</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_dependentvariantid="1418" sys_dependentid="303743" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297189" sys_variantid="1418" sys_contentid="303743">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303592" sys_dependentvariantid="1418" sys_dependentid="303592" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297190" sys_variantid="1418" sys_contentid="303592">Case-Control Study of Renal Cell Cancer among Caucasians and African Americans in the United States</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_dependentvariantid="1418" sys_dependentid="303748" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297191" sys_variantid="1418" sys_contentid="303748">NIH-AARP Diet and Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_dependentvariantid="1418" sys_dependentid="303750" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297192" sys_variantid="1418" sys_contentid="303750">Prostate, Lung, Colon, and Ovary Prospective Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303749" sys_dependentvariantid="1418" sys_dependentid="303749" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297193" sys_variantid="1418" sys_contentid="303749">Shanghai Women's Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303661" sys_dependentvariantid="1418" sys_dependentid="303661" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297194" sys_variantid="1418" sys_contentid="303661">Testicular Cancer among Military Servicemen: the STEED Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_dependentvariantid="1418" sys_dependentid="302552" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7297195" sys_variantid="1418" sys_contentid="302552">U.S. Radiologic Technologists Cohort (USRT)</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="420600" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-hgp/iteb" title="">ITEB Home</a></h3>
<p><a href="/about/organization/programs-hgp/iteb/research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=ITEB">ITEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/ITEB-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/iteb-training" title="">Research Training Opportunities</a></p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ITEB">Publications</a></p>
</div>
<p>Research conducted by ITEB investigators involves:</p>
<ul>
<li>Designing, conducting and analyzing molecular epidemiology studies with tissue collections;</li>
<li>Characterizing tumors using morphology, histopathology and immunohistochemistry/in situ hybridization staining and scoring of tissue slides from formalin-fixed paraffin embedded (FFPE) or fresh frozen (FF) material;</li>
<li>Molecular profiling of tumors, including genomic analyses conducted at the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=460151" sys_contentid="460151" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7344463" sys_siteid="475" rxinlineslot="103" sys_dependentid="460151" sys_dependentvariantid="1422">DCEG Cancer Genomics Research (CGR) Laboratory</a> and external laboratories;</li>
<li>Designing and utilizing large-scale analytic tools for integrated data analytics of high dimensional, complex data;</li>
<li>Using publically available data from resources such as the The Cancer Genome Atlas (TCGA), ENCODE and Genotype-Tissue Expression (GTEx) projects, and the International cancer genome consortium (ICGC);</li>
<li>Participating and contributing to large national and international consortia.</li>
</ul>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1065271" sys_contentid="1065271" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7344466" sys_siteid="475" rxinlineslot="103" sys_dependentid="1065271" sys_dependentvariantid="1418">Learn more about tissue-based studies in ITEB and other branches in DCEG</a></p>
<h2>Major research areas</h2>
<h3>Breast Cancer</h3>
<p>The goal is to study molecular mechanisms underlying breast carcinogenesis and etiologic heterogeneity of breast cancers through integrative molecular epidemiology studies, including morphologic and molecular characterization of normal and tumor breast tissues. Research areas include molecular epidemiology of mammographic density, one of the strongest risk factors for breast cancer; morphologic features of terminal duct lobular units (TDLUs) in non-malignant breast tissue in relation to breast cancer risk; GWAS of breast cancer subtypes; somatic profiling of tumors in relation to germline and environmental exposures in different populations (European, Asian and African ancestry); and study of the interrelation of genetic and environmental risk factors, tumor features and clinical progression using targeted DNA sequencing and immunohistochemistry and in-situ hybridization analysis of thousands of breast tumors in the international consortium <a href="http://www.b-cast.eu/">Breast CAncer STratification (BCAST) Project</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1125534" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1125534" sys_dependentvariantid="1418" sys_relationshipid="7344470" sys_variantid="1418" sys_contentid="1125534">Learn more about breast cancer studies in ITEB.</a></p>
<p>An initiative called the Confluence Project will develop a large research resource to uncover breast cancer genetics through genome-wide association studies. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1123466" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1123466" sys_dependentvariantid="1418" sys_relationshipid="7344471" sys_variantid="1418" sys_contentid="1123466">Learn more about the Confluence Project</a>. If interested in participating, <a href="https://ww2.research-survey.org/efm/se.ashx?s=4B7FCB89085F4226">complete the inventory</a>.</p>
<h3>Chordoma</h3>
<p>Chordoma is a rare bone cancer (diagnosed in about 300 patients in the U.S. each year) that develops at the base of the skull, in a vertebra, or at end of the spine. It is believed to develop from remnants of the notochord. While the majority of people with chordoma have no other family members with this cancer, a small number of families with multiple relatives with chordoma have been reported worldwide, suggesting that genetic factors may cause susceptibility of chordoma in these families.</p>
<p>DCEG investigators have been <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302494" sys_contentid="302494" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7344464" sys_siteid="475" rxinlineslot="103" sys_dependentid="302494" sys_dependentvariantid="1418">studying chordoma families</a> with the goal of finding the mutated or altered genes that cause&nbsp;familial chordoma, and whether chordoma-prone families are at increased risk of other cancers.&nbsp;They are also trying to determine&nbsp;whether the genes altered in chordoma families play a role in the&nbsp;development of chordoma in <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303762" sys_contentid="303762" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7344465" sys_siteid="475" rxinlineslot="103" sys_dependentid="303762" sys_dependentvariantid="1418">people in the general population <em>without</em> family history of this cancer (sporadic chordoma)</a>. Investigators have identified germline duplication of the <em>T</em> gene as a major susceptibility mechanism in some chordoma families, and through subsequent analyses have identified multiple common and rare <em>T</em> variants associated with chordoma risk. Studies to identify additional susceptibility genes in chordoma families are ongoing.</p>
<h3>Kidney Cancer</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1062981" sys_contentid="1062981" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7344467" sys_siteid="475" rxinlineslot="103" sys_dependentid="1062981" sys_dependentvariantid="1418">Intra-tumor heterogeneity and tumor evolution are being studied in kidney cancer histological subtypes</a> based on whole-genome sequencing, deep target sequencing, whole genome methylation and SNP array analyses.</p>
<h3>Lung Cancer</h3>
<p>The goal is to study the genetic and environmental determinants of lung cancer using an integrative approach that allows the investigation of the process that begins with smoking initiation and persistence, continues with lung cancer development, and ends with progression to disseminated disease or response to therapy and survival. Investigators are using data from a large population-based case control study in the Lombardy region of Italy, called the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303605" sys_contentid="303605" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7344468" sys_siteid="475" rxinlineslot="103" sys_dependentid="303605" sys_dependentvariantid="1418">Environment And Genetics in Lung cancer Etiology (EAGLE) study</a>.</p>
<p>Studies include exogenous and host factors in relation to lung cancer risk and determinants of lung cancer progression through integrative analyses of tissue profiling data. Tumor evolution and intra-tumor heterogeneity of different histologic subtypes of lung cancer are being investigated through whole genome sequencing; deep target sequencing of the major driver genes; SNP array; and whole-genome methylation analysis of multiple regions of the same tumor. The impact of lung microbiota and tumor microenvironment on tumor evolution and clinical outcomes is being studied through 16S RNA gene, immunohistochemistry and RNA sequencing analyses.</p>
<h3>Melanoma</h3>
<p>Converging lines of evidence suggest that melanoma comprises biologically distinct subtypes. DCEG investigators are undertaking <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1065467" sys_contentid="1065467" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7344469" sys_siteid="475" rxinlineslot="103" sys_dependentid="1065467" sys_dependentvariantid="1418">tissue-based and genomic studies to provide a comprehensive classification of primary melanomas and the molecular changes associated with metastatic potential</a>.&nbsp;</p>
<p>Additional studies are underway of specific populations, including a&nbsp;<a href="/Rhythmyx/assembler/render?sys_contentid=303618&amp;sys_revision=6&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303618" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7344473">study of melanoma in Italy to determine the role of pigmentation and other host factors</a>, and a consortial approach to studying a wider segment of Mediterranean populations through the&nbsp;<a href="https://melanostrum.nci.nih.gov/">MelaNostrum Consortium.</a></p>
<h3></h3>
<h3></h3>
<h3></h3>
</div>]]></content>
  </row>
  <row para_id="420656" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>CRaVe is a free, open source, software package designed to perform a range of association tests between sets of SNPs and a phenotype.</p>
<ul>
<li>&nbsp;&nbsp;&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=431979" sys_contentid="431979" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7238990" sys_dependentvariantid="1418" sys_dependentid="431979" rxinlineslot="103">Download Software</a></li>
<li>&nbsp;&nbsp;&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420657" sys_contentid="420657" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7238991" sys_dependentvariantid="1418" sys_dependentid="420657" rxinlineslot="103">License Agreement</a></li>
</ul>
<h3>Reference</h3>
<ul>
<li>Ferguson J, Wheeler W, Fu Y, Prokunina-Olsson L, Zhao H, Sampson J. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23092956">Statistical tests for detecting associations with groups of genetic variants: generalization, evaluation, and implementation</a>. <cite> Eur J Hum Genet</cite>2013; 21:680-6.</li>
</ul>
<p>For more information, contact <a href="mailto: ncicontactdceg@mail.nih.gov">DCEG</a></p>
</div>]]></content>
  </row>
  <row para_id="420657" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Non-Proprietary Software License Agreement for CRaVe</p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>CRaVe may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
</div>]]></content>
  </row>
  <row para_id="420787" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Overview</h3>
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-hgp/ltg">LTG Home</a></h3>
<p><a title="" href="/about/organization/programs-hgp/ltg/research">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=LTG">LTG Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/ltg-fellows">Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/ltg-training">Research Training Opportunities</a></p>
<p><a title="" href="/about/organization/programs-hgp/ltg/tools">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=LTG">Publications</a></p>
</div>
<p><img class="left" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=420788" inlinetype="rximage" rxinlineslot="104" sys_dependentid="420788" sys_dependentvariantid="1482" sys_relationshipid="7267123" sys_siteid="475" />The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7267125" sys_siteid="475" sys_variantid="1422">Laboratory of Translational Genomics</a> (LTG) investigates the biological basis of common inherited genetic variants associated with cancer susceptibility. Together with the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=460151" sys_contentid="460151" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="460151" sys_dependentvariantid="1422" sys_relationshipid="7267126" sys_siteid="475" sys_variantid="1422">NCI Cancer Genomics Research Laboratory (CGR)</a>, formerly known as the Core Genotyping Facility (CGF), the Laboratory carries out <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1057944" sys_contentid="1057944" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1057944" sys_dependentvariantid="1418" sys_relationshipid="7267127" sys_siteid="475" sys_variantid="1418">genome-wide association studies (GWAS)</a>.</p>
<p>Using data from large-scale GWAS that evaluate hundreds of thousands of single nucleotide polymorphisms (SNPs), investigators at the LTG are studying the associations between genetic markers and cancer risk. To understand the biology underlying these associations, investigators are following up with focused validation studies, deep-sequencing, and functional analyses, such as analyses of expression levels and methylation patterns. This research relies on multidisciplinary approaches from population genetics, epidemiology and molecular evolution.</p>
<p>LTG has a series of international collaborations collecting cancer patient material and data for pediatric and adult cancers.</p>
<p>LTG works closely with the NCI CGR. CGR designs and conducts high throughput sequencing and genotyping in support of large-scale epidemiologic studies within the Division of Cancer Epidemiology and Genetics. CGR is also involved in the development of powerful bioinformatics tools that handle high volume genotype data generated from GWAS.</p>
<h3>Genome-Wide Association Studies</h3>
<p><img class="left" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=420789" inlinetype="rximage" rxinlineslot="104" sys_dependentid="420789" sys_dependentvariantid="1482" sys_relationshipid="7267124" sys_siteid="475" />GWAS have yielded close to 750 regions in the genome associated with 135 different diseases and traits. Of these,&nbsp;over 500&nbsp;regions are associated with nearly two dozen cancers, and at least 30 regions are associated with multiple cancers. To more fully understand these novel findings, laboratory studies at the LTG are identifying the causal variants responsible for these associations through validation, deep sequencing, and translational work. In doing so, researchers are providing functional and biological insights into the mechanisms of carcinogenesis.</p>
<p>These efforts would not be possible without NCI&rsquo;s long term investment in the <a href="http://epi.grants.cancer.gov/Consortia/cohort.html">Cohort Consortium</a>, an international partnership of four million people from 41 cohorts, comprised of diverse populations. The cohorts provide extensive risk factor data and biospecimens, including germline DNA.</p>
<h3>Partnerships and Collaborations</h3>
<p>Collaborations and partnerships play a pivotal role in the next wave of genome-wide association studies. Data pooling has become essential in order to achieve the statistical power necessary to detect associations between genomic variants and a variety of health outcomes. High-density chips and emerging technologies now allow the genotyping of millions of SNPs across the genome. Partnerships between the LTG and numerous NCI grantee research organizations are underway, allowing investigation into carcinogenic pathways and gene-environment interactions.</p>
</div>]]></content>
  </row>
  <row para_id="431979" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><span style="font-size: x-large;" size="5">CRaVe&nbsp;</span></p>
<h3>Section 0:</h3>
<p><a id="dl"></a>To download a beta-version of CRaVe 0.0.2, please choose</p>
<p>&nbsp;</p>
<table style="width: 285px;" border="1">
<tbody>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 172px;" align="left">UNIX:</td>
<td style="width: 89px;" align="right"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431434" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431434" sys_dependentvariantid="1500" sys_relationshipid="6703600" sys_siteid="475">CRaVe</a><br />&nbsp;</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 172px;" align="left">R-library (Windows 7):</td>
<td style="width: 89px;" align="right"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431433" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431433" sys_dependentvariantid="1500" sys_relationshipid="6703601" sys_siteid="475">CRaVe</a><br />&nbsp;</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 172px;" align="left">R-library (UNIX):</td>
<td style="width: 89px;" align="right"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431432" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431432" sys_dependentvariantid="1500" sys_relationshipid="6703602" sys_siteid="475">CRaVe</a></td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>To install CRaVe, follow these simple steps: <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433266" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433266" sys_dependentvariantid="1418" sys_relationshipid="6703603" sys_siteid="475">setup</a></p>
<p>Our goal is to make this software as user-friendly as possible and therefore we encourage our users to provide feedback. First, as this is a beta-version, we do expect there to be some bugs, so please email us if you encounter any problems: <a href="mailto:joshua.sampson@nih.gov"><span color="0000FF">joshua.sampson@nih.gov</span></a> . However, we also encourage you to let us know if we omitted any options, features, or methods that could make CRaVe more useful.</p>
<h3>Section I: Introduction</h3>
<p>CRaVe is a free, open source, software package designed to perform a range of association tests between sets of SNPs and a phenotype. The basic input for CRaVe includes three types of information:</p>
<p><b>1) Genotypes for a set of individuals at a list of SNPs.&nbsp;</b></p>
<p>&nbsp;</p>
<table border="1">
<tbody>
<tr>
<td align="right">&nbsp;</td>
<td align="right">Subject 1</td>
<td align="right">Subject 2</td>
<td align="right">Subject 3</td>
</tr>
<tr>
<td align="right">SNP 1</td>
<td align="right">AT</td>
<td align="right">CC</td>
<td align="right">AC</td>
</tr>
<tr>
<td align="right">SNP 2</td>
<td align="right">AA</td>
<td align="right">CC</td>
<td align="right">AA</td>
</tr>
<tr>
<td align="right">SNP 3</td>
<td align="right">AA</td>
<td align="right">CG</td>
<td align="right">AC</td>
</tr>
<tr>
<td align="right">.</td>
<td align="right">.</td>
<td align="right">.</td>
<td align="right">.</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p><b>2) The Gene or Group ID for each SNP&nbsp;</b></p>
<p>&nbsp;</p>
<table style="width: 286px;" border="1">
<tbody>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">&nbsp;</td>
<td style="width: 200px;" align="right">Gene ID</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">SNP 1</td>
<td style="width: 200px;" align="right">g1</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">SNP 2</td>
<td style="width: 200px;" align="right">g1</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">SNP 3</td>
<td style="width: 200px;" align="right">g1</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">.</td>
<td style="width: 200px;" align="right">.</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">SNP 41</td>
<td style="width: 200px;" align="right">g2</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">SNP 42</td>
<td style="width: 200px;" align="right">g2</td>
</tr>
<tr>
<td style="width: -1px;" align="right">&nbsp;</td>
<td style="width: 63px;" align="right">.</td>
<td style="width: 200px;" align="right">.</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p><b>3) Phenotypes for a set of individuals&nbsp;</b></p>
<p>&nbsp;</p>
<table style="width: 282px;" border="1">
<tbody>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 65px;" align="right">&nbsp;</td>
<td style="width: 186px;" align="right">Phenotype</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 65px;" align="right">Subject 1</td>
<td style="width: 186px;" align="right">1</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 65px;" align="right">Subject 2</td>
<td style="width: 186px;" align="right">1</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td style="width: 65px;" align="right">Subject 3</td>
<td style="width: 186px;" align="right">0</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>The basic output of CRaVe is</p>
<p><b>1) One or more p-values for each gene. The p-values assess the significance of the relationship between gene and phenotype&nbsp;</b></p>
<p>&nbsp;</p>
<table style="width: 282px;" border="1">
<tbody>
<tr>
<td align="right">&nbsp;</td>
<td align="right">Gene</td>
<td align="right">Sum-Test</td>
<td style="width: 127px;" align="right">Hotelling's T-Test</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td align="right">g1</td>
<td align="right">0.03</td>
<td style="width: 127px;" align="right">0.05</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td align="right">g2</td>
<td align="right">0.67</td>
<td style="width: 127px;" align="right">0.82</td>
</tr>
<tr>
<td align="right">&nbsp;</td>
<td align="right">g3</td>
<td align="right">0.21</td>
<td style="width: 127px;" align="right">0.63</td>
</tr>
</tbody>
</table>
<h3>Section 2: File Formats</h3>
<p>Here, we discuss the actual file formats needed by CRaVe</p>
<p><b>1) Genotypes for a set of individuals at a list of SNPs.&nbsp;</b></p>
<p>The genotype file can either be in variant call format, which usually ends with .vcf or it can be in a transposed PLINK ped file, which usually ends in .tped. Details about each type of file can be found at <a href="http://www.1000genomes.org/wiki/analysis/vcf4.0">.vcf</a> and <a href="http://pngu.mgh.harvard.edu/~purcell/plink/data.shtml#ped">.tped</a> and examples can be found at <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431440" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431440" sys_dependentvariantid="1500" sys_relationshipid="6703604" sys_siteid="475">VCF</a> and <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431439" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431439" sys_dependentvariantid="1500" sys_relationshipid="6703605" sys_siteid="475">TPED</a>.</p>
<p><b>2) Gene or Group ID for each SNP&nbsp;</b></p>
<p>Both .tped and .vcf files include chromosome and position for each SNP. Installed with CRaVe is the database hg19/ncbi build 37. The database is partitioned by chromosome into files named chr_xx.txt.gz, where xx is the chromosome number. These files have the specific format as defined by the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433207" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433207" sys_dependentvariantid="1418" sys_relationshipid="6703614" sys_siteid="475">gene_file</a> option (see link for key details). The <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433207" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433207" sys_dependentvariantid="1418" sys_relationshipid="6703615" sys_siteid="475">gene_file</a> option refers to the <span color="FF0000">directory</span> where the chr_xx.txt.gz files are located. If say, the hg18/build 36 coordinates are needed, then a user can download them from <a href="#dl">here</a>, use the command &amp;quottar &ndash;xzvf hg18.tar.gz" to un-pack the files, and then use the option <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433207" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433207" sys_dependentvariantid="1418" sys_relationshipid="6703616" sys_siteid="475">gene_file</a> when running CRaVe. For instance, if the files for hg18 have been downloaded into folder ./mydata/someFolder3 and un-packed, then an example run might look like:</p>
<p>./crave geno_file=someFile.vcf gene_file=./mydata/someFolder3/hg18 pheno_file=someFile.txt tests=RO,SUM,TH</p>
<p>Note that the folder hg18 gets automatically created when un-packing the file hg18.tar.gz. A user can also specify their own categorization in their own files provided their files are named chr_xx.txt.gz, where xx is the chromosome number, and they all have the format as described in the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433207" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433207" sys_dependentvariantid="1418" sys_relationshipid="6703617" sys_siteid="475">gene_file</a> option. An (uncompressed) example file can be found here <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431435" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431435" sys_dependentvariantid="1500" sys_relationshipid="6703618" sys_siteid="475">geneFile</a>.</p>
<p><b>3) Phenotypes for a set of individuals&nbsp;</b></p>
<p>This file should consist of at least 2 columns. By default, CRaVe asumes column 1 is for the subject ids and column 2 is for the response.</p>
<p>Column 1: Subject ID</p>
<p><span style="color: #ff0000;" color="#FF0000">When the genotype file is a .tped file, the subjects listed in the phenotype file must match their order in the genotype file.</span> When the genotype file is a .vcf file, their order is inconsequential but the subject IDs must match those in the .vcf file.</p>
<p>Column 2: Phenotype Value.</p>
<p>If case/control status, use 0/1 values so CRaVe understands it is looking at a case/control study. Different case-control values can be specified by using the <span color="0000FF">case_value</span> and <span color="0000FF">control_value</span> options.</p>
<p>This file can also contain additional columns containing covariate values for an individual. To adjust for covariates, one must use the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433208" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433208" sys_dependentvariantid="1418" sys_relationshipid="6703606" sys_siteid="475">covars</a> option. An example of a phenotype file can be found here <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431438" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431438" sys_dependentvariantid="1500" sys_relationshipid="6703607" sys_siteid="475">pheno</a>.</p>
<p><b>4) Output files&nbsp;</b></p>
<p>One output file is specified with the out_gene option and has the following columns:</p>
<p>&nbsp;</p>
<table border="1">
<tbody>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 1</td>
<td align="left">Gene ID</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 2</td>
<td align="left">Chromosome</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 3</td>
<td align="left">Gene start position</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 4</td>
<td align="left">Gene end position</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 5</td>
<td align="left">Number of SNPs</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 6</td>
<td align="left">Permutation p-value for the first requested test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 7+</td>
<td align="left">Permutation p-value for additional tests</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>Another output file is specified with the out_snp option that lists results for individual SNPs:</p>
<p>&nbsp;</p>
<table border="1">
<tbody>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 1</td>
<td align="left">Chromosome</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 2</td>
<td align="left">Gene ID</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 3</td>
<td align="left">SNP position</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 4</td>
<td align="left">Minor allele frequency</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 5</td>
<td align="left">Number of subjects with non-missing genotypes</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 6</td>
<td align="left">Effect size of the SNP</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 7</td>
<td align="left">Delta value of the SNP</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">Column 8</td>
<td align="left">P-value (2-sided using delta as the z-test statistic)</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>Examples of both output files can be found at <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431436" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431436" sys_dependentvariantid="1500" sys_relationshipid="6703608" sys_siteid="475">gene-file</a> and <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=431437" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="431437" sys_dependentvariantid="1500" sys_relationshipid="6703609" sys_siteid="475">SNP-file</a>.</p>
<p><b>5) Bioinformatic Weight&nbsp;</b></p>
<p>Prespecified weights can be assigned to each SNP using the <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433262" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433262" sys_dependentvariantid="1418" sys_relationshipid="6703610" sys_siteid="475">weight_file</a> option. These weights should be listed in a file containing one or two columns. Alternatively, a weight of 0 or 1 can be assigned to codons, exons or non-synonomous SNPs using the <span color="0000FF">weight=</span> option.</p>
<h3>Section 3: Statistical Tests</h3>
<p>CRaVe can perform a range of association tests between SNPs and a phenotype. Currently, the possible tests include:</p>
<p>&nbsp;</p>
<table border="1">
<tbody>
<tr>
<td align="left">&nbsp;</td>
<td align="left">ALL</td>
<td align="left">All non-user defined tests</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">BM</td>
<td align="left">Bounded Minimum Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">CMC</td>
<td align="left">Combined Multivariate and Collapsing Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">DAS</td>
<td align="left">Data Adaptive Sum Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">FI</td>
<td align="left">Fisher's Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">HOI</td>
<td align="left">Hotelling's T<sup>2</sup> Test assuming independence</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">HOT</td>
<td align="left">Hotelling's T<sup>2</sup> Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">MDF</td>
<td align="left">Multiple Degrees of Freedom Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">MDP</td>
<td align="left">Multiple Degrees of Freedom Test using positive deltas</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">RO</td>
<td align="left">ROVER</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">RV</td>
<td align="left">ROVER-V test that includes the variances in the weights</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">STO</td>
<td align="left">Stouffer's Z-score Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">STP</td>
<td align="left">Stouffer's Positive Z-score Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">SUM</td>
<td align="left">Sum Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">TH</td>
<td align="left">Threshold Test</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">SKAT</td>
<td align="left">Alias for MDF [Under standard conditions, SKAT [PMID: 21737059] is equivalent to MDF]</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">SKATO &nbsp;&nbsp;</td>
<td align="left">Maximum of linear combinations of MDF and SUM statistics [similar to SKAT-O [PMID: 22863193]]</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left">CAL</td>
<td align="left">Alias for C-alpha [Under standard conditions, the C-alpha statistic [PMID: 21408211] is equivalent to MDF]</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>Some tests are modified versions of those described by their original authors. The user needs to list the desired tests in the command line with the option <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433263" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433263" sys_dependentvariantid="1418" sys_relationshipid="6703611" sys_siteid="475">tests=</a>. Without including any tests, CRaVe defaults to calculating HOI. Some tests run much faster than others because they never require performing a matrix inversion. These faster tests are: FI, HOI, RO, STP and STO.</p>
<h3>Section 4: Command Line</h3>
<p>The simplest command, when the user has listed the SNPs by their hg19 positions, only requests ROVER, and does not use bioinformatic weights would be</p>
<p>./crave geno_file=someFile.vcf pheno_file=someFile.txt</p>
<p>However, in general, the user will want to specify multiple options. Most options are specified by their name, followed by an "=" sign, followed by the desired value. Below are a few examples.</p>
<p>./crave geno_file=someFile.vcf pheno_file=someFile.txt tests=RO,SUM,TH<br />./crave geno_file=someFile.vcf pheno_file=someFile.txt max_miss_rate=0.5<br />./crave geno_file=someFile.vcf pheno_file=someFile.txt exclude_snp=/temp/remove_SNPs.txt<br />./crave geno_file=someFile.vcf pheno_file=someFile.txt include_chr=1-5,22</p>
<p>If crave_001.tar.gz was installed in folder /someFolder1 and the genotype and phenotype files are in folder /someFolder2, then the command would look similar to</p>
<p>/someFolder1/crave geno_file=/someFolder2/someFile.vcf pheno_file=/someFolder2/someFile.txt</p>
<p>The list of options include:</p>
<p>&nbsp;</p>
<table border="1">
<tbody>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">adapt_maxperm</span>={integer}</td>
<td align="left">It is generally inefficient to run the maximum number of permutations for each gene. For those genes with relatively high p-values, only a small set of permutations is needed. We allow CRaVe to stop running permutations once it believes the p-values are sufficiently accurate. When we allow the number of permutations to depend on the p-value, we refer to them as adaptive permutations. However, we still need to define a maximum number of adaptive permutations with this option. Set to 0 for non-adaptive permutations. The default value is 1000000.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">adapt_tol</span>={value}</td>
<td align="left">Stopping tolerance for adaptive permutations. Smaller values guarentee more precise estimates. The algorithm stops if 3.92*sqrt(pval*(1.0-pval)/N)/pval &lt; <span color="0000FF">adapt_tol</span>, where N is the total number of permutations that have been run so far. The default is 0.1.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">addcols</span>={0,1,2}</td>
<td align="left">Option to include additional columns in the <span color="0000FF">out_gene</span> file. If set to 1, then the number of permutations for each test will included. If set to 2, then the number of permutations and number of times the permuted test statistic was greater than the observed are included. These columns are useful for breaking up a large number of permutations into smaller jobs on cluster. The default value is 0.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">allele_miss</span>={character}</td>
<td align="left">Missing value for alleles in a TPED file. The default is 0.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">bm_n</span>={integer}</td>
<td align="left">Number of points to consider in the Bounded Minimum Test. The default is 10.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">case_value</span>={integer}</td>
<td align="left">Value representing cases if <span color="0000FF">response_col</span> is for a case-control study. The default value is 1.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">chr_alias_file</span>={file}</td>
<td align="left">Tab delimited text file with the first column as the chromosome number (1-26) and the second column the chromosome string. This option is only used with VCF genotype files when the chromosome fields are not labeled as integers. An example file is <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=500253" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="500253" sys_dependentvariantid="1500" sys_relationshipid="6703612" sys_siteid="475">chr_alias-file</a>.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">control_value</span>={integer}</td>
<td align="left">Value representing controls if <span color="0000FF">response_col</span> is for a case-control study. The default value is 0.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">covars</span>={list}</td>
<td align="left">Comma separated list of column numbers or variable names in the phenotype file to use as covariates in the analysis. Example: covars=4,7,9 will use columns 4,7 and 9 in the phenotype file as covariates. Values of 1 or 2 are generally not used because those are generally reserved for subject ID and the outcome variable.The default value is to not use covariates.<br />&nbsp;</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">das_alpha</span>={value}</td>
<td align="left">A number between 0 and 1 for the alpha parameter in the Data Adaptive Sum Test. The default is 0.05</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">exclude_chr</span>={list}</td>
<td align="left">List of chromsomes to exclude in the analysis. Examples: 1,4,6 1-11,22, 1,3,5-10,X</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">exclude_gene</span>={file}</td>
<td align="left">File containing 1 column of the genes to exclude in the analysis.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">exclude_snp</span>={file}</td>
<td align="left">File containing 1 column of the SNPs to exclude in the analysis.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">exclude_sub</span>={file}</td>
<td align="left">File containing 1 column of the subject ids to exclude in the analysis.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">gene_file</span>={file}</td>
<td align="left">Directory containing the gene information files partitioned by chromosome. The default value is hg19. More details at <a href="html/crave_gene_file.html">gene_file</a> [Note that geno_file and gene_file define two different types of files.]</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">gene_kb</span>={integer}</td>
<td align="left">Number of kilobases upstream and downstream to expand the gene regions from the gene tables. The default is 10.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">geno_file</span>={file}</td>
<td align="left">Uncompressed VCF or TPED file. No default value, must be specified. [Note that geno_file and gene_file define two different types of files.]</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">geno_sep</span>={character}</td>
<td align="left">File delimiter for the genotype file. Use 't' for tab-delimited, ' ' for space delimited, and ',' for comma delimited files. The default is determined from the file.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">id</span>={string}</td>
<td align="left">Variable name or column number in <span color="0000FF">pheno_file</span> for the subject ids. The default value is 1</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">include_chr</span>={list}</td>
<td align="left">List of chromsomes to include in the analysis. Examples: 1,4,6 1-11,22, 1,3,5-10,X The default value is 1-26</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">include_gene</span>={file}</td>
<td align="left">File containing 1 column of the genes to include in the analysis.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">include_snp</span>={file}</td>
<td align="left">File containing 1 column of the SNPs to include in the analysis.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">include_sub</span>={file}</td>
<td align="left">File containing 1 column of the subject ids to include in the analysis.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">max_maf</span>={value}</td>
<td align="left">Maximum MAF to use for which SNPs to include in the analysis. Any SNP with MAF &gt; <span color="0000FF">max_maf</span> will be ignored. The default value is 0.5</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">max_miss_rate</span>={value}</td>
<td align="left">Maximum missing rate for any SNP to be included in the analysis The default value is 0.8</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">min_maf</span>={value}</td>
<td align="left">Minimum MAF to use for which SNPs to include in the analysis. Any SNP with MAF &lt; <span color="0000FF">min_maf</span> will be ignored. The default value is 0</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">nperm</span>={integer}</td>
<td align="left">For adaptive permutations, <span color="0000FF">nperm</span> is the number of permutations (per round) performed before checking the stopping criteria. (see option adapt_maxperm for definition of adaptive permutations). For non-adaptive permutations, <span color="0000FF">nperm</span> is the total number of permutations. The default value is 500.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">out_gene</span>={file}</td>
<td align="left">Output file for the genes The default value is ./out_gene.txt.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">out_snp</span>={file}</td>
<td align="left">Output file for the SNPs The default value is ./out_snp.txt.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">pheno_file</span>={file}</td>
<td align="left">Uncompressed file containing the response and covariates No default value, must be specified<br />&nbsp;</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">pheno_header</span>={0 or 1}</td>
<td align="left">Set to 1 if row 1 of pheno_file contains column names. The default value is determined from the file.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">pheno_miss</span>={character}</td>
<td align="left">Missing value for the phenotype file. The default value is '.'</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">pheno_sep</span>={character}</td>
<td align="left">One character value for the phenotype file delimiter. Use 't' for tab-delimited, ' ' for space delimited, and ',' for comma delimited files. The default value is determined from the file.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">print</span>={integer}</td>
<td align="left">The larger the integer, the more information will be written to the console. This information is useful to see summary information, the genes that have been processed, and is critical for debugging. The default is 0 (no printing).</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">reflink.geneName</span>={string}</td>
<td align="left">Name of the variable in the INFO field of the VCF file that gives the gene name. The default value is reflink.geneName.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">response</span>={string}</td>
<td align="left">Variable name or column number <span color="0000FF">pheno_file</span> for the response. The default value is 2.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">rover_t</span>={value}</td>
<td align="left">Positive number t to define the weights (w = sqrt(1-exp(-t*delta*delta))) in the Rover Test. The default is 0.2</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">seed</span>={integer}</td>
<td align="left">Initial seed for the random permutations. The default is the returned value from the time() function.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">sortedByLoc</span>={0 or 1}</td>
<td align="left">Set to 0 if the genotype data is not sorted by SNP location within each chromosome. The default is 1.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">store_perms</span>={0 or 1}</td>
<td align="left">Set to 1 to store the permutations for efficiency. Due to memory issues, this option should only be used for a small sample size and number of permutations. The default is 0.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">strata</span>={string}</td>
<td align="left">strata can be set to the name of a variable in the phenotype file. When set, the outcome is permuted among individuals with the same value of the strata variable and the named variable is automatically included as a covariate.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">tests</span>={List of strings}</td>
<td align="left">Comma delimited list of tests to use. The valid tests are: BM, CMC, DAS, FI, HOI, HOT, MDF, MDP, RO, RV, STO, STP, SUM, TH. The strings are not case-sensitive. Example: tests=sto,bm,sum will compute the Stouffer, BM and SUM tests. Example: tests=c1,th will compute the user defined test c1 and the threshold test. Use tests=all to compute all non user defined tests. The default is MDF.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">threshold_alpha</span>={value}</td>
<td align="left">A number between 0 and 1 for the alpha parameter in the Theshold Test. The default is 0.05</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">update_cor</span>={value}</td>
<td align="left">The value such that the correlation matrix will be updated if the relative difference in the observed and permuted Hotelling test statistics is less than <span color="0000FF">update_cor</span>. This option is only valid for case-control data and when the option --useAllSubsForV is not used. The default is 0.3</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">vs</span>={value}</td>
<td align="left">The value of vs, where vs abbreviates variance stabilization, is the value added to the estimated variance of each SNP. The default is 0.005</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">weight=</span>{c, e, or n}</td>
<td align="left">weight=e assigns a weight of 1 to all exomic SNPs and 0 to other SNPs. weight=g assigns a weight of 1 to SNPs between the start and stop codon and 0 to other SNPs. weight=n assigns a weight of 1 to non-synonomous exomic SNPs and 0 to other SNPs. The default is that a weight of 1 is assigned to all SNPs. This option cannot be used with the <span color="0000FF">weight_file=</span> option, and weight=n is only valid for hg18 and hg19.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">weight_file</span>={file}</td>
<td align="left">Uncompressed file containing the SNP weights. This file may have 1 or 2 columns only. For a 1 column file the column of weights must match the order of the SNPs in the genotype file. For a 2 column file, the first column is the SNP id and the second column the weight. This option cannot be used with the <span color="0000FF">weight=</span> option.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">weight_header</span>={0 or 1}</td>
<td align="left">Set to 1 if row 1 of the weight file contains column names. The default value is determined from the file.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">weight_sep</span>={character}</td>
<td align="left">One character value for the weight file delimiter.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">--help</span></td>
<td align="left">Display this information and exit.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">--notGroupedByChr</span></td>
<td align="left">If the genotype file is a TPED file and it is not grouped by chromosome.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">--no_gene_file</span></td>
<td align="left">Do not use the default gene table file for the gene names. Instead use the <span color="0000FF">reflink.geneName</span> value in the VCF file. This option is only valid if geno_file is a VCF file.</td>
</tr>
<tr>
<td align="left">&nbsp;</td>
<td align="left"><span color="0000FF">--version</span></td>
<td align="left">Display the version number and exit.</td>
</tr>
</tbody>
</table>
<p><span color="FF0000">!!!!! IMPORTANT !!!!! For p-values below 10<sup>-5</sup>, we strongly suggest increasing the maximum number of permutations.&nbsp;</span></p>
<h3>Section 5: Frequently Asked Questions</h3>
<p><b>1) How does CRaVe handle highly correlated genotypes?&nbsp;</b></p>
<p>Correlation only poses a problem for statistics that include terms from the inverse of the correlation matrix s. When s is non-invertible, we invert s+cI, where I is the identity matrix and c is a small value.</p>
<p><b>2) Can I define my own test statistic?&nbsp;</b></p>
<p>Yes. A user can define a test statistic as a R function or C function. For those accustomed to R, CRaVe greatly speeds up the calculation of the permuted p-value. For more information see <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433264" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433264" sys_dependentvariantid="1418" sys_relationshipid="6703613" sys_siteid="475">user-defined</a>.</p>
<p>Updated: 6/3/2013</p>
</div>]]></content>
  </row>
  <row para_id="433207" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p><b>Syntax:</b> gene_file=directory<br />&#160;</p><p>To use hg16, hg17, or hg18, set gene_file=folder containing the gene information files. By default, hg19 is used and is installed with CRaVe. The files are named chr_xx.txt.gz.</p><p>Each file contains the columns:<br />Column 1: gene name<br />Column 2: gene start position<br />Column 3: gene end position<br />Column 4: codon start position<br />Column 5: codon end position<br />Column 6: number of exon start and end positions<br />Column 7: comma separated list of exon starting positions<br />Column 8: comma separated list of exon ending positions<br />&#160;</p><p>The files must be tab-delimited and sorted by ascending gene start position. Row 1 has the total number of rows in the file minus 1. Row 2 are the column names. Use the command &quot;tar &#8211;xzvf hg18.tar.gz&quot; to un-pack the files.</p></div>]]></content>
  </row>
  <row para_id="433208" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p><b>Syntax:</b> covars=list<br />The list can either be a list of column numbers or variable names and must be seperated by a comma with no white space.</p><p>Examples:<br />covars=age,gender</p><p>covars=5,6,7,9,11</p></div>]]></content>
  </row>
  <row para_id="433261" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-hgp/cgb" title="">CGB Home</a></h3>
<p><a href="/about/organization/programs-hgp/cgb/clinical-epi-unit" title="">Clinical Epidemiology Unit</a></p>
<p><a href="/about/organization/programs-hgp/cgb/research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=CGB">CGB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/cgb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/cgb-training" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-hgp/cgb/tools-useful-links" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=CGB">Publications</a></p>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239772" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a> investigators conduct clinical, genetic, and epidemiologic studies of individuals at high risk of cancer in order to improve our understanding of cancer etiology and to advance clinical care.</p>
<h3>Clinical Genetics Studies</h3>
<p>CGB investigators&nbsp;conduct&nbsp;etiologic studies of individuals and families at increased risk of cancer to discover new cancer susceptibility or risk-modifying genes,&nbsp;to understand better the molecular pathogenesis of specific disorders, and to investigate possible genotype/phenotype relationships that will improve clinical management and aid in genetic counseling.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303659" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239773" sys_dependentvariantid="1418" sys_dependentid="303659" rxinlineslot="103" sys_variantid="1418" sys_contentid="303659">Familial Testicular Cancer Study</a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303659" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239780" sys_dependentvariantid="1418" sys_dependentid="303659" rxinlineslot="103" sys_variantid="1418" sys_contentid="303659"><br /></a>DCEG investigators are conducting the Familiar Testicular Cancer Study to research the genetic causes of testicular cancer.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303691" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239779" sys_dependentvariantid="1418" sys_dependentid="303691" rxinlineslot="103" sys_variantid="1418" sys_contentid="303691">Inherited Bone Marrow Failure Syndromes</a><br /> The inherited bone marrow failure syndromes (IBMFS) are a group of rare genetic blood disorders. DCEG investigators are leading a clinical study to better understand how cancers develop in persons with IBMFS.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303694" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239775" sys_dependentvariantid="1418" sys_dependentid="303694" rxinlineslot="103" sys_variantid="1418" sys_contentid="303694">Li-Fraumeni Syndrome Study</a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303694" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239781" sys_dependentvariantid="1418" sys_dependentid="303694" rxinlineslot="103" sys_variantid="1418" sys_contentid="303694">&nbsp;<br /></a>Li-Fraumeni Syndrome (LFS) is a rare, inherited disorder which leads to a higher risk of certain cancers. NCI has evaluated families with LFS since the syndrome was first recognized in 1969. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=533039" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239777" sys_dependentvariantid="1418" sys_dependentid="533039" rxinlineslot="103" sys_variantid="1418" sys_contentid="533039">Myotonic Dystrophy and Cancer Susceptibility</a><br />Studies of Myotonic Dystrophy (DM) and possible correlation with cancer susceptibility</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=533092" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239778" sys_dependentvariantid="1418" sys_dependentid="533092" rxinlineslot="103" sys_variantid="1418" sys_contentid="533092">Neurofibromatosis Type 1</a><br />Studies on Neurofibromatosis Type 1 and associations with cancer susceptibility</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303547" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239785" sys_dependentvariantid="1418" sys_dependentid="303547" rxinlineslot="103" sys_variantid="1418" sys_contentid="303547">Osteosarcoma Studies</a><br /> Studies of osteosarcoma,&nbsp;a primary bone cancer of adolescents and young adults</p>
<p><a href="https://ppb.cancer.gov/">Pleuropulmonary Blastoma <i>DICER1</i> Syndrome Study</a>&nbsp;<br />Pleuropulmonary blastoma (PPB) is a rare tumor of the lung. Research has shown that PPB may be part of an inherited cancer predisposition syndrome caused by changes in a gene known as <em>DICER1</em>. The PPB Cancer Study is an observational study of children with PPB and their families.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302639" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239786" sys_dependentvariantid="1418" sys_dependentid="302639" rxinlineslot="103" sys_variantid="1418" sys_contentid="302639">Waldenstr&ouml;m's Macroglobulinemia Study</a><br /> Waldenstr&ouml;m's macroglobulinemia (WM) is a rare type of tumor that belongs to a group of disorders called lymphoproliferative diseases. DCEG researchers are leading a study to determine what causes WM to sometimes develop in two or more family members.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=532556" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239776" sys_dependentvariantid="1418" sys_dependentid="532556" rxinlineslot="103" sys_variantid="1418" sys_contentid="532556">Behavioral, Counseling &amp; Psychosocial Implications of Increased Cancer Risk</a><br />Studies of behavioral, counseling and psychosocial implications related to being at increased genetic risk of developing cancer.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302581" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239774" sys_dependentvariantid="1418" sys_dependentid="302581" rxinlineslot="103" sys_variantid="1418" sys_contentid="302581">Telomere Molecular Epidemiology</a><br />Studies of nucleoprotein structures designed to protect the ends of chromosomes and are critical to chromosome stability. Research covers characterization of telomere length as a cancer risk factor and identification of genetic determinants of telomere length.</p>
<!--
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=7&amp;sys_contentid=335952&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257742" sys_dependentvariantid="1418" sys_dependentid="335952" rxinlineslot="103">Dyskeratosis Congenita Study</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=511073&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257743" sys_dependentvariantid="1418" sys_dependentid="511073" rxinlineslot="103">Telomere Length and Risk of Cancer and Related Diseases</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=2&amp;sys_contentid=511115&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257744" sys_dependentvariantid="1418" sys_dependentid="511115" rxinlineslot="103">Genetic Contribution to Telomere Biology</a></p>-->
<h3>Clinical Epidemiology Studies</h3>
<p>CGB investigators study the molecular etiology and prevention of&nbsp;human papillomavirus (HPV) related cancers and ovarian and endometrial cancers&nbsp;in order to&nbsp;identify at-risk individuals in the general population. We seek to&nbsp;translate our research&nbsp;findings&nbsp;into improved clinical practice and management.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491070" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239784" sys_dependentvariantid="1418" sys_dependentid="491070" rxinlineslot="103" sys_variantid="1418" sys_contentid="491070">Human Papillomavirus (HPV) Natural History, Genomics, and Risk Assessment</a><br /> Investigators have performed a series of studies of HPV natural history, genomics and risk assessment that have&nbsp;led to advances in screening and clinical management.</p>
<!--
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=11&amp;sys_contentid=303538&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257734" sys_dependentvariantid="1418" sys_dependentid="303538" rxinlineslot="103">Anal Cancer Screening Study</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=9&amp;sys_contentid=303573&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257735" sys_dependentvariantid="1418" sys_dependentid="303573" rxinlineslot="103">ASC-US/LSIL Triage Study (ALTS)</a></p>
<p style="padding-left: 30px;"><a href="http://dceg.cancer.gov/research/cancer-types/cervix/biopsy-study-detect-cervical-precancer">Biopsy Study to Improve Detection of Cervical </a><a href="http://dceg.cancer.gov/research/cancer-types/cervix/biopsy-study-detect-cervical-precancer">Precancer</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=8&amp;sys_contentid=303577&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257745" sys_dependentvariantid="1418" sys_dependentid="303577" rxinlineslot="103">Cervical Cancer Screening Among HIV-Infected Women in India</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=2&amp;sys_contentid=491081&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257746" sys_dependentvariantid="1418" sys_dependentid="491081" rxinlineslot="103">Guanacaste HPV Natural History Study</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=4&amp;sys_contentid=491089&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257747" sys_dependentvariantid="1418" sys_dependentid="491089" rxinlineslot="103">Human Papillomavirus (HPV) Cervical Cancer Risk Prediction</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=491095&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257748" sys_dependentvariantid="1418" sys_dependentid="491095" rxinlineslot="103">Human Papillomavirus (HPV) Cervical Visualization Study</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=3&amp;sys_contentid=491103&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257749" sys_dependentvariantid="1418" sys_dependentid="491103" rxinlineslot="103">Human Papillomavirus (HPV) Methylation</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=6&amp;sys_contentid=491113&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257750" sys_dependentvariantid="1418" sys_dependentid="491113" rxinlineslot="103">Human Papillomavirus (HPV) Viral Genomics</a></p>
<p style="padding-left: 30px;"><a href="http://dceg.cancer.gov/research/cancer-types/cervix/hpv-pap-cohort">Human Papillomavirus (HPV) Persistence and Progression Cohort (</a><a href="http://dceg.cancer.gov/research/cancer-types/cervix/hpv-pap-cohort">PaP</a><a href="http://dceg.cancer.gov/research/cancer-types/cervix/hpv-pap-cohort"> Cohort)</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=1&amp;sys_contentid=1043259&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257751" sys_dependentvariantid="1418" sys_dependentid="1043259" rxinlineslot="103">Improvement of Risk-Informed Screening (IRIS)</a></p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=8&amp;sys_contentid=303575&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257752" sys_dependentvariantid="1418" sys_dependentid="303575" rxinlineslot="103">Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED)</a></p>-->
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1043265" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7239782" sys_dependentvariantid="1418" sys_dependentid="1043265" rxinlineslot="103" sys_variantid="1418" sys_contentid="1043265">Ovarian and Endometrial Cancer Studies</a><br /> CGB investigators&nbsp;are&nbsp;studying the etiologic heterogeneity of ovarian cancers and&nbsp;the roles that inflammation and endogenous hormones play in carcinogenesis. They have also&nbsp;been testing novel sampling strategies for collecting endometrial samples.</p>
<!--
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=10&amp;sys_contentid=303581&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257730" sys_dependentvariantid="1418" sys_dependentid="303581" rxinlineslot="103">Assessment of Screening Modalities for Gynecologic Cancers</a><br />A feasibility study to assess the use of alternative sampling techniques and molecular assays to detect endometrial and ovarian cancer.</p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=9&amp;sys_contentid=303630&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257732" sys_dependentvariantid="1418" sys_dependentid="303630" rxinlineslot="103">Benign Reproductive Tissue Evaluation Study</a></p>
</div>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=10&amp;sys_contentid=303633&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257731" sys_dependentvariantid="1418" sys_dependentid="303633" rxinlineslot="103">Ovarian and Endometrial Cancer Case-Control Study in Poland</a><br />A population-based case-control study of ovarian and endometrial cancer conducted among female residents of Warsaw and Lodz (Poland) between 2001 and 2003.</p>
<p style="padding-left: 30px;"><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=8&amp;sys_contentid=303582&amp;sys_context=0&amp;sys_siteid=475" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6257733" sys_dependentvariantid="1418" sys_dependentid="303582" rxinlineslot="103">Study of Endometrial Hyperplasia Progression</a></p>-->
<p>Ovarian Cancer Consortium<br /> Ovarian cancer's rarity and substantial heterogeneity make the need for consortial studies very important. CGB investigators and their extramural colleagues have initiated the <a href="https://sites.google.com/a/channing.harvard.edu/oc3/">Ovarian Cancer Consortium (OC3)</a> to conduct epidemiologic, genetic, and biomarker studies of ovarian cancer.</p>
<h4>Biomarker Evaluation and Absolute Risk Prediction</h4>
<p>CGB investigators, in collaboration with investigators from the Biostatistics Branch (BB), are developing <a href="https://analysistools.nci.nih.gov/biomarkerTools/">methodologies and tools to be used for biomarker discovery and evaluation</a>, as well as risk stratification analysis.</p>
</div>]]></content>
  </row>
  <row para_id="433262" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><b>Syntax:</b> weight_file=filename<br />&nbsp;</p>
<p>The file of weights must be a text file with 1 or 2 columns.</p>
<p><b>File with 1 column:</b><br />The order of weights must match the order of SNPs in the genotype file. This file format is more efficient for a genotype file with a large number of SNPs.</p>
<p><b>File with 2 columns:</b><br />The first column must be the SNP id and the second column must be the weights. Any SNP id in the genotype file that is not matched with an id in the weight file is asigned a weight of 0.</p>
</div>]]></content>
  </row>
  <row para_id="433263" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><b>Syntax:</b> tests=test1,test2,...<br />Tests must be seperated by a comma with no white space.</p>
<p>Examples:<br />tests=SUM,RO,TH will include the SUM, ROVER and Threshold tests.</p>
<p>tests=FI,C1 will include the Fisher test and user defined test C1.</p>
<p>Use tests=ALL to include all non user defined tests.</p>
</div>]]></content>
  </row>
  <row para_id="433264" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Below are steps to define your own test for CRaVe. A maximum of 5 user defined tests are allowed.</p>
<p><b>C function:</b></p>
<ol>
<li>Edit the function c1 in the file user_define.c. The function name, input arguments and return type CANNOT be modified.</li>
<li>Issue the command "make clean" and then "make".</li>
<li>To include this test in an anlaysis, set the option tests=c1,...</li>
<li>For additional tests, modify the functions c2, c3, c4, c5 in the file user_defined.c.</li>
</ol>
<p>&nbsp;</p>
<p><b>R function:</b></p>
<ol>
<li>Write an R function with 4 input arguments, where argument 1 is the vector of delta values, argument 2 is the covariance matrix, argument 3 is the correlation matrix, and argument 4 is the inverse correlation matrix.<br />Example: fnc1 &lt;- function(delta, cov, cor, invcor) { return(sum(delta*delta)) }</li>
<li>In the options list for the crave function, set the option user_func to the name of the function.<br />Example: crave(geno_file, pheno_file, out_file, op=list(user_func="fnc1"))</li>
<li>For additional tests, set the option user_func to be a vector of function names.</li>
</ol>
</div>]]></content>
  </row>
  <row para_id="433266" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><b>UNIX&nbsp;</b></p>
<ol start="1" type="1">
<li>Copy the file crave.tar.gz to a directory where it will be installed.</li>
<li>Issue the command &amp;quottar &ndash;xzvf crave.tar.gz&amp;quot.</li>
<li>Issue the command &amp;quotcd crave&amp;quot.</li>
<li>Issue the command &amp;quotmake&amp;quot.</li>
</ol>
<p><b>R (Windows)&nbsp;</b></p>
<ol start="1" type="1">
<li>After downloading CRaVe, start the R software.</li>
<li>From the RGui, go to the tab &amp;quotPackages" and select &amp;quotInstall Package(s) from local zip files..."</li>
<li>Go to the directory where you downloaded CRaVe to and select CRaVe_0.0.2.zip.</li>
<li>Select Packages-&gt;Load Package...-&gt;CRaVe.</li>
<li>Type ?CRAVE in the RGui to bring up the help pages.</li>
</ol>
<p><b>R (Unix)&nbsp;</b></p>
<ol start="1" type="1">
<li>After downloading CRaVe, start the R software.</li>
<li>Type the R command install.packages(&amp;quotpath_to_CRaVe.tar.gz", &amp;quotpath_to_install_CRaVe")</li>
<li>Type the R command library(CRAVE, lib.loc=&amp;quotpath_to_install_CRaVe")</li>
<li>Type ?CRAVE to bring up the help pages.</li>
</ol>
</div>]]></content>
  </row>
  <row para_id="438648" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Information for Journalists</h3>
<p>To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:</p>
<p><b>E-mail:</b><br /><a href="mailto:ncipressofficers@mail.nih.gov">ncipressofficers@<br />mail.nih.gov</a></p>
<p><b>Phone:</b> 240-760-6600</p>
</div>
<p>For over 50 years, mortality and incidence rates for bladder cancer are higher in New England than in most parts of the United States. This population-based, case-control study of bladder cancer in New Hampshire, Vermont, and Maine sought to explain the reasons for the persistent excess of rates of bladder cancer in the northern New England area.</p>
<p>Investigators collected data on 2,600 participants via personal interview, biological samples (blood, buccal cells, urine, toenails, and tumor tissue), as well as drinking water samples. They found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont. Other risk factors for bladder cancer, such as smoking and occupational exposures, did not explain the excess risk in this region.</p>
<p>See NCI press release "<a href="https://www.cancer.gov/news-events/press-releases/2016/bladder-cancer-risk-arsenic-private-wells">Elevated bladder cancer risk in New England and arsenic in drinking water from private wells</a>."</p>
<div sys_relationshipid="7274751" sys_dependentid="1043938" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2084" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-center-full centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302169&amp;sys_siteid=475&amp;sys_contentid=1043938&amp;sys_command=preview" alt="Maps show bladder cancer mortality rates by color, with red depicting the highest and blue depicting the lowest" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=302169&amp;sys_siteid=475&amp;sys_contentid=1043938&amp;sys_command=preview"><!--Comment--></img>
                                          	          <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302169&amp;sys_siteid=475&amp;sys_contentid=1043938&amp;sys_command=preview" target="_blank" class="article-image-enlarge no-resize" sys_variantid="1518" sys_contentid="1043938">Enlarge</a>                                        </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>Bladder cancer mortality rates (age-adjusted 2000&thinsp;US population per 100, 000) among white men and women by state economic area and time period (1950-1979 and 1980-2004).</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349599" sys_variantid="1965" sys_relationshipid="7274750">Dr. Debra Silverman</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=919003" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="919003" sys_relationshipid="7274752" sys_variantid="1965" sys_contentid="919003">Dr. Stella Koutros</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="418935" sys_variantid="1418" sys_relationshipid="7274749">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
<h3>Selected Publications</h3>
<p>Baris, D. et al.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/27140955">Elevated bladder cancer in northern New England: The role of drinking water and arsenic.</a><em> J. Natl Cancer Inst</em> May 2, 2016.</p>
<p>Baris, D. et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19917915">A case-control study of smoking and bladder cancer risk: Emergent patterns over time</a>. <em>J Natl Cancer Inst</em> Nov 18, 2009.</p>
<p>Colt, J, et al.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20864470">Occupation and bladder cancer in a population-based case-control study in Northern New England</a>. <em>Occup Environ Med</em> April 2011.<strong><br /></strong></p>
<p>Nuckols JR, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21421449">Estimating water supply arsenic levels in the New England Bladder Cancer Study</a>. <em>Environ Health Perspect</em> Sept 2011.</p>
<p>Figueroa JD, et al.&nbsp; <a href="https://www.ncbi.nlm.nih.gov/pubmed/26374428">Modification of occupational exposures on bladder cancer risk by common genetic polymorphisms</a>. <em>J Natl Cancer Inst</em> Sep 14, 2015.</p>
<p>Beane Freeman LE, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28636529">Bladder Cancer and water disinfection by-product exposures through multiple routes: A population-based case-control study (New England, USA)</a>. <em>Environ Health Perspect</em> 2017.</p>
<p>Koutros S, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29548022">RE: Elevated bladder cancer in northern New England: The role of drinking water and arsenic</a>. <em>J Natl Cancer Inst</em> ePub March 2018.</p>
<p>Koutros S, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29981168">Potential effect modifiers of the arsenic-bladder cancer risk relationship</a>. <em>Int J Cancer</em> July 2018.</p>
</div>]]></content>
  </row>
  <row para_id="438694" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Job Exposure Matrices (JEMs) are an efficient way to assign exposure estimates in population-based studies and may be the only exposure assessment option when only job and industry are available for study participants. DCEG investigators develop methods to improve JEMs by incorporating databases of exposure measurements to calibrate JEMs across time and across jobs and industries. For example, in the Shanghai Women's Health Study, investigators developed a novel framework to systematically combine a JEM with historical measurements to calibrate JEM exposure ratings used to estimate historical benzene and lead exposure.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=473518#Job-Exposure-Matrices" sys_contentid="473518#job-exposure-matrices" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7274755" sys_siteid="475" rxinlineslot="103" sys_dependentid="473518" sys_dependentvariantid="1418">Publications on the use of Job Exposure Matrices</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7274753" sys_siteid="475" rxinlineslot="103" sys_dependentid="349680" sys_dependentvariantid="1965">Dr. Melissa Friesen</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7274754" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="438710" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Occupation- and industry-specific modules ask detailed questions about work activities and exposures within its population-based case-control studies to better capture within-occupation differences in exposure. Usually these module responses are reviewed job-by-job by an exposure assessor to assign exposure estimates. DCEG investigators in the Occupational and Environmental Epidemiology Branch (OEEB) develop methods to more efficiently and transparently assign exposure in studies that use modules and examine the validity and reliability of these methods. Decision rules that link questionnaire responses to exposure estimates have been developed to assess occupational exposures in U.S. case-control studies, including metalworking fluids, diesel exhaust, lead and benzene.</p>
<p>In an evaluation of the reliability of decision rule approaches,&nbsp;investigators&nbsp;found that decision rule estimates of occupational diesel exhaust exposure for the New England Bladder Cancer Study had moderately-high agreement with estimates obtained from expert reviews of each job. Exposure estimates in the decision rules are data-driven wherever possible, including use of subjects&rsquo; answers to occupation and industry-specific modules and use of job group medians derived from module responses to assign exposure to those in similar jobs without a completed module. Intensity estimates are based on synthesis of publicly available data sources whenever possible (see next section).&nbsp;Investigators have also developed a method to extract patterns in the questionnaire responses that predict an expert&rsquo;s exposure assignments using classification and regression tree (CART) models. The extracted decision rules have been used to improve the transparency and efficiency of applying the exposure decisions to other study subjects.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=473518#Occupation-Industry-Modules" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="473518" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274759" sys_variantid="1418" sys_contentid="473518#occupation-industry-modules">Publications on the use of occupation- and industry-specific modules</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349680" sys_contentid="349680" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349680" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274757" sys_variantid="1965">Dr. Melissa Friesen</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274758" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="438829" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Publicly available measurements from published literature, regulatory inspections, and NIOSH consultations are extracted to inform exposure assessment efforts in population-based studies.&nbsp; These data are useful to extract time period differences in the use of an agent and differences in exposure across time and between industries and occupations. &nbsp;Selected publications include:&nbsp;</p>
<ul>
<li>Lavou&eacute; J, Friesen MC, Burstyn I. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22952385">Two million exposure measurements now available online from the U.S. Occupational Safety and Health Administration: Descriptive analysis and potential uses for exposure assessment.</a> <i>Ann Occup Hyg</i> doi: 10.1093/annhyg/mes055. PMCID: Pending.</li>
<li>Park D, Stewart PA, Coble JB. (2009a) <a href="http://www.ncbi.nlm.nih.gov/pubmed/19544177">A comprehensive review of the literature on exposure to metalworking fluids</a>. <i>J Occup Environ Hyg</i>; 6: 530-41.</li>
<li>Park D, Stewart PA, Coble JB. (2009b) <a href="http://www.ncbi.nlm.nih.gov/pubmed/19329796">Determinants of exposure to metalworking fluid aerosols: a literature review and analysis of reported measurements.</a> <i>Ann Occup Hyg</i>; 53: 271-88.</li>
<li>Pronk A, Coble J, Stewart PA. (2009) <a href="http://www.ncbi.nlm.nih.gov/pubmed/19277070">Occupational exposure to diesel engine exhaust: a literature review.</a> <i>J Expo Sci Environ Epidemiol</i>; 19: 443-57.</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="445932" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators study geographic patterns and temporal trends in cancer incidence and mortality rates to generate etiologic hypotheses, evaluate consistency with other hypotheses, and identify cancer sites warranting special study. DCEG published a U.S. atlas of cancer mortality data spanning the years 1950 to 1994, which identified geographic areas with high rates of specific cancers and spatial and temporal patterns that may suggest particular carcinogenic exposures.&nbsp;</p>
<p>The atlas was subsequently developed into an interactive website, and was updated over the years. In 2016, the historical cancer mortality data was&nbsp;migrated to the&nbsp;<a href="https://gis.cancer.gov/geoviewer/">NCI GeoViewer</a>, a mapping tool designed to&nbsp;enable researchers to create maps of cancer statistics, demographics, and risk factors.&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1047458" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7274763" sys_dependentvariantid="1418" sys_dependentid="1047458" rxinlineslot="103" sys_variantid="1418" sys_contentid="1047458">Read more about the evolution of the cancer mortality tools</a>.</p>
<p>For more information, contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349664" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7274761" sys_dependentvariantid="1965" sys_dependentid="349664" rxinlineslot="103" sys_variantid="1965" sys_contentid="349664">Dr. Robert N. Hoover</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349681" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7274762" sys_dependentvariantid="1965" sys_dependentid="349681" rxinlineslot="103" sys_variantid="1965" sys_contentid="349681">Dr. Susan Devesa</a>. &nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="447527" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office"><p>DCEG researchers conduct case-control studies of renal cancer to investigate risk factors and genetic susceptibility.</p><ul><li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303592" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303592" sys_dependentvariantid="1418" sys_relationshipid="7205229" sys_siteid="475" sys_variantid="1418" sys_contentid="303592">Case-control Study of Renal Cell Cancer among Caucasians and African Americans in the United States</a></li><li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303593" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303593" sys_dependentvariantid="1418" sys_relationshipid="7205230" sys_siteid="475" sys_variantid="1418" sys_contentid="303593">Case-control Study of Renal Cell Cancer in Eastern Europe</a></li></ul></div>]]></content>
  </row>
  <row para_id="449497" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>Highlights from Panel Discussion with Joseph Fraumeni and David Schottenfeld</p></div>]]></content>
  </row>
  <row para_id="452174" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>DCEG researchers in the Metabolic Epidemiology Branch (MEB) investigate the relationship between dietary intake, nutritional status, and cancer risk using data from a number of large, population-based studies in the United States and abroad. Analyses from these studies consider diet and nutrition in terms of whole foods consumed, micronutrients, and chemicals formed through cooking methods. Selected studies include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_dependentvariantid="1418" sys_dependentid="303743" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248677" sys_variantid="1418" sys_contentid="303743">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302637" sys_dependentvariantid="1418" sys_dependentid="302637" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248678" sys_variantid="1418" sys_contentid="302637">Meat Intake</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_dependentvariantid="1418" sys_dependentid="303748" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248679" sys_variantid="1418" sys_contentid="303748">NIH-AARP Diet and Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303656" sys_dependentvariantid="1418" sys_dependentid="303656" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248680" sys_variantid="1418" sys_contentid="303656">Nutrition Intervention Trials in Linxian, China</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303703" sys_dependentvariantid="1418" sys_dependentid="303703" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248681" sys_variantid="1418" sys_contentid="303703">Polyp Prevention Trial</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_dependentvariantid="1418" sys_dependentid="303750" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248682" sys_variantid="1418" sys_contentid="303750">Prostate, Lung, Colon, and Ovary (PLCO) Prospective Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=454178" sys_dependentvariantid="1418" sys_dependentid="454178" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248683" sys_variantid="1418" sys_contentid="454178">Vitamin D and Cancer Risk</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="454178" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers in the Metabolic Epidemiology Branch (MEB) have been at the forefront of research into the association between vitamin D and cancer risk. While experimental data demonstrate a range of anti-carcinogenic effects for vitamin D, the epidemiological evidence has been inconsistent. MEB research includes prospective analyses of vitamin D status, as measured by circulating 25-hydroxyvitamin D [25(OH)D], the accepted biomarker of vitamin D status, and vitamin D binding protein, the major vitamin D transporter in circulation; vitamin D genetic score analyses; and cell culture experiments of biological mechanisms. In addition, MEB researchers have been examining vitamin D and prostate cancer risk in populations of African ancestry, an understudied group who are at particularly increased risk of prostate cancer. Our research has found that higher vitamin D status is associated with a reduced risk of colorectal cancer and possibly bladder cancer, and with higher risk of prostate cancer, with no association for most other cancer sites, including breast cancer.</p>
<p>MEB researchers have played integral roles in several large collaborative pooling projects investigating vitamin D-cancer associations. For example, the Vitamin D Pooling Project of Rarer Cancers showed no association between circulating 25(OH)D within 10 cohorts and risk of cancers of the endometrium, kidney, ovary, stomach, or esophagus, or non-Hodgkin lymphoma, but did show significantly elevated pancreatic cancer risk with circulating 25(OH)D greater than 100 nmol/L. The Lung Cancer Cohort Consortium found no association between 25(OH)D and lung cancer risk in 20 cohorts. MEB researchers are also involved with lead roles in other pooling projects examining vitamin D, including the Circulating Biomarkers and Breast and Colorectal Cancer Consortium and the Endogenous Hormones and Nutritional Biomarkers Prostate Cancer Consortium.</p>
<p>For more information, contact <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349619" sys_dependentvariantid="1965" sys_dependentid="349619" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6938340">Demetrius Albanes</a>.</p>
<p><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="6938341">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="459457" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-ebp/meb">MEB Home</a></h3>
<p><a title="" href="/about/organization/programs-ebp/meb/research">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows">Meet Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific">Research Training Opportunities</a></p>
<p><a title="" href="/about/organization/programs-ebp/meb/tools">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>DCEG has a long-standing interest in the associations between tobacco and cancer. MEB investigators and collaborators throughout the Division use case-control, prospective studies, and consortia to characterize changing associations between cigarette smoking and cancer. They are also committed to determining the health risks of other tobacco products, including smokeless tobacco, pipes, cigars, as well as new and emerging products such as water pipe.</p>
<p>Examples of studies used in these investigations include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_contentid="303743" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355934" sys_siteid="475" rxinlineslot="103" sys_dependentid="303743" sys_dependentvariantid="1418">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_contentid="303750" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355935" sys_siteid="475" rxinlineslot="103" sys_dependentid="303750" sys_dependentvariantid="1418">Prostate, Lung, Colon, and Ovary Prospective Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_contentid="303748" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355936" sys_siteid="475" rxinlineslot="103" sys_dependentid="303748" sys_dependentvariantid="1418">NIH-AARP Diet and Health Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303605" sys_contentid="303605" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355937" sys_siteid="475" rxinlineslot="103" sys_dependentid="303605" sys_dependentvariantid="1418">Environment And Genetics in Lung cancer Etiology</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303585" sys_contentid="303585" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355938" sys_siteid="475" rxinlineslot="103" sys_dependentid="303585" sys_dependentvariantid="1418">Barrett&rsquo;s and Esophageal Adenocarcinoma Consortium</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303653" sys_contentid="303653" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355940" sys_siteid="475" rxinlineslot="103" sys_dependentid="303653" sys_dependentvariantid="1418">Gastric and Esophageal Malignancies in Northern Iran (GEMINI)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303588" sys_contentid="303588" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355941" sys_siteid="475" rxinlineslot="103" sys_dependentid="303588" sys_dependentvariantid="1418">Golestan Cohort Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355942" sys_siteid="475" rxinlineslot="103" sys_dependentid="302552" sys_dependentvariantid="1418">U.S. Radiologic Technologists Cohort</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355943" sys_siteid="475" rxinlineslot="103" sys_dependentid="438648" sys_dependentvariantid="1418">New England Bladder Cancer Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303543" sys_contentid="303543" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355944" sys_siteid="475" rxinlineslot="103" sys_dependentid="303543" sys_dependentvariantid="1418">Interdisciplinary Case-Control Study of Bladder Cancer in Spain</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303620#Case-Control-MM" sys_contentid="303620#case-control-mm" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7355945" sys_siteid="475" rxinlineslot="103" sys_dependentid="303620" sys_dependentvariantid="1418">Case-Control Studies of Multiple Myeloma and Cancers of the Pancreas and Prostate among Blacks and Whites in the United States</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="459572" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Investigators in the Metabolic Epidemiology Branch (MEB) conduct a synergistic, cutting-edge prostate cancer research program focused on increasing our understanding of the causes of this cancer as well as discovering and validating predictive biomarkers for clinical translation. Central themes include endogenous and exogenous sex steroid hormones, micronutrients and vitamin supplementation, reproductive factors, tissue-based biomarkers, and metabolomics, as well as examination of racial differences.</p>
<p>MEB investigators focus on studying identifiable subsets of clinically-relevant prostate cancer (e.g., aggressive and lethal forms) to ensure clinical relevance and avoid dilution of associations by indolent prostate cancers. They use state-of-the-art methods and novel approaches, drawing upon the distinct features of the Intramural Research Program and collaborating with expert extramural groups around the world.</p>
<h3>Prostate Cancer Research Areas</h3>
<h4>Prostate Cancer Trends and Racial Differences</h4>
<div sys_dependentvariantid="2066" sys_dependentid="1113260" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7248655">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=303013&amp;sys_siteid=475&amp;sys_contentid=1113260&amp;sys_command=edit" alt="&quot;&quot;" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Histological slide showing prostate cancer</p>
</div>
</figcaption>
</figure>
</div>
<p>MEB investigators continue to study prostate cancer trends and the basis of racial differences in this disease. Recentl studies include U.S. incidence trends of lethal prostate cancer, U.S. current trends and future projections of metastatic prostate cancer, and international trends in prostate cancer incidence. They are making full use of the Ghana Prostate Study, the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, AARP Diet and Health Study, and other intramural/extramural resources and collaborations to study racial differences in prostate cancer risks, assessing questionnaire data, germline genetics, serum, and tissue. For example, black-white differences in prostate cancer risk factor profiles were found for height and vitamin D intake, whereas lower risk in diabetic men was common to both races. The recently formed Prostate Cancer Cohort Consortium (PC3) within the <a href="https://epi.grants.cancer.gov/Consortia/cohort.html">NCI Cohort Consortium</a> will provide additional collaborations to further their assessments of racial differences in prostate cancer risks.</p>
<h4>Micronutrients and Vitamin Supplementation</h4>
<p>MEB investigators have aggressively pursued the etiologic role of vitamins D, E and A in prostate cancer. Their studies of vitamin D include measurement of both the accepted biomarker of vitamin D status, 25-hydroxy-vitamin D [25(OH)D], and its major carrier protein, vitamin D binding protein (DBP). A large investigation in the ATBC Study showed significantly elevated risk among men with higher circulating vitamin D, which is now an accepted association supported by analyses of vitamin D genetic variants and polygenic scores from genome-wide association studies (GWAS). By contrast, higher vitamin D status is associated with improved prostate cancer survival. Investigators are examining biological mechanisms through cross-sectional analyses of hormones in the&nbsp;National Health and Nutrition Examination Survey (NHANES) and through ChIP-Seq cell culture functional experiments testing the effect of exposure to vitamin D and DHT on key nuclear receptors (i.e., AR, VDR, RAR/RXR) and gene regulation.<br /><br />The 32% reduction in prostate cancer incidence in the &alpha;-tocopherol (50 IU/day) arm of the ATBC Study was the basis of investigators' research into vitamin E. Their lines of inquiry focus on dose levels, smoking status, tocopherol fractions, mechanisms, and cancer stage, as well as whether genetic variants contributing to vitamin E status play some role. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) trial, higher prostate cancer incidence in men receiving 400 IU of vitamin E daily raised questions concerning supra-physiological supplementation and cancer stage-specific mechanisms for vitamin E and other micronutrients. Investigators have shown improved 20-year survival in cases with higher baseline vitamin E status and those receiving the ATBC 50 IU dose, and an impact of vitamin E on androgens and vascular endothelial growth factor (VEGF) consistent with tumor growth inhibition. They have also shown a direct association between circulating retinol and prostate cancer risk in their studies and in the EHNPCCG consortium.</p>
<h4>Metabolomics</h4>
<p>Metabolomic profiling is a relatively new laboratory methodology that simultaneously measures thousands of low molecular weight biochemicals (i.e., &lt;1kDa) in blood and other biospecimens. MEB investigators have conducted untargeted studies of prostate cancer risk, similar to other agnostic, &ldquo;broad spectrum&rdquo; research approaches such as GWAS, to discover biologically-based etiologic metabolites. Their initial investigations have identified strong lipid signals, including glycerophospholipids, sphingomyelins, and inositols, related to aggressive and lethal prostate cancer. By contrast, they found N-oleolyltaurine and androgens associated with prostate cancer survival, and have leveraged these studies to examine overall and cause-specific mortality.</p>
<h4>Sex Steroid Hormones and Reproductive Factors</h4>
<p>MEB investigators have conducted various studies of sex steroid hormones, reproductive factors, and prostate cancer. For example, they have provided evidence that the estrogen-androgen balance may be important in the development of aggressive prostate cancer and they have provided evidence that circulating measures of sex steroid hormones may be poor proxies of the intraprostatic milieu. Investigators continue to assess other proxies of sex steroid hormones such as male pattern baldness (androgenic alopecia), vasectomy, infertility, sexually transmitted infections as well as assessment of methods to quantitate sex hormones in formalin-fixed, paraffin-embedded prostate biopsy tissues. They have worked closely in collaboration with the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (University of Oxford, U.K.) to discover multiple new findings of prostate cancer etiology through the combined statistical power of more than a dozen cohorts, investigating the role of hormones, growth factors, diabetes, and micronutrients. They are also interested in the effects of exogeneous testosterone on prostate cancer risk.</p>
<h4>Tissue-based Markers for Prognostication</h4>
<p><em>TMPRSS2-ERG</em> brings together an androgen-responsive promoter (<em>TMPRSS2</em>) and an oncogene (<em>ERG</em>), resulting in overexpression of a functional chimeric ERG protein. MEB investigators have assessed this gene fusion&mdash;which is observed in a significant number of prostate cancers&mdash;in the Ghana Prostate Study as well as in a systematic review and meta-analysis to assess racial differences. Negative ERG staining was associated with higher Gleason score in Ghana, while the meta-analysis showed the prevalence of <em>TMPRSS2-ERG</em> fusions in prostate cancer to be highest in men of European descent (49%) followed by Asian (27%) and then African (25%). Investigators are currently conducting studies of intra-prostatic cell cycle proteins and mitotic tissue proteins in relation to the risk of prostate cancer recurrence in the PLCO study. They are also currently conducting studies of computational pathology in an attempt to improve prognostic algorithms.</p>
<h3>Selected Studies</h3>
<h4>The Ghana Prostate Study</h4>
<div sys_dependentvariantid="2090" sys_dependentid="1113261" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7248656">
<figure class="image-right-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=303013&amp;sys_siteid=475&amp;sys_contentid=1113261&amp;sys_command=edit" alt="Map depicting Ghana next to its neighbors in West Africa" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Map of Ghana, West Africa</p>
</div>
</figcaption>
</figure>
</div>
<p>The Ghana Prostate Study is designed to assess the burden, risk factor profiles and biomarkers of prostate cancer in Ghanaian men. In the United States, incidence rates of prostate cancer in African-Americans are 1.6-fold higher than those observed in European Americans, yet the causes of this difference remain unknown. Since West Africa is the principal ancestral origin of a substantial proportion of African-American men, one may hypothesize that genetic susceptibility loci that vary in allele frequency by ancestral population could account for part of the observed differences in prostate cancer rates within the U.S. In addition, little is known about the prostate cancer risk factors in African men. Read more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303643" sys_dependentvariantid="1418" sys_dependentid="303643" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248652" sys_variantid="1418" sys_contentid="303643">Ghana Prostate Study</a>.</p>
<h4>Prostate Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</h4>
<p>The ATBC Study has been an integral male cohort research resource for NCI for nearly three decades. The trial was designed to test hypotheses based on epidemiological and experimental evidence supporting nutritional prevention of cancer, and tested supplementation with &beta;-carotene (20 mg/day) and vitamin E (50 mg/day, as dl-&alpha;-tocopheryl acetate) for 5-8 years in 29,133 male smokers (&gt;5 cigarettes daily), finding a 32% and 40% reduction in prostate cancer incidence and mortality, respectively, in the vitamin E arm. Currently, 2,900 prostate cancers have been ascertained and serum etiologic studies have focused on growth factors, insulin, thyroxine, sex hormones, vitamins D, E, and A, and metabolomic profiling. ATBC has actively contributed to several prostate cancer consortia including BPC3, EHNPCCG, and PRACTICAL. The study has published nearly 100 prostate cancer research studies.</p>
<h4>Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial</h4>
<p>The PLCO Study enrolled 76,683 men aged 55 to 74 years during 1993&ndash;2001 from ten cancer screening centers across the United States. For the prostate component, men were randomly assigned to usual care with opportunistic screening or to annual screening with prostate-specific antigen (PSA) testing at baseline and for a further six years (with optional annual digital rectal exam at baseline and for a further four years). Participants were followed for incident cancer diagnoses and cause-specific mortality. All men were uncompensated volunteers from the general population with no prior medical history of any cancer (except nonmelanoma skin cancer). Men were excluded for prior removal of their prostate gland, participation in another cancer screening or prevention trial, Finasteride use within six months prior to enrollment, and&mdash;starting in 1995 after a study protocol change&mdash;if they had received more than one PSA test in the three-year period prior to enrollment. MEB investigators have leveraged this prospective cohort study to test various hypotheses related to prostate cancer pathogenesis and prognosis, including assessment of questionnaire data, baseline and follow-up blood samples, and tissue microarrays for a subset of men who underwent radical prostatectomy.</p>
</div>]]></content>
  </row>
  <row para_id="459575" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>An international hospital-based case-control study of lymphoma among Chinese in Eastern Asia (AsiaLymph) has been launched to replicate and extend recent and novel observations made in studies among Caucasians in a population that is distinctly different with regard to patterns of key environmental and occupational risk factors and genetic loci. It is employing next-generation occupational exposure modules, combined with historical exposure measurements on key exposures. It is enrolling both lymphoid and myeloid cases and will be the largest study of its kind conducted to date.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7274764" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103">Dr. Qing Lan</a>&nbsp;or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7274766" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103">Dr. Nathaniel Rothman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7274765" sys_dependentvariantid="1418" sys_dependentid="418935" rxinlineslot="103">Occupational and Environmental Epidemiology - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="459581" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><a href="https://epi.grants.cancer.gov/PanScan/">PanScan</a> is a multi-stage genome-wide association study (GWAS) of pancreatic cancer conducted within the framework of the NCI Cohort Consortium. Investigators have conducted three GWAS phases, PanScan I, II and III, and a meta-analysis with the <a href="http://panc4.org/">Pancreatic Cancer Case-Control Consortium (PanC4)</a> GWAS that collectively have led to the discovery of 20 genomic signals associated with risk for pancreatic cancer. Additional epidemiologic and genetic studies using data from these initial studies are now underway.</p>
<p>The next phase of the project will analyze additional pancreatic cancer cases from multiple cohorts, case-control, population-based, and biobank studies&mdash;including those from PanScan I-III&mdash;to discover novel regions of the genome associated with pancreatic cancer susceptibility.</p>
<p>For more information, contact:<br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349636" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349636" sys_dependentvariantid="1965" sys_relationshipid="7274771" sys_siteid="475" sys_variantid="1965" sys_contentid="349636">Rachael Stolzenberg-Solomon</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274772" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a> <br /><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349595" sys_dependentvariantid="1965" sys_dependentid="349595" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274773" sys_variantid="1965" sys_contentid="349595">Laufey Amundadottir</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420787" sys_dependentvariantid="1418" sys_dependentid="420787" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7274774" sys_variantid="1418" sys_contentid="420787">Laboratory of Translational Genomics - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="460077" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Elucidating Etiologic Heterogeneity, Current Patterns, and Future Trends</h2>
<p>DCEG investigators developed a broad-ranging, multi-faceted program of descriptive studies with major themes including the evaluation of tumor heterogeneity, current and future trends, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302509" sys_contentid="302509" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302509" sys_dependentvariantid="1418" sys_relationshipid="7275127" sys_siteid="475" sys_variantid="1418">second cancers</a>. Recent highlights include:</p>
<p>&bull; One of the first demonstrations of breast cancer heterogeneity by hormone receptor expression, as well as novel projections of breast cancer trends by estrogen receptor status was evaluated using <a href="http://seer.cancer.gov/">SEER</a> data.</p>
<p>&bull; A series of studies that showed a major emerging role for human papillomavirus (HPV) infection in the epidemiology of head and neck squamous cell carcinomas, especially among men. Novel projections that DCEG investigators developed for those studies have influenced key policy deliberations pertaining to HPV vaccination of boys in the U.S.</p>
<h4>Future Goals</h4>
<p>Investigators will continue to explore population heterogeneity, racial disparity, geographic variation, and international patterns through three key strategies:</p>
<ol>
<li>Comprehensive comparative analyses of incidence, mortality, and survival patterns for subtypes of many common and less common malignancies;</li>
<li>Analyses of time trends, calendar-period and birth-cohort effects, risk factor patterns, molecular data, and incidence of new malignancies among cancer survivors;</li>
<li>Extensive extramural collaborative efforts with the American Cancer Society (ACS), International Agency for Research on Cancer (IARC), North American Association of Central Cancer Registries (NAACCR), Center for Disease Control and Prevention (CDC), and Danish Breast Cancer Cooperative Group (DBCG), prioritizing studies of breast, ovary, and head and neck cancers.</li>
</ol>
<p>&nbsp;</p>
<p>For more information, contact:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349669" sys_contentid="349669" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349669" sys_dependentvariantid="1965" sys_relationshipid="7275123" sys_siteid="475" sys_variantid="1965">William Anderson</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=349590" sys_contentid="349590" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349590" sys_dependentvariantid="1418" sys_relationshipid="7275124" sys_siteid="475" sys_variantid="1418">Biostatistics Branch - Research Areas</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349694" sys_contentid="349694" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349694" sys_dependentvariantid="1965" sys_relationshipid="7275125" sys_siteid="475" sys_variantid="1965">Allan Hildesheim</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7275126" sys_siteid="475" sys_variantid="1418">Infections and Immunoepidemiology Branch</a></p>
</div>]]></content>
  </row>
  <row para_id="461884" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Selected Agricultural Health Study publications from a list of approximately 280 peer-reviewed publications:</p>
<ol>
<li>Andreotti G, Koutros S, Hofmann JN, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29136183">Glyphosate use and cancer incidence in the Agricultural Health Study</a>. <em>J Natl Cancer Inst</em>; Epub 2017 Nov 9.</li>
<li>Deziel NC, Beane Freeman LE, Hoppin JA, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30375516">An algorithm for quantitatively estimating non-occupational pesticide exposure intensity for spouses in the Agricultural Health Study.</a> <em>Expo Sci Environ Epidemiol</em>; Epub 2018 Oct 30.</li>
<li>Lerro CC, Andreotti G, Koutros S, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29471327">Alachlor use and cancer incidence in the Agricultural Health Study: An updated analysis.</a> <em>J Natl Cancer Inst</em>; Epub 2018 Feb 17.</li>
<li>Andreotti G, Freedman ND, Silverman DT, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28035020">Tobacco use and cancer risk in the Agricultural Health Study.</a> <em>Cancer Epidemiol Biomarkers Prev</em>; Epub 2016 Dec 29.</li>
<li>Bonner MR, Beane Freeman LE, Hoppin JA, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27384818">Occupational exposure to pesticides and the incidence of lung cancer in the Agricultural Health Study.</a> <em>Environ Health Perspect</em>; Epub 2016 Jul 6.</li>
<li>Deziel NC, Beane Freeman LE, Graubard BI, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27458779">Relative contributions of agricultural drift, para-occupational, and residential use exposure pathways to house dust pesticide concentrations: Meta-regression of published data.</a> <em>Environ Health Perspect;</em> Epub 2016 Jul 26.</li>
<li>Engel LS, Werder E, Satagopan J, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28934092">Insecticide Use and Breast Cancer Risk among Farmers' Wives in the Agricultural Health Study.</a> <em>Environ Health Perspect</em>, 2017 Sep 6.</li>
<li>Lerro CC, Beane Freeman LE, Portengen L, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28116766">A longitudinal study of atrazine and 2,4-D exposure and oxidative stress markers among Iowa corn farmers.</a> <em>Environ Mol Mutagen</em> 2017 Jan.</li>
<li>Louis LM, Lerro CC, Friesen MC, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28874165">A prospective study of cancer risk among Agricultural Health Study farm spouses associated with personal use of organochlorine insecticides.</a> <em>Environ Health</em>; 2017 Sep.</li>
<li>Rinsky JL, Richardson DB, Wing S, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28486574">Assessing the potential for bias from non-response to a study follow-up interview: An example from the Agricultural Health Study.</a> <em>Am J Epidemiol</em>; Epub 2017 May 9.</li>
<li>Rusiecki JA, Beane Freeman LE, Bonner MR, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27996157">High pesticide exposure events and DNA methylation among pesticide applicators in the agricultural health study.</a> <em>Environ Mol Mutagen</em>; Epub 2016 Dec 20.</li>
<li>Christensen CH, Barry KH, Andreotti G, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27917368">Sex steroid hormone single-nucleotide polymorphisms, pesticide use, and the risk of prostate cancer: A nested case-control study within the Agricultural Health Study</a>. <em>Frontiers in Oncology</em>; 2016 Nov 21.</li>
<li>Koutros S, Silverman DT, Alavanja MC, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26411407">Occupational exposure to pesticides and bladder cancer risk.</a> <em>Int J Epidemiol</em>; Epub 2015 Sep 27.</li>
<li>Tual S, Silverman DT, Koutros S, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26452295">Use of dieselized farm equipment and incident lung cancer: Findings from the Agricultural Health Study Cohort.</a> <em>Environ Health Perspect</em>; Epub 2015 Oct 9.</li>
<li>Andreotti G, Hoppin JA, Hou L, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26196902">Pesticide use and relative leukocyte telomere length in the Agricultural Health Study.</a> <em>PLoS One</em>; 2015 Jul 21.</li>
<li>Deziel NC, Friesen, M.C., Hoppin JA, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25636067">A review of nonoccupational pathways for pesticide exposure in women living in agricultural areas.</a> <em>Environ Health Perspect</em> 2015 Jun; Epub Jan 30.</li>
<li>Hofmann JN, Hoppin JA, Lynch CF, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25583946">Farm characteristics, allergy symptoms, and risk of non-Hodgkin lymphoid neoplasms in the Agricultural Health Study.</a> <em>Cancer Epidemiol Biomarkers Prev</em> 2015 Mar; Epub 2015 Jan 12.</li>
<li>Jones RR, Barone-Adesi F, Koutros S, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25907210">Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: An updated analysis.</a> <em>Occup Environ Med</em> 2015 Jul; Epub 2015 Apr.</li>
<li>Lerro CC, Koutros S, Andreotti G, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26150671">Organophosphate insecticide use and cancer incidence among spouses of pesticide applicators in the Agricultural Health Study.</a> <em>Occup Environ Med</em>, 2015 Oct; Epub 2015 Jul 6.</li>
<li>Lerro CC, Koutros S, Andreotti G, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25559664">Use of acetochlor and cancer incidence in the Agricultural Health Study.</a> <em>Int J Cancer</em> 2015 Sep 1; Epub 2015 Jan 23.</li>
<li>Silver SR, Bertke SJ, Hines CJ, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26033014">Cancer incidence and metolachlor use in the Agricultural Health Study: An update.</a> <em>Int J Cancer</em> 2015; Epub 2015 May 28.</li>
<li>Hofmann JN, Hoppin JA, Lynch CF, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25583946">Farm characteristics, allergy symptoms, and risk of non-Hodgkin lymphoid neoplasms in the Agricultural Health Study.</a></u> <em>Cancer Epidemiol Biomarkers Prev</em> 2015 Mar; E-pub 2015 Jan 12.&nbsp;</li>
<li>Jones RR, Barone-Adesi F, Koutros S, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25907210">Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: An updated analysis</a><a href="https://www.ncbi.nlm.nih.gov/pubmed/25907210">.</a></u> <em>Occup Environ Med</em> 2015; E-pub 2015 Apr 23.</li>
<li>Wardyn SE, Forshey BM, Farina SA, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25931444">Swine Farming Is a Risk Factor for Infection With and High Prevalence of Carriage of Multidrug-Resistant Staphylococcus aureus.</a></u> <em>Clin Infect Dis</em> 2015. E-pub 2015 Apr 29.</li>
<li>Alavanja MC, Hofmann JN, Lynch CF, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25337994">Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the Agricultural Health Study.</a></u>&nbsp;<em>PLoS One</em> 2014; 9:e109332.</li>
<li>Jones RR, DellaValle CT, Flory AR, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25292160">Accuracy of residential geocoding in the Agricultural Health Study.</a></u> <em>Int J Health Geogr</em> 2014.</li>
<li>Hou L, Andreotti G, Baccarelli AA, et al.&nbsp;<u><a href="https://www.ncbi.nlm.nih.gov/pubmed/23774483">Lifetime pesticide use and telomere shortening among male pesticide applicators in the Agricultural Health Study.</a></u> <em>Environ Health Perspect</em> 2013; E-pub 2013 Jun 7.</li>
<li>Karami S, Andreotti G, Koutros S, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/23833127">Pesticide exposure and inherited variants in vitamin D pathway genes in relation to prostate cancer.</a></u> <em>Cancer Epidemiol Biomarkers Prev</em> 2013; E-pub 2013 Jul 5.</li>
<li>Koutros S, Beane Freeman LE, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/23171882">Risk of total and aggressive prostate cancer and pesticide use in the Agricultural Health Study.</a></u> <em>Am J Epidemiol</em> 2013; E-pub 2012 Nov 21.</li>
<li>Koutros S, Berndt SI, Barry KH, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/23593118">Genetic susceptibility loci, pesticide exposure and prostate cancer risk.</a></u> <em>PLoS One</em> 2013;8:e58195.</li>
<li>Andreotti G, Koutros S, Berndt SI, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22919386">Interaction between pesticide use and genetic variants involved in lipid metabolism on prostate cancer risk.</a></u> <em>J Cancer Epidemiol</em> 2012; E-pub 2012 August 2.</li>
<li>Barry KH, Koutros S, Andreotti G, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22102698">Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk.</a></u> <em>Carcinogenesis</em> 2012; E-pub 2011 Nov 18.</li>
<li>Barry KH, Koutros S, Lubin JH, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22527160">Methyl bromide exposure and cancer risk in the Agricultural Health Study.</a></u> <em>Cancer Causes Control</em> 2012; E-pub 2012 Apr 24.</li>
<li>Beane Freeman LE, Deroos AJ, Koutros S, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22407136">Poultry and livestock exposure and cancer risk among farmers in the agricultural health study.</a></u> <em>Cancer Causes Control</em> 2012; E-pub 2012 Mar 10.</li>
<li>Heltshe SL, Lubin JH, Koutros S, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22569205">Using multiple imputation to assign pesticide use for non-responders in the follow-up questionnaire in the Agricultural Health Study.</a></u> <em>J Expo Sci Environ Epidemiol</em> 2012; E-pub 2012 May 9.</li>
<li>Barry KH, Koutros S, Berndt SI, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/21810555">Genetic variation in base excision repair pathway genes, pesticide exposure, and prostate cancer risk.</a></u> <em>Environ Health Perspect</em> 2011; 119:1726-1732. E-pub 2011 Aug 2.</li>
<li>Beane-Freeman LE, Rusiecki JA, Hoppin JA, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/21622085">Atrazine and Cancer Incidence Among Pesticide Applicators in the Agricultural Health Study (1994-2007)</a></u>. <em>Environ Health Perspect</em> 2011; E-pub 2011 May 27.</li>
<li>Coble J, Thomas KW, Hines CJ, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22408592">An updated algorithm for estimation of pesticide exposure intensity in the agricultural health study.</a></u> <em>Int J Environ Res Public Health</em> 2011; E-pub 2011 Dec 12.</li>
<li>Koutros S, Andreotti G, Berndt SI, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/21716162">Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.</a></u> <em>Pharmacogenet Genomics</em> 2011; E-pub 2011 Jun 29.</li>
<li>Waggoner JK, Kullman GJ, Henneberger PK, et al. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/21084556">Mortality in the agricultural health study, 1993-2007</a></u>. <em>Am J Epidemiol</em> 2011; E-pub 2010 Nov 17.</li>
</ol>
</div>]]></content>
  </row>
  <row para_id="462196" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>DCEG research on the association between smokeless tobacco and cancer has made a significant impact on regulation of these products.</p>

<p><img alt="" class="right" height="243" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462456" sys_dependentid="462456" sys_dependentvariantid="1482" sys_relationshipid="7277729" sys_siteid="475" width="151" />This work began when DCEG investigators studying the U.S. Cancer Mortality Atlas observed a striking elevation of oral cancer rates among women in the rural south. In a case-control study conducted in North Carolina, elevated risk for cancer was associated with long-term use of <b>snuff</b> among nonsmokers, demonstrating 50-fold increased risk for tissues in direct contact with tobacco. The report published in the <i>New England Journal of Medicine</i> (Winn et al., 1981) stimulated congressional hearings that resulted in regulatory actions to control the advertising and labeling of <b>smokeless tobacco</b> and educational campaigns to reduce its use by young people.</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Smokeless_Tobacco" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7277730" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#smokeless_tobacco">Smokeless Tobacco: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303705" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303705" sys_dependentvariantid="1418" sys_relationshipid="7277731" sys_siteid="475" sys_variantid="1418" sys_contentid="303705">Learn about our current research on tobacco</a></p>
</div>]]></content>
  </row>
  <row para_id="462198" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG research into the associations of radiation exposure and cancer has had significant impacts in the following areas:</p>
<h3>Medical Radiation from Therapeutic and Diagnostic Procedures</h3>
<p>DCEG radiation epidemiologists have contributed greatly to the advancement of medical practice through their study of ionizing radiation from therapeutic and diagnostic procedures.</p>
<p><img class="right" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462457" inlinetype="rximage" sys_siteid="475" sys_relationshipid="7277292" sys_dependentvariantid="1482" sys_dependentid="462457" rxinlineslot="104" height="194" width="291" />DCEG experts employed statistical models to estimate future cancer risks associated with radiation exposure from computed tomography (CT) scans. As a result, the NIH adopted a requirement that makers of CT scanners used at NIH facilities incorporate software to measure and track patients&rsquo; radiation doses over time. This patient protection policy is being adopted by other hospitals and imaging facilities (Berrington de Gonz&aacute;lez et al., 2009).</p>
<p>Recent work in this field has identified small but statistically increased risks of leukemia and brain tumors in the first decade after CT exposure in children (Pearce et al., 2012). <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=463653" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7277293" sys_dependentvariantid="1418" sys_dependentid="463653" rxinlineslot="103" sys_variantid="1418" sys_contentid="463653">More information on CT exposure in children</a></p>
<p>DCEG researchers studying children treated for cancer with radiotherapy demonstrated a dose-response relationship: i.e., the higher the radiation dose the children received, the higher the risk that they would develop a second cancer, notably bone sarcoma and thyroid cancer. These findings spurred the medical community to decrease doses of radiotherapy in children. (Tucker et al., 1987, 1991)</p>
<p>Medical practice has been altered to reduce radiation exposure and intensify second cancer screening after DCEG researchers identified the striking dose-related risk of radiation-related second cancers among children treated for retinoblastoma (Kleinerman et al., 2005) in the <a href="http://rbstudy.cancer.gov/">Retinoblastoma Follow-up Study</a>.</p>
<p>After investigators reported that bone marrow recipients showed elevated risk of radiation-related solid cancers (Curtis et al., 1997; Socie et al., 2000; Rizzo et al., 2009), conditioning regimens used to prepare patients prior to stem cell transplantation were shifted from radiation to chemotherapy-based regimens.</p>
<p>DCEG investigators created a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=305&amp;sys_variantid=2297&amp;sys_contentid=13362" inlinetype="rxhyperlink" sys_siteid="305" sys_dependentvariantid="2297" sys_dependentid="13362" rxinlineslot="103" sys_relationshipid="7277297" sys_variantid="2297" sys_contentid="13362">professional education brochure</a> in collaboration with the Society for Pediatric Radiology as part of an effort to minimize the level of radiation from CT scans to children.</p>
<p>DCEG research quantified the dose response for risk of lung and breast cancers in patients treated with radiation for Hodgkin lymphoma (Tucker et al., 1988; Travis et al., 2002, 2003). This information influenced clinical standards to reduce radiation fields, lower exposures, and advise patients to avoid smoking.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302457" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7277295" sys_dependentvariantid="1418" sys_dependentid="302457" rxinlineslot="103" sys_variantid="1418" sys_contentid="302457">Learn about our current research on medical radiation</a></p>
<h3>Radioactive Fallout or Environmental Contamination from Nuclear Weapons</h3>
<p>National and international radiation safety standards have been influenced by findings from DCEG studies of cancer and leukemia among atomic bomb survivors and pooled analyses of radiation-related risk of thyroid cancer from studies of other exposed populations. (Ron et al., 1994, 1995, 1998; Land et al., 1995, 1996, 2003).</p>
<p>When adjudicating personnel claims for compensation due to exposure to ionizing radiation on the job, the National Institute for Occupational Safety and Health and the Veterans Administration have used statistical models and a Web-based interactive program developed by DCEG to estimate the probability that a given cancer in an individual was induced by given exposures to ionizing radiation. (NIH, 1985, 2003; Kocher et al., 2008)</p>
<p>DCEG investigators reported on the potential health risks of exposure to radioactive I-131 fallout from above-ground nuclear testing that occurred in Nevada in the 1950s and 1960s (NCI, 1997; Gilbert et al., 1998). A national educational campaign aimed at informing the public was initiated based on information in these reports. <a href="http://www.cancer.gov/about-cancer/causes-prevention/risk-factors/radiation/i-131">More information on radioactive I-131 from fallout</a>.</p>
<h3>Naturally-occurring Radiation</h3>
<p>Radon, a radioactive gas formed by the natural breakdown of uranium in soil, rock and water, can cause lung cancer. This exposure can be especially hazardous indoors where it can become more concentrated. DCEG researchers quantified lung cancer risks associated with occupational and residential exposures to radon. These findings were critical to the formulation of radon mitigation guidelines issued by policymakers at the U.S. Environmental Protection Agency (EPA) (Qiao et al., 1989; Lubin et al., <a href="http://www.ncbi.nlm.nih.gov/pubmed/2293552">1</a>990, 1997, 1998, 2004; Alavanja et al., 1994, 1999; Wang et al., 2002).</p>
<h3>Ultraviolet Radiation</h3>
<p>It is generally accepted that if ozone levels in the earth&rsquo;s stratosphere are depleted, greater amounts of shortwave ultraviolet radiation will reach the earth's surface, resulting in increased skin cancer. DCEG researchers provided the U.S. EPA with estimates of increases in melanoma and other skin cancers in relation to projected increases in ozone depletion. These estimates were based on analyses of data from surveys of ground-level ultraviolet radiation in relation to time trends for melanoma and other skin cancers (Scotto et al., 1975, 1981; Fears et al., 1976, 1977, 1983).</p>
<h3>Electromagnetic Fields</h3>
<p>DCEG researchers conducted the first study of cellular telephones; they found no association with increased risk of brain tumors. This finding informed U.S. Food and Drug Administration&rsquo;s regulatory policies on radiofrequency radiation (Inskip et al., 2001). In continued followup of this exposure, investigators reported, in 2012, that <a href="https://www.cancer.gov/news-events/press-releases/2012/GliomaCellPhoneUse">incidence trends have remained roughly constant for glioma</a>, the main type of brain cancer hypothesized to be related to cell phone use. They found that while cell phone use increased substantially over the period 1992 to 2008 (from nearly zero to almost 100 percent of the population), the U.S. trends in glioma incidence did not mirror that increase (Little MP 2012). Results of this study were published online March 8, 2012, in the <i>British Medical Journal</i>. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302468" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7277296" sys_dependentvariantid="1418" sys_dependentid="302468" rxinlineslot="103" sys_variantid="1418" sys_contentid="302468">Learn about our current research on cellular phones and brain tumors</a>.</p>
<p>DCEG researchers demonstrated no increased risk for childhood leukemia associated with residential exposure to magnetic fields generated by nearby power lines. This information formed the basis of judicial rulings in the United Kingdom and elsewhere on the potential health effects of these exposures (Linet et al., 1997).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7277294" sys_dependentvariantid="1418" sys_dependentid="467142" rxinlineslot="103" sys_variantid="1418" sys_contentid="467142">Radiation: Full list of article citations</a></p>

<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p></div>]]></content>
  </row>
  <row para_id="462199" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Over the years, DCEG research on the association between ultraviolet radiation and cancer has made a significant impact in the following area:</p>
<p>Surveys of ground-level ultraviolet radiation in relation to time trends for melanoma and other skin cancers have provided EPA with the estimated prevalence of skin cancer in relation to projected increases in ozone depletion (Scotto et al., 1975, 1981; Fears et al., 1976, 1977, 1983).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Ultraviolet_Radiation" sys_contentid="467142#ultraviolet_radiation" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7278019" sys_dependentvariantid="1418" sys_dependentid="467142" rxinlineslot="103">Ultraviolet Radiation: Full list of article citations</a></p>
</div>]]></content>
  </row>
  <row para_id="462200" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Over the years, DCEG research on the association between electromagnetic fields and cancer has made a significant impact in the following areas:</p>
<p>The finding that cell phone use did not increase risk of brain tumors affected FDA&rsquo;s regulatory policies on radiofrequency radiation (Inskip et al., 2001).</p>
<p>Lack of an increased risk for childhood leukemia associated with high residential magnetic fields formed the basis of judicial rulings in the United Kingdom and elsewhere on the potential health effects of these exposures (Linet et al., 1997).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142" sys_contentid="467142" inlinetype="rxhyperlink" sys_variantid="1418" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7275655" sys_siteid="475">Electromagnetic Fields: Full list of article citations</a></p>
</div>]]></content>
  </row>
  <row para_id="462201" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Over the years, DCEG research on the association between occupational exposures and cancer has made a significant impact in the following areas:</p>

<p>The International Agency for Research on Cancer (IARC) classified <b>diesel exhaust</b> as carcinogenic to humans largely based on results from the Diesel Exhaust in Miners Study, which played a pivotal role in the 2012 IARC evaluation. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303765" sys_dependentvariantid="1418" sys_dependentid="303765" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277160" sys_variantid="1418" sys_contentid="303765">More information about diesel exhaust and cancer risk</a></p>

<p>A U.S. Environmental Protection Agency (U.S. EPA) rule limiting the <b>benzene</b> content in gasoline and requiring controls on passenger vehicles and portable fuel containers to reduce pollutants was informed by DCEG research showing evidence of hematotoxicity from benzene exposure at levels below the occupational standard at the time (Lan et al., 2004). This research also resulted in a lower action level in China. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303764" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303764" sys_dependentvariantid="1418" sys_relationshipid="7277156" sys_siteid="475" sys_variantid="1418" sys_contentid="303764">More information on benzene-associated hematoxicity and carcinogenicity</a></p>

<p><img alt="" class="right" height="140" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462459" sys_dependentid="462459" sys_dependentvariantid="1482" sys_relationshipid="7277154" sys_siteid="475" width="201" />IARC and the National Toxicology Program’s Report on Carcinogens classified <b>formaldehyde</b> as a human carcinogen following DCEG research that found elevated risks of nasopharyngeal cancer and leukemia among formaldehyde-exposed workers (Blair et al., 1986; Hauptmann et al., 2003, 2004, 2009; Beane Freeman et al., 2009). This research also led to the EPA establishing regulatory standards for formaldehyde. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303671" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303671" sys_dependentvariantid="1418" sys_relationshipid="7277158" sys_siteid="475" sys_variantid="1418" sys_contentid="303671">More information about DCEG research on formaldehyde exposure</a></p>

<p>The U.S. EPA and IARC evaluated <b>trichloroethylene</b> and concluded that there was sufficient evidence for carcinogenicity in humans. Results from the DCEG cohort study of civilian workers at Hill Air Force Base (Blair et al., 1998; Radican et al., 2008) and the Eastern European kidney cancer case-control study (Moore et al., 2010) provided evidence on cancer risks and genetic susceptibility. A DCEG cross-sectional molecular epidemiology study of healthy workers exposed to trichloroethylene found evidence of both immunotoxicity and kidney toxicity (Lan et al., 2010; Hosgood et al., 2011; Vermeulen et al., 2012).</p>

<p>IARC classified <b>tetrachloroethylene</b> as a probable human carcinogen.&#160;Results from the DCEG study of dry cleaners provided important findings for this conclusion (Blair et al., 1990).</p>

<p><img alt="" class="right" height="190" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462460" sys_dependentid="462460" sys_dependentvariantid="1482" sys_relationshipid="7277155" sys_siteid="475" width="142" />IARC classified airborne <b>arsenic</b> as a human carcinogen, and the U.S. Occupational Safety and Health Administration established new exposure limits for arsenic, following DCEG research that found excess risk of respiratory cancer among copper smelter workers (Lee and Fraumeni, 1969) and nearby residents (Blot and Fraumeni, 1975) exposed to inorganic arsenic.</p>

<p>IARC concluded that there was insufficient evidence (group 3) to classify <b>acrylonitrile</b> as a human carcinogen.&#160;The DCEG cohort was a major study providing information for this conclusion (Blair et al., 1998; Stewart et al., 1998).</p>

<p>IARC classified <b>wood dust</b> exposure as a human carcinogen after studies showed increased nasal cancer among furniture workers (Brinton et al., 1977, 1984).</p>

<p>The U.S. EPA established label instructions to change clothes after <b>2,4-D</b> application, and the Veterans Administration adjusted compensation policies for exposure to <b>Agent Orange</b>, after a DCEG report showed increased lymphoma risk associated with 2,4-D exposure (Hoar et al., 1986).</p>

<p>IARC classified <b>chromium</b> compounds as carcinogenic after DCEG research showed an excess of lung cancer reported among chromium pigment workers (Hayes et al., 1989).</p>

<p>IARC classified <b>silica</b> as a human carcinogen, citing DCEG studies of silica-exposed miners and workers in pottery factories and dusty trades (Chen et al., 1989, 1990, 1992; Amandus et al., 1991, 1995).</p>

<p>DCEG studies of pesticides including <b>trifluralin</b> (Cantor et al., 1992), <b>atrazine</b> (Hoar et al., 1986; Freeman et al., 2011), <b>dichlorvos</b> (Brown et al., 1990), <b>DDT</b> and <b>lindane</b> (Alavanja et al., 2014), <b>diazinon</b> (Jones et al., 2015) and&#160;<b>chlordane</b> (Brown et al., 1990, 1993; Cantor et al., 1992; Pesatori et al., 1994) were used by IARC and the U.S. EPA in their determinations of carcinogenicity.</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Occupation" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7277157" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#occupation">Occupation: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303684" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303684" sys_dependentvariantid="1418" sys_relationshipid="7277159" sys_siteid="475" sys_variantid="1418" sys_contentid="303684">Learn about our current research on occupational exposures</a></p>
</div>]]></content>
  </row>
  <row para_id="462202" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>DCEG research on the association between indoor air pollution and cancer has informed international regulatory actions on this exposure.</p>

<p><img alt="" class="right" height="151" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462461" sys_dependentid="462461" sys_dependentvariantid="1482" sys_relationshipid="7389976" sys_siteid="475" width="223" />The International Agency for Research on Cancer (IARC) classified indoor emissions from <b>household combustion of coal</b> as an established human carcinogen and emissions from <b>high-temperature frying</b> as a probable human carcinogen following DCEG research that found increased lung cancer associated with smoky coal use (Lan et al., 2002, 2008) and cooking fumes (Gao et al., 1987) in China. The findings also informed the World Health Organization’s <i>WHO Guidelines for Indoor Air Quality: Selected Pollutants.</i></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Indoor_Air_Pollution" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7389977" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#indoor_air_pollution">Indoor Air Pollution: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303668" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303668" sys_dependentvariantid="1418" sys_relationshipid="7389978" sys_siteid="475" sys_variantid="1418" sys_contentid="303668">Learn about our current research on air pollutants</a></p>
</div>]]></content>
  </row>
  <row para_id="462203" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Over the years, DCEG research on the association between contaminants in drinking water and cancer has made a significant impact in the following areas:</p>

<p><img alt="" class="right" height="192" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462462" sys_dependentid="462462" sys_dependentvariantid="1482" sys_relationshipid="7275460" sys_siteid="475" width="128" />A DCEG study found no evidence that <b>fluoride</b> in drinking water poses an elevated risk of cancer, as had been suggested by some previous reports. This finding was confirmed by expert panels convened in the United States, the United Kingdom, and other countries, providing further confidence in the safety of water fluoridation (Hoover et al., 1976).</p>

<p>Water suppliers often add disinfectants to drinking water to eliminate disease-causing organisms, or pathogens. These disinfectants react with naturally-occurring organic material in the water to form <b>disinfection byproducts</b>, which may pose health risks. The Environmental Protection Agency lowered the allowable maximum allowable levels for two groups of disinfection byproducts, <b>trihalomethanes</b> and <b>haloacetic acids</b>, in drinking water, after a DCEG study linked them to elevated bladder cancer risk (Cantor et al., 1987).&#160;</p>

<p>DCEG research on <b>dietary and drinking water nitrate</b> contributed to the International Agency for Research on Cancer monograph review (2010) of ingested nitrate and nitrite and cyanobacterial peptides (Ward et al., 1996, 2000, 2007; DeRoos et al., 2003; Coss et al., 2004).&#160;Ingested nitrate and nitrite was determined to be possibly carcinogenic to humans (2A).</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Water_Contaminants" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7275461" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#water_contaminants">Contaminants in Drinking Water: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303673" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303673" sys_dependentvariantid="1418" sys_relationshipid="7275462" sys_siteid="475" sys_variantid="1418" sys_contentid="303673">Learn about our current research on contaminants in drinking water</a></p>


</div>]]></content>
  </row>
  <row para_id="462204" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Over the years, DCEG research on the effects of diet, cooking methods, and supplements on cancer has made a significant impact in the following areas:</p>

<p><img alt="" class="right" height="183" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462988" sys_dependentid="462988" sys_dependentvariantid="1482" sys_relationshipid="7275616" sys_siteid="475" width="275" />The National Toxicology Program’s Report on Carcinogens removed <b>saccharin</b> from their list of potential carcinogens after a DCEG study established the lack of an association between saccharin use and bladder cancer risk (Hoover and Strasser, 1980).</p>

<p>Several DCEG studies indicating that diets high in <b>vegetables and fruits</b> are associated with reduced risk of various cancers (Ziegler et al., 1981, 1986; Winn et al., 1984) influenced public health recommendations.</p>

<p>The Nutrition Intervention Trials in Linxian, China, were the first randomized trials to demonstrate that <b>vitamin/mineral supplementation</b> reduces total mortality and cancer-related deaths in a population with nutritional deficiencies (Blot et al., 1993).</p>

<p>DCEG researchers reported that carcinogenic <b>heterocyclic amines</b> are generated in meat during high-temperature cooking (Sinha et al., 1994, 1995) which led to public health recommendations on cooking practices.</p>

<p>DCEG studies of serum levels of <b>vitamin D</b> in relation to cancer mortality (Freedman et al., 2007) and breast cancer risk (Freedman et al., 2008) provided key evidence to the Institute of Medicine’s 2010 report <i>Dietary Reference Intakes for Calcium and Vitamin D</i>.</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Diet_Cooking_Methods_Supplements" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7275618" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#diet_cooking_methods_supplements">Diet/Cooking Methods/Supplements: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303698" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303698" sys_dependentvariantid="1418" sys_relationshipid="7275617" sys_siteid="475" sys_variantid="1418" sys_contentid="303698">Learn about our current research on diet/cooking methods/supplements</a></p>


</div>]]></content>
  </row>
  <row para_id="462205" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG research on the effect of pharmaceuticals and medical devices on cancer has made a significant impact in the following areas:</p>
<h3>Hormone-related Therapy</h3>
<p><img width="153" height="203" class="right" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462989" inlinetype="rximage" sys_siteid="475" sys_relationshipid="7313013" sys_dependentvariantid="1482" sys_dependentid="462989" rxinlineslot="104" />As early as the mid-1970s DCEG researchers observed that <b>menopausal hormone therapy</b> was associated with increased breast cancer risk&mdash;and that the risk was greater with estrogen-progestin regimens than with estrogen alone (Hoover et al., 1976; Schairer et al., 2000). In the early 2000s, data from the Women&rsquo;s Health Initiative confirmed this observation and resulted in a fundamental shift in medical practice. The change in use of menopausal hormone therapy resulted in a decrease in breast cancer incidence.</p>
<p><b>Diethylstilbestrol (DES)</b> is the first carcinogen to have been shown to cross the placenta and cause cancer in the offspring. Between 1940 and the early 1970s, millions of pregnant women were given DES, the first synthetic estrogen, in the mistaken belief that it would prevent complications of pregnancy. Long-term follow-up of cohorts exposed prenatally to DES revealed a broader spectrum of adverse health outcomes than previously known. These findings have affected medical surveillance of exposed persons and have sparked research on the effects of early-life chemical exposures beyond DES (Hatch et al., 1998, 2001, 2011; Titus-Ernstoff et al., 2001, 2010; Troisi et al., 2007a, 2007b; Hoover et al., 2011). <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=463618" sys_contentid="463618" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7313015" sys_dependentvariantid="1418" sys_dependentid="463618" rxinlineslot="103" sys_variantid="1418">More information on DES</a></p>
<p>DCEG researchers found evidence that <b>ovulation-stimulating agents</b> used in fertility treatments do not significantly increase the risk of ovarian and other cancers (Brinton, Lamb et al., 2004; Brinton, Scoccia, et al., 2004), which has reduced concern about prescribing these increasingly popular drugs.</p>
<h3>Treatment-related Therapy</h3>
<p>The Food and Drug Administration (FDA) released warnings and cancer screening recommendations for transplant patients after a DCEG study quantified the increased risks of lymphoma and certain other cancers associated with <b>immunosuppressive drugs</b> in transplant recipients (Hoover and Fraumeni, 1973).</p>
<p><img width="159" height="240" class="right" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=462990" inlinetype="rximage" sys_siteid="475" sys_relationshipid="7313014" sys_dependentvariantid="1482" sys_dependentid="462990" rxinlineslot="104" />DCEG researchers found evidence showing an excess risk of leukemia among women treated with <b>chlorambucil</b> for ovarian cancer (Greene et al., 1982). This finding was key to the International Agency for Research on Cancer classifying the drug as a human carcinogen and to FDA releasing clinical alerts to curtail its use.</p>
<p>In a study of leukemia after childhood cancer, DCEG researchers found a dose-response relationship with <b>alkylating agent chemotherapy</b>, after adjusting for radiation (Tucker et al., 1987). This finding led to decreased use of these agents for the treatment of childhood cancer.</p>
<p>DCEG researchers found a dose-response risk of childhood leukemia following treatment with <b>chloramphenicol</b> (Shu et al., 1987). As a result of this and other evidence, chloramphenicol is no longer the first-line agent for any infection in developed countries.</p>
<p>A DCEG study of secondary leukemia after treatment for breast cancer affected clinical practice by demonstrating the substantial risk associated with <b>melphalan</b> and the relative safety of the current <b>cyclophosphamide</b>-based chemotherapy regimens (Curtis et al., 1992).</p>
<h3>Medical Devices</h3>
<p>DCEG&rsquo;s studies of silicone <b>breast implants</b> supplied evidence the devices did not cause an increase in breast cancer or connective tissue disorders (Brinton, et al., 2004, 2006). These findings provided welcome reassurance to consumers over FDA&rsquo;s decision to allow implants back on the market.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Pharmaceutical_and_Medical_Devices" sys_contentid="467142#pharmaceutical_and_medical_devices" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7313016" sys_dependentvariantid="1418" sys_dependentid="467142" rxinlineslot="103" sys_variantid="1418">Pharmaceuticals and Medical Devices: Full list of article citations</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303700" sys_contentid="303700" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7313017" sys_dependentvariantid="1418" sys_dependentid="303700" rxinlineslot="103" sys_variantid="1418">Learn about our current research on pharmaceutical agents</a></p>
</div>]]></content>
  </row>
  <row para_id="462206" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Over the years, DCEG research on the association between infectious agents and cancer has made a significant public health impact.</p>
<h2>Recent Highlights</h2>
<h4>National Toxicology Program Cites DCEG Research in Evaluations of Cancer Impact from Viruses</h4>
<div sys_relationshipid="7276318" sys_dependentid="463042" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2090" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302249&amp;sys_siteid=475&amp;sys_contentid=463042&amp;sys_command=preview" alt="HPV vaccine"><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>In 2016, the National Toxicology Program (NTP) released monographs on five viruses as part of its Report on Carcinogens:</p>
<ul>
<li><a href="http://ntp.niehs.nih.gov/ntp/roc/monographs/ebv_final201608_508.pdf">Monograph on Epstein-Barr Virus (EBV) </a></li>
<li><a href="http://ntp.niehs.nih.gov/ntp/roc/monographs/kshv_final201608_508.pdf">Monograph on Kaposi Sarcoma-Associated Herpesvirus (KSHV)</a></li>
<li><a href="http://ntp.niehs.nih.gov/ntp/roc/monographs/hiv_final201608_508.pdf">Monograph on Human Immunodeficiency Virus Type 1 (HIV)</a></li>
<li><a href="http://ntp.niehs.nih.gov/ntp/roc/monographs/htlv_final201608_508.pdf">Monograph on Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1)</a></li>
<li><a href="http://ntp.niehs.nih.gov/ntp/roc/monographs/mcv_final201608_508.pdf">Monograph on Merkel Cell Polyomavirus (MCV)</a></li>
</ul>
<p>The monographs outline current understandings of cancer hazards from particular viruses based on a large body of scientific research. Investigators in DCEG&rsquo;s <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=55&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302590" sys_relationshipid="7276314" sys_variantid="1422" sys_contentid="302590">Infections and Immunoepidemiology Branch (IIB)</a> produced a considerable portion of the evidence cited in the NTP reports. DCEG investigators study the role of viruses in cancer using techniques from molecular epidemiology to linkages of cancer and virus registries. Supported by DCEG research, the NTP&rsquo;s results influence public health policies by regulatory bodies such as the CDC.</p>
<div class="callout-box" style="float: right; width: 50%; margin: 0 0 5px 10px;">
<h4>Find DCEG Publications on Viruses</h4>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Epstein-Barr+Virus+%28EBV%29+&amp;titleOption=and&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle"><span class="show-for-sr">DCEG Publications on </span>Epstein-Barr Virus</a><br /><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Kaposi+Sarcoma-Associated+Herpesvirus+%28KSHV%29&amp;titleOption=and&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle"><span class="show-for-sr">DCEG Publications on </span>Kaposi Sarcoma-Associated Herpesvirus</a><br /><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Human+Immunodeficiency+Virus+%28HIV%29+&amp;titleOption=exact&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle"><span class="show-for-sr">DCEG Publications on </span>Human Immunodeficiency Virus Type 1</a><br /><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=HTLV-1&amp;titleOption=and&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle"><span class="show-for-sr">DCEG Publications on </span>Human T-Cell Lymphotrophic Virus Type 1</a><br /><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Merkel+Cell+Polyomavirus+%28MCV%29&amp;titleOption=and&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle"><span class="show-for-sr">DCEG Publications on </span>Merkel Cell Polyomavirus</a></p>
</div>
<p>Several DCEG investigators served in advisory and review roles in the monograph writing process. James Goedert, M.D., formerly a senior investigator in IIB, was a technical advisor for all five monographs. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349628" sys_relationshipid="7276315" sys_variantid="1965" sys_contentid="349628">Charles S. Rabkin, M.D., M.Sc.</a>, senior investigator, IIB,&nbsp;served on the peer review panel for all five monographs. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349676" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349676" sys_relationshipid="7276316" sys_variantid="1965" sys_contentid="349676">Sam M. Mbulaiteye, MBChB, M.Phil., M.Med.</a>, senior investigator, IIB, was a technical advisor for the KSHV monograph.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303707" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="303707" sys_relationshipid="7276317" sys_variantid="1418" sys_contentid="303707">See summaries of DCEG research&nbsp;on infectious agents.</a></p>
<h4>Negative HPV Test Result is Better Predictor of Low Cervical Cancer Risk than Negative Pap Test</h4>
<p>Human papillomavirus (HPV) is the cause of nearly all cervical cancers. Newer approaches to cervical cancer screening test for DNA (or RNA) of HPV at the cervix, whereas the Pap test detects abnormal cell changes associated with the development of cancer. Co-testing is now recommended for most women but clinicians were still unsure of the reassurance from a negative HPV test. Based on a study that included more than 1 million women, investigators at the National Cancer Institute, led by <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/gage-julia">Julia C. Gage, Ph.D., M.P.H.</a>, determined that a negative test for HPV infection compared to a negative Pap test provides greater safety, or assurance, against future risk of cervical cancer. These findings provide evidence to support the currently recommended cotesting strategy with HPV and Pap, as well as the possibility of primary HPV testing as another alternative for cervical screening.<b> </b><a href="http://dceg.cancer.gov/news-events/research-news-highlights/2014/negative-hpv-test">Read more about this study</a>.<b> Reference:</b> Gage JC, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25038467">Reassurance against future risk of precancer and cancer conferred by a negative HPV test</a>. <i>J Natl Cancer Inst</i> 2014;106(8):pii:dju153.</p>
<h4>Further Evidence <i>H. pylori</i> Treatment Reduces Gastric Cancer Incidence and Mortality</h4>
<p>Infection with <i>Helicobacter pylori</i> (<i>H. pylori</i>) &mdash;a bacterium found in the stomach&mdash;is a major cause of gastric cancer. Approximately two-thirds of the world&rsquo;s population harbors the bacterium, with infection rates much higher in developing countries. Treatment of the infection with antibiotics had been shown in intervention trials to lower gastric cancer incidence when compared to placebo. Lowered gastric cancer mortality was also suggested. But benefits in older people and those with advanced precancerous lesions were unknown. NCI investigator <a href="http://dceg.cancer.gov/about/staff-directory/biographies/K-N/gail-mitchell">Mitchell H. Gail, M.D., Ph.D.</a>, and collaborators found that a two-week course of <i>H. pylori</i> treatment given 15 years earlier was associated with lower gastric cancer incidence and mortality in older adults (aged 55 years and older at the beginning of the study). Incidence, but not mortality, was also statistically significantly reduced in subjects with advanced precancerous lesions initially. <i>H. pylori</i> treatment can benefit an entire population, not just the young or those with mild precancerous lesions in the stomach. <b>Reference: </b>Li WQ, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24925350">Effects of </a><i><a href="http://www.ncbi.nlm.nih.gov/pubmed/24925350">Helicobacter pylori</a></i><a href="http://www.ncbi.nlm.nih.gov/pubmed/24925350"> treatment on gastric cancer incidence and mortality in subgroups</a>. <i>J Natl Cancer Inst</i> 2014;106(7):pii:dju116.</p>
<h2>Additional Research</h2>
<ul>
<li><a href="#Human Papillomavirus (HPV)">Human Papillomavirus (HPV)</a></li>
<li><a href="#Human Immunodeficiency Virus (HIV)">Human Immunodeficiency Virus (HIV)</a></li>
<li><a href="#Other Infectious Agents">Other Infectious Agents</a></li>
</ul>
<h3 id="Human Papillomavirus (HPV)">Human Papillomavirus (HPV)</h3>
<p>Starting in the 1980s, DCEG investigators carried out landmark studies on the natural history of cervical cancer that firmly established HPV as the necessary cause of this malignancy (Schiffman et al., 1993, 2007). Their efforts laid the groundwork for vaccine development and improved strategies for screening.</p>
<h4>Efficacy of HPV Vaccines &ndash; Doses</h4>
<p>The licensure of prophylactic HPV vaccines in the mid-2000s created the opportunity to reduce a large fraction of the disease burden of cervical cancer. However, the cost and logistical challenges of administering a three-dose regimen created a barrier to vaccinating adolescents. DCEG investigators reported that one or two doses of an HPV 16/18 vaccine may prevent cervical cancer just as effectively as three doses (Kreimer et al., 2011, 2015). Such an approach could lower the cost of vaccination and encourage the global dissemination of the vaccine.</p>
<p>In October 2016, the U.S. Food and Drug Administration (FDA) approved a two-dose regimen of the nonavalent HPV vaccine for adolescents ages 9 through 14. Shortly after, the Centers for Disease Control and Prevention (CDC) recommended a two dose regimen for all prophylactic HPV vaccines given to children ages 9 to 14, while keeping the 3 dose regimen for those 15 or older. This decision was based on a review of evidence from randomized clinical trials and other studies, including research conducted by DCEG investigators. <a href="https://www.cancer.gov/news-events/cancer-currents-blog/2016/hpv-vaccine-doses">Read more about the two-dose CDC recommendation at Cancer.gov</a>.</p>
<h4>Efficacy of HPV Vaccines &ndash; Non-Cervical Sites</h4>
<p>DCEG investigators also reported that the HPV 16/18 vaccine provides strong protection against anal HPV infections that could eventually lead to anal cancer (Kreimer et al., 2011).</p>
<h4>HPV-based Screening for Cervical Cancer</h4>
<p>In 2012 the U.S. Preventive Services Task Force and a coalition of health organizations published new guidelines for cervical cancer screening. DCEG studies into the use of HPV DNA testing and cytology to stratify women into accurate and precise risk categories&nbsp;(Katki et al., 2011) have informed these revised&nbsp;guidelines. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303768" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="303768" sys_relationshipid="7276312" sys_variantid="1418" sys_contentid="303768">More information on HPV and cervical cancer</a>.</p>
<h3 id="Human Immunodeficiency Virus (HIV)">Human Immunodeficiency Virus (HIV)</h3>
<p>DCEG research provided the initial assessment of the specificity, sensitivity, and appropriate applications of the first-generation HIV antibody testing system for diagnosis of HIV infection (Weiss et al., 1985). As a result of this work, those tests became standard care in the routine clinical practice of diagnosing individuals thought to have contracted HIV.</p>
<p>A prospective study of HIV infection and the development of AIDS in subjects with hemophilia showed that a much larger proportion of HIV-infected persons would develop AIDS than previously thought (Goedert et al., 1989), a finding with broad impact for public health prevention programs and clinical practice.</p>
<p>DCEG research led to the recognition that CD4 count and HIV viral load predict risk for the development of full-blown AIDS and death from AIDS (Goedert et al., 1987, 1989; Ehmann et al., 1994; O&rsquo;Brien et al., 1996). These biomarkers are now the standard measures used to inform routine clinical care of HIV-positive patients, including counseling, screening, and medication management.</p>
<p>New worker safety recommendations for the handling of concentrated HIV samples in the laboratory were influenced by a DCEG study of HIV infection among laboratory workers (Weiss et al., 1988).</p>
<p>DCEG biostatisticians applied novel statistical methods to derive estimates of HIV prevalence in the U.S. population. Their findings revealed that prevalence was greatest among heterosexual individuals (Rosenberg et al., 1991; Rosenberg, 1995; Rosenberg and Biggar, 1998).</p>
<h3 id="Other Infectious Agents">Other Infectious Agents</h3>
<p>U.S. poliovirus vaccines were accidentally contaminated with simian virus 40 (SV40). These contaminated doses were widely administered from l955 through 1962. The public was alarmed by the possible risks from exposure to this oncogenic virus. DCEG investigators published results from after a study of newborns who received SV40-contaminated polio vaccine showing no increased risk of cancer (Fraumeni et al., 1963; Fraumeni et al., 1970; Mortimer et al., 1981).</p>
<p>The Food and Drug Administration (FDA) recommended screening all blood donations for human T-cell leukemia virus type I and II (HTLV-I/II) antibodies, based on DCEG research that demonstrated increased risks of HTLV-1 and associated complications following exposure to HTLV-I/II in contaminated blood (Blattner et al., 1982; Blayney et al., 1983).</p>
<p>The FDA decided not to screen the U.S. blood supply for human herpesvirus 8 (HHV-8) after DCEG research demonstrated that serological tests for HHV-8 had poor reproducibility (Rabkin et al., 1998).</p>
<p>DCEG studies linking <i>Helicobacter pylori</i> infection to the very high incidence of gastric cancer and precancerous lesions in Shandong province in China prompted a clinical trial that showed a sustained reduction in risk following a two-week course of antibiotics (You et al., 2006; Zhang et al., 2006; Ma et al., 2012; Li et. al., 2014).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303707" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="303707" sys_relationshipid="7276313" sys_variantid="1418" sys_contentid="303707">Learn about our current research on infectious agents</a></p>
</div>]]></content>
  </row>
  <row para_id="462207" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG research on hereditary syndromes and cancer has made a significant impact in the following areas:</p>
<p><img width="150" height="160" class="right" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=463090" inlinetype="rximage" sys_siteid="475" sys_relationshipid="7389965" sys_dependentvariantid="1482" sys_dependentid="463090" rxinlineslot="104" />DCEG researchers have identified <b>genes</b> and <b>mutations</b> responsible for hereditary cancer syndromes. These findings have had a significant impact on the clinical management of these and related conditions, as well as informed research on the genetic determinates of cancer in general. Examples include the discovery of <b>Li-Fraumeni syndrome</b> and the role of <i>p53</i> (Li and Fraumeni, 1969, 1982; Li et al., 1988; Malkin et al., 1990) and the roles of <i>NF2</i> in <b>neurofibromatosis type 2</b> (Rouleau et al., 1993; Trofatter et al., 1993); <i>CDKN2A</i>, <i>CDK4</i>, <i>MITF</i>, and <i>POT1</i> in <b>hereditary melanoma</b> (Hussusian et al., 1994; Zuo et al., 1996; Yokoyama et al., 2011; Shi et al., 2014); <i>PTCH</i> in <b>nevoid basal cell carcinoma syndrome</b> (Hahn et al., 1996); <i>SUFU</i> in <b>medulloblastoma</b> (Taylor et al., 2002); and <i>T</i> (brachyury) duplication in <b>familial chordoma</b> (Yang et al., 2009).</p>
<p>Detailed clinical studies of <b>neurofibromatosis type 2</b> carried out by DCEG investigators revealed heterogeneity of the disease phenotype, changed its clinical management, and informed genetic counseling guidelines (Kaiser-Kupfer et al., 1989; Parry et al., 1994, 1996; Ruttledge et al., 1996).</p>
<p>DCEG researchers identified the <i>PTCH</i> gene as the cause of <b>nevoid basal cell carcinoma syndrome</b> after discovering a novel chromosome 9q deletion in a patient with the syndrome and conducting genetic linkage and fine-mapping studies (Gailani et al., 1992; Hahn et al., 1996; Chidambaram et al., 1996). This work set in motion a research effort that recently culminated in the first U.S. Food and Drug Administration-approved biological agent (vismodegib) to target the Hedgehog signaling pathway, a novel therapy for locally advanced and metastatic basal cell carcinoma of the skin.</p>
<p>DCEG researchers and colleagues published the <i><b>Concise Handbook of Familial Cancer Susceptibility Syndromes</b>,</i> which has provided a useful reference for clinical recognition and management of these rare but important disorders (Lindor and Greene, 1998; Lindor et al., 2008).</p>
<p>DCEG researchers observed that patients with <b>dyskeratosis congenita</b> (DC) have extremely <b>short telomeres</b> and that approximately 60 percent of DC patients have a germline mutation in a telomere biology gene. These discoveries led to the development of telomere length as a diagnostic test for DC and new criteria for evaluating potential bone marrow donors (Alter et al., 2007; Savage et al., 2008).</p>
<p>DCEG studies of <b>monoclonal B-cell lymphomatosis</b> established the condition as a precursor for <b>chronic lymphocytic leukemia</b> (CLL) in high-risk families and in the general population, facilitating the development of screening for early diagnosis of CLL (Landgren et al., 2009; Goldin et al., 2010).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142" sys_contentid="467142" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7389966" sys_dependentvariantid="1418" sys_dependentid="467142" rxinlineslot="103" sys_variantid="1418">Hereditary Syndromes: Full list of article citations</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303693" sys_contentid="303693" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7389967" sys_dependentvariantid="1418" sys_dependentid="303693" rxinlineslot="103" sys_variantid="1418">Learn about our current research on hereditary cancer syndromes</a></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer; top: 47px; left: 18px;">Save</span></p>
</div>]]></content>
  </row>
  <row para_id="462208" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Over the years, DCEG research on breast cancer has made a significant impact in the following areas:</p>

<p><img alt="" class="right" height="224" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=463092" sys_dependentid="463092" sys_dependentvariantid="1482" sys_relationshipid="7275120" sys_siteid="475" width="129" />DCEG studies in hereditary breast and ovarian cancer uncovered the value of risk reducing <b>salpingo-oophorectomy</b>, now considered a standard-of-care treatment option in the management of women in high-risk families&#160;(Tobacman et al., 1982; Struewing et al., 1995; Kramer et al., 2005; Greene et al., 2008, 2011).</p>

<p>DCEG researchers developed the <a href="http://www.cancer.gov/bcrisktool/"><b>Gail breast cancer risk assessment model</b></a> (Gail et al., 1989) to estimate a woman's risk of developing invasive breast cancer. Since its original publication, the tool has been updated and expanded. It is widely used by clinicians and researchers. The Food and Drug Administration guidelines rely on the tool for the recommendation of use of <b>tamoxifen</b> and <b>raloxifene</b> for breast cancer risk reduction.</p>

<p>A DCEG study of <b><i>BRCA1</i></b> and <b><i>BRCA2</i></b> alterations in the Ashkenazi Jewish population of Washington, D.C., reported lower penetrance for breast and ovarian cancers than earlier studies in families with hereditary breast cancer. The findings highlighted the importance of population-specific founder mutations in genetic testing and affected the clinical management of mutation carriers (Struewing et al., 1997).</p>

<p>DCEG researchers conducted epidemiological studies using <b>tumor tissue microarrays</b> that revealed the heterogeneity of breast cancer in terms of risk factors and prognosis (García- Closas et al., 2006, 2008; Yang et al., 2007), which has enhanced clinical care decisions.</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Breast_Cancer" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7275121" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#breast_cancer">Breast Cancer: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303556" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303556" sys_dependentvariantid="1418" sys_relationshipid="7275122" sys_siteid="475" sys_variantid="1418" sys_contentid="303556">Learn about our current research on breast cancer</a></p>


</div>]]></content>
  </row>
  <row para_id="462209" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel" xmlns:o="urn:www.microsoft.com/office">
<p>Over the years, DCEG research on melanoma has made a significant impact in the following areas:</p>

<p><img alt="" class="right" height="192" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=463091" sys_dependentid="463091" sys_dependentvariantid="1482" sys_relationshipid="7276406" sys_siteid="475" width="256" />DCEG research led to the identification and characterization of <b>dysplastic nevi</b> as the major risk factor for melanoma. This finding informed guidelines for melanoma screening and clinical management in high-risk families and in the general population (Reimer et al., 1978; Greene et al., 1985a, 1985b; Tucker et al., 1997).</p>

<p>DCEG research has contributed to important milestones in the management of melanoma, including the creation of a clinical atlas depicting melanoma and precursor lesions, the creation of training videos to help health care providers examine high-risk families, and the development of a <a href="http://www.cancer.gov/melanomarisktool/">risk calculator to estimate an individual’s probability of developing melanoma </a>(Tucker et al., 2002; Fears et al., 2006).</p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142#Melanoma" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7276407" sys_siteid="475" sys_variantid="1418" sys_contentid="467142#melanoma">Melanoma: Full list of article citations</a></p>

<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303615" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303615" sys_dependentvariantid="1418" sys_relationshipid="7276408" sys_siteid="475" sys_variantid="1418" sys_contentid="303615">Learn about our current research on melanoma</a></p>


</div>]]></content>
  </row>
  <row para_id="463618" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>Diethylstilbestrol (DES) is the first carcinogen to have been shown to cross the placenta and cause cancer in the offspring. Between 1940 and the early 1970s millions of pregnant women were given DES, the first synthetic estrogen, in the mistaken belief that it would prevent complications of pregnancy. The earliest suggestion of a problem with DES was reported in a landmark publication in the NEJM that described a group of young women who had a rare vaginal cancer typically seen only in older women.</p>
<p>NCI researchers, led by <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349664" sys_contentid="349664" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7275651" sys_dependentvariantid="1965" sys_dependentid="349664" rxinlineslot="103">Robert N. Hoover, M.D., Sc.D.,</a> developed the DES Follow-up Study in the mid-1990s, bringing together participants from four large clinical studies of DES-exposed and unexposed subjects conducted 20 years prior.</p>
<h3>Advance</h3>
<p>The DES Follow-up Study team located and re-contacted the women in the studies, and systematically followed them for long-term adverse health outcomes. In a landmark publication in the <i>New England Journal of Medicine</i> in late 2011, Dr. Hoover and his colleagues projected the burden of disease experienced by the millions women who were exposed in-utero. The authors report on 12 adverse health outcomes linked to DES exposure: infertility, spontaneous abortion, ectopic pregnancy, second trimester pregnancy loss, preeclampsia, preterm birth, stillbirth, neonatal death, natural menopause prior to age 45, cervical cancer, breast cancer after age 40, and clear-cell adenocarcinoma of the vagina and cervix.</p>
<h3>Impact</h3>
<p>Without the sustained follow-up of these women through the DES Follow-up Study, many of these outcomes would have been missed. The toll of the devastating health effects is unprecedented, particularly since DES was given to healthy individuals. This study has not only documented a public health disaster, but has served as the model for an entire area of research focused on the role of endocrine disruption in early life and subsequent health effects.</p>
</div>]]></content>
  </row>
  <row para_id="463653" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>In the US, radiation exposure from medical sources has risen 600% in the last three decades, mainly as a result of a dramatic increase in the use of CT scans and other diagnostic tests that involve higher doses of ionizing radiation compared to conventional X-rays. &nbsp;These tests provide great medical benefits but also potential risks, including the risk of a radiation-related cancer. &nbsp;The overall public health impact of these trends in medical radiation exposures is not yet known. &nbsp;There are particular concerns about use in children because they are known to be more radiosensitive and radiation doses can be higher.</p>
<h3>Advance</h3>
<p>NCI researchers, led by <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7387932" sys_dependentvariantid="1965" sys_dependentid="349642" rxinlineslot="103">Amy Berrington de Gonz&aacute;lez, D.Phil.,</a> developed state-of-the-art radiation risk modeling tools and estimated that 29,000 future cancers could be related to the number of CT scans performed in a single year in the US. &nbsp;Results from a separate study&mdash;the first to directly study the cancer risks after CT scans in children&mdash;found that cumulative radiation dose from 2-3 head CT scans (based on current scanner settings) could triple the risk of developing brain tumors and 5-10 head CT scans could triple the risk of developing leukemia. However, these two malignancies are relatively rare, and the actual number of additional cases caused by radiation exposure from CT scans is small.</p>
<h3>Impact</h3>
<p>There is increasing recognition of the potential harms resulting from overuse of diagnostic tests. &nbsp;&nbsp;These studies have been cited by the FDA, American College of Radiology and other professional organizations as evidence of the need for clinical practice to change. &nbsp;The new direct evidence of subsequent cancer risks after CT scans in childhood could result in new guidelines for usage in children and technological innovations to reduce doses. &nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="467142" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<p>A complete list of citations associated with the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303763" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="303763" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275423" sys_variantid="1422" sys_contentid="303763">Public Health Impact of DCEG Research</a> is included below. Publications in each section are listed chronologically.</p>
<ul>
<li><a href="#Smokeless_Tobacco">Smokeless Tobacco</a></li>
<li><a href="#Radiation">Radiation</a></li>
<li><a href="#Occupation">Occupation</a></li>
<li><a href="#Indoor_Air_Pollution">Indoor Air Pollution</a></li>
<li><a href="#Water_Contaminants">Contaminants in Drinking Water</a></li>
<li><a href="#Diet_Cooking_Methods_Supplements">Diet/Cooking Methods/Supplements</a></li>
<li><a href="#Physical_Activity">Physical Activity</a></li>
<li><a href="#Pharmaceutical_and_Medical_Devices">Pharmaceuticals and Medical Devices</a></li>
<li><a href="#Infectious_Agents">Infectious Agents</a></li>
<li><a href="#Hereditary_Syndromes">Hereditary Syndromes</a></li>
<li><a href="#Breast_Cancer">Breast Cancer</a></li>
<li><a href="#Melanoma">Melanoma</a></li>
</ul>
<a id="Smokeless_Tobacco"></a>
<h3>Smokeless Tobacco</h3>
<p>Winn DM, Blot WJ, Shy CM, Pickle LW, Toledo A, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7193288">Snuff dipping and oral cancer among women in the southern United States</a>. <i>N Engl J Med</i> 1981 Mar 26;304(13):745-9.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Radiation"></a>
<h3>Radiation</h3>
<h4>Medical Radiation from Therapeutic and Diagnostic Procedures</h4>
<p>Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W, Hoover R, Fraumeni JF JR, and for the Late Effects Study Group. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3475572">Bone sarcomas linked to radiotherapy and chemotherapy in children</a>.<i>N Engl J Med</i> 1987 Sep 3;317(10):588-93.</p>
<p>Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3336397">Risk of second cancers after treatment for Hodgkin's disease</a>. <i>N Engl J Med</i> 1988 Jan 14;318(2):76-81.</p>
<p>Tucker MA, Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE, Meadows AT, Hoover RN, Fraumeni JF Jr, and for the Late Effects Study Group. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1851664">Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group</a>. <i>Cancer Res</i> 1991 Jun 1;51(11):2885-8.</p>
<p>Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Soc&iacute;e G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boice JD Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9070469">Solid cancers after bone marrow transplantation</a>. <i>N Engl J Med</i> 1997 Mar 27;336(13):897-904.</p>
<p>Soci&eacute; G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, Sullivan KM, Rowlings PA, Kingma DW, Banks PM, Travis WD, Witherspoon RP, Sanders J, Jaffe ES, Horowitz MM. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10637249">New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia</a>. <i>J Clin Oncol</i> 2000 Jan;18(2):348-57.</p>
<p>National Cancer Institute and Society for Pediatric Radiology. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=305&amp;sys_variantid=2297&amp;sys_contentid=13362" inlinetype="rxhyperlink" sys_dependentvariantid="2297" sys_dependentid="13362" rxinlineslot="103" sys_siteid="305" sys_relationshipid="7275424" sys_variantid="2297" sys_contentid="13362">Radiation Risk and Pediatric Computed Tomography: A Guide for Health Care Providers</a>. 2002, 2009.</p>
<p>Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11830608">Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease</a>. <i>J Natl Cancer Inst</i> 2002 Feb 6;94(3):182-92.</p>
<p>Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12876089">Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease</a>. <i>JAMA</i> 2003 Jul 23;290(4):465-75.</p>
<p>Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15800318">Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up</a>. <i>J Clin Oncol</i> 2005 Apr 1;23(10):2272-9.</p>
<p>Berrington de Gonz&aacute;lez A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, Land C. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20008689">Projected cancer risks from computed tomographic scans performed in the United States in 2007</a>. <i>Arch Intern Med</i> 2009 Dec 14;169(22):2071-7.</p>
<p>Rizzo JD, Curtis RE, Soci&eacute; G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18971419">Solid cancers after allogeneic hematopoietic cell transplantation</a>. <i>Blood</i> 2009 Jan 29;113(5):1175-83.</p>
<p>Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, de Gonz&aacute;lez AB. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22681860">Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: A retrospective cohort study</a>. <i>Lancet</i> 2012 Aug 4;380(9840):499-505.</p>
<p><a href="#Top">Back to top</a></p>
<h4>Radioactive Fallout or Environmental Contamination from Nuclear Weapons</h4>
<p>National Institutes of Health. <a href="http://www.cdc.gov/niosh/ocas/pdfs/42cfr81/71.pdf">Report of the National Institutes of Health Ad Hoc Working Group to Develop Radioepidemiological Tables (pdf)</a>. National Institutes of Health, Bethesda, MD, 1985, NIH Publication No. 85-2748.</p>
<p>Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8127954">Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality</a>. <i>Radiat Res</i> 1994 Feb;137(2 Suppl):S98-112.</p>
<p>Land CE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7616636">Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer</a>. <i>JAMA</i> 1995 Aug 2;274(5):402-7.</p>
<p>Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7871153">Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies</a>. <i>Radiat Res</i> 1995 Mar;141(3):259-77.</p>
<p>Land CE, Saku T, Hayashi Y, Takahara O, Matsuura H, Tokuoka S, Tokunaga M, Mabuchi K. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8677295">Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk</a>. <i>Radiat Res</i> 1996 Jul;146(1):28-36.</p>
<p>National Cancer Institute. <a href="http://www.cancer.gov/i131/fallout/contents.html">Estimated Exposure and Thyroid Doses Received by the American People from Iodine-131 Fallout Following Nevada Atmospheric Nuclear Bomb Tests</a>. Washington, D.C.: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 1997.</p>
<p>Gilbert ES, Tarone R, Bouville A, Ron E. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9811315">Thyroid cancer rates and 131I doses from Nevada atmospheric nuclear bomb tests</a>. <i>J Natl Cancer Inst</i> 1998 Nov 4;90(21):1654-60.</p>
<p>Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/9686552">Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group</a>. <i>JAMA</i> 1998 Jul 22-29;280(4):347-55.</p>
<p>Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, Tokuoka S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14640793">Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990</a>. <i>Radiat Res</i> 2003 Dec;160(6):707-17.</p>
<p>National Institutes of Health. <a href="https://www.cdc.gov/niosh/docket/archive/pdfs/NIOSH-209/0209-010103-land.pdf">Report of the NCI-CDC Working Group to revise the 1985 NIH Radioepidemiological Tables (pdf)</a>. Washington, DC, 2003, NIH Publication No. 03-5387.</p>
<p>Kocher DC, Apostoaei AI, Henshaw RW, Hoffman FO, Schubauer-Berigan MK, Stancescu DO, Thomas BA, Trabalka JR, Gilbert ES, Land CE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18545036">Interactive RadioEpidemiological Program (IREP): A web-based tool for estimating probability of causation/assigned share of radiogenic cancers</a>. <i>Health Phys</i> 2008 Jul;95(1):119-47.</p>
<p><a href="#Top">Back to top</a></p>
<h4>Naturally-occurring Radiation</h4>
<p>Qiao YL, Taylor PR, Yao SX, Schatzkin A, Mao BL, Lubin J, Rao JY, McAdams M, Xuan XZ, Li JY. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2589328">Relation of radon exposure and tobacco use to lung cancer among tin miners in Yunnan Province, China</a>. <i>Am J Ind Med</i> 1989;16(5):511-21.</p>
<p>Lubin JH, Qiao YL, Taylor PR, Yao SX, Schatzkin A, Mao BL, Rao JY, Xuan XZ, Li JY. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2293552">Quantitative evaluation of the radon and lung cancer association in a case control study of Chinese tin miners</a>.<i>Cancer Res</i> 1990 Jan 1;50(1):174-80.</p>
<p>Alavanja MC, Brownson RC, Lubin JH, Berger E, Chang J, Boice JD Jr.<a href="http://www.ncbi.nlm.nih.gov/pubmed/7990157">Residential radon exposure and lung cancer among nonsmoking women</a>. <i>J Natl Cancer Inst</i> 1994 Dec 21;86(24):1829-37.</p>
<p>Lubin JH, Boice JD Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8978406">Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies</a>. <i>J Natl Cancer Inst</i> 1997 Jan 1;89(1):49-57.</p>
<p>Lubin JH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9692372">The influence of residential radon exposure on the estimation of exposure-response trends for lung cancer in underground miners exposed to radon</a>. <i>Radiat Res</i> 1998 Aug;150(2):259-61.</p>
<p>Alavanja MC, Lubin JH, Mahaffey JA, Brownson RC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10394313">Residential radon exposure and risk of lung cancer in Missouri</a>. <i>Am J Public Health</i> 1999 Jul;89(7):1042-8.</p>
<p>Wang Z, Lubin JH, Wang L, Zhang S, Boice JD Jr, Cui H, Zhang S, Conrath S, Xia Y, Shang B, Brenner A, Lei S, Metayer C, Cao J, Chen KW, Lei S, Kleinerman RA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11882529">Residential radon and lung cancer risk in a high-exposure area of Gansu Province, China</a>. <i>Am J Epidemiol</i> 2002 Mar 15;155(6):554-64.</p>
<p>Lubin JH, Wang ZY, Boice JD Jr, Xu ZY, Blot WJ, De Wang L, Kleinerman RA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14735479">Risk of lung cancer and residential radon in China: pooled results of two studies</a>. <i>Int J Cancer</i> 2004 Mar;109(1):132-7.</p>
<p><a href="#Top">Back to top</a></p>
<h4>Ultraviolet Radiation</h4>
<p>Scotto J, Fears TR, Gori GB. <a href="http://archive.org/details/measurementsoful00scot">Measurements of Ultraviolet Radiation in the United States and Comparisons with Skin Cancer Data</a> <a class="exitNotification" href="http://preview.cancer.gov/global/web/policies/page8"><img title="Exit Disclaimer" alt="Exit Disclaimer" src="http://dcegnewpreview.cancer.gov/publishedcontent/images/images/exit_small.png" /></a>. DHEW Publ. No. (NIH ) 76-1029, Bethesda, MD, National Cancer Institute, 1975.</p>
<p>Fears TR, Scotto J, Schneiderman MA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1275120">Skin cancer, melanoma, and sunlight</a>. <i>Am J Public Health</i> 1976 May;66(5):461-4.</p>
<p>Fears TR, Scotto J, Schneiderman MA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/860705">Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States</a>. <i>Am J Epidemiol</i> 1977 May;105(5):420-7.</p>
<p>Scotto J, Fears TR, Fraumeni JF. <a href="http://www.ciesin.columbia.edu/docs/001-526/001-526.html">Incidence of non-melanoma skin cancer in the United States 1981</a> <a class="exitNotification" href="http://preview.cancer.gov/global/web/policies/page8"><img title="Exit Disclaimer" alt="Exit Disclaimer" src="http://dcegnewpreview.cancer.gov/publishedcontent/images/images/exit_small.png" /></a>. DHHS Publ. No. (NIH) 82-2433, Bethesda, MD, 1981.</p>
<p>Fears TR, Scotto J.<a href="http://www.ncbi.nlm.nih.gov/pubmed/6667401">Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure</a>. <i>Cancer Invest</i> 1983;1(2):119-26.</p>
<p><a href="#Top">Back to top</a></p>
<h4>Electromagnetic Fields</h4>
<p>Linet MS, Hatch EE, Kleinerman RA, Robison LL, Kaune WT, Friedman DR, Severson RK, Haines CM, Hartsock CT, Niwa S, Wacholder S, Tarone RE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9203424">Residential exposure to magnetic fields and acute lymphoblastic leukemia in children</a>. <i>N Engl J Med</i> 1997 Jul 3;337(1):1-7.</p>
<p>Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG, Fine HA, Black PM, Loeffler JS, Linet MS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20008689">Cellular-telephone use and brain tumors</a>. <i>N Engl J Med</i> 2001 Jan 11;344(2):79-86.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Occupation"></a>
<h3>Occupation</h3>
<p>Lee AM, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/5797547">Arsenic and respiratory cancer in man: an occupational study</a>. <i>J Natl Cancer Inst</i> 1969 Jun;42(6):1045-52.</p>
<p>Blot WJ, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/49742">Arsenical air pollution and lung cancer</a>. <i>Lancet</i> 1975 Jul 26;2(7926):142-4.</p>
<p>Brinton LA, Blot WJ, Stone BJ, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/908001">A death certificate analysis of nasal cancer among furniture workers in North Carolina</a>.<i>Cancer Res</i> 1977 Oct;37(10):3473-4.</p>
<p>Silverman DT, Hoover RN, Albert S, Graff KM. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6571931">Occupation and cancer of the lower urinary tract in Detroit</a>. <i>J Natl Cancer Inst</i> 1983 Feb;70(2):237-45.</p>
<p>Brinton LA, Blot WJ, Becker JA, Winn DM, Browder JP, Farmer JC Jr, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6731431">A case-control study of cancers of the nasal cavity and paranasal sinuses</a>. <i>Am J Epidemiol</i> 1984 Jun;119(6):896-906.</p>
<p>Blair A, Stewart P, O'Berg M, Gaffey W, Walrath J, Ward J, Bales R, Kaplan S, Cubit D. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3458945">Mortality among industrial workers exposed to formaldehyde</a>. <i>J Natl Cancer Inst</i> 1986 Jun;76(6):1071-84.</p>
<p>Hoar SK, Blair A, Holmes FF, Boysen CD, Robel RJ, Hoover R, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3801091">Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma</a>. <i>JAMA</i> 1986 Sep 5;256(9):1141-7.</p>
<p>Hayes RB, Sheffet A, Spirtas R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2773944">Cancer mortality among a cohort of chromium pigment workers</a>.&nbsp;<i>Am J Ind Med</i> 1989;16(2):127-33.</p>
<p>Chen SY, Hayes RB, Wang JM, Liang SR, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2799317">Nonmalignant respiratory disease among hematite mine workers in China</a>. <i>Scand J Work Environ Health</i> 1989 Oct;15(5):319-22.</p>
<p>Chen SY, Hayes RB, Liang SR, Li QG, Stewart PA, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2328225">Mortality experience of haematite mine workers in China</a>. <i>Br J Ind Med</i> 1990 Mar;47(3):175-81.</p>
<p>Blair A, Stewart PA, Tolbert PE, Grauman D, Moran FX, Vaught J, Rayner J. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=2328223">Cancer and other causes of death among a cohort of dry cleaners</a>.&nbsp;<i>Br J Ind Med</i> 1990 Mar;47(3):162-8.</p>
<p>Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman LM, Burmeister LF, Van Lier SF, Dick F. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2208120">Pesticide exposures and other agricultural risks factors for leukemia among men in Iowa and Minnesota</a>. <i>Cancer Res</i> 1990 Oct;50(20):6585-91.</p>
<p>Amandus HE, Shy C, Wing S, Blair A, Heineman EF. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1867218">Silicosis and lung cancer in North Carolina dusty trades workers</a>. <i>Am J Ind Med</i> 1991;20(1):57-70.</p>
<p>Cantor KP, Blair A, Everett G, Gibson R, Burmeister LF, Brown LM, Schuman L, Dick FR. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1568215">Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota</a>. <i>Cancer Res</i> 1992 May;52(9):2447-55.</p>
<p>Chen J, McLaughlin JK, Zhang JY, Stone BJ, Luo J, Chen RA, Dosemeci M, Rexing SH, Wu Z, Hearl FJ, McCawley MA, Blot WJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1312152">Mortality among dust-exposed Chinese mine and pottery workers</a>. <i>J Occup Med</i> 1992 Mar;34(3):311-6.</p>
<p>Brown LM, Burmeister LF, Everett GD, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8481493">Pesticide exposures and multiple myeloma in Iowa men</a>. <i>Cancer Causes Control</i> 1993 Mar;4(2):153-6.</p>
<p>Pesatori AC, Sontag JM, Lubin JH, Consonni D, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=8080942">Cohort mortality and nested case-control study of lung cancer among structural pest control workers in Florida (United States)</a>.<i>Cancer Causes Control</i> 1994 Jul;5(4):310-8.</p>
<p>Amandus HE, Shy C, Castellan RM, Blair A, Heineman EF. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8929698">Silicosis and lung cancer among workers in North Carolina dusty trades</a>. <i>Scand J Work Environ Health</i> 1995;21 Suppl 2:81-3.</p>
<p>Blair A, Hartge P, Stewart PA, McAdams M, Lubin J. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=9624267">Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: Extended follow-up</a>. <i>Occup Environ Med</i> 1998 Mar;55(3):161-71.</p>
<p>Blair A, Stewart PA, Zaebst DD, Pottern L, Zey JN, Bloom TF, Miller B, Ward E, Lubin J. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=9714511">Mortality of industrial workers exposed to acrylonitrile</a>.&nbsp;<i>Scand J Work Environ Health</i> 1998;24 Suppl 2:25-41.</p>
<p>Stewart PA, Zaebst D, Zey JN, Herrick R, Dosemeci M, Hornung R, Bloom T, Pottern L, Miller BA, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9714512">Exposure assessment for a study of workers exposed to acrylonitrile</a>. <i>Scand J Work Environ Health</i> 1998;24 (Suppl 2);42-53.</p>
<p>Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14600094">Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries</a>. <i>J Natl Cancer Inst</i> 2003 Nov 5;95(21):1615-23.</p>
<p>Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15191929">Mortality from solid cancers among workers in formaldehyde industries</a>. <i>Am J Epidemiol</i> 2004 Jun 15;159(12):1117-30.</p>
<p>Lan Q, Zhang L, Li G, Vermeulen R, Weinberg RS, Dosemeci M, Rappaport SM, Shen M, Alter BP, Wu Y, Kopp W, Waidyanatha S, Rabkin C, Guo W, Chanock S, Hayes RB, Linet M, Kim S, Yin S, Rothman N, Smith MT. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15576619">Hematotoxicity in workers exposed to low levels of benzene</a>. <i>Science</i> 2004 Dec 3;306(5702):1774-6.</p>
<p>Radican L, Blair A, Stewart P, Warenberg D. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=19001957">Mortality of aircraft maintenance workers exposed to trichloroethylene and other hydrocarbons and chemicals: extended follow-up</a>. <i>J Occup Environ Med</i> 2008 Nov;50(11):1306-19.</p>
<p>Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, Hauptmann M. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436030">Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: The National Cancer Institute Cohort</a>. <i>J Natl Cancer Inst</i> 2009 May 20;101(10):751-61.</p>
<p>Hauptmann M, Stewart PA, Lubin JH, Beane Freeman LE, Hornung RW, Herrick RF, Hoover RN, Fraumeni JF Jr, Blair A, Hayes RB. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19933446">Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde</a>. <i>J Natl Cancer Inst</i> 2009 Dec 16;101(24):1696-708.</p>
<p>Lan Q, Zhang L, Tang X, Shen M, Smith MT, Qiu C, Ge Y, Ji Z, Xiong J, He J, Reiss B, Hao Z, Liu S, Xie Y, Guo W, Purdue MP, Galvan N, Xin KX, Hu W, Beane Freeman LE, Blair AE, Li L, Rothman N, Vermeulen R, Huang H. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=20530238">Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers</a>. <i>Carcinogenesis</i> 2010 Sep;31(9):1592-6.</p>
<p>Moore LE, Boffetta P, Stewart T, Brennan P, Hung, RJ, Karami S, Boffetta P, Toro J, Zaridze D, Janout V, Bencko V, &nbsp;Foretova L, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Welch R, Chanock S, Chow W-H, Rothman N. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=20663906">Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants</a>. <i>Cancer Res</i> 2010 Aug;70(16):6527-36.</p>
<p>Freeman LE, Rusiecki JA, Hoppin JA, Lubin JH, Koutros S, Andreotti G, Zahm SH, Hines CJ, Coble JB, Barone-Adesi F, Sloan J, Sandler DP, Blair A, Alavanja MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=21622085">Atrazine and cancer incidence among pesticide applicators in the Agricultural Health Study (1994-2007)</a>. <i>Environ Health Perspect</i> 2011 Sep;119(9):1253-9.</p>
<p>Hosgood HD 3rd, Zhang L, Tang X, Vermeulen R, Qiu C, Shen M, Smith MT, Ge Y, Ji Z, Xiong J, He J, Reiss B, Liu S, Xie Y, Guo W, Galvan N, Li L, Hao Z, Rothman N, Huang H, Lan Q. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=22649769">Decreased numbers of CD4(+) naive and effector memory T cells, and CD8(+) na&iuml;ve T cells, are associated with trichloroethylene exposure</a>. <i>Front Oncol</i> 2011;1:53.</p>
<p>Silverman DT, Samanic CM, Lubin JH, Blair AE, Stewart PA, Vermeulen R, Coble JB, Rothman N, Schleiff PL, Travis WD, Ziegler RG, Wacholder S, Attfield MD. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22393209">The Diesel Exhaust in Miners study: A nested case-control study of lung cancer and diesel exhaust</a>. <i>J Natl Cancer Inst</i> 2012 Jun 6;104(11):855-68. Epub 2012 Mar 5.</p>
<p>Vermeulen R, Zhang L, Spierenburg A, Tang X, Bonventre JV, Reiss B, Shen M, Smith MT, Qiu C, Ge Y, Ji Z, Xiong J, He J, Hao Z, Liu S, Xie Y, Yue F, Guo W, Purdue M, Beane Freeman LE, Sabbisetti V, Li L, Huang H, Rothman N, Lan Q. <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=22665366">Elevated urinary levels of kidney injury molecule-1 among Chinese factory workers exposed to trichloroethylene</a>. <i>Carcinogenesis</i> 2012 Aug;33(8):1538-41.</p>
<p>Alavanja MC et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25337994">Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the agricultural health study</a>. <i>PLoS One</i> 2014 Oct 22;9(10):e109332. doi: 10.1371/journal.pone.0109332.</p>
<p>Jones RR et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25907210">Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis</a>. <i>Occup Environ Med</i> 2015 Jul;72(7):496-503</p>
<p><a href="#Top">Back to top</a></p>
<a id="Indoor_Air_Pollution"></a>
<h3>Indoor Air Pollution</h3>
<p>Gao YT, Blot WJ, Zheng W, Ershow AG, Hsu CW, Levin LI, Zhang R, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2824385">Lung cancer among Chinese women</a>. <i>Int J Cancer</i> 1987 Nov 15;40(5):604-9.</p>
<p>Lan Q, Chapman RS, Schreinemachers DM, Tian L, He X. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12048270">Household stove improvement and risk of lung cancer in Xuanwei, China</a>. <i>J Natl Cancer Inst</i> 2002 Jun 5;94(11):826-35.</p>
<p>Lan Q, He X, Shen M, Tian L, Liu LZ, Lai H, Chen W, Berndt SI, Hosgood HD, Lee KM, Zheng T, Blair A, Chapman RS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18712724">Variation in lung cancer risk by smoky coal subtype in Xuanwei, China</a>. <i>Int J Cancer</i> 2008 Nov 1;123(9):2164-9.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Water_Contaminants"></a>
<h3>Contaminants in Drinking Water</h3>
<p>Hoover RN, McKay FW, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1003528">Fluoridated drinking water and the occurrence of cancer</a>.&nbsp;<i>J Natl Cancer Inst</i> 1976 Oct;57(4):757-68.</p>
<p>Cantor KP, Hoover R, Hartge P, Mason TJ, Silverman DT, Altman R, Austin DF, Child MA, Key CR, Marrett LD, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3480378">Bladder cancer, drinking water source, and tap water consumption: A case-control study</a>. <i>J Natl Cancer Inst</i> 1987 Dec;79(6):1269-79.&nbsp;</p>
<p>Ward MH, Mark SD, Cantor KP, Weisenburger DD, Correa-Villase&ntilde;or A, Zahm SH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8862975">Drinking water nitrate and risk of non-Hodgkin's lymphoma</a>. <i>Epidemiology</i> 1996 Sep;7(5):465-71.</p>
<p>Ward MH, Pan WH, Cheng YJ, Li FH, Brinton LA, Chen CJ, Hsu MM, Chen IH, Levine PH, Yang CS, Hildesheim A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10797279">Dietary exposure to nitrosamines and risk of nasopharyngeal cancer in Taiwan</a>. <i>Int J Cancer</i> 2000 Jun;86(5):603-9.</p>
<p>De Roos A, Ward MH, Lynch C, Cantor KP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14569178">Nitrate in public water supplies and risk of colon and rectum cancers</a>.&nbsp;<i>Epidemiology</i> 2003 Nov;14(6):640-9.</p>
<p>Coss A, Cantor KP, Reif JS, Lynch CF, Ward MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15033647">Pancreatic cancer and drinking water and dietary sources of nitrate and nitrite</a>. <i>Am J Epidemiol</i> 2004 Apr;159(7):693-701.</p>
<p>Ward MH, Rusiecki J, Lynch CF, Cantor KP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17717631">Nitrate in public water supplies and risk of renal cell carcinoma</a>.&nbsp;<i>Cancer Causes Control</i> 2007 Dec;18(10):1141-51.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Diet_Cooking_Methods_Supplements"></a>
<h3>Diet/Cooking Methods/Supplements</h3>
<p>Hoover RN, Strasser PH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6103207">Artificial sweeteners and human bladder cancer. Preliminary results</a>. <i>Lancet</i> 1980 Apr 19;1(8173):837-40.</p>
<p>Ziegler RG, Morris LE, Blot WJ, Pottern LM, Hoover R, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6947105">Esophageal cancer among black men in Washington, D.C. II. Role of nutrition</a>.<i>J Natl Cancer Inst</i> 1981 Dec;67(6):1199-206.</p>
<p>Winn DM, Ziegler RG, Pickle LW, Gridley G, Blot WJ, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6692405">Diet in the etiology of oral and pharyngeal cancer among women from the southern United States</a>. <i>Cancer Res</i> 1984 Mar;44(3):1216-22.</p>
<p>Ziegler RG, Mason TJ, Stemhagen A, Hoover R, Schoenberg JB, Gridley G, Virgo PW, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3706278">Carotenoid intake, vegetables, and the risk of lung cancer among white men in New Jersey</a>. <i>Am J Epidemiol</i> 1986 Jun;123(6):1080-93.</p>
<p>Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, Yu Y, Liu B-Q, Tangrea J, Sun Y-H, Liu F, Fraumeni JF Jr., Zhang Y-H, Li Bl. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/8360931">Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population</a>.<i>J Natl Cancer Inst</i> 1993 Sep 15;85(18):1483-92.</p>
<p>Sinha R, Rothman N, Brown ED, Mark SD, Hoover RN, Caporaso NE, Levander OA, Knize MG, Lang NP, Kadlubar FF. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7954461">Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans</a>.&nbsp;<i>Cancer Res</i> 1994 Dec 1;54(23):6154-9.</p>
Sinha R, Rothman N, Brown ED, Salmon CP, Knize MG, Swanson CA, Rossi SC, Mark SD, Levander OA, Felton JS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7553619">High concentrations of the carcinogen 2-amino-1-methyl-6-phenylimidazo- [4,5-b]pyridine (PhIP) occur in chicken but are dependent on the cooking method</a>.<i>Cancer Res</i> 1995 Oct 15;55(20):4516-9.
<p>Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, Albanes D. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17047087">A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers</a>.<i>Cancer Res</i> 2006 Oct 15;66(20):10213-9.</p>
<p>Freedman DM, Looker AC, Chang SC, Graubard BI. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17971526">Prospective study of serum vitamin D and cancer mortality in the United States</a>.<i>J Natl Cancer Inst</i> 2007 Nov 7;99(21):1594-602.</p>
<p>Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18381472">Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial</a>.<i>Cancer Epidemiol Biomarkers Prev</i> 2008 Apr;17(4):889-94.</p>
<p>Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19208842">Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial</a>.<i>Cancer Res</i> 2009 Feb 15;69(4):1439-47.</p>
<p>Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, Weinstein SJ, McCullough ML, Purdue MP, Shu XO, Snyder K, Virtamo J, Wilkins LR, Yu K, Zeleniuch-Jacquotte A, Zheng W, Albanes D, Cai Q, Harvey C, Hayes R, Clipp S, Horst RL, Irish L, Koenig K, Le Marchand L, Kolonel LN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20562185">Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers</a>. <i>Am J Epidemiol</i> 2010 Jul 1;172(1):81-93.&nbsp;</p>
<p><a href="#Top">Back to top</a></p>
<a id="Physical_Activity"></a>
<h3>Physical Activity</h3>
<p>Albanes D, Blair A, Taylor PR. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2729471">Physical activity and risk of cancer in the NHANES I population</a>. <i>Am J Public Health</i> 1989 Jun;79(6):744-50.</p>
<p>Chow WH, Dosemeci M, Zheng W, Vetter R, McLaughlin JK, Gao YT, Blot WJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8449643">Physical activity and occupational risk of colon cancer in Shanghai, China</a>. <i>Int J Epidemiol</i> 1993 Feb;22(1):23-9.</p>
<p>Dosemeci M, Hayes RB, Vetter R, Hoover RN, Tucker M, Engin K, Unsal M, Blair A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8347780">Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey</a>. <i>Cancer Causes Control</i> 1993 Jul;4(4):313-21.</p>
<p>Sturgeon SR, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8353048">Past and present physical activity and endometrial cancer risk</a>. <i>Br J Cancer</i> 1993 Sep;68(3):584-9.</p>
<p>Zheng W, Shu XO, McLaughlin JK, Chow WH, Gao YT, Blot WJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8490910">Occupational physical activity and the incidence of cancer of the breast, corpus uteri, and ovary in Shanghai</a>.&nbsp;<i>Cancer</i> 1993 Jun 1;71(11):3620-4.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Pharmaceutical_and_Medical_Devices"></a>
<h3>Pharmaceutical and Medical Devices</h3>
<h4>Hormone-related Therapy</h4>
<p>Hoover R, Gray LA Sr, Cole P, MacMahon B. <a href="http://www.ncbi.nlm.nih.gov/pubmed/180409">Menopausal estrogens and breast cancer</a>. <i>N Engl J Med</i> 1976 Aug 19;295(8):401-5.</p>
<p>Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10927819">Estrogen-progestin replacement and risk of breast cancer</a>.&nbsp;<i>JAMA</i> 2000 Aug 9;284(6):691-4.</p>
<p>Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, Mittendorf R, Robboy SJ, Hyer M, Cowan CM, Adam E, Colton T, Hartge P, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9718055">Cancer risk in women exposed to diethylstilbestrol in utero</a>.<i>JAMA</i> 1998 Aug 19;280(7):630-4.</p>
<p>Titus-Ernstoff L, Hatch EE, Hoover RN, Palmer J, Greenberg ER, Ricker W, Kaufman R, Noller K, Herbst AL, Colton T, Hartge P.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/11139327">Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy</a>.&nbsp;<i>Br J Cancer</i> 2001 Jan 5;84(1):126-33.</p>
<p>Hatch EE, Herbst AL, Hoover RN, Noller KL, Adam E, Kaufman RH, Palmer JR, Titus-Ernstoff L, Hyer M, Hartge P, Robboy SJ.<a href="http://www.ncbi.nlm.nih.gov/pubmed/11714112">Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States)</a>.<i>Cancer Causes Control</i> 2001 Nov;12(9):837-45.</p>
<p>Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17390375">Cancer risk in women prenatally exposed to diethylstilbestrol</a>.&nbsp;<i>Int J Cancer</i> 2007 Jul 15;121(2):356-60.</p>
<p>Troisi R, Titus-Ernstoff L, Hyer M, Hatch EE, Robboy SJ, Strohsnitter W, Palmer JR, &Oslash;glaend B, Adam E, Kaufman R, Herbst AL, Hoover RN.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/17601905">Preeclampsia risk in women exposed in utero to diethylstilbestrol</a>. <i>Obstet Gynecol</i> 2007 Jul;110(1):113-20.</p>
<p>Titus-Ernstoff L, Troisi R, Hatch EE, Palmer JR, Hyer M, Kaufman R, Adam E, Noller K, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20002218">Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES)</a>.&nbsp;<i>Int J Androl</i> 2010 Apr;33(2):377-84.</p>
<p>Hatch EE, Troisi R, Wise LA, Titus-Ernstoff L, Hyer M, Palmer JR, Strohsnitter WC, Robboy SJ, Anderson D, Kaufman R, Adam E, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21130156">Preterm birth, fetal growth, and age at menarche among women exposed prenatally to diethylstilbestrol (DES)</a>. <i>Reprod Toxicol</i> 2011 Feb;31(2):151-7</p>
<p>Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, Colton T, Hartge P, Hatch EE, Herbst AL, Karlan BY, Kaufman R, Noller KL, Palmer JR, Robboy SJ, Saal RC, Strohsnitter W, Titus-Ernstoff L, Troisi R.<a href="http://www.ncbi.nlm.nih.gov/pubmed/21991952">Adverse health outcomes in women exposed in utero to diethylstilbestrol</a>. <i>N Engl J Med</i> 2011 Oct 6;365(14):1304-14.</p>
<p>Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15172852">Ovarian cancer risk after the use of ovulation-stimulating drugs</a>.<i>Obstet Gynecol</i> 2004 Jun;103(6):1194-203.</p>
<p>Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Althuis MD, Mabie JE, Lamb EJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15217997">Breast cancer risk associated with ovulation-stimulating drugs</a>. <i>Hum Reprod</i> 2004 Sep;19(9):2005-13.</p>
<h4>Treatment-related Therapy</h4>
<p>Hoover R, Fraumeni JF Jr.<a href="http://www.ncbi.nlm.nih.gov/pubmed/4123616">Risk of cancer in renal-transplant recipients</a>. <i>Lancet</i> 1973 Jul 14;2(7820):55-7.</p>
<p>Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6752720">Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: A study of five randomized clinical trials</a>.<i>N Engl J Med</i> 1982 Dec 2;307(23):1416-21.</p>
<p>Tucker MA, Meadows AT, Boice JD Jr, Stovall M, Oberlin O, Stone BJ, Birch J, Vo&ucirc;te PA, Hoover RN, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3469460">Leukemia after therapy with alkylating agents for childhood cancer</a>. <i>J Natl Cancer Inst</i> 1987 Mar;78(3):459-64.</p>
<p>Shu XO, Gao YT, Linet MS, Brinton LA, Gao RN, Jin F, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2889862">Chloramphenicol use and childhood leukaemia in Shanghai</a>. <i>Lancet</i> 1987 Oct 24;2(8565):934-7.</p>
<p>Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1594016">Risk of leukemia after chemotherapy and radiation treatment for breast cancer</a>.&nbsp;<i>N Engl J Med</i> 1992 Jun 25;326(26):1745-51.</p>
<h4>Medical Devices</h4>
<p>Brinton LA, Buckley LM, Dvorkina O, Lubin JH, Colton T, Murray MC, Hoover R.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/15383405">Risk of connective tissue disorders among breast implant patients</a>.&nbsp;<i>Am J Epidemiol</i> 2004 Oct 1;160(7):619-27.</p>
<p>Brinton LA, Lubin JH, Murray MC, Colton T, Hoover RN. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16477256">Mortality rates among augmentation mammoplasty patients: An update</a>.&nbsp;<i>Epidemiology</i> 2006 Mar;17(2):162-9.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Infectious_Agents"></a>
<h3>Infectious Agents</h3>
<h4>Human Papillomavirus (HPV)</h4>
<p>Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/8388478">Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia</a>. <i>J Natl Cancer Inst</i> 1993 Jun 16;85(12):958-64.</p>
<p>Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/17826171">Human papillomavirus and cervical cancer</a>. <i>Lancet</i> 2007 Sep 8;370(9590):890-907.</p>
<p>Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/21684207">Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice</a>. <i>Lancet Oncol</i> 2011 Jul;12(7):663-72.</p>
<p>Kreimer AR, Gonz&aacute;lez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jim&eacute;nez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21865087">Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine Trial</a>. <i>Lancet Oncol</i> 2011 Sep;12(9):862-70.</p>
<p>Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonz&aacute;lez P, Solomon D, Jim&eacute;nez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; CVT Vaccine Group. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21908768">Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine</a>. <i>J Natl Cancer Inst</i> 2011 Oct 5;103(19):1444-51.</p>
<h4>Human Immunodeficiency Virus (HIV)</h4>
<p>Weiss SH, Goedert JJ, Sarngadharan MG, Bodner AJ, Gallo RC, Blattner WA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2981369">Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications</a>.&nbsp;<i>JAMA</i> 1985 Jan 11;253(2):221-5.</p>
<p>Goedert JJ, Biggar RJ, Melbye M, Mann DL, Wilson S, Gail MH, Grossman RJ, DiGioia RA, Sanchez WC, Weiss SH, Blattner WA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3491911">Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus</a>. <i>JAMA</i> 1987 Jan 16;257(3):331-4.</p>
<p>Weiss SH, Goedert JJ, Gartner S, Popovic M, Waters D, Markham P, di Marzo Veronese F, Gail MH, Barkley WE, Gibbons J, Gill FA, Leuther M, Shaw GM, Gallo RC, Blattner WA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3336776">Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers</a>. <i>Science</i> 1988 Jan 1;239(4835):68-71.</p>
<p>Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC 2nd, Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, Gail MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2477702">A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia</a>. <i>N Engl J Med</i> 1989 Oct 26;321(17):1141-8.</p>
<p>Rosenberg PS, Biggar RJ, Goedert JJ, Gail MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2000845">Backcalculation of the number with human immunodeficiency virus infection in the United States</a>. <i>Am J Epidemiol</i> 1991 Feb 1;133(3):276-85.</p>
<p>Ehmann WC, Eyster ME, Wilson SE, Andes WA, Goedert JJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7916052">Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV. Multicenter Hemophilia Cohort Study</a>.&nbsp;<i>J Acquir Immune Defic Syndr</i> 1994 Oct;7(10):1095-8.</p>
<p>Rosenberg PS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7481828">Scope of the AIDS epidemic in the United States</a>.&nbsp;<i>Science</i> 1995 Nov 24;270(5240):1372-5.</p>
<p>O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BL, Goedert JJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8656501">Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study</a>. <i>JAMA</i> 1996 Jul 10;276(2):105-10.</p>
<p>Rosenberg PS, Biggar RJ.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/9634261">Trends in HIV incidence among young adults in the United States</a>.&nbsp;<i>JAMA</i> 1998 Jun 17;279(23):1894-9.</p>
<h4>Other Infectious Agents</h4>
<p>Fraumeni JF Jr, Ederer F, Miller RW. <a href="http://www.ncbi.nlm.nih.gov/pubmed/13959363">An evaluation of the carcinogenicity of simian virus 40 in man</a>. <i>JAMA</i> 1963 Aug 31;185:713-8.</p>
<p>Fraumeni JF Jr, Stark CR, Gold E, Lepow ML. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4311216">Simian virus 40 in polio vaccine: follow-up of newborn recipients</a>. <i>Science</i> 1970 Jan 2;167(3914):59-60.</p>
<p>Mortimer EA Jr, Lepow ML, Gold E, Robbins FC, Burton GJ, Fraumeni JF Jr.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/6272114">Long-term follow-up of persons inadvertently inoculated with SV40 as neonates</a>. <i>N Engl J Med</i> 1981 Dec 17;305(25):1517-8.</p>
<p>Blattner WA, Kalyanaraman VS, Robert-Guroff M, Lister TA, Galton DA, Sarin PS, Crawford MH, Catovsky D, Greaves M, Gallo RC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6290401">The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma</a>. <i>Int J Cancer</i> 1982 Sep 15;30(3):257-64.</p>
<p>Blayney DW, Jaffe ES, Blattner WA, Cossman J, Robert-Guroff M, Longo DL, Bunn PA Jr, Gallo RC.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/6223675">The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma</a>. <i>Blood</i> 1983 Aug;62(2):401-5.</p>
<p>Rabkin CS, Schulz TF, Whitby D, Lennette ET, Magpantay LI, Chatlynne L, Biggar RJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9697708">Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group</a>. <i>J Infect Dis</i> 1998 Aug;178(2):304-9.</p>
<p>You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, Xu GW, Gail MH.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/16849680">Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions</a>.&nbsp;<i>J Natl Cancer Inst</i> 2006 Jul 19;98(14):974-83.</p>
<p>Zhang L, Gail MH, Wang YQ, Brown LM, Pan KF, Ma JL, Amagase H, You WC, Moslehi R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17023720">A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins</a>. <i>Am J Clin Nutr</i> 2006 Oct;84(4):912-9.</p>
<p>Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, You WC, Gail MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22271764">Fifteen-year effects of</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/22271764">Helicobacter pylori</a></i><a href="http://www.ncbi.nlm.nih.gov/pubmed/22271764">, garlic, and vitamin treatments on gastric cancer incidence and mortality</a>.&nbsp;<i>J Natl Cancer Inst</i> 2012 Mar 21;104(6):488-92. Epub 2012 Jan 23.</p>
<p>Li WQ, Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, You WC, Gail MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24925350">Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups.</a> J Natl Cancer Inst. 2014 Jun 12;106(7). Print 2014 Jul.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Hereditary_Syndromes"></a>
<h3>Hereditary Syndromes</h3>
<p>Li FP, Fraumeni JF Jr.<a href="http://www.ncbi.nlm.nih.gov/pubmed/5360287">Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?</a> <i>Ann Intern Med</i> 1969 Oct;71(4):747-52.</p>
<p>Li FP, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7077763">Prospective study of a family cancer syndrome</a>. <i>JAMA</i> 1982 May 21;247(19):2692-4.</p>
<p>Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3409256">A cancer family syndrome in twenty-four kindreds</a>. <i>Cancer Res</i> 1988 Sep 15;48(18):5358-62.</p>
<p>Kaiser-Kupfer MI, Freidlin V, Datiles MB, Edwards PA, Sherman JL, Parry D, McCain LM, Eldridge R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2705922">The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2</a>. <i>Arch Ophthalmol</i> 1989 Apr;107(4):541-4.</p>
<p>Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1978757">Germ line</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/1978757">p53</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/1978757">mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms</a>.<i>Science</i> 1990 Nov 30;250(4985):1233-8.</p>
<p>Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, Drum MA, Pastakia B, McBride OW, Kase R, Greene M, Mulvihill JJ, Bale AE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1348213">Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9</a>. <i>Cell</i> 1992 Apr 3;69(1):111-7.</p>
<p>Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldrige R, Aurias A, Delattre O, Thomas G. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8379998">Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2</a>. <i>Nature</i> 1993 Jun 10;363(6429):515-21.</p>
<p>Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CA, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8453669">A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor</a>. <i>Cell</i> 1993 Mar 12;72(5):791-800.</p>
<p>Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7987387">Germline p16 mutations in familial melanoma</a>.<i>Nat Genet</i> 1994 Sep;8(1):15-21.</p>
<p>Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N.<a href="http://www.ncbi.nlm.nih.gov/pubmed/7747758">Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity</a>. <i>Am J Med Genet</i> 1994 Oct 1;52(4):450-61.</p>
<p>Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8528263">Germline mutations in the p16INK4a binding domain of</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/8528263">CDK4</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/8528263">in familial melanoma</a>. <i>Nat Genet</i> 1996 Jan;12(1):97-9.</p>
<p>Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/8681379">Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome</a>. <i>Cell</i> 1996 Jun 14;85(6):841-51.</p>
<p>Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8755919">Type of mutation in the neurofibromatosis type 2 gene (</a><i><a href="http://www.ncbi.nlm.nih.gov/pubmed/8755919">NF2</a></i><a href="http://www.ncbi.nlm.nih.gov/pubmed/8755919">) frequently determines severity of disease</a>. <i>Am J Hum Genet</i> 1996 Aug;59(2):331-42.</p>
<p>Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8751853">Germ-line mutations in the neurofibromatosis 2 gene: Correlations with disease severity and retinal abnormalities</a>. <i>Am J Hum Genet</i> 1996 Sep;59(3):529-39.</p>
<p>Chidambaram A, Goldstein AM, Gailani MR, Gerrard B, Bale SJ, DiGiovanna JJ, Bale AE, Dean M. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8840969">Mutations in the human homologue of the Drosophila patched gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients</a>. <i>Cancer Res</i> 1996 Oct 15;56(20):4599-601.</p>
<p>Lindor NM, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9672254">The concise family handbook of family cancer syndromes</a>. <i>J Natl Cancer Inst</i> 1998;90(14):1040&ndash;1071.</p>
<p>Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, Squire JA, Rutka JT, Hogg D. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12068298">Mutations in</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/12068298">SUFU</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/12068298">predispose to medulloblastoma</a>. <i>Nat Genet</i> 2002 Jul;31(3):306-10.</p>
<p>Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, Peters JA, Giri N, Lansdorp PM. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17468339">Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita</a>. <i>Blood</i> 2007 Sep 1;110(5):1439-47.</p>
<p>Lindor NM, McMaster ML, Lindor CJ, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18559331">Concise handbook of familial cancer susceptibility syndromes - second edition</a>. <i>J Natl Cancer Inst Monogr</i> 2008;(38):1-93.</p>
<p>Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/18252230">TINF2</a></i><a href="http://www.ncbi.nlm.nih.gov/pubmed/18252230">, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita</a>. <i>Am J Hum Genet</i> 2008 Feb;82(2):501-9.</p>
<p>Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, Marti GE, Caporaso NE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19213679">B-cell clones as early markers for chronic lymphocytic leukemia</a>. <i>N Engl J Med</i> 2009 Feb 12;360(7):659-67.</p>
<p>Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM, Kelley MJ. <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/19801981">T</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/19801981">(brachyury) gene duplication confers major susceptibility to familial chordoma</a>. <i>Nat Genet</i> 2009 Nov;41(11):1176-8.</p>
<p>Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20738309">Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families</a>. <i>Br J Haematol</i> 2010 Oct;151(2):152-8.</p>
<p>Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22080950">A novel recurrent mutation in</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/22080950">MITF</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/22080950">predisposes to familial and sporadic melanoma</a>. <i>Nature</i> 2011 Nov 13;480(7375):99-103.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Breast_Cancer"></a>
<h3>Breast Cancer</h3>
<p>Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr.<a href="http://www.ncbi.nlm.nih.gov/pubmed/6126666">Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families</a>. <i>Lancet</i> 1982 Oct 9;2(8302):795-7.</p>
<p>Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2593165">Projecting individualized probabilities of developing breast cancer for white females who are being examined annually</a>. <i>J Natl Cancer Inst</i> 1989 Dec 20;81(24):1879-86.</p>
<p>Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8573450">Prophylactic oophorectomy in inherited breast/ovarian cancer families</a>.<i>J Natl Cancer Inst Monogr</i> 1995;(17):33-5.</p>
<p>Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9145676">The risk of cancer associated with specific mutations of</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/9145676">BRCA1</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/9145676">and</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/9145676">BRCA2</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/9145676">among Ashkenazi Jews</a>.&nbsp;<i>N Engl J Med</i> 1997 May 15;336(20):1401-8.</p>
<p>Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16314625">Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/16314625">BRCA1</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/16314625">mutation carriers</a>.&nbsp;<i>J Clin Oncol</i> 2005 Dec 1;23(34):8629-35.</p>
<p>Garc&iacute;a-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16755295">Established breast cancer risk factors by clinically important tumour characteristics</a>. <i>Br J Cancer</i> 2006 Jul 3;95(1):123-9.</p>
<p>Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garc&iacute;a-Closas M. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17372238">Differences in risk factors for breast cancer molecular subtypes in a population-based study</a>. <i>Cancer Epidemiol Biomarkers Prev</i> 2007 Mar;16(3):439-43.</p>
<p>Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18349277">A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: A Gynecologic Oncology Group study</a>. <i>Cancer Epidemiol Biomarkers Prev</i> 2008 Mar;17(3):594-604.</p>
<p>Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonz&aacute;lez-Neira A, Ben&iacute;tez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, D&ouml;rk T, Sch&uuml;rmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittom&auml;ki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengstr&ouml;m M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X; Australian Ovarian Cancer Management Group; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18437204">Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics</a>. <i>PLoS Genet</i> 2008 Apr 25;4(4):e1000054.</p>
<p>Greene MH, Mai PL, Schwartz PE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20619389">Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/20619389">BRCA1/2</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/20619389">mutation carriers?</a>&nbsp;<i>Am J Obstet Gynecol</i> 2011 Jan;204(1):19.e1-6.</p>
<p><a href="#Top">Back to top</a></p>
<a id="Melanoma"></a>
<h3>Melanoma</h3>
<p>Reimer RR, Clark WH Jr, Greene MH, Ainsworth AM, Fraumeni JF Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/621895">Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome</a>. <i>JAMA</i> 1978 Feb 20;239(8):744-6.</p>
<p>Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D 4th, Witmer WK, Thompson J, Matozzo I, Fraser MC.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/3964923">Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome</a>. <i>N Engl J Med</i> 1985 Jan 10;312(2):91-7.</p>
<p>Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3977193">High risk of malignant melanoma in melanoma-prone families with dysplastic nevi</a>. <i>Ann Intern Med</i> 1985 Apr;102(4):458-65.</p>
<p>Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D 4th, Clark WH Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9145715">Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma</a>. <i>&nbsp;JAMA</i> 1997 May 14;277(18):1439-44.</p>
<p>Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, Chiazze EA, Zametkin DP, Fontaine LS, Clark WH Jr. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12115352">A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families</a>. <i>Cancer</i> 2002 Jun 15;94(12):3192-209.</p>
<p>Fears TR, Guerry D 4th, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/16728488">Identifying individuals at high risk of melanoma: A practical predictor of absolute risk</a>. <i>J Clin Oncol</i> 2006 Aug 1;24(22):3590-6.</p>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="473466" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7276303" sys_dependentid="462461" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=303013&amp;sys_siteid=475&amp;sys_contentid=462461&amp;sys_command=preview" alt="Woman in China cooks indoors over a wok using smoky coal"><!--Comment--></img>
                                                </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              <p>Indoor cooking with smoky coal</p>                                        </div>
          </figcaption>
              </figure>
       </div>
<p>About half of the world&rsquo;s population is exposed to smoke from heating or cooking with solid fuels. Household air pollution (HAP) from solid fuel use was estimated to cause 4.3 million deaths in 2012 (7.7 percent&nbsp;of global mortality). To study the role of indoor air pollution from solid fuel use in lung cancer risk, particularly among never-smoking women, DCEG investigators conducted a series of investigations in Xuanwei County, China, where lung cancer rates among never-smoking women are among the highest in the world. A retrospective cohort study found that use of smoky coal relative to smokeless coal was associated with a 99-fold increase in lung cancer risk among women, almost all of whom were never-smokers. This represents one of the strongest effects of an environmental exposure reported for cancer risk in any population to date. To identify which components of coal combustion account for the striking increase in lung cancer risk in Xuanwei, and to characterize other important exposures, a new case-control study of never-smoking female lung cancer that includes an extensive exposure assessment component has been conducted to identify the components of coal combustion products that drive lung cancer risk in this population and the genetic variants that modify effects. New findings show that we can explain a substantial amount of the high lung cancer risk in this population based on exposure to a subgroup of compounds we have measured.</p>
<p>To expand the study of the environmental and genetic etiology of lung cancer among never-smoking women, we formed the Female Lung Cancer Consortium in Asia and conducted the first large-scale genome-wide association study (GWAS) of lung cancer among never-smoking females anywhere in the world. This study recently identified novel loci that have not been linked to lung cancer among smokers in either Asia or the West, and found evidence for gene-environment interactions with coal use for home cooking and heating. We are in the process of expanding the GWAS and also conducting whole genome sequencing of tumor samples from a subgroup of cases in the study.</p>
<h3>References</h3>
<p>Lan Q, Hsiung CA, Matsuo K,&nbsp;et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23143601">Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia</a>. <em>Nat Genet</em> 2012; Epub Nov 11, 2012.</p>
<p>Barone-Adesi F, Chapman RS, Silverman DT, He X, Hu W, Vermeulen R, Ning B, Fraumeni JF Jr, Rothman N, Lan Q. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22936785">Risk of lung cancer associated with domestic use of coal in Xuanwei, China: Retrospective cohort study</a>. <em>BMJ</em> 2012.</p>
<p>Seow WJ, Matsuo K, Hsiung CA, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28025329">Association between GWAS-identified lung adenocarcinoma susceptibility loci and <em>EGFR</em> mutations in never-smoking Asian women, and comparison with findings from Western populations</a>. <em>Hum Mol Genet</em> January 15, 2017.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349613" sys_variantid="1965" sys_relationshipid="7276301">Dr. Qing Lan</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="418935" sys_variantid="1418" sys_relationshipid="7276302">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="473518" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2><a id="Job-Exposure-Matrices"></a>Publications - Use of Job Exposure Matrices</h2>
<p>Dopart PJ, Friesen MC. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28695485">New opportunities in exposure assessment of occupational epidemiology: Use of measurements to aid exposure reconstruction in population-based studies</a>. <em>Curr Environ Health Rep</em> 2017; 4:355-363. PMCID: PMC5693667.</p>
<p>Stenehjem JS, Friesen MC, Eggen T, Kj&aelig;rheim, Br&aring;tveit M, Grimsrud TK. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25671393">Self-reported occupational exposures relevant for cancer among 28,000 offshore oil industry workers employed between 1965 and 1999</a>. <em>J Occup Environ Hyg</em> 2015; 12:458-68. PMCID: PMC4819329.</p>
<p>Koh DH, Bhatti P, Coble JB, Stewart PA, Lu W, Shu XO, Ji BT, Xue S, Locke SJ, Portengen L, Yang G, Chow WH, Gao YT, Rothman N, Vermeulen R, Friesen MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22910004">Calibrating a population-based job-exposure matrix using inspection measurements to estimate historical occupational exposure to lead for a population-based cohort in Shanghai, China</a>. <i>J Expo Sci Environ Epidemiol</i> 2014;24:9-16. PMCID: PMC3508334.</p>
<p>Friesen MC, Coble J, Ji B-T, Lu W, Shu X-O, Ji B-T, Xue S, Portengen L, Chow W-H, Gao Y-T, Yang G, Rothman N, Vermeulen R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/%2021976309">Combining a job exposure matrix with exposure measurements to assess occupational exposure to benzene in a population-based cohort in Shanghai, China.</a> <i>Ann Occup Hyg</i> 2012;56:80-91. PMCID: PMC3259038.</p>
<h2><a id="Occupation-Industry-Modules"></a>Publications - Occupation- and Industry-specific Modules</h2>
<p>Callahan CL, Locke SJ, Dopart PJ, Stewart PA, Schwartz K, Ruterbusch JJ, Graubard BI, Rothman N, Hofmann JN, Purdue MP, Friesen MC. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30291640">Decision rule approach applied to estimate occupational lead exposure in a case-control study of kidney cancer.</a> <em>Am J Ind Med</em> 2018; 61:901-910. PMID: 30291640.</p>
<p>Ge CB, Friesen MC, Kromhout H, Peters S, Rothman N, Lan Q, Vermeulen R. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30239580">Use and reliability of exposure assessment methods in occupational case-control studies in the general population: Past, present, and future</a>. <em>Ann Work Expo Health</em> 2018; 62:1047-1063. PMID: 30239580.</p>
<p>Su FC, Friesen MC, Stefaniak AB, Henneberger PK, LeBouf RF, Stanton ML, Liang X, Humann M, Virji MA. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29931140">Exposures to volatile organic compounds among healthcare workers: Modeling the effects of cleaning tasks and product use</a>. <em>Ann Work Expo Health</em> 2018; 62:852-870. PMID: 29931140.</p>
<p>Friesen MC, Lan Q, Ge C, Locke SJ, Hosgood D, Fritschi L, Sadkowsky T, Chen YC, Wei H, Xu J, Lam TH, Kwong YL, Chen K, Xu C, Su YC, Chiu BC, Ip KM, Purdue MP, Bassig BA, Rothman N, Vermeulen R. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27250109">Evaluation of automatically assigned job-specific interview modules</a>. <em>Ann Occup Hyg</em> 2016 Aug;60(7):885-99. PMCID: PMC4965807.</p>
<p>Friesen MC, Wheeler DC, Vermeulen R, Locke SJ, Zaebst DD, Koutros S, Pronk A, Colt JS, Baris D, Karagas MR, Malats N, Schwenn M, Johnson A, Armenti KR, Rothman N, Stewart PA, Kogevinas M, Silverman DT. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26732820">Combining decision rules from classification tree models and expert assessment to estimate occupational exposure to diesel exhaust for a case-control study</a>. <em>Ann Occup Hyg</em> 2016; 60:467-78 PMCID: PMC4850897.</p>
<p>Friesen MC, Shortreed SM, Wheeler DC, Burstyn I, Vermeulen, Pronk A, Colt JS, Baris D, Karagas MR, Schwenn M, Johnson A, Armenti KR, Silverman DT, Yu K. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25477475">Using hierarchical cluster models to systematically identify groups of jobs with similar occupational questionnaire response patterns to assist rule-based expert exposure assessment in population-based studies</a>. Ann Occup Hyg 2015; 59:455-66. PMCID: PMC4385262</p>
<p>Wheeler DC, Archer KJ, Burstyn I, Yu K, Stewart PA, Colt JS, Baris D, Karagas MR, Schwenn M, Johnson A, Armenti K, Silverman DT, Friesen MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25433003">Comparison of ordinal and nominal classification trees to predict ordinal expert-based occupational exposure estimates in case-control studies</a>. <em>Ann Occup Hyg</em> 2015; 59:324-335. PMCID: PMC4365762.</p>
<p>Friesen MC, Park D, Colt JS, Baris D, Schwenn M, Karagas MR, Armenti KR, Johnson A, Silverman DT, Stewart PA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25060071">Developing estimates of frequency and intensity of exposure to three types of metalworking fluids in a population-based case-control study of bladder cancer</a>. <em>Am J Ind Med</em> 2014;57:915-927. PMCID: PMC4112469.</p>
<p>Park, DU, Colt, JS, Baris, D, Schwenn, M, Karagas, MR, Armenti, KR, Johnson, A, Silverman, DT, Stewart, PA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25256317">Estimation of the probability of exposure to machining fluids in a population-based case-control study</a>. <em>J Occup Environ Hyg</em> 2014;11:757-770. PMCID: PMC 4359797.</p>
<p>Friesen MC, Locke SJ, Tornow C, Chen YC, Koh DH, Stewart PA, Purdue M, Colt JS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24590110">Systematically extracting metal- and solvent-related occupational information from free-text responses to lifetime occupational history questionnaires</a>. <em>Ann Occup Hyg</em> 2014; 58:612-624. PMCID: PMC4053931.</p>
<p>Friesen MC, Pronk A, Wheeler DC, Chen YC, Locke SJ, Zaebst DD, Schwenn M, Johnson A, Waddell R, Baris D, Colt JS, Silverman DT, Stewart PA, Katki HA. <u><a href="http://www.ncbi.nlm.nih.gov/pubmed/23184256">Comparison of algorithm-based estimates of occupational diesel exhaust exposure to those of multiple independent raters in a population-based case-control study</a>. <em>Ann Occup Hyg</em> 2013;57:470-481. PMCID: PMC3629988.</u></p>
<p>Wheeler DC, Burstyn I, Vermeulen R, Yu K, Shortreed SM, Pronk A, Stewart PA, Colt JS, Baris D, Karagas MR, Schwenn M, Johnson A, Silverman DT, Friesen MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23155187">Inside the black box: starting to uncover the underlying decision rules used in one-by-one expert assessment of occupational exposure in case-control studies</a>. <em>Occup Environ Med</em> 2013;70:203-210. PMCID: PMC3975600.</p>
<p>Pronk A, Stewart PA, Coble JB, Katki HA, Wheeler DC, Colt JS, Baris D, Schwenn M, Karagas MR, Johnson A, Waddell R, Verrill C, Cherala S, Silverman DT, Friesen MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22843440">Comparison of two expert-based assessments of diesel exhaust exposure in a case-controls versus expert review of individual jobs: Programmable decision rules versus expert review of individual jobs.</a> <em>Occ Environ Med</em> 2012;69:752-758. PMCID: PMC3439531.</p>
<p>Friesen MC, Coble JB, Katki HA, Ji B-T, Xue S, Lu W, Stewart PA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21511891">Validity and reliability of exposure assessors: Ratings of exposure intensity by type of occupational questionnaire and type of rater.</a> <em>Ann Occup Hyg</em> 2011;55:601-611. PMC3131504.</p>
<h2><a id="Synthesis-Public-Data-Sources"></a>Publications - Synthesis of Publicly Available Exposure Data Sources</h2>
<p>Locke SJ, Deziel NC, Koh DH, Graubard BI, Purdue MP, Friesen MC. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28079279">Evaluating predictors of lead exposure for activities disturbing materials painted with or containing lead using historic published data from U.S. workplaces</a>. <em>Am J Ind Med </em>2017; 60:189-197. PMCID: PMC5261829.</p>
<p>Deziel NC, Freeman LE, Graubard BI, Jones RR, Hoppin JA, Thomas K, Hines CJ, Blair A, Sandler DP, Chen H, Lubin JH, Andreotti G, Alavanja MC, Friesen MC. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27458779">Relative contributions of agricultural drift, para-occupational, and residential use exposure pathways to house dust pesticide concentrations: Meta-regression of published data.</a> <em>Environ Health Perspect</em> 2017; 125:296-305. PMCID: PMC5332194.</p>
<p>Deziel NC, Friesen MC, Hoppin JA, Hines CJ, Thomas K, Beane Freeman LE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25636067">A review of nonoccupational pathways for pesticide exposure in women living in agricultural areas</a>. <em>Environ Health Perspect</em> E-pub 30 Jan 2015. doi: 10.1289/ehp.1408273.</p>
<p>Koh DH, Locke SJ, Chen YC, Purdue MP, Friesen MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25968240">Lead exposure in U.S. worksites: A literature review and development of an occupational lead exposure database from the published literature</a>. <em>Am J Ind Med</em> 2015;58:605-616.</p>
<p>Koh DH, Nam JM, Graubard BI, Chen YC, Locke SJ, Friesen MC. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25193938">Evaluating temporal trends from occupational lead exposure data reported in the published literature using meta-regression</a>. <em>Ann Occup Hyg</em> 2014;58:1111-1125. PMCID: PMC4227532.</p>
<p>Pronk A, Coble J, Stewart PA. (2009) <a href="http://www.ncbi.nlm.nih.gov/pubmed/19277070">Occupational exposure to diesel engine exhaust:&nbsp;A literature review.</a> <em>J Expo Sci Environ Epidemiol</em>;19:443-457.</p>
<p>Park D, Stewart PA, Coble JB. (2009b) <a href="http://www.ncbi.nlm.nih.gov/pubmed/%2019329796">Determinants of exposure to metalworking fluid aerosols:&nbsp;A literature review and analysis of reported measurements.</a> <em>Ann Occup Hyg</em>;53:271-288.</p>
<p>Park D, Stewart PA, Coble JB. (2009a) <span><a href="http://www.ncbi.nlm.nih.gov/pubmed/%2019544177">A comprehensive review of the literature on exposure to metalworking fluids.</a></span> <em>J Occup Environ Hyg</em>;6:530-541.</p>
</div>]]></content>
  </row>
  <row para_id="474177" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div>
<p>Over the years, DCEG research on the effect of physical activity on cancer has made a significant impact in the following areas:</p>
<p><img alt="" class="right" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=476522" sys_dependentid="476522" sys_dependentvariantid="1482" sys_relationshipid="7277213" sys_siteid="475" height="152" width="229" />DCEG studies indicated a reduced risk of colon, breast, endometrial, and ovarian cancers associated with <b>physical activity</b> (Albanes et al., 1989; Chow et al., 1993; Dosemeci et al., 1993; Sturgeon et al., 1993; Zheng et al., 1993) and were cited in the 1996 <i>Surgeon General&rsquo;s Report on Physical Activity and Health</i>.</p>
<p>A DCEG study found that <b></b>leisure-time physical activity is associated with longer life expectancy, even at relatively low levels of activity and regardless of body weight, a finding that reinforces U.S. guidelines for physical activity for all Americans (Moore SC, et al., 2012).</p>
<p>Pooling data on 1.44 million people from 12 prospective U.S. and European cohorts, DCEG investigators, and colleagues, found that <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1048295" sys_dependentvariantid="1424" sys_dependentid="1048295" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277214" sys_variantid="1424" sys_contentid="1048295">leisure-time physical activity was associated with lower risks of 13 cancer types </a>(esophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukemia, myeloma, colon, head and neck, rectal, bladder, and breast). Most of these associations were evident regardless of body mass index or smoking history (Moore et al 2016). These findings confirm and extend the evidence for a benefit of physical activity on cancer risk and support its role as a key component of population-wide cancer prevention and control efforts.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=467142" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="467142" sys_dependentvariantid="1418" sys_relationshipid="7277212" sys_siteid="475" sys_variantid="1418" sys_contentid="467142">Physical Activity: Full list of article citations</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303702" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="303702" sys_dependentvariantid="1418" sys_relationshipid="7277211" sys_siteid="475" sys_variantid="1418" sys_contentid="303702">Learn about our current research on physical activity</a></p>
</div>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer; top: 62px; left: 18px;">Save</span></p>
</div>]]></content>
  </row>
  <row para_id="491070" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG has been doing research into cervical and other HPV-related cancers for over 30 years. Several studies have led to advances in screening and clinical management. Cervical cancer etiology is better understood than the origins of most major malignancies. Within DCEG, several groups continue to study the most interesting and important research topics. Advances in understanding of HPV natural history and etiology have led in two major directions: (1) vaccinology and immunoepidemiology; and (2) screening and clinical management. It is this second direction that is based in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7317132" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_variantid="1422">Clinical Genetics Branch</a>, because of the remarkable similarity between the HPV work and the analogous work related to familial cancer research. The HPV screening and clinical management area includes three major components:</p>
<ol>
<li>Exploration of remaining important topics in HPV natural history related to cervical multi-stage carcinogenesis</li>
<li>Study by intensive genomic and epigenetic approaches why certain HPV types and type variants are such powerful carcinogens while genetically-related types are not</li>
<li>Translation of natural history estimates into useful clinical risk prediction tools to guide cervical cancer prevention</li>
</ol>
<p>For more information on HPV screening and clinical management, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7317133" sys_dependentvariantid="1965" sys_dependentid="349609" rxinlineslot="103" sys_variantid="1965">Mark Schiffman</a>&nbsp;or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=34&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7317134" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_variantid="1965">Nicolas Wentzensen</a>.</p>
<p>Selected studies include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303573" sys_dependentvariantid="1418" sys_dependentid="303573" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317135" sys_variantid="1418" sys_contentid="303573">ASC-US/LSIL Triage Study (ALTS)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303576" sys_dependentvariantid="1418" sys_dependentid="303576" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317136" sys_variantid="1418" sys_contentid="303576">Biopsy Study to Improve Detection of Cervical Precancer</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303577" sys_dependentvariantid="1418" sys_dependentid="303577" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317137" sys_variantid="1418" sys_contentid="303577">Cervical Cancer Screening Among HIV-Infected Women in India</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491081" sys_dependentvariantid="1418" sys_dependentid="491081" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317138" sys_variantid="1418" sys_contentid="491081">Guanacaste HPV Natural History Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491089" sys_dependentvariantid="1418" sys_dependentid="491089" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317139" sys_variantid="1418" sys_contentid="491089">Human Papillomavirus (HPV) Cervical Cancer Risk Prediction</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491095" sys_dependentvariantid="1418" sys_dependentid="491095" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317140" sys_variantid="1418" sys_contentid="491095">Human Papillomavirus (HPV) Cervical Visualization Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491103" sys_dependentvariantid="1418" sys_dependentid="491103" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317141" sys_variantid="1418" sys_contentid="491103">Human Papillomavirus (HPV) Methylation</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491113" sys_dependentvariantid="1418" sys_dependentid="491113" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317142" sys_variantid="1418" sys_contentid="491113">Human Papillomavirus (HPV) Genomics Project</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491125" sys_dependentvariantid="1418" sys_dependentid="491125" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317143" sys_variantid="1418" sys_contentid="491125">Human Papillomavirus (HPV) Persistence and Progression Cohort (PaP Cohort)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1043259" sys_dependentvariantid="1418" sys_dependentid="1043259" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317144" sys_variantid="1418" sys_contentid="1043259">Improvement of Risk-Informed Screening (IRIS)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303575" sys_dependentvariantid="1418" sys_dependentid="303575" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317145" sys_variantid="1418" sys_contentid="303575">Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED)</a></li>
<li><a href="/Rhythmyx/assembler/render?sys_contentid=1145770&amp;sys_revision=2&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1145770" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7317146">STRIDES: Studying Risk and Improving Disparities of Cervical Cancer in Mississippi</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="491081" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This population-based natural history study of human papillomavirus (HPV) and cervical neoplasia was launched with Costa Rican colleagues in 1993 in the province of Guanacaste. Over 10,000 randomly selected women were followed longitudinally for seven years.&nbsp;The project yielded many insights into HPV natural history and the performance of then-novel HPV and cytologic screening techniques. Residual specimens are being used to study remaining natural history questions.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349609" sys_dependentvariantid="1965" sys_relationshipid="7276169" sys_siteid="475" sys_variantid="1965" sys_contentid="349609">Mark Schiffman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7276170" sys_siteid="475" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="491089" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This study is designed to develop a cervical cancer risk prediction model incorporating clinical and laboratory covariates.&nbsp;The goal is to classify women&rsquo;s risks of cervical intraepithelial neoplasia 2 (CIN 2), CIN 3, and cancer into strata upon which clinical management decisions can be based.&nbsp;Eight articles comprising a supplemental issue in the <i>Journal of Lower Genital Tract Disease</i> formed the early core of this effort. &nbsp;</p>
<p>In current work, risk data from multiple cohorts are being compiled. For example, we have confirmed in two other cohorts that HPV-positive ASC-US (atypical squamous cells of undetermined significance) is equivalent to LSIL (low-grade squamous intraepithelial lesion), while HPV-negative ASC-US is equivalent to a normal pap result. Also, a negative HPV test provides greater reassurance against risk of cancer than a negative pap result. If HPV is negative, knowing that the pap is also negative provides only slight additional reassurance.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7276208" sys_dependentvariantid="1965" sys_dependentid="349609" rxinlineslot="103">Mark Schiffman</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" sys_contentid="349618" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7276209" sys_dependentvariantid="1965" sys_dependentid="349618" rxinlineslot="103">Hormuzd Katki</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7276210" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics Branch - Research Areas</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=349590" sys_contentid="349590" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7276211" sys_dependentvariantid="1418" sys_dependentid="349590" rxinlineslot="103">Biostatistics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="491095" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This collaboration with the National Library of Medicine has produced an open source multi-media database tool for real-time data exploration of cervical images, histology, HPV, and text data from NCI studies of HPV and cervical neoplasia. &nbsp;Collaborative work using the database tool called the Boundary Marking Tool is underway with international and U.S. colleagues.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7276216" sys_dependentvariantid="1965" sys_dependentid="349609" rxinlineslot="103">Mark Schiffman</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7276217" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7276218" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="491103" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Pulling from specimens accumulated in cohort and case-control studies, we are examining the methylation of the HPV viral genome in relation to risk of cervical intraepithelial neoplasia 3 (CIN 3) and cancer. As a general rule for multiple HPV types, increased methylation particularly of CpG sites in the <i>L1</i> gene is strongly associated with increased risk of CIN 3 and cancer. The goal is to understand the etiologic meaning and possible biomarker utility of viral (and cervical) gene methylation.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7276247" sys_dependentvariantid="1965" sys_dependentid="349609" rxinlineslot="103">Mark Schiffman</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_contentid="349668" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7276249" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7276248" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="491113" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This project is designed to interrogate the relationship between sequence changes in the HPV genome and carcinogenicity. There is huge variability in risk of precancer and cancer conferred by different HPV types that is poorly explained. HPV type 16 is known to cause half of all cervical cancer cases worldwide, however the specific reason for its carcinogenicity has been elusive. The simple question is &ldquo;Why is HPV16 so uniquely carcinogenic?&rdquo; High-throughput, next-generation sequencing methods are being used to study HPV 16 variant sub-lineages among women with cancer and cervical intraepithelial neoplasia 3 (CIN 3) in comparison to women with benign HPV infections. An Ampliseq/Ion Torrent-based assay for high-throughput whole-genome sequencing of HPV 16 was developed in 2015 (<a href="#References">Cullen et al, 2015</a>).</p>
<p>The team has demonstrated the reliability, reproducibility, accuracy, and usefulness of this assay for HPV16 and expanded it to the other 13 carcinogenic types. A global, high-risk HPV genome sequencing method has been developed, and is being used to compare HPV16-related types to HPV16. Using the HPV16 assay, investigators sequenced the entire HPV16 genome in samples from over 3,200 infected women and classified the viruses into lineages and sublineages. Through this process they discovered considerable risk differences for precancer and cancer and identified specific variant sublineages that strongly influence HPV 16 carcinogenicity and histologic outcome&nbsp;(<a href="#References">Mirabello et al, 2016</a>).</p>
<p>Further, investigators compared HPV16 genomic sequences between cases and controls and discovered that controls, who had benign infections, had infections with significantly more protein-changing variants throughout the genome, while cases had infections devoid of protein-changing variants particularly in the E7 oncogene (<a href="#References">Mirabello et al, 2017</a>).&nbsp;These findings contribute to resolving the outstanding question of why common and typically benign HPV16 infections only sometimes cause cancer. Follow-up work on the potent carcinogenicity of an intact HPV16 E7 protein is underway.&nbsp;</p>
<p>Additional case-control and prospective approaches are being used to determine how HPV genetic variation informs our understanding of carcinogenesis and influences risk for cancer. Studies are underway to evaluate all the HR-HPV types at the cervix and non-cervical sites, and evaluations of the interplay of host-viral genetics.</p>
<p>DCEG experts have also developed a novel Next-Generation Sequencing HPV genotyping assay based on their HPV genome sequencing. The new approach&nbsp;provides low-cost, high-throughput genotyping that will lead to major cost-savings for large cervical cancer screening and vaccination studies conducted by DCEG and other research groups since most current genotyping assays are expensive and laborious.&nbsp;</p>
<h3><a id="References"></a>References</h3>
<p>Cullen M, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26645052">Deep sequencing of HPV 16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV 16 infection</a>. <em>Papillomavirus Res</em> 2015 Dec 1. DOI: 10.1016/j.pvr.2015.05.004.</p>
<p>Mirabello L, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27130930">HPV 16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women</a>. <em>J Natl Cancer Inst 2016</em> Apr 29. DOI: 10.1093/jnci/djw100.</p>
<p>Mirabello L, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28886384">HPV 16 E7 genetic conservation is critical to carcinogenesis</a>. <em>Cell</em> 2017 Sep 7. DOI: 10.1016/j.cell.2017.08.001.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7375079" sys_siteid="475" rxinlineslot="103" sys_dependentid="639592" sys_dependentvariantid="1965">For more information, contact Lisa Mirabello</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7375078" sys_siteid="475" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="491125" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators teamed with Kaiser Permanente Northern California (KPNC) to create a repository of specimens with carcinogenic human papillomavirus (HPV) genotypes that would be useful for natural history studies of HPV typing, methylation, and HPV variant genomics. Since 2003, KPNC has routinely used an FDA-approved pooled-type DNA test for carcinogenic HPV&nbsp;(HC2) with cytology (&ldquo;cotesting&rdquo;) for cervical cancer screening in women 30 and older.&nbsp;</p>
<p>Investigators have stored approximately 35,000 baseline specimens that have tested positive by HC2 and 5,000 specimens that have tested negative by HC2.&nbsp;They have genotyped specimens selected for testing based on clinical outcomes ascertained by linkage to the KPNC cytology and histology databases and KPNC's active yearly follow-up of all HC2-positive women. The investigators "followed" women for three years after enrollment ended in 2011 by banking their residual specimens collected at their return visits.&nbsp;The subsequent continuing follow-up has focused on incident precancer and cancer. At present, there are more than 110,000 stored specimens, with &gt;20,000 genotyped. The first prospective analyses have confirmed that HPV 16 detection confers a greatly elevated risk of subsequent precancer/cancer, while separate detection of other HPV types yields less clear clinical value.</p>
<p>A new phase of this cohort study will be a comprehensive evaluation of&nbsp;candidate biomarkers for cervical cancer screening and triage&nbsp;for <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1043259" sys_contentid="1043259" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276274" rxinlineslot="103" sys_dependentid="1043259" sys_dependentvariantid="1418" sys_siteid="475">Improvement of Risk-Informed Screening</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349609" sys_contentid="349609" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7276272" rxinlineslot="103" sys_dependentid="349609" sys_dependentvariantid="1965" sys_siteid="475">Mark Schiffman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276273" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_siteid="475">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="501305" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The R package <i>thyroid</i> implements a risk prediction model developed by NCI researchers to calculate the absolute risk of developing a second primary thyroid cancer (SPTC) in individuals who were diagnosed with a cancer during their childhood.</p>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=501304" sys_contentid="501304" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7317628" sys_dependentvariantid="1500" sys_dependentid="501304" rxinlineslot="103">Download Software</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=501306" sys_contentid="501306" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317629" sys_dependentvariantid="1418" sys_dependentid="501306" rxinlineslot="103">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=501307" sys_contentid="501307" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317630" sys_dependentvariantid="1418" sys_dependentid="501307" rxinlineslot="103">License Agreement</a></li>
</ul>
<h4><i><span style="color: #595959;">Reference:</span></i></h4>
<ul class="bulletblu">
<li>Kovalchik SA, Ronckers CM, Veiga LHS et al. Absolute risk prediction of second primary thyroid cancer among five-year survivors of childhood cancer. Journal of Clinical Oncology 2012</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="501306" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>The R package &quot;thyroid&quot; provides software for calculating the absolute risk of second primary thyroid cancer (SPTC) following a childhood cancer based on a prediction model developed and validated by researchers at the National Cancer Institute (NCI).</p><p>Before using the tool, please note the following:</p><ul><li>This program may be useful for research purposes</li><li>The tool is designed for predicting the SPTC risk in individuals who were diagnosed with a childhood cancer (a non-thyroid malignancy before age 21 years) five or more years before the prediction starting age and have not already been diagnosed with another primary cancer.</li></ul><h3>Installation:</h3><ol><li>This package requires R version 2.10 or higher and the packages fgui and survival. To download the latest version of R for Linux, MacOS X, or Windows platforms visit:http://cran.r-project.org/. To install packages use install.packages(). To check if a package is available, use library().</li><li>After downloading thyroid_1.0.zip and decompress the files to a directory of your choice. After decompressing, a subdirectory named &quot;thyroid&quot; will be created and will contain subfolders with the compressed R scripts and documentation files.</li><li>Begin R and use the following command to load the package from where should be replaced by a string indicating the path where the folder &quot;thyroid&quot; is located:<br />&gt; library(&quot;thyroid&quot;, lib.loc = ).<br />For example, if the thyroid_1.0.zip file was decompressed on a Windows machine to C:\Desktop\R Libraries\, the command would be<br />&gt; library(&quot;thyroid&quot;, lib.loc = &quot;C:/Desktop/R Libraries/&quot;)</li></ol></div>]]></content>
  </row>
  <row para_id="501307" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h4><span style=" color: #727272;">Non-Proprietary Software Transfer Agreement</span></h4><p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p><br />By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><br />The TCRAT may be updated periodically as new data or research becomes available.</p><p><br />Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p><br />All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p></div>]]></content>
  </row>
  <row para_id="511115" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_relationshipid="7276121" sys_dependentid="302581" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2392" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
<div class="topic-feature large-4 columns card right no-image">
	<div class="feature-card genGeneral">
		<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=302581&amp;sys_command=preview" sys_variantid="1418" sys_contentid="302581">
			    		    			<h3>Telomere Molecular Epidemiology</h3>
    					        		        			<p>Nucleoprotein structures and chromosomal stability</p>
        							</a>
    </div>
	</div>
</div>
<p>Because telomeres are critical to chromosomal stability, the genes that code for proteins integral in telomere biology may be important in cancer etiology. DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302430" sys_variantid="1422" sys_relationshipid="7276120">Clinical Genetics Branch (CGB)</a> have shown that nucleotide diversity in genes coding for critical proteins in the telomere maintenance pathway is limited when compared with other types of genes. They are also highly conserved between species. Because these genes appear to be under evolutionary constraint, it is possible that germline genetic variation (i.e., single nucleotide polymorphisms (SNPs) in these genes could be a significant risk factor for cancer or other diseases.</p>
<p>Detailed population genetic studies of telomere biology genes in worldwide populations are underway. Several studies have been conducted by CGB investigators that found SNPs in telomere biology genes are associated with risk of certain cancers. SNPs have also been evaluated as regulators of telomere length through candidate gene and genome-wide association studies. Ongoing studies include fine mapping of candidate loci and studies of telomere measurement methods.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22Savage%20SA%22[Author]%20OR%20%22YANG%20XR%22[Author]%29%20AND%20%28%22telomere%20shortening%22[MeSH%20Major%20Topic]%20OR%20%22telomere/genetics%22[MeSH%20Major%20Topic]%20OR%20%22telomere%20length%22[Title/Abstract]%29&amp;cmd=DetailsSearch">Telomere Biology/Genetics Study-Related Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_contentid="349621" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349621" sys_variantid="1965" sys_relationshipid="7276118">Sharon Savage</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="433261" sys_variantid="1418" sys_relationshipid="7276119">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="530177" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Primary Analyses of GOG-0199 Data</h3>
<ul>
<li>Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S: <a href="http://www.ncbi.nlm.nih.gov/pubmed/18349277">A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.</a> <i>Cancer Epidemiol Biomarkers Prev 2008</i>; 17:594-604</li>
<li style="list-style: none;"></li>
<li>Skates SL, Mai PL, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K: <a href="http://www.ncbi.nlm.nih.gov/pubmed/21893500">Large prospective study of ovarian cancer screening in high-risk women: CA125 Cut-point defined by menopausal status.</a> <i>Cancer Prev Res</i> 2011; 4(9):1401-1408</li>
</ul>
<h3>Consortium of Modifiers of <i>BRCA1/2</i> (CIMBA) Collaboration</h3>
<ul>
<li>Antoniou AC, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19656774">Common variants in 8q24, <i>LSP1</i> and 2q35 and breast cancer risk among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Hum Mol Genet</i> 2009; 18:4442-4456</li>
<li style="list-style: none;"></li>
<li>Osorio A, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19920816">Evaluation of a candidate breast cancer associated SNP in <i>ERCC4</i> as a phenotypic modifier in <i>BRCA1/2</i> mutation carriers. Results from the Consortium of Investigators of Modifiers of <i>BRCA1/BRCA2</i> (CIMBA).</a> <i>Br J Cancer</i> 2009; 101: 2048-2054</li>
<li style="list-style: none;"></li>
<li>Antoniou AC, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21118973">Common breast cancer susceptibility alleles and the risk of breast cancer for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: implications for risk prediction.</a> <i>Cancer Res</i> 2010; 70:9742-9754</li>
<li style="list-style: none;"></li>
<li>Antoniou AC, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20852631">A locus on 19p13 modifies risk of breast cancer in <i>BRCA1</i> mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.</a> <i>Nat Genet</i> 2010; 42(10):885-892</li>
<li style="list-style: none;"></li>
<li>Gaudet MM, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21060860">Common genetic variants and modification of penetrance of <i>BRCA2</i>-Associated breast cancer.</a> <i>PLoS Genet</i> 2010; 6(10), e1001183</li>
<li style="list-style: none;"></li>
<li>Jakubowska A, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19876733">The Leu33Pro polymorphism in the <i>ITGB3</i> gene does not modify <i>BRCA1/2</i>-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Br Cancer Res Treat</i> 2010; 121(3):639-49</li>
<li style="list-style: none;"></li>
<li>Im KM, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21597964">Haplotype structure in Ashkenazi Jewish <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Hum Genet</i> 2011; 130(5):685-699</li>
<li style="list-style: none;"></li>
<li>Antoniou AC, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21593217">Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/21593217">BRCA1</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21593217">and</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/21593217">BRCA2</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21593217">mutation carriers.</a> <i>Hum Mol Genet</i> 2011; 20(16):3304-3321</li>
<li style="list-style: none;"></li>
<li>Cox DG, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21890493">Common variants of the <i>BRCA1</i> wild-type allele modify the risk of breast cancer in <i>BRCA1</i> mutation carriers.</a> <i>Hum Mol Genet</i> 2011; 20(23):4732-4747</li>
<li style="list-style: none;"></li>
<li>Ramus SJ, Antoniou AC, et al.: <a href="http://www.ncbi.nlm.nih.gov/pubmed/22253144">Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> carriers.</a> <i>Hum Mutat</i> 2012; 33(4):690-702</li>
<li style="list-style: none;"></li>
<li>Couch F, Gaudet MM, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22351618">Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2012; 21(4):645-657</li>
<li style="list-style: none;"></li>
<li>Stevens KN, Wang X, et al.: <a href="http://www.ncbi.nlm.nih.gov/pubmed/23011509">Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/23011509">BRCA2</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/23011509">mutation carriers.</a> <i>Breast Ca Res Treat</i> 2012; 136(1):395-302</li>
<li style="list-style: none;"></li>
<li>Antoniou AC, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22348646">Common variants at 12p11, 12q24, 9p21, 9q31.2 and in <i>ZNF365</i> are associated with breast cancer risk for <i>BRCA1</i> and/or <i>BRCA2</i> mutation carriers.</a> Breast Cancer Research 2012; 14(1):R33, [Epub in advance of print]</li>
<li style="list-style: none;"></li>
<li>Ding YC, Neuhausen S, et al. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">A nonsynonymous polymorphism in</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">IRS1</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">modifies risk of developing breast and ovarian cancers in</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">BRCA1</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">and ovarian cancer in</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">BRCA2</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/22729394">mutation carriers.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2012; 21(8):1362-1370</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="532556" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>For individuals at increased risk of developing cancer, knowing about the risk can affect decision-making around behavior, couple relationships, family formation, and risk-reduction strategies. DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7274924" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103">Clinical Genetics Branch</a> are studying the genetic counseling, behavioral and psychosocial implications of being at increased genetic risk of cancer by selectively incorporating such research into both new and ongoing clinical research projects. CGB staff members bring a unique combination of training to these studies, including oncology, cancer genetics, genetic counseling, and marriage/family therapy. Capabilities in these areas are further supplemented by collaborations with senior behavioral research colleagues from other NIH divisions and postdoctoral fellows (including NCI Cancer Prevention Fellows), from the Division of Cancer Control and Population Studies (DCCPS) and the National Human Genome Research Institute (NHGRI). To date, nearly 50 publications have resulted from this research.</p>
<p>Projects that currently fall within this domain include (1) the ongoing development of the CEGRM (Colored Ecogenetics Relationship Map), a novel counseling tool aimed at identifying sources of social support; (2) a series of analyses focused on the lives of young <i>BRCA1/2</i> mutation carriers; (3) analyses of surgical decision-making and the influence of test ambiguity on screening behavior among <i>BRCA</i> mutation carriers; (4) a comprehensive set of psychosocial/behavioral analyses, both cross-sectional and longitudinal, among GOG-0199 study participants; and (5) initiation of data collection in our newest clinical research protocol, which targets the Li-Fraumeni syndrome.</p>
<p><a href="http://dcegpreview.cancer.gov/research/what-we-study/genes-host/behavioral-psychosocial-publications">Behavioral, Genetic Counseling, Psychosocial Implications&nbsp;&ndash; Research Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349675" sys_contentid="349675" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7274926" sys_dependentvariantid="1965" sys_dependentid="349675" rxinlineslot="103">Jennifer Loud</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7274925" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="532557" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman C, Struewing JP. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10946349">Psychosocial factors predicting</a> <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/10946349">BRCA1/BRCA2</a></i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/10946349">testing decisions in members of hereditary breast and ovarian cancer families</a>. <i>Am J Med Genet</i> 2000; 93:257-263</p>
<p>Kenen R, Peters J. <a href="http://link.springer.com/article/10.1023/A%3A1016627426430">The Colored Eco-Genetic Relationship Map (CEGRM): A conceptual approach and tool for genetic counseling research.</a> <i>J Genet Counseling</i> 2001; 10: 289-309</p>
<p>Peters JA, McAllister CL, Rubinstein WS. &nbsp;<a href="http://link.springer.com/article/10.1023/A%3A1009491714527">The genetic counselor as a qualitative researcher, Part I: Experiences of a novice ethnographer in a cancer clinic.</a>&nbsp;<i>J Genetic Counseling</i> 2001; 10:133-150</p>
<p>Peters JA, McAllister CL, Rubinstein WS. &nbsp;<a href="http://link.springer.com/article/10.1023/A%3A1009443831365">The genetic counselor as a qualitative researcher, Part II: Findings from an exploratory ethnographic study in a cancer clinic</a>. <i>J Genetic Counseling</i> 2001;10:151-168</p>
<p>Applebaum-Shapiro SE, Peters JA, O&rsquo;Connell JA, Aston CE, Whitcomb DC. &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/11374708">Motivations and concerns of patients with access to genetic testing for hereditary pancreatitis.</a> <i>Am J Gastroenterol 2001</i>; 96:1610-1617</p>
<p>Peters JA, Loud J, Dimond E, Jenkins J. &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/11762507">Cancer genetics fundamentals</a>. &nbsp;<i>Cancer Nursing: An International Journal for Cancer Care</i> 2001; 24:446-461</p>
<p>Loud JT, Peters JA, Fraser M, Jenkins J. &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/11984099">Applications of advances in molecular biology and genomics to clinical cancer care.</a> <i>Cancer Nursing: An International Journal for Cancer Care</i> 2002; 25: 110-122</p>
<p>Rubinstein WS, O&rsquo;Neill SM, Peters JA, Rittmeyer LAJ, Stadler MP. <a href="http://www.cancernetwork.com/display/article/10165/71753#">Mathematical modeling for breast cancer risk assessment: State of the art and role in medicine.</a> <i>Oncology</i> 2002; 16:1082-1094</p>
<p>Peters JA, Kenen R, Giusti R, Loud J, Weissman N, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15378540">Exploratory study of the feasibility and utility of the colored Eco-genetic relationship map (CEGRM) in women at high genetic risk of developing breast cancer.</a> <i>Am J Med Genet</i> 2004; 130A:258-264</p>
<p>Loud JT, Hutson SP. <a href="https://www.ncbi.nlm.nih.gov/pubmed/15491023">The art and science of cancer nursing in the genomic era.</a> <a href="https://www.ncbi.nlm.nih.gov/pubmed/15491023">Sem Oncol Nursing</a> 2004; 20:143-144</p>
<p>Hutson SP, Loud JT. Cancer genetics resources &ndash; A guide for nurses and patients. Sem Oncol Nursing 2004; 20:213-215</p>
<p>McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. <a href="https://www.ncbi.nlm.nih.gov/pubmed/15378542"><i>BRCA1/2</i> testing in hereditary breast and ovarian cancer families: Effectiveness of a problem-solving training as a counseling intervention.</a> <i>Am J Med Genet</i> 2004; 130A:221-227</p>
<p>Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet SC, Manley S, Culver JO, Acton R, Larsen-Haidle J, Correia LA, Bennett R, Pettersen B, Ferlita TD, Costalas JW, Hunt K, Donlon S, Skryznia C, Farrell C, Callif-Daley F, Vockley CW. &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/15604628">Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors.</a> &nbsp;<i>J Genetic Counseling</i> 2004; 13:83-114</p>
<p>Green MJ, Peterson SK, Baker MW, Friedman LC, Harper GR, Rubinstein WS, Peters JA, Mauger DT. <a href="https://www.ncbi.nlm.nih.gov/pubmed/15834239">Use of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions.</a> <i>Genet Med</i> 2005; 7:221-229</p>
<p>Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. <a href="https://www.ncbi.nlm.nih.gov/pubmed/15784723">Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national<br />&nbsp;sample of US physicians.</a> <i>J Med Genet</i> 2005; 42:749-755</p>
<p>McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. <a href="https://www.ncbi.nlm.nih.gov/pubmed/15633195"><i>BRCA1/2</i> testing in hereditary breast and ovarian cancer families II: Impact on relationships.</a> <i>Am J Med Genet</i> 2005; 133A:165-169</p>
<p>Loud JT, Weissman NE, Peters JA, Giusti RM, Wilfond BS, Burke W, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16575016">Deliberate deceit of family members: a challenge to providers of clinical genetics services.</a> <i>J Clin Oncol</i> 2006; 24:1643-1646</p>
<p>McInerney-Leo A, Hadley DW, Kase RG, Giambarresi TR, Struewing JP, Biesecker BB. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16969872"><i>BRCA1/2</i> testing in hereditary breast and ovarian cancer families III: Risk perception and screening.</a> <i>Am J Med Genet</i> 2006; 140A:2198-2206</p>
<p>Peters J, Hoskins L, Prindiville S, Kenen R, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/17111216">Evolution of the Colored Eco-Genetic Relationship Map (CEGRM) for assessing social functioning in women from hereditary breast/ovarian cancer families.</a> <i>J Genetic Counseling</i> 2006;15:477-489</p>
<p>Peters JA, Vadaparampil ST, Kramer J, Moser RP, Peterson-Court LJ, Loud J, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/17172939">Familial testicular cancer &ndash; Interest in genetic testing among high-risk family members.</a> <i>Genet Med</i> 2006; 8:760&ndash;770</p>
<p>O&rsquo;Neill SM, Peters JA, Vogel V, Feingold E, Rubinstein W. <a href="https://www.ncbi.nlm.nih.gov/pubmed/17068804">Referral to genetic counseling: Are there stages of readiness?</a>&nbsp;<i>Am J Med Genet Part C Semin Med Genet</i> 2006; 142C:221-231</p>
<p>Weil J, Ormond K, Peters JA, Peters K, Biesecker BB, LeRoy B. &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/16525897">The relationship of nondirectiveness to genetic counseling: Report of a workshop at the 2003 NSGC Annual Education Conference</a>. &nbsp;<i>J Genetic Counseling</i> 2006; 15:85-94</p>
<p>McDaniel SH, Peters JA, Acheson L. &nbsp;<a href="http://books.wwnorton.com/books/978-0-393-70374-0/">Professional collaboration to assess and care for genetic disorders. in Individuals, Families and the New Era of Genetics</a> (Miller SM, McDaniel SH, Rolland JS, Feetham SL, Eds.), New York, WW Norton, pp. 530-559, 2006</p>
<p>Hutson SP, Alter BP. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16779804">Experiences of siblings of patients with Fanconi anemia.</a> <i>Pediatr Blood Cancer</i> 2007; 48:72-9</p>
<p>Mueller C, Mai P, Bucher J, Peters JA, Loud JT, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18447953">Patterns of complementary and alternative medication use in women at increased genetic risk of breast and ovarian cancer.</a> <i>BMC Compl Alt Med</i> 2008; 8:17, E-Pub</p>
<p>Peters JA, Beckjord EB, Ryan DR, Carr AG, Vadaparampil ST, Loud JT, Korde L, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18481162">Testicular cancer and genetics knowledge among familial testicular cancer family members.</a> <i>J Genet Counsel</i> 2008; 17:351-364</p>
<p>Koehly LM, Peters JA, Kuhn N, Hoskins L, Letocha A, Kenen R, Loud J, Greene &nbsp;MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18688790">Sisters in hereditary breast and ovarian cancer families: Communal coping, social integration and psychological well-being.</a> <i>Psycho-Oncology</i> 2008;17:812-821</p>
<p>Bakos A, Hutson S, Peters J, Giusti R, Carr A, Greene MH, Loud J. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18816319">Transition from high-risk to <i>BRCA</i> mutation-negative status among women from hereditary breast/ovarian cancer families.</a> <i>Health Expectation</i> 2008;11:220-231</p>
<p>Hoskins LM, Roy K, Peters JA, Loud JT, Greene MH: Disclosure of Positive <i>BRCA1/2</i>-Mutation Status in Young Couples: The Journey from Uncertainty to Bonding through Partner Support. <i>Fam Syst Health</i> 2008; 26:296-316</p>
<p>Alter BP, Denny CC, Peters JA, Giri N, Wilfond BS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18831063">Disclosure of &ldquo;Unwanted&rdquo; Genetic Information to Benefit a Family Member with Dyskeratosis Congenita.</a> <i>Am J Med Genet A</i> 2008; 146A:2719-2724</p>
<p>Vadaparampil ST, Moser RP, Loud J, Peters JA, Greene MH, Korde L. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19480691">Factors associated with testicular self-examination among unaffected men from multiple-case testicular cancer families.</a> <i>Hered Cancer Clin Pract</i> 2009; 7:11, E-Pub</p>
<p>Loud, JT, Beckjord E, Peters J, Nichols K, Giusti R, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19602282">Tolerability of breast duct lavage in women from families at high genetic risk of breast cancer.</a> <i>BMC Women&rsquo;s Health</i> 2009; 9:20, July 14, E-Pub</p>
<p>Koehly LM, Peters JA, Kenen R, Hoskins L, Ersig AL, Kuhn N, Loud J, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19833996">Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: Implications for family health communication interventions</a>. <i>Am J Public Health</i> 2009; 99:2203-2209</p>
<p>Savage SA, Dokal I, Armanios M, Aubert G, Cowen EW, Domingo DL, Giri N, Greene MH, Orchard PJ, Tolar J, Tsilou E, Van Waes C, Wong JMY, Young NS, Alter BP. &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/19415736">Dyskeratosis congenita: The first NIH clinical research workshop</a>. <i>Pediatric Blood and Cancer</i> 2009; 53:520-523. &nbsp;</p>
<p>Loud JT and Hutson S.&nbsp;&ldquo;Chapter 7: Genetic Risk and Hereditary Cancer Syndromes.&rdquo; in Yarbro CH, Wujcik D, Gobel GH (Eds), Cancer Nursing: &nbsp;Principles and Practice. (2010) Sudbury, Massachusetts: Jones and Bartlett.</p>
<p>Peters JA. Genetic Counselors &ndash; Caring Mindfully for Ourselves. in &ldquo;Genetic Counseling Practice: Advanced Concepts and Skills&rdquo; (LeRoy BS, PM Veach, DM Bartels, eds). Wiley-Blackwell, New York, pages 307-352, 2010 &nbsp;</p>
<p>Mai PL, Wideroff L, Greene MH, Graubard BI. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20389042">Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study.</a> <i>Public Health Genomics</i> 2010; 13:495-503</p>
<p>Wideroff L, Garceau AO, Greene MH, Dunn M, McNeel T, Mai P, Willis G, Gonsalves L, Martin M, Graubard BI. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20160272">Coherence and completeness of population-based family cancer reports.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2010; 19:799-810</p>
<p>Loud JT. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995214/">Direct-to-consumer genetic and genomic testing: &nbsp;Preparing nurse practitioners for genomic healthcare.</a> <i>J Nursing Pract</i> 2010; 6:585-594</p>
<p>Mai PL, Garceau A, Graubard BI, Dunn M, McNeel T, Gonsalves L, Polednak T, Warren J, Gail MH, Greene MH, Willis G, Wideroff L. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21562245">Confirmation of family cancer history reported in a population-based survey.</a> <i>J Natl Cancer Inst</i> 2011; 103;788-797&nbsp;</p>
<p>Peters JA, Kenen R, Hoskins LM, Koehly LM, Graubard R, Loud JT, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21547418">Unpacking the blockers: Understanding perceptions and social constraints of health communication in hereditary breast/ovarian cancer (HBOC) susceptibility families.</a> <i>J Genet Couns</i> 2011; 20:450-464</p>
<p>Mai PL, Malkin D, Garber J, Schiffman J, Weitzel JN, Strong L, Wyss O, Lock L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters J, Hwang P, Ford J, Tabori U, Ognjanovic S, Dennis P, Wentzensen IM, Greene MH, Fraumeni JF Jr, Savage SA. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22939227">Li-Fraumeni syndrome: Report of the first clinical workshop and creation of a research consortium.</a> <i>Cancer Genetics</i> 2012; 205:479-487</p>
<p>Hoskins L, Roy K, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22429077">Toward a new understanding of risk perception among young female <i>BRCA1/2</i> "previvors".</a> <i>Fam Syst Health</i> 2012; 30:32-46</p>
<p>Hoskins L, Roy K, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22927701">Anticipatory loss and early mastectomy for young female</a> <i><a href="https://www.ncbi.nlm.nih.gov/pubmed/22927701">BRCA1/2</a></i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22927701">mutation carriers.</a> <i>Qual Health Res</i> 2012; 22:1633-1646</p>
<p>Peters JA, Kenen R, Hoskins LM, Kratz CP, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22381132">Close ties-An Exploratory CEGRM (Colored Eco-Genetic Relationship Map) Study of Social Connections Among Men in Familial Testicular Cancer (FTC) Families.</a> <i>Hered Cancer Clin Pract</i> 2012; 10:2, E-pub</p>
<p>Werner-Lin A, Hoskins LM, Doyle M, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22547552">Cancer doesn&rsquo;t have an age &ndash; Genetic testing and risk management in <i>BRCA1/2</i> mutation-positive women.</a> <i>Health</i> 2012; 16:636-654</p>
</div>]]></content>
  </row>
  <row para_id="533039" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Myotonic Dystrophy (dystrophia myotonica - DM) is a slowly progressive multi-system genetic disorder that primarily affects skeletal muscles. It is the most common form of adult muscle dystrophy, but the disease can present at any age and as early as birth. Two types of the disease have been described (type 1 and 2); they are clinically similar, with few exceptions, but genetically distinct. Prior to DCEG&rsquo;s research in this area, cancer was not typically thought of as part of the disease phenotype.</p>
<p>When neurologists at the University of Rochester responsible for the management of DM reported the clinical impression that their patients were developing more cancer than expected, DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7276443" sys_siteid="475" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch (CGB)</a> became involved in trying to answer the question &ldquo;Is myotonic dystrophy a cancer susceptibility disorder?&rdquo; The investigators, first in collaboration with investigators at the Karolinska Institutet, Sweden and the University of Rochester, and later with investigators from the Statens Serum Institut, Denmark, performed quantitative analysis using data obtained from population-based diagnosis and cancer registries. They identified a highly significant, two-fold increase in the risk of all cancers combined&mdash;an excess accounted for by cancers of the colon, endometrium, ovary and brain&mdash;among DM patients.</p>
<p>Subsequent reports have suggested that persons with Type 1 DM are twice as likely as those with Type 2 to report a personal history of cancer, but that there is no clear correlation between nucleotide repeat length (the basic molecular abnormality in DM) and cancer risk. Ongoing investigations aim to 1) determine the genetic, clinical, and environmental predictors that may alter cancer risk for myotonic dystrophy patients; and 2) understand the biological mechanisms by which DM increases cancer risk.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22Greene%2C%20Mark%20H%22[Full%20Author%20Name]%20OR%20%22Greene%20MH%22[Author]%20OR%20%22Gadalla%20SM%22[Author]%29%20AND%20%22myotonic%20dystrophy%22[All%20Fields]&amp;cmd=DetailsSearch">Myotonic Dystrophy - Research Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349606" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349606" sys_dependentvariantid="1965" sys_relationshipid="7276445" sys_siteid="475" sys_variantid="1965" sys_contentid="349606">Shahinaz Gadalla</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="433261" sys_dependentvariantid="1418" sys_relationshipid="7276444" sys_siteid="475" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="533092" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Neurofibromatosis type 1 (NF1) is a common genetic disorder of deregulated cell growth, affecting approximately 100,000 Americans. People with NF1 are at an increased risk of developing a variety of benign and malignant tumors. There are limited therapies and no cures for NF1. At this time, it is essentially impossible to predict how severe the disorder will be in a given individual over time. DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7276471" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a> seek to identify the additional genes (called &ldquo;genetic modifiers&rdquo;) that influence the wide variations in severity seen in individuals with NF1 by applying the principles of translational medicine. Investigators have quantitatively phenotyped a cohort of 135 NF1 individuals from 93 families, and collected multiple research biospecimens.&nbsp;</p>
<p>Analyses of this cohort have yielded multiple novel insights including: 1) recognition of previously-unrecognized tumor associations in NF1, by identifying biallelic NF1 inactivation in glomus tumors, gastrointestinal stromal tumors (GISTs), and giant cell lesions of the jaw; 2) identification of candidate modifier genes influencing caf&eacute;-au-lait macule number; 3) the first genome-wide association study (GWAS) in NF1; and 4) characterization of novel clinical features (phenotypes) in NF1, including its association with pulmonary hypertension. We have also characterized several other phenotypes with features that significantly overlap those of NF1, including the Jaffe-Campanacci syndrome and Legius syndrome. Investigators are currently collaborating with two multi-institutional groups seeking to identify genetic modifiers of tumor-related phenotypes in NF1.</p>
<p>Investigators are also using next-generation sequencing (NGS) to sequence NF1-associated plexiform neurofibromas. Plexiform neurofibromas are congenital neurofibromas (present at birth) affecting up to 50% of people with NF1, which grow unpredictably and can be locally destructive. They are regarded as pre-cancerous lesions from which malignant peripheral nerve sheath tumors (MPNSTs) arise. Investigators are using NGS of tumor/normal-tissue pairs to identify the somatic variation that influences risk of tumorigenesis in NF1, an effort modeled upon the NCI Cancer Genome Atlas. They have &nbsp;developed a statistically rigorous two-stage design to identify driver mutations in plexiform neurofibromas, using DNA from tumor/normal-tissue pairs. They are also collaborating with Drs. Brigitte Widemann and Javed Khan of the NCI Pediatric Oncology Branch in a new effort to sequence germline, plexiform neurofibroma and MPNST samples collected from the same individual with NF1, testing the hypothesis that sequencing of such &ldquo;trios&rdquo; will identify driver genes that promote plexiform and MPNST development.</p>
<p>CGB investigators have also undertaken a systematic literature review of all the NF1-associated case reports and cases series published in the last 50 years, focusing on the types and numbers of cancers which have been described. The goal of this effort is to identify for further clinical and molecular characterization under-recognized rare cancers putatively associated with NF1.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22Stewart%2C%20Douglas%20R%22[Author%20-%20Full]%20OR%20%22Stewart%20DR%22[Author]%29%20AND%20%22neurofibromatosis%20type%201%22[All%20Fields]&amp;cmd=DetailsSearch">Neurofibromatosis Type 1 and Cancer Susceptibility&nbsp;&ndash;&nbsp;Research Publications</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349631" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7276472" sys_dependentvariantid="1965" sys_dependentid="349631" rxinlineslot="103" sys_variantid="1965" sys_contentid="349631">Douglas Stewart</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7276473" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="533930" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">

<h3>Primary Study Publications</h3>
<p>Peters JA, Kenen R, Giusti R, Loud J, Weissman N, Greene MH. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15378540">Exploratory study of the feasibility and utility of the colored eco-genetic relationship map (CEGRM) in women at high genetic risk of developing breast cancer.</a> <i>Am J Med Genet A</i> 2004; 130A:258-64</p>
<p>Abati A, Greene MH, Filie A, Loud J, Prindiville S, Danforth D, Giusti RM: <a href="https://www.ncbi.nlm.nih.gov/pubmed/16355383">Quantification of the cellular components of breast duct lavage samples.</a> <i>Diagn Cytopathol</i> 2006; 34:78-81</p>
<p>Loud JT, Weissman NE, Peters JA, Giusti RM, Wilfond BS, Burke W, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16575016">Deliberate deceit of family members: a challenge to providers of clinical genetics services.</a> <i>J Clin Oncol</i> 2006;2 4:1643-1646</p>
<p>Peters JA, Hoskins LM, Prindiville S, Kenen R, Greene MH: <a href="https://www.ncbi.nlm.nih.gov/pubmed/17111216">Evolution of the colored eco-genetic relationship map (CEGRM) for assessing social functioning in women in hereditary breast-ovarian (HBOC) families.</a> <i>J Genetic Counsel</i> 2006; 15:477-89</p>
<p>Bakos AD, Hutson SP, Loud JT, Peters JA, Giusti RM, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18816319"><i>BRCA</i> mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the <i>BRCA</i>-negative experience.</a> <i>Health Expect</i> 2008; 11:220-31&nbsp;</p>
<p>Hoskins LM, Roy K, Peters JA, Loud JT, Greene MH. <a href="http://www.highbeam.com/doc/1G1-186433448.html">Disclosure of positive <i>BRCA1/2</i>-mutation status in young couples: The journey from uncertainty to bonding through partner support.</a> <i>Families Systems and Health</i> 2008; 26:296-316</p>
<p>Koehly LM, Peters JA, Kuhn N, Hoskins LM, Letocha A, Kenen R, Loud J, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18688790">Sisters in hereditary breast and ovarian cancer families: communal coping, social integration, and psychological well-being.</a> <i>Psycho-Oncology</i> 2008; 17:812-21</p>
<p>Mueller CM, Mai PL, Bucher J, Peters JA, Loud JT, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18447953">Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer.</a> <i>BMC Complement Altern Med</i> 2008; 8:17, E-pub</p>
<p>Koehly LM, Peters JA, Kenen R, Hoskins LM, Ersig AL, Kuhn NR, Loud JT, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19833996">Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions.</a> <i>Am J Public Health</i> 2009; 99:2203-2209</p>
<p>Loud JT, Beckjord EB, Nichols K, Peters J, Giusti R, Greene MH<b>.</b> <a href="https://www.ncbi.nlm.nih.gov/pubmed/19602282">Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer.</a> <i>BMC Womens Health</i> 2009; 9:20, E-pub</p>
<p>Loud JT, Thiebaut AC, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19336560">Ductal lavage in women from <i>BRCA1/2</i> families: is there a future for ductal lavage in women at increased genetic risk of breast cancer?</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2009; 18:1243-1251</p>
<p>Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20130984">Mammographic density does not differ between unaffected <i>BRCA1/2</i> mutation carriers and women at low-to-average risk of breast cancer.</a> <i>Breast Cancer Res Treat</i> 2010; 123:245-255</p>
<p>Freed M, de Zwart JA, Loud JT, El Khouli RH, Myers KJ, Greene MH, Duyn JH, Badano A: <a href="https://www.ncbi.nlm.nih.gov/pubmed/21452712">An anthropomorphic phantom for quantitative evaluation of breast MRI.</a> <i>Med Phys</i> 2011;38:743-753</p>
<p>Peters JA, Kenen R, Hoskins LM, Koehly LM, Graubard R, Loud JT, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21547418">Unpacking the blockers: Understanding perceptions and social constraints of health communication in hereditary breast/ovarian cancer (HBOC) susceptibility families.</a> <i>J Genet Couns</i> 2011; 20(5):&nbsp; (2011):450-464</p>
<p>Hoskins LM, Roy K, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22429077">Toward a new understanding of risk perception among young female <i>BRCA1/2</i> &ldquo;previvors&rdquo;.</a> <i>Family Systems and Health</i> 2012; 30(1): 32-46</p>
<p>Werner-Lin A, Hoskins LM, Doyle M, Greene MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22547552">Cancer doesn&rsquo;t have an age: Genetic testing and cancer risk management in <i>BRCA1/2</i> mutation-positive women aged 18-24.</a> <i>Health</i> 2012; 16(6):636-654</p>
<p>Hoskins LM, Greene MH<b>.</b> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22927701">Anticipatory loss and early mastectomy for young female <i>BRCA1/2</i> mutation carriers.</a> <i>Qualitative Health Research</i> 2012; 22(12) 1633&ndash;1646</p>
<p>Jacobs KB, Yeager M, Zhou W, Kratz CP, Greene MH, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22561519">Detectable clonal mosaicism and its relationship to aging and cancer.</a>&nbsp; <i>Nature Genetics</i> 2012; 44:651-658</p>

<h3>Consortium of Modifiers of BRCA1/2 (CIMBA) Collaboration</h3>
<p>Spurdle AB, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/16434590">The <i>AIB1</i> polyglutamine repeat does not modify breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2006; 15:76-79</p>
<p>Couch FJ, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/17627006"><i>AURKA</i> F31I Polymorphism and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A CIMBA study.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2007; 16:1416-1421</p>
<p>Chenevix-Trench G, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/17466083">An international initiative to identify genetic modifiers of cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: the Consortium of Investigators of Modifiers of <i>BRCA1</i> and <i>BRCA2 (</i>CIMBA).</a> <i>Breast Cancer Res</i> 2007; 9:104-107</p>
<p>Antoniou AC, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/17999359"><i>RAD51</i> 135G&gt;C modifies breast cancer risk among <i>BRCA2</i> mutation carriers: results from a combined analysis of 19 studies.</a> <i>Am J Hum Genetics</i> 2007; 81:1186-1200</p>
<p>Osorio A, Pollan M, Pita G, <i>et al.</i> on behalf of CIMBA. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18781154">An evaluation of the polymorphisms Ins16bp and Arg72Pro in <i>p53</i> as breast cancer risk modifiers in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Br J Cancer</i> 2008; 99:974-977</p>
<p>Antoniou AC, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/18355772">Common breast cancer predisposition alleles are associated with breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Am J Hum Genet</i> 2008; 82:937-948</p>
<p>Rebbeck TR, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/18523885">No association of <i>TGFB1</i> L10P genotypes and breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: a multi-center cohort study.</a> <i>Breast Ca Res Treat</i> 2009; 115:185-192</p>
<p>Sinilnikova O, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/19707196">The <i>TP53</i> Arg72Pro and <i>MDM2</i> 309G&gt;T polymorphisms are not associated with breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Br J Cancer</i> 2009; 101:1456&ndash;1460</p>
<p>Antoniou AC, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/19656774">Common variants in 8q24, <i>LSP1</i> and 2q35 and breast cancer risk among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Hum Molec Genet</i> 2009; 18:4442-56</p>
<p>Osorio A, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/19920816">Evaluation of a candidate breast cancer associated SNP in <i>ERCC4</i> as a phenotypic modifier in <i>BRCA1/2</i> mutation carriers.</a> <i>Br J Cancer</i> 2009; 101: 2048-54</p>
<p>Engel C, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/20978178">Association of the variants <i>CASP8</i> D302H and <i>CASP10</i> V410I with breast and ovarian cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2010; 19:2859-2868</p>
<p>Antoniou AC, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21118973">Common breast cancer susceptibility alleles and the risk of breast cancer for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: implications for risk prediction.</a> <i>Cancer Research</i> 2010; 70:9742-9754</p>
<p>Antoniou AC, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/20852631">A genome-wide association study identifies a 19p13 locus that modifies the risk of breast cancer in <i>BRCA1</i> mutation carriers and which is associated with estrogen receptor-negative and triple-negative breast cancer in the general population.</a> <i>Nature Genetics</i> 2010; 42(10):885-92</p>
<p>Gaudet MM, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21060860">Common genetic variants and modification of penetrance of <i>BRCA2</i>-Associated breast cancer</a>. <i>PLoS Genetics</i> 2010; 6(10), e1001183</p>
<p>Ramus SJ, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/21169536">Genetic variation at 9p22.2 and ovarian cancer risk for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>J Natl Cancer Inst</i> 2011; 103:105-116</p>
<p>Jakubowska A, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/19876733">The Leu33Pro polymorphism in the <i>ITGB3</i> gene does not modify <i>BRCA1/2</i>-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Br Cancer Res Treat</i> 2010; 121:639-649</p>
<p>Im KM, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21597964"><i>BRCA2</i> haplotype structure in Ashkenazi Jewish 6174delT mutation carriers.</a> <i>Human Genet</i> 2011; 130:685-699</p>
<p>Antoniou AC, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21593217">Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Human Molec Genet</i> 2011; 15: 20:3304-3321</p>
<p>Cox DG, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/21890493">Common variants of the <i>BRCA1</i> wild-type allele modify the risk of&nbsp; breast cancer in <i>BRCA1</i> mutation carriers.</a> <i>Human Molec Genet</i> 2011; 20:4732-4747</p>
<p>Mulligan AM, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22053997">Common breast cancer susceptibility alleles are associated with tumour subtypes in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a> <i>Br Cancer Res</i> 2011; 13: R110, E-pub</p>
<p>Mavaddat N, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22144499">Pathology of breast and ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA).</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2012; 21 134-147</p>
<p>Bolton KL, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22274685">Association between <i>BRCA1</i> and <i>BRCA2</i> mutations and survival in women with invasive epithelial ovarian cancer.</a> <i>JAMA</i>2012; 307:382-390</p>
<p>Ramus SJ, Antoniou AC, <i>et al.&nbsp;</i><a href="https://www.ncbi.nlm.nih.gov/pubmed/22253144">Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> carriers.</a> <i>Human Mutation</i> 2012; 33:690-702</p>
<p>Jakubowska A, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22669161">Association of <i>PHB</i> 1630 C&gt;T and <i>MTHFR &nbsp;</i>677 C&gt;T polymorphisms with breast and ovarian cancer risk in <i>BRCA1/2</i> mutation carriers &ndash; results from a multicenter study.</a> <i>Br J Cancer</i> 2012; 106:2016-2024</p>
<p>Couch F, Gaudet MM, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/22351618">Common variants at the 19p13.1 and <i>ZNF365</i> loci are associated with ER subtypes of breast cancer and ovarian cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.</a><i>Cancer Epidemiology Biomarkers Prev</i>2012; 21:645-657</p>
<p>Stevens KN, Wang X, <i>et al.</i> <a href="https://www.ncbi.nlm.nih.gov/pubmed/23011509">Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of <i>BRCA2</i> mutation carriers.</a> <i>Breast Cancer Res Treat</i>2012; 136:295-302</p>
<p>Antoniou AC, <i>et al.</i> <a href="http://www.ncbi.nlm.nih.gov/pubmed/22348646">Common variants at 12p11, 12q24, 9p21, 9q31.2 and in <i>ZNF365</i> are associated with breast cancer risk for <i>BRCA1</i> and/or <i>BRCA2</i> mutation carriers.</a> <i>Breast Cancer Res</i>2012 Feb 20; 14:R33, E-pub</p>
<p>Ding YC, Neuhausen S, <i>et al.</i> &nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/22729394">A nonsynonymous polymorphism in <i>IRS1</i> modifies risk of developing breast and ovarian cancers in <i>BRCA1</i> and ovarian cancer in <i>BRCA2</i> mutation carriers.</a> <i>Cancer Epidemiol Biomarkers Prev</i> 2012; 21:1362-1370</p>
</div>]]></content>
  </row>
  <row para_id="595704" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Breast, Endometrial, and Ovarian Risk Assessment Macros (in SAS software) project absolute risk for breast cancer, endometrial cancer and ovarian cancer, respectively, in the batch mode.</p>
<p>Users can enter data on risk factors and projection interval ages for a group of women, and the macros will return the corresponding absolute risk projections. These programs may be useful for researchers who need risk projections for an entire study population.</p>
<p>The breast macro is appropriate for all races and ethnicities in the United States. The macros for endometrial and ovarian cancer risk are currently available for Caucasian and African American women. These models use information about a woman&rsquo;s history of hysterectomy and/or oophorectomy. Adequate data on these factors was only available for these two groups of women.</p>
<ul class="bullet-blu">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=595705" sys_contentid="595705" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7317681" sys_dependentvariantid="1418" sys_dependentid="595705" rxinlineslot="103">License Agreement</a></li>
</ul>
<h3>Download Software</h3>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=595706" sys_contentid="595706" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7317682" sys_dependentvariantid="1500" sys_dependentid="595706" rxinlineslot="103">Breast Cancer SAS Macro</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=595708" sys_contentid="595708" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7317683" sys_dependentvariantid="1500" sys_dependentid="595708" rxinlineslot="103">Endometrial Cancer SAS Macro</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=595707" sys_contentid="595707" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7317684" sys_dependentvariantid="1500" sys_dependentid="595707" rxinlineslot="103">Ovarian Cancer SAS Macro</a></li>
</ul>
<h4><span style="color: #000000;">Reference:</span></h4>
<ul class="bulletblu">
<li>Pfeiffer RM, Park Y, Kreimer AR, Lacey, Jr. JV, Pee D, &nbsp;Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH, Hartge P. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23935463"><span class="show-for-sr">PubMed Abstract: </span>Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies</a>. <i>PLoS Med;</i> 2013 Jul; 10(7).</li>
</ul>
<h4><span style="color: #000000;">Contact:</span></h4>
<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349627" sys_contentid="349627" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7317685" sys_dependentvariantid="1965" sys_dependentid="349627" rxinlineslot="103">Ruth Pfeiffer</a></div>]]></content>
  </row>
  <row para_id="595705" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h4><span style="color: #727272;">Non-Proprietary Software Transfer Agreement</span></h4>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p><br />By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p><br />The Breast, Endometrial, and Ovarian Risk Assessment Macros may be updated periodically as new data or research becomes available.</p>
<p><br />Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p><br />All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
</div>]]></content>
  </row>
  <row para_id="603590" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2090" sys_dependentid="1057056" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7253397">
<figure class="image-right-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=603280&amp;sys_siteid=475&amp;sys_contentid=1057056&amp;sys_command=edit" alt="Choonsik Lee and summer intern at DCEG poster presentation " /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Choonsik Lee (right)&nbsp;mentors summer intern Min-Joon Choi.</p>
</div>
</figcaption>
</figure>
</div>
<p>Roughly one quarter of DCEG&rsquo;s scientific staff are &ldquo;tenure-track&rdquo;.</p>
<p>These early-to-mid-career scientists design and execute in-depth research into the environmental and genetic causes of cancer, and use and develop new methods for data analysis. Similar to academia, DCEG&rsquo;s tenure-track provides a path to scientific tenure at NIH. Each investigator has one or more mentors and a tenure committee to support his or her research program and preparations for NIH tenure evaluation. Learn more about the <a href="https://oir.nih.gov/sourcebook/tenure-nih-intramural-research-program">tenure-track and criteria for tenure at NIH</a>.</p>
<h3>Life as a Tenure-Track Investigator</h3>
<p>Each investigator is expected to manage an independent research portfolio, demonstrating innovation, creativity, and the ability to work collaboratively in teams. They are also expected to successfully train pre- and postdoctoral fellows.&nbsp;</p>
<p>Tenure-track investigators receive professional development and career training, both within the Division and from NIH in the form of courses and lectures. Choose from a list of <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?by=tti">tenure-track investigators in DCEG</a> and learn about what they do.</p>
<h3>Apply for a DCEG Tenure-Track Position</h3>
<div sys_dependentvariantid="1833" sys_dependentid="1065273" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" sys_folderid="" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7253398">
<figure class="video right size50">
<h4>Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology &amp; Genetics for the SACNAS Conference</h4>
<div class="flex-video widescreen" id="ytplayer-_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" data-video-id="_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" data-video-title="Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology &amp; Genetics for the SACNAS Conference"><noscript>			<p>				<a href="https://www.youtube.com/watch?v=_x7NScOa-YQ?list=PLLDJCzDAv9eVRP-OrW069D_2X6ftbwJI" target="_blank" title="Jackie Lavigne Discusses Job Opportunities in the Division of Cancer Epidemiology & Genetics for the SACNAS Conference">					View this video on YouTube.				</a>			</p>		</noscript></div>
</figure>
</div>
<p>DCEG recruits tenure-track investigators from major academic and research institutions across the country and around the world. See <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=76&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302394" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302394" sys_relationshipid="7253391" sys_variantid="1418" sys_contentid="302394">currently available DCEG tenure-track openings</a>.</p>
<p>In addition, the Division participates in the trans-NIH Earl Stadtman Investigator program. This highly competitive recruitment effort, launched in 2009 in memory of NIH Biochemist Earl Stadtman, brings in outstanding scientists whose interests span the biomedical research enterprise, and who are eager to take on the high-risk, high-impact research that is the signature of the NIH intramural program. Find out more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=52&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302437" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="302437" sys_relationshipid="7253392" sys_variantid="1418" sys_contentid="302437">Earl Stadtman Investigator program</a>.</p>
</div>]]></content>
  </row>
  <row para_id="623919" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators carry out research designed to identify, understand, and quantify the risk of cancer in populations exposed to ionizing radiation (e.g., x-rays, CT scans, radon, and cosmic rays) and non-ionizing radiation (e.g., radiofrequency and extremely low-frequency or power frequency) from various sources, including:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302457" sys_contentid="302457" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="302457" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7197093">Medical radiation</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=623921" sys_contentid="623921" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="623921" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7197094">Occupational radiation</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=623920" sys_contentid="623920" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="623920" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7197095">Environmental radiation</a></li>
</ul>
<p>In addition,&nbsp;DCEG researchers&nbsp;perform <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068" sys_contentid="1091068" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1091068" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7197098">radiation dosimetry research</a> in support of epidemiological studies.</p>
</div>]]></content>
  </row>
  <row para_id="623920" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG scientists&nbsp;are studying&nbsp;cancer risks among populations exposed to radiation from environmental sources, such as nuclear reactor accidents and fallout from weapons testing. In addition, investigators are studying&nbsp;cancer risks from background radiation and ultraviolet radiation.</p>
<p><a href="http://dceg.cancer.gov/research/how-we-study/exposure-assessment/atomic-bomb-survivors">Atomic Bomb Survivors</a><br /> Studies of atomic bomb survivors in Hiroshima and Nagasaki, including updates to cancer incidence, radiation dose risk assessment, and molecular genetics studies.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=810219" sys_contentid="810219" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="810219" sys_dependentvariantid="1418" sys_relationshipid="7275936" sys_siteid="475" sys_variantid="1418">Childhood Leukemia and Background Radiation</a><br /> A record linkage study&nbsp;designed to investigate&nbsp;the association of childhood leukemia with natural background radiation exposure.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1105314" sys_contentid="1105314" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1105314" sys_dependentvariantid="1418" sys_relationshipid="7275939" sys_siteid="475" sys_variantid="1418">Methodologic Studies of Radioactive Fallout</a><br /> Investigators are conducting studies estimating radiation doses from radioactive fallout in regions affected by nuclear weapons testing.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068#Environmental-Radiation-Exposure" sys_contentid="1091068#environmental-radiation-exposure" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1091068" sys_dependentvariantid="1418" sys_relationshipid="7275938" sys_siteid="475" sys_variantid="1418">Radiation Dosimetry Research to Support Epidemiological Studies</a><br /> DCEG dosimetry researchers are developing methods for more accurate dose estimates and for reducing uncertainty in epidemiological studies of thyroid cancer and other thyroid diseases in persons exposed to radionuclides from the Chernobyl accident and to fallout from nuclear weapons testing.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1030358" sys_dependentvariantid="1418" sys_relationshipid="7275937" sys_siteid="475" sys_variantid="1418">Thyroid Disease in Young Persons Near Chernobyl</a><br /> Long-term studies of thyroid cancer among children and adolescents exposed to radioiodines&nbsp;in Ukraine and Belarus following the Chernobyl nuclear accident.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1030358" sys_variantid="1418" sys_relationshipid="7275941"></a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=826431" sys_contentid="826431" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="826431" sys_dependentvariantid="1418" sys_relationshipid="7275940" sys_siteid="475" sys_variantid="1418">Ultraviolet Radiation Exposure and Cancer Risks</a><br /> Ultraviolet radiation (UVR) is the primary risk factor for skin cancer. Investigators are using the U.S. Radiologic Technologists Cohort to further understand the risks of UVR exposure.</p>
</div>]]></content>
  </row>
  <row para_id="623921" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers are studying cancer risks among populations (called cohorts) who&nbsp;have been&nbsp;occupationally exposed to radiation for varying periods of time.&nbsp;These populations include: &nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277164" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1030358" rxinlineslot="103">Chernobyl Clean-up Workers</a><br /> Studies of leukemia and other hematological diseases in a large cohort of clean-up workers exposed to radiation after the Chernobyl accident.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302603" sys_contentid="302603" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277163" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="302603" rxinlineslot="103">Interventional Fluoroscopists</a><br /> A large cohort of radiologists and other physicians assembled to determine the contribution of occupational exposure to ionizing radiation to cancer mortality.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302552" sys_contentid="302552" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277162" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="302552" rxinlineslot="103">U.S. Radiologic Technologists</a><br />A prospective&nbsp;cohort study of 146,022 radiologic technologists&nbsp;designed to evaluate&nbsp;risks of cancer and other health effects associated with protracted exposure to low-to-moderate radiation doses.</p>
</div>]]></content>
  </row>
  <row para_id="623922" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG strives to understand the interplay of molecular and genetic effects and radiation on cancer etiology. This type of work involves biological samples and high-quality dosimetry or other exposure assessment.</p>
<p>Examples of such studies include:</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302434" sys_contentid="302434" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7306068" sys_siteid="475" rxinlineslot="103" sys_dependentid="302434" sys_dependentvariantid="1418">Atomic Bomb Survivors</a></h2>
<p>Studies of cancer incidence among atomic bomb survivors in Hiroshima and Nagasaki</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7306069" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030353" sys_dependentvariantid="1418">Chernobyl Nuclear Accident</a></h2>
<p>DCEG studies of radiation and health effects from the Chernobyl nuclear accident that took place in northern Ukraine, in 1986.</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302605" sys_contentid="302605" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7306070" sys_siteid="475" rxinlineslot="103" sys_dependentid="302605" sys_dependentvariantid="1418">Childhood Cancer Survivor Study</a></h2>
<p>Studies of secondary glioma, meningioma, thyroid, breast, soft tissue, bone, and skin cancers among more than 14,000 five-year survivors of childhood cancer diagnosed between 1970 and 1986.</p>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303648" sys_contentid="303648" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7306072" sys_siteid="475" rxinlineslot="103" sys_dependentid="303648" sys_dependentvariantid="1418">Retinoblastoma Survivors Follow-up Study</a></h2>
<p>A study of long-term cancer risk in survivors of retinoblastoma, a cancer that forms in the tissues of the retina.</p>
<h2><a href="https://dceg.cancer.gov/research/who-we-study/cohorts/us-radiologic-technologists">U.S. Radiologic Technologists Cohort (USRT)</a></h2>
<p>The U.S. Radiologic Technologists (USRT) cohort is a study of cancer and other serious disease risks associated with protracted low-to-moderate dose radiation exposures in an occupational exposed cohort.</p>
</div>]]></content>
  </row>
  <row para_id="660486" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Meet the current fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302673" sys_contentid="302673" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302673" sys_dependentvariantid="1422" sys_relationshipid="7257509" sys_siteid="475" sys_variantid="1422">Epidemiology and Biostatistics Program</a>.</p>
<p></p>
<h3><a id="Shreves"></a>Alaina Shreves, B.S. &ndash; Postbaccalaureate Fellow&nbsp;</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1126531" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7257512">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1126531&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Alaina Shreves, B.S., joined DCEG in June of 2018 after receiving her degree in neuroscience and public health from the College of William and Mary, Williamsburg, Virginia. She has completed research fellowships at West Virginia University&rsquo;s National Center of Excellence in Women's Health and West Virginia University&rsquo;s School of Medicine, where she assisted researchers studying rural health disparities. As an Amgen Scholar at the National Human Genome Research Institute, Ms. Shreves spent the summer of 2017 working in Dr. Laura Koeley&rsquo;s lab studying healthcare trajectories of patients with rare genetic conditions. Her undergraduate research culminated with an honors thesis that utilized electronic health records to analyze clinical trajectories of patients with sickle cell disease. As a DCEG postbaccalaureate fellow, Ms. Shreves works with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349664" sys_contentid="349664" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349664" sys_dependentvariantid="1965" sys_relationshipid="7257510" sys_siteid="475" sys_variantid="1965">Robert Hoover, M.D., Sc.D.</a>, Director, Epidemiology and Biostatistics Program, to study the effects of diethylstilbestrol (DES) on unexposed daughters of exposed women. She is also working with other members of the DCEG staff on the creation a new multi-center cohort study. Her primary research interests include health disparities, women&rsquo;s health, and neuroscience.&nbsp;</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="673538" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers attend scientific meetings and conferences to share their findings. Here are some of the major meetings where they will present their research.</p>
<p><a href="https://www.jhsph.edu/offices-and-services/career-services/events/career-fair/index.html">Johns Hopkins School of Public Health Center Fair</a><br />&nbsp;March 1, 2019 | Baltimore, Maryland<strong><strong><strong><br /></strong></strong></strong></p>
<p><a href="https://aspo.org/annual-meeting/">American Society for Preventive Oncology (ASPO) Annual Meeting</a><br />March 22-24, 2012 | Tuscan, Arizona</p>
<p><a href="http://www.americanepidemiologicalsociety.org/">American Epidemiological Society (AES) Annual Meeting</a><br />March 28-29,&nbsp;2019 | Los Angeles, California</p>
<p><a href="https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=213&amp;DetailItemID=1057">American Association for Cancer Research (AACR)</a><br />April 24-29, 2020 | San Diego, California</p>
<p><a href="http://www.hapai.co.nz/content/epicoh-2019-27th-international-symposium-epidemiology-occupational-health-wellington">EPICOH</a><br />April 29 - May 2, 2019 | Wellington, New Zealand</p>
<p><a href="https://am.asco.org/">American Society of Clinical Oncology (ASCO) Annual Meeting</a><br />May&nbsp;29 - June 2, 2020 | Chicago, Illinois</p>
<p><a href="https://epiresearch.org/annual-meeting/2019-meeting/">Society for Epidemiological Research (SER)</a><br />June 18-21, 2019 | Minneapolis, Minnesota</p>
<p><a href="http://ww2.amstat.org/meetings/jsm/2019/">Joint Statistical Meeting - American Statistical Association</a><br />July 27 - August 1, 2019 | Denver, Colorado</p>
<p><a href="https://researchfestival.nih.gov/2019">NIH Research Festival</a><br />September 11-13, 2019 | Bethesda, Maryland</p>
<p><a href="http://www.ashg.org/2019meeting/">American Society of Human Genetics (ASHG) Annual Meeting</a><br />October 15-19, 2019 |&nbsp;Houston, Texas</p>
<p><a href="https://www.radres.org/page/Meetings">Radiation Research Society (RRS) Annual Meeting</a><br />November 3-6, 2019 | San Diego, California</p>
<p><a href="http://www.hematology.org/Annual-Meeting/">American Society for Hematology (ASH) Annual Meeting</a><br />December 7-10, 2019 | San Diego, California</p>
<p><a href="http://ipvsoc.org/event/33rd-ipvc2020/">International Papillomavirus Conference</a><br />March&nbsp;23-27, 2020 | Barcelona, Spain</p>
<p>NCI Symposium on Cancer Health Disparities<br />April&nbsp;16-17, 2020 | Bethesda, Maryland</p>
<p>More information to come</p>
</div>]]></content>
  </row>
  <row para_id="725733" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>BSR (Bayesian Subset Regression) is an R package that implements the Bayesian subset modeling procedure for high-dimensional generalized linear models.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=725738" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="725738" sys_dependentvariantid="1500" sys_relationshipid="6986713" sys_variantid="1500" sys_contentid="725738">Manual</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=725742" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="725742" sys_dependentvariantid="1500" sys_relationshipid="6986714" sys_siteid="475" sys_variantid="1500" sys_contentid="725742">Vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=725747" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="725747" sys_dependentvariantid="1418" sys_relationshipid="6986715" sys_siteid="475" sys_variantid="1418" sys_contentid="725747">License Agreement</a></li>
</ul>
<p><b>Download Software:</b></p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=725711" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="725711" sys_dependentvariantid="1500" sys_relationshipid="6986716" sys_siteid="475" sys_variantid="1500" sys_contentid="725711">Windows O/S</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=725714" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="725714" sys_dependentvariantid="1500" sys_relationshipid="6986717" sys_siteid="475" sys_variantid="1500" sys_contentid="725714">Unix O/S</a></li>
</ul>
<p><b>Reference:</b></p>
<p>Liang F, Song Q, Yu K.&nbsp;<a href="https://www.tandfonline.com/doi/abs/10.1080/01621459.2012.761942">Bayesian subset modeling for high-dimensional generalized linear models</a>. <em>J Am Stat Assoc</em> 2013; 108:589-606.</p>
<p><b>Support:</b></p>
<p>Authors: <a href="mailto:fliang@stat.tamu.edu">Faming Liang</a> and <a href="mailto:yuka@mail.nih.gov">Kai Yu</a></p>
</div>]]></content>
  </row>
  <row para_id="725747" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>BSR - R Package</h3><p><strong>Non-Proprietary Software Transfer Agreement</strong></p><p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p><b>This is a trial version of the software</b>. The BSR - R package may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p></div>]]></content>
  </row>
  <row para_id="728725" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><img style="float: right;" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=731117" inlinetype="rximage" rxinlineslot="104" sys_dependentid="731117" sys_dependentvariantid="1482" sys_relationshipid="7277840" sys_siteid="475" />In July of 1945, the U.S. government tested the first atomic weapon in south-central New Mexico. The test was code-named Trinity. The National Cancer Institute (NCI) is carrying out a study to quantitatively estimate the range of possible radiation-related cancer cases in New Mexico that may be related to the nuclear test. To accomplish this task, the research team will use published data on radioactive fallout from the test and descriptions of the typical diet and lifestyle of people living in New Mexico in 1945, which will be drawn from the published literature and collected through targeted interviews to be carried out in New Mexico.</p>
<div class="callout-box right">
<h3>Information for Journalists</h3>
<p>To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:</p>
<p><b>E-mail:</b><br /><a href="mailto:ncipressofficers@mail.nih.gov">ncipressofficers@<br />mail.nih.gov</a></p>
<p><b>Phone:</b> 240-760-6600</p>
</div>
<p>The NCI plans to carry out in-depth interviews to ascertain the typical diet of Native American, Hispanic/Latino, Chicano, and white populations living in New Mexico in the mid-1940s. These interviews are an important step in developing estimates of low, intermediate, radiation doses resulting from Trinity.</p>
<p>To determine how best to collect these data, NCI investigators have engaged in discussions with academics with expertise in Native American and Hispanic lifestyles in the 1940s, as well as advocates and local community leaders. NCI has entered into partnership with a key community group to facilitate the identification of elders who can be interviewed about their historical knowledge regarding lifestyle and diet at the time of the Trinity test.</p>
<p>The investigators plan to publish their work&mdash;the dose reconstruction methods and findings, and cancer risk estimates, as well as the dietary and lifestyle findings resulting from this formative research&mdash;in the peer-reviewed scientific literature and in community newsletters in English and Spanish so it is available to other researchers and the broader community.</p>
<p>For more information about the study contact <a href="http://dceg.cancer.gov/about/staff-directory/biographies/O-Z/simon-steven" target="_blank" rel="noopener noreferrer">Steven L. Simon, Ph.D..</a>, Epidemiology and Biostatistics Program.</p>
<p>View a Spanish translation of this page: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=747191" sys_contentid="747191" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="747191" sys_dependentvariantid="1418" sys_relationshipid="7277841" sys_siteid="475" sys_variantid="1418">Estudio para calcular la dosis de radiaci&oacute;n y los riesgos de c&aacute;ncer que resultaron de la lluvia radiactiva de la prueba nuclear &ldquo;Trinity&rdquo;</a></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p>
</div>]]></content>
  </row>
  <row para_id="746739" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This is the R package implementing the testing procedure described in the referred manuscript.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=746759" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="746759" sys_dependentvariantid="1418" sys_relationshipid="7276083" sys_siteid="475" sys_variantid="1418" sys_contentid="746759">License Agreement</a></li>
</ul>
<p><b>Download Software</b></p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=731301" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="731301" sys_dependentvariantid="1500" sys_relationshipid="7276081" sys_siteid="475" sys_variantid="1500" sys_contentid="731301">Het.Tree.0.0.1.tar.gz</a>- Use this version if you have covariates to adjust</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=731300" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="731300" sys_dependentvariantid="1500" sys_relationshipid="7276082" sys_siteid="475" sys_variantid="1500" sys_contentid="731300">Het.Tree.Fast.0.0.1.tar.gz</a> - Use this version if there is no covariate to adjust. &nbsp;This version runs faster than the one above.</li>
</ul>
<p><b>Reference</b></p>
<p>Yu K, Zhang H, Wheeler W, Home HN, Chen J, Figueroa JD. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263227/">A robust association test for detecting genetic variants with heterogeneous effects.</a>&nbsp;<em>Biostatistics.</em>&nbsp;<span class="fm-vol-iss-date">Jul 23, 2014. DOI</span><span class="doi">:&nbsp;<a href="https://dx.doi.org/10.1093%2Fbiostatistics%2Fkxu036" target="pmc_ext" ref="reftype=other&amp;article-id=4263227&amp;issue-id=246406&amp;journal-id=717&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1093/biostatistics/kxu036</a></span></p>
<p><b>Support</b></p>
<p>Questions, please contact Dr. Kai Yu (yuka@mail.nih.gov)</p>
</div>]]></content>
  </row>
  <row para_id="746759" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Het-Tree - R Package</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The Het-Tree - R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="747191" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><img style="float: right;" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=731117" inlinetype="rximage" sys_siteid="475" sys_relationshipid="7275954" sys_dependentvariantid="1482" sys_dependentid="731117" rxinlineslot="104" /></p>
<p>En julio de 1945, el gobierno de Estados Unidos realiz&oacute; la primera prueba de un arma at&oacute;mica en la regi&oacute;n centro sur de Nuevo M&eacute;xico. La prueba recibi&oacute; el nombre clave de "Trinity". El Instituto Nacional del C&aacute;ncer (NCI) est&aacute; realizando un estudio para calcular el rango de los casos de c&aacute;ncer en Nuevo M&eacute;xico que pudieran estar relacionados con la prueba nuclear. Para lograr este objetivo, el equipo de investigaci&oacute;n utilizar&aacute; datos publicados sobre la lluvia radioactiva generada por la prueba y descripciones de la alimentaci&oacute;n y los estilos de vida caracter&iacute;sticos de la gente que viv&iacute;a en Nuevo M&eacute;xico en 1945; estas &uacute;ltimas se recoger&aacute;n de publicaciones y se reunir&aacute;n de grupos de enfoque que se realizar&aacute;n en Nuevo M&eacute;xico.</p>
<div class="callout-box right">
<h3>Information for Journalists</h3>
<p>To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:</p>
<p><b>E-mail:</b><br /><a href="mailto:ncipressofficers@mail.nih.gov">ncipressofficers@<br />mail.nih.gov</a></p>
<p><b>Phone:</b> 240-760-6600</p>
</div>
<p>El NCI tiene planeado realizar grupos de enfoque y entrevistas para determinar la alimentaci&oacute;n caracter&iacute;stica de las poblaciones ind&iacute;genas americanas, hispanas (latinas), chicanas y blancas que viv&iacute;an en Nuevo M&eacute;xico a mediados de 1940.&nbsp; Estos programas para reunir informaci&oacute;n son un paso importante para hacer estimaciones de las dosis bajas, intermedias y altas de radiaci&oacute;n generadas por la prueba Trinity.</p>
<p>Para determinar la mejor forma de recoger estos datos, los investigadores del NCI han entablado conversaciones con acad&eacute;micos expertos en los estilos de vida de los ind&iacute;genas americanos y de los hispanos en los a&ntilde;os cuarenta, as&iacute; como con promotores y l&iacute;deres locales comunitarios.</p>
<p>Los investigadores planean publicar su trabajo &mdash;que consiste de resultados y m&eacute;todos de reconstrucci&oacute;n de dosis, y rango de los casos de c&aacute;ncer posibles, as&iacute; como los datos de dieta y de estilos de vida que resulten de esta investigaci&oacute;n formativa&mdash; en publicaciones cient&iacute;ficas revisadas por expertos y en boletines comunitarios en ingl&eacute;s y en espa&ntilde;ol de forma que est&eacute; a disposici&oacute;n de otros investigadores y de la comunidad en general.</p>
<p>Para obtener m&aacute;s informaci&oacute;n sobre el estudio, puede comunicarse con <a href="http://dceg.cancer.gov/about/staff-directory/biographies/O-Z/simon-steven" target="_blank" rel="noopener noreferrer">Steven L. Simon, Ph.D.</a>, Epidemiology and Biostatistics Program.</p>
<p>Ver esta p&aacute;gina en Ingl&eacute;s: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=728725" sys_contentid="728725" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275955" sys_dependentvariantid="1418" sys_dependentid="728725" rxinlineslot="103" sys_variantid="1418">Study of Radiation Doses and Cancer Risks Resulting from the 1945 "Trinity" Atomic Weapon Test</a></p>
</div>]]></content>
  </row>
  <row para_id="751494" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>TREAT (TREe-based Association Test) version 0.0.5 is an R package for detecting complex joint effects in case-control studies. The test statistic is derived from a tree-structure model by recursive partitioning the data. Ultra-fast algorithm is designed to evaluate the significance of association between candidate gene and disease outcome.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=685285" sys_contentid="685285" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7313947" sys_dependentvariantid="1500" sys_dependentid="685285" rxinlineslot="103">Manual</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=751390" sys_contentid="751390" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7313948" sys_dependentvariantid="1500" sys_dependentid="751390" rxinlineslot="103">Vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=753411" sys_contentid="753411" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7313951" sys_dependentvariantid="1418" sys_dependentid="753411" rxinlineslot="103">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<p>Note: TREAT is designed for 64-bit OS ONLY. Please DO NOT run it on a 32-bit OS, which might give incorrect results.</p>
<ul>
<li>Package Source - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=751377" sys_contentid="751377" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7313949" sys_dependentvariantid="1500" sys_dependentid="751377" rxinlineslot="103">TREAT.0.0.5.tar.gz</a></li>
<li>Windows Binary - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=751378" sys_contentid="751378" inlinetype="rxhyperlink" sys_variantid="1500" sys_siteid="475" sys_relationshipid="7313950" sys_dependentvariantid="1500" sys_dependentid="751378" rxinlineslot="103">TREAT.0.0.5.zip</a></li>
</ul>
<h3>Reference:</h3>
<p>Zhang H, Wheeler W, Wang ZM, Taylor PR, Yu K. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24794927">A fast and powerful tree-based association test for detecting complex joint effect in case-control studies</a>. <em>Bioinformatics</em> 2014</p>
<h3>Support:</h3>
<p><b>Questions?</b> Contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349617" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="349617" rxinlineslot="103" sys_relationshipid="7313952" sys_variantid="1965" sys_contentid="349617">Dr. Kai Yu </a></p>
</div>]]></content>
  </row>
  <row para_id="753411" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>TREAT <strong>Non-Proprietary Software Transfer Agreement</strong></h3>
<h4>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</h4>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The TREAT package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="753548" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>An R package for testing Calibration of Binary Risk Model (CBRM) using different goodness-of-fit statistics.</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=753546" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="753546" sys_dependentvariantid="1500" sys_relationshipid="6816115" sys_siteid="475">Readme</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=753545" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="753545" sys_dependentvariantid="1500" sys_relationshipid="6816116" sys_siteid="475">Manual</a></li>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=753591" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="753591" sys_dependentvariantid="1418" sys_relationshipid="6816117" sys_siteid="475">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Package Source - <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=819311" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="819311" sys_dependentvariantid="1500" sys_relationshipid="6816118" sys_siteid="475">CBRM_0.0.3.tar.gz</a></li>
<li>Windows Binary - <a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=819312" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="819312" sys_dependentvariantid="1500" sys_relationshipid="6816119" sys_siteid="475">CBRM_0.0.3.zip</a></li>
</ul>
<h3>Reference:</h3>
<p>Song M, Kraft P, Joshi AD, Barrdahl M, and Chatterjee N. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25027274">Testing calibration of risk models at extremes of disease-risk</a>. <i>Biostatistics </i>2015<i><br /></i></p>
<h3>Support:</h3>
<p><b>Questions?</b> <a href="mailto:ncicontactdceg@mail.nih.gov">Contact DCEG</a>.</p>
</div>]]></content>
  </row>
  <row para_id="753591" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>CBRM <strong>Non-Proprietary Software Transfer Agreement</strong></h3><h4>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</h4><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p>The CBRM package may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="801811" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>OEEB 2018 Distinguished Lecture Series in Occupational and Environmental Cancer</h2>
<div class="callout-box right">
<h3><a title="" href="/about/organization/programs-ebp/oeeb">OEEB Home</a></h3>
<p><a title="" href="/about/organization/programs-ebp/oeeb/oeeb-research">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=OEEB">OEEB Staff Directory</a></p>
<p><a title="" href="/fellowship-training/what-our-fellows-do/meet-current-fellows/oeeb-fellows">Current Fellows</a></p>
<p><a title="" href="/fellowship-training/become-a-fellow/research-training-areas/training-oeeb">Research Training Opportunities</a></p>
<p><a title="" href="/about/organization/programs-ebp/oeeb/tools">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=OEEB">Publications</a></p>
</div>
<p>The OEEB Distinguished Lecturer Series brings prominent scientists to DCEG to discuss research on occupational and environmental causes of cancer. The objectives of the series are to expand contacts between DCEG investigators and outside experts, provide an opportunity for junior staff to meet with distinguished scientists, and highlight research opportunities in occupational and environmental cancer.</p>
<p>Dr. Kurt Straif, Head of the Evidence Synthesis and Classification Section at the World Health Organization&rsquo;s International Agency for Research on Cancer (IARC), visited OEEB on October 29 and 30&nbsp;as the 2018 Distinguished Lecturer.</p>
<div sys_relationshipid="7254239" sys_dependentid="1136016" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=301991&amp;sys_siteid=475&amp;sys_contentid=1136016&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>2018 OEEB Distinguished Lecture</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<p>Dr. Straif presented a seminar to the Branch, titled &ldquo;The role of occupational cancer epidemiology in cancer hazard identification and risk characterization,&rdquo; during which he described occupational epidemiology&rsquo;s contributions to the IARC Monographs Program. During his visit, he met with branch investigators to discuss areas of mutual scientific interest, and with trainees, to share experiences of his distinguished career.</p>
<h3>Selected Previous Distinguished Lecturers:</h3>
<p><strong>2013</strong>: Kyle Steenland, Ph.D., Departments of Epidemiology and Environmental Health, Rollins School of Public Health, Emory University.<br /> Lecture: PFOA Is in All of Us &ndash; Does it Cause Cancer?</p>
<p><strong>2011</strong>: David A. Savitz, Ph.D., Departments of Epidemiology and Obstetrics and Gynecology, Brown University. <br />Lecture: From Power Lines to Cell Phones: 25 Years of Epidemiologic Evidence on Non-Ionizing Radiation and Cancer.</p>
<p><strong>2010</strong>: David Christiani, M.D., M.P.H., M.S., Elkan Blout Professor of Environmental Genetics, Department of Environmental Health and Department of Epidemiology, Harvard University.<br /> Lecture: Somatic Tissue Analysis in the Molecular Epidemiology of Lung Cancer.</p>
</div>]]></content>
  </row>
  <row para_id="804879" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>While DCEG does not provide housing for summer interns, we have compiled the following information on housing in the metro area.</p>
<p>The <a href="https://www.training.nih.gov/assets/Moving_Guide.pdf">Moving Guide (pdf)</a> prepared by the NIH Office of Intramural Training &amp; Education (OITE) provides housing suggestions along with information on virtually everything you will need to know about moving to Bethesda, Baltimore, or Frederick, MD. The <a href="https://www.training.nih.gov/resources/justarrived">OITE Planning Your Move - Just Arrived</a> page contains additional resources for use in acclimating to the NIH.</p>
<p>The <a href="http://www.fedesp.com/nih/">NIH Recreation &amp; Welfare Association housing list</a> contains information on numerous rentals convenient to the main NIH campus in Bethesda.</p>
<p><a href="http://ishdc.org/">International Student House</a> &nbsp;(For men and women. Students only.)<br /> 1825 R St., N.W.<br /> Washington D.C., 20009<br /> (202) 387-6445 or (202) 232-4007<br /> Fax: (202) 387-4115<br /> Metro: Dupont Circle - Red line</p>
<p><a href="https://tmhdc.org/">Thompson-Markward Hall</a> &nbsp;(For women aged 18 - 35 yrs. Mostly students and interns.)<br /> 235 2nd Street, N.E.<br /> Washington D.C., 20002<br /> (202) 546-3255<br /> Metro: Union Station - Red line</p>
</div>]]></content>
  </row>
  <row para_id="804883" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>As the population of cancer survivors continues to grow (over 13 million in 2012), there is a great need to understand the long-term health of this population. Nearly one in five cancers diagnosed today occurs in an individual with a previous diagnosis of cancer, and these &ldquo;second cancers&rdquo; are a leading cause of morbidity and mortality among cancer survivors. Research into the etiology, prevention, and treatment of second cancers has the potential to improve public health, guide clinical management of survivors, and provide further insight into the mechanisms of carcinogenesis. DCEG investigators are actively engaged in research to address risks associated with:&nbsp;</p>
<a id="Top"></a>
<ul>
<li><a href="#Treatment">Treatment-Related Second Cancers</a></li>
<li><a href="#Lifestyle">Lifestyle, Environmental, and Medical History Factors</a></li>
<li><a href="#Genetic">Genetic Susceptibility</a></li>
</ul>
<h3 id="Treatment">Treatment-Related Second Cancers</h3>
<p>For decades, clinicians and epidemiologists have recognized that radiotherapy and certain chemotherapies may increase risk for developing a second cancer. DCEG investigators study groups of patients with a range of malignancies and varying treatment modalities. This helps to identify risks so that oncologists can refine treatment plans to deliver the most effective treatment dose with the least risk for future cancers. These studies include:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1130864" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1130864" rxinlineslot="103" sys_relationshipid="7280448" sys_variantid="1418" sys_contentid="1130864">Hematopoietic Stem Cell Transplantation</a><br />A study of the risks of cancer following allogeneic hematopoietic stem cell transplantation</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302605" sys_contentid="302605" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280440" sys_dependentvariantid="1418" sys_dependentid="302605" rxinlineslot="103" sys_variantid="1418">Childhood Cancer Survivors</a><br />Studies of secondary glioma, meningioma, and thyroid, breast, soft tissue, bone, and skin cancers among more than 14,000 five-year survivors of childhood cancer diagnosed between 1970 and 1986.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=805096" sys_contentid="805096" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280442" sys_dependentvariantid="1418" sys_dependentid="805096" rxinlineslot="103" sys_variantid="1418">Contralateral Breast Cancer</a><br />A retrospective cohort looking at second cancers in about 7,000 breast cancer patients diagnosed since 1991</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302509" sys_contentid="302509" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280441" sys_dependentvariantid="1418" sys_dependentid="302509" rxinlineslot="103" sys_variantid="1418">Multiple Primary Cancer Monograph</a><br />To identify groups of cancer survivors that are at increased risk for multiple primary cancers, investigators led an effort to provide the first comprehensive population-based analysis of the risk of subsequent cancer in the U.S., resulting in a monograph.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303648" sys_contentid="303648" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280446" sys_dependentvariantid="1418" sys_dependentid="303648" rxinlineslot="103" sys_variantid="1418">Retinoblastoma Survivors</a><br />Study of cancer risk in long-term survivors of retinoblastoma</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302397" sys_contentid="302397" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280443" sys_dependentvariantid="1418" sys_dependentid="302397" rxinlineslot="103" sys_variantid="1418">Second Primary Gastrointestinal Cancers</a><br />A multicenter international study of second primary gastrointestinal (GI) cancers among survivors of Hodgkin lymphoma and cancers of the testis, breast, and cervix</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302661" sys_contentid="302661" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280447" sys_dependentvariantid="1418" sys_dependentid="302661" rxinlineslot="103" sys_variantid="1418">Temporal Trends in Second Cancer Risks Based on SEER Data</a><br />To facilitate research into the etiology of second cancers, investigators from the DCEG Radiation Epidemiology Branch led the development of an interactive PC-based software module (&ldquo;SIR&rdquo;) to perform analyses of multiple primary cancers using NCI&rsquo;s Surveillance, Epidemiology, and End Results (SEER) database.</p>
<p><a href="#Top">Back to Top</a></p>
<h3 id="Lifestyle">Lifestyle, Environmental, and Medical History Factors and Second Cancer Risks</h3>
<p>Investigators are exploring whether the risk of developing second cancers is affected by lifestyle or environmental factors. However, most previous second cancers studies have been based on data from cancer registries or medical records, which generally don&rsquo;t have data on these potential risk factors. By pooling data from large epidemiologic cohort studies, investigators are able to identify whether lifestyle and environmental factors are associated with second cancer risk.&nbsp;</p>
<p>In the first pooled analyses from the Cohort Consortium, DCEG investigators and colleagues have pooled data from five cohorts (the NIH-AARP Diet and Health Study, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, the Agricultural Health Study, the Iowa Women&rsquo;s Study, and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study) and are investigating second cancer risks in relation to obesity and tobacco. DCEG investigators and colleagues are also utilizing the SEER-Medicare linked dataset to investigate medical history risk factors for second cancers in a cohort of over 44,000 survivors of non-Hodgkin lymphoma. For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280444" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_variantid="1965">Lindsay Morton</a>.</p>
<p><a href="#Top">Back to Top</a></p>
<h3 id="Genetic">Genetic Susceptibility to Second Cancers</h3>
<p>It is well established that individuals with certain hereditary disorders such as ataxia telangiectasia have increased sensitivity to the carcinogenic effects of radiation, but less is known about how common genetic variation in the general population may relate to risk for second cancers following radiotherapy. Multiple, complex genetic pathways such as DNA damage repair, oxidative stress, and cell cycle control likely contribute to the development of radiation- and chemotherapy-related neoplasms, supporting a polygenic model for sensitivity to treatment-related neoplasms.</p>
<p>Scientists&nbsp;in the Radiation Epidemiology Branch are partnering with investigators from the Childhood Cancer Survivor Study to conduct a genome-wide association study of subsequent neoplasms in childhood cancer survivors. They are also conducting studies of specific <i>RB1</i> mutations and subsequent neoplasm risk in retinoblastoma survivors, with exome sequencing for patients with selected types of subsequent neoplasms. Opportunities exist for postdoctoral fellows to participate in current and future research on genetic susceptibility to multiple primary cancers. Results from this work may help inform clinical decision-making for cancer patients to minimize future cancer risk. For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7280445" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_variantid="1965">Lindsay Morton</a>.</p>
<p><a href="#Top">Back to Top</a></p>
</div>]]></content>
  </row>
  <row para_id="805096" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Breast cancer survivors constitute about 25% of the growing population of cancer survivors in the US. Contralateral breast cancer is the most common second cancer in women with primary breast cancer. With increasing cure rates comes increasing concern about their long-term health. Radiation Epidemiology Branch (REB) investigators and collaborators from the Kaiser health maintenance organization have developed a retrospective cohort of about 7,000 breast cancer patients diagnosed since 1991. By linking electronic treatment files and the Kaiser cancer registries for information on subsequent cancers, researchers have developed a rich resource for studying the late effects of breast cancer treatments. Tumor tissue samples from both the first and second breast cancers and mammography films have also been collected. Analyses are underway to evaluate the relationship among radiotherapy, newer hormonal therapies, chemotherapy agents, and obesity in survivors.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7275463" sys_dependentvariantid="1965" sys_dependentid="349642" rxinlineslot="103">Amy Berrington de Gonz&aacute;lez</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7275464" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="805970" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG is exploring the relationship between host immune function and risk for glioma; one of the deadliest forms of brain cancer yet a malignancy for which few definitive risk factors have been identified. While previous reports on allergy/atopy and risk of glioma showed an inverse association, these data were mainly from case-control studies and potentially prone to survival and recall bias.&nbsp;</p>
<p>To minimize the bias from earlier studies, DCEG investigators examined medical records for a cohort of black and white male US veterans with relatively homogenous socioeconomic background.&nbsp;</p>
<p>The investigators considered a collection of immune-related conditions and observed that history of allergy/atopy and diabetes of long latency to be associated with reduced risk of subsequent brain cancer. To advance our understanding of the mechanisms underlying these associations, future studies with prospectively ascertained and validated medical diagnoses, treatment information, and biological samples to measure immune function markers are needed.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7276221" sys_siteid="475" rxinlineslot="103" sys_dependentid="349642" sys_dependentvariantid="1965">Amy Berrington de Gonz&aacute;lez</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7276220" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="805971" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This study is designed to improve our understanding of radiation-related risk for intracranial tumors of the brain and nervous system through a pooled analysis of 16 epidemiological studies that have a reasonable number of exposed study subjects, individual estimates of radiation dose to the brain and different reasons for radiation exposure. By including a large number of individuals exposed over a wide range of doses, at different dose rates and ages, we hope to increase precision to quantify the overall dose-response relationship for specific histological types of tumors (glioma, meningioma and acoustic neuroma) and to address effects of possible modifying factors.&nbsp;In particular, results would aid in the assessment of risks related to CT scans, a question of considerable public health importance in light of their growing use.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939428" sys_contentid="939428" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7277222" sys_siteid="475" rxinlineslot="103" sys_dependentid="939428" sys_dependentvariantid="1965">Cari Kitahara</a>.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277223" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="806015" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Taller height and greater body mass index have been consistently associated with an increased risk of thyroid cancer, but few studies have investigated the role of childhood body size. We prospectively examined associations between annual measurements of childhood height and body mass index (at ages 7-13 years) with risk of thyroid cancer in adulthood by linking measurement data from over 320,000 schoolchildren in Copenhagen, with cancer incidence data from the Danish Cancer Registry. Both height and body mass index in childhood were positively associated with thyroid cancer risk, suggesting a potential role for early-life factors related to growth and body weight in thyroid carcinogenesis.</p>
<p>For more information, contact <a href="mailto:kitaharac@mail.nih.gov">Cari Kitahara</a>.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7277328" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="806074" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Taller height and greater body mass index in young adulthood have been associated with an increased risk of glioma, but few studies have investigated the role of body size at birth or during childhood, when the brain undergoes rapid cell growth and differentiation. We prospectively examined associations between birth weight and annual measurements of childhood height and body mass index (at ages 7-13 years) with risk of glioma in adulthood by linking measurement data from over 320,000 schoolchildren in Copenhagen, born between 1930 and 1989 with cancer incidence data from the Danish Cancer Registry. Taller height in boys and greater birth weight in boys and girls was positively associated with glioma risk, suggesting that exposures related to body size in early life may contribute to the etiology of adult glioma.</p>
<p>For more information, contact <a href="mailto:Kitaharac@mail.nih.gov?subject=Record-Linkage%20Study%20of%20Glioma">Cari Kitahara</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277320" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="806124" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>For reasons that are not currently well understood, the incidence of thyroid cancer has rapidly increased in several countries over the past three decades. Individual case-control and cohort studies have suggested links between taller height and greater body mass index with an increased risk of thyroid cancer, particularly for papillary carcinoma, the most common and least aggressive subtype. However, these studies have been underpowered to examine associations for other anthropometric measurements, including waist circumference and weight change, and to evaluate differences by histological subtype.&nbsp;We combined data from 22 prospective studies in North America, Europe, Australia, and Asia to evaluate these questions in one of the largest and most comprehensive studies on this topic to date.</p>
<p>For more information, contact <a href="mailto:kitaharac@mail.nih.gov?subject=International%20Pooled%20Analysis%20of%20Risk%20Factors%20for%20Thyroid%20Cancer">Cari Kitahara</a>.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7276338" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="810219" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Childhood leukemia is among the most radiosensitive cancers. DCEG investigators have contributed to the study of this cancer by verifying that only with adequate statistical power provided by tens of thousands of cases can assessments of risk be determined. In a record linkage study, DCEG investigators and collaborators linked over 60,000 cases from a large UK database and found a significant association of leukemia with natural background radiation exposure. These findings were consistent with the linear low dose risks observed in the Japanese atomic bomb survivors.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349604" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349604" sys_dependentvariantid="1965" sys_relationshipid="7275420" sys_siteid="475" sys_variantid="1965" sys_contentid="349604">Mark Little</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275421" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="810220" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The number of CT scans performed in the United States has increased to more than 70 million per year.&nbsp;CT scans of young patients are of particular concern because, in comparison with adults, children are exposed to higher doses, are generally more sensitive to the carcinogenic effects of radiation, and have a longer life-span to express radiation-related cancers. In a study of 180,000 children, DCEG investigators found increased risks of leukemia and brain tumors after childhood CT scans following linear dose-response relationships for leukemia and brain tumors that were broadly consistent with the risks observed in the Japanese atomic bomb survivors. The absolute risk estimates were small. Work is continuing in the United Kingdom and other cohorts to address further questions about the relationship between pediatric CT scans and subsequent cancer risk.</p>
<p>For more information, contact <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/berrington-amy">Amy Berrington de Gonz&aacute;lez</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=49&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7170162" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="826431" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Cancers of the skin (e.g. melanoma, basal cell carcinoma, and squamous cell carcinoma) are the most common cancers in the United States, constituting over one million diagnosed cases every year, and the primary risk factor is exposure to ultraviolet radiation (UVR). Radiation Epidemiology Branch (REB) investigators are using the U.S. Radiologic Technologists Cohort, the only nationwide U.S. cohort with lifetime residential history and questionnaire-derived estimates of time spent outdoors, to further understand the risk of UVR exposure. By linking historical NASA satellite estimates of ambient UVR to geocoded locations of residence throughout the lifetime, investigators have developed a rich resource for studying the effects of UVR on skin cancers and the potentially protective effects of UVR on other cancer sites. Previous research has included the assessment of photosensitizing drugs, ambient temperature, and methodological studies of personal UVR and vitamin D exposure assessment. REB investigators have also examined the association of UVR with cancer incidence and mortality in the NIH-AARP study, as well as UVR and non-Hodgkin lymphoma subtypes across race/ethnicities in SEER.</p>
<p>For more information, contact&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_dependentvariantid="1965" sys_dependentid="1087122" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="" sys_folderid="" sys_relationshipid="7126079" sys_variantid="1965" sys_contentid="1087122">Elizabeth Cahoon</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7126080" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="826555" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>After a small United States study found children with acute lymphoblastic leukemia who were exposed to high levels of residential magnetic field exposure had poorer survival rates, DCEG investigators sought to reproduce the question in a larger, international pooled analysis. Investigators examined more than 3,000 cases from the United States, Canada, Denmark, Germany, Japan, and the United Kingdom, and no association was found.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965" sys_relationshipid="7276040">Elizabeth Cahoon</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7276039">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="827356" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Epstein&ndash;Barr virus (EBV), also known as human herpesvirus 4, is a virus of the <i>Herpesveridae</i> family, and is one of the most common DNA viruses in humans. EBV infection is associated with several benign and malignant diseases, including Burkitt and some other types of lymphoma, nasopharyngeal carcinoma, and gastric cancer. Monoclonal EBV DNA is found in the tumor cells of about 9% of gastric adenocarcinomas, which have particular molecular characteristics (see References). The etiological significance of the viral infection is uncertain.</p>
<p>The NCI International EBV-Gastric Cancer Consortium is a collaboration among NCI and extramural investigators, established by DCEG in 2006. This Consortium utilizes data and biospecimens from completed and ongoing case series and observational studies of gastric cancer conducted in low- and high-risk populations. The presence of EBV in cancer cells is assessed by <i>in situ</i> hybridization for EBV-encoded RNA (EBER), the gold standard assay for detecting latent infection. This research effort was designed&nbsp;to replicate and extend findings from previous studies hindered by small numbers of EBV-positive cases, and to stimulate multidisciplinary research in this area. Analyses from this research group to date have focused on epidemiological and clinicopathological characterization of EBV-positive gastric cancer (see References). Laboratory studies comparing EBV-positive and -negative cases are currently underway addressing:</p>
<p>&bull; Anti-EBV and anti-<i>Helicobacter pylori</i> antibody profiles<br />&bull; Tissue expression of metabolic pathways<br />&bull; Blood-based methods for diagnosis</p>
<h3><a id="References"></a>References</h3>
<p>Cancer Genome Atlas Research Network. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25079317">Comprehensive molecular characterization of gastric adenocarcinoma</a>. <em>Nature</em> 2014.</p>
<p>Murphy G, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19445939">Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location</a>. <em>Gastroenterology</em> 2009.</p>
<p>Camargo MC, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21654677">Determinants of Epstein-Barr virus-positive gastric cancer: An international pooled analysis</a>. <em>Br J Cancer</em> 2011.</p>
<p>Camargo MC, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23580779">Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis</a>. <em>Gut</em> 2014; Epub 2013.</p>
<p>Camargo MC, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23904115">Case-case comparison of smoking and alcohol risk associations with Epstein-Barr virus-positive gastric cancer</a>. <em>Int J Cancer</em> 2014; Epub 2013.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349628" sys_dependentvariantid="1965" sys_relationshipid="7326030" sys_siteid="475" sys_variantid="1965">Charles Rabkin</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=157&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302548#Song" sys_contentid="302548#song" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302548" sys_dependentvariantid="1418" sys_relationshipid="7326031" sys_siteid="475" sys_variantid="1418">Minkyo Song</a>.</p>
</div>]]></content>
  </row>
  <row para_id="837951" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Breast cancer is known to vary significantly by race/ethnicity. While ER+ breast cancer is a signature disease in Western populations, breast cancer among Asians has been associated with an early age-onset, a higher proportion of ER&ndash; tumors, and a distinct shape of age-specific incidence rate patterns. In addition, Asian women also have a higher proportion of dense breast tissue.&nbsp;</p>
<p>DCEG investigators are conducting studies in several Asian populations, including mainland China, Hong Kong, and Malaysia. In these studies, breast tissues (frozen and/or formalin-fixed paraffin-embedded (FFPE) tissues) as well as information on risk factors, clinical data, breast density, blood or saliva for germline DNA, are being collected. The main goals of these studies are to identify distinct molecular alterations in tumors and adjacent normal tissues among Asian women and to examine the associations of these molecular changes with risk factors (genetic and environmental), breast tissue composition and density, and breast cancer subtypes.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349593" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275114" sys_dependentvariantid="1965" sys_dependentid="349593" rxinlineslot="103" sys_variantid="1965" sys_contentid="349593">Rose Yang</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="420600" rxinlineslot="103" sys_relationshipid="7275115" sys_variantid="1418" sys_contentid="420600">Integrative Tumor&nbsp;Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="838022" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Numerous epidemiological studies suggest that higher levels of physical activity may reduce breast cancer risk among postmenopausal women. Although the mechanisms that account for the protective effect of physical activity are not well understood, it has been hypothesized that physical activity may reduce levels of circulating sex steroid hormones. Investigators in DCEG are conducting a cross-sectional study of approximately 600 postmenopausal controls in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303566" sys_contentid="303566" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7278056" sys_dependentvariantid="1418" sys_dependentid="303566" rxinlineslot="103">Breast Cancer Case-Control Study in Poland</a> with the overall objective of assessing urinary estrogen metabolites in relation to accelerometer-based measures of active and sedentary behavior. In addition to the collection of questionnaire data and biological specimens, women from the Warsaw, Poland site were also asked to wear an accelerometer (Actigraph 7165) for seven days. A comprehensive urinary profile of endogenous estrogens, including 15 estrogens and estrogen metabolites, is being measured via the LC/MS2 assay. Findings from this study will extend our biological understanding of the effects of physical activity and sedentary time on estrogen metabolism.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" sys_relationshipid="7278055" sys_dependentvariantid="1965" sys_dependentid="349652" rxinlineslot="103">Gretchen Gierach</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_contentid="1033621" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7278057" sys_dependentvariantid="1418" sys_dependentid="1033621" rxinlineslot="103">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="840733" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Ghana Breast Health Study, a multidisciplinary case-control study of breast cancer, was launched in Ghana, West Africa, in 2013. The main aims of the study are to:</p>
<ul>
<li>Identify factors that predispose to the development of breast cancer among Ghanaian women;</li>
<li>Identify genetic and other biologic factors predictive of risk;</li>
<li>Assess how these risk factors vary by clinical and molecular characteristics of the tumors</li>
</ul>
<p>The study, which aims ultimately to recruit approximately 2,000 cases and 2,000 population controls, is being conducted in three hospitals in Ghana&mdash; Korle Bu Teaching Hospital in Accra; Komfo Anokye Teaching Hospital, and Peace and Love Hospital in Kumasi. Population controls are randomly selected from the same residential areas as cases are expected to derive. Exposure information is being obtained through detailed personal interviews and anthropometric measurements. Breast tissue samples are being collected prior to treatment and preserved to enable accurate immunohistochemical characterization of tumor subtypes. Blood, saliva and fecal samples are also being collected to enable assessment of genetic risk markers, microbiome characteristics, and other possible biomarkers.</p>
<p>The study began with a one-year pilot, following standardized training of study staff in January 2013. During this time, we achieved questionnaire response rates of 99% in cases and 80% in controls, along with collection of biologic samples from most of the women interviewed. This success supported extension of the study for an additional two years. Preliminary data show a relatively high prevalence of exposure to some novel risk factors (e.g., 25% of women report use of skin lighteners, some of which contain hormonal constituents). The study should provide a wealth of data to inform our knowledge of the epidemiology of breast cancer in African women.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" sys_dependentid="1004366" rxinlineslot="103" sys_relationshipid="7276167" sys_variantid="1965" sys_contentid="1004366">Montserrat Garc&iacute;a-Closas</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_dependentvariantid="1418" sys_dependentid="420600" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276168" sys_variantid="1418" sys_contentid="420600">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="841537" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15172852">Ovarian cancer risk after the use of ovulation-stimulating drugs</a>. <i>Obstet Gynecol</i> 2004;103:1194-203.</p><p>Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15302291">Ovarian cancer risk associated with varying causes of infertility.</a> <i>Fertil Steril</i> 2004;82:405-414.</p><p>Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Althuis MD, Mabie JE, Lamb EJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15217997">Breast cancer risk associated with ovulation-stimulating drugs</a>.&#160;<i>Hum Reprod</i> 2004;19:2005-2013 .</p><p>Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ.&#160; <a href="http://www.ncbi.nlm.nih.gov/pubmed/15705362">Ovulation induction and cancer risk</a> (Review).&#160; <i>Fertil Steril</i> 2005;83:261-274.</p><p>Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, Brinton LA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15781949">Uterine cancer after use of clomiphene citrate to induce ovulation</a>. <i>Am J Epidemiol</i> 2005;161:607-615.</p><p>Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Althuis MD, Mabie JE, Moghissi KS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15951668">Causes of infertility as predictors of subsequent cancer risk</a>. <i>Epidemiology</i> 2005;16:500-507.</p><p>Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16150258">Melanoma, thyroid, cervical and colon cancer risk after use of fertility drugs</a>. <i>Am J Obstet Gynecol</i> 2005;193:668-674.</p><p>Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19939368">Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome)</a>. <i>Fertil Steril</i> 2010;94:1787-93. PMCID: PMC2888728.</p><p>Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Trabert B, Niwa S, Moghissi KS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23943795">Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort</a>. <i>Hum Reprod</i> 2013;28:2813-2821. PMCID: PMC3777572.</p><p>Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA.&#160; <a href="http://www.ncbi.nlm.nih.gov/pubmed/24011610">Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort</a>. <i>Fertil Steril</i> 2013;100:1660-1666. PMCID: PMC3873340.</p><p>Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Trabert B, Lamb EJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24700523">Long-term relationship of ovulation-stimulating drugs to breast cancer risk</a>. <i>Cancer Epidemiol Biomarkers Prev</i> 2014;23:584-593. PMCID: PMC3979528.</p><p>Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, Vangen S, Brinton LA, Storeng R. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25042052">Risk of breast cancer following fertility treatment-A registry based cohort study of parous women in Norway</a>. <i>Int J Cancer</i> 2014 Jul 9; doi: 10.1002/ijc.29069. [Epub ahead of print]</p></div>]]></content>
  </row>
  <row para_id="842207" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL, Schiffman M. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22675168">Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population</a>. <i>Clin Cancer Res</i> 2012 Aug 1;18:4154-4162. doi: 10.1158/1078-0432.CCR-12-0270.</p>
<p>van der Marel J, Quint WG, Schiffman M, van de Sandt MM, Zuna RE, Dunn ST, Smith K, Mathews CA, Gold MA, Walker J, Wentzensen N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22419273">Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16</a>. <i>Int J Cancer</i> 2012 Sep 15;131:E946-953. doi: 10.1002/ijc.27532.</p>
<p>Luhn P, Houldsworth J, Cahill L, Schiffman M, Castle PE, Zuna RE, Dunn ST, Gold MA, Walker J, Wentzensen N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23769811">Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results</a>. <i>Gynecol Oncol</i> 2013 Sep;130:595-600. doi: 10.1016/j.ygyno.2013.06.005.</p>
<p>Sahasrabuddhe VV, Gravitt PE, Dunn ST, Brown D, Allen RA, Eby YJ, Smith K, Zuna RE, Zhang RR, Gold MA, Schiffman M, Walker JL, Castle PE, Wentzensen N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24197879">Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic</a>. <i>J Clin Microbiol</i> 2014 Jan;52:187-192. doi: 10.1128/JCM.01623-13.</p>
<p>Sahasrabuddhe VV, Gravitt PE, Dunn ST, Robbins D, Brown D, Allen RA, Eby YJ, Smith KM, Zuna RE, Zhang RR, Gold MA, Schiffman M, Walker JL, Castle PE, Wentzensen N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24881489">Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic</a>. J Clin Virol 2014 Aug;60:414-417. doi: 10.1016/j.jcv.2014.04.016.</p>
</div>]]></content>
  </row>
  <row para_id="842493" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, Schiffman M, Wacholder S, Allen RA, Block I, Downing K, Jeronimo J, Carreon JD, Safaeian M, Brown D, Walker JL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19124488">Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants</a>. <i>Cancer Epidemiol Biomarkers Prev</i> 2009 Jan;18:113-120. doi: 10.1158/1055-9965.EPI-08-0591.</p>
<p>Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, Zhang R, Sherman ME, Wacholder S, Jeronimo J, Gold MA, Wang SS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19030188">Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma</a>. <i>Int J Cancer</i> 2009 Feb 15;124:964-969. doi: 10.1002/ijc.23969.</p>
<p>Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, Zhang R, Sherman ME, Wacholder S, Walker J, Wang SS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19585494">Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.</a> <i>Int J Cancer</i> 2009 Nov 1;125:2151-2158. doi: 10.1002/ijc.24528.&nbsp;</p>
<p>Wentzensen N, Zuna RE, Sherman ME, Gold MA, Schiffman M, Dunn ST, Jeronimo J, Zhang R, Walker J, Wang SS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19773045">Accuracy of cervical specimens obtained for biomarker studies in women with CIN3</a>. <i>Gynecol Oncol</i> 2009 Dec;115:493-496. doi: 10.1016/j.ygyno.2009.09.001.</p>
<p>Yang HP, Zuna RE, Schiffman M, Walker JL, Sherman ME, Landrum LM, Moxley K, Gold MA, Dunn ST, Allen RA, Zhang R, Long R, Wang SS, Wentzensen N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22253702">Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3</a>. <i>PLoS One</i> 2012;7:e29051. doi: 10.1371/journal.pone.0029051.&nbsp;</p>
<p>Wentzensen N, Gravitt PE, Long R, Schiffman M, Dunn ST, Carreon JD, Allen RA, Gunja M, Zuna RE, Sherman ME, Gold MA, Walker JL, Wang SS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22337992">Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens</a>. <i>J Clin Microbiol</i> 2012 May;50:1564-1570. doi: 10.1128/JCM.06240-11.</p>
<p>Wentzensen N, Walker J, Schiffman M, Yang HP, Zuna RE, Dunn ST, Allen RA, Zhang R, Sherman M, Gold MA, Wang SS. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22488167">Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management</a>. <i>Int J Cancer</i> 2013 Jan 1;132:148-154. doi: 10.1002/ijc.27577.</p>
<p>Koshiol J, Dunn ST, Walker JL, Zuna RE, Schiffman M, Sherman ME, Gold MA, Allen RA, Zhang R, Wang SS, Wentzensen N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23196360">Reproducibility of linear array for human papillomavirus genotyping.</a> <i>J Clin Microbiol</i> 2013 Feb;51:625-628. doi: 10.1128/JCM.03036-12.</p>
<p>Koshiol J, Sklavos M, Wentzensen N, Kemp T, Schiffman M, Dunn ST, Wang SS, Walker JL, Safaeian M, Zuna RE, Hildesheim A, Pfeiffer RM, Pinto LA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23824624">Evaluation of a multiplex panel of immune-related markers in cervical secretions: A methodologic study</a>. <i>Int J Cancer</i> 2014 Jan 15;134:411-425. doi: 10.1002/ijc.28354.</p>
</div>]]></content>
  </row>
  <row para_id="843812" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Linkage studies and candidate locus studies have had limited success in identifying genetic susceptibility genes for testicular germ cell tumors (TGCT).&nbsp;Genome-wide association studies (GWAS), however, have identified a number of important loci, the one with the highest hazard ratio being <i>KITLG</i>, which confers a risk &nbsp;greater than three-fold over background.&nbsp;GWAS have now been completed in a number of populations and investigators have come together to pool their data to study TGCT as a consortium. Study results are being combined to develop better estimates of risk for each genetic variant. In addition, stratified analyses are examining whether risk of each variant varies by other factors such as histology of the TGCT, history of cryptorchidism, and family history of TGCT.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349637" sys_dependentvariantid="1965" sys_relationshipid="7277851" sys_siteid="475" sys_variantid="1965" sys_contentid="349637">Katherine McGlynn</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277852" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="844039" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Wentzensen N, Bakkum-Gamez JN, Killian JK, Sampson J, Guido R, Glass A, Adams L, Luhn P, Brinton LA, Rush B, d'Ambrosio L, Gunja M, Yang HP, Garcia-Closas M, Lacey JV Jr, Lissowska J, Podratz K, Meltzer P, Shridhar V, Sherman ME. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24623538">Discovery and validation of methylation markers for endometrial cancer</a>. <i>Int J Cancer</i> 2014 Oct 15;135:1860-1868. doi: 10.1002/ijc.28843.Epub ahead of print.</p>
<p>De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N; Australian National Endometrial Cancer Study Group, Attia J, Black A, Brinton L, Chen C, Chen C, Cook LS, Crous-Bou M, Doherty J, Dunning AM, Easton DF, Friedenreich CM, Garcia-Closas M, Gaudet MM, Haiman C, Hankinson SE, Hartge P, Henderson BE, Holliday E, Horn-Ross PL, Hunter DJ, Le Marchand L, Liang X, Lissowska J, Long J, Lu L, Magliocco AM, McEvoy M, O'Mara TA, Orlow I, Painter JN, Pooler L, Rastogi R, Rebbeck TR, Risch H, Sacerdote C, Schumacher F, Scott RJ, Sheng X, Shu XO, Spurdle AB, Thompson D, Vanden Berg D, Weiss NS, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Chanock S, Kraft P. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24096698">Genome-wide association study of endometrial cancer in <i>E2C2</i></a>. <i>Hum Genet</i> 2014 Feb;133:211-224. doi: 10.1007/s00439-013-1369-1. Epub ahead of print.</p>
<p>Sieh W, K&ouml;bel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, H&oslash;gdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kj&aelig;r SK, Jensen A, H&oslash;gdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garc&iacute;a-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23845225">Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study</a>. <i>Lancet Oncol</i> 2013 Aug;14:853-862. doi: 10.1016/S1470-2045(13)70253-5.</p>
<p>Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ; Australian National Endometrial Cancer Study Group, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, H&aring;kansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23733771">Type I and II endometrial cancers: have they different risk factors?</a> <i>J Clin Oncol</i> 2013 Jul 10;31:2607-2618. doi: 10.1200/JCO.2012.48.2596. Epub ahead of print.</p>
<p>Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E; Australian Cancer Study; Australian Ovarian Cancer Study Group, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, D&ouml;rk T, du Bois A, D&uuml;rst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, H&oslash;gdall E, H&oslash;gdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubiński J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23535730">GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer</a>. <i>Nat Genet</i> 2013 Apr;45:362-370, 370e1-2. doi: 10.1038/ng.2564.</p>
<p>Pearce CL, Rossing MA, Lee AW, Ness RB, Webb PM; for Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Chenevix-Trench G, Jordan SM, Stram DA, Chang-Claude J, Hein R, Nickels S, Lurie G, Thompson PJ, Carney ME, Goodman MT, Moysich K, Hogdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Vierkant RA, Weber RP, Ziogas A, Anton-Culver H, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Brinton L, Wentzensen N, Lissowska J, Garcia-Closas M, Massuger LF, Kiemeney LA, Van Altena AM, Aben KK, Berchuck A, Doherty JA, Iversen E, McGuire V, Moorman PG, Pharoah P, Pike MC, Risch H, Sieh W, Stram DO, Terry KL, Whittemore A, Wu AH, Schildkraut JM, Kjaer SK; Ovarian Cancer Association Consortium. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23462924">Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer</a>. <i>Cancer Epidemiol Biomarkers Prev</i> 2013 May;22:880-890. doi: 10.1158/1055-9965.EPI-12-1030-T. Epub ahead of print.</p>
<p>Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW, Wise LA, Anderson KE, Bernstein L, De Vivo I, Friedenreich CM, Gapstur SM, Goldbohm RA, Henderson B, Horn-Ross PL, Kolonel L, Lacey JV, Liang X, Lissowska J, Magliocco A, McCullough ML, Miller AB, Olson SH, Palmer JR, Park Y, Patel AV, Prescott J, Rastogi R, Robien K, Rosenberg L, Schairer C, Ou Shu X, van den Brandt PA, Virkus RA, Wentzensen N, Xiang YB, Xu WH, Yang HP, Brinton LA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23348519">The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium</a>. <i>Br J Cancer</i> 2013 Feb 19;108:727-734. doi: 10.1038/bjc.2013.2. Epub 2013 Jan 24.</p>
<p>Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, D&ouml;rk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC; Wellcome Trust Case-Control Consortium, Beesley J, Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, D&uuml;rst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD; Ovarian Cancer Association Consortium (OCAC). <a href="http://www.ncbi.nlm.nih.gov/pubmed/20852632">A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24</a>. <i>Nat Genet</i> 2010 Oct;42:874-879. doi: 10.1038/ng.668. Epub ahead of print.</p>
</div>]]></content>
  </row>
  <row para_id="844106" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>Cook MB, Wang Z,Yeboah ED, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24185611">A genome-wide association study of prostate cancer in West African men</a>. <em>Hum Genet</em> 2014 May;133:509-521</p><p>Chung CC, Hsing AW, Edward Yeboah, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24783269">A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry</a>. <em>Prostate</em> 2014 May;74:579-589.</p><p>Wang Z, Zhu B, Zhang M, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25027329">Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the <em>TERT-CLPTM1L</em> region on chromosome 5p15.33.</a> <em>Hum Mol Genet</em> 2014 Jul 15. pii: ddu363. [Epub ahead of print]</p><p>Al Olama AA, Kote-Jarai Z, Berndt SI, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25217961">A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.</a> <em>Nat Genet</em> 2014 Oct;46:1103-1109. doi: 10.1038/ng.3094. Epub ahead of print.</p><p>Hsing AW, Yeboah E, Biritwum R, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24747091">High prevalence of screen detected prostate cancer in west africans: implications for racial disparity of prostate cancer</a>. <em>J Urol</em> 2014 Sep;192:730-736. doi: 10.1016/j.juro.2014.04.017.</p><p>Chokkalingam AP, Yeboah ED, Demarzo A, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21912428">Prevalence of BPH and lower urinary tract symptoms in West Africans</a>. <em>Prostate Cancer Prostatic Dis</em>. 2012 Jun;15:170-176. doi: 10.1038/pcan.2011.43.</p></div>]]></content>
  </row>
  <row para_id="848053" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><p>Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, Gierach GL. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23607871">Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study</a>. <i>Breast Cancer Res</i> 2013 Apr 22;15:R34. doi: 10.1186/bcr3416.</p><p>Gaudet MM, Falk RT, Gierach GL, Lacey JV Jr, Graubard BI, Dorgan JF, Brinton LA. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20579950">Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?</a> <i>Cancer Epidemiol</i> 2010 Oct;34:580-6. doi: 10.1016/j.canep.2010.05.014.</p></div>]]></content>
  </row>
  <row para_id="856668" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Description</h2>
<p>Age&ndash;period&ndash;cohort (APC) analysis can inform registry-based studies of cancer incidence and mortality, but concerns about statistical identifiability and interpretability, as well as the learning curves of statistical software packages, have limited its uptake. This tool contains a panel of easy-to-interpret estimable APC functions and corresponding Wald tests in R code that can be accessed through a user-friendly Web tool.</p>
<ul>
<li><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=856669" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="6713354" sys_dependentvariantid="1418" sys_dependentid="856669" rxinlineslot="103">License Agreement</a></li>
</ul>
<h2>Details</h2>
<p>Input data for the Web tool consist of age-specific numbers of events and person-years over time, in the form of a rate matrix of paired columns. Output functions include model-based estimators of cross-sectional and longitudinal age-specific rates, period and cohort rate ratios that incorporate the overall annual percentage change (net drift), and estimators of the age-specific annual percentage change (local drifts). The Web tool includes built-in examples for teaching and demonstration. User data can be input from a Microsoft Excel worksheet or by uploading a comma-separated&ndash;value file. Model outputs can be saved in a variety of formats, including R and Excel.</p>
<h2>Website</h2>
<ul>
<li><a href="http://analysistools.nci.nih.gov/apc/">Age Period Cohort Analysis Web Tool</a></li>
<li><a href="http://analysistools.nci.nih.gov/apc/help.html">Manual</a></li>
</ul>
<h3>Support</h3>
<p>Email: <a href="mailto:NCIAPCWebToolAdmin@mail.nih.gov">NCI APCWebToolAdmin</a></p>
<h3>Reference(s)</h3>
<ul>
<li>Rosenberg, PS, Check DP, Anderson WF <a href="http://www.ncbi.nlm.nih.gov/pubmed/25146089">A web tool for age-period-cohort analysis of cancer incidence and mortality rates.</a> <i>Cancer Epid Biomark Prev</i> 2014; 23:2296-302</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="856669" langcode="en">
    <content><![CDATA[<div class="rxbodyfield" xmlns:o="urn:www.microsoft.com/office" xmlns:st1="urn:www.microsoft.com/smarttags" xmlns:st2="urn:www.microsoft.com/smarttags2" xmlns:w="urn:www.microsoft.com/word" xmlns:x="urn:www.microsoft.com/excel"><h3>APC Analysis Webtool</h3><p><strong>Non-Proprietary Software Transfer Agreement</strong></p><p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter &quot;NCI&quot;)</p><p>By accepting Software, Recipient agrees to the terms of this Agreement.</p><p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p><p>The APC Analysis Webtool may be updated periodically as new data or research becomes available.</p><p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p><p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p></div>]]></content>
  </row>
  <row para_id="859565" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>To further scientific collaborations and share technical expertise and resources, DCEG regularly hosts scientists from around the world on short or longer-term sabbaticals. These guest researchers study an array of topics, lending their unique perspectives to collaborative efforts with DCEG investigators.</p>
<h3>Caroline Besson-Maury, M.D., Ph.D.</h3>
<div sys_dependentvariantid="2088" sys_dependentid="859569" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="6981428">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=301955&amp;sys_siteid=475&amp;sys_contentid=859569&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Caroline Besson-Maury</p>
</div>
</figcaption>
</figure>
</div>
<p>Dr. Caroline Besson-Maury joined the Infections and Immunoepidemiology Branch in September 2014 as a guest researcher. &nbsp;She is a graduate of both the Paris V University School of Medicine (M.D.) and the Paris XI University School of Public Health (Ph.D. in Epidemiology). &nbsp;She trained in clinical hematology and is currently an associate professor at Bic&ecirc;tre University Hospital in Le Kremlin-Bic&ecirc;tre, France. &nbsp;Dr. Besson-Maury&rsquo;s research focuses on the association between lymphomas and chronic viral infections. She coordinates the French national cohorts on HIV- related lymphomas (ANRS CO 16 Lymphovir cohort) and hepatitis C virus-related lymphomas (ANRC HC 13 Lympho-C study). She also works on the genetics of Epstein-Barr virus-associated Hodgkin lymphoma.&nbsp;</p>
<p>Dr. Besson-Maury has been awarded a Monahan Scholarship through the Franco-American Fulbright Commission to spend a sabbatical year at DCEG. &nbsp;She will be working initially with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349628" sys_variantid="1965" sys_relationshipid="6981424">Charles Rabkin, M.D.</a>, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349684" sys_contentid="349684" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349684" sys_variantid="1965" sys_relationshipid="6981425">Sonja Berndt, Pharm.D., Ph.D.</a>, on lymphomagenic infections, particularly HIV, Epstein-Barr virus and hepatitis C virus.&nbsp;Dr. Besson-Maury can be reached by email at <a href="mailto:caroline.besson@nih.gov">caroline.besson@nih.gov</a>.</p>
</div>]]></content>
  </row>
  <row para_id="884839" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>In May 2014, NCI&rsquo;s Division of Cancer Epidemiology and Genetics (DCEG) hosted Cancer Epidemiology: From Pedigrees to Populations, a scientific symposium honoring 50 years of visionary leadership by Dr. Joseph F. Fraumeni, Jr., the founding Director of DCEG. The conference provided an opportunity for scientific exchange by the leading experts in cancer epidemiology. Speakers highlighted critical findings made over the past 50 years, as well as opportunities for future research that have the potential to significantly advance our understanding of the causes of cancer.&nbsp;</p>
<div sys_dependentvariantid="2084" sys_dependentid="768399" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7263201">
<figure class="image-center-full centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=642848&amp;sys_siteid=475&amp;sys_contentid=768399&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<h2>Speaker Presentations (Video)</h2>
<h3>WELCOME</h3>
<p>Stephen J. Chanock, M.D., <i>Director, DCEG, National Cancer Institute</i></p>
<h3>SESSION I: "Search for cancer susceptibility genes"</h3>
<p>Moderator: David Schottenfeld, M.D., <i>University of Michigan</i></p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886703" sys_contentid="886703" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886703" sys_variantid="1410" sys_relationshipid="7263184">"Li-Fraumeni syndrome: Discovery and future challenges"</a><br />Louise C. Strong, M.D., <i>University of Texas MD Anderson Cancer Center</i></li>
<li style="list-style: none;"></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886754" sys_contentid="886754" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886754" sys_variantid="1410" sys_relationshipid="7263185">"Li-Fraumeni syndrome: TP53 and beyond"</a><br />David Malkin, M.D., <i>The Hospital for Sick Children</i></li>
<li style="list-style: none;"></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886761" sys_contentid="886761" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886761" sys_variantid="1410" sys_relationshipid="7263186">"Family studies, cancer etiology, and telomere biology"</a><br />Sharon A. Savage, M.D., <i>National Cancer Institute</i></li>
<li style="list-style: none;"></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886763" sys_contentid="886763" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886763" sys_variantid="1410" sys_relationshipid="7263187">"A tale of two genomes: Current generation approaches to cancer susceptibility"</a><br />Kenneth Offit, M.D., M.P.H., <i>Memorial Sloan Kettering Cancer Center</i></li>
</ul>
<h3>SESSION II: "High-risk populations and insights into carcinogenic mechanisms"</h3>
<p>Moderator: Margaret R. Spitz, M.D., M.P.H., <i>Baylor College of Medicine</i></p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886768" sys_contentid="886768" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886768" sys_variantid="1410" sys_relationshipid="7263188">"Transplant-associated immunosuppression and cancer"</a><br />Eric A. Engels, M.D., M.P.H., <i>National Cancer Institute</i></li>
<li style="list-style: none;"></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886770" sys_contentid="886770" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886770" sys_variantid="1410" sys_relationshipid="7263189">"Hormonal carcinogenesis across the life course"</a><br />Robert N. Hoover, M.D., Sc.D., <i>National Cancer Institute</i></li>
</ul>
<h3>SESSION III: "Global health: Opportunities for epidemiologic research"</h3>
<p>Moderator: Brian E. Henderson, M.D., <i>University of Southern California</i></p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886773" sys_contentid="886773" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886773" sys_variantid="1410" sys_relationshipid="7263190">"Using geographic patterns to discover environmental carcinogens"</a><br />William J. Blot, Ph.D., <i>International Epidemiology Institute &amp; Vanderbilt University</i></li>
<li style="list-style: none;"></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886776" sys_contentid="886776" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886776" sys_variantid="1410" sys_relationshipid="7263191">"Lung cancer and indoor air pollution in China"</a><br />Nathaniel Rothman, M.D., M.P.H., M.H.S., <i>National Cancer Institute</i></li>
<li style="list-style: none;"></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886777" sys_contentid="886777" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886777" sys_variantid="1410" sys_relationshipid="7263192">"Polycyclic hydrocarbons: A unifying hypothesis for global patterns of esophageal cancer?"</a><br />Christian C. Abnet, Ph.D., M.P.H., <i>National Cancer Institute</i></li>
</ul>
<h3>CLOSING SESSION</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886778" sys_contentid="886778" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886778" sys_variantid="1410" sys_relationshipid="7263193">Michael Thun, M.D., M.S., <i>American Cancer Society</i></a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886779" sys_contentid="886779" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886779" sys_variantid="1410" sys_relationshipid="7263194">Michael M. Gottesman, M.D., <i>National Institutes of Health</i></a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886780" sys_contentid="886780" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886780" sys_variantid="1410" sys_relationshipid="7263195">Harold E. Varmus, M.D., <i>National Cancer Institute</i></a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=886781" sys_contentid="886781" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="886781" sys_variantid="1410" sys_relationshipid="7263196">Joseph F. Fraumeni, Jr., M.D., <i>National Cancer Institute</i></a></li>
</ul>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=789450" sys_contentid="789450" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="789450" sys_variantid="1418" sys_relationshipid="7263197">Learn more details about this symposium</a></p>
</div>]]></content>
  </row>
  <row para_id="906271" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<p><em>On this page</em>:</p>
<p><a href="#Machiela">Genetic Epidemiology of Cancer - Postdoctoral Fellowship</a><br /><a href="#Landi">Studies of Lung Cancer, Melanoma, and Kidney Cancer using Genomic Data - Postdoctoral Fellowship</a><br /><a href="#Yang">Integratin Genomic and Epidemiological Data to Understand Breast Cancer Etiology - Postdoctoral Fellowship </a></p>
<h3><a id="Machiela"></a>Genetic Epidemiology of Cancer - Postdoctoral Fellowship</h3>
<p>Dr. Mitchell Machiela, an investigator in the DCEG <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7389560" sys_siteid="475" rxinlineslot="103" sys_dependentid="302506" sys_dependentvariantid="1422">Integrative Tumor Epidemiology Branch</a>, is seeking a postdoctoral fellow with interest in conducting integrative analyses on the genetic etiology of cancer. Genetic epidemiology has remarkable potential to improve understanding of cancer etiology by identifying germline genetic variation and acquired somatic mutations associated with cancer risk. Specific areas of Dr. Machiela's research include:</p>
<ol>
<li>Next-generation sequencing studies to identify acquired mutations that could impact cancer risk in special exposure populations (e.g., drug and radiation exposure);</li>
<li>Studies characterizing the distribution and determinants of structural mosaic copy number changes in large cancer case/control and cohort studies (~200,000 participants) with existing array genotyping data; and</li>
<li>Genome-wide association studies (GWAS) in pediatric cancers to identify and functionally map germline variants associated with increased risk (e.g., Ewing sarcoma).</li>
</ol>
<p>All studies of the genetic etiology of cancer are population-based with extensive data on exposures, genetic variation and phenotypic characterization.</p>
<p><strong>Goals</strong>: The potential candidate will be part of an interdisciplinary team of genetic, bioinformatic and laboratory investigators. The NCI&rsquo;s Division of Cancer Epidemiology (DCEG) has a long tradition of carrying out large-scale, state-of-the-art population studies and has excellent computing resources for next-generation sequencing and genetic epidemiologic analyses. In addition, DCEG offers extensive career development training through its <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389557" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Office of Education</a>.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree in genetic epidemiology, genetics/genomics, statistical genetics or related field, are encouraged to apply. Experience in analyses of large complex genomic datasets, next-generation sequencing, GWAS, and/or bioinformatic methods is a plus. A successful candidate will have excellent written and verbal communication skills, be self-motivated and able to work in a multidisciplinary team. Salary and benefits are highly competitive and commensurate with experience.</p>
<p>For more information about this position, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1088176" sys_contentid="1088176" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389558" sys_siteid="475" rxinlineslot="103" sys_dependentid="1088176" sys_dependentvariantid="1965">Mitchell Machiela, Sc.D., M.P.H.</a>, Earl Stadtman Investigator.</p>
<p><strong>To Apply</strong>: See the <a href="/Rhythmyx/assembler/render?sys_contentid=302629&amp;sys_revision=65&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7389737">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Landi"></a>Studies of Lung Cancer, Melanoma, and Kidney Cancer using Genomic Data - Postdoctoral Fellowship</h3>
<p>We use genome-wide association studies (GWAS), next-generation sequencing analysis, and genome-wide methylation analysis to study risk and progression of lung cancer, melanoma, and kidney cancer. Specific goals of our research include:</p>
<ol>
<li>Identifying molecular signatures associated with environmental exposures and clinical outcomes;</li>
<li>Identifying intra-tumor genetic and epigenetic heterogeneity and tumor evolution;</li>
<li>Characterizing the molecular steps that lead from precursor to malignant disease;</li>
<li>Identifying rare genetic variants associated with risk of familial melanoma.</li>
</ol>
<p>All studies are large and population-based. We have strong collaborating biostatistics and laboratory teams, and have excellent computing resources for next-generation sequencing and genetic epidemiologic analyses.</p>
<p>DCEG fellows have access to data from state-of-the-art studies in cancer genomics and work with highly committed and talented researchers with expertise in epidemiology, biostatistics, and genomics. DCEG offers extensive career development training through its Office of Education.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree or background in genetics/genomics, genetic epidemiology, or related field, are encouraged to apply. Experience in analyses of large complex genomic datasets, next-generation sequencing, GWAS, and/or bioinformatics methods is a plus. A successful candidate will have excellent communication skills, be highly motivated and able to work in a large multidisciplinary team. Salary and benefits are highly competitive and commensurate with experience.</p>
<p>For more information contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" sys_contentid="349623" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389552" sys_siteid="475" rxinlineslot="103" sys_dependentid="349623" sys_dependentvariantid="1965">Maria Teresa Landi, M.D., Ph.D</a>.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389553" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Yang"></a>Integrating Genomic and Epidemiological Data to Understand Breast Cancer Etiology - Postdoctoral Fellowship</h3>
<p>The Integrative Tumor Epidemiology Branch is seeking a postdoctoral fellow with an interest in integrating genomic (next-generation sequencing, SNP array, RNASeq, methylation), pathology, morphology, and imaging data (mammographic density) into epidemiologic studies of breast cancer for a better understanding of etiologic and racial heterogeneity. The potential fellow will have the opportunity of working closely with researchers with expertise in epidemiology, biostatistics, bioinformatics, and genetics, and will have extensive career development training opportunities through the DCEG Office of Education.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree in epidemiology, genetics/genomics, or related field are encouraged to apply. Experience in analyses of breast cancer and genomic sequence/array data is a plus.</p>
<p>For more information, please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349593" sys_contentid="349593" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7389555" sys_siteid="475" rxinlineslot="103" sys_dependentid="349593" sys_dependentvariantid="1965">Rose Yang, Ph.D., M.P.H</a>.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389556" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#Top">Back to top</a></p>
<p>Back to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=46&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302414" sys_contentid="302414" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7389554" sys_siteid="475" rxinlineslot="103" sys_dependentid="302414" sys_dependentvariantid="1418">Research Training Opportunities in&nbsp;Integrative Tumor&nbsp;Epidemiology</a></p>
<p style="text-align: center;">DHHS and NIH are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="912901" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2084" sys_dependentid="918952" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7083726">
<figure class="image-center-full centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=918952&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<h3>Welcome, thank you for your interest in this study!</h3>
<p>To <b>START ENROLLMENT</b>, please click on the red box.<a class="no-exit-notification" href="https://www.dod-nci-tricare-feasibilitystudy.org/" target="_blank" rel="noopener noreferrer"><img class="right" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=976393" inlinetype="rximage" sys_siteid="475" sys_dependentvariantid="1482" rxinlineslot="104" sys_dependentid="976393" sys_folderid="" sys_relationshipid="5750908" /></a></p>
<p>If you have trouble with this link, try copying this URL into the address line<br /> of your web browser: <a href="https://www.dod-nci-tricare-feasibilitystudy.org/">https://www.dod-nci-tricare-feasibilitystudy.org/</a></p>
<h4>Questions? Contact us for more information:</h4>
<p>E-mail: <a href="mailto:TRICARE@s-3.com">TRICARE@s-3.com</a><br /> Phone: 1-866-948-1129 (weekdays, 8am - 5pm)</p>
<h4>Who is doing this study?</h4>
<div sys_dependentvariantid="2066" sys_dependentid="918971" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7083727">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=918971&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Researchers from the Walter Reed National Military Medical Center and the National Cancer Institute are working together on the DoD-NCI TRICARE Feasibility Study. This study will help us determine if it is possible to conduct a much larger study.</p>
<h4>Military Investigator</h4>
<p>Colonel Craig Shriver, M.D.<br /> Director, John P. Murtha Cancer Center<br /> Walter Reed National Military Medical Center</p>
</div>]]></content>
  </row>
  <row para_id="923735" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Description</h3>
<p>Exploring linkage disequilibrium (LD) across ancestral populations is a powerful approach for investigating population-specific genetic structure as well as functionally mapping regions of disease susceptibility.&nbsp;<a href="https://ldlink.nci.nih.gov/">LDlink</a>&nbsp;is a suite of web-based applications to easily and efficiently interrogate linkage disequilibrium in population groups, with&nbsp;query flexibility and interactive visualization of results. Haplotype tables and interactive plots generated by LDlink are tailored for investigators interested in mapping common and uncommon disease susceptibility loci with a focus on linking correlated alleles and highlighting potentially functional variants.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=923749" sys_dependentvariantid="1418" sys_dependentid="923749" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7344289" sys_variantid="1418" sys_contentid="923749">License Agreement</a></li>
</ul>
<h3>Details</h3>
<p>All population genotype data for LDlink and its modules originates from Phase 3 of the 1000 Genomes Project. The genotyped set is complete with all individuals having called genotypes at every included locus. Ancestral super-populations include African, Ad-mixed American, East Asian, European, and South Asian. LDlink is flexible to allow for any combination of 1000 Genomes Project super or sub-populations as input. For query input, LDlink uses dbSNP build 142 to reference SNP (RS) numbers and extract genomic coordinates. The current implementation of LDlink only accepts bi-allelic SNPs as input.</p>
<h3>Website</h3>
<ul>
<li><a href="https://ldlink.nci.nih.gov/">LDlink</a></li>
<li><a href="https://ldlink.nci.nih.gov/">Manual</a> - see Help tab on LDlink website</li>
</ul>
<h3>Support</h3>
<p>E-mail: <a href="mailto:NCILDlinkWebAdmin@mail.nih.gov">NCILDlinkWebAdmin@mail.nih.gov</a></p>
<h3>Reference</h3>
<p>Machiela MJ, Chanock SJ. LDlink: <a href="https://www.ncbi.nlm.nih.gov/pubmed/26139635">A web-based application for exploring population-specific haplotype structure and linking correlated alleles of potentially functional variants</a>. <em>Bioinformatics</em> 2015. DOI: 10.1093/bioinformatics/btv402.</p>
</div>]]></content>
  </row>
  <row para_id="923749" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>

<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>

<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>

<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>

<p>LDlink may be updated periodically as new data or research becomes available.</p>

<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>

<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="936063" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Description</h2>
<p>MEGSA: A powerful and flexible framework for analyzing mutual exclusivity of tumor mutations.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=936057" sys_dependentvariantid="1500" sys_dependentid="936057" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7279377" sys_variantid="1500" sys_contentid="936057"> MEGSA_beta.zip</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="937894" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p></p>
<div class="callout-box right">
<h3>Radiation Epidemiology Course Registration</h3>
<p><a id="top"></a>The next <strong>Radiation Epidemiology &amp; Dosimetry Course</strong> will be held September 9-12, 2019, at NCI Shady Grove, Rockville, Maryland.&nbsp;<a href="https://events.cancer.gov/2019RADEPI">Register for the Radiation Epidemiology &amp; Dosimetry Course</a>.</p>
</div>
<p>The Radiation Epidemiology and Dosimetry Course is conducted periodically by the Radiation Epidemiology Branch of the NCI Division of Cancer Epidemiology and Genetics (DCEG). The course is intended for people who are interested in learning about the health effects of radiation exposure. The course begins with the fundamentals and progresses to topical sessions which provide an overview of the methods and key findings from studies of medical, occupational, and environmental radiation exposures.</p>
<p>The course was designed assuming participants will have some familiarity with basic epidemiologic concepts, terminology and methods of data analysis; however, most of the material will be understandable for people with college-level training in basic biology, chemistry and physics.</p>
<h2>Course Format</h2>
<ul>
<li>Large-group (~200 people) lectures</li>
<li>Informal lunchtime and evening gatherings support discussion and networking</li>
<li>Registration is free but required due to space limitations</li>
<li>Participants can register for the full course or selected days</li>
</ul>
<h2>Course Overview</h2>
<div style="width: 100%; overflow: auto;">
<div style="float: left; width: 45%; padding-right: 5%;">
<h4>Monday, Sep. 9, 2019</h4>
<ul>
<li>Fundamentals of radiation epidemiology, dosimetry, risk modeling, and the statistical software package <em>EPICURE</em></li>
</ul>
<h4>Wednesday, Sep. 11, 2019</h4>
<ul>
<li>Medical radiation exposure &ndash; therapeutic&nbsp;</li>
<li>Occupational radiation exposure</li>
</ul>
</div>
<div style="float: left; width: 45%; padding-right: 5%;">
<h4>Tuesday, Sep. 10, 2019</h4>
<ul>
<li>Overview of radiation health effects (cancer/non-cancer), exposure assessment, and radiobiology</li>
<li>Medical radiation exposure &ndash; diagnostic</li>
</ul>
<h4>Thursday, Sep. 12, 2019</h4>
<ul>
<li>Environmental radiation exposure</li>
<li>Genetic susceptibility to radiation health effects</li>
<li>Non-ionizing radiation exposure</li>
</ul>
</div>
</div>
<h2>Agenda</h2>
<p>View the latest <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1138877" sys_contentid="1138877" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7281920" sys_siteid="475" rxinlineslot="103" sys_dependentid="1138877" sys_dependentvariantid="1500">agenda for the 2019 Radiation Epidemiology &amp; Dosimetry Course (pdf, 247 KB)</a></p>
<p><a href="#top">Back to top</a></p>
<h2><a id="Videos-2015"></a>Presentation Videos from the 2015 Radiation Epidemiology &amp; Dosimetry Course</h2>
<p>Click on the presentation titles below to view available course presentations and download slides. (Please note that a few presentations were not made available - some at the speakers&rsquo; requests, others due to technical difficulties). <em>Note: Presentation videos from the 2019 course will be made available after the course</em>.</p>
<div style="width: 100%; overflow: auto;">
<div style="float: left; width: 45%; padding-right: 5%;">
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1036756" sys_contentid="1036756" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7281915" sys_siteid="475" rxinlineslot="103" sys_dependentid="1036756" sys_dependentvariantid="1500">Genetic and Genomics Laboratory Tools and Approaches (slides only - pdf, 4.4 MB)</a> <br /> Meredith Yeager, Ph.D.<br /> <em>National Cancer Institute</em></p>
<p>Introduction to R<br /> Joshua Sampson, Ph.D.<br /> <em>National Cancer Institute</em></p>
<p>Risk Assessment in Radiation Epidemiology I<br /> Risk Assessment in Radiation Epidemiology 2<br /> Mark Little, Ph.D.<br /> <em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1036757" sys_contentid="1036757" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7281918" sys_siteid="475" rxinlineslot="103" sys_dependentid="1036757" sys_dependentvariantid="1500">Dosimetry Tools for Medical Radiation Studies (slides only - pdf, 10.5 MB)</a><br /> Choonsik Lee, Ph.D.<br /> <em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034886" sys_contentid="1034886" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281890" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034886" sys_dependentvariantid="1410">Introduction to Epidemiology Concepts, Study Design and Radiation Epidemiology</a><br />Martha Linet, M.D., M.P.H.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034954" sys_contentid="1034954" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281891" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034954" sys_dependentvariantid="1410">Radiation Risk Modeling</a> <br /> Ethel Gilbert, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034963" sys_contentid="1034963" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281892" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034963" sys_dependentvariantid="1410">Principles of Radiation Physics &amp; Dosimetry I</a> <br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034969" sys_contentid="1034969" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281893" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034969" sys_dependentvariantid="1410">Principles of Radiation Physics &amp; Dosimetry II</a> <br /> Steven Simon, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034972" sys_contentid="1034972" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281894" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034972" sys_dependentvariantid="1410">Radiation Studies &amp; Concepts I</a> <br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034973" sys_contentid="1034973" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281895" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034973" sys_dependentvariantid="1410">Radiation Studies &amp; Concepts II</a> <br />John Boice, Sc.D.<br /><em>National Council on Radiation Protection and Measurements (NCRP) and Vanderbilt University School of Medicine</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034971" sys_contentid="1034971" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281896" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034971" sys_dependentvariantid="1410">Essential Radiobiology for Radiation Epidemiologists</a><br />David Brenner, Ph.D.<br /><em>Center for Radiological Research, Columbia University </em></p>
<p>Low-Dose Radiobiology and Radiation Genetic Risk<br /> Michael Atkinson, Ph.D.<br /> <em>Technical University of Munich (Germany)</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1036749" sys_contentid="1036749" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7281916" sys_siteid="475" rxinlineslot="103" sys_dependentid="1036749" sys_dependentvariantid="1500">Cancer Genomics: Integration with Radiation Studies (slides only - pdf, 7.4 MB)</a><br /> Stephen Chanock, M.D.<br /> <em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1036743" sys_contentid="1036743" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7281917" sys_siteid="475" rxinlineslot="103" sys_dependentid="1036743" sys_dependentvariantid="1500">Cellular Defenses against Radiation Injury (slides only - pdf, 2.9 MB)</a><br /> Leon Mullenders, Ph.D.<br /> <em>Leiden University Medical Centre (Netherlands)</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034974" sys_contentid="1034974" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281897" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034974" sys_dependentvariantid="1410">Non-Cancer Tissue Effects from Radiation Exposure</a><br />William McBride, Ph.D.<br /><em>UCLA Jonsson Cancer Center</em></p>
<p>Central Nervous System Effects after High Energy Radiation Exposure<br /> Jacqueline Williams, Ph.D., FASTRO, and M. Kerry O&rsquo;Banion, M.D., Ph.D.<br /> <em>University of Rochester Medical Center</em></p>
</div>
<div style="float: left; width: 45%; padding-right: 5%;">
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034975" sys_contentid="1034975" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281898" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034975" sys_dependentvariantid="1410">Environmental Dosimetry and Uncertainties in Doses</a> <br />Vladimir Drozdovitch, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034976" sys_contentid="1034976" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281899" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034976" sys_dependentvariantid="1410">Occupational Dosimetry and Uncertainties in Doses</a><br />Steven Simon, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034982" sys_contentid="1034982" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281900" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034982" sys_dependentvariantid="1410">Natural Background Radiation: Health Effects</a> <br />Richard Wakeford, Ph.D.<br /><em>Institute of Population Health, University of Manchester (U.K.)</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034988" sys_contentid="1034988" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281901" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034988" sys_dependentvariantid="1410">Atomic Bomb Survivor Studies: Overview and Recent Findings </a><br />Dale Preston, Ph.D.<br /><em>Hirosoft International</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1034989" sys_contentid="1034989" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281902" sys_siteid="475" rxinlineslot="103" sys_dependentid="1034989" sys_dependentvariantid="1410">Radiation Workers Throughout the World</a><br />Ethel Gilbert, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035117" sys_contentid="1035117" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281903" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035117" sys_dependentvariantid="1410">Radiation-related Cataracts in Clean-up Workers </a><br />Norman Kleiman, Ph.D.<br /><em>Columbia University Mailman School of Public Health</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035118" sys_contentid="1035118" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281904" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035118" sys_dependentvariantid="1410">Late Health Effects of the Chernobyl Accident</a> <br />Maureen Hatch, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035665" sys_contentid="1035665" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281913" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035665" sys_dependentvariantid="1410">Panel Discussion: <em>Low-Dose Radiation Risks </em></a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1037683" sys_contentid="1037683" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7281919" sys_siteid="475" rxinlineslot="103" sys_dependentid="1037683" sys_dependentvariantid="1500">Diagnostic Imaging, Screening and Cancer Risk (slides only - pdf, 1.4 MB)</a><br /> Amy Berrington de Gonz&aacute;lez, D.Phil.<br /> <em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035120" sys_contentid="1035120" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281905" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035120" sys_dependentvariantid="1410">Organ Doses from CT Imaging</a><br /> Choonsik Lee, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035121" sys_contentid="1035121" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281906" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035121" sys_dependentvariantid="1410">Radiation Doses from Cancer Treatment </a><br />Rebecca Howell, Ph.D.<br /><em>University of Texas MD Anderson Cancer Center</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035133" sys_contentid="1035133" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281907" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035133" sys_dependentvariantid="1410">Cancer Risks from Radiation Therapy</a> <br />Flora van Leeuwen, Ph.D.<br /><em>Netherlands Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035161" sys_contentid="1035161" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281908" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035161" sys_dependentvariantid="1410">Cancer Risk from Radiation Exposure: The Role of Genetic Susceptibility</a><br />Preetha Rajaraman, Ph.D.<br /><em>NCI Center for Global Health</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035164" sys_contentid="1035164" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281909" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035164" sys_dependentvariantid="1410">Cardiovascular Outcomes from Radiation Exposure</a> <br />Steve Lipshultz, MD, FAAP, FAHA<br /><em>Children's Hospital of Michigan, Wayne State University School of Medicine</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035664" sys_contentid="1035664" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281914" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035664" sys_dependentvariantid="1410">Panel discussion: <em>Medical Radiation</em></a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035166" sys_contentid="1035166" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281910" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035166" sys_dependentvariantid="1410">Solar Ultraviolet Radiation and Health </a><br />Lisa Cahoon, Ph.D.<br /><em>National Cancer Institute</em></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035168" sys_contentid="1035168" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281911" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035168" sys_dependentvariantid="1410">Extremely Low Frequency (power frequency) Magnetic Field Exposures and Health Risks </a><br /><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1035169" sys_contentid="1035169" inlinetype="rxhyperlink" sys_variantid="1410" sys_relationshipid="7281912" sys_siteid="475" rxinlineslot="103" sys_dependentid="1035169" sys_dependentvariantid="1410">Radiofrequency (mobile telephones) Exposures and Health Risks: Findings and Controversies </a><br />Martha Linet, M.D., M.P.H.<br /><em>National Cancer Institute</em></p>
</div>
</div>
<p><a href="#top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="939444" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>BCRA is an R package that projects absolute risk of invasive breast cancer according to <a href="http://www.cancer.gov/bcrisktool/">NCI&rsquo;s Breast Cancer Risk Assessment Tool</a> (BCRAT) algorithm for specified race/ethnic groups and age intervals.</p>
<p>This package is to project absolute risk of invasive breast cancer according to NCI&rsquo;s Breast Cancer Risk Assessment Tool (BCRAT) algorithm for specified race/ethnic groups and age intervals. The updated version 2.0 includes the new Hispanic model.</p>
<p>This package can be used to estimate the risk of developing breast cancer over a predetermined time interval with risk factors. As the same as Breast Cancer Risk Assessment SAS Macro, the users can specify the time interval as appropriate, not only limited to the 5 years risk prediction available with BCRAT.&nbsp;</p>
<p>The main function in this package is <math>absolute.risk</math>, which is defined based on a statistical model known as the "Gail model". Parameters and constants needed in this function include initial and projection age, recoded covariates using function <math> recode.check</math>, relative risks of BrCa at age "&lt;50" and "&gt;=50" obtained from function <math>relative.risk</math> as well as other known constants listed from function <math>list.constants</math> like BrCa composite incidences, competing hazards, 1-attributable risk using in NCI BrCa Risk Assessment Tool (NCI BCRAT). With risk factors and projection interval ages for a group of women, the function <math>absolute.risk</math> will return the corresponding absolute risk projections. If the function returns any missing values, the function <math>error.table</math> or <math>error.table.all</math> is used to find where the errors occured. The function <math>check.summary</math> can give a quick check for errors of input file and missing values of risks.&nbsp; For further analysis, a data frame is created from the function <math>risk.summary</math>, which includes age, duration of the projection time interval, covariates and the projected risk.</p>
<p>The version 2.0 includes absolute risk projections for Hispanic women (US born and Foreign born) based on race specific RR risk models developed on the San Francisco Bay Area Breast Cancer Study (SFBCS). Race specific attributable risks, breast cancer composite incidences and competing hazards are added to the updated package.</p>
<p>Any changes/modifications to the package would be at the user&rsquo;s own discretion and risk.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=939448" sys_contentid="939448" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317717" sys_siteid="475" rxinlineslot="103" sys_dependentid="939448" sys_dependentvariantid="1500">Manual</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=939449" sys_contentid="939449" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317718" sys_siteid="475" rxinlineslot="103" sys_dependentid="939449" sys_dependentvariantid="1500">Vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=939450" sys_contentid="939450" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317719" sys_siteid="475" rxinlineslot="103" sys_dependentid="939450" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h3>Software Download:</h3>
<ul class="grey-bullets">
<li>Windows O/S - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=939446" sys_contentid="939446" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317720" sys_siteid="475" rxinlineslot="103" sys_dependentid="939446" sys_dependentvariantid="1500">BCRA_2.0.zip</a></li>
<li>Linux O/S - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=939447" sys_contentid="939447" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317721" sys_siteid="475" rxinlineslot="103" sys_dependentid="939447" sys_dependentvariantid="1500">BCRA_2.0.tar.gz</a></li>
</ul>
<p>This package is also available on the Comprehensive R Archive Network (CRAN) - <a href="http://cran.r-project.org/web/packages/BCRA/index.html">BCRA</a></p>
<h3>References:</h3>
<ul class="grey-bullets">
<li>Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Shairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. <cite>JNCI</cite> 1989; 81(24): 1879-86. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/2593165">Pubmed Abstract</a>]</li>
<li>Costantino J, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS. Validation studies for models to project the risk of invasive and total breast cancer. <cite>JNCI</cite> 1999; 91:1541-8. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10491430">Pubmed Abstract</a>]</li>
<li>Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Berstein L. Projecting individualized absolute invasive breast cancer risk in African American women. <cite>JNCI</cite> 2007; 99:1782-92. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18042936">Pubmed Abstract</a>]</li>
<li>Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH. Projecting individualized absolute invasive breast cancer risk in asian and pacific islander american women. <cite>JNCI</cite> 2011; 103:951-61. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21562243">Pubmed Abstract</a>]</li>
<li>Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, LaCroix AZ, Pee D, Chlebowski RT, Hines LM, Thompson CA, Gail MH.&nbsp; Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. <cite>JNCI</cite> 2016; 109.</li>
</ul>
<h3>Support:</h3>
<p>Statistical issues should be directed to: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349622" sys_contentid="349622" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7317722" sys_siteid="475" rxinlineslot="103" sys_dependentid="349622" sys_dependentvariantid="1965">Dr. Mitchell Gail</a></p>
<p>Technical details should be directed to:&nbsp;Fanni Zhang (<a href="mailto:zhangf@imsweb.com?subject=Breast%20Cancer%20Risk%20Assessment%20Macro">zhangf@imsweb.com</a>)</p>
</div>]]></content>
  </row>
  <row para_id="939450" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>BCRA R Package License Agreement</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The BCRA R Package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="969521" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><a id="Top"></a>&nbsp;</p>
<p>Learn more about our <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=981039" sys_contentid="981039" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="981039" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7306527">research training opportunities</a> in the Laboratory of Genetic Susceptibility.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="974511" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>About LGS</h3>
<p><a href="/about/organization/lgs/lgs-research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?1=LGS">LGS Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/lgs-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/training-lgs" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/lgs/tools" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=LGS&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<h3>NCI Resources</h3>
<p><a href="http://cgap.nci.nih.gov/">Cancer Genome Anatomy Project</a></p>
<p>An overview of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1057944" sys_dependentvariantid="1418" sys_dependentid="1057944" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7242513" sys_variantid="1418" sys_contentid="1057944">Genome-wide Association Studies</a></p>
<p><a href="https://ldlink.nci.nih.gov/#">LDlink - A suite of web-based applications designed to easily and efficiently interrogate linkage disequilibrium in population groups</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=460151" inlinetype="rxhyperlink" sys_relationshipid="7242511" sys_siteid="475" rxinlineslot="103" sys_dependentid="460151" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="460151">NCI Cancer Genomics Research Laboratory</a> (formerly the Core Genotyping Facility)</p>
<h3>Apply for Controlled Access Data</h3>
<p><a href="http://www.ncbi.nlm.nih.gov/gap">NCBI dbGaP</a> - The database of Genotypes and Phenotypes (dbGaP) was developed to archive and distribute the results of studies that have investigated the interaction of genotype and phenotype.</p>
<h3>Additional Bioinformatics Tools</h3>
<p><a href="http://genome.ucsc.edu/">UCSC Genome Browser</a></p>
<p>Access the <a href="http://www.genome.gov/gwastudies/">Genome.gov catalog of published Genome-Wide Association Studies</a></p>
</div>]]></content>
  </row>
  <row para_id="976905" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1088516" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7274986">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Objects displayed for size comparisons of particulate matter" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1088516&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1088516&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1088516&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1088516">Enlarge</a></div>
<figcaption>
<div class="caption-container no-resize">
<p>Size comparisons for PM particles</p>
<div class="image-photo-credit">Courtesy of the US EPA</div>
</div>
</figcaption>
</figure>
</div>
<p>The International Agency for Research on Cancer (IARC) has classified ambient outdoor particulate matter (PM) as a Group 1 human carcinogen. It is unclear, however, if the lung cancer risks primarily linked to long-term exposure to fine PM (PM<sub>2.5</sub>, aerodynamic diameter &lt;2.5&micro;m) are driven by its constituent ultrafine particles (UFP, &lt;100nm), which may be more toxic due to their unique physiochemical properties. This prospective cohort study among the NIH-AARP Diet and Health Study participants in the Los Angeles Basin is being conducted in collaboration with the University of Southern California and Utrecht University.&nbsp;The&nbsp;primary aim of the Los Angeles Ultrafines Study is to evaluate the&nbsp;association between long-term exposure to ambient outdoor UFP and lung cancer risk.</p>
<p>The Los Angeles Ultrafines Study population has several important features needed to assess this etiologic relationship, including substantial regional variation in PM concentrations, large numbers of lung cancer cases, and data on smoking and residential histories. A comprehensive retrospective exposure assessment draws upon one of the most complete repositories of historical UFP data available, supplemented by a mobile ambient monitoring campaign in Los Angeles and surrounding counties.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1080328" sys_relationshipid="7274937" sys_variantid="1965">Dr. Rena Jones</a>&nbsp;or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349599" sys_relationshipid="7274935" sys_variantid="1965">Dr. Debra Silverman</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="418935" sys_relationshipid="7274936" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="978892" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>SOCcer is a software used to code free-text job descriptions into standardized occupation classification codes to assist researchers in incorporating occupational risk factors into their studies. Find out more about <a href="http://soccer.nci.nih.gov/">Standardized Occupation Coding for Computer-assisted Epidemiologic Research (SOCcer)</a>.</p>


</div>]]></content>
  </row>
  <row para_id="981039" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Overview</h3>
<p>Scientists in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=966088" inlinetype="rxhyperlink" sys_relationshipid="7253227" sys_siteid="475" rxinlineslot="103" sys_dependentid="966088" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="966088">Laboratory of Genetic Susceptibility</a> participate in genetic, epidemiologic, clinical and methodological studies of populations, families, and persons at risk for cancer. In addition, they collaborate and consult with experts in statistical genetics, bioinformatics, genetic epidemiology, and molecular epidemiology in interdisciplinary studies.</p>
<p>For application details, see below. To discuss potential research opportunities, you may contact branch investigators directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=969521" inlinetype="rxhyperlink" sys_relationshipid="7253228" sys_siteid="475" rxinlineslot="103" sys_dependentid="969521" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="969521">Meet the fellows in the Laboratory of Genetic Susceptibility</a>.</p>
<h3>Qualifications</h3>
<p><i>Postdoctoral fellowships:</i> Fellowship training is for up to 5 years under the supervision of NCI senior scientists. Individuals must hold either an M.D. or Ph.D. in genetics, epidemiology, bioinformatics, molecular biology or a related field. Individuals with laboratory experience and/or expertise in manipulating and analyzing dense genomic data sets are encouraged to apply. Individuals with clinical or epidemiologic training are encouraged to apply.</p>
<p><i>Predoctoral fellowships:</i> Individuals must be enrolled in a doctoral program with a desire to complete their dissertation in LGS or have completed a master&rsquo;s degree in a field relevant to the mission of LGS.</p>
<p><i>Postbaccalaureate fellowships:</i> Fellowships are also available for individuals who have recently completed an undergraduate degree in biology, genetics or laboratory science.</p>
<h3>Application Process</h3>
<p>Postdoctoral fellowship applications in LGS are accepted on an ongoing basis. Fellowships in LGS are provided through the DCEG fellowship program. See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" inlinetype="rxhyperlink" sys_relationshipid="7253226" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302629">Fellowship Information page</a>&nbsp;for an overview, qualifications, and application details.</p>
<h3>Current Training Opportunities</h3>
<p>Applications for both postdoctoral and predoctoral positions are being accepted.</p>
</div>]]></content>
  </row>
  <row para_id="981679" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>About LGS</h3>
<p><a href="/about/organization/lgs/lgs-research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?1=LGS">LGS Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/lgs-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/training-lgs" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/lgs/tools" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=LGS&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>The Laboratory of Genomic Susceptibility (LGS) investigates the biological basis for genetic susceptibility to cancer, including identification and characterization of cancer susceptibility alleles, characterization of the scope of genetic mosaicism and its contribution to cancer risk, investigation of the genetic architecture of cancer susceptibility, and determination of how germline variation informs our understanding of somatic alterations in cancer. &nbsp;</p>
<p>LGS scientists participate in genetic, epidemiologic, clinical and methodological studies of populations, families, and persons at risk for cancer. In addition, they collaborate and consult with experts in statistical genetics, bioinformatics, genetic epidemiology, and molecular epidemiology in interdisciplinary studies. Using large-scale genome-wide association studies, familial linkage studies in high-risk families, and publically available databases, such as TCGA (<a href="http://cancergenome.nih.gov/">The Cancer Genome Atlas</a>), TARGET (<a href="https://ocg.cancer.gov/programs/target">Therapeutically Applicable Research to Generate Effective Treatments</a>), ENCODE (<a href="https://www.encodeproject.org/">Encyclopedia of DNA Elements</a>), and GTEx (<a href="http://www.genome.gov/GTEx/">The Genotype-Tissue Expression Project</a>), investigators continue to identify loci within the human genome that are associated with cancer risk.</p>
<h3>Genome-Wide Association Studies</h3>
<p>The laboratory is at the forefront of applications in bioinformatics and advanced genetic analyses with new platforms designed to evaluate the biological effects of dense sets of single nucleotide polymorphisms (SNPs), which are the most common genetic variants in the human genome. Specifically, the laboratory has integrated approaches to identify and validate common SNPs and ancestral haplotypes, which could be used to dissect the genetic basis of disease susceptibility. Together with NCI&rsquo;s <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=460151" sys_dependentvariantid="1422" sys_dependentid="460151" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7242509" sys_variantid="1422" sys_contentid="460151">Cancer Genomics Research Laboratory</a>, LGS carries out genome-wide association studies (GWAS). Using data from large-scale GWAS that evaluate millions of SNPs, investigators at the LGS are able to identify in great detail new regions in the human genome that are associated with cancer risk and to estimate the magnitude of effect of these risks. GWAS have been instrumental in the discovery of new regions of the genome, which influence the basic etiological risk factors. In addition, these novel findings may, at a later time, also bear important predictive value for disease, particularly in developing a polygenic model as well as highlight potential molecular pathways related to both disease etiology and perhaps therapeutic intervention.</p>
<h3>Investigation of GWAS Signals</h3>
<p>To understand the biology underlying these associations, investigators are following up with focused validation studies, deep-sequencing, and functional analyses, such as analyses of expression levels and methylation patterns. This research relies on multidisciplinary approaches from population genetics, epidemiology and molecular evolution. Investigation of GWAS signals requires extensive bioinformatic follow-up to examine unannotated transcripts, regulatory elements, as well as functional elements for novel transcripts. Regulatory effects are queried with respect to the alteration of gene levels, epigenetics, and long-ranging effects on other genes at a distance using cell lines, normal tissue and tumor tissue, as well as resources from the TCGA and the ICGC (the<a href="https://icgc.org/"> International Cancer Genome Consortium</a>). The LGS is also investigating several possible biologic mechanisms including whether variations in these identified regions may affect regulatory elements of neighboring genes, the impact of miRNA polymorphisms acting upon fragile chromosomal sites, and epigenetic effects across multi-susceptibility regions.</p>
<p>We have developed a series of collaborations with leading epidemiologists and biostatisticians in the Division of Cancer Epidemiology and Genetics (DCEG), the NCI Cohort Consortium, and multiple other international molecular epidemiologic consortia. Data pooling is being used to achieve the statistical power necessary to detect associations between genomic variants and a variety of health outcomes, as well as gene-environment interactions. &nbsp;</p>
<h3>Mosaicism</h3>
<p>An interesting outcome from GWAS studies at LGS has been the identification of a sizeable fraction of apparently healthy individuals that harbor large scale (&gt;2MB) mosaic events detected as copy number changes or copy-neutral uniparental disomies. Investigating human clonal mosaicism has the potential to offer new insights into genomic maintenance as individuals age, as well as explain a portion of the phenotypic heterogeneity of cancer subtypes. With the accumulation of cancer susceptibility regions from GWAS and large new datasets of tumor sequencing data, it is now possible to investigate the interplay between inherited germline genetics and acquired somatic mutations. The expertise of LGS staff and their collaborations with other DCEG experts enable novel investigation into how germline genetics combined with somatically acquired mutations may affect susceptibility to cancer.</p>
</div>]]></content>
  </row>
  <row para_id="1028461" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>An R package to compute Individualized Coherent Absolute Risk Estimators (iCARE)</p>
<h3>Description</h3>
<p>iCARE allows researchers to quickly build models for absolute risk, and apply them to estimate an individual's risk of developing disease during a specifed time interval, based on a set of user defined input parameters. An attractive feature of the software is that it gives users fexibility to update models rapidly based on new knowledge of risk factors and tailor models to different populations. The tool requires three input arguments be specifed: (1) a model for relative risk (2) an age-specifc disease incidence rate and (3) the distribution of risk factors for the population of interest. The tool handles missing risk factor information for individuals for whom risks are to be predicted using a coherent approach where all estimates are derived from a single model after appropriate model averaging. The software allows single nucleotide polymorphisms (SNPs) to be incorporated into the model using published odds ratios and allele frequencies.</p>
<ul>
<li>Download from Bioconductor: <a href="https://bioconductor.org/packages/devel/bioc/html/iCARE.html">packages/devel/bioc/html/iCARE.html</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1028480" sys_dependentvariantid="1418" sys_dependentid="1028480" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276089" sys_variantid="1418" sys_contentid="1028480">License Agreement</a></li>
</ul>
<h3>Authors</h3>
<p>Parichoy Pal Choudhury; Paige Maas; Amber Wilcox; William Wheeler; Mark Brook; David Check; Montserrat Garcia-Closas; Nilanjan Chatterjee</p>
<h3>Reference</h3>
<p>Choudhury PP, Maas P, Wilcox A, Wheeler W, Brook M, Check D, Garcia-Cloasa M, Chatterjee N. iCARE: an R package to build, validate and apply absolute risk models.&nbsp;<em>Submitted</em></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1028480" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong><br /> Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The iCARE- R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1030353" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275415" sys_dependentid="1030353" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275416" sys_dependentid="1138842" rxinlineslot="103" sys_dependentvariantid="2428" sys_variantid="2428">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275417" sys_dependentid="1030358" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275418" sys_dependentid="1030489" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275419" sys_dependentid="1030593" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">About the Accident</a></p>
</div>
<p>On April 26, 1986, an accident occurred at the Chernobyl nuclear power plant in northern Ukraine. In addition to 28 near-term deaths due to radiation, the accident resulted in the exposure of 5 million people in Belarus, Russia and Ukraine to fallout from the accident, principally radioiodines.</p>
<h2>DCEG Studies of Radiation and Health Effects</h2>
<p>This exposure has led to substantial epidemiological research, especially among clean-up workers and children. The governments of Ukraine, Belarus and the United States (namely the Radiation Epidemiology Branch at NCI), and other research partners, have been conducting these studies.</p>
<h3>DCEG Research on Chernobyl</h3>
<p>Research conducted&nbsp;by DCEG investigators falls into three main categories: Epidemiological, Molecular Genomic, and Dosimetric. For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_relationshipid="7275408" sys_dependentid="1087122" rxinlineslot="103" sys_dependentvariantid="1965" sys_variantid="1965">Elizabeth K. Cahoon, Ph.D.</a>, or read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275405" sys_dependentid="1030358" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">DCEG research on Chernobyl</a>.</p>
<h3>Researchers and&nbsp;Collaborators</h3>
<p>Dr. Gilbert W. Beebe (1912&ndash;2003) and fellow NCI staff launched multidisciplinary studies in cooperation with many international radiation experts as well as investigators from Belarus and Ukraine.&nbsp;Read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275406" sys_dependentid="1030489" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">researchers and&nbsp;collaborators for Chernobyl research</a>.</p>
<h3>About the Chernobyl Accident</h3>
<p>Learn more details <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7275407" sys_dependentid="1030593" rxinlineslot="103" sys_dependentvariantid="1418" sys_variantid="1418">about the 1986 accident at the Chernobyl nuclear power plant</a> in Ukraine.</p>
<h3>Study Publications from Chernobyl Research</h3>
<p>The research into the effects of the Chernobyl accident have resulted in numerous scientific papers. <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Chernobyl+Chornobyl&amp;titleOption=or&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Obtain a list of Chernobyl study publications</a>.</p>
<div class="callout-box center">
<h3>Information for Journalists</h3>
<p>To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:</p>
<p><strong>E-mail:</strong> <a href="mailto:ncipressofficers@mail.nih.gov">ncipressofficers@mail.nih.gov</a></p>
<p><strong>Phone: </strong>240-760-6600</p>
</div>
</div>]]></content>
  </row>
  <row para_id="1030358" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390423" sys_dependentvariantid="1418" sys_dependentid="1030353" rxinlineslot="103" sys_siteid="475">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_variantid="2428" sys_relationshipid="7390424" sys_dependentvariantid="2428" sys_dependentid="1138842" rxinlineslot="103" sys_siteid="475">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390425" sys_dependentvariantid="1418" sys_dependentid="1030358" rxinlineslot="103" sys_siteid="475">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390426" sys_dependentvariantid="1418" sys_dependentid="1030489" rxinlineslot="103" sys_siteid="475">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390427" sys_dependentvariantid="1418" sys_dependentid="1030593" rxinlineslot="103" sys_siteid="475">About the Accident</a></p>
</div>
<p>Research conducted by DCEG investigators falls into three main categories: <a href="#Epidemiological">Epidemiological</a>, <a href="#Molecular">Molecular Genomic</a>, and <a href="#Dosimetric">Dosimetric</a>.</p>
<h3><a id="Epidemiological"></a>Epidemiological Studies of Radiation-Related Cancers and Other Diseases</h3>
<p>Scientists in the Radiation Epidemiology Branch (REB) have been involved in a multilateral collaboration for several years with researchers and scientists in Belarus, Ukraine, and Russia to conduct epidemiological studies of thyroid diseases and leukemia among the populations affected by the 1986 Chernobyl accident in Ukraine.</p>
<h4><a id="Thyroid-Chernobyl"></a>Thyroid Disease in Young Persons Near Chernobyl</h4>
<p>The accident exposed large numbers of people in Ukraine, Belarus and Russia to radioactive iodines, principally I-131, which concentrates in the thyroid gland (Hatch, et al., 2005; Cardis and Hatch, 2011). From 1998 to 2007/8, biennial thyroid screening examinations were conducted among approximately 25,000 individuals exposed to the accident as children or adolescents in Ukraine and Belarus. The initial report from Ukraine provides convincing evidence in support of earlier reports of a five- or six-fold radiation-related increase in thyroid cancer among those who were young at the time of the accident and includes individual dose estimates on all subjects. The data show a strong, approximately linear dose-response relationship.</p>
<p>Other studies in Ukraine include individuals exposed <em>in utero</em> to radioiodines, who may have a raised risk of thyroid neoplasia. The relationships between radiation and autoimmune thyroiditis, follicular adenoma, hyperthyroidism and hypothyroidism have also been assessed. Current efforts utilize national cancer registries for follow-up and various strategies for maintaining contact with these cohorts.</p>
<p>For more information, read about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030455" sys_contentid="1030455" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390412" sys_dependentvariantid="1418" sys_dependentid="1030455" rxinlineslot="103" sys_siteid="475">Study of Thyroid Cancer in Ukraine</a>, and the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030471" sys_contentid="1030471" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390413" sys_dependentvariantid="1418" sys_dependentid="1030471" rxinlineslot="103" sys_siteid="475">Study of Thyroid Cancer in Belarus</a>.</p>
<h4><a id="Leukemia-Chernobyl"></a>Leukemia Risk in Chernobyl Clean-up Workers</h4>
<p>Following the accident, hundreds of thousands of clean-up workers (also called liquidators) from Ukraine were exposed primarily to external radiation with those sent earliest receiving the highest doses (185 mGy in 1986, 112 mGy in 1987 and 47 mGy in 1988-89). To date, studies of cancer among clean-up workers have focused on leukemia. The Radiation Epidemiology Branch (REB) in collaboration with the Research Center for Radiation Medicine in Ukraine has conducted a case-control study of leukemia and other hematological diseases based on a large cohort of male clean-up workers (~110,000), with individual doses to the bone marrow estimated using a new method developed for this study. Findings from the first phase of the study based on cases diagnosed between 1987-2000 have been summarized in three companion papers (Methods, Dosimetry, Risk analysis) published in Radiation Research (vol. 170, 2008). The study was extended to accrue cases for an additional six years.</p>
<p>For more information, read about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030482" sys_contentid="1030482" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390414" sys_dependentvariantid="1418" sys_dependentid="1030482" rxinlineslot="103" sys_siteid="475">Study of Leukemia and Other Hematological Diseases Among&nbsp;Clean-up Workers&nbsp;in Ukraine After the Chernobyl Accident</a></p>
<h3><a id="Molecular"></a>Advanced Molecular Genomic Research Studies</h3>
<p>DCEG investigators are applying the full capabilities of cutting edge molecular and genetic epidemiological methods to expand our knowledge on the relationship between ionizing radiation and cancer. To understand how exposure to parents may affect future offspring, experts have launched a study of parent-child trios in which at least one parent was exposed to Chernobyl radiation as a clean-up worker and/or evacuee from a contaminated area. REB researchers are applying whole genome sequencing techniques to thyroid tumor, adjacent normal, and blood samples obtained through the Chernobyl Tissue Bank to better understand the genetic makeup of this malignancy.</p>
<p>For more information, read about:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030547" sys_contentid="1030547" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390415" sys_dependentvariantid="1418" sys_dependentid="1030547" rxinlineslot="103" sys_siteid="475"> Genetic Effects in the Children of Adults Exposed to Radiation from the Chernobyl Accident - TRIO Study</a>&nbsp;and<br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030563" sys_contentid="1030563" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390416" sys_dependentvariantid="1418" sys_dependentid="1030563" rxinlineslot="103" sys_siteid="475">Comprehensive Genomic Characterization of Radiation-Related Thyroid Cancer in the Ukraine</a>.</p>
<h3><a id="Dosimetric"></a>Dosimetric Studies</h3>
<p>Good dosimetry is essential to estimate with reasonable accuracy the radiation risks resulting from the Chernobyl accident.&nbsp;The task of the REB dosimetrists has been to estimate the radiation doses, and their uncertainties, for all individuals involved in these epidemiological studies. Dosimetry work for the Chernobyl study includes:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100557" sys_contentid="1100557" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390418" sys_dependentvariantid="1418" sys_dependentid="1100557" rxinlineslot="103" sys_siteid="475">Chernobyl Childhood Thyroid Dosimetry</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100762" sys_contentid="1100762" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390417" sys_dependentvariantid="1418" sys_dependentid="1100762" rxinlineslot="103" sys_siteid="475"><em>In utero </em>Exposure in Belarus and Ukraine</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100732" sys_contentid="1100732" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390419" sys_dependentvariantid="1418" sys_dependentid="1100732" rxinlineslot="103" sys_siteid="475">Dosimetry for the TRIO (parent + child) Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1105307" sys_contentid="1105307" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390421" sys_dependentvariantid="1418" sys_dependentid="1105307" rxinlineslot="103" sys_siteid="475">Radiation Dose to Post-Chernobyl Cleanup Workers</a></li>
</ul>
<p>Find more information about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091068" sys_contentid="1091068" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7390420" sys_dependentvariantid="1418" sys_dependentid="1091068" rxinlineslot="103" sys_siteid="475">Radiation Dosimetry Research to Support Epidemiologic Studies</a>.</p>
<p><span>For more information about DCEG research on Chernobyl, contact<span class="Apple-converted-space">&nbsp;</span></span><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7390422" sys_dependentvariantid="1965" sys_dependentid="1087122" rxinlineslot="103">Elizabeth K. Cahoon, Ph.D.</a></p>
</div>]]></content>
  </row>
  <row para_id="1030455" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030353" sys_dependentvariantid="1418" sys_relationshipid="7258934" sys_variantid="1418">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1138842" sys_dependentvariantid="2428" sys_relationshipid="7258935" sys_variantid="2428">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030358" sys_dependentvariantid="1418" sys_relationshipid="7258936" sys_variantid="1418">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030489" sys_dependentvariantid="1418" sys_relationshipid="7258937" sys_variantid="1418">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030593" sys_dependentvariantid="1418" sys_relationshipid="7258938" sys_variantid="1418">About the Accident</a></p>
</div>
<p><a href="#Overview">Program Overview</a><br /><a href="#Objectives">Objectives</a><br /><a href="#Progress">Progress to Date</a><br /><a href="#Benefits">Benefits to Ukrainians</a><br /><a href="#Roles">Roles of United States Participants</a></p>
<p>Several years after an initial agreement was reached between the United States and the USSR in 1988, to cooperate in the area of nuclear reactor safety, the National Cancer Institute (NCI) undertook to develop long-term studies of thyroid cancer among exposed children in Ukraine and Belarus. The incidence of thyroid cancer in children, ordinarily very rare, had begun to increase markedly following the accident, and a rigorous investigation was needed to assess the relationship between exposure to I-131 from Chernobyl and the occurrence of thyroid cancer and other thyroid disorders. Responsibility for the study resides in the Radiation Epidemiology Branch of NCI.</p>
<p>The first contacts between the U.S. and Ukrainian governments concerning this project were made in the early 1990s. In the next few years, a study protocol was developed and approved, and in 1995 an agreement for funding was signed in Kiev. Thyroid cancer screening of study participants began in 1998.</p>
<h3><a id="Overview"></a>Program Overview</h3>
<p>The screening program, which was carried out in the heavily contaminated norther regions of Ukraine (Kiev, Chernigov and Zhitomir oblasts as well as Kiev City), consisted of biennial examinations of the thyroid glands of approximately 13,000 individuals who were exposed as children (aged 0-17 years old) and who had thyroid radioactivity measurements made in the weeks following the accident. The screening protocol was designed to determine whether a participant had thyroid cancer or a range of other thyroid diseases, such as benign nodules.</p>
<p>The screening program consisted of the following: a medical history; palpation of the thyroid by an endocrinologist and an ultrasonographer; an ultrasound examination of the thyroid; and collection of a blood sample (for measurement of thyroid hormones and thyroid auto-antibodies) and a spot urine sample (to measure excreted iodine); as well as a detailed interview for estimating cumulative individual radiation dose to the thyroid gland that included a residential history, data on consumption of contaminated foods, and use of iodine prophylaxis. A study of those exposed to the accident while <em>in utero</em> (N=1494) and a comparison cohort of unexposed <em>in utero</em> subjects (N=1088) has been completed (Hatch et al., 2009).</p>
<p>The radioiodine doses estimated for each cohort member are based on the thyroid radioactivity measurements, ecologic data (for example, deposition patterns), and interview data on residential location and consumption of contaminated foods around the time of the accident. Fetal thyroid doses were derived from maternal doses (Likhtarev et al., in press).</p>
<p>The active screening program was completed in 2007/8. Follow-up of the cohort continues via linkage with the National Cancer Registry of Ukraine, (NCRU). The study center is located in Kiev and includes the facilities of the Institute of Endocrinology and Metabolism, the Scientific Center for Radiation Medicine, Academy of Medical Sciences, the NCRU and the University of Illinois at Chicago, Kiev Data Management Center.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="Objectives"><a id="Objectives"></a>Objectives</h3>
<p>The primary objective of this collaborative research is to determine the relationship between I-131 exposure from the Chernobyl accident and risk of thyroid cancer. The effect of dose level, age at the time of exposure and gender are of particular interest, with effects of stable iodine also being considered. Associations between I-131 and benign thyroid nodules and other thyroid diseases have also been evaluated. The effects of I-131 in inducing thyroid cancer are being compared with published data on external radiation to assess their relative potency.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="Progress"><a id="Progress"></a>Progress&nbsp;to Date</h3>
<h4>1st Screening Cycle</h4>
<p>The initial enrollment in the first round of screening was 13,243. To insure a high level of participation, the screening examinations were conducted both at the stationary center in Kiev (28%) and in mobile units (72%) that were sent out to parts of the study area some distance from Kiev. The first cycle was completed in 2001.&nbsp;Forty-five cancers were diagnosed as a result of the first round of screening.</p>
<p>Results of the analysis of radiation dose-response in relation to the prevalent cancers from the first round of screening in Ukraine (excess odds ratio per Gray (EOR/GY) of 5.25; 95% confidence interval (CI): 1.7, 27.5) were published in JNCI (2006, vol. 98 (13):897-903).</p>
<h4>2nd - 4th Cycles</h4>
<p>Sixty-five incident cancers were identified in the 2nd-4th cycles. The analysis of the dose-response relationship for incident thyroid cancers yielded an excess relative risk per Gray (ERR/Gy) two decades after exposure of 1.91 (95% CI: 0.43, 6.34 (Brenner et al., 2011).</p>
<p>Current research opportunities include a variety of projects concerning incidence of the many benign thyroid diseases identified in the study cohort, as well as genetic projects (gene expression, analysis of candidate SNPs) utilizing tissue samples archived in the Chernobyl Tissue Bank and blood samples collected from study subjects. Clinical follow-up of subjects with nodules detected during active screening is also underway.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="Benefits"><a id="Benefits"></a>Benefits&nbsp;to Ukrainians</h3>
<p>One benefit to Ukrainians has been the long-term screening and evaluation of the population at risk that may reduce problems and increase survival by detecting thyroid disease early when treatment is most effective. The project has also assisted local health officials in developing appropriate health-care programs by providing pertinent, valuable data on a range of topics, including iodine nutrition. Technical and scientific training has been provided to collaborators and the general population has been educated on the importance of early detection and regular screening in preventing morbidity and death from thyroid cancer. Our published findings have contributed to the data base that health care providers, health policy and nuclear safety experts will draw upon to formulate future plans for similar exposure situations. In addition, the results are contributing to a basic understanding of the carcinogenic and other adverse health effects of I-131.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="Roles"><a id="Roles"></a>Roles&nbsp;of United States&nbsp;Participants</h3>
<ul>
<li>The NCI staff is charged with scientific direction and management of the projects.</li>
<li>The Thyroid Advisory Group, comprised of experts in all relevant areas, provides external oversight. The Group reviews the progress of each arm of the thyroid studies at least once per year. A Report including in-depth observations and recommendations is sent to the Director of the Division of Cancer Epidemiology and Genetics, NCI, as well as to the directors of our collaborating Ukrainian and Belarusian institutions.</li>
</ul>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="1030471" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030353" sys_dependentvariantid="1418" sys_relationshipid="7258929" sys_variantid="1418">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1138842" sys_dependentvariantid="2428" sys_relationshipid="7258930" sys_variantid="2428">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030358" sys_dependentvariantid="1418" sys_relationshipid="7258931" sys_variantid="1418">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030489" sys_dependentvariantid="1418" sys_relationshipid="7258932" sys_variantid="1418">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030593" sys_dependentvariantid="1418" sys_relationshipid="7258933" sys_variantid="1418">About the Accident</a></p>
</div>
<p><a id="Top"></a></p>
<p><a href="#Overview">Program Overview</a><br /><a href="#Objectives">Objectives</a><br /><a href="#Progress">Progress to Date</a><br /><a href="#Benefits">Benefits to Belarusians</a><br /><a href="#Roles">Roles of United States Participants</a></p>
<p>Several years after an initial agreement was reached between the United States and the USSR in 1988, to cooperate in the area of nuclear reactor safety, the National Cancer Institute (NCI) undertook to develop long-term studies of thyroid cancer among exposed children in Ukraine and Belarus. The incidence of thyroid cancer in children, ordinarily very rare, had begun to increase markedly following the accident, and a rigorous investigation was needed to assess the relationship between exposure to I-131 from Chernobyl and the occurrence of thyroid cancer and other thyroid disorders. Responsibility for the study resides in the Radiation Epidemiology Branch of NCI.</p>
<p>The first contacts between the U.S. and Belarusian governments concerning this project were made in the early 1990s. In the next few years, a study protocol was developed and approved and agreement for funding was signed in 1996. Thyroid cancer screening of study participants began in 1998.</p>
<h3><a id="Overview"></a>Program Overview</h3>
<p>The screening program carried out in all six oblasts of Belarus comprised three cycles and consisted of serial examinations of the thyroid glands of approximately 12,000 individuals who were exposed as children (0-18 years) and who had thyroid radioactivity measurements made in the weeks following the accident. The screening protocol was designed to determine whether a participant had thyroid cancer or a range of other thyroid diseases, such as benign nodules.</p>
<p>Most members of the cohort reside in Gomel, Minsk and Mogilev Oblasts. The screening program consists of the following: a medical history; palpation of the thyroid by an endocrinologist and an ultrasonographer; an ultrasound examination of the thyroid; and collection of a blood sample (for measurement of thyroid hormones and thyroid auto-antibodies) and a spot urine sample (to measure excreted iodine); a detailed dosimetry interview to obtain a residential history, data on consumption of contaminated foods, and use of iodine prophylaxis is also administered.</p>
<p>The radioiodine doses estimated for each cohort member have been based on the thyroid radioactivity measurements, ecologic data (for example, deposition patterns), and interview data on residential location and consumption of contaminated foods around the time of the accident.</p>
<p>Active screening was completed in 2008. Follow-up of the cohort continues through linkage with the Belarus Cancer Registry. The study center, originally based at the Research Institute of Radiation Medicine and Endocrinology in Minsk, was transferred in 2004 to the new Republican Research Center of Radiation Medicine and Human Ecology in Gomel.</p>
<h3><a id="Objectives"></a>Objectives</h3>
<p>The primary objective of this collaborative research is to determine the relationship between I-131 exposure from the Chernobyl accident and risk of thyroid cancer. The effect of dose level, age at the time of exposure and gender are of particular interest, along with effects of stable iodine status. Associations between I -131 and benign thyroid nodules and other thyroid diseases are also being evaluated. The effect of I-131 in inducing thyroid cancer will be compared with published data on external radiation to assess their relative potency.</p>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Progress"></a>Progress&nbsp;to Date</h3>
<p><strong><em>1st Screening Cycle</em></strong><br /> The initial enrollment in the first round of screening was 11,918. To insure a high level of participation, the screening examinations were conducted both at the stationary center in Minsk (approximately 40%) and in mobile units (approximately 60%) that were sent out to parts of the study area some distance from Minsk. The first cycle was completed in 2001. As a result of the first screening, 85 cases with doses &lt; 5 Gy were identified. The excess odds ratio per Gy for this group was 2.15 (95% CI: 0.81, 5.47) (Zablotska et al., 2011).</p>
<p><strong><em>2nd - 3rd Screening Cycles</em></strong><br /> Seventy-one confirmed thyroid cancers cases were identified in the 2nd and 3rd cycles. Active screening has been terminated but future follow-up of the cancer experience of the cohort continues through linkage with the national Belarus Cancer Registry.</p>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Benefits"></a>Benefits&nbsp;to Belarusians</h3>
<p>Benefits to Belarusians include the long-term screening and evaluation of the population at risk and continued monitoring through the Belarus Cancer Registry. The project also assists local health officials in developing appropriate health-care programs by providing pertinent, valuable data on a range of topics, including iodine nutrition. Technical and scientific training has been offered to collaborators and the general population has been educated on the importance of early detection and regular screening in preventing morbidity and death from thyroid cancer. Publications describing the findings are beginning to appear. Our research findings contribute to the data base that health care providers, health policy and nuclear safety experts will draw upon to formulate future plans for similar exposure situations. In addition, the results will add to our basic understanding of the carcinogenic and other adverse health effects of I-131.</p>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Roles"></a>Roles&nbsp;of United States Participants</h3>
<ul>
<li>The NCI staff is charged with scientific direction and management of the projects.</li>
<li>The Thyroid Advisory Group provides external review and is comprised of experts in all relevant areas. They review progress one-two times per year and make in-depth comments as well as recommendations to the Director of the Division of Cancer Epidemiology and Genetics at NCI and the heads of the collaborating foreign institutions.</li>
</ul>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="1030482" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277828" sys_dependentvariantid="1418" sys_dependentid="1030353" rxinlineslot="103" sys_siteid="475">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_variantid="2428" sys_relationshipid="7277829" sys_dependentvariantid="2428" sys_dependentid="1138842" rxinlineslot="103" sys_siteid="475">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277830" sys_dependentvariantid="1418" sys_dependentid="1030358" rxinlineslot="103" sys_siteid="475">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277831" sys_dependentvariantid="1418" sys_dependentid="1030489" rxinlineslot="103" sys_siteid="475">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277832" sys_dependentvariantid="1418" sys_dependentid="1030593" rxinlineslot="103" sys_siteid="475">About the Accident</a></p>
</div>
<p><a href="#Overview">Program Overview</a><br /><a href="#Objectives">Objectives</a><br /><a href="#Progress">Progress to Date</a><br /><a href="#Benefits">Benefits to Ukrainians</a><br /><a href="#Roles">Roles of United States Participants</a></p>
<p>Several years after a 1988 agreement between the United States and the USSR to cooperate in the area of nuclear reactor safety, the National Cancer Institute (NCI), NIH undertook to develop a study of leukemia risk among Ukrainian men potentially exposed to external radiation during clean-up operations (e.g., liquidators) following the Chernobyl accident. Responsibility for the study resides in the Radiation Epidemiology Branch of NCI.</p>
<p>Leukemia, a malignancy arising from the bone marrow, is strongly associated with radiation exposure because of the sensitivity of the bone marrow to the carcinogenic effects of external radiation. Leukemia is also among the earliest cancer sites to show an increase following radiation exposure, and one of the malignancies most consistently associated with external radiation exposure. Evaluating leukemia risk among the Chernobyl clean-up workers was important both in and of itself and also because of the information it would provide about risks to individuals in similar circumstances involving protracted exposure, such as nuclear workers.</p>
<p>Efforts to develop a research plan for studying leukemia among clean-up workers in Ukraine began as early as 1989-1990. A pilot phase, conducted between 1997-1999 to establish the feasibility of the proposed investigation, showed that a suitable cohort could be assembled and that representative clean-up workers could be located and interviewed regarding their experience during the clean-up operations. Leukemia cases were registered in hematologic facilities in central oblast dispensaries and the medical records were found to be readily available. A sample of 100 cases of leukemia and related disorders was collected and reviewed by an international group of hematologists and pathologists, with a high level of confirmation of the preliminary diagnoses made by local hematologists.</p>
<h3 id="overview"><a id="Overview"></a>Program Overview</h3>
<p>The cohort consists of approximately 110,000 clean-up workers in Ukraine who worked in the 30 km zone around the plant during 1986-1990 and resided in Kiev City or in one of the following oblasts: Cherkassy, Chernigov, Dnepropetrovsk, Kharkov, Kiev. The cohort was identified through the State Chernobyl Registry. In the first phase of the study, cases of leukemia and other hematologic disorders (specifically multiple myleoma and myelodysplasia ) were sought in all relevant health care institutions and assembled into a leukemia registry. Ultimately, record linkage was used to identify cases occurring among members of the cohort between 1987-2000. For each case, five controls were drawn from cohort members who did not develop hematologic disorders, matched to the case on age and area of residence. To gather information for estimating individual dose, detailed interviews are conducted to obtain data related to cumulative estimated dose to bone marrow. Estimated bone marrow doses based on a specially-developed time-and-motion approach have been evaluated in a statistical analysis (Romanenko et al., 2008) to evaluate the dose response relationship with leukemia risk overall, as well as with two separate subgroups: chronic lymphocytic leukemia (CLL, a hematologic malignancy generally thought not to be related to radiation exposure) and non-CLL cases.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="objectives"><a id="Objectives"></a>Objectives</h3>
<p>The principal objective of the study is to evaluate whether there is a dose-related increase in risk of leukemia among the clean-up workers. Possible modifiers of risk such as age at exposure or time since exposure are of particular interest. Also of interest will be to compare the magnitude of the observed risk per unit dose from a protracted exposure with that seen in the atomic bomb survivors, who received an acute exposure.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="progress"><a id="Progress"></a>Progress&nbsp;to Date</h3>
<p>The records of 28 health care institutions were searched and abstracted to assemble a list of cases occurring in the study time period. Linkage with the list of cohort members has yielded a total of 137 cases: 110 leukemia, 17 myelodysplasia and 10 multiple myelomas. For the approximately 100 deceased cases and controls, interviews with two proxy respondents are conducted: one with the spouse and one with at least one co-worker. An International Diagnostic Review Panel verified 86 leukemias.</p>
<p>Since only about half of the clean-up workers had official doses recorded, independent methods were evaluated for estimation of the doses based on environmental data combined with characteristics of individual exposures obtained through detailed interviews. In addition, laboratories were set up to implement new methods of biological dosimetry: Fluorescence in Situ Hybridization (FISH) technique on blood samples and Electron Paramagnetic Resonance (EPR) Spectroscopy measurements of tooth enamel. Both approaches proved to be helpful but not sensitive enough to measure the low doses that were received by a substantial number of clean-up workers. The current approach is to use a recently developed method called RADRUE (Radiation Dose Reconstruction with Uncertainty Estimates), based on the detailed interviews with the subjects. RADRUE provides estimates of subjects' bone marrow doses and of the attendant uncertainties.</p>
<p>A decision was made to accrue additional cases for the next six years, bringing the total time of follow-up to twenty years. This second phase uses the National Cancer Registry of Ukraine to identify the cases.</p>
<p>The ERR/Gy for all leukemia in the initial phase of the study was found to be 3.44/Gy (95% CI: 0.47, 9.78). Risk estimates were elevated for both types of cases (CLL: ERR/Gy=4.09; 95% CI: 0, 14.4, and non-CLL ERR/Gy=2.73;95% CI: 0, 13.5). A publication combining data from the initial and later phases of the leukemia study is in preparation.</p>
<p>The clean-up workers sent to the site and/or residing nearby in 1986-87 also sustained some exposure to internal radiation, raising the possibility that thyroid cancer risk might also be elevated in this population. We are completing a pilot study to investigate the feasibility of launching a new study to investigate this hypothesis in the liquidator cohort.</p>
<p>The study is based in Kiev, in the Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine and includes a collaboration with the National Cancer Registry of Ukraine.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="benefits"><a id="Benefits"></a>Benefits&nbsp;to Ukrainians</h3>
<p>The major benefit to Ukrainians and the scientific community at large is that the study will address concerns about the health effects of the accident on the workers who were involved with the clean-up. Other benefits include the establishment of a leukemia registry set up to identify all the cases that occurred during 1987-2000. A panel of international experts has provided local hematologists with a valuable opportunity for professional interaction. Publications describing the findings provide important new data \on the risks associated with low-dose, protracted exposure to external radiation.</p>
<p><a href="#Top">Back to top</a></p>
<h3 id="roles"><a id="Roles"></a>Roles&nbsp;of United States Participants</h3>
<ul>
<li>The NCI staff is charged with scientific direction and management of the projects.</li>
<li>The external advisory group (LAG) is comprised of recognized experts in the relevant scientific fields. They review the activities of the collaborative studies approximately once a year and report to the Director of the Division of Cancer Epidemiology and Genetics, NCI. Their comments and recommendations are also shared with the collaborating investigators.</li>
</ul>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="1030489" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030353" sys_dependentvariantid="1418" sys_relationshipid="7311034" sys_variantid="1418">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1138842" sys_dependentvariantid="2428" sys_relationshipid="7311038" sys_variantid="2428">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030358" sys_dependentvariantid="1418" sys_relationshipid="7311035" sys_variantid="1418">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030489" sys_dependentvariantid="1418" sys_relationshipid="7311036" sys_variantid="1418">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030593" sys_dependentvariantid="1418" sys_relationshipid="7311037" sys_variantid="1418">About the Accident</a></p>
</div>
<h3><a id="Top"></a>National Cancer Institute Research Staff</h3>
<h4>Chernobyl Research Program, Radiation Epidemiology Branch (REB)</h4>
<h5>Epidemiology</h5>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965" sys_relationshipid="7311055" sys_folderid="" sys_variantid="1965" sys_contentid="1087122">Elizabeth Cahoon, Ph.D., M.H.S., S.M.</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349690" sys_contentid="349690" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349690" sys_dependentvariantid="1965" sys_relationshipid="7311027" sys_variantid="1965">Kiyohiko Mabuchi, M.D., Dr.P.H.</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349683" sys_contentid="349683" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349683" sys_dependentvariantid="1965" sys_relationshipid="7311028" sys_variantid="1965">Maureen Hatch, Ph.D.</a></li>
</ul>
<h5>Dosimetry</h5>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_contentid="939611" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="939611" sys_dependentvariantid="1965" sys_relationshipid="7311029" sys_variantid="1965">Vladimir Drozdovitch, Ph.D.</a></li>
</ul>
<h5>Genetics</h5>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349630" sys_contentid="349630" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349630" sys_dependentvariantid="1965" sys_relationshipid="7311032" sys_variantid="1965">Stephen Chanock, M.D.</a> Director, DCEG</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=966087" sys_contentid="966087" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="966087" sys_dependentvariantid="1965" sys_relationshipid="7311033" sys_variantid="1965">Michael Dean, Ph.D.</a>, Chief, Laboratory of Translational Genomics</li>
<li>Meredith Yeager, Ph.D., Scientific Director (Contractor), Cancer Genomics Research (CGR) Laboratory</li>
<li>Amy Hutchinson, M.S., Director of Operations (Contractor), CGR</li>
</ul>
<h5>Statistics</h5>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349604" sys_contentid="349604" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349604" sys_dependentvariantid="1965" sys_relationshipid="7311031" sys_variantid="1965">Mark Little, D.Phil.</a></li>
</ul>
<h5>Program Support</h5>
<ul>
<li>Kathleen Stine, M.B.A.</li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h3>Current Collaborators</h3>
<h4>United States</h4>
<ul>
<li>Stewart Finch, M.D.&nbsp;&ndash; Hematology</li>
<li>Robert McConnell, M.D.&nbsp;&ndash; Endocrinology</li>
<li>Robert Reiss, M.D.&nbsp;&ndash; Hematology</li>
<li>Lydia Zablotska, M.D., Ph.D.&nbsp;&ndash; Epidemiology</li>
</ul>
<h4>Research Institute of Endocrinology &amp; Metabolism, Kyiv, Ukraine</h4>
<ul>
<li>Mykola Tronko, M.D., Ph.D.&nbsp;&ndash; Director</li>
<li>Valeriy Tereshchenko, M.D., Ph.D.&nbsp;&ndash; Project Director, Epidemiology</li>
<li>Tatiana Bogdanova, Ph.D. &ndash; Pathology</li>
<li>Viktor Shpak &ndash; Data Management</li>
</ul>
<h4>Republican Research Center of Radiation Medicine &amp; Human Ecology, Gomel, Belarus</h4>
<ul>
<li>Alexander Rozhko, M.D., Ph.D.&nbsp;&ndash; Director</li>
<li>Eldar Nadyrov, M.D., Ph.D. &ndash; Deputy Director, Pathology</li>
<li>Vasilina Yauseyenka, Ph.D.&nbsp;&ndash; Epidemology</li>
<li>Victor Minenko, Ph.D. &ndash; Dosimetry</li>
<li>Ilya Veyalkin, Ph.D.&nbsp;&ndash; Epidemiology</li>
<li>Olga Polyanskaya, M.D., Ph.D. &ndash; Epidemiology</li>
</ul>
<h4>Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, Kyiv, Ukraine</h4>
<ul>
<li>Dimitry A. Bazyka, M.D. &ndash; Director</li>
<li>Anatoly Ye Romanenko, M.D. &ndash; Honorary Director</li>
<li>Natalia A. Gudzenko, M.D., Ph.D. &ndash; Epidemiology</li>
<li>Vadim V. Chumak, Ph.D. &ndash; Dosimetry</li>
<li>Yuriy Belayev&nbsp;&ndash; Data Management</li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h4>In Memoriam</h4>
<div class="callout-box center">
<p>Dr. Elaine Ron (1943-2010), NCI, provided extraordinary leadership and helped shape and oversee the NCI-Chernobyl program.</p>
<p>Dr. Geoffrey Howe (1943-2006), Columbia University, made invaluable contributions.</p>
<p>Dr. Daniel Fink (1948-2007), Columbia University, was instrumental in designing the protocol for analyzing laboratory samples.</p>
<p>Dr. Gilbert Beebe (1912-2003), NCI, Dr. Jacob Robbins (1923-2008), NIDDK, and Dr.Terry Thomas (1948-2002), NCI, were involved from the earliest days following the accident and continued to provide scientific input until the time of their respective deaths.</p>
</div>
</div>]]></content>
  </row>
  <row para_id="1030547" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7258942" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030353" sys_dependentvariantid="1418">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_variantid="2428" sys_relationshipid="7258943" sys_siteid="475" rxinlineslot="103" sys_dependentid="1138842" sys_dependentvariantid="2428">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7258944" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030358" sys_dependentvariantid="1418">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7258945" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030489" sys_dependentvariantid="1418">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7258946" sys_siteid="475" rxinlineslot="103" sys_dependentid="1030593" sys_dependentvariantid="1418">About the Accident</a></p>
</div>
<p>Data on heritable effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. However, few studies to date have had adequate statistical power to detect effects of the magnitude expected based on animal data, and most have not been of low-dose, protracted exposures associated with nuclear accidents and environmental exposures. Moreover, they have not taken advantage of the new genomic technologies that are capable of surveying the landscape of both the genome and transcriptome, including somatic alterations.</p>
<p>In Chernobyl-exposed areas of Ukraine and Belarus, excess minisatellite mutations have been reported, by some but not all studies, in children born after the accident. To pursue this observation and to generate new data on heritable effects of parental radiation exposure, investigators are&nbsp;carrying out a study of parent-child trios in which at least one parent was exposed to Chernobyl radiation as a clean-up worker (mean dose&gt;=100 mGy) and/or evacuee from a contaminated area (mean &gt;= 50 mGy). The aim is to investigate the heritable and <em>de novo</em> mutation rates of the spectrum of genetic variants in trios, in particular looking at effects in children and mapping them to possible parental origin of the chromosome.</p>
<p>In collaboration with the Research Center for Radiation Medicine in Ukraine, REB investigators have collected&nbsp;blood and/or buccal cell samples and epidemiologic data for 220 out of the planned&nbsp;450 trios of parents with preconception doses and their unexposed offspring to date. Doses to the gonads from the time of the accident to the time of conception have been&nbsp;reconstructed for all parents, both&nbsp;clean-up workers (also referred to&nbsp;as&nbsp;&ldquo;liquidators&rdquo;) and evacuees. The study is using&nbsp;state-of-the-art genomic technologies to characterize the genomes of the trios to determine whether parental radiation exposure is associated with genetic mutations in the offspring. Investigators are&nbsp;examinin&nbsp;<em>de novo</em> mutation rates, minisatellite mutations, copy number alterations, and variations in telomere length.</p>
<p>Read details about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100732" sys_contentid="1100732" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7258939" sys_siteid="475" rxinlineslot="103" sys_dependentid="1100732" sys_dependentvariantid="1418">dosimetry developed for the TRIO study</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349604" sys_contentid="349604" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7258940" rxinlineslot="103" sys_dependentid="349604" sys_dependentvariantid="1965">Mark Little</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349642" sys_contentid="349642" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7258941" rxinlineslot="103" sys_dependentid="349642" sys_dependentvariantid="1965">Amy Berrington de Gonz&aacute;lez</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1030563" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3>Chernobyl Accident: Radiation and Health Effects</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030353" sys_contentid="1030353" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1030353" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275448" sys_variantid="1418">Chernobyl Nuclear Accident - Home</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=2428&amp;sys_contentid=1138842" sys_contentid="1138842" inlinetype="rxhyperlink" sys_dependentvariantid="2428" sys_dependentid="1138842" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275449" sys_variantid="2428">Publications</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030358" sys_contentid="1030358" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1030358" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275450" sys_variantid="1418">DCEG Research on Chernobyl</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030489" sys_contentid="1030489" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1030489" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275451" sys_variantid="1418">Researchers and Collaborators</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030593" sys_contentid="1030593" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1030593" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275452" sys_variantid="1418">About the Accident</a></p>
</div>
<p>A major health effect of the 1986 Chernobyl nuclear power plant accident is the increase in incidence of thyroid cancer, particularly among those exposed to radioactive fallout as children or adolescents. Studies of this population, carried out by REB and the Institute of Endocrinology and Metabolism in Ukraine, have found a strong, linear relationship between individual I-131 thyroid dose and risk of thyroid cancer that remains elevated two decades after exposure (Brenner et al., 2011). The investigators estimate that half of incident cancers in the cohort could be attributed to I-131 exposure. A parallel study in Belarus found a similarly strong association for prevalent thyroid cancers (Zablotska et al., 2011).</p>
<p>To date, the molecular signatures as well as the mechanisms underlying this association remain poorly understood. Jointly with colleagues at IEM, Bundeswehr Institute of Radiobiology, and University of Pittsburgh, we recently conducted studies of mRNA expression and targeted somatic alterations using DNA and RNA aliquots extracted from tumor/normal pairs drawn from 62 Ukrainian cases received through the Chernobyl Tissue Bank (CTB) (Abend et al., 2012; Abend et al., 2013; Leeman-Neill et al., 2013; Leeman-Neill et al., 2014). For the first time, we were able to link altered gene expression with individual I-131 doses; we identified and validated 11 genes with evidence of differential (tumor/normal tissue) dose-expression (Abend et al., 2012), and an additional eight genes in tumor tissue and six genes in normal tissue exhibiting dose-expression associations (Abend et al., 2013). We further evaluated dose-response relationship for known somatic alterations that may occur in sporadic and radiation-related thyroid cancer (<em>BRAF</em>, <em>RAS</em> point mutations and <em>RET/PTC,</em> <em>PAX8/PPARG </em>rearrangements). We reported a significant inverse association between I-131 dose and either <em>BRAF </em>or <em>RAS </em>point mutations as well as a significant concave association with I-131 dose for <em>RET/PTC</em> and <em>PAX8/PPARG </em>chromosomal rearrangements (Leeman-Neill et al., 2013). In an early pilot study of RNA-seq analysis in two UkrAm cases, we identified an additional rearrangement, an <em>ETV6</em>-<em>NTRK3</em> fusion that was then confirmed by qRT-PCR to be present in 15% of all cases (Leeman-Neill et al., 2014).</p>
<p>Following up on these focused genetic studies, REB researchers are conducting a large-scale study of comprehensive genomic characterization of radiation-related PTCs using a combination of biological samples and information on radiation exposure, clinical, and demographic characteristics from the CTB. The primary objective of the study is to evaluate genomic, transcriptomic, and epigenomic landscapes of 450 radiation-related PTCs using the whole genome sequencing technologies and to compare these with sporadic, unrelated to radiation exposure PTCs (500 TCGA and 50 CTB cases from the Ukraine) and across different levels of I-131 exposure. The study has the potential to provide unique insights into the mechanisms of radiation carcinogenesis and to generate a rich data resource.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275447" sys_variantid="1965">Lindsay Morton</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275446" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
<h3>Key Publications</h3>
<p>Brenner AV, Tronko MD, Hatch M, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21406336">I-131 dose-response for incident thyroid cancers related to the Chornobyl accident in Ukraine</a>. <span><em>Environ Health Perspect </em></span>2011;119:933-939.</p>
<p>Zablotska LB, Ron E, Rozhko AV, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21102590">Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chornobyl accident</a>. <em>BJC</em> 2011;104:181-187.</p>
<p>Abend M, Pfeiffer RM, Ruf C, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22848350"><sup> </sup>Dose dependent gene expression in thyroid cancer and corresponding normal tissue following the Chernobyl accident</a>. <em>PloS One</em> 2012;7: e39103.</p>
<p>Abend M, Pfeiffer RM, Ruf C, et al. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24045656">Iodine-131 dose-dependent gene expression: Alterations in both normal and tumour thyroid tissues of post-Chernobyl thyroid cancers</a>. <em>Br J Cancer</em> 2013;109:2286-2294.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1030593" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The accident of April 26, 1986 at the Chernobyl nuclear power plant in Ukraine was the most severe ever to have occurred in the civilian nuclear power industry (UNSCEAR 2008). It happened during a routine test, intended to demonstrate how long the turbines would spin after a power loss. Prior to the test, the automatic shutdown mechanisms had been disabled. Improper, unstable operation of the reactor, which itself had design flaws, allowed an uncontrollable power surge to occur, resulting in steam explosions that completely destroyed the reactor.</p>
<h3><strong>Occupational Exposures and Health Effects</strong></h3>
<p>Two workers died in the immediate aftermath, and high doses of radiation to 134 plant staff and emergency personnel resulted in acute radiation syndrome that rapidly proved fatal for 28 of them. In addition to this group of emergency workers, several hundred thousand were involved in clean-up operations during the first four years following the accident. These workers were exposed to both external radiation and to radioiodines. The incidence of leukemia, thyroid cancer, and cataracts among groups of clean-up workers has been the subject of epidemiologic studies.</p>
<h3><strong>Environmental Exposures and Health Effects</strong></h3>
<p>The accident also caused the largest uncontrolled atmospheric releases of radioactive materials ever recorded for any civilian operation. Two radionuclides, short-lived iodine-131 (<sup>131</sup>I with a half-life of eight days) and long-lived cesium-137 (<sup>137</sup>Cs with a half-life of 30 years), were particularly significant with respect to the environmental contamination and to the radiation doses they delivered to vast numbers of people. The atmospheric releases lasted about 10 days, during which time the wind changed direction several times. This, coupled with rainfall, led to widespread, substantial contamination of an area within approximately 300 miles of the plant, principally to northern Ukraine, Belarus and parts of Russia (see map of <sup>137</sup>Cs fallout on the ground). The radioactive clouds further dispersed over the entire northern hemisphere, depositing lesser amounts of radioactive material over large areas of the former Soviet Union and some other countries in Europe.</p>
<p>For the short-lived <sup>131</sup>I, the main pathway of human exposure was via the transfer of&nbsp;material deposited on pasture grass to cow&rsquo;s milk. Young children residing in contaminated areas, who consume relatively large quantities of fresh cow&rsquo;s milk, received high thyroid doses of <sup>131</sup>I because iodine concentrates in the thyroid, and their thyroid mass is small. Since the Chernobyl accident, there has been a striking increase in the reported incidence of thyroid cancer among children who resided in parts of Belarus, Russia, and Ukraine.</p>
<div sys_dependentvariantid="2084" sys_dependentid="1038727" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7274844">
<figure class="image-center-full centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1038727&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1038727&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1038727&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1038727">Enlarge</a></div>
<figcaption>
<div class="caption-container no-resize">
<p>Map from the 2008 United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) report showing 137-Cs deposition levels in Belarus, the Russian Federation and Ukraine as of December 1989</p>
</div>
</figcaption>
</figure>
</div>
<p></p>
<p></p>
<p>The increase in the reported incidence of thyroid cancer started some four to five years after the accident and has continued to manifest itself. As the underlying incidence rate of thyroid cancer in young children is normally very low, many of the cases diagnosed before age 15 have been attributed to the releases from the Chernobyl accident.&nbsp;As of 2005, four thousand cases of thyroid cancer have resulted, including 15 thyroid cancer deaths. Several thousands more are expected to develop among people who were children when the accident occurred. A number of epidemiologic studies of thyroid cancer and other thyroid diseases have been or are being conducted in Belarus and in Ukraine. To date, there has been no persuasive evidence of any health effect, other than thyroid cancer, that can be attributed to radioactive releases from the Chernobyl accident (UNSCEAR 2008). However, the accident is presumably the cause of a range of mental health issues, among both workers and members of the public.</p>
<h3>Key Publication</h3>
<p><a href="http://www.unscear.org/docs/reports/2008/11-80076_Report_2008_Annex_D.pdf">UNSCEAR 2008 Report, Vol. II, Annex D: Health effects due to radiation from the Chernobyl accident (pdf, 5.5 MB)</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1033198" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p></p>
<p>Meet the current&nbsp;fellows in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_relationshipid="7376280" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Metabolic Epidemiology Branch</a> and learn about <a href="http://dceg.cancer.gov/fellowship-training/become-a-fellow/research-training-areas/meb-specific">research training opportunities.</a></p>
<p><strong></strong></p>
<h3><strong><a id="Privado"></a>Christian S. Alvarez Privado, Ph.D., M.S.P.H. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376298" sys_dependentid="1119850" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1119850&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Christian S. Alvarez Privado, Ph.D., M.S.P.H., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in May 2018. He earned his Ph.D in epidemiology from the University of Michigan, Ann Arbor. Prior to pursuing his Ph.D., Dr. Alvarez received an M.S. in public health from Pompeu Fabra University in Barcelona, Spain. For his doctoral research, he explored the current epidemiological profile of prostate cancer in southern Thailand and assessed the potential impact of introducing a population-based screening program for prostate cancer on the burden of the disease in that region. Dr. Alvarez has also conducted research on cervical cancer screening programs in Latin America and in the Caribbean. He coordinated the development of a national plan for the prevention and control of cervical cancer in Guatemala. In MEB, Dr. Alvarez works with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/mcglynn-katherine">Katherine A. McGlynn, Ph.D.</a>, senior investigator, on studies of liver cancer in the United States and internationally.</p>
<p>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/myncbi/christian.alvarez%20privado.1/bibliography/public/">Scientific publications -Christian Alvarez</a></p>
<h3><strong><a id="Aversa"></a>John Aversa, M.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376299" sys_dependentid="1146735" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1146735&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>John Aversa, M.D., became a postdoctoral fellow in the DCEG Metabolic Epidemiology Branch (MEB) in July 2018. He earned a B.S. in chemical and biomolecular engineering from the University of Notre Dame in 2012 and an M.D. from the Indiana University School of Medicine in 2016. He has completed two years of general surgery residency at Indiana University. He came to the National Institutes of Health as part of the NCI&rsquo;s Surgical Oncology Fellowship Program. He will spend a total of 17 months working under the tutelage of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052539" sys_contentid="1052539" inlinetype="rxhyperlink" sys_relationshipid="7376297" sys_dependentvariantid="1965" sys_dependentid="1052539" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Constanza Camargo, Ph.D., Earl Stadtman Investigator, MEB</a> and will assist in efforts to better understand the epidemiology and early detection of gastrointestinal tumors with a special focus on esophageal cancer.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h3><strong><a id="Butler"></a>Ebone&eacute; Nicole Butler, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376300" sys_dependentid="1101323" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1101323&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Ebone&eacute; Nicole Butler, Ph.D., M.P.H., joined DCEG as an NCI Cancer Prevention Fellow in October 2017. Dr. Butler earned a B.A. in biochemistry from Rice University in Houston, Texas and an M.P.H. in epidemiology from Emory University in Atlanta, Georgia. She completed her Ph.D. in epidemiology at the University of North Carolina at Chapel Hill. Dr. Butler&rsquo;s research interests center on integrating epidemiology, molecular biology, and pathology to identify and evaluate prognostic and predictive biomarkers in prostate and breast tumors. Her research also seeks to better understand prostate and breast cancer etiology in people of African descent. In the Metabolic Epidemiology Branch, Dr. Butler works with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349597" sys_contentid="349597" inlinetype="rxhyperlink" sys_relationshipid="7376286" sys_dependentvariantid="1965" sys_dependentid="349597" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Michael B. Cook, Ph.D., </a>investigator, to examine prostate cancer etiology and to evaluate novel biomarkers that may identify aggressive prostate tumors at time of diagnosis.</p>
<p>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/ebonee.butler.2/bibliography/40896570/public/?sort=date&amp;direction=ascending">Scientific Publications - Ebone&eacute; Butler</a></p>
<h3><strong><a id="Byrd"></a>Doratha (Armen) Byrd, Ph.D., M.P.H. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376301" sys_dependentid="1142713" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1142713&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Doratha (Armen) Byrd, Ph.D., M.P.H., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in January 2019. Dr. Byrd received a B.S. in biology and an M.P.H. in epidemiology from the University of Florida. She completed her Ph.D. in epidemiology from Emory University, where her dissertation research focused on the development and validation of novel, inflammation biomarker panel-weighted dietary and lifestyle inflammation scores, and their associations with colorectal neoplasms.&nbsp; In MEB, Dr. Byrd works under the mentorship of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/sinha-rashmi">Rashmi Sinha, Ph.D.</a>, senior investigator, <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/abnet-christian">Christian Abnet, Ph.D, M.P.H</a>, Chief and senior investigator, MEB, <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/vogtmann-emily">Emily Vogtmann, Ph.D, M.P.H.</a>, Earl Stadtman tenure-track investigator, and <a href="https://dceg.cancer.gov/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows">Erikka Loftfield, Ph.D</a><u>.</u>, research fellow. Currently, Dr. Byrd is conducting methodologic and etiologic microbiome studies and investigating associations of diet with the gut metabolome.</p>
<h3><strong><a id="Gutierrez"></a>Andres Julian Gutierrez Escobar, Ph.D. &ndash; Postdoctoral Fellow </strong></h3>
<div sys_relationshipid="7376302" sys_dependentid="1142680" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1142680&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Andres J. Gutierrez-Escobar, Ph.D., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in February 2019. He received an M.S. in biomedical sciences from the Universidad del Quind&iacute;o and a Ph.D. in biology from the Pontificia Universidad Javeriana in Colombia. His dissertation focused on phylogenomic analysis of <em>Helicobacter pylori</em> isolates from residents in high gastric cancer risk area in Colombia.&nbsp; Dr. Gutierrez works on the <em>Helicobacter pylori</em> Genome Project under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052539" sys_contentid="1052539" inlinetype="rxhyperlink" sys_relationshipid="7376290" sys_dependentvariantid="1965" sys_dependentid="1052539" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">M. Constanza Camargo, Ph.D., </a>Earl Stadtman Tenure-Track Investigator, MEB, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" sys_relationshipid="7376291" sys_dependentvariantid="1965" sys_dependentid="349628" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Charles Rabkin, M.D., </a>senior investigator, Infections and Immunoepidemiology Branch. He also works with Dr. Camargo and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=52&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_contentid="349612" inlinetype="rxhyperlink" sys_relationshipid="7376292" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Christian Abnet, Ph.D., M.P.H., </a>Chief and senior investigator, MEB, on a gastric cancer genome-wide association study in Hispanics/Latinos.</p>
<h3><a id="Hada"></a>Manila Hada, Ph.D., M.P.H. &ndash; Postdoctoral Fellow</h3>
<div sys_relationshipid="7376303" sys_dependentid="1080875" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1080875&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Dr. Manila Hada joined the Metabolic Epidemiology Branch (MEB) in January 2017 as a postdoctoral fellow.  Dr. Hada received her B.Sc. in pharmacy from the Kathmandu University, Nepal. She obtained her Ph.D. in biological chemistry in 2015 and her M.P.H. in epidemiology with a certification in global health in 2016, both from the University of Michigan, Ann Arbor. Her Ph.D. thesis focused on understanding how cancer cells use different mechanisms to prevent their own death. In neuroblastoma cells, she demonstrated that a DNA repair factor Ku70 acts as a survival factor to prevent cell death by binding to a pro-cell death protein --Bax. During her M.P.H. studies, she investigated the prevalence of cervical cancer and attitudes towards cervical self-sampling in southern Thailand and assessed the role of serum-retinol and risk of overall and site-specific cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study.&nbsp; Working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_relationshipid="7376284" sys_dependentvariantid="1965" sys_dependentid="349652" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Gretchen Gierach, Ph.D.</a>, investigator, MEB, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=802306" sys_contentid="802306" inlinetype="rxhyperlink" sys_relationshipid="7376285" sys_dependentvariantid="1965" sys_dependentid="802306" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Dr. Britton Trabert</a>, investigator, MEB, Dr. Hada's research focuses on molecular epidemiologic studies of breast and gynecologic cancers, using circulating hormones and intermediate endpoints to elucidate the etiology of hormonally-related female cancers.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Hada%2C%20Manila%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications &ndash; Manila Hada</a></p>
<h3><a id="Hashemian"></a>Maryam Hashemian, M.D., Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_relationshipid="7376304" sys_dependentid="1067271" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1067271&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Maryam Hashemian, M.D., Ph.D., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in August 2016. She earned an M.D., from Mashhad University of Medical Sciences, Iran in 2002 and a Ph.D. in nutrition from Shahid Beheshti University of Medical Sciences, Iran in 2015. Dr. Hashemian&rsquo;s interest in nutritional epidemiology led her to study the association between dietary intake of minerals and esophageal cancer for her Ph.D. dissertation, utilizing the Golestan Cohort Study and working with Reza Malekzadeh, M.D., professor, Tehran University of Medical Sciences (TUMS) and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=52&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_contentid="349612" inlinetype="rxhyperlink" sys_relationshipid="7376283" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Christian Abnet, Ph.D., M.P.H.</a>, Chief and senior investigator, MEB. Subsequently, Dr. Hashemian did a postdoctoral fellowship in the Digestive Disease Research Institute, TUMS, working on biomarkers in relation to diet and esophageal cancer in the Golestan Cohort Study. Her primary research interest is the nutritional epidemiology of gastrointestinal cancers. She is also interested in metabolic syndrome and non-alcoholic fatty liver disease. Currently, Dr. Hashemian is working on toenail trace element status and esophageal cancer with her mentors, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1033924" sys_contentid="1033924" inlinetype="rxhyperlink" sys_relationshipid="7376288" sys_dependentvariantid="1965" sys_dependentid="1033924" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Gwen Murphy, Ph.D., M.P.H., </a>staff scientist, MEB, and Dr. Abnet.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/maryam.hashemian.1/bibliography/public/">Scientific Publications &ndash; Maryam Hashemian</a></p>
<h3><a id="Huang"></a>Jiaqi Huang, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_relationshipid="7376305" sys_dependentid="1042114" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1042114&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Jiaqi Huang, Ph.D., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in January 2016. Dr. Huang received her M.S. in molecular biology/biomedicine in June 2009 and her Ph.D. in epidemiology in December 2015, both from the Karolinska Institute of Sweden. Her doctoral research focused on the epidemiology and etiology of pancreatic cancer and included both molecular and cancer registry-based epidemiologic studies.&nbsp; Her work included variant profiling of candidate genes in pancreatic cancer based on the anchored-multiplex PCR method. She also evaluated potential risk factors for pancreatic cancer, including poor oral hygiene, hepatitis C or B virus infection, <em>Helicobacter pylori</em> infection, <em>N</em>-nitrosamine, and psychological stress. &nbsp;She is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349619" sys_contentid="349619" inlinetype="rxhyperlink" sys_relationshipid="7376282" sys_dependentvariantid="1965" sys_dependentid="349619" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Demetrius Albanes, M.D.</a>, senior investigator, MEB, to investigate prostate cancer etiology, metabolomics profiling of cancer, and vitamin/nutrient exposures as they relate to cancer.&nbsp;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/1tqmt-hsqmtkj/bibliography/public/">Scientific Publications - Jiaqi Huang</a></p>
<h3><strong><a id="Hurwitz"></a>Lauren Hurwitz, Ph.D. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376306" sys_dependentid="1133138" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133138&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Lauren Hurwitz, Ph.D., joined the Metabolic Epidemiology Branch as a Cancer Prevention Fellow in September 2018. Dr. Hurwitz received her Ph.D. in epidemiology from the Johns Hopkins Bloomberg School of Public Health in 2018. &nbsp; For her doctoral research, she evaluated associations between use of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence, mortality, and recurrence. She also investigated the relationship between aspirin use and markers of immune cells in prostate tissue. In MEB, Dr. Hurwitz is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/trabert-britton">Britton Trabert, Ph.D.</a>, investigator, to examine whether modifiable risk factors modify associations between aspirin use and cancer risk, and <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/cook-michael-b">Michael Cook, Ph.D.</a>, investigator, to study the etiology of and risk factors for prostate cancer.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Hurwitz%2C%20Lauren%20M%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications &ndash; Lauren Hurwitz</a></p>
<h3><strong><a id="Julian-Serrano"></a>Sachelly Julian-Serrano, M.H.S.N.&ndash; Postbaccalaureate Fellow </strong></h3>
<div sys_relationshipid="7376307" sys_dependentid="1144201" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1144201&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Sachelly Julian-Serrano joined the Metabolic Epidemiology Branch (MEB) as a postbaccalaureate fellow in October 2018. Ms. Julian-Serrano earned her master&rsquo;s degree in public health with specialization in nutrition from the University of Puerto Rico, Medical Sciences Campus in 2017. Her master&rsquo;s research project focused on the modifying effect of genetic ancestry in the association of red and processed meats consumption and colorectal neoplasia risk in Puerto Rican Hispanics, under the mentorship of Dr. Marcia Cruz-Correa. In July 2018, she completed her dietetic internship program from the same university. Sachelly is currently working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349636" sys_contentid="349636" inlinetype="rxhyperlink" sys_relationshipid="7376293" sys_dependentvariantid="1965" sys_dependentid="349636" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D., senior investigator, MEB</a>, where she investigates the genetic susceptibility of higher blood iron levels and hematologic traits and risk of pancreatic cancer within the PanScan and PanC4 consortia.</p>
<h3></h3>
<h3><a id="Loftfield"></a>Erikka Loftfield,&nbsp;Ph.D.&nbsp;&ndash; Research Fellow</h3>
<div sys_relationshipid="7376308" sys_dependentid="662095" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=662095&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Erikka Loftfield, Ph.D., joined DCEG as a predoctoral fellow through the Yale University-NCI Partnership Training Program in August 2013. Dr. Loftfield completed her Ph.D. at Yale University in 2015, became a postdoctoral fellow in the Nutritional Epidemiology Branch (NEB) in March 2015, and was promoted to Research Fellow in the <a href="http://dceg.cancer.gov/about/organization/programs-ebp/meb">Metabolic Epidemiology Branch (MEB)</a> in November 2016. She earned a B.A. in biology from Cornell University and an M.P.H. in chronic disease epidemiology with a concentration in global health from the Yale School of Public Health.&nbsp;Dr. Loftfield&rsquo;s dissertation research explored the associations of coffee drinking with mortality and cancer and used emerging technologies, including untargeted metabolomics and multiplex immune and inflammatory marker panels, to help elucidate potential mechanisms underlying these associations.&nbsp;Currently, under the mentorship of&nbsp;<a href="http://dcegpreview.cancer.gov/about/staff-directory/biographies/O-Z/sinha-rashmi">Rashmi Sinha, Ph.D.</a>, senior investigator and&nbsp;<a href="http://dcegpreview.cancer.gov/about/staff-directory/biographies/K-N/freedman-neal">Neal D. Freedman, Ph.D., M.P.H.</a>, senior investigator,&nbsp;Dr. Loftfield&rsquo;s research seeks to advance our understanding of associations between prevalent diet-related exposures, such as coffee and obesity, and cancer risk through integrated studies of dietary intake, diet-related metabolites, and the microbiome. In addition, Dr. Loftfield is interested in dietary assessment and epidemiologic methods including the profiling of heterogeneous foods, such as coffee, using metabolomics, and the evaluation of biospecimen collection methods for multi-omic analyses in large, population-based studies.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0branch=ALL&amp;searchTxtAuth=Loftfield%20e&amp;authorOption=exact&amp;pi=2001309575">Scientific Publications - Erikka Loftfield</a></p>
<h3><strong><a id="McClain"></a>Kathleen M. McClain, Ph.D., M.S. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376309" sys_dependentid="1133137" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133137&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Kathleen M. McClain, Ph.D., M.S., joined the Metabolic Epidemiology Branch (MEB) of DCEG as a postdoctoral fellow in September 2018. Dr. McClain earned her Ph.D. in epidemiology from the University of North Carolina at Chapel Hill in May 2018, her M.S. in biostatistics from Georgetown University, and her B.S. in mathematics from Hofstra University. Her doctoral research focused on associations between dietary intake of polyunsaturated fatty acids and Barrett&rsquo;s esophagus, esophageal adenocarcinoma, and gastric cardia adenocarcinoma under the mentorship of Dr. Marilie Gammon. Her research interests include modifiable lifestyle factors and cancer, particularly in rare tumors. In DCEG, Dr. McClain is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/Moore-Steven">Steven C. Moore, Ph.D., M.P.H.</a>, investigator, MEB, on studies examining the components of energy balance, metabolomics, and cancer.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=McClain%2C%20Kathleen%20M%5BFull%20Author%20Name%5D%20OR%20McClain%20KM%5BAuthor%5D%20NOT%2027725734%5Buid%5D&amp;cmd=DetailsSearch">Scientific Publications - Kathleen McClain</a></p>
<h3><br /><a id="Michels"></a>Kara Michels, Ph.D.- Postdoctoral Fellow</h3>
<div sys_relationshipid="7376310" sys_dependentid="1061492" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1061492&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Kara Michels, Ph.D., joined the Metabolic Epidemiology Branch (MEB) of DCEG in 2016 after having completed two years of postdoctoral research at the&nbsp;<em>Eunice Kennedy Shriver&nbsp;</em>National Institute of Child Health and Human Development (NICHD). She received her Ph.D. in Epidemiology from Vanderbilt University (2014), her M.P.H. from the University of Kentucky, and her B.A. in biology from Willamette University. Dr. Michels is interested in how potentially modifiable factors, such as diet, inflammation, and hormonal exposures, influence women&rsquo;s reproductive health across the lifespan. At DCEG, working under the mentorship of&nbsp;<a href="http://dcegpreview.cancer.gov/fellowship-training/what-our-fellows-do/meet-current-fellows/hreb-fellows#Trabert">Britton Trabert, Ph.D., M.S.</a>, investigator, MEB, she is studying the etiology of ovarian and endometrial cancers&mdash;focusing on cancer risk associated with molecular markers and reproductive factors. Some of her recent work explored the interaction between and influence of oral contraceptive use and health behaviors on cancer development. Dr. Michels is also investigating one-carbon metabolism and risk for endometrial cancer and is evaluating factors associated with postmenopausal androgen metabolism.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/kara.michels.1/bibliography/public/">Scientific Publications - Kara Michels</a></p>
<h3 id="Petrick"><a id="Petrick"></a>Jessica Petrick, Ph.D., M.P.H.&nbsp;&ndash; Postdoctoral Fellow</h3>
<div sys_relationshipid="7376311" sys_dependentid="810215" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=810215&amp;sys_command=preview" alt="Jessica Petrick"><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Jessica L. Petrick, Ph.D., M.P.H., joined&nbsp;DCEG as a postdoctoral fellow in June 2014.&nbsp;She obtained a B.A. in public health studies and medical anthropology, and an M.P.H. (2008) in epidemiology and health policy from Case Western Reserve University. Dr. Petrick received her Ph.D. in epidemiology from the University of North Carolina at Chapel Hill in 2014. For her doctoral dissertation, Dr. Petrick examined the intake of dietary flavonoids in relation to the incidence of Barrett esophagus and esophageal and gastric cancer, and to survival among esophageal and gastric cancer cases. Her Ph.D. mentor was Dr. Marilie Gammon. In the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_relationshipid="7376281" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Metabolic Epidemiology Branch (MEB)</a>, Dr. Petrick works with <a href="http://dcegpreview.cancer.gov/about/staff-directory/biographies/K-N/mcglynn-katherine">Katherine A. McGlynn, Ph.D.</a>, senior investigator, on liver cancer studies assessing gender-specific effects of risk factors such as coffee consumption, diabetes, obesity and steroid hormone levels, and with <a href="http://dcegpreview.cancer.gov/about/staff-directory/biographies/K-N/cook-michael-b">Michael B. Cook, Ph.D.</a>, investigator, on the effects of adiposity on esophageal adenocarcinoma risk.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Petrick+J&amp;authorOption=exact&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications - Jessica Petrick</a></p>
<h3><strong><a id="Pritchett"></a>Natalie Rose Pritchett, M.S.P.H. &ndash; Predoctoral Fellow </strong></h3>
<div sys_relationshipid="7376312" sys_dependentid="1133140" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133140&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Natalie Rose Pritchett, M.S.P.H., joined the Metabolic Epidemiology Branch (MEB) as a predoctoral fellow in September 2018. Ms. Pritchett earned her M.S.P.H. in health policy and management from the University of North Carolina at Chapel Hill in 2011. Working with Dr. Douglas Morgan, her thesis research focused on a cost-effectiveness analysis of screening and treating <em>H. </em><em>pylori </em>to prevent stomach cancer in a high-risk population in Honduras. Since her graduation, she completed a Peace Corps service in Nicaragua and worked as an oncology research assistant in Rwanda for Partners in Health. In September 2018, Ms. Pritchett returned to school to earn a D.R.P.H. from George Washington University with a concentration in environmental and occupational health. Ms. Pritchett&rsquo;s research interests include the study of upper gastrointestinal cancers in high-risk populations and environmental exposure risk factors, particularly indoor air pollution and polycyclic aromatic hydrocarbons (PAHs). Ms. Pritchett is working with <u></u><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349670" sys_contentid="349670" inlinetype="rxhyperlink" sys_relationshipid="7376289" sys_dependentvariantid="1965" sys_dependentid="349670" rxinlineslot="103" sys_siteid="475" sys_variantid="1965"><u>Sanford M. Dawsey M.D.</u>, </a>senior investigator, MEB, to investigate the epidemiology of esophageal squamous cell carcinoma in hotspot areas, especially the distinct geographic band along the eastern Africa corridor extending from Ethiopia to South Africa.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Pritchett%2C+Natalie+%5BFull+Author+Name%5D">Scientific Publications &ndash; Natalie Pritchett</a></p>
<h3>&nbsp;<a id="Saint-Maurice"></a>Pedro F. Saint-Maurice, Ph.D. &ndash; Postdoctoral Fellow</h3>
<div sys_relationshipid="7376313" sys_dependentid="1068088" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1068088&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Pedro Saint-Maurice, Ph.D., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in October 2016. He obtained his Ph.D. in kinesiology at Iowa State University in 2013 under the supervision of Gregory Welk. He subsequently worked as a research consultant, establishing research collaborations/consulting services between the Physical Activity and Health Promotion Laboratory at Iowa State University and the Cooper Institute, located in Dallas, Texas. His dissertation work focused on developing more accurate methods to build/test physical activity measures for epidemiology research and culminated with the creation and calibration of an online instrument called the Youth Activity Profile (YAP) that is now being used as part of a large childhood obesity campaign in the NFL PLAY60 FITNESSGRAM project. &nbsp;In MEB, Dr. Saint-Maurice is working under the mentorship of <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/matthews-charles">Charles E. Matthews</a>, Ph.D., senior investigator.&nbsp;His research focuses on understanding the dose-response relationship between physical activity and different chronic diseases, including cancer. Dr. Saint-Maurice is also interested in different physical activity measurement tools and the impact of measurement error when studying the benefits of physical activity for health.&nbsp;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/myncbi/pedro.de%20saint-maurice%20maduro.1/bibliography/public/">Scientific Publications &ndash; Pedro Saint-Maurice</a></p>
<h3><strong><a id="Salerno"></a>Elizabeth Ann Salerno, Ph.D., M.P.H. - Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376314" sys_dependentid="1133139" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1133139&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Elizabeth Ann Salerno, Ph.D., M.P.H., joined the Metabolic Epidemiology Branch (MEB) as a Cancer Prevention Fellow in September 2018. Dr. Salerno earned her Ph.D. in kinesiology with an emphasis in exercise psychology from the University of Illinois at Urbana-Champaign in 2017 under the mentorship of Dr. Edward McAuley. Her doctoral research focused on understanding the social cognitive determinants and consequences of physical activity behavior in aging populations and breast cancer survivors. In May 2018, Dr. Salerno earned an M.P.H. from the Johns Hopkins Bloomberg School of Public Health with a concentration in biostatistical and epidemiological methods for public health and clinical research. Dr. Salerno&rsquo;s interests include leveraging physical activity behavior to improve health outcomes during and after cancer, specifically cancer-related cognitive impairment, and advocating for the implementation of lifestyle behaviors into the standard of care for survivors. Dr. Salerno is working with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/matthews-charles">Charles E. Matthews, Ph.D.</a>, senior investigator, MEB, to investigate physical activity behavior across the cancer continuum from an epidemiological perspective.</p>
<p>&nbsp;<a href="https://www.ncbi.nlm.nih.gov/myncbi/elizabeth.awick.2/bibliography/public/">Scientific Publications - Elizabeth Salerno</a></p>
<h3><strong><a id="Spillane"></a>Susan Spillane, Ph.D., M.S.P.H., M.Pharm &ndash; Postdoctoral Fellow </strong></h3>
<div sys_relationshipid="7376315" sys_dependentid="1105320" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1105320&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Susan Spillane, Ph.D., M.S.P.H., M.Pharm., joined the Metabolic Epidemiology Branch as a Cancer Prevention Fellow in November 2017. Following her pharmacy studies, Dr. Spillane earned her Ph.D. in cancer pharmacoepidemiology from Trinity College Dublin in April 2014. Her doctoral research examined colorectal cancer outcomes following exposure to anti-diabetic treatments, particularly metformin, and to aspirin. Prior to joining the Cancer Prevention Fellowship Program, Dr. Spillane performed drug utilization research and pharmacoeconomic assessment with the National Medicines Management Programme and the National Centre for Pharmacoeconomics in Ireland, and went on to study her M.S.P.H. (health economics stream), at the London School of Hygiene and Tropical Medicine. Dr. Spillane is working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349608" sys_contentid="349608" inlinetype="rxhyperlink" sys_relationshipid="7376287" sys_dependentvariantid="1965" sys_dependentid="349608" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Neal Freedman, Ph.D., </a>senior investigator, MEB, on a program of descriptive epidemiology research. This work includes examination of causes of premature mortality among cancer survivors and the general population within the U.S.A.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Spillane+S%5BAuthor%5D+ireland">Scientific Publications - Susan Spillane</a></p>
<h3><strong><a id="Yano"></a>Yukiko Yano, Ph.D., M.P.H. &ndash; Postdoctoral Fellow</strong></h3>
<div sys_relationshipid="7376316" sys_dependentid="1146435" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2088" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-small centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800247&amp;sys_siteid=475&amp;sys_contentid=1146435&amp;sys_command=preview" alt=""><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Yukiko Yano, Ph.D., M.P.H., joined the Metabolic Epidemiology Branch (MEB) as a postdoctoral fellow in January 2019. Dr. Yano earned her Ph.D. in environmental health sciences from the University of California, Berkeley in 2018. Prior to obtaining her Ph.D., Dr. Yano received an M.P.H. in environmental health from Emory University. Her doctoral research involved measurements of protein adducts in archived newborn dried blood spots to explore fetal exposures associated with childhood leukemia. Dr. Yano is working with the MEB microbiome group under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=52&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_contentid="349612" inlinetype="rxhyperlink" sys_relationshipid="7376294" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Christian Abnet, Ph.D., M.P.H., Chief and senior investigator</a>; <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349692" sys_contentid="349692" inlinetype="rxhyperlink" sys_relationshipid="7376295" sys_dependentvariantid="1965" sys_dependentid="349692" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Rashmi Sinha, Ph.D., senior investigator</a>; and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1134872" sys_contentid="1134872" inlinetype="rxhyperlink" sys_relationshipid="7376296" sys_dependentvariantid="1965" sys_dependentid="1134872" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Emily Vogtmann, Ph.D., M.P.H., Earl Stadtman Tenure-Track Investigator</a>. Her research includes methodologic and etiologic studies of the human oral microbiome as well as studies of risk factors for esophageal and gastric cancer.</p>
</div>]]></content>
  </row>
  <row para_id="1033621" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>The Metabolic Epidemiology Branch focuses on high-quality, high-impact research that seeks to understand the etiology of a number of malignancies and the role of various lifestyle factors and unique exposures. Our research is predicated on rigorous epidemiologic approaches, with integration of state-of-the-art methods for defining exposures of interest.</p>
<h3 id="Cancer-Types">Cancer Types</h3>
<p>Studies focused on understanding the etiology of various cancers include:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=417416" inlinetype="rxhyperlink" sys_relationshipid="7248627" sys_siteid="475" rxinlineslot="103" sys_dependentid="417416" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="417416">Breast Cancer</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033632" sys_dependentvariantid="1418" sys_dependentid="1033632" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248636" sys_variantid="1418" sys_contentid="1033632">Gastric and Esophageal Cancers</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1113672" sys_dependentvariantid="1418" sys_dependentid="1113672" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248635" sys_variantid="1418" sys_contentid="1113672">Liver Cancer</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1109571" sys_dependentvariantid="1418" sys_dependentid="1109571" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248634" sys_variantid="1418" sys_contentid="1109571">Ovarian/Endometrial Cancers</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1113687" sys_dependentvariantid="1418" sys_dependentid="1113687" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7248637" sys_variantid="1418" sys_contentid="1113687">Pancreatic Cancer</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=459572" inlinetype="rxhyperlink" sys_relationshipid="7248626" sys_siteid="475" rxinlineslot="103" sys_dependentid="459572" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="459572">Prostate Cancer</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=417518" inlinetype="rxhyperlink" sys_relationshipid="7248628" sys_siteid="475" rxinlineslot="103" sys_dependentid="417518" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="417518">Testicular Cancer</a></li>
</ul>
<h3 id="Lifestyle-Other-Exposures">Lifestyle and Other Exposures</h3>
<p>Studies that seek to define the role of lifestyle and other exposures in cancer risk include:</p>
<ul style="list-style-type: disc;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=452174" inlinetype="rxhyperlink" sys_relationshipid="7248624" sys_siteid="475" rxinlineslot="103" sys_dependentid="452174" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="452174">Diet, Micronutrients and Supplements</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=417525" inlinetype="rxhyperlink" sys_relationshipid="7248630" sys_siteid="475" rxinlineslot="103" sys_dependentid="417525" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="417525">Endogenous Hormones</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420419" inlinetype="rxhyperlink" sys_relationshipid="7248629" sys_siteid="475" rxinlineslot="103" sys_dependentid="420419" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="420419">Energy Balance/Obesity</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303702" inlinetype="rxhyperlink" sys_relationshipid="7248633" sys_siteid="475" rxinlineslot="103" sys_dependentid="303702" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="303702">Physical Activity</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=459457" inlinetype="rxhyperlink" sys_relationshipid="7248625" sys_siteid="475" rxinlineslot="103" sys_dependentid="459457" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="459457">Tobacco Use&nbsp;</a></li>
</ul>
<h3 id="Emerging-Methods">Emerging Methods and Technologies</h3>
<p>MEB investigators are utilizing emerging methods and technologies to further their research, including:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303721" inlinetype="rxhyperlink" sys_relationshipid="7248631" sys_siteid="475" rxinlineslot="103" sys_dependentid="303721" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="303721">Metabolomics</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303730" inlinetype="rxhyperlink" sys_relationshipid="7248632" sys_siteid="475" rxinlineslot="103" sys_dependentid="303730" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="303730">Microbiome</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1033632" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div id="genSlotBody">
<div class="contentid-420420 slot-item first-SI">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Gastric and esophageal cancers are the 2nd and 6th most common causes of cancer death in the world, respectively, and together they kill over 1 million people each year. DCEG investigators' participation in UGI cancer research began with the Nutrition Intervention Trials (1985-1991) in Linxian, China, two randomized multivitamin/mineral supplementation trials in a population with some of the highest rates of esophageal squamous cell carcinoma (ESCC) and gastric cardia cancer in the world.&nbsp;&nbsp;DCEG investigators have since expanded their research to include:</p>
<ul>
<li>Etiologic studies of ESCC (focused on polycyclic aromatic hydrocarbon (PAH) exposure) and gastric cancer (focused on the effects of <i>H. pylori</i> and gut hormones)&nbsp;</li>
<li>Etiological studies of esophageal adenocarcinoma (EA) and its precursor, Barrett's esophagus</li>
<li>Genetic studies (including genome-wide association studies) of esophageal and gastric cancer&nbsp;</li>
<li>Development of an endoscopic early detection and treatment program for esophageal squamous dysplasia, the precursor of ESCC, which is now used to screen 100,000 adults in China each year</li>
</ul>
Selected studies include:
<ul style="list-style-type: disc;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303585" sys_dependentvariantid="1418" sys_dependentid="303585" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251744" sys_variantid="1418" sys_contentid="303585">Barrett's and Esophageal Adenocarcinoma Consortium (BEACON)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303653" sys_dependentvariantid="1418" sys_dependentid="303653" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251747" sys_variantid="1418" sys_contentid="303653">Gastric and Esophageal Malignancies in Northern Iran (GEMINI)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303588" sys_dependentvariantid="1418" sys_dependentid="303588" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251745" sys_variantid="1418" sys_contentid="303588">Golestan Cohort Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303656" sys_dependentvariantid="1418" sys_dependentid="303656" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251746" sys_variantid="1418" sys_contentid="303656">Nutrition Intervention Trials in Linxian, China</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090903" sys_dependentvariantid="1418" sys_dependentid="1090903" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251748" sys_variantid="1418" sys_contentid="1090903">African Esophageal Cancer Consortium (AfrECC)</a></li>
</ul>
</div>
</div>
</div>]]></content>
  </row>
  <row para_id="1033657" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-ebp/meb" title="">MEB Home</a></h3>
<p><a href="/about/organization/programs-ebp/meb/research" title="">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/meb-fellows" title="">Meet Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/meb-specific" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-ebp/meb/tools" title="">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>Investigators in the Metabolic Epidemiology Branch (MEB) develop and test tools, methods and resources designed to improve assessment of diet, physical activity and obesity, in support of nutrition-related studies. Selected examples include:</p>
<h3>Web-based instruments for 24-hour recall of dietary intake and physical activity</h3>
<ul>
<li><a href="https://epi.grants.cancer.gov/asa24/">Automated Self-administered 24-hour Dietary Assessment Tool</a></li>
<li><a href="http://dceg.cancer.gov/research/how-we-study/exposure-assessment/physical-activities-completed-over-time-24-hours-act-24">Physical activities completed over time in 24 hours</a></li>
</ul>
<h3>Questionnaire development resources related to dietary and supplement intake as well as physical activity</h3>
<ul style="list-style-type: disc;">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251752" sys_variantid="1418" sys_contentid="303828">Non-alcoholic beverages, food, and dietary supplement intake</a><a href="http://percussion.cancer.gov/Rhythmyx/assembler/render?sys_authtype=0&amp;sys_variantid=1418&amp;sys_revision=1&amp;sys_contentid=303828&amp;sys_context=0&amp;sys_siteid=475"><br /></a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303828" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303828" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251753" sys_variantid="1418" sys_contentid="303828">Physical activity</a></li>
</ul>
<h3>Software applications&nbsp;</h3>
<p><a href="http://dceg.cancer.gov/tools/design/charred">CHARRED: Computerized Heterocyclic Amines Resource for Research in Epidemiology of Disease</a></p>
<!--<h3>Tissue Microarrays and Archival Surgical Material</h3>
<p>Human tissue specimens are among the most valuable resources that biomedical researchers can use in their efforts to reach a molecular understanding of the malignant process which might ultimately translate into improvements in the treatment and survival of cancer patients. At the same time, the tissue that has been removed from a patient during a therapeutic intervention remains essential to that patient's care. In an effort to balance these competing needs of tissue-based medical research and also preserve the samples for essential patient care, new tools<span><a name="_msoanchor_1" href="http://percussion.cancer.gov/Rhythmyx/psx_cegenGeneral/genGeneral.html?sys_view=sys_All&amp;sys_command=edit&amp;sys_folderid=1031941#_msocom_1"></a> </span>have been developed for performing research on patients' surgical material. Read more about tissue microarrays and archival surgical material.</p>-->
<h3>Useful Links</h3>
<ul>
<li><a href="http://www.cancer.gov/cancertopics">The National Institute of Health Cancer Topics</a></li>
<li><a href="http://www.cancer.org/docroot/home/index.asp">The American Cancer Society</a></li>
<li><a href="http://www.prostatecancerfoundation.org/">The Prostate Cancer Foundation</a></li>
<li><a href="http://www.livestrong.org/">The Lance Armstrong Foundation</a></li>
<li><a href="http://ww5.komen.org/">The Susan G. Komen Foundation</a></li>
<li><a href="http://seer.cancer.gov/">Surveillance, Epidemiology and End Results Program</a></li>
<li><a href="https://epiresearch.org/">Society for Epidemiologic Research</a></li>
<li><a href="http://acepidemiology.org/">American College of Epidemiology</a></li>
<li><a href="http://www.aacr.org/">American Association for Cancer Research</a></li>
</ul>
<br />
<p></p>
</div>]]></content>
  </row>
  <row para_id="1033658" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Metabolic Epidemiology Branch (MEB) conducts research to identify risk factors for a wide range of malignancies, in particular those associated with lifestyle and environmental factors that influence metabolic response to a given exposure. Another major area of research is focusing on the role of the human papillomaviruses in the etiology of tumors. Emphasis is also being given to defining risk factors for several rare malignancies, including cancers of the liver and biliary tract.</p>
<p>Fellows in MEB:</p>
<ul>
<li>collaborate and learn from investigators in a world-renowned research program;</li>
<li>have access to large population-based studies with biological specimens;</li>
<li>learn how to validate biomarkers determined by new molecular techniques;</li>
<li>apply new biomarkers to large epidemiological studies;</li>
<li>have opportunities to initiate new investigations and to compete for funding; and</li>
<li>are compensated comparable to or exceeding most entry-level academic positions.</li>
</ul>
<p>For application details, see below. To discuss potential research opportunities, you may <a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">contact branch investigators<span>&nbsp;</span></a>directly. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=108&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033198" sys_contentid="1033198" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033198" sys_dependentvariantid="1418" sys_relationshipid="7389784" sys_variantid="1418">Meet fellows in the Metabolic Epidemiology Branch</a>.</p>
<h3>Qualifications</h3>
<p><em>Postdoctoral fellowships:</em> Individuals must either hold a doctorate degree in or be enrolled in a doctoral program in epidemiology. Individuals with a strong understanding of biological processes are encouraged to apply. Fellowship training is for up to 5 years under the supervision of NCI senior scientists.</p>
<p><em>Predoctoral fellowships:</em> Individuals must either be enrolled in a doctoral program with the desire to complete their dissertation in MEB, or have a Master's degree in a field relevant to MEB.</p>
<h3>Application Process</h3>
<p>Predoctoral and postdoctoral fellowship applications in the branch are accepted on an ongoing basis. See the <a href="http://dceg.cancer.gov/fellowship-training/become-a-fellow">Fellowship Information page</a> for an overview, qualifications, and application details. Branch-specific opportunities are listed below.</p>
<h3>Training Opportunities</h3>
<p>Examples of research opportunities include:</p>
<ul>
<li>Assessment of gene-environment interactions in multiple large population-based studies</li>
<li>Bone density, endogenous hormones, and cancer risk</li>
<li>Biologic correlates of mammographic density</li>
<li>Tissue measures of hormones and breast cancer</li>
<li>Performance of low-cost screening strategies for underserved populations</li>
<li>Biomarker discovery and validation</li>
<li>Clinical and molecular epidemiology methods</li>
<li>Etiologic studies of specific cancer sites, including breast, cervix, esophagus, stomach, colorectum, pancreas, liver, ovary, and prostate;</li>
<li>Integrative studies of multifactorial nutritional exposures, such as dietary patterns and glycemic load;</li>
<li>Energy balance studies, including those focusing on body size and physical activity studies;</li>
<li>Molecular epidemiologic studies to investigate genetic and hormonal interactions in nutrition-related cancer;</li>
<li>Improving exposure assessment tools for energy balance, dietary intake, biomarkers, and others</li>
</ul>
<h3>Training Opportunities with Specific Investigators</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033659#Cook" sys_contentid="1033659#cook" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033659" sys_dependentvariantid="1418" sys_relationshipid="7389787" sys_variantid="1418">Epidemiology&nbsp;of Esophageal Adenocarcinoma &ndash; Postdoctoral Fellowship</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033659#Albanes" sys_contentid="1033659#albanes" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033659" sys_dependentvariantid="1418" sys_relationshipid="7389786" sys_variantid="1418">Nutritional Status, Vitamin Supplementation, and Metabolomic Risk Profiling in Cancer Risk and Survival - Postdoctoral Fellowship</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033659#Stolzenberg-Solomon" sys_contentid="1033659#stolzenberg-solomon" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033659" sys_dependentvariantid="1418" sys_relationshipid="7389785" sys_variantid="1418">Epidemiology of Pancreatic Cancer - Postdoctoral Fellowship</a></p>
</div>]]></content>
  </row>
  <row para_id="1033659" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><em>On this page:</em></p>
<a id="top"></a>
<p><a href="#Cook">Epidemiology of Esophageal Adenocarcinoma &ndash; Postdoctoral Fellowship</a><br /><a href="#Albanes">Nutritional Status, Vitamin Supplementation, and Metabolomic Risk Profiling in Cancer Risk and Survival &ndash; Postdoctoral Fellowship</a><br /><a href="#Stolzenberg-Solomon">Epidemiology of Pancreatic Cancer &ndash; Postdoctoral Fellowship</a></p>
<h3><a id="Cook"></a>Epidemiology of Esophageal Adenocarcinoma &ndash; Postdoctoral Fellowship</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349597" sys_contentid="349597" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349597" sys_dependentvariantid="1965" sys_relationshipid="7389801" sys_variantid="1965">Michael B. Cook, Ph.D.</a>,&nbsp;is seeking an applicant with training in epidemiology and/or molecular epidemiology to study esophageal adenocarcinoma. Projects may include the study of questionnaire data, routine data, EHR data, as well as tissue and circulating biomarkers to inform on esophageal adenocarcinoma risk factors and predictive modelling. Various approaches may be used to test hypotheses&mdash;from prospective cohorts to consortia, from unique clinical databases to examinations of cancer registry data, from cutting-edge microRNA platforms to computational pathology.</p>
<p><strong>Goals</strong>: The successful candidate will be mentored to achieve&nbsp;his/her goals, progressing to greater independence during the fellowship.</p>
<p><strong>Qualifications</strong>: Individuals must either hold, or expect to soon attain, a doctorate degree in epidemiology or a related field. Review of applications will be conducted periodically and continue until the position is filled. Applicants may be U.S. citizens or permanent residents; for a visiting fellowship, visa requirements apply. Postdoctoral Fellowship positions are subject to a background investigation. DHHS, NIH and NCI are Equal Opportunity Employers and are dedicated to building a diverse community in their training and employment programs.</p>
<p>For more information about this position, please contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=36&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349597" sys_contentid="349597" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349597" sys_dependentvariantid="1965" sys_relationshipid="7389802" sys_variantid="1965">Dr. Michael Cook</a>, investigator.</p>
<p><strong>To Apply:</strong> See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389796" sys_variantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Albanes"></a>Nutritional Status, Vitamin Supplementation, and Metabolomic Risk&nbsp;Profiling in Cancer Risk and Survival - Postdoctoral Fellowship</h3>
<p>Dr. Demetrius Albanes is seeking a highly motivated and talented scientist (Ph.D., M.D., or equivalent) to join his research team to focus on cancer risk and survival with an emphasis on the role of nutritional status, vitamin supplementation, and the metabolomic profiling of risk and these etiologic factors. We investigate the biochemical, genetic, and mechanistic aspects of these interrelationships, particularly with respect to prostate cancer because of the limited knowledge regarding the etiology and prevention of this high-incidence malignancy.</p>
<p>Cohort, nested case-control and interventional investigations are conducted. Research resources including blood samples and germline DNA, are available for the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) Trial, and through several international consortium collaborations, including the Consortium of Metabolomics Studies (COMETS).</p>
<p>Goals of the fellowship include further developing cancer epidemiologic research skills related to study methodology and analysis, gaining a deeper understanding of cancer etiology and means for prevention, actively publishing study findings in high-quality journals, career advancement, and participating in a collaborative team science environment.</p>
<p><strong>Qualifications</strong>: Candidates should possess a strong background in epidemiology and the biological sciences, as well as excellent writing and statistical analytical skills.</p>
<p>For more information about this opportunity, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349619" sys_contentid="349619" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349619" sys_dependentvariantid="1965" sys_relationshipid="7389797" sys_variantid="1965">Dr. Demetrius Albanes</a>.</p>
<p><strong>To Apply:</strong> See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389803" sys_variantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Stolzenberg-Solomon"></a>Epidemiology of Pancreatic Cancer &ndash; Postdoctoral Fellowship</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349636" sys_contentid="349636" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349636" sys_dependentvariantid="1965" sys_relationshipid="7389798" sys_variantid="1965">Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D.</a>, senior investigator in the Metabolic Epidemiology Branch, is looking to recruit a motivated postdoctoral fellow who is interested in clarifying the etiology of pancreatic cancer through various study design and molecular approaches, as well as biomarker and metabolic studies particularly related to nutritional exposures.</p>
<p>Potential opportunities include:</p>
<p>1) Molecular epidemiologic studies to investigate biomarkers (including metabolomics) and genetic susceptibility (e.g. genome-wide association studies in prospective studies);</p>
<p>2) Cohort analyses of diet and lifestyle exposures;</p>
<p>3) Studying biologic mechanisms underlying epidemiologic risk factors using biomarkers.</p>
<p><strong>Qualifications</strong>: Applicants must have a doctoral degree or be enrolled in a graduate degree program in epidemiology, nutrition or related field. Individuals with training in epidemiologic methods and statistics, strong quantitative skills, and an understanding of biological and molecular processes and population genetics are encouraged to apply. Good writing skills are also desirable.</p>
<p>For more information about this position, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349636" sys_contentid="349636" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349636" sys_dependentvariantid="1965" sys_relationshipid="7389799" sys_variantid="1965">Dr. Rachael Stolzenberg-Solomon</a>.</p>
<p><strong>To Apply:</strong> See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389800" sys_variantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<p style="text-align: center;">DHHS and NIH are Equal Opportunity Employers.</p>
</div>]]></content>
  </row>
  <row para_id="1041183" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/about/organization/programs-hgp/cgb" title="">CGB Home</a></h3>
<p><a href="/about/organization/programs-hgp/cgb/clinical-epi-unit" title="">Clinical Epidemiology Unit</a></p>
<p><a href="/about/organization/programs-hgp/cgb/research" title="">Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=CGB">CGB Staff Directory</a></p>
<p><a href="/fellowship-training/what-our-fellows-do/meet-current-fellows/cgb-fellows" title="">Current Fellows</a></p>
<p><a href="/fellowship-training/become-a-fellow/research-training-areas/cgb-training" title="">Research Training Opportunities</a></p>
<p><a href="/about/organization/programs-hgp/cgb/tools-useful-links" title="">Tools &amp; Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=CGB">Publications</a></p>
</div>
<p>The Clinical Epidemiology Unit (CEU) conducts etiologic research with potential clinical and public health applications, and leads studies evaluating population-based early detection and cancer prevention strategies.</p>
<p>CEU has a strong focus on studies of absolute cancer risk, ranging from discovery of risk markers to assay development and evaluation, with the goal of guiding promising markers into clinical and public health use. Risk markers may include genetics, epidemiologic factors, molecular biomarkers, imaging, or any routine clinical test. The risk estimates ultimately inform the development of risk-based guidelines. CEU investigators are actively involved in developing screening and management guidelines for gynecological cancers.</p>
<p>Current research areas include:</p>
<ul>
<li>Molecular epidemiology of HPV and multi-stage pathogenesis of related cancers</li>
<li>Screening and prevention of anogenital cancers</li>
<li>Etiologic heterogeneity and cell of origin of ovarian cancers</li>
<li>Evaluation of risk prediction and early detection strategies for ovarian cancers, in high risk women (<em>BRCA</em> carriers) and in the general population, using novel approaches like lower genital tract sampling</li>
<li>Risk prediction and early detection strategies for endometrial cancer that can be applied to individuals at increased risk, either genetic (e.g. Lynch Syndrome) or non-genetic (high BMI, irregular bleeding)</li>
<li>Molecular classification of gynecological cancers</li>
<li>Studies evaluating novel methodologic approaches to applying risk markers for clinical and public health use</li>
</ul>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7239771" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>, head, Clinical Epidemiology Unit</p>
</div>]]></content>
  </row>
  <row para_id="1043259" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Despite HPV vaccines, screening will remain central for decades to control cervical cancer. Recently, HPV testing alone or with cytology was introduced in the U.S. as an alternative to cytology screening. However, most HPV infections are harmless and additional tests are required to identify women at highest cancer risk. With three options for primary screening, and without clear strategies for triage of screen-positive women, there is great confusion about the best approach. Also, increasing HPV vaccination coverage will lead to lower cervical cancer prevalence and predictive value of a positive screen, and force new screening approaches. Therefore, we propose to evaluate performance of several promising biomarkers head-to-head in a screening population. We will follow 70,000 women from Kaiser Permanente Northern California and store &ldquo;discard&rdquo; cytology and HPV test specimens. This is an expansion of the infrastructure and existing agreements from the ongoing <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=491125" inlinetype="rxhyperlink" sys_relationshipid="7276232" sys_dependentvariantid="1418" sys_dependentid="491125" rxinlineslot="103" sys_siteid="475" sys_variantid="1418" sys_contentid="491125">HPV Persistence and Progression (PaP) cohort</a>. The new phase of the cohort study will be the only U.S. effort and the largest study in the world to evaluate comprehensively candidate cervical cancer screening and triage biomarkers. The proposed effort addresses important gaps of knowledge identified in recent guidelines and will impact screening practice. Furthermore, the cohort will be an important resource for ongoing and future etiologic work on HPV-related cancers, particularly the work on HPV viral and host genetics, epigenetics, and cervicovaginal microbiome.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_relationshipid="7276233" sys_dependentvariantid="1965" sys_dependentid="349668" rxinlineslot="103" sys_siteid="475" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" inlinetype="rxhyperlink" sys_relationshipid="7276234" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_siteid="475" sys_variantid="1418" sys_contentid="433261">Clinical Genetics Branch&nbsp;&ndash; Research Areas</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1043265" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>CGB investigators&nbsp;are&nbsp;studying the etiologic heterogeneity of ovarian cancers and&nbsp;the roles that inflammation and endogenous hormones play in carcinogenesis. They have also&nbsp;been testing novel sampling strategies for collecting endometrial samples. Selected studies include:</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303581&amp;sys_revision=11&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303581" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297072">Assessment of Screening Modalities for Gynecologic Cancers</a></h2>
<p>A feasibility study to assess the use of alternative sampling techniques and molecular assays to detect endometrial and ovarian cancer</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303630&amp;sys_revision=10&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303630" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297073">Benign Reproductive Tissue Evaluation Study</a></h2>
<p>A study to investigate the association of risk factors with molecular changes in the ovaries and endometrium</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303582&amp;sys_revision=9&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303582" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297074">Study of Endometrial Hyperplasia Progression</a></h2>
<p>DCEG is conducting research on cancers of the endometrium and uterus.</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303633&amp;sys_revision=12&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303633" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297075">Ovarian and Endometrial Cancer Case-Control Study in Poland</a></h2>
<p>A study of common inherited variation associated with risk of ovarian cancer, carried out using data and biospeciments from a population-based case-control study of ovarian and endometrial cancer conducted among female residents of Warsaw and Lodz (Poland).</p>
<h2><a href="https://dceg.cancer.gov/research/cancer-types/ovary/ovarian-cancer-prevention-early-detection-study">National Ovarian Cancer Prevention and Early Detection Study</a></h2>
<p>A national prospective study of women who are at increased risk of ovarian cancer</p>
</div>]]></content>
  </row>
  <row para_id="1052096" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG places a special emphasis on the inclusion and promotion of women in science. Female investigators in the Division elect Women Scientist Advisors (WSAs) to represent the interests of their fellow women scientists, raise awareness of issues facing women scientists, and to work towards improving women's representation in the faculty of the National Institutes of Health (NIH) at all levels. WSAs focus on supporting and promoting career development across the career span.</p>
<p>To recognize outstanding women in science, the NCI WSA sponsor the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1072641" sys_contentid="1072641" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7253308" sys_dependentvariantid="1418" sys_dependentid="1072641" rxinlineslot="103" sys_siteid="475">Rosalind E. Franklin Award and Lecture</a> at the annual NCI Intramural Retreat, and the WSA Mentoring and Leadership Award, which recognizes men and women scientists in the NCI community who have shown strong support, scientific leadership, and/or direct mentoring to women scientists leading to professional scientific and career achievement of women scientists at the National Cancer Institute.</p>
<p>To learn more about the history of the WSA at NIH, vist the&nbsp;<a href="http://sigs.nih.gov/wsa/Pages/default.aspx">NIH Women Scientist Advisors Committee website</a>.</p>
<p>The current DCEG WSAs are:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349627" sys_contentid="349627" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253305" sys_dependentvariantid="1965" sys_dependentid="349627" rxinlineslot="103" sys_siteid="475">Ruth Pfeiffer, Ph.D.</a>, senior investigator. Three-year term (2016-2019).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253306" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_siteid="475">Lindsay Morton, Ph.D.</a>, senior investigator. One-year term (2018-2021).</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=974527" sys_contentid="974527" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253307" sys_dependentvariantid="1965" sys_dependentid="974527" rxinlineslot="103" sys_siteid="475">Gabriella Andreotti, M.P.H., Ph.D.</a>, staff scientist. Two-year term (2016-2018).</p>
<p></p>
<p>If you have questions or concerns for a WSA representative, contact any of the above, or contact the NCI WSA via their general mailbox: <a href="mailto:NCIWSA@mail.nih.gov">NCIWSA@mail.nih.gov</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1057944" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A genome-wide association study (GWAS) is an approach to compare the genomes from many different people to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1061078" sys_contentid="1061078" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276156" sys_dependentvariantid="1418" sys_dependentid="1061078" rxinlineslot="103" sys_siteid="475">find genetic markers associated with a particular phenotype or risk of disease</a>. The goal is to understand how genes contribute to the disease and to use that understanding to help develop better prevention and treatment strategies.</p>
<p>The Division maintains a robust research program including GWAS for a number of cancers, and more recently, exposures and survival. Researchers apply fine-mapping and deep sequencing techniques to regions or loci identified by these scans to pinpoint the specific functional variants responsible for disease risk and the biologic mechanisms involved.</p>
<p>Large-scale consortial arrangements make it possible to combine study resources in a coordinated intramural/extramural approach that enables rapid replication of positive findings using independent data sets. When reproducible findings emerge, the pooling of data sets provides the statistical power to quantify the risks associated with specific gene variants and exposures, and enables subset analyses that can uncover gene-gene and gene-environment interactions. This collaborative infrastructure presents the cancer research community with an extraordinary opportunity to advance research while taking advantage of economies of scale. It also provides an opportunity for NCI to partner with other NIH institutes to investigate a series of complex diseases and traits including diabetes, cardiovascular, neurological disorders, obesity, and smoking behaviors.</p>
<p>By making the data available through rapid posting, NIH can leverage its resources to ensure that the dramatic advances in genomics are incorporated into rigorous population-based studies. Ultimately, findings from these studies may yield new preventive, diagnostic, and therapeutic interventions for cancer.</p>
<p>Read the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=410191" sys_contentid="410191" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276157" sys_dependentvariantid="1418" sys_dependentid="410191" rxinlineslot="103" sys_siteid="475">DCEG data sharing policy</a>.</p>
<p>Browse <a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=genome-wide+association+stud&amp;titleOption=and&amp;searchTxtAbstract=1&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">DCEG scientific publications on genome-wide association studies</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1059147" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h4>This version of the Macro is for projecting the risk for Hispanic Americans:</h4>
<p><br /><br />The Breast Cancer Risk Assessment Macro (commonly referred to as the Gail Model) &nbsp;is a SAS macro that &nbsp;projects absolute risk of invasive breast cancer in the batch mode, according to NCIs Breast Cancer Risk Assessment Tool (BCRAT) algorithm for specific race/ethnic groups.<br /><br />Users enter data on risk factors and projection interval ages for a group of women, and the macro will return the corresponding absolute risk projections. This program may be useful for researchers who need risk projections for an entire study population. Latest Update (August 2016): Version for Hispanic American Women.</p>
<h4>Documents</h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1109530" sys_contentid="1109530" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317650" sys_siteid="475" rxinlineslot="103" sys_dependentid="1109530" sys_dependentvariantid="1500">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1109529" sys_contentid="1109529" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317651" sys_siteid="475" rxinlineslot="103" sys_dependentid="1109529" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h4>Software Download</h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1059146" sys_contentid="1059146" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317652" sys_siteid="475" rxinlineslot="103" sys_dependentid="1059146" sys_dependentvariantid="1500">HispBrCa_RAM_Ver2_1.zip</a></li>
</ul>
<h4>References:</h4>
<ul>
<li>Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, LaCroix AZ, Pee D, Chlebowski RT, Hines LM, Thompson CA, Gail MH. Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. <cite>JNCI</cite> 2016; 109 [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10491430">Pubmed Abstract</a>]</li>
<li>Costantino J, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS. Validation studies for models to project the risk of invasive and total breast cancer. <cite>JNCI</cite> 1999; 91:1541-8. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10491430">Pubmed Abstract</a>]</li>
</ul>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1061078" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1061094" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276124">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302249&amp;sys_siteid=475&amp;sys_contentid=1061094&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>Building on its long history of <a href="http://dceg.cancer.gov/research/public-health-impact/hereditary-syndromes">mapping susceptibility genes in cancer-prone families</a>, DCEG investigators were some of the first in the early 2000s to adopt the emerging technology of genome-wide association studies (GWAS), a powerful tool for investigating common inherited variation associated with cancer and other diseases.</p>
<p>The first results using this approach were published in <em>Nature Genetics</em> in 2007 as a part of the pilot multi-institutional project known as Cancer Genetic Markers of Susceptibility (CGEMS), an investigation of &gt;500,000 common inherited variants&mdash;known as single nucleotide polymorphisms (SNPs)&mdash;and risk of prostate and breast cancer. As the technology improved and processing speed increased, CGEMS expanded to numerous other malignancies, using&nbsp;increasingly complex sequencing techniques.</p>
<p>To accelerate research using the new genetic approaches, DCEG established the NCI <a href="http://dceg.cancer.gov/about/organization/programs-hgp/cgr">Cancer Genomics Research Laboratory</a> (CGR) in 2001. The CGR&rsquo;s state-of-the-art robotics and genomics technologies provide rapid, high quality preparation and scanning of hundreds of thousands of samples collected through rigorous epidemiological studies.</p>
<p>Today, genotyping, exome sequencing, and analysis are conducted at CGR and at research facilities across the globe, utilizing the <a href="http://epi.grants.cancer.gov/Consortia/cohort.html">massive power of consortia,</a> resulting in the identification of more than 600 susceptibility loci for over 29 types of cancer. Colleagues in the co-located <a href="http://dceg.cancer.gov/about/organization/programs-hgp/ltg">Laboratory of Translational Genomics</a> follow up on the markers identified through GWAS to interrogate the functional effects of variants and pinpoint the biological pathways through which these SNPs influence cancer etiology. Perhaps the most enduring discovery produced through GWAS is the ability to utilize SNPs for disease risk stratification and risk prediction.</p>
<p>Learn about our <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303692" sys_contentid="303692" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="303692" sys_variantid="1418" sys_relationshipid="7276122">current research on genetic susceptibility</a>.</p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=CGR">CGR full list of article citations</a></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 0.85; z-index: 8675309; display: none; cursor: pointer; top: 30px; left: 59px;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 0.85; z-index: 8675309; display: none; cursor: pointer; top: 30px; left: 59px;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer; top: 30px; left: 59px;">Save</span></p>
<p><span style="border-radius: 2px; text-indent: 20px; width: auto; padding: 0px 4px 0px 0px; text-align: center; font: bold 11px/20px 'Helvetica Neue',Helvetica,sans-serif; color: #ffffff; background: #bd081c  no-repeat scroll 3px 50% / 14px 14px; position: absolute; opacity: 1; z-index: 8675309; display: none; cursor: pointer;">Save</span></p>
</div>]]></content>
  </row>
  <row para_id="1062786" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303611" sys_contentid="303611" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303611" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277133">InterLymph</a> investigators pooled data from 20 studies to comprehensively evaluate the etiology of 11 non-Hodgkin lymphoma (NHL) subtypes, considering family and medical history, lifestyle and occupational risk factors. While scientists have long suspected etiologic similarities and differences among the various lymphoid diseases, previous studies had been limited by small sample sizes and consideration of limited risk factors.&nbsp; <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Journal+of+the+National+Cancer+Institute[Jour]+AND+2014[volume]+AND+48[issue]+AND+2014[pdat]&amp;cmd=detailssearch">Findings were published in a <em>Journal of the National Cancer Institute</em> monograph in 2014</a>.</p>
<p>Additionally, the consortium has developed national and international collaborations to facilitate accrual of blood or buccal cell DNA on a large set of NHL cases for a genome-wide association study (GWAS) to understand the role of genetic variation in NHL risk, and identify new genes or genomic regions that may be important in NHL pathogenesis.&nbsp;Follow-up will include genotyping and sequence analyses of genomic regions associated with NHL.&nbsp;</p>
<p>Together these efforts will allow investigators to leverage our understanding of risk factors in the context of inherited genetic susceptibility.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=25569183[uid]%20OR%2025261932[uid]%20OR%2025279986[uid]%20OR%2023770605[uid]&amp;cmd=DetailsSearch">Selected publications from the NHL genome-wide association study</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303607" sys_contentid="303607" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303607" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277137">See all DCEG Research on NHL</a>.</p>
<p>For more information on the subtypes project, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277134">Lindsay Morton</a>. For more information on the NHL GWAS, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349644" sys_contentid="349644" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349644" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277135">Nathaniel Rothman</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349613" sys_contentid="349613" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="349613" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277136">Qing Lan</a>.&nbsp;</p>
<p>&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="1062980" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators are helping to lead large-scale molecular pathology studies within the <a href="http://bcac.ccge.medschl.cam.ac.uk/">Breast Cancer Association Consortium (BCAC)</a>, an international consortium of more than 80 epidemiological and clinical breast cancer studies. Analyses from BCAC&rsquo;s large resource of genetic and environmental risk factors, tissue microarrays and clinical data, have revealed important tumor markers that delineate the etiologic heterogeneity of breast cancer.</p>
<p>BCAC collaborators are characterizing thousands of breast tumors using targeted DNA sequencing and immunohistochemistry and <em>in-situ</em> hybridization analysis in an effort known as <a href="http://www.b-cast.eu/">Breast CAncer STratification (BCAST)</a>. Investigators are studying how genetic and environmental risk factors are related to tumor features and clinical progression, providing critical information for the development and validation of integrated risk and prognostic models.</p>
<p>The ultimate goal of this research is to better understand breast cancer etiology and clinical progression, and inform the development of targeted prevention and screening strategies for different types of breast cancer.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" sys_contentid="1004366" inlinetype="rxhyperlink" sys_relationshipid="7275117" sys_dependentvariantid="1965" sys_dependentid="1004366" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Montserrat Garc&iacute;a-Closas</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1061744" sys_contentid="1061744" inlinetype="rxhyperlink" sys_relationshipid="7275118" sys_dependentvariantid="1965" sys_dependentid="1061744" rxinlineslot="103" sys_siteid="475" sys_variantid="1965">Thomas Ahearn</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" sys_relationshipid="7275119" sys_dependentvariantid="1418" sys_dependentid="420600" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1062981" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Somatic studies on kidney cancer utilize tumor samples compiled from various efforts in Italy, the US, Eastern Europe, and Guatemala. As more samples and accompanying exposure information are collected, investigators are able to study increasingly rare cancer subtypes.</p>
<h3>Papillary renal cell carcinoma (PRCC)</h3>
<p>Papillary renal cell carcinoma (PRCC) is the second most common kidney cancer subtype, comprising 10-15 percent&nbsp;of cases. Previous studies have identified two main types of PRCC: Type 1, which is not particularly aggressive, and Type 2, which has a worse prognosis. Further, Type 2 has at least three distinct subtypes with different somatic driver mutations and varying clinical prognoses. DCEG investigators seek to use cutting-edge DNA analysis techniques to further determine the genetic landscape of PRCC tumors and its link with exposures and metastasis.</p>
<h3>Collecting Ducts (CD)</h3>
<p>Collecting Ducts (CD) cancer is an extremely aggressive and rare type of kidney cancer. DCEG investigators have access to tumor samples from dozens of CD cases and use them to conduct whole genome and whole exome studies samples to investigate the tumor landscape also in relation to tumor immune-related cells and metastasis. They are also working towards analyzing cases of high grade urothelial carcinomas in the differential diagnosis of CD, to provide a molecular-based diagnostic tool to correctly distinguish these cancer types.</p>
<h3>Chromophobe renal cell carcinoma (ChRCC)</h3>
<p>Chromophobe renal cell carcinoma (ChRCC) is relatively rare, making up about 5 percent&nbsp;of all cases. It is characterized by slow but persistent growth that is highly resistant to conventional cancer therapies. A tiny fraction of ChRCC is hereditary, with some known driver mutations, but the genetic basis of sporadic ChRCC is largely undiscovered. This type of kidney cancer is similar to renal oncocytoma (benign) and they are often hard to distinguish. Hybrids of the two exist as well, suggesting a common origin. DCEG studies tumor samples, working to provide a grading score based on ChRCC&rsquo;s genetic landscape to distinguish indolent from aggressive cases. Investigators also perform molecular tests to more finely distinguish ChRCC from oncocytomas and identify tumors that have the potential to be more aggressive.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" sys_contentid="349623" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7278018" sys_dependentvariantid="1965" sys_dependentid="349623" rxinlineslot="103" sys_siteid="475">Maria Teresa Landi</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1065271" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The recognition of cancer as a heterogeneous disease, coupled with technological advances in molecular/genomic profiling of tumors, provides epidemiologists with the opportunity to integrate tissue profiling into etiologic studies to study the carcinogenic process, and pinpoint specific factors associated with risk for developing specific molecular or genomic cancer subtypes. This work is already underway in a number of existing cohort studies, including the Prostate, Lung, Colorectal, Ovarian Screening Trial (PLCO). <a href="https://biometry.nci.nih.gov/cdas/learn/plco/biospecimens/">Learn more about the biological samples available through PLCO</a>.</p>
<p><span>In October 2018, the National Cancer Institute convened a group of experts to discuss the current state of the science of mutational signatures in cancer research and related opportunities and challenges. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1130171" sys_dependentvariantid="1418" sys_dependentid="1130171" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7278013" sys_variantid="1418" sys_contentid="1130171">Read the Executive Summary of the Tumor Signatures Meeting.</a></span></p>
<p>DCEG investigators are undertaking foundational research to identify novel molecular and genomic signatures in tumors that are&nbsp;linked to germline genetic variants and key environmental exposures. We expect this approach will allow the identification of new risk factors and yield novel insights into biological mechanism of carcinogenesis.</p>
<p>Examples of specific studies include:</p>
<h3>Biliary Cancer</h3>
<p>Tumor tissue collected from populations in China and Chile are being used to examine the genomic landscape of cancer at different sites in the biliary tract and to look for potential molecular subtypes. A better understanding of the genetic and molecular differences across these malignancies can lead to more precise diagnoses and effective treatments, as well as providing clues as to etiology.</p>
<h3>Bladder Cancer</h3>
<p>Molecular pathology investigations of bladder tumors are ongoing in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=33&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278010" sys_dependentvariantid="1418" sys_dependentid="438648" rxinlineslot="103" sys_siteid="475">New England Bladder Cancer Study</a> using collected tumor DNA and tissue microarrays. Analyses to characterize important molecular alterations in tumors are in progress and are being integrated with germline genetic variation as well as environmental and occupational exposures to provide insight into the mechanisms of bladder carcinogenesis.</p>
<h3>Breast Cancer</h3>
<p>Analyses of risk factors measured by questionnaires, genotyping and blood/urine biomarkers in relation to molecular characteristics of breast cancer tumors and adjacent benign breast tissues, and clinical outcomes in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303566" sys_contentid="303566" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277999" sys_dependentvariantid="1418" sys_dependentid="303566" rxinlineslot="103" sys_siteid="475">Polish Breast Cancer Study</a>&nbsp;and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=840733" sys_contentid="840733" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278000" sys_dependentvariantid="1418" sys_dependentid="840733" rxinlineslot="103" sys_siteid="475">Ghana Breast Cancer Study</a>.</p>
<p>Large-scale evaluation of how genetic and environmental risk factors, molecular tumor characteristics and clinical progression interrelate in the <a href="http://www.b-cast.eu/">Breast CAncer STratification (BCAST) Project</a>.</p>
<p>Studies of breast tissues, risk factors, clinical data, breast density, blood or saliva for germline DNA to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=837951" sys_contentid="837951" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278001" sys_dependentvariantid="1418" sys_dependentid="837951" rxinlineslot="103" sys_siteid="475">identify distinct molecular alterations in tumors and adjacent benign breast tissues among Asian women</a>&nbsp;and to examine the associations of molecular changes with genetic and environmental risk factors, breast tissue composition and density, and breast cancer subtypes.</p>
<p>Characterizing the radiologic, histologic, and molecular features of dense breast tissue among women referred for diagnostic breast biopsy following an abnormal mammogram in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303567" sys_contentid="303567" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278005" sys_dependentvariantid="1418" sys_dependentid="303567" rxinlineslot="103" sys_siteid="475">Breast Radiology Evaluation and Study of Tissues (BREAST) Stamp Project</a>.</p>
<p>Conducting molecular and histomorphometric analyses of breast tissues in relation to mammographic density and breast cancer outcomes among <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=805096" sys_contentid="805096" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278006" sys_dependentvariantid="1418" sys_dependentid="805096" rxinlineslot="103" sys_siteid="475">breast cancer patients diagnosed within a general community health care plan</a>.</p>
<p>Molecular epidemiologic studies of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303564" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303564" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7278012" sys_variantid="1418" sys_contentid="303564">Terminal Duct Lobular Unit Involution&nbsp;of the Normal Breast </a>are being conducted in collaboration with the Susan G. Komen&reg; Tissue Bank.</p>
<h3>Kidney Cancer</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1062981" sys_contentid="1062981" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278007" sys_dependentvariantid="1418" sys_dependentid="1062981" rxinlineslot="103" sys_siteid="475">Intra-tumor heterogeneity and tumor evolution are being studied in kidney cancer histological subtypes</a> based on whole-genome sequencing, deep target sequencing, whole genome methylation and SNP array analyses.</p>
<h3>Lung Cancer</h3>
<p>A large <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303605" sys_contentid="303605" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278003" sys_dependentvariantid="1418" sys_dependentid="303605" rxinlineslot="103" sys_siteid="475">population-based case-control study of lung cancer</a>, in the Lombardy region of Italy, designed to investigate the genetic and environmental determinants of lung cancer, and their influence on risk for individual molecular subtypes.</p>
<p><span></span><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1135394" sys_dependentvariantid="1418" sys_dependentid="1135394" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7278014" sys_variantid="1418" sys_contentid="1135394"><span>Sherlock-</span><em>lung</em><span>&nbsp;is a comprehensive study that aims to trace lung cancer etiology in never smokers</span></a><span> by analyzing genomic data in tumor and surrounding lung tissue.</span></p>
<h3>Melanoma</h3>
<p>Converging lines of evidence suggest that melanoma comprises biologically distinct subtypes. DCEG investigators are undertaking <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1065467" sys_contentid="1065467" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278008" sys_dependentvariantid="1418" sys_dependentid="1065467" rxinlineslot="103" sys_siteid="475">tissue-based and genomic studies to provide a comprehensive classification of primary melanomas and the molecular changes associated with metastatic potential</a>.</p>
<h3>Ovarian and Endometrial Cancer</h3>
<p>Analyses of biomarkers in DNA (somatic changes), cryopreserved blood cells, serum/plasma, and urine in relationship to cancer risk and clinical outcomes in <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303633" sys_contentid="303633" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278004" sys_dependentvariantid="1418" sys_dependentid="303633" rxinlineslot="103" sys_siteid="475">a population of women in Poland</a>.</p>
<h3>Signatures of Radiation- and Chemotherapy-Induced Carcinogenesis</h3>
<p>Second cancers may occur as a late adverse effect of radiotherapy and certain systemic therapies for first primary cancer. We are <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=804883" sys_contentid="804883" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278009" sys_dependentvariantid="1418" sys_dependentid="804883" rxinlineslot="103" sys_siteid="475">evaluating whether the molecular profiles of treatment-related cancers differ from those of sporadic tumors</a> to identify whether there are signatures of radiation- and chemotherapy-induced carcinogenesis.</p>
<h3>Thyroid Cancer</h3>
<p>Evaluation of genomic, transcriptomic, and epigenomic landscapes of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030563" sys_contentid="1030563" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278011" sys_dependentvariantid="1418" sys_dependentid="1030563" rxinlineslot="103" sys_siteid="475">radiation-related papillary thyroid cancers in a cohort exposed to Chernobyl fallout in Ukraine</a>.</p>
<h3>Upper Gastrointestinal Cancer</h3>
<p>Identification of somatic genetic alterations, including changes that might serve as <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303657" sys_contentid="303657" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7278002" sys_dependentvariantid="1418" sys_dependentid="303657" rxinlineslot="103" sys_siteid="475">early detection biomarkers for cancers of the upper gastrointestinal tract</a>&nbsp;in a population in Shanxi Province, China.</p>
</div>]]></content>
  </row>
  <row para_id="1065467" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Converging lines of evidence suggest that melanoma comprises biologically distinct subtypes arising through multiple causal pathways. The distribution of melanoma subtypes differs by age, anatomical location of the cancer, and sun exposure. Somatic mutation patterns vary across melanoma subtypes, though the large majority of studies suggesting this phenomenon were based on metastatic melanoma alone, due to the difficulty in obtaining sufficient genetic material from thin primary melanomas once they are used for diagnostic review.</p>
<p>To further our understanding of the heterogeneity of melanoma, and to determine a predictive pattern of progression for dysplastic nevi, a melanoma precursor and risk factor, we are conducting tissue-based analyses of precursors, melanoma tumors and metastases within existing study populations. These cases are well annotated with detailed clinical and epidemiological data, and sufficient biological samples.</p>
<p>We are undertaking genetic analyses as well as targeted sequencing of previously identified driver genes for a more comprehensive classification of primary melanomas and the molecular changes associated with metastatic potential. In addition, with the extensive pathology data, particularly on lymphocyte infiltration and presence of other inflammatory cells, we can examine the link between molecular changes and tissue microenvironment.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" inlinetype="rxhyperlink" sys_relationshipid="7359715" rxinlineslot="103" sys_dependentid="349623" sys_dependentvariantid="1965" sys_siteid="475" sys_variantid="1965" sys_contentid="349623">Maria Teresa Landi</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="420600" sys_dependentvariantid="1418" sys_siteid="475" sys_relationshipid="7359716" sys_variantid="1418" sys_contentid="420600">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1066000" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG periodically hosts fellows in science communications and public affairs, mainly through the NCI Communications Fellowship (NCF). This fellowship gives graduate students and recent graduate degree recipients the opportunity to hone their science writing and communications skills in the world&rsquo;s largest cancer epidemiology research group. NCF fellows gain first-hand experience in fielding press inquiries, preparing scientists for interacting with the media, and translating high-profile scientific findings into practical public health messages.</p>
<p>The DCEG communications team manages the division website and social media presence, fields inquiries from the general public and Congressional staff, produces the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=193&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=303874" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303874" sys_dependentvariantid="1422" sys_relationshipid="7228025" sys_variantid="1422" sys_contentid="303874">online newsletter <em>Linkage</em></a>, and writes plain language summaries of cutting edge research.</p>
<p>The team works side-by-side with some of the leading experts in cancer epidemiology, genetics and biostatistics, and other communications staff across NCI.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=936140" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="936140" sys_dependentvariantid="1965" sys_relationshipid="7228024" sys_variantid="1965" sys_contentid="936140">Jennifer Loukissas</a>.</p>
<p><a href="https://ncf.nci.nih.gov/index.html">Learn more about the NCI Communications Fellowship</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1066576" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="top"></a>
<p><em>On this page</em>:</p>
<ul>
<li><a href="#Shiels-Engels">Epidemiology of Cancer in Immunosuppressed Populations</a></li>
<li><a href="#OBrien">Hepatitis Virus Infections and their Relationship to Liver Cancer</a></li>
</ul>
<h3><a id="Shiels-Engels"></a>Epidemiology of Cancer in Immunosuppressed Populations &ndash; Postdoctoral Fellowship</h3>
<p>Dr. Eric Engels&nbsp;and Dr. Meredith Shiels of the Infections and Immunoepidemiology Branch (IIB)&nbsp;are seeking a postdoctoral fellow interested in the epidemiology of cancer in immunosuppressed populations.</p>
<p>Specific risk factors for cancer that will be a focus of research include HIV infection, solid organ transplantation, autoimmune diseases, use of immunosuppressive medications, and viral infections.</p>
<p><strong>Qualifications</strong>: Candidates should possess a strong background and skill in epidemiology, particularly in relation to infectious causes of cancer; statistical analysis; and critical thinking and writing. There will be opportunities to lead pre-defined projects. In addition, new fellow-initiated projects are encouraged. The fellow will also have the ability to work with other investigators in IIB to gain experience in other areas of research.</p>
<p>For more information about this position,&nbsp;please&nbsp;contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" rxinlineslot="103" sys_dependentid="349601" sys_dependentvariantid="1965" sys_relationshipid="7389823">Eric Engels, M.D., M.P.H.</a>, Chief and senior investigator, or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052540" sys_contentid="1052540" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" rxinlineslot="103" sys_dependentid="1052540" sys_dependentvariantid="1965" sys_relationshipid="7389821">Meredith Shiels, Ph.D.</a>, investigator.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389822">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="OBrien"></a>Hepatitis Virus Infections and their Relationship to Liver Cancer &ndash; Postdoctoral Fellowship</h3>
<p>Dr. Thomas O&rsquo;Brien of the Infections and Immunoepidemiology Branch (IIB) is seeking a postdoctoral fellow to conduct studies of hepatitis virus infections and the relationship of these infections to liver cancer. His research program emphasizes translating scientific findings for clinical and public health benefits. Specific areas of Dr. O&rsquo;Brien&rsquo;s research include:</p>
<ol>
<li><em>IFNL4</em> Genotype and Hepatitis C Virus Infection<br /> Dr. O&rsquo;Brien provided the epidemiological leadership for studies that led to the discovery of a novel gene that determines HCV clearance.</li>
<li>Hepatitis D Virus Infection and Liver Cancer<br /> HDV is the most pathogenic virus for the risk of liver cancer. Dr. O&rsquo;Brien conducts studies of HDV in the United States and Africa.</li>
<li>Surveillance Studies of Hepatitis Virus-associated Liver Cancer<br /> New therapies promise to reduce the incidence of liver cancer in the United States and around the world. Surveillance studies examine if the availability of these therapies is fulfilling public health goals.</li>
</ol>
<p><strong>Qualifications</strong>: Individuals must either hold, or expect to soon attain, a medical degree, a doctorate degree in epidemiology or a doctorate degree in a related field. Review of applications will be conducted periodically and continue until the position is filled. Applicants may be U.S. citizens or permanent residents; for a visiting fellowship, visa requirements apply Postdoctoral Fellowship positions are subject to a background investigation. DHHS, NIH and NCI are Equal Opportunity Employers and are dedicated to building a diverse community in their training and employment programs.</p>
<p>For more information about this position, please contact: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349689" sys_contentid="349689" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" rxinlineslot="103" sys_dependentid="349689" sys_dependentvariantid="1965" sys_relationshipid="7389824">Thomas O&rsquo;Brien, M.D., M.P.H.</a>, senior investigator.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_relationshipid="7389825">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p></p>
<p>DHHS and NIH are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="1067316" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Investigators are conducting genetic studies of osteosarcoma to better understand the role that genetic variation plays in risk and patient outcomes, and to identify new genes or genomic regions that may be important in osteosarcoma pathogenesis. Our global collaborative effort includes researchers from The NCI Children&rsquo;s Oncology Group (COG), Children&rsquo;s Oncology Group study at the University of Minnesota and the Harvard School of Dental Medicine, U.S.A.; Universidad de Navarra, Pamplona, Spain; Institut Curie, France; Rizzoli Instituti, Italy; Royal Orthopaedic Hospital, UK; University of Toronto, Litwin Centre for Cancer Genetics, Canada; Instituto de Oncologia Pedi&aacute;trica GRAACC/UNIFESP, Brazil; Ankara Oncology and Education Research Hospital, Turkey; Peter MacCallum Cancer Centre, Kinghorn Cancer Centre, and Garvan Institute of Medical Research, Australia. We estimate that approximately 2500 germline (blood or buccal cell) DNA samples will be genotyped at the NCI's Cancer Genomics Research (CGR) Laboratory and subsequently available for genome-wide association analyses. A team of biostatisticians has been assembled to create a common control set that will be derived from existing studies. Follow-up will include genotyping and sequence analyses of genomic regions associated with osteosarcoma.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=19&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=639592" sys_contentid="639592" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7276154" sys_dependentvariantid="1965" sys_dependentid="639592" rxinlineslot="103" sys_siteid="475">Lisa Mirabello</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=433261" sys_contentid="433261" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276155" sys_dependentvariantid="1418" sys_dependentid="433261" rxinlineslot="103" sys_siteid="475">Clinical Genetics Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1067844" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Division of Cancer Epidemiology and Genetics (DCEG) of the National Cancer Institute is recruiting a visionary, senior investigator to serve as Chief of the newly-formed Integrative Tumor Epidemiology Branch (ITEB) within DCEG&rsquo;s Human Genetics Program. The position of Chief is equivalent to that of an academic department chair.</p>
<p>The ITEB conducts research to advance our understanding of cancer etiology and progression through integrative analyses of environmental and germline risk factors with data on histological and molecular profiling of tumors and their precursors, including somatic genomic analyses. The Branch develops methods to integrate molecular pathology, somatic and germline genomics, and epidemiology; trains pre- and post-doctoral fellows in integrative epidemiologic research; and participates in and contributes to national and international organizations and consortia to promote integrative tumor epidemiologic research.&nbsp;</p>
<p><span>The Branch Chief will shape the research direction of ITEB and oversee all aspects of its development, including recruitment of faculty. She/he will also have resources to conduct an independent program of research.&nbsp; The Branch currently includes a staff of three tenured investigators, as well as pre- and postdoctoral fellows and administrative staff. Resources available to ITEB include epidemiologic studies with well-annotated tissue collections, including germline genetics, biomarkers and detailed information on environmental risk factors for cancer (e.g. breast, bladder, endometrial, esophageal, kidney, lung); access to biorepositories for processing and storage of biospecimens; core laboratory facilities for genotyping, sequencing, and molecular/digital pathology services; and contract support for computer programming and for epidemiologic field studies. In addition to managing these resources, the Chief oversees the administrative management of the Branch, supervises staff members, and mentors tenure-track investigators and postdoctoral fellows.&nbsp; The Chief will also provide leadership in integrated somatic analyses conducted across DCEG. Other duties include providing consultation to national and international investigators and public health officials, and acting as liaison with agencies and organizations seeking expertise related to the mission of the Branch.<o:p></o:p></span></p>
<p>The successful candidate must hold either a medical degree or a doctoral degree in a relevant discipline (e.g., epidemiology, molecular pathology, cancer genomics, bioinformatics/computational science, or related fields).&nbsp;Applicants must have a proven track record of scientific excellence at the international level, publish in peer-reviewed scientific or medical journals, and present at scientific meetings, with international recognition for their research contributions. The candidate must also demonstrate administrative experience, including successful mentoring, supervision, and scientific management.</p>
<p>The Chief of the ITEB will be eligible for a tenured appointment at a salary commensurate with qualifications and experience.&nbsp;Applicants may be U.S. citizens, resident aliens, or non-resident aliens with, or eligible to obtain, a valid employment-authorization visa.&nbsp;Full Federal benefits including leave, health and life insurance, long-term care insurance, retirement, and savings plan (401k equivalent) will be provided.&nbsp;</p>
<p>Interested individuals should send a cover letter briefly summarizing research interests, accomplishments, and scientific management experience; curriculum vitae and bibliography; copies of up to five publications or preprints; and the names and addresses of three references to:</p>
<p style="text-align: center;">Dr. Hannah Yang<br />Division of Cancer Epidemiology and Genetics, National Cancer Institute<br />E-mail: <a href="mailto:NCI-ITEB-CHIEF@mail.nih.gov">NCI-ITEB-CHIEF@mail.nih.gov</a></p>
<p style="text-align: center;">Applications received by June 29, 2018 will be considered for a first round of interviews, but applications will be accepted until the position is filled.</p>
<p style="text-align: center;">The DHHS and NIH are Equal Opportunity Employers.</p>
</div>]]></content>
  </row>
  <row para_id="1067861" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">In both the absence and presence of screening, the R package calculates individual risks of lung cancer and lung cancer death based on covariates: age, education, sex, race, smoking intensity/duration/quit-years, Body Mass Index, family history of lung-cancer, and self-reported emphysema.&nbsp; In the presence of CT screening akin to the NLST (3 yearly screens, 5 years of follow-up), it uses the covariates to estimate risk of false-positive CT screen as well as the reduction in risk of lung cancer death and increase in risk of lung cancer screening.&nbsp; <br />
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1067872" sys_contentid="1067872" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317631" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067872" sys_dependentvariantid="1500">Manual and vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1067873" sys_contentid="1067873" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317636" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067873" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h3>Software Download (Version 2.0.0):</h3>
<ul class="grey-bullets">
<li>Windows O/S - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1067868" sys_contentid="1067868" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317632" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067868" sys_dependentvariantid="1500">lcrisks.zip</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1067867" sys_contentid="1067867" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317633" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067867" sys_dependentvariantid="1500">coxph.risk.zip</a></li>
<li>Mac O/S - <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1067871" sys_contentid="1067871" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317634" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067871" sys_dependentvariantid="1500">lcrisks.tar.gz</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1067869" sys_contentid="1067869" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317635" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067869" sys_dependentvariantid="1500">coxph.risk.tar.gz</a></li>
</ul>
<p></p>
<h3>References:</h3>
<ul class="grey-bullets">
<li>Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016; 315(21):2300-2311. doi: 10.1001/jama.2016.6255. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/27179989" target="_blank" rel="noopener noreferrer">PubMed</a>]</li>
</ul>
<h3>Support:</h3>
<p>Email: <a href="mailto:li.chueng@nih.gov?subject=lcrisk"> Li Cheung </a> and <a href="mailto:katkih@mail.nih.gov?subject=lcrisk"> Hormuzd Katki </a></p>
</div>]]></content>
  </row>
  <row para_id="1067873" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting the lcrisk R Package Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The lcrisks - R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1072641" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Given at the annual NCI Intramural Retreat, this prize honors the commitment of women in cancer research.&nbsp;It is given in tribute to Dr. Franklin, an accomplished chemist and X-ray crystallographer who played a critical role in the discovery of the DNA double helix structure.</p>
<div sys_dependentvariantid="2066" sys_dependentid="1072656" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7297036">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800517&amp;sys_siteid=475&amp;sys_contentid=1072656&amp;sys_command=edit" alt="" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Rosalind Franklin. Courtesy of Jenifer Glynn.</p>
</div>
</figcaption>
</figure>
</div>
<h3>Past Award Winners</h3>
<p>2019 -&nbsp;<strong>Flora&nbsp;E.&nbsp;van Leeuwen</strong>,&nbsp;Netherlands Cancer Institute, "Second Malignancy Risk After Cancer Treatment: From Old Medical Records to Survivorship Care Programs"</p>
<p>2018 -&nbsp;<strong>Mary Beckerle</strong>, Huntsman Cancer Institute, "Interface between cytoskeletal dynamics and tumor biology"</p>
<p>2017 - <strong>Silvia Franceschi</strong>, International Agency for Research on Cancer, &ldquo;The unequal burden of cancer attributable to infections across the world&rdquo;</p>
<p>2016 - <strong>Kornelia Polyak</strong>, Dana-Farber Cancer Institute, "2016 Rosalind Franklin Award Recipient"</p>
<p>2015 - <strong>Lisa M. Coussens</strong>, Oregon Health and Science University, "13th Rosalind E. Franklin Award for Women in Science"</p>
<p>2014 - <strong>Valerie Beral</strong>, University of Oxford, "Rosalind Franklin and Cancer in Women"</p>
<p>2012 - <strong>Titia de Lange</strong>, The Rockefeller University, "How Telomeres Solve the End-Protection Problem"</p>
<p>2011 - <strong>Kathryn Bloch Horwitz</strong>, University of Colorado-Anschutz Medical Campus, "Origin of Luminal vs. Basal Breast Cancer Subtypes: Control by Steroid Hormones and Notch Signaling"</p>
<p>2010 - <strong>Leslie Bernstein</strong>, City of Hope National Medical Center, "Reducing Breast Cancer Risk Through Biology, Epidemiology, and Serendipity"</p>
<p>2009 - <strong>Carol Prives</strong>, Columbia University, "New Insights into p53 and Mdm2"</p>
<p>2008 - <strong>Nancy Davidson</strong>, Johns Hopkins University, "Epigenetics and Breast Cancer"</p>
<p>2007 - <strong>Alice Whittemore</strong>, Stanford University, "Preventing Deaths from Breast and Ovarian Cancer"</p>
<p>2006 - <strong>Joan A. Steitz</strong>, Yale University, "More Surprises of snRNPs"</p>
<p>2005 - <strong>Joan S. Brugge</strong>, Harvard Medical School, "Probing Mechanisms of Breast Epithelial Oncogenesis in a 3D Culture Model"</p>
<p>2004 - <strong>Janet Rowley</strong>, University of Chicago, "Analysis of Gene Expression in Leukemia in the 21st Century"</p>
<p>2003 - <strong>Margaret Spitz</strong>, MD Anderson, "An Approach to Studying Genetic Susceptibility of Lung Cancer"</p>
<p>2002 - <strong>Maxine Singer</strong>, Carnegie Institute, no title</p>
</div>]]></content>
  </row>
  <row para_id="1080215" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<ol></ol>
<p>The R package and webtool fits Prevalence Incidence Mixture models to left-censored and irregularly interval-censored time to event data that is commonly found in screening cohorts assembled from electronic health records.&nbsp; Absolute and relative risk can be estimated for simple random sampling, &nbsp;and stratified sampling (the two approaches of superpopulation and a finite population are supported for target populations).&nbsp; Non-parametric (absolute risks only), semi-parametric, weakly-parametric (using B-splines), and some fully parametric (such as the logistic-Weibull) models are supported.</p>
<h3>Documentation:</h3>
<ul>
<li>PIMixture Help File: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1080214" sys_contentid="1080214" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7279609" sys_siteid="475" rxinlineslot="103" sys_dependentid="1080214" sys_dependentvariantid="1500">PIMixture.pdf</a></li>
<li>PIMixture.Predict Help File: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1080213" sys_contentid="1080213" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7279610" sys_siteid="475" rxinlineslot="103" sys_dependentid="1080213" sys_dependentvariantid="1500">PIMixture.predict.pdf</a></li>
<li>Example Data: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1089223" sys_contentid="1089223" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7279612" sys_siteid="475" rxinlineslot="103" sys_dependentid="1089223" sys_dependentvariantid="1500">PIData1.pdf</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1080216" sys_contentid="1080216" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7279611" sys_siteid="475" rxinlineslot="103" sys_dependentid="1080216" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Mac O/S: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1080212" sys_contentid="1080212" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7279607" sys_siteid="475" rxinlineslot="103" sys_dependentid="1080212" sys_dependentvariantid="1500">PIMixture_0.3.0.tar.gz</a></li>
<li>Windows O/S: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1080211" sys_contentid="1080211" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7279608" sys_siteid="475" rxinlineslot="103" sys_dependentid="1080211" sys_dependentvariantid="1500">PIMixture_0.3.0.zip</a></li>
</ul>
<h3>Support:</h3>
<ul>
<li>Contact <a href="mailto:ncicontactdceg@mail.nih.gov">DCEG</a></li>
</ul>
<h3>References:</h3>
<ul>
<li>Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, Lorey T, Katki HA. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28660629" target="_blank" rel="noopener noreferrer">Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records</a>. <cite>Stat Med </cite>2017; 30:3583-95.</li>
<li>Hyun N, Cheung, LC, Pan Q, Schiffman M, Katki HA. <a href="https://projecteuclid.org/euclid.aoas/1500537735" target="_blank" rel="noopener noreferrer">Flexible risk prediction models for left or interval-censored data from electronic health records</a>. <cite> Ann Applied Stat</cite> 2017; 11:1063-1084.</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1080216" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Provider:</strong> National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
<p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:</p>
<p>Questions? Contact: Dr. Horuzd Katki <a href="mailto:katkih@mail.nih.gov">katkih@mail.nih.gov</a></p>
</div>]]></content>
  </row>
  <row para_id="1081661" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1081665" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7108441">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1081665&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>DCEG has a long-standing commitment to the recruitment, retention, and development of a diverse group of investigators and trainees. These efforts are led by <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/lavigne-jackie">Jackie Lavigne, Ph.D., M.P.H.</a>, Chief of the Office of Education, who oversees training and career development for fellows and various levels of scientific staff. Dr. Lavigne received the NCI Leading Diversity Award in 2015 for her work with trainee populations underrepresented in the sciences.</p>
<p>Learn more about our efforts to build a diverse workforce.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1052096" sys_contentid="1052096" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1052096" sys_relationshipid="7108434" sys_variantid="1418"><strong></strong>Learn about our Women Scientist Advisors&nbsp;</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1123474" sys_dependentvariantid="1418" sys_dependentid="1123474" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7108439" sys_variantid="1418" sys_contentid="1123474">Inclusivity Minute: Monthly messages to staff with information and resources</a></li>
<li><strong>Video</strong>:&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1065273" sys_contentid="1065273" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="1065273" sys_relationshipid="7108433" sys_variantid="1410">Jackie Lavigne discusses DCEG job opportunities for the Society for the Advancement of Chicanos/Hispanics and Native Americans in Science Conference</a></li>
<li><strong>Video</strong>: <a href="https://videocast.nih.gov/Summary.asp?File=16180&amp;start=4503&amp;bhcp=1">Occupational exposures and cancer risk: Women are not just small men</a>. Dr. Melissa Friesen discusses her research at an Environmental Exposures and Women's Health seminar.</li>
</ul>
<h3>Resources for Fellows</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1068104" sys_contentid="1068104" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1068104" sys_relationshipid="7108435" sys_variantid="1418">DCEG fellows complete Diversity Career Development Program</a></li>
<li><a href="https://www.cancer.gov/grants-training/training/at-nci/srk">Learn about the Sallie Rosen Kaplan Postdoctoral Fellowship for Women Scientists</a></li>
<li><strong>Video</strong>:&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1031751" sys_contentid="1031751" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="1031751" sys_relationshipid="7108436" sys_variantid="1410">Former DCEG fellow Dr. Ashley Felix discusses her work as an epidemiologist to identify risk factors for cancer in women</a></li>
</ul>
<h3>High School Students</h3>
<p>DCEG supports NIH summer enrichment program for high school students:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1123254" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1424" rxinlineslot="103" sys_dependentid="1123254" sys_relationshipid="7108437" sys_variantid="1424" sys_contentid="1123254">Hi-STEP 2018</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1061185" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1061185" sys_relationshipid="7108438" sys_variantid="1418" sys_contentid="1061185">Hi-STEP 2016</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1082096" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The R package provides individual risks of lung cancer and lung cancer death based on various published papers: Bach et al., 2003; Spitz et al., 2007; Cassidy et al., 2008 (LLP); Hoggart et al., 2012; Tammemagi et al., 2013; Marcus et al., 2015 (LLPi); Wilson and Weissfeld, 2015 (Pittsburgh); Katki et al., 2016 (LCRAT and LCDRAT)</p>
<ul>
<li></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Windows O/S:</li>
<li>Mac O/S:</li>
</ul>
<h3>References:</h3>
<ul>
<li>Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8.</li>
<li>Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26.</li>
<li>Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-6.</li>
<li>Hoggart C, Brennan P, Tjonneland A, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila) 2012;5:834-46.</li>
<li>Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36.</li>
<li>Marcus MW, Chen Y, Raji OY, Duffy SW, Field JK. LLPi: Liverpool lung project risk prediction model for lung cancer incidence. Cancer Prev Res (Phila) 2015;8:570-5.</li>
<li>Wilson DO, Weissfeld J. A simple model for predicting lung cancer occurrence in a lung cancer screening program: the Pittsburgh predictor. Lung Cancer 2015;89:31-37.</li>
<li>Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA 2016;315:2300-11. doi: 10.1001/jama.2016.6255.</li>
</ul>
<h3>Contact:</h3>
<ul>
<li></li>
<li></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1082128" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting the lcmodels R Package Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The lcmodels - R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1083375" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Firefighting is a hazardous occupation that involves excess risk of deaths from accidents, cardiovascular disease, and respiratory disease. There is also concern that firefighters may experience excess risk of cancer, particularly since the widespread introduction of synthetic building materials and furnishings. To address this question, DCEG conducted a cohort study examining the mortality rate among 7,789 firefighters employed by the City of Philadelphia between 1910 and 1987. Later, these data were pooled with other studies to form a cohort totaling 29,993 U.S. firefighters. The findings from these studies, to date, suggest that firefighters experience elevated risk of death from leukemia and digestive, respiratory and urinary cancers.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=%28Zahm%20SH[Author]%20AND%20firefighters[Title/Abstract]%29%20AND%20Philadelphia[Title/Abstract]&amp;cmd=DetailsSearch">View publications about the Philadelphia Firefighters study</a></p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=983937" sys_contentid="983937" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7202114" sys_siteid="475" rxinlineslot="103" sys_dependentid="983937" sys_dependentvariantid="1965">Mark Purdue</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7202115" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1087302" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1088352" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7249783">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Large group of cows feeding at a trough on a farm. " src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302251&amp;sys_siteid=475&amp;sys_contentid=1088352&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Industrialized animal agriculture is a major source of air pollutants and other emissions to the surrounding environment.</p>
<div class="image-photo-credit">iStock</div>
</div>
</figcaption>
</figure>
</div>
<p>Concentrated animal feeding operations (CAFOs), where large numbers of animals are raised and often confined, are becomingly increasingly common as agriculture becomes more industrialized. Waste (e.g., manure, urine and byproducts), animal husbandry-related products (e.g., feed, pesticides, antibiotics, hormones) and the animals themselves are sources of hazardous emissions into the environment, including microorganisms, endotoxins, air pollutants (e.g., particulate and gaseous emissions), and an array of malodorous compounds. Animal waste from CAFOs is also frequently sprayed onto crop fields, resulting in environmental contamination over large regions. Using Geographic Information Systems (GIS)-based models, we are estimating CAFO-derived&nbsp;outdoor air&nbsp;pollution exposures for the Agricultural Health Study cohort and evaluating associations with health outcomes in this rural population.<br /><br />For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1080328" sys_relationshipid="7249771" sys_variantid="1965">Dr. Rena Jones</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="418935" sys_relationshipid="7249772" sys_variantid="1418">Occupational and Environment Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1087366" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Polychlorinated dibenzo-<em>p</em>-dioxins and dibenzofurans (PCDD/F) are persistent organic pollutants primarily emitted from industrial combustion facilities such as incinerators&nbsp;and coal-fired power plants, and are also by-products of the manufacture and use of polychlorinated biphenyls, paper pulp bleaching, and chlorophenols and chlorophenoxy herbicides. Several PCDD/F congeners are classified by IARC as carcinogenic. However, much of the evidence in human populations, including increased risks of non-Hodgkin lymphoma and breast cancer, is derived from occupational settings and studies of accidental industrial releases. General population exposures to PCDD/F from non-dietary sources are not well characterized.</p>
<p>Exposure studies in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303612" sys_contentid="303612" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303612" sys_dependentvariantid="1418" sys_relationshipid="7274890" sys_variantid="1418">NCI SEER Non-Hodgkin lymphoma (NHL) Study</a> have shown that emissions of certain PCDD/F are dispersed, transported, and distributed in a distance-dependent manner and that the facility type influences residential exposures. Investigators in the Occupational and Environmental Epidemiology Branch have ongoing efforts to verify the geographic location of PCDD/F-emitting sources in the U.S., improve the characterization of exposure determinants, and validate Geographic Information Systems (GIS)-based exposure metrics with serum measurements. These exposure assessment enhancements support multiple current and future studies of ambient dioxin exposure and cancer risk, including a re-analysis of NHL risk in the NCI SEER-NHL Study, which found an increased risk of NHL with residential proximity to cement kilns.<br /><br />For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1080328" sys_dependentvariantid="1965" sys_relationshipid="7274888" sys_variantid="1965">Dr. Rena Jones</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7274889" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1087367" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Outdoor air pollutants are emitted from a variety of sources including traffic and other transportation, agriculture, wildfires, and industry. Consequently, the general population is exposed to a heterogenous mixture of particles and gases with varying chemical constituency. DCEG researchers investigate various outdoor air pollutants thought to be associated with cancer risk. These include the traffic-related pollutants most concentrated in urban settings, as well as those arising from agricultural and other industrial activities.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087366" sys_contentid="1087366" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087366" sys_dependentvariantid="1418" sys_relationshipid="7277180" sys_variantid="1418">Ambient Emissions from Industrial Sources</a><br />Ongoing efforts to examine emissions from industrial sources, verify proximity-based emission exposure metrics, and evaluate their associations with non-Hodgkin lymphoma and other cancers</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=976905" sys_contentid="976905" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="976905" sys_dependentvariantid="1418" sys_relationshipid="7277181" sys_variantid="1418">Ambient Outdoor Ultrafine Particulate Matter and Lung Cancer Risk</a><br />Investigation of the etiologic relationship between long-term exposure to ambient outdoor ultrafine particle pollution and lung cancer risk in southern California</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087302" sys_contentid="1087302" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087302" sys_dependentvariantid="1418" sys_relationshipid="7277182" sys_variantid="1418">Outdoor Air Pollution from Intensive Animal Agriculture</a><br />Studies of ambient pollution exposures from concentrated animal feeding operations and their associations with health outcomes in the Agricultural Health Study cohort</p>
</div>]]></content>
  </row>
  <row para_id="1087390" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1088515" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276163">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="GIS crop maps are used in estimating exposures" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1088515&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1088515&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1088515">Enlarge</a></div>
<figcaption>
<div class="caption-container no-resize">
<p>This GIS land usage map displays an agricultural area with two residences whose locations are indicated by concentric circles representing buffer zones of increasing size. Scientists estimate exposures&mdash;such as pesticide exposure&mdash;for each residence by calculating how much area each relevant land usage type covers within the different buffer zones.</p>
</div>
</figcaption>
</figure>
</div>
<p>Epidemiologic investigations of environment-cancer relationships rely on accurate, quantifiable exposure measurements. Such studies may use Geographic Information Systems (GIS) and regulatory and other environmental monitoring data to complement retrospective surveys, which are sometimes limited by participants&rsquo; knowledge of exposures in their surrounding environments. Cancer studies have benefited from the increasing availability of historical air and water monitoring data, satellite imagery, census, and other geographic datasets that allow for reconstruction of residence- and other location-based exposures over a substantial portion of a person&rsquo;s lifetime.</p>
<p>Investigators in the Occupational and Environmental Epidemiology Branch implement GIS-based exposure assessments using georeferenced historical data resources and residential histories collected in our studies of environmental hazards and cancer risk. Our approaches include using GIS and spatial-analytic methods to characterize exposure to environmental risk factors, incorporating space-time-activity information in exposure assessments, and employing biological and environmental measurements for exposure validation. This work addresses important epidemiologic considerations in geography-based environmental exposure assessments, including residential mobility, positional error, and the challenges of extrapolation over space and time.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1135726" sys_contentid="1135726" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1135726" sys_relationshipid="7276161" sys_variantid="1418">Publications on the use of GIS for exposure assessment</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349624" sys_contentid="349624" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349624" sys_relationshipid="7276158" sys_variantid="1965">Dr. Mary Ward</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1080328" sys_contentid="1080328" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1080328" sys_relationshipid="7276159" sys_variantid="1965">Dr. Rena Jones</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="418935" sys_relationshipid="7276160" sys_variantid="1418">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1087952" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Somatic copy number alternation (SCNA) is a common feature of the cancer genome and is associated with cancer etiology and prognosis. The allele-specific SCNA analysis of a tumor sample aims to identify the allele-specific copy numbers of both alleles, adjusting for the ploidy and the tumor purity. Next generation sequencing platforms produce abundant read counts at the basepair resolution across the exome or whole genome which is susceptible to hypersegmentation, a phenomenon where numerous regions with very short length are falsely identified as SCNA. This package employs a robust hidden Markov model approach that accounts for hypersegmentation for allele-specific SCNA analysis, and an efficient E-M algorithm procedure that uses a forwardbackward algorithm for evaluating the E-step. The main function that performs this method is hsegHMM_main.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1087951" target="_blank" rel="noopener noreferrer" sys_contentid="1087951" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7276084" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087951" sys_dependentvariantid="1500">Manual</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1087950" target="_blank" rel="noopener noreferrer" sys_contentid="1087950" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7276085" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087950" sys_dependentvariantid="1500">Vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087953" sys_contentid="1087953" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276088" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087953" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h3>Download Software</h3>
<ul>
<li>Windows O/S: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1087948" sys_contentid="1087948" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7276086" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087948" sys_dependentvariantid="1500">hsegHMM_0.0.4.zip</a></li>
<li>Unix O/S: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1087949" sys_contentid="1087949" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7276087" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087949" sys_dependentvariantid="1500">hsegHMM_0.0.4.tar.gz</a></li>
<li>On github: <a href="https://github.com/wheelerb/hsegHMM">https://github.com/wheelerb/hsegHMM</a></li>
</ul>
<h3>Reference</h3>
<p>Choo-Wosoba, H., Albert, P.S., Zhu, B. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30428830">hsegHMM: Hidden Markov Model-based Allele-specific Copy Number Alteration Analysis Accounting for Hypersegmentation</a>. <em>BMC Bioinformatics</em> 2018 Nov 14.</p>
<h3>Support</h3>
<p>Questions, please contact Dr. Choo-Wosoba (hyoyoung.choo-wosoba@mail.nih.gov)</p>
</div>]]></content>
  </row>
  <row para_id="1087953" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>hsegHMM - R Package</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The hsegHMM - R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1087954" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The R package provides individual risks of lung cancer and lung cancer death based on various published papers: Bach et al., 2003; Spitz et al., 2007; Cassidy et al., 2008 (LLP); Hoggart et al., 2012; Tammemagi et al., 2013; Marcus et al., 2015 (LLPi); Wilson and Weissfeld, 2015 (Pittsburgh); Katki et al., 2016 (LCRAT and LCDRAT)</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1081768" sys_contentid="1081768" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317637" sys_siteid="475" rxinlineslot="103" sys_dependentid="1081768" sys_dependentvariantid="1500">LCModels Manual</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1082128" sys_contentid="1082128" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7317638" sys_siteid="475" rxinlineslot="103" sys_dependentid="1082128" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Windows O/S: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1081766" sys_contentid="1081766" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317639" sys_siteid="475" rxinlineslot="103" sys_dependentid="1081766" sys_dependentvariantid="1500">lcmodels.2.0.0.zip</a>&nbsp;and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1067867" sys_contentid="1067867" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317642" sys_siteid="475" rxinlineslot="103" sys_dependentid="1067867" sys_dependentvariantid="1500">coxph.risk.zip</a></li>
<li>Linux: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1081767" sys_contentid="1081767" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317640" sys_siteid="475" rxinlineslot="103" sys_dependentid="1081767" sys_dependentvariantid="1500">lcmodels.2.0.0.tar.gz</a>&nbsp;and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=1067869" sys_contentid="1067869" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7317643" rxinlineslot="103" sys_dependentid="1067869" sys_dependentvariantid="1500">coxph.risk.tar.gz</a></li>
</ul>
<h3>References:</h3>
<ul>
<li>Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8.</li>
<li>Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26.</li>
<li>Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-6.</li>
<li>Hoggart C, Brennan P, Tjonneland A, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila) 2012;5:834-46.</li>
<li>Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36.</li>
<li>Marcus MW, Chen Y, Raji OY, Duffy SW, Field JK. LLPi: Liverpool lung project risk prediction model for lung cancer incidence. Cancer Prev Res (Phila) 2015;8:570-5.</li>
<li>Wilson DO, Weissfeld J. A simple model for predicting lung cancer occurrence in a lung cancer screening program: the Pittsburgh predictor. Lung Cancer 2015;89:31-37.</li>
<li>Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA 2016;315:2300-11. doi: 10.1001/jama.2016.6255.</li>
<li>Katki HA, Kovalchik SA, Petito LC, Cheung LC, Jacobs E, Jemal A, Berg CD, Chaturvedi AK. Implications of nine risk prediction models for selecting ever-smokers for computed tomography lung cancer screening. Ann Intern Med. 2018;doi: 10.7326/M17-2701.</li>
</ul>
<h3>Contact:</h3>
<ul>
<li><a href="&quot;mailto:li.cheung@nih.gov">Li Cheung</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" sys_contentid="349618" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7317641" sys_siteid="475" rxinlineslot="103" sys_dependentid="349618" sys_dependentvariantid="1965">Dr. Hormuzd Katki </a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1088547" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>The U.S. Preventive Services Task Force (USPSTF) recommends annual computed tomography (CT) screening for individuals between 55 and 80 years old with a history of heavy smoking (at least one pack of cigarettes per day for 30 years or more) and who currently smoke or have quit within the past 15 years. However, selecting ever-smokers for screening using individualized lung cancer risk calculations may be more effective and efficient at preventing deaths than current USPSTF recommendations.</p>
<h3>Advance</h3>
<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" sys_contentid="349618" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275667" sys_siteid="475" rxinlineslot="103" sys_dependentid="349618" sys_dependentvariantid="1965"> </a>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" sys_contentid="349618" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275668" sys_siteid="475" rxinlineslot="103" sys_dependentid="349618" sys_dependentvariantid="1965">Hormuzd Katki, Ph.D.</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349667" sys_contentid="349667" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275669" sys_siteid="475" rxinlineslot="103" sys_dependentid="349667" sys_dependentvariantid="1965">Anil Chaturvedi, Ph.D.</a>, and colleagues, used data from two lung cancer screening studies and a U.S. health survey to develop and validate risk models for selecting smokers and former smokers who may be candidates for lung cancer screening with low-dose CT, and estimated the performance of risk-based selection into lung screening programs.</p>
<h3>Impact</h3>
<p>Because the researchers estimated that risk-based selection for screening might prevent more lung-cancer deaths, with greater effectiveness and efficiency, than would current screening recommendations, they have created an online lung-cancer screening risk-tool to provide individualized risk information for patients considering entering lung screening.</p>
<h3>Publications</h3>
<p>Katki HA, Kovalchik SA, Berg CD, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27179989">Development and validation of risk models to select ever-smokers for CT lung cancer screening</a>. <em>JAMA. </em>2016;315(21):2300-2311</p>
<p><a href="https://analysistools.nci.nih.gov/lungCancerScreening/" target="_blank" rel="noopener noreferrer">Access the online lung cancer screening risk tool </a></p>
<p>&nbsp;</p>
</div>]]></content>
  </row>
  <row para_id="1088550" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators regularly develop tools to predict risk of developing cancer. Many of these models are used in clinical settings to manage patient care, or assign patients to appropriate cancer screening.</p>
<ul>
<li><a href="https://bcrisktool.cancer.gov/">Breast Cancer Risk Assessment tool</a> (BCRAT)<br />The BCRAT (Gail et al., 1989) estimates a woman's risk of developing invasive breast cancer. Since its original publication, the tool has been updated and expanded. It is widely used by clinicians and researchers. The Food and Drug Administration guidelines rely on the tool for the recommendation of use of tamoxifen and raloxifene for breast cancer risk reduction.</li>
<li><a href="https://ccrisktool.cancer.gov/">Colorectal Cancer RiskTool</a> (CCRAT)<br /> The CCRAT is a tool for health care providers to&nbsp;estimate a patient's&nbsp;risk of developing colorectal cancer. CCRAT is available as a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302539" sys_contentid="302539" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302539" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277344" sys_variantid="1418">SAS Macro</a> or a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302628" sys_contentid="302628" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302628" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277345" sys_variantid="1418">Gauss Program</a>.</li>
<li><a href="https://analysistools.nci.nih.gov/lungCancerScreening/#/">Lung Cancer Risk Assessment Tool</a> <br />The <a href="https://analysistools.nci.nih.gov/lungCancerScreening/#/">Lung Cancer Risk Assessment Tool</a> (Katki 2016) estimates lung cancer risk for current and former smokers who may consider undergoing lung cancer screening to prevent lung cancer death. Read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1088547" sys_contentid="1088547" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1088547" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277343" sys_variantid="1418">enhanced risk-based lung cancer screening</a>.</li>
<li><a href="https://mrisktool.cancer.gov/">Melanoma Risk Assessment tool</a> (MRAT) <br /> The MRAT estimates an individual's risk of developing melanoma (Tucker et al., 2002; Fears et al., 2006)</li>
<li><a href="https://analysistools.nci.nih.gov/nevustool/?page=home">Moles to Melanoma Online Tool</a><br /> Moles to Melanoma helps health care providers, patients, and others recognize common moles, dysplastic nevi (precursor lesions that may develop into melanoma), and melanomas by presenting case study photographs of lesions as they change over time.</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1088554" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>As more and more low penetrant common single nucleotide polymorphisms associated with breast cancer risk are discovered through genomics studies, there is a pressing need for an understanding of their utility in guiding public health strategies.</p>
<h3>Advance</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" sys_contentid="1004366" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275116" sys_siteid="475" rxinlineslot="103" sys_dependentid="1004366" sys_dependentvariantid="1965">Montserrat Garcia-Closas, M.D., Dr.P.H.</a>,&nbsp;Paige Maas, Ph.D., Nilanjan Chatterjee, Ph.D., and colleagues developed a risk prediction model, based on both modifiable (alcohol use, exercise, etc.) and nonmodifiable (genetics) risk factors, to assess the absolute risk of breast cancer in women of European background in the United States. They showed that women with high genetic risk have a greater potential for reduction in absolute risk by changing modifiable factors than women with low genetic risk.</p>
<h3>Impact</h3>
<p>This study demonstrated that incorporating common genetic variation risk factors into breast cancer risk models would substantially improve risk stratification and lifestyle recommendations over existing models, which only consider genetics broadly, in terms of family history.</p>
<p>Maas P, Barrdahl M, Joshi AD, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27228256">Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States</a>. <em>JAMA Oncol; </em>Published online May 26, 2016. doi:10.1001/jamaoncol.2016.1025</p>
</div>]]></content>
  </row>
  <row para_id="1088555" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>Cigarette smoking is known to cause more than 20 types of cancer as well as other diseases, but the effects of low-intensity smoking (10 or fewer cigarettes per day) have not been well studied.</p>
<h3>Advance</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1016601" sys_contentid="1016601" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="1016601" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276382" sys_variantid="1965">Maki Inoue-Choi, Ph.D., M.S., R.D.</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349608" sys_contentid="349608" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349608" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276383" sys_variantid="1965">Neal Freedman, Ph.D., M.P.H.,</a> and colleagues showed that among 290,215 adults in the National Institutes of Health-AARP Diet and Health Study, current smokers who had smoked less than 1 cigarette per day over their lifetime had 1.64 times higher mortality risk and smokers who had smoked 1 to 10 cigarettes per day had 1.87 times higher mortality risk than never smokers. Risks were lower among former smokers compared to those who continued to smoke and fell with earlier age at quitting.</p>
<h3>Impact</h3>
<p>These results provide further evidence that there is no safe level of exposure to tobacco smoke and that even low-intensity smokers benefit from cessation.</p>
<p>Inoue-Choi M, Liao L, Reyes-Guzman C, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27918784">Association of long-term low-intensity smoking with all-cause and cause-specific mortality in the NIH-AARP Diet and Health Study</a>. <em>JAMA Internal Medicine</em> 2016. DOI: 10.1001/jamainternmed.2016.7511</p>
</div>]]></content>
  </row>
  <row para_id="1088556" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG research on the association between <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=462196" sys_contentid="462196" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277856" sys_siteid="475" rxinlineslot="103" sys_dependentid="462196" sys_dependentvariantid="1418">smokeless tobacco and cancer </a>has made a significant impact on regulation of these products.</p>
<p>Investigation of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1088555" sys_contentid="1088555" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277857" sys_siteid="475" rxinlineslot="103" sys_dependentid="1088555" sys_dependentvariantid="1418">low-intensity smoking</a> provides further evidence that there is no safe level of exposure to tobacco smoke and that even low-intensity smokers benefit from cessation.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1088558" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Challenge</h3>
<p>High rates of APOBEC-signature mutations (generated by APOBEC3 enzymes) are found in many tumors, but factors affecting this mutation pattern are not well understood.</p>
<h3>Advance</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=34&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349662" sys_contentid="349662" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349662" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276080" sys_variantid="1965">Ludmila Prokunina-Olsson, Ph.D.</a>, and collaborators found that two common germline variants in the <em>APOBEC3</em> region on chromosome 22, previously associated with risk for bladder and breast cancer, were also associated with increased expression of mRNA transcripts that encode the APOBEC3B and APOBEC3A enzymes in bladder and breast tumors in The Cancer Genome Atlas (TCGA). Furthermore, the same germline variants and mRNA transcripts were significantly associated with increased number of APOBEC-signature mutations in these tumors. When the investigators exposed cancer cell lines to a viral infection or a DNA-damaging drug, they observed a strongly induced expression of APOBEC3A and APOBEC3B.</p>
<h3>Impact</h3>
<p>These findings suggest a tissue-specific role of environmental triggers for APOBEC mutagenesis that may lead to cancer, particularly in individuals with germline APOBEC3 risk variants.</p>
<p>Middlebrooks CD, Banday AR, Matsuda K, et al.&nbsp;<a href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3670.html">Association of germline variants in the <em>APOBEC3</em> region with cancer risk and enrichment with APOBEC-signature mutations in tumors</a>. <em>Nature Genetics</em> 2016</p>
</div>]]></content>
  </row>
  <row para_id="1088559" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG conducts a wide range of studies of the genetic and molecular epidemiology of cancer. Below are some of the major public health advances achieved by investigators in our Division.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1061078" sys_contentid="1061078" inlinetype="rxhyperlink" sys_relationshipid="7276111" sys_variantid="1418" sys_dependentid="1061078" rxinlineslot="103" sys_dependentvariantid="1418" sys_siteid="475">Genetic Etiology of Cancer</a><br /> DCEG has utilized ever-evolving technology to expand knowledge on common inherited genetic variations and the role of germline DNA in cancer susceptibility. Building on its long history of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=462207" sys_contentid="462207" inlinetype="rxhyperlink" sys_relationshipid="7276114" sys_variantid="1418" sys_dependentid="462207" rxinlineslot="103" sys_dependentvariantid="1418" sys_siteid="475">mapping susceptibility genes in cancer-prone families</a>, DCEG investigators were some of the first in the early 2000s to adopt the emerging technology of genome-wide association studies (GWAS), a powerful tool for investigating common inherited variation associated with cancer and other diseases.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1088558" sys_contentid="1088558" inlinetype="rxhyperlink" sys_relationshipid="7276112" sys_variantid="1418" sys_dependentid="1088558" rxinlineslot="103" sys_dependentvariantid="1418" sys_siteid="475">Genetic and Environmental Factors Influence APOBEC Mutagenesis in Tumors</a><br /> Researchers studying the high rates of APOBEC-signature mutations in tumor tissue (generated by APOBEC3 enzymes) identified possible tissue-specific role for environmental triggers of APOBEC mutagenesis, particularly among individuals with germline APOBEC3 risk variants.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=462207" sys_contentid="462207" inlinetype="rxhyperlink" sys_relationshipid="7276113" sys_variantid="1418" sys_dependentid="462207" rxinlineslot="103" sys_dependentvariantid="1418" sys_siteid="475">Hereditary Syndromes</a><br /> Clinical genetics researchers in DCEG have identified genetic mutations responsible for several hereditary cancer syndromes. Examples include the discovery of Li-Fraumeni syndrome and the role of <em>p53</em> and the contribution of <em>NF2</em> in neurofibromatosis type 2. These findings have had a significant impact on the clinical management of these and related conditions, as well as informed research on the genetic determinates of cancer in the general population.</p>
</div>]]></content>
  </row>
  <row para_id="1089023" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Therapeutic Radiation Dosimetry</h2>
<p>DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7277146" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422">Radiation Epidemiology Branch</a> are developing a novel method to estimate normal tissue doses from external radiotherapy for epidemiologic studies based on multiple dose calculation tools. These tools range from a commercial treatment planning system (TPS) to Monte Carlo calculation codes. The system, called the National Cancer Institute dosimetry system for Radiation Treatment (NCIRT), includes two independent modules for photon and proton treatments. Both photon and proton modules are validated by dosimetry measurements in collaboration with clinical institutions. NCIRT is designed for different scenarios of dose reconstruction in which radiological images are available or not available for an epidemiological cohort.</p>
<div sys_dependentvariantid="2082" sys_dependentid="1091094" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7277152">
<figure class="image-center centered-set">
<div class="centered-element"><img alt="Display of a proton therapy machine with a human patient, calculating the dose to a patient. " src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1091094&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>A novel method, the National Cancer Institute dosimetry system for Radiation Treatment (NCIRT), has been used to estimate normal tissue doses to patients from proton therapy.</p>
</div>
</figcaption>
</figure>
</div>
<h3>Examples to Date</h3>
<p>The system has been used to estimate doses to patients&rsquo; stomachs of variable shapes and locations within the study of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302397" sys_contentid="302397" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277150" sys_siteid="475" rxinlineslot="103" sys_dependentid="302397" sys_dependentvariantid="1418">second primary gastrointestinal cancers among survivors of Hodgkin lymphoma and other cancers</a>. NCIRT also is being used to estimate normal tissue doses for the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=805096" sys_contentid="805096" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277148" sys_siteid="475" rxinlineslot="103" sys_dependentid="805096" sys_dependentvariantid="1418">study of contralateral breast cancer in collaboration with the Kaiser health maintenance organization</a>. In addition, the system is being used for external collaborations, including the National Wilms Tumor Study and the clinical trial of Proton vs. Photon Therapy for Breast Cancer patients.</p>
<h3>Related Links</h3>
<p>Read <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1087876" sys_contentid="1087876" inlinetype="rxhyperlink" sys_variantid="1424" sys_relationshipid="7277147" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087876" sys_dependentvariantid="1424">Applying 3-Dimensional Printing for Radiation Exposure Assessment</a> for more information on computational and physical phantoms.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7277145" sys_siteid="475" rxinlineslot="103" sys_dependentid="349634" sys_dependentvariantid="1965">Choonsik Lee, Ph.D.</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7277149" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1090882" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Diagnostic Radiation Dosimetry</h2>
<div sys_relationshipid="7275949" sys_dependentid="1090900" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1090900&amp;sys_command=preview" alt="Graphical user interface for the NCICT program displays parameters entered by users, along with organ dose calculations."><!--Comment--></img>
                                                </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              <p><cite>The graphical user interface of NCICT showing organ dose calculations for the head scan of a newborn female patient.<br /></cite></p>                                        </div>
          </figcaption>
              </figure>
       </div>
<p>DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302459" sys_variantid="1422" sys_relationshipid="7275946">Radiation Epidemiology Branch</a> have been developing methods to estimate organ doses to pediatric and adolescent patients undergoing computed tomography (CT) scans. For this effort, they developed cutting edge age- and body size-dependent computational human phantoms and coupled them with a simulated x-ray beam from a reference CT scanner using a Monte Carlo transport code. They validated the resulting simulated organ doses for illustrative CT scans using dose measurements based on physical human phantoms combined with radiation dosimeters. The investigators combined these results with a graphical user interface and user-friendly computer software, calling the resulting program the National Cancer Institute dosimetry system for Computed Tomography (NCICT).</p>
<p>The NCICT has been used in major epidemiological investigations including assessment of subsequent cancer risk in the UK-NCI cohort study, <a href="http://epi-ct.iarc.fr/">European Pediatric CT Scan study (EPI-CT)</a>, and the <a href="https://www.ncbi.nlm.nih.gov/pubmed/28267354">National Lung Screening Trial</a>. The NCICT program is being shared with the radiological community for research purposes via the <a href="https://ncidose.cancer.gov/#home">NCIDose website</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349634" sys_variantid="1965" sys_relationshipid="7275947">Dr. Choonsik Lee</a>.</p>
<h3>Related Links</h3>
<p>Read <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1087876" sys_contentid="1087876" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1424" rxinlineslot="103" sys_dependentid="1087876" sys_variantid="1424" sys_relationshipid="7275948">Applying 3-Dimensional Printing for Radiation Exposure Assessment</a> for more information on computational and physical phantoms.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1090901" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Diagnostic Radiation Dosimetry</h2>
<p>To support epidemiological studies of medical radiation and cancer risk, DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7275950" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422">Radiation Epidemiology Branch</a> are developing more accurate methods to estimate radiation doses from diagnostic examinations such as radiography and fluoroscopy. As part of that effort, they are developing a new dose calculator, titled the National Cancer Institute dosimetry system for Radiography and Fluoroscopy (NCIRF). The NCIRF is designed to calculate radiation doses more accurately using a new streamlined Monte Carlo transport code combined with a series of computational human phantoms and a graphical user interface.&nbsp;</p>
<div sys_relationshipid="7275953" sys_dependentid="1091032" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1091032&amp;sys_command=preview" alt="Radiography images display a close-up of the stomach area on the left, and a close-up of the thoracic area on the right."><!--Comment--></img>
                                                </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>Radiography images:(left) close-up of stomach area and (right) close-up of thoracic area</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<p>Simulated radiation doses produced by the system are being validated using physical human phantoms in combination with a radiation dosimeter system.</p>
<p>The NCIRF's design addresses limitations in&nbsp;the PCXMC&trade;, an older radiographic dose calculator that was used to derive organ doses for specific types of x-ray examinations using estimates of entrance skin dose described in historical literature. Radiographic fields and x-ray technical parameters for the PCXMC&trade; were based on information from a well-known series of radiographic imaging handbooks. This dosimetry approach was previously used to estimate individual medical doses for the U.S. Radiologic Technologists cohort. The NCIRF method is currently being used to update the organ dosimetry.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275951" sys_siteid="475" rxinlineslot="103" sys_dependentid="349634" sys_dependentvariantid="1965">Dr. Choonsik Lee</a>.</p>
<h3>Related Links</h3>
<p>Read <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1087876" sys_contentid="1087876" inlinetype="rxhyperlink" sys_variantid="1424" sys_relationshipid="7275952" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087876" sys_dependentvariantid="1424">Applying 3-Dimensional Printing for Radiation Exposure Assessment</a> for more information on computational and physical phantoms.</p>
</div>]]></content>
  </row>
  <row para_id="1090903" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1091232" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7274853">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302185&amp;sys_siteid=475&amp;sys_contentid=1091232&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302185&amp;sys_siteid=475&amp;sys_contentid=1091232&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1091232">Enlarge</a></div>
<figcaption>
<div class="caption-container no-resize">
<p>Incidence of esophageal squamous cell carcinoma (age standardized rates, per 100,000) for males.</p>
</div>
</figcaption>
</figure>
</div>
<p>Esophageal cancer is the eighth most common cause of cancer worldwide and the sixth most common cause of cancer-related death worldwide. Esophageal cancer kills 400,000 people every year, most of whom live in two distinct geographic bands across central Asia and along the eastern Africa corridor extending from Ethiopia to South Africa. In these high-risk areas, nearly all cases are esophageal squamous cell carcinoma (ESCC).</p>
<p>ESCC symptoms, such as dysphagia (difficulty swallowing) and weight loss, develop late. Most patients present with advance disease, and survival is usually poor (3-6 months). Afflicted patients are readily identifiable in surgical and medical hospital wards, profoundly wasted and holding spittoon cups to manage secretions.</p>
<p>NCI investigators and others have performed many etiologic, genetic, early detection, and treatment studies of ESCC in central Asia, but this disease remains essentially unstudied in eastern Africa.</p>
<h3>About the African Esophageal Cancer Consortium (AfrECC)</h3>
<div sys_dependentvariantid="2066" sys_dependentid="1091285" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7274854">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302185&amp;sys_siteid=475&amp;sys_contentid=1091285&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>To address this research gap, NCI and others are supporting fieldwork and case-control studies in different settings in East Africa. Over the past few years, African Esophageal Cancer Consortium (AfrECC) members have begun quality studies, including case-control studies in:</p>
<ul>
<li>Addis Ababa, Ethiopia (IARC and Addis Ababa University)</li>
<li>Eldoret, Kenya (IARC and Moi University)</li>
<li>Bomet, Kenya (NCI and Tenwek Hospital)</li>
<li>Moshi, Tanzania (IARC and Kilimanjaro Christian Medical Center)</li>
<li>Dar es Salaam, Tanzania (UCSF and Muhimbili University)</li>
<li>Lilongwe, Malawi (NCI and the UNC-Malawi Project)</li>
<li>Blantyre, Malawi (IARC and Queen Elizabeth Central Hospital)</li>
<li>Lusaka, Zambia (University Teaching Hospital and Queen Mary University of London)</li>
<li>Johannesburg and Cape Town, South Africa (University of the Witwatersrand and University of Cape Town)</li>
</ul>
<p>At the <a href="https://dceg.cancer.gov/news-events/people-in-the-news/archive/esophageal-workshop">NCI-IARC Tumor Workshop on ESCC</a> in September 2016, these groups met and decided to formally establish AfrECC.</p>
<h3>Consortium Outcomes and Future Objectives</h3>
<div sys_dependentvariantid="2066" sys_dependentid="1091271" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7274855">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302185&amp;sys_siteid=475&amp;sys_contentid=1091271&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Five year survival for esophageal squamous cell carcinoma is dramatically different depending on the stage of disease.</p>
</div>
</figcaption>
</figure>
</div>
<p><strong>Research</strong><br /> To coordinate etiologic and molecular studies of ESCC in this high risk population</p>
<ul>
<li>Data are being collected using an mHealth application tailored to the consortium, which increases efficiency, eliminates transcription mistakes, and allows real-time QC and supervision of field activities from any location.</li>
<li>Unified data entry on mobile devices instantly harmonizes data and facilitates an internationally-coordinated effort.</li>
<li>Case-control studies are in various stages of implementation at institutions in collaboration with the <a href="http://esccape.iarc.fr/">Oesophageal Squamous Cell Carcinoma African Prevention Research (ESCCAPE).</a></li>
<li>Case-control studies will examine the etiological effects of dietary, lifestyle, and environmental risk factors for ESCC.</li>
<li>Future molecular and genomic research is also planned, including a coordinated GWAS study.</li>
</ul>
<p><strong>Clinical Capacity Building</strong><br /> To improve outcomes for early detection, treatment, and palliation of this cancer</p>
<ul>
<li>Central coordination is encouraging sites to learn from one another and spread technical research expertise.</li>
<li>Biospecimen procedures and tumor biobanks are being standardized.</li>
<li>A survey of regional endoscopy capacity is being conducted.</li>
<li>The consortium will establish an in-region training center to teach stent placement and other endoscopic and surgical skills.</li>
<li>An important priority at all sites is provision of self-expanding metal stents (SEMS) for ESCC palliation. The consortium is actively working with international partners to provide affordable stents in Africa.</li>
</ul>
<div sys_dependentvariantid="2066" sys_dependentid="1091254" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7274856">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302185&amp;sys_siteid=475&amp;sys_contentid=1091254&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302185&amp;sys_siteid=475&amp;sys_contentid=1091254&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1091254">Enlarge</a></div>
<figcaption>
<div class="caption-container no-resize">
<p>In May 2017, AfrECC Consortium members visited each of the research sites to see the various research settings and capacities and to meet the investigators from other sites. This photo was taken at Tenwek Hospital in Bomet, Kenya.</p>
</div>
</figcaption>
</figure>
</div>
<p><strong>Advocacy and Awareness</strong><br /> To raise awareness (both in Africa and elsewhere) of the importance of ESCC for physicians, at-risk populations, and policymakers</p>
<ul>
<li>Education among at-risk populations and physicians to promote earlier presentations for clinical care, earlier diagnosis, and referrals to centers equipped to provide the necessary treatment or palliation.</li>
<li>Advocacy for local ministries of health and international funding agencies is critical for the provision of resources to increase access to relevant therapies and to support the necessary research to drive development of evidence-based policies for prevention and palliation.</li>
</ul>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1093205" sys_contentid="1093205" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1093205" sys_variantid="1418" sys_relationshipid="7274848">View a list of publications from AfrECC</a>.</p>
<br />
<div class="callout-box right">
<h3>African Esophageal Cancer Consortium</h3>
<p>For more information, contact:<br /><a href="mailto:natalie.pritchett@nih.gov">Natalie Pritchett</a> <br />(study coordinator)</p>
<p><a title="" href="/research/cancer-types/esophagus/AfrECC-publications">View a list of publications from the consortium</a></p>
</div>
</div>]]></content>
  </row>
  <row para_id="1091068" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators in the Dosimetry Unit of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=111&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281747" sys_variantid="1422">Radiation Epidemiology Branch</a> (REB) conduct dosimetry research in collaboration with branch epidemiologists and statisticians. Our research focuses on developing new dosimetry methods and refining existing methods to achieve more accurate dose estimates, as well as quantifying and incorporating related uncertainties.</p>
<a id="Top"></a>
<p><strong><em>On This Page:</em></strong></p>
<ul>
<li><a href="#Dosimetry-Methods-and-Tools">Dosimetry Methods and Tools</a></li>
<li><a href="#Medical-Radiation-Exposure">Medical Radiation Exposure</a></li>
<li><a href="#Environmental-Radiation-Exposure">Environmental Radiation Exposure</a></li>
<li><a href="#Occupational-Radiation-Exposure">Occupational Radiation Exposure</a></li>
<li><a href="#Related-Links">Related Links</a></li>
</ul>
<h3><a id="General-Methods-and-Tools"></a>Dosimetry Methods and Tools</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1108341" sys_contentid="1108341" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1108341" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281758" sys_variantid="1418">Dosimetry methods and tools</a> developed by REB investigators are made widely available to encourage use by other radiation dosimetrists and epidemiologists. Examples include:</p>
<ul>
<li>Computational and Physical Human Phantoms</li>
<li>Monte Carlo Simulation Methods</li>
<li>Uncertainties in Doses</li>
<li>Radiation Measurements</li>
</ul>
<p>Learn more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1108341" sys_contentid="1108341" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1108341" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281757" sys_variantid="1418">Dosimetry Methods and Tools</a>.</p>
<h3><a id="Medical-Radiation-Exposure"></a>Medical Radiation Exposure</h3>
<p>Exposure to diagnostic examinations involving radiation has increased dramatically among the U.S. population. In order to support epidemiological studies of medical radiation and cancer risk, DCEG dosimetry researchers are developing more accurate methods to estimate radiation doses from diagnostic radiologic examinations, such as computed tomography (CT) scans, radiography or fluoroscopically-guided interventional procedures, and nuclear medicine exams. They are also studying how to estimate radiation doses to normal tissues from radiological cancer treatments, including external radiation treatments and therapeutic nuclear medicine procedures, in order to better support studies of second cancers and their possible causes.</p>
<h4>Diagnostic Radiation Procedures</h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090882" sys_contentid="1090882" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1090882" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281745" sys_variantid="1418">Radiation Dose to Patients Undergoing CT Scans</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090901" sys_contentid="1090901" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1090901" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281746" sys_variantid="1418">Radiation Dose to Patients Undergoing Radiography/Fluoroscopy Exams</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1107071" sys_contentid="1107071" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1107071" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281756" sys_variantid="1418">Radiation Dose to Patients Undergoing Nuclear Medicine Exams</a></li>
</ul>
<h4>Therapeutic Radiation Procedures</h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1089023" sys_contentid="1089023" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1089023" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281748" sys_variantid="1418">Normal Tissue Dose for External Radiation Therapy Patients</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1091102" sys_contentid="1091102" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1091102" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281749" sys_variantid="1418">Normal Tissue Dose Estimates for Patients Undergoing Nuclear Medicine Procedures</a></li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Occupational-Radiation-Exposure"></a>Occupational Radiation Exposure</h3>
<p>There are an estimated 1.5 million radiation workers in the United States, and questions remain about optimal radiation protection strategies for protracted low-dose occupational radiation exposures. The public is also concerned about radiation protection because of ubiquitous, protracted, low-dose exposures from certain medical procedures, air travel, natural background, and other sources. Studies of cancer among occupationally exposed populations are important therefore for radiation protection purposes, and for estimating and projecting risks to the public. DCEG dosimetry researchers in the REB are developing methods to more accurately estimate organ dose and quantify uncertainties for radiation workers exposed to medical radiation procedures and involved in radiation accidents.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302586" sys_contentid="302586" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302586" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281752" sys_variantid="1418">Radiation Dose Estimation for Medical Radiation Workers</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1105307" sys_contentid="1105307" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1105307" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281753" sys_variantid="1418">Radiation Dose to Post-Chernobyl Cleanup Workers</a></li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Environmental-Radiation-Exposure"></a>Environmental Radiation Exposure</h3>
<p>Fundamental questions remain unanswered about the potential hazards of low-dose, protracted radiation exposures from environmental radiation sources. The Fukushima nuclear power plant accident was an important reminder of the need to understand the long-term effects of low-dose protracted exposures from radioactive cesium (<sup>137</sup>Cs) deposited on the ground and internal exposure to radionuclides especially radioiodine (<sup>131</sup>I) resulting from the accident. In support of epidemiological studies of cancer risk from environmental radiation exposure, DCEG dosimetry researchers in the REB are developing methods for more accurate dose estimates and for reducing uncertainty in studies of thyroid cancer and other thyroid diseases in persons exposed to radionuclides from the Chernobyl accident and to fallout from nuclear weapons testing.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100557" sys_contentid="1100557" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1100557" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281751" sys_variantid="1418">Chernobyl Childhood Thyroid Dosimetry</a></li>
<li><em></em><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100762" sys_contentid="1100762" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1100762" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281750" sys_variantid="1418"><em>In utero</em> Exposure in Belarus and Ukraine</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1100732" sys_contentid="1100732" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1100732" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281755" sys_variantid="1418">Dosimetry for the TRIO Study</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1105314" sys_contentid="1105314" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1105314" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281754" sys_variantid="1418">Methodologic Studies of Radioactive Fallout</a></li>
</ul>
<p><a href="#Top">Back to top</a></p>
<h3><a id="Related-Links"></a>Related Links</h3>
<ul>
<li><a href="https://ncidose.cancer.gov/#home">NCIDose: A collection of tools and data for medical radiation dosimetry</a> developed by the REB Dosimetry Unit</li>
<li><strong>Radiation Epidemiology and Dosimetry Course</strong> -&nbsp;World-renowned radiation experts discuss basic principles and the most up-to-date thinking about the health effects of radiation exposure. The next Radiation Epidemiology &amp; Dosimetry Course will be held September 9-12, 2019, at NCI Shady Grove, Rockville, Maryland. <a href="https://events.cancer.gov/2019RADEPI">Register for the Radiation Epidemiology &amp; Dosimetry Course</a>.<br /><br />
<p>Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=937894" sys_contentid="937894" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="937894" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7281759" sys_variantid="1418">2019 Radiation Epidemiology &amp; Dosimetry Course</a> and view videos and course content from the 2015 course.</p>
</li>
</ul>
<p><a href="#Top">Back to top</a></p>
</div>]]></content>
  </row>
  <row para_id="1091102" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Therapeutic Radiation Dosimetry</h2>
<p>DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277140" sys_variantid="1422">Radiation Epidemiology Branch</a> (REB) develop dosimetry methods for patients undergoing therapeutic nuclear medicine procedures, in which a radiative substance (radionuclide) is introduced into the body either intravenously or orally, and that substance emits ionizing radiation within a small area inside the body. Dosimetry for nuclear medicine requires biokinetic models for given radionuclides and organ dose coefficients, which convert radionuclide uptake to absorbed dose.</p>
<p>REB investigators are developing different biokinetic models specific to epidemiological study cohorts and a library of dose coefficients by using Monte Carlo radiation transport techniques combined with computational human phantoms. By using comprehensive dose coefficients coupled with an <span>International Commission on Radiological Protection </span>(ICRP) reference biokinetic model, REB investigators are developing a user-friendly computer program, titled National Cancer Institute dosimetry system for Nuclear Medicine (NCINM).&nbsp; The methods have been used for dose estimates to the thyroid, active bone marrow, and other organs for a cohort of 35,593 hyperthyroid patients. The dose estimates will be used for dose-response risk assessment in the extended follow-up of cancer mortality risks among patients with hyperthyroidism treated with <sup>131</sup>I.</p>
<div sys_dependentvariantid="2082" sys_dependentid="1091192" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7277144">
<figure class="image-center centered-set">
<div class="centered-element"><img alt="This biokinetic model for iodine was developed to derive organ residence times and to reconstruct the radiation-absorbed doses to the thyroid gland and to other organs resulting from administration of (131)I to hyperthyroid patients" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1091192&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Schematic representation of the iodine biokinetic model for hyperthyroid patients</p>
<p>Based on Melo D, et al. <em>Radiation Research</em> 2015.</p>
</div>
</figcaption>
</figure>
</div>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349634" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277141" sys_variantid="1965">Dr. Choonsik Lee</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277142" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1091127" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>A Subregion-based Burden Test for Simultaneous Identification of Susceptibility Loci and Sub-regions within </strong></p>
<p>In rare-variant association studies, aggregating rare and/or low frequency variants, may increase statistical power for detection of the underlying susceptibility gene or region. However, it&rsquo;s unclear which variants, or class of them, in a gene contribute most to the association. We proposed a subregion-based burden test (REBET) to simultaneously select susceptibility genes and identify important underlying sub-regions. The sub-regions are predefined based on shared common biologic characteristics, such as the protein domain or possible functional impact.&nbsp; Based on a subset-based approach considering local correlations between combinations of test statistics of sub-regions, REBET is able to properly control the type I error rate while adjusting for multiple comparisons in a computationally efficient manner. Simulation studies show that REBET can achieve power competitive to alternative methods when rare variants cluster within sub-regions. In two case studies, REBET is able to identify known disease susceptibility genes, and more importantly pinpoint the unreported most susceptible sub-regions, which represent protein domains essential for gene function.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1119647" sys_dependentvariantid="1418" sys_dependentid="1119647" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7279620" sys_variantid="1418" sys_contentid="1119647">License Agreement</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1091126" sys_dependentvariantid="1500" sys_dependentid="1091126" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7279621" sys_variantid="1500" sys_contentid="1091126">Rebet Vignette</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1119461" sys_dependentvariantid="1500" sys_dependentid="1119461" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7279619" sys_variantid="1500" sys_contentid="1119461">Installation Instructions</a></li>
</ul>
<h3>Download Software:</h3>
<ul>
<li>Windows O/S: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1091230" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1091230" sys_dependentvariantid="1500" sys_relationshipid="7279617" sys_variantid="1500" sys_contentid="1091230">REBET_0.99.0.zip</a></li>
<li>Unix: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1091231" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1091231" sys_dependentvariantid="1500" sys_relationshipid="7279618" sys_variantid="1500" sys_contentid="1091231">REBET_0.99.0.tar.gz</a></li>
</ul>
<h3>Support:</h3>
<ul>
<li>Questions on software issues? Contact: <a href="mailto:zhub@nih.gov">Dr. Bin Zhu</a></li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1093205" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Menya D, Maina SK, Kibosia C, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30582155">Dental fluorosis and oral health in the African Esophageal Cancer Corridor: Findings from the Kenya ESCCAPE case-control study and a pan-African perspective.</a> <em>Int J Cancer</em>. 2018 Dec 23. doi: 10.1002/ijc.32086. [Epub ahead of print]</p>
<p>Menya D, Oduor M, Kigen N, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30300838">Cancer epidemiology fieldwork in a resource-limited setting: Experience from the western Kenya ESCCAPE esophageal cancer case-control pilot study.</a> <em>Cancer Epidemiol</em>. 2018 Dec;57:45-52. doi: 10.1016/j.canep.2018.09.006. Epub 2018 Oct 6.</p>
<p>Middleton DR, Menya D, Kigen N, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30496610">Hot beverages and oesophageal cancer risk in western Kenya: findings from the ESCCAPE case-control study.</a> <em>Int J Cancer.</em> 2018 Nov 29. doi: 10.1002/ijc.32032. [Epub ahead of print]</p>
<p>Middleton DRS, McCormack VA, Munishi MO, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30242267">Intra-household agreement of urinary elemental concentrations in Tanzania and Kenya: Potential surrogates in case-control studies.</a> <em>J Expo Sci Environ Epidemiol</em>. 2018 Sep 21. doi: 10.1038/s41370-018-0071-8. [Epub ahead of print]</p>
<p>Come J, Castro C, Morais A, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30398947">Clinical&nbsp;and&nbsp;Pathologic&nbsp;Profiles&nbsp;of&nbsp;Esophageal&nbsp;Cancer&nbsp;in&nbsp;Mozambique: A&nbsp;Study&nbsp;of&nbsp;Consecutive&nbsp;Patients&nbsp;Admitted&nbsp;to&nbsp;Maputo&nbsp;Central&nbsp;Hospital.</a> <em>J Glob Oncol.</em> 2018 Nov;(4):1-9. doi: 10.1200/JGO.18.00147.</p>
<p>Kayamba V, Zyambo K, Kelly P. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30321216">Presence of blood in gastric juice: A sensitive marker for gastric cancer screening in a poor resource setting.</a> <em>PLoS One</em>. 2018 Oct 15;13(10):e0205185. doi: 10.1371/journal.pone.0205185. eCollection 2018.</p>
<p>Menya, D, Kigen N, Oduor M,&nbsp;et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30117158">Traditional and commercial alcohols and esophageal cancer risk in Kenya</a>. <em>Int J Cancer</em>. Epub 2018 Aug.</p>
<p>Mwachiro M, Mitchell E, Topazian HM, White R. <a href="https://www.sciencedirect.com/science/article/pii/S104306791730151X">Esophagectomy in patients with human immunodeficiency virus and acquired immune deficiency syndrome: A viable option</a>. <em>Semin Thorac Cardiovasc Surg</em> 2018, 30(1):116-121.</p>
<p>Van Loon K, Mwachiro M, Abnet C, et al. <a href="http://ascopubs.org/doi/full/10.1200/JGO.17.00163">The African Esophageal Cancer Consortium (AfrECC): A call to action</a>. <em>Journal of Global Oncology.</em> Epub 2018 Jan.</p>
<p>Middleton DRS, Bouaoun L, Hanisch R, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29414631">Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends</a>. <em>Cancer Epidemiology</em>. Epub 2018 Jan.</p>
<p>Pritchett NR, Burgert SL, Murphy GA, et al. C<a href="https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3837-9">ross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya</a>. <em>BMC Cancer</em>. Epub 2017 Dec.</p>
<p>Murphy G, McCormack V, Abedi B, et al. <a href="https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx279/3868067/International-cancer-seminars-a-focus-on" target="_blank" rel="noopener noreferrer">International cancer seminars: A focus on esophageal squamous cell carcinoma</a>. <em>Annals of Oncology.</em> Epub 2017 June 14.</p>
<p>McCormack VA, Menya D, Munishi MO, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27466161" target="_blank" rel="noopener noreferrer">Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting-specific exposures to known and putative risk factors</a>. <em>Int J Cancer</em> 2017, 140:259-71.</p>
<p>Mmbaga EJ, Deardorff KV, Mushi B, et al. <a href="http://ascopubs.org/doi/full/10.1200/JGO.2016.006619" target="_blank" rel="noopener noreferrer">Characteristics of esophageal cancer cases in Tanzania</a>. <em>JGO</em> 2017, JGO.2016.006619.</p>
<p>Liu W, Snell JM, Jeck WR, et al. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053149/" target="_blank" rel="noopener noreferrer">Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis</a>. <em>JCI Insight </em>2016, 1(16):e88755.</p>
<p>Mwachiro MM, Burgert SL, Lando J, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26902228" target="_blank" rel="noopener noreferrer">Esophageal squamous dysplasia is common in asymptomatic Kenyans: A prospective, community-based, cross-sectional study</a>. <em>Am J Gastroenterol </em>2016, 111(4):500-7.</p>
<p>Mmbaga E, Deardorff K, Mushi B, et al. <a href="http://ascopubs.org/doi/abs/10.1200/jgo.2016.004267" target="_blank" rel="noopener noreferrer">A case-control study to evaluate the etiology of esophageal cancer in Tanzania</a>. <em>JGO </em>2016, 2(3):5s.</p>
<p>Schaafsma T, Wakefield J, Hanisch R, et al. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598094/" target="_blank" rel="noopener noreferrer">Africa's oesophageal cancer corridor: Geographic variations in incidence correlate with certain micronutrient deficiencies</a>.<em> PLoS One</em> 2015, 10:e0140107.</p>
<p>Munishi MO, Hanisch R, Mapunda O, et al. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838015/" target="_blank" rel="noopener noreferrer">Africa's oesophageal cancer corridor: Do hot beverages contribute</a>? <em>Cancer Causes Control</em> 2015, 26:1477-86.</p>
<p>Kayamba V, Bateman AC, Asombang AW, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25641622" target="_blank" rel="noopener noreferrer">HIV infection and domestic smoke exposure, but not human papillomavirus, are risk factors for esophageal squamous cell carcinoma in Zambia: A case-control study</a>. <em>Cancer Med</em> 2015, 4(4):588-595.</p>
<p>Parker RK, Dawsey SM, Abnet CC, White RE. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505035/" target="_blank" rel="noopener noreferrer">Frequent occurrence of esophageal cancer in young people in western Kenya</a>. <em>Dis Esophagus </em>2010, 23(2):128-135.</p>
<p>White RE, Parker RK, Fitzwater JW, Kasepoi Z, Topazian M. <a href="https://www.ncbi.nlm.nih.gov/labs/articles/19230771/" target="_blank" rel="noopener noreferrer">Stents as sole therapy for oesophageal cancer: A prospective analysis of outcomes after placement</a>. <em>Lancet Oncol</em> 2009, 10(3):240-246.</p>
<p>White RE, Abnet CC, Mungatana CK, Dawsey SM. <a href="https://www.ncbi.nlm.nih.gov/pubmed/12241722" target="_blank" rel="noopener noreferrer">Oesophageal cancer: A common malignancy in young people of Bomet District, Kenya</a>. <em>Lancet </em>2002, 360(9331):462-463.</p>
<h3>African Esophageal Cancer Consortium</h3>
<p>For more information, contact:<br /><a href="mailto:natalie.pritchett@nih.gov">Natalie Pritchett</a> (study coordinator)</p>
<p><a title="" href="/research/cancer-types/esophagus/AfrECC">Go back to the AfrECC main page</a></p>
</div>]]></content>
  </row>
  <row para_id="1097514" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Former DCEG fellows discuss their career paths and offer advice for current and future fellows. Click on a name to read a Q&amp;A:</p>
<div style="width: 100%; overflow: auto;">
<div style="float: left; width: 45%; padding-right: 5%;">
<div sys_dependentvariantid="2066" sys_dependentid="1148507" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7362460">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Dr. Madison is a former DCEG fellow " src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1148507&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Hisani Madison</p>
</div>
</figcaption>
</figure>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1148477" sys_contentid="1148477" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1148477" sys_relationshipid="7362451" sys_variantid="1418">Hisani Madison, Ph.D., M.P.H.</a><br /> Associate Director, Diagnostics Expert, Oncology, AstraZeneca<br />(Summer 2019)</p>
<div style="clear: both;">
<div sys_dependentvariantid="2066" sys_dependentid="1148541" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7362461">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Mia Gaudet is a former DCEG fellow" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1148541&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Mia Gaudet</p>
</div>
</figcaption>
</figure>
</div>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1147573" sys_contentid="1147573" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1147573" sys_relationshipid="7362450" sys_variantid="1418">Mia Gaudet, Ph.D.</a><br />Scientific Director, Epidemiology Research, American Cancer Society<br />(Fall 2018)</p>
</div>
<div style="float: left; width: 45%; padding-right: 5%;">
<div sys_dependentvariantid="2066" sys_dependentid="1115190" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7362462">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Todd Gibson" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1115190&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1115190&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Todd Gibson</p>
</div>
</figcaption>
</figure>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1115184" sys_contentid="1115184" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1115184" sys_relationshipid="7362449" sys_variantid="1418">Todd Gibson, Ph.D.</a><br />Assistant Member, St. Jude Children's Research Hospital<br />(Summer 2018)</p>
<div style="clear: both;"></div>
<div sys_dependentvariantid="2066" sys_dependentid="1098025" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7362463">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Liz Yanik" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1098025&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1098025&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Liz Yanik</p>
</div>
</figcaption>
</figure>
</div>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1097515" sys_contentid="1097515" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1097515" sys_relationshipid="7362448" sys_variantid="1418">Elizabeth Yanik, Ph.D.</a><br /> Assistant Professor, Washington University School of Medicine in St. Louis<br />(Fall 2017)</p>
</div>
</div>
</div>]]></content>
  </row>
  <row para_id="1097515" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2090" sys_dependentid="1098025" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7104853">
<figure class="image-right-small centered-set">
<div class="centered-element"><img alt="Liz Yanik" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1098025&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1098025&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Liz Yanik</p>
</div>
</figcaption>
</figure>
</div>
<p><strong>Years at DCEG</strong>: Summer 2013 - Summer 2016<br /><strong>DCEG title</strong>: Postdoctoral Fellow<br /><strong>Current organization</strong>: Washington University School of Medicine in St. Louis<br /><strong>Current title</strong>: Assistant Professor</p>
<p><br /><strong><em>Who was your mentor at DCEG? What did you work on?</em></strong><br />My DCEG mentor was <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349601" sys_variantid="1965" sys_relationshipid="7104849">Eric Engels, M.D., M.P.H.</a>,&nbsp;in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302590" sys_variantid="1422" sys_relationshipid="7104851">Infections and Immunoepidemiology Branch</a>&nbsp;(IIB). With his mentorship, my research focused on using cancer registry linkages and other large databases to study cancer in solid organ transplant recipients and HIV-infected individuals.</p>
<p><strong><em>What is your current position?</em></strong><br />I am an Assistant Professor at Washington University in St. Louis with my primary appointment in the Department of Orthopaedic Surgery and a co-appointment in the Division of Public Health Sciences.&nbsp;I am currently developing research investigating risk factors for the development of rotator cuff disease.&nbsp;I also provide epidemiology&nbsp;and biostatistics expertise to clinical investigators interested in a range of research questions related to musculoskeletal disease.</p>
<p><strong><em>How do you apply the skills you developed at DCEG in your current job?</em></strong><br />Even though my research has transitioned to a different topical focus, I&rsquo;m heavily using skills I developed or enhanced at DCEG. While at DCEG, I sharpened my communication skills, improved my ability to defend my methodologic approaches, and gained experience developing and pursuing my own research ideas. All these skills are now vital to my success in my current job.&nbsp;</p>
<p><strong><em>Do you have any memories from your fellowship that you would like to share?</em></strong><br />I really appreciated the amount of support I received during my academic job search, which can be a long and grueling process.&nbsp;Eric, my mentor, helped me think through my options and career goals and reviewed my application materials. He and others in my branch gave me important feedback during dry runs of my job talk.&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349643" sys_contentid="349643" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349643" sys_variantid="1965" sys_relationshipid="7104850">Jackie Lavigne, Ph.D., M.P.H.</a>,&nbsp;provided me with invaluable counsel during my negotiation process. All of this really proved to me the extent to which DCEG values the aspirations and futures of their fellows.</p>
<p><strong><em>What do you do in your free time?</em></strong><br />My husband and I are expecting our first child in January. So I am &lsquo;nesting&rsquo; and also enjoying lazy weekend mornings while I still have them!</p>
<p><strong><em>Do you have any advice for current or future DCEG fellows?</em></strong><br />Take advantage of the wealth of educational opportunities that are available during your fellowship.&nbsp;DCEG (and NIH in general) is unique in the quantity and quality of seminars, workshops, and short-courses that are targeted towards fellows. Through some of these programs I gained training in grant-writing, mentoring, communicating with the media, and teaching&mdash;just to name a few. Most of these types of skills will serve you well regardless of your future career direction, and you likely will not have the same array of opportunities (or time to take advantage of them) once you move on from your fellowship.</p>
<p></p>
<p><a href="https://percussion.cancer.gov/Rhythmyx/assembler/render?sys_contentid=1097514&amp;sys_revision=4&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1097514" sys_folderid="" sys_relationshipid="7104854"><strong>Read more conversations with former fellows</strong></a><strong>.</strong></p>
</div>]]></content>
  </row>
  <row para_id="1100557" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275403" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a> (REB) investigators coordinated a study of thyroid cancer and other thyroid diseases in a cohort of 25,000 persons from Belarus and Ukraine who were exposed in childhood to fallout from the Chernobyl accident. Each member of this unique cohort had individual direct thyroid measurements of <sup>131</sup>I activity in thyroid gland taken shortly after the accident. Recent efforts have been focused on improving estimated radiation doses to the thyroid from all exposure pathways and evaluating uncertainties in thyroid doses from intake of <sup>131</sup>I, which contributes about 90% of the total thyroid dose.</p>
<p>Key improvements included:</p>
<ul>
<li>Use of an expanded questionnaire to capture more detailed residential history and consumption of important dietary components;</li>
<li>Use of geographic region, age, and gender-specific values of thyroid masses derived from approximately 120,000 thyroid volume measurements of children obtained in Belarus and Ukraine;</li>
<li>Comprehensive reanalysis of the direct radiation thyroid measurements; and</li>
<li>Preparation of a database of meteorological and radiation measurements done during the first three months following the accident.</li>
</ul>
<p>The average thyroid dose was 0.65 Gy (0.00035 &ndash; 42 Gy) in 13,204 persons in the Ukrainian screening cohort and an average thyroid dose of 0.68 Gy (0.0005 &ndash; 39 Gy) in 11,732 persons in the Belarusian cohort. These dose estimates were used to evaluate radiation-associated risk of thyroid cancer that incorporates estimates of uncertainty.<br /><br />For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_dependentvariantid="1965" sys_dependentid="939611" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275404" sys_variantid="1965" sys_contentid="939611">Dr. Vladimir Drozdovitch</a>.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1100732" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">In Ukraine and Belarus, which were affected by the Chernobyl accident, excess mini-satellite mutations&nbsp; have been reported, by some but not all studies, in children born after the accident. To further pursue this observation and to generate new data on the heritable effects of parental radiation exposure, DCEG investigators are carrying out a study of up to 450 trios of parents with preconception doses and their unexposed offspring. The aim is to investigate the heritable and <em>de novo</em> mutation rates of the spectrum of genetic variants in trios looking at effects in children and mapping them to possible parental origin of the chromosome. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1030547" sys_dependentvariantid="1418" sys_dependentid="1030547" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275620" sys_variantid="1418" sys_contentid="1030547">Read more details about the TRIO study</a>. DCEG dosimetrists are estimating radiation doses to the gonads from the time of the accident to the time of conception for all parents.<br />&nbsp;<br />Radiation gonadal dose for the subjects of the TRIO study includes three components:
<ol>
<li>Dose from external irradiation during the cleanup mission at the Chernobyl site;</li>
<li>Dose from external irradiation during residence in the town of Pripyat between the time of the accident and evacuation; and</li>
<li>Dose from external irradiation and ingestion of long-lived cesium isotopes (<sup>134</sup>Cs and <sup>137</sup>Cs) in local food during residence at contaminated locations after completion of the cleanup mission and/or evacuation from the town of Pripyat.</li>
</ol>
<p>The preliminary parental gonadal dose from all exposure pathways among the first 50 trios averaged around 300 mGy, ranging from essentially zero to 4,300 mGy. For the majority of families, parental exposure mainly occurred during the cleanup mission at the Chernobyl site.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_dependentvariantid="1965" sys_dependentid="939611" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275619" sys_variantid="1965" sys_contentid="939611">Dr. Vladimir Drozdovitch</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1100762" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators in the Radiation Epidemiology Branch (REB) coordinated a study of health effects in persons exposed to Chernobyl fallout <em>in utero</em> and early life in Belarus (2,964 subjects) and in Ukraine (2,582 subjects). They applied comprehensive efforts to develop a complex dosimetry system for these cohort studies, recontructing the following individual doses for each cohort member:</p>
<ul>
<li>Doses to the fetus's thyroid gland from intake of <sup>131</sup>I by mothers; and</li>
<li>Postnatal (if applicable) dose to the thyroid gland from intake of <sup>131</sup>I by the infant from breast milk and other foodstuffs.</li>
</ul>
<p>In addition, in Belarus, investigators reconstructed thyroid and whole-body doses due to prenatal and postnatal external irradiation from gamma-emitting radionuclides deposited on the ground, and prenatal and postnatal intake of long-lived cesium isotopes (<sup>134</sup>Cs and <sup>137</sup>Cs). The estimates of <em>in utero</em> thyroid doses from <sup>131</sup>I intakes were derived from the model recommended by the International Commission on Radiological Protection (ICRP) Publication 88 with account to maternal direct thyroid gland measurements of <sup>131</sup>I activity, if available. Mean <em>in utero</em> thyroid doses for cohort members from intakes of <sup>131</sup>I by the mothers were estimated to be 106 mGy in Belarus (preliminary) and 72 mGy in Ukraine (Likhtarov et al. 2011). Special efforts are underway to evaluate uncertainty in reconstructed questionnaire-based doses due possibly to poor memory recall of mother during dosimetry interview (Drozdovitch et al. 2016).</p>
<h3>References</h3>
<p>Drozdovitch V, Kukhta T, Minenko V, Trofimik S, Bouville A, Potischman N. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26606068">Reliability of questionnaire data in the distant past: Relevance for radiation exposure assessment. <span class="show-for-sr">Article abstract</span></a> <em>Health Phys</em> 2016 110(1):74-92.</p>
<p>Likhtarov I., Kovgan L., Chepurny M., Ivanova O., Boyko Z., Ratia G., Masiuk S., Gerasymenko V., Drozdovitch V., Berkovski V., Hatch M., Brenner A., Luckyanov N., Voillequ&eacute; P., Bouville A. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22004928">Estimation of the thyroid doses for Ukrainian children exposed <em>in utero</em> after the Chernobyl accident. <span class="show-for-sr">Article abstract</span></a> <em>Health Phys</em> 2011; 100(6):583-593</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965" sys_relationshipid="7276236" sys_variantid="1965" sys_contentid="1087122">Elizabeth Cahoon</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349690" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349690" sys_dependentvariantid="1965" sys_relationshipid="7276237" sys_variantid="1965" sys_contentid="349690">Kiyohiko Mabuchi</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276235" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1102867" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Certain types of human papillomavirus (HPV) cause almost all cases of cervical cancer, as well as cancers at other anatomic sites in men and women. Vaccines that protect against HPV can substantially reduce the risk of cervical cancer, and other cancers attributable to HPV infection. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer and low resources. These vaccines are expensive&mdash;many countries cannot afford them&mdash;more than one dose is needed, and giving multiple doses can be difficult, <em>especially</em> in low resource settings. Researchers are conducting a new study in order to determine if one dose of the HPV vaccines works as well as giving two doses of these vaccines to young women.</p>
<h3>Potential Public Health Impact</h3>
<p>If one dose of an HPV vaccine were found to be sufficient to reduce cervical cancer burden, we would expect more widespread vaccine uptake in the United States, and around the world, with vaccination programs being able to operate at an overall lower cost.</p>
<p>Additionally, findings from the trial may make it possible for future evaluations of one-dose HPV vaccination to be smaller-scale immunogenicity trials, rather than efficacy trials, which could expedite expansion to other populations, ages, and vaccine formulations.</p>
<p>Finally, these findings could transform the current vaccine development paradigm by providing the first example of a single-dose subunit vaccine that induces durable protective immunity.</p>
<h3>Study Design</h3>
<p>There are two components to the study: (1) a controlled, randomized, double-blinded non-inferiority clinical trial to compare one-dose to two-dose vaccination; and (2) a concurrent epidemiologic survey for HPV <em>infection</em> status among unvaccinated women.</p>
<p>The trial will enroll 20,000 girls 12 to 16 years old residing in Costa Rica. Participants will be randomized in two stages to one of four arms (one dose of the bivalent vaccine, two doses of the bivalent vaccine, one dose of the nonavalent vaccine and two doses of the nonavalent vaccine); the first randomization at enrollment will assign participants to one of the two study vaccines and at the second visit they will be randomized to one or two doses. Girls randomized to the one dose arm will receive an active control (i.e. Tdap) at the time of the second vaccine dose. After vaccination, girls will be followed every six months for four years to assess the presence of persistent cervical HPV infections and antibody titers, by dose group and vaccine type. In the U.S., Cervarix<sup>&reg;</sup> and GARDASIL<sup>&reg;</sup>9 are currently approved for two doses in younger recipients and three doses in older recipients.&nbsp;</p>
<p>The epidemiologic HPV survey will enroll a group of unvaccinated females from the same geographic areas; they will range in age from 17 to 20. These females will attend two study visits six months apart to determine their HPV DNA status; there will be no additional follow-up. These females will be offered HPV vaccination at the enrollment and six-month study visits.</p>
<p>At each visit, participants will fill out a questionnaire and give a urine sample. They may give blood samples. The older participants will use a swab to collect cells from their cervix and vagina.</p>
<h3><strong>Study Rationale and Background</strong></h3>
<p>The impetus for this trial stemmed from the NCI Costa Rica Vaccine Trial, a phase-III efficacy trial that launched in 2004; in post-hoc analyses, investigators from that trial reported that one or two doses may be efficacious and that antibody titers remained elevated for years after a single vaccine dose. The latter finding was particularly novel and unexpected, given that previous subunit vaccines have typically required more than one dose (prime/boost regimen) to induce lasting responses.</p>
<p>* ESCUDDO (&ldquo;<u>Es</u>tudio de <u>C</u>omparacion de <u>U</u>na y <u>D</u>os <u>D</u>osis de Vacunas Contra el Virus de Papiloma Humano (VPH)&rdquo;) is a scientific evaluation of one or two doses of vaccine against human papillomavirus.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03180034">Clinical trials identifier: NCT03180034 </a></p>
<p>ESCUDDO is co-funded by the NCI and the Bill &amp; Melinda Gates Foundation, with support from the International Agency for Research on Cancer.&nbsp;</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=27&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349605" sys_dependentvariantid="1965" sys_dependentid="349605" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277645" sys_variantid="1965" sys_contentid="349605">Dr. Aim&eacute;e Kreimer</a>.<br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_dependentvariantid="1418" sys_dependentid="419183" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277646" sys_variantid="1418" sys_contentid="419183">Infections and Immunoepidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1105307" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG investigators from the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277256" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch (REB)</a> are assessing radiation dose estimates to post-Chernobyl cleanup workers in Ukraine, whose external radiation exposure was mainly due to fallout. Bone marrow doses were estimated by the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=491829" sys_dependentvariantid="1500" sys_dependentid="491829" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277257" sys_variantid="1500" sys_contentid="491829">RADRUE dose reconstruction method (pdf, 356 KB)</a> for the subjects of the case-control study of leukemia among the Ukrainian cleanup workers. These bone marrow doses among the 1,000 subjects averaged 92 mGy ranging from essentially zero to 3,260 mGy. <br /><br />NCI investigators and Ukrainian collaborators are also conducting a study of thyroid cancer among the Ukrainian cleanup workers. They have estimated thyroid doses from external irradiation using the RADRUE approach. In addition, they calculated thyroid doses due to intake of <sup>131</sup>I via inhalation at the Chernobyl site and/or ingestion of contaminated foodstuffs. The thyroid dose from all exposure pathways among 608 study subjects averaged 190 mGy, ranging from 0.14 to 8,300 mGy. For almost half of the subjects, the internal dose due to <sup>131</sup>I intake was greater than the dose due to external irradiation. There was no correlation between external and internal doses.<br /><br />For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_dependentvariantid="1965" sys_dependentid="939611" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277258" sys_variantid="1965" sys_contentid="939611">Dr. Vladimir Drozdovitch</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_dependentvariantid="1418" sys_dependentid="401127" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277259" sys_variantid="1418" sys_contentid="401127">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1105314" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Investigators in DCEG are conducting studies related to regions affected by radioactive fallout from nuclear weapons testing.</p>
<h3><a id="Trinity"></a>Trinity Nuclear Test, New Mexico</h3>
<p>Investigators from DCEG and across the NCI are estimating radiation doses from fallout in New Mexico following the July 1945 test by the U.S. government of the first atomic weapon. The test was code-named Trinity. DCEG investigators have carried out in-depth interviews to ascertain the typical diet of populations living in New Mexico in the mid-1940s. These interviews are an important step in developing estimates of low, intermediate, radiation doses resulting from Trinity. To determine how best to collect these data, DCEG investigators have engaged in discussions with academics with expertise in Native American and Hispanic lifestyles in the 1940s, as well as advocates and local community leaders. The study quantitatively will estimate the number of cancer cases in New Mexico (past and future) that may be related to the nuclear test. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=728725" sys_dependentvariantid="1418" sys_dependentid="728725" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276422" sys_variantid="1418" sys_contentid="728725">Find more detailed information on Trinity</a>.</p>
<h3><a id="Marshall-Islands"></a>Nuclear Test, Republic of the Marshall Islands</h3>
<div sys_relationshipid="7276424" sys_dependentid="1107715" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1107715&amp;sys_command=preview" alt="Map of Marshall Islands nuclear test" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1107715&amp;sys_command=preview"><!--Comment--></img>
                                          	          <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1107715&amp;sys_command=preview" target="_blank" class="article-image-enlarge no-resize" sys_variantid="1518" sys_contentid="1107715">Enlarge</a>                                        </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>Marshall Islands nuclear test site atolls</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<p>DCEG investigators estimated radiation dose and risk from atmospheric nuclear weapons tests conducted in the Republic of the Marshall Islands from 1946 through 1958. This effort included a detailed assessment of all historical and contemporary measurements of environmental radiation on all atolls of the Marshall Islands as well as the use of a model of atmospheric dispersion and deposition. Results from these analyses were published in the August 2010 issue of <em>Health Physics</em>.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302507" sys_dependentvariantid="1418" sys_dependentid="302507" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276421" sys_variantid="1418" sys_contentid="302507">Summary of the Marshall Islands research project and findings</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302471" sys_dependentvariantid="1418" sys_dependentid="302471" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276420" sys_variantid="1418" sys_contentid="302471">Bibliography of publications related to the Marshall Islands</a></li>
</ul>
<h3><a id="Semipalatinsk"></a>Semipalatinsk Nuclear Test, Kazakhstan</h3>
<p>DCEG investigators together with investigators from Kazakhstan and Russia are studying thyroid disease prevalence and radiation dose in a cohort of 2,994 subjects exposed at young ages to radioactive fallout from nuclear weapons testing during 1949-1962 at the Semipalatinsk Nuclear Test Site in northeastern Kazakhstan. Radiation exposure to the thyroid gland was from external radiation sources on the ground and other surfaces, and internally from radioactive iodine taken up by the thyroid gland following ingestion of milk from dairy animals grazing on contaminated pasture. Preliminary point estimates of individual external and internal dose averaged 0.04 Gy (range 0-0.65) and 0.31 Gy (0-9.6), respectively. Ultrasound-detected thyroid nodule prevalence, 18% among males and 39% among females, was significantly and independently associated with both external and internal exposure.</p>
<h3><a id="Risk-Calculator"></a>Thyroid Dose and Risk Calculator for Nuclear Weapons Fallout</h3>
<p>Between 1945 and 1980, the U.S., the U.S.S.R., the U.K., France and China carried out more than 500 atmospheric tests of nuclear weapons totaling the explosive equivalent of 440 megatons of TNT. These tests emitted radioactive material into the atmosphere, much of which became widely dispersed before being deposited as fallout. DCEG investigators developed an <a href="https://radiationcalculators.cancer.gov/fallout/">online calculator to estimate the radiation dose received by the thyroid gland from radionuclides in fallout from nuclear tests</a>. The early version of this tool estimated exposure and risk from fallout from the Nevada Test Site. In 2017, investigators released a new version of the tool that includes exposures from sites outside of the United States (global fallout).</p>
<h3><a id="Dose-Reconstruction"></a>Dose Reconstruction and Health Consequences from Fallout</h3>
<p>In collaboration with the Centers for Disease Control and Prevention, DCEG investigators estimated, for the first time, the radiation doses and risks of related health effects to representative persons in all counties of the contiguous United States from a set of important radionuclides produced from the testing of nuclear weapons from 1951 through 1962 by the United States and other nations. The findings of this feasibility study suggest that the health risks from exposure to fallout from past nuclear weapons tests may be small, but that it is technically feasible to conduct a detailed study of the health effects on the American people. The draft of this technical report was peer reviewed by the National Academy of Sciences/National Research Council (NAS/NRC) Committee. To the extent possible, the Committee&rsquo;s recommendations were taken into account in the final report. Read the <a href="https://www.cdc.gov/nceh/radiation/fallout/default.htm">Final Report: Public summary on radioactive fallout from global weapons testing</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349596" sys_dependentvariantid="1965" sys_dependentid="349596" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276423" sys_variantid="1965" sys_contentid="349596">Dr. Steven Simon</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1107071" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Dosimetry Research</h2>
<p>DCEG investigators in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277253" sys_variantid="1422">Radiation Epidemiology Branch</a> are developing a resource of dose estimates for use in epidemiological studies of radiation exposure from nuclear medicine examinations and cancer risk. As part of this effort, the investigators estimated organ doses received by patients who underwent nuclear medicine diagnostic exams over a 50-year period (1960&ndash;2010). They calculated radiation doses per examination to 14 organs, for 17 examination types, using different radiopharmaceuticals (also called radionuclides). The investigators determined the percentage of use of each radiopharmaceutical and the administered activity of the radiopharmaceutical based on a comprehensive literature review and International Commission on Radiological Protection (ICRP) dose coefficients.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_contentid="939611" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="939611" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277254" sys_variantid="1965">Dr. Vladimir Drozdovitch</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=59&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7277255" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1108341" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Dosimetry Research</h2>
<p>DCEG investigators in the Dosimetry Unit of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7275623" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422">Radiation Epidemiology Branch (REB)</a> develop new dosimetry methods and refine existing methods to achieve more accurate dose estimates, and quantify and incorporate related uncertainties. Methods and tools developed by REB investigators are made widely available to encourage use by other radiation dosimetrists and epidemiologists.</p>
<p><strong><em>On This Page:</em></strong></p>
<ul>
<li><a href="#Phantoms">Computational and Physical Human Phantoms</a></li>
<li><a href="#Monte-Carlo">Monte Carlo Simulation Methods</a></li>
<li><a href="#Uncertainties">Uncertainties in Doses</a></li>
<li><a href="#Radiation-Measurements">Radiation Measurements</a></li>
<li><a href="#Related-Links">Related Links</a></li>
</ul>
<h3><a id="Phantoms"></a>Computational and Physical Human Phantoms</h3>
<p>REB investigators are developing models of human anatomy in both computational and physical formats, enabling them to estimate radiation doses to the human body and individual organs. Investigators use computational human phantoms for computing radiation dose by computer simulations, and then validate their results by using physical phantoms combined with radiation dosimeters.</p>
<div sys_relationshipid="7275626" sys_dependentid="1090875" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1090875&amp;sys_command=preview" alt="A series of computational human phantoms, ranging in size from newborn to adult, showing skeletons and organs, differentiating them with various colors."><!--Comment--></img>
                                          	          <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1090875&amp;sys_command=preview" target="_blank" class="article-image-enlarge no-resize" sys_variantid="1518" sys_contentid="1090875">Enlarge</a>                                        </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>A "family picture" of computational phantoms,&nbsp;modeling a range of ages from newborn to adult.</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<h4>Computational Phantoms</h4>
<p>Two sets of computational human phantoms have been developed in collaboration with University of Florida: a series of reference body size phantoms and a library of body size-dependent phantoms. These computational phantoms are combined with a Monte Carlo radiation transport technique to simulate a variety of radiation exposure scenarios and to estimate organ doses.</p>
<p>The computational phantoms are shared with the radiological community for research purposes via the <a href="https://ncidose.cancer.gov/#home">NCIDose website</a>.</p>
<div style="clear: both; margin-top: 28px;"></div>
<h4>Physical Phantoms</h4>
<div sys_relationshipid="7275627" sys_dependentid="1090876" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2066" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-right-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302233&amp;sys_siteid=475&amp;sys_contentid=1090876&amp;sys_command=preview" alt="3D printer in use to print a modified &quot;slice&quot; of a human phantom."><!--Comment--></img>
                                                </div>
                  <figcaption>
            <div class="caption-container no-resize">
                              
<p>3D printer producing a "slice" of a phantom</p>
                                        </div>
          </figcaption>
              </figure>
       </div>
<p>The second version of human phantoms, called physical human phantoms, are made of stackable layers (called "slices"), each one dotted with a grid of holes into which tiny radiation sensors called dosimeters are inserted. This kind of physical phantom can be used to provide accurate dose measurements when placed in a CT scanner or other source of radiation, but time and cost are substantial considerations. In addition, physical phantoms available for purchase are limited in their sizes and features. So REB investigators are exploring the feasibility of producing 3D-print tissue blocks radiologically equivalent to human tissues. The 3D-printed tissue blocks could be used to customize physical phantoms to simulate features such as women's breast tissue and fat tissue for both male and females, enabling them to match computational human phantoms with varying body sizes.</p>
<p>Read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1087876" sys_contentid="1087876" inlinetype="rxhyperlink" sys_variantid="1424" sys_relationshipid="7275621" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087876" sys_dependentvariantid="1424">3D printing and human phantoms</a>.</p>
<h3><a id="Monte-Carlo"></a>Monte Carlo Simulation Methods</h3>
<p>Monte Carlo is a class of numerical simulation methods used widely to solve complex physical and math problems. REB investigators are using three-dimensional Monte Carlo radiation transport. Detailed radiation propagation is modeled with Monte Carlo methods in computer simulations. This is a flexible and rigorous approach to simulate radiation transport within different materials, including human anatomy. The computational approach is extremely useful, particularly in dose reconstruction for large-scale epidemiological studies, where dose measurements are not feasible. REB investigators are using this method in dosimetry research&nbsp;to support several epidemiological studies of medical, occupational, and environmental exposure scenarios.</p>
<h3><a id="Uncertainties"></a>Uncertainties in Doses</h3>
<p>Radiation doses calculated for epidemiological studies are associated with uncertainties because it is impossible to obtain precise and complete data for exposure assessment. For this reason, REB investigators are using Monte Carlo simulation methods to incorporate dosimetric uncertainties into radiation dose estimates. When incorporating uncertainty, some parameters associated with dose reconstruction are shared by cohort members and some are not. By using the two-dimensional Monte Carlo (2DMC) sampling method, the two types of parameters can be sampled separately and utilized for dose estimations. Multiple plausible doses (called realizations) are derived from the process, which then are used for risk analysis.</p>
<h3><a id="Radiation-Measurements"></a>Radiation Measurements</h3>
<p>REB investigators are using radiation measurements to validate radiation doses derived using computational methods. Instruments for radiation measurement available at REB are:</p>
<ul>
<li>Physical anthropomorphic phantoms representing a 5-year-old child and an adult</li>
<li>Female breast phantoms specialized for dose measurement in breast radiotherapy</li>
<li>Different types of dosimeters such as optically-stimulated luminescence dosimeter (OSLD) and ion chamber dosimeters; OSLD reading systems; and medical radiation spectrum measurement systems</li>
</ul>
<p>Irradiation of physical phantoms equipped with dosimeters is conducted in collaboration with the NIH Clinical Center, the National Institute of Standards and Technology (NIST), and several medical facilities outside the NIH. Dose measurements using the equipment have been used to validate radiation doses computed for fluoroscopy, computed tomography, and radiation treatment procedures. &nbsp;<br /><br />In addition, DCEG investigators are constructing physical anthropomorphic phantoms in-house using 3D printing techniques for more accurate and customized dose comparison with computational human phantoms.</p>
<h3><a id="Related-Links"></a>Related Links</h3>
<p>Read <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1087876" sys_contentid="1087876" inlinetype="rxhyperlink" sys_variantid="1424" sys_relationshipid="7275622" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087876" sys_dependentvariantid="1424">Applying 3-Dimensional Printing for Radiation Exposure Assessment</a> in <em>Linkage</em> newsletter.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349634" sys_contentid="349634" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275624" sys_siteid="475" rxinlineslot="103" sys_dependentid="349634" sys_dependentvariantid="1965">Dr. Choonsik Lee</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=939611" sys_contentid="939611" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7275625" sys_siteid="475" rxinlineslot="103" sys_dependentid="939611" sys_dependentvariantid="1965">Dr. Vladimir Drozdovitch</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1109529" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>(Hisp)anic-American (BrCa) (R)isk (A)ssessment (M)acro Ver2_1</h3>
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The Hisp_BrCa_RAM may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1109571" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right">
<h3><a href="/Rhythmyx/assembler/render?sys_contentid=1033171&amp;sys_revision=23&amp;sys_variantid=1422&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1422" sys_dependentid="1033171" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297135">MEB Home</a></h3>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033621&amp;sys_revision=20&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297136">MEB Research Areas</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin/Personnel.pl?2=MEB">MEB Staff Directory</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033198&amp;sys_revision=89&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033198" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297137">Meet Current Fellows</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033659&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033659" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297138">Research Training Opportunities</a></p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1033657&amp;sys_revision=10&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="1033657" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297139">Tools, Methods, and Resources</a></p>
<p><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=MEB&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Publications</a></p>
</div>
<p>DCEG researchers in the Metabolic Epidemiology Branch are studying the etiologic heterogeneity of ovarian and endometrial cancers and the roles that inflammation and endogenous hormones play in carcinogenesis. Selected studies include:</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303756&amp;sys_revision=17&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303756" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297140">Bone Density and Cancer Risk: A Follow-Up Study of Women in the Fracture Intervention Trial (BFIT)</a></h2>
<p>A retrospective cohort study that uses data from the FIT clinical trial to evaluate how bone mineral density of the hip is related to subsequent cancer risk; including a nested case-cohort study of circulating sex steroid hormones in relation to breast, endometrial, ovarian, and colorectal cancer risk</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303757&amp;sys_revision=15&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303757" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297141">Follow-up Studies of Women Evaluated and Treated for Infertility</a></h2>
<p>Retrospective cohort studies of women treated for infertility with ovulation-stimulating drugs to evaluate risk of breast and gynecologic cancers</p>
<h2><a href="/Rhythmyx/assembler/render?sys_contentid=303634&amp;sys_revision=22&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" sys_dependentvariantid="1418" sys_dependentid="303634" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7297142">Serum Sex Steroids and Their Metabolites in Relation to Ovarian and Endometrial Cancer</a></h2>
<p>A nested case-control study of endometrial and ovarian cancers assessing the roles of estrogens, estrogen metabolites, androgens, and androgen metabolites in the etiologies of these cancers</p>
</div>]]></content>
  </row>
  <row para_id="1110245" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>This R package can be used to calculate the required samples size for unconditional multivariate analyses of&nbsp; unmatched case-control studies.&nbsp; The sample sizes are for a scalar exposure effect, such as binary, ordinal or continuous exposures.&nbsp; The sample sizes can also be computed for scalar interaction effects.&nbsp; The analyses account for the effects of potential confounder variables that are also included in the multivariate logistic model.</p>
<h4>Documents</h4>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1110277" sys_contentid="1110277" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7121660" sys_siteid="475" rxinlineslot="103" sys_dependentid="1110277" sys_dependentvariantid="1500">Readme</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1110278" sys_contentid="1110278" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7121661" sys_siteid="475" rxinlineslot="103" sys_dependentid="1110278" sys_dependentvariantid="1418">License Agreement</a></li>
</ul>
<h4>Software</h4>
<ul>
<li><a href="https://cran.r-project.org/web/packages/samplesizelogisticcasecontrol/index.html">samplesizelogisticcasecontrol</a> (Link to CRAN)</li>
</ul>
<h4>Reference</h4>
<ul>
<li>Gail MH, Haneuse S. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29145780">Power and sample size for multivariate logistic modeling of unmatched case-control studies</a>. <em>Stat Methods Med Res</em> 2017 Jan 1:962280217737157. doi: 10.1177/0962280217737157.&nbsp;</li>
</ul>
</div>]]></content>
  </row>
  <row para_id="1110278" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Non-Proprietary Software Transfer Agreement</strong></p>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The samplesizelogisticcasecontrol R package may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1110652" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><a id="top"></a>
<p><strong><em>On this page</em>:</strong></p>
<p><a href="#Chernobyl">Environmental Epidemiology Research on the Health Consequences of the Chernobyl Nuclear Accident</a><br /><a href="#Skin-Cancer">Skin Cancer Prevention and Etiology</a></p>
<h3><a id="Chernobyl"></a>Environmental Epidemiology Research on the Health Consequences of the Chernobyl Nuclear Accident - Postbaccalaureate (Masters-level) or Postdoctoral Fellowship</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253213" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965">Elizabeth Khaykin Cahoon, Ph.D.</a>, an investigator in the Radiation Epidemiology Branch (REB) of the NCI Division of Cancer Epidemiology and Genetics, is recruiting a postbaccalaureate (Masters level) or postdoctoral fellow to conduct research on thyroid cancer and other disease risks in residents of Ukraine and Belarus exposed as children to fallout from the Chernobyl nuclear power plant. The accident at the Chernobyl plant in April 1986 released massive amounts of radioactive material into the environment. The general population, particularly children, were exposed to internal radioactive iodine (I-131), primarily through consumption of contaminated milk. Because the thyroid gland uses iodine to synthesize thyroid hormones, iodine concentrates in this organ. However, the thyroid gland cannot distinguish between the radioactive and inert forms of iodine, so iodine-deficient populations may be subject to higher accumulations of radioactive I-131. Through a long-term, multi-country, international collaboration, we are comprehensively evaluating radiation-related risks of thyroid disease in individuals exposed to Chernobyl fallout as children and adolescents.</p>
<p>A successful candidate will work with deeply committed and talented researchers with expertise in epidemiology, oncology, and biostatistics. Fellows in DCEG have extensive career development and training opportunities through REB and the Division&rsquo;s Office of Education. Salary and benefits are highly competitive and commensurate with experience.</p>
<p><strong>Qualifications</strong>: Applicants with a masters degree or doctoral degree in biostatistics, epidemiology, or related fields are encouraged to apply. Excellent writing skills and experience with analyses of large and complex data is highly desired.</p>
<p>For more information about this opportunity, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253214" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965">Dr. Cahoon</a>.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7253215" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Skin-Cancer"></a>Skin Cancer Prevention and Etiology - Postdoctoral Fellowship</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253216" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965">Elizabeth Khaykin Cahoon, Ph.D.</a>, an investigator in the Radiation Epidemiology Branch (REB) of the NCI Division of Cancer Epidemiology and Genetics, is recruiting a postdoctoral fellow to conduct research on skin cancer risk in individuals exposed to photosensitizing medications. Solar ultraviolet radiation (UVR) is the primary environmental risk factor for most types of skin cancers, which occur in approximately five million people and result in over ten thousand deaths each year in the U.S. Sensitivity to sunlight is influenced not only by constitutional characteristics such as skin complexion, but also by exposure to some potentially modifiable factors like photosensitizing medications, which reduce the minimal UVR dose needed to produce an erythemal response, or reddening of the skin, and potentially increase the risk of photocarcinogenesis. Using a large nationwide administrative dataset, we have planned a series of comprehensive analyses of photosensitizing medications in relation to the most UV-sensitive cancers, keratinocyte carcinomas and their precursors (e.g., actinic keratosis).</p>
<p>A successful candidate will work with committed and talented researchers with expertise in epidemiology, oncology, and biostatistics. Fellows in DCEG have extensive career development and training opportunities through REB and the Division&rsquo;s Office of Education. Salary and benefits are highly competitive and commensurate with experience.</p>
<p><strong>Qualifications</strong>: Applicants with a doctoral degree in biostatistics, epidemiology, or related fields are encouraged to apply. Excellent writing skills and experience with analyses of large and complex data is highly desired.</p>
<p>For more information about this opportunity, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1087122" sys_contentid="1087122" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7253217" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087122" sys_dependentvariantid="1965">Dr. Cahoon</a>.</p>
<p><strong>To Apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7253218" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
<p><a href="#top">Back to top</a></p>
<p style="text-align: center;">DHHS and NIH are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="1113672" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Liver cancer is the sixth most commonly occurring cancer in the world and due to a very poor prognosis, the second largest contributor to cancer mortality. Liver cancer is composed of two major histologic types: hepatocellular carcinoma (HCC, ~70%) and intrahepatic cholangiocarcinoma (ICC, ~15%).&nbsp; The incidence of both types has been increasing in many countries for the past several decades. MEB investigators conduct research on a variety of factors in relationship to liver cancer including:</p>
<ul>
<li>Metabolic conditions (e.g., obesity, diabetes, and metabolomic syndrome)</li>
<li>Exogenous and endogenous hormonal exposures</li>
<li>Diet</li>
<li>Coffee</li>
<li>Cigarette smoking</li>
<li>Medications</li>
<li>Hepatitis B virus and hepatitis C virus (HBV/HCV)</li>
<li>Aflatoxins (AFB1)</li>
<li>Metabolomics (including lipidomics, bile acids, and fatty acids)</li>
<li>Microbiome (including circulating markers of bacterial translocation)</li>
</ul>
<p>MEB investigators are conducting liver cancer studies using the following resources:</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_dependentvariantid="1418" sys_dependentid="303743" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7305698" sys_variantid="1418" sys_contentid="303743">Alpha-Tocopherol, Beta-Carotene Cohort Study in Finland</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000430.v1.p1">Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial (HALT-C)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303748" sys_dependentvariantid="1418" sys_dependentid="303748" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7305699" sys_variantid="1418" sys_contentid="303748">NIH-AARP Diet and Health Cohort Study</a></li>
<li><a href="https://www.cprd.com/intro.asp">U.K. Clinical Practice Research Datalink</a></li>
<li><a href="http://www.ukbiobank.ac.uk/">U.K. Biobank</a></li>
<li><a href="https://seer.cancer.gov/">Surveillance, Epidemiology, and End Results Program Cancer Registries</a></li>
<li><a href="https://www.naaccr.org/">North American Association of Central Cancer Registries</a></li>
<li><a href="http://ci5.iarc.fr/Default.aspx">Cancer Incidence in Five Continents</a></li>
</ul>
<p>Learn about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303602" sys_dependentvariantid="1418" sys_dependentid="303602" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7305697" sys_variantid="1418" sys_contentid="303602">Liver Cancer Pooling Project (LCPP)</a><br /> A pooling project of prospective cohort studies that seeks to understand the factors behind the rising incidence of HCC and ICC in the U.S.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349637" sys_dependentvariantid="1965" sys_dependentid="349637" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7305700" sys_variantid="1965" sys_contentid="349637">Katherine McGlynn</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349608" sys_dependentvariantid="1965" sys_dependentid="349608" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7305701" sys_variantid="1965" sys_contentid="349608">Neal Freedman</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1113687" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Pancreatic cancer is a rapidly fatal tumor that causes a substantial public health burden worldwide. In the U.S., it's among the few cancers whose incidence are increasing. Because the pancreas is a metabolically important organ, many dietary and metabolic hypotheses have been posited for this cancer. Epidemiologic studies are challenging, both because of concerns about reverse causality related to latent disease and because most cohort studies lack substantial case numbers. In order to evaluate risk factors for this cancer, DCEG investigators in the Metabolic Epidemiology Branch have taken advantage of prospective data from DCEG cohorts and pooled consortia.<br /><br />Recent findings for pancreatic cancer have included temporal trends over the past 40 years by demographics and histologic types using data from the Surveillance, Epidemiology and End Results registries, positive associations for childhood and early adulthood BMI, and identification of 20 risk signals in individuals of European descent within genome-wide associations studies. The diabetes associated with PDAC may be more heterogeneous than previously appreciated. In addition to Type 2 diabetes related to insulin resistance and adiposity, diabetes related to pancreatogenic disease and common single nucleotide polymorphisms (SNPs) in genes related to maturity onset diabetes of the young contributes to the association between diabetes and pancreatic cancer.</p>
<p>Learn about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=459581" sys_dependentvariantid="1418" sys_dependentid="459581" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251749" sys_variantid="1418" sys_contentid="459581">PanScan Study</a>.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349636" sys_dependentvariantid="1965" sys_dependentid="349636" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251750" sys_variantid="1965" sys_contentid="349636">Rachael Stolzenberg-Solomon</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1033621" sys_dependentvariantid="1418" sys_dependentid="1033621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7251751" sys_variantid="1418" sys_contentid="1033621">Metabolic Epidemiology Branch (MEB) - Research Areas</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1115184" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2090" sys_dependentid="1115190" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7104847">
<figure class="image-right-small centered-set">
<div class="centered-element"><img alt="Todd Gibson" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1115190&amp;sys_command=edit" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1115190&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Todd Gibson</p>
</div>
</figcaption>
</figure>
</div>
<p><strong>Years at DCEG</strong>: Summer 2007 &ndash; Winter 2014<br /><strong>DCEG title</strong>: Pre-doctoral fellow&nbsp;in Nutritional Epidemiology 2007-2010; Cancer Prevention Fellow in Radiation Epidemiology 2010-2014<br /><strong>Current organization</strong>: St. Jude Children&rsquo;s Research Hospital<br /><strong>Current title</strong>: Assistant Member (faculty)</p>
<p></p>
<p><em><strong>Who was your mentor at DCEG? What did you work on?</strong></em><br />I completed my dissertation research in the Nutritional Epidemiology Branch (now <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="1033171" sys_variantid="1422" sys_relationshipid="7104844">Metabolic Epidemiology Branch</a>) under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349636" sys_contentid="349636" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349636" sys_variantid="1965" sys_relationshipid="7104841">Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D.</a>,&nbsp;where I studied associations between folate or one-carbon metabolism and risk of colorectal and renal cancers. I then joined the Cancer Prevention Fellowship as a post-doc and transitioned to the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=84&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" rxinlineslot="103" sys_dependentid="302459" sys_variantid="1422" sys_relationshipid="7104845">Radiation Epidemiology Branch</a> so that I could work with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349616" sys_variantid="1965" sys_relationshipid="7104842">Lindsay Morton, Ph.D.</a> There, I worked on a variety of projects, including molecular epidemiology of lymphoma, cancer risk in the context of immunodeficiency (with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349601" sys_contentid="349601" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349601" sys_variantid="1965" sys_relationshipid="7104843">Eric Engels, M.D., M.P.H.</a>), and risk of subsequent cancers in cancer survivors.</p>
<p><em><strong>What is your current position?</strong></em><br />I am an Assistant Member (equivalent to Assistant Professor) at St. Jude Children&rsquo;s Research Hospital in Memphis, Tennessee. The goal of my research is to better understand the long-term health of childhood cancer survivors, who have increased risk of serious late health effects due to the potentially complex interactions of treatment-related toxicity, genetic susceptibility and lifestyle-related factors, and then to develop and test intervention strategies to reduce their risk. I also serve as the Project Director of the <a href="https://ccss.stjude.org/">Childhood Cancer Survivor Study (CCSS)</a>, and in that role, oversee the Coordinating Center located at St. Jude.</p>
<p><em><strong>How do you apply the skills you developed at DCEG in your current job?</strong></em><br />There are so many ways I can&rsquo;t even list them all! The rigorous epidemiology training I received at DCEG is an asset every single day, whether in my own research or through my work with the CCSS. Just as important, though, have been all the other skills I learned, such as leadership, effective collaboration, project management, time management, and communication skills. I&rsquo;m still working on all of these, of course, but the foundation I received in DCEG has allowed me to take on a job I couldn&rsquo;t imagine being able to perform otherwise.</p>
<p><em><strong>Do you have any memories from your fellowship that you would like to share?</strong> </em><br />Many of my fondest memories are the relationships and just the casual interactions I had every day with other fellows, investigators and staff. Everyone was so supportive and generous with their time, and all these amazingly accomplished scientists treated me as a colleague, and not &ldquo;just a fellow&rdquo;. There was definitely a fair amount of stress, but there was a lot of fun, too&mdash;and that was because of all the great people at DCEG.</p>
<p><em><strong>What do you do in your free time?</strong></em><br />I have a daughter (7) and a son (9) who are very active, so we spend a lot of our time going back and forth to sporting events and school activities. Personally, I enjoy relaxing time with my family, and I still play in a soccer league once a week.</p>
<p><em><strong>Do you have any advice for current or future DCEG fellows?</strong></em><br />I would say a DCEG fellowship offers an incredible and unique opportunity for growth, so try to identify areas where you have weaknesses, and then push out of your comfort zone to try new things. In addition to a much needed new listing on your CV, view each potential project as a chance to learn new skills, because that is what will really help you in the long run.</p>
<p></p>
<p><a href="https://percussion.cancer.gov/Rhythmyx/assembler/render?sys_contentid=1097514&amp;sys_revision=4&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1097514" sys_folderid="" sys_relationshipid="7104848"><strong>Read more conversations with former fellows</strong></a><strong>.</strong></p>
</div>]]></content>
  </row>
  <row para_id="1116544" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Biostatistics Branches (BB) of the Division of Cancer Epidemiology and Genetics (DCEG) at the National Cancer Institute (NCI) seek qualified applicants for post-doctoral fellowships for statistical research on important analytic problems in cancer epidemiology and genetics. BB is an intramural research program in biostatistics in DCEG at NCI.</p>
<p>BB statisticians develop statistical research programs and actively collaborate both in cutting-edge studies of genetic, lifestyle, and environmental causes of cancer as well as in studies of cancer prevention, descriptive and clinical epidemiology. Statistical research is typically motivated by challenges encountered in DCEG studies, such as choosing an efficient study and sampling design, optimally combining data from multiple sources such as electronic medical records, genetic data bases, disease and bio-specimen registries, as well as designing validation studies and methods to evaluate and correct for measurement error in exposures and disease outcomes. The branch has active methodological research programs in areas that include: absolute risk prediction, the analysis of molecular data, environmental statistics, epidemiologic study design, the analysis of longitudinal and survival data, and cancer genetics. BB statistical investigators can and do conduct innovative methodological research in an environment of one-of-a-kind population-based epidemiologic and genetics studies.</p>
<p>We are seeking a postdoctoral candidate with a Ph.D. in statistics or biostatistics with solid statistical training and strong computer programming skills who is eligible to work in the US (US citizenship is not required). The position is for the development of new statistical methods and tools and will allow a recent Ph.D. to build his or her methodological and collaborative research program. The candidate is expected to participate in research team efforts, and lead several projects, leading to publications. Preference will be given to candidates interested in applied problems, and with superior methodological and communication skills. The stipend is commensurate with training and relevant research experience.</p>
<p>Applicants should send: 1) a curriculum vitae; 2) a statement of research interests to be pursued during training; and 3) three letters of reference to:</p>
<p>Ms. Adrienne Rolls<br /> Biostatistics Branch<br /> Division of Cancer Epidemiology and Genetics<br /> National Cancer Institute<br /><a href="mailto:adrienne.rolls@nih.hhs.gov">adrienne.rolls@nih.hhs.gov</a></p>
<p>Please contact Dr. Paul S. Albert (phone 240-276-7593 or <a href="mailto:albertp@mail.nih.gov">Email</a>) for questions about the position. Further information about the Biostatistics Branch and Division may be found at&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_dependentvariantid="1422" sys_dependentid="302568" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7300291" sys_variantid="1422" sys_contentid="302568">http://www.dceg.cancer.gov</a>&nbsp; This position will remain open until qualified applicants are found.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=1131833" sys_dependentvariantid="1500" sys_dependentid="1131833" inlinetype="rxhyperlink" rxinlineslot="103" sys_relationshipid="7300292" sys_variantid="1500" sys_contentid="1131833">Download this position announcement in pdf format.</a></p>
<p style="text-align: center;">HHS and NIH are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="1119647" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Provider:</strong> National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
<p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software. Reports should be forwarded to the Provider at the address given below:</p>
<p>Questions? Contact: Dr. Bin Zhu <a href="mailto:katkih@mail.nih.gov">zhub@mail.nih.gov</a></p>
</div>]]></content>
  </row>
  <row para_id="1121560" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h2>Ewing Sarcoma Genome-wide Association Study</h2>
<p>Ewing sarcoma (EWS) is a pediatric bone tumor for which genetic risk factors remain poorly understood. DCEG investigators are studying inherited genetic variation to identify regions in the genome associated with increased risk of EWS by comparing the frequency of genotyped genetic variants between EWS cases and ancestry-matched, cancer-free controls to identify variants more frequently observed in EWS cases. This&nbsp;large (2,000+ cases), international consortium combines previously published data with new EWS cases to perform&nbsp;integrative analyses of newly discovered genetic susceptibility regions to identify local genomic structures and nearby target genes that may be important for EWS risk. The overall goal of the study is to expand our understanding of EWS etiology and provide insight into improved treatment and potentially preventative measures to reduce the overall burden of EWS.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1088176" sys_dependentvariantid="1965" sys_dependentid="1088176" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391641" sys_variantid="1965" sys_contentid="1088176">Mitchell Machiela.</a></p>
<p><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=&amp;authorOption=and&amp;searchTxtTitle=Ewing+sarcoma&amp;titleOption=and&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Ewing Sarcoma - Related Publications</a>&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_dependentvariantid="1418" sys_dependentid="420600" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7391642" sys_variantid="1418" sys_contentid="420600">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1121724" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Division of Cancer Epidemiology and Genetics (DCEG) offers training to clinically-focused investigators through the <a href="https://ccr.cancer.gov/training/clinical/clinical-investigator-development-program">NCI&rsquo;s Clinical Investigator Development Program (CIDP)</a>, administered by the Center for Cancer Research.</p>
<p>CIDP trainees who come to DCEG will have the opportunity to develop a research program in cancer etiology and prevention in a highly collaborative environment, with access to high-quality data from long-term family- and population-based epidemiologic and clinical studies and utilizing our high-throughput genomics facility, molecular pathology resources, biostatics and epidemiology methodological expertise, and resources at the NIH Clinical Center.</p>
<p>Trainees will have the opportunity to conduct research in cancer genetics and epidmeiology alongside investigators in DCEG.</p>
<p><a href="https://ccr.cancer.gov/training/clinical/clinical-investigator-development-program">Learn more about the CIDP program and the application process.</a><span>&nbsp;</span></p>
<p>For questions about becoming a CIDP investigator in DCEG, contact <a href="https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/savage-sharon">Sharon Savage.</a><span>&nbsp;</span></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1123466" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2088" sys_dependentid="1123895" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7368565">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302177&amp;sys_siteid=475&amp;sys_contentid=1123895&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>The Confluence project will develop a large research resource by 2020 to uncover breast cancer genetics through genome-wide association studies (GWAS). The resource will include at least 300,000 breast cancer cases and 300,000 controls of different races/ethnicities. This will be accomplished by the confluence of existing GWAS and new genome-wide genotyping data to be generated through this project.</p>
<p>Broad scientific aims that can be addressed through this resource include:</p>
<ol>
<li><span>To discover susceptibility loci and advance knowledge of etiology of breast cancer overall and by subtypes.</span></li>
<li><span>To develop polygenic risk scores and integrate them with known risk factors for personalized risk assessment for breast cancer overall and by subtypes.&nbsp;</span></li>
<li><span>To discover loci for breast cancer prognosis, long-term survival, response to treatment, and second breast cancer.&nbsp;</span></li>
</ol>
<p><strong>Eligibility criteria </strong></p>
<p>To be eligible to participate, studies with cases of <em>in situ</em> or invasive breast cancer (females or males) must have:</p>
<ul>
<li>Genome-wide genotyping data or germline DNA for genotyping, i.e.:</li>
<ul>
<li>existing genome-wide genotyping data, or</li>
<li>germline DNA available for new genotyping, or</li>
<li>blood/buccal samples for germline DNA isolation and genotyping.</li>
</ul>
<li>Basic phenotype data (e.g. age at diagnosis, gender, family history of breast cancer)</li>
<li>Appropriate ethics approval for genetic studies and data sharing</li>
</ul>
<!--<p>Please refer to the study protocol and/or this presentation for more details on Confluence and how studies can participate.</p>-->
<p>Please refer to the <a href="/Rhythmyx/assembler/render?sys_contentid=1148346&amp;sys_revision=2&amp;sys_variantid=1500&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1500" rxinlineslot="103" sys_dependentid="1148346" sys_folderid="" sys_relationshipid="7368566">Confluence study&nbsp;project (pdf, 788 KB)</a> for more details on Confluence and how studies can participate.</p>
<p><a href="https://ww2.research-survey.org/efm/se.ashx?s=4B7FCB89085F4226">Please complete the study inventory</a> if you are interested in participating in Confluence. <span>This inventory is for planning purposes only and implies no commitment to participate.</span></p>
<p>Confluence is supported by NCI Intramural Research funds.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=420600" sys_contentid="420600" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="420600" sys_variantid="1418" sys_relationshipid="7368562">Integrative Tumor Epidemiology Branch- Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1123474" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Inclusivity Minute email project began in 2018 as a joint effort between the DCEG Fellows Committee and Division Director to cultivate a culture of inclusion in the Division. Monthly Inclusivity Minute<strong>&nbsp;</strong>email messages are&nbsp;archived below; each address relevant topics and provide resources for learning more. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1129000" sys_contentid="1129000" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1129000" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390540" sys_variantid="1418">Read the Frequently Asked Questions about the Inclusivity Minute email project</a>.</p>
<p><em><a id="top"></a>On this page:</em></p>
<p><a href="#Equity-Equality">Equity &amp; Equality (July 2019)</a><br /><a href="#Taking-Stock">Taking Stock of the Initiative So Far (June 2019)</a><br /> <a href="#Privilege">Privilege (May 2019)</a><br /> <a href="#Mental-Health">Mental Health at Work (March 2019)</a><br /> <a href="#Microaggressions">What are Microaggressions? (February 2019)</a><br /> <a href="#New-Years-Resolution">Your New Year's Resolution: A More Diverse and Inclusive Workplace (January 2019)</a><br /> <a href="#Imposter-Phenomenon">Imposter Phenomenon (October 2018)</a><br /> <a href="#In-groups">In-groups (September 2018)</a><br /> <a href="#Introduction">Introduction (August 2018)</a></p>
<h3><a id="Equity-Equality"></a>Equity &amp; Equality (July 2019)</h3>
<p>Equity and equality? How different could they be? Significantly!</p>
<div sys_dependentvariantid="2066" sys_dependentid="1150897" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390548">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Visualizing Infographic depicts Equality versus Equity. Equality shows people of different heights, one in a wheelchair, each trying to ride bikes of the same type and size. Equity depicts those same people riding correctly-sized bikes, with the person formerly shown in a wheelchair riding a bike configured with 3 wheels and hand controls." src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1150897&amp;sys_command=edit" /><!--Comment--> <a class="article-image-enlarge no-resize" href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1150897&amp;sys_command=edit" target="_blank" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1150897">Enlarge</a></div>
<figcaption>
<div class="caption-container no-resize">
<p>Visualizing Health Equity: One Size Does Not Fit All</p>
<div class="image-photo-credit">Robert Wood Johnson Foundation</div>
</div>
</figcaption>
</figure>
</div>
<p>Equality is what we learn as kids&mdash;everyone gets a turn on the slide, everyone gets the same size piece of cake. In other words, resources are distributed equally.</p>
<p>Equity is distributing resources to meet the specific needs of an individual or group.</p>
<p>As demonstrated in the graphic from the Robert Wood Johnson Foundation, equitable policies, programs, and interventions allocate resources in ways that respond to the distinct and existing advantages and disadvantages faced by different subgroups of a population. This approach provides equal opportunity for everyone to succeed.</p>
<p>At NIH, equity-focused programs such as targeted recruitment of under-represented groups help to create and sustain a diverse and inclusive scientific workforce.</p>
<p><strong>To learn more:</strong><br />The former CEO of the Gates Foundation wrote about <a href="https://www.forbes.com/sites/jeffraikes/2019/05/06/the-power-of-equity/#ad2e51e2d439">The Power of Equity</a> in this article from <em>Forbes</em>.</p>
<p>Lots of cartoons have been used to illustrate the equity vs. equality distinction and some interesting debate has arisen about which ones do the best job. Read about them:</p>
<p><a href="http://culturalorganizing.org/the-problem-with-that-equity-vs-equality-graphic/">The problem with that equity vs. equality graphic you&rsquo;re using</a> from culturalorganizing.org</p>
<p><a href="https://medium.com/@CRA1G/the-evolution-of-an-accidental-meme-ddc4e139e0e4">The evolution of an accidental meme</a> from Medium.com</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Taking-Stock"></a>Taking Stock of the Initiative So Far (June 2019)</h3>
<p>Reflecting on the last 10 months and six Inclusivity Minutes, has prompted a reassessment of the vision for this initiative. At the outset, the <a href="#Introduction">stated goal</a> was to educate and to spark conversation and inquiry about issues related to workplace inclusion and diversity, which remains true. An equally important goal is to amplify the voices and perspectives of staff who are part of the out-groups, who experience less <a href="#Privilege">privilege</a>, or are generally under-represented in the Division.</p>
<p>Have these communications made you feel uncomfortable at times? The work of achieving equity can be uncomfortable and requires us to extend ourselves beyond our comfort zone. These communications are raising key issues that we need to understand better, and it is true that sometimes new insights can be born of challenging moments. In the end, these topics should stimulate further thought and make us more aware of their importance.</p>
<p>Please continue to send your feedback and share the conversations you are having about the Inclusivity Minute. The more conversations about inclusion and diversity the better!</p>
<p>Currently, the topic and content of each Inclusivity Minute is reached through consensus by members of the Office of the Director, the Fellows committee, and the Office of Education (for more information, see the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1129000" sys_contentid="1129000" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1129000" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390543" sys_variantid="1418">FAQs</a>). This ad hoc Inclusivity Minute committee is open to any who are interested in participating: administrative, scientific, and support staff. Do you have an idea for a topic? Would you like to be part of an in-person discussion about topics we touch on? Please <a href="mailto:Withrow,%20Diana%20(NIH/NCI)%20%5bE%5d%20%3cdiana.withrow@nih.gov%3e;%20Lavigne,%20Jackie%20(NIH/NCI)%20%5bE%5d%20%3clavignej@mail.nih.gov%3e?subject=Inclusivity%20Minute">reach out via email</a> or through an anonymous, open-ended <a href="https://forms.gle/9JavPMtUT2zhynkF8">one-question survey</a>.</p>
<p>Here are some resources that address the topic of inclusivity and diversity more broadly:</p>
<p><a href="https://www.ted.com/talks/liz_kleinrock_how_to_teach_kids_to_talk_about_taboo_topics?language=en#t-709329">Teaching Kids to Talk About Taboo Topics</a> (Ted Talk with nearly 1.5 million views); many of the lessons apply to adults too.</p>
<p><a href="https://www.forbes.com/sites/jeffraikes/2019/05/06/the-power-of-equity/#343ea84e2d43">The Power of Equity</a>, <em>Forbes Magazine</em>, by former CEO of the Gates Foundation.</p>
<p><a href="https://www.npr.org/2019/04/03/709567750/radically-normal-how-gay-rights-activists-changed-the-minds-of-their-opponents">Radically normal: How Gay Rights Activists Changed the Minds of Their Opponents (NPR Hidden Brain Podcast episode)</a></p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Privilege"></a>Privilege (May 2019)</h3>
<p>As we seek to create a more diverse and inclusive work environment, we have learned in a previous Inclusivity Minute to consider the role of &lsquo;in-group bias&rsquo;. A related and important concept is that of privilege. Privilege is defined as a special right, advantage, or immunity granted or available only to a particular person or group. Privilege affects who has access to career paths in science, the opportunities available when pursuing those paths, and interpersonal interactions at school and at work.</p>
<p>Privilege can apply to any specific individual or group. For example, white privilege allows people of fair skin to escape being stereotyped or harassed because of the color of their skin. Socio-economic privilege can provide a debt-free college education, or the opportunity to build generational wealth. A society free of oppression is one where all individuals experience equal privilege.</p>
<p>Acknowledging one&rsquo;s own privilege and making efforts to better understand the circumstances of those without it encourages an equitable work environment and society. Such an environment will help us to best achieve our collective scientific goals.</p>
<p><strong>To learn more:</strong><br />In the <strong>popular media</strong>, we suggest the Elite Daily article, &ldquo;<a href="https://www.elitedaily.com/life/privilege-benefiting-from-no-idea/1496370">5 Types of Privilege You Probably Have No Idea You're Benefiting From</a>&rdquo; and from the New Yorker &ldquo;<a href="https://www.newyorker.com/books/page-turner/the-origins-of-privilege">The Origins of Privilege</a>&rdquo;.</p>
<p>For <strong>historical context</strong>, you can see W.E.B. Du Bois&rsquo; 1935 seminal work describing the concept of <a href="http://ouleft.org/wp-content/uploads/2012/blackreconstruction.pdf">psychological wage (large pdf, see p.700)</a>.</p>
<p>The University of Southern California offers a <a href="https://msw.usc.edu/mswusc-blog/diversity-workshop-guide-to-discussing-identity-power-and-privilege/#unpack">guided exercise on privilege</a>. Teaching Tolerance, a project of the Southern Poverty Law Center, also has a <a href="https://www.tolerance.org/magazine/fall-2018/toolkit-for-what-is-white-privilege-really">toolkit for educators</a> that includes useful resources.&nbsp;</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Mental-Health"></a>Mental Health at Work (March 2019)</h3>
<p>An inclusive workplace values the contributions of all and accommodates the needs of diverse people, including people with mental illness. <br />&nbsp;<br />Every person who struggles with mental health has a right to work, should be treated equally without reproach or discrimination, and should be provided with support in the workplace. Access to evidence-based treatments works; however, attitudinal factors surrounding mental health play a role in restricting access to these treatments (see link below).<br />&nbsp;<br />We can do our part to reduce the stigmatization around mental disorders through willingness to talk openly with our colleagues and those we care about, and by taking time to reflect and consider the wellbeing of those around us.</p>
<p><strong>To learn more:</strong></p>
<ul>
<li>The U.S. Equal Employment Opportunity Commission (EEOC) offers frequently answered questions (FAQ) and a list of resources about legal rights in the workplace.
<ul>
<li><a href="https://www.eeoc.gov/eeoc/publications/mental_health.cfm">EEOC FAQ page</a></li>
<li><a href="https://www.eeoc.gov/laws/types/disability_regulations.cfm">EEOC resources about legal rights in the workplace</a></li>
</ul>
</li>
<li>The NIH Employee Assistance Program (EAP) provides personalized consultation, short-term support, referral and follow up services to enhance personal and professional well-being. Their services are free to all employees and their immediate family members.
<ul>
<li>Direct phone: 301-496-3164</li>
<li><a href="https://www.ors.od.nih.gov/sr/dohs/Documents/NIH-EmplAssistPrgrm-508.pdf">EAP brochure (pdf, 739 KB)</a></li>
<li><a href="https://www.ors.od.nih.gov/sr/dohs/HealthAndWellness/EAP/Pages/EAP-Services.aspx">Description of NIH EAP services</a></li>
</ul>
</li>
</ul>
<p>From the peer-reviewed literature:</p>
<ul>
<li><a href="http://doi.org/10.1038/nbt.4089">Evidence for a mental health crisis in graduate education</a> - <em>Nature Biotechnology</em></li>
<li><a href="http://doi.org/10.1097/JOM.0000000000001271">Mental Health in the Workplace</a> - <em>Journal of Occupational and Environmental Medicine</em></li>
<li><a href="http://doi.org/10.1097/JOM.0000000000000472">Barriers to Mental Health Service Use Among Workers with Depression and Work Productivity</a> - <em>Journal of Occupational and Environmental Medicine</em></li>
</ul>
<p>In the <strong>popular media</strong>, we suggest Author Andrew Solomon&rsquo;s article&nbsp;<a href="http://andrewsolomon.com/articles/anatomy-of-melancholy/">Anatomy of Melancholy</a> and book <em>The Noonday Demon</em>.</p>
<ul>
<li><a href="https://catalog.dclibrary.org/client/en_US/dcpl/search/results?qu=The+Noonday+Demon%3A+An+Atlas+Of+Depression&amp;te=">Find <em>The Noonday Demon</em> in the DC library</a></li>
<li><a href="https://mdpl.ent.sirsi.net/client/en_US/catalog/search/results?qu=The+Noonday+Demon%3A+An+Atlas+Of+Depression&amp;te=">Find <em>The Noonday Demon</em> in the Montgomery County Public libraries</a></li>
</ul>
<p><a href="#top">Back to top</a></p>
<h3><a id="Microaggressions"></a>What are Microaggressions? (February 2019)</h3>
<div class="callout-box" style="float: right; width: 25%; margin: 0 0 5px 10px;">
<div sys_dependentvariantid="2066" sys_dependentid="1136866" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7390549">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Video What is a Microaggression? - https://www.amazon.com/dp/B07CNJGVGN?ref=dp_vse_rvc0 by Professor Derald Wing Sue " src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1136866&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p><strong>Watch video:</strong><br /><br /><a href="https://www.amazon.com/dp/B07CNJGVGN?ref=dp_vse_rvc0">What is a Microaggression?</a> by Professor Sue</p>
</div>
<p>According to Columbia University Professor Derald Wing Sue, microaggressions "are the everyday slights, indignities, put downs and insults that minorities experience in their day to day interactions with well-intentioned individuals who are unaware that they have engaged in an offensive act or made an offensive statement."</p>
<p>These comments are normally related to a person&rsquo;s race, gender, sexual orientation or disability status, and may seem like a compliment to the person speaking them, e.g., &ldquo;Your English is so good!&rdquo; In aggregate, comments like this contribute to a stressful and unpleasant environment for members of under-represented groups.</p>
<p>For examples of common microaggressions, or how to respond in different situations&mdash;when someone points out that you have made a microaggression, if you are the recipient of a microaggression, or when you witness a microaggression&mdash;here are some thoughtful articles:</p>
<ul>
<li><a href="https://www.businessinsider.com/microaggression-unconscious-bias-at-work-2018-6">14 things people think are fine to say at work&mdash;but are actually racist, sexist, or offensive</a> - <em>Business Insider</em></li>
<li><a href="https://blog.cultureamp.com/the-importance-of-understanding-microaggressions-at-work-">The importance of understanding microaggressions at work</a> - <em>Culture Amp Blog</em></li>
<li><a href="https://www.cnbc.com/2018/04/25/workplace-microaggressions-can-kill-your-confidence-heres-what-to-do.html">4 workplace microaggressions that can kill your confidence&mdash;and what to do about them</a> - <em>CNBC</em></li>
<li><a href="https://www.fastcompany.com/3068670/how-to-shut-down-microagressions-at-work">How To Shut Down Microaggressions at Work</a> - <em>Fast Company</em></li>
</ul>
<p><a href="#top">Back to top</a></p>
<h3><a id="New-Years-Resolution"></a>Your New Year's resolution:&nbsp;A More Diverse and Inclusive Workplace (January 2019)</h3>
<p>If you are one to make New Year&rsquo;s resolutions, consider when and how you will actively contribute to a more diverse and inclusive workplace. Resources provided through the Inclusivity Minute are designed to facilitate our shared learning and understanding of these values so we may all act as champions of diversity and inclusion at DCEG. Below are some definitions to get you started:</p>
<p><strong>Diversity</strong> is a term used to describe the range of human differences, including but not limited to race, ethnicity, gender, sexual orientation, age, social class, physical abilities or attributes, religious or ethical value systems, national origin or political beliefs. When we talk about diversity, we are talking about the composition of a group. In DCEG (as everywhere in the NIH), diversity is not ornamental, not a destination or goal. Rather, diversity is integral to our success as a research organization and part of our elemental nature.</p>
<p><strong>Inclusion</strong> refers to the involvement and empowerment of diverse people, where the inherent worth and dignity of all people is recognized. An inclusive organization promotes and sustains a sense of belonging for all, demonstrates values and practices respect for the talents, beliefs, backgrounds and ways of living of all its members.</p>
<p>To learn more vocabulary, please visit the <a href="https://diversity.nih.gov/find-read-learn/glossary">NIH Office of Scientific Workforce Diversity Glossary</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1129000" sys_contentid="1129000" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1129000" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390541" sys_variantid="1418">Read the Frequently Asked Questions about the Inclusivity Minute email project</a>.</p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Imposter-Phenomenon"></a>Imposter Phenomenon (October 2018)&nbsp;</h3>
<p><strong>Imposter phenomenon&nbsp;</strong>is the persistent feeling that one&rsquo;s success is due to luck or chance, rather than competence, despite evidence to the contrary. The phenomenon has been observed in individuals at all career levels; it is more common among women, minorities, in interdisciplinary settings, and among people in the midst of a job transition.</p>
<p>Imposter phenomenon can manifest in several ways. Self-doubt can result in procrastination, risk aversion and avoidance (for career advancement, job applications, etc.), or compromising health and work-life balance. People suffering from the imposter phenomenon are unlikely to talk about their experience with others. While you may not have heard of it, it may be occurring to someone around you.</p>
<p>If you are feeling like an imposter, have an open discussion about it with trusted mentors and peers.</p>
<p>As a mentor, you can help your mentees by attributing their successes to internal factors and by acknowledging failure as a common and necessary step for learning and growth.</p>
<p><strong>To learn more:</strong> <br />Self-evaluation test: <a href="http://paulineroseclance.com/pdf/IPTestandscoring.pdf">Clance Imposter Phenomenon Scale (PDF)</a><br />Nature Jobs article: <a href="https://www.nature.com/naturejobs/science/articles/10.1038/nj7245-468a">Unmasking the Impostor</a><br />Book review: <a href="https://www.huffingtonpost.com/caroline-dowdhiggins/impostor-syndrome_b_1651762.html">The Secret Thoughts of Successful Women: Why capable people suffer from the imposter syndrome and how to thrive in spite of it</a><br />Peer-reviewed article: <a href="https://www.tci-thaijo.org/index.php/IJBS/article/view/521/pdf">Imposter Phenomenon</a> <br />Podcast: <a href="https://www.apmpodcasts.org/thwod/2018/08/impostor-syndrome-true-tales-tricks-and-tactics-for-when-youre-feeling-fraudulent/">Impostor Syndrome: True tales, tricks, and tactics for when you&rsquo;re feeling fraudulent</a></p>
<p><a href="#top">Back to top</a></p>
<h3><a id="In-groups"></a>In-groups (September 2018)</h3>
<p><strong>Have you heard of in-groups?</strong> An in-group is a group of people who identify with each other based on factors including gender, race, religion, or nationality/geography.</p>
<p>In-group bias has an evolutionary basis: Humans evolved to be more empathetic toward in-group members, making it an unconscious bias. In-group favoritism does not necessarily imply negative behavior toward out-group members. It may manifest as disproportionate kindness and generosity to in-group members, causing out-group members to experience the negative effects of that preference.</p>
<p>In the workplace, in-group bias can affect hiring, award nomination, committee membership, and peer review processes, among others. Being aware of in-groups allows you to make thoughtful, conscious decisions to overcome automatic, potentially unfair decisions and/or actions.</p>
<p><strong>To learn more:</strong><br /> Media article: <a href="http://www.spsp.org/news-center/blog/intergroup-bias">&ldquo;Us&rdquo; and &ldquo;Them&rdquo;: The Nature of Intergroup Bias</a><br /> Peer-reviewed article: <a href="https://www.sciencedirect.com/science/article/pii/S0167268109001310">Identity and in-group/out-group differentiation in work and giving behaviors</a><br /> Book: <a href="https://www.washingtonpost.com/opinions/blindspot-hidden-biases-of-good-people-by-mahzarin-r-banaji-and-anthony-g-greenwald/2013/02/08/4c42d6b8-6a1b-11e2-ada3-d86a4806d5ee_story.html?noredirect=on&amp;utm_term=.38051b8454a">Blindspot: Hidden Biases of Good People</a></p>
<p><a href="#top">Back to top</a></p>
<h3><a id="Introduction"></a>Introduction (August 2018)</h3>
<p>A message from <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349630" sys_contentid="349630" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349630" rxinlineslot="103" sys_relationshipid="7390539" sys_variantid="1965">Dr. Stephen Chanock</a>, Director, DCEG:</p>
<p>The DCEG Fellows Committee and I are joining forces in a learning initiative to increase our awareness of issues related to diversity, inclusion and equity. We are launching a monthly&nbsp;<strong>Inclusivity Minute&nbsp;</strong>email, which will address relevant topics and provide resources for learning more. I will send the first installment next month.</p>
<p>This project was inspired by findings from the 2018 DCEG Fellows Survey which revealed that 13% of fellows have been made to feel uncomfortable or witnessed others being made to feel uncomfortable in our workplace because of their gender, gender identity, sexual orientation, race, religion or other personal qualities. We aspire to a DCEG culture in which everyone feels comfortable, welcome and valued.&nbsp;&nbsp;</p>
<p>I am confident we are all equally committed to building and sustaining a positive environment for all; we hope that you will take advantage of this initiative to learn together.</p>
<p><a href="#top">Back to top</a></p>
<hr />
<p>This&nbsp;archive of the monthly messages also features a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1129000" sys_contentid="1129000" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1129000" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390542" sys_variantid="1418">Frequently Asked Questions</a> page.&nbsp;If you would like to provide feedback or suggestions, please contact&nbsp;<u><a href="mailto:lavignej@mail.nih.gov">Jackie Lavigne</a></u>&nbsp;or&nbsp;<u><a href="mailto:diana.withrow@nih.gov">Diana Withrow</a></u>, or leave a note in one of the DCEG suggestion boxes (located in the kitchen on each floor).</p>
</div>]]></content>
  </row>
  <row para_id="1123950" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>A mutation-based score test for identify driver genes and subtype heterogeneity of driver genes in cancer genome sequencing studies</strong></p>
<h3>Description</h3>
<p>Identifying driver genes that drive cancer initiation and progression is essential for understanding mechanisms of carcinogenesis and designing therapeutic strategies. While cancer genomes are heterogeneous across patients, no method has been developed to investigate whether the sets of driver gene are distinct across cancer subtypes. We developed a statistical framework MutScot that utilizes patient information to investigate subtype heterogeneity of driver genes.</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1124000" sys_dependentvariantid="1418" sys_dependentid="1124000" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7118846" sys_variantid="1418" sys_contentid="1124000">License Agreement</a></li>
</ul>
<strong>Download:</strong><br />
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1500&amp;sys_contentid=1123999" sys_dependentvariantid="1500" sys_dependentid="1123999" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7118847" sys_variantid="1500" sys_contentid="1123999">MutScot R Package</a></li>
</ul>
<h3>Support</h3>
<p>E-mail: <a href="mailto:ncicontactdceg@mail.nih.gov">DCEG</a></p>
</div>]]></content>
  </row>
  <row para_id="1124000" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p><strong>Provider:</strong> National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
<p>Recipient will send to Provider general reports regarding the application of the Software and the effectiveness and problems encountered in using the Software, without disclosing Recipient's confidential information. Information from general reports may be used by the Provider to enhance the capabilities of the Software.</p>
</div>]]></content>
  </row>
  <row para_id="1125534" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>DCEG researchers conduct studies on breast cancer, a cancer that usually forms in the breast ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). Breast cancer occurs in both men and women, although male breast cancer is rare. Selected studies in the Integrative Tumor Epidemiology Branch include:</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=837951" sys_contentid="837951" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="837951" sys_dependentvariantid="1418" sys_relationshipid="7390708" sys_variantid="1418">Breast Cancer Among Asian Women</a><br />Studies of breast tissues, risk factors, clinical data, breast density, blood or saliva for germline DNA to identify distinct molecular alterations in tumors and adjacent benign breast tissues among Asian women and to examine the associations of molecular changes with genetic and environmental risk factors, breast tissue composition and density, and breast cancer subtypes.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303566" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303566" sys_dependentvariantid="1418" sys_relationshipid="7390717" sys_variantid="1418" sys_contentid="303566">Breast Cancer Case-Control Study in Poland</a><br />A population-based case-control study of breast cancer in Poland that combines state-of-the art techniques of exposure assessment and collection of biological specimens</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303562" sys_contentid="303562" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303562" sys_dependentvariantid="1418" sys_relationshipid="7390709" sys_variantid="1418">Breast Cancer Detection Demonstration Project Follow-up Study</a><br />A follow-up study of women who were participants in the Breast Cancer Detection Demonstration Project.</p>
<p><a href="http://www.b-cast.eu/">Breast CAncer STratification (BCAST) Project</a><br />A large-scale evaluation of how genetic and environmental risk factors, molecular tumor characteristics and clinical progression interrelate.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303567" sys_contentid="303567" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303567" sys_dependentvariantid="1418" sys_relationshipid="7390710" sys_variantid="1418">Breast Radiology Evaluation and Study of Tissues (BREAST) Stamp Project</a><br />A study that aims to characterize the radiologic, histologic, and molecular features of dense breast tissue.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303561" sys_contentid="303561" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303561" sys_dependentvariantid="1418" sys_relationshipid="7390711" sys_variantid="1418">Columbia, Missouri Serum Bank Follow-up Study</a><br />A study established as part of NCI's Biological Markers Project to identify serum markers for breast cancer.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1123466" sys_contentid="1123466" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1123466" sys_dependentvariantid="1418" sys_relationshipid="7390712" sys_variantid="1418">Confluence Project</a><br />A&nbsp;large research resource&nbsp;that&nbsp;aims to&nbsp;uncover breast cancer genetics through genome-wide association studies.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=805096" sys_contentid="805096" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="805096" sys_dependentvariantid="1418" sys_relationshipid="7390713" sys_variantid="1418">Contralateral Breast Cancer</a><br />Molecular and histomorphometric analyses of breast tissues in relation to mammographic density and breast cancer outcomes among breast cancer patients diagnosed within a general community health care plan.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=840733" sys_contentid="840733" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="840733" sys_dependentvariantid="1418" sys_relationshipid="7390714" sys_variantid="1418">Ghana Breast Health Study</a><br />The Ghana Breast Health Study is a multidisciplinary case-control study of breast cancer in Ghana, West Africa.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303564" sys_contentid="303564" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303564" sys_dependentvariantid="1418" sys_relationshipid="7390715" sys_variantid="1418">Terminal Duct Lobular Unit Involution of the Normal Breast</a><br />A molecular epidemiologic study of terminal duct lobular units of the normal breast, conducted in collaboration with the Susan G. Komen&reg; Tissue Bank.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303569" sys_contentid="303569" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="303569" sys_dependentvariantid="1418" sys_relationshipid="7390716" sys_variantid="1418">Ultrasound Study of the Effects of Tamoxifen on Breast Tissue</a><br />A study using ultrasound tomography to define the time course of volumetric breast density changes among women receiving tamoxifen treatment.</p>
</div>]]></content>
  </row>
  <row para_id="1127098" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>Description</h3>
<p>IRRAD is an Excel spreadsheet that extends the &ldquo;Axelson adjustment&rdquo; for binary variables to adjust observed RRs for a (measured or unmeasured) confounding variable when exposure and confounder have multiple categories.&nbsp; IRRAD allows the User to designate a multiplicative or an additive relative risk (RR) model for the joint association of exposure (X) and confounder (C). &nbsp;Additionally, the spreadsheet solves linear equations to define those characteristics that a confounder must have to explain fully or partially an observed association.&nbsp;</p>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1127099" sys_dependentvariantid="1418" sys_dependentid="1127099" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276103" sys_variantid="1418" sys_contentid="1127099">License Agreement</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=1127097" sys_dependentvariantid="1500" sys_dependentid="1127097" inlinetype="rxhyperlink" rxinlineslot="103" sys_relationshipid="7276104" sys_variantid="1500" sys_contentid="1127097">IndirectRRAdjustment(IRRAD)_NCI_DCEG_ 2018_v1.3.xlsm</a>
<ul>
<li>Note: End users will need to enable macros, which are used throughout to create an interactive user interface. &nbsp;All calculations however, are done within the excel worksheets.&nbsp;<em>Updated: December, 2018</em></li>
</ul>
</li>
</ul>
<h3>Details</h3>
<p>The spreadsheet incorporates four approaches to assess confounder effects under either a multiplicative or additive model. These include:</p>
<ul>
<li><b>Binary exposure and binary confounder</b>: a) find the adjusted RR given the observed RR, P(C=1|X=1) and P(C=1|X=0) [or equivalently the observed RR, P(C=1|X=0) and the odds ratio OR(X,C)]; and b) solve for the necessary OR(X,C) given the observed, adjusted and confounder RRs and P(C=1|X=0);</li>
<li><b>Categorical exposure and categorical confounder</b>: find the adjusted RRs for each level of exposure given the observed RRs, the confounder distribution at each level of exposure P(C|X) and confounder RRs at the reference level of exposure;</li>
<li><b>Categorical exposure and binary confounder</b>: solve for the conditional distribution of the confounder at each level of X, P(C=1|X), given the observed, adjusted and confounder RRs and P(C=1|X=0);</li>
<li><b>Categorical exposure and catgorical confounder</b>: solve for the confounder RRs given the observed RRs, the adjusted RRs and P(C|X).</li>
</ul>
<p>IRRAD includes the data used for the examples in Lubin et al.</p>
<h3>Support</h3>
<p>Email: <a href="mailto:ncicontactdceg@mail.nih.gov" target="_blank" rel="noopener noreferrer">Contact DCEG</a></p>
<h3>Reference</h3>
<ul>
<li>Lubin JH, Hauptmann M, Blair A. Indirect adjustment of relative risks of an exposure with multiple categories for an unmeasured confounder. Ann Epidemiol 2018&nbsp;<cite>In Press</cite></li>
</ul>
<p><strong>Note</strong>: IRRAD is currently under review and development for 508-compliance.</p>
</div>]]></content>
  </row>
  <row para_id="1127099" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3><strong>Non-Proprietary Software Transfer Agreement</strong></h3>
<p>Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</p>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p>The IRRAD&nbsp;may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties</p>
</div>]]></content>
  </row>
  <row para_id="1129000" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3>What is the goal of this initiative?</h3>
The Inclusivity Minute Email Project is an initiative of the OD and the DCEG Fellows Committee, composed of representatives from each branch. The goal is to introduce DCEG staff to topics related to diversity and inclusion that they might not already be familiar with and to provide resources to learn more.
<p>We all come to DCEG with different backgrounds and experience. The Inclusivity Minute aims to spark conversation and inquiry.</p>
<h3><strong> </strong>Why an email?</h3>
In 2017, the NCI offered a staff training on the topic of Unconscious Bias which was attended by many across the Division. Afterwards, the DCEG Fellows Committee received some feedback that those who might benefit most from the training had not attended, a phenomenon that has been observed elsewhere (Kulik et al. <a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/job.444">The rich get richer: predicting participation in voluntary diversity training.</a>&nbsp;<span><em>J Organiz Behav</em></span>).<span>&nbsp;</span>
<p></p>
<p>In 2018, the DCEG Fellows Survey revealed that 13% of fellows have been made to feel uncomfortable or witnessed others being made to feel uncomfortable in our workplace because of their gender, gender identity, sexual orientation, race, religion or other personal qualities.</p>
<p>Spurred by these findings, the Fellows Committee proposed a short, DCEG-specific email to both complement the Unconscious Bias training and reach a broader audience.</p>
<h3>How are the topics selected?</h3>
Members of the DCEG Fellows Committee have brainstormed an initial list of topics, and they hope to continue adding to this list with your help. They select a topic for the following month&rsquo;s email message during monthly meetings. They try to prioritize topics that are new and may not otherwise be covered by NIH and NCI-wide emails.
<h3></h3>
<h3>What is the writing/review process?</h3>
So far, authors have been volunteers from the DCEG Fellows Committee. The writing responsibilities are rotated among members of the committee. Each Inclusivity Minute is first reviewed by the DCEG Fellows Committee, and then by staff in the DCEG Office of Education and the Communications team.
<p>If you would like to be an author or to participate in the review process, please reach out to <a href="mailto:Jackie.lavigne@nih.gov">Jackie Lavigne</a> in the&nbsp;Office of Education or <a href="mailto:diana.withrow@nih.gov">Diana Withrow</a> on the DCEG Fellows Committee.</p>
<h3><strong> </strong><strong>Where can I go for more resources?</strong></h3>
Resources on each specific topic are provided in the emails. In general, more information on issues of diversity and inclusion can be found at the <span><a href="https://www.edi.nih.gov/consulting/outreach/who-call/NCI">NIH Office of Equity, Diversity, and Inclusion</a></span>.<strong>&nbsp;</strong></div>]]></content>
  </row>
  <row para_id="1130171" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>On October 11 and 12, 2018, the National Cancer Institute (NCI) convened a group of experts to discuss the current state of the science of mutational signatures in cancer research and related opportunities and challenges. The goals of the meeting were to:</p>
<ul>
<li>Identify major issues and future directions in the characterization of mutational signatures that could lead to new insights into etiology, outcomes, and risk factors for specific cancers.</li>
<li>Encourage discussion to inform NCI priorities and frame critical research questions.</li>
<li>Develop new collaborations to advance research on mutational signatures and their application in clinical practice.</li>
</ul>
<p>Next steps to be considered by the NCI include the following:&nbsp;</p>
<ul>
<li>Increase integration with the field of cancer biology, including developing larger data sets and collaborations with basic scientists. NCI is developing an organoid library that might be useful to test exposures to different chemicals following exposure over time.<span> </span></li>
<li>Evaluate current algorithms used to benchmark mutational signatures in coordinated competition open to entire community.</li>
<li>Determine the relative importance of coverage of the cancer genome (targeted vs. whole genome) for signature discovery and assessment, especially in clinical settings. Pursue the question of how deep coverage should be through a separate NCI-supported competition.</li>
<li>Determine how to assess and use Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples.</li>
<li>Increase the depth of understanding of somatic signatures through integration with the genomic landscape, examining mistakes/mis-repairs and the role of germline mutations.</li>
<li>Determine the degree of precision for detecting signatures with respect to exposure/prognosis, beginning with known carcinogens.</li>
<li>Investigate the possible importance of tumor signatures by disparities, especially geographic and environmental differences as well as migration differentials.</li>
<li>Develop consensus on use of clinical signatures.</li>
<li>Support studies to address reverse assessments to identify promising therapies or germline/environmental triggers.</li>
</ul>
<p></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1130174" sys_dependentvariantid="1418" sys_dependentid="1130174" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7390411" sys_variantid="1418" sys_contentid="1130174">See participant list</a></p>
</div>]]></content>
  </row>
  <row para_id="1130174" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p></p>
<table width="610" height="224">
<tbody>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Ludmil Alexandrov, University of California&ndash;San Diego</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Max Leiserson,&nbsp;University of Maryland</span></li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Michelle Bennett,&nbsp;National Cancer Institute</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Doug Lowy,&nbsp;National Cancer Institute<o:p></o:p></span></li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Paul Brennan,&nbsp;International Agency for Research on Cancer</span></li>
</ul>
</div>
<div></div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Mitchell Machiela,&nbsp;National Cancer Institute</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Neil Caporaso,&nbsp;National Cancer Institute</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Andre Nussenzweig,&nbsp;National Cancer Institute</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li><span>Stephen Chanock,&nbsp;National Cancer Institute</span></li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Elli Papaemmanuil,&nbsp;Memorial Sloan Kettering Cancer Center</span></li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span></span><span>Nilanjan Chatterjee,&nbsp;Johns Hopkins University</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Gloria Petersen,&nbsp;The Mayo Clinic</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Eric Dawson,&nbsp;National Cancer Institute</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Paz Polak,&nbsp;Mount Sinai Hospital</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>William Foulkes,&nbsp;McGill University</li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<ul>
<li>
<p>Ludmila Prokunina-Olsson,&nbsp;National Cancer Institute</p>
</li>
</ul>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>
<p>Montserrat Garcia-Closas,&nbsp;National Cancer Institute</p>
</li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<ul>
<li>
<p>Nathaniel Rothman,&nbsp;National Cancer Institute</p>
</li>
</ul>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>
<p>Daniela Gerhard,&nbsp;National Cancer Institute</p>
</li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Steven Rozen,&nbsp;Duke University</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Gad Getz,&nbsp;Harvard University</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Manuel Salto-Tellez,&nbsp;Queen's University (Belfast)</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>Dmitry Gordenin,&nbsp;National Institute of Environmental Health&nbsp;Sciences</li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Ned Sharpless,&nbsp;National Cancer Institute</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li><span>Ed Harlow,&nbsp;National Cancer Institute</span></li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Adam Shlien,&nbsp;SickKids</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>Curt Harris,&nbsp;National Cancer Institute</li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Dinah Singer,&nbsp;National Cancer Institute</span></li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>Raymond Hughley,&nbsp;National Cancer Institute</li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Louis Staudt,&nbsp;National Cancer Institute</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>Maureen Johnson,&nbsp;National Cancer Institute</li>
</ul>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>Melissa Troester,&nbsp;University of North Carolina at Chapel Hill</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<div>
<ul>
<li><span>Jaegil Kim,&nbsp;Broad Institute</span></li>
</ul>
</div>
</div>
</td>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li>John Weinstein,&nbsp;The University of Texas MD Anderson Center</li>
</ul>
</div>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<div>
<ul>
<li><span>Qing Lan,&nbsp;National Cancer Institute</span></li>
</ul>
</div>
</td>
<td style="width: 297.6000061035156px;">
<ul>
<li>Debbie Winn,&nbsp;National Cancer Institute</li>
</ul>
</td>
</tr>
<tr>
<td style="width: 297.6000061035156px;">
<ul>
<li>Teri Landi,&nbsp;National Cancer Institute</li>
</ul>
</td>
<td style="width: 297.6000061035156px;"></td>
</tr>
</tbody>
</table>
</div>]]></content>
  </row>
  <row para_id="1130864" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Over the last three decades, advances in treatment and supportive care have translated into steady improvements in survival after hematopoietic stem cell transplantation (HSCT) given for patients with leukemia and other malignant and nonmalignant diseases. With larger numbers of transplant recipients surviving long term, concern has turned to quantifying the late effects of this treatment, particularly total-body irradiation and long-term immunosuppression. Investigators in the Radiation Epidemiology Branch have an extensive history of collaborating with the Center for International Blood and Marrow Transplantation to evaluate risk factors for new solid malignancies and post-transplant lymphoproliferative disorders among allogeneic HSCT recipients. Studies focus on specific outcomes, such as melanoma.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" inlinetype="rxhyperlink" sys_contentid="349616" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="349616" sys_dependentvariantid="1965" sys_relationshipid="7164897" sys_variantid="1965">Lindsay Morton</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=48&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" inlinetype="rxhyperlink" sys_contentid="401127" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="401127" sys_dependentvariantid="1418" sys_relationshipid="7164898" sys_variantid="1418">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1130869" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The last several decades have seen dramatic improvements in cancer survival, mainly due to advances in treatment and the increased detection of cancer at an early stage. With more than 16 million cancer survivors in the U.S. alone, concern has turned to potential late effects, particularly the development of a new malignancy. To identify groups of cancer survivors that are at increased risk for multiple primary cancers, Radiation Epidemiology Branch (REB) investigators&nbsp;have been leading&nbsp;a series of studies using registry data to monitor second cancer risks in a range of survivor populations.</p>
<p>The foundation of the research is a comprehensive population-based analysis of the risk of subsequent cancer in the U.S. [See <a href="http://seer.cancer.gov/archive/publications/mpmono/index.html">New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000</a> (Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker D, Edwards B, Tucker P, Fraumeni JF, Jr., eds.) National Cancer Institute. NIH Publication No. 05-5302. Bethesda, MD, 2006 (available at <a href="http://seer.cancer.gov/publications/mpmono/index.html">SEER Monograph</a>)]. The 500-page monograph utilized data from nine cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program from 1973 to 2000. The monograph describes the patterns of subsequent cancer risk for over 50 adult first primary cancers and 19 types of childhood cancers, by gender, age at initial diagnosis, time since diagnosis, initial treatment by radiation, and histologic type. Each chapter focuses on a specific initial cancer, presents the risk of subsequent cancers, and discusses potential causal mechanisms.</p>
<p>Additional studies have quantified contralateral breast cancer risk, breast cancer after Hodgkin lymphoma, melanoma after non-Hodgkin lymphoma, sarcoma risk after young adulthood cancers, and leukemia risk after chemotherapy for solid tumors and lymphoid malignancies among adult and childhood cancer survivors. The data from the monograph and these studies provide a resource that will be useful to clinicians, researchers, policy makers, and cancer survivors, especially in tailoring appropriate guidelines and strategies for prevention and early detection of new malignancies.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349616" sys_contentid="349616" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7164987" sys_dependentvariantid="1965" sys_dependentid="349616" rxinlineslot="103" sys_siteid="475" sys_folderid="">Lindsay Morton</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=48&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=401127" sys_contentid="401127" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7164988" sys_dependentvariantid="1418" sys_dependentid="401127" rxinlineslot="103" sys_siteid="475" sys_folderid="">Radiation Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1132646" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" sys_variantid="1422" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="302506" sys_dependentvariantid="1422" sys_relationshipid="7179793">Integrative Tumor Epidemiology Branch</a> of the NCI Division of Cancer Epidemiology and Genetics (DCEG) is recruiting a bioinformatician to support a research program in molecular epidemiology of cancer, under the direction of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" sys_contentid="349623" inlinetype="rxhyperlink" sys_variantid="1965" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="349623" sys_dependentvariantid="1965" sys_relationshipid="7179794">Maria Teresa Landi, M.D., Ph.D.</a>, senior investigator.</p>
<p>The overall aim of the research program is to identify the determinants of cancer risk and progression, integrating genomic analyses of tumor and germline in combination with host and environmental factors. Specific areas of research include:</p>
<ol>
<li>Characterization of genetic and epigenetic intra-tumor heterogeneity and clonal evolution of solid tumors and their associations with exposures and clinical outcomes;</li>
<li>Molecular characterization of tumors to identify exposure signatures and subtype-specific causes of cancer;</li>
<li>Tumor evolution, from precursor lesions to malignant features and metastatic events;</li>
<li>Genetic susceptibility of tumors in large population-based or family-based studies.</li>
</ol>
<h3>Position Description</h3>
<p>The successful candidate will conduct bioinformatics analyses of large genomics data, such as whole genome sequencing, whole exome sequencing, genome-wide methylation data, ultra-deep target sequencing and others. He/she will be involved in collaborative research with intramural and extramural researchers and several international consortia, with opportunities for a lead role in publications.</p>
<p><strong>Qualifications</strong> include a Ph.D. in bioinformatics, cancer genomics, tumor evolution, or related fields. An M.S. degree with several years of experience would be considered. Methodological and analytical skills and excellent written and oral (English) communication are required. Prior postdoctoral training experience in somatic genomics analyses with a history of publications that reflect superb writing skills is highly desirable. Job also requires organizational ability, attention to detail, initiative, flexibility, and an aptitude for multi-tasking, interpersonal relationships, and teamwork. U.S. citizenship is not a requirement.</p>
<p>The candidate will work in the Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics (DCEG) at NCI, NIH.</p>
<p>Salary is commensurate with research experience and accomplishments. Full federal benefits including salary, leave, health and life insurance, long-term care insurance, retirement, and savings plan (401k equivalent) will be provided. All employees of the federal government are subject to the conflict of interest statutes and regulations, including the Standards of Ethical Conduct. Find <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=45&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1420&amp;sys_contentid=302687" sys_contentid="302687" inlinetype="rxhyperlink" sys_variantid="1420" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="302687" sys_dependentvariantid="1420" sys_relationshipid="7179795">additional information on&nbsp;DCEG</a>.</p>
<p><strong>To apply</strong>:<br />Please send a cover letter, curriculum vitae, bibliography, statement of research interests, and the names/contact information&nbsp;of three references to <a href="mailto:landim@mail.nih.gov">Dr. Maria Teresa Landi</a>.</p>
<p>We are hoping to fill the position as quickly as possible; the position will remain open until the position is filled.</p>
<p style="text-align: center;">DHHS, NIH, and NCI are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="1134691" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Dry cleaning industry workers are exposed to tetrachloroethylene and other chlorinated solvents that are possibly carcinogenic to humans. In order to investigate the cancer mortality patterns associated with employment and exposures in the dry cleaning industry, NCI investigators conducted a retrospective cohort study of 5,369 workers who were members of a dry cleaning union in St Louis, Missouri between 1948 and 1978 for at least one year.</p>
<p>In a recently completed 22-year follow-up of the cohort, workers experiencing high solvent exposures were at increased risk of death from cancers of the bladder and kidney, hematologic malignancies, and heart disease.</p>
<p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=983937&amp;sys_revision=10&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="983937" sys_dependentvariantid="1965" sys_relationshipid="7202105">Dr. Mark Purdue</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=418935&amp;sys_revision=15&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="418935" sys_dependentvariantid="1418" sys_relationshipid="7202106">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1134698" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1134703" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7233955">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img alt="Field workers collects biospecimens, including blood, urine, buccal cells, and house dust" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=1134703&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Collecting biospecimens for use in the BEEA Study</p>
</div>
</figcaption>
</figure>
</div>
<p>Agricultural exposures including pesticides, endotoxins, and diesel exhaust have been associated with risk of various cancers, although the biological mechanisms underlying these associations are generally not well understood. To address this gap, DCEG investigators initiated the Biomarkers of Exposure and Effect in Agriculture (BEEA) study within the Agricultural Health Study, a cohort that includes pesticide applicators in Iowa and North Carolina.&nbsp;Within BEEA,&nbsp;they collected biospecimens (blood, urine, buccal cells, and house dust) and updated information about pesticide use and other agricultural exposures from over 1,600 farmers/pesticide applicators.</p>
<p>The BEEA study biorepository will be a resource for future cross-sectional molecular epidemiologic investigations to elucidate the biological mechanisms underlying associations between agricultural exposures and risk of cancer and other chronic diseases. For example, within BEEA investigators are studying&nbsp;agricultural exposures that might influence the risk of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance, which was previously shown to be in excess in the Agricultural Health Study.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=1135987&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1135987" sys_folderid="" sys_relationshipid="7233956">BEEA Study Publications</a></p>
<p>For more information on BEEA, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=917441" sys_contentid="917441" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="917441" sys_variantid="1965" sys_folderid="" sys_relationshipid="7202125">Dr. Jonathan Hofmann</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=418935" sys_contentid="418935" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="418935" sys_variantid="1418" sys_folderid="" sys_relationshipid="7202126">Occupational and Environmental Epidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1135394" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Sherlock-<em>lung</em> is a comprehensive study that aims to trace lung cancer etiology in never smokers by analyzing genomic data in tumor and surrounding lung tissue. Whole genome sequencing, whole transcriptome, and genome-wide methylation data will be analyzed to identify exogenous and endogenous processes involved in lung tumorigenesis. Analysis of the tumor microenvironment, clonal evolution, and circulating tumor DNA will be conducted in a subgroup of the cases. The molecular landscape will be integrated with histological and radiological features in order to develop a more refined classification of lung cancer in never smokers and provide insights into prognosis and treatment strategies.</p>
<p>Sherlock-<em>lung</em> will include 2,500 never smoker lung cancer patients, a subset (n=~500) with &ldquo;special exposures,&rdquo; such as coal, radon, asbestos, air pollution, and microbial infection. The remaining ~2000 cases will come from the &ldquo;general population,&rdquo; with unknown exposures to lung cancer risk factors.</p>
<p>For more information about Sherlock-<em>lung</em>, please contact <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/landi-maria">Maria Teresa Landi, M.D., Ph.D.</a></p>
<p><a href="https://dceg.cancer.gov/about/organization/programs-hgp/iteb/research">Integrative Tumor Epidemiology Branch - Research Areas</a></p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1135726" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<ol>
<li>Jones RR, VoPham T, Sevilla B, Airola M, Flory A, Deziel NC, Laden F, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/30302014">Verifying locations of historical environmental releases of dioxin-like compounds from facilities in the United States and implications for epidemiologic inference</a></u>. <em>J Expo Sci Environ Epidemiol</em> Oct 2018.</li>
<li>Gonzales FA, Jones RR, Deardorff J, Windham GC, Hiatt RA, Kushi LH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/26908165">Neighborhood deprivation, race/ethnicity, and urinary metal concentrations among young girls in California</a></u>. <em>Environ Int</em> Feb 2016.</li>
<li>Terzian AS, Younes N, Opoku J, Hubbard J, Happ LP, Jones RR, Kunmar P, Castel AD, Greenberg AE. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/29603112">Identifying spatial variation along the HIV care continuum: The role of distance to care on retention and viral suppression</a></u>. <em>AIDS Behav</em> Sept 2018.</li>
<li>Deziel NC, Nuckols JR, Jones RR, Graubard B, De Roos AJ, Colt JS, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC5330683">Comparison of industrial emissions and carpet dust concentrations of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans in a multi-center U.S. study</a></u>. <em>Sci Tot Environ</em> Feb 2017.</li>
<li>Zirkle KW, Nolan BT, Jones RR, Weyer PJ, Ward MH, Wheeler DC. <span><a href="https://www.ncbi.nlm.nih.gov/pubmed/27277210">Assessing the relationship between groundwater nitrate and animal feeding operations in Iowa</a></span>. <em>Sci Total Environ</em> Oct 2016.</li>
<li>Baris D, Waddell R, Beane Freeman LE, Schwenn M, Colt JS, Ayotte J, Ward MH, Nuckols J, Schned A, Jackson B, Clerkin C, Rothman N, Moore LE, Taylor A, Robinson G, Hosain MG, Armenti KR, McCoy R, Samanic C, Hoover RN, Fraumeni JF, Johnson A, Karagas MR, Silverman DT. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/27140955">Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic</a></u>. <em>J Natl Cancer Inst</em> Sept 2016.</li>
<li>DellaValle CT, Deziel NC, Jones RR, Colt JC, De Roos AJ, Cerhan JR, Cozen W, Severson RK, Flory AR, Morton LM, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/26573845">Polycyclic aromatic hydrocarbons: determinants of residential carpet dust levels and risk of non-Hodgkin lymphoma</a></u>. <em>Cancer Causes Control</em>, Nov 2016.</li>
<li>Wheeler DC, Nolan BT, Flory AR, DellaValle CT, Ward MH. <u><a href="https://www.sciencedirect.com/science/article/pii/S0048969715304241">Modeling groundwater nitrate concentrations in private wells in Iowa</a></u>. <em>Science Tot Environ</em>, Dec 2015.</li>
<li>Kirrane E. Bowman C, Davis JA, Hoppin JA, Blair A, Chen H, Patel M, Sandler DP, Tanner CM, Vinikoor-Imler L, Ward MH, Luben TJ, Kamel F. <span><a href="https://www.ncbi.nlm.nih.gov/pubmed/25951420">Associations of ozone and PM2.5 concentrations with Parkinson's disease among participants in the Agricultural Health Study</a></span><u>.</u> <em>J Occup Environ Med</em>, May 2015.</li>
<li>Jones RR, DellaValle CT, Flory AR, Nordan A, Hoppin JA, Hofmann JN, Chen H, Giglierano J, Lynch CF, Beane Freeman LE, Rushton G, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25292160">Accuracy of residential geocoding in the Agricultural Health Study</a></u>. <em>Int J Health Geographics</em> Oct 2014.</li>
<li>Jones RR, Yu C-Y, Nuckols JR, Cerhan JR, Airola M, Ross JA, Robien K, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/25038451">Farm residence and lymphohematopoietic cancers in the Iowa Women&rsquo;s Health Study</a></u>. <em>Environ Res</em> July 2014.</li>
<li>DellaValle CT, Wheeler DC, Deziel NC, De Roos AJ, Cerhan JR, Cozen W, Severson RK, Flory AR, Locke SJ, Colt JS, Hartge P, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/23952055">Environmental determinants of polychlorinated biphenyl concentrations in residential carpet dust</a></u>. <em>Environ Sci Technol</em> Aug 2013.</li>
<li>Pronk A, Nuckols JR, De Roos AJ, Airola M, Colt JS, Cerhan JR, Morton L, Cozen W, Severson R, Blair A, Cleverly D, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/23433489">Residential exposure to industrial combustion facilities and risk of non-Hodgkin lymphoma: a case-control study</a></u>. <em>Environ Health</em>, Feb 2013.</li>
<li>Deziel NC, Nuckols JR, Colt JS, De Roos AJ, Pronk A, Gourley C, Severson RK, Cozen W, Cerhan JR, Hartge P, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/22832089">Determinants of polychlorinated dibenzo<em>-p</em>-dioxins and polychlorinated dibenzofurans in house dust samples from four areas of the United States</a></u>. <em>Sci Total Environ</em>, Sept 2012.</li>
<li>Wheeler DC, Waller LA, Cozen W, Ward MH. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22682442">Spatial-temporal analysis of non-Hodgkin lymphoma risk using multiple residential locations</a>. <em>Spatial Spatiotemporal Epidemiol</em>, June 2012.</li>
<li>Aschebrook-Kilfoy B, Heltshe<sup> </sup>SL, Nuckols JR, Sabra<sup> </sup>MM, Shuldiner<sup> </sup>AR,<sup> </sup>Mitchell<sup> </sup>BD, Airola<sup> </sup>M, Holford<sup> </sup>TR, Zhang<sup> </sup>Y, Ward<sup> </sup>MH. <u><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305600/">Modeled nitrate levels in well water supplies and prevalence of abnormal thyroid conditions among the Old Order Amish in Pennsylvania</a></u>. <em>Environ Health</em> Feb 2012.</li>
<li>Nuckols JR, Beane Freeman LE, Lubin JH, Airola MS, Baris D, Ayotte JD, Taylor A, Paulu C, Karagas MR, Colt J, Ward MH, Huang AT, Bress W, Cherala C, Silverman DT, Cantor KP. <span><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230387/">Estimating water supply arsenic levels in the New England Bladder Cancer Study</a></span>. <em>Environ Health Perspect</em> Sept 2011.</li>
<li>Gunier RB, Ward MH, Airola M, Bell EM, Colt J, Nishioka M, Buffler PA, Reynolds P, Rull R, Hertz A, Metayer C, Nuckols JR. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/21330232">Determinants of agricultural pesticide concentrations in carpet dust in California</a></u>. <em>Environ Health Perspect</em> July 2011.</li>
<li>De Roos AJ, Davis S, Colt JS, Blair A, Airola M, Severson R, Cozen W, Cerhan JR, Hartge P, Nuckols JR, Ward MH. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/19840879">Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma</a></u>. <em>Environ Research</em> Jan 2010.</li>
<li>Savitz D, Alaee M, Dominici F, Ramachandran G, Seibert WG, Stayner L, Waller LA, Ward MH, Webster TF, Woskie S. Institute of Medicine Committee Report. <u><a href="https://www.nap.edu/catalog/12059/the-utility-of-proximity-based-herbicide-exposure-assessment-in-epidemiologic-studies-of-vietnam-veterans">Utility of Proximity-based Herbicide Exposure Assessment in Epidemiologic Studies of Vietnam Veterans</a></u>. Washington, DC: <em>The National Academies Press</em> 2008</li>
<li>Nuckols JR, Gunier RB, Riggs P, Miller R, Reynolds P, Ward MH<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867967/">. Linkage of the California Pesticide Use Reporting database with spatial land use data for exposure assessment</a>. <em>Environ Health Perspect</em> May 2007.</li>
<li>Ward MH, Wartenberg D. <u><a href="https://academic.oup.com/aje/article/164/3/208/70090">Invited Commentary: On the road to improved exposure assessment using GIS</a></u>. <em>Am J Epidemiol</em> June 2006.</li>
<li>Ward MH, Lubin J, Giglierano J, Wolter C, Colt JS, Bekiroglu N, Camann D, Hartge P, Nuckols JR. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/16759991">Proximity to crops and residential exposure to agricultural herbicides in Iowa</a></u>. <em>Environ Health Perspect</em> June 2006.</li>
<li>Maxwell SK, Nuckols JR, Ward MH. <u><a href="https://pubs.er.usgs.gov/publication/70030442">A method for mapping corn using the US Geological Survey 1992 National Land Cover Dataset</a></u>. <em>Computers and Electronics in Agriculture</em>, 2006.</li>
<li>Ward MH, Nuckols JR, Giglierano J, Bonner MR, Wolter C, Airola M, Mix W, Colt JS, Hartge P. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/15951673">Positional accuracy of two methods of geocoding.&nbsp;</a></u><em>Epidemiology</em> July 2005.</li>
<li>Boscoe FP, Ward MH, Reynolds P. 2004. <span><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539245/">Current practices in spatial analysis of cancer data: Data sources and data characteristics for geographic studies of cancer</a></span>. <em>Int J Health Geogr</em> Dec 2004.</li>
<li>Nuckols JR, Ward MH, Jarup L. <u><a href="https://www.ncbi.nlm.nih.gov/pubmed/15198921">Using GIS for exposure assessment in environmental epidemiology studies</a></u>. <em>Environ Health Perspect</em> April 2004.</li>
<li>Maxwell SK, Nuckols JR, Ward MH, Hoffer RM. <u><a href="https://pubs.er.usgs.gov/publication/70026878">An automated approach to mapping corn from Landsat imagery</a></u>. <em>Computers and Electronics in Agriculture</em> 2004.</li>
<li>Colt JS, Baris D, Clark SF, Karagas M, Ayotte JD, Ward M, Nuckols JR, Cantor KP, Silverman DT. <span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Sampling+private+wells+in+past+homes+to+estimate+lifetime+arsenic+exposure%3A+A+methodologic+study+in+New+England.">Sampling private wells in past homes to estimate lifetime arsenic exposure: A methodologic study in New England. </a></span> <em>J Environ Epidemiol Expos Anal</em> Aug 2002.</li>
<li>Ward MH, Nuckols JR, Weigel SJ, Maxwell SK, Cantor KP, Miller RS. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1637858/">Identifying populations potentially exposed to agricultural pesticides using remote sensing and a geographic information system.</a> <em>Environ Health Perspect</em> Jan 2000.</li>
</ol>
</div>]]></content>
  </row>
  <row para_id="1135987" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><p>Hofmann JN, Beane Freeman LE, Lynch CF, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26555155">The Biomarkers of Exposure and Effect in Agriculture (BEEA) Study: Rationale, design, methods, and participant characteristics</a>. <em>J Toxicol Environ Health A</em> 2015; Epub Nov 9 2015.&nbsp;</p>
<p>Lerro CC, Beane Freeman LE, DellaValle C, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28775130">Occupational pesticide exposure and subclinical hypothyroidism among male pesticide applicators</a>.&nbsp; <em>Occup and Environ Med</em> 2018; Epub Aug 3, 2017.</p>
<p>Hofmann JN, Shiels MS, Friesen MC, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29055885">Industrial hog farming is associated with altered circulating immunological markers</a>. <em>Occup and Environ Med</em> 2018; Epub Oct 21, 2017.&nbsp;</p>
<p>Stapleton EM, O&rsquo;Shaughnessy PT, Locke SJ, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29286870">A task-based analysis of black carbon exposure in Iowa farmers during harvest</a>. <em>J&nbsp;Occup and Environ Hyg</em> 2018 April 15.</p></div>]]></content>
  </row>
  <row para_id="1138849" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<h3><strong>Non-Proprietary Software Transfer Agreement</strong><br />Provider: National Institutes of Health (NIH), National Cancer Institute (hereinafter "NCI")</h3>
<p>By accepting Software, Recipient agrees to the terms of this Agreement.</p>
<p>The Software transferred under this agreement was created by Federal Government employees in the course of official duties. Transfer of Software to Recipient does not constitute endorsement by the NCI of the Recipient or any product, service or company and no endorsement should be inferred. SOFTWARE IS NOT INTENDED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS.</p>
<p><b>This is a trial version of the software</b>. The SubHMM R Package&nbsp;may be updated periodically as new data or research becomes available.</p>
<p>Software is supplied AS IS, without any accompanying services or improvements from NIH. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.</p>
<p>All risk as to quality and performance of Software is with Recipient. In no event will the United States Government or NCI be liable to Recipient for damages arising out of the use or inability to use Software, including but not limited to loss of data or data being rendered inaccurate or losses sustained by Recipient or third parties.</p>
</div>]]></content>
  </row>
  <row para_id="1139544" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2090" sys_dependentid="1138974" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7360759">
<figure class="image-right-small centered-set">
<div class="centered-element"><img alt="Kelly Bolton" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=1117650&amp;sys_siteid=475&amp;sys_contentid=1138974&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p><strong>Years at DCEG:</strong> 2007-2011<br /><strong>DCEG title:</strong> Predoctoral Fellow<br /><strong>Current organization:</strong> Memorial Sloan Kettering Cancer Center<br /><strong>Current title:</strong> Instructor, Leukemia<br /> <br /><em><strong>Who was your mentor at DCEG? What did you work on?</strong></em><br />My mentors were <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" sys_contentid="1004366" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1004366" sys_variantid="1965" sys_relationshipid="7360754">Montserrat Garcia-Closas, M.D., Dr.P.H.</a>&nbsp;and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=38&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349630" sys_contentid="349630" inlinetype="rxhyperlink" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349630" sys_variantid="1965" sys_relationshipid="7360755">Stephen J. Chanock, M.D.</a> I worked on how germline genetics influences ovarian cancer survival. I also worked a lot with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349622" sys_contentid="349622" inlinetype="rxhyperlink" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349622" sys_variantid="1965" sys_relationshipid="7360756">Mitchell Gail, M.D.</a>, Mark Sherman, M.D. (former investigator, DCEG), and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=31&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349627" sys_contentid="349627" inlinetype="rxhyperlink" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349627" sys_variantid="1965" sys_relationshipid="7360757">Ruth Pfeiffer, Ph.D.</a></p>
<p><em><strong>What is your current position?</strong></em><br />I am an instructor in the Leukemia Department at Memorial Sloan Kettering Cancer Center. I do research characterizing the early genetic events leading to malignancy and the environmental exposures that promote carcinogenesis.</p>
<p><em><strong>How do you apply the skills you developed at DCEG in your current job?</strong></em><br />I learned how to lead a multi-center project and developed a solid background in data management, statistics, and genetic epidemiology. I also learned about how to work in an interdisciplinary team and foster collaborative science.</p>
<p><em><strong>Do you have any memories from your fellowship that you would like to share?</strong></em><br />On my first day at DCEG, I didn&rsquo;t have a computer and Montse gave me one of her own computers to use. She spent an hour of her own time setting it up for me, making sure I had a good monitor, etc. It made me feel so valued. Here was an incredible scientist, spending her time setting up my monitor!</p>
<p>Stephen planned my wedding, literally. After I got engaged to my husband, who I met at NIH in the Cloisters, I told Stephen I was thinking of trying to get married at the Cloisters. He made a grimace. He emailed me and my fianc&eacute;e some suggestions, including a venue in Italy where we eventually were married. Thanks, Stephen, for saving my wedding!</p>
<p><em><strong>What do you do in your free time?</strong></em><br />I entertain my 2 year-old and 3.5 year-old sons.</p>
<p><em><strong>Do you have any advice for current or future DCEG fellows?</strong></em><br /> Work hard. Be brave. Foster personal relationships with the people you work with and be respectful to them.</p>
</div>]]></content>
  </row>
  <row para_id="1140233" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide; most cases result from chronic hepatitis virus infection. To address scientific questions concerning these infections,&nbsp;DCEG investigators conduct interdisciplinary collaborative studies that integrate epidemiology, virology and human genetics. One such effort led to the discovery of the interferon lambda 4 (<em>IFNL4</em>) gene (Prokunina-Olsson et al., 2013). The&nbsp;<em>IFNL4</em> genotype plays a key role in hepatitis C virus (HCV) infection, as well as in other conditions (<em>IFNL4</em> Phenotypes Research Area). Investigators in the Infections and Immunoepidemiology Branch (IIB) attempt to translate our scientific findings for clinical and public health benefits. Currently,&nbsp;they are examining the role of <em>IFNL4</em> genotype in response to treatment with highly effective, but costly, direct-acting antiviral agents for treatment of HCV.</p>
<p>Hepatitis D virus (HDV) is the most pathogenic hepatitis virus and it requires hepatitis B virus (HBV) for its life cycle. Compared to individuals infected with HBV alone, HBV/HDV coinfected people have an even higher incidence of HCC. New therapeutic agents are in clinical trials for treatment of chronic hepatitis D, therefore, studies of HDV infection are timely. IIB investigators conduct studies of HDV infection in the United States (Mahale et al., 2018) and Africa (Mahale et al., 2019).</p>
<p>In addition to these activities, IIB investigators conduct surveillance studies of the effect of hepatitis virus infection on HCC rates in the United States.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349689" sys_contentid="349689" inlinetype="rxhyperlink" sys_relationshipid="7271021" sys_dependentvariantid="1965" sys_dependentid="349689" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_variantid="1965">Thomas O&rsquo;Brien</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" sys_contentid="419183" inlinetype="rxhyperlink" sys_relationshipid="7271022" sys_dependentvariantid="1418" sys_dependentid="419183" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_variantid="1418">Infections and Immunoepidemiology Branch - Research Areas</a></p>
<h2>References</h2>
<p>Mahale, P, P Aka, X Chen, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30661282">Hepatitis D virus infection and hepatocellular carcinoma in The Gambia</a>.<em> J Viral Hepat</em> 2019 Jan 20. doi: 10.1111/jvh.13065. Epub ahead of print.</p>
<p>Mahale P, Aka PV,2, Chen X, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29800369">Hepatitis D viremia among injection drug users in San Francisco</a>. <em>J Infect Dis</em> 2018 May 25; doi: 10.1093/infdis/jiy157.</p>
<p>Prokunina-Olsson L, Muchmore B, Tang W, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23291588">A variant upstream of <em>IFNL3</em> (IL28B) creating a new interferon gene <em>IFNL4</em> is associated with impaired clearance of hepatitis C virus</a>. <em>Nat Genet</em> 2013 Feb; doi: 10.1038/ng.2521. Epub 2013 Jan 6.</p>
<p></p>
</div>]]></content>
  </row>
  <row para_id="1140677" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>A collaboration led by DCEG investigators in the Infections and Immunoepidemiology Branch (IIB) and the Laboratory of Translational Genomics (LTG) led to the discovery of the interferon lambda 4 <em>(IFNL4</em>) gene (Prokunina-Olsson L, Muchmore B, Tang W, et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23291588">A variant upstream of <em>IFNL3</em> (IL28B) creating a new interferon gene <em>IFNL4</em> is associated with impaired clearance of hepatitis C virus</a>. <em>Nat Genet</em> 2013). Recent epidemiological studies have associated <em>IFNL4</em> genotype with hepatic inflammation and fibrosis, which are precursors of hepatocellular carcinoma (HCC), as well as mucinous ovarian carcinoma, a rare cancer subtype of uncertain etiology. Evidence of strong evolutionary selection against the <em>IFNL4-&Delta;G</em> allele suggests <em>IFNL4</em> could impact diseases besides HCV infection; recent studies in mice demonstrated that the interferon lambda family plays an important role in a wide range of infections. Taken together, these findings make <em>IFNL4</em> a candidate gene for many infections and conditions.</p>
<p>IIB&nbsp;researchers have initiated investigations to examine the phenotypic range of the <em>IFNL4</em> genotype, including studies of: hepatic inflammation and fibrosis, which are precursors of hepatocellular carcinoma; mucinous ovarian carcinoma; opportunistic infections and malignancies; and neuroinvasive West Nile virus infection. In addition,&nbsp;they plan a phenome-wide association study for the <em>IFNL4</em> genotype among patients enrolled in a large managed care organization.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349689" inlinetype="rxhyperlink" sys_contentid="349689" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="349689" sys_dependentvariantid="1965" sys_relationshipid="7275379" sys_variantid="1965">Thomas O&rsquo;Brien</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=22&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=419183" inlinetype="rxhyperlink" sys_contentid="419183" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7275380" sys_variantid="1418">Infections and Immunoepidemiology Branch - Research Areas</a></p>
</div>]]></content>
  </row>
  <row para_id="1140727" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><p>The Epstein-Barr virus (EBV) Screening for the Early Detection of Nasopharyngeal Carcinoma (NPC) in China demonstration project includes a group of approximately 30,000 men and women ages 35-69 recruited into the active screening arm of a community-randomized trial to evaluate the impact of EBV-based antibody screening on NPC mortality rates. As part of this effort, NCI is collaborating on a substudy to evaluate the sensitivity and specificity of endoscopy versus MRI for the detection of NPC and the utility of nasopharynx viral load testing to triage EBV antibody positive individuals. Approximately 1,400 individuals who participated in the larger EBV screening program are included in this effort. Participants undergo endoscopy and MRI procedures. When lesions are observed by either method, biopsy specimens are collected for pathological evaluation. Blood and nasopharyngeal swab samples are also collected from participants.</p>
<p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=349694&amp;sys_revision=17&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="349694" sys_dependentvariantid="1965" sys_relationshipid="7275781">Allan Hildesheim</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=419183&amp;sys_revision=23&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7275782">Infections and Immunoepidemiology Branch - Research Areas</a></p></div>]]></content>
  </row>
  <row para_id="1140986" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2066" sys_dependentid="1140989" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7280211">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=1140989&amp;sys_command=edit" alt="connect cohort logo" /><!--Comment--></div>
</figure>
</div>
<p>The Connect study is a new prospective cohort of 200,000 adults in the United States designed to further investigate the etiology of cancer and its outcomes, which may inform new approaches in precision prevention and early detection. The new cohort will capitalize on research innovations to advance the field of cancer epidemiology and prevention including:</p>
<ol>
<li>New technologies (e.g., tracking and sensors to measure behavior and environment);</li>
<li>Large-scale analyses of the genome, epigenome, transcriptome, proteome, metabolome, microbiome;</li>
<li>Molecular profiling of tumors and precursor lesions to study the natural history of cancer and its etiologic heterogeneity.</li>
</ol>
<p><strong>Overview of Study Setting and Design</strong></p>
<div sys_dependentvariantid="2066" sys_dependentid="1141204" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7280212">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=1141204&amp;sys_command=edit" alt="Connect study design" longdesc="/https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=2068&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=1141204&amp;sys_command=edit" /><!--Comment--> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=302263&amp;sys_siteid=475&amp;sys_contentid=1141204&amp;sys_command=edit" target="_blank" class="article-image-enlarge no-resize" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1141204">Enlarge</a></div>
</figure>
</div>
<p>The Connect study will be conducted within a set of integrated health care systems, with electronic medical records (EMRs), a passive follow-up system that is both cost effective and thorough. Consented participants ages 40-65 with no history of invasive cancer other than non-melanoma skin cancer from participating health systems will complete an online questionnaire at baseline and periodically throughout the duration of follow-up. Passive follow-up via tumor registries and EMRs will provide outcome information for cancers and their precursors. Blood, urine and saliva samples will be collected at baseline and repeatedly during follow-up in local clinics. Additional biological specimens including fecal and tissue specimens will be collected. This state-of-the-art cohort will be built with an efficient, flexible and integrated infrastructure that makes the most of modern interoperability standards in order to serve as a research workhorse for future generations of scientists at the NCI and across the extramural research community.</p>
<p>The Connect study is supported by the <a href="https://irp.nih.gov/">NIH Intramural Research Program</a>.</p>
<p>Initial contracts were awarded to the following institutions:</p>
<ul>
<li>HealthPartners, Minneapolis, MN</li>
<li>Henry Ford Health System, Detroit, MI</li>
<li>Kaiser Permanente Colorado, Denver, CO</li>
<li>Kaiser Permanente Hawaii, Honolulu, HI</li>
<li>Kaiser Permanente Northwest, Portland, OR</li>
<li>Marshfield Health Clinic, Marshfield, WI</li>
<li>Sanford Health, Sioux Falls, SD</li>
<li>University of Chicago Medical Center, Chicago, IL</li>
</ul>
<ul>
<li>NORC at the University of Chicago, Chicago, IL</li>
</ul>
<p>For more information, contact Michelle Brotzman at&nbsp;<a href="mailto:EpiCohortNCI@mail.nih.gov">EpiCohortNCI@mail.nih.gov</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1141197" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), National Institutes of Health (NIH) is recruiting a staff scientist in the Integrative Tumor Epidemiology Branch (ITEB).&nbsp;</p>
<p>ITEB conducts large-scale, international epidemiological research on cancer etiology and progression through integrative analyses of risk factors and tissue profiling to inform prevention and clinical strategies.&nbsp; ITEB develops methods to support this cutting-edge research, integrating molecular pathology, somatic and germline genomics, tissue imaging, and epidemiology; trains pre- and postdoctoral fellows in integrative epidemiologic research; and participates in and contributes to national and international organizations and consortia to promote integrative tumor epidemiologic research.&nbsp; All ITEB studies are highly interdisciplinary.</p>
<p>The staff scientist, working under the direction of a senior investigator within ITEB, will have responsibilities for all aspects of two major studies of lung cancer and melanoma and other related projects. Specific duties will include assisting with study design (developing protocols, questionnaires, tools for exposure assessment, specimen and imaging collection procedures), management (human subjects&rsquo; approvals, contracts and purchasing orders, data coding and cleaning, manipulating and harmonizing data from a variety of sources, specimens tracking, communication with International investigators to monitor study progress, organizing and coordinating meetings), basic statistical analysis, and preparation of reports for presentation or publication. Some international travel is required.</p>
<p>The successful candidate must hold a doctoral degree or equivalent in a relevant discipline (e.g., epidemiology or public health).&nbsp; Experience in field-based epidemiological research would be an asset. Experience in genetics and genomics studies would also be an asset.&nbsp;The position requires organizational abilities, attention to detail, initiative, and an aptitude for multi-tasking. The ability to communicate effectively in speech and in writing is essential, as demonstrated in presentations and publications. Salary is commensurate with experience.</p>
<p>Interested individuals should send a cover letter, curriculum vitae, brief summary of research interests and experience, and two letters of reference to:</p>
<p style="text-align: center;"><br />Ms. Sadie Holmes-Lillie<br />Division of Cancer Epidemiology and Genetics, National Cancer Institute<br />&nbsp;9609 Medical Center Drive, Rm. 7E202 MSC 9774<br />Bethesda, MD 20892<br />E-mail: <a href="mailto:ITEBSTAFFSCIENTIST@nih.gov">ITEBSTAFFSCIENTIST@nih.gov</a></p>
<p style="text-align: center;"><br />Closing date for applications is&nbsp;September 30, 2019</p>
<p style="text-align: center;">DHHS, NIH, and NCI are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
  <row para_id="1141199" langcode="en">
    <content><![CDATA[<div class="rxbodyfield"><p>DCEG investigators in the Infections and Immunoepidemiology Branch (IIB) have documented unprecedented increases of noncardia gastric cancer among younger generations in the U.S. Analyses of incidence trends reveal a coherent set of features that suggest autoimmune gastritis may be the underlying cause, including predominance among non-Hispanic whites, women, higher-income groups, and gastric corpus-localization. Additional efforts are underway examining large-scale medical record databases to assess magnitude of gastric cancer associations with autoimmune conditions and estimate population attributable risk. Follow-up studies are planned to evaluate potential biomarkers of risk in prospective cohorts.</p>
<p>For more information, contact <a href="/Rhythmyx/assembler/render?sys_contentid=349628&amp;sys_revision=20&amp;sys_variantid=1965&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="349628" sys_dependentvariantid="1965" sys_relationshipid="7279601">Charles Rabkin</a>.</p>
<p><a href="/Rhythmyx/assembler/render?sys_contentid=419183&amp;sys_revision=26&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="419183" sys_dependentvariantid="1418" sys_relationshipid="7279602">Infections and Immunoepidemiology Branch - Research Areas</a></p></div>]]></content>
  </row>
  <row para_id="1141200" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Investigators in the Infections and Immunoepidemiology Branch and the Metabolic Epidemiology Branch of DCEG are undertaking a joint effort to&nbsp;catalog comprehensively bacterial genetic and epigenetic variation potentially related to long-term outcomes of infection. Isolates from patients with gastric cancer or advanced premalignant lesions are compared to controls with benign infection (superficial gastritis) from the same geographic area. The study goal is to sequence 1000 strains representing both high and low gastric cancer risk populations worldwide, with over 300 isolates from 16 different countries completed to date. An international team of experts is collaborating on analyses of these complex data to identify associations with the gastric carcinogenesis cascade.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349628" sys_dependentvariantid="1965" sys_relationshipid="7313336" sys_variantid="1965">Charles Rabkin</a>, Infections and Immunoepidemiology Branch <br />or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1052539" sys_contentid="1052539" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1052539" sys_dependentvariantid="1965" sys_relationshipid="7313337" sys_variantid="1965">M. Constanza Camargo</a>, Metabolic Epidemiology Branch.</p>
</div>]]></content>
  </row>
  <row para_id="1141836" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Several DCEG scientists will present their research at the AACR Annual Meeting in Atlanta, Georgia, between March 29&nbsp;- April 03, 2019. A full list of abstracts can be found on the <a href="http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=136#.WrkT4PnwZaQ">AACR website</a>.</p>
<p><a href="https://dcegpreview.cancer.gov/about/staff-directory/biographies/A-J/lavigne-jackie">Jackie Lavigne, Ph.D., M.P.H.</a>, Chief of the Office of Education, will be available to answer questions about DCEG fellowship opportunities at the <em><strong>NCI exhibit booth (#2111) on Monday, April&nbsp;1 from 9:00 AM - 11:00 AM.</strong></em></p>
<p>Unless otherwise noted, all events will take place in the Georgia World Conference Center.</p>
<h4><span style="text-decoration: underline;">Oral Presentations</span></h4>
<table class="table-default" style="width: 100%;"><caption>Friday, March 29</caption>
<tbody>
<tr>
<th style="width: 25%;" scope="col">Presenter</th>
<th style="width: 35%;" scope="col">Presentation Title</th>
<th style="width: 23%;" scope="col">Time</th>
<th style="width: 17%;" scope="col">Location</th>
</tr>
<tr>
<td>Ruth Pfeiffer</td>
<td>Educational Session:&nbsp;<a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/1222 ">Population risk stratification: Integrating biomarkers in cancer risk assessment</a></td>
<td>6:45 PM - 7:10 PM</td>
<td>Room A313</td>
</tr>
</tbody>
</table>
<table class="table-default" style="width: 100%;"><caption>Saturday, March 30</caption>
<tbody>
<tr>
<th style="width: 244.53px;" scope="col">Presenter</th>
<th style="width: 343.96px;" scope="col">Presentation Title</th>
<th style="width: 224.66px;" scope="col">Time</th>
<th style="width: 165.01px;" scope="col">Location</th>
</tr>
<tr>
<td style="width: 244.53px;">Rashmi Sinha</td>
<td style="width: 343.96px;">Methods Workshop:&nbsp;<a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/1021 ">Moving microbiome research into population studies: Need for standardization</a></td>
<td style="width: 224.66px;">1:00 PM - 1:25 PM</td>
<td style="width: 165.01px;">Room&nbsp;B304&nbsp;</td>
</tr>
</tbody>
</table>
<table class="table-default" style="width: 100%;"><caption>Sunday, March 31
<p></p>
<p><span>Special Symposium</span><span>:<span class="Apple-converted-space">&nbsp;</span></span><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1279">Li-Fraumeni Syndrome and p53: Celebrating Gold and Ruby Anniversaries of Paradigm Models of Cancer Predisposition and Tumor Suppression</a>,&nbsp;<span>1:00 PM - 3:00 PM, Room A313</span>&nbsp;</p>
</caption>
<tbody>
<tr>
<th style="width: 244.53px;" scope="col">Presenter</th>
<th style="width: 343.96px;" scope="col">Presentation Title</th>
<th style="width: 224.66px;" scope="col">Time</th>
<th style="width: 165.01px;" scope="col"><span>Location</span></th>
</tr>
<tr>
<td style="width: 244.53px;">Parichoy&nbsp;Pal Choudhury</td>
<td style="width: 343.96px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/7921 ">Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries</a></td>
<td style="width: 224.66px;">3:35 PM - 3:50 PM</td>
<td style="width: 165.01px;">
<p>Room B401</p>
</td>
</tr>
<tr>
<td style="width: 244.53px;">Stella Koutros</td>
<td style="width: 343.96px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/9407 ">Integrative, targeted deep sequencing of bladder tumors reveals novel associations between cancer gene mutations and mutational signatures with major risk factors&nbsp;</a></td>
<td style="width: 224.66px;">3:50 PM - 4:05 PM</td>
<td style="width: 165.01px;">Room A402</td>
</tr>
</tbody>
</table>
<table class="table-default" style="width: 100%;"><caption>Monday, April 1</caption>
<tbody>
<tr>
<th style="width: 244.53px; text-align: center;"><strong>Presenter</strong></th>
<th style="width: 343.96px; text-align: center;"><strong>Presentation Title</strong></th>
<th style="width: 224.66px; text-align: center;"><strong>Time</strong></th>
<th style="width: 165.01px; text-align: center;"><strong>Location</strong></th>
</tr>
<tr>
<td style="width: 244.53px; text-align: left;">Maria Teresa Landi</td>
<td style="width: 343.96px; text-align: left;"><a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/1080">Sherlock-Lung:&nbsp; Tracing lung cancer mutational processes in never smokers</a></td>
<td style="width: 224.66px; text-align: left;">11:05 AM - 11:30 AM</td>
<td style="width: 165.01px; text-align: left;">Room B302&nbsp;</td>
</tr>
<tr>
<td style="width: 244.53px; text-align: left;"><span>Sharon Savage</span></td>
<td style="width: 343.96px; text-align: left;"><a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/8280">New NCI Collaborative Initiatives on Rare Tumors and RASopathies: Clinical, genetic, and epidemiologic approaches to cancer etiology</a></td>
<td style="width: 224.66px; text-align: left;"><span>1:45 PM - 2:45 PM</span></td>
<td style="width: 165.01px; text-align: left;"><span>Room A406&nbsp;</span></td>
</tr>
</tbody>
</table>
<p><strong><a href="https://www.abstractsonline.com/pp8/#!/6812/session/12">Molecular Epidemiology Working Group (MEG) Town Hall Meeting and Network Reception</a>, 6:30 PM - 8:00 PM, Room A315</strong></p>
<table class="table-default" style="width: 100%;"><caption>Tuesday, April 2</caption>
<tbody>
<tr>
<th style="width: 244.53px; text-align: center;"><strong>Presenter</strong></th>
<th style="width: 343.96px; text-align: center;"><strong>Presentation Title</strong></th>
<th style="width: 224.66px; text-align: center;"><strong>Time</strong></th>
<th style="width: 165.01px; text-align: center;"><strong>Location</strong></th>
</tr>
<tr>
<td style="width: 244.53px; text-align: left;"><span>Britton Trabert</span></td>
<td style="width: 343.96px; text-align: left;">Meet the Expert Session:&nbsp;Endogenous Hormones and Their Role in the Etiology of Gynecologic Cancers</td>
<td style="width: 224.66px; text-align: left;">10:30 AM - 11:00 AM</td>
<td style="width: 165.01px; text-align: left;">NCI Exhibit Booth - #2111</td>
</tr>
<tr>
<td style="width: 244.53px; text-align: left;"><span>Stephen Chanock</span></td>
<td style="width: 343.96px; text-align: left;"><a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/7674">Identification of enhancer elements at kidney cancer susceptibility loci using genome-wide approaches in which post-GWAS functional studies implicate the SWI/SNF DPF3 gene for the 14q24 risk locus&nbsp;</a></td>
<td style="width: 224.66px; text-align: left;">
<p>10:35 AM - 11:00 AM</p>
</td>
<td style="width: 165.01px; text-align: left;">Georgia Ballroom 1- Building C</td>
</tr>
</tbody>
</table>
<h4><span style="text-decoration: underline;">Poster Presentations</span></h4>
<table class="table-default" style="width: 100%;"><caption>Sunday,&nbsp;March 31<a id="PosterMar31"></a></caption>
<tbody>
<tr>
<th style="width: 35%;" scope="col">Session Title</th>
<th style="width: 30%;" scope="col">Time</th>
<th style="width: 35%;" scope="col">Poster Hall</th>
</tr>
<tr>
<td><a href="https://www.abstractsonline.com/pp8/#!/6812/session/891">Biomarkers in Risk and Outcomes</a></td>
<td>1:00 PM - 5:00 PM</td>
<td>Section 26</td>
</tr>
<tr>
<td><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1035">Gene Expression and the Tumor Microenvironment</a></td>
<td>1:00 PM - 5:00 PM</td>
<td>Section 6</td>
</tr>
<tr>
<td><a href="https://www.abstractsonline.com/pp8/#!/6812/session/889">Lifestyle Factors and Cancer Risk</a></td>
<td>1:00 PM - 5:00 PM</td>
<td>Section 27</td>
</tr>
</tbody>
</table>
<table class="table-default" style="width: 100%;"><caption>Monday, April 1<a id="PosterApril1"></a></caption>
<tbody>
<tr style="height: 17px;">
<th style="width: 35%; height: 17px;" scope="col">Session Title</th>
<th style="width: 30%; height: 17px;" scope="col">Time</th>
<th style="width: 35%; height: 17px;" scope="col">Poster Hall</th>
</tr>
<tr style="height: 17px;">
<td style="height: 17px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/852">Convergence Science for Biomarkers, Early Detection, and Diagnosis</a></td>
<td style="height: 17px;">8:00 AM - 12:00 PM</td>
<td style="height: 17px;">Section 30</td>
</tr>
<tr style="height: 15.86px;">
<td style="height: 15.86px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/895">Genetics and Genomics 1: Outcomes</a></td>
<td style="height: 15.86px;">8:00 AM - 12:00 PM</td>
<td style="height: 15.86px;">Section 26</td>
</tr>
<tr style="height: 15.86px;">
<td style="height: 15.86px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/893">Genetics and Genomics 2: Risk</a></td>
<td style="height: 15.86px;">8:00 AM - 12:00 PM</td>
<td style="height: 15.86px;">Section 27</td>
</tr>
<tr style="height: 17px;">
<td style="height: 17px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1010">Behavioral Science and Cancer Control</a></td>
<td style="height: 17px;">1:00 PM - 5:00 PM</td>
<td style="height: 17px;"><span>Section 27</span></td>
</tr>
<tr style="height: 17px;">
<td style="height: 17px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/955">Cancer and Inflammation</a></td>
<td style="height: 17px;">1:00 PM - 5:00 PM</td>
<td style="height: 17px;"><span>Section 23</span></td>
</tr>
</tbody>
</table>
<table class="table-default" style="width: 100%;"><caption>Tuesday, April 2<a id="PosterApril2"></a></caption>
<tbody>
<tr style="height: 15px;">
<th style="width: 35%; height: 15px;" scope="col">Session Title</th>
<th style="width: 30%; height: 15px;" scope="col">Time</th>
<th style="width: 35%; height: 15px;" scope="col">Poster Hall</th>
</tr>
<tr style="height: 30.5333px;">
<td style="height: 30.5333px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1008">Clinical Prevention, Early Detection, and Interception 1</a></td>
<td style="height: 30.5333px;">8:00 AM - 12:00 PM</td>
<td style="height: 30.5333px;">Section 28</td>
</tr>
<tr style="height: 15px;">
<td style="height: 15px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1263">Late-Breaking Research: Epidemiology</a></td>
<td style="height: 15px;">8:00 AM - 12:00 PM</td>
<td style="height: 15px;">Section 40</td>
</tr>
<tr style="height: 15px;">
<td style="height: 15px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/863">New Discoveries in Childhood Cancer</a></td>
<td style="height: 15px;">8:00 AM - 12:00 PM</td>
<td style="height: 15px;">Section 19</td>
</tr>
<tr style="height: 15px;">
<td style="height: 15px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1011">Science and Health Policy 2 / Regulatory Science and Policy </a></td>
<td style="height: 15px;">8:00 AM - 12:00 PM</td>
<td style="height: 15px;">Section 30</td>
</tr>
<tr style="height: 15px;">
<td style="height: 15px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/1050">Tumor Evolution and Heterogeneity 1</a></td>
<td style="height: 15px;">8:00 AM - 12:00 PM</td>
<td style="height: 15px;">Section 7</td>
</tr>
<tr style="height: 15px;">
<td style="height: 15px;"><a href="https://www.abstractsonline.com/pp8/#!/6812/session/894">Cancer Predisposition</a></td>
<td style="height: 15px;">1:00 PM - 5:00 PM</td>
<td style="height: 15px;">Section 26</td>
</tr>
</tbody>
</table>
<table class="table-default" style="width: 100%;"><caption>Wednesday, April 3<a id="PosterApril3"></a></caption>
<tbody>
<tr>
<th style="width: 35%;" scope="col">Session Title</th>
<th style="width: 30%;" scope="col">Time</th>
<th style="width: 35%;" scope="col">Poster Hall</th>
</tr>
<tr>
<td><a href="https://www.abstractsonline.com/pp8/#!/6812/session/890">Influences on Cancer Risk and Outcomes</a></td>
<td>8:00 AM - 12:00 PM</td>
<td>Section 26</td>
</tr>
</tbody>
</table>
</div>]]></content>
  </row>
  <row para_id="1142671" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The new Data Science Group recently created within the NCI Division of Cancer Epidemiology and Genetics (DCEG) is opening postdoctoral positions in research projects ranging from distributed machine learning to computational pathology and population science. These are technology and data-intensive projects that explore computational solutions at the consumer-facing intersection of cloud and web computing.</p>
<p>DCEG is involved in cohort studies, both national and international, that involve hundreds of thousands of participants. The data types are constantly evolving and range from genomics and digital pathology to environmental and behavioral signals. The technology landscape is evolving just as fast, with wearable sensing and consumer-facing health services creating entirely new opportunities to research and develop precision prevention of cancer. Self-directed and community-driven education play a major role in the configuration of these positions. The candidates selected will be invited to contribute to hackathons such as <a href="https://cloud4bio.github.io/">cloud4bio.github.io</a>.</p>
<p><strong>Goals</strong>: This position will engage the new data landscape being populated by three of the newest cohort studies, the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140986" inlinetype="rxhyperlink" sys_relationshipid="7299674" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140986" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="1140986">Connect study</a>, the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1123466" inlinetype="rxhyperlink" sys_relationshipid="7299675" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="1123466" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="1123466">Confluence project</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1135394" inlinetype="rxhyperlink" sys_relationshipid="7299676" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="1135394" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="1135394">Sherlock-lung</a> (a genomic epidemiologic study of lung cancer in never smokers).&nbsp;<br />&nbsp;&nbsp; <br /><strong>Qualifications</strong>: A doctoral degree with an emphasis in bioinformatics, computational statistics, computer science, media science or data science. Candidates familiar with neural network -based artificial intelligence (AI), web and cloud technologies, or with an interest in exploring AI-first software engineering applications to cancer research and prevention will be favored. These positions welcome both national and non-resident candidates.</p>
<p>For more information about the position, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1134633" sys_contentid="1134633" inlinetype="rxhyperlink" sys_relationshipid="7299668" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="1134633" sys_dependentvariantid="1965" sys_variantid="1965">Jonas Almeida, Ph.D.</a>, Chief Data Scientist.</p>
<p><strong>To apply</strong>: See the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=65&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302629" sys_contentid="302629" inlinetype="rxhyperlink" sys_relationshipid="7299669" sys_folderid="" sys_siteid="475" rxinlineslot="103" sys_dependentid="302629" sys_dependentvariantid="1418" sys_variantid="1418">Division Fellowship Information page</a> for an overview, qualifications, and application details.</p>
</div>]]></content>
  </row>
  <row para_id="1142712" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Radiation Epidemiology (REB) and Biostatistics Branches (BB) of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute/National Institutes of Health/Department of Health and Human Services seek qualified applicants for postdoctoral fellowships for interdisciplinary research on statistical issues in studying the role of radiation in cancer etiology. The Division of Cancer Epidemiology and Genetics (DCEG) of the National Cancer Institute conducts a national and international program of population- and familybased studies to elucidate the environmental and genetic determinants of cancer. REB conducts research to identify, understand, and quantify the risks of cancer in populations exposed to medical occupational, or environmental radiations, and to advance understanding of radiation carcinogenesis. BB statisticians collaborate across wide variety of studies in DCEG and develop cutting-edge statistical methods in diverse areas such as study design, the analysis of correlated data, measurement error, statistical genetics, genomics, and risk&ndash;prediction.</p>
<p>Successful candidates for these positions will be jointly mentored by investigators from REB and BB. Depending on one&rsquo;s interest, projects may include the collaboration on radiation epidemiologic studies that require non-standard modeling of the dose-response relationship between radiation and cancer risk, the analysis of genetic susceptibility and treatment effects on secondary cancers, and the analysis of incidence data from cancer registries for evaluating secondary cancer risks related to radiotherapy treatment. Candidate will also be given flexibility to pursue research in broader statistical areas, such as measurement error, disease surveillance, longitudinal and spatial-temporal modeling that have applications beyond radiation epidemiologic studies. Fellows will have opportunity to work together with a highly talented team of researchers with experience in radiation, statistics, epidemiology, dosimetry, and genomics. Access to data from a large variety of one-of-a- kind cohort studies (e.g., REB&rsquo;s signature cohort studies of cancer risks in children who underwent CT scans and a case-control study of children exposed to background radiation in the UK) would provide an excellent opportunity for identifying important problems, testing and validating the statistical methods and eventually applying them for improved analysis and interpretation of substantive studies. Fellows will have access to high performance computing facilities.</p>
<p>A Ph.D. in statistics, biostatistics or in a similar quantitative field is required. Individuals with both theoretical and applied backgrounds with strong computational skills are encouraged to apply. The appointments can continue up to three years and can be extended for an additional one to two&nbsp;years. For further information about the research program of the Division of Cancer Epidemiology and Genetics at NCI, and the Radiation and Biostatistics Branches within DCEG consult the website: <a href="http://www.dceg.cancer.gov">www.dceg.cancer.gov</a>.</p>
<p>Interested candidate should send a cover letter, curriculum vitae and three letters of references to <a href="mailto:adrienne.rolls@nih.gov">Ms Adrienne Rolls</a>.</p>
<p>Please contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=20&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1057578" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1057578" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7355525" sys_variantid="1965" sys_contentid="1057578"> Dr. Paul Albert</a> or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349642" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="349642" sys_dependentvariantid="1965" sys_siteid="475" sys_relationshipid="7355526" sys_variantid="1965" sys_contentid="349642">Dr. Amy Berrington de Gonz&aacute;lez</a> for questions about the positions. Applicants should mention in their cover letter that they are applying for the joint REB-BB postdoctoral fellowship position.&nbsp;</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1500&amp;sys_contentid=1131834" sys_contentid="1131834" inlinetype="rxhyperlink" sys_variantid="1500" sys_relationshipid="7355524" rxinlineslot="103" sys_dependentid="1131834" sys_dependentvariantid="1500">Download this position announcement in pdf format.</a></p>
<p style="text-align: center;">DHHS and NIH are Equal Opportunity Employers.</p>
</div>]]></content>
  </row>
  <row para_id="1142925" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div class="callout-box right" style="width: 27%;">
<h3>Data Science Research Group</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1134633" sys_contentid="1134633" inlinetype="rxhyperlink" sys_variantid="1965" sys_dependentvariantid="1965" sys_dependentid="1134633" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7355706">Jonas Almeida, Ph.D.</a> - Chief and senior investigator</p>
<p>Geeta Joshi(C) - project manager</p>
<p>Praful Bhawsar - current fellow</p>
<p><strong>We are hiring!</strong> Check out our <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1142671" sys_contentid="1142671" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1142671" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7355707">research training opportunities</a>.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1134646" sys_contentid="1134646" inlinetype="rxhyperlink" sys_variantid="1424" sys_dependentvariantid="1424" sys_dependentid="1134646" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7355708">Read about Dr. Almeida's appointment.</a></p>
</div>
<p>The DCEG Data Science Research Group seeks to advance research and infrastructure for data-intensive precision prevention studies. The primary goals of the Group are to:</p>
<ul>
<li>Accelerate the investigation of the causes of cancer</li>
<li>Advance cloud computing infrastructure for precision prevention</li>
<li>Develop transdisciplinary human capital through weekly <a href="https://cloud4bio.github.io/">Cloud4Bio Hackathons</a> at the NCI Shady Grove campus</li>
</ul>
<h3>Research Areas and Topics of Interest</h3>
<p><strong>EpiSphere</strong><br /><a href="https://episphere.github.io/">EpiSphere</a> is an online environment for web-based tools to operate in the Cancer Epidemiology Commons.</p>
<p><strong>FeatureScape</strong><br /><a href="https://github.com/SBU-BMI/featurescape">FeatureScape</a> is an interactive representation and analysis of feature landscapes.</p>
<p><strong>Serverless OpenHealth</strong><br /> Serverless OpenHealth supports large-scale interactive data access and analysis entirely through the web computing environment.<br /> <a href="https://www.ncbi.nlm.nih.gov/pubmed/30671301">Serverless OpenHealth (PubMed abstract)</a><br /> See a <a href="https://mathbiol.github.io/#load%20sparcs">live demo of Serverless OpenHealth</a></p>
<p><strong>The Connect for Cancer Prevention Study</strong><br /> The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1140986" sys_contentid="1140986" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1140986" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7355704">Connect</a> study is a "next-generation" cohort study based in integrated healthcare systems. The goal is to enroll 200,000 adults in the United States&nbsp;to further investigate the etiology of cancer and its outcomes, which may inform new approaches in precision prevention and early detection.</p>
<p><strong>The Confluence Project</strong><br />The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1123466" sys_contentid="1123466" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="1123466" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7355705">Confluence Project</a> is a research resource currently under development, designed to uncover breast cancer genetics through genome-wide association studies (GWAS). The study will include at least 300,000 breast cancer cases.</p>
</div>]]></content>
  </row>
  <row para_id="1145013" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), National Institutes of Health (NIH) is recruiting an accomplished Senior Scientist in the Epidemiology and Biostatistics Program (EBP). DCEG&rsquo;s epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division&rsquo;s research has an impact on public health policy in the United States and around the world.</p>
<p>The Senior Scientist will provide overall direction to a new prospective cohort study of 200,000 adults in the U.S. to understand the etiology and natural history of cancer, which can inform new approaches in precision prevention and early detection of cancer. The Senior Scientist will oversee the DCEG cohort coordinating center of approximately five staff members and all cohort activities, and be responsible for the overall success of the cohort. The Senior Scientist will also play a key role in consulting with DCEG Principal Investigators and provide technical/scientific advice. Additionally, the Senior Scientist will serve as liaison to NCI and NIH standing committees and represent the Division to other agencies and outside organizations to coordinate activities, enhance communication, and develop new initiatives and infrastructure.</p>
<p>The successful candidate will hold a doctoral degree in epidemiology or a related field, have substantial relevant experience and responsibility for managing and directing large prospective epidemiological cohort studies, and be a successful supervisor. He or she must also be recognized as an international expert in cancer epidemiology; demonstrate expertise in managing a complex, outstanding program of epidemiological research; have exemplary skills and innovative approaches to epidemiological research and relevant new technologies; and have extensively published in peer-reviewed scientific or medical journals and presented at scientific meetings.</p>
<p>Salary and benefits are commensurate based on the incumbent&rsquo;s qualifications and experience. The Senior Scientist is a Full-Time Equivalent (FTE) employment position. See <a href="https://oir.nih.gov/sourcebook/personnel/ipds-appointment-mechanisms/senior-scientist">more information on this position</a>. Full Federal benefits including leave, health and life insurance, long-term care insurance, retirement, and savings plan (401k equivalent) will be provided. For full detailed application procedures,&nbsp;go to the vacancy announcement on <a href="https://www.usajobs.gov/">USAJobs</a> and search for NIH-NCI-DE-19-10485430.&nbsp;Opening May 15, 2019 and closing May 24, 2019.</p>
<p>This position is subject to a background investigation.&nbsp;The NIH is dedicated to building a diverse community in its training and employment programs.</p>
<p style="text-align: center;">DHHS,&nbsp;NIH, and NCI&nbsp;are Equal Opportunity Employers.</p>
</div>]]></content>
  </row>
  <row para_id="1145770" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>Over 500,000 cervical cancers occur every year world-wide, with a disproportionate burden affecting low-resource settings. NCI has a focused research program to understand the etiology of cervical cancer and to accelerate global cervical cancer control. We now understand cervical cancer etiology very well and there are multiple tools available to develop successful screening and management programs.</p>
<p>Despite the widespread availability of cervical cancer screening and management programs in the U.S., over 13,000 women are diagnosed with this malignancy and over 4,000 die from their cancer in the U.S. every year. Mississippi is among the top five states in the nation for cervical cancer incidence and mortality, making the state a critical setting for NCI&rsquo;s cervical cancer prevention and control efforts.</p>
<p>Reasons for these disproportionately high rates are likely multi-factorial, including:</p>
<ul>
<li>lack of access to cervical cancer screening,</li>
<li>delayed or loss-to diagnostic follow-up and treatment,</li>
<li>disparities related to race/ethnicity, socioeconomic status, and access to care.</li>
</ul>
<p>There is a unique opportunity for the NCI to join forces with multiple partners in Mississippi to address these challenges and work towards reducing cervical cancer mortality.</p>
<p>The NCI is partnering with the University of Mississippi Medical Center and the Mississippi State Department of Health to conduct a study to evaluate risk of cervical precancer and to study novel biomarkers in women undergoing cervical cancer screening. The STRIDES Study (STudying Risk to Improve DisparitiES of cervical cancer in Mississippi) is a collaborative, team-science effort involving clinicians, laboratory scientists, epidemiologists, and implementation scientists to address all aspects of cervical cancer prevention and control in Mississippi.</p>
<p>For more information, contact <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=35&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1965&amp;sys_contentid=349668" sys_dependentvariantid="1965" sys_dependentid="349668" inlinetype="rxhyperlink" rxinlineslot="103" sys_relationshipid="7317432" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen, M.D., Ph.D.</a>, or <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=1067259" sys_dependentvariantid="1482" sys_dependentid="1067259" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7317433" sys_variantid="1482" sys_contentid="1067259">Megan Clarke, Ph.D., M.H.S.</a></p>
<p>Related links:&nbsp;<a href="https://dceg.cancer.gov/news-events/research-news-highlights/2019/controlling-cervical-cancer">Controlling Cervical Cancer: DCEG&rsquo;s Ongoing Commitment to Improving Women&rsquo;s Health</a></p>
</div>]]></content>
  </row>
  <row para_id="1147391" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_relationshipid="7358028" sys_siteid="475" sys_variantid="1422">Biostatistics Branch</a> (BB) hosts an ongoing seminar series.</p>
<table class="blue-table" style="width: 500px;" cellspacing="0"><caption>Biostatistics Branch Seminar Topics and Schedules&nbsp;&ndash; Present to 2016</caption>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Lung screening economics: from resource utilization to research utilization</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, June 26, 2019<br />10:00-11:30am<br />3E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Sonya Cressman<br />Health Economist<br />British Columbia Cancer Agency</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Personalized Treatment Plans with Multivariate Outcome Measures</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, June 12, 2019<br />10:30-11:30am<br />7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Somnath Datta, PhD<br />Professor<br />Department of Biostatistics<br />University of Florida</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Computationally-Efficient Framework for Inferring the Evolutionary History of a Tumor Given Single-Cell Sequencing Data</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, June 5, 2019<br />10:30-11:30am<br />7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Julia Chifman, PhD<br />Assistant Professor<br />Department of Biostatistics<br />American University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Use of Bayesian Non-Parametrics for Problems in Causal Inference</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, May 29, 2019<br />10:30-11:30am<br />7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Mike Daniels, PhD<br />Professor<br />Department of Statistics &amp; Andrew Banks Family Endowed Chair<br />University of Florida</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Assessing and utilizing reproducibility of high-throughput experiments</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, May 1st, 2019<br />10:30-11:30am<br />7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Qunhua Li, PhD<br />Associate Professor<br />Department of Statistics<br />Penn State University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Incorporating American Community Survey Uncertainty into Disease Mapping Models</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, April 23rd, 2019<br />10:30-11:30am<br />5E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Lance Waller, PhD<br />Professor<br />Department of Biostatistics and Bioinformatics<br />Rollins School of Public Health<br />Emory University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Some proposals for aggregate &amp; individualized cost-effectiveness analysis</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Monday, April 1st, 2019<br />10:30-11:30am<br />1E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Aryana Arsham, PhD Candidate<br />Statistician<br />University of Maryland Baltimore County</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Development of an International Prostate Cancer Risk Tool integrating data from multiple heterogeneous cohorts</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Thursday, March 21st, 2019<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Donna Ankerst, PhD<br />Department of Mathematics<br />Technical University of Munich</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Receiver Operating Characteristic (ROC) Curves in their Natural Habitats</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, March 20th, 2019<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Albert Vexler, PhD<br />Professor <br /> Department of Biostatistics <br /> School of Public Health <br /> State University of New York at Buffalo</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Ranking and regression calibration: methods to address bias induced from correlated covariate and time-to-event error</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, November 7th, 2018<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Pamela Shaw, PhD<br />Associate Professor<br />University of Pennsylvania<br />Perlman School of Medicine</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Causal inference with high dimensional confounders</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Friday, September 28th, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Andrea Rotnizky, PhD<br />Professor of Statistics<br />Universidad Torcuato di Tella<br />Principle Investigator <br />CONICET<br />Argentina<br />Adjunct Professor<br />Harvard School of Public Health<br />Boston MA</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Mutlistate modeling of dependent disease, selection and observation processes in health research</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, September 19th, 2018<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Richard Cook, PhD<br />Professor, Canada Research Chair<br /> Department of Statistics and Actuarial Science<br /> Facutly of Mathematics <br />University of Waterloo</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Harnessing genetic interactions to advance whole genome precision cancer treatment</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, September 4th, 2018<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Eytan Ruppin, MD, PhD<br />Cheif<br /> Cancer Data Science Lab (CDSL)<br /> National Cancer Institute, NIH</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Cost-efficient Analysis of Survival Data under the Proportional Hazards model with Pooled Covariates</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, August 22nd, 2018<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Paramita Chaudhuri, PhD<br />Cheif<br /> Associate Professor, Biostatistics<br /> Department of Epidemiology, Biostatistics &amp; Occupational Health<br /> McGill University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Generalized Group Testing: Some Results and Open Problems</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, August 15th, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Yaakov Malinovsky, PhD<br />Associate Professor<br /> Department of Mathematics and Statistics<br /> University of Maryland</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Statistical and Computational Analysis Tools for Massive Genomic Data</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Monday, August 6th, 2018<br />10:00-11:00am<br /> TE408/410</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Xiuwen Zheng, PhD<br />Senior Research Fellow<br /> Department of Biostatistics<br /> University of Washington</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>CISNET: NCIs Consortium for Population Modeling to Guide Public Health Research and Priorities</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, July 11th, 2018<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Eric (Rocky) Feuer, PhD<br />Chief <br /> Statistical Research and Applications Branch<br /> Surveillance Research Program, DCCPS&lt; br/&gt; NCI Project Scientist - CISNET</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Statistical methods for testing carryover effects</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Friday, June 29th, 2018<br />10:30-11:30am<br /> 4E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Gwynn Sturdevant, PhD<br />Professor <br /> Post-Doctoral Fellow<br /> University of Massachusetts, Amherst</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Shared and Study Specific Dietary Patterns and Their Association with Head and Neck Cancer Risk</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Friday, June 15th, 2018<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Valeria Edefonti, PhD<br />Professor <br /> Department of Clinical &amp; Community Sciences<br /> Laboratory of Medical Sciences<br /> Milan University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>The Latent Scale Covariogram: A Tool for Exploring the Spatial Dependence Structure of Non-Normal Responses</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, May 1st, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Samuel D. Oman, PhD<br />Professor <br /> Department of Statistics<br /> Hebrew University of Jerusalem</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Methods for Identifying Etiologically Distinct Sub-Types of Cancers</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, April 11th, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Colin B. Begg, PhD<br />Chairman <br /> Department of Epidemiology and Biostatistics<br /> Memorial Sloan Kettering Cancer Center</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>A Bayesian Nonparametric Approach to Causal Inference on Quantiles</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, March 21st, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Mike Daniels, PhD<br />Professor and Chair<br />Andrew Banks Family Endowed Chai<br />Department of Statistics<br />University of Florida</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Evaluating Diagnostic Tests for Clinical Utility in Ruling In or Ruling Out Disease</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, February 28th, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Gene Pennello, PhD<br />Diagnostic Statistics Branch II, Division of Biostatistics<br /> Office of Surveillance and Biometrics<br />Center for Devices and Radiological Health<br />US Food and Drug Administration</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Expression Recovery in Single Cell RNA Sequencing</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, January 31st, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Nancy Zhang, PhD<br />Associate Professor of Statistics<br />The Wharton School<br />University of Pennsylvania</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Analysis of Linear Transformation Models with Covariate Measurement Error and Interval Censoring</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, January 30th, 2018<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Soutrik Mandal<br />PhD Student<br /> Texas A&amp;M University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>On the construction of unbiased estimators for the group testing problem</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, January 10th, 2018<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Greg Haber, MS<br />University of Maryland<br /> Baltimore County</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Challenges and Opportunities for Analysis of Massive Data from Genome, Exposome, and Phenome</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, November 8th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Xihong Lin, PhD<br />Department of Biostatistics and Statistics<br /> Harvard University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Statistical Methods for Studying Disease Etiologic Heterogeneity</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Thursday, October 19th, 2017<br />10:30-11:30am<br /> TE406</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Molin Wang, PhD<br />Assistant Professor<br />Department of Biostatistics and Epidemiology<br /> Harvard T.H. Chan School of Public Health<br />Harvard Medical School</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>From Genetics to CRISPR Gene Editing with Machine Learning</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Thursday, September 28th, 2017<br />2:00-3:00pm<br /> 3W032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Jennifer Listgarten, PhD<br />Senior Researcher<br />Microsoft Reserch Lab</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>An Imputation-Consistency Algorithm for Biomedical Complex Data Analysis</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Friday, August 25th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Faming Liang, PhD<br />Professor of Statistics<br />Purdue University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Linking microbiome composition with phenotype: the variable selection problem in microbiome data analysis</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, August 8th, 2017<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Diego Tomassi, PhD<br />Professor<br />Department of Mathematics<br /> Facultad de Ingenieria Quimica <br /> Universidad Nacional del Litoral</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Nested Group Testing Procedures and Generalized GT Problem</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Monday, August 7th, 2017<br />10:30-11:30am<br /> 4E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Yaakov Malinvosky, PhD<br />Associate Professor<br />Department of Mathematics and Statistics<br /> University of Maryland, Baltimore</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Statistical and Computational Approaches for Metagenomics Data Analysis</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Monday, July 17th, 2017<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Fengzhu Sun, PhD<br />Professor<br /> Molecular and Computational Biology &amp; Mathematics<br /> University of Southern California</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Optimal screening schedules for disease progression with applications to diabetic</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, July 12th, 2017<br />10:30-11:30am<br /> 2E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Ionut Bebu, PhD<br />The Biostatistics Center<br /> Milken School of Public Health<br /> The George Washington University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>What level of cervical screening is appropriate for women vaccinated against HPV? A microsimulation study</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Thursday, June 29th, 2017<br />3:00-4:00pm<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Rebecca Landy, PhD<br />Statistician<br />Centre for Cancer Prevention<br /> Wolfson Institute of Preventive Medicine Barts and the London School of Medicine and Dentistry<br />Queen Mary University of London</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Fractional imputation for handling missing data in survey sampling</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, June 27th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Jae-Kwang Kim, PhD<br />Chief<br />Professor of Statistics<br />Iowa State University</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Analysis of germline variants in cancer in the Laboratory of Translational Genetics (LTG)</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, June 14th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Michael Dean, PhD<br />Chief<br />Laboratory of Translational Genetics<br />DCEG, NCI, NIH</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Regression Analysis of Informatively Interval-censored Failure Time Data</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, May 10th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Tony Jianguo Sun, PhD<br />Professor of Statistics<br />Department of Statistics<br />University of Missouri</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Analysis of asynchronous longitudinal data with partially linear models</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Friday, April 21, 2017<br />10:30-11:30am<br /> 2W910/912</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Hongyuan Cao, PhD<br />Assistant Professor<br />Statistics<br />University of Missouri</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Challenges and Methods in Biomarker Combination for Risk Prediction with Application to a Fetal Growth Study</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Monday, April 17th, 2017<br />10:30-11:30am<br /> TE/406</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Danping Liu, Ph.D.<br />Investigator<br />Biostatistics and Bioinformatics Branch<br />National Institute of Child Health and Human Development</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Methods for evaluating the time-varying prognostic performance of survival models</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Monday, April 3rd, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Jason Liang, Ph.D.<br />Investigator<br />National Institute of Allergy and Infectious Diseases&lt;\br&gt;National Institutes of Health</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Bayesian regression for group testing data</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Thursday, March 30th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Joshua M. Tebbs, Ph.D.<br />Professor, Department of Statistics<br />University of South Carolina</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Principal Component Analysis for Vector Time Series</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, March 21st, 2017<br />10:30-11:30am<br /> 4W032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Qiwei Yao, Ph.D.<br />Professor of Statistics<br />London School of Economics</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Enhanced statistical models, visualization, and data collection for precision cancer risk prediction</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Friday, March, 17th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Donna Ankerst, Ph.D.<br />Department of Mathematics<br />Technical University of Munich<br />and<br />Department of Urology<br />UT Health, San Antonio</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>The interplay of somatic copy number aberration, DNA methylation, and gene expression</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Thursday, March, 16th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">
<p>Wei Sun, Ph.D.<br />Associate Member<br />Biostatistics &amp; Bioinformatics / Public Health Sciences Division<br />Fred Hutchinson Cancer Research Center<br />&amp;<br />Adjunct Associate Professor<br />Department of Biostatistics<br />University of North Carolina<br />Gillings School of Public Health</p>
</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Concordant integrative analysis of multiple two-sample genome-wide expression data sets</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, February 14th, 2017<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">Yinglei Lai, Ph.D.<br />Professor of Statistics<br />The George Washington University</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Big Data Analysis with application to Vaccine-Adverse Event Data</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Tuesday, January 24th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">J. Jian-Jian Ren, Ph.D.<br />Professor of Statistics<br />University of Maryland<br />College Park</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 497px; height: 30px;" colspan="2"><strong>Big Data Integration in Biomedical Studies</strong></th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122.85px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 374.15px; height: 45px;">Wednesday, January 25th, 2017<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122.85px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 374.15px; height: 60.4px;">Hongtu Zu, Ph.D.<br />Professor of Biostatistics<br />The University of Texas<br />MD Anderson Cancer Center</td>
</tr>
</tbody>
<tbody>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">Statistical Methods for Microbiome Data Analysis</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Tuesday, December 13th, 2016<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 60.4px;">Jun Chen, Ph.D.<br />Professor<br />Mayo Clinic<br />Rochester, NY</td>
</tr>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">High-dimensional Multivariate Mediation with Application to Neuroimaging Data</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Wednesday, November 9th, 2016<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60.4px;">
<td class="first" style="width: 122px; height: 60.4px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 60.4px;">Martin Lindquist, Ph.D.<br />Professort<br />Department of Biostatistics<br />Johns Hopkins University</td>
</tr>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">Improving the robustness of doubly robust estimators in missing data analysis</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Wednesday, October 12th, 2016<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60px;">
<td class="first" style="width: 122px; height: 60px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 60px;">Peisong Han, Ph.D.<br />Assistant Professort<br />Statistics and Actuarial Science<br />University of Waterloo</td>
</tr>
<tr style="height: 15px;">
<th style="width: 498px; height: 15px;" colspan="2">New Methods for Analyzing Data from 16S rRNA Microbiome Studies</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Tuesday, May 24th, 2016<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60px;">
<td class="first" style="width: 122px; height: 60px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 60px;">Glen Satten, Ph.D.<br />Adjunct Professort<br />School of Medicine, Department of Human Genetics<br />Emory University</td>
</tr>
<tr style="height: 15px;">
<th style="width: 498px; height: 15px;" colspan="2">Evaluating Biomarkers for Guiding Treatment</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Tuesday, May 17th, 2016<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 90px;">
<td class="first" style="width: 122px; height: 90px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 90px;">Holly Janes, Ph.D.<br />Associate Member<br />Vaccine &amp; Infectious Disease / Public Health Sciences Division<br />Fred Hutchinson Cancer Research Center<br />Graduate Faculty, Biostatistics<br />University of Washington</td>
</tr>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">General regression model for competing risks- and recurrent event cancer data subject to competing terminal events</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Monday, May 16th, 2016<br />10:30-11:30am<br /> 5E032/34</td>
</tr>
<tr class="odd" style="height: 60px;">
<td class="first" style="width: 122px; height: 60px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 60px;">Anna Bellach.<br />PhD Candidate<br />Department of Public Health, Biostatistics<br />University of Copenhagen</td>
</tr>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">Biomarker assessment and combination with differential covariate effects and an unknown gold standard</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Wednesday, May 11th, 2016<br />10:30-11:30am<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 105px;">
<td class="first" style="width: 122px; height: 105px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 105px;">Zheyu Wang, Ph.D.<br />Assistant Professort<br />Division of Biostatistics and Bioinformatics<br />Sidney Kimmel Comprehensive Cancer Center<br />Johns Hopkins University School of Medicine <br />Department of Biostatistics<br />Johns Hopkins Bloomberg School of Public Health</td>
</tr>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">A Multivariate Distance Based Test on Microbial Interdependence Non-parametric Test (MINT)</th>
</tr>
<tr style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 45px;">Tuesday, March 22nd, 2016<br />10:30-11:30am<br /> 7E032/34</td>
</tr>
<tr class="odd" style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 45px;">Yilong Zhang, MS<br />PhD Candidate<br />New York University</td>
</tr>
<tr style="height: 15px;">
<th style="width: 498px; height: 15px;" colspan="2">Methodological advances in the analysis of genetic data</th>
</tr>
<tr style="height: 30px;">
<td class="first" style="width: 122px; height: 30px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 30px;">Wednesday, February 24th, 2016<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 45px;">Benjamin Neale, PhD<br />Psychiatric &amp; Neurodevelopmental Genetics Unit<br />Massachusetts General Hospital Research Institute</td>
</tr>
<tr style="height: 30px;">
<th style="width: 498px; height: 30px;" colspan="2">Construction, Characterization and Validation of Multiscale Gene Networks in Complex Human Diseases</th>
</tr>
<tr style="height: 30px;">
<td class="first" style="width: 122px; height: 30px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 30px;">Friday, February 19th, 2016<br /> 6E032/34</td>
</tr>
<tr class="odd" style="height: 60px;">
<td class="first" style="width: 122px; height: 60px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 60px;">Bin Zhang, PhD <br />Associate Professor <br />Dept of Genetics and Genomic Sciences <br />Ican School of Medicine at Mount Sinai</td>
</tr>
<tr style="height: 15px;">
<th style="width: 498px; height: 15px;" colspan="2">Using Nonlocal Priors for Variable Selection in Generalized Linear Models</th>
</tr>
<tr style="height: 30px;">
<td class="first" style="width: 122px; height: 30px;">Date and Time:</td>
<td class="second" style="width: 376px; height: 30px;">Thursday, January 21st, 2016<br /> 4E032/34</td>
</tr>
<tr class="odd" style="height: 45px;">
<td class="first" style="width: 122px; height: 45px;">Lecturer:</td>
<td class="second" style="width: 376px; height: 45px;">Ho-Hsiang Wu, MA<br /> PhD Candidate, Statistics<br /> University of Missouri</td>
</tr>
<!-- End bb/about/events content   --></tbody>
</table>
</div>]]></content>
  </row>
  <row para_id="1147573" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2090" sys_dependentid="1121808" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7344993">
<figure class="image-right-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=568389&amp;sys_siteid=475&amp;sys_contentid=1121808&amp;sys_command=edit" alt="Headshot of Mia Gaudet, Ph.D" /><!--Comment--></div>
</figure>
</div>
<p><strong>Years at DCEG:</strong> June 2005 to December 2007 <br /> <strong>DCEG title:</strong> Research Fellow <br /> <strong>Current organization:</strong> American Cancer Society (ACS)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br /> <strong>Current title:</strong> Scientific Director, Epidemiology Research</p>
<p></p>
<p><em><strong>Who was your mentor at DCEG?</strong></em> <br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="1004366" sys_relationshipid="7344991" sys_variantid="1965" sys_contentid="1004366">Montserrat Garcia-Closas, M.D., Dr.P.H.</a>&ndash; the best mentor EVER.</p>
<p><em><strong>What did you work on (briefly)? </strong></em> <br /> I primarily analyzed genetic variation in individual genes and risk of breast and endometrial cancer. I also examined breast cancer risk factors by molecular subtypes.</p>
<p><em><strong>What is your current position?</strong></em> <br /> As scientific director for epidemiology research at the American Cancer Society, my position is equivalent to that of an associate professor in a department of epidemiology, but with less grant writing. Most of my day is spent generating new research ideas, overseeing statistical analyses, and writing manuscripts. I contribute to the collection of new exposure data through the development of follow-up questionnaires, and lead the collection of breast and ovarian tissue samples in the ACS&rsquo;s Cancer Prevention Study cohorts. I mentor students, fellows, and junior faculty at ACS and Emory University, and lecture occasionally at local universities. I also have the opportunity to share my research with the broader public by commenting to the media and advising my ACS colleagues working in communications and implementation.</p>
<p><em><strong>How do you apply the skills you developed at DCEG in your current job?</strong></em><br /> On a daily basis, I employ the skills developed during my fellowship; though I focus on the same areas, my research has grown and shifted over time.</p>
<p><em><strong>Do you have any memories from your fellowship that you would like to share?</strong></em> <br />I have horrible memories of the vegetarian options at the cafeteria next to the old DCEG office*, but fond memories of tea times, branch celebrations, and office yoga!</p>
<p><em><strong>What do you do in your free time?</strong></em><br /> With two kids and a career, I don&rsquo;t have much free time. I relax when I can cook dinner in the evening with no interruptions.</p>
<p><em><strong>Do you have any advice for current or future DCEG fellows?</strong></em><br /> My friendships with fellows training concurrently with me will last a lifetime! Be sure to cultivate those relationships as they will become an important base to your network as you move beyond DCEG. Also, form collaborations with investigators outside of your comfort zone &ndash; expose yourself to their language and methods.</p>
<p><em>*Editor&rsquo;s note:</em> the NCI Shady Grove cafeteria has much better lunch options.</p>
<p></p>
<p><strong><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1097514" sys_contentid="1097514" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1097514" sys_variantid="1418" sys_relationshipid="7344992">Read more conversations with former fellows</a>.</strong></p>
</div>]]></content>
  </row>
  <row para_id="1148477" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<div sys_dependentvariantid="2090" sys_dependentid="1148507" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7361501">
<figure class="image-right-small centered-set">
<div class="centered-element"><img alt="Dr. Madison is a former DCEG fellow " src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=799973&amp;sys_siteid=475&amp;sys_contentid=1148507&amp;sys_command=edit" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Hisani Madison</p>
</div>
</figcaption>
</figure>
</div>
<p><strong>Years at DCEG:</strong> May 2010 to July 2014<br /> <strong>DCEG Title:</strong> Postdoctoral Fellow<br /> <strong>Current Organization:</strong> AstraZeneca<br /> <strong>Current Title: </strong>Associate Director, Diagnostics Expert, Oncology</p>
<p><strong>Who was your mentor at DCEG? What did you work on?</strong><br /> My mentor was Dr. Jonine Figueroa. As part of the branch formerly known as the Hormonal and Reproductive Epidemiology Branch, I worked on projects aiming to understand the molecular and histological heterogeneity that exists in breast and ovarian cancer. Since I was a part of the Cancer Prevention Fellowship, I had the pleasure of also working with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349652" sys_contentid="349652" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349652" sys_variantid="1965" sys_relationshipid="7361230" sys_folderid="">Gretchen Gierach, Ph.D., M.P.H.</a>, Dr. Mark Sherman, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349593" sys_contentid="349593" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349593" sys_variantid="1965" sys_relationshipid="7361231" sys_folderid="">Rose Yang, Ph.D., M.P.H.</a>, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349669" sys_contentid="349669" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1965" rxinlineslot="103" sys_dependentid="349669" sys_variantid="1965" sys_relationshipid="7361232" sys_folderid="">William Anderson, M.D., M.P.H.</a>, on a range of projects.</p>
<p><strong>What is your current position?</strong><br /> I am currently working at AstraZeneca, based in Gaithersburg, Maryland,&nbsp;as an Associate Director, Diagnostics Expert in the Oncology R&amp;D Unit. In this role, I serve as the Diagnostics Lead for the gastrointestinal cancer global product team within the ImmunoOncology franchise.</p>
<p><strong>How do you apply the skills you developed at DCEG in your current job?</strong><br /> As a Diagnostics Lead, I&rsquo;m tasked with surveying the literature, clinical data and my own knowledgebase to apply science to strategy when working to develop the right drug for the right cancer patient (precision medicine). The leadership and critical thinking skills, as well as the thorough understanding of the scientific process and cancer as a disease that was developed during my time as a DCEG Fellow has served me well in my current role.</p>
<p><strong>Do you have any memories from your fellowship that you would like to share?</strong><br /> So many, where do I start?! I think my fondest memories as a fellow are largely centered around the great group of people that started out as colleagues but became friends. Having friends to talk over everything from science to fashion was one of my favorite pastimes as a fellow. Over the years since my fellowship ended, they have continued to be my biggest cheerleaders on my scientific journey.</p>
<p><strong>What do you do in your free time?</strong><br /> What free time? Just kidding. I have a husband and two little girls/competitive gymnasts that get the most of my free time. But I also have a passion project, an art education non-profit called ArtWorks 4 ENA, Inc., that also gets a bit of my free time.</p>
<p><strong>Do you have any advice for current or future DCEG fellows?</strong><br /> The biggest advice I can give is to reach back and use your network to your advantage. Since leaving DCEG, I have had more informational interviews than I can count. Some of those have led to jobs at either FDA (my former employer) or at AstraZeneca (my current employer). Former fellows are a wealth of knowledge, be sure to tap into it.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1097514" sys_contentid="1097514" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1097514" sys_variantid="1418" sys_relationshipid="7361243" sys_folderid="">Read more conversations with former fellows</a>.</p>
</div>]]></content>
  </row>
  <row para_id="1148881" langcode="en">
    <content><![CDATA[<div class="rxbodyfield">
<p>The Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), National Institutes of Health (NIH) is recruiting a staff scientist to work in the Metabolic Epidemiology Branch (MEB) under the direction of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=52&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" inlinetype="rxhyperlink" sys_relationshipid="7363549" sys_dependentvariantid="1965" sys_dependentid="349612" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_variantid="1965" sys_contentid="349612">Christian Abnet, Ph.D., M.P.H.</a>, Chief and senior investigator, MEB.</p>
<p>MEB conducts interdisciplinary research to understand the role of diet, energy balance, hormones, tobacco, and other exposures in causing and preventing cancer. MEB researchers study how these exposures relate to a broad variety of cancers with researchers focusing on breast, colon, endometrium, esophagus, liver, stomach, ovary, pancreas, and prostate. MEB researchers use traditional epidemiological methods combined with a variety of molecular methods including genomic analysis, metabolomics, microbiomics, and molecular pathology. The overarching mission of MEB is to conduct collaborative high-impact epidemiological research on metabolic and lifestyle causes of cancer that will guide prevention strategies worldwide.</p>
<p>The incumbent will have responsibilities related to all aspects of Dr. Abnet&rsquo;s research program examining the etiology of esophageal and gastric cancer, as well as projects related to characterizing the human microbiome. Specific duties will include assisting with study design (developing protocols, questionnaires, specimen handling procedures), management (data coding and cleaning, specimen tracking, human subjects&rsquo; approvals), statistical analysis, and preparation of reports for presentation or publication. Some international travel in support of field studies may be required.&nbsp;The incumbent will also be asked to assist Dr. Abnet with the administration of the overall MEB research program.</p>
<p>The successful candidate must hold a doctoral degree or equivalent in a relevant discipline (e.g., epidemiology, biostatistics, or public health).&nbsp;The position requires organizational abilities, attention to detail, initiative, an aptitude for multi-tasking, and the ability to work independently. The position requires effective oral and written communication skills as demonstrated through presentations and publications. Salary is commensurate with experience.</p>
<p>Interested individuals should send a cover letter, curriculum vitae, brief summary of research interests and experience, and the names and contact information for three professional references to:</p>
<p style="text-align: center;">Ms. Jennifer Connor<br />Division of Cancer Epidemiology and Genetics, National Cancer Institute<br />9609 Medical Center Drive, Rm. 7E314 MSC 9775<br />Bethesda, MD 20892<br />E-mail: <a href="mailto:connorj@mail.nih.gov">connorj@mail.nih.gov</a></p>
<p style="text-align: center;">The closing date for applications is 7/8/19.</p>
<p style="text-align: center;">DHHS, NIH, and NCI are Equal Opportunity Employers</p>
</div>]]></content>
  </row>
</rows>